PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	EY	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Duysburgh, E; Kerstens, B; Diaz, M; Fardhdiani, V; Reyes, KA; Phommachanh, K; Rodriques, B; Zaka, N				Duysburgh, E.; Kerstens, B.; Diaz, M.; Fardhdiani, V.; Reyes, K. A.; Phommachanh, K.; Rodriques, B.; Zaka, N.			Newborn care in three selected South East Asian countries: a comprehensive needs assessment	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Duysburgh, E.] Univ Ghent, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium; [Kerstens, B.; Diaz, M.; Fardhdiani, V.; Reyes, K. A.; Phommachanh, K.] HERA, Reet, Belgium; [Rodriques, B.; Zaka, N.] UNICEF East Asia Pacific Reg Off, Bangkok, Thailand								0	0	0	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		83	83						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000217					2019-03-26	
J	Habimana, L; Kabange, ET; Kayamba, MK; Robert, A				Habimana, L.; Kabange, E. T.; Kayamba, M. K.; Robert, A.			Is neonatal TSH a useful indicator of iodine deficiency in Lubumbashi?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Habimana, L.; Robert, A.] Catholic Univ Louvain, Louvain, Belgium; [Kabange, E. T.; Kayamba, M. K.] Univ Lubumbashi, Lubumbashi, Zaire								0	0	0	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		85	85						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000221					2019-03-26	
J	Philips, M; Niccartaigh, N; Pineda, S; Van Herp, M; Van Overloop, C				Philips, M.; Niccartaigh, N.; Pineda, S.; Van Herp, M.; Van Overloop, C.			Access to effective primary care and referral for patients in Afghanistan problematic due to health service performance and specific financial, geographic and insecurity barriers	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Philips, M.; Niccartaigh, N.; Pineda, S.; Van Herp, M.; Van Overloop, C.] MSF Brussels, Brussels, Belgium								0	0	0	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		90	90						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000236					2019-03-26	
J	Mbonye, MK; Van Geertruyden, JP; Burnett, SM; Naikoba, S; Colebunders, R; Willis, K; Weaver, MR				Mbonye, M. K.; Van Geertruyden, J. -P.; Burnett, S. M.; Naikoba, S.; Colebunders, R.; Willis, K.; Weaver, M. R.			Trusting malaria test results: fever and young age predicts inappropriate malaria treatment in Uganda	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Mbonye, M. K.; Van Geertruyden, J. -P.; Naikoba, S.; Colebunders, R.] Univ Antwerp, Antwerp, Belgium; [Mbonye, M. K.; Naikoba, S.] Makerere Univ, Infect Dis Inst, Kampala, Uganda; [Burnett, S. M.; Willis, K.] Accordia Global Hlth Fdn, Washington, DC USA; [Weaver, M. R.] Int Training & Educ Ctr Hlth I TECH, Washington, DC USA			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		108	108						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000289					2019-03-26	
J	Naikoba, S; Mbonye, M; Van Gertruyden, JP				Naikoba, S.; Mbonye, M.; Van Gertruyden, J. P.			Prevalence of malaria diagnosis in infants below 6 months of age presenting with fever at rural health facilities in Uganda	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Naikoba, S.; Mbonye, M.] Infect Dis Inst, Kampala, Uganda; [Van Gertruyden, J. P.] Univ Antwerp, Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		109	109						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000291					2019-03-26	
J	Trevisan, C; Praet, N; Pondja, A; Assane, YA; Dorny, P; Magnussen, P; Thamsborg, SM; Johansen, MV				Trevisan, C.; Praet, N.; Pondja, A.; Assane, Y. A.; Dorny, P.; Magnussen, P.; Thamsborg, S. M.; Johansen, M. V.			Assessment of the social burden of Taenia solium Cysticercosis in Angonia District, Mozambique	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Trevisan, C.; Magnussen, P.; Thamsborg, S. M.; Johansen, M. V.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet Dis Biol, Sect Parasitol & Aquat Dis, Frederiksberg, Denmark; [Praet, N.; Dorny, P.] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Pondja, A.; Assane, Y. A.] Eduardo Mondlane Univ, Fac Vet Med, Maputo, Mozambique								0	0	0	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		109	110						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000293					2019-03-26	
J	Van Esbroeck, M; Van den Bossche, D; Cnops, L; Van Gompel, A				Van Esbroeck, M.; Van den Bossche, D.; Cnops, L.; Van Gompel, A.			Chikungunya virus infections imported in Belgium in the post Indian Ocean Islands outbreak era	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Van Esbroeck, M.; Van den Bossche, D.; Cnops, L.; Van Gompel, A.] Inst Trop Med, B-2000 Antwerp, Belgium								0	1	1	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		113	114						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000306					2019-03-26	
J	Bosschaerts, T; Hernandez, L; Montoya, A; Galvez, R; Dado, D; Checa, R; Bello, A; Jansen, H; Fortin, A; Miro, G				Bosschaerts, T.; Hernandez, L.; Montoya, A.; Galvez, R.; Dado, D.; Checa, R.; Bello, A.; Jansen, H.; Fortin, A.; Miro, G.			Short oral therapy with oleylphosphocholine is safe and effective to treat Leishmania infantum canine leishmaniasis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bosschaerts, T.; Jansen, H.; Fortin, A.] Dafra Pharma, R&D, Turnhout, Belgium; [Hernandez, L.; Montoya, A.; Galvez, R.; Dado, D.; Checa, R.; Bello, A.; Miro, G.] Univ Complutense Madrid, Fac Vet, Dept Sanidad Anim, Madrid, Spain; [Fortin, A.] McGill Univ, Dept Biochem, Montreal, PQ, Canada			Galvez, Rosa/B-4859-2014; MONTOYA, ANA/C-1602-2018	Galvez, Rosa/0000-0001-9247-3136; MONTOYA, ANA/0000-0003-1911-8642				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		115	115						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000310					2019-03-26	
J	Rijal, S; Uranw, S; Bhattarai, N; Boelaert, M				Rijal, S.; Uranw, S.; Bhattarai, N.; Boelaert, M.			An outbreak investigation of Kala-azar in tribal community of eastern Nepal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Rijal, S.; Uranw, S.; Bhattarai, N.] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Boelaert, M.] Inst Trop Med, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		137	137						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000366					2019-03-26	
J	Maketa, V; Matangila, A; Muhindo, H; de Luz, RI; Lutumba, P; Van Geertruyden, JP				Maketa, V.; Matangila, A.; Muhindo, H.; de Luz, R. I.; Lutumba, P.; Van Geertruyden, J. P.			Correlation of malaria infection and anemia in children under 5 years of age without fever in the health zone of Mont NgafulaI a hyper endemic area for malaria in Kinshasa, democratic Republic of Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Maketa, V.; Matangila, A.; Muhindo, H.; Lutumba, P.] Univ Kinshasa Kinshasa, Dept Trop Med, DRC, Kinshasa, DEM REP CONGO; [de Luz, R. I.; Van Geertruyden, J. P.] Univ Antwerp, Int Hlth Unit, Fac Med, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		142	142						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000382					2019-03-26	
J	Manyando, C; Njunju, E; Alessandro, UD; Van Geertruyden, JP				Manyando, C.; Njunju, E.; Alessandro, U. D.; Van Geertruyden, J-P			Safety and efficacy of Co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Manyando, C.; Njunju, E.] Trop Dis Res Ctr, Ndola, Zambia; [Alessandro, U. D.] Inst Trop Med, B-2000 Antwerp, Belgium; [Alessandro, U. D.] MRC Unit, Fajara, Gambia; [Van Geertruyden, J-P] Univ Antwerp, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		143	143						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000385					2019-03-26	
J	Manyando, C; Njunju, E; Mwakazanga, D; Chongwe, G; Mkandawire, R; Alessandro, UD; Van Geertruyden, JP				Manyando, C.; Njunju, E.; Mwakazanga, D.; Chongwe, G.; Mkandawire, R.; Alessandro, U. D.; Van Geertruyden, J-P			The effect of daily Co-trimoxazole in pregnancy in an area of change in malaria epidemiology	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Manyando, C.; Njunju, E.; Mwakazanga, D.; Chongwe, G.] Trop Dis Res Ctr, Ndola, Zambia; [Mkandawire, R.] Dist Hlth Off, Choma, Zambia; [Alessandro, U. D.] Inst Trop Med, B-2000 Antwerp, Belgium; [Alessandro, U. D.] Malaria Res Council Unit, Fajara, Gambia; [Van Geertruyden, J-P] Univ Antwerp, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		146	147						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000397					2019-03-26	
J	Gies, S; Lompo, O; Coulibaly, SO; D'Alessandro, U				Gies, S.; Lompo, O.; Coulibaly, S. O.; D'Alessandro, U.			Placental malaria and seasonal patterns in rural Burkina Faso	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Gies, S.; D'Alessandro, U.] ITM, Antwerp, Belgium; [Gies, S.] IRSS, Bobo Dioulasso, Burkina Faso; [Lompo, O.; Coulibaly, S. O.] Univ Ouagadougou, UFR Sci Sant, Ouagadougou, Burkina Faso			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		149	149						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000405					2019-03-26	
J	Matangila, J; Ibalanky, A; da Luz, RL; Lutumba, P; Van Geertruyden, JP				Matangila, J.; Ibalanky, A.; da Luz, R. L.; Lutumba, P.; Van Geertruyden, J. -P.			Asymptomatic malaria and related anemia among pregnant women in Kinshasa, Democratic Republic of the Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Matangila, J.; Ibalanky, A.; Lutumba, P.] Univ Kinshasa, Dept Trop Med, Kinshasa, Zaire; [da Luz, R. L.; Van Geertruyden, J. -P.] Univ Antwerp, Dept Epidemiol, Int Hlth Unit, Antwerp, Belgium			Inocencio da Luz, Raquel/L-9676-2016; Van geertruyden, Jean-Pierre/K-6425-2014	Inocencio da Luz, Raquel/0000-0002-2870-0311; Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		149	149						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000404					2019-03-26	
J	Samadoulougou, S; Valea, I; Tinto, H; Kirakoya-Samadoulougou, F; D'Alessandro, U; Robert, A				Samadoulougou, S.; Valea, I.; Tinto, H.; Kirakoya-Samadoulougou, F.; D'Alessandro, U.; Robert, A.			Incidence of malaria infection and related risk factors among pregnant women in rural Burkina Faso	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Samadoulougou, S.; Kirakoya-Samadoulougou, F.; Robert, A.] Catholic Univ Louvain, FSP, IREC, B-1200 Brussels, Belgium; [Valea, I.; Tinto, H.] Ctr Muraz, Lab Parasitol & Entomol, Bobo Dioulasso, Burkina Faso; [Tinto, H.] Direct Reg Ouest, Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso; [D'Alessandro, U.] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium; [D'Alessandro, U.] MRC Unit, Fajara, Gambia			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		150	150						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000407					2019-03-26	
J	Gryseels, C; Uk, S; Erhart, A; Sochantha, T; D'Allessandro, U; Coosemans, M; Peeters, K				Gryseels, C.; Uk, S.; Erhart, A.; Sochantha, T.; D'Allessandro, U.; Coosemans, M.; Peeters, K.			Injections, cocktails and diviners: therapeutic flexibility in the context of malaria elimination and drug resistance in Northeast Cambodia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Gryseels, C.; Erhart, A.; D'Allessandro, U.; Coosemans, M.; Peeters, K.] Inst Trop Med, B-2000 Antwerp, Belgium; [Uk, S.; Sochantha, T.] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia; Malaria Res Council Unit, Fajara, Gambia								0	0	0	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		152	153						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000414					2019-03-26	
J	Gryseels, C; Uk, S; Sluydts, V; Durnez, L; Sochantha, T; Coosemans, M; Peeters, K				Gryseels, C.; Uk, S.; Sluydts, V.; Durnez, L.; Sochantha, T.; Coosemans, M.; Peeters, K.			Socio-cultural factors contributing to the use, non-use and alternative use of topical repellents by indigenous populations in Northeast Cambodia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Gryseels, C.; Sluydts, V.; Durnez, L.; Coosemans, M.; Peeters, K.] Inst Trop Med, B-2000 Antwerp, Belgium; [Uk, S.; Sochantha, T.] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia								0	0	0	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		153	153						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000415					2019-03-26	
J	Takem, E; Affara, M; Ngwa, A; Okebe, J; Ceesay, S; Jawara, M; Oriero, E; Nwakanma, D; Pinder, M; Clifford, C; Taal, M; Sowe, M; Suso, P; Mendy, A; Mbaye, A; Drakeley, C; D'Alessandro, U				Takem, E.; Affara, M.; Ngwa, A.; Okebe, J.; Ceesay, S.; Jawara, M.; Oriero, E.; Nwakanma, D.; Pinder, M.; Clifford, C.; Taal, M.; Sowe, M.; Suso, P.; Mendy, A.; Mbaye, A.; Drakeley, C.; D'Alessandro, U.			Detecting foci of malaria transmission with school surveys: a pilot study in the Gambia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Takem, E.; Affara, M.; Ngwa, A.; Okebe, J.; Ceesay, S.; Jawara, M.; Oriero, E.; Nwakanma, D.; Pinder, M.; D'Alessandro, U.] MRC Unit, Fajara, Gambia; [Clifford, C.] Univ Manchester, Manchester M13 9PL, Lancs, England; [Taal, M.; Sowe, M.; Suso, P.; Mendy, A.] Natl Publ Hlth Lab, Kotu, Gambia; [Mbaye, A.] Minist Basic & Secondary Educ, Banjul, Gambia; [Drakeley, C.] London Sch Hyg & Trop Med, London WC1, England; [D'Alessandro, U.] Inst Trop Med, B-2000 Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		153	153						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000416					2019-03-26	
J	Maketa, V; Matangila, A; Muhindo, H; de Luz, RI; Lutumba, P; Van Geertruyden, JP				Maketa, V.; Matangila, A.; Muhindo, H.; de Luz, R. I.; Lutumba, P.; Van Geertruyden, J. P.			Accuracy of MRDT on the diagnosis of malaria infection in children under 5 years without fever in the health zone of Mont NgafulaI, a hyper endemic area for malaria in Kinshasa, Democratic Republic of Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Maketa, V.; Matangila, A.; Muhindo, H.; Lutumba, P.; Van Geertruyden, J. P.] Univ Kinshasa Kinshasa, Dept Trop Med, Kinshasa, Zaire; [de Luz, R. I.] Univ Antwerp, Int Hlth Unit, Fac Med, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		156	156						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000425					2019-03-26	
J	Ilombe, G; Mavoko, HM; Maketa, V; Matangila, J; Kalabuanga, M; Luz, RD; Van Geertruyden, JP; Lutumba, P				Ilombe, G.; Mavoko, H. M.; Maketa, V.; Matangila, J.; Kalabuanga, M.; Luz, R. D.; Van Geertruyden, J. -P.; Lutumba, P.			Accuracy of the malaria rapid diagnostic test SD Bioline (R) in symptomatic children versus non symptomatic	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Ilombe, G.; Mavoko, H. M.; Maketa, V.; Matangila, J.; Kalabuanga, M.; Lutumba, P.] Univ Kinshasa, Dept Trop Med, Kinshasa, DEM REP CONGO; [Luz, R. D.; Van Geertruyden, J. -P.] Univ Antwerp, Int Hlth Unit, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		157	+						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000428					2019-03-26	
J	Mavoko, HM; Luz, RD; Maketa, V; Matangila, J; Lutumba, P; Van Geertruyden, JP; Deshpande, S				Mavoko, H. M.; Luz, R. D.; Maketa, V.; Matangila, J.; Lutumba, P.; Van Geertruyden, J. -P.; Deshpande, S.			SDC PlasmoDetect (R): a diagnosis based on the multi-angle light scattering spectroscopy for the presence of Plasmodium sp in red blood cells	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Mavoko, H. M.; Maketa, V.; Matangila, J.; Lutumba, P.] Univ Kinshasa, Dept Trop Med, Kinshasa, DEM REP CONGO; [Luz, R. D.; Van Geertruyden, J. -P.] Univ Antwerp, Int Hlth Unit, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		158	158						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000430					2019-03-26	
J	Kirakoya-Samadoulougou, F; Sanou, M; Kienou, K; Kiba-Koumare, A; Dahourou, H; Yacouba, NK; le Bakiono, F; Ouattara, S; Kabore, MI; Robert, A				Kirakoya-Samadoulougou, F.; Sanou, M.; Kienou, K.; Kiba-Koumare, A.; Dahourou, H.; Yacouba, N. K.; le Bakiono, F.; Ouattara, S.; Kabore, M. I.; Robert, A.			Current prevalence, incidence, and residual risk of infectious diseases markers among blood donors in Burkina Faso, 2008-2011	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Kirakoya-Samadoulougou, F.; le Bakiono, F.; Robert, A.] UCL, FSP, IREC, Pole Epidemiol & Biostat, Brussels, Belgium; [Sanou, M.; Kienou, K.; Kiba-Koumare, A.; Dahourou, H.; Yacouba, N. K.; Ouattara, S.; Kabore, M. I.] Ctr Natl Transfus Sanguine, Ouagadougou, Burkina Faso; [Sanou, M.] Univ Ouagadougou, Ouagadougou, Burkina Faso								0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		176	177						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000478					2019-03-26	
J	Philips, M; Cartier, N; Dethier, T; Akerfeldt, K; Bemelmans, M				Philips, M.; Cartier, N.; Dethier, T.; Akerfeldt, K.; Bemelmans, M.			Why do low HIV prevalence contexts in Africa often fail to reach effective ART coverage? Lessons learned on programmatic and delivery model adaptations in Guinea and Democratic Republic of Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Philips, M.; Akerfeldt, K.; Bemelmans, M.] MSF Brussels, Anal & Advocacy Unit, Brussels, Belgium; [Cartier, N.] MSF Conakry, Conakry, Guinea; [Dethier, T.] MSF Kinshasa, Kinshasa, DEM REP CONGO								0	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		177	+						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000481					2019-03-26	
J	Bakiono, F; Guiguimde, WPL; Samadoulougou, S; Kirakoya, F; Niamba, PA; Ouedraogo, L; Robert, A				Bakiono, F.; Guiguimde, W. P. L.; Samadoulougou, S.; Kirakoya, F.; Niamba, P. A.; Ouedraogo, L.; Robert, A.			Psychometric properties of Moore version of WHOQOL-HIV BREF in patients with HIV infection in Burkina Faso	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bakiono, F.; Samadoulougou, S.; Kirakoya, F.; Niamba, P. A.; Robert, A.] Catholic Univ Louvain, Fac Sante Publ, Inst Rech Expt & Clin IREC, Pole Epidemiol & Biostat, Louvain, Belgium; [Guiguimde, W. P. L.; Ouedraogo, L.] Univ Ouagadougou, Unite Format & Rech Sci Sante, Ouagadougou, Burkina Faso; Ctr Informat Conseil & Documentat VIH Sida & TB C, Ouagadougou, Burkina Faso								0	0	0	1	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		178	178						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000483					2019-03-26	
J	Duysburgh, E; Ye, M; Williams, A; Massawe, S; Temmerman, M				Duysburgh, E.; Ye, M.; Williams, A.; Massawe, S.; Temmerman, M.			Health workers' counselling practices on and women's awareness of pregnancy danger signs in selected rural health facilities in Burkina Faso, Ghana and Tanzania	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Duysburgh, E.; Temmerman, M.] Univ Ghent, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium; [Ye, M.] CRSN, Nouna, Burkina Faso; [Williams, A.] Navrongo Hlth Res Ctr, Navrongo, Ghana; [Massawe, S.] MUHAS, Sch Publ Hlth & Social Sci, Dept Epidemiol & Biostat, Dar Es Salaam, Tanzania								0	0	0	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		183	183						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000497					2019-03-26	
J	Maulet, N; Berthe, A; Macq, J				Maulet, N.; Berthe, A.; Macq, J.			Patients' experience of obstetric fistula care in Mali and Niger	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Maulet, N.; Macq, J.] Catholic Univ Louvain, Inst Hlth & Soc, Louvain, Belgium; [Berthe, A.] Ctr Muraz, Bobo Dioulasso, Burkina Faso								0	0	0	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		187	187						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000506					2019-03-26	
J	Maulet, N; Macq, J				Maulet, N.; Macq, J.			Deemed incurable obstetric fistula patients' care pathways in Mali and Niger: a mixed methods research	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Maulet, N.; Macq, J.] Catholic Univ Louvain, Louvain, Belgium								0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		187	188						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000508					2019-03-26	
J	Maulet, N; Macq, J				Maulet, N.; Macq, J.			Living in obstetric fistula repair centres within general hospitals in Mali and Niger	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Maulet, N.; Macq, J.] Catholic Univ Louvain, Louvain, Belgium								0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		188	188						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000509					2019-03-26	
J	Hoang, T; Van, PNN; Le, NDN; The, DN; Gillerot, Y; Reding, R; Robert, A				Hoang, T.; Van, P. N. N.; Le, N. D. N.; The, D. N.; Gillerot, Y.; Reding, R.; Robert, A.			Determinants and causes of neonatal mortality: a prospective population-based study in rural southern of Vietnam	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Hoang, T.; Van, P. N. N.; Le, N. D. N.; Gillerot, Y.; Reding, R.; Robert, A.] Catholic Univ Louvain, Louvain, Belgium; [Hoang, T.; Van, P. N. N.; The, D. N.] Pham Ngoc Thach Univ Med, Ho Chi Minh City, Vietnam; [Le, N. D. N.] Childrens Hosp 2, Ho Chi Minh City, Vietnam								0	0	0	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		189	189						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000512					2019-03-26	
J	Van, PNN; Kim, TH; Hoang, T				Van, P. N. N.; Kim, T. Hong; Hoang, T.			Physical activiy and overweight among adolescents in Ho Chi Minh City, Vietnam	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Van, P. N. N.; Kim, T. Hong; Hoang, T.] Catholic Univ Louvain, Louvain, Belgium								0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		191	191						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000517					2019-03-26	
J	Smith, KW; Lachat, C; Alberts, M; Van Geertruyden, JP				Smith, K. W.; Lachat, C.; Alberts, M.; Van Geertruyden, J. -P.			Stunting, overweight in young children occur simultaneously in rural South Africa, and are related to quality of diet	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Smith, K. W.; Van Geertruyden, J. -P.] Univ Antwerp, Antwerp, Belgium; [Lachat, C.] Univ Ghent, B-9000 Ghent, Belgium; [Alberts, M.] Univ Limpopo, Sovenga, South Africa			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		194	194						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000523					2019-03-26	
J	Bottieau, E; Mukendi, D; Kalo, JR; Barbe, B; Gillet, P; Yansouni, C; Winkler, A; Jacobs, J; Chappuis, F; Lutumba, P; Boelaert, M				Bottieau, E.; Mukendi, D.; Kalo, J. -R.; Barbe, B.; Gillet, P.; Yansouni, C.; Winkler, A.; Jacobs, J.; Chappuis, F.; Lutumba, P.; Boelaert, M.			Etiology and outcome of neurological disorders in the Rural Hospital of Mosango, Province of Bandundu, Democratic Republic of Congo: preliminary results	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bottieau, E.; Barbe, B.; Gillet, P.; Jacobs, J.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Mukendi, D.; Kalo, J. -R.; Lutumba, P.] Inst Natl Rech Biomed, Kinshasa, Zaire; [Yansouni, C.] McGill Univ, Ctr Hlth, Ctr Trop Dis, Montreal, PQ, Canada; [Winkler, A.] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-80290 Munich, Germany; [Chappuis, F.] Univ Hosp Geneva, Div Int & Humanitarian Med, Geneva, Switzerland; [Boelaert, M.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		197	198						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000531					2019-03-26	
J	Rodriguez-Salva, A; De Vos, P; Diaz-Pinera, A; Garcia-Roche, R; Guerra-Chang, M; Balcindes-Acosta, S; Jova-Morel, R; Janssens, K; Vanlerberghe, V; Bonet-Gorbea, M; Van der Stuyft, P				Rodriguez-Salva, A.; De Vos, P.; Diaz-Pinera, A.; Garcia-Roche, R.; Guerra-Chang, M.; Balcindes-Acosta, S.; Jova-Morel, R.; Janssens, K.; Vanlerberghe, V.; Bonet-Gorbea, M.; Van der Stuyft, P.			Utilization of curative care and health service entry point preferences in Centro Habana, Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Rodriguez-Salva, A.; Diaz-Pinera, A.; Garcia-Roche, R.; Balcindes-Acosta, S.; Jova-Morel, R.; Bonet-Gorbea, M.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; [De Vos, P.; Janssens, K.; Vanlerberghe, V.; Van der Stuyft, P.] Inst Trop Med, B-2000 Antwerp, Belgium; [Guerra-Chang, M.] Ctr Habana, Municipal Hlth Direct, Havana, Cuba; [Van der Stuyft, P.] Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium			De Vos, Pol/D-3370-2009					0	0	0	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		201	201						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000540					2019-03-26	
J	Philips, M; Weiggheleire, A; Gerard, S				Philips, M.; Weiggheleire, A.; Gerard, S.			Repeated outbreaks of infectious diseases reveal need to create improved response capacity of the health system in Democratic Republic of Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Philips, M.; Gerard, S.] MSF Brussels, Brussels, Belgium; [Weiggheleire, A.] MSF Kinshasa, Kinshasa, Zaire								0	0	0	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2013	18			1	SI		204	204						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	213BS	WOS:000324029000549					2019-03-26	
J	Biselele, T; Naulaers, G; Muntu, PB; Nkidiaka, E; Kapepela, M; Mavinga, L; Tady, B				Biselele, Therese; Naulaers, Gunnar; Muntu, Paulo Bunga; Nkidiaka, Emmanuel; Kapepela, Marie; Mavinga, Laetitia; Tady, Bruno			A Descriptive Study of Perinatal Asphyxia at the University Hospital of Kinshasa (Democratic Republic Of Congo)	JOURNAL OF TROPICAL PEDIATRICS			English	Article						perinatal asphyxia; hypoxic-ischemic encephalopathy; Congo; neonate	INTRAUTERINE GROWTH RESTRICTION; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; RANDOMIZED CONTROLLED-TRIAL; INDUCED CEREBRAL APOPTOSIS; BIRTH ASPHYXIA; NEONATAL ENCEPHALOPATHY; NEWBORN-INFANTS; HYPOTHERMIA; AFRICA; DEATHS	Objective: The purpose of this study was to determine the incidence, the etiology and the HIE score at the first day in term and near-term newborns with perinatal asphyxia at the University Hospital of Kinshasa. Methods: 50 term and near-term neonates with perinatal asphyxia were studied prospectively after they were admitted in neonatal intensive care from November 2009 to January 2011. For each patient admitted the perinatal data were collected. Clinical assessment was performed by the Sarnat grading and the Thompson score within twenty-four hours. Medcalc (R) was used for statistics. Results: 50 babies were scored. The median maternal age was 31 years. In 22% of the mothers preeclampsia was diagnosed. Urogenital infection, IUGR were other prenatal diagnoses. Median Apgar score was 4 after 1 minute, 5 after 5 minutes and 6 after 10 minutes. Sarnat grade 1 was seen in 16 patients, Sarnat grade 2 in 20 patients and grade 3 in 8. Thompson score in the first 24 hours was more than 7 in 60% of the patients. A good correlation was found between the Thompson score and the Sarnat grade (r: 0,77; p < 0,0001). 14 of the 50 babies died. Both Sarnat and Thompson score correlated significantly with mortality. Conclusion: The incidence of perinatal asphyxia at the University Hospital of Kinshasa remains high and the majority of patients had a severe HIE.	[Biselele, Therese; Muntu, Paulo Bunga; Nkidiaka, Emmanuel; Kapepela, Marie; Mavinga, Laetitia; Tady, Bruno] Univ Hosp Kinshasa, Dept Pediat, Neonatal Unit, Kinshasa, Zaire; [Naulaers, Gunnar] Katholieke Univ Leuven, Dept Growth & Regenerat, Louvain, Belgium	Naulaers, G (reprint author), Katholieke Univ Leuven Hosp, Neonatal Intens Care Unit, Herestr 49, B-3000 Louvain, Belgium.	gunnar.naulaers@uzleuven.be			UNIFOS (Universitair Fonds voor Ontwikkelingssamenwerking) KU Leuven	Therese Biselele is partly funded by UNIFOS (Universitair Fonds voor Ontwikkelingssamenwerking) KU Leuven.	Azzopardi D, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-17; Badr LK, 2006, J PERINAT NEONAT NUR, V20, P163, DOI 10.1097/00005237-200604000-00011; Burke C, 2006, BRAIN RES, V1098, P19, DOI 10.1016/j.brainres.2006.04.129; Chen Zi-Li, 2009, Zhongguo Dang Dai Er Ke Za Zhi, V11, P161; Cisse MB, 1997, BAM MAL 2 C ANN APAN; Compagnoni G, 2002, BIOL NEONATE, V82, P222, DOI 10.1159/000065890; de Guevara MTPV, 2006, REV NEUROLOGIA, V43, P3, DOI 10.33588/rn.4301.2004016; Ducarme G, 2012, GYNECOL OBSTET FERTI, V40, P642, DOI 10.1016/j.gyobfe.2012.09.002; Girard S, 2009, PEDIATR NEUROL, V40, P168, DOI 10.1016/j.pediatrneurol.2008.09.016; Gonzales de Dios J, 1996, REV NEUROL, V24, P812; Hagberg B, 2001, ACTA PAEDIATR, V90, P271, DOI 10.1080/080352501300067532; Haram K, 2006, INT J GYNECOL OBSTET, V93, P5, DOI 10.1016/j.ijgo.2005.11.011; Horn AR, 2012, J TROP PEDIATRICS, V58, P236, DOI 10.1093/tropej/fmr069; Jacobs S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub2; Kadhim Hazim, 2002, Eur J Paediatr Neurol, V6, P139, DOI 10.1053/ejpn.2002.0581; KINOTI SN, 1993, E AFR MED J, V70, P422; Klingenberg C, 2003, ANN TROP PAEDIATR, V23, P293, DOI 10.1179/027249303225007806; Kumar S, 2010, EARLY HUM DEV, V86, P339, DOI 10.1016/j.earlhumdev.2010.05.009; Lane RH, 2001, BRAIN RES, V895, P186, DOI 10.1016/S0006-8993(01)02074-1; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lubambu NP, 1999, SOUFFRANCES FAETALES; Mesples B, 2005, ACTA PAEDIATR, V94, P185, DOI 10.1080/08035250410022378; Mustafa R, 2012, J PREGNANCY, V2012, DOI [10.1155/2012/105918, DOI 10.1155/2012/105918]; Ngimbi D., 2001, DEVENIR SOMATIQUE PS; Nkidiaka DE, 2006, SEM NEON CLIN U KINS; Oswyn G., 2000, Papua New Guinea Medical Journal, V43, P110; Robertson NJ, 2008, LANCET, V372, P801, DOI 10.1016/S0140-6736(08)61329-X; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Schneider H, 2001, Z GEBURTSH NEONATOL, V205, P205, DOI 10.1055/s-2001-19051; Thompson CM, 1997, ACTA PAEDIATR, V86, P757, DOI 10.1111/j.1651-2227.1997.tb08581.x; THORNBERG E, 1995, ACTA PAEDIATR, V84, P927, DOI 10.1111/j.1651-2227.1995.tb13794.x; Velaphi S, 2007, ANN TROP PAEDIATR, V27, P99, DOI 10.1179/146532807X192462; Wachtel EV, 2011, CURR PROB PEDIATR AD, V41, P132, DOI 10.1016/j.cppeds.2010.12.002; Wayenberg JL, 1998, ARCH PEDIATRIE, V5, P1065, DOI 10.1016/S0929-693X(99)80002-5; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839	35	7	7	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0142-6338	1465-3664		J TROP PEDIATRICS	J. Trop. Pediatr.	AUG	2013	59	4					274	279		10.1093/tropej/fmt011				6	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	194XE	WOS:000322665200004	23486392	Bronze			2019-03-26	
J	Cnops, L; Soentjens, P; Clerinx, J; Van Esbroeck, M				Cnops, Lieselotte; Soentjens, Patrick; Clerinx, Jan; Van Esbroeck, Marjan			A Schistosoma haematobium-Specific Real-Time PCR for Diagnosis of Urogenital Schistosomiasis in Serum Samples of International Travelers and Migrants	PLOS NEGLECTED TROPICAL DISEASES			English	Article							POLYMERASE-CHAIN-REACTION; URINE SAMPLES; IMPORTED SCHISTOSOMIASIS; PARASITE DNA; INFECTION; MANSONI; SURVEILLANCE; ASSAY; TOOL; MICROBIOLOGY	Background: Diagnosis of urogenital schistosomiasis by microscopy and serological tests may be elusive in travelers due to low egg load and the absence of seroconversion upon arrival. There is need for a more sensitive diagnostic test. Therefore, we developed a real-time PCR targeting the Schistosoma haematobium-specific Dra1 sequence. Methodology/Principal Findings: The PCR was evaluated on urine (n = 111), stool (n = 84) and serum samples (n = 135), and one biopsy from travelers and migrants with confirmed or suspected schistosomiasis. PCR revealed a positive result in 7/7 urine samples, 11/11 stool samples and 1/1 biopsy containing S. haematobium eggs as demonstrated by microscopy and in 22/23 serum samples from patients with a parasitological confirmed S. haematobium infection. S. haematobium DNA was additionally detected by PCR in 7 urine, 3 stool and 5 serum samples of patients suspected of having schistosomiasis without egg excretion in urine and feces. None of these suspected patients demonstrated other parasitic infections except one with Blastocystis hominis and Entamoeba cyst in a fecal sample. The PCR was negative in all stool samples containing S. mansoni eggs (n = 21) and in all serum samples of patients with a microscopically confirmed S. mansoni (n = 22), Ascaris lumbricoides (n = 1), Ancylostomidae (n = 1), Strongyloides stercoralis (n = 1) or Trichuris trichuria infection (n = 1). The PCR demonstrated a high specificity, reproducibility and analytical sensitivity (0.5 eggs per gram of feces). Conclusion/Significance: The real-time PCR targeting the Dra1 sequence for S. haematobium-specific detection in urine, feces, and particularly serum, is a promising tool to confirm the diagnosis, also during the acute phase of urogenital schistosomiasis.	[Cnops, Lieselotte; Soentjens, Patrick; Clerinx, Jan; Van Esbroeck, Marjan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium	Cnops, L (reprint author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	lcnops@itg.be			Ministry of Health	The ITM receives funding from the Ministry of Health for its tasks as reference laboratory for the diagnosis and treatment of infectious and tropical diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AZAR J. E., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P562, DOI 10.1016/0035-9203(58)90105-6; Bischoff FZ, 2005, HUM REPROD UPDATE, V11, P59, DOI 10.1093/humupd/dmh053; Clerinx J, 2011, J TRAVEL MED, V18, P367, DOI 10.1111/j.1708-8305.2011.00552.x; Clerinx J, 2011, TRAVEL MED INFECT DI, V9, P6, DOI 10.1016/j.tmaid.2010.11.002; Cnops L, 2012, TROP MED INT HEALTH, V17, P1208, DOI 10.1111/j.1365-3156.2012.03060.x; Cnops L, 2010, J MICROBIOL METH, V80, P310, DOI 10.1016/j.mimet.2010.01.001; Doenhoff MJ, 2004, TRENDS PARASITOL, V20, P35, DOI 10.1016/j.pt.2003.10.019; Driscoll AJ, 2005, PARASITOLOGY, V131, P497, DOI 10.1017/S0031182005007961; Emery AM, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-185; Enk MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038947; Espy MJ, 2006, CLIN MICROBIOL REV, V19, P165, DOI 10.1128/CMR.19.1.165-256.2006; Grobusch MP, 2003, J TRAVEL MED, V10, P164; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Hamburger J, 2004, AM J TROP MED HYG, V71, P765, DOI 10.4269/ajtmh.2004.71.765; Hamburger J, 2001, AM J TROP MED HYG, V65, P907, DOI 10.4269/ajtmh.2001.65.907; HAMBURGER J, 1991, MOL BIOCHEM PARASIT, V44, P73, DOI 10.1016/0166-6851(91)90222-R; Hussein HM, 2012, PARASITOL RES, V111, P475, DOI 10.1007/s00436-012-2822-0; Ibironke OA, 2011, AM J TROP MED HYG, V84, P998, DOI 10.4269/ajtmh.2011.10-0691; Jaureguiberry S, 2009, CLIN INFECT DIS, V48, P1163, DOI 10.1086/597497; Jen J, 2000, ANN NY ACAD SCI, V906, P8; KING CH, 2001, SCHISTOSOMIASIS, P265; Kjetland EF, 2012, TRENDS PARASITOL, V28, P58, DOI 10.1016/j.pt.2011.10.008; Laughlin E, 1949, J AM MED ASS, V15, P997; Mackay IM, 2004, CLIN MICROBIOL INFEC, V10, P190, DOI 10.1111/j.1198-743X.2004.00722.x; Melkonyan HS, 2008, ANN NY ACAD SCI, V1137, P73, DOI 10.1196/annals.1448.015; Mharakurwa S, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-103; Nicolls DJ, 2008, AM J TROP MED HYG, V79, P729, DOI 10.4269/ajtmh.2008.79.729; Obeng BB, 2008, ANN TROP MED PARASIT, V102, P625, DOI 10.1179/136485908X337490; Pontes LA, 2002, AM J TROP MED HYG, V66, P157, DOI 10.4269/ajtmh.2002.66.157; Rabello A, 2002, MEM I OSWALDO CRUZ, V97, P171, DOI 10.1590/S0074-02762002000900033; Sandoval N, 2006, PARASITOLOGY, V133, P581, DOI 10.1017/S0031182006000898; ten Hove RJ, 2008, T ROY SOC TROP MED H, V102, P179, DOI 10.1016/j.trstmh.2007.10.011; van Delft F, 2007, NETH J MED, V65, P304; van Gool T, 2002, J CLIN MICROBIOL, V40, P3432, DOI 10.1128/JCM.40.9.3432-3437.2002; Van Hellemond JJ, 2006, INT J PARASITOL, V36, P691, DOI 10.1016/j.ijpara.2006.01.007; van Lieshout L, 2000, ACTA TROP, V77, P69, DOI 10.1016/S0001-706X(00)00115-7; Whitty CJM, 2000, TROP MED INT HEALTH, V5, P818, DOI 10.1046/j.1365-3156.2000.00642.x; Wichmann D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000422; World Health Organization, 2002, WHO TECHN REP SER; Xu J, 2010, INT J PARASITOL, V40, P327, DOI 10.1016/j.ijpara.2009.08.010	40	28	29	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	AUG	2013	7	8							e2413	10.1371/journal.pntd.0002413				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	211WE	WOS:000323941500060	24009791	DOAJ Gold, Green Published			2019-03-26	
J	Sumaye, RD; Geubbels, E; Mbeyela, E; Berkvens, D				Sumaye, Robert D.; Geubbels, Eveline; Mbeyela, Edgar; Berkvens, Dirk			Inter-epidemic Transmission of Rift Valley Fever in Livestock in the Kilombero River Valley, Tanzania: A Cross-Sectional Survey	PLOS NEGLECTED TROPICAL DISEASES			English	Article							LINKED-IMMUNOSORBENT-ASSAY; SOUTH-AFRICA; DOMESTIC RUMINANTS; NORTHEASTERN KENYA; SAUDI-ARABIA; VIRUS; OUTBREAK; PREVALENCE; ANTIBODY; SENEGAL	Background: In recent years, evidence of Rift Valley fever (RVF) transmission during inter-epidemic periods in parts of Africa has increasingly been reported. The inter-epidemic transmissions generally pass undetected where there is no surveillance in the livestock or human populations. We studied the presence of and the determinants for inter-epidemic RVF transmission in an area experiencing annual flooding in southern Tanzania. Methodology: A cross-sectional sero-survey was conducted in randomly selected cattle, sheep and goats in the Kilombero river valley from May to August 2011, approximately four years after the 2006/07 RVF outbreak in Tanzania. The exposure status to RVF virus (RVFV) was determined using two commercial ELISA kits, detecting IgM and IgG antibodies in serum. Information about determinants was obtained through structured interviews with herd owners. Findings: An overall seroprevalence of 11.3% (n = 1680) was recorded; 5.5% in animals born after the 2006/07 RVF outbreak and 22.7% in animals present during the outbreak. There was a linear increase in prevalence in the post-epidemic annual cohorts. Nine inhibition-ELISA positive samples were also positive for RVFV IgM antibodies indicating a recent infection. The spatial distribution of seroprevalence exhibited a few hotspots. The sex difference in seroprevalence in animals born after the previous epidemic was not significant (6.1% vs. 4.6% for females and males respectively, p = 0.158) whereas it was significant in animals present during the outbreak (26.0% vs. 7.8% for females and males respectively, p<0.001). Animals living >15 km from the flood plain were more likely to have antibodies than those living,5 km (OR 1.92; 95% CI 1.04-3.56). Species, breed, herd composition, grazing practices and altitude were not associated with seropositivity. Conclusion: These findings indicate post-epidemic transmission of RVFV in the study area. The linear increase in seroprevalence in the post-epidemic annual cohorts implies a constant exposure and presence of active foci transmission preceding the survey.	[Sumaye, Robert D.; Geubbels, Eveline; Mbeyela, Edgar] Ifakara Hlth Inst, Ifakara, Tanzania; [Sumaye, Robert D.] Univ Liege, Fac Vet Med, Dept Infect & Parasit Dis, Liege, Belgium; [Sumaye, Robert D.; Berkvens, Dirk] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium	Sumaye, RD (reprint author), Ifakara Hlth Inst, Ifakara, Tanzania.	rsumaye@ihi.or.tz			Directorate General for Development Cooperation (DGDC), Belgium, through Institute of Tropical Medicine, Antwerp; Hassan Mshinda Fellowship of the Liverpool School of Tropical Medicine (LSTM), UK; Ifakara Health Institute (IHI), Tanzania	This work was funded by the generous support through PhD scholarship awarded to RDS by Directorate General for Development Cooperation (DGDC), Belgium, through Institute of Tropical Medicine, Antwerp. Part of the research work was also supported by Hassan Mshinda Fellowship of the Liverpool School of Tropical Medicine (LSTM), UK and Ifakara Health Institute (IHI), Tanzania. The funders of this study had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AbuElyazeed R, 1996, B WORLD HEALTH ORGAN, V74, P155; Al-Hazmi M, 2003, CLIN INFECT DIS, V36, P245, DOI 10.1086/345671; Anderson EC, 1998, EPIDEMIOL INFECT, V121, P441, DOI 10.1017/S0950268898001289; Anyamba A, 2009, P NATL ACAD SCI USA, V106, P955, DOI 10.1073/pnas.0806490106; Archer BN, 2011, SAMJ S AFR MED J, V101, P263, DOI 10.7196/SAMJ.4544; Armstrong-Schellenberg J, 2002, POPULATION HLTH DEV, V1, P159; Balkhy HH, 2003, INT J ANTIMICROB AG, V21, P153, DOI 10.1016/S0924-8579(02)00295-9; Chevalier V, 2009, TRANSBOUND EMERG DIS, V56, P372, DOI 10.1111/j.1865-1682.2009.01083.x; Chevalier V, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001423; Daubney R, 1931, J PATHOL BACTERIOL, V34, P545, DOI 10.1002/path.1700340418; Davies F Glyn, 2006, Vet Ital, V42, P31; DAVIES FG, 1985, B WORLD HEALTH ORGAN, V63, P941; Evans A, 2008, EPIDEMIOL INFECT, V136, P1261, DOI 10.1017/S0950268807009806; Geering WA, 2002, FAO ANIMAL HLTH MANU, V15, P7; Gora D, 2000, MICROBES INFECT, V2, P343, DOI 10.1016/S1286-4579(00)00334-8; Hay SI, 2000, P NATL ACAD SCI USA, V97, P9335, DOI 10.1073/pnas.97.16.9335; Heinrich N, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001557; Hetzel MW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-7; HOOGSTRAAL H, 1979, T ROY SOC TROP MED H, V73, P624, DOI 10.1016/0035-9203(79)90005-1; Hussein N. A., 1985, Revue Scientifique et Technique, Office Internationale des Epizooties, V4, P325; ILCA, 1990, LIV SYST RES MAN; Jeanmaire EM, 2011, VECTOR-BORNE ZOONOT, V11, P395, DOI 10.1089/vbz.2009.0249; Killeen GF, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-121; Kitchen S. F., 1934, AM J TROP MED, V14, P547; LaBeaud AD, 2008, EMERG INFECT DIS, V14, P1240, DOI 10.3201/eid1408.080082; LaBeaud AD, 2007, AM J TROP MED HYG, V76, P795, DOI 10.4269/ajtmh.2007.76.795; LaBeaud AD, 2011, AM J TROP MED HYG, V84, P641, DOI 10.4269/ajtmh.2011.10-0187; LINTHICUM KJ, 1985, J HYG-CAMBRIDGE, V95, P197, DOI 10.1017/S0022172400062434; Madani TA, 2003, CLIN INFECT DIS, V37, P1084, DOI 10.1086/378747; MCINTOSH BM, 1980, S AFR MED J, V58, P803; Mohamed M, 2010, AM J TROP MED HYG, V83, P22, DOI 10.4269/ajtmh.2010.09-0318; MORITA C, 1988, J VET MED B, V35, P157, DOI 10.1111/j.1439-0450.1988.tb00482.x; Morrill JC, 2011, J INFECT DIS, V204, P617, DOI 10.1093/infdis/jir354; MORVAN J, 1992, T ROY SOC TROP MED H, V86, P675, DOI 10.1016/0035-9203(92)90187-H; MULLER R, 1995, AM J TROP MED HYG, V53, P405, DOI 10.4269/ajtmh.1995.53.405; Munyua P, 2010, AM J TROP MED HYG, V83, P58, DOI [10.4269/ajtmh.2010.09-0292, 10.4269/ajtmh.2010.09.0292]; Narh-Bana SA, 2012, TROP MED INT HEALTH, V17, P1396, DOI 10.1111/j.1365-3156.2012.03080.x; Nfon CK, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001623; Ogoma SB, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000773; Olaleye OD, 1996, REV SCI TECH OIE, V15, P937, DOI 10.20506/rst.15.3.966; Paweska JT, 2005, J VIROL METHODS, V127, P10, DOI 10.1016/j.jviromet.2005.02.008; Paweska JT, 2003, J VIROL METHODS, V113, P103, DOI 10.1016/S0166-0934(03)00228-3; Pepin M, 2010, VET RES, V41, DOI 10.1051/vetres/2010033; Pourrut X, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000763; Ringot D, 2004, EMERG INFECT DIS, V10, P945, DOI 10.3201/eid1005.030621; SMITHBURN KC, 1949, J IMMUNOL, V62, P213; Soumare B, 2007, VET MICROBIOL, V121, P249, DOI 10.1016/j.vetmic.2006.12.017; Swanepoel R., 2004, INFECT DIS LIVESTOCK, V2, P1037; SWANEPOEL R, 1981, CONTRIB EPIDEMIOL BI, V3, P83; Swanepoel R, 2011, OXFORD TXB ZOONOSES, P423; THIONGANE Y, 1991, RES VIROLOGY, V142, P67, DOI 10.1016/0923-2516(91)90029-3; Weaver SC, 2004, NAT REV MICROBIOL, V2, P789, DOI 10.1038/nrmicro1006; WHO, 2006, WKLY EPIDEMIOL REC, V82, P169; WHO, 2009, WHOHSEGARBDP20092; WHO, 2007, RIFT VALL FEV KEN; WILSON ML, 1994, AM J TROP MED HYG, V50, P663, DOI 10.4269/ajtmh.1994.50.663; Woods CW, 2002, EMERG INFECT DIS, V8, P138, DOI 10.3201/eid0802.010023; Zeller HG, 1997, AM J TROP MED HYG, V56, P265, DOI 10.4269/ajtmh.1997.56.265	58	34	38	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	AUG	2013	7	8							e2356	10.1371/journal.pntd.0002356				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	211WE	WOS:000323941500021	23951376	DOAJ Gold, Green Published			2019-03-26	
J	Keugoung, B; Kongnyu, ET; Meli, J; Criel, B				Keugoung, Basile; Kongnyu, Emmanuel Tabah; Meli, Jean; Criel, Bart			Profile of suicide in rural Cameroon: are health systems doing enough?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Cameroon; developing countries; health district; mental health; Sub-Saharan Africa; suicide	MIDDLE-INCOME COUNTRIES; MENTAL-HEALTH; SOUTH-AFRICA; DISORDERS; PREVENTION; PREVALENCE; INTERFACE; MORTALITY; LIFETIME	ObjectivesTo describe the characteristics of suicide and assess the capacity of health services at the district level in Cameroon to deliver quality mental health care. MethodsThe study covered the period between 1999 and 2008 and was carried out in Guidiguis health district which had a population of 145700 inhabitants in 2008. Data collection was based on psychological autopsy methods. To collect data, we used documentary review of medical archives, semi-structured interviews of relatives of suicide completers, a focus group discussion of health committee members and a survey to consulting nurses working at the primary health care level. ResultsForty-seven suicides were recorded from 1999 to 2008: 37 (78.7%) males and 10 (21.3%) females, yielding rates of reported suicides that ranged from 0.89 to 6.54 per 100000 inhabitants. The most frequently used suicide method was the ingestion of toxic agricultural chemicals (in 76.6% of cases). According to the relatives, the suicides were due to an ongoing chronic illness (31.9%), sexual and marital conflicts (25.5%), witchcraft (14.9%), financial problems (8.5%) or unknown cause (25.5%). In 25 (53.2%) cases, suicide victims exhibited symptoms suggestive of a mental disorder but only six of the suicide committers who presented behavioural symptoms sought health care. Only two of the 15 consulting nurses were able to cite at least three symptoms of depression and were aware that depression can lead to suicide. All of the nurses acknowledged that they had never received any specific training or supervision in mental health care. ConclusionsSuicides are not a rare event in rural settings in Cameroon. The health district capacity to provide quality mental care is almost insignificant. The integration of minimal mental health care services at the community and primary health care levels should be considered a priority in sub-Saharan Africa.	[Keugoung, Basile] Minist Publ Hlth, Yaounde, Cameroon; [Keugoung, Basile] Res Educ & Hlth Dev Grp GARES Falaise, Dschang, Cameroon; [Keugoung, Basile; Criel, Bart] Inst Trop Med, B-2000 Antwerp, Belgium; [Kongnyu, Emmanuel Tabah] Guidiguis Hlth Dist, Guidiguis, Cameroon; [Meli, Jean] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon	Keugoung, B (reprint author), Res Educ & Hlth Dev Grp GARES Falaise, POB 31, Yaounde 694, Cameroon.	bkeugoung@itg.be					Ajdacic-Gross V, 2008, B WORLD HEALTH ORGAN, V86, P726, DOI 10.2471/BLT.07.043489; Bekri A. A., 1999, ETHIOP J HEALTH DEV, V13, P247; Brigham J, 2003, US PUBL HLTH SERV C, P1; Bruckner TA, 2011, B WORLD HEALTH ORGAN, V89, P184, DOI 10.2471/BLT.10.082784; Desjarlais  R, 1995, WORLD MENTAL HLTH PR; Dong X, 2001, Int J Occup Environ Health, V7, P333; Dzamalala CP, 2005, J CLIN FORENSIC MED, V13, P65; Gask L, 2011, BRIT J PSYCHIAT, V198, P3, DOI 10.1192/bjp.bp.109.075382; Gunnell D, 2003, INT J EPIDEMIOL, V32, P902, DOI 10.1093/ije/dyg307; Gureje O, 2006, BRIT J PSYCHIAT, V188, P465, DOI 10.1192/bjp.188.5.465; Gureje O, 2000, B WORLD HEALTH ORGAN, V78, P475; [Inserm INSERM Collective Expertise Centre], 2004, INS COLL EXP REP; JACOBS D, 1995, B AM ACAD PSYCH LAW, V23, P165; Keugoung B, 2011, TROP MED INT HEALTH, V16, P478, DOI 10.1111/j.1365-3156.2010.02716.x; Khan MM, 2005, J ROY SOC MED, V98, P459, DOI 10.1258/jrsm.98.10.459; MINSANTE, 2002, STRAT SECTR SANT 200, P1; National Conference of State Legislatures, 2005, STAT HLTH LAWM DIG 5; Nwosu S O, 2001, West Afr J Med, V20, P259; Okasha Ahmed, 2002, World Psychiatry, V1, P32; Patel V, 2007, LANCET, V370, P991, DOI 10.1016/S01406736(07)61240-9; Patel V, 2012, LANCET, V379, P2343, DOI 10.1016/S0140-6736(12)60606-0; Petersen I, 2009, HEALTH POLICY PLANN, V24, P140, DOI 10.1093/heapol/czn049; Reza A, 2001, Inj Prev, V7, P104, DOI 10.1136/ip.7.2.104; Richard A, 2002, PSYCHIAT TIMES, VXIX; Simon GE, 2007, AM J PSYCHIAT, V164, P1029, DOI 10.1176/appi.ajp.164.7.1029; Stein DJ, 2008, BRIT J PSYCHIAT, V192, P112, DOI 10.1192/bjp.bp.106.029280; Ventevogel P, 2006, INTERVENTION, V4, P272, DOI 10.1097/WTF.0b013e328011497b; Vijayakumar L, 2004, 27DIS CONTR PRIOR PR; WHO, 2008, SCAL CAR MENT NEUR S; WHO, 2004, WORLD SUIC PREV DAY; WHO, 2000, WHO TECHN REP SER; World Health Organization, 2008, INT MENT HLTH PRIM C; World Health Organization, 2007, MENT HLTH POL PLANN; World Health Organization, 2001, WORLD HLTH REP 2001; World Health Organization, 2008, GLOB BURD DIS 2004 U	35	4	4	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2013	18	8					985	992		10.1111/tmi.12140				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	179FB	WOS:000321504000010	23786446	Bronze			2019-03-26	
J	Tayler-Smith, K; Zachariah, R; Manzi, M; Van den Boogaard, W; Nyandwi, G; Reid, T; De Plecker, E; Lambert, V; Nicolai, M; Goetghebuer, S; Christiaens, B; Ndelema, B; Kabangu, A; Manirampa, J; Harries, AD				Tayler-Smith, K.; Zachariah, R.; Manzi, M.; Van den Boogaard, W.; Nyandwi, G.; Reid, T.; De Plecker, E.; Lambert, V.; Nicolai, M.; Goetghebuer, S.; Christiaens, B.; Ndelema, B.; Kabangu, A.; Manirampa, J.; Harries, A. D.			An ambulance referral network improves access to emergency obstetric and neonatal care in a district of rural Burundi with high maternal mortality	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						ambulance; referral; emergency obstetric care; Burundi	SURVIVAL	ObjectivesIn 2006, Medecins sans Frontieres (MSF) established an emergency obstetric and neonatal care (EmONC) referral facility linked to an ambulance referral system for the transfer of women with obstetric complications from peripheral maternity units in Kabezi district, rural Burundi. This study aimed to (i) describe the communication and ambulance service together with the cost; (ii) examine the association between referral times and maternal and early neonatal deaths; and (iii) assess the impact of the referral service on coverage of complicated obstetric cases and caesarean sections. MethodsData were collected for the period January to December 2011, using ambulance log books, patient registers and logistics records. ResultsIn 2011, there were 1478 ambulance call-outs. The median referral time (time from maternity calling for an ambulance to the time the patient arrived at the MSF referral facility) was 78min (interquartile range, 52-130min). The total annual cost of the referral system (comprising 1.6 ambulances linked with nine maternity units) was Euro 85586 (Euro 61/obstetric case transferred or Euro 0.43/capita/year). Referral times exceeding 3h were associated with a significantly higher risk of early neonatal deaths (OR, 1.9; 95% CI, 1.1-3.2). MSF coverage of complicated obstetric cases and caesarean sections was estimated to be 80% and 92%, respectively. ConclusionThis study demonstrates that it is possible to implement an effective communication and transport system to ensure access to EmONC and also highlights some of the important operational factors to consider, particularly in relation to minimising referral delays.	[Tayler-Smith, K.; Zachariah, R.; Manzi, M.; Reid, T.] Medecins Sans Frontieres, Med Dept Operat Res, Luxembourg, Luxembourg; [De Plecker, E.; Lambert, V.; Nicolai, M.; Goetghebuer, S.] Medecins Sans Frontieres, Operat Ctr Brussels, Brussels, Belgium; [Van den Boogaard, W.; Nyandwi, G.; Christiaens, B.; Ndelema, B.; Kabangu, A.] Medecins Sans Frontieres, Bujumbura, Burundi; [Manirampa, J.] Minist Hlth, Kabezi, Burundi; [Harries, A. D.] Int Union TB & Lung Dis, Paris, France; [Harries, A. D.] London Sch Hyg & Trop Med, London WC1, England	Tayler-Smith, K (reprint author), Medecins Sans Frontieres Brussels Operat Ctr, Med Dept Operat Res, Rue Dupre 94, B-1090 Brussels, Belgium.	katie_harries@yahoo.co.uk			MSF-Operational Centre Brussels	We are grateful to the Burundi Ministry of Health for their collaboration, and we are particularly grateful to the staff in the field for their hard work. We are also very grateful to Michele Telaro for her kind assistance in obtaining the cost-related data. The Burundi CURGO project is funded by MSF-Operational Centre Brussels.	[Anonymous], 2012, TRENDS MAT MORT 1990; Burundi Ministry of Health, 2011, ANN STAT DONN CTR SA; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Fauveau V, 2007, LANCET, V370, P1310, DOI 10.1016/S0140-6736(07)61571-2; Fournier P, 2009, B WORLD HEALTH ORGAN, V87, P30, DOI 10.2471/BLT.07.047076; Hofman JJ, 2008, INT J GYNECOL OBSTET, V102, P191, DOI 10.1016/j.ijgo.2008.04.001; Inter-agency Working Group on Reproductive Health in Crises, 2010, INT FIELD MAN REP HL; Lungu K, 2001, MALAWI MED J, V12, P16; Murray SF, 2001, HEALTH POLICY PLANN, V16, P353, DOI 10.1093/heapol/16.4.353; Paxton A, 2005, INT J GYNECOL OBSTET, V88, P181, DOI 10.1016/j.ijgo.2004.11.026; Somigliana E, 2011, TROP MED INT HEALTH, V16, P1151, DOI 10.1111/j.1365-3156.2011.02819.x; Tayler-Smith K, 2013, TROP MED INT HEALTH, V18, P166, DOI 10.1111/tmi.12022; WHO, 2006, MAK DIFF COUNTR STRA; WHO, 2005, WORLD HLTH REP 2005; WHO, 2007, REP HLTH RES; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2; World Health Organization, 2006, NEON PER MORT COUNTR; World Health Organization, 2012, WORLD HLTH STAT IND	19	33	34	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2013	18	8					993	1001		10.1111/tmi.12121				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	179FB	WOS:000321504000011	23682859	Bronze, Green Published			2019-03-26	
J	Zachariah, R; Reid, T; Van den Bergh, R; Dahmane, A; Kosgei, RJ; Hinderaker, SG; Tayler-Smith, K; Manzi, M; Kizito, W; Khogali, M; Kumar, AMV; Baruani, B; Bishinga, A; Kilale, AM; Nqobili, M; Patten, G; Sobry, A; Cheti, E; Nakanwagi, A; Enarson, DA; Edginton, ME; Upshur, R; Harries, AD				Zachariah, R.; Reid, T.; Van den Bergh, R.; Dahmane, A.; Kosgei, R. J.; Hinderaker, S. G.; Tayler-Smith, K.; Manzi, M.; Kizito, W.; Khogali, M.; Kumar, A. M. V.; Baruani, B.; Bishinga, A.; Kilale, A. M.; Nqobili, M.; Patten, G.; Sobry, A.; Cheti, E.; Nakanwagi, A.; Enarson, D. A.; Edginton, M. E.; Upshur, R.; Harries, A. D.			Applying the ICMJE authorship criteria to operational research in low-income countries: the need to engage programme managers and policy makers	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						ICMJE; authorship; operational research; policy; practice	TUBERCULOSIS-CONTROL; DIFFERENCE; THERAPY; MALAWI		[Zachariah, R.; Reid, T.; Van den Bergh, R.; Dahmane, A.; Tayler-Smith, K.; Manzi, M.; Nakanwagi, A.] MSF Luxembourg, Operat Ctr Brussels, Medecins Sans Frontieres, Med Dept,Operat Res Unit, Luxembourg, Luxembourg; [Van den Bergh, R.] Flemish Inst Biotechnol, Dept Mol & Cellular Interact, Brussels, Belgium; [Van den Bergh, R.] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium; [Kosgei, R. J.] Univ Nairobi, Dept Obstet & Gynecol, Nairobi, Kenya; [Hinderaker, S. G.] Univ Bergen, Ctr Int Hlth, Bergen, Norway; [Hinderaker, S. G.; Enarson, D. A.; Edginton, M. E.; Harries, A. D.] Ctr Operat Res, Int Union TB & Lung Dis, Paris, France; [Kizito, W.] Int Union TB & Lung Dis, Kampala, Uganda; [Khogali, M.] Medecins Sans Frontieres, Addis Ababa, Ethiopia; [Kumar, A. M. V.] Int Union TB & Lung Dis, South East Asia Off, New Delhi, India; [Baruani, B.] Medecins Sans Frontieres, Somali Mission, Somalia; [Bishinga, A.] Medecins Sans Frontieres, Bujumbura, Burundi; [Kilale, A. M.] Natl Inst Med Res, Dar Es Salaam, Tanzania; [Nqobili, M.] Natl TB Control Programme, Harare, Zimbabwe; [Patten, G.] Medecins Sans Frontieres, Cape Town, South Africa; [Sobry, A.; Cheti, E.] Medecins Sans Frontieres, Nairobi, Kenya; [Upshur, R.] Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada; [Harries, A. D.] London Sch Hyg & Trop Med, London WC1, England	Zachariah, R (reprint author), Medecins Sans Frontieres, Brussels Operat Ctr, Operat Res Unit, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu		Van den Bergh, Rafael/0000-0001-6277-8713; Patten, Gabriela/0000-0003-2511-1367			Ford N, 2013, TROP MED INT HEALTH, V18, P504, DOI 10.1111/tmi.12075; Harries AD, 2011, INT J TUBERC LUNG D, V15, P144; Harries AD, 2004, INT J TUBERC LUNG D, V8, P614; Harries AD, 2003, TUBERCULOSIS, V83, P143, DOI 10.1016/S1472-9792(02)00061-6; Harries AD, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-593; Horton R, 2013, LANCET, V381, P278, DOI 10.1016/S0140-6736(13)60099-9; Hutchinson E, 2010, NATL POLICY DEV CONT; ICMJE, 1979, ICMJE UNPUB; Nyangulu DS, 1997, LANCET, V350, P1284, DOI 10.1016/S0140-6736(97)05023-X; Zachariah R, 2008, T ROY SOC TROP MED H, V102, P288, DOI 10.1016/j.trstmh.2007.12.007; Zachariah R, 2011, INT J TUBERC LUNG D, V15, P1426, DOI 10.5588/ijtld.11.0316; Zachariah R, 2012, LANCET INFECT DIS, V12, P415, DOI [10.1016/S1473-3099(11)70309-7, 10.1016/S1473-3099(11)20309-7]; Zachariah R, 2009, LANCET INFECT DIS, V9, P711, DOI 10.1016/S1473-3099(09)70229-4	13	12	12	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2013	18	8					1025	1028		10.1111/tmi.12133				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	179FB	WOS:000321504000015	23718688				2019-03-26	
J	Schaffner, F; Bellini, R; Petric, D; Scholte, EJ; Zeller, H; Rakotoarivony, LM				Schaffner, Francis; Bellini, Romeo; Petric, Dusan; Scholte, Ernst-Jan; Zeller, Herve; Rakotoarivony, Laurence Marrama			Development of guidelines for the surveillance of invasive mosquitoes in Europe	PARASITES & VECTORS			English	Article						Invasive mosquitoes; Aedes; Surveillance; Monitoring; Vector; Dengue; Chikungunya; Europe; Guidelines	METROPOLITAN FRANCE; AEDINI DIPTERA; DENGUE VIRUS; LIFE STAGES; CULICIDAE; CLASSIFICATION; AEDES; OCHLEROTATUS; PHYLOGENY; JAPONICUS	Background: The recent notifications of autochthonous cases of dengue and chikungunya in Europe prove that the region is vulnerable to these diseases in areas where known mosquito vectors (Aedes albopictus and Aedes aegypti) are present. Strengthening surveillance of these species as well as other invasive container-breeding aedine mosquito species such as Aedes atropalpus, Aedes japonicus, Aedes koreicus and Aedes triseriatus is therefore required. In order to support and harmonize surveillance activities in Europe, the European Centre for Disease Prevention and Control (ECDC) launched the production of 'Guidelines for the surveillance of invasive mosquitoes in Europe'. This article describes these guidelines in the context of the key issues surrounding invasive mosquitoes surveillance in Europe. Methods: Based on an open call for tender, ECDC granted a pan-European expert team to write the guidelines draft. It content is founded on published and grey literature, contractor's expert knowledge, as well as appropriate field missions. Entomologists, public health experts and end users from 17 EU/EEA and neighbouring countries contributed to a reviewing and validation process. The final version of the guidelines was edited by ECDC (Additional file 1). Results: The guidelines describe all procedures to be applied for the surveillance of invasive mosquito species. The first part addresses strategic issues and options to be taken by the stakeholders for the decision-making process, according to the aim and scope of surveillance, its organisation and management. As the strategy to be developed needs to be adapted to the local situation, three likely scenarios are proposed. The second part addresses all operational issues and suggests options for the activities to be implemented, i.e. key procedures for field surveillance of invasive mosquito species, methods of identification of these mosquitoes, key and optional procedures for field collection of population parameters, pathogen screening, and environmental parameters. In addition, methods for data management and analysis are recommended, as well as strategies for data dissemination and mapping. Finally, the third part provides information and support for cost estimates of the planned programmes and for the evaluation of the applied surveillance process. Conclusion: The 'Guidelines for the surveillance of invasive mosquitoes in Europe' aim at supporting the implementation of tailored surveillance of invasive mosquito species of public health importance. They are intended to provide support to professionals involved in mosquito surveillance or control, decision/policy makers, stakeholders in public health and non-experts in mosquito surveillance. Surveillance also aims to support control of mosquito-borne diseases, including integrated vector control, and the guidelines are therefore part of a tool set for managing mosquito-borne disease risk in Europe.	[Schaffner, Francis] Avia GIS, B-2980 Zoersel, Belgium; [Bellini, Romeo] Ctr Agr Ambiente G Nicoli, I-40014 Crevalcore, Italy; [Petric, Dusan] Univ Novi Sad, Fac Agr, Lab Med Entomol, Novi Sad 21000, Serbia; [Scholte, Ernst-Jan] Dutch Food & Consumer Prod Safety Author NVWA, Natl Ctr Monitoring Vectors, NL-6700 HC Wageningen, Netherlands; [Zeller, Herve; Rakotoarivony, Laurence Marrama] European Ctr Dis Prevent & Control, ECDC, S-17183 Stockholm, Sweden	Schaffner, F (reprint author), Avia GIS, Risschotlei 33, B-2980 Zoersel, Belgium.	fschaffner@avia-gis.com; Laurence.Marrama@ecdc.europa.eu		Schaffner, Francis/0000-0001-9166-7617			Angelini R, 2007, Euro Surveill, V12; Caminade C, 2012, J R SOC INTERFACE, V9, P2708, DOI 10.1098/rsif.2012.0138; European Centre for Disease Prevention and Control, 2009, ECDC TECHNICAL REPOR; European Centre for Disease Prevention and Control (ECDC), WEST NILE VIRUS INFE; European Centre for Disease Prevention and Control ( ECDC), 2011, CONSULTATION ON MOSQ; European Centre for Disease Prevention and Control (ECDC), 2012, ECDC TECHNICAL REPOR; European Centre for Disease Prevention and Control ( ECDC), 2012, EXPERT CONSULTATION; Fischer D, 2011, GLOBAL PLANET CHANGE, V78, P54, DOI 10.1016/j.gloplacha.2011.05.008; Giovannini F, 2012, CONTROLLO DELLA ZANZ, V73, P192; Gjenero-Margan I, 2011, EUROSURVEILLANCE, V16, P2; Grandadam M, 2011, EMERG INFECT DIS, V17, P910, DOI 10.3201/eid1705.101873; Hales S, 2002, LANCET, V360, P830, DOI 10.1016/S0140-6736(02)09964-6; Halstead SB, 2008, ANNU REV ENTOMOL, V53, P273, DOI 10.1146/annurev.ento.53.103106.093326; JME Editorial Board, 2005, J MED ENTOMOL, V42, P511; La Ruche G, 2010, EUROSURVEILLANCE, V15, P2; Medlock JM, 2012, VECTOR-BORNE ZOONOT, V12, P435, DOI 10.1089/vbz.2011.0814; Ooi EE, 2009, FUTURE VIROL, V4, P571, DOI 10.2217/FVL.09.55; Randolph SE, 2010, NAT REV MICROBIOL, V8, P361, DOI 10.1038/nrmicro2336; Reinert JF, 2000, J AM MOSQUITO CONTR, V16, P175; Reinert JF, 2004, ZOOL J LINN SOC-LOND, V142, P289, DOI 10.1111/j.1096-3642.2004.00144.x; Reinert JF, 2006, ZOOL J LINN SOC-LOND, V148, P1, DOI 10.1111/j.1096-3642.2006.00254.x; Reinert JF, 2009, ZOOL J LINN SOC-LOND, V157, P700, DOI 10.1111/j.1096-3642.2009.00570.x; Savage HM, 2004, J AM MOSQUITO CONTR, V20, P208; Schaffner F, 2013, CLIN MICROBIOL INFEC, V19, P685, DOI 10.1111/1469-0691.12189; Schaffner F, 2009, MED VET ENTOMOL, V23, P448, DOI 10.1111/j.1365-2915.2009.00825.x; Schaffner F, 2003, J AM MOSQUITO CONTR, V19, P1; Scott TW, 2012, TRENDS PARASITOL, V28, P114, DOI 10.1016/j.pt.2012.01.001; Soumahoro MK, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001197; Sousa CA, 2012, EUROSURVEILLANCE, V17, P15; Straetemans M., 2008, Eurosurveillance, V13, P8040; Vanwambeke SO, 2006, GEOGRAPHIC MEDICINE, V1, P202	31	40	41	1	33	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	JUL 18	2013	6								209	10.1186/1756-3305-6-209				10	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	191FS	WOS:000322399000001	23866915	DOAJ Gold, Green Published			2019-03-26	
J	Van Reet, N; Pyana, P; Roge, S; Claes, F; Buscher, P				Van Reet, Nick; Pyana, Pati; Roge, Stijn; Claes, Filip; Buscher, Philippe			Luminescent multiplex viability assay for Trypanosoma brucei gambiense	PARASITES & VECTORS			English	Article						Trypanosoma brucei gambiense; Democratic Republic of the Congo; Viability; Multiplex; Luminescence; Renilla luciferase	HUMAN AFRICAN TRYPANOSOMIASIS; DL-ALPHA-DIFLUOROMETHYLORNITHINE; NITROIMIDAZOLE DRUG CANDIDATE; THROUGHPUT SCREENING ASSAY; SLEEPING SICKNESS PATIENTS; BLOOD-STREAM FORMS; IN-VITRO; FIREFLY LUCIFERASE; 384-WELL FORMAT; STRAIN 427	Background: New compounds for the treatment of human African trypanosomiasis (HAT) are urgently required. Trypanosoma brucei (T.b.) gambiense is the leading cause of HAT, yet T.b. gambiense is often not the prime target organism in drug discovery. This may be attributed to the difficulties in handling this subspecies and the lack of an efficient viability assay to monitor drug efficacy. Methods: In this study, a T.b. gambiense strain, recently isolated in the D. R. Congo, was made bioluminescent by transfection with Renilla luciferase (RLuc) without altering its in vitro and in vivo growth characteristics. A luminescent multiplex viability assay (LMVA), based on measurement of the Renilla luciferase activity and the ATP content of the cells within the same experiment, was investigated as an alternative to the standard fluorimetric resazurin viability assay for drug sensitivity testing of T.b. gambiense. Results: In a 96-well format, the RLuc transfected strain showed a detection limit of 2 x 10(4) cells ml(-1) for the Renilla luciferase measurement and 5 x 10(3) cells ml(-1) for the ATP measurement. Both assays of the LMVA showed linearity up to 10(6) cells ml(-1) and correlated well with the cell density during exponential growth of the long slender bloodstream forms. The LMVA was compared to the fluorimetric resazurin viability assay for drug sensitivity testing of pentamidine, eflornithine, nifurtimox and melarsoprol with both the wild type and the RLuc transfected population. For each drug, the IC50 value of the RLuc population was similar to that of the wild type when determined with either the fluorimetric resazurin method or the LMVA. For eflornithine, nifurtimox and melarsoprol we found no difference between the IC50 values in both viability assays. In contrast, the IC50 value of pentamidine was higher when determined with the fluorimetric resazurin method than in both assays of the LMVA. Conclusions: LMVA has some advantages for viability measurement of T.b. gambiense: it requires less incubation time for viability detection than the fluorimetric resazurin assay and in LMVA, two sensitive and independent viability assays are performed in the same experiment.	[Van Reet, Nick; Pyana, Pati; Roge, Stijn; Claes, Filip; Buscher, Philippe] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Pyana, Pati] Inst Natl Rech Biomed, Kinshasa, Zaire	Van Reet, N (reprint author), Inst Trop Med, Dept Biomed Sci, Natl Str 155, B-2000 Antwerp, Belgium.	nvanreet@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472	Fonds voor Wetenschappelijk onderzoek (FWO) [1.5.147.09, G.0229.10 N]	The pHD 309 vector was a kind gift of Dr George Cross. Authors like to thank Maarten Van Den Boogaerde, Jeroen Swiers en Nicolas Bebronne for technical assistance. This work was supported by the Fonds voor Wetenschappelijk onderzoek (FWO) [grant 1.5.147.09, G.0229.10 N]. The funding agency had no role in the collection, analysis, interpretation of data, writing of the manuscript and in the decision to submit the manuscript for publication.	Ang KKH, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001023; BACCHI CJ, 1990, ANTIMICROB AGENTS CH, V34, P1183, DOI 10.1128/AAC.34.6.1183; Bacchi Cyrus J, 2009, Interdiscip Perspect Infect Dis, V2009, P195040, DOI 10.1155/2009/195040; Bot C, 2010, ANTIMICROB AGENTS CH, V54, P4246, DOI 10.1128/AAC.00800-10; Bowling T, 2012, INT J PARASITOL-DRUG, V2, P262, DOI 10.1016/j.ijpddr.2012.02.002; Brand S, 2012, J MED CHEM, V55, P140, DOI 10.1021/jm201091t; BRUN R, 1989, ACTA TROP, V46, P369, DOI 10.1016/0001-706X(89)90049-1; Burkard G, 2007, MOL BIOCHEM PARASIT, V153, P220, DOI 10.1016/j.molbiopara.2007.02.008; Canavaci AMC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000740; Che PL, 2012, ASSAY DRUG DEV TECHN, V10, P61, DOI 10.1089/adt.2011.0378; Claes F, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000486; Coustou V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000618; Cui L, 2008, EXP PARASITOL, V120, P80, DOI 10.1016/j.exppara.2008.05.003; De Rycker M, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001932; Gilbert DF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028338; Gillingwater K, 2007, VET PARASITOL, V148, P114, DOI 10.1016/j.vetpar.2007.05.020; Giroud C, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000509; Gould MK, 2008, ANAL BIOCHEM, V382, P87, DOI 10.1016/j.ab.2008.07.036; HERBERT WJ, 1976, EXP PARASITOL, V40, P427, DOI 10.1016/0014-4894(76)90110-7; ITEN M, 1995, TROP MED PARASITOL, V46, P190; Jackson AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000658; Jacobs RT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001151; Jones DC, 2010, BIOCHEM PHARMACOL, V80, P1478, DOI 10.1016/j.bcp.2010.07.038; Kaiser M, 2011, ANTIMICROB AGENTS CH, V55, P5602, DOI 10.1128/AAC.00246-11; Kaminsky R, 1998, ANTIMICROB AGENTS CH, V42, P2858, DOI 10.1128/AAC.42.11.2858; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Mackey ZB, 2011, CHEM BIOL DRUG DES, V78, P454, DOI 10.1111/j.1747-0285.2011.01156.x; Maser P, 2012, CURR OPIN PHARMACOL, V12, P562, DOI 10.1016/j.coph.2012.05.001; Maina NWN, 2007, T ROY SOC TROP MED H, V101, P540, DOI 10.1016/j.trstmh.2006.11.008; Masocha W, 2012, VIRULENCE, V3, P202, DOI 10.4161/viru.19178; McCulloch Richard, 2004, Methods Mol Biol, V262, P53; Merschjohann K, 2001, PLANTA MED, V67, P623, DOI 10.1055/s-2001-17351; Mesia GK, 2008, J ETHNOPHARMACOL, V115, P409, DOI 10.1016/j.jep.2007.10.028; Michel G, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001323; Nare B, 2010, ANTIMICROB AGENTS CH, V54, P4379, DOI 10.1128/AAC.00498-10; Navarro G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046172; Ngoyi DM, 2010, J INFECT DIS, V201, P453, DOI 10.1086/649917; Pulido SA, 2012, ACTA TROP, V122, P36, DOI 10.1016/j.actatropica.2011.11.015; Pyana PP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001025; Raz B, 1997, ACTA TROP, V68, P139, DOI 10.1016/S0001-706X(97)00079-X; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001; Simarro PP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001007; Steverding D, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-15; Sykes ML, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-54; Sykes ML, 2009, AM J TROP MED HYG, V81, P665, DOI 10.4269/ajtmh.2009.09-0015; Torreele E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000923; Van Reet N, 2011, EXP PARASITOL, V128, P285, DOI 10.1016/j.exppara.2011.02.018; Vodnala S.K., 2009, PLOS NEGLECT TROP D, V3, pe495; Wenzler T, 2009, ANTIMICROB AGENTS CH, V53, P4185, DOI 10.1128/AAC.00225-09; Xie XP, 2011, J VIROL, V85, P11183, DOI 10.1128/JVI.05468-11	50	6	6	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	JUL 15	2013	6								207	10.1186/1756-3305-6-207				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	192BF	WOS:000322458200001	23856321	DOAJ Gold, Green Published			2019-03-26	
J	Kanobana, K; Ruiz, A; Rojas, L; Andrade, R; Rosado, F; Polman, K; Nunez, FA				Kanobana, Kirezi; Ruiz, Aniran; Rojas, Lazara; Andrade, Rene; Rosado, Felix; Polman, Katja; Aangel Nunez, Felix			Taenia solium Cysticercosis: The Case of Cuba	PLOS NEGLECTED TROPICAL DISEASES			English	Article							NEUROCYSTICERCOSIS; EPILEPSY; MEXICO; HEALTH; BURDEN		[Kanobana, Kirezi; Polman, Katja] Inst Trop Med, B-2000 Antwerp, Belgium; [Ruiz, Aniran; Rojas, Lazara; Rosado, Felix; Aangel Nunez, Felix] Inst Trop Med Pedro Kouri, Havana, Cuba; [Andrade, Rene] Inst Neurol & Neurosurg, Havana, Cuba	Kanobana, K (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	kkanobana@itg.be			Institute of Tropical Medicine in Antwerp; Instituto Pedro Kouri in Havana	The study was funded by the Belgian development Cooperation as part of the Framework Agreement 3 programme between the Institute of Tropical Medicine in Antwerp and the Instituto Pedro Kouri in Havana. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1984, NEW ENGL J MED, V311, P1425, DOI [10.1056/NEJM198411293112208, DOI 10.1056/NEJM198411293112208]; Bhattarai R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001521; Deckers N, 2010, TRENDS PARASITOL, V26, P137, DOI 10.1016/j.pt.2009.12.008; Del Brutto OH, 2001, NEUROLOGY, V57, P177, DOI 10.1212/WNL.57.2.177; Dorta-Contreras AJ, 2001, REV NEUROLOGIA, V32, P600, DOI 10.33588/rn.3206.2000537; Dumenigo RB, 1984, REV CUBA MED TROP, V36, P201; Fleet W F 3rd, 1990, J Tenn Med Assoc, V83, P400; Flisser A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000831; Gilman RH, 2012, PATHOG GLOB HEALTH, V106, P312, DOI 10.1179/2047773212Y.0000000045; GOMEZIZQUIERDO I, 1901, REV MED MEX, V13, P205; Hernandez-Cossio O, 1999, REV NEUROLOGIA, V29, P1003, DOI 10.33588/rn.2911.99111; Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000300; Marin-Fernandez G, 1967, REV CUBA MED TROP, P63; Ndimubanzi PC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000870; Perez-Berenger JL, 1991, REV CUBANA MED, V30, P61; Raccurt CP, 2009, J HELMINTHOL, V83, P113, DOI 10.1017/S0022149X09232330; Rojas Lázara, 2012, Rev Cubana Med Trop, V64, P15; Rivero LR, 2008, TRENDS PARASITOL, V24, P440, DOI 10.1016/j.pt.2008.06.008; Spiegel JM, 2008, HEALTH PROMOT INT, V23, P60, DOI 10.1093/heapro/dam040; Vega-Basulto S, 2001, REV NEUROLOGIA, V32, P1000, DOI 10.33588/rn.3210.2000570; Vega-Basulto S, 1989, REV I CIENCIAS MED C, V4, P22	21	1	1	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUL	2013	7	7							e2202	10.1371/journal.pntd.0002202				3	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	190EJ	WOS:000322321500003	23951367	DOAJ Gold, Green Published			2019-03-26	
J	Vanlerberghe, V; Trongtokit, Y; Jirarojwatana, S; Jirarojwatana, R; Lenhart, A; Apiwathnasorn, C; McCall, PJ; Van der Stuyft, P				Vanlerberghe, Veerle; Trongtokit, Yuwadee; Jirarojwatana, Somchai; Jirarojwatana, Ravisara; Lenhart, Audrey; Apiwathnasorn, Chamnarn; McCall, Philip J.; Van der Stuyft, Patrick			Coverage-Dependent Effect of Insecticide-Treated Curtains for Dengue Control in Thailand	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							VECTOR CONTROL INTERVENTIONS; RANDOMIZED CONTROLLED-TRIAL; WATER CONTAINER COVERS; AEDES-AEGYPTI DIPTERA; LETHAL OVITRAP; TRANSMISSION; ALBOPICTUS; CULICIDAE; EFFICACY; VILLAGES	Evidence on the effectiveness of insecticide-treated curtains (ITCs) for reducing densities of Aedes mosquitoes, the principal vectors of dengue, is scarce. In Laem Chabang southeast of Bangkok, Thailand, the Breteau Index (BI) (number of positive containers/100 houses) was 45 in October 2006. In March 2007, we distributed long-lasting ITCs in 22 clusters (2,032 houses) and selected 66 control clusters (661 houses). Routine control activities continued in all clusters. Six months after distribution, the BI was 25.8 and 77.6 in intervention and control areas, respectively (P < 0.001). Eighteen months after distribution, the BI was 21.8 and 23.8, respectively (P = 0.28). The average number of ITCs/house at cluster level was associated with the BI (P < 0.01) after six months, when 70.5% of households still used ITCs, but not at 18 months, when ITC coverage had decreased to 33.2%. Deployment of ITCs can result in considerable reductions in Aedes infestation levels, but the effect is coverage dependent.	Inst Trop Med, Unit Gen Epidemiol & Dis Control, B-2000 Antwerp, Belgium; Mahidol Univ, Fac Trop Med, Dept Med Entomol, Bangkok, Thailand; Reg Off Dis Prevent & Control Reg 3, Chon Buri, Thailand; Univ Liverpool, Liverpool Sch Trop Med, Dept Vector Biol, Liverpool L3 5QA, Merseyside, England; Univ Ghent, Dept Publ Hlth, B-9000 Ghent, Belgium; [Vanlerberghe, Veerle] Inst Trop Med, B-2000 Antwerp, Belgium; [Trongtokit, Yuwadee; Apiwathnasorn, Chamnarn] Mahidol Univ, Bangkok 10700, Thailand; [Jirarojwatana, Somchai; Jirarojwatana, Ravisara] Reg Off Dis Prevent & Control, Chon Buri, Thailand; [Lenhart, Audrey; McCall, Philip J.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Van der Stuyft, Patrick] Inst Trop Med, Ghent, Belgium; [Van der Stuyft, Patrick] Univ Ghent, B-9000 Ghent, Belgium	Vanlerberghe, V (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	vvanlerberghe@itg.be; ytrongtokit@gmail.com; sjiraroj@yahoo.com; rjiraroj@hotmail.com; ajl8@cdc.gov; tmcaw@mahidol.ac.th; mccall@liv.ac.uk; pvdstuyft@itg.be		McCall, Philip/0000-0002-0007-3985	European Union project DENCO [INCO-CT-2004-517708]	This study was supported by the European Union project DENCO: INCO-CT-2004-517708.	Arredondo-Jimenez JI, 2006, ANN TROP MED PARASIT, V100, pS17, DOI 10.1179/136485906X105480; Baly A, 2011, AM J TROP MED HYG, V84, P747, DOI 10.4269/ajtmh.2011.10-0532; Castro M, 2012, T ROY SOC TROP MED H, V106, P315, DOI 10.1016/j.trstmh.2012.01.013; Castro Mirley, 2007, Rev. salud pública, V9, P106, DOI 10.1590/S0124-00642007000100011; Corbel V, 2012, LANCET INFECT DIS, V12, P617, DOI 10.1016/S1473-3099(12)70081-6; Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5; Erlanger TE, 2008, MED VET ENTOMOL, V22, P203, DOI 10.1111/j.1365-2915.2008.00740.x; Esu E, 2010, TROP MED INT HEALTH, V15, P619, DOI 10.1111/j.1365-3156.2010.02489.x; Focks DA, 1997, AM J TROP MED HYG, V56, P159, DOI 10.4269/ajtmh.1997.56.159; Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Kilian A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-49; Kroeger A, 2006, BRIT MED J, V332, P1247, DOI 10.1136/bmj.332.7552.1247; Lenhart A, 2012, AM J TROP MED HYG, V88, P254; Luz PM, 2011, LANCET, V377, P1673, DOI 10.1016/S0140-6736(11)60246-8; Mani TR, 2005, TROP MED INT HEALTH, V10, P1298, DOI 10.1111/j.1365-3156.2005.01522.x; Morrison A. C., 2008, PLoS Medicine, V5, pe68, DOI 10.1371/journal.pmed.0050068; Morrison AC, 2004, J MED ENTOMOL, V41, P1123, DOI 10.1603/0022-2585-41.6.1123; Perich MJ, 2003, MED VET ENTOMOL, V17, P205, DOI 10.1046/j.1365-2915.2003.00427.x; Ponlawat A, 2005, J MED ENTOMOL, V42, P821, DOI 10.1603/0022-2585(2005)042[0821:ISOAAA]2.0.CO;2; Reiter Paul, 1997, P425; Romani MET, 2007, SOC SCI MED, V64, P976, DOI 10.1016/j.socscimed.2006.10.033; Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7; Scott TW, 2000, J MED ENTOMOL, V37, P77, DOI 10.1603/0022-2585-37.1.77; Seng CM, 2008, J VECTOR ECOL, V33, P333, DOI 10.3376/1081-1710-33.2.333; TDR, 2006, TDRSWG08 WHO; Tsuda Y, 2006, J AM MOSQUITO CONTR, V22, P222, DOI 10.2987/8756-971X(2006)22[222:DSDOAA]2.0.CO;2; Tun-Lin W, 2009, TROP MED INT HEALTH, V14, P1143, DOI 10.1111/j.1365-3156.2009.02341.x; Vanlerberghe V, 2011, TROP MED INT HEALTH, V16, P162, DOI 10.1111/j.1365-3156.2010.02668.x; Vanlerberghe V, 2010, TROP MED INT HEALTH, V15, P1067, DOI 10.1111/j.1365-3156.2010.02582.x; Vanlerberghe V, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000994; Williams CR, 2007, J MED ENTOMOL, V44, P256, DOI 10.1603/0022-2585(2007)44[256:IOABLO]2.0.CO;2; World Health Organization, 1998, TEST PROC INS RES MO; World Health Organization, 2012, GLOB STRAT DENG PREV; World Health Organization, 2001, WHOVBC81806; Yoon IK, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001730	36	22	22	0	13	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUL	2013	89	1					93	98		10.4269/ajtmh.13-0015				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	185BG	WOS:000321939600015	23669233	Green Published, Bronze			2019-03-26	
J	Obsomer, V; Wirtgen, M; Linden, A; Claerebout, E; Heyman, P; Heylen, D; Madder, M; Maris, J; Lebrun, M; Tack, W; Lempereur, L; Hance, T; Van Impe, G				Obsomer, Valerie; Wirtgen, Marc; Linden, Annick; Claerebout, Edwin; Heyman, Paul; Heylen, Dieter; Madder, Maxime; Maris, Jo; Lebrun, Maude; Tack, Wesley; Lempereur, Laetitia; Hance, Thierry; Van Impe, Georges			Spatial disaggregation of tick occurrence and ecology at a local scale as a preliminary step for spatial surveillance of tick-borne diseases: general framework and health implications in Belgium	PARASITES & VECTORS			English	Article						Tick; Vector; Spatial distribution; Ecology; Vector-borne diseases	BURGDORFERI SENSU-LATO; IXODES-RICINUS TICKS; BORRELIA-BURGDORFERI; DERMACENTOR-RETICULATUS; ANAPLASMA-PHAGOCYTOPHILUM; RHIPICEPHALUS-SANGUINEUS; LYME BORRELIOSIS; ARGAS-REFLEXUS; BABESIA-MICROTI; UNITED-KINGDOM	Background: The incidence of tick-borne diseases is increasing in Europe. Sub national information on tick distribution, ecology and vector status is often lacking. However, precise location of infection risk can lead to better targeted prevention measures, surveillance and control. Methods: In this context, the current paper compiled geolocated tick occurrences in Belgium, a country where tick-borne disease has received little attention, in order to highlight the potential value of spatial approaches and draw some recommendations for future research priorities. Results: Mapping of 89,289 ticks over 654 sites revealed that ticks such as Ixodes ricinus and Ixodes hexagonus are largely present while Dermacentor reticulatus has a patchy distribution. Suspected hot spots of tick diversity might favor pathogen exchanges and suspected hot spots of I. ricinus abundance might increase human-vector contact locally. This underlines the necessity to map pathogens and ticks in detail. While I. ricinus is the main vector, I. hexagonus is a vector and reservoir of Borrelia burgdorferi s.l., which is active the whole year and is also found in urban settings. This and other nidiculous species bite humans less frequently, but seem to harbour pathogens. Their role in maintaining a pathogenic cycle within the wildlife merits investigation as they might facilitate transmission to humans if co-occurring with I. ricinus. Many micro-organisms are found abroad in tick species present in Belgium. Most have not been recorded locally but have not been searched for. Some are transmitted directly at the time of the bite, suggesting promotion of tick avoidance additionally to tick removal. Conclusion: This countrywide approach to tick-borne diseases has helped delineate recommendations for future research priorities necessary to design public health policies aimed at spatially integrating the major components of the ecological cycle of tick-borne diseases. A systematic survey of tick species and associated pathogens is called for in Europe, as well as better characterisation of species interaction in the ecology of tick-borne diseases, those being all tick species, pathogens, hosts and other species which might play a role in tick-borne diseases complex ecosystems.	[Obsomer, Valerie] Catholic Univ Louvain, Earth & Life Inst, Georges Lemaitre Climate & Earth Res Ctr, B-1348 Louvain, Belgium; [Obsomer, Valerie; Hance, Thierry; Van Impe, Georges] Catholic Univ Louvain, Earth & Life Inst, Biodivers Dept ELIB, B-1348 Louvain, Belgium; [Wirtgen, Marc; Linden, Annick] Univ Liege, Dept Infect & Parasit Dis Hlth & Pathol Wildlife, B-4000 Liege, Belgium; [Claerebout, Edwin] Univ Ghent, Parasitol Lab, Fac Vet Med, B-9820 Merelbeke, Belgium; [Heyman, Paul] Queen Astrid Mil Hosp, Reference Lab Vector Borne Dis, B-1120 Brussels, Belgium; [Heylen, Dieter] Univ Antwerp, Dept Biol, Evolutionary Ecol Grp, B-2020 Antwerp, Belgium; [Madder, Maxime] Inst Trop Med, B-2000 Antwerp, Belgium; [Madder, Maxime] Univ Pretoria, Dept Vet Trop Dis, ZA-0002 Pretoria, South Africa; [Maris, Jo] ARSIA, B-5590 Ciney, Belgium; [Lebrun, Maude] DGZ Vlaanderen, Dierenarts Gezondheidszorg Herkauwers Veepeiler, B-2500 Lier, Belgium; [Tack, Wesley] Univ Ghent, Lab Forestry, Dept Forest & Water Management, B-9090 Ghent, Belgium; [Lempereur, Laetitia] Univ Liege, Lab Parasitol & Pathol Parasit Dis, Dept Infect & Parasit Dis, Fac Vet Med, B-4000 Liege, Belgium	Obsomer, V (reprint author), Catholic Univ Louvain, Earth & Life Inst, Georges Lemaitre Climate & Earth Res Ctr, Pl Louis Pasteur 3, B-1348 Louvain, Belgium.	valerie.obsomer@uclouvain.be		Linden, Annick/0000-0002-8957-0573	Belgian Sciences Policy Office	Many thanks to Adrien Nahayo and other collaborators of the WILDSCREEN network for monitoring of diseases in wildlife and for their time and effort in collecting ticks. The authors would also like to thank Philippe Martin from the Saint-Luc hospital in Bouge Belgium, Thomas Kesteman from the UCL IREC Institute, the staff of the Royal Institute for Natural Sciences of Belgium (IRSNB) including Georges Wauthy and Leon Baert, the staff of GlaxoSmithKline including Yves Lobet and Pierre Voet for providing fresh records or additional details on their published records. The authors are grateful to the nature organisation NATAGORA and NATUURPUNT and particularly Wouter Vanreusel, Marc Herremans, Karin Gielen, Jean-Yves Paquet and Antoine Derouaux for providing details and numerous records of tick location. Thanks to Sophie Vanwambeke, Eva De Clercq, Sen li and Nienke Harteminck for support and raw literature. Thanks to BAYER for accepting to share their records for our research. Many thanks to the Belgian Sciences Policy Office for funding this work through the STEREO II project for Earth Observation (MULTITICK project).	Acunman K, 2010, THESIS KARLSRUHE I T; AESCHLIMANN A, 1970, Revue Suisse de Zoologie, V77, P527; Aeschlimann A, 1972, IXODES RICINUS LINNE; Aeschlimann A, 1975, B SOC ENTOMOL SUISSE, V48, P69; [Anonymous], W REED BIOS UN TICKM; Arthur D.R., 1963, BRIT TICKS; Aubert M.F.A., 1975, ACAROLOGIA, V17, P452; Barker SC, 2008, TICKS: BIOLOGY, DISEASE AND CONTROL, P1, DOI 10.1017/CBO9780511551802.002; BEAUCOURNU J. C, 1963, ANN SPELEOL, V18, P519; BEAUCOURNU J-C, 1967, Annales de Speleologie, V22, P543; BIGAIGNON G, 1989, ACTA CLIN BELG, V44, P174, DOI 10.1080/17843286.1989.11718010; BIGAIGNON G, 1989, Revue Medicale de Liege, V44, P489; Blanc J, 1932, ARCH I PASTEUR TUNIS, V20, P343; Bonnet S, 2007, PARASITOLOGY, V134, P197, DOI 10.1017/S0031182006001545; Bonnet S, 2009, VET RES, V40, DOI 10.1051/vetres/2009004; Bown KJ, 2008, APPL ENVIRON MICROB, V74, P7118, DOI 10.1128/AEM.00625-08; Boyard C, 2008, EXP APPL ACAROL, V44, P61, DOI 10.1007/s10493-008-9132-3; Bronswijk JEMH, 1979, TEKEN IXODIDA BENELU; CAMPBELL BS, 1994, J WILDERNESS MED, V5, P405, DOI 10.1580/0953-9859-5.4.405; Charrel RN, 2004, CLIN MICROBIOL INFEC, V10, P1040, DOI 10.1111/j.1469-0691.2004.01022.x; Claerebout E, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-183; Cochez C, 2012, MED VET ENTOMOL, V26, P355, DOI 10.1111/j.1365-2915.2011.00998.x; Crooks E, 2006, J EXP BIOL, V209, P2138, DOI 10.1242/jeb.02238; Daniel MJ, 2004, PARASITOLOGY, V129, P329; Dantas-Torres F, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-26; DAUTEL H, 1991, J APPL ENTOMOL, V111, P380, DOI 10.1111/j.1439-0418.1991.tb00338.x; Dautel H, 1999, ZBL BAKT-INT J MED M, V289, P745; Dobec M, 2009, EMERG INFECT DIS, V15, P98, DOI 10.3201/eid1501.080815; Dobson ADM, 2011, TICKS TICK-BORNE DIS, V2, P67, DOI 10.1016/j.ttbdis.2011.03.002; Doby J.M., 1991, Bulletin de la Societe Francaise de Parasitologie, V9, P279; Doby J.M., 1990, Bulletin de la Societe Francaise de Parasitologie, V8, P311; Ducoffre G, 2009, SURVEILLANCE MALADIE; EFSA Panel on Animal Health and Welfare (AHAW), 2010, EFSA J, V8, P1723, DOI DOI 10.2903/J.EFSA.2010.1723; Eibach D, 2012, EUROSURVEILLANCE, V17, P1; Eskow E, 2003, JCR-J CLIN RHEUMATOL, V9, P77, DOI 10.1097/01.RHU.0000062510.04724.07; Estrada-Pea A., 2004, TICKS DOMESTIC ANIMA; Estrada-Pena A, 1999, EXP APPL ACAROL, V23, P685, DOI 10.1023/A:1006241108739; Estrada-Pena A, 2004, MED VET ENTOMOL, V18, P387, DOI 10.1111/j.0269-283X.2004.00523.x; Estrada-Pena A, 2013, EXP APPL ACAROL, V59, P351, DOI 10.1007/s10493-012-9600-7; ESTRADAPENA A, 1995, EXP APPL ACAROL, V19, P173, DOI 10.1007/BF00046289; Evans NJ, 2009, EMERG INFECT DIS, V15, P1331, DOI 10.3201/eid1508.090475; FAIN A, 1993, BELG J ZOOL, V123, P3; Fain A, 1990, TIQUES BELGIQUE ACAR; Fameree L, 1977, Rev Med Liege, V32, P383; Gern L, 1997, FOLIA PARASIT, V44, P309; GERN L, 1991, MED VET ENTOMOL, V5, P431, DOI 10.1111/j.1365-2915.1991.tb00571.x; Gilot B, 1997, PARASITE, V4, P197, DOI 10.1051/parasite/1997042197; GILOT B, 1985, ACAROLOGIA, V26, P215; GRAF J-F, 1979, Bulletin de la Societe Neuchateloise des Sciences Naturelles, V102, P55; Gray J, 2002, J CLIN MICROBIOL, V40, P1259, DOI 10.1128/JCM.40.4.1259-1263.2002; Gray J S, 2009, Interdiscip Perspect Infect Dis, V2009, P593232, DOI 10.1155/2009/593232; Hemmersbach-Miller M, 2004, CLIN INFECT DIS, V38, P1412, DOI 10.1086/420751; Herrmann C, 2013, INT J PARASITOL, V43, P477, DOI 10.1016/j.ijpara.2012.12.010; Heylen DJA, 2010, PARASITOLOGY, V137, P661, DOI 10.1017/S0031182009991582; Heylen D, 2013, ENVIRON MICROBIOL, V15, P663, DOI 10.1111/1462-2920.12059; Heylen DJA, 2011, PARASITOLOGY, V138, P1011, DOI 10.1017/S0031182011000618; Heylen DJA, 2011, OIKOS, V120, P1209, DOI 10.1111/j.1600-0706.2010.19358.x; Heylen DJA, 2010, INT J PARASITOL, V40, P183, DOI 10.1016/j.ijpara.2009.07.011; Heyman P, 2010, EXPERT REV ANTI-INFE, V8, P33, DOI 10.1586/ERI.09.118; Hilger C, 2005, J ALLERGY CLIN IMMUN, V115, P617, DOI 10.1016/j.jaci.2004.11.052; Hillyard P.D., 1996, TICKS N W EUROPE KEY; Hoffmann G, 1981, BUNDESGESUNDHEITSBLA, V24, P153; Hofhuis A, 2010, INFECTIEZIEKTEN B, V21, P84; HOOGSTRAAL H, 1985, ADV PARASIT, V24, P135, DOI 10.1016/S0065-308X(08)60563-1; Hornok S, 2009, MED VET ENTOMOL, V23, P41, DOI 10.1111/j.1365-2915.2008.00768.x; Hubbard MJ, 1998, MED VET ENTOMOL, V12, P89, DOI 10.1046/j.1365-2915.1998.00088.x; JAENSON TGT, 1994, J MED ENTOMOL, V31, P240, DOI 10.1093/jmedent/31.2.240; Kesteman T, 2010, ACTA CLIN BELG, V65, P319, DOI 10.1179/acb.2010.069; Kurtenbach K, 1998, APPL ENVIRON MICROB, V64, P1169; Lempereur L, 2012, PARASITOL RES, V110, P1525, DOI 10.1007/s00436-011-2657-0; Li S, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-149; LIEBISCH A, 1976, TROPENMED PARASITOL, V27, P393; Linden A, 2011, REV EPID SAN ANIM, V59-60, P213; Losson B, 1999, ANN MED VET, V143, P119; Mans BJ, 2008, TICKS: BIOLOGY, DISEASE AND CONTROL, P108, DOI 10.1017/CBO9780511551802.006; Marsot M, 2012, INT J PARASITOL, V42, P781, DOI 10.1016/j.ijpara.2012.05.010; MATUSCHKA FR, 1990, MED VET ENTOMOL, V4, P415, DOI 10.1111/j.1365-2915.1990.tb00459.x; Mehl R, 1983, NORW J ENTOMOL, V30, P46; Monks D, 2006, J SMALL ANIM PRACT, V47, P451, DOI 10.1111/j.1748-5827.2006.00031.x; Movila A, 2008, INT J MED MICROBIOL, V298, P149, DOI 10.1016/j.ijmm.2007.12.009; Obsomer V, 2013, ANOPHELES MOSQUITOES - NEW INSIGHTS INTO MALARIA VECTORS, P447, DOI 10.5772/55622; Obsomer V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050475; Ogden NH, 2000, MED VET ENTOMOL, V14, P332, DOI 10.1046/j.1365-2915.2000.00244.x; Panas E, 1976, Acarologia, V28, P51; Parola P, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000338; Perret JL, 2003, J EXP BIOL, V206, P1809, DOI 10.1242/jeb.00345; PETER O, 1984, Z PARASITENKD, V70, P265, DOI 10.1007/BF00942229; Petney TN, 2012, SYST APPL ACAROL-UK, V17, P115; Pfaffle M, 2011, EXP APPL ACAROL, V54, P151, DOI 10.1007/s10493-011-9432-x; Pisanu B, 2010, INT J PARASITOL, V40, P1277, DOI 10.1016/j.ijpara.2010.03.012; Polkowska A, 2012, EUROSURVEILLANCE, V17, P1; Rageau J., 1972, WLADOMOSCI PARAZYTOL, V18, P707; SCHOFFEL I, 1991, BERL MUNCH TIERARZTL, V104, P153; Sevcik Martin, 2010, Vespertilio, V13-14, P139; SIBOMANA G, 1986, ANN SOC BELG MED TR, V66, P79; Sinka ME, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-89; SMITH MW, 1972, ANN TROP MED PARASIT, V66, P281, DOI 10.1080/00034983.1972.11686826; Spitalska E, 2011, VECTOR-BORNE ZOONOT, V11, P1235, DOI 10.1089/vbz.2010.0210; Sprong H, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-294; Stanek G, 2011, CLIN MICROBIOL INFEC, V17, P69, DOI 10.1111/j.1469-0691.2010.03175.x; Tack W, 2012, FOREST ECOL MANAG, V265, P30, DOI 10.1016/j.foreco.2011.10.028; Tack W, 2011, EXP APPL ACAROL, V54, P285, DOI 10.1007/s10493-011-9444-6; TROTTER WR, 1990, LANCET, V336, P1563, DOI 10.1016/0140-6736(90)93325-J; UCHIKAWA K, 1969, J MED ENTOMOL, V6, P95, DOI 10.1093/jmedent/6.1.95; ULMANEN I, 1977, OIKOS, V28, P20, DOI 10.2307/3543318; Vanthomme K, 2012, EUR J CLIN MICROBIOL, V31, P2385, DOI 10.1007/s10096-012-1580-3; Wielinga PR, 2006, APPL ENVIRON MICROB, V72, P7594, DOI 10.1128/AEM.01851-06; Zahler M, 1995, INT J PARASITOL, V25, P1413, DOI 10.1016/0020-7519(95)00081-X	108	14	15	1	50	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	JUN 22	2013	6								190	10.1186/1756-3305-6-190				19	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	191FK	WOS:000322398200001	23800283	DOAJ Gold, Green Published			2019-03-26	
J	Claerebout, E; Losson, B; Cochez, C; Casaert, S; Dalemans, AC; De Cat, A; Madder, M; Saegerman, C; Heyman, P; Lempereur, L				Claerebout, Edwin; Losson, Bertrand; Cochez, Christel; Casaert, Stijn; Dalemans, Anne-Catherine; De Cat, Ann; Madder, Maxime; Saegerman, Claude; Heyman, Paul; Lempereur, Laetitia			Ticks and associated pathogens collected from dogs and cats in Belgium	PARASITES & VECTORS			English	Article						Ticks; Dermacentor reticulatus; Dogs; Cats; Belgium; Borrelia; Anaplasma; Rickettsia	IXODES-RICINUS TICKS; BURGDORFERI SENSU-LATO; BORRELIA-BURGDORFERI; ANAPLASMA-PHAGOCYTOPHILUM; GRANULOCYTIC EHRLICHIOSIS; DERMACENTOR-RETICULATUS; BORNE DISEASES; GENETIC-HETEROGENEITY; RICKETTSIA-HELVETICA; MOLECULAR EVIDENCE	Background: Although Ixodes spp. are the most common ticks in North-Western Europe, recent reports indicated an expanding geographical distribution of Dermacentor reticulatus in Western Europe. Recently, the establishment of a D. reticulatus population in Belgium was described. D. reticulatus is an important vector of canine and equine babesiosis and can transmit several Rickettsia species, Coxiella burnetii and tick-borne encephalitis virus (TBEV), whilst Ixodes spp. are vectors of pathogens causing babesiosis, borreliosis, anaplasmosis, rickettsiosis and TBEV. Methods: A survey was conducted in 2008-2009 to investigate the presence of different tick species and associated pathogens on dogs and cats in Belgium. Ticks were collected from dogs and cats in 75 veterinary practices, selected by stratified randomization. All collected ticks were morphologically determined and analysed for the presence of Babesia spp., Borrelia spp., Anaplasma phagocytophilum and Rickettsia DNA. Results: In total 2373 ticks were collected from 647 dogs and 506 cats. Ixodes ricinus (76.4%) and I. hexagonus (22.6%) were the predominant species. Rhipicephalus sanguineus (0.3%) and D. reticulatus (0.8%) were found in low numbers on dogs only. All dogs infested with R. sanguineus had a recent travel history, but D. reticulatus were collected from a dog without a history of travelling abroad. Of the collected Ixodes ticks, 19.5% were positive for A. phagocytophilum and 10.1% for Borrelia spp. (B. afzelii, B. garinii, B. burgdorferi s.s., B. lusitaniae, B. valaisiana and B. spielmanii). Rickettsia helvetica was found in 14.1% of Ixodes ticks. All Dermacentor ticks were negative for all the investigated pathogens, but one R. sanguineus tick was positive for Rickettsia massiliae. Conclusion: D. reticulatus was confirmed to be present as an indigenous parasite in Belgium. B. lusitaniae and R. helvetica were detected in ticks in Belgium for the first time.	[Claerebout, Edwin; Casaert, Stijn; De Cat, Ann] Univ Ghent, Fac Vet Med, Parasitol Lab, Merelbeke, Belgium; [Losson, Bertrand] Univ Liege, Lab Parasitol & Pathol Parasit Dis, Liege, Belgium; [Cochez, Christel; Heyman, Paul] Queen Astrid Mil Hosp, Res Lab Vector Borne Dis, Brussels, Belgium; [Dalemans, Anne-Catherine] Bayer HealthCare, Div Anim Hlth, Diegem, Belgium; [Madder, Maxime] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Madder, Maxime] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Pretoria, South Africa; [Saegerman, Claude; Lempereur, Laetitia] Univ Liege, Res Unit Epidemiol & Risk Anal Appl Vet Sci, Liege, Belgium	Claerebout, E (reprint author), Univ Ghent, Fac Vet Med, Parasitol Lab, Merelbeke, Belgium.	claerebout@ugent.be			Bayer Health Care, Animal Health Division; Bayer Health Care; Merial; Pfizer Animal Health	This study was partially financed by Bayer Health Care, Animal Health Division. In the last 5 years, EC has obtained funding from, lectured or consulted for the following companies selling products to treat tick infestations in dogs and cats: Bayer Health Care, Merial, Pfizer Animal Health.	Arthur D.R., 1963, BRIT TICKS; Bakken JS, 2008, INFECT DIS CLIN N AM, V22, P433, DOI 10.1016/j.idc.2008.03.011; Baumgarten BU, 1999, J CLIN MICROBIOL, V37, P3448; Beichel E, 1996, VET PARASITOL, V65, P147, DOI 10.1016/0304-4017(96)00943-0; BOOM R, 1990, J CLIN MICROBIOL, V28, P495; Boretti FS, 2009, APPL ENVIRON MICROB, V75, P3230, DOI 10.1128/AEM.00220-09; Carrade DD, 2009, J VET INTERN MED, V23, P1129, DOI 10.1111/j.1939-1676.2009.0384.x; CIMMINO MA, 1989, JAMA-J AM MED ASSOC, V262, P2997, DOI 10.1001/jama.262.21.2997; Cochez C, 2012, MED VET ENTOMOL, V26, P355, DOI 10.1111/j.1365-2915.2011.00998.x; Cochez C, 2011, TICKS TICK-BORNE DIS, V2, P156, DOI 10.1016/j.ttbdis.2011.06.004; Courtney JW, 2004, J CLIN MICROBIOL, V42, P3164, DOI 10.1128/JCM.42.7.3164-3168.2004; Dantas-Torres F, 2012, TRENDS PARASITOL, V28, P437, DOI 10.1016/j.pt.2012.07.003; Dautel H, 2006, INT J MED MICROBIOL, V296, P149, DOI 10.1016/j.ijmm.2006.01.013; Day MJ, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-49; ENG TR, 1988, J INFECT DIS, V158, P1410, DOI 10.1093/infdis/158.6.1410; Fernandez-Soto P, 2006, EUR J CLIN MICROBIOL, V25, P811, DOI 10.1007/s10096-006-0217-9; Foldvari G, 2005, VET PARASITOL, V129, P125, DOI 10.1016/j.vetpar.2004.11.032; Goossens HAT, 2001, J CLIN MICROBIOL, V39, P844, DOI 10.1128/JCM.39.3.844-848.2001; Gray J. S., 1991, Review of Medical and Veterinary Entomology, V79, P323; Heile C, 2006, BERL MUNCH TIERARZTL, V119, P330; Heyman P, 2003, J INFECTION, V47, P129, DOI 10.1016/S0163-4453(03)00056-2; Hovius KE, 1998, VET QUART, V20, P143, DOI 10.1080/01652176.1998.9694860; JOHANSSON KE, 1995, RES VET SCI, V58, P109, DOI 10.1016/0034-5288(95)90061-6; Kesteman T, 2010, ACTA CLIN BELG, V65, P319, DOI 10.1179/acb.2010.069; Lempereur L, 2011, VECTOR-BORNE ZOONOT, V11, P125, DOI 10.1089/vbz.2009.0189; Li S, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-149; Little SE, 2010, TRENDS PARASITOL, V26, P213, DOI 10.1016/j.pt.2010.01.006; Losson B, 1999, ANN MED VET, V143, P119; Mannelli A, 2012, FEMS MICROBIOL REV, V36, P837, DOI 10.1111/j.1574-6976.2011.00312.x; Misonne MC, 1998, J CLIN MICROBIOL, V36, P3352; Nielsen H, 2004, SCAND J INFECT DIS, V36, P559, DOI 10.1080/00365540410020776; Nijhof AM, 2007, VECTOR-BORNE ZOONOT, V7, P1; Ogden NH, 2000, MED VET ENTOMOL, V14, P332, DOI 10.1046/j.1365-2915.2000.00244.x; Pfaffle M, 2011, EXP APPL ACAROL, V54, P151, DOI 10.1007/s10493-011-9432-x; Pusterla N, 1997, J CLIN MICROBIOL, V35, P2307; Randolph SE, 2002, INT J PARASITOL, V32, P979, DOI 10.1016/S0020-7519(02)00030-9; Rauter C, 2005, APPL ENVIRON MICROB, V71, P7203, DOI 10.1128/AEM.71.11.7203-7216.2005; Reis C, 2011, VECTOR-BORNE ZOONOT, V11, P907, DOI 10.1089/vbz.2010.0103; Reye AL, 2010, APPL ENVIRON MICROB, V76, P2923, DOI 10.1128/AEM.03061-09; Rudenko N, 2011, TICKS TICK-BORNE DIS, V2, P123, DOI 10.1016/j.ttbdis.2011.04.002; Shaw SE, 2001, TRENDS PARASITOL, V17, P74, DOI 10.1016/S1471-4922(00)01856-0; Skerget M, 2003, EMERG INFECT DIS, V9, P1337; Skuballa J, 2010, VECTOR-BORNE ZOONOT, V10, P1055, DOI 10.1089/vbz.2009.0150; Smith FD, 2011, MED VET ENTOMOL, V25, P377, DOI 10.1111/j.1365-2915.2011.00954.x; Smith FD, 2012, COMP IMMUNOL MICROB, V35, P163, DOI 10.1016/j.cimid.2011.12.009; Stanek G, 2011, CLIN MICROBIOL INFEC, V17, P487, DOI 10.1111/j.1469-0691.2011.03492.x; Talleklint L, 1996, J MED ENTOMOL, V33, P592, DOI 10.1093/jmedent/33.4.592; Tijsse-Klasen E, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-17; Zygner W, 2008, VET PARASITOL, V153, P139, DOI 10.1016/j.vetpar.2008.01.036	49	57	59	4	44	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	JUN 19	2013	6								183	10.1186/1756-3305-6-183				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	167ZA	WOS:000320672900001	23777784	DOAJ Gold, Green Published			2019-03-26	
J	Bodi, JM; Nsibu, CN; Longenge, RL; Aloni, MN; Akilimali, PZ; Tshibassu, PM; Kayembe, PK; Omar, AH; Hirayama, K; Verhaegen, J				Bodi, Joseph M.; Nsibu, Celestin N.; Longenge, Roland L.; Aloni, Michel N.; Akilimali, Pierre Z.; Tshibassu, Pierre M.; Kayembe, Patrick K.; Omar, Ahmeddin H.; Hirayama, Kenji; Verhaegen, Jan			Blackwater fever in Congolese children: a report of clinical, laboratory features and risk factors	MALARIA JOURNAL			English	Article						Blackwater fever; Children; Quinine ingestion; Parasitaemia; Kinshasa; Democratic Republic of Congo	ACUTE-RENAL-FAILURE; SEVERE MALARIA; HEMOGLOBINURIA; HEMOLYSIS; AFRICA	Background: Blackwater fever (BWF) is one of the severe forms of malaria. This complication was first described among non-immune European expatriates in the malaria endemic areas. Recently, resurgence of this form of malaria has been reported among the indigenous populations. The objective of this study was to investigate the risk factors among BWF patients. Methods: A case-control study was conducted between in four hospitals located in Kinshasa, Democratic Republic of Congo from January 2010 to December 2011. One hundred and twenty nine children were recruited with 43 (cases) and 86 (control). Results: No significant difference in the gender and age distribution was observed between the case and control). The sex-ratio male to female in the case group and control group was respectively 1:1.0 and 1:1.1. The mean age was 8.62 years (SD = 3.84) in patients with haemoglobinuria and 8.55 years (SD = 3.77) in the control group. No difference in frequency of co-infection with Plasmodium falciparum and Plasmodium malariae was observed between the two groups. Significant differences in haemoglobin, haematocrit, creatinine, urea and platelets levels were observed between the two groups (p < 0.001), but not for blood group and lactate dehydrogenase (LDH) level. Majority of the BWF cases occurred during the rainy season (88.4%). Treatment with quinine (95.3%) was significantly associated with cases (p < 0.001). Seven (16.2%) of the haemoglobinuric children developed acute renal failure. Conclusion: Rainy season, low parasitaemia and quinine ingestion were the major risk factors significantly associated with haemoglobinuria. Acute renal failure was observed as the major complication of BWF.	[Bodi, Joseph M.; Nsibu, Celestin N.; Longenge, Roland L.] Univ Kinshasa, Univ Hosp Kinshasa, Sch Med, Dept Paediat,Paediat Emergency & Intens Care Unit, Kinshasa, Zaire; [Aloni, Michel N.] Univ Kinshasa, Univ Hosp Kinshasa, Sch Med, Dept Paediat,Div Haematooncol & Pediat Nephrol, Kinshasa, Zaire; [Akilimali, Pierre Z.; Kayembe, Patrick K.] Univ Kinshasa, Sch Publ Hlth, Div Biostat & Epidemiol, Kinshasa, Zaire; [Tshibassu, Pierre M.] Univ Kinshasa, Univ Hosp Kinshasa, Sch Med, Dept Paediat,Paediat Gastroenterol & Neurol Unit, Kinshasa, Zaire; [Omar, Ahmeddin H.] Minist Hlth, Div Malaria Control DOMC, Nairobi, Kenya; [Hirayama, Kenji] Nagasaki Univ, Inst Trop Med Nekken, Dept Immunogenet, Tokyo, Japan; [Verhaegen, Jan] Katholieke Univ Leuven, Dept Microbiol, Brussels, Belgium	Bodi, JM (reprint author), Univ Kinshasa, Univ Hosp Kinshasa, Sch Med, Dept Paediat,Paediat Emergency & Intens Care Unit, Kinshasa, Zaire.	jbodi1@yahoo.fr		Kayembe Kalambayi, Patrick/0000-0002-5693-2144; Hirayama, Kenji/0000-0001-9467-1777	Katholieke Universiteit de Leuven, Belgium	This research project was supported by the Katholieke Universiteit de Leuven, Belgium through the programme of scholarship for young Congolese researchers (Bourses chaires scientifiques pour jeunes congolais).	ADU D, 1976, BRIT MED J, V1, P890, DOI 10.1136/bmj.1.6014.890; Ajetunmobi WA, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-336; Aloni M, 2010, B SOC PATHOL EXOT, V103, P296; Aloni MN, 2012, ACTA PAEDIATR, V101, P514; Anochie IC, 2005, PEDIATR NEPHROL, V20, P1610, DOI 10.1007/s00467-005-1984-8; Ansari N, 2011, INT J NEPHROL, V2011; Assounga AG, 2011, SAUDI J KIDNEY DIS T, V11, P40; BEUTLER E, 1968, BLOOD, V32, P816; Bisoffi Z, 1999, TROP MED INT HEALTH, V4, P72; Bodi J, SAUDI J KID IN PRESS; BRUCE-CHWATT L J, 1987, Acta Leidensia, V55, P181; Bruneel F, 2001, CLIN INFECT DIS, V32, P1133, DOI 10.1086/319743; Das B. S., 2008, Journal of Vector Borne Diseases, V45, P83; Daubrey PT, 2004, B SOC PATHOL EXOT, V97, P325; DELACOLLETTE C, 1995, ANN SOC BELG MED TR, V75, P51; Gobbi F, 2005, EMERG INFECT DIS, V11, P1118, DOI 10.3201/eid1107.041237; Idro R, 2006, TROP MED INT HEALTH, V11, P115, DOI 10.1111/j.1365-3156.2005.01518.x; Jelliffe DB, 1951, BRIT MED J, V19, P1117; Mishra SK, 2002, J INDIAN ACAD CLIN M, V3, P141; Mockenhaupt FP, 2004, AM J TROP MED HYG, V71, P167, DOI 10.4269/ajtmh.2004.71.167; Motulsky AG, 1966, AM J HUM GENET, V18, P513; O'Donnell A, 2006, T ROY SOC TROP MED H, V100, P817, DOI 10.1016/j.trstmh.2005.11.015; Oumar AA, 2007, ARCH PEDIATRIE, V14, P993, DOI 10.1016/j.arcped.2007.04.005; Patil Vc, 2012, Trop Parasitol, V2, P49, DOI 10.4103/2229-5070.97240; Rivera N, 2013, PARASITOL RES, V112, P1021, DOI 10.1007/s00436-012-3224-z; Rogier C, 2003, T ROY SOC TROP MED H, V97, P193, DOI 10.1016/S0035-9203(03)90116-7; Taylor SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016420; TRAN TH, 1996, CLIN INFECT DIS, V23, P1274; Van Biesen W, 2006, CLIN J AM SOC NEPHRO, V1, P1314, DOI 10.2215/CJN.02070606; Van den Ende J, 1998, TROP MED INT HEALTH, V3, P632, DOI 10.1046/j.1365-3156.1998.00287.x; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2006, GUID MAL TREATM; [World Health Organization Severe falciparum malaria], 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6	33	7	7	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JUN 15	2013	12								205	10.1186/1475-2875-12-205				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	170AV	WOS:000320822800001	23767699	DOAJ Gold, Green Published			2019-03-26	
J	Cencig, S; Coltel, N; Truyens, C; Carlier, Y				Cencig, Sabrina; Coltel, Nicolas; Truyens, Carine; Carlier, Yves			Fertility, Gestation Outcome and Parasite Congenital Transmissibility in Mice Infected with TcI, TcII and TcVI Genotypes of Trypanosoma cruzi	PLOS NEGLECTED TROPICAL DISEASES			English	Article							CHAGAS-DISEASE; PREGNANT-WOMEN; IFN-GAMMA; VERTICAL TRANSMISSION; TNF-ALPHA; LINEAGES; ANTIBODIES; MORBIDITY; MORTALITY; NEWBORNS	This work aims to compare the effects of acute or chronic infections with the T. cruzi genotypes TcI (X10 strain), TcII (Y strain) and TcVI (Tulahuen strain) on fertility, gestation, pup growth and the possible vertical transmission of parasites in BALB/c mice. The occurrence of congenital infection was evaluated by microscopic examination of blood and/or qPCR on blood and heart in newborn pups and/or older offspring submitted to cyclophosphamide-induced immunosuppression in order to detect possible cryptic congenital infection. Altogether, the results show that: i) for the three strains tested, acute infection occurring after the embryo implantation in the uterus (parasite inoculation 4 days before mating), or close to delivery (parasite inoculation on day 13 of gestation), prevents or severely jeopardizes gestation outcome (inducing pup mortality and intra-uterine growth retardation); ii) for the three strains tested, gestation during chronic infection results in intra-uterine growth retardation, whereas re-inoculation of TcVI parasites during gestation in such chronically infected mice, in addition, strongly increases pup mortality; iii) congenital infection remains a rare consequence of infection (occurring in approximately 4% of living pups born to acutely infected dams); iv) PCR, detecting parasitic DNA and not living parasites, is not convenient to detect congenial infection close to delivery; v) transmission of parasites by breast milk is unlikely. This study should encourage further investigations using other parasite strains and genotypes to explore the role of virulence and other factors, as well as the mechanisms of such effects on gestation and on the establishment of congenital infection.	[Cencig, Sabrina; Coltel, Nicolas; Truyens, Carine; Carlier, Yves] Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium	Cencig, S (reprint author), Univ Libre Bruxelles, Fac Med, Parasitol Lab, Brussels, Belgium.	ycarlier@ulb.ac.be			European Community [223034]	This study was supported by the European Community's Seventh Framework Programme [FP7] under the grant agreement No. 223034. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alarcon M, 2009, INVEST CLIN, V50, P335; Alkmim-Oliveira SM, 2013, PARASITOL RES, V112, P671, DOI 10.1007/s00436-012-3184-3; Martins LPA, 2011, BRAZ J INFECT DIS, V15, P116, DOI 10.1590/S1413-86702011000200004; ANDRADE SG, 1982, T ROY SOC TROP MED H, V76, P123, DOI 10.1016/0035-9203(82)90036-0; APT W, 1968, Boletin Chileno de Parasitologia, V23, P9; APT W, 1968, Boletin Chileno de Parasitologia, V23, P15; Bern C, 2009, CLIN INFECT DIS, V49, P1667, DOI 10.1086/648070; BITTENCOURT AI, 1985, ANN TROP MED PARASIT, V79, P393, DOI 10.1080/00034983.1985.11811937; Bittencourt AL, 1988, PARASITIC INFECT PRE, P62; Boufker HI, 2006, AM J PATHOL, V169, P1730, DOI 10.2353/ajpath.2006.060309; Brutus L, 2011, AM J TROP MED HYG, V84, P808, DOI 10.4269/ajtmh.2011.10-0577; Burgos JM, 2007, INT J PARASITOL, V37, P1319, DOI 10.1016/j.ijpara.2007.04.015; Bustamante JM, 2002, INT J PARASITOL, V32, P889, DOI 10.1016/S0020-7519(02)00023-1; Bustamante JM, 2008, NAT MED, V14, P542, DOI 10.1038/nm1744; CABEZAMECKERT P, 1980, MEDICINA-BUENOS AIRE, V40, P40; CALABRESE KS, 1994, INT J EXP PATHOL, V75, P453; CARLIER Y, 1987, AM J TROP MED HYG, V37, P534, DOI 10.4269/ajtmh.1987.37.534; CARLIER Y, 1992, AM J TROP MED HYG, V46, P116, DOI 10.4269/ajtmh.1992.46.116; CARLIER Y, 1995, PARASITOL TODAY, V11, P94, DOI 10.1016/0169-4758(95)80165-0; Carlier Y, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001250; Carlier Y, 2010, ELSEV INSIGHT, P539, DOI 10.1016/B978-0-12-384876-5.00022-8; CASTANYS S, 1984, Z PARASITENKD, V70, P443, DOI 10.1007/BF00926684; Cencig S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001216; Corrales RM, 2009, INFECT GENET EVOL, V9, P278, DOI 10.1016/j.meegid.2008.12.008; Coura JR, 2010, NATURE, V465, pS6, DOI 10.1038/nature09221; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Cummings KL, 2003, MOL BIOCHEM PARASIT, V129, P53, DOI 10.1016/S0166-6851(03)00093-8; Davila HO, 1997, IMMUNOPHARMACOLOGY, V37, P1, DOI 10.1016/S0162-3109(97)00046-5; DAVILA HO, 1994, AM J TROP MED HYG, V50, P506, DOI 10.4269/ajtmh.1994.50.506; de Cunio R W, 1980, Medicina (B Aires), V40 Suppl 1, P50; del Puerto F, 2010, AM J TROP MED HYG, V82, P386, DOI 10.4269/ajtmh.2010.09-0006; DELGADO MA, 1978, AM J TROP MED HYG, V27, P1108, DOI 10.4269/ajtmh.1978.27.1108; Diaz-Lujan C, 2012, PLACENTA, V33, P264, DOI 10.1016/j.placenta.2012.01.005; DISKO R, 1971, Z TROPENMED PARASIT, V22, P56; ELBOUHDIDI A, 1994, PARASITE IMMUNOL, V16, P69; Falla A, 2009, ACTA TROP, V110, P15, DOI 10.1016/j.actatropica.2008.12.003; Fernandez-Aguilar S, 2005, REV SOC BRAS MED TRO, V38, P84; Hall CA, 2010, J PARASITOL, V96, P371, DOI 10.1645/GE-2296.1; HERNANDEZMATHESON IM, 1983, T ROY SOC TROP MED H, V77, P405, DOI 10.1016/0035-9203(83)90174-8; Jackson Y, 2009, EMERG INFECT DIS, V15, P601, DOI 10.3201/eid1504.080438; Lazarte Raul A., 2012, Morbidity and Mortality Weekly Report, V61, P477; Lenzi HL, 1998, ACTA TROP, V71, P117, DOI 10.1016/S0001-706X(98)00058-8; Marinho CRF, 2007, SCAND J IMMUNOL, V66, P297, DOI 10.1111/j.1365-3083.2007.01958.x; Menezes C A, 1992, Rev Soc Bras Med Trop, V25, P109; Mjihdi A, 2004, EXP PARASITOL, V107, P58, DOI 10.1016/j.exppara.2004.03.016; Mjihdi A, 2002, AM J PATHOL, V161, P673, DOI 10.1016/S0002-9440(10)64223-X; Moreno Elio A., 2003, Invest. clín, V44, P241; Munoz J, 2009, CLIN INFECT DIS, V48, P1736, DOI 10.1086/599223; OLIVEIRA FAUSTO da CUNHA, 1966, REV INST MED TROP SAO PAULO, V8, P184; Ortiz S, 2012, ACTA TROP, V124, P243, DOI 10.1016/j.actatropica.2012.08.001; Pan American Health Organization, 2006, OPSHDMCD42506 PAN AM; Pena DA, 2011, J INFECT DIS, V204, P478, DOI 10.1093/infdis/jir292; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; RIVERA MT, 1995, INFECT IMMUN, V63, P591; Rodrigues AA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001598; Sala MA, 2006, PARASITOL LATINOAM, V61, P69; SCHENONE H, 1985, Boletin Chileno de Parasitologia, V40, P24; SHAW GL, 1975, EXP PARASITOL, V37, P211, DOI 10.1016/0014-4894(75)90072-7; Siriano LD, 2011, AM J TROP MED HYG, V84, P569, DOI 10.4269/ajtmh.2011.10-0015; Solana ME, 2009, PARASITOLOGY, V136, P627, DOI 10.1017/S0031182009005770; Solana ME, 2002, J PARASITOL, V88, P102, DOI 10.2307/3285399; Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x; STORNI P, 1979, MEDICINA-BUENOS AIRE, V39, P193; TERUEL J R, 1970, Revista do Instituto de Medicina Tropical de Sao Paulo, V12, P239; Torrico F, 2006, TROP MED INT HEALTH, V11, P628, DOI 10.1111/j.1365-3156.2006.01623.x; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Truyens C, 1995, PARASITE IMMUNOL, V17, P561, DOI 10.1111/j.1365-3024.1995.tb00999.x; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; Virreira M, 2007, AM J TROP MED HYG, V77, P102, DOI 10.4269/ajtmh.2007.77.102; Virreira M, 2006, AM J TROP MED HYG, V75, P871, DOI 10.4269/ajtmh.2006.75.871; VRAY B, 1991, INFECT IMMUN, V59, P3303; WERNER H, 1971, Z TROPENMED PARASIT, V22, P224; Werner H, 1958, Z TROPENMED PARASIT, V8, P17; Zingales B, 2012, INFECT GENET EVOL, V12, P240, DOI 10.1016/j.meegid.2011.12.009	74	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUN	2013	7	6							e2271	10.1371/journal.pntd.0002271				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	175AL	WOS:000321201300028	23785533	DOAJ Gold, Green Published			2019-03-26	
J	Guilmot, A; Bosse, J; Carlier, Y; Truyens, C				Guilmot, Aline; Bosse, Julie; Carlier, Yves; Truyens, Carine			Monocytes Play an IL-12-Dependent Crucial Role in Driving Cord Blood NK Cells to Produce IFN-g in Response to Trypanosoma cruzi	PLOS NEGLECTED TROPICAL DISEASES			English	Article							NATURAL-KILLER-CELLS; CD4(+) T-CELLS; DENDRITIC CELLS; CHAGAS-DISEASE; IMMUNE-RESPONSES; GAMMA PRODUCTION; GENE-EXPRESSION; MESSENGER-RNA; INFECTION; ACTIVATION	We previously reported that foetuses congenitally infected with Trypanosoma cruzi, the agent of Chagas disease, mount an adult-like parasite-specific CD8(+) T-cell response, producing IFN-g, and present an altered NK cell phenotype, possibly reflecting a post-activation state supported by the ability of the parasite to trigger IFN-g synthesis by NK cells in vitro. We here extended our knowledge on NK cell activation by the parasite. We compared the ability of T. cruzi to activate cord blood and adult NK cells from healthy individuals. Twenty-four hours co-culture of cord blood mononuclear cells with T. cruzi trypomastigotes and IL-15 induced high accumulation of IFN-g transcripts and IFN-g release. TNF-a, but not IL-10, was also produced. This was associated with up-regulation of CD69 and CD54, and down-regulation of CD62L on NK cells. The CD56(bright) NK cell subset was the major IFN-g responding subset (up to 70% IFN-g-positive cells), while CD56(dim) NK cells produced IFN-g to a lesser extent. The response points to a synergy between parasites and IL-15. The neonatal response, observed in all newborns, remained however slightly inferior to that of adults. Activation of IL-15-sensitized cord blood NK cells by the parasite required contacts with live/intact parasites. In addition, it depended on the engagement of TLR-2 and 4 and involved IL-12 and cross-talk with monocytes but not with myeloid dendritic cells, as shown by the use of neutralizing antibodies and cell depletion. This work highlights the ability of T. cruzi to trigger a robust IFN-g response by IL-15-sensitized human neonatal NK cells and the important role of monocytes in it, which might perhaps partially compensate for the neonatal defects of DCs. It suggests that monocyte-and IL-12-dependent IFN-g release by NK cells is a potentially important innate immune response pathway allowing T. cruzi to favour a type 1 immune response in neonates.	[Guilmot, Aline; Bosse, Julie; Carlier, Yves; Truyens, Carine] Univ Libre Brussels, Fac Med, Parasitol Lab, Brussels, Belgium	Guilmot, A (reprint author), Univ Libre Brussels, Fac Med, Parasitol Lab, Brussels, Belgium.	ctruyens@ulb.ac.be			Fond National de la Recherche Scientifique [3461505F, 1.5.284.08F]; Fonds Emile Defay (ULB); Fondation Van Buuren (ULB)	This work was supported by the Fond National de la Recherche Scientifique (grants 3461505F and 1.5.284.08F), the Fonds Emile Defay (ULB) and the Fondation Van Buuren (ULB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antunez MI, 2001, IMMUNOL LETT, V79, P189, DOI 10.1016/S0165-2478(01)00283-8; Bafica A, 2006, J IMMUNOL, V177, P3515, DOI 10.4049/jimmunol.177.6.3515; Balasubramani A, 2010, IMMUNOL REV, V238, P216, DOI 10.1111/j.1600-065X.2010.00961.x; Becker I, 2003, MOL BIOCHEM PARASIT, V130, P65, DOI 10.1016/S0166-6851(03)00160-9; Bihl F, 2010, J IMMUNOL, V185, P2174, DOI 10.4049/jimmunol.1001486; Borg C, 2004, BLOOD, V104, P3267, DOI 10.1182/blood-2004-01-0380; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Carlier Y, 2010, ELSEV INSIGHT, P539, DOI 10.1016/B978-0-12-384876-5.00022-8; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P17095, DOI 10.1073/pnas.0502129102; Combe CL, 2005, INFECT IMMUN, V73, P4913, DOI 10.1128/IAI.73.8.4913-4921.2005; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Dalbeth N, 2004, J IMMUNOL, V173, P6418, DOI 10.4049/jimmunol.173.10.6418; Dalle JH, 2005, PEDIATR RES, V57, P649, DOI 10.1203/01.PDR.0000156501.55431.20; Dauby N, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000571; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Fonseca SG, 2007, SCAND J IMMUNOL, V66, P362, DOI 10.1111/j.1365-3083.2007.01987.x; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; Gregoire C, 2007, IMMUNOL REV, V220, P169, DOI 10.1111/j.1600-065X.2007.00563.x; Guilmot A, 2011, J INNATE IMMUN, V3, P280, DOI 10.1159/000323934; Hermann E, 2002, BLOOD, V100, P2153; Hermann E, 2006, PEDIATR RES, V60, P38, DOI 10.1203/01.pdr.0000220335.05588.ea; Horowitz A, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00088; Kanevskiy LM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00011; Kayama H, 2010, MICROBES INFECT, V12, P511, DOI 10.1016/j.micinf.2010.03.005; Kokkinopoulos I, 2005, MOL IMMUNOL, V42, P957, DOI 10.1016/j.molimm.2004.09.037; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; Korbel DS, 2004, INT J PARASITOL, V34, P1517, DOI 10.1016/j.ijpara.2004.10.006; Le Garff-Tavernier M, 2010, AGING CELL, V9, P527, DOI 10.1111/j.1474-9726.2010.00584.x; Lee GA, 2011, J IMMUNOL, V187, P1212, DOI 10.4049/jimmunol.1100331; Lucas M, 2007, IMMUNITY, V26, P503, DOI 10.1016/j.immuni.2007.03.006; Maaser C, 2004, IMMUNOLOGY, V112, P437, DOI 10.1111/j.1365-2567.2004.01895.x; Mavropoulos A, 2005, BLOOD, V105, P282, DOI 10.1182/blood-2004-07-2782; Meazza R, 2011, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2011/861920; Mian MF, 2010, MOL THER, V18, P1379, DOI 10.1038/mt.2010.75; Nagao M, 2000, HEPATOLOGY, V32, P491, DOI 10.1053/jhep.2000.16470; Newman KC, 2007, NAT REV IMMUNOL, V7, P279, DOI 10.1038/nri2057; Newman KC, 2006, PLOS PATHOG, V2, P1120, DOI 10.1371/journal.ppat.0020118; Nguyen M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010407; Nomura A, 2001, EXP HEMATOL, V29, P1169, DOI 10.1016/S0301-472X(01)00689-0; Pillet AH, 2011, HUM IMMUNOL, V72, P1013, DOI 10.1016/j.humimm.2011.07.311; PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; Rodrigues Mauricio M., 2012, Journal of Parasitology Research, P507874, DOI 10.1155/2012/507874; Rodriguez P, 2012, MED MICROBIOL IMMUN, V201, P157, DOI 10.1007/s00430-011-0217-y; Sathler-Avelar R, 2003, SCAND J IMMUNOL, V58, P655, DOI 10.1111/j.1365-3083.2003.01340.x; Sohlberg E, 2011, IMMUNOLOGY, V133, P41, DOI 10.1111/j.1365-2567.2011.03407.x; Souza PEA, 2004, INFECT IMMUN, V72, P5283, DOI 10.1128/IAI.72.9.5283-5291.2004; Strengell M, 2003, J IMMUNOL, V170, P5464, DOI 10.4049/jimmunol.170.11.5464; Tamassia N, 2010, FASEB J, V24, P1365, DOI 10.1096/fj.09-145573; Tarleton RL, 2007, CURR OPIN IMMUNOL, V19, P430, DOI 10.1016/j.coi.2007.06.003; Vekemans J, 2000, INFECT IMMUN, V68, P5430, DOI 10.1128/IAI.68.9.5430-5434.2000; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Walzer T, 2005, BLOOD, V106, P2252, DOI 10.1182/blood-2005-03-1154; Watford WT, 2003, CYTOKINE GROWTH F R, V14, P361, DOI 10.1016/S1359-6101(03)00043-1; Watzl C, 2012, FRONT BIOSCI-LANDMRK, V17, P1418, DOI 10.2741/3995; Young HA, 2007, CURR TOP MICROBIOL, V316, P97; Zaghouani H, 2009, TRENDS IMMUNOL, V30, P585, DOI 10.1016/j.it.2009.09.002; Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021	58	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUN	2013	7	6							e2291	10.1371/journal.pntd.0002291				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	175AL	WOS:000321201300042	23819002	DOAJ Gold, Green Published			2019-03-26	
J	Mekonnen, Z; Levecke, B; Boulet, G; Bogers, JP; Vercruysse, J				Mekonnen, Z.; Levecke, B.; Boulet, G.; Bogers, J. -P.; Vercruysse, J.			Efficacy of different albendazole and mebendazole regimens against heavy-intensity Trichuris trichiura infections in school children, Jimma Town, Ethiopia	PATHOGENS AND GLOBAL HEALTH			English	Article						Efficacy; Albendazole; Mebendazole; Trichuris trichiura	SOIL-TRANSMITTED HELMINTHS; FECAL EGG COUNTS	Recent studies have shown that the efficacy of benzimidazole drugs is influenced by the intensity of trichuriasis. Therefore, the objective of this study was to determine the efficacy of albendazole (ALB) and mebendazole (MBZ) administered randomly for 1 (ALB x 1 and MBZ x 1) or 2 days (ALB x 2 and MBZ x 2) to 385 school children with heavy-intensity trichuriasis (mean faecal egg counts (FEC) > 1000 eggs per gram of stool (epg)) in Jimma Town, Ethiopia. The efficacies (95% confidence intervals) by means of reduction in faecal egg counts (FECs) were 29.3% (-9.9-56.2), 60.0% (48.5-70.9), 73.5% (64.2-81.3), and 87.1% (81.4-91.2) for ALB x 1, MBZ x 1, ALB x 2, and MBZ x 2, respectively. These observations highlight that assessment of the anthelmintic efficacy of existing or new compounds against Trichuris trichiura should be assessed under varying levels of infection intensity.	[Mekonnen, Z.] Jimma Univ, Dept Med Lab Sci & Pathol, Coll Publ Hlth & Med Sci, Jimma, Ethiopia; [Mekonnen, Z.; Levecke, B.; Vercruysse, J.] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Merelbeke, Belgium; [Boulet, G.; Bogers, J. -P.] Univ Antwerp, Appl Mol Biol Res AMBIOR Grp, Lab Cell Biol & Histol, Antwerp, Belgium	Mekonnen, Z (reprint author), POB 1047, Jimma, Ethiopia.	Zeleke.Mekonnen@ju.edu.et		Levecke, Bruno/0000-0001-8912-5595; Bogers, John-Paul/0000-0001-9107-132X	Flemish interuniversity Council (VLIR-IUC/JU) programme; Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen)	The fieldwork received financial support from the Flemish interuniversity Council (VLIR-IUC/JU) programme. BL is funded by the Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen).	Bennett A, 2000, PARASITOL TODAY, V16, P71, DOI 10.1016/S0169-4758(99)01544-6; Keiser J, 2008, JAMA-J AM MED ASSOC, V299, P1937, DOI 10.1001/jama.299.16.1937; Levecke B, 2012, T ROY SOC TROP MED H, V106, P128, DOI 10.1016/j.trstmh.2011.09.007; Levecke B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001201; Vercruysse J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000948	5	8	8	2	14	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	2047-7724			PATHOG GLOB HEALTH	Pathog. Glob. Health	JUN	2013	107	4					207	209		10.1179/2047773213Y.0000000092				3	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	173YK	WOS:000321119300009	23816513	Green Published			2019-03-26	
J	Wirtz, VJ; Herrera-Patino, JJ; Santa-Ana-Tellez, Y; Dreser, A; Elseviers, M; Vander Stichele, RH				Wirtz, V. J.; Herrera-Patino, J. J.; Santa-Ana-Tellez, Y.; Dreser, A.; Elseviers, M.; Vander Stichele, R. H.			Analysing policy interventions to prohibit over-the-counter antibiotic sales in four Latin American countries	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						antibiotics; over-the-counter; Latin America; policy; drug utilisation	CONSUMPTION; VENEZUELA	OBJECTIVES To describe and evaluate policies implemented in Chile, Colombia, Venezuela and Mexico (1995-2009) to prohibit antibiotic OTC sales and explore limitations in available data. METHODS We searched and analysed legislation, grey literature and peer-reviewed publications on regulatory interventions and implementation strategies to enforce prohibition of OTC antibiotic sales. We also assessed the impact using private sector retail sales data of antibiotics studying changes in level and consumption trends before and after the policy change using segmented time series analysis. Finally, we assessed the completeness and data quality through an established checklist to test the suitability of the data for analysis of the interventions. RESULTS Whereas Chile implemented a comprehensive package of interventions to accompany regulation changes, Colombia's reform was limited to the capital district and Venezuela's limited to only some antibiotics and without awareness campaigns. In Mexico, no enforcement was enacted. The data showed a differential effect of the intervention among the countries studied with a significant change in level of consumption in Chile (-5.56 DID) and in Colombia (-1.00DID). In Venezuela and Mexico, no significant change in level and slope was found. Changes in population coverage were identified as principal limitations of using sales data for evaluating the reform impact. CONCLUSION Retail sales data can be useful when assessing policy impact but should be supplemented by other data sources such as public sector sales and prescription data. Implementing regulatory enforcement has shown some impact, but a sustainable, concerted approach will be needed to address OTC sales in the future.	[Wirtz, V. J.; Santa-Ana-Tellez, Y.; Dreser, A.] Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, Mexico; [Herrera-Patino, J. J.] Natl Inst Publ Hlth, Ctr Evaluat Res & Surveys, Cuernavaca, Morelos, Mexico; [Elseviers, M.] Univ Antwerp, Ctr Res & Innovat Care, Antwerp, Belgium; [Vander Stichele, R. H.] Univ Ghent, Ctr Clin Pharmacol, Heymans Inst Pharmacol, Fac Med & Hlth Sci, Ghent, Belgium	Wirtz, VJ (reprint author), Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca, Morelos, Mexico.	veronika.wirtz@insp.mx	Vander Stichele, Robert/K-7203-2015	Vander Stichele, Robert/0000-0001-9118-9651; Wirtz, Veronika J./0000-0002-0863-8768			[Anonymous], 2001, GLOB STRAT CONT ANT; Bavestrello FL, 2011, REV CHIL INFECTOL, V28, P107, DOI DOI 10.4067/S0716-10182011000200001; Bavestrello FL, 2002, REV MED CHILE, V130, P1265; Bonvecchio A, 2011, SALUD PUBLICA MEXICO, V53, pS275; Health IMS, 2011, PHARM MARK CHIL; IMS Health, 2011, INT C IMPR US MED AN; Leung E, 2011, B WORLD HEALTH ORGAN, V89, P390, DOI 10.2471/BLT.11.088435; Lopez Jose J, 2009, Rev Salud Publica (Bogota), V11, P432; MacDougall C, 2005, CLIN MICROBIOL REV, V18, P638, DOI 10.1128/CMR.18.4.638-656.2005; Olaiz G, 2006, ENCUESTA NACL SALUD; Pan American Health Organization, 2004, LEG ANT AM LAT; Vacca CP, 2011, REV PANAM SALUD PUBL, V30, P586; Rivas P, 2011, REV PANAM SALUD PUBL, V30, P592, DOI 10.1590/S1020-49892011001200016; Soto P, 1999, REV CHIL INFECT, V16, P191; Vander Stichele RH, BRIT J CLIN PHARM, V58, P419; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health, 2011, ATC DDD IND; Wirtz V, 2007, PATRONES PRESCRIPCIO; Wirtz VJ, 2010, REV PANAM SALUD PUBL, V27, P219, DOI 10.1590/S1020-49892010000300009; World Bank, 2012, HOUS SURV LAT AM	20	14	14	0	29	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2013	18	6					665	673		10.1111/tmi.12096				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	163KK	WOS:000320334600002	23551290				2019-03-26	
J	Shamu, S; Abrahams, N; Zarowsky, C; Shefer, T; Temmerman, M				Shamu, Simukai; Abrahams, Naeema; Zarowsky, Christina; Shefer, Tamara; Temmerman, Marleen			Intimate partner violence during pregnancy in Zimbabwe: a cross-sectional study of prevalence, predictors and associations with HIV	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						intimate partner violence; pregnancy; HIV; prevalence; risk factors; Zimbabwe	GENDER-BASED VIOLENCE; DOMESTIC VIOLENCE; UNINTENDED PREGNANCY; NATIONAL SAMPLE; SOUTH-AFRICA; RISK-FACTORS; WOMEN; PREVENTION; ABUSE; INFECTION	OBJECTIVE To describe the occurrence, dynamics and predictors of intimate partner violence (IPV) during pregnancy, including links with HIV, in urban Zimbabwe. METHODS A cross-sectional survey of 2042 post-natal women aged 15-49 years was conducted in six public primary healthcare clinics in low-income urban Zimbabwe. An adapted WHO questionnaire was used to measure IPV. Multivariate logistic regression was used to assess factors associated with IPV and severe (six or more episodes) IPV during pregnancy. RESULTS 63.1% of respondents reported physical, emotional and/or sexual IPV during pregnancy: 46.2% reported physical and/or sexual violence, 38.9% sexual violence, 15.9% physical violence and 10% reported severe violence during pregnancy. Physical violence was less common during pregnancy than during the last 12 months before pregnancy (15.9% [95% CI 14.3-17.5] vs. 21.3% [95% confidence interval 19.5-23.1]). Reported rates of emotional (40.3% [95% CI 38.1-42.3] vs. 44.0% [95% CI 41.8-46.1]) and sexual violence (35.6% [95% CI 33.5-37.7] vs. 38.9% [95% CI 36.8-41.0]) were high during and before pregnancy. Associated factors were having a younger male partner, gender inequities, past abuse, problem drinking, partner control of woman's reproductive health and risky sexual practices. HIV status was not associated with either IPV or severe IPV, but reporting a partner with a known HIV status was associated with a lower likelihood of severe abuse. CONCLUSION The rates of IPV during pregnancy in Zimbabwe are among the highest ever reported globally. Primary prevention of violence during childhood through adolescence is urgently needed. Antenatal care may provide an opportunity for secondary prevention but this requires further work. The relationship between IPV and HIV is complex in contexts where both are endemic.	[Shamu, Simukai; Abrahams, Naeema; Zarowsky, Christina] Univ Western Cape, Sch Publ Hlth, ZA-7535 Cape Town, South Africa; [Shamu, Simukai; Abrahams, Naeema] MRC, Gender & Hlth Res Unit, Cape Town, South Africa; [Shamu, Simukai] Univ Zimbabwe, Dept Community Med, Harare, Zimbabwe; [Shefer, Tamara] Univ Western Cape, ZA-7535 Cape Town, South Africa; [Temmerman, Marleen] Univ Ghent, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium	Shamu, S (reprint author), Univ Western Cape, Sch Publ Hlth, Bag X17, ZA-7535 Cape Town, South Africa.	shamuts@yahoo.com		Abrahams, Naeemah/0000-0002-6138-6256	Flemish Inter-University cooperation (VLIR-UOS); University of the Western Cape (UWC); African Population and Heath Research Centre; Ford Foundation and International Development Research Centre	SS received funding for PhD studies, towards which this article contributes, from the Flemish Inter-University cooperation (VLIR-UOS) with the University of the Western Cape (UWC). We acknowledge fieldwork support from the African Doctoral Dissertation Research Fellowship provided by the African Population and Heath Research Centre in partnership with the Ford Foundation and International Development Research Centre and additional support from the South African Medical Research Council (MRC). We thank Dr Kristien Roelens (Ghent University - ICRH) for commenting on the draft. We thank colleagues from the UWC's School of Public Health, Gent University's International Centre for Reproductive Health and MRC's Gender and Health Research Unit for their comments on the drafts, and Carl Lombard and Alfred Musekiwa (MRC's Biostatistics Unit) for their statistical input, Amanda Fourie (MRC's Biostatistics Unit) for data entry and our data collectors from the University of Zimbabwe: Ashley Kundishora (team leader), Linda Madziwanzira, Nobuhle Moyo, Rumbidzai Dapira, Precious Chiwara and Norma Kasaira.	Abramsky T, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-109; Alhabib S, 2010, J FAM VIOLENCE, V25, P369, DOI 10.1007/s10896-009-9298-4; Ansell N, 2001, J S AFR STUD, V27, P697, DOI 10.1080/03057070120090691; Auerbach JD, 2011, GLOB PUBLIC HEALTH, V6, pS293, DOI 10.1080/17441692.2011.594451; Bacchus L, 2006, VIOLENCE AGAINST WOM, V12, P588, DOI 10.1177/1077801206289131; Campbell JC, 2008, INT J INJ CONTROL SA, V15, P221, DOI 10.1080/17457300802423224; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Clark C. J., 2009, Eastern Mediterranean Health Journal, V15, P880; Covington DL, 2002, OBSTET GYNECOLOGICAL, V57, P329; Cripe SM, 2008, INT J GYNECOL OBSTET, V100, P104, DOI 10.1016/j.ijgo.2007.08.003; CSO and Macro, 2007, ZIMB DEM HLTH SURV 2; Devries KM, 2010, REPROD HEALTH MATTER, V18, P158, DOI 10.1016/S0968-8080(10)36533-5; Dunbar MS, 2010, J PREV INTERV COMMUN, V38, P147, DOI 10.1080/10852351003640849; Dunkle KL, 2004, LANCET, V363, P1415, DOI 10.1016/S0140-6736(04)16098-4; Eaton LA, 2012, J COMMUN HEALTH, V37, P208, DOI 10.1007/s10900-011-9438-7; Fanslow J, 2008, AUST NZ J OBSTET GYN, V48, P398, DOI 10.1111/j.1479-828X.2008.00890.x; Farid M, 2008, INT J GYNECOL OBSTET, V101, P141, DOI 10.1016/j.ijgo.2007.11.015; Fawole AO, 2008, AUST NZ J OBSTET GYN, V48, P405, DOI 10.1111/j.1479-828X.2008.00868.x; Garcia-Moreno C., 2005, WHO MULTICOUNTRY STU; Gilbert L, 2007, J URBAN HEALTH, V84, P667, DOI 10.1007/s11524-007-9214-2; Goodwin M M, 2000, Matern Child Health J, V4, P85; Gregson S, 2006, SCIENCE, V311, P664, DOI 10.1126/science.1121054; Guo SF, 2004, INT J GYNECOL OBSTET, V84, P281, DOI 10.1016/j.ijgo.2003.08.019; Hallett TB, 2006, SEX TRANSM INFECT, V82, pI1, DOI 10.1136/sti.2005.016014; Hallfors D, 2011, AM J PUBLIC HEALTH, V101, P1082, DOI 10.2105/AJPH.2010.300042; Halperin DT, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000414; Harling G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014257; Heise L, 2002, INT J GYNECOL OBSTET, V78, pS5, DOI 10.1016/S0020-7292(02)00038-3; Heise L L, 1998, Violence Against Women, V4, P262, DOI 10.1177/1077801298004003002; Jewkes R, 2006, INT J EPIDEMIOL, V35, P1461, DOI 10.1093/ije/dyl218; Jewkes R, 2002, SOC SCI MED, V55, P1603, DOI 10.1016/S0277-9536(01)00294-5; Jewkes R, 2002, LANCET, V359, P1423, DOI 10.1016/S0140-6736(02)08357-5; Jewkes R, 2006, SOC SCI MED, V63, P2949, DOI 10.1016/j.socscimed.2006.07.027; Jewkes R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038210; Jewkes R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024256; Jewkes R, 2010, SCIENCE, V329, P145, DOI 10.1126/science.1193794; Jewkes RK, 2010, LANCET, V376, P41, DOI 10.1016/S0140-6736(10)60548-X; Johnson JK, 2003, BJOG-INT J OBSTET GY, V110, P272, DOI 10.1016/S1470-0328(02)02926-4; Kayibanda JF, 2012, JAIDS-J ACQ IMM DEF, V59, P300, DOI 10.1097/QAI.0b013e31823dc634; Koski AD, 2011, J HEALTH POPUL NUTR, V29, P245, DOI 10.3329/jhpn.v29i3.7872; Leung WC, 1999, INT J GYNECOL OBSTET, V66, P23, DOI 10.1016/S0020-7292(99)00053-3; Matavire M, 2012, INT J HUMANITIES SOC, V2, P218; Miller E, 2011, CONTRACEPTION, V83, P274, DOI 10.1016/j.contraception.2010.07.013; Miller E, 2010, CONTRACEPTION, V81, P316, DOI 10.1016/j.contraception.2009.12.004; Moore AM, 2010, SOC SCI MED, V70, P1737, DOI 10.1016/j.socscimed.2010.02.009; Munjanja SP, 2009, MATERNAL PERINATAL M; Njovana Eunice, 1996, REPROD HEALTH MATTER, V4, P46; Ntaganira J, 2009, RURAL REMOTE HEALTH, V9; Ntaganira Joseph, 2008, BMC Womens Health, V8, P17, DOI 10.1186/1472-6874-8-17; Nyamayemombe C, 2010, ZIMBABWE WORKING PAP; Olagbuji B, 2010, INT J GYNECOL OBSTET, V108, P101, DOI 10.1016/j.ijgo.2009.09.024; Pallitto CC, 2004, INT FAM PLAN PERSPEC, V30, P165, DOI 10.1363/3016504; Perales MT, 2009, VIOLENCE AGAINST WOM, V15, P224, DOI 10.1177/1077801208329387; Rabin RF, 2009, AM J PREV MED, V36, P439, DOI 10.1016/j.amepre.2009.01.024; Shah PS, 2010, J WOMENS HEALTH, V19, P2017, DOI 10.1089/jwh.2010.2051; Shamu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043148; Shamu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017591; Shumba A, 2001, CHILD ABUSE NEGLECT, V25, P265, DOI 10.1016/S0145-2134(00)00244-1; Shumway J, 1999, J Matern Fetal Med, V8, P76; Silverman JG, 2007, BJOG-INT J OBSTET GY, V114, P1246, DOI 10.1111/j.1471-0528.2007.01481.x; StataCorp, 2009, STAT STAT SOFTW REL; Taillieu TL, 2010, AGGRESS VIOLENT BEH, V15, P14, DOI 10.1016/j.avb.2009.07.013; Tsai AC, 2012, AIDS, V26, P381, DOI 10.1097/QAD.0b013e32834e1ccb; Watts C., 1998, REPROD HEALTH MATTER, V6, P57; Widom Cathy Spatz, 2006, Violence Vict, V21, P675, DOI 10.1891/vv-v21i6a001	65	22	22	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2013	18	6					696	711		10.1111/tmi.12078				16	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	163KK	WOS:000320334600006	23414103	Bronze			2019-03-26	
J	Ostyn, B; Malaviya, P; Hasker, E; Uranw, S; Singh, RP; Rijal, S; Sundar, S; Dujardin, JC; Boelaert, M				Ostyn, Bart; Malaviya, Paritosh; Hasker, Epco; Uranw, Surendra; Singh, Rudra P.; Rijal, Suman; Sundar, Shyam; Dujardin, Jean-Claude; Boelaert, Marleen			Retrospective Quarterly Cohort Monitoring for patients with Visceral Leishmaniasis in the Indian subcontinent: outcomes of a pilot project	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Leishmaniasis; Visceral; treatment outcome; retrospective cohort monitoring; resistance; treatment failure; intention-to-treat analysis; Miltefosine; Amphotericin B; efficacy; Visceral Leishmaniasis elimination	PALESTINE REFUGEES; KALA-AZAR; BIHAR; MILTEFOSINE; ELIMINATION; MANAGEMENT; JORDAN	OBJECTIVE To evaluate a new tool for the monitoring of Visceral Leishmaniasis (VL) treatment outcomes in primary healthcare (PHC) settings, adapted from the standardised Retrospective Quarterly Cohort Monitoring done in tuberculosis control. METHODS We developed standard case definitions for early and late VL treatment outcomes, a single register allowing for one-line entry per patient as registration tool, and quarterly reporting formats for the clinical outcomes. We pilot-tested these tools in three Indian Primary Health Centres and two Nepalese district hospitals, as well as in a charity VL treatment centre and a university hospital. RESULTS Data collection for early treatment outcome was easily implemented but information on late treatment outcome was hard to obtain. Effectiveness of Miltefosine under routine care conditions was about 87% at end of treatment, and 76% at 6 months post-treatment related to the high number of patients lost to follow up at the latter end point. CONCLUSION A retrospective cohort monitoring methodology is conceptually a good framework for monitoring clinical outcomes for chronic conditions as VL. The monitoring of early outcomes of VL treatment is perfectly feasible in Primary Care settings. The completeness of information on late outcomes can be improved by a number of strategies that remain to be field tested. Generally, clinical outcome monitoring should be strengthened in the VL control programmes.	[Ostyn, Bart; Hasker, Epco; Dujardin, Jean-Claude; Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Malaviya, Paritosh; Singh, Rudra P.; Sundar, Shyam] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Uranw, Surendra; Rijal, Suman] BP Koirala Inst Hlth Sci, Ghopa, Dharan, Nepal	Ostyn, B (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	bostyn@itg.be	Boelaert, Marleen/E-2698-2012; Malaviya, Paritosh/B-1819-2012	Boelaert, Marleen/0000-0001-8051-6776; Malaviya, Paritosh/0000-0002-7558-152X			Alvar J, PLOS ONE, V7, DOI [10.1371/journal. pone.0035671, DOI 10.1371/J0URNAL.P0NE.0035671.EPUB]; Bhattacharya SK, 2006, INDIAN J MED RES, V123, P195; Boelaert M, 2009, TROP MED INT HEALTH, V14, P639, DOI 10.1111/j.1365-3156.2009.02279.x; Chemtob D, 2001, ISRAEL MED ASSOC J, V3, P479; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]; Hasker E, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02562.x; Joshi A B, 2006, Kathmandu Univ Med J (KUMJ), V4, P488; Khader A, 2012, TROP MED INT HEALTH, V17, P1569, DOI 10.1111/j.1365-3156.2012.03097.x; Khader A, 2012, TROP MED INT HEALTH, V17, P1163, DOI 10.1111/j.1365-3156.2012.03048.x; Lowrance D, 2007, TROP MED INT HEALTH, V12, P377, DOI 10.1111/j.1365-3156.2006.01800.x; Maher D, 2012, TROP MED INT HEALTH, V17, P1567, DOI 10.1111/j.1365-3156.2012.03094.x; Malaviya P, 2013, TROP MED INT HEALTH, V18, P188, DOI 10.1111/tmi.12031; Malaviya P, 2011, TROP MED INT HEALTH, V16, P1159, DOI 10.1111/j.1365-3156.2011.02803.x; Mondal D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000355; Ormerod LP, 2002, J INFECTION, V45, P88, DOI 10.1053/jinf.2002.1031; Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213; Rijal S, 2013, CLIN INFECT DIS; Singh Shri Prakash, 2011, PLoS Negl Trop Dis, V5, pe960, DOI 10.1371/journal.pntd.0000960; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 2012, CLIN INFECT DIS, V55, P543, DOI 10.1093/cid/cis474; TDR/World Health Organization, 2010, IND MON EV KAL AZ EL; UNRWA Health Department, 2009, TECHN INSTR SER; Veen J, 1998, EUR RESPIR J, V12, P505, DOI 10.1183/09031936.98.12020505; Volmink J., 2007, COCHRANE DB SYST REV, V18; WHO, 2006, WHOHTMTB2006373; *WHO, 2003, WHOCDSTB2003316; World Health Organization, 2005, REG OFF SE AS REG ST	27	4	4	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2013	18	6					725	733		10.1111/tmi.12092				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	163KK	WOS:000320334600008	23464638				2019-03-26	
J	Ngoyi, DM; Menten, J; Pyana, PP; Buscher, P; Lejon, V				Ngoyi, Dieudonne Mumba; Menten, Joris; Pyana, Pati Patient; Buscher, Philippe; Lejon, Veerle			Stage determination in sleeping sickness: comparison of two cell counting and two parasite detection techniques	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						sleeping sickness; cerebrospinal fluid; Trypanosoma brucei gambiense; human African trypanosomiasis	HUMAN AFRICAN TRYPANOSOMIASIS; CEREBROSPINAL-FLUID; SINGLE CENTRIFUGATION; DIAGNOSIS	OBJECTIVES Diagnosis of the neurological stage of human African trypanosomiasis is performed by examination of cerebrospinal fluid (CSF) for the presence of trypanosomes and numbers of white blood cells (WBC). Both CSF parameters are also used to assess treatment outcome during follow-up. In view of the importance of CSF examination, and the practical problems encountered with it, we compared the sensitivity of two trypanosome concentration techniques and the repeatability of two cell counting METHODS, as well as occurrence of systematic differences between them. methods Patients were recruited at Dipumba hospital, in Mbuji-Mayi in the Democratic Republic of the Congo. In 94 CSF samples, trypanosome detection was performed with modified single centrifugation (MSC) and double centrifugation (DC). On 189 CSF samples with <= 30 cells/mu l, cell counting was performed in duplicate in a Fuchs-Rosenthal counting chamber and in a disposable Uriglass counting chamber. RESULTS Modified single centrifugation detected trypanosomes in significantly (P < 0.0001) more patients (85) than DC (46). Cell counts did not differ systematically in the two methods. Variability in the differences between duplicate cell counts was significantly higher (P = 0.002) in Uriglass (SD of differences 2.03) than in Fuchs-Rosenthal (SD of differences 1.62). CONCLUSIONS For analysis of CSF in the context of sleeping sickness stage determination and follow-up after treatment, we strongly recommend the MSC for parasite detection and the application of disposable counting chambers. When the first cell count is <= 20 cells/mu l, we recommend repeating the counting procedure on the same CSF specimen and taking the average of both countings.	[Ngoyi, Dieudonne Mumba; Pyana, Pati Patient] Inst Natl Rech Biomed, Kinshasa, Zaire; [Ngoyi, Dieudonne Mumba] Univ Kinshasa, Fac Med, Kinshasa, Zaire; [Menten, Joris; Lejon, Veerle] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Buscher, Philippe] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Lejon, Veerle] UMR 177 IRD CIRAD INTERTRYP, Inst Rech Dev, Montpellier, France	Buscher, P (reprint author), Inst Trop Med, Dept Biomed Sci, Natl Str 155, B-2000 Antwerp, Belgium.	pbuscher@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472; Lejon, Veerle/0000-0002-6795-0962	European Union [FP6-2004-INCO-DEV-3 032324 NEUROTRYP]; Belgian Directorate General for Development Cooperation	This work was supported by a grant from the European Union (FP6-2004-INCO-DEV-3 032324 NEUROTRYP). DMN received a PhD grant from the Belgian Directorate General for Development Cooperation.	BLAND JM, 1986, LANCET, V1, P307; Buscher P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000471; CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Kande Betu-Ku-Mesu V, 2009, RAPPORT ANN 2008; KJELDSBERG C, 1993, BODY FLUIDS, P65; Lejon V, 2005, TROP MED INT HEALTH, V10, P395, DOI 10.1111/j.1365-3156.2005.01403.x; Miezan TW, 2000, T ROY SOC TROP MED H, V94, P293, DOI 10.1016/S0035-9203(00)90327-4; Ngoyi DM, 2010, J INFECT DIS, V201, P453, DOI 10.1086/649917; Peeling RW, 2006, SEX TRANSM INFECT, V82, pV1, DOI 10.1136/sti.2006.024265; PENTREATH VW, 1992, ANN TROP MED PARASIT, V86, P29, DOI 10.1080/00034983.1992.11812627; Priotto G, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001662; Tiberti N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040909; World Health Organization Expert Committee, 1998, WHO TECH REP SER, V881, P1	14	9	9	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2013	18	6					778	782		10.1111/tmi.12102				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	163KK	WOS:000320334600014	23506188				2019-03-26	
J	Ndofor, E; van Gool, T; Gillis, H				Ndofor, Eric; van Gool, Tom; Gillis, Henk			Laboratory diagnosis of malaria in the North West Region of Cameroon: analysis of limitations	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Malaria; Quality; Microscopic diagnosis; Governmental health facilities; Improvement; Cameroon	RELIABILITY	Malaria is still rife and perennial in Cameroon despite remarkable progress in controlling the disease. About 95 of the country is malaria endemic. Prompt and accurate diagnosis of malaria may lead to improved patient care and reduced morbidity. This paper analyses limitations in malaria diagnosis in the North West Region of Cameroon and opportunities for improvement. The sample units were 40 laboratories in governmental health facilities (GHFs) selected by cluster (Health Districts) and stratified sampling. The three categories of GHFs in the Region Hospitals, District Medical Centres (Centre Mdical dArrondissement [CMAs]) and Integrated Health Centres (IHCs) were strata in the sample. With pre-tested interviewer-administered structured questionnaires and visits to laboratories, mechanical and optical components of microscopes and malaria diagnostic techniques were studied systematically and in detail. The main finding was that locally prepared Giemsa-stained malaria smears were of unusable quality in 52 and 46 of GHFs for thick and thin smears respectively. Some loss of quality was observed in laboratories with good and moderate quality smears. The quality of malaria diagnosis was not optimal and GHFs did not have sufficient tools and resources to overcome loss of quality. Nonetheless, limitations in malaria diagnosis in the Region can be corrected.	[Ndofor, Eric] Vrije Univ Brussel, Dept Human Ecol, Fac Med & Pharm, B-1090 Brussels, Belgium; [van Gool, Tom; Gillis, Henk] Univ Amsterdam, Clin Parasitol Dept, Acad Med Ctr, NL-1100 DD Amsterdam, Netherlands	Ndofor, E (reprint author), 8000 Chanute Pl 15, Falls Church, VA 22042 USA.	ericndofor@yahoo.fr			Clinical Parasitology Department, University of Amsterdam	This work was supported by Prof. Tom van Gool (TvG), MD, Clinical Parasitology Department, University of Amsterdam	[Anonymous], 2011, UN ACC MAL DIAGN TES; Caprette DR, 2012, LIGHT MICROSCOPY EXP; Garcia LS, 2001, DIAGNOSTIC MED PARAS; Gemperli A, 2006, TROP MED INT HEALTH, V11, P1035; Kahama-Maro J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-332; Kakkilaya BS, 2003, LAB MED, V8, P602, DOI 10.1309/J4ANKCCJ147JB2FR; Lau YL, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-197; Mace K. E., 2011, Morbidity and Mortality Weekly Report, V60, P476; Maina RN, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-S3-S4; MC-CCAM, 2011, MAL ADV KIT GLOB FUN, DOI MC-CCAM; Minja DTR, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-211; Nkuo AT, 2008, AFRICAN J HLTH SCI, V13, P20; Ochola LB, 2006, LANCET INFECT DIS, V6, P582, DOI 10.1016/S1473-3099(06)70579-5; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Tchekountouo O., 2011, MALARIA CONTROL ACTI; *WHO, 1993, TECHN REP SER, V839; WHO/USAID, 1999, NEW PERP MAL DIAGN; Wikipedia contributors, NW REG CAM STAT PROV; World Health Organization, 2005, WHO SEARO WPRO WORKS; World Health Organization, 2009, MAL MICR QUAL ASS MA; Worldpress, 2012, CAM PROF	21	1	1	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUN	2013	107	6					341	348		10.1093/trstmh/trt025				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	150ZJ	WOS:000319430100002	23479359	Bronze			2019-03-26	
J	Obsomer, V; Dufrene, M; Defourny, P; Coosemans, M				Obsomer, Valerie; Dufrene, Marc; Defourny, Pierre; Coosemans, Marc			Anopheles species associations in Southeast Asia: indicator species and environmental influences	PARASITES & VECTORS			English	Article							GLOBAL LAND AREAS; MALARIA TRANSMISSION; MOSQUITOS; VECTORS; ASSEMBLAGES; LANDSCAPE; CULICIDAE; THAILAND; PACIFIC; BEETLES	Background: Southeast Asia presents a high diversity of Anopheles. Environmental requirements differ for each species and should be clarified because of their influence on malaria transmission potential. Monitoring projects collect vast quantities of entomological data over the whole region and could bring valuable information to malaria control staff but collections are not always standardized and are thus difficult to analyze. In this context studying species associations and their relation to the environment offer some opportunities as they are less subject to sampling error than individual species. Methods: Using asymmetrical similarity coefficients, indirect clustering and the search of indicator species, this paper identified species associations. Environmental influences were then analysed through canonical and discriminant analysis using climatic and topographic data, land cover in a 3 km buffer around villages and vegetation indices. Results: Six groups of sites characterized the structure of the species assemblage. Temperature, rainfall and vegetation factors all play a role. Four out of the six groups of sites based on species similarities could be discriminated using environmental information only. Conclusions: Vegetation indices derived from satellite imagery proved very valuable with one variable explaining more variance of the species dataset than any other variable. The analysis could be improved by integrating seasonality in the sampling and collecting at least 4 consecutive days.	[Obsomer, Valerie; Coosemans, Marc] Prince Leopold Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Obsomer, Valerie; Defourny, Pierre] Catholic Univ Louvain, Earth & Life Inst Environm Sci, B-1348 Louvain, Belgium; [Dufrene, Marc] Univ Liege, Biodivers & Landscape Dept, Gembloux AgrobioTech, B-5030 Gembloux, Belgium	Obsomer, V (reprint author), Prince Leopold Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	valerie.obsomer@gmail.com		Marc, Dufrene/0000-0002-5664-9955	Belgian Sciences Policy Office (BELSPO) through the DYNMAP; European Union through the MALVECASIA project [IC4-CT-2002-10041]; INCODEV [ERBIC18.CT.970211]	The authors thank the staff of the malaria national control program and particularly the members of the MALVECASIA network which provided fresh information on the distribution of Anopheles in the Southeast Asian region. Those include Dr Trung and Dr Thuan from the National Institute of Malariology, Parasitology and Entomology of Vietnam (NIMPE), Dr Tho and Dr Socheat from the National Centre for Malaria Control, Parasitology and Entomology of Cambodia (CNM), Dr Kalounna, Dr Bouasy and Dr Samlane from the Centre of Malariology, Parasitology and Entomology of Laos (IMPE) and Dr Visut Baimai from the Mahidol University (MU) of Thailand and Ralph Harbach and Yvonne Linton from the Natural History Museum of London (NHM). This work was funded by the Belgian Sciences Policy Office (BELSPO) through the DYNMAP project and by the European Union through the MALVECASIA project (IC4-CT-2002-10041) in the framework of the INCODEV program (ERBIC18.CT.970211). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhatt R. N., 1993, Indian Journal of Malariology, V30, P91; Bicheron P., 2006, P 2 INT S REC ADV QU, P538; Bontemps S., 2012, REMOTE SENSING LAND, P243; BRADSHAW WE, 1983, OECOLOGIA, V57, P239, DOI 10.1007/BF00379586; Bruelheide H, 2000, J VEG SCI, V11, P167, DOI 10.2307/3236796; Campos RE, 2004, HYDROBIOLOGIA, V524, P91, DOI 10.1023/B:HYDR.0000036122.10578.d0; COLE LC, 1949, ECOLOGY, V30, P411, DOI 10.2307/1932444; De Caceres M, 2009, ECOLOGY, V90, P3566; de Warnaffe GD, 2004, ECOGRAPHY, V27, P701, DOI 10.1111/j.0906-7590.2004.03880.x; Defourny P, 2012, REMOTE SENSING LAND, P207; Dufrene M, 1997, ECOL MONOGR, V67, P345, DOI 10.1890/0012-9615(1997)067[0345:SAAIST]2.0.CO;2; FAGER EW, 1963, SCIENCE, V140, P453, DOI 10.1126/science.140.3566.453; GOWER JC, 1966, BIOMETRIKA, V53, P325, DOI 10.2307/2333639; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; Hill DA, 2005, HDB BIODIVERSITY MET; Hill M. O., 1979, TWINSPAN FORTRAN PRO; HURLBERT SH, 1969, ECOLOGY, V50, P1, DOI 10.2307/1934657; HUTCHINSON GE, 1957, COLD SPRING HARB SYM, V22, P415, DOI 10.1101/SQB.1957.022.01.039; Jain A. K., 1988, ALGORITHMS CLUSTERIN; Kant R, 1999, INDIAN J MALARIOL, V365, P53; Kant Rajni, 1998, Indian Journal of Malariology, V35, P22; Lee DK, 1998, J VECTOR ECOL, V23, P161; Legendre P., 1998, DEV ENV MODELLING; LOUNIBOS LP, 1981, ECOL ENTOMOL, V6, P129, DOI 10.1111/j.1365-2311.1981.tb00601.x; MacKenzie D. I., 2005, OCCUPANCY ESTIMATION; May R.M., 1975, P81; McGarigal K, 1995, PNWGTR351 USDA FOR S; McGeoch MA, 2002, J APPL ECOL, V39, P661, DOI 10.1046/j.1365-2664.2002.00743.x; MCNAUGHTON SJ, 1967, NATURE, V216, P168, DOI 10.1038/216168b0; Motyka J., 1947, ZADANIACH METODACH B, VSupplement I, p[viii, 168]; New M, 2002, CLIMATE RES, V21, P1, DOI 10.3354/cr021001; Overgaard HJ, 2003, LANDSCAPE ECOL, V18, P605, DOI 10.1023/A:1026074910038; R Development Core Team, 2009, R LANG ENV STAT COMP; Rattanarithikul R, 1995, J AM MOSQUITO CONTR, V11, P428; Reisen WK, 1981, PAKISTAN J SCI RES, V3, P1; ROSENBERG R, 1982, AM J TROP MED HYG, V31, P183, DOI 10.4269/ajtmh.1982.31.183; SERVICE MW, 1968, J ZOOL, V156, P313; Sinka ME, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-89; Southwood T.R.E., 1978, ECOLOGICAL METHODS P; Suwonkerd Wannapa, 1996, Tropical Medicine, V38, P101; Ter Braak C. J. F., 1985, CANOCO FORTRAN PROGR; Tichy L, 2006, J VEG SCI, V17, P809, DOI 10.1658/1100-9233(2006)17[809:SDODSF]2.0.CO;2; Titeux N., 2006, THESIS U CATHOLIQUE; Trung HD, 2005, TROP MED INT HEALTH, V10, P251, DOI 10.1111/j.1365-3156.2004.01378.x; Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x; Van Bortel W, 2008, MALARIA J, V1, P7; Vancutsem C, 2007, INT J REMOTE SENS, V28, P5123, DOI 10.1080/01431160701253212; Vanwambeke SO, 2007, J MED ENTOMOL, V44, P133, DOI 10.1603/0022-2585(2007)44[133:LALCFI]2.0.CO;2; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; WHITTAKER RH, 1962, BOT REV, V28, P1, DOI 10.1007/BF02860872; Yadav R. S., 1997, Indian Journal of Malariology, V34, P8; Zhang ZJ, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-11	52	6	7	3	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	MAY 4	2013	6								136	10.1186/1756-3305-6-136				14	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	147JK	WOS:000319162700004	23642279	DOAJ Gold, Green Published			2019-03-26	
J	Mekonnen, Z; Meka, S; Ayana, M; Bogers, J; Vercruysse, J; Levecke, B				Mekonnen, Zeleke; Meka, Selima; Ayana, Mio; Bogers, Johannes; Vercruysse, Jozef; Levecke, Bruno			Comparison of Individual and Pooled Stool Samples for the Assessment of Soil-Transmitted Helminth Infection Intensity and Drug Efficacy	PLOS NEGLECTED TROPICAL DISEASES			English	Article							FECAL EGG COUNTS; DIAGNOSIS; COST; METAANALYSIS; ALBENDAZOLE; RESISTANCE; FLOTAC; IMPACT	Background:In veterinary parasitology samples are often pooled for a rapid assessment of infection intensity and drug efficacy. Currently,studies evaluating this strategy in large-scale drug administration programs to control human soil-transmitted helminths (STHs; Ascaris lumbricoides,Trichuris trichiura, and hookworm), are absent. Therefore, we developed and evaluated a pooling strategy to assess intensity of STH infections and drug efficacy. Methods/Principal Findings:Stool samples from 840 children attending 14 primary schools in Jimma, Ethiopia were pooled (pool sizes of 10, 20, and 60) to evaluate the infection intensity of STHs. In addition, the efficacy of a single dose of mebendazole (500 mg) in terms of fecal egg count reduction (FECR; synonym of egg reduction rate) was evaluated in 600 children from two of these schools. Individual and pooled samples were examined with the McMaster egg counting method. For each of the three STHs, we found a significant positive correlation between mean fecal egg counts (FECs) of individual stool samples and FEC of pooled stool samples, ranging from 0.62 to 0.98. Only for A. lumbricoides was any significant difference in mean FEC of the individual and pooled samples found. For this STH species, pools of 60 samples resulted in significantly higher FECs. FECR for the different number of samples pooled was comparable in all pool sizes,except for hookworm. For this parasite, pools of 10 and 60 samples provided significantly higher FECR results. Conclusion/Significance:This study highlights that pooling stool samples holds promise as a strategy for rapidly assessing infection intensity and efficacy of administered drugs in programs to control human STHs. However, further research is required to determine when and how pooling of stool samples can be cost-effectively applied along a control program, and to verify whether this approach is also applicable to other NTDs.	[Mekonnen, Zeleke; Vercruysse, Jozef; Levecke, Bruno] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium; [Mekonnen, Zeleke; Meka, Selima; Ayana, Mio] Jimma Univ, Coll Publ Hlth & Med Sci, Dept Med Lab Sci & Pathol, Jimma, Ethiopia; [Bogers, Johannes] Antwerp Univ, AMBIOR Grp, Lab Cell Biol & Histol, Antwerp, Belgium	Levecke, B (reprint author), Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium.	bruno.levecke@ugent.be		Levecke, Bruno/0000-0001-8912-5595; Bogers, John-Paul/0000-0001-9107-132X	WHO and FWO;  [G.0853.09N]	This study was supported by the VLIR-IUC-JU (http://www.iucju.ugent.be/), WHO and FWO (www.FWO.be, Ref Nr G.0853.09N). BL is a postdoctoral fellow of FWO (www.FWO.be, Ref Nr 05_05 1.2.853.13). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bennett A, 2000, PARASITOL TODAY, V16, P71, DOI 10.1016/S0169-4758(99)01544-6; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Cringoli G, 2010, NAT PROTOC, V5, P503, DOI 10.1038/nprot.2009.235; Eysker M, 2008, VET PARASITOL, V151, P249, DOI 10.1016/j.vetpar.2007.10.008; Gabrielli AF, 2011, T ROY SOC TROP MED H, V105, P683, DOI 10.1016/j.trstmh.2011.08.013; Geerts S, 2001, TROP MED INT HEALTH, V6, P915, DOI 10.1046/j.1365-3156.2001.00774.x; Hall A, 2008, MATERN CHILD NUTR, V4, P118, DOI 10.1111/j.1740-8709.2007.00127.x; KEISER J, 1948, JAMA-J AM MED ASSOC, V299, P1937; KRAUTH SJ, 2012, PLOS NEGLECT TROP D; Levecke B, 2012, T ROY SOC TROP MED H, V106, P128, DOI 10.1016/j.trstmh.2011.09.007; Levecke B, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000366; Levecke B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001427; Levecke B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001201; MEKONNEN Z, 2012, PATHOG GLOB HLTH; Morgan ER, 2005, VET PARASITOL, V131, P79, DOI 10.1016/j.vetpar.2005.04.021; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; NTD PARTN WEBS, 2012, UN COMB NEGL TROP DI; Shipitsyna E, 2007, ACTA DERM-VENEREOL, V87, P140, DOI 10.2340/00015555-0196; Singer RS, 2006, J VET DIAGN INVEST, V18, P319, DOI 10.1177/104063870601800401; Speich B, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-71; Speybroeck N, 2012, MED VET ENTOMOL, V26, P361, DOI 10.1111/j.1365-2915.2012.01015.x; Van Wyk JA, 2001, ONDERSTEPOORT J VET, V68, P55; Vercruysse J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000948; Verstraeten T, 1998, TROP MED INT HEALTH, V3, P747; WAHLQUIST SP, 1991, J CLIN MICROBIOL, V29, P1725; WHO, 2011, HELMINTH CONTROL IN SCHOOL-AGE CHILDREN: A GUIDE FOR MANAGERS OF CONTROL PROGRAMMES, SECOND EDITION, P1; *WHO, 2006, PREV CHEM HUM BELM C; Wolstenholme AJ, 2004, TRENDS PARASITOL, V20, P469, DOI 10.1016/j.pt.2004.07.010	28	17	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2013	7	5							e2189	10.1371/journal.pntd.0002189				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	158SW	WOS:000319994400049	23696905	DOAJ Gold, Green Published			2019-03-26	
J	Gehre, F; Otu, J; DeRiemer, K; de Sessions, PF; Hibberd, ML; Mulders, W; Corrah, T; de Jong, BC; Antonio, M				Gehre, Florian; Otu, Jacob; DeRiemer, Kathryn; de Sessions, Paola Florez; Hibberd, Martin L.; Mulders, Wim; Corrah, Tumani; de Jong, Bouke C.; Antonio, Martin			Deciphering the Growth Behaviour of Mycobacterium africanum	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TUBERCULOSIS COMPLEX; GENOME; ACQUISITION; VIRULENCE; SEQUENCE; IDENTIFICATION; TRANSPORTER; METABOLISM; RESISTANCE; SECRETION	Background: Human tuberculosis (TB) in West Africa is not only caused by M. tuberculosis but also by bacteria of the two lineages of M. africanum. For instance, in The Gambia, 40% of TB is due to infections with M. africanum West African 2. This bacterial lineage is associated with HIV infection, reduced ESAT-6 immunogenicity and slower progression to active disease. Although these characteristics suggest an attenuated phenotype of M. africanum, no underlying mechanism has been described. From the first descriptions of M. africanum in the literature in 1969, the time to a positive culture of M. africanum on solid medium was known to be longer than the time to a positive culture of M. tuberculosis. However, the delayed growth of M. africanum, which may correlate with the less virulent phenotype in the human host, has not previously been studied in detail. Methodology/Principal Findings: We compared the growth rates of M. tuberculosis and M. africanum isolates from The Gambia in two liquid culture systems. M. africanum grows significantly slower than M. tuberculosis, not only when grown directly from sputa, but also in growth experiments under defined laboratory conditions. We also sequenced four M. africanum isolates and compared their whole genomes with the published M. tuberculosis H37Rv genome. M. africanum strains have several non-synonymous SNPs or frameshift mutations in genes that were previously associated with growth-attenuation. M. africanum strains also have a higher mutation frequency in genes crucial for transport of sulphur, ions and lipids/fatty acids across the cell membrane into the bacterial cell. Surprisingly, 5 of 7 operons, recently described as essential for intracellular survival of H37Rv in the host macrophage, showed at least one non-synonymously mutated gene in M. africanum. Conclusions/Significance: The altered growth behaviour of M. africanum might indicate a different survival strategy within host cells.	[Gehre, Florian; Mulders, Wim; de Jong, Bouke C.] Inst Trop Med, B-2000 Antwerp, Belgium; [Gehre, Florian; Otu, Jacob; Corrah, Tumani; de Jong, Bouke C.; Antonio, Martin] MRC Unit, Fajara, Gambia; [DeRiemer, Kathryn] Univ Calif Davis, Davis, CA 95616 USA; [de Sessions, Paola Florez; Hibberd, Martin L.] Genome Inst Singapore, Singapore, Singapore; [de Jong, Bouke C.] NYU, New York, NY USA	Gehre, F (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	fgehre@itg.be	de Jong, Bouke/A-3636-2013	de Jong, Bouke/0000-0002-1017-4675; DeRiemer, Kathryn/0000-0002-8375-7505; Hibberd, Martin/0000-0001-8587-1849	UK's Medical Research Council; Flemish Science Foundation (FWO)	The study was funded by the UK's Medical Research Council. Florian Gehre was supported by a "Travel Grant for a long stay abroad", awarded by the Flemish Science Foundation (FWO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agranoff D, 2004, FRONT BIOSCI-LANDMRK, V9, P2996, DOI 10.2741/1454; Amon J, 2009, J MOL MICROB BIOTECH, V17, P20, DOI 10.1159/000159195; Bentley SD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001552; Bhave Devayani P., 2007, Infectious Disorders - Drug Targets, V7, P140; Bold TD, 2012, J INFECT DIS, V205, P984, DOI 10.1093/infdis/jir883; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Buchmeier N, 2000, MOL MICROBIOL, V35, P1375, DOI 10.1046/j.1365-2958.2000.01797.x; Carlsson F, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000285; Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179; Castets M, 1979, Med Trop (Mars), V39, P145; Champion PAD, 2006, SCIENCE, V313, P1632, DOI 10.1126/science.1131167; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cook GM, 2009, ADV MICROB PHYSL, V55, P318; Cook GM, 2009, ADV MICROB PHYSIOL, V55, P81, DOI 10.1016/S0065-2911(09)05502-7; de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977; de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504; de Jong BC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000744; de Jong BC, 2009, J CLIN MICROBIOL, V47, P994, DOI 10.1128/JCM.01216-08; Domenech P, 2005, INFECT IMMUN, V73, P3492, DOI 10.1128/IAI.73.6.3492-3501.2005; Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103; Hatzios SK, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002036; Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907; Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601; Niederweis M, 2008, MICROBIOL-SGM, V154, P679, DOI 10.1099/mic.0.2007/012872-0; Rengarajan J, 2005, P NATL ACAD SCI USA, V102, P8327, DOI 10.1073/pnas.0503272102; Rodriguez GM, 2006, J BACTERIOL, V188, P424, DOI 10.1128/JB.188.2.424-430.2006; Rowland JL, 2012, TUBERCULOSIS, V92, P202, DOI 10.1016/j.tube.2011.12.006; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Sharma AK, 2011, J BIOL CHEM, V286, P8534, DOI 10.1074/jbc.M110.165449; Stephan J, 2005, MOL MICROBIOL, V58, P714, DOI 10.1111/j.1365-2958.2005.04878.x; Stewart GR, 2005, PLOS PATHOG, V1, P269, DOI 10.1371/journal.ppat.0010033; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406; Wooff E, 2002, MOL MICROBIOL, V43, P653, DOI 10.1046/j.1365-2958.2002.02771.x; Zeng JM, 2012, J PROTEOME RES, V11, P4682, DOI 10.1021/pr3006233	35	15	15	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2013	7	5							e2220	10.1371/journal.pntd.0002220				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	158SW	WOS:000319994400025	23696911	DOAJ Gold, Green Published			2019-03-26	
J	Krolewiecki, AJ; Lammie, P; Jacobson, J; Gabrielli, AF; Levecke, B; Socias, E; Arias, LM; Sosa, N; Abraham, D; Cimino, R; Echazu, A; Crudo, F; Vercruysse, J; Albonico, M				Krolewiecki, Alejandro J.; Lammie, Patrick; Jacobson, Julie; Gabrielli, Albis-Francesco; Levecke, Bruno; Socias, Eugenia; Arias, Luis M.; Sosa, Nicanor; Abraham, David; Cimino, Ruben; Echazu, Adriana; Crudo, Favio; Vercruysse, Jozef; Albonico, Marco			A Public Health Response against Strongyloides stercoralis : Time to Look at Soil-Transmitted Helminthiasis in Full	PLOS NEGLECTED TROPICAL DISEASES			English	Review							IVERMECTIN; INFECTIONS; ALBENDAZOLE; DIAGNOSIS; CHILDREN; TRIAL; COMMUNITY; EFFICACY; ASSAY; THIABENDAZOLE	Strongyloides stercoralis infections have a worldwide distribution with a global burden in terms of prevalence and morbidity that is largely ignored. A public health response against soil-transmitted helminth (STH) infections should broaden the strategy to include S. stercoralis and overcome the epidemiological, diagnostic, and therapeutic challenges that this parasite poses in comparison to Ascaris lumbricoides, Trichuris trichiura, and hookworms. The relatively poor sensitivity of single stool evaluations, which is further lowered when quantitative techniques aimed at detecting eggs are used, also complicates morbidity evaluations and adequate drug efficacy measurements, since S. stercoralis is eliminated in stools in a larval stage. Specific stool techniques for the detection of larvae of S. stercoralis, like Baermann's and Koga's agar plate, despite superiority over direct techniques are still suboptimal. New serologies using recombinant antigens and molecular-based techniques offer new hopes in those areas. The use of ivermectin rather than benzimidazoles for its treatment and the need to have curative regimens rather than lowering the parasite burden are also unique for S. stercoralis in comparison to the other STH due to its life cycle, which allows reproduction and amplification of the worm burden within the human host. The potential impact on STH of the benzimidazoles/ivermectin combinations, already used for control/elimination of lymphatic filariasis, should be further evaluated in public health settings. While waiting for more effective single-dose drug regimens and new sensitive diagnostics, the evidence and the tools already available warrant the planning of a common platform for STH and S. stercoralis control.	[Krolewiecki, Alejandro J.; Cimino, Ruben; Echazu, Adriana] Univ Nacl Salta, Inst Invest Enfermedades Trop, Oran, Argentina; [Krolewiecki, Alejandro J.] Inst Patol Expt CONICET, Salta, Argentina; [Lammie, Patrick] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA; [Jacobson, Julie] Bill & Melinda Gates Fdn, Seattle, WA USA; [Gabrielli, Albis-Francesco] World Hlth Org, Dept Control Neglected Trop Dis, Geneva, Switzerland; [Levecke, Bruno; Vercruysse, Jozef] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium; [Socias, Eugenia] Fdn Mundo Sano, Buenos Aires, DF, Argentina; [Arias, Luis M.; Sosa, Nicanor] Minist Salud Publ Prov Salta, Salta, Argentina; [Abraham, David] Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Crudo, Favio] Municipalidad Zarate, Subsecretaria Salud, Zarate, Argentina; [Albonico, Marco] Sacro Cuore Hosp, Ctr Trop Dis, Negrar, Italy; [Albonico, Marco] Ivo de Carneri Fdn IdCF, Milan, Italy	Krolewiecki, AJ (reprint author), Univ Nacl Salta, Inst Invest Enfermedades Trop, Oran, Argentina.	alekrol@hotmail.com		ALBONICO, Marco/0000-0002-7805-2391; Levecke, Bruno/0000-0001-8912-5595	Bill & Melinda Gates Foundation; Ministry of Health of the Province of Salta, Argentina; Fundacion Mundo Sano, Oran, Salta, Argentina; EC [FP7-GA-261495]; WHO	This paper was produced as a result of a Meeting on "Optimizing Therapeutic Options for STH", sponsored by the Bill & Melinda Gates Foundation, the Ministry of Health of the Province of Salta, Argentina and Fundacion Mundo Sano, held in Oran, Salta, Argentina; 16 and 17 August 2011. This paper reflects the personal views of the authors and should not be interpreted to represent official policies or positions of their respective institutions. The Bill & Melinda Gates Foundation supported the participation of most international experts. MA was co-funded by the EC within the 7th Framework Program under grant agreement no. FP7-GA-261495 (COHEMI network). AFG's participation was supported by WHO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham D, 2011, VACCINE, V29, P8134, DOI 10.1016/j.vaccine.2011.08.030; Albonico M, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000126; Albonico M, 2006, ADV PARASIT, V61, P311, DOI 10.1016/S0065-308X(05)61008-1; Amazigo UV, 2012, TRENDS PARASITOL, V28, P231, DOI 10.1016/j.pt.2012.03.002; Anderson R, 2012, LANCET, V379, P289, DOI 10.1016/S0140-6736(12)60120-2; Basuni M, 2011, AM J TROP MED HYG, V84, P338, DOI 10.4269/ajtmh.2011.10-0499; Beach MJ, 1999, AM J TROP MED HYG, V60, P479, DOI 10.4269/ajtmh.1999.60.479; Becker SL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001292; Belizario VY, 2003, B WORLD HEALTH ORGAN, V81, P35; Bisoffi Z, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001254; Bonne-Annee S, 2011, IMMUNOL RES, V51, P205, DOI 10.1007/s12026-011-8258-2; Chaccour CJ, 2012, NEW ENGL J MED, V367, P1670, DOI 10.1056/NEJMc1210168; de PAOLA DOMINGOS, 1962, AMER JOUR DIGEST DIS, V7, P1086; Dreyer G, 1996, J CLIN MICROBIOL, V34, P2569; GABRIELLI AF, 2008, T R SOC TROP MED HYG, V105, P683; GANN PH, 1994, J INFECT DIS, V169, P1076, DOI 10.1093/infdis/169.5.1076; Geerts S, 1997, PARASITOL TODAY, V13, P149, DOI 10.1016/S0169-4758(97)01024-7; Glinz D, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000754; Grove D. I., 1989, Strongyloidiasis: a major roundworm infection of man., P155; Iriemenam NC, 2010, PARASITOL INT, V59, P9, DOI 10.1016/j.parint.2009.10.009; Keiser J, 2008, JAMA-J AM MED ASSOC, V299, P1937, DOI 10.1001/jama.299.16.1937; King CH, 2010, ADV PARASIT, V73, P51, DOI 10.1016/S0065-308X(10)73003-7; Knopp S, 2010, CLIN INFECT DIS, V51, P1420, DOI 10.1086/657310; Knopp S, 2009, AM J TROP MED HYG, V81, P1071, DOI 10.4269/ajtmh.2009.09-0377; Krolewiecki A, 2011, AM J TROP MED HYG, V85, P475; Krolewiecki AJ, 2010, CLIN VACCINE IMMUNOL, V17, P1624, DOI 10.1128/CVI.00259-10; Lammie PJ, 2012, INT J PARASITOL, V42, P797, DOI 10.1016/j.ijpara.2012.07.002; Lawrence G, 2005, B WORLD HEALTH ORGAN, V83, P34; Levecke B, 2011, PARASITOL RES, V109, P953, DOI 10.1007/s00436-011-2338-z; Marti H, 1996, AM J TROP MED HYG, V55, P477, DOI 10.4269/ajtmh.1996.55.477; Mejia R, 2012, CURR OPIN INFECT DIS, V25, P458, DOI 10.1097/QCO.0b013e3283551dbd; Moss DM, 2011, AM J TROP MED HYG, V85, P229, DOI 10.4269/ajtmh.2011.11-0029; OGBUOKIRI JE, 1994, EUR J CLIN PHARMACOL, V46, P89; Olsen A, 2009, T ROY SOC TROP MED H, V103, P967, DOI 10.1016/j.trstmh.2009.02.013; Ramanathan R, 2008, J INFECT DIS, V198, P444, DOI 10.1086/589718; Roulet A, 2003, EUR J PHARMACOL, V460, P85, DOI 10.1016/S0014-2999(02)02955-2; Satoh M, 2004, EXPERT OPIN PHARMACO, V5, P2293, DOI 10.1517/14656566.5.11.2293; SCHAD GA, 1989, J PARASITOL, V75, P740, DOI 10.2307/3283059; Schneider B, 2011, HUM VACCINES, V7, P1234, DOI 10.4161/hv.7.11.18443; Siddiqui AA, 2001, CLIN INFECT DIS, V33, P1040, DOI 10.1086/322707; Steinmann P, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000075; STEMMERMANN GN, 1967, GASTROENTEROLOGY, V53, P59; Taniuchi M, 2011, AM J TROP MED HYG, V84, P332, DOI 10.4269/ajtmh.2011.10-0461; Utzinger J, 2008, T ROY SOC TROP MED H, V102, P84, DOI 10.1016/j.trstmh.2007.09.009; Vercruysse J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000948; Victora CG, 2004, AM J PUBLIC HEALTH, V94, P400, DOI 10.2105/AJPH.94.3.400; World Health Organization, 2006, PREV CHEM HUM HELM C	47	50	53	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2013	7	5							e2165	10.1371/journal.pntd.0002165				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	158SW	WOS:000319994400004	23675541	DOAJ Gold, Green Published			2019-03-26	
J	Ali, E; Zachariah, R; Shams, Z; Vernaeve, L; Alders, P; Salio, F; Manzi, M; Allaouna, M; Draguez, B; Delchevalerie, P; Harries, AD				Ali, Engy; Zachariah, Rony; Shams, Zubair; Vernaeve, Lieven; Alders, Petra; Salio, Flavio; Manzi, Marcel; Allaouna, Malik; Draguez, Bertrand; Delchevalerie, Pascale; Harries, Anthony D.			Is mid-upper arm circumference alone sufficient for deciding admission to a nutritional programme for childhood severe acute malnutrition in Bangladesh?	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Mid-upper arm circumference; Weight-for-height Z-score; Severe acute malnutrition; Operational research; Bangladesh	WEIGHT-FOR-HEIGHT; CHILDREN; COMMUNITY; MALAWI; KENYA; TOOL	Mid-upper arm circumference (MUAC) and weight-for-height Z-score (WHZ) identify different populations of children with severe acute malnutrition (SAM) with only some degree of overlap. In an urban slum in Bangladesh, we conducted a prospective cohort study on children assessed as being severely malnourished by WHZ (3) but not by MUAC (115 mm), to: 1. Assess their nutritional outcomes, and 2. Report on morbidity and mortality. Children underwent 2-weekly prospective follow-up home visits for 3 months and their anthropometric evolution, morbidity and mortality were monitored. Of 158 children, 21 did not complete follow-up (six were lost to follow-up and 15 changed residence). Of the remaining 137 children, nine (7) required admission to the nutrition programme because of: MUAC dropping to 115 mm (5/9 children), weight loss 10 (1/9 children) and severe medical complications (3/9 children, of whom one died). Of the remaining 128 children who completed follow-up, 91 (66) improved in nutritional status while 37 (27) maintained a WHZ of 3. Cough was less frequent among those whose nutritional status improved. It seems acceptable to rely on MUAC as a single assessment tool for case finding and for admission of children with SAM to nutritional programmes.	[Ali, Engy; Zachariah, Rony; Manzi, Marcel] Med Sans Frontieres, Med Dept Operat Res, Brussels, Belgium; [Ali, Engy; Zachariah, Rony; Manzi, Marcel] Med Sans Frontieres Luxembourg, L-1617 Luxembourg, Luxembourg; [Shams, Zubair; Vernaeve, Lieven; Salio, Flavio] Med Sans Frontieres, Dhaka, Bangladesh; [Alders, Petra; Allaouna, Malik; Draguez, Bertrand; Delchevalerie, Pascale] Med Sans Frontieres, Brussels Operat Ctr, Brussels, Belgium; [Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France; [Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England	Ali, E (reprint author), Med Sans Frontieres, Med Dept Operat Res, Brussels, Belgium.	engy.y.ali@gmail.com			MSF-Brussels Operational Centre; Ministry of Foreign Affairs, Luxembourg	The study was funded by MSF-Brussels Operational Centre and the Ministry of Foreign Affairs, Luxembourg.	Ahmed T, 2012, J HEALTH POPUL NUTR, V30, P1; Berkley J, 2005, JAMA-J AM MED ASSOC, V294, P591, DOI 10.1001/jama.294.5.591; BERN C, 1995, LANCET, V345, P631, DOI 10.1016/S0140-6736(95)90527-8; Briend A, 2012, MATERN CHILD NUTR, V8, P130, DOI 10.1111/j.1740-8709.2011.00340.x; Collins S, 2006, FOOD NUTR BULL, V27, pS49, DOI 10.1177/15648265060273S304; Dario MD, 2012, INT J BIOMED SCI, V8, P140; Goossens S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049320; Kerac M, 2009, LANCET, V374, P136, DOI 10.1016/S0140-6736(09)60884-9; Mei ZG, 2007, B WORLD HEALTH ORGAN, V85, P441, DOI 10.2471/BLT.06.034421; Mogeni P, 2011, B WORLD HEALTH ORGAN, V89, P900, DOI 10.2471/BLT.11.091280; Myatt M, 1992, WEIGHT FOR HEIGHT MU; Myatt M, 2009, ANN HUM BIOL, V36, P5, DOI 10.1080/03014460802471205; Myatt M, 2006, FOOD NUTR BULL, V27, pS7, DOI 10.1177/15648265060273S302; National Institute of Population Research and Training (NIPORT), 2012, DEM HLTH SURV 2011 P; PELLETIER DL, 1994, J NUTR, V124, pS2082; Sadler K., 2011, COMMUNITY CASE MANAG; WHO WFP UNSCN UNICEF, COMM BAS MAN SEV AC; World Health Organization, WHO CHILD GROWTH STA; World Health Organization, WHO BANGL COUNTR COO	19	13	13	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY	2013	107	5					319	323		10.1093/trstmh/trt018				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	133AK	WOS:000318109600007	23471920	Green Published			2019-03-26	
J	Maulet, N; Keita, M; Macq, J				Maulet, Nathalie; Keita, Mahamoudou; Macq, Jean			Medico-social pathways of obstetric fistula patients in Mali and Niger: an 18-month cohort follow-up	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						vesicovaginal fistula; urinary incontinence; long-term care; West Africa; cohort study	URINARY-INCONTINENCE; SURGICAL-TREATMENT; WOMEN; REPAIR; FERTILITY; ETHIOPIA; MALAWI	Objectives To gain understanding of care pathways and induced mobility patterns of obstetric fistula patients in French-speaking West African fistula repair centres. Methods We followed prospectively during 18 months a cohort of obstetric fistula patients in Mali and Niger (20082009). 120 patients were recruited at different stages of their care process in 5 reference fistula repair centres. Follow-up was carried out in repair centres and communities. Quantitative data were collected through close-ended questionnaires at three time points. Medico-social pathways were explored through a longitudinal analysis focusing on six indicators: fistula duration, care process duration, patients' mobility, marital status, number of surgeries and continence status. Results Patients' pathways were characterised by their length: fistula duration (median 4years), care process duration (median 2.7years), aggregated time spent in repair centres during study (median 7months). Patients developed four mobility patterns (homebound, itinerant, institutionalised and urbanised). Adverse marital status change continued over time. Sample stratification according to number of previous surgeries revealed differences in care process duration and outcome: 23/31 new cases (1 surgery) gained continence with a mean of 1.5 surgeries in a median of 0.6year while only 17/78 old cases (2 surgeries) became continent with a mean of 4 surgeries in a median time of 4.9years. Conclusion The quest for continence does not end with admission to a fistula repair centre. Analysing fistula care experience across time within the varying settings highlights the twofold population and mixed medico-social outcomes that should prompt new development in obstetric fistula care management and research.	[Maulet, Nathalie; Macq, Jean] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium	Maulet, N (reprint author), Catholic Univ Louvain, Inst Hlth & Soc, 30 B1 30-16, B-1200 Brussels, Belgium.	nathalie.maulet@uclouvain.be					Arrowsmith S, 1996, Obstet Gynecol Surv, V51, P568, DOI 10.1097/00006254-199609000-00024; Bangser M, 2011, INT UROGYNECOL J, V22, P91, DOI 10.1007/s00192-010-1236-8; Benfield N, 2011, INT J GYNECOL OBSTET, V114, P265, DOI 10.1016/j.ijgo.2011.02.024; Browning A, 2008, BJOG-INT J OBSTET GY, V115, P1564, DOI 10.1111/j.1471-0528.2008.01900.x; Browning A, 2007, BJOG-INT J OBSTET GY, V114, P1439, DOI 10.1111/j.1471-0528.2007.01419.x; Browning A, 2006, BJOG-INT J OBSTET GY, V113, P482, DOI 10.1111/j.1471-0528.2006.00875.x; Browning A, 2009, BJOG-INT J OBSTET GY, V116, P1265, DOI 10.1111/j.1471-0528.2009.02182.x; Cam C, 2010, TAIWAN J OBSTET GYNE, V49, P291, DOI 10.1016/S1028-4559(10)60063-0; Donnay F, 2006, INT J GYNECOL OBSTET, V94, P254, DOI 10.1016/j.ijgo.2006.04.005; Gharoro EP, 2009, J OBSTET GYNAECOL, V29, P644, DOI 10.1080/01443610903100609; Gutman RE, 2007, INT J GYNECOL OBSTET, V99, pS57, DOI 10.1016/j.ijgo.2007.06.027; Kelly J, 2007, INT J GYNECOL OBSTET, V99, P21; Muleta M, 2008, J OBSTET GYNAECOL CA, V30, P44, DOI 10.1016/S1701-2163(16)32712-8; Ndiaye P, 2009, Med Trop (Mars), V69, P61; Nielsen HS, 2009, BJOG-INT J OBSTET GY, V116, P1258, DOI 10.1111/j.1471-0528.2009.02200.x; Pope R, 2011, GLOB PUBLIC HEALTH, V6, P859, DOI 10.1080/17441692.2010.551519; Turan Janet Molzan, 2007, Glob Public Health, V2, P64, DOI 10.1080/17441690600648728; Umoiyoho AJ, 2011, RURAL REMOTE HEALTH, V11; Wall L L, 2005, Obstet Gynecol Surv, V60, pS3, DOI 10.1097/00006254-200507001-00002; Weston K, 2011, INT J GYNECOL OBSTET, V115, P31, DOI 10.1016/j.ijgo.2011.04.015; WHO, 2006, OBST FIST GUID PRINC; Wilson AL, 2011, INT J GYNECOL OBSTET, V113, P196, DOI 10.1016/j.ijgo.2011.01.006; Yeakey MP, 2011, GLOB PUBLIC HEALTH, V6, P153, DOI 10.1080/17441692.2010.491833; Yeakey MP, 2009, CULT HEALTH SEX, V11, P499, DOI 10.1080/13691050902874777	24	20	20	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2013	18	5					524	533		10.1111/tmi.12086				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	123VZ	WOS:000317420800002	23489380	Bronze			2019-03-26	
J	Duysburgh, E; Zhang, WH; Ye, M; Williams, A; Massawe, S; Sie, A; Williams, J; Mpembeni, R; Loukanova, S; Temmerman, M				Duysburgh, E.; Zhang, W-H.; Ye, M.; Williams, A.; Massawe, S.; Sie, A.; Williams, J.; Mpembeni, R.; Loukanova, S.; Temmerman, M.			Quality of antenatal and childbirth care in selected rural health facilities in Burkina Faso, Ghana and Tanzania: similar finding	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						quality of care; maternal and newborn health; childbirth; antenatal care; sub-Saharan Africa; emergency obstetric care; haemorrhage; pre-eclampsia/eclampsia; obstructed labour	EMERGENCY OBSTETRIC CARE; OF-CARE; MATERNAL MORTALITY; WORKER PERFORMANCE; PERCEIVED QUALITY; CASE-MANAGEMENT; DANGER SIGNS; SERVICES; AVAILABILITY; SURVIVAL	Objectives To measure pre-intervention quality of routine antenatal and childbirth care in rural districts of Burkina Faso, Ghana and Tanzania and to identify shortcomings. Methods In each country, we selected two adjoining rural districts. Within each district, we randomly sampled 6 primary healthcare facilities. Quality of care was assessed through health facility surveys, direct observation of antenatal and childbirth care, exit interviews and review of patient records. Results By and large, quality of antenatal and childbirth care in the six districts was satisfactory, but we did identify some critical gaps common to the study sites in all three countries. Counselling and health education practices are poor; laboratory investigations are often not performed; examination and monitoring of mother and newborn during childbirth are inadequate; partographs are not used. Equipment required to provide assisted vaginal deliveries (vacuum extractor or forceps) was absent in all surveyed facilities. Conclusion Quality of care in the three study sites can be improved with the available human resources and without major investments. This improvement could reduce maternal and neonatal mortality and morbidity.	[Duysburgh, E.; Zhang, W-H.; Temmerman, M.] Univ Ghent, ICRH, B-9000 Ghent, Belgium; [Ye, M.; Sie, A.] Ctr Rech Sante Nouna, Nouna, Burkina Faso; [Williams, A.; Williams, J.] Navrongo Hlth Res Ctr, Navrongo, Ghana; [Massawe, S.; Mpembeni, R.] Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth & Social Sci, Dar Es Salaam, Tanzania; [Loukanova, S.] Heidelberg Univ, Dept Publ Hlth, Heidelberg, Germany	Duysburgh, E (reprint author), Univ Ghent, ICRH, De Pintelaan 185,UZP114, B-9000 Ghent, Belgium.	els.duysburgh@ugent.be		SIE, Ali/0000-0002-3959-2520; Zhang, Wei-Hong/0000-0003-0380-770X	European Union [22982]	The QUALMAT research project (Quality of Maternal and Prenatal Care: Bridging the Know-do Gap), funded as part of the 7th Framework Programme of the European Union (grant agreement 22982), is a collaboration between the Centre de Recherche en Sante de Nouna (Burkina Faso), Ghent University (Belgium), Heidelberg University (Germany), Karolinska Institute (Sweden), Muhimbili University of Health and Allied Sciences (Tanzania) and Navrongo Health Research Centre (Ghana). The overall objective of this research is to improve the motivation and performance of health workers and ultimately the quality of antenatal and childbirth care. The intervention packages include the development and implementation of a system of performance-based incentives and computer-assisted clinical decision support based on WHO guidelines. The interventions are evaluated in a pre/post controlled study design in rural Burkina Faso, Ghana and Tanzania between 2009 and 2014.	Al Tehewy M, 2009, INT J QUAL HEALTH C, V21, P183, DOI 10.1093/intqhc/mzp014; [Anonymous], 2012, TRENDS MAT MORT 1990; Baker U, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-31; Baltussen RMPM, 2002, HEALTH POLICY PLANN, V17, P42, DOI 10.1093/heapol/17.1.42; Bhutta ZA, 2008, LANCET, V372, P972, DOI 10.1016/S0140-6736(08)61407-5; Boller C, 2003, B WORLD HEALTH ORGAN, V81, P116; Bosse G, 2002, INT J GYNECOL OBSTET, V77, P243, DOI 10.1016/S0020-7292(02)00004-8; BRUCE J, 1990, STUD FAMILY PLANN, V21, P61, DOI 10.2307/1966669; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Campbell SM, 2000, SOC SCI MED, V51, P1611, DOI 10.1016/S0277-9536(00)00057-5; Delvaux Therese, 2007, Afr J Reprod Health, V11, P22; Delvaux T, 2008, TROP MED INT HEALTH, V13, P970, DOI 10.1111/j.1365-3156.2008.02105.x; Donabedian A, 1997, ARCH PATHOL LAB MED, V121, P1145; Eriksen J, 2007, TROP MED INT HEALTH, V12, P52, DOI 10.1111/j.1365-3156.2006.01753.x; Fawole A O, 2008, Afr J Reprod Health, V12, P22; Freedman LP, 2007, LANCET, V370, P1383, DOI 10.1016/S0140-6736(07)61581-5; Gabrysch S, 2011, INT J GYNECOL OBSTET, V114, P174, DOI 10.1016/j.ijgo.2011.05.007; Ghana Statistical Service (GSS) Ghana Health Service (GHS) and ICF Macro, 2009, GHAN DEM HLTH SURV 2; Ghana Statistical Service (GSS) Ghana Health Service (GHS) and Macro International, 2009, GHAN MAT HLTH SURV 2; Haddad S, 1998, INT J QUAL HEALTH C, V10, P93, DOI 10.1093/intqhc/10.2.93; Hulton L, 2000, FRAM EV QUAL CAR MAT; INSD and ICF International, 2012, ENQ DEM SANT IND MUL; Jennings L, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-75; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Kim YM, 2011, MIDWIFERY, V71, P1739; Kongnyuy EJ, 2009, MATERN CHILD HLTH J, V13, P687, DOI 10.1007/s10995-008-0380-y; Leigh B, 2008, INT J GYNECOL OBSTET, V101, P107, DOI 10.1016/j.ijgo.2008.01.012; Leonard K, 2006, SOC SCI MED, V63, P2330, DOI 10.1016/j.socscimed.2006.06.003; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Magoma M, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-64; Miller S, 2003, INT J GYNECOL OBSTET, V82, P89, DOI 10.1016/S0020-7292(03)00148-6; MoH, 2006, PLAN ACC RED MORT MA; MoHSW-Tanzania, 2008, NAT ROAD MAP STRAT P; National Bureau of Statistics (NBS) [ Tanzania] and ICF Macro, 2011, TANZ DEM HLTH SURV 2; Nikiema L, 2010, J HEALTH POPUL NUTR, V28, P67, DOI 10.3329/jhpn.v28i1.4525; Nyamtema AS, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-30; Olsen OE, 2005, HEALTH POLICY PLANN, V20, P167, DOI 10.1093/heapol/czi022; Ouma W, 2006, ACCEPTABILITY SUSTAI; Paxton A, 2006, INT J GYNECOL OBSTET, V93, P300, DOI 10.1016/j.ijgo.2006.01.030; Pearson L, 2005, INT J GYNECOL OBSTET, V88, P208, DOI 10.1016/j.ijgo.2004.09.027; Pembe AB, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-35; Pembe AB, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-12; Pitchforth E, 2010, SOC SCI MED, V71, P1739, DOI 10.1016/j.socscimed.2010.08.001; PRB, 2011, 2011 WORLD POP DAT S; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S01406736(06)69380-X; Sarker Malabika, 2010, BMC Res Notes, V3, P209, DOI 10.1186/1756-0500-3-209; The Partnership for Maternal Newborn and Child Health, 2011, GLOB REV KEY INT REL; UNICEF, 2012, REG STAT SUBS AFR; UNICEF, 2008, PROGR CHILDR REP CAR; UNICEF WHO World Bank and United Nation Population Division, 2011, LEV TRENDS CHILD MOR; Urassa David P, 2003, Afr J Reprod Health, V7, P69, DOI 10.2307/3583291; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; van Duong D, 2004, INT J QUAL HEALTH C, V16, P447, DOI 10.1093/intqhc/mzh073; Wahlstrom R, 2003, TROP MED INT HEALTH, V8, P901, DOI 10.1046/j.1365-3156.2003.01105.x; WHO, 2006, PREGN CHILDB POSTP N; WHO World Bank UNICEF & UNFPA, 2010, WHOFCH1006 UNICEF UN; World Health Organization, 2009, MON EM OBST CAR HDB; Ziraba AK, 2009, BMC PUBLIC HEALTH, V9, DOI [10.1186/1471-2458-9-465, 10.1186/1472-6963-9-46]	58	34	34	0	29	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2013	18	5					534	547		10.1111/tmi.12076				14	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	123VZ	WOS:000317420800003	23398053	Bronze			2019-03-26	
J	Srivastava, P; Gidwani, K; Picado, A; Van der Auwera, G; Tiwary, P; Ostyn, B; Dujardin, JC; Boelaert, M; Sundar, S				Srivastava, Pankaj; Gidwani, Kamlesh; Picado, Albert; Van der Auwera, Gert; Tiwary, Puja; Ostyn, Bart; Dujardin, Jean-Claude; Boelaert, Marleen; Sundar, Shyam			Molecular and serological markers of Leishmania donovani infection in healthy individuals from endemic areas of Bihar, India	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						PCR; Direct Agglutination Test; rK39 ELISA; asymptomatic; visceral leishmaniasis; kala-azar	DIRECT AGGLUTINATION-TEST; LINKED-IMMUNOSORBENT-ASSAY; VISCERAL LEISHMANIASIS; KALA-AZAR; ASYMPTOMATIC INFECTION; DIAGNOSIS; NEPAL; PCR; INFANTUM; DISEASE	Objectives Recent epidemiological reports indicate that asymptomatic human infections with Leishmania donovani, the causative agent of visceral leishmaniasis or Kala-azar (KA), occur frequently in India. We explored markers of infection. Methods Blood samples were collected from 286 healthy subjects from 16 villages in the Muzaffarpur district of Bihar. These individuals were classified into three groups: (i) persons with no history of KA and living in a house where no KA cases were previously reported, (ii) persons with no history of KA but living in a house where KA cases were diagnosed at the time of sampling or in the past, and (iii) successfully treated KA patients. Each sample was tested using a Leishmania-specific PCR to detect Leishmania DNA, and two serological tests to demonstrate anti-Leishmania antibodies: the Direct Agglutination Test and rK39 ELISA. Results PCR positivity was similar among the three groups (2025%). In contrast, among treated patients, the percentage of serologically positive individuals was roughly five times that of healthy individuals with no KA history, as measured with either test. Living in a house where KA had been reported did not affect seropositivity. Conclusion A significant proportion of asymptomatic infections of Leishmania exist in endemic regions. Using a combination of molecular and serological tests increases the capacity to detect infections at different stages. Further work is required to understand the kinetics of the markers.	[Srivastava, Pankaj; Gidwani, Kamlesh; Tiwary, Puja; Sundar, Shyam] Banaras Hindu Univ, Infect Dis Res Lab, Varanasi 221005, Uttar Pradesh, India; [Srivastava, Pankaj] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Picado, Albert; Ostyn, Bart; Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Van der Auwera, Gert; Dujardin, Jean-Claude] Inst Trop Med, Mol Parasitol Unit, B-2000 Antwerp, Belgium; [Dujardin, Jean-Claude] Univ Antwerp, Dept Biomed Sci, B-2020 Antwerp, Belgium	Sundar, S (reprint author), Banaras Hindu Univ, Inst Med Sci, Dept Med, Varanasi 221005, Uttar Pradesh, India.	drshyamsundar@hotmail.com	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Picado, Albert/0000-0001-7344-628X	EU [015374]	We acknowledge our colleagues for their support in conducting this study in any manner. We would also like to thank all those healthy blood donors for providing valuable clinical samples. This study was conducted with the support of EU funded INCO-Dev KALANET project (EU contract no 015374).	Alvar J, 2004, ADV PARASIT, V57, P1, DOI 10.1016/S0065-308X(04)57001-X; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Bhattarai NR, 2009, TROP MED INT HEALTH, V14, P404, DOI 10.1111/j.1365-3156.2009.02242.x; BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Chappuis F, 2006, BRIT MED J, V333, P723, DOI 10.1136/bmj.38917.503056.7C; Costa CHN, 2002, AM J TROP MED HYG, V66, P334, DOI 10.4269/ajtmh.2002.66.334; Davies CR, 1999, PARASITOLOGY, V119, P247, DOI 10.1017/S0031182099004680; Deborggraeve S, 2008, TROP MED INT HEALTH, V13, P1378, DOI 10.1111/j.1365-3156.2008.02154.x; ELHARITH A, 1988, J CLIN MICROBIOL, V26, P1321; Gidwani K, 2011, CLIN VACCINE IMMUNOL, V18, P346, DOI 10.1128/CVI.00473-10; Graham P, 1998, J CLIN EPIDEMIOL, V51, P763, DOI 10.1016/S0895-4356(98)00048-1; Jacquet D, 2006, TROP MED INT HEALTH, V11, P1777, DOI 10.1111/j.1365-3156.2006.01743.x; Junior AD, 1997, MEM I OSWALDO CRUZ, V92, P15, DOI 10.1590/S0074-02761997000100003; Khanal B, 2010, TROP MED INT HEALTH, V15, P1390, DOI 10.1111/j.1365-3156.2010.02631.x; le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953; Maurya R, 2005, J CLIN MICROBIOL, V43, P3038, DOI 10.1128/JCM.43.7.3038-3041.2005; Moreno EC, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000536; Ostyn B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001284; Picado A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6760; Prina E, 2007, MICROBES INFECT, V9, P1307, DOI 10.1016/j.micinf.2007.06.005; Riera C, 2004, T ROY SOC TROP MED H, V98, P102, DOI 10.1016/S0035-9203(03)00015-4; Rijal S, 2007, MICROBES INFECT, V9, P529, DOI 10.1016/j.micinf.2007.01.009; Saha S, 2009, T ROY SOC TROP MED H, V103, P737, DOI 10.1016/j.trstmh.2008.10.006; Samsa GP, 1996, J CLIN EPIDEMIOL, V49, P917, DOI 10.1016/0895-4356(96)00042-X; Singh SP, 2010, TROP MED INT HEALTH, V15, P12, DOI 10.1111/j.1365-3156.2010.02519.x; Stauch A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001405; Sundar S, 2012, NATL MED J INDIA, V25, P85; Topno RK, 2010, AM J TROP MED HYG, V83, P502, DOI 10.4269/ajtmh.2010.09-0345; Vaish M, 2012, CLIN MICROBIOL INFEC, V18, P81, DOI 10.1111/j.1469-0691.2011.03540.x; WESTGARD JO, 1981, CLIN CHEM, V27, P493; Wright P F, 1993, Rev Sci Tech, V12, P435; Zijlstra EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717	33	21	22	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2013	18	5					548	554		10.1111/tmi.12085				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	123VZ	WOS:000317420800004	23464581				2019-03-26	
J	Praet, N; Verweij, JJ; Mwape, KE; Phiri, IK; Muma, JB; Zulu, G; van Lieshout, L; Rodriguez-Hidalgo, R; Benitez-Ortiz, W; Dorny, P; Gabriel, S				Praet, Nicolas; Verweij, Jaco J.; Mwape, Kabemba E.; Phiri, Isaac K.; Muma, John B.; Zulu, Gideon; van Lieshout, Lisette; Rodriguez-Hidalgo, Richar; Benitez-Ortiz, Washington; Dorny, Pierre; Gabriel, Sarah			Bayesian modelling to estimate the test characteristics of coprology, coproantigen ELISA and a novel real-time PCR for the diagnosis of taeniasis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						taeniasis; Taenia solium; Bayesian methodology; diagnosis; sensitivity; specificity	POLYMERASE-CHAIN-REACTION; SOLIUM TAENIASIS; DIFFERENTIAL-DIAGNOSIS; FECAL SAMPLES; CYSTICERCOSIS; ASSAY; INFECTIONS; FRAMEWORK; SAGINATA	Objective To estimate and compare the performances of coprology, copro-Ag ELISA and real-time polymerase chain reaction assay (copro-PCR) for detection of Taenia solium tapeworm carriers. Methods The three diagnostic tests were applied on 817 stool samples collected in two Zambian communities where taeniasis is endemic. A Bayesian approach was used to allow estimation of the test characteristics. Two (0.2%; 95% Confidence Interval (CI): 00.8), 67 (8.2%; 95% CI: 6.410.3) and 10 (1.2%; 95% CI: 0.52.2) samples were positive using coprology, copro-Ag ELISA and copro-PCR, respectively. Results Specificities of 99.9%, 92.0% and 99.0% were determined for coprology, copro-Ag ELISA and copro-PCR, respectively. Sensitivities of 52.5%, 84.5% and 82.7% were determined for coprology, copro-Ag ELISA and copro-PCR, respectively. Conclusions We urge for additional studies exploring possible cross-reactions of the copro-Ag ELISA and for the use of more sensitive tests, such as copro-PCR, for the detection of tapeworm carriers, which is a key factor in controlling the parasite in endemic areas.	[Praet, Nicolas; Dorny, Pierre; Gabriel, Sarah] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Verweij, Jaco J.] St Elizabeth Hosp, Lab Med Microbiol & Immunol, Tilburg, Netherlands; [Mwape, Kabemba E.; Phiri, Isaac K.] Univ Zambia, Sch Vet Med, Dept Clin Studies, Lusaka, Zambia; [Mwape, Kabemba E.] Univ Pretoria, Dept Vet Trop Dis, Fac Vet Sci, ZA-0002 Pretoria, South Africa; [Muma, John B.] Univ Zambia, Sch Vet Med, Dept Dis Control, Lusaka, Zambia; [Zulu, Gideon] Petauke Dist Hosp, Petauke, Zambia; [van Lieshout, Lisette] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands; [Rodriguez-Hidalgo, Richar; Benitez-Ortiz, Washington] Univ Cent Ecuador, Ctr Int Zoonosis, Quito, Ecuador; [Rodriguez-Hidalgo, Richar; Benitez-Ortiz, Washington] Univ Cent Ecuador, Fac Med Vet & Zootecnia, Quito, Ecuador; [Dorny, Pierre] Univ Ghent, Fac Vet Med, Lab Vet Parasitol, Merelbeke, Belgium	Praet, N (reprint author), Inst Trop Med, Dept Biomed Sci, Natl Str 155, B-2000 Antwerp, Belgium.	npraet@itg.be	Rodriguez-Hidalgo, Richar/P-8877-2015	Rodriguez-Hidalgo, Richar/0000-0002-9338-1062; GABRIEL, SARAH/0000-0002-2523-233X			ALLAN JC, 1990, PARASITOLOGY, V101, P473, DOI 10.1017/S0031182000060686; Allan JC, 2003, ACTA TROP, V87, P87, DOI 10.1016/S0001-706X(03)00059-7; Allan JC, 1996, AM J TROP MED HYG, V54, P352, DOI 10.4269/ajtmh.1996.54.352; Berkvens D, 2006, EPIDEMIOLOGY, V17, P145, DOI 10.1097/01.ede.0000198422.64801.8d; Carabin H, 2006, TROP MED INT HEALTH, V11, P906, DOI 10.1111/j.1365-3156.2006.01627.x; Dorny P, 2004, TRENDS PARASITOL, V20, P259, DOI 10.1016/j.pt.2004.04.001; Flisser A, 2006, PARASITOL INT, V55, pS117, DOI 10.1016/j.parint.2005.11.018; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; Gelman A., 2003, BAYESIAN DATA ANAL; Guezala MC, 2009, AM J TROP MED HYG, V81, P433, DOI 10.4269/ajtmh.2009.81.433; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713; Ito A, 2003, TRENDS PARASITOL, V19, P377, DOI 10.1016/S1471-4922(03)00200-9; Jeon HK, 2011, PARASITOL INT, V60, P203, DOI 10.1016/j.parint.2010.12.001; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Mayta H, 2008, J CLIN MICROBIOL, V46, P286, DOI 10.1128/JCM.01172-07; Murrell KD, 2005, WHO FAO OIE GUIDELIN, P27; Mwape KE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001594; Niesters HGM, 2002, J CLIN VIROL, V25, pS3; Nkouawa A, 2009, J CLIN MICROBIOL, V47, P168, DOI 10.1128/JCM.01573-08; Nunes CM, 2005, EXP PARASITOL, V110, P412, DOI 10.1016/j.exppara.2005.03.008; Nunes CRM, 2003, EXP PARASITOL, V104, P67, DOI 10.1016/S0014-4894(03)00111-5; Praet N, 2010, AM J TROP MED HYG, V83, P413, DOI 10.4269/ajtmh.2010.10-0121; Praet N, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000406; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; Somers R, 2006, TROP MED INT HEALTH, V11, P65, DOI 10.1111/j.1365-3156.2005.01537.x; Spiegelhalter DJ, 2002, J ROY STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; ten Hove RJ, 2008, DIAGN MICR INFEC DIS, V61, P280, DOI 10.1016/j.diagmicrobio.2008.03.003; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Verweij JJ, 2009, T ROY SOC TROP MED H, V103, P342, DOI 10.1016/j.trstmh.2008.12.001; Wilkins PP, 1999, AM J TROP MED HYG, V60, P199, DOI 10.4269/ajtmh.1999.60.199; Yamasaki H, 2004, J CLIN MICROBIOL, V42, P548, DOI 10.1128/JCM.42.2.548-553.2004; Zamora HSR, 2004, AM J TROP MED HYG  S, V71, P42	32	35	36	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2013	18	5					608	614		10.1111/tmi.12089				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	123VZ	WOS:000317420800010	23464616	Bronze			2019-03-26	
J	Suleman, S; Vandercruyssen, K; Wynendaele, E; D'Hondt, M; Bracke, N; Duchateau, L; Burvenich, C; Peremans, K; De Spiegeleer, B				Suleman, Sultan; Vandercruyssen, Kirsten; Wynendaele, Evelien; D'Hondt, Matthias; Bracke, Nathalie; Duchateau, Luc; Burvenich, Christian; Peremans, Kathelijne; De Spiegeleer, Bart			A rapid stability-indicating, fused-core HPLC method for simultaneous determination of beta-artemether and lumefantrine in anti-malarial fixed dose combination products	MALARIA JOURNAL			English	Article						Anti-malaria; beta-artemether; Lumefantrine; Stability-indicating assay; HPLC-UV; Fused-core; Finished pharmaceutical product; Quality-by-design (QbD)	PERFORMANCE LIQUID-CHROMATOGRAPHY; MALARIA; PREDICTION	Background: Artemisinin-based fixed dose combination (FDC) products are recommended by World Health Organization (WHO) as a first-line treatment. However, the current artemisinin FDC products, such as beta-artemether and lumefantrine, are inherently unstable and require controlled distribution and storage conditions, which are not always available in resource-limited settings. Moreover, quality control is hampered by lack of suitable analytical methods. Thus, there is a need for a rapid and simple, but stability-indicating method for the simultaneous assay of beta-artemether and lumefantrine FDC products. Methods: Three reversed-phase fused-core HPLC columns (Halo RP-Amide, Halo C18 and Halo Phenyl-hexyl), all thermostated at 30 degrees C, were evaluated. beta-artemether and lumefantrine (unstressed and stressed), and reference-related impurities were injected and chromatographic parameters were assessed. Optimal chromatographic parameters were obtained using Halo RP-Amide column and an isocratic mobile phase composed of acetonitrile and 1mM phosphate buffer pH 3.0 (52:48; V/V) at a flow of 1.0 ml/min and 3 mu l injection volume. Quantification was performed at 210 nm and 335 nm for beta-artemether and for lumefantrine, respectively. In-silico toxicological evaluation of the related impurities was made using Derek Nexus v2.0 (R). Results: Both beta-artemether and lumefantrine were separated from each other as well as from the specified and unspecified related impurities including degradants. A complete chromatographic run only took four minutes. Evaluation of the method, including a Plackett-Burman robustness verification within analytical QbD-principles, and real-life samples showed the method is suitable for quantitative assay purposes of both active pharmaceutical ingredients, with a mean recovery relative standard deviation (+/- RSD) of 99.7 % (+/- 0.7%) for beta-artemether and 99.7 % (+/- 0.6%) for lumefantrine. All identified beta-artemether-related impurities were predicted in Derek Nexus v2.0 (R) to have toxicity risks similar to beta-artemether active pharmaceutical ingredient (API) itself. Conclusions: A rapid, robust, precise and accurate stability-indicating, quantitative fused-core isocratic HPLC method was developed for simultaneous assay of beta-artemether and lumefantrine. This method can be applied in the routine regulatory quality control of FDC products. The in-silico toxicological investigation using Derek Nexus (R) indicated that the overall toxicity risk for beta-artemether-related impurities is comparable to that of beta-artemether API.	[Suleman, Sultan; Vandercruyssen, Kirsten; Wynendaele, Evelien; D'Hondt, Matthias; Bracke, Nathalie; De Spiegeleer, Bart] Univ Ghent, Fac Pharmaceut Sci, Drug Qual & Registrat DruQuaR Grp, B-9000 Ghent, Belgium; [Suleman, Sultan] Jimma Univ, Sch Pharm, Jimma, Ethiopia; [Duchateau, Luc; Burvenich, Christian; Peremans, Kathelijne] Univ Ghent, Fac Vet Med, Dept Med Imaging Physiol & Biometr, B-9820 Merelbeke, Belgium	De Spiegeleer, B (reprint author), Univ Ghent, Fac Pharmaceut Sci, Drug Qual & Registrat DruQuaR Grp, Harelbekestr 72, B-9000 Ghent, Belgium.	Bart.Despiegeleer@UGent.be	De Spiegeleer, Bart/A-2001-2008	De Spiegeleer, Bart/0000-0001-6794-3108	Infectious Diseases and Epidemiology Project within Institutional University Cooperation Programme (Jimma University) of VLIR; Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen) [110533, 101529]; Special Research Fund of Ghent University [BOF 01J22510]	The authors would like to thank Dafra Pharmaceuticals (Turnhout, Belgium) for the provision of the reference substances. SS is supported by the Infectious Diseases and Epidemiology Project within Institutional University Cooperation Programme (Jimma University) of VLIR. KV and MD are supported by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen) (Nos. 110533 and 101529), while EW and BDS are supported by the Special Research Fund of Ghent University (Grant number BOF 01J22510).	[Anonymous], 2009, AUTHORIZED LUMEFANTR; [Anonymous], 2001, MERCK INDEX; Ashley EA, 2005, CURR OPIN INFECT DIS, V18, P531, DOI 10.1097/01.qco.0000186848.46417.6c; Atemnkeng Katelijne De C, 2001, TROP MED INT HEALTH, V6, P980; Baert B, 2010, ANAL BIOANAL CHEM, V398, P125, DOI 10.1007/s00216-010-3912-4; Cesar ID, 2008, J PHARMACEUT BIOMED, V48, P951, DOI 10.1016/j.jpba.2008.05.022; Cesar ID, 2008, J PHARMACEUT BIOMED, V48, P223, DOI 10.1016/j.jpba.2008.05.006; Cesar ID, 2009, BRAZ J PHARM SCI, V45, P737, DOI 10.1590/S1984-82502009000400018; De Spiegeleer BMJ, 2012, J PHARMACEUT BIOMED, V70, P111, DOI 10.1016/j.jpba.2012.06.002; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Ellison CM, 2010, MOL INFORM, V29, P97, DOI 10.1002/minf.200900006; European Directorate for the Quality of Medicines, 2006, EUROPEAN PHARMACOPOE; Gilles HM, 1993, ESSENTIAL MALARIOLOG, P188; Hamid K, 2010, CUR PHARM ANAL, V6, P142; Health Canada/Health Products and Food Branch Inspectorate, 2012, GUID TEMP CONTR DRUG; ICH guidelines - International Conference on Harmonization, 2003, STABILITY TESTING NE; Kaur HH, 2010, THERAPY, V7, P49, DOI DOI 10.2217/THY.09.84; Martindale, 2009, COMPLETE DRUG REFERE, P598; Mohan CG, 2007, MINI-REV MED CHEM, V7, P499; Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8; Patil KR, 2009, CHROMATOGRAPHIA, V69, P375, DOI 10.1365/s10337-008-0894-x; Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876; SANDERSON DM, 1991, HUM EXP TOXICOL, V10, P261, DOI 10.1177/096032719101000405; Shabir GA, 2003, J CHROMATOGR A, V987, P57, DOI 10.1016/S0021-9673(02)01536-4; Vandercruyssen K, 2013, J PHARM ANAL UNPUB; Verbeken M, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-51; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2008, INT PHARM; WHO, DRUG POL; WHO, 2008, WORLD MAL REP GLOB M; World Health Organization, 2010, GUID TREATM MAL; World Health Organization Geneva, 2006, COUNT MED	32	10	10	1	25	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	APR 30	2013	12								145	10.1186/1475-2875-12-145				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	144YM	WOS:000318978800002	23631682	DOAJ Gold, Green Published			2019-03-26	
J	Henriques, G; Martinelli, A; Rodrigues, L; Modrzynska, K; Fawcett, R; Houston, DR; Borges, ST; d'Alessandro, U; Tinto, H; Karema, C; Hunt, P; Cravo, P				Henriques, Gisela; Martinelli, Axel; Rodrigues, Louise; Modrzynska, Katarzyna; Fawcett, Richard; Houston, Douglas R.; Borges, Sofia T.; d'Alessandro, Umberto; Tinto, Halidou; Karema, Corine; Hunt, Paul; Cravo, Pedro			Artemisinin resistance in rodent malaria - mutation in the AP2 adaptor mu-chain suggests involvement of endocytosis and membrane protein trafficking	MALARIA JOURNAL			English	Article						Malaria; Artemisinin; Drug resistance; Genomics; Plasmodium chabaudi; Mutation; Endocytic machinery	PLASMODIUM-FALCIPARUM MALARIA; TRYPANOCIDAL DRUG SURAMIN; SERCA-TYPE PFATPASE6; PFMDR1 COPY NUMBER; IN-VITRO; CHLOROQUINE RESISTANCE; MEFLOQUINE RESISTANCE; COMBINATION THERAPY; MULTIPLE MUTATIONS; TRYPANOSOMA-BRUCEI	Background: The control of malaria, caused by Plasmodium falciparum, is hampered by the relentless evolution of drug resistance. Because artemisinin derivatives are now used in the most effective anti-malarial therapy, resistance to artemisinin would be catastrophic. Indeed, studies suggest that artemisinin resistance has already appeared in natural infections. Understanding the mechanisms of resistance would help to prolong the effective lifetime of these drugs. Genetic markers of resistance are therefore required urgently. Previously, a mutation in a de-ubiquitinating enzyme was shown to confer artemisinin resistance in the rodent malaria parasite Plasmodium chabaudi. Methods: Here, for a mutant P. chabaudi malaria parasite and its immediate progenitor, the in vivo artemisinin resistance phenotypes and the mutations arising using Illumina whole-genome re-sequencing were compared. Results: An increased artemisinin resistance phenotype is accompanied by one non-synonymous substitution. The mutated gene encodes the mu-chain of the AP2 adaptor complex, a component of the endocytic machinery. Homology models indicate that the mutated residue interacts with a cargo recognition sequence. In natural infections of the human malaria parasite P. falciparum, 12 polymorphisms (nine SNPs and three indels) were identified in the orthologous gene. Conclusion: An increased artemisinin-resistant phenotype occurs along with a mutation in a functional element of the AP2 adaptor protein complex. This suggests that endocytosis and trafficking of membrane proteins may be involved, generating new insights into possible mechanisms of resistance. The genotypes of this adaptor protein can be evaluated for its role in artemisinin responses in human infections of P. falciparum.	[Henriques, Gisela; Martinelli, Axel; Rodrigues, Louise; Borges, Sofia T.; Cravo, Pedro] Univ Nova Lisboa, Ctr Malaria & Doencas Trop, LA, IHMT, P-1200 Lisbon, Portugal; [Martinelli, Axel; Modrzynska, Katarzyna; Fawcett, Richard; Hunt, Paul] Univ Edinburgh, Sch Biol Sci, Inst Immunol & Infect Res, Edinburgh, Midlothian, Scotland; [Houston, Douglas R.] Univ Edinburgh, Sch Biol Sci, Inst Struct & Mol Biol, Edinburgh, Midlothian, Scotland; [d'Alessandro, Umberto] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; [Tinto, Halidou] Ctr Muraz, Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso; [Karema, Corine] Natl Malaria Control Programme, Kigali, Rwanda; [Hunt, Paul] Univ Edinburgh, Sch Biol Sci, Ctr Immun Infect & Evolut, Edinburgh, Midlothian, Scotland; [Cravo, Pedro] Univ Fed Goias, CAPES Brazil, Inst Patol Trop & Saude Publ, BR-74605050 Goiania, Go, Brazil	Henriques, G (reprint author), Univ London London Sch Hyg & Trop Med, Room 490,Keppel St, London WC1E 7HT, England.	gisela.henriques@lshtm.ac.uk	Cravo, Pedro/G-3532-2012; D'Alessandro, Umberto/D-3457-2015	Cravo, Pedro/0000-0003-1675-4504; D'Alessandro, Umberto/0000-0001-6341-5009	Medical Research Council (MRC), UK [G0400476]; Fundacao para a Ciencia e a Tecnologia (FCT), Portugal [PTDC/SAU-MII/65028/2006, SFRH/BD/63129/2009, SRFH/BPD/35017/2007, SFRH/BD/31518/2006, SFRH/BD/25096/2005]; Wellcome Trust Centre In Development (Centre for Immunity, Infection and Evolution) [082611]; Medical Research Council [G0400476]	Research was supported by Medical Research Council (MRC), UK (G0400476) and Fundacao para a Ciencia e a Tecnologia (FCT), Portugal (PTDC/SAU-MII/65028/2006). For personal support, we thank Centro de Malaria & Doencas Tropicais.LA/IHMT Universidade Nova de Lisboa (PC), CAPES/PVE of Brazil (PC), FCT (AM, GH, LR, SB), Scottish Enterprise (DH), the Darwin Trust (KM), MRC (RF, PH), Wellcome Trust (PH) and School of Biological Science, University of Edinburgh (PH). GH, AM, LR and STB were each supported by the Fundacao para a Ciencia e a Tecnologia (FCT) of Portugal (grant numbers SFRH/BD/63129/2009, SRFH/BPD/35017/2007, SFRH/BD/31518/2006 and SFRH/BD/25096/2005, respectively). DNA sequencing was carried out in the GenePool Genomics Facility in the University of Edinburgh and we thank Marian Thomson, Karim Gharbi and other GenePool staff for assistance with sequencing. Members of the Pathogen Genomics group at the Wellcome Trust Sanger Institute and core sequencing and informatics groups gave valuable access to the P. chabaudi genome sequence, assembly and annotation data. We thank the staff of the following institutions for the P. falciparum samples used in this study: Centro Nacional de Endemias, Sao Tome, Democratic Republic of Sao Tome and Principe, Secretaria de Vigilancia em Saude, Instituto Evandro Chagas, Belem, Para, Brazil and the National Malaria Control Program, Kigali, Rwanda. Artemisinin was a kind gift from Dafra Pharma.; Wellcome Trust will fund all Open Access charges for any work carried out or partially carried out under one of their grants. Article Processing Charges were supported by grant number 082611: Wellcome Trust Centre In Development (Centre for Immunity, Infection and Evolution). Principal PI: Prof. Rick Maizels.	Abu Bakar N, 2010, J CELL SCI, V123, P441, DOI 10.1242/jcs.061499; Afonso A, 2006, ANTIMICROB AGENTS CH, V50, P480, DOI 10.1128/AAC.50.2.480-489.2006; Alsford S, 2012, NATURE, V482, P232, DOI 10.1038/nature10771; Beez D, 2011, ANTIMICROB AGENTS CH, V55, P50, DOI 10.1128/AAC.00916-10; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Borges S, 2011, ANTIMICROB AGENTS CH, V55, P4858, DOI 10.1128/AAC.01748-10; Brandstrom M, 2007, GENETICS, V176, P1691, DOI 10.1534/genetics.107.070805; Carlton JMR, 2001, TRENDS PARASITOL, V17, P236, DOI 10.1016/S1471-4922(01)01899-2; Chavchich M, 2010, ANTIMICROB AGENTS CH, V54, P2455, DOI 10.1128/AAC.00947-09; Cheeseman IH, 2012, SCIENCE, V336, P79, DOI 10.1126/science.1215966; Clark TG, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r180; Coelho AC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001512; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Cravo PVL, 2003, ANTIMICROB AGENTS CH, V47, P709, DOI 10.1128/AAC.47.2.709-718.2003; Crespo MD, 2008, ANTIMICROB AGENTS CH, V52, P98, DOI 10.1128/AAC.00609-07; Ding XC, 2011, TRENDS PARASITOL, V27, P73, DOI 10.1016/j.pt.2010.11.006; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; Feng TS, 2011, BIOCHEM PHARMACOL, V82, P236, DOI 10.1016/j.bcp.2011.04.018; Ferreira ID, 2008, TROP MED INT HEALTH, V13, P199, DOI 10.1111/j.1365-3156.2007.01991.x; Ferreira ID, 2007, TROP MED INT HEALTH, V12, P353, DOI 10.1111/j.1365-3156.2006.01789.x; Grech K, 2002, MOL BIOCHEM PARASIT, V123, P95, DOI 10.1016/S0166-6851(02)00142-1; Hartwig CL, 2009, BIOCHEM PHARMACOL, V77, P322, DOI 10.1016/j.bcp.2008.10.015; Heung KM, 1999, EMBO J, V18, P3897; Hoppe HC, 2004, ANTIMICROB AGENTS CH, V48, P2370, DOI 10.1128/AAC.48.7.2370-2378.2004; Hunt P, 2007, MOL MICROBIOL, V65, P27, DOI 10.1111/j.1365-2958.2007.05753.x; Hunt P, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-499; Hyde JE, 2007, FEBS J, V274, P4688, DOI 10.1111/j.1742-4658.2007.05999.x; Imwong M, 2010, ANTIMICROB AGENTS CH, V54, P2886, DOI 10.1128/AAC.00032-10; Jackson LP, 2010, CELL, V141, P1220, DOI 10.1016/j.cell.2010.05.006; Jambou R, 2005, LANCET, V366, P1960, DOI 10.1016/S0140-6736(05)67787-2; Klonis N, 2011, P NATL ACAD SCI USA, V108, P11405, DOI 10.1073/pnas.1104063108; Kuhn Y, 2010, TRAFFIC, V11, P236, DOI 10.1111/j.1600-0854.2009.01018.x; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Lim P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-11; Martinelli A, 2011, INT J PARASITOL, V41, P165, DOI 10.1016/j.ijpara.2010.08.008; Maude RJ, 2010, DRUG DEVELOP RES, V71, P12, DOI 10.1002/ddr.20344; Modrzynska KK, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-106; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Ning ZM, 2001, GENOME RES, V11, P1725, DOI 10.1101/gr.194201; Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011; Noedl H, 2009, NEW ENGL J MED, V361, P540, DOI 10.1056/NEJMc0900231; O'Neill PM, 2010, MOLECULES, V15, P1705, DOI 10.3390/molecules15031705; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; PADUA RA, 1981, EXP PARASITOL, V52, P419, DOI 10.1016/0014-4894(81)90101-6; Pal A, 2002, MOL BIOCHEM PARASIT, V122, P217, DOI 10.1016/S0166-6851(02)00096-8; Phyo AP, 2012, LANCET, V379, P1960, DOI 10.1016/S0140-6736(12)60484-X; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Price RN, 2004, LANCET, V364, P438, DOI 10.1016/S0140-6736(04)16767-6; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Roberts L, 2008, ANTIMICROB AGENTS CH, V52, P1840, DOI 10.1128/AAC.01478-07; Rogers WO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-10; ROSARIO VE, 1976, NATURE, V261, P585, DOI 10.1038/261585a0; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Sidhu ABS, 2006, J INFECT DIS, V194, P528, DOI 10.1086/507115; Smythe WA, 2008, CELL MICROBIOL, V10, P452, DOI 10.1111/j.1462-5822.2007.01058.x; Takala-Harrison S, 2013, P NATL ACAD SCI USA, V110, P240, DOI 10.1073/pnas.1211205110; Teuscher F, 2010, J INFECT DIS, V202, P1362, DOI 10.1086/656476; Tinto H, 2006, T ROY SOC TROP MED H, V100, P509, DOI 10.1016/j.trstmh.2005.09.018; Traub LM, 2009, NAT REV MOL CELL BIO, V10, P583, DOI 10.1038/nrm2751; Uhlemann AC, 2005, NAT STRUCT MOL BIOL, V12, P628, DOI 10.1038/nsmb947; Vaid A, 2010, BLOOD, V115, P2500, DOI 10.1182/blood-2009-08-238972; VANSTERKENBURG ELM, 1993, ACTA TROP, V54, P237, DOI 10.1016/0001-706X(93)90096-T; WALLIKER D, 1975, PARASITOLOGY, V70, P19, DOI 10.1017/S0031182000048824; Witkowski B, 2010, ANTIMICROB AGENTS CH, V54, P1872, DOI 10.1128/AAC.01636-09; Yeung BG, 1999, MOL BIOL CELL, V10, P3643, DOI 10.1091/mbc.10.11.3643	68	18	18	0	16	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	APR 5	2013	12								118	10.1186/1475-2875-12-118				15	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	144YH	WOS:000318978200001	23561245	DOAJ Gold, Green Published			2019-03-26	
J	Gillet, P; Ngoyi, DM; Lukuka, A; Kande, V; Atua, B; van Griensven, J; Muyembe, JJ; Jacobs, J; Lejon, V				Gillet, Philippe; Ngoyi, Dieudonne Mumba; Lukuka, Albert; Kande, Viktor; Atua, Benjamin; van Griensven, Johan; Muyembe, Jean-Jacques; Jacobs, Jan; Lejon, Veerle			False Positivity of Non-Targeted Infections in Malaria Rapid Diagnostic Tests: The Case of Human African Trypanosomiasis	PLOS NEGLECTED TROPICAL DISEASES			English	Article							REAL-TIME PCR; SLEEPING SICKNESS; RHEUMATOID FACTORS; CONGO; ACCURACY; SINGLE; SERUM; ASSAY	Background: In endemic settings, diagnosis of malaria increasingly relies on the use of rapid diagnostic tests (RDTs). False positivity of such RDTs is poorly documented, although it is especially relevant in those infections that resemble malaria, such as human African trypanosomiasis (HAT). We therefore examined specificity of malaria RDT products among patients infected with Trypanosoma brucei gambiense. Methodology/Principal Findings: Blood samples of 117 HAT patients and 117 matched non-HAT controls were prospectively collected in the Democratic Republic of the Congo. Reference malaria diagnosis was based on real-time PCR. Ten commonly used malaria RDT products were assessed including three two-band and seven three-band products, targeting HRP-2, Pf-pLDH and/or pan-pLDH antigens. Rheumatoid factor was determined in PCR negative subjects. Specificity of the 10 malaria RDT products varied between 79.5 and 100% in HAT-negative controls and between 11.3 and 98.8% in HAT patients. For seven RDT products, specificity was significantly lower in HAT patients compared to controls. False positive reactions in HAT were mainly observed for pan-pLDH test lines (specificities between 13.8 and 97.5%), but also occurred frequently for the HRP-2 test line (specificities between 67.9 and 98.8%). The Pf-pLDH test line was not affected by false-positive lines in HAT patients (specificities between 97.5 and 100%). False positivity was not associated to rheumatoid factor, detected in 7.6% of controls and 1.2% of HAT patients. Conclusions/Significance: Specificity of some malaria RDT products in HAT was surprisingly low, and constitutes a risk for misdiagnosis of a fatal but treatable infection. Our results show the importance to assess RDT specificity in non-targeted infections when evaluating diagnostic tests.	[Gillet, Philippe; van Griensven, Johan; Jacobs, Jan; Lejon, Veerle] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Ngoyi, Dieudonne Mumba; Lukuka, Albert; Muyembe, Jean-Jacques] Inst Natl Rech Biomed, Kinshasa, Zaire; [Kande, Viktor] PNLTHA, Kinshasa, Zaire; [Atua, Benjamin] PNLP, Kinshasa, Zaire; [Lejon, Veerle] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Lejon, Veerle] Inst Rech Dev, UMR IRD CIRAD INTERTRYP 177, Montpellier, France	Gillet, P (reprint author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	veerle.lejon@ird.fr		gillet, philippe/0000-0001-5878-6446; Lejon, Veerle/0000-0002-6795-0962	Secondary Research Funding of the Institute of Tropical Medicine; Belgian Directorate General for Development Cooperation; Inbev-Baillet Latour Fund	The study was financed by the Secondary Research Funding of the Institute of Tropical Medicine. DMN received a Post-Doc grant from the Belgian Directorate General for Development Cooperation. JvG is supported by the Inbev-Baillet Latour Fund. The study funder(s) had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.	Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2; Bartoloni A, 1998, NEW ENGL J MED, V338, P1075, DOI 10.1056/NEJM199804093381518; Buscher P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000471; Buscher P, 2013, NEW ENGL J MED, V368, P1069, DOI 10.1056/NEJMc1210373; Cnops L, 2011, CLIN MICROBIOL INFEC, V17, P1101, DOI 10.1111/j.1469-0691.2010.03344.x; Cnops L, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-370; Grobusch MP, 1999, LANCET, V353, P297, DOI 10.1016/S0140-6736(05)74930-8; Hasker E, 2011, TROP MED INT HEALTH, V16, P869, DOI 10.1111/j.1365-3156.2011.02772.x; HAY FC, 1976, CLIN EXP IMMUNOL, V25, P185; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000290; Iqbal J, 2000, J CLIN MICROBIOL, V38, P1184; Kennedy PGE, 2008, ANN NEUROL, V64, P116, DOI 10.1002/ana.21429; Laferi H, 1997, NEW ENGL J MED, V337, P1635, DOI 10.1056/NEJM199711273372219; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; Lejon V, 2003, J INFECT DIS, V187, P1475, DOI 10.1086/374645; Lejon V, 2010, J CLIN MICROBIOL, V48, P2836, DOI 10.1128/JCM.00456-10; Leshem E, 2011, J CLIN MICROBIOL, V49, P2331, DOI 10.1128/JCM.00307-11; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P103; Muhindo HM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-224; Mukadi P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-308; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Swarthout TD, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-58; WHO, 2011, WORLD MALARIA REPORT 2011, P1; World Health Organization, 2011, MAL RAP DIAGN TEST P; World Health Organization, 2010, BAS MAL MICR 1; World Health Organization Global Malaria Programme, 2012, INF NOT REC SEL CRIT	27	14	14	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	APR	2013	7	4							e2180	10.1371/journal.pntd.0002180				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	133QC	WOS:000318153100034	23638201	DOAJ Gold, Green Published			2019-03-26	
J	Lederer, S; Lattwein, E; Hanke, M; Sonnenberg, K; Stoecker, W; Lundkvist, A; Vaheri, A; Vapalahti, O; Chan, PKS; Feldmann, H; Dick, D; Schmidt-Chanasit, J; Padula, P; Vial, PA; Panculescu-Gatej, R; Ceianu, C; Heyman, P; Avsic-Zupanc, T; Niedrig, M				Lederer, Sabine; Lattwein, Erik; Hanke, Merle; Sonnenberg, Karen; Stoecker, Winfried; Lundkvist, Ake; Vaheri, Antti; Vapalahti, Olli; Chan, Paul K. S.; Feldmann, Heinz; Dick, Daryl; Schmidt-Chanasit, Jonas; Padula, Paula; Vial, Pablo A.; Panculescu-Gatej, Raluca; Ceianu, Cornelia; Heyman, Paul; Avsic-Zupanc, Tatjana; Niedrig, Matthias			Indirect Immunofluorescence Assay for the Simultaneous Detection of Antibodies against Clinically Important Old and New World Hantaviruses	PLOS NEGLECTED TROPICAL DISEASES			English	Article							RECOMBINANT NUCLEOCAPSID PROTEINS; KOREAN HEMORRHAGIC-FEVER; SIN NOMBRE VIRUS; NEPHROPATHIA-EPIDEMICA; SEROLOGICAL DIAGNOSIS; RENAL SYNDROME; PUUMALA VIRUS; HANTAAN VIRUS; DOBRAVA VIRUS; GENETIC IDENTIFICATION	In order to detect serum antibodies against clinically important Old and New World hantaviruses simultaneously, multiparametric indirect immunofluorescence assays (IFAs) based on biochip mosaics were developed. Each of the mosaic substrates consisted of cells infected with one of the virus types Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Saaremaa (SAAV), Dobrava (DOBV), Sin Nombre (SNV) or Andes (ANDV). For assay evaluation, serum IgG and IgM antibodies were analyzed using 184 laboratory-confirmed hantavirus-positive sera collected at six diagnostic centers from patients actively or previously infected with the following hantavirus serotypes: PUUV (Finland, n = 97); SEOV (China, n = 5); DOBV (Romania, n = 7); SNV (Canada, n = 23); ANDV (Argentina and Chile, n = 52). The control panel comprised 89 sera from healthy blood donors. According to the reference tests, all 184 patient samples were seropositive for hantavirus-specific IgG (n = 177; 96%) and/or IgM (n = 131; 72%), while all control samples were tested negative. In the multiparametric IFA applied in this study, 183 (99%) of the patient sera were IgG and 131 (71%) IgM positive (accordance with the reference tests: IgG, 96%; IgM, 93%). Overall IFA sensitivity for combined IgG and IgM analysis amounted to 100% for all serotypes, except for SNV (96%). Of the 89 control sera, 2 (2%) showed IgG reactivity against the HTNV substrate, but not against any other hantavirus. Due to the high cross-reactivity of hantaviral nucleocapsid proteins, endpoint titrations were conducted, allowing serotype determination in >90% of PUUV- and ANDV-infected patients. Thus, multiparametric IFA enables highly sensitive and specific serological diagnosis of hantavirus infections and can be used to differentiate PUUV and ANDV infection from infections with Murinae-borne hantaviruses (e.g. DOBV and SEOV).	[Lederer, Sabine; Lattwein, Erik; Hanke, Merle; Sonnenberg, Karen; Stoecker, Winfried] EUROIMMUN Med Lab Diagnostika AG, Lubeck, Germany; [Lundkvist, Ake] Karolinska Inst, Swedish Inst Infect Dis Control, Stockholm, Sweden; [Vaheri, Antti; Vapalahti, Olli] Univ Helsinki, Dept Virol, Haartman Inst, Helsinki, Finland; [Chan, Paul K. S.] Chinese Univ Hong Kong, Fac Med, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; [Feldmann, Heinz; Dick, Daryl] Canadian Sci Ctr Human & Anim Hlth, Publ Hlth Agcy Canada, Special Pathogens Program, Natl Microbiol Lab, Winnipeg, MB, Canada; [Schmidt-Chanasit, Jonas] Bernhard Nocht Inst Trop Med, WHO Collaborating Ctr Arbovirus & Haemorrhag Feve, D-20359 Hamburg, Germany; ANLIS Dr Carlos G Malbran, Inst Nacl Enfermedades Infecciosas, Dept Virol, Buenos Aires, DF, Argentina; [Vial, Pablo A.] Univ Desarrollo, Inst Sci, Clin Alemana Sch Med, Santiago, Chile; [Panculescu-Gatej, Raluca; Ceianu, Cornelia] CANTACUZINO Natl Inst Res & Dev Microbiol & Immun, Lab Vector Borne Infect & Med Entomol, Bucharest, Romania; [Heyman, Paul] Queen Astrid Mil Hosp, Res Lab Vector Borne Dis, Brussels, Belgium; [Avsic-Zupanc, Tatjana] Inst Microbiol & Immunol, Lab Diag Zoonoses, Ljubljana, Slovenia; [Avsic-Zupanc, Tatjana] WHO Lab, Ljubljana, Slovenia; [Niedrig, Matthias] Robert Koch Inst, Ctr Biol Safety ZBS 1, Berlin, Germany	Lederer, S (reprint author), EUROIMMUN Med Lab Diagnostika AG, Lubeck, Germany.	e.lattwein@euroimmun.de	Chan, Paul/J-9360-2013; Ceianu, Cornelia-Svetlana/A-7423-2018	Chan, Paul/0000-0002-6360-4608; Vapalahti, Olli/0000-0003-2270-6824; AVSIC ZUPANC, TATJANA/0000-0001-6243-0688; Schmidt-Chanasit, Jonas/0000-0003-4433-0231; Ceianu, Cornelia Svetlana/0000-0001-6222-0752			Araki K, 2001, J CLIN MICROBIOL, V39, P2397, DOI 10.1128/JCM.39.7.2397-2404.2001; AVSICZUPANC T, 1992, J MED VIROL, V38, P132, DOI 10.1002/jmv.1890380211; Biel SS, 2003, J CLIN VIROL, V28, P248, DOI 10.1016/S1386-6532(03)00009-X; Billecocq A, 2003, CLIN DIAGN LAB IMMUN, V10, P658, DOI 10.1128/CDLI.10.4.658-663.2003; BRUMMERKORVENKONTIO M, 1980, J INFECT DIS, V141, P131, DOI 10.1093/infdis/141.2.131; Centers for Disease Control and Prevention, 2012, OUTBR HANT INF YOS N; Denecke B, 2010, MAYO CLIN PROC, V85, P1016, DOI 10.4065/mcp.2009.0040; DZAGUROVA T, 1995, ARCH VIROL, V140, P1763, DOI 10.1007/BF01384340; Elgh F, 1998, FEMS IMMUNOL MED MIC, V22, P309; Elgh F, 1997, J CLIN MICROBIOL, V35, P1122; ELLIOTT RM, 1990, J GEN VIROL, V71, P501, DOI 10.1099/0022-1317-71-3-501; Escadafal C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001607; Fhogartaigh Caoimhe Nic, 2011, BMJ Case Rep, V2011, DOI 10.1136/bcr.06.2011.4326; Geldmacher A, 2004, VIRAL IMMUNOL, V17, P115, DOI 10.1089/088282404322875511; GROEN J, 1992, J MED VIROL, V37, P283, DOI 10.1002/jmv.1890370409; Hepojoki J, 2012, J GEN VIROL, V93, P1631, DOI 10.1099/vir.0.042218-0; Heyman P., 2008, Eurosurveillance, V13, P18925; Heyman P., 2011, EURO SURVEILL, V16; Hjelle B, 2010, VIRUSES-BASEL, V2, P2559, DOI 10.3390/v2122559; Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09; Kallio-Kokko H, 1998, CLIN DIAGN VIROL, V10, P83, DOI 10.1016/S0928-0197(97)10019-8; Kallio-Kokko V, 2001, J MED VIROL, V65, P605; KAMRUD KI, 1994, VIRUS RES, V31, P109, DOI 10.1016/0168-1702(94)90074-4; KIM YS, 1995, NEPHRON, V71, P419, DOI 10.1159/000188762; Koma T, 2010, J CLIN MICROBIOL, V48, P1635, DOI 10.1128/JCM.00072-10; KSIAZEK TG, 1995, AM J TROP MED HYG, V52, P117, DOI 10.4269/ajtmh.1995.52.117; LEE HW, 1982, J INFECT DIS, V146, P638, DOI 10.1093/infdis/146.5.638; LEE HW, 1978, J INFECT DIS, V137, P298, DOI 10.1093/infdis/137.3.298; Lindkvist M, 2008, VIRUS RES, V137, P97, DOI 10.1016/j.virusres.2008.06.003; Lopez N, 1996, VIROLOGY, V220, P223, DOI 10.1006/viro.1996.0305; Lundkvist A, 1997, J MED VIROL, V53, P51; MacNeil A, 2010, J INFECT DIS, V202, P242, DOI 10.1086/653482; Maftei ID, 2012, INT UROL NEPHROL, V44, P1185, DOI 10.1007/s11255-011-0013-z; Meisel H, 2006, CLIN VACCINE IMMUNOL, V13, P1349, DOI 10.1128/CVI.00208-06; Nakamura I, 2008, ARCH VIROL, V153, P1537, DOI 10.1007/s00705-008-0128-4; Nemirov K, 1999, J GEN VIROL, V80, P371, DOI 10.1099/0022-1317-80-2-371; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; Plyusnina A, 2009, J MED VIROL, V81, P2045, DOI 10.1002/jmv.21635; Razanskiene A, 2004, J BIOTECHNOL, V111, P319, DOI 10.1016/j.jbiotec.2004.04.010; Saksida A, 2008, J INFECT DIS, V197, P681, DOI 10.1086/527485; Sariguzel N, 2012, EMERG INFECT DIS, V18, P1180, DOI 10.3201/eid1807.111746; Schilling S, 2007, J CLIN MICROBIOL, V45, P3008, DOI 10.1128/JCM.02573-06; Schmaljohn C, 1997, EMERG INFECT DIS, V3, P95, DOI 10.3201/eid0302.970202; SCHMALJOHN CS, 1983, VIROLOGY, V131, P482, DOI 10.1016/0042-6822(83)90514-7; SCHMALJOHN CS, 1985, SCIENCE, V227, P1041, DOI 10.1126/science.2858126; Schmidt J, 2006, INTERVIROLOGY, V49, P173, DOI 10.1159/000089378; Schmidt J, 2005, J CLIN VIROL, V33, P247, DOI 10.1016/j.jcv.2005.01.003; Sironen T, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-90; Sjolander KB, 1999, J VIROL METHODS, V80, P137; Tai Pei-Wen, 2006, Journal of Microbiology Immunology and Infection, V39, P225; Vaheri A., 2011, ZOONOSES BIOL CLIN P, P307; Vaheri A, 2008, REV MED VIROL, V18, P277, DOI 10.1002/rmv.581; Vaheri A, 2013, REV MED VIROL, V23, P35, DOI 10.1002/rmv.1722; VAPALAHTI O, 1995, J MED VIROL, V46, P293, DOI 10.1002/jmv.1890460402; Vapalahti O, 2003, LANCET INFECT DIS, V3, P653, DOI 10.1016/S1473-3099(03)00774-6; Vapalahti O, 1996, J CLIN MICROBIOL, V34, P119; Vu TQH, 2010, EMERG INFECT DIS, V16, P363, DOI 10.3201/eid1602.091204; Xiao RB, 2006, J INFECT DIS, V194, P1403, DOI 10.1086/508494; Yi J, 2012, J INFECT DIS; Zentrale Ethikkomission, 2003, WEITER VERWENDUNG ME; Zhang YZ, 2007, J MED VIROL, V79, P1208, DOI 10.1002/jmv.20871; ZOLLER L, 1993, J MED VIROL, V39, P200, DOI 10.1002/jmv.1890390305	62	9	11	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	APR	2013	7	4							e2157	10.1371/journal.pntd.0002157				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	133QC	WOS:000318153100018	23593524	DOAJ Gold, Green Published			2019-03-26	
J	Couvreur, B				Couvreur, Bernard			Whole-cell antigenicity data support sequence-based kinetoplastid taxonomy	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Editorial Material						molecular taxonomy; Leishmania; Trypanosoma; antigen; immunodiffusion	RIBOSOMAL-RNA; EVOLUTION; TRYPANOSOMATIDAE; PHYLOGENY	Early immunological data, obtained by immunodiffusion and immunoelectrophoresis, on the whole-cell antigenicity of kinetoplastid protozoa were retrieved and used to construct a dendrogram of antigenic distances. Remarkably, they supported the same taxonomic conclusions as analyses based on DNA and protein sequence data.	ASBL Culture Vivo, Nivelles, Belgium	Couvreur, B (reprint author), ASBL Culture Vivo, Nivelles, Belgium.	couvreur.bernard@gmail.com					AFCHAIN D, 1979, J PARASITOL, V65, P507, DOI 10.2307/3280312; Afchain D, 1976, THESIS U SCI TECHNIQ; CAPRON A R, 1970, Journal of Parasitology, V56, P515; Fraga J, 2010, INFECT GENET EVOL, V10, P238, DOI 10.1016/j.meegid.2009.11.007; Hamilton PB, 2004, INT J PARASITOL, V34, P1393, DOI 10.1016/j.ijpara.2004.08.011; Le Ray D, 1975, Ann Soc Belg Med Trop, V55, P129; Leonard G, 2011, INFECT GENET EVOL, V11, P955, DOI 10.1016/j.meegid.2011.03.005; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Piontkivska H, 2005, MOL BIOCHEM PARASIT, V144, P94, DOI 10.1016/j.molbiopara.2005.08.007; Simpson AGB, 2006, TRENDS PARASITOL, V22, P168, DOI 10.1016/j.pt.2006.02.006; Stevens JR, 2008, PARASITE, V15, P226, DOI 10.1051/parasite/2008153226; Stevens JR, 2001, ADV PARASIT, V48, P1, DOI 10.1016/S0065-308X(01)48003-1; Vickerman K, 2002, PROTIST, V153, P9, DOI 10.1078/1434-4610-00079	13	1	1	0	3	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276			MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz	APR	2013	108	2					248	250		10.1590/0074-0276108022013021				3	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	125FS	WOS:000317525600021	23579809	DOAJ Gold, Green Published			2019-03-26	
J	Tinto, H; Noor, RA; Wanga, CL; Valea, I; Mbaye, MN; D'Alessandro, U; Ravinetto, RM				Tinto, Halidou; Noor, Ramadhani A.; Wanga, Charles L.; Valea, Innocent; Mbaye, Maimouna Ndour; D'Alessandro, Umberto; Ravinetto, Raffaella M.			Perspective Piece: Good Clinical Practice in Resource-Limited Settings: Translating Theory into Practice	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							PARTNERSHIP; WORLD	A Good Clinical Practices (GCPs) course, based on the combination of theoretical modules with a practical training in real-life conditions, was held in 2010 in Burkina Faso. It was attended by 15 trainees from nine African, Asian, and Latin American countries. There were some discrepancies between the average good results at the end of the theoretical phase and the GCP application during the first days of the practical phase, underlying the difficulties of translating theoretical knowledge into good practices. Most of the findings were not unexpected and reflected the challenges commonly faced by clinical investigators in resource-poor contexts (i.e., the high workload at peripheral health facilities, the need to conciliate routine clinical activities with clinical research, and the risk of creating a double standard among patients attending the same health facility [free care for recruited patients versus user fees for non-recruited patients with the same medical condition]). Even if limited in number and time, these observations suggest that a theoretical training alone may not be sufficient to prepare trainees for the challenges of medical research in real-life settings. Conversely, when a practical phase immediately follows a theoretical one, trainees can immediately experience what the research methodology implicates in terms of work organization and relationship with recruited and non-recruited patients. This initial experience shows the complexity of translating GCP into practice and suggests the need to rethink the current conception of GCP training.	[Tinto, Halidou; Valea, Innocent] Inst Rech Sci Sante Direct Rege Ouest IRSS Ctr Mu, Clin Res Unit Nanoro, Bobo Dioulasso, Burkina Faso; QGates Clin Res Org, Darjeeling, India; [Mbaye, Maimouna Ndour] Hop Abass Ndao, Serv Med Interne, Dakar, Senegal; [D'Alessandro, Umberto] Inst Trop Med, Malariol Unit, B-2000 Antwerp, Belgium; Inst Trop Med, Clin Trials Unit, Dept Clin Sci, B-2000 Antwerp, Belgium; [D'Alessandro, Umberto] MRC Unit, Banjul, Gambia; [Ravinetto, Raffaella M.] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Louvain, Belgium	Ravinetto, RM (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	tintohalidou@yahoo.fr; ramanoor@gmail.com; charles.wanga@gmail.com; innocentvalea@yahoo.fr; mbayester@gmail.com; udalessandro@mrc.gm; rravinetto@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Tinto, Halidou/0000-0002-0472-3586	Belgian Directorate-General for Development Cooperation (DGD) [3 (FA3)]; Institute of Tropical Medicine, Antwerp (Belgium); Department of Economy, Science and Innovation of the Flemish Government	This course was funded by the Belgian Directorate-General for Development Cooperation (DGD) under the Framework Agreement 3 (FA3) with the Institute of Tropical Medicine, Antwerp (Belgium). The Clinical Trials Unit of the Institute of Tropical Medicine (ITM) is supported by the Department of Economy, Science and Innovation of the Flemish Government.	Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; [Anonymous], 1996, TRIP GUID GOOD CLIN; Chilengi R, 2010, WEBMEDCENTRAL CLIN T, V1; Claeys Y, 2011, TROPICAL MED INT S1, V16; Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO), 2002, INT ETH GUID BIOM RE; Dolgin E, 2010, NAT MED, V16, P8, DOI 10.1038/nm0110-8a; Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709; European Medicines Agency, 2012, EMA1213402011; Frenk J, 2010, LANCET, V376, P1923, DOI 10.1016/S0140-6736(10)61854-5; Glickman SW, 2009, NEW ENGL J MED, V360, P816, DOI 10.1056/NEJMsb0803929; Heimburger DC, 2011, AM J TROP MED HYG, V85, P971, DOI 10.4269/ajtmh.2011.11-0141; Lancet, 2007, LANCET, V369, P1233; Lang T, 2011, LANCET, V377, P1553, DOI 10.1016/S0140-6736(10)62052-1; Levinson DR, 2010, OEI010800510 US DEP; Mgone CS, 2009, TROP MED INT HEALTH, V14, P1327, DOI 10.1111/j.1365-3156.2009.02391.x; [New Technologies to the European Commission European Group on Ethics in Science], 2003, OP ETH ASP CLIN RES; Nuffield Council on Bioethics, 1999, ETH CLIN RES DEV COU; Nuffield Council on Bioethics, 2002, ETH RES REL HEALTHC; Pare Toe L, 2011, COMMUNICATION; RAVINETTO R, 2010, ITALIAN J TROPICAL M, V15, P15; Ravinetto R, 2011, TROP MED INT HEALTH, V16, P527, DOI 10.1111/j.1365-3156.2011.02732.x; The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979, BELM REP ETH PRINC G; van Loen H, 2011, COMMUNICATION; WHO, 1995, WHO TECHN REP SER; World Health Organization, 2002, WHO HDB GOOD CLIN RE; World Health Organization, 2008, B WORLD HEALTH ORGAN, V86, P58; World Medical Association Declaration of Helsinki, 2011, 18 WMA GEN ASS HELS; 1996, JAMA, V276, P1691	28	9	9	0	8	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	APR	2013	88	4					608	613		10.4269/ajtmh.12-0330				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	118KP	WOS:000317024700002	23553224	Green Published, Bronze			2019-03-26	
J	Choun, K; Thai, S; Pe, R; Lorent, N; Lynen, L; van Griensven, J				Choun, Kimcheng; Thai, Sopheak; Pe, Reaksmey; Lorent, Natalie; Lynen, Lutgarde; van Griensven, Johan			Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Tuberculosis; HIV; Antiretroviral treatment; Incidence; Asia; Risk factor	ISONIAZID PREVENTIVE THERAPY; BODY-MASS INDEX; POSITIVE PATIENTS; INCOME COUNTRIES; HAART INITIATION; PROGRAMS; ASSOCIATION; STRATEGIES; ALGORITHM; MORTALITY	Given the lack of detailed studies on tuberculosis (TB) in patients on antiretroviral treatment (ART) in South-East Asia, we aimed to determine the incidence and risk factors for early (after 6 months of ART) and late (after 6 months of ART) incident TB in Cambodia. We conducted a retrospective analysis of all patients started on ART at a non-governmental hospital in Phnom Penh (March 2003December 2010). TB diagnosis was performed according to WHO algorithms. Risk factor analysis was performed using multivariate Cox regression modeling. Overall, 2984 patients started ART. The median baseline CD4 count was 89 cells l(1) (IQR 25209), median age 34 years (IQR 2940). Fifty-three percent of the patients were female. Median follow-up time on ART was 2.4 years. In addition to 932 (31.2) patients already on TB treatment at ART initiation, 313 (10.5) developed TB, with an overall incidence rate of 3.9/100 patient-years. Of those developing TB, 179 (6.0) patients were diagnosed with early TB and 134 (4.5) with late TB, corresponding with a rate of 13.5 and 2.0 per 100 patient-years respectively. Risk factors for early TB included low body mass index, low baseline CD4 count and low hemoglobin levels. Low on-treatment CD4 counts and hemoglobin levels, being underweight while on ART and prevalent TB were identified as risk factors for late TB. The incidence of early TB was high, and predominantly associated with advanced HIV progression markers. Earlier ART initiation and enhanced TB screening prior to and after ART initiation is warranted. Late TB amounts to almost half of the total TB burden, meriting specific preventive and diagnostic approaches.	[Choun, Kimcheng; Thai, Sopheak; Pe, Reaksmey; Lorent, Natalie; van Griensven, Johan] Sihanouk Hosp Ctr HOPE, Phnom Penh, Cambodia; [Lorent, Natalie; Lynen, Lutgarde; van Griensven, Johan] Inst Trop Med, B-2000 Antwerp, Belgium	Choun, K (reprint author), Sihanouk Hosp Ctr HOPE, Phnom Penh, Cambodia.	kimchengchoun@sihosp.org	Lynen, Lutgarde/A-1212-2014	Lynen, Lutgarde/0000-0001-7183-4895	Belgian Directorate General of Development Cooperation; Institute of Tropical Medicine; Antwerp; Global Fund to fight AIDS, Tuberculosis and Malaria; World Mate; HOPE Worldwide; InBev-Baillet Latour Fund, Belgium; Research Foundation Flanders	The HIV program was supported by the Belgian Directorate General of Development Cooperation through the framework agreement with the Institute of Tropical Medicine, Antwerp, the Global Fund to fight AIDS, Tuberculosis and Malaria, World Mate, and HOPE Worldwide. JvG is supported by the InBev-Baillet Latour Fund, Belgium. NL is supported by a grant from the Research Foundation Flanders.	Ait-Khaled N, 2009, INT J TUBERC LUNG D, V13, P927; [Anonymous], 2010, PRIOR RES QUEST TB H; [Anonymous], 2006, IMPR DIAGN TREATM SM; Barba C, 2004, LANCET, V363, P157; Bonnet MMB, 2006, AIDS, V20, P1275, DOI 10.1097/01.aids.0000232235.26630.ee; Brinkhof MWG, 2007, CLIN INFECT DIS, V45, P1518, DOI 10.1086/522986; Cain KP, 2010, NEW ENGL J MED, V362, P707, DOI 10.1056/NEJMoa0907488; Dembele M, 2010, INT J TUBERC LUNG D, V14, P318; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Fenner L, 2011, INT J TUBERC LUNG D, V15, P620, DOI 10.5588/ijtld.10.0249; Golub JE, 2007, AIDS, V21, P1441, DOI 10.1097/QAD.0b013e328216f441; Hanrahan CF, 2010, AIDS, V24, P1501, DOI 10.1097/QAD.0b013e32833a2a4a; Koole O, 2011, PLOS ONE, V6, DOI DOI 10.1371/JOURNAL; Kowalska JD, 2007, AIDS RES HUM RETROV, V23, P1183, DOI 10.1089/aid.2006.0292; Kranzer K, 2011, PLOS ONE, V6; Lawn SD, 2005, CLIN INFECT DIS, V41, P1783, DOI 10.1086/498308; Lawn SD, 2005, AIDS, V19, P1113, DOI 10.1097/01.aids.0000176211.08581.5a; Lawn SD, 2011, INT J TUBERC LUNG D, V15, P1272, DOI 10.5588/ijtld.11.0407; Lawn SD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001067; Lawn SD, 2010, LANCET INFECT DIS, V10, P489, DOI 10.1016/S1473-3099(10)70078-5; Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d; Leung CC, 2007, ARCH INTERN MED, V167, P1297, DOI 10.1001/archinte.167.12.1297; Lonnroth K, 2010, INT J EPIDEMIOL, V39, P149, DOI 10.1093/ije/dyp308; Lynen L, 2009, JAIDS-J ACQ IMM DEF, V52, P40, DOI 10.1097/QAI.0b013e3181af6705; Miranda A, 2007, PLOS ONE, V2, ppe826; National Center for HIV/AIDS DaSN, 2010, ANN REP 2010; National Tuberculosis Program (CENAT), 2010, ANN REP 2010; National Tuberculosis Program (CENAT), 2012, NAT HLTH STRAT PLAN; Nicholas S, 2011, JAIDS-J ACQ IMM DEF, V57, P311, DOI 10.1097/QAI.0b013e318218a713; Pednekar MS, 2008, INT J EPIDEMIOL, V37, P524, DOI 10.1093/ije/dyn001; Phan V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030647; Rajasekaran S, 2009, Indian J Tuberc, V56, P69; Seyler C, 2006, AIDS, V20, P1463, DOI 10.1097/01.aids.0000233585.87338.79; Thai S, 2009, TROP MED INT HEALTH, V14, P1048, DOI 10.1111/j.1365-3156.2009.02334.x; van Griensven J, 2011, T ROY SOC TROP MED H, V105, P694, DOI 10.1016/j.trstmh.2011.08.007; Van Rie A, 2011, JAIDS-J ACQ IMM DEF, V56, P349, DOI 10.1097/QAI.0b013e3181f9fb39; WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1; WHO, 2009, GLOB TUB CONTR 2009; *WHO, 2003, TREATM TUB GUID NAT; *WHO, 2006, ANT THER HIV INF AD; World Health Organization, 2010, ANT THER HIV INF AD; World Health Organization (WHO), 2011, GUID INT TUB CAS FIN	42	8	8	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	APR	2013	107	4					235	242		10.1093/trstmh/trt001				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	110DK	WOS:000316422100006	23324313	Bronze			2019-03-26	
J	Kanobana, K; Vereecken, K; Diaz, RJ; Sariego, I; Rojas, L; Gorbea, MB; Polman, K				Kanobana, K.; Vereecken, K.; Diaz, R. Junco; Sariego, I.; Rojas, L.; Gorbea, M. Bonet; Polman, K.			Toxocara seropositivity, atopy and asthma: a study in Cuban schoolchildren	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Toxocara; toxocariasis; asthma; atopy; Cuba	INTESTINAL HELMINTH INFECTIONS; ALLERGIC RHINOCONJUNCTIVITIS; RISK-FACTOR; CHILDREN; PREVALENCE; PARASITES; ISAAC	Introduction Evidence suggests that human toxocariasis (HT) could stimulate the onset of allergic diseases such as asthma. More specifically, in subjects having a hypothetical atopic genotype', HT could boost preexistent allergy symptoms. We tested the latter hypothesis in Cuba, a country where both asthma and HT are prevalent. Material and methods In a group of Cuban school-aged children (n=958), we investigated the association of Toxocara seropositivity and atopic status with asthma. Toxocara seropositivity was diagnosed with ELISA and atopy by allergen skin prick test. Both physician-diagnosed asthma and current wheeze, as determined by International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire, were considered. Associations were assessed using multivariable logistic regression analyses, with either physician-diagnosed asthma' or current wheeze' as outcome variable. Results 40.1% of the children were Toxocara seropositive. Prevalences were 21.7% for current wheeze and 32.7% for physician-diagnosed asthma. The odds of having asthma were almost two times higher in atopic children, but only reached borderline significance (OR=1.90, CI 95%: 0.953.80 for physician-diagnosed asthma and OR=1.94, CI 95%: 0.983.85 for current wheeze). Toxocara seropositivity and physician-diagnosed asthma were associated (OR=1.51, CI 95%: 1.012.26). Moreover, in children without antibodies to Toxocara, being atopic was significantly associated with having physician-diagnosed asthma (OR=2.53, CI 95%: 1.633.90), while this association was not present in Toxocara positives (OR=1.38, CI 95%: 0.822.37). Conclusion Our data confirm previous observations of higher Toxocara seropositivity rates in asthmatic children. Toxocara seropositivity appeared to abrogate the apparent association between atopy and asthma in Cuban children. Although this observation was limited to physician-diagnosed asthma, it challenges the hypothesis that HT stimulates the onset of allergic diseases such as asthma in atopic individuals. Introduction Des preuves suggerent que la toxocarose humaine (TH) pourrait stimuler l'apparition de maladies allergiques telles que l'asthme. Plus precisement, chez les sujets ayant un hypothetique genotype atopique, la TH pourrait augmenter les symptomes d'allergies preexistantes. Nous avons teste cette hypothese a Cuba, un pays oU l'asthme et la TH sont repandus. Materiel et methodes Dans un groupe d'enfants cubains d'age scolaire (n=958), nous avons etudie l'association entre la seropositivite au Toxocara et le statut atopique avec l'asthme. La seropositivite au Toxocara a ete diagnostiquee par ELISA, l'atopie par un test d'allergene par piqure cutanee. Autant l'asthme diagnostique par un medecin que la presence de sifflements respiratoires actuels, tels que determines par le questionnaire de l'Etude Internationale de l'Asthme et des Allergies chez l'enfant (ISAAC), ont ete pris en compte. Les associations ont ete evaluees a l'aide d'analyses de regression logistique multivariees, avec comme variable de resultat, soit << asthme diagnostique par un medecin >> ou << sifflements respiratoires actuels >>. Resultats 40,1% des enfants etaient seropositifs au Toxocara. Les prevalences etaient de 21.7% pour une respiration sifflante actuelle et de 32.7% pour l'asthme diagnostique par un medecin. Les chances de souffrir d'asthme etaient pres de deux fois plus elevees chez les enfants atopiques, mais atteignaient seulement une signification limite (OR=1.90; IC 95%:0.95 3. 80 pour l'asthme diagnostique par un medecin et OR=1.94; IC 95%: 0.98 3,85 pour la respiration sifflante). La seropositivite au Toxocara et l'asthme diagnostique par un medecin etaient associes (OR=1.51; IC 95%: 01.01 02,26). En outre, chez les enfants sans anticorps anti-Toxocara, etre atopique etait significativement associe au fait d'avoir un asthme diagnostique par un medecin (OR=2.53; IC 95%: 1.63 3.90), tandis que cette association n'etait pas presente chez les enfants Toxocara positifs (OR=1.38; IC95%: 0.82 2.37). Conclusion Nos donnees confirment les observations anterieures de taux de seropositivite au Toxocara plus eleves chez les enfants asthmatiques. La seropositivite au Toxocara semblerait abroger l'association apparente entre l'atopie et l'asthme chez les enfants cubains. Bien que cette observation fut limitee a l'asthme diagnostique par un medecin, elle remet en cause l'hypothese selon laquelle la TH stimule l'apparition de maladies allergiques telles que l'asthme chez les sujets atopiques. Introduccion Las evidencian sugieren que la toxocariasis humana (TH) podria estimular el comienzo de enfermedades alergicas tales como el asma. Mas especificamente en sujetos con un hipotetico genotipo atopico', la TH podria incrementar los sintomas alergicos preexistentes. Hemos evaluado esta ultima hipotesis en Cuba, un pais en donde hay prevalencia tanto de asma como de TH. Materiales y metodos En un grupo de ninos cubanos en edad escolar (n=958) hemos investigado la asociacion que existe entre la seropositividad por Toxocara y el estatus atopico, con el asma. La seropositividad por Toxocara se diagnostico mediante ELISA; la atopia mediante una prueba cutanea con alergenos. Se tuvieron en cuenta tanto el asma diagnosticada por un medico como la presencia de sibilancias, tal y como lo determina el cuestionario del Estudio Internacional de Asma y Alergias en la Ninez (ISAAC). Se evaluaron las asociaciones mediante un analisis de regresion logistica multivariable, tanto de asma diagnosticada por el medico' o la presencia de sibilancias en la actualidad como variables de resultados. Results Un 40.1% de los ninos eran Toxocara seropositivos. Las prevalencias eran del 21.7% para presencia de sibilancias y del 32.7% para asma diagnosticada por medicos. La probabilidad de tener asma era al menos dos veces mayor en ninos atopicos, pero solo llego al limite de significancia (OR=1.90, IC 95%:0.953.80 para asma diagnosticada por un medico y OR=1.94, IC 95%: 0.983.85 para presencia de sibilancias). La seropositividad por Toxocara y el asma diagnosticada por un medico estaban asociadas (OR=1.51, IC 95%: 1.012.26). Mas aun, en los ninos sin anticuerpos para Toxocara, el ser atopicos estaba significativamente asociado con tener un asma diagnosticada por un medico (OR=2.53, IC 95%: 1.63-3.90) mientras que esta asociacion no estaba presente en ninos Toxocara positivos (OR=1.38, CI 95%: 0.82-2.37). Conclusion Nuestros datos confirman observaciones previas de una alta tasa de seropositividad por Toxocara en ninos asmaticos. La seropositividad por Toxocara parecia derogar la aparente asociacion entre atopia y asma en ninos Cubanos. Aunque esta observacion estaba limitada al asma diagnosticada por un medico, reta la hipotesis de que la TH estimula el desarrollo de enfermedades alergicas tales como el asma en individuos atopicos.	[Kanobana, K.; Vereecken, K.; Polman, K.] Inst Trop Med, B-2000 Antwerp, Belgium; [Diaz, R. Junco; Gorbea, M. Bonet] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; [Sariego, I.; Rojas, L.] Inst Trop Med Pedro Kouri, Havana, Cuba	Kanobana, K (reprint author), Inst Trop Med, Dept Biomed Sci, Unit Med Helminthol, Nationalestr 155, B-2000 Antwerp, Belgium.	kkanobana@itg.be					Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Buijs J, 1997, EUR RESPIR J, V10, P1467, DOI 10.1183/09031936.97.10071467; BUIJS J, 1995, EUR J PHARM-ENVIRON, V293, P207, DOI 10.1016/S0922-4106(05)80045-8; Cooper PJ, 2008, CLIN EXP ALLERGY, V38, P551, DOI 10.1111/j.1365-2222.2008.02934.x; Cooper PJ, 2009, CURR OPIN ALLERGY CL, V9, P29, DOI 10.1097/ACI.0b013e32831f44a6; Despommier D, 2003, CLIN MICROBIOL REV, V16, P265, DOI 10.1128/CMR.16.2.265-272.2003; Kemp T, 1996, Respirology, V1, P183; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Magnaval JF, 2006, J HELMINTHOL, V80, P417, DOI 10.1017/JHL2006369; Ministerio de Salud Publica, 1999, PROGR NAC ASM BRONQ; Pinelli E, 2008, CLIN EXP ALLERGY, V38, P649, DOI 10.1111/j.1365-2222.2007.02908.x; Pinelli E, 2006, TOXOCARA: THE ENIGMATIC PARASITE, P42; Sariego I, 2012, TROP MED INT HEALTH, V17, P711, DOI 10.1111/j.1365-3156.2012.02996.x; Sharghi N, 2001, CLIN INFECT DIS, V32, pE111, DOI 10.1086/319593; Varona P, 2005, ENCUESTA NACL ASMA E; Vereecken K, 2012, PEDIAT ALLERG IMM-UK, V23, P332, DOI 10.1111/j.1399-3038.2011.01267.x; Walsh MG, 2011, INT J PARASITOL, V41, P243, DOI 10.1016/j.ijpara.2010.09.006; Wordemann M, 2006, TROP MED INT HEALTH, V11, P1813, DOI 10.1111/j.1365-3156.2006.01745.x; Wordemann M, 2006, ALLERGY, V61, P1125, DOI 10.1111/j.1398-9995.2006.01129.x; Wordemann M, 2008, TROP MED INT HEALTH, V13, P180, DOI 10.1111/j.1365-3156.2007.01988.x; 1998, LANCET, V351, P1225	21	10	11	0	23	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2013	18	4					403	406		10.1111/tmi.12073				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	112XF	WOS:000316627200004	23397907				2019-03-26	
J	Wirtz, VJ; Mol, PGM; Verdijk, J; Stichele, RHV; Taxis, K				Wirtz, Veronika J.; Mol, Peter G. M.; Verdijk, Jonneke; Stichele, Robert H. Vander; Taxis, Katja			Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						antibiotics; fixed-dose combinations; Latin America; safety; antimicrobial resistance	RESISTANCE	Objective To assesses the safety and rationale of antibacterial fixed-dose combinations in the private sector in Latin America and determine the extent of their use. Methods Analysis of FDCs was based on retail sales data for eight Latin American countries (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Uruguay and Venezuela) between 1999 and 2009. FDCs were classified according to the pre-defined criteria. Use was expressed as daily defined doses per 1000 inhabitants per day (DDD/TID). Results A total of 175 antibacterial FDCs contained a mean of 1.3 antibacterial substances and 3.2 other active substances. Thirty-seven (21%) FDCs were classified as unsafe, 124 (70%) as lacking sufficient evidence for efficacy and only 14 (9%) of all FDCs were considered rational, for example amoxicillin and clavulanic acid. Consumption of unsafe FDCs decreased by 0.011 DDD/TID (95% CI: 0.012 to 0.009) annually, from 0.173 DDD/TID in 1999 to 0.070 DDD/TID in 2009 (overall decrease, 59.7%). Consumption of FDCs lacking sufficient evidence decreased by 30.3% (0.018 DDD/TID [95% CI: 0.028 to 0.008] annually), while use of rational FDCs increased by 17.1% (from 1.283 DDD/TID to 1.497 DDD/TID annually). Conclusion The majority of antibacterial FDCs in the private sector lack therapeutic benefit. Despite the decrease in the consumption of unsafe antibacterials and those lacking sufficient evidence, their use remains high and their marketing does not fit into strategies of prudent use of antibiotics to contain antibacterial resistance. ObjectifEvaluer la securite et la justification des combinaisons d'antibacteriens a dose fixe (CADF) dans le secteur prive en Amerique latine et determiner l'etendue de leur utilisation. MethodesL'analyse des CADF a ete basee sur les donnees des ventes en detail dans huit pays d'Amerique latine (Argentine, Bresil, Chili, Colombie, Mexique, Perou, Uruguay et Venezuela) entre 1999 et 2009. Les CADF ont ete classees selon des criteres predefinis. L'utilisation a ete exprimee en Doses Journaliere Definies pour 1000 habitants par jour (DDD/TID). ResultatsUn total de 175 CADF contenaient en moyenne 1,3 substances antibacteriennes et 3,2 autres substances actives. Trente-sept (21%) CADF ont ete classees comme dangereuses, 124 (70%) comme manquant de preuves suffisantes d'efficacite et seulement 14 (9%) de toutes les CADF ont ete considerees comme justifiees, ex: amoxicilline et acide clavulanique. La consommation de CADF dangereuses a diminue de 0.011 DDD/TID (IC95%: - 0.012 a 0.009) chaque annee, passant de 0.173 DDD/TID en 1999 a 0.070 DDD/TID en 2009 (diminution globale de 59.7%). La consommation de CADF non dotees de preuves suffisantes a diminue de 30.3% (0.018 DDD/TID [IC95%: 0.028 a 0.008] par an), tandis que l'utilisation rationnelle des CADF a augmente de 17.1% (passant de 1.283 DDD/TID a 1.497 DDD/TID par an). ConclusionLa majorite des CADF dans le secteur prive manque de benefice therapeutique. Malgre une baisse de la consommation d'antibiotiques a risque et de ceux manquant des preuves suffisantes, leur utilisation reste elevee et leur commercialisation ne rentre pas dans les strategies d'utilisation prudente des antibiotiques pour endiguer la resistance aux antibacteriens. ObjetivoEvaluar la seguridad y el fundamento de combinaciones de dosis fijas (CDFs) de antibacterianos en el sector privado en America Latina y determinar la extension de su uso. MetodosEl analisis de las CDFs se baso en datos de ventas al por menor de ocho paises Latinoamericanos (Argentina, Brasil, Chile, Colombia, Mejico, Peru, Uruguay y Venezuela) entre 1999 y 2009. Las CDFs se clasificaron segun criterios predefinidos. El uso se expreso como Dosis Diarias Definidas por cada 1000 habitantes por dia (DDD/TID). ResultadosUn total de 175 CDFs de antibacterianos contenian una media de 1.3 sustancias antibacterianas y otras 3.2 sustancias activas. Treinta y siete (21%) CDFs fueron clasificadas como no seguras, 124 (70%) como faltandoles suficiente evidencia de eficacia, y solo un 14 (9%) de todas las CDFs fueron consideradas como fundamentadas, ej. amoxicilina y acido clavulanico. El consumo de CDFs no seguras disminuyo en 0.011 DDD/TID (95% IC: 0.012 a 0.009) anualmente, de 0.173 DDD/TID en 1999 a 0.070 DDD/TID en 2009 (disminucion total 59.7%). El consumo de CDFs con falta de evidencia disminuyo en un 30.3% (0.018 DDD/TID [95% IC: 0.028 a 0.008] anualmente), mientras que el uso racional de CDFs aumento en un 17.1% (de 1.283 DDD/TID a 1.497 DDD/TID anualmente). ConclusionA la mayoria de CDFs de antibacterianos en el sector privado les hace falta un beneficio terapeutico. A pesar de la caida en el consumo de antibacterianos no seguros asi como de aquellos sin suficiente evidencia, su uso continua siendo alto y su marketing no sigue estrategias de uso prudente de antibioticos que contengan el aumento de la resistencia a antibacterianos.	[Wirtz, Veronika J.] Natl Inst Publ Hlth, Ctr Hlth Syst Res, Cuernavaca 62100, Morelos, Mexico; [Mol, Peter G. M.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Verdijk, Jonneke; Taxis, Katja] Univ Groningen, Groningen, Netherlands; [Stichele, Robert H. Vander] Univ Ghent, Heymans Inst Pharmacol, B-9000 Ghent, Belgium	Wirtz, VJ (reprint author), Natl Inst Publ Hlth, Ctr Hlth Syst Res, Av Univ 655, Cuernavaca 62100, Morelos, Mexico.	veronika.wirtz@insp.mx	Vander Stichele, Robert/K-7203-2015	Vander Stichele, Robert/0000-0001-9118-9651; Wirtz, Veronika J./0000-0002-0863-8768; Taxis, Katja/0000-0001-8539-2004; Mol, Peter/0000-0002-4262-3180			[Anonymous], 1984, DRUG THERAPEUTIC B, V22, P5; [Anonymous], 2001, GLOB STRAT CONT ANT; Ball P, 2003, J ANTIMICROB CHEMOTH, V51, P21, DOI 10.1093/jac/dkg209; Castel JM, 1997, CLIN PHARMACOL THER, V61, P488, DOI 10.1016/S0009-9236(97)90199-5; Center for Disease Control, 2012, INT TASK FORC ANT RE; European Medicines Agency, 2009, GUID FIX COMB MED PR; Gautam C. S., 2006, Indian Journal of Pharmacology, V38, P169; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Grigoryan L, 2010, CURR DRUG SAF, V5, P329, DOI 10.2174/157488610792246046; Gustafsson LL, 1981, LANCET, V317, P31; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Ibanez L, 2005, EUR J CLIN PHARMACOL, V60, P821, DOI 10.1007/s00228-004-0836-y; IMS-Health, 2009, FREQ ASK QUEST; International Society for Pharmacoeconomics and Outcome Research, 1 LAT AM C; Leung E, 2011, B WORLD HEALTH ORGAN, V89, P390, DOI 10.2471/BLT.11.088435; New Zealand Medicines & Medical Devices Safety Authority, 1999, NOV 1999 MED CLASS C; OAKLEY GP, 1973, JAMA-J AM MED ASSOC, V225, P395, DOI 10.1001/jama.225.4.395; Okeke IN, 2005, LANCET INFECT DIS, V5, P8481; Organizacion Panamericana de la Salud, 2004, LEG ANT AM LAT; Pan American Health Organization, 2008, DAT STAT; Pan American Health Organization, 2012, HLTH SYST COUNTR PRO; Parker KL, 2005, GOODMAN GILMANS PHAR; Perrotta DM, 1996, JAMA-J AM MED ASSOC, V276, P1711; Podolsky SH, 2011, NEW ENGL J MED, V365, P488, DOI 10.1056/NEJMp1106161; Sweetman, 2009, MARTINDALE COMPLETE; Thomson PLM, 2010, DICCIONARIO ESPECIAL; Thomson PLM, 2008, DICCIONARIO ESPECIAL; US Department of State, 2012, MEX COUNTR SPEC INF; Wirtz VJ, 2010, REV PANAM SALUD PUBL, V27, P219, DOI 10.1590/S1020-49892010000300009; WOLFF MJ, 1993, CLIN INFECT DIS, V17, pS346, DOI 10.1093/clinids/17.Supplement_2.S346; World Gastroenterology Organization, 2010, HEL PYL DEV COUNTR; World Health Organization, 2011, LIST ESS MED; World Health Organization Collaborating Centre for Drug Statistics Methodology, 2011, GUID ATC CLASS DDD A; YUNIS AA, 1988, ANNU REV PHARMACOL, V28, P83, DOI 10.1146/annurev.pa.28.040188.000503	34	6	6	2	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2013	18	4					416	425		10.1111/tmi.12068				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	112XF	WOS:000316627200006	23379471				2019-03-26	
J	Abouchadi, S; Alaoui, AB; Meski, FZ; Bezad, R; De Brouwere, V				Abouchadi, Saloua; Alaoui, Abdelali Belghiti; Meski, Fatima Zahra; Bezad, Rachid; De Brouwere, Vincent			Preventable maternal mortality in Morocco: the role of hospitals	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						confidential enquiry; maternal deaths; avoidable factors; audit; substandard care	DEATHS; JAMAICA; MOTHERS	Objective In 2009, the Ministry of Health of Morocco launched a national confidential enquiry around maternal deaths based on the newly implemented routine maternal death surveillance system (MDSS). The objective of this paper is to show the importance of substandard care among the factors associated with maternal deaths. Methods The Moroccan National Expert Committee (NEC) organised an audit of maternal deaths identified by the MDSS to determine the medical cause, the preventability of the deaths and the type of substandard care involved. Results Three hundred and three cases of maternal deaths were analysed for the year 2009. Direct causes accounted for 80.8%. 75.9% were considered avoidable by the NEC. The three main factors were insufficient follow-up of care in 45.6% of cases, inadequate treatment in 43.9% and delay in seeking care in 41.3%. The auditors found that 54.3% of all maternal deaths could have been avoided if appropriate action had been taken at the health facilities. Conclusion The audit of maternal deaths in Morocco enabled a better understanding of the circumstances contributing to maternal deaths and pinpointed that more than half of maternal deaths were associated with substandard care in hospitals. Objectif En 2009, le ministere de la Sante du Maroc a lance une enquete nationale confidentielle sur les deces maternels, sur la base du nouveau systeme mis en OEuvre pour la surveillance systematique de la mortalite maternelle (SSMM). L'objectif de cet article est de montrer l'importance des soins de qualite inferieure aux normes, parmi les facteurs associes a la mortalite maternelle. Methodes Le Comite National d'Experts (CNE) Marocain a organise un audit des deces maternels identifies par la SSMM pour determiner la cause medicale, le caractere evitable du deces et le type de soins impliques, inferieurs aux normes. Resultats Of 303 cas de deces maternels ont ete analyses pour l'annee 2009. Les causes directes representaient 80.8%. Of 75.9% ont ete consideres comme evitables par le CNE. Les trois principaux facteurs etaient: un suivi insuffisant des soins dans 45.6% des cas, un traitement inadequat dans 43.9% et le retard dans le recours aux soins dans 41.3%. Les experts ont constate que 54.3% de tous les deces maternels auraient pu etre evites si des mesures appropriees avaient ete prises au niveau des etablissements de sante. Conclusion L'audit des deces maternels au Maroc a permis de mieux comprendre les circonstances qui contribuent a la mortalite maternelle et a revele que plus de la moitie des deces maternels etaient associes a des soins de qualite inferieure aux normes dans les hopitaux. Objetivo En el 2009 el Ministerio de Salud de Marruecos lanzo una encuesta confidencial a nivel nacional basada en el recientemente establecido programa de vigilancia de muertes maternas (PVMM). El objetivo de esta publicacion es mostrar la importancia de cuidados subestandar entre los factores asociados con las muertes maternas. Metodos El Comite Nacional de Expertos de Marruecos (CNEM) organizo una auditoria de las muertes maternas identificadas mediante el PVMM con el fin de determinar las causas medicas, la posibilidad de prevenir las muertes y el tipo de cuidados subestandar involucrados. Resultados Se analizaron 303 casos de muertes maternas para el ano 2009. Las causas directas eran responsables del 80.8% de las muertes. Un 75.9% fueron consideradas como prevenibles por el CNEM. Los tres factores principales eran un seguimiento insuficiente en un 45.6% de los casos, tratamiento inadecuado en un 43. 9%, y un retraso en la busqueda de cuidados en un 41.3%. Los auditores encontraron que un 54.3% de todas las muertes maternas podrian haberse evitado si en los centros sanitarios se hubiesen realizado las acciones apropiadas. Conclusion La auditoria de muertes maternas en Marruecos nos permite entender mejor las circunstancias que contribuyen a las muertes maternas y senalan que mas de la mitad de estas muertes estaban asociadas a unos cuidados hospitalarios subestandar.	[Abouchadi, Saloua; Alaoui, Abdelali Belghiti] Direct Hop & Soins Ambulatoires, Minist Sante, Rabat, Morocco; [Meski, Fatima Zahra] Inst Natl Adm Sanit, Minist Sante, Rabat, Morocco; [Bezad, Rachid] Ibn Sina Hosp, Reprod Hlth Natl Ctr, Rabat, Morocco; [De Brouwere, Vincent] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [De Brouwere, Vincent] Inst Rech Dev, Marseille, France; [De Brouwere, Vincent] Inst Natl Adm Sanit, Rabat, Morocco	Abouchadi, S (reprint author), Direct Hop & Soins Ambulatoires, Minist Sante, 4 Rue Abou Fariss Al Marini Ex Pl Pietri, Rabat, Morocco.	s.abouchadi@yahoo.fr			Ministry of the Interior; WHO; UNPFA; Fundacio clinic	We thank the regional and provincial managers and the provincial team responsible for the maternal mortality surveillance system for their commitment and their contribution to the setup of this system. Our thanks for their collaboration also go to the Ministry of the Interior, the members of the NEC, the WHO, the UNPFA and the Fundacio clinic for their support to the NEC. Particular thanks go to Marilys Corbex (Maternal & Reproductive Health Unit, Institute of Tropical Medicine) for her useful comments and to Rachel Hammonds (International Health Policy Unit, Institute of Tropical Medicine) for her careful editing.	Abdel-Hady ES, 2007, J OBSTET GYNAECOL RE, V33, P283, DOI 10.1111/j.1447-0756.2007.00525.x; Abouchadi S, 2013, TROP MED INT HEALTH, V18, P357, DOI 10.1111/tmi.12053; [Anonymous], 2012, TRENDS MAT MORT 1990; Benbow A, 1998, BRIT MED J, V317, P1431, DOI 10.1136/bmj.317.7170.1431; Benhamou D, 2009, ANN FR ANESTH, V28, P38, DOI 10.1016/j.annfar.2008.11.002; BOUVIERCOLLE MH, 1995, EUR J OBSTET GYN R B, V58, P3, DOI 10.1016/0028-2243(94)01976-E; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Chopra M, 2009, LANCET, V374, P835, DOI 10.1016/S0140-6736(09)61123-5; CMACE, 2011, BJOG S1, V118, P1; DEMUYLDER X, 1990, ARCH GYNECOL OBSTET, V247, P131, DOI 10.1007/BF02390861; Fawcus S, 1996, STUD FAMILY PLANN, V27, P319, DOI 10.2307/2138027; Granja A C, 2000, Afr J Health Sci, V7, P83; Gretton J, 1986, HLTH CARE UK 1986, P79; Kildea S, 2008, AUST NZ J OBSTET GYN, V48, P130, DOI 10.1111/j.1479-828X.2008.00846.x; Kongnyuy EJ, 2009, WOMEN HEALTH ISS, V19, P14, DOI 10.1016/j.whi.2008.09.008; Ministere de la Sante du Royaume du Maroc, 2008, PLAN ACT SANT 2008 2; Ministere de la Sante du Royaume du Maroc, 2012, PLAN ACT 2012 2016 A, P1; Ministere de la Sante du Royaume du Maroc, 2012, ENQ NAT POP SANT FAM; Ozumba BC, 2008, PUBLIC HEALTH, V122, P354, DOI 10.1016/j.puhe.2007.04.018; WALKER GJA, 1990, INT J EPIDEMIOL, V19, P599, DOI 10.1093/ije/19.3.599; WALKER GJA, 1986, LANCET, V1, P486; World Health Organization, 2009, MED EL CRIT CONTR US, P1	22	6	6	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2013	18	4					444	450		10.1111/tmi.12065				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	112XF	WOS:000316627200009	23360349	Bronze			2019-03-26	
J	Van Nieuwenhove, L; Buscher, P; Balharbi, F; Humbert, M; Guisez, Y; Lejon, V				Van Nieuwenhove, Liesbeth; Buescher, Philippe; Balharbi, Fatima; Humbert, Michael; Guisez, Yves; Lejon, Veerle			A LiTat 1.5 variant surface glycoprotein-derived peptide with diagnostic potential for Trypanosoma brucei gambiense	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						diagnosis; sensitivity; specificity; sleeping sickness; Trypanosoma brucei gambiense; variant surface glycoprotein		Objective To evaluate the accuracy of a peptide, corresponding to the variant surface glycoprotein (VSG) LiTat 1.5 amino acid (AA) sequence 268281 and identified through alignment of monoclonal antibody selected mimotopes, for diagnosis of Trypanosoma brucei gambiense sleeping sickness. Methods A synthetic biotinylated peptide (peptide 1.5/268281), native VSG LiTat 1.3 and VSG LiTat 1.5 were tested in an indirect ELISA with 102 sera from patients with HAT and 102 endemic HAT-negative controls. Results The area under the curve (AUC) of peptide 1.5/268281 was 0.954 (95% confidence interval 0.9180.980), indicating diagnostic potential. The areas under the curve of VSG LiTat 1.3 and LiTat 1.5 were 1.000 (0.9821.000) and 0.997 (0.9731.000), respectively, and significantly higher than the AUC of peptide 1.5/268281. On a model of VSG LiTat 1.5, peptide 1.5/268281 was mapped near the top of the VSG. Conclusions A biotinylated peptide corresponding to AA 268281 of VSG LiTat 1.5 may replace the native VSG in serodiagnostic tests, but the diagnostic accuracy is lower than for the full-length native VSG LiTat 1.3 and VSG LiTat 1.5. Objectif Evaluer la precision diagnostique d'un peptide correspondant a une variante de la sequence des acides amines 268 a 281 de la glycoproteine de surface LiTat 1.5 et identifie grace a l'alignement des mimotopes selectionnes des anticorps monoclonaux, pour le diagnostic de la maladie du sommeil due a Trypanosoma brucei gambiense. Methodes Un peptide synthetique biotinyle (peptide 1.5/268-281) et les proteines de surface natives LiTat 1.3 et LiTat 1.5 ont ete testes dans une reaction ELISA indirecte sur 102 echantillons de serum provenant de patients atteints de THA et 102 controles negatifs de zone endemique. Resultats L'aire sous la courbe (AUC) du peptide 1.5/268-281 etait de 0.954 (IC95%: 0.918 a 0.980), ce qui indique un potentiel diagnostique. Les aires sous la courbe de LiTat 1.3 et LiTat 1.5 etaient de 1000 (0.982 a 1000) et 0.997 (0.973 a 1000), respectivement, et nettement superieures a l'AUC du peptide 1.5/268-281. Sur un modele de LiTat 1.5, le peptide 1.5/268-281 a ete cartographie pres du sommet de la glycoproteine de surface. Conclusions Un peptide biotinyle correspondant a la sequence des acides amines 268 a 281 de LiTat 1.5 pourrait remplacer la glycoproteine de surface native dans les tests de serodiagnostic, mais la precision du diagnostic est plus faible qu'avec l'entierete des glycoproteines de surfaces natives LiTat 1.3 et LiTat 1.5. Objetivo Evaluar la precision diagnostica de un peptido correspondiente a la secuencia de aminoacidos 268281 de la glicoproteina variante de superficie (VSG) LiTat 1.5, identificados mediante un alineamiento de una seleccion de mimotopes de anticuerpos monoclonales, para el diagnostico de la enfermedad del sueno por Trypanosoma brucei gambiense (HAT). Metodos Utilizando un ELISA indirecto, se probaron el peptido sintetico biotinilado (peptido 1.5/268-281), la VSG nativa LiTat 1.3 y la VSG LiTat 1.5, con 102 sueros de pacientes con HAT y 102 controles negativos endemicos. Resultados El area bajo la curva (ABC) del peptido 1.5/268-281 era de 0.954 (IC 95% 0.9180.980), indicando su potencial diagnostico. Las ABC de VSG LiTat 1.3 y LiTat 1.5 eran 1.000 (0.982-1.000) y 0.997 (0.9731.000) respectivamente, y significativamente mayor que el ABC del peptido 1.5/268-281. En un modelo del VSG LiTat 1.5, el peptido 1.5/268-281 se mapeo cerca de la parte superior del VSG. Conclusiones Un peptido biotinilado, que corresponde al AA 268281 del VSG LiTat 1. 5, podria reemplazar las pruebas serodiagnosticas basadas en la VSG nativa, pero la precision diagnostica es menor que para la VSG LiTat 1.3 nativa de tamano completo y la VSG LiTat 1.5.	[Van Nieuwenhove, Liesbeth; Buescher, Philippe; Balharbi, Fatima; Lejon, Veerle] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Humbert, Michael] Dana Farber Canc Inst, Boston, MA 02115 USA; [Humbert, Michael] Harvard Univ, Sch Med, Boston, MA USA; [Guisez, Yves] Univ Antwerp, Dept Biol, B-2020 Antwerp, Belgium	Lejon, V (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	vlejon@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472; Lejon, Veerle/0000-0002-6795-0962	Belgian Directorate General for Development Cooperation; Research Foundation of Flanders; FWO	We are grateful to Nicolas Bebronne and Annelies Ceusters for technical assistance. The project was funded by the Belgian Directorate General for Development Cooperation and the Research Foundation of Flanders. Liesbeth Van Nieuwenhove was supported by a PhD scholarship of the FWO. Development of the UCSF Chimera package from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, was supported by the NIH. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.		0	6	6	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2013	18	4					461	465		10.1111/tmi.12058				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	112XF	WOS:000316627200011	23289521	Green Accepted, Bronze			2019-03-26	
J	Phe, T; Vlieghe, E; Reid, T; Harries, AD; Lim, K; Thai, S; De Smet, B; Veng, C; Kham, C; Ieng, S; van Griensven, J; Jacobs, J				Thong Phe; Vlieghe, Erika; Reid, Tony; Harries, Anthony D.; Lim, Kruy; Thai, Sopheak; De Smet, Birgit; Veng, Chhunheng; Kham, Chun; Ieng, Sovann; van Griensven, Johan; Jacobs, Jan			Does HIV status affect the aetiology, bacterial resistance patterns and recommended empiric antibiotic treatment in adult patients with bloodstream infection in Cambodia?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Bloodstream infection; human immunodeficiency virus(HIV); adult; Cambodia	ANTIMICROBIAL DRUG-RESISTANCE; HUMAN-IMMUNODEFICIENCY-VIRUS; ESCHERICHIA-COLI; RISK-FACTORS; BACTEREMIA; THERAPY; EPIDEMIOLOGY; DETERMINANT; PNEUMONIA; COUNTRIES	Objective The microbiologic causes of bloodstream infections (BSI) may differ between HIV-positive and HIV-negative patients and direct initial empiric antibiotic treatment (i.e. treatment before culture results are available). We retrospectively assessed community-acquired BSI episodes in adults in Cambodia according to HIV status for spectrum of bacterial pathogens, antibiotic resistance patterns and appropriateness of empiric antibiotics. Methods Blood cultures were systematically performed in patients suspected of BSI in a referral hospital in Phnom Penh, Cambodia. Data were collected between 1 January 2009 and 31 December 2011. Results A total of 452 culture-confirmed episodes of BSI were recorded in 435 patients, of whom 17.9% and 82.1% were HIV-positive and HIV-negative, respectively. Escherichia coli accounted for one-third (n=155, 32.9%) of 471 organisms, with similar rates in both patient groups. Staphylococcus aureus and Salmonella cholereasuis were more frequent in HIV-positive vs. HIV-negative patients (17/88 vs. 38/383 (P=0.02) and 10/88 vs. 5/383 (P<0.001)). Burkholderia pseudomallei was more common in HIV-negative than in HIV-positive patients (39/383 vs. 2/88, P<0.001). High resistance rates among commonly used antibiotics were observed, including 46.6% ceftriaxone resistance among E.coli isolates. Empiric antibiotic treatments were similarly appropriate in both patient groups but did not cover antibiotic-resistant E.coli (both patient groups), S.aureus (both groups) and B.pseudomallei (HIV-negative patients). Conclusion The present data do not warrant different empiric antibiotic regimens for HIV-positive vs. HIV-negative patients in Cambodia. The overall resistance rates compromise the appropriateness of the current treatment guidelines. Objectif Les causes microbiologiques de septicemie peuvent differer entre patients VIH seropositifs et seronegatifs et guider dans le traitement initial antibiotique empirique (i.e. traitement avant que les resultats de culture soient disponibles). Nous avons analyse retrospectivement les episodes de septicemies acquises dans la communaute chez les adultes au Cambodge selon leur statut VIH pour un spectre de bacteries pathogenes, les profils de resistance aux antibiotiques et la pertinence des antibiotiques empiriques. MethodesLes hemocultures ont ete systematiquement realisees chez des patients suspectes de septicemie dans un hopital de reference a Phnom Penh, au Cambodge. Les donnees ont ete recueillies entre le 1er janvier 2009 et le 31 decembre 2011. Resultats Au total 452 episodes de septicemie confirmes par culture ont ete enregistres chez 435 patients, dont 17.9% et 82.1% etaient seropositifs et seronegatifs respectivement. Escherichia coli representait un tiers (n=155, 32.9%) des 471 organismes, avec des taux similaires dans les deux groupes de patients. Staphylococcus aureus et Salmonella Choleraesuis etaient plus frequents chez les patients VIH-positifs que chez les VIH-negatifs [17/88 contre 38/383 (P=0.02) et 10/88 contre 5/383 (P<0.001)]. Burkholderia pseudomallei etait plus frequent chez les patients VIH seronegatifs que chez les VIH positifs (39/383 vs 2/88, P<0.001). Des taux de resistance eleves parmi les antibiotiques couramment utilises ont ete observes, y compris 46.6% de resistance a la ceftriaxone parmi les isolats d'E.coli. Les traitements d'antibiotiques empiriques etaient tout aussi appropries dans les deux groupes de patients, mais ne couvraient pas les resistances aux antibiotiques dans les cas d'E.coli (dans les deux groupes de patients), de S. aureus (dans les deux groupes de patients) et de B.pseudomallei (chez patients VIH-negatifs). Conclusion Les donnees presentes ne justifient pas differents schemas empiriques d'antibiotiques pour les patients VIH-positifs par rapport aux patients VIH-negatifs au Cambodge. Les taux de resistance globaux compromettent le bien-fonde des recommandations de traitement actuelles. Objetivo Averiguar si las causas microbiologicas de las infecciones sanguineas (IS) y el tratamiento antibiotico empirico inicial recibido (es decir, el tratamiento antes de que los resultados del cultivo esten disponibles) son diferentes entre pacientes VIH-positivos y VIH-negativos. Hemos evaluad, de forma retrospectiva, los episodios de IS adquiridos en la comunidad de adultos camboyanos, segun su estatus de VIH, para un espectro de patogenos bacterianos, segun los patrones de resistencia a los antibioticos y a lo apropiado de los antibioticos empiricos. MetodosLos cultivos de sangre se realizaron de forma sistematica en pacientes con sospecha de IS en un hospital de referencia en Phnom Penh, Camboya. Se recolectaron datos entre el 1 de Enero del 2009 y el 31 de Diciembre del 2011. ResultadosSe registraron un total de 452 episodios de IS, confirmados mediante cultivo en 435 pacientes, de los cuales 17.9% y 82.1% eran VIH-positivos y VIH- negativos respectivamente. Escherichia coli era responsable de una tercera parte (n=155, 32.9%) de los 471 microorganismos aislados, con tasas similares en ambos grupos de pacientes. Staphylococcus aureus y Salmonella Choleraesuis eran mas frecuentes entre pacientes VIH-positivos vs VIH-negativos (17/88 vs 38/383 (P=0.02) y 10/88 vs 5/383 (P<0.001)). Burkholderia pseudomallei era mas comun entre pacientes VIH -negativos que entre VIH-positivos (39/383 vs 2/88, P<0.001). Se observaron altos niveles de resistencia para los antibioticos de uso comun, incluyendo un 46.6% de resistencia a la ceftriaxona entre aislados de E.coli. Los tratamientos antibioticos empiricos eran similares para ambos grupos de pacientes en cuanto a lo apropiado, pero no cubrian los niveles de resistencia para E.coli (ambos grupos de pacientes), S.aureus (ambos grupos) y B.pseudomallei (pacientes VIH- negativos). ConclusionLos datos actuales no garantizan regimenes antibioticos empiricos diferentes para los pacientes VIH-positivos vs VIH-negativos en Camboya. Las tasas de resistencia generales comprometen la idoneidad de las guias de tratamiento actuales.	[Thong Phe; Lim, Kruy; Thai, Sopheak; Veng, Chhunheng; Kham, Chun; Ieng, Sovann; van Griensven, Johan] Sihanouk Hosp Ctr HOPE, Dept Infect Dis, Phnom Penh, Cambodia; [Vlieghe, Erika; De Smet, Birgit; van Griensven, Johan; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Reid, Tony] Brussels Operat Ctr, Dept Med, Brussels, Belgium; [Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France; [Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England	Phe, T (reprint author), Sihanouk Hosp Ctr HOPE SHCH, Dept Infect Dis, POB 2318,St 134,Khan 7 Makara, Phnom Penh, Cambodia.	thongphe@sihosp.org	De Smet, Birgit/F-4638-2014	De Smet, Birgit/0000-0002-1790-1900	Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, France; Operational Research Unit, Medecins sans Frontieres, Brussels-Luxembourg; Center for International Health, University of Bergen, Norway; Department for International Development, UK;  [2.08]	This research was supported through an operational research course, which was jointly developed and run by the Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, France, and the Operational Research Unit, Medecins sans Frontieres, Brussels-Luxembourg. Additional support for running the course was provided by the Center for International Health, University of Bergen, Norway. We also thank all patients, the hospital management team and microbiology staff at the SHCH and ITM for their support for this study. Funding for the course was from an anonymous donor and the Department for International Development, UK. The Bloodstream Infection Surveillance Project in SHCH was supported by Project 2.08 of the third framework agreement between the Belgian Directorate General of Development Cooperation and the Institute of Tropical Medicine, Antwerp, Belgium.	Apisarnthanarak A, 2007, AM J INFECT CONTROL, V35, P606, DOI 10.1016/j.ajic.2007.05.008; Archibald LK, 2000, J INFECT DIS, V181, P1414, DOI 10.1086/315367; Becker JU, 2009, LANCET INFECT DIS, V9, P577, DOI 10.1016/S1473-3099(09)70135-5; Bowman N, 2012, CLIN INFECT DIS, V55, P749, DOI 10.1093/cid/cis532; Chau TT, 2007, ANTIMICROB AGENTS CH, V51, P4315, DOI 10.1128/AAC.00294-07; CLSI, 2012, M100S22 CLSI; Deen J, 2012, LANCET INFECT DIS, V12, P480, DOI 10.1016/S1473-3099(12)70028-2; FICHTENBAUM CJ, 1995, J ACQ IMMUN DEF SYND, V8, P51; Garnacho-Montero J, 2006, CRIT CARE, V10, DOI 10.1186/cc4995; Gill CJ, 2004, B WORLD HEALTH ORGAN, V82, P290; Hallin M, 2012, 15 ICID JUN 13 16 20; Houck PM, 2004, ARCH INTERN MED, V164, P637, DOI 10.1001/archinte.164.6.637; Ibrahim EH, 2000, CHEST, V118, P146, DOI 10.1378/chest.118.1.146; Kaushik R, 2012, APPL ENVIRON MICROB, V78, P2813, DOI 10.1128/AEM.07695-11; Kumar A, 2009, CRIT CARE CLIN, V25, P733, DOI [10.1016/j.ccc.2009.08.004, 10.1097/01.CCM.0000217961.75225.E9]; Mayanja BN, 2010, TROP MED INT HEALTH, V15, P697, DOI 10.1111/j.1365-3156.2010.02528.x; Mootsikapun P, 2007, INT J INFECT DIS, V11, P226, DOI 10.1016/j.ijid.2006.02.010; NCHADS, 2011, CONS WORKSH HIV EST; Ortega M, 2008, EUR J CLIN MICROBIOL, V27, P969, DOI 10.1007/s10096-008-0531-5; Perello R, 2010, AM J EMERG MED, V28, P454, DOI 10.1016/j.ajem.2009.01.024; Phetsouvanh R, 2006, AM J TROP MED HYG, V75, P978; Ruppe E, 2009, EMERG INFECT DIS, V15, P741, DOI 10.3201/eid1505.071299; Srifuengfung Somporn, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P347; Ssali FN, 1998, J ACQ IMMUN DEF SYND, V19, P484, DOI 10.1097/00042560-199812150-00007; TUMBARELLO M, 1995, J INFECTION, V31, P123, DOI 10.1016/S0163-4453(95)92110-9; Vlieghe E, 2011, 51 ICAAC SEPT 18 21; Vlieghe E, 2011, EMERG INFECT DIS, V17, P1289, DOI 10.3201/eid1707.101069; World Health Organization, 2010, ANT THER HIV INF AD	28	8	8	1	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2013	18	4					485	494		10.1111/tmi.12060				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	112XF	WOS:000316627200014	23294446	Green Published			2019-03-26	
J	Keugoung, B; Ymele, FF; Mabou, JD; Nangue, C; Kougoum, PN; Takoudjou, L; Hercot, D; Meli, J				Keugoung, B.; Ymele, Fouelifack F.; Mabou, Dongtsa J.; Nangue, C.; Kougoum, Ngouadjio P.; Takoudjou, L.; Hercot, D.; Meli, J.			Funding of a free healthcare campaign in a rural district of Cameroon: Optimizing the role of civil society in sub-Saharan Africa	MEDECINE ET SANTE TROPICALES			French	Letter						Sub-Saharan Africa; Cameroon; healthcare financing; free medical care; Bamako Initiative; civil society		Financial barriers represent a major obstacle to access to health care in sub-Saharan Africa and thus to the implementation of the Bamako Initiative. We describe an experience in which a civil society organization financed a free healthcare campaign in a rural health district in Cameroon. In all, 2,073 patients received free consultations, laboratory tests, and drugs. Adults older than 40 years accounted for 55.7% of all patients. The most frequent diseases were: osteoarticular conditions (24.1%), malaria (20.8%), and intestinal parasitosis (12.5%). In health systems financed mainly by cost recovery, some population needs remain uncovered by health services. There is a need to involve and reinforce the role of civil society in health system financing. It can help to pool more funds and improve the management of health resources to increase financial access to health care for poor people.	[Keugoung, B.] Minist Sante Publ, BP 31694, Yaounde 31694, Cameroon; [Keugoung, B.; Ymele, Fouelifack F.; Nangue, C.] GARES Falaise, Dschang, Cameroon; [Ymele, Fouelifack F.] Hop Cent Yaounde, Yaounde, Cameroon; [Mabou, Dongtsa J.] Hop Cent Yaounde, Serv Lab, Yaounde, Cameroon; [Nangue, C.] Hop Cent Yaounde, Serv Anatomopathol, Yaounde, Cameroon; [Kougoum, Ngouadjio P.] Delegat Reg Sante Publ Littoral, Douala, Cameroon; [Takoudjou, L.] Dist Sante Penka Michel, Penka Michel, Cameroon; [Hercot, D.] Inst Med Trop, Dept Sante Publ, Antwerp, Belgium; [Meli, J.] Univ Yaounde I, Fac Med & Sci Biomed, Yaounde, Cameroon	Keugoung, B (reprint author), Minist Sante Publ, BP 31694, Yaounde 31694, Cameroon.						Abdu Z, 2004, INT J HEALTH PLAN M, V19, pS95, DOI 10.1002/hpm.777; Akazili J, 2012, HEALTH POLICY PLANN, V27, pi13, DOI 10.1093/heapol/czs004; Falisse JB, 2012, TROP MED INT HEALTH, V17, P674, DOI 10.1111/j.1365-3156.2012.02973.x; Gilson L., 1996, SUSTAINABLE HLTH CAR, P35; Israr SM, 2000, TROP MED INT HEALTH, V5, P288, DOI 10.1046/j.1365-3156.2000.00547.x; Lu CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039282; Medard JF, 2006, B APAD, V21; Ngugi R., 1999, 95 AERC; Ridde V, 2011, HEALTH POLICY PLANN, V26, P1, DOI 10.1093/heapol/czq021; Samuelsen H., 2004, ANTHROPOL MED, V11, P41; WHO, 2007, EV BOD BUS STRENGTH; WHO, 2011, GLOB TUB CONTR WHO R; Wiseman V, 2005, TROP DOCT, V35, P193, DOI 10.1258/004947505774938639; World Health Organization, 2012, WORLD HLTH STAT 2012; World Health Organization, 2011, GLOB HIV AIDS RESP E; Yates R, 2009, LANCET, V373, P2078, DOI 10.1016/S0140-6736(09)60258-0	16	0	0	0	0	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	2261-3684	2261-2211		MED SANTE TROP	Med. Sante Trop.	APR-JUN	2013	23	2					222	224						3	Tropical Medicine	Tropical Medicine	VD5VM	WOS:000437142600027	23774675				2019-03-26	
J	Ouattara, JPN; Pigeon, O; Spanoghe, P				Ouattara, Jean Pierre Nableni; Pigeon, Olivier; Spanoghe, Pieter			Validation of a multi-residue method to determine deltamethrin and alpha-cypermethrin in mosquito nets by gas chromatography with electron capture detection (GC-mu ECD)	PARASITES & VECTORS			English	Article						Analytical method validation; Mosquito net; Deltamethrin; Alpha-cypermethrin; GC-mu ECD	LASTING INSECTICIDAL NETS; WASH-RESISTANCE; TREATED NETS; BIOEFFICACY	Background: Nowadays long-lasting insecticidal mosquito nets (LNs) are frequently used around the world to protect people against malaria vectors. As they contain insecticide, laboratory control is needed to check whether the content of the active ingredient follows the conditions of the manufacturer and also if the active ingredient is still present after some time of use. For this purpose, an analytical method had to be developed. The fact that LNs include a range of polymers for the yarn and use coated or incorporated technologies for the active ingredient, it is a challenge to find only one analytical method determining the active ingredient in LNs, which takes into account both impregnation technologies. Some methods are provided by international organizations but are limited by the determination of only one pesticide per method. The aim of this study was to optimize a short time extraction method for deltamethrin and alpha-cypermethrin from coated and incorporated mosquito nets and also to detect both insecticides in one analytical run, using gas chromatography with electron capture detection (GC-mu ECD). Methods: Based on the literature, the most suitable solvent and the adequate extraction process for the insecticides used for net making were identified and adapted for the new multi-residue method. Results: The validation data of the multi-residue method to determine deltamethrin and alpha-cypermethrin in mosquito nets by GC-mu ECD are given. Depending on the concentration of the active ingredient spiked on the nets, the mean recovery for alpha-cypermethrin ranged between 86% and 107% with a relative standard deviation below 3.5%. For deltamethrin it ranged between 90% and 108% with a relative standard deviation also below 3.5%. The limit of detection is 0.009 g.a.i/kg of net (0.3 mg a.i./m(2) of net) both for alpha-cypermethrin and deltamethrin. Conclusions: Data obtained are excellent. A 30 minutes reflux extraction method with xylene was developed to determine alpha-cypermethrin and deltamethrin in long-lasting insecticidal mosquito nets (LNs) by gas chromatography with electron capture detection (GC-mu ECD). The method can be easily extended to others pyrethroid used for mosquito net treatment. This paper also presents an overview of the studies dealing with pesticide determination in mosquito nets.	[Ouattara, Jean Pierre Nableni; Spanoghe, Pieter] Univ Ghent, Dept Crop Protect, Lab Crop Protect Chem, B-9000 Ghent, Belgium; [Pigeon, Olivier] CRA W, Agr & Nat Environm Dept, Plant Protect & Biocides Physicochem & Residues U, B-5030 Gembloux, Belgium	Ouattara, JPN (reprint author), Univ Ghent, Dept Crop Protect, Lab Crop Protect Chem, Coupure Links 653, B-9000 Ghent, Belgium.	JeanPierreNableni.Ouattara@Ugent.be	Spanoghe, Pieter/B-9440-2015	Spanoghe, Pieter/0000-0002-8158-4401	Islamic Development Bank Merit Scholarship Program, Jeddah- Saudi Arabia	The work was performed under research scholarship funded by the Islamic Development Bank Merit Scholarship Program, Jeddah- Saudi Arabia.	APVMA, 2004, GUID VAL AN METH ACT; Banek K, 2010, MALARIA J, V9, P1; CEAEQ - Centre d'expertise en analyse environnementale du Quebec, 2009, PROT VAL METH AN CHI; CIPAC 3807, GUID METH VAL PERF S; CIPAC - Collaborative International Pesticides Analytical Council, 2007, PERM LONG LAST INS N; CIPAC - Collaborative International Pesticides Analytical Council, 2007, DELT LONG LAST INS N; CIPAC - Collaborative International Pesticides Analytical Council, 2010, LAMBD LONG LAST INS; CIPAC - Collaborative International Pesticides Analytical Council, 2007, ALPH INS NETS 454 LN; CIPAC - Collaborative International Pesticides Analytical Council, 2009, PIP BUT LONG LAST IN; CIPAC - Collaborative International Pesticides Analytical Council, 2009, DELT LONG LAST INS N; Corbel V, 2010, MALARIA J, V9, P1; Faulde M, 2012, PARASITOL RES, V110, P2341, DOI 10.1007/s00436-011-2769-6; Faulde MK, 2010, PARASITOL RES, V106, P957, DOI 10.1007/s00436-010-1749-6; Gimnig JE, 2005, TROP MED INT HEALTH, V10, P1022, DOI 10.1111/j.1365-3156.2005.01481.x; Graham K, 2005, MED VET ENTOMOL, V19, P72, DOI 10.1111/j.0269-283X.2005.00543.x; Green JM, 1996, ANAL CHEM, V68, pA305, DOI 10.1021/ac961912f; Hassan V, 2010, ASIAN PAC J TROP MED, V3, P642, DOI 10.1016/S1995-7645(10)60155-1; HEMINGWAY RJ, 1984, PURE APPL CHEM, V56, P1131, DOI 10.1351/pac198456081131; International Organization for Standardization, 2005, 170252005 ISOIEC; Jones C. M., 2012, MALARIA J, V11, P1; Kayedi MH, 2009, ANN TROP MED PARASIT, V103, P85, DOI 10.1179/136485909X385018; Kilian A, 2011, MALARIA J, V10, P1; Kilian A, 2008, MALARIA J, V7, P1; Lindblade KA, 2005, TROP MED INT HEALTH, V10, P1141, DOI 10.1111/j.1365-3156.2005.01501.x; Miller JN, 2000, MANUAL BASIC STAT; Muller MD, CIPAC GUIDELINE LN M; Muller O, 2002, T ROY SOC TROP MED H, V96, P483, DOI 10.1016/S0035-9203(02)90411-6; Oxborough RM, 2009, ACTA TROP, V112, P49, DOI 10.1016/j.actatropica.2009.06.005; Pigeon O, 2009, RESSM015 CRAW PLANT; Pigeon O, 2010, RESSM014 CRAW PLANT; Pigeon O, 2009, 53 COLL INT PEST AN; Pigeon O, 2010, RESSM016 CRAW PLANT; Rafinejad J., 2008, Journal of Vector Borne Diseases, V45, P143; Skovmand O, 2008, MALARIA J, V7, P1; Tungu P, 2010, MALARIA J, V9, P1; WHO, 2007, INS TREAT MOSQ NETS; Yates A, 2005, MALARIA J, V4, P1	37	6	6	0	54	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	MAR 20	2013	6								77	10.1186/1756-3305-6-77				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	112VR	WOS:000316622800001	23514225	DOAJ Gold, Green Published			2019-03-26	
J	Adam, Y; Cecchi, G; Kgori, PM; Marcotty, T; Mahama, CI; Abavana, M; Anderson, B; Paone, M; Mattioli, R; Bouyer, J				Adam, Yahaya; Cecchi, Giuliano; Kgori, Patrick M.; Marcotty, Tanguy; Mahama, Charles I.; Abavana, Martin; Anderson, Benita; Paone, Massimo; Mattioli, Raffaele; Bouyer, Jeremy			The Sequential Aerosol Technique: A Major Component in an Integrated Strategy of Intervention against Riverine Tsetse in Ghana	PLOS NEGLECTED TROPICAL DISEASES			English	Article							GLOSSINA-PALPALIS-GAMBIENSIS; AFRICAN ANIMAL TRYPANOSOMOSIS; BURKINA-FASO CONSEQUENCES; WEST-AFRICA; BOVINE TRYPANOSOMOSIS; DIPTERA GLOSSINIDAE; SLEEPING SICKNESS; ELIMINATE TSETSE; PEST-MANAGEMENT; INSECTICIDES	Background: An integrated strategy of intervention against tsetse flies was implemented in the Upper West Region of Ghana (9.62 degrees-11.00 degrees N, 1.40 degrees-2.76 degrees W), covering an area of approximate to 18,000 km(2) within the framework of the Pan-African Tsetse and Trypanosomosis Eradication Campaign. Two species were targeted: Glossina tachinoides and Glossina palpalis gambiensis. Methodology/Principal Findings: The objectives were to test the potentiality of the sequential aerosol technique (SAT) to eliminate riverine tsetse species in a challenging subsection (dense tree canopy and high tsetse densities) of the total sprayed area (6,745 km(2)) and the subsequent efficacy of an integrated strategy including ground spraying (approximate to 100 km(2)), insecticide treated targets (20,000) and insecticide treated cattle (45,000) in sustaining the results of tsetse suppression in the whole intervention area. The aerial application of low-dosage deltamethrin aerosols (0.33-0.35 g a.i/ha) was conducted along the three main rivers using five custom designed fixed-wings Turbo thrush aircraft. The impact of SAT on tsetse densities was monitored using 30 biconical traps deployed from two weeks before until two weeks after the operations. Results of the SAT monitoring indicated an overall reduction rate of 98% (from a pre-intervention mean apparent density per trap per day (ADT) of 16.7 to 0.3 at the end of the fourth and last cycle). One year after the SAT operations, a second survey using 200 biconical traps set in 20 sites during 3 weeks was conducted throughout the intervention area to measure the impact of the integrated control strategy. Both target species were still detected, albeit at very low densities (ADT of 0.27 inside sprayed blocks and 0.10 outside sprayed blocks). Conclusions/Significance: The SAT operations failed to achieve elimination in the monitored section, but the subsequent integrated strategy maintained high levels of suppression throughout the intervention area, which will contribute to improving animal health, increasing animal production and fostering food security.	[Adam, Yahaya; Mahama, Charles I.; Abavana, Martin] Minist Food & Agr, Vet Serv Dept, Pong Tamale, Ghana; [Cecchi, Giuliano; Paone, Massimo; Mattioli, Raffaele] Food & Agr Org United Nations, Anim Prod & Hlth Div, Rome, Italy; [Kgori, Patrick M.] Minist Agr, Dept Vet Serv, Maun, Botswana; [Marcotty, Tanguy] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Marcotty, Tanguy] Univ Pretoria, Dept Vet Trop Dis, Fac Vet Sci, ZA-0002 Pretoria, South Africa; [Anderson, Benita] Minist Food & Agr, Vet Serv Dept, Accra, Ghana; [Bouyer, Jeremy] Ctr Cooperat Int Rech Agron Dev, Unite Mixte Rech Controles Malad Anim & Emergente, Montpellier, France; [Bouyer, Jeremy] Inst Senegalais Rech Agr, Lab Natl Elevage & Rech Vet, Dakar, Senegal	Adam, Y (reprint author), Minist Food & Agr, Vet Serv Dept, Pong Tamale, Ghana.	bouyer@cirad.fr			Pan-African Tsetse and Trypanosomosis Eradication Campaign/Ghana; International Fund for Agricultural Development (IFAD) [GCP/RAF/442/IFA]	The work was funded by the Pan-African Tsetse and Trypanosomosis Eradication Campaign/Ghana and the International Fund for Agricultural Development (IFAD) (project GCP/RAF/442/IFA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam Y, 2012, RES VET SCI, V92, P462, DOI 10.1016/j.rvsc.2011.04.004; Allsopp R., 2002, Pesticide Outlook, V13, P73, DOI 10.1039/b202993f; BALDRY DAT, 1981, TROP PEST MANAGE, V27, P83, DOI 10.1080/09670878109414174; BALDRY DAT, 1978, PANS, V24, P423, DOI 10.1080/09670877809414136; Barclay HJ, 2005, B ENTOMOL RES, V95, P1, DOI 10.1079/BER2004331; Bauer B, 1999, TROP ANIM HEALTH PRO, V31, P89, DOI 10.1023/A:1005115707181; Bouyer J, 2007, PREV VET MED, V78, P223, DOI 10.1016/j.prevetmed.2006.10.008; Bouyer J, 2005, MED VET ENTOMOL, V19, P372, DOI 10.1111/j.1365-2915.2005.00584.x; Bouyer J, 2009, MOL ECOL, V18, P2787, DOI 10.1111/j.1365-294X.2009.04233.x; Bouyer J, 2009, VET PARASITOL, V161, P187, DOI 10.1016/j.vetpar.2009.01.018; Bouyer J., 2010, INFECT PARASITIC DIS, P1936; Bouyer J, 2007, BIOL LETT-UK, V3, P113, DOI 10.1098/rsbl.2006.0578; Bouyer J, 2006, VET RES, V37, P633, DOI 10.1051/vetres:2006025; Bouyer J, 2010, J MED ENTOMOL, V47, P543; Bouyer J, 2010, INFECT GENET EVOL, V10, P321, DOI 10.1016/j.meegid.2009.12.009; Cecchi G, 2008, MED VET ENTOMOL, V22, P364, DOI 10.1111/j.1365-2915.2008.00747.x; Cecchi G, 2009, PARASITE, V16, P99, DOI 10.1051/parasite/2009162099; CHALLIER A, 1973, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V11, P251; CUISANCE D, 1984, REV ELEV MED VET PAY, V37, P449; de La Rocque S., 2005, Parassitologia (Rome), V47, P97; Grant IF, 2010, ASSESSMENT IMPACT SE; Guerrini L, 2008, J MED ENTOMOL, V45, P1180, DOI 10.1603/0022-2585(2008)45[1180:FAFPOS]2.0.CO;2; Hargrove J. W., 2003, TSETSE ERADICATION S; Hargrove JW, 2003, B ENTOMOL RES, V93, P203, DOI 10.1079/BER2003234; Kabayo JP, 2002, TRENDS PARASITOL, V18, P473, DOI 10.1016/S1471-4922(02)02371-1; Kagbadouno MS, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-18; Kagbadouno MS, 2011, P 31 ISCTRC C AFR UN; Kgori PM, 2006, ACTA TROP, V99, P184, DOI 10.1016/j.actatropica.2006.07.007; Kgori P.M, 2009, GEOSPATIAL DATASETS, V9, P61; Kone N, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001217; LAVEISSIERE C, 2000, GLOSSINES VECTRICES; LEE CW, 1978, PANS, V24, P404, DOI 10.1080/09670877809414135; Mahama C.I., 2003, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V56, P27; MORRIS KRS, 1949, B ENTOMOL RES, V39, P491, DOI 10.1017/S0007485300022598; MORRIS KRS, 1946, B ENTOMOL RES, V37, P201, DOI 10.1017/S0007485300022161; POLITZAR H, 1984, INSECT SCI APPL, V5, P439, DOI 10.1017/S1742758400008791; Ramatu MA, 2008, SOCIOECONOMIC BASELI; Shaw APM, 2013, PLOS NEGLECT TROP D; Simarro PP, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-57; Simarro PP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001859; Simpson J. J., 1914, Bulletin of Entomological Research London, V5; Stewart J, 1937, REPORT ERADICATION T; Vreysen M, 2013, PLOS NEGL T IN PRESS	43	14	14	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAR	2013	7	3							e2135	10.1371/journal.pntd.0002135				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	117HI	WOS:000316943800048	23516662	DOAJ Gold, Green Published			2019-03-26	
J	Lunguya, O; Lejon, V; Phoba, MF; Bertrand, S; Vanhoof, R; Glupczynski, Y; Verhaegen, J; Muyembe-Tamfum, JJ; Jacobs, J				Lunguya, Octavie; Lejon, Veerle; Phoba, Marie-France; Bertrand, Sophie; Vanhoof, Raymond; Glupczynski, Youri; Verhaegen, Jan; Muyembe-Tamfum, Jean-Jacques; Jacobs, Jan			Antimicrobial Resistance in Invasive Non-typhoid Salmonella from the Democratic Republic of the Congo: Emergence of Decreased Fluoroquinolone Susceptibility and Extended-spectrum Beta Lactamases	PLOS NEGLECTED TROPICAL DISEASES			English	Article							NON-TYPHOIDAL SALMONELLA; ENTERICA SEROVAR ENTERITIDIS; CHILDREN; AFRICA; INFECTIONS; BACTEREMIA; DIAGNOSIS; PATTERNS; DISEASE; HUMANS	Background: Co-resistance against the first-line antibiotics ampicillin, chloramphenicol and trimethoprim/sulphamethoxazole or multidrug resistance (MDR) is common in non typhoid Salmonella (NTS). Use of alternative antibiotics, such as fluoroquinolones or third generation cephalosporins is threatened by increasing resistance, but remains poorly documented in Central-Africa. Methodology/Principal findings: As part of a microbiological surveillance study in DR Congo, blood cultures were collected between 2007 and 2011. Isolated NTS were assessed for serotype and antimicrobial resistance including decreased ciprofloxacin susceptibility and extended-spectrum beta-lactamase (ESBL) production. In total, 233 NTS isolates (representing 23.6% of clinically significant organisms) were collected, mainly consisting of Salmonella Typhimurium (79%) and Salmonella Enteritidis (18%). The majority of NTS were isolated in the rainy season, and recovered from children <= 2 years old. MDR, decreased ciprofloxacin susceptibility, azithromycin and cefotaxime resistance were 80.7%, 4.3%, 3.0% and 2.1% respectively. ESBL production was noted in three (1.3%) isolates. Decreased ciprofloxacin susceptibility was associated with mutations in codon 87 of the gyrA gene, while ESBLs all belonged to the SHV-2a type. Conclusions/Significance: Presence of almost full MDR among NTS isolates from blood cultures in Central Africa was confirmed. Resistance to fluoroquinolones, azithromycin and third generation cephalosporins is still low, but emerging. Increased microbiological surveillance in DR Congo is crucial for adapted antibiotic therapy and the development of treatment guidelines.	[Lunguya, Octavie; Phoba, Marie-France; Muyembe-Tamfum, Jean-Jacques] Natl Inst Biomed Res, Kinshasa, Zaire; [Lunguya, Octavie; Phoba, Marie-France; Muyembe-Tamfum, Jean-Jacques] Univ Hosp Kinshasa, Kinshasa, Zaire; [Lejon, Veerle; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Lejon, Veerle] Inst Rech Dev, UMR IRD CIRAD INTERTRYP 177, Montpellier, France; [Bertrand, Sophie; Vanhoof, Raymond] Inst Publ Hlth, Brussels, Belgium; [Glupczynski, Youri] Clin Univ UCL Mt Godinne, Natl Reference Lab Monitoring Antimicrobial Resis, Yvoir, Belgium; [Verhaegen, Jan] Katholieke Univ Leuven Hosp, Louvain, Belgium	Lunguya, O (reprint author), Natl Inst Biomed Res, Kinshasa, Zaire.	vlejon@itg.be		Lejon, Veerle/0000-0002-6795-0962	Development Cooperation of the Belgian Government through Institutional Collaboration INRB-ITM [2.01]	This study was funded by Directorate General of Development Cooperation of the Belgian Government through Institutional Collaboration INRB-ITM (Project 2.01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akinyemi KO, 2007, J HEALTH POPUL NUTR, V25, P351; Bahwere P, 2001, Int J Infect Dis, V5, P180, DOI 10.1016/S1201-9712(01)90067-0; Bogaerts P, 2011, ANTIMICROB AGENTS CH, V55, P4457, DOI 10.1128/AAC.00353-11; Boisrame-Gastrin S, 2011, J ANTIMICROB CHEMOTH, V66, P2271, DOI 10.1093/jac/dkr307; Cavaco LM, 2008, MICROB DRUG RESIST, V14, P163, DOI 10.1089/mdr.2008.0821; Cheesbrough JS, 1997, PEDIATR INFECT DIS J, V16, P277, DOI 10.1097/00006454-199703000-00005; CLSI, 2012, PERF STAND ANT SUSC; Dagnra AY, 2007, MED MALADIES INFECT, V37, P266, DOI 10.1016/j.medmal.2007.02.002; De Boeck H, 2012, EMERG INFECT DIS, V18; Dougle ML, 1997, E AFR MED J, V74, P353; European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2012, BREAKP TABL INT MICS; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; Garcia LS, 2007, CLIN MICROBIOLOGY PR; Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146; GREEN SDR, 1993, ANN TROP PAEDIATR, V13, P45, DOI 10.1080/02724936.1993.11747624; Grimont P. A., 2007, ANTIGENIC FORMULAE S; Hakanen AJ, 2005, J CLIN MICROBIOL, V43, P5775, DOI 10.1128/JCM.43.11.5775-5778.2005; Kariuki S, 2006, J MED MICROBIOL, V55, P585, DOI 10.1099/jmm.0.46375-0; Kariuki S, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-101; Kim SH, 2008, J MICROBIOL, V46, P209, DOI 10.1007/s12275-007-0197-1; Kingsley RA, 2009, GENOME RES, V19, P2279, DOI 10.1101/gr.091017.109; Lunguya O, 2005, CONGO MED, V4, P227; Lunguya Octavie, 2012, PLoS Negl Trop Dis, V6, pe1921, DOI 10.1371/journal.pntd.0001921; Lunguya O, 2012, T ROY SOC TROP MED H, V106, P348, DOI 10.1016/j.trstmh.2012.03.006; Mandomando I, 2009, TROP MED INT HEALTH, V14, P1467, DOI 10.1111/j.1365-3156.2009.02399.x; Morpeth SC, 2009, CLIN INFECT DIS, V49, P606, DOI 10.1086/603553; Mtove G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009244; MUYEMBE TL, 1977, ANN SOC BELG MED TR, V57, P545; Muyembe-Tamfum JJ, 2009, TRAVEL MED INFECT DI, V7, P40, DOI 10.1016/j.tmaid.2008.12.006; Nielsen MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044063; Okoro CK, 2012, NAT GENET, V44, P1215, DOI 10.1038/ng.2423; Pang JC, 2007, INT J FOOD MICROBIOL, V116, P305, DOI 10.1016/j.ijfoodmicro.2006.05.024; Phoba MF, 2012, EMERG INFECT DIS, V18, P1692, DOI 10.3201/eid1810.120525; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Ribot EM, 2006, FOODBORNE PATHOG DIS, V3, P59, DOI 10.1089/fpd.2006.3.59; Tabu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031237; Technical Centre for Agricultural and Rural Cooperation, 2011, AGRITRADE        SEP, P1; Tien YY, 2012, J MED MICROBIOL, V61, P223, DOI 10.1099/jmm.0.037291-0; UNAIDS, 2012, HIV AIDS EST 2009; USDA, 2010, INT EGG POULTRY REV, V13; Usha G, 2008, DIAGN MICR INFEC DIS, V62, P86, DOI 10.1016/j.diagmicrobio.2008.04.014; Vandenberg O, 2010, PEDIATR INFECT DIS J, V29, P504, DOI 10.1097/INF.0b013e3181cd615a; Vlieghe E, 2009, INT J ANTIMICROB AG, V34, P295, DOI 10.1016/j.ijantimicag.2009.04.015; WHO, 2011, WORLD MALARIA REPORT 2011, P1; World Health Organization, 2012, IMM PROF CONG; World Health Organization Communicable Disease Surveillance and Response Vaccines and Biologicals, 2003, DIAGN TREATM PREV TY	46	36	38	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAR	2013	7	3							e2103	10.1371/journal.pntd.0002103				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	117HI	WOS:000316943800023	23516651	DOAJ Gold, Green Published			2019-03-26	
J	Masure, D; Vlaminck, J; Wang, T; Chiers, K; Van den Broeck, W; Vercruysse, J; Geldhof, P				Masure, Dries; Vlaminck, Johnny; Wang, Tao; Chiers, Koen; Van den Broeck, Wim; Vercruysse, Jozef; Geldhof, Peter			A Role for Eosinophils in the Intestinal Immunity against Infective Ascaris suum Larvae	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HOST-DEFENSE; PIGS; PARASITES; COMPLEMENT; NEMATODES; HUMANS; SWINE; LUMBRICOIDES; COMPONENT; BINDING	The aim of this study was to explore the mechanisms of resistance against invading Ascaris suum larvae in pigs. Pigs received a low dose of 100 A. suum eggs daily for 14 weeks. This resulted in a >99% reduction in the number of larvae that could migrate through the host after a challenge infection of 5000 A. suum eggs, compared to naive pigs. Histological analysis at the site of parasite entry, i.e. the caecum, identified eosinophilia, mastocytosis and goblet cell hyperplasia. Increased local transcription levels of genes for IL5, IL13, eosinophil peroxidase and eotaxin further supported the observed eosinophil influx. Further analysis showed that eosinophils degranulated in vitro in response to contact with infective Ascaris larvae in the presence of serum from both immune and naive animals. This effect was diminished with heat-inactivated serum, indicating a complement dependent mechanism. Furthermore, eosinophils were efficient in killing the larvae in vitro when incubated together with serum from immune animals, suggesting that A. suum specific antibodies are required for efficient elimination of the larvae. Together, these results indicate an important role for eosinophils in the intestinal defense against invading A. suum larvae.	[Masure, Dries; Vlaminck, Johnny; Wang, Tao; Vercruysse, Jozef; Geldhof, Peter] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Merelbeke, Belgium; [Chiers, Koen] Univ Ghent, Dept Pathol Bacteriol & Avian Dis, Fac Vet Med, Merelbeke, Belgium; [Van den Broeck, Wim] Univ Ghent, Dept Morphol, Fac Vet Med, Merelbeke, Belgium	Masure, D (reprint author), Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Merelbeke, Belgium.	peter.geldhof@ugent.be		Wang, Tao/0000-0003-1359-8913	Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT)	DM was funded by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Arizono N, 2010, JPN J INFECT DIS, V63, P447; Artis D, 2004, P NATL ACAD SCI USA, V101, P13596, DOI 10.1073/pnas.0404034101; ASHRAF M, 1988, VET PARASITOL, V29, P143, DOI 10.1016/0304-4017(88)90122-7; Crompton DWT, 2001, ADV PARASIT, V48, P285, DOI 10.1016/S0065-308X(01)48008-0; DAVID JR, 1980, AM J TROP MED HYG, V29, P842, DOI 10.4269/ajtmh.1980.29.842; Donne E, 2005, VET MICROBIOL, V107, P205, DOI 10.1016/j.vetmic.2005.01.027; ERIKSEN L, 1992, PARASITOL RES, V78, P241, DOI 10.1007/BF00931733; ERIKSEN L, 1992, VET PARASITOL, V41, P137, DOI 10.1016/0304-4017(92)90017-4; Giacomin PR, 2005, INFECT IMMUN, V73, P7442, DOI 10.1128/IAI.73.11.7442-7449.2005; Giembycz MA, 1999, PHARMACOL REV, V51, P213; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Hasnain SZ, 2011, J EXP MED, V208, P893, DOI 10.1084/jem.20102057; Herbert DR, 2009, J EXP MED, V206, P2947, DOI 10.1084/jem.20091268; Jackson JA, 2004, J INFECT DIS, V190, P1804, DOI 10.1086/425014; James CE, 2007, PARASITOL RES, V101, P975, DOI 10.1007/s00436-007-0572-1; Kermanizadeh P, 1997, PARASITOL TODAY, V13, P405, DOI 10.1016/S0169-4758(97)87088-3; Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050; Kringel H, 2006, INT J PARASITOL, V36, P915, DOI 10.1016/j.ijpara.2006.04.008; LAUBACH HE, 1991, ZBL BAKT-INT J MED M, V275, P397, DOI 10.1016/S0934-8840(11)80307-5; Leles D, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-42; LEVENTHAL R, 1977, EXP PARASITOL, V41, P423, DOI 10.1016/0014-4894(77)90115-1; Liu GH, 2012, GENE, V492, P110, DOI 10.1016/j.gene.2011.10.043; Malik A, 2012, CRIT REV MICROBIOL, V38, P168, DOI 10.3109/1040841X.2011.645519; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; Murrell KD, 1997, J PARASITOL, V83, P255, DOI 10.2307/3284450; Nejsum P, 2005, J CLIN MICROBIOL, V43, P1142, DOI 10.1128/JCM.43.3.1142-1148.2005; Nejsum P, 2009, J PARASITOL, V95, P1048, DOI 10.1645/GE-1987.1; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Rozen S, 2000, Methods Mol Biol, V132, P365; Steenhard NR, 2009, VACCINE, V27, P5161, DOI 10.1016/j.vaccine.2009.05.075; STEWART TB, 1988, J ANIM SCI, V66, P1548; URBAN JF, 1986, VET CLIN N AM-FOOD A, V2, P765, DOI 10.1016/S0749-0720(15)31218-4; URBAN JF, 1988, EXP PARASITOL, V66, P66, DOI 10.1016/0014-4894(88)90051-3; Uston PI, 2007, PARASITOL RES, V100, P603, DOI 10.1007/s00436-006-0362-1; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Webb RA, 2007, PARASITE IMMUNOL, V29, P11, DOI 10.1111/j.1365-3024.2006.00908.x	37	23	23	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAR	2013	7	3							e2138	10.1371/journal.pntd.0002138				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	117HI	WOS:000316943800051	23556022	DOAJ Gold, Green Published			2019-03-26	
J	Mwape, KE; Phiri, IK; Praet, N; Speybroeck, N; Muma, JB; Dorny, P; Gabriel, S				Mwape, Kabemba E.; Phiri, Isaac K.; Praet, Nicolas; Speybroeck, Niko; Muma, John B.; Dorny, Pierre; Gabriel, Sarah			The Incidence of Human Cysticercosis in a Rural Community of Eastern Zambia	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TAENIA-SOLIUM; PORCINE CYSTICERCOSIS; NEUROCYSTICERCOSIS; INFECTION; PREVALENCE; SEROPREVALENCE; EXPOSURE; EPILEPSY; DISEASE	A community-based longitudinal study was performed in the Eastern Province of Zambia, in which repeated serological samplings were done to determine the incidence of human cysticercosis. Three sampling rounds were carried out at six months intervals. A total of 867 participants presented for all three samplings. All samples were tested for the presence of cysticercus antigens using a monoclonal antibody-based enzyme-linked immunosorbent assay (sero-Ag-ELISA), while a randomly selected sub-sample of 161 samples from each sampling round was tested for specific antibodies using a commercial enzyme-linked immunoelectrotransfer blot (EITB) assay. Stool samples (n = 226) were also collected during the final round of sampling for taeniosis diagnosis by coprology and coproantigen ELISA. Cysticercosis seroprevalence varied from 12.2% to 14.5% (sero-Ag) and from 33.5% to 38.5% (sero-Ab) during the study period. A taeniosis prevalence of 11.9% was determined. Incidence rates of 6300 (sero-Ag, per 100000 persons-year) and 23600 (sero-Ab, per 100000 persons-year) were determined. Seroreversion rates of 44% for sero-Ag and 38.7% for sero-Ab were recorded over the whole period. In conclusion, this study has shown the dynamic nature of T. solium infections; many of the people at risk become (re) infected due to the high environmental contamination, with a high number turning seronegative within a year after infection. An important number of infections probably never fully establish, leading to transient antibody responses and short-term antigen presence.	[Mwape, Kabemba E.; Phiri, Isaac K.] Univ Zambia, Dept Clin Studies, Sch Vet Med, Lusaka, Zambia; [Mwape, Kabemba E.] Univ Pretoria, Dept Vet Trop Dis, Fac Vet Sci, ZA-0002 Pretoria, South Africa; [Praet, Nicolas; Dorny, Pierre; Gabriel, Sarah] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Speybroeck, Niko] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium; [Muma, John B.] Univ Zambia, Dept Dis Control, Sch Vet Med, Lusaka, Zambia; [Dorny, Pierre] Univ Ghent, Lab Vet Parasitol, Fac Vet Med, Merelbeke, Belgium	Mwape, KE (reprint author), Univ Zambia, Dept Clin Studies, Sch Vet Med, Lusaka, Zambia.	sgabriel@itg.be			Flemish Interuniversity Co-operation, Research Initiatives Programme, Zambia [VLIR-UOS.ZIUS2008RIP-8961]; Institute of Tropical Medicine in Antwerp, Belgium; University of Pretoria, Pretoria, South Africa	The study received financial support from the Flemish Interuniversity Co-operation, Research Initiatives Programme, Zambia (VLIR-UOS.ZIUS2008RIP-8961). Support was also obtained from the Belgian Cooperation in the framework of the institutional collaboration between the Institute of Tropical Medicine in Antwerp, Belgium, and the University of Pretoria, Pretoria, South Africa. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLAN JC, 1990, PARASITOLOGY, V101, P473, DOI 10.1017/S0031182000060686; Deckers N, 2008, INT J PARASITOL, V38, P1191, DOI 10.1016/j.ijpara.2008.01.005; Del Brutto OH, 2001, NEUROLOGY, V57, P177, DOI 10.1212/WNL.57.2.177; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Fleury A, 2004, J NEUROL, V251, P830, DOI 10.1007/s00415-004-0437-9; Garcia HH, 2010, NEUROLOGY, V75, P654, DOI 10.1212/WNL.0b013e3181ed9eae; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; Garcia HH, 2005, LANCET NEUROL, V4, P653, DOI 10.1016/S1474-4422(05)70194-0; Garcia HH, 2003, PREV VET MED, V57, P227, DOI 10.1016/S0167-5877(02)00234-9; Kanobana K, 2011, INT J PARASITOL, V41, P1015, DOI 10.1016/j.ijpara.2011.06.004; Murrell KD, 2005, WHO FAO OIE GUIDELIN; Mwape KE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001594; Ndimubanzi PC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000870; Parija Subhash Chandra, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P331, DOI 10.1590/S0036-46652007000500011; Praet N, 2010, INT J PARASITOL, V40, P85, DOI 10.1016/j.ijpara.2009.07.007; Praet N, 2010, AM J TROP MED HYG, V83, P413, DOI 10.4269/ajtmh.2010.10-0121; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; Sacks L V, 1990, Trop Gastroenterol, V11, P30; Sikasunge CS, 2008, VET J, V176, P240, DOI 10.1016/j.tvjl.2007.02.030; Torgerson PR, 2011, VET PARASITOL, V182, P79, DOI 10.1016/j.vetpar.2011.07.017; Vilhena M, 1999, AM J TROP MED HYG, V61, P59, DOI 10.4269/ajtmh.1999.61.59; Villaran MV, 2009, NEUROEPIDEMIOLOGY, V33, P25, DOI 10.1159/000210019	22	26	26	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAR	2013	7	3							e2142	10.1371/journal.pntd.0002142				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	117HI	WOS:000316943800055	23556026	DOAJ Gold, Green Published			2019-03-26	
J	Pomajbikova, K; Obornik, M; Horak, A; Petrzelkova, KJ; Grim, JN; Levecke, B; Todd, A; Mulama, M; Kiyang, J; Modry, D				Pomajbikova, Katerina; Obornik, Miroslav; Horak, Ales; Petrzelkova, Klara J.; Grim, J. Norman; Levecke, Bruno; Todd, Angelique; Mulama, Martin; Kiyang, John; Modry, David			Novel Insights into the Genetic Diversity of Balantidium and Balantidium-like Cyst-forming Ciliates	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TROGLODYTELLA-ABRASSARTI; INTESTINAL PARASITES; COLI INFECTION; NATIONAL-PARK; CILIOPHORA; LITOSTOMATEA; PHYLOGENY; CHIMPANZEES; IDENTIFICATION; PREVALENCE	Balantidiasis is considered a neglected zoonotic disease with pigs serving as reservoir hosts. However, Balantidium coli has been recorded in many other mammalian species, including primates. Here, we evaluated the genetic diversity of B. coli in non-human primates using two gene markers (SSrDNA and ITS1-5.8SDNA-ITS2). We analyzed 49 isolates of ciliates from fecal samples originating from 11 species of captive and wild primates, domestic pigs and wild boar. The phylogenetic trees were computed using Bayesian inference and Maximum likelihood. Balantidium entozoon from edible frog and Buxtonella sulcata from cattle were included in the analyses as the closest relatives of B. coli, as well as reference sequences of vestibuliferids. The SSrDNA tree showed the same phylogenetic diversification of B. coli at genus level as the tree constructed based on the ITS region. Based on the polymorphism of SSrDNA sequences, the type species of the genus, namely B. entozoon, appeared to be phylogenetically distinct from B. coli. Thus, we propose a new genus Neobalantidium for the homeothermic clade. Moreover, several isolates from both captive and wild primates (excluding great apes) clustered with B. sulcata with high support, suggesting the existence of a new species within this genus. The cysts of Buxtonella and Neobalantidium are morphologically indistinguishable and the presence of Buxtonella-like ciliates in primates opens the question about possible occurrence of these pathogens in humans.	[Pomajbikova, Katerina; Petrzelkova, Klara J.] Univ Vet & Pharmaceut Sci, Dept Pathol & Parasitol, Fac Vet Med, Brno, Czech Republic; [Obornik, Miroslav; Horak, Ales; Petrzelkova, Klara J.; Modry, David] Acad Sci Czech Republic, Inst Parasitol, Ctr Biol, CR-37005 Ceske Budejovice, Czech Republic; [Obornik, Miroslav; Horak, Ales] Univ South Bohemia, Fac Sci, Ceske Budejovice, Czech Republic; [Petrzelkova, Klara J.] Acad Sci Czech Republic, Inst Vertebrate Biol, Brno, Czech Republic; [Petrzelkova, Klara J.] Liberec Zoo, Liberec, Czech Republic; [Grim, J. Norman] No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA; [Levecke, Bruno] Univ Ghent, Parasitol Lab, Fac Vet Med, B-9000 Ghent, Belgium; [Levecke, Bruno] Royal Zool Soc Antwerp, Ctr Res & Conservat, Antwerp, Belgium; [Todd, Angelique] World Wildlife Fund, Bangui, Cent Afr Republ; [Mulama, Martin] Ol Pejeta Conservamcy, Sweetwaters Chimpanzee Sanctuary, Nanyuki, Kenya; [Kiyang, John] Limbe Wildlife Ctr, Limbe, Cameroon; [Modry, David] Univ Vet & Pharmaceut Sci, CEITEC Cent European Inst Technol, Brno, Czech Republic	Pomajbikova, K (reprint author), Univ Vet & Pharmaceut Sci, Dept Pathol & Parasitol, Fac Vet Med, Brno, Czech Republic.	kpomajbik@gmail.com	Modry, David/G-7815-2014; Obornik, Miroslav/G-9350-2014; Petrzelkova, Klara/G-7111-2014; Jirku Pomajbikova, Katerina/G-9858-2014; Horak, Ales/H-6723-2012	Levecke, Bruno/0000-0001-8912-5595	project "CEITEC" - Central European Institute of Technology'' from the European Regional Development Fund [CZ.1.05/1.1.00/02.0068]; Grant Agency of the Czech Republic [206/09/0927]; Institute of Vertebrate Biology Academy of Sciences of the Czech Republic [RVO:68081766]; OPVK 2.3 project - Development of Scientific Team and Laboratory for Infectious Diseases Common to Humans and Great Apes [CZ.1.07/2.3.00/20.0300]	This work was supported by the project "CEITEC" - Central European Institute of Technology'' (grant no. CZ.1.05/1.1.00/02.0068) from the European Regional Development Fund, by grant from the Grant Agency of the Czech Republic (grant no. 206/09/0927), and by institutional support of Institute of Vertebrate Biology Academy of Sciences of the Czech Republic (grant no. RVO:68081766) and by OPVK 2.3 project - Development of Scientific Team and Laboratory for Infectious Diseases Common to Humans and Great Apes (CZ.1.07/2.3.00/20.0300). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anargyrou K, 2003, AM J HEMATOL, V73, P180, DOI 10.1002/ajh.10336; AREAN VM, 1956, AM J PATHOL, V22, P1089; Bakuza JS, 2009, INT J PRIMATOL, V30, P43, DOI 10.1007/s10764-008-9329-7; Bernhard D, 1998, J MOL EVOL, V46, P344, DOI 10.1007/PL00006311; Cameron SL, 2003, ACTA PROTOZOOL, V42, P1; Cameron SL, 2002, INT J PARASITOL, V33, P347; Cermeno JR, 2003, AIDS, V17, P941, DOI 10.1097/01.aids.0000060335.12269.8f; Claparede E, 1858, ETUDES INFUSOIRES RH, P247; Clyti E, 1998, B SOC PATHOL EXOT, V91, P309; Esteban JG, 1998, AM J TROP MED HYG, V59, P922, DOI 10.4269/ajtmh.1998.59.922; Ferry T, 2004, EUR J CLIN MICROBIOL, V23, P393, DOI 10.1007/s10096-004-1126-4; FOX MT, 1986, RES VET SCI, V41, P90, DOI 10.1016/S0034-5288(18)30578-2; Garcia LS, 2008, EMERGING PROTOZOAN P; Grim JN, 2009, EUR J PROTISTOL, V45, P147; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008; Hegner R, 1934, AM J HYG, V19, P38, DOI 10.1093/oxfordjournals.aje.a117992; Israel RL, 2002, EVOLUTION, V56, P1110; JAMESON A. PRINGLE, 1926, PARASITOLOGY, V18, P182; KENNEDY C. C., 1957, TRANS ROY SOC TROP MED AND HYG, V51, P549, DOI 10.1016/0035-9203(57)90045-7; Lartillot N, 2009, BIOINFORMATICS, V25, P2286, DOI 10.1093/bioinformatics/btp368; Lassmann T, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-298; Lassmann T., 2006, NUCLEIC ACIDS RES, V34, P596; Levecke B, 2010, THESIS GHENT U, P72; Levecke B, 2007, VET PARASITOL, V148, P236, DOI 10.1016/j.vetpar.2007.06.020; Li M, 2008, PARASITOL RES, V102, P605, DOI 10.1007/s00436-007-0795-1; Lilly AA, 2002, INT J PRIMATOL, V23, P555, DOI 10.1023/A:1014969617036; Nilles-Bije ML, 2010, PARASITOL RES, V106, P387, DOI 10.1007/s00436-009-1673-9; Lynn D. H., 2000, ILLUSTRATED GUIDE PR; Lynn D. H, 2008, CILIATED PROTOZOA CH; Maino A, 2010, J NEPHROL, V23, P732; MALMSTEN PH, 1857, VIRCHOWS ARCH PATHOL, V12, P302; MCGREW WC, 1989, AM J PRIMATOL, V17, P147, DOI 10.1002/ajp.1350170204; Modry D, 2009, J EUKARYOT MICROBIOL, V56, P83, DOI 10.1111/j.1550-7408.2008.00369.x; Nakauchi K, 1999, J VET MED SCI, V61, P63, DOI 10.1292/jvms.61.63; Owen IL, 2005, J HELMINTHOL, V79, P1, DOI 10.1079/JOH2004266; Pomajbikova K, 2010, J PARASITOL, V96, P1139, DOI 10.1645/GE-2433.1; Ponce-Gordo F, 2008, VET PARASITOL, V157, P41, DOI 10.1016/j.vetpar.2008.06.024; Ponce-Gordo F, 2011, PROTIST, V162, P774, DOI 10.1016/j.protis.2011.06.008; QUADRI SS, 1966, RIV PARASSITOL, V27, P89; Schuster FL, 2008, CLIN MICROBIOL REV, V21, P626, DOI 10.1128/CMR.00021-08; Shimodaira H, 2001, BIOINFORMATICS, V17, P1246, DOI 10.1093/bioinformatics/17.12.1246; Shimodaira H, 2004, ANN STAT, V32, P2616, DOI 10.1214/009053604000000823; Skotarczak B, 1999, FOLIA BIOL-KRAKOW, V47, P61; Solaymani-Mohammadi S, 2005, TRENDS PARASITOL, V21, P160, DOI 10.1016/j.pt.2005.02.001; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Stein F, 1863, AMTL BERL DTSCH CHEM, V37, P165; Struder-Kypke MC, 2006, PROTIST, V157, P261, DOI 10.1016/j.protis.2006.03.003; Struder-Kypke MC, 2007, EUR J PROTISTOL, V43, P319, DOI 10.1016/j.ejop.2007.06.005; Tourancheau AB, 1998, MOL PHYLOGENET EVOL, V10, P299, DOI 10.1006/mpev.1998.0534; Vallo P, 2012, AM J PHYS ANTHROPOL, V148, P525, DOI 10.1002/ajpa.22067; Vd'acny P, 2011, MOL PHYLOGENET EVOL, V59, P510, DOI 10.1016/j.ympev.2011.02.016; Weyher AH, 2006, INT J PRIMATOL, V27, P1519, DOI 10.1007/s10764-006-9089-1; Williams AG, 1992, RUMEN PROTOZOA; Wright ADG, 1999, J EUKARYOT MICROBIOL, V46, P445, DOI 10.1111/j.1550-7408.1999.tb04627.x; Zaman V., 1978, PARASITIC PROTOZOA, V2, P633; Zhang QQ, 2012, P ROY SOC B-BIOL SCI, V279, P2625, DOI 10.1098/rspb.2011.2688	57	18	21	1	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAR	2013	7	3							e2140	10.1371/journal.pntd.0002140				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	117HI	WOS:000316943800053	23556024	DOAJ Gold, Green Published			2019-03-26	
J	Bottieau, E; Gillet, P; De Weggheleire, A; Scheirlinck, A; Stokx, J; Mosse, CD; Jacobs, J				Bottieau, E.; Gillet, P.; De Weggheleire, A.; Scheirlinck, A.; Stokx, J.; Das Dores Mosse, C.; Jacobs, J.			Treatment practices in patients with suspected malaria in Provincial Hospital of Tete, Mozambique	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Malaria; Rapid diagnostic tests; Treatment practice; Microscopy; Antimalarials; Antibiotics	RAPID DIAGNOSTIC-TESTS; DAR-ES-SALAAM; AFRICAN CHILDREN; RANDOMIZED-TRIAL; FEBRILE CHILDREN; BURKINA-FASO; TANZANIA; MICROSCOPY; UGANDA; INFECTIONS	Background: Nowadays, parasite-based diagnosis by microscopy or malaria rapid diagnostic tests (RDT) is universally promoted before malaria treatment. However, studies on adherence of primary caregivers to malaria test results have provided conflicting results. Methods: The antimalarial and antibiotic prescription rates in patients with suspected malaria at Provincial Hospital of Tete, Mozambique, and the features associated with antibiotic prescription in non-severely ill parasite-negative patients were assessed. Results: In March and April 2010, Plasmodium falciparum malaria was diagnosed by microscopy or RDT in 728 (27.2%) of 2672 patients tested. Almost all malaria patients were prescribed antimalarials and 20% were also given antibiotics. Of 1944 parasite-negative patients, 126 (6.5%) were prescribed antimalarials and 1213 (62.4%) antibiotics. Among non-severely ill parasite-negative patients with complete information (n = 1607), the antibiotic prescription rate was 68.8% and was more frequent with respiratory symptoms and leukocyte counts >10 000/mu L (adjusted OR = 1.62, 95% CI 1.18-2.23 and adjusted OR = 2.12, 95% CI 1.66-2.71, respectively). Conclusions: Adherence to malaria test results was good in this reference setting, but antibiotic prescription was relatively frequent in clinically stable non-malaria patients. Optimal management of parasite-negative patients must be further defined along with programmatic deployment of the parasite-based strategy.	[Bottieau, E.; Gillet, P.; De Weggheleire, A.; Scheirlinck, A.; Stokx, J.; Jacobs, J.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Das Dores Mosse, C.] Direccao Prov Saude, Tete, Mozambique	Bottieau, E (reprint author), Inst Trop Med, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium.	ebottieau@itg.be	De Weggheleire, Anja/C-7345-2018	De Weggheleire, Anja/0000-0001-9377-4766; gillet, philippe/0000-0001-5878-6446	Flemish International Cooperation Agency	This work was conducted within a collaborative health project (Rede Integrada II) financed by the Flemish International Cooperation Agency.	Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Batwala V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-373; Batwala V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-372; Batwala V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-377; Batwala V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-349; Bisoffi Z, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-192; Bisoffi Z, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000063; Bisoffi Z, 2009, TROP MED INT HEALTH, V14, P491, DOI 10.1111/j.1365-3156.2009.02246.x; Chalwe V, 2009, EMERG INFECT DIS, V15, P749, DOI 10.3201/eid1505.081009; D'Acremont V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-107; D'Acremont V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-240; d'Acremont V, 2010, CLIN INFECT DIS, V51, P506, DOI 10.1086/655688; English M, 2009, PLOS MED, V6, P7, DOI 10.1371/journal.pmed.1000015; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-166; Graz B, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-136; Hendriksen ICE, 2011, CLIN INFECT DIS, V52, P1100, DOI 10.1093/cid/cir143; Masanja IM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-221; Masanja MI, 2010, AM J TROP MED HYG, V83, P1238, DOI 10.4269/ajtmh.2010.10-0194; Msellem MI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000070; Mtove G, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-320; Mtove G, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-290; Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8; Nadjm B, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1350; Naing C, 2012, T ROY SOC TROP MED H, V106, P331, DOI 10.1016/j.trstmh.2012.03.003; Peeling RW, 2010, CLIN MICROBIOL INFEC, V16, P1062, DOI 10.1111/j.1469-0691.2010.03279.x; Reyburn H, 2007, BRIT MED J, V334, P403, DOI 10.1136/bmj.39073.496829.AE; Rosenthal PJ, 2012, AM J TROP MED HYG, V86, P192, DOI 10.4269/ajtmh.2012.11-0619; Trape JF, 2011, LANCET INFECT DIS, V11, P925, DOI 10.1016/S1473-3099(11)70194-3; Van den Bruel A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3082; Van den Bruel A, 2010, LANCET, V375, P834, DOI 10.1016/S0140-6736(09)62000-6; Were T, 2011, J CLIN MICROBIOL, V49, P671, DOI 10.1128/JCM.01864-10; *WHO, 2000, T R SOC TROP MED S1, V94; World Health Organization, 2010, GUID TREATM MAL; Young Taryn, 2012, Int J Epidemiol, V41, P607, DOI 10.1093/ije/dys083; Yukich J, 2010, AM J TROP MED HYG, V83, P61, DOI 10.4269/ajtmh.2010.09-0632	36	8	8	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAR	2013	107	3					176	182		10.1093/trstmh/trs012				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	102GI	WOS:000315832500007	23382275				2019-03-26	
J	Trung, DD; Praet, N; Thach, DTC; Binh, VTL; Manh, HN; Gabriel, S; Dorny, P				Dung Do Trung; Praet, Nicolas; Thach Dang Thi Cam; Binh Vu Thi Lam; Hung Nguyen Manh; Gabriel, Sarah; Dorny, Pierre			Assessing the burden of human cysticercosis in Vietnam	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Taenia solium; Vietnam; neurocysticercosis; clinical signs; burden	TAENIA-SOLIUM CYSTICERCOSIS; SOUTHEAST-ASIA; NORTH VIETNAM; NEUROCYSTICERCOSIS; EPILEPSY; PREVALENCE; ANTIGEN; EXPOSURE; ELISA	Objectives To describe the occurrence of cysticercosis in patients living in rural areas of Northern Vietnam presenting clinical signs of neurocysticercosis. Methods Serological antigen detection, reflecting current infection with viable larval stages of Taenia solium, was used to estimate the prevalence of active cysticercosis in this patient population. Results The seroprevalence in epileptic patient population was <10%. However, antigen detection cannot detect dead cysticerci, which may also cause clinical signs. Therefore, the seroprevalence figures shown here may underestimate the role of neurocysticercosis as a causal agent of epilepsy and headaches in this population. Conclusions Human and porcine cysticercosis remain public and veterinary public health problems in Northern Vietnam and probably in other parts of the country.	[Dung Do Trung; Thach Dang Thi Cam; Binh Vu Thi Lam; Hung Nguyen Manh] Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam; [Praet, Nicolas; Gabriel, Sarah; Dorny, Pierre] Inst Trop Med, B-2000 Antwerp, Belgium	Praet, N (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	npraet@itg.be		GABRIEL, SARAH/0000-0002-2523-233X	Belgian Cooperation in the framework of the Institutional Collaboration; Institute of Tropical Medicine in Antwerp, Belgium; National Institute of Malariology, Parasitology and Entomology, Ministry of Health in Hanoi, Vietnam	The authors would like to acknowledge the staff of the Preventive Medical Centers of the provinces, districts and communes for their collaboration in the present study. This work was supported by the Belgian Cooperation in the framework of the Institutional Collaboration between the Institute of Tropical Medicine in Antwerp, Belgium and the National Institute of Malariology, Parasitology and Entomology, Ministry of Health in Hanoi, Vietnam.	Bhattarai R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001521; Carabin H, 2006, TROP MED INT HEALTH, V11, P906, DOI 10.1111/j.1365-3156.2006.01627.x; Carabin H, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001152; Cavellani CL, 2007, ANN DIAGN PATHOL, V11, P330, DOI 10.1016/j.anndiagpath.2006.12.008; Conlan JV, 2009, TRENDS PARASITOL, V25, P398, DOI 10.1016/j.pt.2009.06.005; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Fleury A, 2004, J NEUROL, V251, P830, DOI 10.1007/s00415-004-0437-9; Gabriel S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001851; Goel D, 2011, NEUROL INDIA, V59, P37, DOI 10.4103/0028-3886.76855; MURRELL KD, 2005, GUIDELINES SURVEILLA; Ndimubanzi PC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000870; Nitiema P, 2012, ACTA NEUROL SCAND, V126, P270, DOI 10.1111/j.1600-0404.2011.01639.x; Prabhakar Sudesh, 2002, P169; Prado-Jean A, 2007, TROP MED INT HEALTH, V12, P895, DOI 10.1111/j.1365-3156.2007.01860.x; Praet N, 2010, INT J PARASITOL, V40, P85, DOI 10.1016/j.ijpara.2009.07.007; Praet N, 2010, AM J TROP MED HYG, V83, P413, DOI 10.4269/ajtmh.2010.10-0121; Praet N, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000406; Raghava MV, 2010, T ROY SOC TROP MED H, V104, P601, DOI 10.1016/j.trstmh.2010.06.002; Raina Sunil Kumar, 2012, Epilepsy Res Treat, V2012, P802747, DOI 10.1155/2012/802747; Rajshekhar V, 2006, NEUROLOGY, V67, P2135, DOI 10.1212/01.wnl.0000249113.11824.64; Secka A, 2010, TROP MED INT HEALTH, V15, P476, DOI 10.1111/j.1365-3156.2010.02470.x; Somers R, 2006, TROP MED INT HEALTH, V11, P65, DOI 10.1111/j.1365-3156.2005.01537.x; Somers R, 2007, T ROY SOC TROP MED H, V101, P275, DOI 10.1016/j.trstmh.2006.04.007; Willingham A Lee 3rd, 2003, Southeast Asian J Trop Med Public Health, V34 Suppl 1, P35; Willingham AL, 2010, ADV PARASIT, V72, P235, DOI 10.1016/S0065-308X(10)72009-1	26	7	7	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2013	18	3					352	356		10.1111/tmi.12043				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	092FC	WOS:000315103700013	23279716	Bronze			2019-03-26	
J	Abouchadi, S; Alaoui, AB; Meski, FZ; De Brouwere, V				Abouchadi, S.; Belghiti Alaoui, A.; Meski, F. Z.; De Brouwere, V.			Implementing a maternal mortality surveillance system in Morocco challenges and opportunities	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						maternal mortality; surveillance system; causes; Morocco	DEATHS	Objective To describe the development of the maternal death surveillance system (MDSS) in Morocco and discuss the initial results. Method The nationwide MDSS was implemented in 2009 with the involvement of health professionals and local authorities. It comprises (i) notification of all deaths of women of reproductive age (from 15 to 49years); (ii) a preliminary survey to identify pregnancy-related deaths; (iii) a confidential enquiry into all pregnancy-related deaths. The information thus obtained describes socio-demographic characteristics of the women, their obstetric and medical history, the mode of delivery, its follow-up and the medical cause of death. Results From 1st of January 2009 to 31st of December 2009, 3814 deaths of women of reproductive age were recorded, and a total of 436 pregnancy-related deaths were identified, with 73.4% of those occurring in health facilities. Among the 313 reviewed records, 80.8% were direct obstetric deaths, and 13.5% were classified as indirect. Haemorrhage was the first direct obstetric cause of death (33%). Heart disease was the main indirect obstetric cause of death (39% of indirect causes). Conclusion The Moroccan MDSS is a powerful tool for understanding the causes and circumstances of maternal deaths. However, challenges remain regarding the full coverage of the system, the decentralisation of the data entry and analysis and the completeness of medical records.	[Abouchadi, S.; Belghiti Alaoui, A.] Direct Hop & Soins Ambulatoires, Minist Hlth, Rabat, Morocco; [Meski, F. Z.] Inst Natl Adm Sanitaire, Minist Hlth, Rabat, Morocco; [De Brouwere, V.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [De Brouwere, V.] Inst Rech Dev, Marseille, France; [De Brouwere, V.] Inst Natl Adm Sanitaire, Rabat, Morocco	Abouchadi, S (reprint author), Direct Hop & Soins Ambulatoires, Minist Hlth, 4 Rue Abou Fariss Al Marini,Ex Pl Pietri, Rabat, Morocco.	s.abouchadi@yahoo.fr					Barnett Sarah, 2008, BMC Pregnancy Childbirth, V8, P6, DOI 10.1186/1471-2393-8-6; Bradshaw D, 2012, SAJOG-S AFR J OBSTET, V18, P38; Campbell O., 1999, SAFE MOTHERHOOD INIT, P31; Commission on Information and Accountability for Women's and Children's Health, 2011, KEEP PROM MEAS RES; Countdown to 2015 Health metrics network UNICEF World Health Organization, 2011, MON MAT NEWB CHILD H; Danel I, 2011, B WORLD HEALTH ORGAN, V89, P779, DOI 10.2471/BLT.11.097220; Dellagi R. T., 2008, Eastern Mediterranean Health Journal, V14, P1380; Deneux-Tharaux C, 2005, OBSTET GYNECOL, V106, P684, DOI 10.1097/01.AOG.0000174580.24281.e6; Drife J, 2005, J ROY COLL PHYS EDIN, V35, P332; Egyptian Initiative for Personal Rights, 2010, MAT HLTH; Gilmore K, 2012, LANCET, V380, P87, DOI 10.1016/S0140-6736(12)60982-9; Gipson R, 2004, 132 ANN M NOV 6 10 A; Graham WJ, 2006, INT J GYNECOL OBSTET, V94, P234, DOI 10.1016/j.ijgo.2006.04.004; Graham WJ, 1996, HEALTH POLICY PLANN, V11, P16, DOI 10.1093/heapol/11.1.16; GRUBB GS, 1988, INT J EPIDEMIOL, V17, P385, DOI 10.1093/ije/17.2.385; Haut-Commisariat au Plan du Royaume du Maroc, 2011, ENQ NAT DEM PASS REP; Horon IL, 2005, AM J PUBLIC HEALTH, V95, P478, DOI 10.2105/AJPH.2004.040063; INSERM & InVS, 2006, RAPP COM NAT EXP MOR, P149; Lewis G, 2007, 7 CEMACH; Ministere de la Sante du Royaume du Maroc, 2008, PLAN ACT SANT 2008 2; Ministere de la Sante du Royaume du Maroc, 2012, ENQ NAT POP SANT FAM; Ministere de la Sante du Royaume du Maroc, 2010, PLAN NAT 2008 2012 A; Ministere de la Sante du Royaume du Maroc & Ligue des Etats arabes, 1997, ENQ NAT SANT MER ENF, P36; Ministere de la Sante du Royaume du Maroc ORC Macro & Projet PAPFAM, 2005, ENQ POP SANT FAM 200; National Committee for Confidential Enquiry into Maternal Deaths, 2008, 4 NAT COMM CONF ENQ; Ronsmans C, 1998, INT J EPIDEMIOL, V27, P660, DOI 10.1093/ije/27.4.660; Ronsmans C, 2001, SAFE MOTHERHOOD STRA, P207; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S01406736(06)69380-X; Roushdy N, 2007, MATERNAL MORTALITY S; Stanton C, 2000, STUD FAMILY PLANN, V31, P111, DOI 10.1111/j.1728-4465.2000.00111.x; WHO, 2010, TRENDS MAT MORT 1990; WHO, 2004, NUMB REV MAT DEATHS, P150; WHO UNICEF UNFPA & The World Bank, 2012, TRENDS MAT MORT 1990; World Health Organization, 2004, ICD 10 INT STAT CLAS	34	9	9	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2013	18	3					357	365		10.1111/tmi.12053				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	092FC	WOS:000315103700014	23289440				2019-03-26	
J	Briet, OJT; Penny, MA; Hardy, D; Awolola, TS; Van Bortel, W; Corbel, V; Dabire, RK; Etang, J; Koudou, BG; Tungu, PK; Chitnis, N				Briet, Olivier J. T.; Penny, Melissa A.; Hardy, Diggory; Awolola, Taiwo S.; Van Bortel, Wim; Corbel, Vincent; Dabire, Roch K.; Etang, Josiane; Koudou, Benjamin G.; Tungu, Patrick K.; Chitnis, Nakul			Effects of pyrethroid resistance on the cost effectiveness of a mass distribution of long-lasting insecticidal nets: a modelling study	MALARIA JOURNAL			English	Article						Pyrethroid; Insecticide; Resistance; LLIN; ITN; Modelling; Piperonyl butoxide	CULEX-QUINQUEFASCIATUS MOSQUITOS; ANOPHELES-GAMBIAE S.S.; EXPERIMENTAL HUT; PERMANET(R) 3.0; COMBINATION NET; SOUTHERN BENIN; TREATED NETS; COTE-DIVOIRE; MALARIA; EPIDEMIOLOGY	Background: The effectiveness of insecticide-treated nets in preventing malaria is threatened by developing resistance against pyrethroids. Little is known about how strongly this affects the effectiveness of vector control programmes. Methods: Data from experimental hut studies on the effects of long-lasting, insecticidal nets (LLINs) on nine anopheline mosquito populations, with varying levels of mortality in World Health Organization susceptibility tests, were used to parameterize malaria models. Both simple static models predicting population-level insecticidal effectiveness and protection against blood feeding, and complex dynamic epidemiological models, where LLINs decayed over time, were used. The epidemiological models, implemented in OpenMalaria, were employed to study the impact of a single mass distribution of LLINs on malaria, both in terms of episodes prevented during the effective lifetime of the batch of LLINs, and in terms of net health benefits (NHB) expressed in disability-adjusted life years (DALYs) averted during that period, depending on net type (standard pyrethroid-only LLIN or pyrethroid-piperonyl butoxide combination LLIN), resistance status, coverage and pre-intervention transmission level. Results: There were strong positive correlations between insecticide susceptibility status and predicted population level insecticidal effectiveness of and protection against blood feeding by LLIN intervention programmes. With the most resistant mosquito population, the LLIN mass distribution averted up to about 40% fewer episodes and DALYs during the effective lifetime of the batch than with fully susceptible populations. However, cost effectiveness of LLINs was more sensitive to the pre-intervention transmission level and coverage than to susceptibility status. For four out of the six Anopheles gambiae sensu lato populations where direct comparisons between standard LLINs and combination LLINs were possible, combination nets were more cost effective, despite being more expensive. With one resistant population, both net types were equally effective, and with one of the two susceptible populations, standard LLINs were more cost effective. Conclusion: Despite being less effective when compared to areas with susceptible mosquito populations, standard and combination LLINs are likely to (still) be cost effective against malaria even in areas with strong pyrethroid resistance. Combination nets are likely to be more cost effective than standard nets in areas with resistant mosquito populations.	[Briet, Olivier J. T.; Penny, Melissa A.; Hardy, Diggory; Chitnis, Nakul] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland; [Briet, Olivier J. T.; Penny, Melissa A.; Hardy, Diggory; Chitnis, Nakul] Univ Basel, Basel, Switzerland; [Awolola, Taiwo S.] Nigerian Inst Med Res, Mol Entomol & Vector Control Res Lab, Yaba Lagos, Nigeria; [Van Bortel, Wim] Inst Trop Med, Dept Parasitol Entomol, B-2000 Antwerp, Belgium; [Corbel, Vincent] Malad Infect & Vecteurs Ecol Genet Evolut & Contr, IRD, Montpellier 5, France; [Corbel, Vincent] Kasetsart Univ, Fac Agr, Dept Entomol, Bangkok 10900, Thailand; [Dabire, Roch K.] IRSS, Ctr Muraz, Bobo Dioulasso 01, Burkina Faso; [Etang, Josiane] OCEAC, Yaounde, Cameroon; [Etang, Josiane] Univ Douala, Fac Med & Pharmaceut Sci, Douala, Cameroon; [Koudou, Benjamin G.] Ctr Suisse Rech Sci, Dept Environm & Sante, Abidjan, Cote Ivoire; [Koudou, Benjamin G.] Univ Abobo Adjame, UFR Sci Nat, Abidjan, Cote Ivoire; [Koudou, Benjamin G.] Univ Liverpool, Liverpool Sch Trop Med, Ctr Neglected Trop Dis, Liverpool L3 5QA, Merseyside, England; [Tungu, Patrick K.] Natl Inst Med Res, Amani Med Res Ctr, Muheza, Tanzania	Briet, OJT (reprint author), Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland.	olivier.briet@unibas.ch	Penny, Melissa/N-6838-2015; Corbel, VIncent/G-9576-2016; Briet, Olivier/K-1917-2015; Chitnis, Nakul/B-3105-2013	Penny, Melissa/0000-0002-4972-593X; Briet, Olivier/0000-0003-1186-2688; Van Bortel, Wim/0000-0002-6644-518X	Vestergaard-Frandsen; Belgian Directorate-General for Development Cooperation and WHOPES	The experimental hut field studies testing P3 used to parameterize the model, and the modelling study itself, were funded by Vestergaard-Frandsen. The study in Zeneti [8] was conducted through the WHO Pesticide Evaluation Scheme (WHOPES). The study in Van Duc A [13] was supported by the Belgian Directorate-General for Development Cooperation and WHOPES, with Vestergaard-Frandsen providing the nets. Dr Kim, Dr Pates Jamet, Dr Knox and Dr Bwambok of Vestergaard Frandsen commented on the manuscript. The findings described in this manuscript are those of the authors and do not necessarily reflect views of Vestergaard Frandsen.	Adeogun AO, 2012, NIG J CLIN BIOMED RE, V6, P37; Briet OJT, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-256; Briet OJT, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-20; Chandre F, 1999, B WORLD HEALTH ORGAN, V77, P230; Chitnis N, 2012, B MATH BIOL, V74, P1098, DOI 10.1007/s11538-011-9710-0; Corbel V, 2007, ACTA TROP, V101, P207, DOI 10.1016/j.actatropica.2007.01.005; Corbel V, 2012, LANCET INFECT DIS, V12, P617, DOI 10.1016/S1473-3099(12)70081-6; Corbel V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-113; Djouaka RF, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-538; Erhart A, 2004, TROP MED INT HEALTH, V9, P1081, DOI 10.1111/j.1365-3156.2004.01310.x; Hawley WA, 2003, AM J TROP MED HYG, V68, P121, DOI 10.4269/ajtmh.2003.68.121; Irish SR, 2008, PARASITE VECTOR, V1, DOI 10.1186/1756-3305-1-17; Johansson EW, 2010, ROLL BACK MALARIA PR, V2; Killeen GF, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-160; Kitau J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031481; Koffi AA, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-68; Koudou BG, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-172; Lines J.D., 1985, WHOVBC85920; Moiroux N, 2012, J INFECT DIS, V206, P1622, DOI 10.1093/infdis/jis565; N'Guessan R, 2010, T ROY SOC TROP MED H, V104, P758, DOI 10.1016/j.trstmh.2010.08.008; Ranson H, 2011, TRENDS PARASITOL, V27, P91, DOI 10.1016/j.pt.2010.08.004; Smith T, 2008, PARASITOLOGY, V135, P1507, DOI 10.1017/S0031182008000371; Smith T, 2006, AM J TROP MED HYG, V75, P1; Smith T, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001157; Trape JF, 2011, LANCET INFECT DIS, V11, P925, DOI 10.1016/S1473-3099(11)70194-3; Tungu P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-21; Van Bortel W, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-248; WHO, 2011, WORLD MALARIA REPORT 2011, P1; World Health Organization, 2011, DELT LONG LAST COAT; World Health Organization, 2006, WHOCDSNTDWHOPESGCDPP	30	29	29	0	22	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	FEB 25	2013	12								77	10.1186/1475-2875-12-77				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	119AW	WOS:000317069900001	23442575	DOAJ Gold, Green Published			2019-03-26	
J	Bhattacharyya, T; Boelaert, M; Miles, MA				Bhattacharyya, Tapan; Boelaert, Marleen; Miles, Michael A.			Comparison of Visceral Leishmaniasis Diagnostic Antigens in African and Asian Leishmania donovani Reveals Extensive Diversity and Region-specific Polymorphisms	PLOS NEGLECTED TROPICAL DISEASES			English	Article							INDIAN SUBCONTINENT; SURFACE-PROTEINS; EXPRESSION; KINESIN; TESTS; IMMUNIZATION; POPULATIONS; CHAGASI; COMPLEX; CLONING	Background: Visceral leishmaniasis (VL), caused by infection with Leishmania donovani complex, remains a major public health problem in endemic regions of South Asia, East Africa, and Brazil. If untreated, symptomatic VL is usually fatal. Rapid field diagnosis relies principally on demonstration of anti-Leishmania antibodies in clinically suspect cases. The rK39 immunochromatographic rapid diagnostic test (RDT) is based on rK39, encoded by a fragment of a kinesin-related gene derived from a Brazilian L. chagasi, now recognised as L. infantum, originating from Europe. Despite its reliability in South Asia, the rK39 test is reported to have lower sensitivity in East Africa. A reason for this differential response may reside in the molecular diversity of the rK39 homologous sequences among East African L. donovani strains. Methodology/Principal Findings: Coding sequences of rK39 homologues from East African L. donovani strains were amplified from genomic DNA, analysed for diversity from the rK39 sequence, and compared to South Asian sequences. East African sequences were revealed to display significant diversity from rK39. Most coding changes in the 59 half of repeats were non-conservative, with multiple substitutions involving charge changes, whereas amino acid substitutions in the 39 half of repeats were conservative. Specific polymorphisms were found between South Asian and East African strains. Diversity of HASPB1 and HASPB2 gene repeat sequences, used to flank sequences of a kinesin homologue in the synthetic antigen rK28 designed to reduce variable RDT performance, was also investigated. Non-canonical combination repeat arrangements were revealed for HASPB1 and HASPB2 gene products in strains producing unpredicted size amplicons. Conclusions/Significance: We demonstrate that there is extensive kinesin genetic diversity among strains in East Africa and between East Africa and South Asia, with ample scope for influencing performance of rK39 diagnostic assays. We also show the importance of targeted comparative genomics in guiding optimisation of recombinant/synthetic diagnostic antigens.	[Bhattacharyya, Tapan; Miles, Michael A.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England; [Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Bhattacharyya, T (reprint author), Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Keppel St, London WC1E 7HT, England.	Tapan.Bhattacharyya@lshtm.ac.uk	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	European Commission under the Health Cooperation Work Programme of the 7th Framework Programme [260260]	This work is part of the NIDIAG network research partnership supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme (Grant agreement no. 260260, http://cordis.europa.eu/fp7/home_en.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam MZ, 2009, INFECT GENET EVOL, V9, P24, DOI 10.1016/j.meegid.2008.09.005; Alce TM, 1999, MOL BIOCHEM PARASIT, V102, P191, DOI 10.1016/S0166-6851(99)00074-2; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Bhatia A, 1999, MOL BIOCHEM PARASIT, V102, P249, DOI 10.1016/S0166-6851(99)00098-5; Boelaert M, 2008, T ROY SOC TROP MED H, V102, P32, DOI 10.1016/j.trstmh.2007.09.003; BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Costa MM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001622; Cunningham J, 2012, CLIN INFECT DIS, V55, P1312, DOI 10.1093/cid/cis716; Depledge DP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000829; Dey A, 2007, AM J TROP MED HYG, V77, P95, DOI 10.4269/ajtmh.2007.77.95; Downing T, 2011, GENOME RES, V21, P2143, DOI 10.1101/gr.123430.111; Gerald NJ, 2007, MOL MICROBIOL, V63, P962, DOI 10.1111/j.1365-2958.2006.05487.x; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008; Haralambous C, 2008, DIAGN MICR INFEC DIS, V60, P33, DOI 10.1016/j.diagmicrobio.2007.07.019; Kuhls K, 2007, MICROBES INFECT, V9, P334, DOI 10.1016/j.micinf.2006.12.009; Kuhls K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001155; Lukes J, 2007, P NATL ACAD SCI USA, V104, P9375, DOI 10.1073/pnas.0703678104; Maroof A, 2012, J INFECT DIS, V205, P853, DOI 10.1093/infdis/jir842; McKean PG, 1997, MOL BIOCHEM PARASIT, V86, P225, DOI 10.1016/S0166-6851(97)00035-2; Moreno J, 2007, VACCINE, V25, P5290, DOI 10.1016/j.vaccine.2007.05.010; Pattabhi S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000822; Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053; Sadlova J, 2010, CELL MICROBIOL, V12, P1765, DOI 10.1111/j.1462-5822.2010.01507.x; Sivakumar R, 2006, PROTEIN EXPRES PURIF, V46, P156, DOI 10.1016/j.pep.2005.07.027; Srivastava P, 2011, T ROY SOC TROP MED H, V105, P1, DOI 10.1016/j.trstmh.2010.09.006; Stager S, 2000, J IMMUNOL, V165, P7064, DOI 10.4049/jimmunol.165.12.7064; Takagi H, 2007, AM J TROP MED HYG, V76, P902, DOI 10.4269/ajtmh.2007.76.902; Vaish M, 2012, CLIN MICROBIOL INFEC, V18, P81, DOI 10.1111/j.1469-0691.2011.03540.x; WHO, 2010, WHO TECH REP SER, V949, P1; WHO \ ATLAS, 2010, 1 WHO	31	25	25	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	FEB	2013	7	2							e2057	10.1371/journal.pntd.0002057				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	099TM	WOS:000315644900022	23469296	DOAJ Gold, Green Published			2019-03-26	
J	Hasker, E; Kansal, S; Malaviya, P; Gidwani, K; Picado, A; Singh, RP; Chourasia, A; Singh, AK; Shankar, R; Menten, J; Wilson, ME; Boelaert, M; Sundar, S				Hasker, Epco; Kansal, Sangeeta; Malaviya, Paritosh; Gidwani, Kamlesh; Picado, Albert; Singh, Rudra Pratap; Chourasia, Ankita; Singh, Abhishek Kumar; Shankar, Ravi; Menten, Joris; Wilson, Mary Elizabeth; Boelaert, Marleen; Sundar, Shyam			Latent Infection with Leishmania donovani in Highly Endemic Villages in Bihar, India	PLOS NEGLECTED TROPICAL DISEASES			English	Article							DIRECT AGGLUTINATION-TEST; CLUSTER RANDOMIZED-TRIAL; HIGH-TRANSMISSION FOCI; VISCERAL LEISHMANIASIS; KALA-AZAR; EPIDEMIOLOGY; NEPAL; AGREEMENT; ETHIOPIA; CHAGASI	Introduction: Asymptomatic persons infected with the parasites causing visceral leishmaniasis (VL) usually outnumber clinically apparent cases by a ratio of 4-10 to 1. We describe patterns of markers of Leishmania donovani infection and clinical VL in relation to age in Bihar, India. Methods: We selected eleven villages highly endemic for Leishmania donovani. During a 1-year interval we conducted two house to house surveys during which we collected blood samples on filter paper from all consenting individuals aged 2 years and above. Samples were tested for anti-leishmania serology by Direct Agglutination Test (DAT) and rK39 ELISA. Data collected during the surveys included information on episodes of clinical VL among study participants. Results: We enrolled 13,163 persons; 6.2% were reactive to DAT and 5.9% to rK39. Agreement between the tests was weak (kappa = 0.30). Among those who were negative on both tests at baseline, 3.6% had converted to sero-positive on either of the two tests one year later. Proportions of sero-positives and sero-converters increased steadily with age. Clinical VL occurred mainly among children and young adults (median age 19 years). Discussion: Although infection with L. donovani is assumed to be permanent, serological markers revert to negative. Most VL cases occur at younger ages, yet we observed a steady increase with age in the frequency of sero-positivity and sero-conversion. Our findings can be explained by a boosting effect upon repeated exposure to the parasite or by intermittent release of parasites in infected subjects from safe target cells. A certain proportion of sero-negative subjects could have been infected but below the threshold of antibody abundance for our serologic testing.	[Hasker, Epco; Picado, Albert; Menten, Joris; Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Kansal, Sangeeta; Malaviya, Paritosh; Gidwani, Kamlesh; Singh, Rudra Pratap; Chourasia, Ankita; Singh, Abhishek Kumar; Shankar, Ravi; Sundar, Shyam] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Picado, Albert] Univ Barcelona, Hosp Clin, CRESIB, Barcelona Ctr Int Hlth Res, Barcelona, Spain; [Wilson, Mary Elizabeth] Univ Iowa, Iowa City, IA USA; [Wilson, Mary Elizabeth] Vet Affairs Med Ctr, Iowa City, IA 52242 USA	Hasker, E (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	ehasker@itg.be	Malaviya, Paritosh/B-1819-2012; Boelaert, Marleen/E-2698-2012	Malaviya, Paritosh/0000-0002-7558-152X; Boelaert, Marleen/0000-0001-8051-6776; Picado, Albert/0000-0001-7344-628X	NIAID, NIH TMRC Grant [1P50AI074321]; US NIH [R01 AI076233]; Department of Veterans' Affairs	This work was supported by NIAID, NIH TMRC Grant No. 1P50AI074321; R01 AI076233 from the US NIH; and a Merit Review and an OEF-OIF RFA grant from the Department of Veterans' Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvar J, 2006, TRENDS PARASITOL, V22, P552, DOI 10.1016/j.pt.2006.09.004; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; Bern C, 2007, AM J TROP MED HYG, V76, P909; Bhattarai NR, 2010, EMERG INFECT DIS, V16, P231, DOI 10.3201/eid1602.090623; Bhattarai NR, 2009, TROP MED INT HEALTH, V14, P404, DOI 10.1111/j.1365-3156.2009.02242.x; Biglino A, 2010, J CLIN MICROBIOL, V48, P131, DOI 10.1128/JCM.00416-09; Bimal S, 2005, ANN TROP MED PARASIT, V99, P743, DOI 10.1179/136485905X65107; Bogdan C, 2008, CELL MICROBIOL, V10, P1221, DOI 10.1111/j.1462-5822.2008.01146.x; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Costa CHN, 2000, J INFECT DIS, V182, P997, DOI 10.1086/315795; Costa CHN, 2002, AM J TROP MED HYG, V66, P334, DOI 10.4269/ajtmh.2002.66.334; Cunningham J, 2012, CLIN INFECT DIS, V55, P1312, DOI 10.1093/cid/cis716; Custodio E, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001813; Davies CR, 1999, PARASITOLOGY, V119, P247, DOI 10.1017/S0031182099004680; Elnaiem DA, 2001, PARASITOLOGY, V122, P531, DOI 10.1017/S0031182001007594; EVANS TG, 1992, J INFECT DIS, V166, P1124, DOI 10.1093/infdis/166.5.1124; Gadisa E, 2012, AM J TROP MED HYG, V86, P792, DOI 10.4269/ajtmh.2012.11-0196; Gavgani ASM, 2002, LANCET, V360, P374, DOI 10.1016/S0140-6736(02)09609-5; Gidwani K, 2009, AM J TROP MED HYG, V80, P345, DOI 10.4269/ajtmh.2009.80.345; Hailu A, 2009, ANN TROP MED PARASIT, V103, P659, DOI 10.1179/000349809X12554106963555; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; Hasker E, 2012, EMERG INFECT DIS, V18, P1662, DOI 10.3201/eid1810.111083; Joshi A. B., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P583; Khanal B, 2010, TROP MED INT HEALTH, V15, P1390, DOI 10.1111/j.1365-3156.2010.02631.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953; Malaviya P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014751; MANSON-BAHR P. E. C., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P380, DOI 10.1016/0035-9203(59)90038-0; Michel G, 2011, ACTA TROP, V119, P69, DOI 10.1016/j.actatropica.2011.05.012; MIRKOVICH AM, 1986, CLIN EXP IMMUNOL, V64, P1; Ostyn B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001284; PAMPIGLIONE S, 1974, T ROY SOC TROP MED H, V68, P349, DOI 10.1016/0035-9203(74)90148-5; Picado A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6760; Ranjan A, 2005, AM J TROP MED HYG, V73, P74, DOI 10.4269/ajtmh.2005.73.74; Rijal S, 2010, TROP MED INT HEALTH, V15, P21, DOI 10.1111/j.1365-3156.2010.02518.x; Saha S, 2009, T ROY SOC TROP MED H, V103, P737, DOI 10.1016/j.trstmh.2008.10.006; SCHAEFER KU, 1995, T ROY SOC TROP MED H, V89, P471, DOI 10.1016/0035-9203(95)90070-5; Singh SP, 2010, TROP MED INT HEALTH, V15, P12, DOI 10.1111/j.1365-3156.2010.02519.x; Stauch A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001405; WHO, 2010, WHO TECH REP SER, V949, P1; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	41	26	26	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	FEB	2013	7	2							e2053	10.1371/journal.pntd.0002053				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	099TM	WOS:000315644900018	23459501	DOAJ Gold, Green Published			2019-03-26	
J	Tiberti, N; Lejon, V; Hainard, A; Courtioux, B; Robin, X; Turck, N; Kristensson, K; Matovu, E; Enyaru, JC; Ngoyi, DM; Krishna, S; Bisser, S; Ndung'u, JM; Buscher, P; Sanchez, JC				Tiberti, Natalia; Lejon, Veerle; Hainard, Alexandre; Courtioux, Bertrand; Robin, Xavier; Turck, Natacha; Kristensson, Krister; Matovu, Enock; Enyaru, John Charles; Ngoyi, Dieudonne Mumba; Krishna, Sanjeev; Bisser, Sylvie; Ndung'u, Joseph Mathu; Buscher, Philippe; Sanchez, Jean-Charles			Neopterin Is a Cerebrospinal Fluid Marker for Treatment Outcome Evaluation in Patients Affected by Trypanosoma brucei gambiense Sleeping Sickness	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HUMAN AFRICAN TRYPANOSOMIASIS; NERVOUS-SYSTEM INVOLVEMENT; POSTTREATMENT FOLLOW-UP; DIAGNOSTIC-TESTS; STAGE; IMMUNOGLOBULINS; CONGO	Background: Post-therapeutic follow-up is essential to confirm cure and to detect early treatment failures in patients affected by sleeping sickness (HAT). Current methods, based on finding of parasites in blood and cerebrospinal fluid (CSF) and counting of white blood cells (WBC) in CSF, are imperfect. New markers for treatment outcome evaluation are needed. We hypothesized that alternative CSF markers, able to diagnose the meningo-encephalitic stage of the disease, could also be useful for the evaluation of treatment outcome. Methodology/Principal findings: Cerebrospinal fluid from patients affected by Trypanosoma brucei gambiense HAT and followed for two years after treatment was investigated. The population comprised stage 2 (S2) patients either cured or experiencing treatment failure during the follow-up. IgM, neopterin, B2MG, MMP-9, ICAM-1, VCAM-1, CXCL10 and CXCL13 were first screened on a small number of HAT patients (n = 97). Neopterin and CXCL13 showed the highest accuracy in discriminating between S2 cured and S2 relapsed patients (AUC 99% and 94%, respectively). When verified on a larger cohort (n = 242), neopterin resulted to be the most efficient predictor of outcome. High levels of this molecule before treatment were already associated with an increased risk of treatment failure. At six months after treatment, neopterin discriminated between cured and relapsed S2 patients with 87% specificity and 92% sensitivity, showing a higher accuracy than white blood cell numbers. Conclusions/Significance: In the present study, neopterin was highlighted as a useful marker for the evaluation of the post-therapeutic outcome in patients suffering from sleeping sickness. Detectable levels of this marker in the CSF have the potential to shorten the follow-up for HAT patients to six months after the end of the treatment.	[Tiberti, Natalia; Hainard, Alexandre; Robin, Xavier; Turck, Natacha; Sanchez, Jean-Charles] Univ Geneva, Translat Biomarker Grp, Dept Human Prot Sci, Geneva, Switzerland; [Lejon, Veerle; Buscher, Philippe] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Courtioux, Bertrand; Bisser, Sylvie] INSERM, Trop Neuroepidemiol UMR1094, Limoges, France; [Courtioux, Bertrand; Bisser, Sylvie] Univ Limoges, Inst Neuroepidemiol & Trop Neurol, Sch Med, CNRS FR GEIST 3503, Limoges, France; [Kristensson, Krister] Karolinska Inst, Dept Neurosci, Stockholm, Sweden; [Matovu, Enock] Makerere Univ, Dept Vet Parasitol & Microbiol, Sch Vet Med, Kampala, Uganda; [Enyaru, John Charles] Makerere Univ, Dept Biochem, Coll Nat Sci, Kampala, Uganda; [Ngoyi, Dieudonne Mumba] Inst Natl Rech Biomed, Dept Parasitol, Kinshasa, Zaire; [Krishna, Sanjeev] Univ London, Div Cellular & Mol Med, Ctr Infect, London, England; [Ndung'u, Joseph Mathu] FIND, Geneva, Switzerland	Tiberti, N (reprint author), Univ Geneva, Translat Biomarker Grp, Dept Human Prot Sci, Geneva, Switzerland.	Jean-Charles.Sanchez@unige.ch	Buscher, Philippe/B-9956-2012; Robin, Xavier/A-1680-2009; Tiberti, Natalia/I-7928-2018	Buscher, Philippe/0000-0002-1926-7472; Robin, Xavier/0000-0002-6813-3200; Tiberti, Natalia/0000-0002-2981-5233; Lejon, Veerle/0000-0002-6795-0962; Matovu, Enock/0000-0003-0714-7032; Krishna, Sanjeev/0000-0003-0066-0634	Foundation for Innovative New Diagnostics (FIND); UBS Optimus Foundation; Belgian Directorate General for International Cooperation	This work was supported by the Foundation for Innovative New Diagnostics (FIND) (http://www.finddiagnostics.org/) with funding from UBS Optimus Foundation (www.ubs.com/optimus/). D. Mumba Ngoyi received financial support from the Belgian Directorate General for International Cooperation. The Foundation for Innovative New Diagnostics (FIND) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin DN, 2009, J INFECT DIS, V200, P1556, DOI 10.1086/644597; Amin DN, 2010, AM J TROP MED HYG, V82, P983, DOI 10.4269/ajtmh.2010.09-0770; [Anonymous], 2007, WHOCDSNTDIDM20071; Berdowska A, 2001, J CLIN PHARM THER, V26, P319, DOI 10.1046/j.1365-2710.2001.00358.x; Bisser S, 2002, J NEUROL SCI, V193, P127, DOI 10.1016/S0022-510X(01)00655-4; Courtioux B, 2009, TROP MED INT HEALTH, V14, P529, DOI 10.1111/j.1365-3156.2009.02263.x; Deborggraeve S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000972; Deeks JJ, 2004, BRIT MED J, V329, P168, DOI 10.1136/bmj.329.7458.168; Hagberg L, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-15; Hainard A, 2011, TROP MED INT HEALTH, V16, P119, DOI 10.1111/j.1365-3156.2010.02642.x; Hainard A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000459; Hoffmann G, 2003, INFLAMM RES, V52, P313, DOI 10.1007/s00011-003-1181-9; Kennedy PGE, 2008, ANN NEUROL, V64, P116, DOI 10.1002/ana.21429; Kennedy PGE, 2008, T ROY SOC TROP MED H, V102, P306, DOI 10.1016/j.trstmh.2007.11.011; Kristensson K, 2010, PROG NEUROBIOL, V91, P152, DOI 10.1016/j.pneurobio.2009.12.001; Lejon V, 2005, TROP MED INT HEALTH, V10, P395, DOI 10.1111/j.1365-3156.2005.01403.x; Lejon V, 2003, J INFECT DIS, V187, P1475, DOI 10.1086/374645; Lejon V, 2008, CLIN INFECT DIS, V47, P15, DOI 10.1086/588668; Malvy D, 2011, CLIN MICROBIOL INFEC, V17, P986, DOI 10.1111/j.1469-0691.2011.03536.x; Miezan TW, 2000, T ROY SOC TROP MED H, V94, P293, DOI 10.1016/S0035-9203(00)90327-4; Ngotho M, 2009, TROP MED INT HEALTH, V14, P736, DOI 10.1111/j.1365-3156.2009.02285.x; Ngoyi DM, 2009, TROP MED INT HEALTH, V14, P438, DOI 10.1111/j.1365-3156.2009.02248.x; Ngoyi DM, 2010, J INFECT DIS, V201, P453, DOI 10.1086/649917; Peeling RW, 2006, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro1569; Priotto G, 2007, CLIN INFECT DIS, V45, P1435, DOI 10.1086/522982; Priotto G, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001662; Robays J, 2008, EMERG INFECT DIS, V14, P966, DOI 10.3201/eid1406.071266; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Simarro PP, 2012, PARASITOLOGY, V139, P842, DOI 10.1017/S0031182012000169; Simarro PP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001007; Tiberti N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040909; Tiberti N, 2010, MOL CELL PROTEOMICS, V9, P2783, DOI 10.1074/mcp.M110.001008; Truc P, 1999, B WORLD HEALTH ORGAN, V77, P745; *WHO, 1998, WHO TECH REP SER, V881, pR1	34	10	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	FEB	2013	7	2							e2088	10.1371/journal.pntd.0002088				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	099TM	WOS:000315644900048	23469311	DOAJ Gold, Green Published			2019-03-26	
J	Uranw, S; Meheus, F; Baltussen, R; Rijal, S; Boelaert, M				Uranw, Surendra; Meheus, Filip; Baltussen, Rob; Rijal, Suman; Boelaert, Marleen			The Household Costs of Visceral Leishmaniasis Care in South-eastern Nepal	PLOS NEGLECTED TROPICAL DISEASES			English	Article							INDIA; BIHAR; ELIMINATION; BANGLADESH; POVERTY	Background and objectives: Visceral leishmaniasis (VL) is an important public health problem in south-eastern Nepal affecting very poor rural communities. Since 2005, Nepal is involved in a regional initiative to eliminate VL. This study assessed the economic impact of VL on households and examined whether the intensified VL control efforts induced by the government resulted in a decrease in household costs. Methods: Between August and September 2010, a household survey was conducted among 168 patients that had been treated for VL within 12 months prior to the survey in five districts in south-eastern Nepal. We collected data on health-seeking behaviour, direct and indirect costs and coping strategies. Results: The median total cost of one episode of VL was US$ 165 or 11% of annual household income. The median delay between the onset of symptoms and presentation to a qualified provider was 25 days. Once the patient presented to a qualified provider, the delay to correct diagnosis was minimal (median 3 days). Direct and indirect costs (income losses) represented 47% and 53% of total costs respectively. Households used multiple strategies to cope with the cost of illness, mainly mobilizing cash/savings (71%) or taking a loan (56%). Conclusions: The provision of free VL diagnosis and drugs by the Nepalese control programme has been an important policy measure to reduce the cost of VL to households. But despite the free VL drugs, the economic burden is still important for households. More effort should be put into reducing indirect costs, in particular the length of treatment, and preventing the transmission of VL through vector control.	[Uranw, Surendra; Rijal, Suman] BP Koirala Inst Hlth Sci, Dept Internal Med, Ghopa, Dharan, Nepal; [Uranw, Surendra; Meheus, Filip; Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Baltussen, Rob] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands	Uranw, S (reprint author), BP Koirala Inst Hlth Sci, Dept Internal Med, Ghopa, Dharan, Nepal.	fmeheus@itg.be	Baltussen, R.M.P.M./L-4181-2015; Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	European Union funded Visceral Leishmaniasis Control Project, Belgium [93040, FP6/INCO-DEV]; ITM VL Fund; ITM SOFI-A; Flemish Government; Radboud University Nijmegen Medical Centre	The study was supported by the European Union funded Visceral Leishmaniasis Control Project (Proposal Contract number 93040; FP6/INCO-DEV), Belgium. During the time of the study, F. Meheus was supported by the ITM VL Fund and the ITM SOFI-A programme funded by the Flemish Government. R. Baltussen is supported through core funding by Radboud University Nijmegen Medical Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhikari SR, 2009, HEALTH POLICY PLANN, V24, P129, DOI 10.1093/heapol/czn052; Adhikari SR, 2005, INDIAN J COMMUNITY M, V30, P121; Adhikari SR, 2011, REV DEMAND SIDE FINA, P1; Alvar J, 2006, TRENDS PARASITOL, V22, P552, DOI 10.1016/j.pt.2006.09.004; Boelaert M, 2009, TROP MED INT HEALTH, V14, P639, DOI 10.1111/j.1365-3156.2009.02279.x; Chowdhury R, 2011, ANN TROP MED PARASIT, V105, P31, DOI 10.1179/136485911X12899838683124; Chowdhury R, 2011, AM J TROP MED HYG, V84, P662, DOI 10.4269/ajtmh.2011.10-0682; Epidemiology and Diseases Control Division, 2010, KAL AZ ANN REP NEP, P97; Joshi Durga Datt, 2006, J Commun Dis, V38, P139; Meheus F, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000818; MILLS A, 1993, TROP MED PARASITOL, V44, P9; Mondal D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000355; O'Donnell O, 2008, ANAL HLTH EQUITY USI; Olliaro P, 2009, TROP MED INT HEALTH, V14, P88, DOI 10.1111/j.1365-3156.2008.02195.x; Ranson MK, 2002, B WORLD HEALTH ORGAN, V80, P613; Rijal S, 2006, T ROY SOC TROP MED H, V100, P838, DOI 10.1016/j.trstmh.2005.09.017; Rijal S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2; Singh SP, 2006, TROP MED INT HEALTH, V11, P899, DOI 10.1111/j.1365-3156.2006.01647.x; Singh SP, 2010, TROP MED INT HEALTH, V15, P29, DOI 10.1111/j.1365-3156.2010.02515.x; Singh VP, 2010, AM J TROP MED HYG, V82, P9, DOI 10.4269/ajtmh.2010.09-0235; WHO, 2005, REG STRAT FRAM EL KA; World Bank, 2012, WORLD DEV IND; World Health Organization, 2007, HLTH SYST NEP CHALL	23	16	16	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	FEB	2013	7	2							e2062	10.1371/journal.pntd.0002062				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	099TM	WOS:000315644900026	23469298	DOAJ Gold, Green Published			2019-03-26	
J	Apt, W; Zulantay, I; Arnello, M; Oddo, D; Gonzalez, S; Rodriguez, J; Kemmerling, U; Truyens, C; Carlier, Y				Apt, Werner; Zulantay, Ines; Arnello, Marcela; Oddo, David; Gonzalez, Sandra; Rodriguez, Jorge; Kemmerling, Ulrike; Truyens, Carine; Carlier, Yves			Congenital infection by Trypanosoma cruzi in an endemic area of Chile: a multidisciplinary study	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Congenital Chagas disease; Newborn; Maternal infection; Trypanosoma cruzi	POLYMERASE-CHAIN-REACTION; CHAGAS-DISEASE; PREGNANT-WOMEN; TRANSMISSION; DIAGNOSIS; NEWBORNS; BOLIVIA	Background: This study investigated the prevalence of Chagas disease (ChD) in pregnant women in Choapa Province (IV Region, Chile) and the vertical transmission of Trypanosoma cruzi. Method: ELISA and IFI IgG for ChD was performed for the pregnant women. PCR for T. cruzi was done for all chagasic mothers and their newborns. The congenital infection was confirmed by serial positive PCR and/or ELISA or IFI IgG after age of nine months. The placentas of mothers, with and without ChD, were submitted for histopathology and immunohistochemical study. Results: From 4831 deliveries in 2005 - 2009 with a serological coverage of 88.6%, it was established that 147 cases (3.4%) had ChD. More than 80% of the pregnancies had a physiological evolution and 90% of the newborn were term. Congenital transmission was demonstrated in six children (4.7%) of the 127 newborn studied by serial PCR (at birth and/or between 3 - 18 months) and/or ELISA or IIF IgG after age nine months. Most of congenital cases were asymptomatic (67%). The histopathology shows edema, necrosis, fibrinoid deposit in the placentas of 28 of 29 chagasic mothers. In three cases the immnunochemistry demonstrated a decrease in actin expression in trophoblast cells. In one congenital case amastigote nests was observed. Conclusions: These results indicate that T. cruzi infection in pregnant women and vertical transmission in Chile are still prevalent. For this reason it is important to propose control measures in endemic areas of the country.	[Apt, Werner; Zulantay, Ines; Arnello, Marcela; Gonzalez, Sandra] Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol,Lab Parasitol Basicoc, Santiago 1027, Chile; [Oddo, David] Inst Nacl Canc, Santiago, Chile; [Rodriguez, Jorge] Univ Chile, Fac Med, Escuela Salud Publ, Santiago 1027, Chile; [Kemmerling, Ulrike] Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Anat & Biol Desarrollo, Santiago 1027, Chile; [Truyens, Carine; Carlier, Yves] Free Univ Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium	Apt, W (reprint author), POB 427,Santiago 3, Santiago, Chile.	wapt@med.uchile.cl	Kemmerling, Ulrike/H-8783-2013	Kemmerling, Ulrike/0000-0002-0201-1665; Oddo, David/0000-0002-3974-7393	FONDECYT [1080445, 1100768, 1120382, 1120230]; Project 5.1 "Chagas congenital", Wallonie-Bruxelles International (WBI), Cooperation Bilaterale [ULB-University of Chile]; Project 6 "Chagas congenital", Wallonie-Bruxelles International (WBI), Cooperation Bilaterale [ULB-University of Chile]	This study was funded by FONDECYT Projects 1080445, 1100768, 1120382 and 1120230, Projects 5.1 and 6 "Chagas congenital", Wallonie-Bruxelles International (WBI), Cooperation Bilaterale [ULB-University of Chile 2003-2009].	Apt W, 2010, DRUG DES DEV THER, V4, P243, DOI 10.2147/DDDT.S8338; Apt W, 2010, BIOL RES, V43, P269, DOI [/S0716-97602010000300002, 10.4067/S0716-97602010000300002]; Briceno-Leon R, 2009, CAD SAUDE PUBLICA, V25, pS71, DOI 10.1590/S0102-311X2009001300007; Burgos JM, 2009, DIAGN MICR INFEC DIS, V65, P58, DOI 10.1016/j.diagmicrobio.2009.04.010; Carlier Y, 2012, ACTA TROP, V121, P55, DOI 10.1016/j.actatropica.2011.10.018; Carlier Y, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001250; Coura JR, 2009, MEM I OSWALDO CRUZ, V104, P31, DOI 10.1590/S0074-02762009000900006; de Andrade AQ, 2008, REV SOC BRAS MED TRO, V41, P615, DOI 10.1590/S0037-86822008000600012; Freilij H, 2004, PAHO CONSULTATION CO; Garcia A, 2001, REV MED CHILE, V129, P330; Klein JO, 2006, INFECT DIS FETUS NEW, P13; Luquetti AO, 2005, REV SOC BRAS MED TRO, V38, P27; Ministry of Health, 2011, CLIN GUID GUID DIAGN; Ministry of Health, 2005, DIAGN SIT HLTH; OPS/MSF, 2005, ORG STRUCT HLTH CAR; Organizacion Panamericana de la Salud, 2006, QUANT EST CHAG DIS A; Dias JCP, 2009, MEM I OSWALDO CRUZ, V104, P41, DOI 10.1590/S0074-02762009000900007; Russomando G, 2005, REV SOC BRAS MED TRO, V38, P49; Sanchez NO, 2005, PEDIATRICS, V115, P668; Sartori MJ, 2003, PLACENTA, V24, P767, DOI 10.1016/S0143-4004(03)00111-5; Schenone H, 1989, B CHILE PARASIT, V1, P84; Schijman AG, 2003, J ANTIMICROB CHEMOTH, V52, P441, DOI 10.1093/jac/dkg338; Sosa-Estani S, 2008, AM J TROP MED HYG, V79, P755, DOI 10.4269/ajtmh.2008.79.755; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Veas F., 1994, ACTA TROP, V48, P79; WHO, 2000, TDR NEWS, V61, P10; Yadon ZE, 2009, AM J TROP MED HYG, V81, P927, DOI 10.4269/ajtmh.2009.09-0257; Zulantay I, 2004, DIAGN MICR INFEC DIS, V48, P253, DOI 10.1016/j.diagmicrobio.2003.10.011; Zulantay I, 2011, ANN TROP MED PARASIT, V105, P123, DOI 10.1179/136485911X12899838413583	29	8	12	1	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	FEB	2013	107	2					98	104		10.1093/trstmh/trs013				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	095EX	WOS:000315318600005	23222947				2019-03-26	
J	Ponce, MC; Incani, RN; Pinelli, E; ten Kulve, N; Ramak, R; Polman, K; Doak, CM				Ponce, Maiza Campos; Incani, Renzo Nino; Pinelli, Elena; ten Kulve, Nikki; Ramak, Robbert; Polman, Katja; Doak, Colleen Marie			Are intestinal parasites fuelling the rise in dual burden households in Venezuela?	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Giardia lamblia; Geohelminths; Dual burden; Overweight/obesity; Stunting; Venezuela	DEVELOPING-COUNTRIES; NUTRITION TRANSITION; TROPICAL SLUM; SAO-PAULO; CHILDREN; OBESITY; BRAZIL; UNDERNUTRITION; UNDERWEIGHT; POPULATION	Background: In developing countries undergoing rapid economic development, the number of dual burden households (i.e. co-existing overweight/obesity and stunting) is increasing. While intestinal parasites are prevalent in these countries, their contribution to dual burden households has so far been neglected. We studied the association between intestinal parasite infection and belonging to a dual burden household in a rural community of Venezuela. Methods: We examined 225 individuals. A dual burden household was defined as a household with at least one overweight/obese adult (BMI > 25) and at least one stunted child (height -for-age z score <-2). Intestinal parasite (Giardia lamblia and geohelminth) infection was determined by faecal smears. Results: In this community, 47.3% of the individuals were infected with intestinal parasites. Among adults, 65.2% were overweight/obese and 13.8% of the children were stunted. More than one in four households (26.8%) were dual burden households. Being infected with G. lamblia & geohelminths was significantly associated with being in a dual burden household (OR = 4.75, 95% CI: 1.01-22.20, n = 188), indicating a triple burden of disease in this community in Venezuela. Conclusion: While the relationship between intestinal parasite infection and stunting has been well established, these results indicate a need to further explore the association of intestinal parasite infection with dual burden households.	[Ponce, Maiza Campos; ten Kulve, Nikki; Ramak, Robbert; Polman, Katja; Doak, Colleen Marie] Vrije Univ Amsterdam, Dept Hlth Sci, NL-1081 HV Amsterdam, Netherlands; [Incani, Renzo Nino] Univ Carabobo, Fac Hlth Sci, Dept Parasitol, Valencia, Venezuela; [Pinelli, Elena] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control Netherlands, Amsterdam, Netherlands; [Polman, Katja] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium	Ponce, MC (reprint author), Vrije Univ Amsterdam, Dept Hlth Sci, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	m.camposponce@vu.nl		Campos Ponce, Maiza/0000-0003-1700-4756	Universidad de Carabobo-LOCTI Project [1.235]	Universidad de Carabobo-LOCTI Project no. 1.235.	Ash LR, 1997, ATLAS HUMAN PARASITO, P4; Boeke CE, 2010, J TROP PEDIATRICS, V56, P299, DOI 10.1093/tropej/fmp136; Caballero B, 2005, NEW ENGL J MED, V352, P1514, DOI 10.1056/NEJMp048310; Carvalho-Costa Filipe Anibal, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P147, DOI 10.1590/S0036-46652007000300003; Castejon HV, 2004, NUTR NEUROSCI, V7, P113, DOI 10.1080/10284150410001704534; de Onis M, 2010, INT J PEDIATR OBES, V5, P458, DOI 10.3109/17477161003615583; Doak CM, 2005, INT J OBESITY, V29, P129, DOI 10.1038/sj.ijo.0802824; Doak CM, 2000, J NUTR, V130, P2965; Ford ES, 2008, J CLIN ENDOCR METAB, V93, pS1, DOI 10.1210/jc.2008-1356; Garrett James L., 2005, Food and Nutrition Bulletin, V26, P209; Hagel I, 1999, J TROP PEDIATRICS, V45, P215, DOI 10.1093/tropej/45.4.215; Hoffman DJ, 2007, NUTRITION, V23, P640, DOI 10.1016/j.nut.2007.06.006; Hotez P, 2008, ANN NY ACAD SCI, V1136, P38, DOI 10.1196/annals.1425.000; Koski KG, 2001, ANNU REV NUTR, V21, P297, DOI 10.1146/annurev.nutr.21.1.297; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; Lee J, 2010, ECON HUM BIOL, V8, P188, DOI 10.1016/j.ehb.2010.05.014; Lohmann T. G., 1988, ANTHROPOMETRIC STAND; LYNCH NR, 1993, PARASITOL RES, V79, P547, DOI 10.1007/BF00932238; Martins PA, 2004, BRIT J NUTR, V92, P819, DOI 10.1079/BJN20041274; Mendez-Castellano HM, 1994, SOC ESTRATIFICACION, P7; Miller SA, 2003, TROP MED INT HEALTH, V8, P342, DOI 10.1046/j.1365-3156.2003.01011.x; Monteiro CA, 2004, B WORLD HEALTH ORGAN, V82, P940; Monteiro CA, 2002, PUBLIC HEALTH NUTR, V5, P105, DOI 10.1079/PHN2001281; Petrou S, 2010, SOC SCI MED, V71, P1366, DOI 10.1016/j.socscimed.2010.06.038; Popkin BM, 2004, NUTR REV, V62, pS140, DOI 10.1301/nr.2004.jul.S140-S143; Sawaya AL, 1998, J NUTR, V128, p415S, DOI 10.1093/jn/128.2.415S; Sawaya AL, 2009, NESTLE NUTR WORKSHOP, V63, P259; Sawaya AL, 2009, NESTLE NUTR WORKSHOP, V63, P105; Sawaya AL, 2009, NESTLE NUTR WORKS SE, V63, P95, DOI 10.1159/000209975; The World Bank, DAT VEN RB; Uauy R, 2001, J NUTR, V131, p893S; WHO, GLOB DAT BOD MASS IN	32	4	4	1	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	FEB	2013	107	2					119	123		10.1093/trstmh/trs014				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	095EX	WOS:000315318600008	23222948				2019-03-26	
J	Lindsay, TC; Jawara, M; D'Alessandro, U; Pinder, M; Lindsay, SW				Lindsay, T. C.; Jawara, M.; D'Alessandro, U.; Pinder, M.; Lindsay, S. W.			Preliminary studies developing methods for the control of Chrysomya putoria, the African latrine fly, in pit latrines in The Gambia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Chrysomya putoria; African latrine fly; sanitation; fly control; pit latrines; diarrhoeal diseases	POLYSTYRENE BEADS; LARVAL HABITATS; MALARIA VECTORS; PYRIPROXYFEN; DIPTERA; MUSCIDAE	Objective To explore ways of controlling Chrysomya putoria, the African latrine fly, in pit latrines. As pit latrines are a major source of these flies, eliminating these important breeding sites is likely to reduce village fly populations, and may reduce the spread of diarrhoeal pathogens. Methods We treated 24 latrines in a Gambian village: six each with (i) pyriproxyfen, an insect juvenile hormone mimic formulated as Sumilarv (R) 0.5G, a 0.5% pyriproxyfen granule, (ii) expanded polystyrene beads (EPB), (iii) local soap or (iv) no treatment as controls. Flies were collected using exit traps placed over the drop holes, weekly for five weeks. In a separate study, we tested whether latrines also function as efficient flytraps using the faecal odours as attractants. We constructed six pit latrines each with a built-in flytrap and tested their catching efficiency compared to six fish-baited box traps positioned 10 m from the latrine. Focus group discussions conducted afterwards assessed the acceptability of the flytrap latrines. Results Numbers of emerging C. putoria were reduced by 96.0% (95% CIs: 94.597.2%) 45 weeks after treatment with pyriproxyfen; by 64.2% (95% CIs: 51.873.5%) after treatment with local soap; by 41.3% (95% CIs = 24.054.7%) after treatment with EPB 35 weeks after treatment. Flytraps placed on latrines collected C. putoria and were deemed acceptable to local communities. Conclusions Sumilarv 0.5G shows promise as a chemical control agent, whilst odour-baited latrine traps may prove a useful method of non-chemical fly control. Both methods warrant further development to reduce fly production from pit latrines. A combination of interventions may prove effective for the control of latrine flies and the diseases they transmit.	[Lindsay, T. C.; Pinder, M.; Lindsay, S. W.] London Sch Hyg & Trop Med, London WC1, England; [Jawara, M.; D'Alessandro, U.; Pinder, M.] MRC Unit, Fajara, Gambia; [D'Alessandro, U.] Inst Trop Med, B-2000 Antwerp, Belgium; [Lindsay, S. W.] Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3HP, England	Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3HP, England.	S.W.Lindsay@durham.ac.uk	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009	Bill and Melinda Gates Foundation; Research and Policy for Infectious Disease Dynamics (RAPIDD) Program of the Science and Technology Directory; Department of Homeland Security; Fogarty International Center, National Institutes of Health	We are grateful to those in the study villages who participated in this study. We also acknowledge the assistance of Omar Jallow and Alhaji Sidibeh with the fieldwork and Abdoulie Jallow in the laboratory. We thank Sumitomo Chemical for donating the pyriproxyfen. The work was supported by the Bill and Melinda Gates Foundation. SWL is supported by the Research and Policy for Infectious Disease Dynamics (RAPIDD) Program of the Science and Technology Directory, Department of Homeland Security, and Fogarty International Center, National Institutes of Health.	[Anonymous], 2006, PEST THEIR APPL CONT; BULL DL, 1994, J ECON ENTOMOL, V87, P1407, DOI 10.1093/jee/87.6.1407; Curtis C, 2005, TRENDS PARASITOL, V21, P504, DOI 10.1016/j.pt.2005.08.025; CURTIS C F, 1985, Parasitology Today, V1, P36, DOI 10.1016/0169-4758(85)90106-1; Curtis CF, 1984, T ROY SOC TROP MED H, V76, P99; Dawson S, 1993, MANUAL USE FOCUS GRO; Devine GJ, 2009, P NATL ACAD SCI USA, V106, P11530, DOI 10.1073/pnas.0901369106; Dumpert J, 2009, WATERLINES, V28, P250; Emerson PM, 2005, TROP MED INT HEALTH, V10, P706, DOI 10.1111/j.1365-3156.2005.01432.x; Geden CJ, 2012, J MED ENTOMOL, V49, P606, DOI 10.1603/ME11226; Hatakoshi M., 1987, Japanese Journal of Sanitary Zoology, V38, P271; Invest J.F., 2008, P 6 INT C URB PESTS; Kawada H, 1987, JAPANESE J SANITARY, V38, P317; LAURENCE BR, 1988, MED VET ENTOMOL, V2, P285, DOI 10.1111/j.1365-2915.1988.tb00197.x; Lindsay SW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001895; Lindsay TC, PLOS ONE IN PRESS; Londershausen M, 1996, ARCH INSECT BIOCHEM, V32, P651, DOI 10.1002/(SICI)1520-6327(1996)32:3/4<651::AID-ARCH36>3.3.CO;2-M; Morgan P R, 1977, Cent Afr J Med, V23, P1; Reiter P., 1985, J AM MOSQUITO CONTR, V4, P519; Rozendaal J. A., 1997, VECTOR CONTROL METHO; SERVICE M. W., 1976, MOSQUITO ECOLOGY FIE; Sihuincha M, 2005, J MED ENTOMOL, V42, P620, DOI 10.1603/0022-2585(2005)042[0620:PUOPFC]2.0.CO;2; Simms VM, 2005, T ROY SOC TROP MED H, V99, P631, DOI 10.1016/j.trstmh.2004.10.004; THOMSON RCM, 1948, B ENTOMOL RES, V38, P527, DOI 10.1017/S0007485300023221; UNICEF and World Health Organization, 2012, PROGR DRINK WAT SAN, P66; Yapabandara AMGM, 2002, ACTA TROP, V81, P211, DOI 10.1016/S0001-706X(01)00208-X	26	6	6	0	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2013	18	2					159	165		10.1111/tmi.12033				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	075NR	WOS:000313894300005	23198767	Green Published, Bronze			2019-03-26	
J	Tayler-Smith, K; Zachariah, R; Manzi, M; Van den Boogaard, W; Nyandwi, G; Reid, T; Van den Bergh, R; De Plecker, E; Lambert, V; Nicolai, M; Goetghebuer, S; Christaens, B; Ndelema, B; Kabangu, A; Manirampa, J; Harries, AD				Tayler-Smith, K.; Zachariah, R.; Manzi, M.; Van den Boogaard, W.; Nyandwi, G.; Reid, T.; Van den Bergh, R.; De Plecker, E.; Lambert, V.; Nicolai, M.; Goetghebuer, S.; Christaens, B.; Ndelema, B.; Kabangu, A.; Manirampa, J.; Harries, A. D.			Achieving the Millennium Development Goal of reducing maternal mortality in rural Africa: an experience from Burundi	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Burundi; maternal mortality; emergency obstetric care; Millennium Development Goal	EMERGENCY OBSTETRIC CARE; NEAR-MISS; MORBIDITY	Objectives To estimate the reduction in maternal mortality associated with the emergency obstetric care provided by Medecins Sans Frontieres (MSF) and to compare this to the fifth Millennium Development Goal of reducing maternal mortality. Methods The impact of MSF's intervention was approximated by estimating how many deaths were averted among women transferred to and treated at MSF's emergency obstetric care facility in Kabezi, Burundi, with a severe acute maternal morbidity. Using this estimate, the resulting theoretical maternal mortality ratio in Kabezi was calculated and compared to the Millennium Development Goal for Burundi. Results In 2011, 1385 women from Kabezi were transferred to the MSF facility, of whom 55% had a severe acute maternal morbidity. We estimated that the MSF intervention averted 74% (range 55-99%) of maternal deaths in Kabezi district, equating to a district maternal mortality rate of 208 (range 8360) deaths/100 similar to 000 live births. This lies very near to the 2015 MDG 5 target for Burundi (285 deaths/100 similar to 000 live births). Conclusion Provision of quality emergency obstetric care combined with a functional patient transfer system can be associated with a rapid and substantial reduction in maternal mortality, and may thus be a possible way to achieve Millennium Development Goal 5 in rural Africa.	[Tayler-Smith, K.; Zachariah, R.; Manzi, M.; Reid, T.; Van den Bergh, R.] Med Sans Frontieres, Med Dept Operat Res, Operat Ctr Brussels, MSF Luxembourg, Luxembourg, Luxembourg; [Van den Boogaard, W.; Nyandwi, G.; Christaens, B.; Ndelema, B.; Kabangu, A.] Med Sans Frontieres, Bujumbura, Burundi; [Tayler-Smith, K.] Med Sans Frontieres, Med Dept Operat Res, Brussels Operat Ctr, B-1090 Brussels, Belgium; [Manirampa, J.] Minist Hlth, Kabezi, Burundi; [Harries, A. D.] Int Union TB & Lung Dis, Paris, France; [Harries, A. D.] London Sch Hyg & Trop Med, London WC1, England	Tayler-Smith, K (reprint author), Med Sans Frontieres, Med Dept Operat Res, Brussels Operat Ctr, Rue Dupre 94, B-1090 Brussels, Belgium.	katie_harries@yahoo.co.uk		Van den Bergh, Rafael/0000-0001-6277-8713			Baskett TF, 2008, BEST PRACT RES CL OB, V22, P763, DOI 10.1016/j.bpobgyn.2008.06.002; Burundi Ministry of Health, 2011, ANN STAT DONN CTR SA; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Filippi V, 2005, ACTA OBSTET GYN SCAN, V84, P11, DOI 10.1111/j.0001-6349.2005.00636.x; Fournier P, 2009, B WORLD HEALTH ORGAN, V87, P30, DOI 10.2471/BLT.07.047076; Graham W, 2008, BMC MED, V6, P6; Kongnyuy EJ, 2009, BJOG-INT J OBSTET GY, V116, P41, DOI 10.1111/j.1471-0528.2009.02332.x; Li XF, 1996, INT J GYNECOL OBSTET, V54, P1, DOI 10.1016/0020-7292(96)02667-7; Maine D, 1999, AM J PUBLIC HEALTH, V89, P480, DOI 10.2105/AJPH.89.4.480; Mantel GD, 1998, BRIT J OBSTET GYNAEC, V105, P985, DOI 10.1111/j.1471-0528.1998.tb10262.x; Maternal Mortality Estimation Interagency Group (MMEIG), 2012, TRENDS MAT MORT 1990; Maternal Mortality Estimation Interagency Group (MMEIG), 2010, TRENDS MAT MORT 1990; Murray SF, 2001, HEALTH POLICY PLANN, V16, P353, DOI 10.1093/heapol/16.4.353; Pattinson RC, 2003, BRIT MED BULL, V67, P231, DOI 10.1093/bmb/ldg007; Paxton A, 2005, INT J GYNECOL OBSTET, V88, P181, DOI 10.1016/j.ijgo.2004.11.026; Penney G, 2007, CURR OPIN OBSTET GYN, V19, P145, DOI 10.1097/GCO.0b013e328014a860; Prual A, 2000, B WORLD HEALTH ORGAN, V78, P593; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S01406736(06)69380-X; Say L, 2004, REPROD HLTH, V1, P3, DOI DOI 10.1186/1742-4755-1-3; *UNICEF WHO UNFPA, 1997, GUID MON AV US OBST; Waterstone M, 2001, BMJ-BRIT MED J, V322, P1089, DOI 10.1136/bmj.322.7294.1089; WHO, 1994, WHOFHEMSM9414; World Health Organization, 1993, ICD 10 INT STAT CLAS, V2; Zachariah R, 2011, T ROY SOC TROP MED H, V105, P301, DOI 10.1016/j.trstmh.2011.03.002	24	16	17	0	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2013	18	2					166	174		10.1111/tmi.12022				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	075NR	WOS:000313894300006	23163431	Green Published			2019-03-26	
J	Uranw, S; Ostyn, B; Dorlo, TPC; Hasker, E; Dujardin, B; Dujardin, JC; Rijal, S; Boelaert, M				Uranw, Surendra; Ostyn, Bart; Dorlo, Thomas P. C.; Hasker, Epco; Dujardin, Bruno; Dujardin, Jean-Claude; Rijal, Suman; Boelaert, Marleen			Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; treatment; miltefosine; adherence; Nepal	KALA-AZAR; MEDICATION; EFFICACY; TRIAL; INDIA; CHILDREN; THERAPY; ADULTS; POLICY	Objective To assess patient adherence to unsupervised single-drug miltefosine treatment for visceral leishmaniasis and to identify the factors influencing adherence. Methods This is a prospective cohort study of 171 patients with Visceral leishmaniasis (VL) in three healthcare settings in Nepal. Adherence was assessed through pill count, checking of treatment cards and adherence questionnaires, as well as miltefosine concentration measurements at the end of treatment. Poor adherence was defined as less than 90% of required capsules taken. Results Patient adherence to miltefosine was 83%. Predictors of adherence were being the male sex (OR = 2.60, 95% CI 1.026.67) and knowing the duration of treatment (OR = 3.05, 95% CI 1.168.04). Adherence was also better for patients who were literate and knew the side effects of treatment. Gastrointestinal side effects and negligence after the resolution of clinical symptoms of VL were the main reasons for poor adherence. Poor adherence was associated (though not statistically significant) with future relapse. Conclusion Effective counselling during the treatment, a short take-home message on VL and on side effects and action of miltefosine, and follow-up visits are the best way to prevent poor adherence. Single end-of-treatment measurements of miltefosine concentrations as objective assessment of adherence would only be useful in addition to the subjective assessments when substantial doses of miltefosine have been missed.	[Uranw, Surendra] BP Koirala Inst Hlth Sci, Dept Internal Med, Ghopa, Dharan, Nepal; [Uranw, Surendra; Ostyn, Bart; Hasker, Epco; Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Dorlo, Thomas P. C.] Slotervaart Hosp, Dept Pharm & Pharmacol, Netherlands Canc Inst, Amsterdam, Netherlands; [Dorlo, Thomas P. C.] Univ Amsterdam, Acad Med Ctr, Div Infect Dis, NL-1105 AZ Amsterdam, Netherlands; [Dujardin, Bruno] Res Ctr Polit & Syst Sante Sante Int, ESP ULB, Brussels, Belgium; [Dujardin, Jean-Claude] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Ostyn, B (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	bostyn@itg.be	Boelaert, Marleen/E-2698-2012; Dorlo, Thomas/F-1339-2011	Boelaert, Marleen/0000-0001-8051-6776; Dorlo, Thomas/0000-0003-3076-8435	ITM-DGD; Belgian Federal Cooperation	We wish to express our gratitude to all patients with VL in the study area for their active participation in the study and the health worker's staff in the three study sites. This research was funded as part of the ITM-DGD Framework Agreement supported by the Belgian Federal Cooperation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The work is an extension of the Kaladrug-R study, from which we have used clinical data, with kind permission from the PI.	Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575; Bryceson A, 2001, TROP MED INT HEALTH, V6, P928, DOI 10.1046/j.1365-3156.2001.00795.x; Dorlo TPC, 2008, J CHROMATOGR B, V865, P55, DOI 10.1016/j.jchromb.2008.02.005; Dorlo TPC, 2012, ANTIMICROB AGENTS CH, V56, P3864, DOI 10.1128/AAC.00292-12; Dorlo TPC, 2012, ANALYST, V137, P1265, DOI 10.1039/c2an15641e; Epidemiology and Disease Control Division (EDCD), 2009, NAT STRAT GUID KAL E; Farmer KC, 1999, CLIN THER, V21, P1074, DOI 10.1016/S0149-2918(99)80026-5; MATSUI D, 1994, J CLIN PHARMACOL, V34, P944, DOI 10.1002/j.1552-4604.1994.tb04009.x; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Nackers F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032140; NORELL SE, 1981, SOC SCI MED-MED PSYC, V15, P57, DOI 10.1016/S0277-9536(81)80007-X; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Rahman M, 2011, AM J TROP MED HYG, V85, P66, DOI 10.4269/ajtmh.2011.10-0661; Rijal S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2; Rijal S, 2012, INCREASING IN PRESS; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; Sundar S, 2005, B WORLD HEALTH ORGAN, V83, P394; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Sundar S, 2012, CLIN INFECT DIS, V55, P543, DOI 10.1093/cid/cis474; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; Vitolins MZ, 2000, CONTROL CLIN TRIALS, V21, p188S, DOI 10.1016/S0197-2456(00)00077-5; WHO SEARO, 2005, SEAVBC85 WHO SEARO; World Health Organization, 2003, ADH LONG TERM THER E	25	11	11	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2013	18	2					179	187		10.1111/tmi.12025				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	075NR	WOS:000313894300008	23199340	Bronze			2019-03-26	
J	Malaviya, P; Hasker, E; Singh, RP; Van Geertruyden, JP; Boelaert, M; Sundar, S				Malaviya, P.; Hasker, E.; Singh, R. P.; Van Geertruyden, J. P.; Boelaert, M.; Sundar, S.			Village health workers in Bihar, India: an untapped resource in the struggle against kala-azar	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						KAP survey; visceral leishmaniasis; tuberculosis; drug monitoring; drug effectiveness; public health system; supervised treatment; patient follow-up; auxiliary nurse; midwife; Accredited Social Health Activist network	VISCERAL LEISHMANIASIS; TUBERCULOSIS; BANGLADESH	Introduction In 2005 a visceral leishmaniasis (VL) elimination initiative was launched on the Indian subcontinent; important components of early case finding and treatment are entrusted to the primary health care system (PHC). In an earlier study in Bihar, India, we discovered some major shortcomings in implementation, in particular related to monitoring of treatment and treatment outcomes. These shortcomings could be addressed through involvement of village health workers. In the current study we assessed knowledge, attitude and practice of these village health workers in relation to VL. Main objective was to assess the feasibility of their involvement in VL control. Methods We obtained a list of auxiliary nurses/midwives and accredited social health activists for the highly endemic district of Muzaffarpur. We randomly sampled 100 auxiliary nurses and 100 activists, who were visited in their homes for an interview. Questions were asked on knowledge, attitude and practice related to visceral leishmaniasis and to tuberculosis. Results Auxiliary nurses and activists know the presenting symptoms of visceral leishmaniasis, they know how it is diagnosed but they are not aware of the recommended first-line treatment. Many are already involved in tuberculosis control and are very well aware of the treatment modalities of tuberculosis, but few are involved in control of visceral leishmaniasis control. They are well organised, have strong links to the primary healthcare system and are ready to get more involved in visceral leishmaniasis control. Conclusion To ensure adequate monitoring of visceral leishmaniasis treatment and treatment outcomes, the control programme urgently needs to consider involving auxiliary nurses and activists.	[Sundar, S.] Banaras Hindu Univ, Inst Med Sci, Dept Med, Varanasi 221005, Uttar Pradesh, India; [Hasker, E.; Boelaert, M.] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Van Geertruyden, J. P.] Univ Antwerp, Int Hlth Unit, B-2020 Antwerp, Belgium	Sundar, S (reprint author), Banaras Hindu Univ, Inst Med Sci, Dept Med, Varanasi 221005, Uttar Pradesh, India.	drshyamsundar@hotmail.com	Boelaert, Marleen/E-2698-2012; Van geertruyden, Jean-Pierre/K-6425-2014; Malaviya, Paritosh/B-1819-2012	Boelaert, Marleen/0000-0001-8051-6776; Van geertruyden, Jean-Pierre/0000-0001-5006-6364; Malaviya, Paritosh/0000-0002-7558-152X	NIAID, NIH TMRC Grant [1P50AI074321]	We acknowledge the important inputs of our social scientists who conducted the interviews: Dr. V. Dubey, Dr. Shanti, B. Pathak, Kamlesh and Dr. Chandra Bhushan. This work was supported by NIAID, NIH TMRC Grant No. 1P50AI074321.	Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; [Anonymous], 2011, REV NAT TB CONTR PRO; [Anonymous], MAJ STAK THEIR ROL; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]; Cunningham J, 2012, CLIN INFECT DIS, V55, P1312, DOI 10.1093/cid/cis716; Gopalan SS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001557; Hasker E, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02562.x; Hirve S, 2010, AM J TROP MED HYG, V83, P507, DOI 10.4269/ajtmh.2010.09-0685; Malaviya P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014751; Mondal D, 2009, PLOS NEGLECT TROP D, V3, P355; Mondal D, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000832; National Vector Borne Disease Control Programme (NVBDCP), GUID US MILT; Singh Shri Prakash, 2011, PLoS Negl Trop Dis, V5, pe960, DOI 10.1371/journal.pntd.0000960; STYBLO K, 1976, INT J EPIDEMIOL, V5, P63, DOI 10.1093/ije/5.1.63; van Griensven J, 2011, LANCET, V377, P443, DOI 10.1016/S0140-6736(10)62237-4; Veen J, 1998, EUR RESPIR J, V12, P505, DOI 10.1183/09031936.98.12020505; WHO, 2005, REG STRAT FRAM EL KA	17	5	5	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2013	18	2					188	193		10.1111/tmi.12031				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	075NR	WOS:000313894300009	23279554	Bronze, Green Accepted			2019-03-26	
J	Ravinetto, RM; Talisuna, A; De Crop, M; van Loen, H; Menten, J; Van Overmeir, C; Tinto, H; Gonzalez, R; Meremikwu, M; Nabasuma, C; Ngoma, GM; Karema, C; Adoke, Y; Chaponda, M; Van Geertruyden, JP; D'Alessandro, U				Ravinetto, Raffaella M.; Talisuna, Ambrose; De Crop, Maaike; van Loen, Harry; Menten, Joris; Van Overmeir, Chantal; Tinto, Halidou; Gonzalez, Raquel; Meremikwu, Martin; Nabasuma, Carolyn; Ngoma, Ghyslain M.; Karema, Corine; Adoke, Yeka; Chaponda, Mike; Van Geertruyden, Jean-Pierre; D'Alessandro, Umberto			Challenges of non-commercial multicentre North-South collaborative clinical trials	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						Malaria; multicentre clinical trial; sub-Saharan Africa; good clinical practice		The last decade has witnessed a substantial increase of multi-centre, public health-oriented clinical trials in poor countries. However, non-commercial research groups have less staff and financial resources than traditional commercial sponsors, so the trial teams have to be creative to comply with Good Clinical Practices (GCP) requirements. According to the recent experience of a large multicentre trial on antimalarials, major challenges result from the complexity of multiple ethical review, the costs of in-depth monitoring at several sites, setting up an adequate Good Clinical Laboratory Practices (GCLP) framework, lack of insurers in host countries, and lack of adequate non-commercial data management software. Public research funding agencies need to consider these challenges in their funding policies. They also could support common spaces where North-South collaborative research groups may share critical information, such as on research insurance and open-source, GCP-compliant software. WHO should update its GCP guidelines, which date back to 1995, to incorporate the perspectives and needs of non-commercial clinical research.	[Ravinetto, Raffaella M.; De Crop, Maaike; van Loen, Harry; Menten, Joris] Inst Trop Med, Clin Trials Unit, Dept Clin Sci, B-2000 Antwerp, Belgium; [Ravinetto, Raffaella M.] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Louvain, Belgium; [Talisuna, Ambrose; Adoke, Yeka] Makerere Univ, Sch Publ Hlth, Kampala, Uganda; [Talisuna, Ambrose; Adoke, Yeka] Uganda Malaria Surveillance Project, Kampala, Uganda; [Van Overmeir, Chantal; D'Alessandro, Umberto] Inst Trop Med, Malariol Unit, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Tinto, Halidou] IRSS, Ctr Muraz, Clin Res Unit Nanoro, Bobo Dioulasso, Burkina Faso; [Gonzalez, Raquel] Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain; [Gonzalez, Raquel] CISM, Manhica, Mozambique; [Meremikwu, Martin] Univ Calabar, Dept Paediat, Calabar, Nigeria; [Meremikwu, Martin] Inst Trop Dis Res & Prevent Calabar, Calabar, Nigeria; [Nabasuma, Carolyn] Epicentre, Paris, France; [Nabasuma, Carolyn] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda; [Ngoma, Ghyslain M.] Ctr Rech Med Ngounie, Fougamou, Gabon; [Ngoma, Ghyslain M.] Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon; [Ngoma, Ghyslain M.] Univ Tubingen, Inst Trop Med, Tubingen, Germany; [Karema, Corine] Rwanda Biomed Ctr, Minist Hlth, Malaria & Other Parasit Dis Div, Kigali, Rwanda; [Chaponda, Mike] Trop Dis Res Ctr, Ndola, Zambia; [Van Geertruyden, Jean-Pierre] Univ Antwerp, Int Hlth Unit, B-2020 Antwerp, Belgium	Ravinetto, RM (reprint author), Inst Trop Med, Clin Trials Unit, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium.	rravinetto@itg.be	D'Alessandro, Umberto/D-3457-2015; Van geertruyden, Jean-Pierre/K-6425-2014; Gonzalez, Raquel/J-3604-2017	D'Alessandro, Umberto/0000-0001-6341-5009; Van geertruyden, Jean-Pierre/0000-0001-5006-6364; Gonzalez, Raquel/0000-0001-5487-801X; Tinto, Halidou/0000-0002-0472-3586			[Anonymous], 1947, JAMA, V276, P1691; [Anonymous], 1979, BELM REP ETH PRINC G; [Anonymous], 1995, WHO TECHN REP SER, V850; Chilengi R, 2010, CLIN TRIALS, V1; Christensen M, 2012, LANCET, V379, P30, DOI [10.1016/S0140-6736(12)60024-5, 10.1016/S0140-6736(11)61920-X]; Council for International Organization of Medical Sciences, 2002, INT ETH GUID BIOM RE; Department of Health and Human Services, 2010, OEI010800510 DEP HLT; European Medicines Agency, 2012, EMA1213402011; International Conference of Harmonization, 1996, ICH TRIP GUID GOOD E, VE6; Lang T, 2011, LANCET, V377, P1553, DOI 10.1016/S0140-6736(10)62052-1; Ravinetto R, 2011, TROP MED INT HEALTH, V16, P527, DOI 10.1111/j.1365-3156.2011.02732.x; The Four Artemisinin-Based Combinations (4ABC) Study Group, 2011, PLOS MED, V8, P1; van Loen H, 2011, EDCTP FOR 2011 ADD A; WHO Good Clinical Laboratory Practices, 2009, WHO BEH SPEC PROGR R; World Medical Association Declaration of Helsinki, 1964, 18 WMA GEN ASS HELS	15	10	10	0	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2013	18	2					237	241		10.1111/tmi.12036				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	075NR	WOS:000313894300016	23217117	Bronze, Green Published			2019-03-26	
J	Lenhart, A; Trongtokit, Y; Alexander, N; Apiwathnasorn, C; Satimai, W; Vanlerberghe, V; Van der Stuyft, P; McCall, PJ				Lenhart, Audrey; Trongtokit, Yuwadee; Alexander, Neal; Apiwathnasorn, Chamnarn; Satimai, Wichai; Vanlerberghe, Veerle; Van der Stuyft, Patrick; McCall, Philip J.			A Cluster-Randomized Trial of Insecticide-Treated Curtains for Dengue Vector Control in Thailand	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							WATER CONTAINER COVERS; AEDES-AEGYPTI; DETERMINANTS; DISPERSAL; URBAN	The efficacy of insecticide-treated window curtains (ITCs) for dengue vector control was evaluated in Thailand in a cluster-randomized controlled trial. A total of 2,037 houses in 26 clusters was randomized to receive the intervention or act as control (no treatment). Entomological surveys measured Aedes infestations (Breteau index, house index, container index, and pupae per person index) and oviposition indices (mean numbers of eggs laid in oviposition traps) immediately before and after intervention, and at 3-month intervals over 12 months. There were no consistent statistically significant differences in entomological indices between intervention and control clusters, although oviposition indices were lower (P < 0.01) in ITC clusters during the wet season. It is possible that the open housing structures in the study reduced the likelihood of mosquitoes making contact with ITCs. ITCs deployed in a region where this house design is common may be unsuitable for dengue vector control.	Univ Liverpool, Liverpool Sch Trop Med, Vector Grp, Liverpool L3 5QA, Merseyside, England; Mahidol Univ, Dept Med Entomol, Bangkok 10700, Thailand; London Sch Hyg & Trop Med, London WC1, England; [Satimai, Wichai] Minist Publ Hlth, Dept Dis Control, Bur Vector Borne Dis, Bangkok, Thailand; Inst Trop Med, B-2000 Antwerp, Belgium	McCall, PJ (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.	ajl8@cdc.gov; ytrongtokit@gmail.com; neal.alexander@lshtm.ac.uk; tmcaw@mahidol.ac.th; wichaisatimai@yahoo.co.th; vvanlerberghe@itg.be; pvdstuyft@itg.be; mccall@liv.ac.uk		McCall, Philip/0000-0002-0007-3985	European Commission [INCO-CT-2004-517708]; Medical Research Council [G0700837]	This research was undertaken within the DENCO (Dengue Control - Towards Successful Dengue Prevention and Control) project financed within the 6th Framework Programme of the European Commission (INCO-CT-2004-517708).	Arunachalam N, 2010, B WORLD HEALTH ORGAN, V88, P173, DOI 10.2471/BLT.09.067892; Esu E, 2010, TROP MED INT HEALTH, V15, P619, DOI 10.1111/j.1365-3156.2010.02489.x; Focks DA, 2003, REV ENTOMOLOGICAL SA; Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Igarashi A, 1997, FEMS IMMUNOL MED MIC, V18, P291, DOI 10.1016/S0928-8244(97)00060-6; Itoh Takaaki, 1996, Medical Entomology and Zoology, V47, P171; Kroeger A, 2006, BRIT MED J, V332, P1247, DOI 10.1136/bmj.332.7552.1247; Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144; Madarieta S. K., 1999, Dengue Bulletin, V23, P51; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Muir LE, 1998, AM J TROP MED HYG, V58, P277, DOI 10.4269/ajtmh.1998.58.277; Nam VS, 1993, DENGUE NEWSLETTER, V18, P23; Nguyen HT, 1996, DENGUE B, V20, P87; REITER P, 1995, AM J TROP MED HYG, V52, P177, DOI 10.4269/ajtmh.1995.52.177; Reiter P, 1997, DENGUE DENGUE HAEMOR; Seng CM, 2008, J VECTOR ECOL, V33, P333, DOI 10.3376/1081-1710-33.2.333; Vanlerberghe V, 2011, TROP MED INT HEALTH, V16, P162, DOI 10.1111/j.1365-3156.2010.02668.x; Vanlerberghe V, 2010, TROP MED INT HEALTH, V15, P1067, DOI 10.1111/j.1365-3156.2010.02582.x; Vanlerberghe V, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000994; WHO, 2007, REP CAS DF DHF SEL C; *WHO, 2007, SCI WORK GROUP REP D; WHOPES - World Health Organization Pesticide Evaluation Scheme, 2008, 12 WHOPES WORK GROUP; World Health Organization, 2009, DENG GUID DIAGN TREA; World Health Organization, 1981, INSTR DET SUSC RES A; World Health Organization (WHO), 2003, SPAC SPRAY APPL INS	26	21	21	0	13	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	FEB	2013	88	2					254	259		10.4269/ajtmh.2012.12-0423				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	082ZG	WOS:000314431900010	23166195	Green Published, Bronze			2019-03-26	
J	Otsyula, N; Angov, E; Bergmann-Leitner, E; Koech, M; Khan, F; Bennett, J; Otieno, L; Cummings, J; Andagalu, B; Tosh, D; Waitumbi, J; Richie, N; Shi, M; Miller, L; Otieno, W; Otieno, GA; Ware, L; House, B; Godeaux, O; Dubois, MC; Ogutu, B; Ballou, WR; Soisson, L; Diggs, C; Cohen, J; Polhemus, M; Heppner, DG; Ockenhouse, CF; Spring, MD				Otsyula, Nekoye; Angov, Evelina; Bergmann-Leitner, Elke; Koech, Margaret; Khan, Farhat; Bennett, Jason; Otieno, Lucas; Cummings, James; Andagalu, Ben; Tosh, Donna; Waitumbi, John; Richie, Nancy; Shi, Meng; Miller, Lori; Otieno, Walter; Otieno, Godfrey Allan; Ware, Lisa; House, Brent; Godeaux, Olivier; Dubois, Marie-Claude; Ogutu, Bernhards; Ballou, W. Ripley; Soisson, Lorraine; Diggs, Carter; Cohen, Joe; Polhemus, Mark; Heppner, D. Gray, Jr.; Ockenhouse, Christian F.; Spring, Michele D.			Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01	MALARIA JOURNAL			English	Article						Malaria; Vaccine; Merozoite surface protein-1; Plasmodium	PROTECTS AOTUS MONKEYS; MALARIA-NAIVE ADULTS; BLOOD-STAGE VACCINE; C-TERMINAL FRAGMENT; INHIBITORY ANTIBODIES; TRIAL; CHALLENGE; GROWTH; RTS,S/AS02A; PARASITES	Background: The development of an asexual blood stage vaccine against Plasmodium falciparum malaria based on the major merozoite surface protein-1 (MSP1) antigen is founded on the protective efficacy observed in preclinical studies and induction of invasion and growth inhibitory antibody responses. The 42 kDa C-terminus of MSP1 has been developed as the recombinant protein vaccine antigen, and the 3D7 allotype, formulated with the Adjuvant System AS02A, has been evaluated extensively in human clinical trials. In preclinical rabbit studies, the FVO allele of MSP1(42) has been shown to have improved immunogenicity over the 3D7 allele, in terms of antibody titres as well as growth inhibitory activity of antibodies against both the heterologous 3D7 and homologous FVO parasites. Methods: Two Phase 1 clinical studies were conducted to examine the safety, reactogenicity and immunogenicity of the FVO allele of MSP1(42) in the adjuvant system AS01 administered intramuscularly at 0-, 1-, and 2-months: one in the USA and, after evaluation of safety data results, one in Western Kenya. The US study was an open-label, dose escalation study of 10 and 50 mu g doses of MSP1(42) in 26 adults, while the Kenya study, evaluating 30 volunteers, was a double-blind, randomized study of only the 50 mu g dose with a rabies vaccine comparator. Results: In these studies it was demonstrated that this vaccine formulation has an acceptable safety profile and is immunogenic in malaria-naive and malaria-experienced populations. High titres of anti-MSP1 antibodies were induced in both study populations, although there was a limited number of volunteers whose serum demonstrated significant inhibition of blood-stage parasites as measured by growth inhibition assay. In the US volunteers, the antibodies generated exhibited better cross-reactivity to heterologous MSP1 alleles than a MSP1-based vaccine (3D7 allele) previously tested at both study sites. Conclusions: Given that the primary effector mechanism for blood stage vaccine targets is humoral, the antibody responses demonstrated to this vaccine candidate, both quantitative (total antibody titres) and qualitative (functional antibodies inhibiting parasite growth) warrant further consideration of its application in endemic settings.	[Otsyula, Nekoye; Koech, Margaret; Otieno, Lucas; Andagalu, Ben; Waitumbi, John; Otieno, Walter; Otieno, Godfrey Allan; Ogutu, Bernhards] Kenya Govt Med Res Ctr, Walter Reed Project, Kisumu, Kenya; [Angov, Evelina; Bergmann-Leitner, Elke; Khan, Farhat; Bennett, Jason; Cummings, James; Tosh, Donna; Richie, Nancy; Shi, Meng; Miller, Lori; Ware, Lisa; House, Brent; Polhemus, Mark; Heppner, D. Gray, Jr.; Ockenhouse, Christian F.; Spring, Michele D.] Walter Reed Army Inst Res, Malaria Vaccine Branch, Silver Spring, MD USA; [Godeaux, Olivier; Dubois, Marie-Claude; Ballou, W. Ripley; Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium; [Soisson, Lorraine; Diggs, Carter] US Agcy Int Dev, Washington, DC 20523 USA	Ockenhouse, CF (reprint author), Walter Reed Army Inst Res, Malaria Vaccine Branch, 2460 Linden Lane,Bldg 503, Silver Spring, MD USA.	christian.f.ockenhouse@us.army.mil	Bennett, Jason/B-3547-2011; Bergmann-Leitner, Elke/B-3548-2011	Bergmann-Leitner, Elke/0000-0002-8571-8956	Office of the Surgeon General, US Army; US Agency for International Development (USAID); GlaxoSmithKline Biologicals (GSK); US Army Medical and Materiel Research Command (USAMRMC)	MCD, OG, JC and WRB are employees of GlaxoSmithKline Biologicals s.a. (GSK). They own shares and options to shares in GSK. In addition JC and WRB are listed as inventors of patented malaria vaccines, but do not hold a patent for a malaria vaccine. Specifically EA and JC are listed as inventors on patent for this MSP1<INF>42</INF>FVO antigen. The Study Sponsor was the Office of the Surgeon General, US Army. This study was funded by the US Agency for International Development (USAID), with partial support from GlaxoSmithKline Biologicals (GSK) and the US Army Medical and Materiel Research Command (USAMRMC). There are no other competing interests.	Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Angov E, 2003, MOL BIOCHEM PARASIT, V128, P195, DOI 10.1016/S0166-6851(03)00077-X; Bergmann-Leitner ES, 2008, AM J TROP MED HYG, V78, P468, DOI 10.4269/ajtmh.2008.78.468; Bergmann-Leitner ES, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-183; Chang SP, 1996, INFECT IMMUN, V64, P253; Courtin D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007590; Crompton PD, 2010, INFECT IMMUN, V78, P737, DOI 10.1128/IAI.00960-09; Cummings JF, 2010, VACCINE, V28, P5135, DOI 10.1016/j.vaccine.2009.08.046; Darko CA, 2005, INFECT IMMUN, V73, P287, DOI 10.1128/IAI.73.1.287-297.2004; de Koning-Ward TF, 2003, J EXP MED, V198, P869, DOI 10.1084/jem.20030085; Dent AE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003557; Dluzewski AR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003085; Ellis RD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008787; Galamo CD, 2009, J INFECT DIS, V199, P1151, DOI 10.1086/597426; Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342; Heppner DG, 2005, VACCINE, V23, P2243, DOI 10.1016/j.vaccine.2005.01.042; Holder AA, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P409; HUI GSN, 1994, J IMMUNOL, V153, P2544; Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120; Lyon JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002830; Malkin E, 2007, PLOS CLIN TRIALS, V2, DOI 10.1371/journal.pctr.0020012; McCallum FJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003571; McIntosh RS, 2007, PLOS PATHOG, V3, P647, DOI 10.1371/journal.ppat.0030072; Nwuba RI, 2002, INFECT IMMUN, V70, P5328, DOI 10.1128/IAI.70.9.5328-5331.2002; Ockenhouse CF, 2006, VACCINE, V24, P3009, DOI 10.1016/j.vaccine.2005.11.028; OGUTU BR, 2009, PLOS ONE, V4, P4708, DOI DOI 10.1371/J0URNAL.P0NE.0004708; Okech BA, 2004, INFECT IMMUN, V72, P1557, DOI 10.1128/IAI.72.3.1557-1567.2004; Perraut R, 2005, J INFECT DIS, V191, P264, DOI 10.1086/426398; Persson KEM, 2006, J CLIN MICROBIOL, V44, P1665, DOI 10.1128/JCM.44.5.1665-1673.2006; Polhemus ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006465; Renia L, 1997, INFECT IMMUN, V65, P4419; Singh S, 2003, INFECT IMMUN, V71, P6766, DOI 10.1128/IAI.71.12.6766-6774.2003; Spring MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005254; Stoute JA, 2007, VACCINE, V25, P176, DOI 10.1016/j.vaccine.2005.11.037; Stowers AW, 2002, P NATL ACAD SCI USA, V99, P339, DOI 10.1073/pnas.012590199; Stowers AW, 2001, INFECT IMMUN, V69, P1536, DOI 10.1128/IAI.69.3.1536-1546.2001; Thera MA, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010034; UDHAYAKUMAR V, 1995, J IMMUNOL, V154, P6022; Withers MR, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010032	39	20	20	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JAN 23	2013	12								29	10.1186/1475-2875-12-29				13	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	118YC	WOS:000317062200001	23342996	DOAJ Gold, Green Published			2019-03-26	
J	Abdulla, S; Salim, N; Machera, F; Kamata, R; Juma, O; Shomari, M; Kubhoja, S; Mohammed, A; Mwangoka, G; Aebi, T; Mshinda, H; Schellenberg, D; Carter, T; Villafana, T; Dubois, MC; Leach, A; Lievens, M; Vekemans, J; Cohen, J; Ballou, WR; Tanner, M				Abdulla, Salim; Salim, Nahya; Machera, Francisca; Kamata, Richard; Juma, Omar; Shomari, Mwanajaa; Kubhoja, Sulende; Mohammed, Ali; Mwangoka, Grace; Aebi, Thomas; Mshinda, Hassan; Schellenberg, David; Carter, Terrell; Villafana, Tonya; Dubois, Marie-Claude; Leach, Amanda; Lievens, Marc; Vekemans, Johan; Cohen, Joe; Ballou, W. Ripley; Tanner, Marcel			Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region	MALARIA JOURNAL			English	Article						RTS,S/AS02; Falciparum; Malaria; Infants; Immunogenicity; Safety; Efficacy; EPI	PHASE-IIB TRIAL; MOZAMBICAN CHILDREN; EXPANDED-PROGRAM; DOUBLE-BLIND; CANDIDATE; IMMUNIZATION	Background: The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization. Safety, immunogenicity and efficacy of the RTS,S/AS02(D) vaccine candidate when integrated into a standard EPI schedule for infants have been reported over a nine-month surveillance period. This paper describes results following 20 months of follow up. Methods: This Phase IIb, single-centre, randomized controlled trial enrolled 340 infants in Tanzania to receive three doses of RTS,S/AS02(D) or hepatitis B vaccine at 8, 12, and 16 weeks of age. All infants also received DTPw/Hib (diphtheria and tetanus toxoids, whole-cell pertussis vaccine, conjugated Haemophilus influenzae type b vaccine) at the same timepoints. The study was double-blinded to month 9 and single-blinded from months 9 to 20. Results: From month 0 to 20, at least one SAE was reported in 57/170 infants who received RTS,S/AS02(D) (33.5%; 95% confidence interval [CI]: 26.5, 41.2) and 62/170 infants who received hepatitis B vaccine (36.5%; 95% CI: 29.2, 44.2). The SAE profile was similar in both vaccine groups; none were considered to be related to vaccination. At month 20, 18 months after completion of vaccination, 71.8% of recipients of RTS,S/AS02(D) and 3.8% of recipients of hepatitis B vaccine had seropositive titres for anti-CS antibodies; seroprotective levels of anti-HBs antibodies remained in 100% of recipients of RTS,S/AS02(D) and 97.7% recipients of hepatitis B vaccine. Anti-HBs antibody GMTs were higher in the RTS,S/AS02(D) group at all post-vaccination time points compared to control. According to protocol population, vaccine efficacy against multiple episodes of malaria disease was 50.7% (95% CI: -6.5 to 77.1, p = 0.072) and 26.7% (95% CI: -33.1 to 59.6, p = 0.307) over 12 and 18 months post vaccination, respectively. In the Intention to Treat population, over the 20-month follow up, vaccine efficacy against multiple episodes of malaria disease was 14.4% (95% CI: -41.9 to 48.4, p = 0.545). Conclusions: The acceptable safety profile and good tolerability of RTS,S/AS02(D) in combination with EPI vaccines previously reported from month 0 to 9 was confirmed over a 20 month surveillance period in this infant population. Antibodies against both CS and HBsAg in the RTS,S/AS02(D) group remained significantly higher compared to control for the study duration. Over 18 months follow up, RTS,S/AS02(D) prevented approximately a quarter of malaria cases in the study population.	[Abdulla, Salim; Salim, Nahya; Machera, Francisca; Kamata, Richard; Juma, Omar; Shomari, Mwanajaa; Mohammed, Ali; Mwangoka, Grace; Aebi, Thomas] Ifakara Hlth Inst, Bagamoyo Res & Training Ctr, Pwani, Tanzania; [Kubhoja, Sulende] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania; [Aebi, Thomas; Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Mshinda, Hassan] Tanzania Commiss Sci & Technol, Dar Es Salaam, Tanzania; [Schellenberg, David] London Sch Hyg & Trop Med, London WC1, England; [Carter, Terrell; Villafana, Tonya] PATH Malaria Vaccine Initiat, Washington, DC USA; [Dubois, Marie-Claude; Leach, Amanda; Lievens, Marc; Vekemans, Johan; Cohen, Joe; Ballou, W. Ripley] GlaxoSmithKline Biol, Rixensart, Belgium; [Tanner, Marcel] Univ Basel, Basel, Switzerland; [Abdulla, Salim] Ifakara Hlth Inst, Dar Es Salaam, Tanzania	Abdulla, S (reprint author), Ifakara Hlth Inst, Bagamoyo Res & Training Ctr, Pwani, Tanzania.	sabdulla@ihi.or.tz			GSK Biologicals SA Belgium; GSK Biologicals; PATH Malaria Vaccine Initiative (MVI); MVI; MVI through the Bill and Melinda Gates Foundation; team from Centro de Investigacao em Saude de Manhica at Manhica, Mozambique; MVI through the CPTC network; MCTA initiative of the Bill & Melinda Gates Foundation; team of Manhica	This study was sponsored by GSK Biologicals SA Belgium, and funded by both GSK Biologicals and the PATH Malaria Vaccine Initiative (MVI). MVI supports the development and testing of several malaria vaccine candidates. MAD, MCD, AL, ML, JV, JC, and WRB are employees of the GlaxoSmithKline group of companies. MAD, MCD, AL, JV, JC and WRB own shares in GSK Biologicals. JC and WRB are listed as the inventors of patented malaria vaccines. However, neither individual holds a patent for a malaria vaccine. TC and TV were, at the time of the study, employees at PATH MVI. DS declares his institution receiving consultancy fees from MVI for other work. MT is a board member of the UBS-Optimus foundation and declares his institution received compensation for his membership of a Novartis scientific advisory board, and reimbursements from the Bill & Melinda Gates Foundation and Wellcome Trust as compensation for travel costs. None of the other authors declare any further potential competing interests.; The trial was supported by the PATH Malaria Vaccine Initiative (MVI) and by GSK Biologicals. We thank all the children and parents who participated in this study; the Bagamoyo communities and their leaders; the entire staff at Bagamoyo Research and Training Centre of Ifakara Health Institute, Bagamoyo District Hospital, and the dispensaries in the study area; and Zaria Said and Richard Kamata, study counselors. The staff at the Swiss TPH, Basel, for providing key support to this trial and acting as site partners; Christoph Hatz for serving as a liaison between the trial team and the Swiss institutional review boards; Christine Walliser and Christian Wirz for their administrative and logistic support; Hans-Peter Marti for providing assistance with laboratory procedures; Rahiya Shariff for her coordination of the communications team; our colleagues in other trial sites supported by MVI through the Bill and Melinda Gates Foundation, particularly the team from Centro de Investigacao em Saude de Manhica at Manhica, Mozambique, which provided support and advice for the implementation of the trial; the staff of the Malaria Project Team at GSK Biologicals, particularly Nathalie Annez, Delphine Beauport, Sarah Benns, Issam Jaimai, Isabelle Ramboer, Shantala Rao, Christine Swysen, Marie Chantal Uwamwezi, and Laurence Vigneron. We are grateful to the fruitful exchanges with our colleagues in the various other MVI supported trial sites through the CPTC network and the MCTA initiative of the Bill & Melinda Gates Foundation, particularly the team of Manhica that provided support and advice for building up BRTC-IHI and the implementation of the trial based on their experience with the proof-of concept trial and the staggered approach among infants. Christian Loucq, Melinda Moree, and Regina Rabinovich for their hard work and dedication to the project; Karim Manji for providing continuous support and guidance; Malcolm Molyneux, chair of the data and safety monitoring board, for his instruction and support; Andrew Kitua, director of the National Institute of Health at the Ministry of Health and Social Welfare; and the staff of the Contract Laboratory Services of South Africa for providing invaluable support.	Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773; Agnandji ST, 2010, J INFECT DIS, V202, P1076, DOI 10.1086/656190; Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Aide P, 2011, VACCINE, V29, P6059, DOI 10.1016/j.vaccine.2011.03.041; Aide P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013838; Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6; Asante KP, 2011, LANCET INFECT DIS, V11, P741, DOI 10.1016/S1473-3099(11)70100-1; Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381; Bojang KA, 2005, VACCINE, V23, P4148, DOI 10.1016/j.vaccine.2005.03.019; Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120; Lell B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007611; Macete E, 2007, TROP MED INT HEALTH, V12, P37, DOI 10.1111/j.1365-3156.2006.01754.x; Macete EV, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-11; MedDRA, 2007, MEDDRA MED DICT REGU; Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394; Olotu A, 2011, LANCET INFECT DIS, V11, P102, DOI [10.1016/S1473-3099(10)70262-0, 10.1016/51473-3099(10)70262-0]; Owusu-Agyei S, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0006682, 10.1371/journal.pone.0007302]; Sacarlal J, 2008, VACCINE, V26, P174, DOI 10.1016/j.vaccine.2007.11.003; Sacarlal J, 2009, J INFECT DIS, V200, P329, DOI 10.1086/600119; White MT, 2010, MALARIA J, V9, P1475; WHO, 2010, WORLD MALARIA REPORT 2010, P1; [WHO IVR], 2011, IN VACC RES WHO; World Health Organization, 2007, VERB AUT STAND ASC A	23	22	22	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	JAN 8	2013	12								11	10.1186/1475-2875-12-11				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	086IU	WOS:000314678100001	23297680	DOAJ Gold, Green Published			2019-03-26	
J	Medlock, JM; Hansford, KM; Bormane, A; Derdakova, M; Estrada-Pena, A; George, JC; Golovljova, I; Jaenson, TGT; Jensen, JK; Jensen, PM; Kazimirova, M; Oteo, JA; Papa, A; Pfister, K; Plantard, O; Randolph, SE; Rizzoli, A; Santos-Silva, MM; Sprong, H; Vial, L; Hendrickx, G; Zeller, H; Van Bortel, W				Medlock, Jolyon M.; Hansford, Kayleigh M.; Bormane, Antra; Derdakova, Marketa; Estrada-Pena, Agustin; George, Jean-Claude; Golovljova, Irina; Jaenson, Thomas G. T.; Jensen, Jens-Kjeld; Jensen, Per M.; Kazimirova, Maria; Oteo, Jose A.; Papa, Anna; Pfister, Kurt; Plantard, Olivier; Randolph, Sarah E.; Rizzoli, Annapaola; Santos-Silva, Maria Margarida; Sprong, Hein; Vial, Laurence; Hendrickx, Guy; Zeller, Herve; Van Bortel, Wim			Driving forces for changes in geographical distribution of Ixodes ricinus ticks in Europe	PARASITES & VECTORS			English	Review						Tick; Ixodes; Europe; Distribution; Climate; Ecology; Surveillance; Tick-borne disease	BURGDORFERI SENSU-LATO; FACING ALTITUDINAL GRADIENT; BORNE ENCEPHALITIS-VIRUS; BORRELIA-BURGDORFERI; LYME BORRELIOSIS; ACARI IXODIDAE; DERMACENTOR-RETICULATUS; INFORMATION-SYSTEMS; POPULATION-DYNAMICS; SATURATION DEFICIT	Many factors are involved in determining the latitudinal and altitudinal spread of the important tick vector Ixodes ricinus (Acari: Ixodidae) in Europe, as well as in changes in the distribution within its prior endemic zones. This paper builds on published literature and unpublished expert opinion from the VBORNET network with the aim of reviewing the evidence for these changes in Europe and discusses the many climatic, ecological, landscape and anthropogenic drivers. These can be divided into those directly related to climatic change, contributing to an expansion in the tick's geographic range at extremes of altitude in central Europe, and at extremes of latitude in Scandinavia; those related to changes in the distribution of tick hosts, particularly roe deer and other cervids; other ecological changes such as habitat connectivity and changes in land management; and finally, anthropogenically induced changes. These factors are strongly interlinked and often not well quantified. Although a change in climate plays an important role in certain geographic regions, for much of Europe it is non-climatic factors that are becoming increasingly important. How we manage habitats on a landscape scale, and the changes in the distribution and abundance of tick hosts are important considerations during our assessment and management of the public health risks associated with ticks and tick-borne disease issues in 21st century Europe. Better understanding and mapping of the spread of I. ricinus (and changes in its abundance) is, however, essential to assess the risk of the spread of infections transmitted by this vector species. Enhanced tick surveillance with harmonized approaches for comparison of data enabling the follow-up of trends at EU level will improve the messages on risk related to tick-borne diseases to policy makers, other stake holders and to the general public.	[Medlock, Jolyon M.; Hansford, Kayleigh M.] Hlth Protect Agcy, Emergency Response Dept, MRA, Med Entomol Grp, Salisbury, Wilts, England; [Bormane, Antra] Ctr Dis Control & Prevent, Riga, Latvia; [Derdakova, Marketa] Slovak Acad Sci, Inst Parasitol, Kosice, Slovakia; [Estrada-Pena, Agustin] Univ Zaragoza, Zaragoza, Spain; [Golovljova, Irina] Natl Inst Hlth Dev, Dept Virol, Tallinn, Estonia; [Jaenson, Thomas G. T.] Uppsala Univ, Uppsala, Sweden; [Jensen, Per M.] Univ Copenhagen, Copenhagen, Denmark; [Derdakova, Marketa; Kazimirova, Maria] Slovak Acad Sci, Inst Zool, Bratislava, Slovakia; [Oteo, Jose A.] Hosp San Pedro, Ctr Invest Biomed La Rioja, Logrono, Spain; [Papa, Anna] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece; [Pfister, Kurt] Univ Munich, Munich, Germany; [Plantard, Olivier] Ecole Natl Vet Agroalimentaire & Alimentat, Inst Natl Rech Agron, Nantes, France; [Randolph, Sarah E.] Univ Oxford, Oxford, England; [Rizzoli, Annapaola] Fdn Edmund Mach, San Michele All Adige, TN, Italy; [Santos-Silva, Maria Margarida] CEVDI, Inst Nacl Saude Dr Ricardo Jorge, Lisbon, Portugal; [Sprong, Hein] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands; [Vial, Laurence] CIRAD, Montpellier, France; [Hendrickx, Guy] Avia GIS, Zoersel, Belgium; [Zeller, Herve; Van Bortel, Wim] European Ctr Dis Prevent & Control, Stockholm, Sweden	Medlock, JM (reprint author), Hlth Protect Agcy, Emergency Response Dept, MRA, Med Entomol Grp, Salisbury, Wilts, England.	jolyon.medlock@hpa.org.uk	Rizzoli, Annapaola/B-8583-2011; Rizzoli, Annapaola/J-2439-2012; Jensen, Per/J-8182-2012; Santos-Silva, Maria Margarida/T-9174-2018; Kazimirova, Maria/U-8222-2017	Rizzoli, Annapaola/0000-0003-3997-6783; Jensen, Per/0000-0001-8792-7711; Santos-Silva, Maria Margarida/0000-0003-4104-6622; Van Bortel, Wim/0000-0002-6644-518X; Jaenson, Thomas/0000-0003-0780-7475; Sprong, Hein/0000-0002-0218-4320; Estrada Pena, Agustin/0000-0001-7483-046X	EU [FP7-261504 EDENext]; ECDC service [ECD 2009/018]	The work was conducted by the European network of medical entomologists and public health experts (VBORNET) under ECDC service contract ECD 2009/018. The authors gratefully acknowledge experts from the network for their input. This work was partially funded by EU grant FP7-261504 EDENext and is catalogued by the EDENext Steering Committee as EDENext081 (http://www.edenext.eu,http://www.edenext.eu/).	Bullova M, 2008, ECOLOGY VET MED, P82; Burri C, 2007, VECTOR-BORNE ZOONOT, V7, P50, DOI 10.1089/vbz.2006.0569; Cadenas FM, 2007, J MED ENTOMOL, V44, P683, DOI 10.1603/0022-2585(2007)44[683:POIRAI]2.0.CO;2; Cagnacci F, 2011, OIKOS, V120, P1790, DOI 10.1111/j.1600-0706.2011.19441.x; Campbell JA, 1948, THESIS U EDINBURGH E; Casati S, 2008, INFECT GENET EVOL, V8, P152, DOI 10.1016/j.meeid.2007.11.007; CRAINE NG, 1995, FOLIA PARASIT, V42, P73; Daniel M, 2004, INT J MED MICROBIOL, V293, P55, DOI 10.1016/S1433-1128(04)80009-3; Daniel M, 2003, EUR J CLIN MICROBIOL, V22, P327, DOI 10.1007/s10096-003-0918-2; Daniel M, 2008, INT J MED MICROBIOL, V298, P81, DOI 10.1016/j.ijmm.2008.02.006; Danielova V, 2006, INT J MED MICROBIOL, V296, P48, DOI 10.1016/j.ijmm.2006.02.007; Danielova Vlasta, 2008, Central European Journal of Public Health, V16, P4; Danielova V, 2008, INT J MED MICROBIOL, V298, P68, DOI 10.1016/j.ijmm.2008.02.005; Danielova V, 2010, VECTOR-BORNE ZOONOT, V10, P223, DOI 10.1089/vbz.2009.0020; de Meeus T, 2002, EVOLUTION, V56, P1802, DOI 10.1554/0014-3820(2002)056[1802:SBGSIT]2.0.CO;2; Delaye C, 1997, INT J PARASITOL, V27, P769, DOI 10.1016/S0020-7519(97)00040-4; Dobson ADM, 2011, J APPL ECOL, V48, P1029, DOI 10.1111/j.1365-2664.2011.02004.x; Dobson ADM, 2011, TICKS TICK-BORNE DIS, V2, P67, DOI 10.1016/j.ttbdis.2011.03.002; Estrada-Pena A, 2003, ECOGRAPHY, V26, P661, DOI 10.1034/j.1600-0587.2003.03530.x; Estrada-Pena A, 1998, ZBL BAKT-INT J MED M, V287, P185; Estrada-Pena A, 2002, EXP APPL ACAROL, V28, P239, DOI 10.1023/A:1025362903620; Estrada-Pena A, 2001, VET PARASITOL, V98, P111, DOI 10.1016/S0304-4017(01)00426-5; Estrada-Pena A, 2012, EXP APPL ACAROL, V28; EstradaPena A, 1996, EXP APPL ACAROL, V20, P457, DOI 10.1007/BF00053309; Fourie LJ, 2001, MED VET ENTOMOL, V15, P335, DOI 10.1046/j.0269-283x.2001.00313.x; Gargili A, 2010, J FACULTY VET MED; Gassner F, 2011, VECTOR-BORNE ZOONOT, V11, P523, DOI 10.1089/vbz.2010.0026; George JC, 2002, B SOC PATHOL EXOT, V95, P95; Gern L, 2008, INT J MED MICROBIOL, V298, P55, DOI 10.1016/j.ijmm.2008.01.005; Gilbert L, 2010, OECOLOGIA, V162, P217, DOI 10.1007/s00442-009-1430-x; GRAY JS, 1992, J MED ENTOMOL, V29, P915, DOI 10.1093/jmedent/29.6.915; Han HQ, 2001, J MED VIROL, V64, P21, DOI 10.1002/jmv.1012; HOFHUIS A, 2006, EUROSURVEILLANCE, V11; Holzmann H, 2009, EMERG INFECT DIS, V15, P1671, DOI 10.3201/eid1510.090743; Hoodless AN, 1998, GIBIER FANE SAUVAGE - GAME AND WILDLIFE, VOL 15 (SPECIAL NUMBER PTS 2 AND 3) 1998, P477; Hrkl'ova G., 2008, Folia Veterinaria, V52, P62; Hubalek Z, 1996, J MED ENTOMOL, V33, P766, DOI 10.1093/jmedent/33.5.766; Hubalek Zdenek, 2009, V37, P31, DOI 10.1159/000213069; HUMAIR PF, 1993, FOLIA PARASIT, V40, P237; HUMAIR PF, 1993, FOLIA PARASIT, V40, P65; Humair PF, 1998, ZBL BAKT-INT J MED M, V287, P521, DOI 10.1016/S0934-8840(98)80194-1; Jaenson TGT, 2009, MED VET ENTOMOL, V23, P226, DOI 10.1111/j.1365-2915.2009.00813.x; Jaenson TGT, 1996, J MED ENTOMOL, V33, P339, DOI 10.1093/jmedent/33.3.339; JAENSON TGT, 1994, J MED ENTOMOL, V31, P240, DOI 10.1093/jmedent/31.2.240; Jaenson TGT, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-8; Jaenson TGT, 2011, TICKS TICK-BORNE DIS, V2, P44, DOI 10.1016/j.ttbdis.2010.10.006; Jaenson Thomas G. T., 2007, Norwegian Journal of Entomology, V54, P11; Jameson LJ, 2011, VECTOR-BORNE ZOONOT, V11, P403, DOI 10.1089/vbz.2010.0079; Jensen PM, 2000, SCAND J INFECT DIS, V32, P545, DOI 10.1080/003655400458857; Jensen PM, 2005, EXP APPL ACAROL, V35, P131, DOI 10.1007/s10493-004-1991-7; Jore S, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-84; Jouda F, 2004, J MED ENTOMOL, V41, P162, DOI 10.1603/0022-2585-41.2.162; Jouda F, 2004, VECTOR-BORNE ZOONOT, V4, P23, DOI 10.1089/153036604773082960; Kempf F, 2011, INFECT GENET EVOL, V11, P2043, DOI 10.1016/j.meegid.2011.09.016; Kjelland V, 2010, ACTA VET SCAND, V52, DOI 10.1186/1751-0147-52-59; Lindgren E, 2000, ENVIRON HEALTH PERSP, V108, P119, DOI 10.2307/3454509; Lindgren E, 2006, STUD WRIT, V18, P157; Materna J., 2005, Central European Journal of Public Health, V13, P24; Materna J, 2008, INT J MED MICROBIOL, V298, P25, DOI 10.1016/j.ijmm.2008.05.004; Medlock JM, 2008, J MED ENTOMOL, V45, P314, DOI 10.1603/0022-2585(2008)45[314:IOEAED]2.0.CO;2; Medlock JM, 2012, J VECTOR ECOL, V37, P307, DOI 10.1111/j.1948-7134.2012.00232.x; MILNE A, 1949, PARASITOLOGY, V39, P173, DOI 10.1017/S0031182000083736; Milne A, 1943, ANN APPL BIOL, V30, P240, DOI 10.1111/j.1744-7348.1943.tb06195.x; MILNE A, 1950, PARASITOLOGY, V40, P14, DOI 10.1017/S0031182000017820; Noureddine R, 2011, INT J PARASITOL, V41, P183, DOI 10.1016/j.ijpara.2010.08.010; OLSEN B, 1995, APPL ENVIRON MICROB, V61, P3082; Omeragic J, 2011, EXP APPL ACAROL, V53, P301, DOI 10.1007/s10493-010-9402-8; Papa A, 2008, EMERG INFECT DIS, V14, P330, DOI 10.3201/eid1402.070889; Papa A, 2011, VECTOR-BORNE ZOONOT, V11, P539, DOI 10.1089/vbz.2010.0036; Parola P, 2001, CLIN MICROBIOL INFEC, V7, P80, DOI 10.1046/j.1469-0691.2001.00200.x; Perret JL, 2000, PARASITOL RES, V86, P554, DOI 10.1007/s004360000209; Perret JL, 2003, J EXP BIOL, V206, P1809, DOI 10.1242/jeb.00345; Randolph SE, 2002, INT J PARASITOL, V32, P979, DOI 10.1016/S0020-7519(02)00030-9; Randolph SE, 2004, PARASITOLOGY, V129, pS37, DOI 10.1017/S0031182004004925; Randolph SE, 2008, PARASITE VECTOR, V1, pe44; Rizzoli A, 2002, J MED ENTOMOL, V39, P485, DOI 10.1603/0022-2585-39.3.485; Rizzoli A, 2011, EUROSURVEILLANCE, V16, P2; Rizzoli A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004336; Santos-Silva MM, 2011, EXP APPL ACAROL, V55, P85, DOI 10.1007/s10493-011-9440-x; Santos-Silva MM, 2011, INT C TICKS TICK BOR; Scharlemann JPW, 2008, MED VET ENTOMOL, V22, P238, DOI 10.1111/j.1365-2915.2008.00734.x; Schwarz A, 2009, INT J HYG ENVIR HEAL, V212, P87, DOI 10.1016/j.ijheh.2007.12.001; Sreter T, 2005, VET PARASITOL, V128, P347, DOI 10.1016/j.vetpar.2004.11.025; Sumilo D, 2008, REV MED VIROL, V18, P81, DOI 10.1002/rmv.566; Sumilo D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000500; Szell Z, 2006, VET PARASITOL, V141, P377, DOI 10.1016/j.vetpar.2006.06.008; TALLEKLINT L, 1994, J MED ENTOMOL, V31, P880, DOI 10.1093/jmedent/31.6.880; Talleklint L, 1998, J MED ENTOMOL, V35, P521, DOI 10.1093/jmedent/35.4.521; Tersago K, 2011, EPIDEMIOL INFECT, V139, P381, DOI 10.1017/S0950268810000956; Vanwambeke SO, 2010, VECTOR-BORNE ZOONOT, V10, P497, DOI 10.1089/vbz.2009.0116; Zeman P, 2004, INT J MED MICROBIOL, V293, P48, DOI 10.1016/S1433-1128(04)80008-1	91	211	216	55	454	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	JAN 2	2013	6								1	10.1186/1756-3305-6-1				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	075TE	WOS:000313908600001	23281838	DOAJ Gold, Green Published	Y	N	2019-03-26	
J	Pieretti, S; Haanstra, JR; Mazet, M; Perozzo, R; Bergamini, C; Prati, F; Fato, R; Lenaz, G; Capranico, G; Brun, R; Bakker, BM; Michels, PAM; Scapozza, L; Bolognesi, ML; Cavalli, A				Pieretti, Simone; Haanstra, Jurgen R.; Mazet, Muriel; Perozzo, Remo; Bergamini, Christian; Prati, Federica; Fato, Romana; Lenaz, Giorgio; Capranico, Giovanni; Brun, Reto; Bakker, Barbara M.; Michels, Paul A. M.; Scapozza, Leonardo; Bolognesi, Maria Laura; Cavalli, Andrea			Naphthoquinone Derivatives Exert Their Antitrypanosomal Activity via a Multi-Target Mechanism	PLOS NEGLECTED TROPICAL DISEASES			English	Article							GLYCOSOMAL GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PROCYCLIC TRYPANOSOMA-BRUCEI; DRUG DISCOVERY; CHEMICAL PROTEOMICS; SYNTHETIC NAPHTHOQUINONES; TROPICAL DISEASES; BLOOD-STREAM; IN-VITRO; TARGET; CRUZI	Background and Methodology: Recently, we reported on a new class of naphthoquinone derivatives showing a promising anti-trypanosomatid profile in cell-based experiments. The lead of this series (B6, 2-phenoxy-1,4-naphthoquinone) showed an ED50 of 80 nM against Trypanosoma brucei rhodesiense, and a selectivity index of 74 with respect to mammalian cells. A multitarget profile for this compound is easily conceivable, because quinones, as natural products, serve plants as potent defense chemicals with an intrinsic multifunctional mechanism of action. To disclose such a multitarget profile of B6, we exploited a chemical proteomics approach. Principal Findings: A functionalized congener of B6 was immobilized on a solid matrix and used to isolate target proteins from Trypanosoma brucei lysates. Mass analysis delivered two enzymes, i.e. glycosomal glycerol kinase and glycosomal glyceraldehyde-3-phosphate dehydrogenase, as potential molecular targets for B6. Both enzymes were recombinantly expressed and purified, and used for chemical validation. Indeed, B6 was able to inhibit both enzymes with IC50 values in the micromolar range. The multifunctional profile was further characterized in experiments using permeabilized Trypanosoma brucei cells and mitochondrial cell fractions. It turned out that B6 was also able to generate oxygen radicals, a mechanism that may additionally contribute to its observed potent trypanocidal activity. Conclusions and Significance: Overall, B6 showed a multitarget mechanism of action, which provides a molecular explanation of its promising anti-trypanosomatid activity. Furthermore, the forward chemical genetics approach here applied may be viable in the molecular characterization of novel multitarget ligands.	[Pieretti, Simone; Prati, Federica; Bolognesi, Maria Laura; Cavalli, Andrea] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy; [Pieretti, Simone; Perozzo, Remo; Scapozza, Leonardo] Univ Lausanne, Univ Geneva, Sch Pharmaceut Sci, Pharmaceut Biochem Grp, Geneva, Switzerland; [Pieretti, Simone; Bergamini, Christian; Fato, Romana; Lenaz, Giorgio; Capranico, Giovanni] Univ Bologna, Dept Biochem, I-40126 Bologna, Italy; [Haanstra, Jurgen R.; Bakker, Barbara M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Ctr Liver Digest & Metab Dis, NL-9700 AB Groningen, Netherlands; [Haanstra, Jurgen R.; Bakker, Barbara M.] Vrije Univ Amsterdam, Dept Mol Cell Physiol, Fac Earth & Life Sci, Amsterdam, Netherlands; [Mazet, Muriel; Michels, Paul A. M.] Catholic Univ Louvain, Duve Inst, Trop Dis Res Unit, B-1200 Brussels, Belgium; [Mazet, Muriel; Michels, Paul A. M.] Catholic Univ Louvain, Biochem Lab, B-1200 Brussels, Belgium; [Prati, Federica; Cavalli, Andrea] Ist Italiano Tecnol, Dept Drug Discovery & Dev, Genoa, Italy; [Brun, Reto] Swiss Trop Inst, CH-4002 Basel, Switzerland	Pieretti, S (reprint author), Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.	marialaura.bolognesi@unibo.it; andrea.cavalli@unibo.it	Pieretti, Stefano/I-8634-2018; Capranico, Giovanni/K-1678-2014; Michels, Paul/A-5637-2009	Pieretti, Stefano/0000-0001-5926-6194; Capranico, Giovanni/0000-0002-8708-6454; Michels, Paul/0000-0003-3726-6104; Haanstra, Jurgen/0000-0001-9652-0219; Bakker, Barbara/0000-0001-6274-3633; Prati, Federica/0000-0002-8483-7646	University of Bologna; University of Geneva; Swiss National Science Foundation [3100A0-120566/1]; NWO Vernieuwingsimpuls grant; SysMO project SilicoTryp; University of Groningen, The Netherlands; EC [CM-0801]; F.R.S.-FNRS (Belgium)	The following sources have provided funding for this work: the University of Bologna, the University of Geneva, and in part the Swiss National Science Foundation grant no. 3100A0-120566/1. JRH and BMB were supported by an NWO Vernieuwingsimpuls grant to BMB and by SysMO project SilicoTryp. BMB has a Rosalind Franklin Fellowship from the University of Groningen, The Netherlands. SP thanks the COST Action CM-0801 ''New Drugs for Neglected Diseases'' of the EC for a grant that enabled him to work for three months in the 'de Duve Institute' in Brussels. MM acknowledges a postdoctoral fellowship from the F.R.S.-FNRS (Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Albert MA, 2005, J BIOL CHEM, V280, P28306, DOI 10.1074/jbc.M502403200; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; Bergmeyer H. U., 1974, METHODS ENZYMATIC AN; Biebinger S, 1997, MOL BIOCHEM PARASIT, V85, P99, DOI 10.1016/S0166-6851(96)02815-0; Bolognesi ML, 2008, BIOORG MED CHEM LETT, V18, P2272, DOI 10.1016/j.bmcl.2008.03.009; Bolognesi ML, 2011, CURR TOP MED CHEM, V11, P2824; BOVERIS A, 1978, COMP BIOCHEM PHYS C, V61, P327, DOI 10.1016/0306-4492(78)90063-1; BRUN R, 1979, ACTA TROP, V36, P289; BRUN R, 1994, VET PARASITOL, V52, P37, DOI 10.1016/0304-4017(94)90033-7; Brun R, 2010, LANCET, V375, P148, DOI 10.1016/S0140-6736(09)60829-1; Castillo E, 2010, CURR MED CHEM, V17, P4027, DOI 10.2174/092986710793205345; Cavalli A, 2010, FEMS IMMUNOL MED MIC, V58, P51, DOI 10.1111/j.1574-695X.2009.00615.x; Cavalli A, 2009, J MED CHEM, V52, P7339, DOI 10.1021/jm9004835; Collins MH, 2011, INFECT IMMUN, V79, P3397, DOI 10.1128/IAI.01080-10; Copeland R. A., 2000, ENZYMES PRACTICAL IN; Copeland Robert A, 2005, Methods Biochem Anal, V46, P1; Cordeiro AT, 2009, BIOORGAN MED CHEM, V17, P2483, DOI 10.1016/j.bmc.2009.01.068; DEDUVE C, 1964, J THEOR BIOL, V6, P33, DOI 10.1016/0022-5193(64)90065-7; Fato R, 2008, BIOFACTORS, V32, P31, DOI 10.1002/biof.5520320105; Fevre EM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000333; Gilbert IH, 2011, CURR TOP MED CHEM, V11, P1284; Guiffant Damien, 2007, Biotechnology Journal, V2, P68, DOI 10.1002/biot.200600223; Gupta S, 2011, MOL BIOCH PARASITOL; Haanstra JR, 2011, MOL MICROBIOL, V79, P94, DOI 10.1111/j.1365-2958.2010.07435.x; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V; HANNAERT V, 1995, PROTEIN EXPRES PURIF, V6, P244, DOI 10.1006/prep.1995.1031; Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142; Jeffery DA, 2003, CURR OPIN BIOTECH, V14, P87, DOI 10.1016/S0958-1669(02)00010-1; Jenwitheesuk E, 2005, JAMA-J AM MED ASSOC, V294, P1490, DOI 10.1001/jama.294.12.1490; Kayser O, 2003, PARASITOL RES, V90, pS55, DOI 10.1007/s00436-002-0768-3; Kralova I, 2000, EUR J BIOCHEM, V267, P2323, DOI 10.1046/j.1432-1327.2000.01238.x; Krohn K, 2007, LAPACHOL OVERVIEW AR, P145; Kuettel S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000506; Lamour N, 2005, J BIOL CHEM, V280, P11902, DOI 10.1074/jbc.M414274200; Lomenick B, 2011, ACS CHEM BIOL, V6, P34, DOI 10.1021/cb100294v; Menna-Barreto RFS, 2009, FREE RADICAL BIO MED, V47, P644, DOI 10.1016/j.freeradbiomed.2009.06.004; Mercer L, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000956; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; Morello A, 1995, COMP BIOCHEM PHYS C, V112, P119, DOI 10.1016/0742-8413(95)02003-9; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144; Olivier BG, 2005, BIOINFORMATICS, V21, P560, DOI 10.1093/bioinformatics/bti046; Orhan I, 2006, PHYTOMEDICINE, V13, P388, DOI 10.1016/j.phymed.2005.10.010; Pink R, 2005, NAT REV DRUG DISCOV, V4, P727, DOI 10.1038//nrd1824; Pinto AV, 2009, MOLECULES, V14, P4570, DOI 10.3390/molecules14114570; Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X; Raz B, 1997, ACTA TROP, V68, P139, DOI 10.1016/S0001-706X(97)00079-X; Renslo AR, 2006, NAT CHEM BIOL, V2, P701, DOI 10.1038/nchembio837; Salas CO, 2011, CURR MED CHEM, V18, P144; Sato S, 2010, CHEM BIOL, V17, P616, DOI 10.1016/j.chembiol.2010.05.015; Schelling P, 2001, ANAL BIOCHEM, V295, P82, DOI 10.1006/abio.2001.5191; Shiyama T, 2004, BIOORGAN MED CHEM, V12, P2831, DOI 10.1016/j.bmc.2004.03.052; Stuart K, 2008, J CLIN INVEST, V118, P1301, DOI 10.1172/JCI33945; Terstappen GC, 2007, NAT REV DRUG DISCOV, V6, P891, DOI 10.1038/nrd2410; Tisdale EJ, 2004, J BIOL CHEM, V279, P54046, DOI 10.1074/jbc.M409472200; Totrov M, 1997, PROTEINS, P215; Totrov M., 2001, DRUG RECEPTOR THERMO, P603; Turrens Julio F., 2004, Molecular Aspects of Medicine, V25, P211, DOI 10.1016/j.mam.2004.02.021; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; Verlinde CLM, 2001, DRUG RESIST UPDATE, V4, P50, DOI 10.1054/drup.2000.0177; WINK M, 2008, MODERN ALKALOIDS STR, P1; Wissner A, 2005, J MED CHEM, V48, P7560, DOI 10.1021/jm050559f; Wu HQ, 2005, EUR J MED CHEM, V40, P1341, DOI 10.1016/j.ejmech.2005.05.004; Yamey G, 2002, BRIT MED J, V325, P176, DOI 10.1136/bmj.325.7357.176	65	20	20	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JAN	2013	7	1							e2012	10.1371/journal.pntd.0002012				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	081ZB	WOS:000314360200040	23350008	DOAJ Gold, Green Published			2019-03-26	
J	Mohan, VR; Tharmalingam, J; Muliyil, J; Oommen, A; Dorny, P; Vercruysse, J; Vedantam, R				Mohan, Venkata Raghava; Tharmalingam, Jayaraman; Muliyil, J.; Oommen, A.; Dorny, P.; Vercruysse, J.; Vedantam, Rajshekhar			Prevalence of porcine cysticercosis in Vellore, South India	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Taenia solium; Cysticercosis; Pig; ELISA; EITB; India	EXCRETORY-SECRETORY ANTIGENS; TAENIA-SOLIUM INFECTION; PIGS; NEUROCYSTICERCOSIS; DIAGNOSIS; ANTIBODY; ELISA; ASSAY; BLOT	Background: Porcine cysticercosis is acquired by pigs through consumption of human faeces containing Taenia solium ova and indicates the presence of active transmission of the parasite between pigs and humans. Methods: The prevalence of porcine cysticercosis was assessed by an antigen ELISA and enzyme linked immunoelectrotransfer blot (EITB) for antibodies in rural and urban areas of southern India. Results: Of the 112 porcine blood samples, 13 (11.6%) were positive for cysticercal antigens and the free-range pigs were 3.6 times more likely to be infected than the slaughtered pigs and 67 (59.8 %) tested positive for serum antibodies indicating high exposure to T. solium eggs. Conclusion: The high prevalence of porcine cysticercosis recorded in the study areas mandates public health measures, which includes meat inspection.	[Mohan, Venkata Raghava; Muliyil, J.] Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632002, Tamil Nadu, India; [Tharmalingam, Jayaraman; Oommen, A.; Vedantam, Rajshekhar] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632002, Tamil Nadu, India; [Dorny, P.; Vercruysse, J.] Univ Ghent, Dept Virol Parasitol & Immunol, Ghent, Belgium; [Dorny, P.] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium	Mohan, VR (reprint author), Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632002, Tamil Nadu, India.	venkat@cmcvellore.ac.in	Tharmalingam, Jayaraman/G-2542-2013	Tharmalingam, Jayaraman/0000-0002-7071-2797; Mohan, Venkata Raghava/0000-0001-5787-7223	Flemish Interuniversity Council, Belgium	This study was part of a larger study which was supported by the Flemish Interuniversity Council, Belgium.	BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; D'Souza Placid E., 1999, Indian Veterinary Journal, V76, P285; DIAZ F, 1992, AM J EPIDEMIOL, V135, P875, DOI 10.1093/oxfordjournals.aje.a116383; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; DRAELANTS E, 1995, PARASITE IMMUNOL, V17, P119, DOI 10.1111/j.1365-3024.1995.tb01013.x; Garcia HH, 2006, LANCET NEUROL, V5, P20; Mohammed H, 2004, J PARASIT DIS, V28, P118; PATHAK KML, 1990, VET PARASITOL, V34, P353, DOI 10.1016/0304-4017(90)90081-L; PATHAK KML, 1982, VET PARASITOL, V10, P91, DOI 10.1016/0304-4017(82)90012-7; PATHAK KML, 1994, VET PARASITOL, V53, P209, DOI 10.1016/0304-4017(94)90184-8; Prabhakaran V, 2004, T ROY SOC TROP MED H, V98, P478, DOI 10.1016/j.trstmh.2003.12.006; Prakash A, 2007, TROP ANIM HEALTH PRO, V39, P391, DOI 10.1007/s11250-007-9040-2; Prasad KN, 2002, T ROY SOC TROP MED H, V96, P515, DOI 10.1016/S0035-9203(02)90423-2; Rajnish Sharma, 2004, Journal of Parasitic Diseases, V28, P124; Rajshekhar V, 2006, NEUROLOGY, V67, P2135, DOI 10.1212/01.wnl.0000249113.11824.64; Sciutto E, 1998, VET PARASITOL, V78, P185, DOI 10.1016/S0304-4017(98)00129-0; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50	17	6	6	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN	2013	107	1					62	64		10.1093/trstmh/trs003				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	079TI	WOS:000314194700010	23296699				2019-03-26	
J	Thomas, SJ; Eckels, KH; Carletti, I; De La Barrera, R; Dessy, F; Fernandez, S; Putnak, R; Toussaint, JF; Sun, W; Bauer, K; Gibbons, RV; Innis, BL				Thomas, Stephen J.; Eckels, Kenneth H.; Carletti, Isabelle; De La Barrera, Rafael; Dessy, Francis; Fernandez, Stefan; Putnak, Robert; Toussaint, Jean-Francois; Sun, Wellington; Bauer, Kristen; Gibbons, Robert V.; Innis, Bruce L.			A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							FLAVIVIRUS-NAIVE ADULTS; HEMORRHAGIC-FEVER; CANDIDATE; FORMULATIONS; SEROTYPES; SEVERITY; CELLS; TRIAL	Two formulations of a new live tetravalent dengue virus (DENV) vaccine produced using re-derived master seeds from a precursor vaccine and that same precursor vaccine as a control were compared in a placebo-controlled, randomized, observer-blind, phase II trial of 86 healthy adults. Two vaccine doses were administered 6 months apart; a third dose was offered to a subset. Symptoms and signs of dengue-like illness reported after vaccination were mild to moderate, transient, and occurred with similar frequency among recipients of the new DENV vaccine and placebo, except for rash. Neither dengue nor vaccine-related serious adverse events were reported. The first DENV vaccine dose was moderately immunogenic; the second dose increased the potency and breadth of the neutralizing antibody response. Tetravalent response rates to the new formulations were 60% and 66.7% in unprimed subjects. A third dose did not increase tetravalent antibody rates. The new DENV vaccine candidates merit additional evaluation.	[Thomas, Stephen J.; Putnak, Robert] Walter Reed Army Inst Res, Viral Dis Branch, Silver Spring, MD 20910 USA; [Eckels, Kenneth H.; De La Barrera, Rafael] Walter Reed Army Inst Res, Div Regulated Activ, Pilot Bioprod Facil, Silver Spring, MD 20910 USA; [Dessy, Francis] GlaxoSmithKline Vaccines, Vaccine Discovery & Dev, Viral Funct Immunol, Wavre, Belgium; [Gibbons, Robert V.] US Army Med Component Armed Forces Res Inst Med S, Dept Virol, Bangkok, Thailand; [Innis, Bruce L.] GlaxoSmithKline Vaccines, King Of Prussia, PA USA	Thomas, SJ (reprint author), Walter Reed Army Inst Res, Viral Dis Branch, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	stephen.thomas@amedd.army.mil; kenneth.eckels@amedd.army.mil; isabelle.x.carletti@gsk.com; rafael.delabarrera@amedd.army.mil; francis.dessy@gsk.com; Stefan.Fernandez@afrims.org; robert.putnak@amedd.army.mil; jean-francois.x.toussaint@gsk.com; Wellington.Sun@fda.hhs.gov; Kristen.Bauer@afrims.org; Robert.gibbons@afrims.org; bruce.2.innis@gsk.com		Toussaint, Jean-Francois/0000-0003-1964-5039; Innis, Bruce/0000-0002-1753-7248	US Army Medical Research and Materiel Command (Fort Detrick, MD); GlaxoSmithKline Biologicals S.A. (Rixensart, Belgium); US Department of Defense	This work was funded by US Army Medical Research and Materiel Command (Fort Detrick, MD) and GlaxoSmithKline Biologicals S.A. (Rixensart, Belgium).; S.J.T. received travel grants from the US Department of Defense. K.H.E., R.P., W.S., and B.L.I. are named inventors on several patents or patent applications related to the field of vaccine development. I.C., F.D., J.-F.T. and B.L.I. are employees of the GSK group of companies. R.P. received royalties from GSK. J.-F.T. and B.L.I. own shares and options to shares in GSK. All other authors import no potential conflicts. The opinions or assertions contained herein are the private views of the authors and are not to be construed as reflecting the official views of the US Army or the US Department of Defense.	Anderson KB, 2011, J INFECT DIS, V204, P442, DOI 10.1093/infdis/jir279; DELA CSB, 2007, ARCH VIROL, V152, P533, DOI DOI 10.1007/S00705-006-0869-X; Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405; Eckels KH, 2003, AM J TROP MED HYG, V69, P12, DOI 10.4269/ajtmh.2003.69.12; Edelman R, 2003, AM J TROP MED HYG, V69, P48, DOI 10.4269/ajtmh.2003.69.48; Guy B, 2010, HUM VACCINES, V6, P696, DOI 10.4161/hv.6.9.12739; Innis BL, 2003, AM J TROP MED HYG, V69, P1; International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), 2011, MED DICT REG ACT MAI; Lee IK, 2010, INT J INFECT DIS, V14, pE919, DOI 10.1016/j.ijid.2010.06.011; MACKOWIAK PA, 1994, CLIN INFECT DIS, V19, P948, DOI 10.1093/clinids/19.5.948; Morrison D, 2010, J INFECT DIS, V201, P370, DOI 10.1086/649916; Mustafa M S, 2008, Med J Armed Forces India, V64, P161, DOI 10.1016/S0377-1237(08)80065-2; Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008; Sadon N, 2008, J VIROL METHODS, V153, P1, DOI 10.1016/j.jviromet.2008.06.023; Shepard DS, 2004, VACCINE, V22, P1275, DOI 10.1016/j.vaccine.2003.09.019; Simasathien S, 2008, AM J TROP MED HYG, V78, P426, DOI 10.4269/ajtmh.2008.78.426; Sun W, 2009, HUM VACCINES, V5, P33, DOI 10.4161/hv.5.1.6348; Thomas SJ, 2011, J INFECT DIS, V203, P299, DOI 10.1093/infdis/jiq060; Thomas SJ, 2009, AM J TROP MED HYG, V81, P825, DOI 10.4269/ajtmh.2009.08-0625; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215; Watanaveeradej V, 2011, AM J TROP MED HYG, V85, P341, DOI 10.4269/ajtmh.2011.10-0501; WHO, 2012, DENG SEV DENG FACT S; Wu SJL, 2000, NAT MED, V6, P816	23	52	56	0	12	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JAN	2013	88	1					73	88		10.4269/ajtmh.2012.12-0361				16	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	073QL	WOS:000313757500013	23208878	Bronze, Green Published			2019-03-26	
J	Chitanga, S; Namangala, B; De Deken, R; Marcotty, T				Chitanga, Simbarashe; Namangala, Boniface; De Deken, Reginald; Marcotty, Tanguy			Shifting from wild to domestic hosts: The effect on the transmission of Trypanosoma congolense to tsetse flies	ACTA TROPICA			English	Article						Trypanosoma congolense; Transmissibility; Virulence; Cattle; Livestock; Wildlife; Tsetse; Glossina morsitans	GLOSSINA-MORSITANS-MORSITANS; EASTERN ZAMBIA; LIVESTOCK TRYPANOSOMIASIS; ENDEMIC AREA; STRAINS; CATTLE; EPIDEMIOLOGY; INFECTIONS; VIRULENCE; FLY	The epidemiology and impact of animal African trypanosomosis are influenced by the transmissibility and the pathogenicity of the circulating trypanosome strains in a particular biotope. The transmissibility of 22 Trypanosoma congolense strains isolated from domestic and wild animals was evaluated in a total of 1213 flies. Multivariate mixed models were used to compare infection and maturation rates in function of trypanosome origin (domestic or sylvatic) and pathogenicity. Both trypanosome pathogenicity and origin significantly affected the ability to establish a midgut infection in tsetse flies but not the maturation rates. The interaction between pathogenicity and origin was not significant. Since being pathogenic and having a domestic origin both increased transmissibility, dominant lowly pathogenic trypanosomes from domestic environments and highly pathogenic trypanosomes from sylvatic environments presented similar levels of transmissibility: 12% and 15%, respectively. Blood meals with parasite concentration ranging from 0.05 to 50 trypanosomes/mu l blood for 3 strains of T. congolense were provided to different batches of tsetse flies to evaluate the relationship between the parasite load in blood meals and the likelihood for a fly to become infected. A linear relationship between parasite load and transmissibility was observed at low parasitaemia and a plateau was observed for meals containing more than 5 trypanosomes/mu l. Maximum transmission was reached with 12.5 trypanosomes/mu l blood. About 50% of the flies were refractory to T. congolense. whatever their concentration in the blood meal. The results suggest that the dose-transmissibility relationship presents a similar profile for different T. congolense isolates. (C) 2012 Elsevier B.V. All rights reserved.	[Chitanga, Simbarashe; De Deken, Reginald; Marcotty, Tanguy] Inst Trop Med Antwerp, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Chitanga, Simbarashe; Namangala, Boniface] Univ Zambia, Sch Vet Med, Dept Paraclin Studies, Lusaka, Zambia; [Marcotty, Tanguy] Univ Pretoria, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa	Marcotty, T (reprint author), Inst Trop Med, Dept Biomed Sci, Natl Str 155, B-2000 Antwerp, Belgium.	tmarcotty@itg.be			Belgian Directorate General for Development Cooperation (DGDC)	Part of this work was supported by a PhD scholarship granted to S. Chitanga, by the Belgian Directorate General for Development Cooperation (DGDC) through the framework agreement between DGDC and the Institute of Tropical Medicine, Antwerp. We are indebted to Peter Van den Bossche (+ 11 November 2010) who initiated this research. We warmly thank Vincent Delespaux for his technical support during the experiments and for the preparation of this manuscript.	Akoda K, 2008, ACTA TROP, V107, P17, DOI 10.1016/j.actatropica.2008.04.002; Akoda K, 2009, J MED ENTOMOL, V46, P1446, DOI 10.1603/033.046.0629; Akoda K, 2009, ACTA TROP, V111, P263, DOI 10.1016/j.actatropica.2009.05.005; Aksoy S, 2003, ADV PARASIT, V53, P1, DOI 10.1016/S0065-308X(03)53002-0; ANDERSON RM, 1982, PARASITOLOGY, V85, P411, DOI 10.1017/S0031182000055360; Ducheyne E, 2009, PREV VET MED, V91, P11, DOI 10.1016/j.prevetmed.2009.05.009; Elsen Pierre, 1993, Journal of African Zoology, V107, P439; Haines LR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000793; Kubi C, 2006, MED VET ENTOMOL, V20, P388, DOI 10.1111/j.1365-2915.2006.00644.x; Lloyd LL, 1924, B ENTOMOL RES, V14, P225; Marcotty T, 2008, PREV VET MED, V87, P288, DOI 10.1016/j.prevetmed.2008.05.002; Masumu J, 2006, PARASITOLOGY, V133, P331, DOI 10.1017/S0031182006000369; Masumu J, 2006, INT J PARASITOL, V36, P497, DOI 10.1016/j.ijpara.2006.01.003; Masumu J, 2010, ACTA TROP, V113, P195, DOI 10.1016/j.actatropica.2009.09.002; Masumu J, 2009, VET PARASITOL, V163, P127, DOI 10.1016/j.vetpar.2009.04.006; MAUDLIN I, 1989, ANN TROP MED PARASIT, V83, P431, DOI 10.1080/00034983.1989.11812368; MULLA AF, 1988, PARASITOL TODAY, V4, P352, DOI 10.1016/0169-4758(88)90005-1; Neuhaus J M, 1992, Stat Methods Med Res, V1, P249, DOI 10.1177/096228029200100303; Simukoko H, 2007, VET PARASITOL, V147, P231, DOI 10.1016/j.vetpar.2007.04.005; Swallow B.M., 2000, IMP TRYP AFR AGR; Van den Bossche P, 2011, VET PARASITOL, V181, P37, DOI 10.1016/j.vetpar.2011.04.021; Van den Bossche P, 2011, PARASITE IMMUNOL, V33, P456, DOI 10.1111/j.1365-3024.2010.01277.x; Van den Bossche P, 2010, TRENDS PARASITOL, V26, P236, DOI 10.1016/j.pt.2010.02.010; Walshe DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026984	24	2	3	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	JAN	2013	125	1					32	36		10.1016/j.actatropica.2012.08.019				5	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	055LG	WOS:000312417200004	23000543				2019-03-26	
J	Bruschi, F; Carlier, Y				Bruschi, Fabrizio; Carlier, Yves			Does congenital trichinellosis exist?	ACTA TROPICA			English	Letter						Congenital trichinellosis	PREGNANCY		[Bruschi, Fabrizio] Univ Pisa, Sch Med, Dept Translat Res, NTMS, I-56126 Pisa, Italy; [Carlier, Yves] ULB, Fac Med, Lab Parasitol, B-1070 Brussels, Belgium	Bruschi, F (reprint author), Univ Pisa, Sch Med, Dept Translat Res, NTMS, Via Roma 55, I-56126 Pisa, Italy.	fabrizio.bruschi@med.unipi.it					ANCELLE T, 1988, AM J EPIDEMIOL, V127, P1302, DOI 10.1093/oxfordjournals.aje.a114923; Carlier Y, 2012, ACTA TROP, V121, P55, DOI 10.1016/j.actatropica.2011.10.018; Dubinsky P, 2001, PARASITE, V8, pS180, DOI 10.1051/parasite/200108s2180; Nunez GG, 2008, T ROY SOC TROP MED H, V102, P662, DOI 10.1016/j.trstmh.2008.03.009; Taybouavone T, 2009, VET PARASITOL, V159, P332, DOI 10.1016/j.vetpar.2008.10.046	5	0	0	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	JAN	2013	125	1					122	122		10.1016/j.actatropica.2012.09.009				1	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	055LG	WOS:000312417200019	23017824				2019-03-26	
J	Obala, AA; Simiyu, CJ; Odhiambo, DO; Nanyu, V; Chege, P; Downing, R; Mwaliko, E; Mwangi, AW; Menya, D; Chelagat, D; Nyamogoba, HDN; Ayuo, PO; O'Meara, WP; Twagirumukiza, M; Vandenbroek, D; Otsyula, BBO; de Maeseneer, J				Obala, A. A.; Simiyu, C. J.; Odhiambo, D. O.; Nanyu, V.; Chege, P.; Downing, R.; Mwaliko, E.; Mwangi, A. W.; Menya, D.; Chelagat, D.; Nyamogoba, H. D. N.; Ayuo, P. O.; O'Meara, W. P.; Twagirumukiza, M.; Vandenbroek, D.; Otsyula, B. B. O.; de Maeseneer, J.			Webuye Health and Demographic Surveillance Systems Baseline Survey of Soil-Transmitted Helminths and Intestinal Protozoa among Children up to Five Years	JOURNAL OF TROPICAL MEDICINE			English	Article								Background. The intestinal parasitic infections (IPIs) are globally endemic, and they constitute the greatest cause of illness and disease worldwide. Transmission of IPIs occurs as a result of inadequate sanitation, inaccessibility to potable water, and poor living conditions. Objectives. To determine a baseline prevalence of IPIs among children of five years and below atWebuye Health and Demographic Surveillance (HDSS) area in western Kenya. Methods. Cross-sectional survey was used to collect data. Direct saline and formal-ether-sedimentation techniques were used to process the specimens. Descriptive and inferential statistics such as Chi-square statistics were used to analyze the data. Results. A prevalence of 52.3% (417/797) was obtained with the male child slightly more infected than the female (53.5% versus 51%), but this was not significant (chi 2 = 0.482, p > 0.05). Giardia lamblia and Entamoeba histolyticawere themost common pathogenic IPIs with a prevalence of 26.1% (208/797) and 11.2% (89/797), respectively. Soil-transmitted helminths (STHs) were less common with a prevalence of 4.8% (38/797), 3.8% (30/797), and 0.13% (1/797) for Ascaris lumbricoides, hookworms, and Trichuris trichiura, respectively. Conclusions. Giardia lamblia and E. histolytica were the most prevalent pathogenic intestinal protozoa, while STHs were less common. Community-based health promotion techniques are recommended for controlling these parasites.	[Obala, A. A.; Simiyu, C. J.; Odhiambo, D. O.; Nanyu, V.; Chege, P.; Downing, R.; Mwaliko, E.; Mwangi, A. W.; Nyamogoba, H. D. N.; Ayuo, P. O.; Otsyula, B. B. O.] Moi Univ, Sch Med, Eldoret, Kenya; [Menya, D.] Moi Univ, Sch Publ Hlth, Eldoret, Kenya; [Chelagat, D.] Moi Univ, Sch Nursing, Eldoret, Kenya; [O'Meara, W. P.] Duke Univ, Durham, NC 27706 USA; [Twagirumukiza, M.; Vandenbroek, D.; de Maeseneer, J.] Univ Ghent, Ghent, Belgium	Obala, AA (reprint author), Moi Univ, Sch Med, Eldoret, Kenya.	andrew.obala@gmail.com			Moi University (Kenya)-VLIR UOS (Belgium)	The authors acknowledge the assistance received from the Provincial Administration and other stakeholders for making it possible to access the community. They thank Webuye residents for their cooperation and for accepting to participate in this study. They acknowledge the assistance of the Webuye HDSS project field supervisors and enumerators for supervision of field activities and specimen collection, respectively. Mr. Arthur Aroko, Ms. Edna Kurgat, Mr. Isaac Mutai, and Mr. Paul Olang processed and examined the specimen for which they are very grateful. They thank the Deans of Schools of Medicine, Public Health, and Nursing for granting them permission to collect data and compile this report. Funds for this project were provided by the Moi University (Kenya)-VLIR UOS (Belgium) collaborative programme.	[Anonymous], 2008, WEBUYE DISTRIC UNPUB; [Anonymous], 2012, WEBUYE CLIMATE PATTE; Appleton CC, 2009, ANN TROP MED PARASIT, V103, P249, DOI 10.1179/136485909X398212; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Chaudhry Zahid Hussain, 2004, Pakistan Journal of Zoology, V36, P267; Curtale F, 1998, HEALTH POLICY PLANN, V13, P423, DOI 10.1093/heapol/13.4.423; FAO Corporate Document Repository, 1988, P C HELD ILCA ADD AB; Hotez PJ, 2008, J CLIN INVEST, V118, P1311, DOI 10.1172/JCI34261; Jardim-Botelho A, 2008, TROP MED INT HEALTH, V13, P994, DOI 10.1111/j.1365-3156.2008.02103.x; KEUSCH GT, 1982, REV INFECT DIS, V4, P880; Mehraj V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003680; Mineno T, 2003, CURR PHARM DESIGN, V9, P841, DOI 10.2174/1381612033455260; Mugenda O. M., 1999, RES METHODS QUANTITA; Muller R., 1975, WORMS DIS MANUAL MED; Ndyomugyenyi R, 2008, T ROY SOC TROP MED H, V102, P130, DOI 10.1016/j.trstmh.2007.09.015; NOKES C, 1992, PARASITOLOGY, V104, P539, DOI 10.1017/S0031182000063800; Olsen A, 1998, T ROY SOC TROP MED H, V92, P643, DOI 10.1016/S0035-9203(98)90795-7; PILLAI DR, 2003, CURR TREAT OPT INFEC, V5, P207; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; Siddiqui M I, 2002, J Pak Med Assoc, V52, P315; Simiyu C. J., 2013, POP ASS AM ANN M PRO; SRINIVASAN V, 1987, T ROY SOC TROP MED H, V81, P973, DOI 10.1016/0035-9203(87)90369-5; Steketee RW, 2003, J NUTR, V133, p1661S, DOI 10.1093/jn/133.5.1661S; Tahir Z., 2002, BIOMEDICA, V18, P74; van Eijk AM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000370; Waqar S. N., 2003, INFECT DIS J, V12, P73	26	4	4	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-9686	1687-9694		J TROP MED	J. Trop. Med.		2013									734562	10.1155/2013/734562				7	Tropical Medicine	Tropical Medicine	V15ZU	WOS:000214587300022	23533444	DOAJ Gold, Green Published			2019-03-26	
J	Durant, JF; Irenge, LM; Fogt-Wyrwas, R; Dumont, C; Doucet, JP; Mignon, B; Losson, B; Gala, JL				Durant, Jean-Francois; Irenge, Leonid M.; Fogt-Wyrwas, Renata; Dumont, Catherine; Doucet, Jean-Pierre; Mignon, Bernard; Losson, Bertrand; Gala, Jean-Luc			Duplex quantitative real-time PCR assay for the detection and discrimination of the eggs of Toxocara canis and Toxocara cati (Nematoda, Ascaridoidea) in soil and fecal samples	PARASITES & VECTORS			English	Article						Duplex real-time PCR; ITS2; Toxocara; Eggs; Fecal; Soil; Samples	PARASITES; IDENTIFICATION; TRANSMISSION; DIAGNOSIS; ZOONOSES; IDENTITY; DOGS; FOX	Background: Toxocarosis is a zoonotic disease caused by Toxocara canis (T. canis) and/or Toxocara cati (T. cati), two worldwide distributed roundworms which are parasites of canids and felids, respectively. Infections of humans occur through ingestion of embryonated eggs of T. canis or T. cati, when playing with soils contaminated with dogs or cats feces. Accordingly, the assessment of potential contamination of these areas with these roundworms eggs is paramount. Methods: A duplex quantitative real-time PCR (2qPCR) targeting the ribosomal RNA gene internal transcribed spacer (ITS2) has been developed and used for rapid and specific identification of T. canis and T. cati eggs in fecal and soil samples. The assay was set up on DNA samples extracted from 53 adult worms including T. canis, T. cati, T. leonina, Ascaris suum (A. suum) and Parascaris equorum (P. equorum). The assay was used to assess the presence of T. cati eggs in several samples, including 12 clean soil samples spiked with eggs of either T. cati or A. suum, 10 actual soil samples randomly collected from playgrounds in Brussels, and fecal samples from cats, dogs, and other animals. 2qPCR results on dogs and cats fecal samples were compared with results from microscopic examination. Results: 2qPCR assay allowed specific detection of T. canis and T. cati, whether adult worms, eggs spiked in soil or fecal samples. The 2qPCR limit of detection (LOD) in spiked soil samples was 2 eggs per g of soil for a turnaround time of 3 hours. A perfect concordance was observed between 2qPCR assay and microscopic examination on dogs and cats feces. Conclusion: The newly developed 2qPCR assay can be useful for high throughput prospective or retrospective detection of T. canis and/or T. cati eggs in fecal samples as well as in soil samples from playgrounds, parks and sandpits.	[Durant, Jean-Francois; Irenge, Leonid M.; Gala, Jean-Luc] Catholic Univ Louvain, Inst Rech Expt & Clin, Ctr Technol Mol Appl, B-1200 Brussels, Belgium; [Irenge, Leonid M.; Gala, Jean-Luc] Belgian Armed Forces, ACOS Ops & Trg, Def Labs Dept, B-1800 Peutie, Belgium; [Fogt-Wyrwas, Renata] Univ Sch Phys Educ, Dept Biol & Environm Protect, PL-61871 Poznan, Poland; [Dumont, Catherine] Royal Mil Acad, B-1000 Brussels, Belgium; [Doucet, Jean-Pierre] Clinivet, Clin Vet Gosselies, B-6041 Gosselies, Belgium; [Mignon, Bernard; Losson, Bertrand] Univ Liege Ulg, Dept Malad Infect & Parasitaires, Fac Med Vet, B-4000 Liege, Belgium	Gala, JL (reprint author), Catholic Univ Louvain, Inst Rech Expt & Clin, Ctr Technol Mol Appl, Clos Chapelle Aux Champs 30 B1-30-24, B-1200 Brussels, Belgium.	jean-luc.gala@uclouvain.be			Ministere de la Region Wallonne (DGTRE Division de la Recherche et de la Cooperation Scientifique - project RESPIBAC) [616313]; Department Management of Scientific and Technological Research of Defence (IRSD-RSTD, Royal High Institute for Defence)	This work was funded by the Ministere de la Region Wallonne (DGTRE Division de la Recherche et de la Cooperation Scientifique - project RESPIBAC no. 616313) supporting research and development and supported by the Department Management of Scientific and Technological Research of Defence (IRSD-RSTD, Royal High Institute for Defence). We thank Elodie Carlier (IRSD-RSTD), Pierre-Alain Fonteyne (Universite catholique de Louvain - UCL) and Francoise Marechal (Universite de Liege - Ulg) for their outstanding contribution to this work.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Borecka A, 2008, J HELMINTHOL, V82, P119, DOI 10.1017/S0022149X07877522; Bouchaud O, 2000, CLIN INFECT DIS, V31, P493, DOI 10.1086/313942; Brochier B, 2007, PREV VET MED, V80, P65, DOI 10.1016/j.prevetmed.2007.01.004; Chen J, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-152; Chen J, 2012, INFECT GENET EVOL, V12, P1344, DOI 10.1016/j.meegid.2012.04.019; Dado D, 2012, ZOONOSES PUBLIC HLTH, V59, P23, DOI 10.1111/j.1863-2378.2011.01411.x; Deplazes P, 2011, VET PARASITOL, V182, P41, DOI 10.1016/j.vetpar.2011.07.014; Despommier D, 2003, CLIN MICROBIOL REV, V16, P265, DOI 10.1128/CMR.16.2.265-272.2003; Epe C, 1999, VET PARASITOL, V84, P101, DOI 10.1016/S0304-4017(99)00080-1; Falavigna-Guilherme AL, 2011, J HELMINTHOL, V25, P1; Fogt-Wyrwas R, 2007, J HELMINTHOL, V81, P75, DOI 10.1017/S0022149X07241872; Jacobs DE, 1997, ACTA TROP, V68, P191, DOI 10.1016/S0001-706X(97)00093-4; Lecouvet F, 2004, ARTHRITIS RHEUM-US, V50, P2985, DOI 10.1002/art.20462; Li MW, 2007, MOL CELL PROBE, V21, P349, DOI 10.1016/j.mcp.2007.04.004; Otranto D, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-41; Reinhard K. J., 1986, Homo, V37, P217; Robardet E, 2011, INT J PARASITOL, V41, P145, DOI 10.1016/j.ijpara.2010.08.007; Ruff MD, 1999, VET PARASITOL, V84, P337, DOI 10.1016/S0304-4017(99)00076-X; SAEGERMAN C., 2006, EPIDEMIOL SANTE ANIM, V50, P97; Smith H, 2009, TRENDS PARASITOL, V25, P182, DOI 10.1016/j.pt.2009.01.006; Uga S, 2000, VET PARASITOL, V92, P287, DOI 10.1016/S0304-4017(00)00323-X; Wise ME, 2005, MICROBES INFECT, V7, P317, DOI 10.1016/j.micinf.2004.12.005; WONG ML, 2005, BIOTECHNIQUES, V39, P1	24	14	14	1	37	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	DEC 7	2012	5								288	10.1186/1756-3305-5-288				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	066JX	WOS:000313218100001	23216873	DOAJ Gold, Green Published			2019-03-26	
J	D'Alessandro, U; Ubben, D; Hamed, K; Ceesay, SJ; Okebe, J; Taal, M; Lama, EK; Keita, M; Koivogui, L; Nahum, A; Bojang, K; Sonko, AAJ; Lalya, HF; Brabin, B				D'Alessandro, Umberto; Ubben, David; Hamed, Kamal; Ceesay, Serign Jawo; Okebe, Joseph; Taal, Makie; Lama, Eugene Kaman; Keita, Moussa; Koivogui, Lamine; Nahum, Alain; Bojang, Kalifa; Sonko, Aja Adam Jagne; Lalya, Honorat Francis; Brabin, Bernard			Malaria in infants aged less than six months - is it an area of unmet medical need?	MALARIA JOURNAL			English	Article						Malaria; Neonate; Congenital; Prevalence; Parasitaemia; Artemisinin-based combination therapy	PLASMODIUM-FALCIPARUM MALARIA; SUB-SAHARAN AFRICA; CONGENITAL MALARIA; HYPERENDEMIC AREA; NEONATAL MALARIA; CHILDREN; NIGERIA; MORTALITY; INFECTION; DISTRICT	Despite the protection provided by several factors, including maternal antibodies, the burden of malaria in young infants may be higher than previously thought. Infants with congenital or neonatal malaria may have a different clinical presentation than older children, and diagnosis may be confused with other neonatal diseases due to an overlap of clinical manifestations. In addition, there is little information on the use of artemisinin-based combination therapy in young infants. There is the need for a more accurate estimate of the parasite prevalence and the incidence of clinical malaria in infants under 6 months old, as well as a better characterization of risk factors, pharmacokinetic profiles, safety and efficacy of currently available anti-malarial treatments, in order to develop evidence-based treatment guidelines for this population.	[D'Alessandro, Umberto; Ceesay, Serign Jawo; Okebe, Joseph; Bojang, Kalifa] MRC Unit, Banjul, Gambia; [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium; [Ubben, David] MMV, CH-1215 Geneva 15, Switzerland; [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ 07936 USA; [Taal, Makie; Sonko, Aja Adam Jagne] Minist Hlth & Social Welf, Banjul, Gambia; [Lama, Eugene Kaman; Keita, Moussa; Koivogui, Lamine] Minist Hlth, Conakry, Guinea; [Nahum, Alain] Ctr Rech Entomol Cotonou, Cotonou, Benin; [Lalya, Honorat Francis] Ctr Natl Hosp Univ Hubert K Maga, Cotonou, Benin; [Brabin, Bernard] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England	D'Alessandro, U (reprint author), MRC Unit, POB 273, Banjul, Gambia.	udalessandro@mrc.gm	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Hamed, Kamal/0000-0003-1896-9736; Okebe, Joseph/0000-0001-5466-1611; Bojang, Kalifa/0000-0001-7506-0938	Sigma Tau; MMV; Medical Research Council [MC_UP_A900_1118]	UD has been invited as speaker at symposia organized by Sigma Tau and Novartis Pharma, and has received a research grant from Sigma Tau. KH is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. This declaration is made in the interest of full disclosure and not because the author considers this to be a competing interest. The other authors have no competing interest to declare.; Editorial assistance was provided by Caroline Sharp (PreScript Communications), with funding from MMV.	Abdullah S, 2007, AM J TROP MED HYG, V77, P99; Adja E Akaffou, 2009, Mali Med, V24, P36; Afolabi BM, 2001, AM J TROP MED HYG, V65, P822, DOI 10.4269/ajtmh.2001.65.822; Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; AKINDELE JA, 1993, ANN TROP PAEDIATR, V13, P273, DOI 10.1080/02724936.1993.11747658; Amaratunga C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014798; Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7; Bardaji A, 2011, J INFECT DIS, V203, P691, DOI 10.1093/infdis/jiq049; BIGGAR RJ, 1980, AM J TROP MED HYG, V29, P720, DOI 10.4269/ajtmh.1980.29.720; Brabin B., 1990, TROP DIS B, V87, P1; Carneiro I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008988; CORKILL JA, 1989, ARCH DIS CHILD, V64, P541, DOI 10.1136/adc.64.4.541; Daily JP, 2012, NEW ENGL J MED, V367, P2349, DOI 10.1056/NEJMe1213392; Dicko-Traore F., 2011, J PEDIAT PUERIC, V24, P57, DOI [10.1016/j.jpp.2011.01.002, DOI 10.1016/J.JPP.2011.01.002]; Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08; Ekanem AD, 2008, TROP DOCT, V38, P73, DOI 10.1258/td.2007.005274; Falade C, 2007, TROP MED INT HEALTH, V12, P1279, DOI 10.1111/j.1365-3156.2007.01931.x; Fischer PR, 1997, CLIN PEDIATR, V36, P411, DOI 10.1177/000992289703600706; Fischer PR, 2003, J TROP PEDIATRICS, V49, P132, DOI 10.1093/tropej/49.3.132; FISCHER PR, 1995, WESTERN J MED, V163, P395; FOLL CV, 1968, B WORLD HEALTH ORGAN, V38, P255; Geerligs PDP, 2003, B WORLD HEALTH ORGAN, V81, P205; Gitau GM, 2005, OBSTET GYNAECOL, V7, P5, DOI 10.1576/toag.7.1.005.27036; Gosling RD, 2011, CLIN MICROBIOL INFEC, V17, P1617, DOI 10.1111/j.1469-0691.2011.03660.x; Guinovart C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-36; Gwamaka M, 2012, CLIN INFECT DIS, V54, P1137, DOI 10.1093/cid/cis010; Hailegiorgis B, 2010, TROP MED INT HEALTH, V15, P1449, DOI 10.1111/j.1365-3156.2010.02646.x; Hashemzadeh A, 2005, ARCH IRAN MED, V8, P226; Ibhanesebhor SE, 1995, J TROP PEDIATRICS, V41, P330, DOI 10.1093/tropej/41.6.330; Ishengoma DRS, 2010, ANN TROP MED PARASIT, V104, P123, DOI 10.1179/136485910X12607012373993; Kamwendo DD, 2002, T ROY SOC TROP MED H, V96, P145, DOI 10.1016/S0035-9203(02)90284-1; Kassim OO, 2000, J TROP PEDIATRICS, V46, P92, DOI 10.1093/tropej/46.2.92; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Klouwenberg PMCK, 2005, ACTA TROP, V95, P81, DOI 10.1016/j.actatropica.2005.05.003; LARKIN GL, 1991, AM J TROP MED HYG, V45, P587, DOI 10.4269/ajtmh.1991.45.587; Larru B, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-310; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lesi FEA, 2010, NIGER J CLIN PRACT, V13, P134; Macdonald G., 1950, Tropical Diseases Bulletin, V47, P915; Malhotra I, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000116; MCGREGOR IA, 1956, BRIT MED J, V2, P686, DOI 10.1136/bmj.2.4994.686; Menendez C, 2007, SEMIN FETAL NEONAT M, V12, P207, DOI 10.1016/j.siny.2007.01.018; Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394; MILSAP RL, 1994, ENVIRON HEALTH PERSP, V102, P107, DOI 10.1289/ehp.94102s11107; Mosha TCE, 2010, TANZANIA J HLTH RES, V12, P1; Mukhtar M, 2007, Niger J Med, V16, P25; Mukhtar MY, 2006, J TROP PEDIATRICS, V52, P19, DOI 10.1093/tropej/fmi044; Mwangoka GW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-117; Mwaniki MK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-313; Nankabirwa V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021862; Obiajunwa PO, 2005, J TROP PEDIATRICS, V51, P219, DOI 10.1093/tropej/fmi003; Oduwole OA, 2011, AM J TROP MED HYG, V84, P386, DOI 10.4269/ajtmh.2011.10-0253; Ojukwu JU, 2004, NIG J PAEDIAT, V31, P48; Okafor U H, 2006, J Obstet Gynaecol, V26, P612, DOI 10.1080/09638280600902893; Okechukwu AA, 2011, NIGERIAN J PAEDIAT, V38, P82; Omalu IC, 2012, J TROP MED, V201; Orogade AA, 2008, J PEDIAT INFECT DISE, V3, P181; Pedro R, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-307; Pineros-Jimenez JG, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-239; Riley EM, 2000, INFECT IMMUN, V68, P5856, DOI 10.1128/IAI.68.10.5856-5863.2000; Riley EM, 2001, PARASITE IMMUNOL, V23, P51, DOI 10.1046/j.1365-3024.2001.00364.x; Runsewe-Abiodun Iyabo T, 2006, BMC Pediatr, V6, P19, DOI 10.1186/1471-2431-6-19; Sacarlal J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-67; Schwarz NG, 2008, CLIN INFECT DIS, V47, P1017, DOI 10.1086/591968; Sehgal V M, 1989, Trans R Soc Trop Med Hyg, V83 Suppl, P105, DOI 10.1016/0035-9203(89)90616-0; Sule-Odu A O, 2002, J Obstet Gynaecol, V22, P25, DOI 10.1080/01443610120101664; Thomson J G, 1935, Proc R Soc Med, V28, P391; Uneke CJ, 2007, PARASITOL RES, V101, P835, DOI 10.1007/s00436-007-0577-9; van Eijk AM, 2007, J INFECT DIS, V196, P30, DOI 10.1086/518441; Wagner G, 1998, AM J TROP MED HYG, V59, P115, DOI 10.4269/ajtmh.1998.59.115; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO Global Malaria Programme, 2012, WHO POL REC SEAS MAL; World Health Organization, 2010, GUID TREATM MAL	73	22	23	0	10	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	DEC 2	2012	11								400	10.1186/1475-2875-11-400				6	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	058SZ	WOS:000312655600001	23198986	DOAJ Gold, Green Published			2019-03-26	
J	Lunguya, O; Phoba, MF; Mundeke, SA; Bonebe, E; Mukadi, P; Muyembe, JJ; Verhaegen, J; Jacobs, J				Lunguya, Octavie; Phoba, Marie-France; Mundeke, Steve Ahuka; Bonebe, Edmonde; Mukadi, Pierre; Muyembe, Jean-Jacques; Verhaegen, Jan; Jacobs, Jan			Reply to comment on: The diagnosis of typhoid fever in the Democratic Republic of the Congo	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Letter							EXTERNAL QUALITY ASSESSMENT; TESTS		[Lunguya, Octavie; Phoba, Marie-France; Mundeke, Steve Ahuka; Bonebe, Edmonde; Mukadi, Pierre; Muyembe, Jean-Jacques] Natl Inst Biomed Res, Kinshasa, Zaire; [Lunguya, Octavie; Phoba, Marie-France; Mundeke, Steve Ahuka; Muyembe, Jean-Jacques] Univ Hosp Kinshasa, Kinshasa, Zaire; [Verhaegen, Jan] Katholieke Univ Leuven Hosp, Louvain, Belgium; [Jacobs, Jan] Inst Trop Med, B-2000 Antwerp, Belgium	Jacobs, J (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	jjacobs@itg.be					Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; Klarkowski DB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000206; Lunguya O, 2012, T ROY SOC TROP MED H, V106, P348, DOI 10.1016/j.trstmh.2012.03.006; Mukadi P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-308; Nkengasong JN, 2010, AM J CLIN PATHOL, V134, P368, DOI [10.1309/AJCPMPSINQ9BRMU6, 10.1309/AJCPMPSINO9BRMU6]; Parry CM, 2011, EXPERT REV ANTI-INFE, V9, P711, DOI [10.1586/eri.11.47, 10.1586/ERI.11.47]; World Health Organization, 2009, MAL MICR QUAL ASS MA	7	0	0	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	DEC	2012	106	12					777	777		10.1016/j.trstmh.2012.09.002				1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	076YL	WOS:000313995000013					2019-03-26	
J	Adams, ER; Jacquet, D; Schoone, G; Gidwani, K; Boelaert, M; Cunningham, J				Adams, Emily R.; Jacquet, Diane; Schoone, Gerard; Gidwani, Kamlesh; Boelaert, Marleen; Cunningham, Jane			Leishmaniasis Direct Agglutination Test: Using Pictorials as Training Materials to Reduce Inter-Reader Variability and Improve Accuracy	PLOS NEGLECTED TROPICAL DISEASES			English	Article							VISCERAL LEISHMANIASIS	Background: The Direct Agglutination Test (DAT) has a high diagnostic accuracy and remains, in some geographical areas, part of the diagnostic algorithm for Visceral Leishmaniasis (VL). However, subjective interpretation of results introduces potential for inter-reader variation. We report an assessment of inter-laboratory agreement and propose a pictorial-based approach to standardize reading of the DAT. Methodology: In preparation for a comparative evaluation of immunochromatographic diagnostics for VL, a proficiency panel of 15 well-characterized sera, DAT-antigen from a single batch and common protocol was sent to nine laboratories in Latin-America, East-Africa and Asia. Agreement (i.e., equal titre or within 1 titer) with the reading by the reference laboratory was computed. Due to significant inter-laboratory disagreement on-site refresher training was provided to all technicians performing DAT. Photos of training plates were made, and end-titres agreed upon by experienced users of DAT within the Visceral-Leishmaniasis Laboratory-Network (VL-LN). Results: Pre-training, concordance in DAT results with reference laboratories was only 50%, although agreement on negative sera was high (94%). After refresher training concordance increased to 84%; agreement on negative controls increased to 98%. Variance in readings significantly decreased after training from 3.3 titres to an average of 1.0 titre (two-sample Wilcoxon rank-sum (Mann-Whitney) test (z = -3,624 and p = 0.0003)). Conclusion: The most probable explanation for disagreement was subjective endpoint reading. Using pictorials as training materials may be a useful tool to reduce disparity in results and promote more standardized reading of DAT, without compromising diagnostic sensitivity.	[Adams, Emily R.; Schoone, Gerard] Royal Trop Inst, NL-1105 AZ Amsterdam, Netherlands; [Jacquet, Diane; Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Gidwani, Kamlesh] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Cunningham, Jane] UNICEF UNDP World Bank World Hlth Org Special Pro, Geneva, Switzerland	Adams, ER (reprint author), Royal Trop Inst, NL-1105 AZ Amsterdam, Netherlands.	e.adams@kit.nl	Adams, Emily/N-7661-2015; Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Adams, Emily/0000-0002-0816-2835	KIT; ITM; WHO/TDR	This work was supported by KIT, ITM and WHO/TDR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boelaert M, 1999, TROP MED INT HEALTH, V4, P31, DOI 10.1046/j.1365-3156.1999.00348.x; Chappuis F, 2006, BRIT MED J, V333, P723, DOI 10.1136/bmj.38917.503056.7C; Cunningham J, 2012, CLIN INFECT DIS, V55, P1312, DOI 10.1093/cid/cis716; El Harith, 1988, J CLIN MICROBIOL, V26, P1321; ELSAFI SH, 1989, T ROY SOC TROP MED H, V83, P334, DOI 10.1016/0035-9203(89)90493-8; MEREDITH SEO, 1995, J CLIN MICROBIOL, V33, P1742; Ostyn B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001284; Srividya G, 2011, PARASITOL RES, V110, P1065	8	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2012	6	12							e1946	10.1371/journal.pntd.0001946				6	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	062HN	WOS:000312910200019	23272257	DOAJ Gold, Green Published			2019-03-26	
J	Hasker, E; Lutumba, P; Chappuis, F; Kande, V; Potet, J; De Weggheleire, A; Kambo, C; Depoortere, E; Pecoul, B; Boelaert, M				Hasker, Epco; Lutumba, Pascal; Chappuis, Francois; Kande, Victor; Potet, Julien; De Weggheleire, Anja; Kambo, Charles; Depoortere, Evelyn; Pecoul, Bernard; Boelaert, Marleen			Human African Trypanosomiasis in the Democratic Republic of the Congo: A Looming Emergency?	PLOS NEGLECTED TROPICAL DISEASES			English	Editorial Material							SLEEPING SICKNESS; GAMBIENSE TRYPANOSOMIASIS; BRUCEI-GAMBIENSE		[Hasker, Epco; Depoortere, Evelyn; Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Lutumba, Pascal] Univ Kinshasa, Kinshasa, Zaire; [Chappuis, Francois] Univ Hosp Geneva, Div Int & Humanitarian Med, Geneva, Switzerland; [Chappuis, Francois] Univ Geneva, Geneva, Switzerland; [Kande, Victor] Programme Natl Lutte Trypanosomiase Humaine Afric, Kinshasa, Zaire; [Potet, Julien] Med Sans Frontieres Access Campaign, Paris, France; [De Weggheleire, Anja] Med Sans Frontieres, Kinshasa, Zaire; [Pecoul, Bernard] Drugs Neglected Dis Initiat, Geneva, Switzerland	Hasker, E (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	bpecoul@dndi.org	De Weggheleire, Anja/C-7345-2018; Boelaert, Marleen/E-2698-2012	De Weggheleire, Anja/0000-0001-9377-4766; Boelaert, Marleen/0000-0001-8051-6776			Barrett MP, 1999, LANCET, V353, P1113, DOI 10.1016/S0140-6736(98)00416-4; Chappuis F, 2010, EMERG INFECT DIS, V16, P354, DOI 10.3201/eid1602.090967; Checchi F, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-16; DEBROUWERE V, 1989, ANN SOC BELG MED TR, V69, P221; FIND, 2011, LOOP MED IS AMPL LAM; Hasker E, 2011, TROP MED INT HEALTH, V16, P869, DOI 10.1111/j.1365-3156.2011.02772.x; Laveissiere C, 1998, B WORLD HEALTH ORGAN, V76, P559; Lutumba P, 2005, EMERG INFECT DIS, V11, P1382; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Malvy D, 2011, CLIN MICROBIOL INFEC, V17, P986, DOI 10.1111/j.1469-0691.2011.03536.x; Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X; Robays J, 2007, TROP MED INT HEALTH, V12, P290, DOI 10.1111/j.1365-3165.2006.01768.x; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; Simarro PP, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-57; Torreele E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000923; Van den Enden E, 2010, ILLUSTRATED LECT NOT; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; Wembonyama S, 2007, Med Trop (Mars), V67, P447; World Health Organization, INN INT DIS MAN IDM; World Health Organization, 2012, HUM AFR TRYP SLEEP S	20	12	12	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2012	6	12							e1950	10.1371/journal.pntd.0001950				3	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	062HN	WOS:000312910200023	23272260	DOAJ Gold, Green Published			2019-03-26	
J	Mukherjee, S; Mukherjee, B; Mukhopadhyay, R; Naskar, K; Sundar, S; Dujardin, JC; Das, AK; Roy, S				Mukherjee, Sandip; Mukherjee, Budhaditya; Mukhopadhyay, Rupkatha; Naskar, Kshudiram; Sundar, Shyam; Dujardin, Jean Claude; Das, Anjan Kumar; Roy, Syamal			Imipramine Is an Orally Active Drug against Both Antimony Sensitive and Resistant Leishmania donovani Clinical Isolates in Experimental Infection	PLOS NEGLECTED TROPICAL DISEASES			English	Article							EXPERIMENTAL VISCERAL LEISHMANIASIS; APOPTOSIS-LIKE DEATH; GROWTH-FACTOR-BETA; NITRIC-OXIDE; TGF-BETA; AMPHOTERICIN-B; DNA VACCINATION; HOST-CELLS; IN-VIVO; PROMASTIGOTES	Background: In an endeavor to find an orally active and affordable antileishmanial drug, we tested the efficacy of a cationic amphiphilic drug, imipramine, commonly used for the treatment of depression in humans. The only available orally active antileishmanial drug is miltefosine with long half life and teratogenic potential limits patient compliance. Thus there is a genuine need for an orally active antileishmanial drug. Previously it was shown that imipramine, a tricyclic antidepressant alters the protonmotive force in promastigotes, but its in vivo efficacy was not reported. Methodology/Principal Findings: Here we show that the drug is highly active against antimony sensitive and resistant Leishmania donovani in both promastigotes and intracellular amastigotes and in LD infected hamster model. The drug was found to decrease the mitochondrial transmembrane potential of Leishmania donovani (LD) promastigotes and purified amastigotes after 8 h of treatment, whereas miltefosine effected only a marginal change even after 24 h. The drug restores defective antigen presenting ability of the parasitized macrophages. The status of the host protective factors TNF alpha, IFN gamma and iNOS activity increased with the concomitant decrease in IL 10 and TGF beta level in imipramine treated infected hamsters and evolution of matured sterile hepatic granuloma. The 10-day therapeutic window as a monotherapy, showing about 90% clearance of organ parasites in infected hamsters regardless of their SSG sensitivity. Conclusions: This study showed that imipramine possibly qualifies for a new use of an old drug and can be used as an effective orally active drug for the treatment of Kala-azar.	[Mukherjee, Sandip; Mukherjee, Budhaditya; Mukhopadhyay, Rupkatha; Naskar, Kshudiram; Roy, Syamal] Indian Inst Chem Biol, Council Sci & Ind Res, Kolkata, India; [Sundar, Shyam] Benaras Hindu Univ, Inst Med Sci, Varanasi, Uttar Pradesh, India; [Dujardin, Jean Claude] Inst Trop Med, B-2000 Antwerp, Belgium; [Das, Anjan Kumar] Calcutta Natl Med Coll & Hosp, Kolkata, India	Mukherjee, S (reprint author), Indian Inst Chem Biol, Council Sci & Ind Res, Kolkata, India.	sroy@iicb.res.in		mukherjee, Budhaditya/0000-0002-1058-3620	Council of Scientific and Industrial Research (CSIR), New Delhi, India; European Commission [Health-F3-2008-222895]; CSIR	This work was supported by the Council of Scientific and Industrial Research (CSIR), New Delhi, India, www.csir.res.in; and European Commission-funded Kaladrug-R project (Health-F3-2008-222895), www.leishrisk.net/kaladrug. SM, BM and RM are thankful to CSIR for fellowships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Alberts B., 2002, MOL BIOL CELL, P583; Anderson CF, 2008, J IMMUNOL, V180, P4090, DOI 10.4049/jimmunol.180.6.4090; Banerjee S, 2009, INFECT IMMUN, V77, P2330, DOI 10.1128/IAI.00057-09; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; Basu JM, 2008, ANTIMICROB AGENTS CH, V52, P1080, DOI 10.1128/AAC.01196-07; Basu JM, 2006, ANTIMICROB AGENTS CH, V50, P1788, DOI [10.1128/AAC.50.5.1788-1797.2006, 10.1128/AAC.50.5.1768-1797.2006]; Basu R, 2005, J IMMUNOL, V174, P7160, DOI 10.4049/jimmunol.174.11.7160; Basu R, 2007, J INFECT DIS, V195, P1373, DOI 10.1086/513439; Benkert O, 1996, J PSYCHIAT RES, V30, P441, DOI 10.1016/S0022-3956(96)00029-5; BENSON TJ, 1992, BIOCHEM J, V286, P9, DOI 10.1042/bj2860009; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Cagnoni PJ, 2000, J CLIN ONCOL, V18, P2476, DOI 10.1200/JCO.2000.18.12.2476; Carter KC, 2007, VACCINE, V25, P4502, DOI 10.1016/j.vaccine.2007.03.014; Chakraborty D, 2005, J IMMUNOL, V175, P3214, DOI 10.4049/jimmunol.175.5.3214; Chatelain E, 2011, DRUG DES DEV THER, V5, P175, DOI 10.2147/DDDT.S16381; Clem A, 2010, J GLOB INFECT DIS, V2, P124, DOI 10.4103/0974-777X.62863; da Luz RI, 2009, ANTIMICROB AGENTS CH, V53, P5197, DOI 10.1128/AAC.00866-09; ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E; Esperanca M, 1969, Can Med Assoc J, V101, P65; EVANS AT, 1994, BIOCHEM PHARMACOL, V48, P613, DOI 10.1016/0006-2952(94)90293-3; GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570; Gilman AG, 1990, GOODMAN GILMANS PHAR, P383; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Haldar AK, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000907; Halliwell WH, 1997, TOXICOL PATHOL, V25, P53, DOI 10.1177/019262339702500111; Kaye PM, 2004, IMMUNOL REV, V201, P239, DOI 10.1111/j.0105-2896.2004.00188.x; Kremb S, 2010, ANTIMICROB AGENTS CH, V54, P5257, DOI 10.1128/AAC.00515-10; Kubera M, 2004, INT IMMUNOPHARMACOL, V4, P185, DOI 10.1016/j.intimp.2003.11.006; Lee YJ, 1997, J IMMUNOL, V158, P2065; Li J, 1999, J IMMUNOL, V162, P974; Liew FY, 1997, PHILOS T R SOC B, V352, P1311, DOI 10.1098/rstb.1997.0115; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; McNeely TB, 1996, ARCH BIOCHEM BIOPHYS, V334, P1, DOI 10.1006/abbi.1996.0422; Melby PC, 2001, J IMMUNOL, V166, P1912, DOI 10.4049/jimmunol.166.3.1912; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mukherjee SB, 2002, J BIOL CHEM, V277, P24717, DOI 10.1074/jbc.M201961200; Mukhopadhyay R, 2011, INT J PARASITOL, V41, P1311, DOI 10.1016/j.ijpara.2011.07.013; Murphy ML, 2001, EUR J IMMUNOL, V31, P2848, DOI 10.1002/1521-4141(2001010)31:10<2848::AID-IMMU2848>3.3.CO;2-K; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; Murray HW, 2001, INT J EXP PATHOL, V82, P249, DOI 10.1046/j.1365-2613.2001.00199.x; Padigel UM, 2003, J IMMUNOL, V171, P3705, DOI 10.4049/jimmunol.171.7.3705; Pandey BD, 2009, AM J TROP MED HYG, V80, P580, DOI 10.4269/ajtmh.2009.80.580; Paris C, 2004, ANTIMICROB AGENTS CH, V48, P852, DOI 10.1128/AAC.48.3.852-859.2004; Peghini PL, 1998, GUT, V42, P807, DOI 10.1136/gut.42.6.807; Ranatunga D, 2009, P NATL ACAD SCI USA, V106, P17123, DOI 10.1073/pnas.0904955106; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rybczynska M, 2001, BRIT J CANCER, V84, P1405, DOI 10.1054/bjoc.2001.1776; Saha S, 2007, J IMMUNOL, V179, P5592, DOI 10.4049/jimmunol.179.8.5592; Sen S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002229; SHINITZKY M, 1974, J MOL BIOL, V85, P603, DOI 10.1016/0022-2836(74)90318-0; Smelt SC, 2000, J IMMUNOL, V164, P3681, DOI 10.4049/jimmunol.164.7.3681; Srivastava P, 2011, J CLIN MICROBIOL, V49, P3088, DOI 10.1128/JCM.00173-11; Stager S, 2003, INFECT IMMUN, V71, P4804, DOI 10.1128/IAI.71.8.4804-4807.2003; Stanley AC, 2007, IMMUNOL CELL BIOL, V85, P138, DOI 10.1038/sj.icb.7100011; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Sundar S, 2011, LANCET, V377, P477, DOI 10.1016/S0140-6736(10)62050-8; Sundar Shyam, 2007, Ther Clin Risk Manag, V3, P733; Szabo D, 1999, CANCER LETT, V139, P115, DOI 10.1016/S0304-3835(99)00020-8; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; TUMANG MCT, 1994, J IMMUNOL, V153, P768; Verma NK, 2004, ANTIMICROB AGENTS CH, V48, P3010, DOI 10.1128/AAC.48.8.3010-3015.2004; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; Wilson ME, 1998, J IMMUNOL, V161, P6148; ZILBERSTEIN D, 1984, SCIENCE, V226, P977, DOI 10.1126/science.6505677; ZILBERSTEIN D, 1990, BIOCHEM PHARMACOL, V39, P935, DOI 10.1016/0006-2952(90)90210-C	69	25	25	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2012	6	12							e1987	10.1371/journal.pntd.0001987				15	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	062HN	WOS:000312910200043	23301108	DOAJ Gold, Green Published			2019-03-26	
J	Stauch, A; Duerr, HP; Dujardin, JC; Vanaerschot, M; Sundar, S; Eichner, M				Stauch, Anette; Duerr, Hans-Peter; Dujardin, Jean-Claude; Vanaerschot, Manu; Sundar, Shyam; Eichner, Martin			Treatment of Visceral Leishmaniasis: Model-Based Analyses on the Spread of Antimony-Resistant L. donovani in Bihar, India	PLOS NEGLECTED TROPICAL DISEASES			English	Article							AZAR DERMAL LEISHMANIASIS; KALA-AZAR; SODIUM STIBOGLUCONATE; DRUG-RESISTANCE; TREATMENT FAILURE; IN-VIVO; THERAPY; EPIDEMIOLOGY; SUBCONTINENT; MECHANISMS	Background: Pentavalent antimonials have been the mainstay of antileishmanial therapy for decades, but increasing failure rates under antimonial treatment have challenged further use of these drugs in the Indian subcontinent. Experimental evidence has suggested that parasites which are resistant against antimonials have superior survival skills than sensitive ones even in the absence of antimonial treatment. Methods and Findings: We use simulation studies based on a mathematical L. donovani transmission model to identify parameters which can explain why treatment failure rates under antimonial treatment increased up to 65% in Bihar between 1980 and 1997. Model analyses suggest that resistance to treatment alone cannot explain the observed treatment failure rates. We explore two hypotheses referring to an increased fitness of antimony-resistant parasites: the additional fitness is (i) disease-related, by causing more clinical cases (higher pathogenicity) or more severe disease (higher virulence), or (ii) is transmission-related, by increasing the transmissibility from sand flies to humans or vice versa. Conclusions: Both hypotheses can potentially explain the Bihar observations. However, increased transmissibility as an explanation appears more plausible because it can occur in the background of asymptomatically transmitted infection whereas disease-related factors would most probably be observable. Irrespective of the cause of fitness, parasites with a higher fitness will finally replace sensitive parasites, even if antimonials are replaced by another drug.	[Stauch, Anette; Duerr, Hans-Peter; Eichner, Martin] Univ Tubingen, Dept Med Biometry, Tubingen, Germany; [Dujardin, Jean-Claude; Vanaerschot, Manu] Univ Antwerp, Lab Microbiol Parasitol & Hyg, B-2020 Antwerp, Belgium; [Dujardin, Jean-Claude; Vanaerschot, Manu] Inst Trop Med Antwerp, Dept Biomed Sci, Antwerp, Belgium; [Sundar, Shyam] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India	Stauch, A (reprint author), Univ Tubingen, Dept Med Biometry, Tubingen, Germany.	anette.stauch@medizin.uni-tuebingen.de	Vanaerschot, Manu/B-6812-2013	Vanaerschot, Manu/0000-0002-9141-2347; Duerr, Hans-Peter/0000-0001-7289-6019	EU project KalaDrug-R [EC-FP7-222895]	This investigation was funded by the EU project KalaDrug-R (EC-FP7-222895). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; Bacaer N, 2006, J MATH BIOL, V53, P421, DOI 10.1007/s00285-006-0015-0; Basu JM, 2006, ANTIMICROB AGENTS CH, V50, P1788, DOI [10.1128/AAC.50.5.1788-1797.2006, 10.1128/AAC.50.5.1768-1797.2006]; Borrell S, 2009, INT J TUBERC LUNG D, V13, P1456; Carter KC, 2005, PARASITOLOGY, V131, P747, DOI 10.1017/S0031182005008486; Courtenay O, 2002, J INFECT DIS, V186, P1314, DOI 10.1086/344312; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]; Decuypere S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001514; Downing T, 2011, GENOME RES, V21, P2143, DOI 10.1101/gr.123430.111; DYE C, 1992, PARASITOLOGY, V105, P35, DOI 10.1017/S0031182000073662; Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125; DYE C, 1992, PARASITOLOGY, V104, pS7, DOI 10.1017/S0031182000075211; DYE C, 1988, T ROY SOC TROP MED H, V82, P843, DOI 10.1016/0035-9203(88)90013-2; ELmojtaba IM, 2013, MATH METHOD APPL SCI, V36, P216, DOI 10.1002/mma.2589; ELmojtaba IM, 2010, APPL MATH COMPUT, V217, P2567, DOI 10.1016/j.amc.2010.07.069; ELmojtaba IM, 2010, NONLINEAR ANAL-REAL, V11, P2175, DOI 10.1016/j.nonrwa.2010.01.011; Hailu A, 2009, ANN TROP MED PARASIT, V103, P659, DOI 10.1179/000349809X12554106963555; Haldar AK, 2011, MOL BIOL INT, DOI [2011, DOI 10.4061/2011/571242]; Haldar AK, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000907; HARDIN G, 1960, SCIENCE, V131, P1292, DOI 10.1126/science.131.3409.1292; Hasker E, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02562.x; HATI AK, 1991, INDIAN J MED RES-A, V93, P388; Hurissa Z, 2010, TROP MED INT HEALTH, V15, P848, DOI 10.1111/j.1365-3156.2010.02550.x; Langer BM, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-1; Lira R, 1999, J INFECT DIS, V180, P564, DOI 10.1086/314896; Llanos-Cuentas A, 2008, CLIN INFECT DIS, V46, P223, DOI 10.1086/524042; Mubayi A, 2010, J THEOR BIOL, V262, P177, DOI 10.1016/j.jtbi.2009.09.012; Mukhopadhyay R, 2011, INT J PARASITOL, V41, P1311, DOI 10.1016/j.ijpara.2011.07.013; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; Olliaro PL, 2005, LANCET INFECT DIS, V5, P763, DOI 10.1016/S1473-3099(05)70296-6; Orr HA, 2009, NAT REV GENET, V10, P531, DOI 10.1038/nrg2603; Ostyn B, 2008, TROP MED INT HEALTH, V13, P1073, DOI 10.1111/j.1365-3156.2008.02110.x; Ostyn B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001284; Ouakad M, 2011, PARASITOLOGY, V138, P1392, DOI 10.1017/S0031182011001120; Palatnik-De-Sousai CB, 2004, AN ACAD BRAS CIENC, V76, P583, DOI 10.1590/S0001-37652004000300012; Perry MR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001227; PETERS W, 1981, INDIAN J MED RES, V73, P1; Rahman KM, 2010, CLIN INFECT DIS, V50, P73, DOI 10.1086/648727; Rais S, 2000, ANTIMICROB AGENTS CH, V44, P2406, DOI 10.1128/AAC.44.9.2406-2410.2000; RAMESH V, 1995, INT J DERMATOL, V34, P85, DOI 10.1111/j.1365-4362.1995.tb03584.x; Reithinger R, 2004, INT J PARASITOL, V34, P55, DOI 10.1016/j.ipara.2003.09.006; Rijal S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2; Rijal S, 2010, T ROY SOC TROP MED H, V104, P225, DOI 10.1016/j.trstmh.2009.08.002; Rijal S, 2007, MICROBES INFECT, V9, P529, DOI 10.1016/j.micinf.2007.01.009; SACKS DL, 1985, AM J TROP MED HYG, V34, P456, DOI 10.4269/ajtmh.1985.34.456; Srinivasan R., 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P536; Stauch A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001405; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Thakur CP, 2004, INDIAN J MED RES, V120, P166; THAKUR CP, 1984, BRIT MED J, V288, P895, DOI 10.1136/bmj.288.6421.895; THAKUR CP, 1991, INDIAN J MED RES-A, V93, P103; THAKUR CP, 1988, BRIT MED J, V296, P1557, DOI 10.1136/bmj.296.6636.1557; Uranw S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001433; van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6; Vanaerschot M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023120; Vanaerschot M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012211; WHO, 1996, TDRGEN961 WHO; World Health Organization, 2010, M WHO EXP COMM CONTR, V9492010; Wyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6	61	30	30	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2012	6	12							e1973	10.1371/journal.pntd.0001973				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	062HN	WOS:000312910200037	23285309	DOAJ Gold, Green Published			2019-03-26	
J	Vlieghe, ER; Phe, T; De Smet, B; Veng, CH; Kham, C; Bertrand, S; Vanhoof, R; Lynen, L; Peetermans, WE; Jacobs, JA				Vlieghe, Erika R.; Phe, Thong; De Smet, Birgit; Veng, Chhun H.; Kham, Chun; Bertrand, Sophie; Vanhoof, Raymond; Lynen, Lut; Peetermans, Willy E.; Jacobs, Jan A.			Azithromycin and Ciprofloxacin Resistance in Salmonella Bloodstream Infections in Cambodian Adults	PLOS NEGLECTED TROPICAL DISEASES			English	Article							UNCOMPLICATED TYPHOID-FEVER; ENTERICA SEROVAR TYPHI; IN-VITRO ACTIVITY; REDUCED SUSCEPTIBILITY; MULTIDRUG-RESISTANT; ANTIMICROBIAL RESISTANCE; SEROTYPE CHOLERAESUIS; CONTROLLED-TRIAL; OFLOXACIN; DISEASE	Background: Salmonella enterica is a frequent cause of bloodstream infection (BSI) in Asia but few data are available from Cambodia. We describe Salmonella BSI isolates recovered from patients presenting at Sihanouk Hospital Centre of Hope, Phnom Penh, Cambodia (July 2007-December 2010). Methodology: Blood was cultured as part of a microbiological prospective surveillance study. Identification of Salmonella isolates was performed by conventional methods and serotyping. Antibiotic susceptibilities were assessed using disk diffusion, MicroScan and E-test macromethod. Clonal relationships were assessed by Pulsed Field Gel Electrophoresis; PCR and sequencing for detection of mutations in Gyrase and Topoisomerase IV and presence of qnr genes. Principal Findings: Seventy-two Salmonella isolates grew from 58 patients (mean age 34.2 years, range 8-71). Twenty isolates were identified as Salmonella Typhi, 2 as Salmonella Paratyphi A, 37 as Salmonella Choleraesuis and 13 as other nontyphoid Salmonella spp. Infection with human immunodeficiency virus (HIV) was present in 21 of 24 (87.5%) patients with S. Choleraesuis BSI. Five patients (8.7%) had at least one recurrent infection, all with S. Choleraesuis; five patients died. Overall, multi drug resistance (i.e., co-resistance to ampicillin, sulphamethoxazole-trimethoprim and chloramphenicol) was high (42/59 isolates, 71.2%). S. Typhi displayed high rates of decreased ciprofloxacin susceptibility (18/20 isolates, 90.0%), while azithromycin resistance was very common in S. Choleraesuis (17/24 isolates, 70.8%). Two S. Choleraesuis isolates were extended spectrum beta-lactamase producer. Conclusions and Significance: Resistance rates in Salmonella spp. in Cambodia are alarming, in particular for azithromycin and ciprofloxacin. This warrants nationwide surveillance and revision of treatment guidelines.	[Vlieghe, Erika R.; De Smet, Birgit; Lynen, Lut; Jacobs, Jan A.] Antwerp ITM, Dept Clin Sci, Inst Trop Med, Antwerp, Belgium; [Phe, Thong; Veng, Chhun H.; Kham, Chun] SHCH, Phnom Penh, Cambodia; [Bertrand, Sophie; Vanhoof, Raymond] Sci Inst Publ Hlth IPH, Belgian Reference Ctr Salmonella, Brussels, Belgium; [Peetermans, Willy E.] Univ Hosp, Dept Internal Med, Louvain, Belgium	Vlieghe, ER (reprint author), Antwerp ITM, Dept Clin Sci, Inst Trop Med, Antwerp, Belgium.	evlieghe@itg.be; jjacobs@itg.be	De Smet, Birgit/F-4638-2014; Lynen, Lutgarde/A-1212-2014	De Smet, Birgit/0000-0002-1790-1900; Lynen, Lutgarde/0000-0001-7183-4895	Belgian Directorate General of Development Cooperation [2.08]; Institute of Tropical Medicine, Antwerp (Belgium); "Secundaire Onderzoeks Financiering ITG type A'' (SOFI-A) grant of the Institute of Tropical Medicine, Antwerp (Belgium)	This work was supported by Project 2.08 of the third Framework Agreement between the Belgian Directorate General of Development Cooperation (http://diplomatie.belgium.be/en/policy/development_cooperation/) and the Institute of Tropical Medicine, Antwerp (Belgium). Erika Vlieghe was supported by the "Secundaire Onderzoeks Financiering ITG type A'' (SOFI-A) grant of the Institute of Tropical Medicine, Antwerp (Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, GARP VIETNAM REPORT; Arjyal A, 2011, LANCET INFECT DIS, V11, P445, DOI 10.1016/S1473-3099(11)70089-5; Basnyat B, 2005, CLIN INFECT DIS, V41, P1467, DOI 10.1086/497136; Butler T, 1999, J ANTIMICROB CHEMOTH, V44, P243, DOI 10.1093/jac/44.2.243; Capoor MR, 2007, J MED MICROBIOL, V56, P1490, DOI 10.1099/jmm.0.47353-0; Cavaco LM, 2009, ANTIMICROB AGENTS CH, V53, P603, DOI 10.1128/AAC.00997-08; CDC, 2012, PULSENET; Chau TT, 2007, ANTIMICROB AGENTS CH, V51, P4315, DOI 10.1128/AAC.00294-07; Chinh NT, 2000, ANTIMICROB AGENTS CH, V44, P1855, DOI 10.1128/AAC.44.7.1855-1859.2000; Chiu CH, 2004, LANCET, V363, P1285, DOI 10.1016/S0140-6736(04)16003-0; Chiu CH, 2004, CLIN MICROBIOL REV, V17, P311, DOI 10.1128/CMR.17.2.311-322.2004; CLSI, 2012, M100S22 CLSI; Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Crump JA, 2010, CLIN INFECT DIS, V50, P241, DOI 10.1086/649541; Dolecek C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002188; Effa EE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006083.pub2; Endimiani A, 2010, J CLIN MICROBIOL, V48, P2618, DOI 10.1128/JCM.00568-10; EUCAST, 2011, EUR COMM ANT SUSC TE; Frenck RW, 2004, CLIN INFECT DIS, V38, P951; Girgis NI, 1999, ANTIMICROB AGENTS CH, V43, P1441, DOI 10.1128/AAC.43.6.1441; Gordon MA, 2002, AIDS, V16, P1633, DOI 10.1097/00002030-200208160-00009; Griggs DJ, 1996, ANTIMICROB AGENTS CH, V40, P1009, DOI 10.1128/AAC.40.4.1009; Grimont P. A., 2007, ANTIGENIC FORMULAE S; Gunell M, 2010, ANTIMICROB AGENTS CH, V54, P3498, DOI 10.1128/AAC.01678-09; Hendriksen RS, 2009, FOODBORNE PATHOG DIS, V6, P1009, DOI 10.1089/fpd.2008.0245; Hsueh PR, 2004, EMERG INFECT DIS, V10, P60, DOI 10.3201/eid1001.030171; Kasper MR, 2010, DIAGN MICR INFEC DIS, V66, P207, DOI 10.1016/j.diagmicrobio.2009.09.002; Kingdom of Cambodia Ministry of Health, 1999, CLIN THER GUID REF H; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Molloy A, 2010, J CLIN MICROBIOL, V48, P4655, DOI 10.1128/JCM.00648-10; Morpeth SC, 2009, CLIN INFECT DIS, V49, P606, DOI 10.1086/603553; Nguyen MCP, 2009, EMERG INFECT DIS, V15, P1648, DOI 10.3201/eid1510.090696; Ochiai RL, 2008, B WORLD HEALTH ORGAN, V86, P260, DOI 10.2471/BLT.06.039818; Parry CM, 2008, CURR OPIN INFECT DIS, V21, P531, DOI 10.1097/QCO.0b013e32830f453a; Parry CM, 2007, ANTIMICROB AGENTS CH, V51, P819, DOI 10.1128/AAC.00447-06; Parry CM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001163; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Sjolund-Karlsson M, 2011, ANTIMICROB AGENTS CH, V55, P3985, DOI 10.1128/AAC.00590-11; Su LH, 2004, CLIN INFECT DIS, V39, P546, DOI 10.1086/422726; Su LH, 2011, EMERG INFECT DIS, V17, P1086, DOI [10.3201/eid/1706.101949, 10.3201/eid1706.101949]; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233; Vlieghe E, 2011, 51 ICAAC SEPT 18 21; WHO, 2012, CAMB HLTH PROF; Yodprorn R, 2007, OCUL IMMUNOL INFLAMM, V15, P135, DOI 10.1080/09273940701244228	44	28	29	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2012	6	12							e1933	10.1371/journal.pntd.0001933				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	062HN	WOS:000312910200008	23272255	DOAJ Gold, Green Published			2019-03-26	
J	Nguyen, HV; van den Eede, P; van Overmeir, C; Thang, ND; Hung, LX; D'Alessandro, U; Erhart, A				Hong Van Nguyen; van den Eede, Peter; van Overmeir, Chantal; Ngo Duc Thang; Le Xuan Hung; D'Alessandro, Umberto; Erhart, Annette			Marked Age-Dependent Prevalence of Symptomatic and Patent Infections and Complexity of Distribution of Human Plasmodium Species in Central Vietnam	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							MALARIA CONTROL; FOREST MALARIA; FALCIPARUM; POPULATIONS; IMMUNITY; EPIDEMIOLOGY; TRANSMISSION; THAILAND; AMAZON; BRAZIL	In Vietnam, Plasmodium falciparum and P. vivax are responsible for most malaria infections, and P. malariae and P. ovale infections are rarely reported. Nevertheless, species-specific polymerase chain reaction analysis on 2,303 blood samples collected during a cross-sectional survey conducted in a forest area of central Vietnam identified 223 (9.7%) P. falciparum, 170 (7.4%) P. vivax, 95 (4.1%) P. malariae, and 19 (0.8%) P. ovale mono-infections and 164 (7.1%) mixed infections. Of the 671 Plasmodium-positive samples by polymerase chain reaction, only 331 were detected by microscopy. Microscopy poorly diagnosed P. malariae, P. ovate, and mixed infections. Clinical and sub-clinical infections occurred in all age groups. The risk for infection and disease decreased with age, probably because of acquired partial immunity. The common occurrence of sub-patent infections seems to indicate that the malaria burden is underestimated and that diagnostic and therapeutic policies should be adapted accordingly.	[van den Eede, Peter; van Overmeir, Chantal; D'Alessandro, Umberto; Erhart, Annette] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Hong Van Nguyen; Ngo Duc Thang; Le Xuan Hung] Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam	Erhart, A (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	nvhong1982@yahoo.com; pvandeneede@itg.be; cvovermeir@itg.be; thangnimpevn@yahoo.com; lxhung1952@yahoo.com; udalessandro@itg.be; aerhart@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009	Research Foundation, Flanders; Directorate-General for Development Cooperation Framework Agreement III	This study was supported by the Research Foundation, Flanders and the Directorate-General for Development Cooperation Framework Agreement III.	Alves FP, 2005, J MED ENTOMOL, V42, P777, DOI 10.1603/0022-2585(2005)042[0777:ACOPSA]2.0.CO;2; Alves FP, 2002, AM J TROP MED HYG, V66, P641, DOI 10.4269/ajtmh.2002.66.641; Baird JK, 2003, ANN TROP MED PARASIT, V97, P557, DOI 10.1179/000349803225001472; BAIRD JK, 1993, AM J TROP MED HYG, V49, P707, DOI 10.4269/ajtmh.1993.49.707; Bousema JT, 2006, J INFECT DIS, V193, P1151, DOI 10.1086/503051; Bousema T, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-136; Coleman RE, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-121; Collins WE, 2007, CLIN MICROBIOL REV, V20, P579, DOI 10.1128/CMR.00027-07; Coura JR, 2006, MEM I OSWALDO CRUZ, V101, P229, DOI 10.1590/S0074-02762006000300001; Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08; Erhart A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-58; GLEASON NN, 1970, B WORLD HEALTH ORGAN, V42, P399; Grietens KP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-23; Kawamoto F, 1996, J CLIN MICROBIOL, V34, P2287; Ladeia-Andrade S, 2009, AM J TROP MED HYG, V80, P452, DOI 10.4269/ajtmh.2009.80.452; Mayor A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-3; Oguike MC, 2011, INT J PARASITOL, V41, P677, DOI 10.1016/j.ijpara.2011.01.004; Okell LC, 2009, J INFECT DIS, V200, P1509, DOI 10.1086/644781; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Proietti C, 2011, AM J TROP MED HYG, V84, P830, DOI 10.4269/ajtmh.2011.10-0498; Putaporntip C, 2009, J INFECT DIS, V199, P1143, DOI 10.1086/597414; Rubio J M, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS199, DOI 10.1016/S0035-9203(02)90077-5; Steenkeste N, 2010, CAMBODIA IMPLICATION, V9, P108; Thang Ngo Duc, 2009, Malar J, V8, P3, DOI 10.1186/1475-2875-8-3; Thang ND, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-28; Van den Eede P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-249	26	17	18	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2012	87	6					989	995		10.4269/ajtmh.2012.12-0047				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	052YG	WOS:000312236000006	23128294	Bronze, Green Published			2019-03-26	
J	Ortiz, S; Zulantay, I; Solari, A; Bisio, M; Schijman, A; Carlier, Y; Apt, W				Ortiz, Sylvia; Zulantay, Ines; Solari, Aldo; Bisio, Margarita; Schijman, Alejandro; Carlier, Yves; Apt, Werner			Presence of Trypanosoma cruzi in pregnant women and typing of lineages in congenital cases	ACTA TROPICA			English	Article						Trypanosoma cruzi genotypes; Chronic chagasic mothers; Newborn; PCR; Hybridization	POLYMERASE-CHAIN-REACTION; CHAGAS-DISEASE; VERTICAL TRANSMISSION; ENDEMIC AREA; CHILE; PARASITEMIA; CLONES; DNA	The objective of this study was to determine the presence of Trypanosoma cruzi in blood samples of mothers with chronic Chagas disease and their newborn by conventional PCR targeted to minicircle kinetoplastidic DNA (kDNA), and to determine the lineages in mother/newborn pairs of the congenital cases by hybridization assays with probes belonging to the TcII,TcI and TcV Discrete Typing Units (DTU). In 63(57.2%) of the mothers the presence of circulating T. cruzi was demonstrated by PCR immediately before delivery and in three newborn (3%) congenital transmission was confirmed by serial PCR and conventional serology between 1 and 16 months of life, at which point treatment was started. The hybridization signals showed that two of the newborn had the same DTU as their mother (TcI, TcII and TcV), whilst in the third congenital case only TcV was detected in the cord blood, suggesting that in this infant TcI and TcII did not cross the placenta or the parasite was not present at a detectable level. Levels T. cruzi DNA was determined by TaqMan Probe based Real Time PCR assay targeted to nuclear satellite sequences in these three pairs of samples. (C) 2012 Elsevier B.V. All rights reserved.	[Ortiz, Sylvia; Zulantay, Ines; Solari, Aldo; Apt, Werner] Univ Chile, Fac Med, Inst Ciencias Biomed, Santiago 3, Chile; [Bisio, Margarita; Schijman, Alejandro] Consejo Nacl Invest Cient & Tecn, Inst Invest Ingn Genet & Biol Mol, RA-1033 Buenos Aires, DF, Argentina; [Carlier, Yves] Univ Libre Brussels, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium	Apt, W (reprint author), Univ Chile, Fac Med, Inst Ciencias Biomed, POB 427, Santiago 3, Chile.	wapt@med.uchile.cl			Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT-Chile) [1080445, 1100768]; University of Chile [DI-SAL 05/17-2]; Valona Region, Belgium [06/09]	This work was supported by Grant 1080445 and 1100768 from the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT-Chile), DI-SAL 05/17-2 of the University of Chile and Project 06/09 Valona Region, Belgium. The authors give special thanks to the health teams of the Choapa Province, IV Region, Chile. Finally, we are grateful to Miguel Saavedra, Eduardo Araya and Gabriela Martinez, for invaluable technical support.	APT W, 1987, AM J TROP MED HYG, V37, P302, DOI 10.4269/ajtmh.1987.37.302; Apt W, 2010, BIOL RES, V43, P269, DOI [/S0716-97602010000300002, 10.4067/S0716-97602010000300002]; Barnabe C, 2001, ACTA TROP, V78, P127, DOI 10.1016/S0001-706X(00)00183-2; Bern C, 2009, CLIN INFECT DIS, V49, P1667, DOI 10.1086/648070; BRAVO N, 2012, PARASITE VECTOR, V5, pE59; Breniere SF, 1998, EXP PARASITOL, V89, P285, DOI 10.1006/expr.1998.4295; Brutus L, 2010, AM J TROP MED HYG, V83, P1044, DOI [10.4269/ajtmh.2010.10.0326, 10.4269/ajtmh.2010.10-0326]; Duffy T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000419; Hall CA, 2010, J PARASITOL, V96, P371, DOI 10.1645/GE-2296.1; Hermann E, 2004, J INFECT DIS, V189, P1274, DOI 10.1086/382511; MILES MA, 1984, T ROY SOC TROP MED H, V78, P526, DOI 10.1016/0035-9203(84)90076-2; Dias JCP, 2009, MEM I OSWALDO CRUZ, V104, P41, DOI 10.1590/S0074-02762009000900007; Schijman AG, 2003, J ANTIMICROB CHEMOTH, V52, P441, DOI 10.1093/jac/dkg338; Schijman AG, 2011, PLOS NEGLECT TROP D, V5, P931; Solari A, 2001, EXP PARASITOL, V97, P226, DOI 10.1006/expr.2001.4607; Torres JP, 2004, PARASITOLOGY, V128, P161, DOI 10.1017/S0031182003004475; VEAS F, 1991, CELL MOL BIOL, V37, P73; Veas F., 1994, ACTA TROP, V48, P79; Virreira M, 2007, AM J TROP MED HYG, V77, P102, DOI 10.4269/ajtmh.2007.77.102; Virreira M, 2006, AM J TROP MED HYG, V75, P871, DOI 10.4269/ajtmh.2006.75.871; WINCKER P, 1994, AM J TROP MED HYG, V51, P771, DOI 10.4269/ajtmh.1994.51.771; Zulantay I, 2011, ANN TROP MED PARASIT, V105, P123, DOI 10.1179/136485911X12899838413583	22	17	17	1	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X			ACTA TROP	Acta Trop.	DEC	2012	124	3					243	246		10.1016/j.actatropica.2012.08.001				4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	038NN	WOS:000311181500012	22906640				2019-03-26	
J	Monzote, L; Cuesta-Rubio, O; Fernandez, MC; Hernandez, IM; Fraga, J; Perez, K; Kerstens, M; Maes, L; Cos, P				Monzote, Lianet; Cuesta-Rubio, Osmany; Campo Fernandez, Mercedes; Marquez Hernandez, Ingrid; Fraga, Jorge; Perez, Kleich; Kerstens, Monique; Maes, Louis; Cos, Paul			In vitro antimicrobial assessment of Cuban propolis extracts	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Article						propolis; Cuban; antibacterial; antifungal; antiprotozoal	FALCIPARUM DRUG-SENSITIVITY; TRIGONA-LAEVICEPS PROPOLIS; BREAST-CANCER CELLS; ANTIPROLIFERATIVE ACTIVITY; CHEMICAL-COMPOSITION; BRAZILIAN PROPOLIS; TRYPANOSOMA-CRUZI; MEXICAN-PROPOLIS; NATURAL-PRODUCTS; GROWTH	Propolis is a resinous mixture of different plant exudates collected by honeybees. Currently, propolis is widely used as a food supplement and in folk medicine. We have evaluated 20 Cuban propolis extracts of different chemical types, brown (BCP), red and yellow (YCP), with respect to their in vitro antibacterial, antifungal and antiprotozoal properties. The extracts inhibited the growth of Staphylococcus aureus and Trichophyton rubrum at low mu g/mL concentrations, whereas they were not active against Escherichia coli and Candida albicans. The major activity of the extracts was found against the protozoa Leishmania, Trypanosoma and Plasmodium, although cytotoxicity against MRC-5 cells was also observed. The BCP-3, YCP-39 and YCP-60 extracts showed the highest activity against P. falciparum, with 50% of microbial growth (IC50) values of 0.2 mu g/mL. A positive correlation between the biological activity and the chemical composition was observed for YCP extracts. The most promising antimicrobial activity corresponds to YCP subtype B, which contains acetyl triterpenes as the main constituents. The present in vitro study highlights the potential of propolis against protozoa, but further research is needed to increase selectivity towards the parasite. The observed chemical composition-activity relationship of propolis can contribute to the identification of the active principles and standardisation of this bee product.	[Monzote, Lianet; Fraga, Jorge] Inst Trop Med Pedro Kouri, Dept Parasitol, Havana, Cuba; [Perez, Kleich] Inst Trop Med Pedro Kouri, Epidemiol Div, Havana, Cuba; [Cuesta-Rubio, Osmany; Campo Fernandez, Mercedes; Marquez Hernandez, Ingrid] Univ Havana, Dept Pharm, Inst Pharm & Food, Havana, Cuba; [Kerstens, Monique; Maes, Louis; Cos, Paul] Univ Antwerp, Lab Microbiol Parasitol & Hyg, Fac Pharmaceut Biomed & Vet Sci, B-2020 Antwerp, Belgium	Cos, P (reprint author), Univ Antwerp, Lab Microbiol Parasitol & Hyg, Fac Pharmaceut Biomed & Vet Sci, B-2020 Antwerp, Belgium.	paul.cos@ua.ac.be	Maes, Louis/A-2384-2017; Cos, Paul/L-9717-2015	Maes, Louis/0000-0002-2324-9509; Cos, Paul/0000-0003-4361-8911			Ayres DC, 2007, MEM I OSWALDO CRUZ, V102, P215, DOI 10.1590/S0074-02762007000200015; Bankova V, 2005, J ETHNOPHARMACOL, V100, P114, DOI 10.1016/j.jep.2005.05.004; Banskota AH, 2001, PHYTOTHER RES, V15, P561, DOI 10.1002/ptr.1029; BONVEHI JS, 1994, J AM OIL CHEM SOC, V71, P529, DOI 10.1007/BF02540666; Buckner FS, 1996, ANTIMICROB AGENTS CH, V40, P2592, DOI 10.1128/AAC.40.11.2592; Cos P, 2006, J ETHNOPHARMACOL, V106, P290, DOI 10.1016/j.jep.2006.04.003; Cuesta-Rubio O, 2007, J AGR FOOD CHEM, V55, P7502, DOI 10.1021/jf071296w; Dantas AP, 2006, MEM I OSWALDO CRUZ, V101, P207, DOI 10.1590/S0074-02762006000200013; Dota KF, 2011, EVID-BASED COMPL ALT, V2011; Duran G, 2008, PARASITOL RES, V102, P1217, DOI 10.1007/s00436-008-0896-5; Duran N, 2011, PARASITOL RES, V108, P95, DOI 10.1007/s00436-010-2039-z; Flegr J, 1998, PARASITOL RES, V84, P590, DOI 10.1007/s004360050454; Flegr Jaroslav, 1997, Acta Societatis Zoologicae Bohemicae, V61, P91; Ghasem Yousef-Beigi, 2007, Pak J Biol Sci, V10, P1343; Gispert E, 2000, REV CUBANA ESTOMATOL, V37, P166; GREENAWAY W, 1990, BEE WORLD, V71, P107, DOI 10.1080/0005772X.1990.11099047; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Khalil Mahmoud Lotfy, 2006, Asian Pac J Cancer Prev, V7, P22; Khaomek P, 2008, J NAT MED, V62, P217, DOI 10.1007/s11418-007-0214-z; Ledon N, 1996, REV CUBANA FARM, V30, P36; Quintero-Mora ML, 2008, REV IBEROAM MICOL, V25, P22, DOI 10.1016/S1130-1406(08)70006-8; Li F, 2010, NAT PROD COMMUN, V5, P1601; MAKLER MT, 1993, AM J TROP MED HYG, V48, P739, DOI 10.4269/ajtmh.1993.48.739; MARCUCCI MC, 1995, APIDOLOGIE, V26, P83, DOI 10.1051/apido:19950202; Hernandez IM, 2010, J AGR FOOD CHEM, V58, P4725, DOI 10.1021/jf904527n; Miyares C, 1988, Acta Gastroenterol Latinoam, V18, P195; Monzote L, 2011, PHYTOTHER RES, V25, P458, DOI 10.1002/ptr.3401; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Pavlicek A, 1999, FOLIA BIOL-PRAGUE, V45, P97; PETERSON G, 1991, BIOCHEM BIOPH RES CO, V179, P661, DOI 10.1016/0006-291X(91)91423-A; Popolo A, 2009, NAT PROD COMMUN, V4, P1711; Quintana JC, 1997, REV CUBANA ESTOMATOL, V34, P25; Quintana TJ, 1996, REV CUB MED GEN INTE, V12, P255; Raz B, 1997, ACTA TROP, V68, P139, DOI 10.1016/S0001-706X(97)00079-X; Salomao K, 2008, EVID-BASED COMPL ALT, V5, P317, DOI 10.1093/ecam/nem058; Santana E, 1995, REV CUBANA ENFERM, V11, P13; Sartorelli P, 2009, PARASITOL RES, V104, P311, DOI 10.1007/s00436-008-1193-z; SNEATH PHA, 1957, J GEN MICROBIOL, V17, P201, DOI 10.1099/00221287-17-1-201; Takahashi M, 2006, CHEM PHARM BULL, V54, P915, DOI 10.1248/cpb.54.915; Taylor Patricia L., 2008, Animal Health Research Reviews, V9, P237, DOI 10.1017/S1466252308001527; Topalkara A, 2007, J OCUL PHARMACOL TH, V23, P40, DOI 10.1089/jop.2006.0053; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Ugur A, 2004, J MED FOOD, V7, P90, DOI 10.1089/109662004322984761; Umthong S, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-37; Umthong S, 2009, AM J CHINESE MED, V37, P855, DOI 10.1142/S0192415X09007338; Ziegler HL, 2002, ANTIMICROB AGENTS CH, V46, P1441, DOI 10.1128/AAC.46.5.1441-1446.2002	46	23	26	1	12	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276	1678-8060		MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz	DEC	2012	107	8					978	+		10.1590/S0074-02762012000800003				8	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	267NR	WOS:000328105100003	23295746	DOAJ Gold			2019-03-26	
J	Rigot, T; Conte, A; Goffredo, M; Ducheyne, E; Hendrickx, G; Gilbert, M				Rigot, Thibaud; Conte, Annamaria; Goffredo, Maria; Ducheyne, Els; Hendrickx, Guy; Gilbert, Marius			Predicting the spatio-temporal distribution of Culicoides imicola in Sardinia using a discrete-time population model	PARASITES & VECTORS			English	Article						Spatial ecology; Infectious disease; Remote-sensing; Dynamic model; Longitudinal entomological surveillance network; Mediterranean basin	AFRICAN HORSE SICKNESS; BITING MIDGES DIPTERA; SATELLITE IMAGERY; BLUETONGUE VIRUS; SEASONAL DISTRIBUTION; OBSOLETUS COMPLEX; SPECIES DIPTERA; ENTOMOLOGICAL SURVEILLANCE; CLIMATIC REGIONS; SOUTHERN AFRICA	Background: Culicoides imicola KIEFFER, 1913 (Diptera: Ceratopogonidae) is the principal vector of Bluetongue disease in the Mediterranean basin, Africa and Asia. Previous studies have identified a range of eco-climatic variables associated with the distribution of C. imicola, and these relationships have been used to predict the large-scale distribution of the vector. However, these studies are not temporally-explicit and can not be used to predict the seasonality in C. imicola abundances. Between 2001 and 2006, longitudinal entomological surveillance was carried out throughout Italy, and provided a comprehensive spatio-temporal dataset of C. imicola catches in Onderstepoort-type black-light traps, in particular in Sardinia where the species is considered endemic. Methods: We built a dynamic model that allows describing the effect of eco-climatic indicators on the monthly abundances of C. imicola in Sardinia. Model precision and accuracy were evaluated according to the influence of process and observation errors. Results: A first-order autoregressive cofactor, a digital elevation model and MODIS Land Surface Temperature (LST)/or temperatures acquired from weather stations explained similar to 77% of the variability encountered in the samplings carried out in 9 sites during 6 years. Incorporating Normalized Difference Vegetation Index (NDVI) or rainfall did not increase the model's predictive capacity. On average, dynamics simulations showed good accuracy (predicted vs. observed r corr = 0.9). Although the model did not always reproduce the absolute levels of monthly abundances peaks, it succeeded in reproducing the seasonality in population level and allowed identifying the periods of low abundances and with no apparent activity. On that basis, we mapped C. imicola monthly distribution over the entire Sardinian region. Conclusions: This study demonstrated prospects for modelling data arising from Culicoides longitudinal entomological surveillance. The framework explicitly incorporates the influence of eco-climatic factors on population growth rates and accounts for observation and process errors. Upon validation, such a model could be used to predict monthly population abundances on the basis of environmental conditions, and hence can potentially reduce the amount of entomological surveillance.	[Rigot, Thibaud; Gilbert, Marius] Univ Libre Brussels, Biol Control & Spatial Ecol LUBIES, B-1050 Brussels, Belgium; [Rigot, Thibaud] INRA, UMR 1202, F-33610 Cestas, France; [Conte, Annamaria; Goffredo, Maria] Ist Zooprofilatt Sperimentale Abruzzo & Molise G, I-64100 Teramo, Italy; [Ducheyne, Els; Hendrickx, Guy] Avia GIS, B-2980 Zoersel, Belgium; [Gilbert, Marius] Fonds Natl Rech Sci, B-1000 Brussels, Belgium	Rigot, T (reprint author), Univ Libre Brussels, Biol Control & Spatial Ecol LUBIES, Av FD Roosevelt 50, B-1050 Brussels, Belgium.	thbdrgt@yahoo.fr	Conte, Annamaria/H-5869-2016; Vita, Serafina/D-9445-2016	Conte, Annamaria/0000-0001-6975-2698; Vita, Serafina/0000-0002-8045-1236; Goffredo, Maria/0000-0002-6831-4167; Gilbert, Marius/0000-0003-3708-3359	Belgian Science Policy, research programme for earth observation Stereo II, research project EPISTIS [SR/00/102]	The authors would like to thank the farmers, veterinarians and laboratory technicians involved in the sampling and identification of Culicoides species throughout Italy between 2000 and 2007. We are also grateful to two anonymous referees for the important comments provided on the initial manuscript, which warrants further interesting analytical perspectives. This study was funded by the Belgian Science Policy, research programme for earth observation Stereo II, research project EPISTIS (contract No SR/00/102).	Acevedo P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014236; Baylis M, 1998, MED VET ENTOMOL, V12, P255; Baylis M, 1998, ARCH VIROL, P137; Baylis M, 2004, VETER ITAL SER, V40, P176; Baylis M, 1997, MED VET ENTOMOL, V11, P203, DOI 10.1111/j.1365-2915.1997.tb00397.x; Baylis M, 1999, J S AFR VET ASSOC, V70, P80; Baylis M, 2001, VET REC, V149, P639, DOI 10.1136/vr.149.21.639; BRAVERMAN Y, 1974, MOSQ NEWS, V34, P303; Calder C, 2003, ECOLOGY, V84, P1395, DOI 10.1890/0012-9658(2003)084[1395:IMSOSI]2.0.CO;2; Calistri P, 2003, J VET MED B, V50, P132, DOI 10.1046/j.1439-0450.2003.00631.x; Calvete C, 2008, MED VET ENTOMOL, V22, P124, DOI 10.1111/j.1365-2915.2008.00728.x; Conte A, 2007, VET PARASITOL, V150, P333, DOI 10.1016/j.vetpar.2007.09.021; Conte A, 2004, VETER ITAL SER, V40, P311; Conte A, 2003, J VET MED B, V50, P139, DOI 10.1046/j.1439-0450.2003.00632.x; Conte A, 2009, J APPL ECOL, V46, P1332, DOI 10.1111/j.1365-2664.2009.01723.x; De Liberato C, 2003, MED VET ENTOMOL, V17, P388, DOI 10.1111/j.1365-2915.2003.00456.x; De Valpine P, 2002, ECOL MONOGR, V72, P57, DOI 10.1890/0012-9615(2002)072[0057:FPMIPN]2.0.CO;2; Dormann CF, 2007, ECOGRAPHY, V30, P609, DOI 10.1111/j.2007.0906-7590.05171.x; Elith J, 2008, J ANIM ECOL, V77, P802, DOI 10.1111/j.1365-2656.2008.01390.x; Fitzpatrick M.C., 2011, ECOL APPL, V22, P472; Gallien L, 2010, DIVERS DISTRIB, V16, P331, DOI 10.1111/j.1472-4642.2010.00652.x; Goffredo M, 2004, VETER ITAL SER, V40, P270; Goffredo M, 2004, VETER ITAL SER, V40, P260; Goffredo M., 2003, Veterinaria Italiana, V39, P22; Hendrickx G, 2008, PREV VET MED, V87, P162, DOI 10.1016/j.prevetmed.2008.06.009; Hijmans R. J., 2011, PACKAGE RASTER; Holmes EE, 2012, R J, V4, P11; Kaufmann C, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-246; Lassen SB, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-143; Lehmann K, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-213; LUBEGA R, 1976, B ENTOMOL RES, V66, P421, DOI 10.1017/S0007485300006829; Martinez-de la Puente J, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-147; Meiswinkel R, 1994, INFECT DIS LIVESTOCK, V1, P69; Mellor PS, 2000, ANNU REV ENTOMOL, V45, P307, DOI 10.1146/annurev.ento.45.1.307; MELLOR PS, 1995, ANN TROP MED PARASIT, V89, P1; Mellor PS, 2002, VET J, V164, P20, DOI 10.1053/tvjl.2002.0713; Miranda MA, 2003, MED VET ENTOMOL, V17, P52, DOI 10.1046/j.1365-2915.2003.00405.x; Napp S, 2013, MED VET ENTOMOL, V27, P19, DOI 10.1111/j.1365-2915.2012.01016.x; Ortega MD, 1997, J AM MOSQUITO CONTR, V13, P227; Patakakis MJ, 2009, J VECTOR ECOL, V34, P243, DOI [10.1111/j.1948-7134.2009.00033.x, 10.3376/038.034.0211]; Patakakis MJ, 2004, VETER ITAL SER, V40, P232; Pebesma EJ, 2004, COMPUT GEOSCI-UK, V30, P683, DOI [10.1016/j.cageo.2004.03.012, 10.1016/j.cargo.2004.03.012]; Purse BV, 2004, MED VET ENTOMOL, V18, P90, DOI 10.1111/j.0269-283X.2004.00492.x; R Develompment Core Team, 2011, R LANG ENV STAT COMP; Rawlings P, 1997, MED VET ENTOMOL, V11, P49, DOI 10.1111/j.1365-2915.1997.tb00289.x; Rawlings P, 2003, ECOL ENTOMOL, V28, P559, DOI 10.1046/j.1365-2311.2003.00545.x; Rawlings P, 1998, Arch Virol Suppl, V14, P95; Rigot T, 2013, MED VET ENTOMOL, V27, P29, DOI 10.1111/j.1365-2915.2012.01032.x; Sanders CJ, 2011, J APPL ECOL, V48, P1355, DOI 10.1111/j.1365-2664.2011.02051.x; Scharlemann JPW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001408; Searle KR, 2013, B ENTOMOL RES, V103, P155, DOI 10.1017/S0007485312000466; Tatem AJ, 2003, VET MICROBIOL, V97, P13, DOI 10.1016/j.vetmic.2003.08.009; Torina A, 2004, MED VET ENTOMOL, V18, P81, DOI 10.1111/j.0269-283X.2004.00493.x; Venables WN, 2002, MODERN APPL STAT S; Venter GJ, 1997, ONDERSTEPOORT J VET, V64, P259; Venter GJ, 1996, ONDERSTEPOORT J VET, V63, P315; Veronesi E, 2009, VET PARASITOL, V163, P370, DOI 10.1016/j.vetpar.2009.04.031; Viennet E, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-119; WALKER AR, 1971, J HYG-CAMB, V69, P47, DOI 10.1017/S0022172400021239; WALKER AR, 1977, B ENTOMOL RES, V67, P217, DOI 10.1017/S0007485300011032; Wittman EJ, 2001, REV SCI TECH OIE, V20, P731, DOI 10.20506/rst.20.3.1306; Zuur A, 2009, MIXED EFFECTS MODELS	62	11	11	0	23	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	NOV 22	2012	5						1	11	270	10.1186/1756-3305-5-270				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	084CR	WOS:000314514600001	23174043	DOAJ Gold, Green Published			2019-03-26	
J	Clement, F; Dewar, V; Van Braeckel, E; Desombere, I; Dewerchin, M; Swysen, C; Demoitie, MA; Jongert, E; Cohen, J; Leroux-Roels, G; Cambron, P				Clement, Frederic; Dewar, Vincent; Van Braeckel, Eva; Desombere, Isabelle; Dewerchin, Marianne; Swysen, Christine; Demoitie, Marie-Ange; Jongert, Erik; Cohen, Joe; Leroux-Roels, Geert; Cambron, Pierre			Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum	MALARIA JOURNAL			English	Article						Malaria; Plasmodium falciparum; Circumsporozoite protein; Enzyme-linked immunosorbent assay; R32LR; Validation	CANDIDATE MALARIA VACCINE; RANDOMIZED CONTROLLED-TRIAL; IN-VITRO ASSAY; PHASE 2A TRIAL; NAIVE ADULTS; PROTECTIVE ANTIBODIES; SYNTHETIC PEPTIDES; ESCHERICHIA-COLI; EXPANDED-PROGRAM; AFRICAN CHILDREN	Background: Several pre-erythrocytic malaria vaccines based on the circumsporozoite protein (CSP) antigen of Plasmodium falciparum are in clinical development. Vaccine immunogenicity is commonly evaluated by the determination of anti-CSP antibody levels using IgG-based assays, but no standard assay is available to allow comparison of the different vaccines. Methods: The validation of an anti-CSP repeat region enzyme-linked immunosorbent assay (ELISA) is described. This assay is based on the binding of serum antibodies to R32LR, a recombinant protein composed of the repeat region of P. falciparum CSP. In addition to the original recombinant R32LR, an easy to purify recombinant His-tagged R32LR protein has been constructed to be used as solid phase antigen in the assay. Also, hybridoma cell lines have been generated producing human anti-R32LR monoclonal antibodies to be used as a potential inexhaustible source of anti-CSP repeats standard, instead of a reference serum. Results: The anti-CSP repeats ELISA was shown to be robust, specific and linear within the analytical range, and adequately fulfilled all validation criteria as defined in the ICH guidelines. Furthermore, the coefficient of variation for repeatability and intermediate precision did not exceed 23%. Non-interference was demonstrated for R32LR-binding sera, and the assay was shown to be stable over time. Conclusions: This ELISA, specific for antibodies directed against the CSP repeat region, can be used as a standard assay for the determination of humoral immunogenicity in the development of any CSP-based P. falciparum malaria vaccine.	[Clement, Frederic; Van Braeckel, Eva; Desombere, Isabelle; Leroux-Roels, Geert] Univ Ghent, Ctr Vaccinol, B-9000 Ghent, Belgium; [Dewar, Vincent; Dewerchin, Marianne; Swysen, Christine; Demoitie, Marie-Ange; Jongert, Erik; Cohen, Joe; Cambron, Pierre] GlaxoSmithKline Vaccines, B-1330 Rixensart, Belgium	Cambron, P (reprint author), GlaxoSmithKline Vaccines, Rue Inst 89, B-1330 Rixensart, Belgium.	pierre.cambron@gsk.com	Clement, Frederic/B-2204-2009	Clement, Frederic/0000-0002-2720-3655	GlaxoSmithKline Biologicals SA (GSK); GSK	The study was funded by GlaxoSmithKline Biologicals SA (GSK). VD, MD, CS, MAD, EJ, JC and PC are employees of GSK. JC, MAD and PC own shares and/or options to shares in GSK. In addition, JC is a designated inventor on patented malaria vaccines, but does not hold a patent for a malaria vaccine. GLR has received fees from GSK for consultancy and lectures on different vaccine topics, and for travel and accommodations for the participation to a congress. The other authors declare no potential conflict of interest.	Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773; Agnandji ST, 2010, J INFECT DIS, V202, P1076, DOI 10.1086/656190; Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Aide P, 2011, VACCINE, V29, P6059, DOI 10.1016/j.vaccine.2011.03.041; Aide P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013838; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Ansong D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018891; Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6; Asante KP, 2011, LANCET INFECT DIS, V11, P741, DOI 10.1016/S1473-3099(11)70100-1; Ballou WR, 2009, PARASITE IMMUNOL, V31, P492, DOI 10.1111/j.1365-3024.2009.01143.x; BALLOU WR, 1985, SCIENCE, V228, P996, DOI 10.1126/science.2988126; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; CAMPBELL GH, 1987, AM J TROP MED HYG, V37, P17, DOI 10.4269/ajtmh.1987.37.17; Cavanagh DR, 2011, VACCINE, V29, P3093, DOI 10.1016/j.vaccine.2011.01.070; CHAROENVIT Y, 1991, J IMMUNOL, V146, P1020; Cohen J, 2010, HUM VACCINES, V6, P90, DOI 10.4161/hv.6.1.9677; DELGIUDICE G, 1989, B WORLD HEALTH ORGAN, V67, P515; Depraetere S, 2001, J IMMUNOL, V166, P2929, DOI 10.4049/jimmunol.166.5.2929; European Medicines Agency, NOT GUID VAL AN PROC; FOLENAWASSERMAN G, 1987, J CHROMATOGR, V411, P345, DOI 10.1016/S0021-9673(00)93985-2; Food and Drug Administration (FDA), GUID IND BIOAN METH; HOLLINGDALE MR, 1984, J IMMUNOL, V132, P909; Kebaier C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000399; Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534; Kester KE, 2008, VACCINE, V26, P2191, DOI 10.1016/j.vaccine.2008.02.048; Kester KE, 2007, VACCINE, V25, P5359, DOI 10.1016/j.vaccine.2007.05.005; Kostense S, 2011, CLIN VACCINE IMMUNOL, V18, P776, DOI 10.1128/CVI.00547-10; Kumar KA, 2004, J IMMUNOL METHODS, V292, P157, DOI 10.1016/j.jim.2004.06.017; Leach A, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-224; LINNET K, 1993, CLIN CHEM, V39, P424; Macete EV, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-11; MACIEL R, 1985, J CLIN IMMUNOASSAY, V8, P98; MANDEL J, 1984, J QUAL TECHNOL, V16, P1; MELLOUK S, 1990, B WORLD HEALTH ORGAN, V68, P52; Mishra S, 2012, J IMMUNOL METHODS, V377, P47, DOI 10.1016/j.jim.2012.01.009; Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8; NUZZOLO CA, 1990, J IMMUNOASSAY, V11, P389, DOI 10.1080/01971529008055041; Okitsu SL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001278; Olotu A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025786; Olotu A, 2011, LANCET INFECT DIS, V11, P102, DOI [10.1016/S1473-3099(10)70262-0, 10.1016/51473-3099(10)70262-0]; Olotu AI, 2010, J INFECT DIS, V201, P970, DOI 10.1086/651025; Owusu-Agyei S, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0006682, 10.1371/journal.pone.0007302]; Persson C, 2002, J IMMUNOL, V169, P6681, DOI 10.4049/jimmunol.169.12.6681; Polhemus ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006465; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; Quinn CP, 2002, EMERG INFECT DIS, V8, P1103, DOI 10.3201/eid0810.020380; Regules JA, 2011, EXPERT REV VACCINES, V10, P589, DOI [10.1586/erv.11.57, 10.1586/ERV.11.57]; Schwenk R, 2003, PARASITE IMMUNOL, V25, P17, DOI 10.1046/j.1365-3024.2003.00495.x; STOUTE JA, 1995, INFECT IMMUN, V63, P934; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; Tan CY, 1999, TECHNOMETRICS, V41, P192, DOI 10.2307/1270564; Vandepapeliere P, 2008, VACCINE, V26, P1375, DOI 10.1016/j.vaccine.2007.12.038; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2015, TABL MAL VACC PROJ G; WIRTZ RA, 1987, EXP PARASITOL, V63, P166, DOI 10.1016/0014-4894(87)90158-5; YOUNG JF, 1985, SCIENCE, V228, P958, DOI 10.1126/science.2988125; ZAVALA F, 1987, J EXP MED, V166, P1591, DOI 10.1084/jem.166.5.1591; ZAVALA F, 1986, J IMMUNOL METHODS, V93, P55, DOI 10.1016/0022-1759(86)90432-1; ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	61	18	18	2	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	NOV 22	2012	11								384	10.1186/1475-2875-11-384				15	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	250TL	WOS:000326877800001	23173602	DOAJ Gold, Green Published			2019-03-26	
J	Caljon, G; Stijlemans, B; Saerens, D; Van Den Abbeele, J; Muyldermans, S; Magez, S; De Baetselier, P				Caljon, Guy; Stijlemans, Benoit; Saerens, Dirk; Van Den Abbeele, Jan; Muyldermans, Serge; Magez, Stefan; De Baetselier, Patrick			Affinity Is an Important Determinant of the Anti-Trypanosome Activity of Nanobodies	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HEAVY-CHAIN ANTIBODIES; VARIANT SURFACE GLYCOPROTEIN; SINGLE-DOMAIN ANTIBODIES; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; IN-VITRO; BRUCEI; IDENTIFICATION; ENDOCYTOSIS; EXPRESSION	Background: The discovery of Nanobodies (Nbs) with a direct toxic activity against African trypanosomes is a recent advancement towards a new strategy against these extracellular parasites. The anti-trypanosomal activity relies on perturbing the highly active recycling of the Variant-specific Surface Glycoprotein (VSG) that occurs in the parasite's flagellar pocket. Methodology/Principal Findings: Here we expand the existing panel of Nbs with anti-Trypanosoma brucei potential and identify four categories based on their epitope specificity. We modified the binding properties of previously identified Nanobodies Nb_An05 and Nb_An33 by site-directed mutagenesis in the paratope and found this to strongly affect trypanotoxicity despite retention of antigen-targeting properties. Affinity measurements for all identified anti-trypanosomal Nbs reveal a strong correlation between trypanotoxicity and affinity (KD), suggesting that it is a crucial determinant for this activity. Half maximal effective (50%) affinity of 57 nM was calculated from the non-linear dose-response curves. In line with these observations, Nb humanizing mutations only preserved the trypanotoxic activity if the KD remained unaffected. Conclusions/Significance: This study reveals that the binding properties of Nanobodies need to be compatible with achieving an occupancy of >95% saturation of the parasite surface VSG in order to exert an anti-trypanosomal activity. As such, Nb-based approaches directed against the VSG target would require binding to an accessible, conserved epitope with high affinity.	[Caljon, Guy; Van Den Abbeele, Jan] Inst Trop Med Antwerp, Unit Vet Protozool, Dept Biomed Sci, Antwerp, Belgium; [Caljon, Guy; Stijlemans, Benoit; Saerens, Dirk; Muyldermans, Serge; Magez, Stefan; De Baetselier, Patrick] Vrije Univ Brussel, Res Unit Cellular & Mol Immunol, Brussels, Belgium; [Caljon, Guy; Stijlemans, Benoit; De Baetselier, Patrick] VIB, Lab Myeloid Cell Immunol, Brussels, Belgium; [Saerens, Dirk; Muyldermans, Serge; Magez, Stefan] VIB, Dept Biol Struct, Brussels, Belgium	Caljon, G (reprint author), Inst Trop Med Antwerp, Unit Vet Protozool, Dept Biomed Sci, Antwerp, Belgium.	gcaljon@itg.be	Caljon, Guy/E-1310-2017; Muyldermans, Serge/C-6418-2016; Magez, Stefan/D-9497-2014; De Baetselier, Patrick/D-3866-2014	Caljon, Guy/0000-0002-4870-3202; Muyldermans, Serge/0000-0002-3678-3575; Magez, Stefan/0000-0003-3760-7968; Saerens, Dirk/0000-0001-8894-8039; Van Den Abbeele, Jan/0000-0002-4533-4480; Stijlemans, Benoit/0000-0003-0082-9751	InterUniversity Attraction Poles Programme [IUAP] of the Belgian Science Policy; Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen; EU/FP7 ERC [282312]; ITM; VUB	This work was supported by the InterUniversity Attraction Poles Programme [IUAP, P6 and P7] of the Belgian Science Policy, the Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen and the EU/FP7 ERC starting grant "NANOSYM" [282312]. This project was also supported by ITM and VUB fundings. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; AUFFRET CA, 1981, BIOCHEM J, V193, P647, DOI 10.1042/bj1930647; BALBER AE, 1979, INFECT IMMUN, V24, P617; Barry JD, 2001, ADV PARASIT, V49, P1; Beschin A, 1998, J LEUKOCYTE BIOL, V63, P429; Bockstal V, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002089; Conrath K, 2005, J MOL BIOL, V350, P112, DOI 10.1016/j.jmb.2005.04.050; Conrath KE, 2001, ANTIMICROB AGENTS CH, V45, P2807, DOI 10.1128/AAC.45.10.2807-2812.2001; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Darji A, 1996, INFECT IMMUN, V64, P1937; De Vooght L, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-23; Donelson JE, 2003, ACTA TROP, V85, P391, DOI 10.1016/S0001-706X(02)00237-1; Engstler M, 2004, J CELL SCI, V117, P1105, DOI 10.1242/jcs.00938; Garcia-Salcedo JA, 2004, EMBO J, V23, P780, DOI 10.1038/sj.emboj.7600094; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; Hall BS, 2005, EUKARYOT CELL, V4, P971, DOI 10.1128/EC.4.5.971-980.2005; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Leal S, 2004, J BIOL CHEM, V279, P28979, DOI 10.1074/jbc.M403479200; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; O'Beirne C, 1998, MOL BIOCHEM PARASIT, V91, P165, DOI 10.1016/S0166-6851(97)00191-6; Pays E, 2004, CURR OPIN MICROBIOL, V7, P369, DOI 10.1016/j.mib.2004.05.001; Pearson TW, 2000, MOL BIOCHEM PARASIT, V111, P333, DOI 10.1016/S0166-6851(00)00327-3; Radwanska M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000078; Saerens D, 2004, J BIOL CHEM, V279, P51965, DOI 10.1074/jbc.M409292200; Saerens D, 2008, J IMMUNOL METHODS, V329, P138, DOI 10.1016/j.jim.2007.10.005; Spitznagel D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012282; Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200; Stijlemans B, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002072; Teeling JL, 2006, J IMMUNOL, V177, P362, DOI 10.4049/jimmunol.177.1.362; Teeling JL, 2004, BLOOD, V104, P1793, DOI 10.1182/blood-2004-01-0039; Vanhamme L, 2001, INT J PARASITOL, V31, P523, DOI 10.1016/S0020-7519(01)00143-6; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	35	11	12	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	NOV	2012	6	11							e1902	10.1371/journal.pntd.0001902				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	048CX	WOS:000311888900030	23166849	DOAJ Gold, Green Published			2019-03-26	
J	Lindsay, SW; Lindsay, TC; Duprez, J; Hall, MJR; Kwambana, BA; Jawara, M; Nurudeen, IU; Sallah, N; Wyatt, N; D'Alessandro, U; Pinder, M; Antonio, M				Lindsay, Steven W.; Lindsay, Thomas C.; Duprez, Jessica; Hall, Martin J. R.; Kwambana, Brenda A.; Jawara, Musa; Nurudeen, Ikumapayi U.; Sallah, Neneh; Wyatt, Nigel; D'Alessandro, Umberto; Pinder, Margaret; Antonio, Martin			Chrysomya putoria, a Putative Vector of Diarrheal Diseases	PLOS NEGLECTED TROPICAL DISEASES			English	Article							ESCHERICHIA-COLI; DIPTERA CALLIPHORIDAE; MUSCA-DOMESTICA; FLY CONTROL; GAMBIA; FLIES; TRANSMISSION; SALMONELLA; HOUSEFLIES; SANITATION	Background: Chrysomya spp are common blowflies in Africa, Asia and parts of South America and some species can reproduce in prodigious numbers in pit latrines. Because of their strong association with human feces and their synanthropic nature, we examined whether these flies are likely to be vectors of diarrheal pathogens. Methodology/Principal Findings: Flies were sampled using exit traps placed over the drop holes of latrines in Gambian villages. Odor-baited fly traps were used to determine the relative attractiveness of different breeding and feeding media. The presence of bacteria on flies was confirmed by culture and bacterial DNA identified using PCR. A median of 7.00 flies/latrine/day (IQR = 0.0-25.25) was collected, of which 95% were Chrysomya spp, and of these nearly all were Chrysomya putoria (99%). More flies were collected from traps with feces from young children (median = 3.0, IQR = 1.75-10.75) and dogs (median = 1.50, IQR = 0.0-13.25) than from herbivores (median = 0.0, IQR = 0.0-0.0; goat, horse, cow and calf; p<0.001). Flies were strongly attracted to raw meat (median = 44.5, IQR = 26.25-143.00) compared with fish (median = 0.0, IQR = 0.0-19.75, ns), cooked and uncooked rice, and mangoes (median = 0.0, IQR = 0.0-0.0; p<0.001). Escherichia coli were cultured from the surface of 21% (15/72 agar plates) of Chrysomya spp and 10% of these were enterotoxigenic. Enteroaggregative E. coli were identified by PCR in 2% of homogenized Chrysomya spp, Shigella spp in 1.4% and Salmonella spp in 0.6% of samples. Conclusions/Significance: The large numbers of C. putoria that can emerge from pit latrines, the presence of enteric pathogens on flies, and their strong attraction to raw meat and fish suggests these flies may be common vectors of diarrheal diseases in Africa.	[Lindsay, Steven W.; Pinder, Margaret] Univ Durham, Sch Biol & Biomed Sci, Durham, England; [Lindsay, Steven W.; Lindsay, Thomas C.; Duprez, Jessica; Pinder, Margaret] London Sch Hyg & Trop Med, London WC1, England; [Hall, Martin J. R.; Wyatt, Nigel] Nat Hist Museum, London SW7 5BD, England; [Kwambana, Brenda A.; Jawara, Musa; Nurudeen, Ikumapayi U.; Sallah, Neneh; D'Alessandro, Umberto; Antonio, Martin] MRC Unit, Fajara, Gambia; [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium	Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, Durham, England.	S.W.Lindsay@durham.ac.uk	D'Alessandro, Umberto/D-3457-2015; Kwambana, Brenda/U-5786-2017	D'Alessandro, Umberto/0000-0001-6341-5009; Kwambana, Brenda/0000-0002-1202-8540; Hall, Martin/0000-0002-8917-9646	Bill and Melinda Gates Foundation [OPP1034747]; Research and Policy for Infectious Disease Dynamics (RAPIDD) Program of the Science and Technology Directory; Department of Homeland Security; Fogarty International Center, National Institutes of Health, Medical Research Council, UK; Medical Research Council [MC_UP_A900_1119, MC_U190081991, MC_U190074190]	The work was supported by the Bill and Melinda Gates Foundation (#OPP1034747; Grand Challenges Explorations Phase I, Round 6 Project Grant). SLW received support from the Research and Policy for Infectious Disease Dynamics (RAPIDD) Program of the Science and Technology Directory, Department of Homeland Security, and Fogarty International Center, National Institutes of Health, Medical Research Council, UK. The sponsors of the study did not have a role in the design of the study, data collection, analysis, interpretation and writing of this manuscript.	Bang YH, 1973, WHOVBC73451; BERTRAM D. S., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P217, DOI 10.1016/0035-9203(58)90079-8; Bervoets W, 1958, MEM ACAD ROY SCI COL, V7, P1; Biggerstaff BJ, 2009, POOLEDINFRATE VERSIO; BRYGOO E. R., 1962, BULL SOC PATHOL EXOT, V55, P866; Cairncross S, 2010, INT J EPIDEMIOL, V39, P193, DOI 10.1093/ije/dyq035; Cerigatto W, 2009, J ANIM VET ADV, V8, P534; Chavasse DC, 1999, LANCET, V353, P22, DOI 10.1016/S0140-6736(98)03366-2; Clermont O, 2000, APPL ENVIRON MICROB, V66, P4555, DOI 10.1128/AEM.66.10.4555-4558.2000; COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N; Cunningham SA, 2010, J CLIN MICROBIOL, V48, P2929, DOI 10.1128/JCM.00339-10; CURTIS CF, 1982, T ROY SOC TROP MED H, V76, P99, DOI 10.1016/0035-9203(82)90031-1; Dione MM, 2011, J INFECT DEV COUNTR, V5, P765; Emerson PM, 2005, TROP MED INT HEALTH, V10, P706, DOI 10.1111/j.1365-3156.2005.01432.x; Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1; Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2; Feachem RG, 1983, SANITATION DIS HLTH; GREENBERG B, 1965, SCI AM, V213, P92, DOI 10.1038/scientificamerican0765-92; Greenberg B, 1966, BACTERIAL INTERACTIO, P371; GREENBERG B, 1971, FLIES DIS ECOLOGY CL; Greenberg B, 1973, FLIES DIS BIOL DIS T; Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x; Kobayashi M, 1999, AM J TROP MED HYG, V61, P625, DOI 10.4269/ajtmh.1999.61.625; Lane R.P., 1993, MED INSECTS ARACHNID; LAURENCE BR, 1988, MED VET ENTOMOL, V2, P285, DOI 10.1111/j.1365-2915.1988.tb00197.x; LEWIS D. J., 1955, BULL SOC ENT EGYPTE, V39, P275; Mara D, 1984, DESIGN VENTILATED IM; Mendonca PM, 2012, MICROSC RES TECHNIQ, V75, P206, DOI 10.1002/jemt.21044; Morgan P R, 1977, Cent Afr J Med, V23, P1; Nguyen TV, 2005, J CLIN MICROBIOL, V43, P755, DOI 10.1128/JCM.43.2.755-760.2005; NORRIS KR, 1965, ANNU REV ENTOMOL, V10, P47, DOI 10.1146/annurev.en.10.010165.000403; Prins A.J., 1982, Annals of the South African Museum, V90, P201; Rozendaal J. A., 1997, VECTOR CONTROL METHO; SERVICE M. W., 1976, MOSQUITO ECOLOGY FIE; Simms VM, 2005, T ROY SOC TROP MED H, V99, P631, DOI 10.1016/j.trstmh.2004.10.004; Smith KG, 1973, INSECTS OTHER ARTHRO; Smith KGV, 1986, MANUAL FORENSIC ENTO; Thyssen PJ, 2010, CURRENT CONCEPTS IN FORENSIC ENTOMOLOGY, P25, DOI 10.1007/978-1-4020-9684-6_2; UNICEF and World Health Organisation, 2012, PROGR DRINK WAT SAN; UNICEF/ WHO, 2009, DIARRH WHY CHILDR ST; United Nations, 2011, MILL DEV GOALS REP 2; WATT J, 1948, PUBLIC HEALTH REP, V63, P1319, DOI 10.2307/4586723; Woodhill Gurney W, 1926, AGRIC DEPT NEW SOUTH, V27, P4; Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338; Zumpt F., 1965, MYIASIS MAN ANIMALS	45	14	14	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	NOV	2012	6	11							e1895	10.1371/journal.pntd.0001895				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	048CX	WOS:000311888900023	23133694	DOAJ Gold, Green Published			2019-03-26	
J	Mitashi, P; Hasker, E; Lejon, V; Kande, V; Muyembe, JJ; Lutumba, P; Boelaert, M				Mitashi, Patrick; Hasker, Epco; Lejon, Veerle; Kande, Victor; Muyembe, Jean-Jacques; Lutumba, Pascal; Boelaert, Marleen			Human African Trypanosomiasis Diagnosis in First-Line Health Services of Endemic Countries, a Systematic Review	PLOS NEGLECTED TROPICAL DISEASES			English	Review							MEDIATED ISOTHERMAL AMPLIFICATION; SLEEPING SICKNESS DIAGNOSIS; POLYMERASE-CHAIN-REACTION; CATT/TRYPANOSOMA-BRUCEI-GAMBIENSE; SEQUENCE-BASED AMPLIFICATION; CARD-AGGLUTINATION-TEST; HUMAN BLOOD-SAMPLES; COTE-DIVOIRE; SOUTHERN SUDAN; B.-GAMBIENSE	While the incidence of Human African Trypanosomiasis (HAT) is decreasing, the control approach is shifting from active population screening by mobile teams to passive case detection in primary care centers. We conducted a systematic review of the literature between 1970 and 2011 to assess which diagnostic tools are most suitable for use in first-line health facilities in endemic countries. Our search retrieved 16 different screening and confirmation tests for HAT. The thermostable format of the Card Agglutination Test for Trypanosomiasis (CATT test) was the most appropriate screening test. Lateral flow antibody detection tests could become alternative screening tests in the near future. Confirmation of HAT diagnosis still depends on visualizing the parasite in direct microscopy. All other currently available confirmation tests are either technically too demanding and/or lack sensitivity and thus rather inappropriate for use at health center level. Novel applications of molecular tests may have potential for use at district hospital level.	[Mitashi, Patrick; Lutumba, Pascal] Kinshasa Univ, Dept Trop Med, Parasitol Serv, Fac Med, Kinshasa, DEM REP CONGO; [Mitashi, Patrick; Hasker, Epco; Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, Grp Epidemiol & Dis Control, B-2000 Antwerp, Belgium; [Lejon, Veerle] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Kande, Victor] Programme Natl Lutte Trypanosomiase Humaine Afric, Kinshasa, DEM REP CONGO; [Muyembe, Jean-Jacques; Lutumba, Pascal] Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO	Mitashi, P (reprint author), Kinshasa Univ, Dept Trop Med, Parasitol Serv, Fac Med, Kinshasa, DEM REP CONGO.	mboelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Lejon, Veerle/0000-0002-6795-0962			[Anonymous], 1976, Bull World Health Organ, V54, P141; BAFORT JM, 1986, S AFR MED J, V69, P541; BAILEY JW, 1992, T ROY SOC TROP MED H, V86, P630, DOI 10.1016/0035-9203(92)90160-E; Becker S, 2004, DIAGN MICR INFEC DIS, V50, P193, DOI 10.1016/j.diagmicrobio.2004.07.001; Boehme CC, 2007, J CLIN MICROBIOL, V45, P1936, DOI 10.1128/JCM.02352-06; Bossuyt PM, 2003, BRIT MED J, V326, P41, DOI 10.1136/bmj.326.7379.41; Buscher P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000471; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; Camara M, 2010, TROP MED INT HEALTH, V15, P796, DOI 10.1111/j.1365-3156.2010.02546.x; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Chappuis F, 2004, AM J TROP MED HYG, V71, P313, DOI 10.4269/ajtmh.2004.71.313; Chappuis F, 2002, TROP MED INT HEALTH, V7, P942, DOI 10.1046/j.1365-3156.2002.00956.x; Checchi F, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001233; COMPTON J, 1991, NATURE, V350, P91, DOI 10.1038/350091a0; Deborggraeve S, 2006, J CLIN MICROBIOL, V44, P2884, DOI 10.1128/JCM.02594-05; Deborggraeve S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000972; DUVALLET G, 1979, NOUV PRESSE MED, V8, P214; Duvallet G., 1978, Medecine Tropicale, V38, P69; Elrayah I. E., 2007, Eastern Mediterranean Health Journal, V13, P1098; FIND, 2011, SER ANT DET TEST; FREZIL JL, 1977, B SOC PATHOL EXOT, V70, P65; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; Hasker E, 2010, TROP MED INT HEALTH, V15, P263, DOI 10.1111/j.1365-3156.2009.02446.x; Hasker E, 2010, AM J TROP MED HYG, V83, P374, DOI 10.4269/ajtmh.2010.09-0735; HENRY MC, 1981, ANN SOC BELG MED TR, V61, P79; HOUWEN B, 1990, CLIN LAB HAEMATOL, V12, P157; Inojosa WO, 2006, BRIT MED J, V332, P1479, DOI 10.1136/bmj.38859.531354.7C; Jamonneau V, 2000, ACTA TROP, V76, P175, DOI 10.1016/S0001-706X(00)00095-4; Jamonneau V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000917; Kabiri M, 1999, TROP MED INT HEALTH, V4, P658, DOI 10.1046/j.1365-3156.1999.00465.x; Kanmogne GD, 1996, ANN TROP MED PARASIT, V90, P475, DOI 10.1080/00034983.1996.11813072; Koffi M, 2006, ACTA TROP, V98, P183, DOI 10.1016/j.actatropica.2006.04.001; Kuboki N, 2003, J CLIN MICROBIOL, V41, P5517, DOI 10.1128/JCM.41.12.5517-5524.2003; Kyambadde JW, 2000, B WORLD HEALTH ORGAN, V78, P119; Laveissiere C, 1998, B WORLD HEALTH ORGAN, V76, P559; Lejon V, 2006, TROP MED INT HEALTH, V11, P620, DOI 10.1111/j.1365-3156.2006.01620.x; Lejon V, 2003, TROP MED INT HEALTH, V8, P585, DOI 10.1046/j.1365-3156.2003.01077.x; Lutumba P, 2006, TROP MED INT HEALTH, V11, P470, DOI [10.1111/j.1365-3156.2006.01591.x, 10.1111/j.1365-3159.2006.01591.x]; Lutumba P, 2005, TROP MED INT HEALTH, V10, P347, DOI 10.1111/j.1365-3156.2005.01391.x; Magez S, 2009, FUTURE MICROBIOL, V4, P1075, DOI [10.2217/fmb.09.65, 10.2217/FMB.09.65]; Magnus E, 2002, ACTA TROP, V81, P7, DOI 10.1016/S0001-706X(01)00184-X; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Matovu E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000737; MCNAMARA JJ, 1995, T ROY SOC TROP MED H, V89, P388, DOI 10.1016/0035-9203(95)90021-7; MIEZAN T, 1991, B WORLD HEALTH ORGAN, V69, P603; MIEZAN TW, 1994, B SOC PATHOL EXOT, V87, P101; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; Mugasa CM, 2008, DIAGN MICR INFEC DIS, V61, P440, DOI 10.1016/j.diagmicrobio.2008.03.019; Mugasa CM, 2009, J CLIN MICROBIOL, V47, P630, DOI 10.1128/JCM.01430-08; NANTULYA VM, 1992, T ROY SOC TROP MED H, V86, P42, DOI 10.1016/0035-9203(92)90435-F; Nantulya VM, 1997, T ROY SOC TROP MED H, V91, P551, DOI 10.1016/S0035-9203(97)90023-7; Njiru ZK, 2008, INT J PARASITOL, V38, P589, DOI 10.1016/j.ijpara.2007.09.006; Njiru ZK, 2011, J CLIN MICROBIOL, V49, P1530, DOI 10.1128/JCM.01817-10; Njiru ZK, 2011, DIAGN MICR INFEC DIS, V69, P205, DOI 10.1016/j.diagmicrobio.2010.08.026; Noireau F, 1991, Bull World Health Organ, V69, P603; NOIREAU F, 1987, B SOC PATHOL EXOT, V80, P797; Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63; Pang T, 2007, T ROY SOC TROP MED H, V101, P856, DOI 10.1016/j.trstmh.2007.04.014; Peeling RW, 2010, CLIN MICROBIOL INFEC, V16, P1062, DOI 10.1111/j.1469-0691.2010.03279.x; Penchenier L, 2000, T ROY SOC TROP MED H, V94, P392, DOI 10.1016/S0035-9203(00)90116-0; Penchenier L, 2003, ACTA TROP, V85, P31, DOI 10.1016/S0001-706X(02)00232-2; PEPIN J, 1986, ANN SOC BELG MED TR, V66, P213; Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X; Programme National de Lutte contre la Trypanosomiase Humaine Africaine, 2010, PROGR NAT LUTT TRYP; Radwanska M, 2002, AM J TROP MED HYG, V67, P289, DOI 10.4269/ajtmh.2002.67.289; Robays J, 2007, TROP MED INT HEALTH, V12, P290, DOI 10.1111/j.1365-3165.2006.01768.x; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Simarro PP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001007; Solano P, 2002, ACTA TROP, V82, P349, DOI 10.1016/S0001-706X(02)00029-3; Thekisoe OMM, 2007, ACTA TROP, V102, P182, DOI 10.1016/j.actatropica.2007.05.004; TRUC P, 1994, T ROY SOC TROP MED H, V88, P419, DOI 10.1016/0035-9203(94)90410-3; Truc P, 2002, B WORLD HEALTH ORGAN, V80, P882; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; Wastling SL, 2011, TRENDS PARASITOL, V27, P394, DOI 10.1016/j.pt.2011.04.005; WERY M, 1970, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V50, P613; World Health Organization, 1998, WHO TECH REP SER, V881, P114	77	28	28	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	NOV	2012	6	11							e1919	10.1371/journal.pntd.0001919				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	048CX	WOS:000311888900044	23209860	DOAJ Gold, Green Published			2019-03-26	
J	Mueller, YK; Nackers, F; Ahmed, KA; Boelaert, M; Djoumessi, JC; Eltigani, R; Gorashi, HA; Hammam, O; Ritmeijer, K; Salih, N; Worku, D; Etard, JF; Chappuis, F				Mueller, Yolanda Kathrin; Nackers, Fabienne; Ahmed, Khalid A.; Boelaert, Marleen; Djoumessi, Jean-Claude; Eltigani, Rahma; Gorashi, Himida Ali; Hammam, Omer; Ritmeijer, Koert; Salih, Niven; Worku, Dagemlidet; Etard, Jean-Francois; Chappuis, Francois			Burden of Visceral Leishmaniasis in Villages of Eastern Gedaref State, Sudan: An Exhaustive Cross-Sectional Survey	PLOS NEGLECTED TROPICAL DISEASES			English	Article							AZAR DERMAL LEISHMANIASIS; DIRECT AGGLUTINATION-TEST; ENDEMIC KALA-AZAR; EPIDEMIOLOGY; ELIMINATION; INFECTION	Background: Since December 2009, Medecins Sans Frontieres has diagnosed and treated patients with visceral leishmaniasis (VL) in Tabarak Allah Hospital, eastern Gedaref State, one of the main endemic foci of VL in Sudan. A survey was conducted to estimate the VL incidence in villages around Tabarak Allah. Methods: Between the 5th of May and the 17th of June 2011, we conducted an exhaustive door-to-door survey in 45 villages of Al-Gureisha locality. Deaths were investigated by verbal autopsies. All individuals with (i) fever of at least two weeks, (ii) VL diagnosed and treated in the previous year, and (iii) clinical suspicion of post-kala-azar dermal leishmaniasis (PKDL) were referred to medical teams for case ascertainment. A new case of VL was a clinical suspect with a positive rk39 rapid test or direct agglutination test (DAT). Results: In the 45 villages screened, 17,702 households were interviewed, for a population of 94,369 inhabitants. The crude mortality rate over the mean recall period of 409 days was 0.13/10'000 people per day. VL was a possible or probable cause for 19% of all deaths. The VL-specific mortality rate was estimated at 0.9/1000 per year. The medical teams examined 551 individuals referred for a history of fever of at least two weeks. Out of these, 16 were diagnosed with primary VL. The overall incidence of VL over the past year was 7.0/1000 persons per year, or 7.9/1000 per year when deaths possibly or probably due to VL were included. Overall, 12.5% (11,943/95,609) of the population reported a past VL treatment episode. Discussion and Conclusion: VL represents a significant health burden in eastern Gedaref State. Active VL case detection had a very low yield in this specific setting with adequate access to care and may not be the priority intervention to enhance control in similar contexts.	[Mueller, Yolanda Kathrin; Nackers, Fabienne; Etard, Jean-Francois] Epictr, Paris, France; [Ahmed, Khalid A.; Djoumessi, Jean-Claude; Hammam, Omer; Salih, Niven; Worku, Dagemlidet; Chappuis, Francois] Med Sans Frontieres Operat Ctr Geneva, Geneva, Switzerland; [Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Eltigani, Rahma] Fed Minist Hlth, Khartoum, Sudan; [Gorashi, Himida Ali] Univ Gedaref, Dept Community Med, Gedaref, Sudan; [Ritmeijer, Koert] Med Sans Frontieres Operat Ctr Amsterdam, Amsterdam, Netherlands; [Etard, Jean-Francois] IRD, Montpellier, France; [Chappuis, Francois] Univ Hosp Geneva, Geneva, Switzerland; [Chappuis, Francois] Univ Geneva, Geneva, Switzerland	Mueller, YK (reprint author), Epictr, Paris, France.	yolanda.muller@geneva.msf.org	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Mueller, Yolanda/0000-0002-8861-4538	Medecins Sans Frontieres	This work was funded by Medecins Sans Frontieres. MSF gave technical input in preparation and implementation of the survey. MSF co-authors reviewed this manuscript and agreed for its publication. However, final decisions were the responsibility of the principal investigator who certifies the absence of interests that could have affected the reliability of these results.	Adam GK, 2009, INT J GYNECOL OBSTET, V107, P208, DOI 10.1016/j.ijgo.2009.08.002; Bucheton B, 2002, MICROBES INFECT, V4, P1449, DOI 10.1016/S1286-4579(02)00027-8; Chappuis F, 2006, BRIT MED J, V333, P723, DOI 10.1136/bmj.38917.503056.7C; Elnaiem D E A, 2003, East Mediterr Health J, V9, P827; Elnaiem DEA, 2003, AM J TROP MED HYG, V68, P10, DOI 10.4269/ajtmh.2003.68.1.0680010; Ismail A, 1997, T ROY SOC TROP MED H, V91, P283, DOI 10.1016/S0035-9203(97)90075-4; Joshi AB, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-54; Khalil EAG, 2002, TROP MED INT HEALTH, V7, P35, DOI 10.1046/j.1365-3156.2002.00832.x; Kolaczinski JH, 2008, EMERG INFECT DIS, V14, P664, DOI 10.3201/eid1404.071099; Luz ZMP, 2009, CAD SAUDE PUBLICA, V25, P1176; MEREDITH SEO, 1995, J CLIN MICROBIOL, V33, P1742; Mueller Y, 2009, TROP MED INT HEALTH, V14, P910, DOI 10.1111/j.1365-3156.2009.02305.x; Musa AM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000855; Osman OF, 2000, TROP MED INT HEALTH, V5, P553, DOI 10.1046/j.1365-3156.2000.00598.x; Ritmeijer K, 2006, AM J TROP MED HYG, V74, P76, DOI 10.4269/ajtmh.2006.74.76; Ritmeijer K, 2003, T ROY SOC TROP MED H, V97, P609, DOI 10.1016/S0035-9203(03)80047-0; Ritmeijer K, 2007, TROP MED INT HEALTH, V12, P404, DOI 10.1111/j.1365-3156.2006.01807.x; Stauch A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001405; Thakur CP, 2007, INDIAN J MED RES, V126, P447; United Nations D of E and SAPD, 2011, WORLD POP PROSP 2010; Veeken H, 2000, TROP MED INT HEALTH, V5, P312, DOI 10.1046/j.1365-3156.2000.00555.x; World Health Organization, 2010, M WHO EXP COMM CONTR, V9492010; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6; Zijlstra EE, 2000, BRIT J DERMATOL, V143, P136, DOI 10.1046/j.1365-2133.2000.03603.x; ZIJLSTRA EE, 1995, AM J TROP MED HYG, V52, P299, DOI 10.4269/ajtmh.1995.52.299; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826	26	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	NOV	2012	6	11							e1872	10.1371/journal.pntd.0001872				6	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	048CX	WOS:000311888900006	23133683	DOAJ Gold, Green Published			2019-03-26	
J	Singh, RP; Picado, A; Alam, S; Hasker, E; Singh, SP; Ostyn, B; Chappuis, F; Sundar, S; Boelaert, M				Singh, Rudra Pratap; Picado, Albert; Alam, Shahnawaz; Hasker, Epco; Singh, Shri Prakash; Ostyn, Bart; Chappuis, Francois; Sundar, Shyam; Boelaert, Marleen			Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Post-kala-azar dermal leishmaniasis; PKDL; Leishmania donovani; visceral leishmaniasis; kala azar; Bihar; leishmaniose cutanee post kala-azar; PKLD; Leishmania donovani; leishmaniose viscerale; kala-azar; Bihar; leishmaniasis cutanea post-kala-azar; LCPK; Leishmania donovani; leishmaniasis visceral; kala azar; Bihar	AMPHOTERICIN-B; PKDL; MILTEFOSINE; NEPAL	We assessed the prevalence of post-kala-azar dermal leishmaniasis (PKDL), a late cutaneous manifestation of visceral leishmaniasis (VL), in 16 VL-endemic communities in Bihar, India. The prevalence of confirmed PKDL cases was 4.4 per 10 000 individuals and 7.8 if probable cases were also considered. The clinical history and treatment of the post-kala-azar dermal leishmaniasis cases are discussed.	[Picado, Albert] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, E-08036 Barcelona, Spain; [Singh, Rudra Pratap; Alam, Shahnawaz; Singh, Shri Prakash; Sundar, Shyam] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Picado, Albert; Hasker, Epco; Ostyn, Bart; Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Chappuis, Francois] Univ Hosp Geneva, Geneva, Switzerland	Picado, A (reprint author), Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, Rossello 132,4th Floor, E-08036 Barcelona, Spain.	albert.picado@cresib.cat	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Picado, Albert/0000-0001-7344-628X	European Union [INCO-DEV FP-6015374]; Fonds Wetenschappelijk Onderzoek - Vlaanderen [FWO-1511309]	We are grateful to Surendra Uranw for his assistance in preparing the picture album used in the household survey. This work was supported by the European Union [INCO-DEV FP-6015374] and Fonds Wetenschappelijk Onderzoek - Vlaanderen [FWO-1511309].	Boelaert M, 2009, TROP MED INT HEALTH, V14, P639, DOI 10.1111/j.1365-3156.2009.02279.x; Control of the leishmaniasis, 2010, WHO TECHN REP SER; Das VNR, 2009, AM J TROP MED HYG, V80, P336, DOI 10.4269/ajtmh.2009.80.336; Kumar D, 2009, ANN TROP MED PARASIT, V103, P727, DOI 10.1179/000349809X12554106963438; Mondal D, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000832; Pandey K, 2012, J CLIN MICROBIOL, V50, P1478, DOI 10.1128/JCM.05966-11; Picado A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6760; Rahman KM, 2010, CLIN INFECT DIS, V50, P73, DOI 10.1086/648727; RAI R N, 1989, Journal of Communicable Diseases, V21, P214; Singh S, 2000, Int J Infect Dis, V4, P203, DOI 10.1016/S1201-9712(00)90110-3; Stauch A, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001405; Thakur CP, 2008, INDIAN J MED RES, V128, P38; Uranw S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001433; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6	14	10	10	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2012	17	11					1345	1348		10.1111/j.1365-3156.2012.03067.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	023JJ	WOS:000310028400005	22882665	Bronze			2019-03-26	
J	Tayler-Smith, K; Zachariah, R; Hinderaker, SG; Manzi, M; De Plecker, E; Van Wolvelaer, P; Gil, T; Goetghebuer, S; Ritter, H; Bawo, L; Davis-Worzi, C				Tayler-Smith, K.; Zachariah, R.; Hinderaker, S. G.; Manzi, M.; De Plecker, E.; Van Wolvelaer, P.; Gil, T.; Goetghebuer, S.; Ritter, H.; Bawo, L.; Davis-Worzi, C.			Sexual violence in post-conflict Liberia: survivors and their care	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						sexual violence; survivors; care; Liberia; violence sexuelle; survivants; soins; Liberia; violencia sexual; supervivientes; cuidados; Liberia		Using routine data from three clinics offering care to survivors of sexual violence (SV) in Monrovia, Liberia, we describe the characteristics of SV survivors and the pattern of SV and discuss how the current approach could be better adapted to meet survivors needs. There were 1500 survivors seeking SV care between January 2008 and December 2009. Most survivors were women (98%) and median age was 13 years (Interquartile range: 917 years). Sexual aggression occurred during day-to-day activities in 822 (55%) cases and in the survivors home in 552 (37%) cases. The perpetrator was a known civilian in 1037 (69%) SV events. Only 619 (41%) survivors sought care within 72 h. The current approach could be improved by: effectively addressing the psychosocial needs of child survivors, reaching male survivors, targeting the perpetrators in awareness and advocacy campaigns and reducing delays in seeking care.	[Tayler-Smith, K.; Zachariah, R.; Manzi, M.] Medecins Sans Frontieres, Dept Med, Operat Ctr Brussels, Luxembourg, Luxembourg; [Hinderaker, S. G.] Univ Bergen, Ctr Int Hlth, Bergen, Norway; [Hinderaker, S. G.] Int Union TB & Lung Dis, Paris, France; [Tayler-Smith, K.; De Plecker, E.; Van Wolvelaer, P.; Gil, T.; Goetghebuer, S.] Medecins Sans Frontieres, Brussels Operat Ctr, Dept Med, Operat Res, B-1090 Brussels, Belgium; [Ritter, H.] Medecins Sans Frontieres, Monrovia, Liberia; [Bawo, L.] Minist Hlth & Social Welf, Monrovia, Liberia; [Davis-Worzi, C.] Minist Gender & Dev, Monrovia, Liberia	Tayler-Smith, K (reprint author), Medecins Sans Frontieres, Brussels Operat Ctr, Dept Med, Operat Res, Rue Dupre 94, B-1090 Brussels, Belgium.	katie_harries@yahoo.co.uk			Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, France; Operational Research Unit, Medecins sans Frontieres, Brussels-Luxembourg; Centre for International Health, University of Bergen, Norway	We are grateful to the Liberian Ministry of Health and Social Welfare for their collaboration and support in implementing the package of care for survivors of SV and we are particularly grateful to the staff in the field for their hard work. A special thanks also goes to Angie Huyskens for her valuable comments and inputs. This research was supported through an operational research course, which was jointly developed and run by the Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, France, and the Operational Research Unit, Medecins sans Frontieres, Brussels-Luxembourg. Additional support for running the course was provided by the Centre for International Health, University of Bergen, Norway.	Amnesty International, 2004, LIB NO IMP RAP CRIM; Etienne K, 2002, WORLD REPORT VIOLENC; Jejeebhoy S. J., 2003, NONCONSENSUAL SEXUAL; Johnson K, 2010, JAMA-J AM MED ASSOC, V304, P553, DOI 10.1001/jama.2010.1086; Medecins Sans Frontieres, 2009, SPECIAL REPORT SHATT; Ministry of Health and Social Welfare, 2008, LIB DEM HLTH SURV 20; Population Council, 2008, SEX GEND BAS VIOL AF; United Nations Mission in Liberia (UNMIL), 2008, RES PREV ATT RAP LIB; WHO, 2003, GUID MED CAR SEX VIO; World Health Organization, 2002, WORLD REPORT VIOLENC; Yarney A, 2008, RES PREVALENCE ATTIT	11	8	8	1	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2012	17	11					1356	1360		10.1111/j.1365-3156.2012.03066.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	023JJ	WOS:000310028400007	22882628	Bronze			2019-03-26	
J	Zachariah, R; Reid, T; Ford, N; Van den Bergh, R; Dahmane, A; Khogali, M; Delaunois, P; Harries, AD				Zachariah, Rony; Reid, Tony; Ford, Nathan; Van den Bergh, Rafael; Dahmane, Amine; Khogali, Mohammed; Delaunois, Paul; Harries, Anthony D.			The 2012 world health report no health without research': the endpoint needs to go beyond publication outputs	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						operational research; health; capacity; outputs; recherche operationnelle; sante; capacite; resultats; investigacion operativa; salud; capacidad; resultados	LOW-INCOME COUNTRIES; OPERATIONAL-RESEARCH; CAPACITY; PROGRAM		[Zachariah, Rony; Reid, Tony; Van den Bergh, Rafael; Dahmane, Amine] Medecins Sans Frontieres, Brussels Operat Ctr, Dept Med, Operat Res Unit, D-1617 Luxembourg, Germany; [Ford, Nathan] Medecins Sans Frontieres, Geneva, Switzerland; [Van den Bergh, Rafael] Flemish Inst Biotechnol, Dept Mol & Cellular Interact, Brussels, Belgium; [Van den Bergh, Rafael] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium; [Khogali, Mohammed] Medecins Sans Frontieres, Addis Ababa, Ethiopia; [Delaunois, Paul] Medecins Sans Frontieres, Direct Gen, Operat Ctr Brussels, D-1617 Luxembourg, Germany; [Harries, Anthony D.] Ctr Operat Res, Int Union TB & Lung Dis, Paris, France; [Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England	Zachariah, R (reprint author), Medecins Sans Frontieres, Brussels Operat Ctr, Dept Med, Operat Res Unit, 68 Rue Gasperich, D-1617 Luxembourg, Germany.	zachariah@internet.lu		Van den Bergh, Rafael/0000-0001-6277-8713			Frenk J, 2011, HEALTH RES POLICY SY, V9, DOI 10.1186/1478-4505-9-11; Graham ID, 2009, J CAN ACAD CHILD ADO, V18, P46; Harries AD, 2011, INT J TUBERC LUNG D, V15, P144; Harries AD, 2012, PUBLIC HEALTH ACTION, V2, P1, DOI 10.5588/pha.12.0005; Mckee M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001209; Ohkado A, 2010, INT J TUBERC LUNG D, V14, P371; Walley J, 2007, B WORLD HEALTH ORGAN, V85, P424, DOI 10.2471/BLT.07.042531; Whitworth JAG, 2008, LANCET, V372, P1590, DOI 10.1016/S0140-6736(08)61660-8; World Health Organization, 2005, BRIDG KNOW DO GAP M; Zachariah R, 2011, INT J TUBERC LUNG D, V15, P1426, DOI 10.5588/ijtld.11.0316; Zachariah R, 2010, TROP MED INT HEALTH, V15, P1274, DOI 10.1111/j.1365-3156.2010.02630.x; Zachariah R, 2012, LANCET INFECT DIS, V12, P415, DOI [10.1016/S1473-3099(11)70309-7, 10.1016/S1473-3099(11)20309-7]; Zachariah R, 2009, LANCET INFECT DIS, V9, P711, DOI 10.1016/S1473-3099(09)70229-4; Zumla A, 2010, TROP MED INT HEALTH, V15, P489, DOI 10.1111/j.1365-3156.2010.02479.x	14	4	4	1	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2012	17	11					1409	1411		10.1111/j.1365-3156.2012.03072.x				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	023JJ	WOS:000310028400015	22897763				2019-03-26	
J	Ravinetto, RM; Boelaert, M; Jacobs, J; Pouget, C; Luyckx, C				Ravinetto, Raffaella M.; Boelaert, Marleen; Jacobs, Jan; Pouget, Corinne; Luyckx, Christophe			Poor-quality medical products: time to address substandards, not only counterfeits	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						quality of medicines; quality of IVDs; medicines regulation; substandard; counterfeit; World Health Assembly; qualite des medicaments; qualite des DIV; reglementation sur les medicaments; sous-normes; contrefacon; Assemblee Mondiale sur la sante; calidad de medicamentos; calidad de productos de diagnostico in vitro; regulacion de medicamentos; calidad inferior; falsificaciones; Asamblea Mundial de la Salud	ANTIMALARIAL-DRUG QUALITY; DIETHYLENE GLYCOL; PAKISTAN; AMODIAQUINE; PHARMACIES; MEDICINES; SETTINGS; EPIDEMIC; CHILDREN; TANZANIA		[Ravinetto, Raffaella M.; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Boelaert, Marleen; Luyckx, Christophe] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Jacobs, Jan] Fac Hlth & Life Sci, Dept Med Microbiol, Mastricht, Netherlands	Ravinetto, RM (reprint author), Inst Trop Med, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium.	rravinetto@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Abdo-Rabbo A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-28; Abubukar A., 2009, Morbidity and Mortality Weekly Report, V58, P1345; African Medicines Regulatory Harmonization Initiative (AMRHI), 2008, WHO DRUG INFORM, V22, P182; Alfadl AA, 2006, SUDANESE J PUBLIC HL, V1, P108; Amin AA, 2007, J CLIN PHARM THER, V32, P429, DOI 10.1111/j.1365-2710.2007.00847.x; Amin AA, 2005, J CLIN PHARM THER, V30, P559, DOI 10.1111/j.1365-2710.2005.00685.x; [Anonymous], 2011, COUNC EUR CONV COUNT; [Anonymous], 2008, WHO DRUG INFORM, V22, P262; Arie S, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e951; Atemnkeng MA, 2007, TROP MED INT HEALTH, V12, P68, DOI 10.1111/j.1365-3156.2006.01769.x; Bate R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002132; Caudron JM, 2008, TROP MED INT HEALTH, V13, P1062, DOI 10.1111/j.1365-3156.2008.02106.x; Dorlo TPC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001544; Editorial, 2012, LANCET, P379; Eichie FE, 2009, AFR J PHARM PHARMACO, V3, P491; Gaudiano MC, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-22; Gaurvika M.L.N., 2012, LANCET INFECT DIS, V12, P488; Geiling E, 1938, JAMA-J AM MED ASSOC, V111, P919, DOI DOI 10.1001/JAMA.1938.72790360005007; HANIF M, 1995, BRIT MED J, V311, P88, DOI 10.1136/bmj.311.6997.88; Kaur H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003403; Kelesidis T, 2007, J ANTIMICROB CHEMOTH, V60, P214, DOI 10.1093/jac/dkm109; Laing R, 2004, INT J TUBERC LUNG D, V8, P1043; Laroche ML, 2005, EPILEPSIA, V46, P1293, DOI 10.1111/j.1528-1167.2005.01805.x; Laserson KF, 2001, INT J TUBERC LUNG D, V5, P448; Leslie T, 2009, EMERG INFECT DIS, V15, P1753, DOI 10.3201/eid1511.090886; Maponga C, 2003, QUALITY ANTIMALARIAL; Minzi OMS, 2003, J CLIN PHARM THER, V28, P117, DOI 10.1046/j.1365-2710.2003.00470.x; Mori M, 2011, TROP MED INT HEALTH, V16, P1439, DOI 10.1111/j.1365-3156.2011.02852.x; Newton P.N., 2009, PLOS MED, V6, P0252; Newton PN, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001139; Newton PN, 2010, TRENDS PHARMACOL SCI, V31, P99, DOI 10.1016/j.tips.2009.11.005; Nishtar S, 2012, LANCET, V379, P1084, DOI 10.1016/S0140-6736(12)60277-3; OKUONGHAE HO, 1992, ANN TROP PAEDIATR, V12, P235, DOI 10.1080/02724936.1992.11747577; OMS, 1995, QUAL MED MARCH PHARM; Rentz D, 2008, B WORLD HEALTH ORGAN, V86, P749; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; Singh J, 2001, B WORLD HEALTH ORGAN, V79, P88; Sundar S, 1998, AM J TROP MED HYG, V59, P139, DOI 10.4269/ajtmh.1998.59.139; Taylor RB, 2001, LANCET, V357, P1933, DOI 10.1016/S0140-6736(00)05065-0; The USP Drug Quality and Information Program, 2004, REV DRUG QUAL AS FOC; Tipke M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-95; WHO, 2011, WHO TECH REP SER, V961, P1; WHO, 2011, WHO QUAL ASS SAF MED; WHO, 2010, ASS MED REG SYST SUB; WHO, 2011, SURV QUAL SEL ANT ME; WHO, WHO FACT SHEET 275; WHO quality assurance and safety medicines policy and standards, 2007, WHOPSMQSM20079; Woolf AD, 1998, JAMA-J AM MED ASSOC, V279, P1215, DOI 10.1001/jama.279.15.1215; World Health Organization, 1999, COUNT SUBST DRUGS MY; World Health Organization, WHO FREQ ASK QUEST	50	8	8	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2012	17	11					1412	1416		10.1111/j.1365-3156.2012.03076.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	023JJ	WOS:000310028400016	22909082	Bronze			2019-03-26	
J	Heutmekers, M; Gillet, P; Cnops, L; Bottieau, E; Van Esbroeck, M; Maltha, J; Jacobs, J				Heutmekers, Marloes; Gillet, Philippe; Cnops, Lieselotte; Bottieau, Emmanuel; Van Esbroeck, Marjan; Maltha, Jessica; Jacobs, Jan			Evaluation of the malaria rapid diagnostic test SDFK90: detection of both PfHRP2 and Pf-pLDH	MALARIA JOURNAL			English	Article						Malaria; Plasmodium falciparum; Diagnosis; Rapid diagnostic test; Histidine-rich protein; Plasmodium falciparum-specific Plasmodium lactate dehydrogenase; Evaluation	PARASITE LACTATE-DEHYDROGENASE; VIVAX MALARIA; FALCIPARUM; ACCURACY; INFECTIONS; TRAVELERS; PROZONE; QUALITY; AREA	Background: Rapid diagnosis of Plasmodium falciparum infections is important because of the potentially fatal complications. SDFK90 is a recently marketed malaria rapid diagnostic test (RDT) targeting both histidine-rich protein 2 (PfHRP2) and P. falciparum-specific Plasmodium lactate dehydrogenase (Pf-pLDH). The present study evaluated its diagnostic accuracy. Methods: SDFK90 was tested against a panel of stored whole blood samples (n=591) obtained from international travellers suspected of malaria, including the four human Plasmodium species and Plasmodium negative samples. Microscopy was used as a reference method, corrected by PCR for species diagnosis. In addition, SDFK90 was challenged against 59 P. falciparum samples with parasite density >= 4% to assess the prozone effect (no or weak visible line on initial testing and a higher intensity upon 10-fold dilution). Results: Overall sensitivity for the detection of P. falciparum was 98.5% and reached 99.3% at parasite densities >100/mu l. There were significantly more PfHRP2 lines visible compared to Pf-pLDH (97.3% vs 86.9%), which was mainly absent at parasite densities <100/mu l. Specificity of SDFK90 was 98.8%. No lot-to-lot variability was observed (p = 1.00) and test results were reproducible. A prozone effect was seen for the PfHRP2 line in 14/59 (23.7%) P. falciparum samples tested, but not for the Pf-pLDH line. Few minor shortcomings were observed in the kit's packaging and information insert. Conclusions: SDFK90 performed excellent for P. falciparum diagnosis. The combination of PfHRP2 and Pf-pLDH ensures a low detection threshold and counters potential problems of PfHRP2 detection such as gene deletions and the prozone effect.	[Heutmekers, Marloes; Gillet, Philippe; Cnops, Lieselotte; Bottieau, Emmanuel; Van Esbroeck, Marjan; Maltha, Jessica; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium	Maltha, J (reprint author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	jmaltha@itg.be	Heutmekers, Marloes/P-6140-2015	Heutmekers, Marloes/0000-0003-0880-409X; gillet, philippe/0000-0001-5878-6446			Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2; [Anonymous], 2011, UN ACC MAL DIAGN TES; Ashley EA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-241; Bossuyt PM, 2003, CROAT MED J, V44, P639; Chiodini PL, 2007, T ROY SOC TROP MED H, V101, P331, DOI 10.1016/j.trstmh.2006.09.007; Cnops L, 2011, CLIN MICROBIOL INFEC, V17, P1101, DOI 10.1111/j.1469-0691.2010.03344.x; Craig MH, 2002, T ROY SOC TROP MED H, V96, P258, DOI 10.1016/S0035-9203(02)90092-1; Gamboa D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008091; Gerstl S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-28; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-166; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-39; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-271; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-262; Iqbal J, 2004, J CLIN MICROBIOL, V42, P4237, DOI 10.1128/JCM.42.9.4237-4241.2004; Makler MT, 2009, AM J TROP MED HYG, V81, P921, DOI 10.4269/ajtmh.2009.09-0202; Maltha J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043094; Maltha J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-7; Maltha J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-198; Maltha J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-171; Marx A, 2005, ANN INTERN MED, V142, P836, DOI 10.7326/0003-4819-142-10-200505170-00009; Miller RS, 2001, BRIT J HAEMATOL, V113, P558, DOI 10.1046/j.1365-2141.2001.02782.x; Moody A H, 2002, Br J Biomed Sci, V59, P228; Mueller I, 2007, J CLIN MICROBIOL, V45, P627, DOI 10.1128/JCM.00816-06; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Rennie W, 2007, T ROY SOC TROP MED H, V101, P9, DOI 10.1016/j.trstmh.2006.03.011; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; van Dijk DPJ, 2010, EUR J CLIN MICROBIOL, V29, P577, DOI 10.1007/s10096-010-0898-y; van Dijk DPJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-293; *WHO, 2009, MAL RAP DIAGN TEST P; World Health Organisation, 2010, BAS MAL MICR 2; World Health Organization, 2011, MAL RAP DIAGN TEST P; World Health Organization, 2010, MAL RAP DIAGN TEST P; World Health Organization, 2010, BAS MAL MICR 1	34	9	9	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	OCT 29	2012	11								359	10.1186/1475-2875-11-359				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	046GJ	WOS:000311753200001	23107162	DOAJ Gold, Green Published			2019-03-26	
J	Gabriel, S; Blocher, J; Dorny, P; Abatih, EN; Schmutzhard, E; Ombay, M; Mathias, B; Winkler, AS				Gabriel, Sarah; Blocher, Joachim; Dorny, Pierre; Abatih, Emmanuel Nji; Schmutzhard, Erich; Ombay, Michaeli; Mathias, Bartholomayo; Winkler, Andrea Sylvia			Added Value of Antigen ELISA in the Diagnosis of Neurocysticercosis in Resource Poor Settings	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TAENIA-SOLIUM; RURAL TANZANIA; EPILEPSY; CYSTICERCOSIS; AFRICA; PEOPLE; SERUM; ANTIBODIES; EASTERN; SAMPLES	Background: Neurocysticercosis (NCC) is the most common cause of acquired epilepsy in Taenia solium endemic areas, primarily situated in low-income countries. Diagnosis is largely based upon the "Del Brutto diagnostic criteria" using the definitive/probable/no NCC diagnosis approach. Neuroimaging and specific T. solium cysticercosis antibody detection results are at the mainstay of this diagnosis, while antigen detection in serum has never been included. This study aimed at evaluating the addition of antigen detection as a major diagnostic criterion, especially in areas where neuroimaging is absent. Methods: The B158/B60 monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) for the detection of circulating cysticercus antigen was carried out retrospectively on serum samples collected during a hospital-based study from 83 people with epilepsy (PWE) in an endemic area. Results: The addition of antigen results as a major criterion allowed the correct diagnosis of definitive NCC in 10 out of 17 patients as opposed to 0/17 without antigen results in the absence of neuroimaging. A sensitivity of 100% and a specificity of 84% were determined for the diagnosis of active NCC using antigen ELISA. While the use of a higher cutoff improves the specificity of the test to 96%, it decreases its sensitivity to 83%. Conclusions: In areas where neuroimaging is absent, NCC diagnosis according to the existing criteria is problematic. Taking into account its limitations for diagnosis of inactive NCC, antigen detection can be of added value for diagnosing NCC in PWE by supporting diagnostic and treatment decisions. Therefore, we recommend a revision of the "Del Brutto diagnostic criteria" for use in resource poor areas and suggest the inclusion of serum antigen detection as a major criterion.	[Gabriel, Sarah; Dorny, Pierre; Abatih, Emmanuel Nji] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Blocher, Joachim; Schmutzhard, Erich] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria; [Blocher, Joachim] Univ Med Ctr Gottingen, Dept Neurol, Gottingen, Germany; [Ombay, Michaeli; Mathias, Bartholomayo] Haydom Lutheran Hosp, Mental Hlth Unit, Mbulu, Tanzania; [Winkler, Andrea Sylvia] Tech Univ Munich, Dept Neurol, Munich, Germany	Gabriel, S (reprint author), Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium.	Joachim.blocher@med.uni-goettingen.de			Savoy Epilepsy Foundation, Quebec, Canada; Center for International Migration, Frankfurt, Germany; Deutsche Forschungsgemeinschaft; Open Access Publication Funds of Gottingen University Medical Centre (UMG)	The study was supported by The Savoy Epilepsy Foundation, Quebec, Canada, and ASW was supported by The Center for International Migration, Frankfurt, Germany. The publication fees in an open access journal were covered by the Deutsche Forschungsgemeinschaft and Open Access Publication Funds of Gottingen University Medical Centre (UMG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham R, 2010, ARQ NEURO-PSIQUIAT, V68, P7, DOI 10.1590/S0004-282X2010000100003; Blocher J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001185; Chang KH, 1998, JMRI-J MAGN RESON IM, V8, P297, DOI 10.1002/jmri.1880080209; Da Silva Ribeiro V, 2010, IMMUNOL LETT, V129, P94; Deckers N, 2010, TRENDS PARASITOL, V26, P137, DOI 10.1016/j.pt.2009.12.008; Del Brutto OH, 2001, NEUROLOGY, V57, P177, DOI 10.1212/WNL.57.2.177; Dorny P, 2004, TRENDS PARASITOL, V20, P259, DOI 10.1016/j.pt.2004.04.001; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Fleury A, 2007, J NEUROL NEUROSUR PS, V78, P970, DOI 10.1136/jnnp.2006.107243; Foyaca-Sibat H, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000562; Graeff-Teixeira C, 2009, CLIN MICROBIOL REV, V22, P322, DOI 10.1128/CMR.00044-08; Ito Akira, 1999, Parasitology International, V48, P95, DOI 10.1016/S1383-5769(99)00005-7; Mafojane NA, 2003, ACTA TROP, V87, P25, DOI 10.1016/S0001-706X(03)00052-4; Manhani MN, 2011, PARASITE IMMUNOL, V33, P322, DOI 10.1111/j.1365-3024.2011.01283.x; MARTINEZ HR, 1989, AM J NEURORADIOL, V10, P1011; Meyer AC, 2010, B WORLD HEALTH ORGAN, V88, P260, DOI 10.2471/BLT.09.064147; Nash TE, 2011, NAT REV NEUROL, V7, P584, DOI 10.1038/nrneurol.2011.135; Ndimubanzi PC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000870; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Praet N, 2010, AM J TROP MED HYG, V83, P413, DOI 10.4269/ajtmh.2010.10-0121; Preux PM, 2005, LANCET NEUROL, V4, P21, DOI 10.1016/S1474-4422(04)00963-9; R, 2011, LANGUAGE ENV STAT CO; RABIELA MT, 1989, PARASITOL TODAY, V5, P357, DOI 10.1016/0169-4758(89)90111-7; Rodriguez S, 2009, J INFECT DIS, V199, P1345, DOI 10.1086/597757; Sahu PS, 2010, ACTA TROP, V115, P257, DOI 10.1016/j.actatropica.2010.04.006; SOKAL R, 1981, BIOMETRY PRINCIPALS; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Winkler AS, 2008, T ROY SOC TROP MED H, V102, P1032, DOI 10.1016/j.trstmh.2008.05.004; Winkler AS, 2007, EPILEPSIA, V48, P1029, DOI 10.1111/j.1528-1167.2007.01009_1.x; Winkler AS, 2009, WIEN KLIN WOCHENSCHR, V121, P3, DOI 10.1007/s00508-009-1242-3; Winkler AS, 2009, EPILEPSIA, V50, P987, DOI 10.1111/j.1528-1167.2008.01867.x	32	35	36	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	OCT	2012	6	10							e1851	10.1371/journal.pntd.0001851				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	029WH	WOS:000310527200018	23094118	DOAJ Gold, Green Published			2019-03-26	
J	Cnops, L; Tannich, E; Polman, K; Clerinx, J; Van Esbroeck, M				Cnops, Lieselotte; Tannich, Egbert; Polman, Katja; Clerinx, Jan; Van Esbroeck, Marjan			Schistosoma real-time PCR as diagnostic tool for international travellers and migrants	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						real-time PCR; Schistosoma; diagnosis; travellers; imported schistosomiasis; PCR en temps reel; Schistosoma; diagnostic; voyageurs; schistosomiase importee; PCR a tiempo real; Schistosoma; diagnostico; viajeros; esquistosomiasis importada	POLYMERASE-CHAIN-REACTION; URINE SAMPLES; IMPORTED SCHISTOSOMIASIS; HAEMATOBIUM INFECTION; STOOL SAMPLES; MANSONI DNA; ASSAY; MICROSCOPY; SEROLOGY; SENEGAL	Objective To evaluate the use of a genus-specific PCR that combines high sensitivity with the detection of different Schistosoma species for diagnosis in international travellers and migrants in comparison to standard microscopy. Methods and results The genus-specific real-time PCR was developed to target the 28S ribosomal RNA gene of the major human Schistosoma species. It was validated for analytical specificity and reproducibility and demonstrated an analytical sensitivity of 0.2 eggs per gram of faeces. Its diagnostic performance was further evaluated on 152 faecal, 32 urine and 38 serum samples from patients presenting at the outpatient clinic of the Institute of Tropical Medicine in Antwerp (Belgium). We detected Schistosoma DNA in 76 faecal (50.0%) and five urine (15.6%) samples of which, respectively, nine and one were not detected by standard microscopy. Only two of the 38 serum samples of patients with confirmed schistosomiasis were positive with the presently developed PCR. Sequence analysis on positive faecal samples allowed identification of the Schistosoma species complex. Conclusion The real-time PCR is highly sensitive and may offer added value in diagnosing imported schistosomiasis. The genus-specific PCR can detect all schistosome species that are infectious to humans and performs very well with faeces and urine, but not in serum.	[Cnops, Lieselotte; Clerinx, Jan; Van Esbroeck, Marjan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Tannich, Egbert] Bernhard Nocht Inst Trop Med, Hamburg, Germany; [Polman, Katja] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium	Cnops, L (reprint author), Inst Trop Med, Dept Clin Sci, Kronenburgstr 43-3, B-2000 Antwerp, Belgium.	lcnops@itg.be					Oliveira LMA, 2010, DIAGN MICR INFEC DIS, V68, P416, DOI 10.1016/j.diagmicrobio.2010.07.016; Allam AF, 2009, TROP MED INT HEALTH, V14, P316, DOI 10.1111/j.1365-3156.2009.02225.x; Bierman WFW, 2005, J TRAVEL MED, V12, P9; Clerinx J, 2011, J TRAVEL MED, V18, P367, DOI 10.1111/j.1708-8305.2011.00552.x; Clerinx J, 2011, TRAVEL MED INFECT DI, V9, P6, DOI 10.1016/j.tmaid.2010.11.002; Cnops L, 2010, CLIN MICROBIOL INFEC, V17, P1101; Cnops L, 2010, J MICROBIOL METH, V80, P310, DOI 10.1016/j.mimet.2010.01.001; Doumenge J P, 1984, World Health Stat Q, V37, P186; Gomes LI, 2009, MEM I OSWALDO CRUZ, V104, P1194, DOI 10.1590/S0074-02762009000800021; Gomes LI, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000664; Grobusch MP, 2003, J TRAVEL MED, V10, P164; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Hamburger J, 2001, AM J TROP MED HYG, V65, P907, DOI 10.4269/ajtmh.2001.65.907; HAMBURGER J, 1991, MOL BIOCHEM PARASIT, V44, P73, DOI 10.1016/0166-6851(91)90222-R; Haque R, 2010, J CLIN MICROBIOL, V48, P2798, DOI 10.1128/JCM.00152-10; Huyse T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000571; Ibironke OA, 2011, AM J TROP MED HYG, V84, P998, DOI 10.4269/ajtmh.2011.10-0691; Jimenez M, 2011, EXP PARASITOL, V127, P282, DOI 10.1016/j.exppara.2010.06.019; Kjetland EF, 2009, AM J TROP MED HYG, V81, P1050, DOI 10.4269/ajtmh.2009.09-0081; Lier T, 2009, AM J TROP MED HYG, V81, P428, DOI 10.4269/ajtmh.2009.81.428; Mackay IM, 2004, CLIN MICROBIOL INFEC, V10, P190, DOI 10.1111/j.1198-743X.2004.00722.x; Midzi N, 2008, T ROY SOC TROP MED H, V103, P45; Mwinzi PNM, 2004, AM J TROP MED HYG, V71, P783, DOI 10.4269/ajtmh.2004.71.783; Nicolls DJ, 2008, AM J TROP MED HYG, V79, P729, DOI 10.4269/ajtmh.2008.79.729; Obeng BB, 2008, ANN TROP MED PARASIT, V102, P625, DOI 10.1179/136485908X337490; Pontes LA, 2003, AM J TROP MED HYG, V68, P652, DOI 10.4269/ajtmh.2003.68.652; Pontes LA, 2002, AM J TROP MED HYG, V66, P157, DOI 10.4269/ajtmh.2002.66.157; Sandoval N, 2006, PARASITOLOGY, V133, P581, DOI 10.1017/S0031182006000898; TAYLOR M G, 1970, Journal of Helminthology, V44, P253; ten Hove RJ, 2008, T ROY SOC TROP MED H, V102, P179, DOI 10.1016/j.trstmh.2007.10.011; VERCRUYSSE J, 1994, TROP GEOGR MED, V46, P220; Webster BL, 2010, J HELMINTHOL, V84, P107, DOI 10.1017/S0022149X09990447; Webster BL, 2006, INT J PARASITOL, V36, P947, DOI 10.1016/j.ijpara.2006.03.005; Whitty CJM, 2000, TROP MED INT HEALTH, V5, P818, DOI 10.1046/j.1365-3156.2000.00642.x; *WHO, 1985, WHO TECH REP SER, V728, P1; Wichmann D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000422; Xu J, 2010, INT J PARASITOL, V40, P327, DOI 10.1016/j.ijpara.2009.08.010	37	29	31	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2012	17	10					1208	1216		10.1111/j.1365-3156.2012.03060.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	004XG	WOS:000308714200006	22882536				2019-03-26	
J	Labhardt, ND; Sello, M; Lejone, T; Ehmer, J; Mokhantso, M; Lynen, L; Pfeiffer, K				Labhardt, Niklaus D.; Sello, Motlalepula; Lejone, Thabo; Ehmer, Jochen; Mokhantso, Mohlaba; Lynen, Lutgarde; Pfeiffer, Karolin			Adoption of new HIV treatment guidelines and drug substitutions within first-line as a measure of quality of care in rural Lesotho: health centers and hospitals compared	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						HIV; antiretroviral therapy; decentralization; task shifting; quality of care; therapie antiretrovirale du VIH; SIDA; decentralisation des services de sante; delegation des taches; soins bases sur les infirmieres; Terapia antirretroviral; descentralizacion de los servicios sanitarios; VIH; SIDA; cuidados de enfermeria	COMMUNITY-BASED PROGRAM; ANTIRETROVIRAL TREATMENT; OUTCOMES; THERAPY; TOXICITY; AFRICA; COHORT; UGANDA; KENYA; MODEL	Objective In 2007, Lesotho launched new national antiretroviral treatment (ART) guidelines, prioritising tenofovir and zidovudine over stavudine as a backbone together with lamivudine. We compared the rate of adoption of these new guidelines and substitution of first-line drugs by health centers (HC) and hospitals in two catchment areas in rural Lesotho. Methods Retrospective cohort analysis. Patients aged =16 years were stratified into a HC- and a hospital-group. Main outcome variables: Type of backbone at ART-initiation (i), substitutions within first line (ii) and type of backbone among patients retained by December 2010 (iii). A multiple logistic regression model including HC vs. hospital, patient characteristics (sex, age, WHO-stage, baseline CD4-count, concurrent pregnancy, concurrent tuberculosis treatment) and year of ART-start, was used. Results Of 3936 adult patients initiated on ART between 2007 and 2010, 1971 started at hospitals and 1965 at HCs. Hospitals were more likely to follow the new guidelines as measured by prescription of backbones without stavudine (Odds-ratio 1.55; 95%CI: 1.321.81) and had a higher rate of drug substitutions while on first-line ART (2.39; 1.833.13). By December 2010, patients followed at health centres were more likely to still receive stavudine (2.28; 1.832.84). Conclusions Health centers took longer to adopt the new guidelines and substituted drugs less frequently. Decentralised ART-programmes need close support, supervision and mentoring to absorb new guidelines and to adhere to them.	[Labhardt, Niklaus D.; Sello, Motlalepula] SolidarMed, Maseru, Lesotho; [Labhardt, Niklaus D.; Lejone, Thabo; Mokhantso, Mohlaba] Seboche Hosp, Botha Bothe, Lesotho; [Ehmer, Jochen; Pfeiffer, Karolin] SolidarMed, Luzern, Switzerland; [Lynen, Lutgarde] Inst Trop Med, B-2000 Antwerp, Belgium	Labhardt, ND (reprint author), SolidarMed, Maseru, Lesotho.	niklaus.labhardt@gmail.com	Lynen, Lutgarde/A-1212-2014	Lynen, Lutgarde/0000-0001-7183-4895; Labhardt, Niklaus Daniel/0000-0003-3599-1791			[Anonymous], 2010, WORLD HLTH STAT 2010; Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Boulle A, 2007, ANTIVIR THER, V12, P753; Braitstein P, 2010, JAIDS-J ACQ IMM DEF, V53, P254, DOI 10.1097/QAI.0b013e3181b8f26e; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Chang LVW, 2009, JAIDS-J ACQ IMM DEF, V50, P276, DOI 10.1097/QAI.0b013e3181988375; Cohen R, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-23; Forna F, 2007, JAIDS-J ACQ IMM DEF, V44, P456, DOI 10.1097/QAI.0b013e318033ffa1; Humphreys CP, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-229; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Massaquoi M, 2009, T ROY SOC TROP MED H, V103, P594, DOI 10.1016/j.trstmh.2009.02.012; Ministry of Health and Social Welfare/National AIDS Commission, 2009, NAT HIV AIDS EST LES; Ministry of Health and Social Welfare of Lesotho, 2004, NAT ANT TREATM GUID; Ministry of Health and Social Welfare of Lesotho, 2007, NAT ANT TREATM GUID; Morris MB, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-5; National AIDS Commission, 2010, ANN REP NAT RESP HIV; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; Selke HM, 2010, JAIDS-J ACQ IMM DEF, V55, P483, DOI 10.1097/QAI.0b013e3181eb5edb; Shumbusho F, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000163; Suarez-Lozano I, 2009, HIV MED, V10, P573, DOI 10.1111/j.1468-1293.2009.00731.x; UNAIDS, 2010, GLOB REP; van Griensven J, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-39; WHO, 2009, RAP ADV ANT THER HIV; World Health Organization, 2008, TASK SHIFT GLOB REC; World Health Organization HIV/AIDS Programme, 2007, TASK SHIFT TACKL HLT	25	12	12	1	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2012	17	10					1245	1254		10.1111/j.1365-3156.2012.03051.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	004XG	WOS:000308714200011	22845835	Bronze			2019-03-26	
J	Simo, G; Silatsa, B; Flobert, N; Lutumba, P; Mansinsa, P; Madinga, J; Manzambi, E; De Deken, R; Asonganyi, T				Simo, Gustave; Silatsa, Barberine; Flobert, Njiokou; Lutumba, Pascal; Mansinsa, Philemon; Madinga, Joule; Manzambi, Emile; De Deken, Reginald; Asonganyi, Tazoacha			Identification of different trypanosome species in the mid-guts of tsetse flies of the Malanga (Kimpese) sleeping sickness focus of the Democratic Republic of Congo	PARASITES & VECTORS			English	Article						Sleeping sickness; Animal African trypanosomiasis; Trypanosomes; Blood meals; Tsetse flies; Mid-guts	POLYMERASE-CHAIN-REACTION; BRUCEI-GAMBIENSE; DNA AMPLIFICATION; COTE-DIVOIRE; SOUTHERN CAMEROON; ANIMAL RESERVOIR; MIXED INFECTIONS; HOST PREFERENCE; HIGH PREVALENCE; WILD TSETSE	Background: The Malanga sleeping sickness focus of the Democratic Republic of Congo has shown an epidemic evolution of disease during the last century. However, following case detection and treatment, the prevalence of the disease decreased considerably. No active survey has been undertaken in this focus for a couple of years. To understand the current epidemiological status of sleeping sickness as well as the animal African trypanosomiasis in the Malanga focus, we undertook the identification of tsetse blood meals as well as different trypanosome species in flies trapped in this focus. Methods: Pyramidal traps were use to trap tsetse flies. All flies caught were identified and live flies were dissected and their mid-guts collected. Fly mid-gut was used for the molecular identification of the blood meal source, as well as for the presence of different trypanosome species. Results: About 949 Glossina palpalis palpalis were trapped; 296 (31.2%) of which were dissected, 60 (20.3%) blood meals collected and 57 (19.3%) trypanosome infections identified. The infection rates were 13.4%, 5.1%, 3.5% and 0.4% for Trypanosoma congolense savannah type, Trypanosoma brucei s.l., Trypanosoma congolense forest type and Trypanosoma vivax, respectively. Three mixed infections including Trypanosoma brucei s.l. and Trypanosoma congolense savannah type, and one mixed infection of Trypanosoma vivax and Trypanosoma congolense savannah type were identified. Eleven Trypanosoma brucei gambiense infections were identified; indicating an active circulation of this trypanosome subspecies. Of all the identified blood meals, about 58.3% were identified as being taken on pigs, while 33.3% and 8.3% were from man and other mammals, respectively. Conclusion: The presence of Trypanosoma brucei in tsetse mid-guts associated with human blood meals is indicative of an active transmission of this parasite between tsetse and man. The considerable number of pig blood meals combined with the circulation of Trypanosoma brucei gambiense in this focus suggests a transmission cycle involving humans and domestic animals and could hamper eradication strategies. The various species of trypanosomes identified in the Malanga sleeping sickness focus indicates the coexistence of animal and human African Trypanosomiasis. The development of new strategies integrating control measures for human and animal trypanosomiasis may enable the reduction of the control costs in this locality.	[Simo, Gustave; Silatsa, Barberine] Univ Dschang, Fac Sci, Dept Biochem, Dschang, Cameroon; [Flobert, Njiokou] Univ Yaounde I, Fac Sci, Yaounde, Cameroon; [Lutumba, Pascal; Madinga, Joule] Kinshasa Univ, Sch Med, Dept Trop Med, Kinshasa, Zaire; [Mansinsa, Philemon] Programme Natl Lutte Trypanosomiase Humaine Afric, Kinshasa, Zaire; [Manzambi, Emile] Inst Natl Rech Biomed, Kinshasa, Zaire; [De Deken, Reginald] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Asonganyi, Tazoacha] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon	Simo, G (reprint author), Univ Dschang, Fac Sci, Dept Biochem, POB 67, Dschang, Cameroon.	gsimoca@yahoo.fr		Joule, Madinga/0000-0003-2661-234X	"European Foundation Initiative for NTDs" (EFINTD); University of Yaounde I; University of Dschang	This work was supported by "European Foundation Initiative for NTDs" (EFINTD), the University of Yaounde I and the University of Dschang.	Biteau N, 2000, MOL BIOCHEM PARASIT, V105, P185, DOI 10.1016/S0166-6851(99)00171-1; Boakye DA, 1999, MED VET ENTOMOL, V13, P282, DOI 10.1046/j.1365-2915.1999.00193.x; BROMIDGE T, 1993, ACTA TROP, V53, P107, DOI 10.1016/0001-706X(93)90023-5; Desquesnes M, 2001, INT J PARASITOL, V31, P610, DOI 10.1016/S0020-7519(01)00161-8; Farikou O, 2010, ACTA TROP, V116, P81, DOI 10.1016/j.actatropica.2010.06.002; GOUTEUX JP, 1986, TROP MED PARASITOL, V37, P61; Herder S, 2002, PARASITE, V9, P345, DOI 10.1051/parasite/2002094345; Jamonneau V, 2004, PARASITOLOGY, V129, P693, DOI 10.1017/S0031182004005876; Lehane MJ, 2000, PARASITOLOGY, V120, P583, DOI 10.1017/S0031182099005983; MacLeod A, 1999, MOL BIOCHEM PARASIT, V102, P237, DOI 10.1016/S0166-6851(99)00101-2; MAJIWA PAO, 1994, PARASITOLOGY, V108, P313, DOI 10.1017/S0031182000076150; MAJIWA PAO, 1990, MOL BIOCHEM PARASIT, V40, P245, DOI 10.1016/0166-6851(90)90046-O; MAKUMYAVIRI A, 1989, TROP MED PARASITOL, V40, P258; MASIGA DK, 1992, INT J PARASITOL, V22, P909, DOI 10.1016/0020-7519(92)90047-O; Masiga DK, 1996, PARASITOLOGY, V112, P75, DOI 10.1017/S0031182000065094; MCNAMARA JJ, 1995, ACTA TROP, V59, P85, DOI 10.1016/0001-706X(94)00087-H; Morlais I, 1998, ACTA TROP, V70, P109, DOI 10.1016/S0001-706X(98)00014-X; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; Nimpaye H, 2011, PARASITE, V18, P171, DOI 10.1051/parasite/2011182171; Njiokou F, 2006, INFECT GENET EVOL, V6, P147, DOI 10.1016/j.meegid.2005.04.003; Njiokou F, 2004, ACTA TROP, V92, P139, DOI 10.1016/j.actatropica.2004.04.011; Njiokou F, 2004, ACTA TROP, V91, P117, DOI 10.1016/j.actatropica.2004.03.006; Penchenier L, 1996, B LIAIS DOC OCEAC, V29, P11; Radwanska M, 2002, AM J TROP MED HYG, V67, P289, DOI 10.4269/ajtmh.2002.67.289; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Simarro PP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001007; Simo G, 2008, INFECT GENET EVOL, V8, P34, DOI 10.1016/j.meegid.2007.09.005; Simo G, 2006, VET PARASITOL, V139, P57, DOI 10.1016/j.vetpar.2006.02.026; Simo G, 2011, EXP PARASITOL, V128, P272, DOI 10.1016/j.exppara.2011.02.023	29	18	18	0	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	SEP 19	2012	5								201	10.1186/1756-3305-5-201				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	019SL	WOS:000309759500001	22992486	DOAJ Gold, Green Published			2019-03-26	
J	Barbe, B; Gillet, P; Beelaert, G; Fransen, K; Jacobs, J				Barbe, Barbara; Gillet, Philippe; Beelaert, Greet; Fransen, Katrien; Jacobs, Jan			Assessment of desiccants and their instructions for use in rapid diagnostic tests	MALARIA JOURNAL			English	Article						Desiccant; Silica gel; Rapid diagnostic test; RDT-malaria; HIV; Diagnosis	MALARIA; QUALITY	Background: Malaria rapid diagnostic tests (RDTs) are protected from humidity-caused degradation by a desiccant added to the device packaging. The present study assessed malaria RDT products for the availability, type and design of desiccants and their information supplied in the instructions for use (IFU). Methods: Criteria were based on recommendations of the World Health Organization (WHO), the European Community (CE) and own observations. Silica gel sachets were defined as self-indicating (all beads coated with a humidity indicator that changes colour upon saturation), partial-indicating (part of beads coated) and non-indicating (none of the beads coated). Indicating silica gel sachets were individually assessed for humidity saturation and (in case of partial-indicating silica gels) for the presence of indicating beads. Results: Fifty malaria RDT products from 25 manufacturers were assessed, 14 (28%) products were listed by the "Global Fund Quality Assurance Policy" and 31 (62%) were CE-marked. All but one product contained a desiccant, mostly (47/50, 94%) silica gel. Twenty (40%) RDT products (one with no desiccant and 19 with non-indicating desiccant) did not meet the WHO guidelines recommending indicating desiccant. All RDT products with self- or partial-indicating silica gel (n = 22 and 8 respectively) contained the toxic cobalt dichloride as humidity indicator. Colour change indicating humidity saturation was observed for 8/16 RDT products, at a median incidence of 0.8% (range 0.05%-4.6%) of sachets inspected. In all RDTs with partial-indicating silica gel, sachets with no colour indicating beads were found (median proportion 13.5% (0.6%-17.8%) per product) and additional light was needed to assess the humidity colour. Less than half (14/30, 47%) IFUs of RDT products with indicating desiccants mentioned to check the humidity saturation before using the test. Information on properties, safety hazards and disposal of the desiccant was not included in any of the IFUs. There were no differences between Global Fund-listed and CE marked RDT products compared to those which were not. Similar findings were noted for a panel of 11 HIV RDTs that was assessed with the same checklist as the malaria RDTs. Conclusion: RDTs showed shortcomings in desiccant type and information supplied in the IFU.	[Barbe, Barbara; Gillet, Philippe; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, Unit Trop Lab Med, B-2000 Antwerp, Belgium; [Beelaert, Greet; Fransen, Katrien] Inst Trop Med, Dept Clin Sci, HIV STI Reference Lab, B-2000 Antwerp, Belgium	Jacobs, J (reprint author), Inst Trop Med, Dept Clin Sci, Unit Trop Lab Med, B-2000 Antwerp, Belgium.	jjacobs@itg.be		gillet, philippe/0000-0001-5878-6446			Bronstein AC, 2011, CLIN TOXICOL, V49, P910, DOI 10.3109/15563650.2011.635149; Brownell Limited, 2008, MATERIAL SAFETY DATA; Chiodini PL, 2007, T ROY SOC TROP MED H, V101, P331, DOI 10.1016/j.trstmh.2006.09.007; Clinical and Laboratory Standards Institute (CLSI), 2007, BLOOD COLLECTION ON, V27; Conservation by Design Limited, 2012, MSDS SELF INDICATING; Craig MH, 2002, T ROY SOC TROP MED H, V96, P258, DOI 10.1016/S0035-9203(02)90092-1; Crucitti T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013592; European Chemicals Agency, 2011, BACKGROUND DOCUMENT; European Chemicals Agency, 2011, SUPPORT DOCUMENT FOR; GeeJay Chemicals Ltd, 2012, UK SUPPLIER OF DESIC; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-166; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-39; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-262; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-129; Hermans V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-331; Maltha J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-7; McMorrow ML, 2010, AM J TROP MED HYG, V82, P151, DOI 10.4269/ajtmh.2010.09-0440; Millipore Corporation, 2008, RAPID LATERAL FLOW T; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; National Institute for Occupational Safety and Health, 2004, INTERNATIONAL CHEMIC; Rennie W, 2004, FIELD REPORT DEVELOP; Schier JG, 2002, VET HUM TOXICOL, V44, P343; Science Lab, 2012, MATERIAL SAFETY DATA; The Global Fund, 2012, LIST OF RDT KITS FOR; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; van Dijk DPJ, 2010, EUR J CLIN MICROBIOL, V29, P577, DOI 10.1007/s10096-010-0898-y; van Dijk DPJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-293; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2010, GUIDELINES FOR THE T; WHO, 2011, GOOD PRACTICES FOR S; WHO, 2008, METHODS AND TECHNIQU; World Health Organization, 1999, THE MICROSCOPE A PRA; World Health Organization, 2009, TRANSPORTING STORING; World Health Organization, 2010, METHODS MANUAL FOR L; World Health Organization, 2008, HOW TO USE A RAPID D; World Health Organization, 2011, MALARIA RAPID DIAGNO; World Health Organization, 2008, MAINTENANCE MANUAL F; World Health Organization, 2010, HOW TO DO THE RAPID; World Health Organization, 2003, REGIONAL OFFICE FOR; World Health Organization (WHO), 2011, UNIVERSAL ACCESS TO	40	5	5	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	SEP 13	2012	11								326	10.1186/1475-2875-11-326				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	037MY	WOS:000311111200001	22974115	DOAJ Gold, Green Published			2019-03-26	
J	Kajungu, DK; Selemani, M; Masanja, I; Baraka, A; Njozi, M; Khatib, R; Dodoo, AN; Binka, F; Macq, J; D'Alessandro, U; Speybroeck, N				Kajungu, Dan K.; Selemani, Majige; Masanja, Irene; Baraka, Amuri; Njozi, Mustafa; Khatib, Rashid; Dodoo, Alexander N.; Binka, Fred; Macq, Jean; D'Alessandro, Umberto; Speybroeck, Niko			Using classification tree modelling to investigate drug prescription practices at health facilities in rural Tanzania	MALARIA JOURNAL			English	Article						Polypharmacy; Co-prescription; Anti-malarials; Classification trees; Data mining; Tanzania	INAPPROPRIATE MEDICATION USE; UNCOMPLICATED MALARIA; RISK-FACTORS; MANAGEMENT; KENYA	Background: Drug prescription practices depend on several factors related to the patient, health worker and health facilities. A better understanding of the factors influencing prescription patterns is essential to develop strategies to mitigate the negative consequences associated with poor practices in both the public and private sectors. Methods: A cross-sectional study was conducted in rural Tanzania among patients attending health facilities, and health workers. Patients, health workers and health facilities-related factors with the potential to influence drug prescription patterns were used to build a model of key predictors. Standard data mining methodology of classification tree analysis was used to define the importance of the different factors on prescription patterns. Results: This analysis included 1,470 patients and 71 health workers practicing in 30 health facilities. Patients were mostly treated in dispensaries. Twenty two variables were used to construct two classification tree models: one for polypharmacy (prescription of >= 3 drugs) on a single clinic visit and one for co-prescription of artemether-lumefantrine (AL) with antibiotics. The most important predictor of polypharmacy was the diagnosis of several illnesses. Polypharmacy was also associated with little or no supervision of the health workers, administration of AL and private facilities. Co-prescription of AL with antibiotics was more frequent in children under five years of age and the other important predictors were transmission season, mode of diagnosis and the location of the health facility. Conclusion: Standard data mining methodology is an easy-to-implement analytical approach that can be useful for decision-making. Polypharmacy is mainly due to the diagnosis of multiple illnesses.	[Kajungu, Dan K.; Dodoo, Alexander N.; Binka, Fred] INDEPTH Network, Accra, Ghana; [Kajungu, Dan K.; Macq, Jean; Speybroeck, Niko] Catholic Univ Louvain, Louvain, Belgium; [Selemani, Majige; Masanja, Irene; Baraka, Amuri; Njozi, Mustafa; Khatib, Rashid] Ifakara Hlth Inst, Dar Es Salaam, Tanzania; [Dodoo, Alexander N.] Univ Ghana, Ctr Trop Clin Pharmacol & Therapeut, Sch Med, Accra, Ghana; [D'Alessandro, Umberto] MRC Unit, Serrekunda, Gambia; [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium	Kajungu, DK (reprint author), INDEPTH Network, POB KD 213 Kanda, Accra, Ghana.	kajungu_dan@yahoo.co.uk	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Kajungu, Dan/0000-0002-3363-7062; AMURI, Mbaraka/0000-0002-8583-9555	Bill and Melinda Gates Foundation	The authors wish to thank the many investigators, data collectors and field supervisors who contributed to the collection and analyses of these data. In addition, we wish to acknowledge the community members who participated in or otherwise contributed to these studies. This work was conducted as part of the INESS platform, a multicountry consortium funded by the Bill and Melinda Gates Foundation.	[Anonymous], 2012, AFFORDABLE MED FACIL; Breiman L, 1984, CLASSIFICATION REGRE; Brugha R, 1999, TROP MED INT HEALTH, V4, P402, DOI 10.1046/j.1365-3156.1999.00411.x; Chrischilles EA, 2009, J AM GERIATR SOC, V57, P1000, DOI 10.1111/j.1532-5415.2009.02269.x; Dodoo ANO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-2; Frischer M, 2001, J PUBLIC HEALTH MED, V23, P69, DOI 10.1093/pubmed/23.1.69; Fu AZ, 2004, J AM GERIATR SOC, V52, P1934, DOI 10.1111/j.1532-5415.2004.52522.x; HDSS Ifakara, TANZ; Laroche ML, 2007, BRIT J CLIN PHARMACO, V63, P177, DOI 10.1111/j.1365-2125.2006.02831.x; Lauritsen JM, 2003, EPIDATA VERSION 3 CO; MCCARTHY FD, 2000, GROWTH COSTS MALARIA; McManus P, 1997, MED J AUSTRALIA, V167, P124, DOI 10.5694/j.1326-5377.1997.tb138809.x; *MIN HLTH SOC WELF, 2006, NAT GUID DIAGN TREAT, V11; Mino-Leon D, 2011, REV INVEST CLIN, V63, P170; Protopopoff N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008022; Rennie W, 2009, WILLINGNESS USE PAY; Rufiji DSS, TANZANIA ESSENTIAL C; Saegerman C, 2004, J CLIN MICROBIOL, V42, P172, DOI 10.1128/JCM.42.1.172-178.2004; Skarbinski J, 2009, AM J TROP MED HYG, V80, P919; Speybroeck N, 2004, AGR SYST, V80, P133, DOI 10.1016/j.agsy.2003.06.006; Speybroeck N, 2012, INT J PUBLIC HEALTH, V57, P243, DOI 10.1007/s00038-011-0315-z; SPSS, 2007, SPSS WIND VERS 16; StataCorp LP, 2012, STATA VERS 11 2012; Thang ND, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-28; Trostle J, 1996, SOC SCI MED, V42, P1117, DOI 10.1016/0277-9536(95)00384-3; vanEngelsdorp D, 2010, J ECON ENTOMOL, V103, P1517, DOI 10.1603/EC09429; WHO/UNICEF, 1999, WHOCHSCAH98; World Health Organization, 2006, WHOHTMMAL2006; World Health Organization, 1987, RAT US DRUGS, P25; World Health Organization, 2003, INTR DRUG UT RES; World Health Organization, 2009, MED US PRIM CAR DEV; Zhang H, 1999, REC PART HLTH SCI; Zurovac D, 2004, INT J EPIDEMIOL, V33, P1080, DOI 10.1093/ije/dyh253	33	6	6	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	SEP 5	2012	11								311	10.1186/1475-2875-11-311				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	043WC	WOS:000311580300001	22950486	DOAJ Gold, Green Published			2019-03-26	
J	Rodriguez, S; Wilkins, P; Dorny, P				Rodriguez, Silvia; Wilkins, Patricia; Dorny, Pierre			Immunological and molecular diagnosis of cysticercosis	PATHOGENS AND GLOBAL HEALTH			English	Article						Cysticercosis; Neurocysticercosis; Immunodiagnosis; Antibody; Antigen; Serology; Taenia solium; Western blot	LINKED-IMMUNOSORBENT-ASSAY; TAENIA-SOLIUM CYSTICERCOSIS; IMMUNOELECTROTRANSFER BLOT ASSAY; INTRAVENTRICULAR HUMAN NEUROCYSTICERCOSIS; EXCRETORY-SECRETORY ANTIGENS; HUMORAL IMMUNE-RESPONSE; CEREBROSPINAL-FLUID; CEREBRAL CYSTICERCOSIS; PORCINE CYSTICERCOSIS; ECHINOCOCCUS-GRANULOSUS	Cysticercosis, the infection with the larval stage of Taenia solium, is a cause of neurological symptoms including seizures, affecting the quality of life of patients and their families. Diagnosis focuses on brain imaging and serological tests are mostly used as confirmatory tools. Most cases, however, occur in poor endemic areas, where both kinds of diagnostic tools are poorly available. Development of point of care diagnostic tests is one of the most important priorities for cysticercosis researches today. The ideal point of care test would require detection of viable cysticercosis and hopefully identify cases with severe or progressive forms of neurocysticercosis, leading to referral of the patient for specialized medical attention. This manuscript describes the evolution of the serological diagnosis of cysticercosis over time, and the characteristics of the most common currently available tools, their advantages and disadvantages, and their potential use in future diagnostic tests.	[Rodriguez, Silvia] Inst Nacl Ciencias Neurol, Lima 1, Peru; [Wilkins, Patricia] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA; [Dorny, Pierre] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium	Rodriguez, S (reprint author), Inst Nacl Ciencias Neurol, Jr Anchash 1271, Lima 1, Peru.	silvia@peruresearch.org					ACOSTA E, 1990, J CLIN LAB ANAL, V4, P90, DOI 10.1002/jcla.1860040204; Aguilar-Rebolledo F, 2002, J CHILD NEUROL, V17, P416, DOI 10.1177/088307380201700604; Alexander AM, 2010, T ROY SOC TROP MED H, V104, P809, DOI 10.1016/j.trstmh.2010.07.005; Almeida CR, 2006, EUR ARCH PSY CLIN N, V256, P307, DOI 10.1007/s00406-006-0612-3; Amit P, 2011, EXP PARASITOL, V127, P687, DOI 10.1016/j.exppara.2010.11.006; ARAMBULO PV, 1978, ACTA TROP, V35, P63; ArandaAlvarez JG, 1995, ANN TROP MED PARASIT, V89, P689, DOI 10.1080/00034983.1995.11813004; Atluri SRV, 2009, PARASITE IMMUNOL, V31, P151, DOI 10.1111/j.1365-3024.2008.01085.x; Atluri SRV, 2009, ACTA TROP, V110, P22, DOI 10.1016/j.actatropica.2008.12.004; Baig S, 2005, PARASITOLOGY, V131, P411, DOI 10.1017/S0031182005007821; Barcelos ISD, 2005, MEM I OSWALDO CRUZ, V100, P427, DOI 10.1590/S0074-02762005000400014; BIAGI F, 1958, AM J TROP MED HYG, V7, P63, DOI 10.4269/ajtmh.1958.7.63; BIAGI F, 1961, Rev Med Hosp Gen (Mex), V24, P501; Bobes RJ, 2006, TROP MED INT HEALTH, V11, P943, DOI 10.1111/j.1365-3156.2006.01642.x; Braga F M, 1983, Arq Neuropsiquiatr, V41, P254; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Bueno EC, 2005, AM J TROP MED HYG, V72, P278, DOI 10.4269/ajtmh.2005.72.278; Bueno EC, 2001, CLIN DIAGN LAB IMMUN, V8, P1140, DOI 10.1128/CDLI.8.6.1140-1144.2001; CAMACHO SPD, 1991, AM J TROP MED HYG, V45, P522, DOI 10.4269/ajtmh.1991.45.522; Carod-Artal FJ, 2009, REV NEUROLOGIA, V49, P475, DOI 10.33588/rn.4909.2009212; Castillo Y, 2009, AM J TROP MED HYG, V80, P379, DOI 10.4269/ajtmh.2009.80.379; Chavarria A, 2005, CLIN IMMUNOL, V116, P271, DOI 10.1016/j.clim.2005.04.008; Chen J P, 1991, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V9, P122; CHO S-Y, 1986, Korean Journal of Parasitology, V24, P25; CHOROMANSKI L, 1990, J PARASITOL, V76, P69, DOI 10.2307/3282629; Chung JY, 1999, J INFECT DIS, V180, P1307, DOI 10.1086/315020; COKER-VANN M R, 1981, Southeast Asian Journal of Tropical Medicine and Public Health, V12, P499; COKERVANN M, 1984, T ROY SOC TROP MED H, V78, P492, DOI 10.1016/0035-9203(84)90070-1; CORONA T, 1986, J NEUROL NEUROSUR PS, V49, P1044, DOI 10.1136/jnnp.49.9.1044; CORREA D, 1989, T ROY SOC TROP MED H, V83, P814, DOI 10.1016/0035-9203(89)90340-4; Correa D, 1999, ANN TROP MED PARASIT, V93, P69; Costa J M, 1982, Rev Inst Med Trop Sao Paulo, V24, P337; COSTA J M, 1986, Arquivos de Neuro-Psiquiatria, V44, P15; da Silva ADT, 2000, DIAGN MICR INFEC DIS, V37, P87, DOI 10.1016/S0732-8893(00)00137-1; Das S, 2002, TROP MED INT HEALTH, V7, P53, DOI 10.1046/j.1365-3156.2002.00810.x; Deckers N, 2008, INT J PARASITOL, V38, P1191, DOI 10.1016/j.ijpara.2008.01.005; Deckers N, 2009, INT J PARASITOL, V39, P625, DOI 10.1016/j.ijpara.2008.10.012; Del Brutto OH, 2000, SOLITARY CYSTICERCUS, P153; DIAZ JF, 1992, AM J TROP MED HYG, V46, P610, DOI 10.4269/ajtmh.1992.46.610; DIWAN AR, 1982, AM J TROP MED HYG, V31, P364, DOI 10.4269/ajtmh.1982.31.364; DRAELANTS E, 1995, PARASITE IMMUNOL, V17, P119, DOI 10.1111/j.1365-3024.1995.tb01013.x; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; ESPINOZA B, 1986, J CLIN MICROBIOL, V24, P536; Esquivel-Velazquez M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/516042; ESTANOL B, 1989, J NEUROL NEUROSUR PS, V52, P254, DOI 10.1136/jnnp.52.2.254; ESTRADA JJ, 1989, AM J TROP MED HYG, V41, P50, DOI 10.4269/ajtmh.1989.41.50; ESTRADA JJ, 1985, J NEUROL SCI, V71, P39, DOI 10.1016/0022-510X(85)90035-8; FELDMAN M, 1990, T ROY SOC TROP MED H, V84, P559, DOI 10.1016/0035-9203(90)90040-L; Ferrer E, 2005, T ROY SOC TROP MED H, V99, P568, DOI 10.1016/j.trstmh.2005.02.003; Ferrer E, 2007, MOL BIOCHEM PARASIT, V152, P90, DOI 10.1016/j.molbiopara.2006.12.003; Ferrer E, 2012, EXP PARASITOL, V130, P78, DOI 10.1016/j.exppara.2011.10.010; Ferrer E, 2009, MOL BIOCHEM PARASIT, V168, P168, DOI 10.1016/j.molbiopara.2009.08.003; Fleury A, 2007, J NEUROL NEUROSUR PS, V78, P970, DOI 10.1136/jnnp.2006.107243; Fleury A, 2003, T ROY SOC TROP MED H, V97, P542, DOI 10.1016/S0035-9203(03)80019-6; Fleury A, 2003, TROP MED INT HEALTH, V8, P1124, DOI 10.1046/j.1360-2276.2003.01132.x; Fleury A, 2001, TROP MED INT HEALTH, V6, P688, DOI 10.1046/j.1365-3156.2001.00767.x; FLISSER A, 1990, ANN PARASIT HUM COMP, V65, P95, DOI 10.1051/parasite/1990651095; FLISSER A, 1975, ARCH INVEST MED, V6, P1; FLISSER A, 1980, CLIN EXP IMMUNOL, V39, P27; FLISSER A, 1976, ARCH INVEST MED, V7, P107; FLISSER A, 1979, B WORLD HEALTH ORGAN, V57, P839; FREILIJ HL, 1987, J CLIN MICROBIOL, V25, P133; Furrows SJ, 2006, CLIN MICROBIOL INFEC, V12, P459, DOI 10.1111/j.1469-0691.2006.01381.x; Garcia HH, 2010, NEUROLOGY, V75, P654, DOI 10.1212/WNL.0b013e3181ed9eae; Garcia HH, 2000, T ROY SOC TROP MED H, V94, P673, DOI 10.1016/S0035-9203(00)90228-1; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; Garcia HH, 1998, T ROY SOC TROP MED H, V92, P411, DOI 10.1016/S0035-9203(98)91069-0; Garcia HH, 1997, J INFECT DIS, V175, P486, DOI 10.1093/infdis/175.2.486; Garcia HH, 2010, J NEUROPARASITOL, V1, P1; Garg Ravindra Kumar, 2002, Neurosurg Focus, V12, pe4; Garg RK, 2000, EPILEPSY RES, V38, P91, DOI 10.1016/S0920-1211(99)00092-3; GONZALEZ AE, 1990, AM J TROP MED HYG, V43, P194, DOI 10.4269/ajtmh.1990.43.194; GONZALEZ AE, 1994, AM J TROP MED HYG, V51, P847, DOI 10.4269/ajtmh.1994.51.847; GOTTSTEIN B, 1986, AM J TROP MED HYG, V35, P308, DOI 10.4269/ajtmh.1986.35.308; Greene RM, 1999, MOL BIOCHEM PARASIT, V99, P257, DOI 10.1016/S0166-6851(99)00004-3; Greene RM, 2000, J PARASITOL, V86, P1001, DOI 10.1645/0022-3395(2000)086[1001:TSMCAS]2.0.CO;2; GROGL M, 1985, J PARASITOL, V71, P433, DOI 10.2307/3281534; Hancock K, 2006, MOL BIOCHEM PARASIT, V147, P109, DOI 10.1016/j.molbiopara.2006.02.004; Hancock K, 2004, MOL BIOCHEM PARASIT, V133, P115, DOI 10.1016/j.molbiopara.2003.10.001; Hancock K, 2003, J CLIN MICROBIOL, V41, P2577, DOI 10.1128/JCM.41.6.2577-2586.2003; Handali S, 2004, AM J TROP MED HYG, V71, P322, DOI 10.4269/ajtmh.2004.71.322; Handali S, 2007, J IMMUNOL METHODS, V320, P164, DOI 10.1016/j.jim.2006.12.007; Handali S, 2010, CLIN VACCINE IMMUNOL, V17, P631, DOI 10.1128/CVI.00511-09; Handali S, 2010, J IMMUNOASS IMMUNOCH, V31, P60, DOI 10.1080/15321810903405068; Handali S, 2010, CLIN VACCINE IMMUNOL, V17, P68, DOI 10.1128/CVI.00339-09; Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2; HARRISON LJS, 1989, PARASITE IMMUNOL, V11, P351, DOI 10.1111/j.1365-3024.1989.tb00673.x; Hell RCR, 2009, CLIN IMMUNOL, V131, P129, DOI 10.1016/j.clim.2008.10.012; Hernandez M, 2008, ANN TROP MED PARASIT, V102, P317, DOI 10.1179/136485908X278856; Hernandez M, 2000, IMMUNOL LETT, V71, P13, DOI 10.1016/S0165-2478(99)00166-2; Huang BC, 2002, CHINESE MED J-PEKING, V115, P580; Ishida MMI, 2011, REV SOC BRAS MED TRO, V44, P339, DOI [10.1590/s0037-86822011005000040, 10.1590/S0037-86822011005000040]; Intapan PM, 2008, ASIAN PAC J ALLERGY, V26, P237; Ito A, 2003, TRENDS PARASITOL, V19, P377, DOI 10.1016/S1471-4922(03)00200-9; Jafri HS, 1998, AM J TROP MED HYG, V58, P313, DOI 10.4269/ajtmh.1998.58.313; Jia WZ, 2011, CHINESE MED J-PEKING, V124, P2849, DOI 10.3760/cma.j.issn.0366-6999.2011.18.010; KIM S-I, 1986, Korean Journal of Parasitology, V24, P145; Kojic EM, 2003, CLIN INFECT DIS, V36, pE7, DOI 10.1086/344445; Krecek RC, 2008, VET PARASITOL, V154, P38, DOI 10.1016/j.vetpar.2008.03.005; KREMSNER PG, 1993, T ROY SOC TROP MED H, V87, P167, DOI 10.1016/0035-9203(93)90474-5; KUMAR D, 1987, VET PARASITOL, V24, P195, DOI 10.1016/0304-4017(87)90040-9; LACLETTE JP, 1987, J PARASITOL, V73, P121, DOI 10.2307/3282356; LACLETTE JP, 1991, MOL BIOCHEM PARASIT, V44, P287, DOI 10.1016/0166-6851(91)90015-X; Lee YM, 2011, AM J TROP MED HYG, V84, P587, DOI 10.4269/ajtmh.2011.10-0079; Li AH, 2006, VET PARASITOL, V141, P251, DOI 10.1016/j.vetpar.2006.05.015; Lin X, 1999, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V17, P146; Livramento J A, 1987, Arq Neuropsiquiatr, V45, P261; Machado LR, 2002, ARQ NEURO-PSIQUIAT, V60, P395, DOI 10.1590/S0004-282X2002000300011; MADDISON SE, 1989, AM J TROP MED HYG, V40, P377, DOI 10.4269/ajtmh.1989.40.377; Malla Nancy, 2005, Nepal Med Coll J, V7, P1; Manhani MN, 2011, PARASITE IMMUNOL, V33, P322, DOI 10.1111/j.1365-3024.2011.01283.x; Manoutcharian K, 1999, CLIN IMMUNOL, V91, P117, DOI 10.1006/clim.1998.4669; McManus Donald P., 1995, Papua New Guinea Medical Journal, V38, P287; McManus DP, 2006, PARASITOL INT, V55, pS31, DOI 10.1016/j.parint.2005.11.004; Mendoza J, 1991, Enferm Infecc Microbiol Clin, V9, P537; MICHAULT A, 1989, PATHOL BIOL, V37, P249; Michelet L, 2011, J CLIN MICROBIOL, V49, P195, DOI 10.1128/JCM.01554-10; MILLER B, 1984, NEUROLOGY, V34, P695, DOI 10.1212/WNL.34.5.695; MILLER BL, 1985, ARCH NEUROL-CHICAGO, V42, P782, DOI 10.1001/archneur.1985.04210090046013; MOHAMMAD IN, 1984, J CLIN MICROBIOL, V20, P775; Monteiro KM, 2007, BBA-PROTEINS PROTEOM, V1774, P278, DOI 10.1016/j.bbapap.2006.11.006; Moses A, 1911, MEMORIAS I O CRUZX, V3, P322; Mwape KE, 2011, T ROY SOC TROP MED H, V105, P574, DOI 10.1016/j.trstmh.2011.05.010; Newell E, 1997, T ROY SOC TROP MED H, V91, P389, DOI 10.1016/S0035-9203(97)90251-0; Nguekam, 2003, PARASITE, V10, P65, DOI 10.1051/parasite/2003101p65; Noya O, 2003, CURR PROTEIN PEPT SC, V4, P299, DOI 10.2174/1389203033487153; Parija M, 2004, ACTA TROP, V92, P253, DOI 10.1016/j.actatropica.2004.08.007; Parija SC, 1997, J CLIN MICROBIOL, V35, P1571; Pina R, 2011, ANN TROP MED PARASIT, V105, P311, DOI 10.1179/136485911X12987676649782; Plancarte A, 1999, PARASITOL RES, V85, P680, DOI 10.1007/s004360050615; PLANCARTE A, 1983, CYTOBIOS, V36, P83; Poretti D, 1999, AM J TROP MED HYG, V60, P193, DOI 10.4269/ajtmh.1999.60.193; Prabhakaran V, 2007, T ROY SOC TROP MED H, V101, P570, DOI 10.1016/j.trstmh.2006.10.001; Praet N, 2010, AM J TROP MED HYG, V83, P413, DOI 10.4269/ajtmh.2010.10-0121; Prasad A, 2008, DIAGN MICR INFEC DIS, V61, P198, DOI 10.1016/j.diagmicrobio.2007.12.016; Proano-Narvaez JV, 2002, J CLIN MICROBIOL, V40, P2115, DOI 10.1128/JCM.40.6.2115-2118.2002; RAJSHEKHAR V, 1991, ACTA NEUROL SCAND, V84, P465, DOI 10.1111/j.1600-0404.1991.tb04996.x; Rajshekhar V, 2001, NEUROL INDIA, V49, P75; Ramahefarisoa RM, 2010, VET PARASITOL, V173, P336, DOI 10.1016/j.vetpar.2010.05.002; Ribeiro VD, 2010, IMMUNOL LETT, V129, P94, DOI 10.1016/j.imlet.2010.01.008; Rigano R, 2001, INFECT IMMUN, V69, P288, DOI 10.1128/IAI.69.1.288-296.2001; Rodriguez S, 2009, J INFECT DIS, V199, P1345, DOI 10.1086/597757; Rodriguez-Canul R, 1998, VET PARASITOL, V79, P165, DOI 10.1016/S0304-4017(98)00161-7; Rodriguez-Hidalgo R, 2006, MEM I OSWALDO CRUZ, V101, P779, DOI 10.1590/S0074-02762006000700012; Rossi C L, 1989, Arq Neuropsiquiatr, V47, P287; RYDZEWSKI AK, 1975, J PARASITOL, V61, P154, DOI 10.2307/3279132; Sahu PS, 2008, ACTA TROP, V106, P168, DOI 10.1016/j.actatropica.2008.03.004; Sahu PS, 2009, ACTA TROP, V110, P38, DOI 10.1016/j.actatropica.2009.01.002; Salazar-Anton F, 2011, EXP PARASITOL, V128, P371, DOI 10.1016/j.exppara.2011.05.010; Salinas P, 1996, Bol Chil Parasitol, V51, P85; SARTIGUTIERREZ EJ, 1988, TROP MED PARASITOL, V39, P194; Sato MO, 2003, VET PARASITOL, V111, P309, DOI 10.1016/S0304-4017(02)00383-7; SCHANTZ P M, 1989, Acta Leidensia, V57, P153; SCHANTZ PM, 1994, CLIN INFECT DIS, V18, P879, DOI 10.1093/clinids/18.6.879; SCHANTZ PM, 1980, AM J TROP MED HYG, V29, P609, DOI 10.4269/ajtmh.1980.29.609; Scheel CM, 2005, AM J TROP MED HYG, V73, P771, DOI 10.4269/ajtmh.2005.73.771; SCHENONE H, 1971, Boletin Chileno de Parasitologia, V26, P121; Schoop G, 1970, Dtsch Tierarztl Wochenschr, V77, P156; SETHI PP, 1994, J TROP MED HYG, V97, P347; SHORT JA, 1990, J CLIN MICROBIOL, V28, P1635; Simac C, 1994, Arch Inst Pasteur Madagascar, V61, P21; Singh G, 1999, NEUROL INDIA, V47, P47; Takayanagui O M, 1983, Arq Neuropsiquiatr, V41, P50; Teive HAG, 2006, ARQ NEURO-PSIQUIAT, V64, P534, DOI 10.1590/S0004-282X2006000300036; TELLEZGIRON E, 1987, AM J TROP MED HYG, V37, P169, DOI 10.4269/ajtmh.1987.37.169; Torres-Corzo JG, 2009, SURG NEUROL, V71, P376, DOI 10.1016/j.surneu.2007.11.020; TSANG VCW, 1991, VET IMMUNOL IMMUNOP, V29, P69, DOI 10.1016/0165-2427(91)90053-F; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Van Kerckhoven I, 1998, VET PARASITOL, V76, P269, DOI 10.1016/S0304-4017(97)00226-4; VIDAL BE, 1989, REV INVEST CLIN, V41, P327; Wang C Y, 1993, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V11, P276; WANG CY, 1992, HYBRIDOMA, V11, P825; Wang Li-na, 2004, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V22, P98; Waterhouse R, 1913, Q J MED, V6, P469; Weinberg M., 1909, Compte Rendu de la Societe de Biologie Paris, V66; WILSON M, 1991, J INFECT DIS, V164, P1007, DOI 10.1093/infdis/164.5.1007; Yang HJ, 1998, PARASITE IMMUNOL, V20, P483; ZHENG HJ, 1987, AM J TROP MED HYG, V36, P554; Zimic M, 2009, AM J TROP MED HYG, V80, P964, DOI 10.4269/ajtmh.2009.80.964; ZINI D, 1990, J NEUROL NEUROSUR PS, V53, P656, DOI 10.1136/jnnp.53.8.656	181	51	52	1	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2047-7724	2047-7732		PATHOG GLOB HEALTH	Pathog. Glob. Health	SEP	2012	106	5					286	298		10.1179/2047773212Y.0000000048				13	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	068IK	WOS:000313359700007	23265553	Green Published			2019-03-26	
J	Meurs, L; Mbow, M; Vereecken, K; Menten, J; Mboup, S; Polman, K				Meurs, Lynn; Mbow, Moustapha; Vereecken, Kim; Menten, Joris; Mboup, Souleymane; Polman, Katja			Bladder Morbidity and Hepatic Fibrosis in Mixed Schistosoma haematobium and S. mansoni Infections: A Population-Wide Study in Northern Senegal	PLOS NEGLECTED TROPICAL DISEASES			English	Article							RIVER-BASIN; URINARY SCHISTOSOMIASIS; INTESTINAL SCHISTOSOMIASIS; PRAZIQUANTEL TREATMENT; MALIAN CHILDREN; COMMUNITY; EPIDEMIOLOGY; ULTRASOUND; ULTRASONOGRAPHY; DISEASE	Background: The global distribution map of schistosomiasis shows a large overlap of Schistosoma haematobium- and S. mansoni-endemic areas in Africa. Yet, little is known about the consequences of mixed Schistosoma infections for the human host. A recent study in two neighboring co-endemic communities in Senegal indicated that infection intensities of both species were higher in mixed than in single infections. Here, we investigated the relationship between mixed Schistosoma infections and morbidity in the same population. So far, this has only been studied in children. Methods: Schistosoma infection was assessed by microscopy. Schistosoma-specific morbidity was assessed by ultrasound according to WHO guidelines. Multivariable logistic regression models were used to identify independent risk factors for morbidity. Principal Findings: Complete parasitological and morbidity data were obtained from 403 individuals. Schistosoma haematobium-specific bladder morbidity was observed in 83% and S. mansoni-specific hepatic fibrosis in 27% of the participants. Bladder morbidity was positively associated with S. haematobium infection intensity (OR = 1.9 (95% CI 1.3-2.9) for a 10-fold increase in intensity). Moreover, people with mixed infections tended to have less bladder morbidity than those with single S. haematobium infections (OR = 0.3 (95% CI 0.1-1.1)). This effect appeared to be related to ectopic S. mansoni egg elimination in urine. Hepatic fibrosis on the other hand was not related to S. mansoni infection intensity (OR = 0.9 (95% CI 0.6-1.3)), nor to mixed infections (OR = 1.0 (95% CI 0.7-1.7)). Conclusions/Significance: This is the first population-wide study on the relationship between mixed Schistosoma infections and morbidity. Mixed infections did not increase the risk of S. mansoni-associated morbidity. They even tended to reduce the risk of S. haematobium-associated morbidity, suggesting a protective effect of S. mansoni infection on bladder morbidity. These unexpected results may have important consequences for schistosomiasis control in co-endemic areas and warrant further investigation.	[Meurs, Lynn; Vereecken, Kim; Menten, Joris; Polman, Katja] Inst Trop Med, B-2000 Antwerp, Belgium; [Mbow, Moustapha; Mboup, Souleymane] Ctr Hosp Univ Aristide Le Dantec, Lab Bacteriol & Virol, Dakar, Senegal	Meurs, L (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	LMeurs@itg.be	Meurs, Lynn/J-8661-2016	Meurs, Lynn/0000-0002-6973-1237	European Union [INCO-CT-2006-032405]	This work was funded by the European Union's sixth framework programme (INCO-CT-2006-032405) (Website: http://cordis.europa.eu/fp6/dc/index.cfm?fuseaction=UserSite.FP6HomePage). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSON RM, 1985, ADV PARASIT, V24, P1, DOI 10.1016/S0065-308X(08)60561-8; Berhe N, 2007, AM J TROP MED HYG, V77, P1079, DOI 10.4269/ajtmh.2007.77.1079; Boisier P, 2001, TROP MED INT HEALTH, V6, P699, DOI 10.1046/j.1365-3156.2001.00781.x; Booth M, 2004, J IMMUNOL, V172, P1295, DOI 10.4049/jimmunol.172.2.1295; Booth M, 2004, T ROY SOC TROP MED H, V98, P125, DOI 10.1016/S0035-9203(03)00018-X; Brouwer KC, 2003, ACTA TROP, V85, P339, DOI 10.1016/S0001-706X(02)00262-0; Brouwer Kimberly C, 2004, Afr Health Sci, V4, P115; BUTTERWORTH AE, 1994, TROP GEOGR MED, V46, P197; Chan MS, 1996, AM J TROP MED HYG, V55, P52, DOI 10.4269/ajtmh.1996.55.52; Cunin P, 2003, TROP MED INT HEALTH, V8, P1110, DOI 10.1046/j.1360-2276.2003.01139.x; De Clercq D, 1999, TROP MED INT HEALTH, V4, P544; de Moira AP, 2007, TROP MED INT HEALTH, V12, P724, DOI 10.1111/j.1365-3156.2007.01842.x; Doumenge JP, 1987, ATLAS GLOBAL DISTRIB; El-Khoby T, 2000, AM J TROP MED HYG, V62, P88, DOI 10.4269/ajtmh.2000.62.88; Ernould JC, 1999, ACTA TROP, V73, P143, DOI 10.1016/S0001-706X(99)00013-3; Friis H, 1996, AM J TROP MED HYG, V55, P290, DOI 10.4269/ajtmh.1996.55.290; Garba A, 2010, ACTA TROP, V115, P84, DOI 10.1016/j.actatropica.2010.02.007; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; Guyatt H, 1995, AM J TROP MED HYG, V53, P660, DOI 10.4269/ajtmh.1995.53.660; HATZ C, 1990, B WORLD HEALTH ORGAN, V68, P777; HEURTIER Y, 1986, AM J TROP MED HYG, V35, P1163, DOI 10.4269/ajtmh.1986.35.1163; Huyse T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000571; JOURDANE J, 1995, PARASITOL TODAY, V11, P427, DOI 10.1016/0169-4758(95)80029-8; Kardorff R, 1996, AM J TROP MED HYG, V54, P586; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; KHALIL SB, 1995, J PARASITOL, V81, P8, DOI 10.2307/3283998; King CH, 2003, TROP MED INT HEALTH, V8, P109, DOI 10.1046/j.1365-3156.2003.00994.x; King CH, 2004, AM J TROP MED HYG, V70, P57, DOI 10.4269/ajtmh.2004.70.57; King CH, 2002, MEM I OSWALDO CRUZ, V97, P149, DOI 10.1590/S0074-02762002000900028; King CL, 2001, J INFECT DIS, V184, P1176, DOI 10.1086/323802; Koukounari A, 2006, AM J TROP MED HYG, V75, P1042, DOI 10.4269/ajtmh.2006.75.1042; Koukounari A, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-227; Kouriba B, 2005, J INFECT DIS, V192, P2152, DOI 10.1086/498214; Leutscher PDC, 2000, TROP MED INT HEALTH, V5, P88, DOI 10.1046/j.1365-3156.2000.00522.x; MAHMOUD AA, 2001, SCHISTOSOMIASIS; Malenganisho WLM, 2008, T ROY SOC TROP MED H, V102, P532, DOI 10.1016/j.trstmh.2008.03.006; MANSOUR NS, 1984, Z PARASITENKD, V70, P345, DOI 10.1007/BF00927821; Medhat A, 1997, AM J TROP MED HYG, V57, P16, DOI 10.4269/ajtmh.1997.57.16; Meurs L, 2012, INT J PARASITOL, V42, P305, DOI 10.1016/j.ijpara.2012.02.002; Mohamed-Ali Q, 1999, J INFECT DIS, V180, P1298, DOI 10.1086/314999; Montgomery S, 2011, YELLOW BOOK; Picquet M, 1996, T ROY SOC TROP MED H, V90, P340, DOI 10.1016/S0035-9203(96)90501-5; RATARD RC, 1991, J TROP MED HYG, V94, P348; Richter J, 1996, TDRSTRSCH001; ROBERT CF, 1989, TROP MED PARASITOL, V40, P153; Serieye J, 1996, T ROY SOC TROP MED H, V90, P398, DOI 10.1016/S0035-9203(96)90521-0; Shiff C, 2006, T ROY SOC TROP MED H, V100, P847, DOI 10.1016/j.trstmh.2005.10.010; SMITH JH, 1986, HUM PATHOL, V17, P333, DOI 10.1016/S0046-8177(86)80456-7; SOLIMAN GN, 1986, Z PARASITENKD, V72, P353, DOI 10.1007/BF00928746; Southgate VR, 2001, MEM I OSWALDO CRUZ, V96, P75, DOI 10.1590/S0074-02762001000900010; Southgate VR, 1998, INT J PARASITOL, V28, P1159, DOI 10.1016/S0020-7519(98)00021-6; TALLA I, 1992, T ROY SOC TROP MED H, V86, P182, DOI 10.1016/0035-9203(92)90562-Q; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; ten Hove RJ, 2008, T ROY SOC TROP MED H, V102, P179, DOI 10.1016/j.trstmh.2007.10.011; Traore M, 1998, AM J TROP MED HYG, V59, P407, DOI 10.4269/ajtmh.1998.59.407; van der Werf MJ, 2002, TROP MED INT HEALTH, V7, P70, DOI 10.1046/j.1365-3156.2002.00823.x; Wagatsuma Y, 1999, J INFECT DIS, V179, P1515, DOI 10.1086/314786; WEBBE G, 1979, T ROY SOC TROP MED H, V73, P42, DOI 10.1016/0035-9203(79)90128-7; Webster BL, 1999, J HELMINTHOL, V73, P351; *WHO, 1991, BAS LAB METH MED PAR; WHO, 2010, SCHIST FACT SHEET; Wilson S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001149; World Health Organization, 2006, PREV CHEM HUM HELM C	63	17	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	SEP	2012	6	9							e1829	10.1371/journal.pntd.0001829				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	016OH	WOS:000309528100030	23029589	DOAJ Gold, Green Published			2019-03-26	
J	Ron-Roman, J; Saegerman, C; Minda-Aluisa, E; Benitez-Ortiz, W; Brandt, J; Douce, R				Ron-Roman, Jorge; Saegerman, Claude; Minda-Aluisa, Elizabeth; Benitez-Ortiz, Washington; Brandt, Jef; Douce, Richard			Case Report: First Report of Orchitis in Man Caused by Brucella abortus Biovar 1 in Ecuador	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							VACCINE STRAINS; AMOS PCR; EPIDIDYMOORCHITIS; EPIDIDIMOORCHITIS; MELITENSIS; DIFFERENTIATION; COMPLICATIONS; ANATOLIA; ABSCESS; TURKEY	We present a 44-year-old man from a rural community in northern Ecuador who worked on a cattle farm where he was involved with primary veterinary care, including assistance during births (or calving) and placenta retention and artificial insemination, with minimal precautions. In September of 2009, quite abruptly, he developed asthenia and hypersomnia without any apparent cause or symptoms like fever, chills, or night sweats. On November 14, 2009, he suffered from pain and edema in the right testicle that coincided with pain in the abdomen. Clinical, serological, and bacteriological investigations confirmed the first case of unilateral orchitis in man in Ecuador caused by Brucella abortus biovar 1. Because brucellosis is a neglected disease, special attention should be given to it in the training of medical and veterinary students.	[Saegerman, Claude] Univ Liege, Res Unit Epidemiol & Risk Anal Appl Vet Sci UREAR, Dept Infect & Parasit Dis, Fac Vet Med, B-4000 Liege, Belgium; [Ron-Roman, Jorge; Minda-Aluisa, Elizabeth; Benitez-Ortiz, Washington] Cent Univ Ecuador, Int Ctr Zoonoses, Quito, Ecuador; [Brandt, Jef] RSZA, Antwerp, Belgium; [Douce, Richard] Hosp Vozandes Quito, Dept Internal Med & Infect Dis, Quito, Ecuador	Saegerman, C (reprint author), Univ Liege, Res Unit Epidemiol & Risk Anal Appl Vet Sci UREAR, Dept Infect & Parasit Dis, Fac Vet Med, Blvd Colonster 20,B43B, B-4000 Liege, Belgium.	jron-ciz@uce.edu.ec; claude.saegerman@ulg.ac.be; eminda-ciz@uce.edu.ec; wbenitez-ciz@uce.edu.ec; jbrandt@telenet.be; rdouce@hcjb.org.ec		Douce, Richard/0000-0002-8675-7658; Minda-Aluisa, Elizabeth/0000-0001-7077-2370	International Center for Zoonoses (CIZ) of Central University of Ecuador; Belgian Development Agency (BTC-CTB)	This study was supported by the International Center for Zoonoses (CIZ) of Central University of Ecuador and the Belgian Development Agency (BTC-CTB).	Acha PN, 2003, ZOONOSES COMMUNICABL, V1; AFSAR H, 1993, BRIT J UROL, V72, P104, DOI 10.1111/j.1464-410X.1993.tb06468.x; Aguilar E., 2009, CASOS BRUCELOSIS HUM; Akinci E, 2006, INT J INFECT DIS, V10, P171, DOI 10.1016/j.ijid.2005.02.006; Al-Tawfiq Jaffar A., 2006, Int. braz j urol., V32, P313, DOI 10.1590/S1677-55382006000300011; Alapont Alacreu J M, 2004, Actas Urol Esp, V28, P774; Ariza J, 2007, PLOS MED, V4, P1872, DOI 10.1371/journal.pmed.0040317; BRICKER BJ, 1994, J CLIN MICROBIOL, V32, P2660; BRICKER BJ, 1995, J CLIN MICROBIOL, V33, P1640; Castillo Soria J L, 1994, Arch Esp Urol, V47, P533; Cesur S, 2003, J INFECTION, V46, P251, DOI 10.1053/jinf.2002.1121; Colmenero JD, 1996, MEDICINE, V75, P195, DOI 10.1097/00005792-199607000-00003; Corbel MJ, 1997, EMERG INFECT DIS, V3, P213, DOI 10.3201/eid0302.970219; CROSBY E, 1984, J INFECT DIS, V150, P419, DOI 10.1093/infdis/150.3.419; Ewalt DR, 2000, J CLIN MICROBIOL, V38, P3085; Gallego Vilar Daniel, 2008, Archivos Espanoles de Urologia, V61, P442; Gul HC, 2009, UROL INT, V82, P158, DOI 10.1159/000200791; Heyman D.L., 2004, CONTROL COMMUNICABLE, P75; IBRAHIM AIA, 1988, BRIT J UROL, V61, P294, DOI 10.1111/j.1464-410X.1988.tb13960.x; Kadikoylu G, 2002, UROL INT, V69, P33, DOI 10.1159/000064357; KHAN MS, 1989, BRIT J UROL, V63, P87, DOI 10.1111/j.1464-410X.1989.tb05131.x; Mantur B G, 2001, Indian J Med Microbiol, V19, P208; Memish ZA, 2001, BJU INT, V88, P72, DOI 10.1046/j.1464-410x.2001.02243.x; MEVORACH RA, 1986, J UROLOGY, V136, P1213, DOI 10.1016/S0022-5347(17)45286-4; Navarro-Martinez A, 2001, CLIN INFECT DIS, V33, P2017, DOI 10.1086/324489; Papatsoris Athanasios G., 2002, International Journal of Infectious Diseases, V6, P309, DOI 10.1016/S1201-9712(02)90166-9; Pappas G, 2006, LANCET INFECT DIS, V6, P91, DOI 10.1016/S1473-3099(06)70382-6; Sozen EE, 2007, MIKROBIYOL BUL, V41, P465; Solera J, 1999, CLIN INFECT DIS, V29, P1440, DOI 10.1086/313524; Turan T., 1999, International Urology and Nephrology, V31, P117, DOI 10.1023/A:1007140310879; WHO, 2011, INT STAT CLASS DIS R; World Health Organization, 2006, BRUC HUM AN; Yetkin MA, 2005, UROL INT, V75, P235, DOI 10.1159/000087801; YOUNG EJ, 1995, CLIN INFECT DIS, V21, P283, DOI 10.1093/clinids/21.2.283; YURDAKUL T, 1995, UROL INT, V55, P141, DOI 10.1159/000282771	35	7	7	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	SEP	2012	87	3					524	528		10.4269/ajtmh.2012.11-0341				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	004KH	WOS:000308680100024	22826490	Green Published, Bronze			2019-03-26	
J	Olesen, OF; Parker, MI				Olesen, Ole F.; Parker, M. Iqbal			Health research in Africa: getting priorities right	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						Sub-Saharan Africa; health transition; non-communicable diseases; risk factors; comorbidity; health research funding	CANCER; EPIDEMIOLOGY; INFECTIONS; MORTALITY; DISEASES; MALARIA; BURDEN		[Olesen, Ole F.; Parker, M. Iqbal] Int Ctr Genet Engn & Biotechnol, Cape Town, South Africa	Olesen, OF (reprint author), Commiss European Communities, Directorate Gen Res, Rue Champ de Mars 21, B-1050 Brussels, Belgium.	ole.olesen@ec.europa.eu					Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Bukhman G, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000097; Carapetis JR, 1999, CLIN INFECT DIS, V28, P205, DOI 10.1086/515114; Economist Intelligence Unit, 2007, WORLD INV PROSP 2011, P58; Ferlay J, 2010, IARC CANCERBASE, V10; Heyns CF, 2008, CAN J UROL, V15, P3899; Hotez PJ, 2009, LANCET, V373, P1570, DOI 10.1016/S0140-6736(09)60233-6; International Diabetes Federation, 2011, DIABETES ATLAS; Jessop S, 2006, DERMATOL CLIN, V24, P509, DOI 10.1016/j.det.2006.06.006; Jones SB, 1999, BRIT MED J, V319, P505, DOI 10.1136/bmj.319.7208.505; Kutok JL, 2006, ANNU REV PATHOL-MECH, V1, P375, DOI 10.1146/annurev.pathol.1.110304.100209; Lehrer S, 2010, ANTICANCER RES, V30, P1371; Manzella A, 2008, ABDOM IMAGING, V33, P144, DOI 10.1007/s00261-007-9329-7; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mbanya JCN, 2010, LANCET, V375, P2254, DOI 10.1016/S0140-6736(10)60550-8; Mccoy D, 2009, LANCET, V373, P1645, DOI 10.1016/S0140-6736(09)60571-7; Moran M, 2009, PLOS MED, V6, P137, DOI 10.1371/journal.pmed.1000030; Motola-Kuba Daniel, 2006, Ann Hepatol, V5, P16; Myer L, 2008, AIDS PATIENT CARE ST, V22, P147, DOI 10.1089/apc.2007.0102; Ngoungou EB, 2008, EPILEPSIA, V49, P19, DOI 10.1111/j.1528-1167.2008.01752.x; Rainey JJ, 2007, INT J CANCER, V120, P121, DOI 10.1002/ijc.22179; Sinha S, 2009, J CLIN NEUROSCI, V16, P867, DOI 10.1016/j.jocn.2008.10.030; Sitas F, 2008, LANCET ONCOL, V9, P786, DOI 10.1016/S1470-2045(08)70198-0; Stoltzfus RJ, 1997, AM J CLIN NUTR, V65, P153; Stuckler D, 2008, LANCET, V372, P1563, DOI 10.1016/S0140-6736(08)61656-6; TAYLORROBINSON D, 2000, J INFECT DIS S3, V181, P437; Vorster HH, 2011, NUTRIENTS, V3, P429, DOI 10.3390/nu3040429; World Health Organization, 2008, GLOB BURD DIS 2004 U	28	4	4	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2012	17	9					1048	1052		10.1111/j.1365-3156.2012.03027.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	994OQ	WOS:000307940800002	22716126	Bronze			2019-03-26	
J	Hasker, E; Mpanya, A; Makabuza, J; Mbo, F; Lumbala, C; Kumpel, J; Claeys, Y; Kande, V; Ravinetto, R; Menten, J; Lutumba, P; Boelaert, M				Hasker, E.; Mpanya, A.; Makabuza, J.; Mbo, F.; Lumbala, C.; Kumpel, J.; Claeys, Y.; Kande, V.; Ravinetto, R.; Menten, J.; Lutumba, P.; Boelaert, M.			Treatment outcomes for human African Trypanosomiasis in the Democratic Republic of the Congo: analysis of routine program data from the world's largest sleeping sickness control program	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						African trypanosomiasis; disease notification; treatment outcome; patient compliance	GAMBIENSE	Objective To enable the human African trypanosomiasis (HAT) control program of the Democratic Republic of the Congo to generate data on treatment outcomes, an electronic database was developed. The database was piloted in two provinces, Bandundu and Kasai Oriental. In this study, we analysed routine data from the two provinces for the period 20062008. Methods Data were extracted from case declaration cards and monthly reports available at national and provincial HAT coordination units and entered into the database. Results Data were retrieved for 15 086 of 15 741 cases reported in the two provinces for the period (96%). Compliance with post-treatment follow-up was very poor in both provinces; only 25% had undergone at least one post-treatment follow-up examination, <1% had undergone the required four follow-up examinations. Relapse rates among those presenting for follow-up were high in Kasai (18%) but low in Bandundu (0.3%). Conclusions High relapse rates in Kasai and poor compliance with post-treatment follow-up in both provinces are important problems that the HAT control program urgently needs to address. Moreover, in analogy to tuberculosis control programs, HAT control programs need to adopt a recording and reporting routine that includes reporting on treatment outcomes.	[Hasker, E.; Boelaert, M.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Mpanya, A.; Makabuza, J.; Mbo, F.; Lumbala, C.; Kumpel, J.; Kande, V.] Natl Program Control Human African Trypanosomiasi, Kinshasa, Zaire; [Claeys, Y.; Ravinetto, R.; Menten, J.] Inst Trop Med, Dept Clin Sci, Clin Trials Unit, B-2000 Antwerp, Belgium; [Lutumba, P.] Univ Kinshasa, Fac Med, Kinshasa, Zaire	Hasker, E (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, Nationalestr 155, B-2000 Antwerp, Belgium.	ehasker@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	Belgian Development Cooperation (DGCD) under the Framework Agreement 3 (FA3); Institute of Tropical Medicine (ITM), Antwerp (Belgium)	Jo Robays who did the initial exploratory mission for this data management project. This study was funded by the Belgian Development Cooperation (DGCD) under the Framework Agreement 3 (FA3) with the Institute of Tropical Medicine (ITM), Antwerp (Belgium).	De Deken R, 2005, MED VET ENTOMOL, V19, P353, DOI 10.1111/j.1365-2915.2005.00580.x; Fevre EM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000333; Lutumba P, 2005, EMERG INFECT DIS, V11, P1382; Lutumba P, 2005, TROP MED INT HEALTH, V10, P347, DOI 10.1111/j.1365-3156.2005.01391.x; Ngoyi DM, 2010, J INFECT DIS, V201, P453, DOI 10.1086/649917; Organization WH, 2008, IMPL WHO STOP TB STR; Pepin J, 2001, ADV PARASIT, V49, P71, DOI 10.1016/S0065-308X(01)49038-5; Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; Robays J, 2008, EMERG INFECT DIS, V14, P966, DOI 10.3201/eid1406.071266; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Simarro PP, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-57; STYBLO K, 1976, INT J EPIDEMIOL, V5, P63, DOI 10.1093/ije/5.1.63; World Health Organization, 2006, REV TB REC REP FORMS	14	5	5	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2012	17	9					1127	1132		10.1111/j.1365-3156.2012.03042.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	994OQ	WOS:000307940800012	22809002	Bronze			2019-03-26	
J	Zachariah, R; Bienvenue, B; Ayada, L; Manzi, M; Maalim, A; Engy, E; Jemmy, JP; Said, AI; Hassan, A; Abdulrahaman, F; Abdulrahman, O; Bseiso, J; Amin, H; Michalski, D; Oberreit, J; Draguez, B; Stokes, C; Reid, T; Harries, AD				Zachariah, R.; Bienvenue, B.; Ayada, L.; Manzi, M.; Maalim, A.; Engy, E.; Jemmy, J. P.; Said, A. Ibrahim; Hassan, A.; Abdulrahaman, F.; Abdulrahman, O.; Bseiso, J.; Amin, H.; Michalski, D.; Oberreit, J.; Draguez, B.; Stokes, C.; Reid, T.; Harries, A. D.			Practicing medicine without borders: tele-consultations and tele-mentoring for improving paediatric care in a conflict setting in Somalia?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Somalia; conflict; telemedicine; children; quality; outcomes	HEALTH-CARE; TELEMEDICINE; PERSPECTIVES; TECHNOLOGY; CHILDREN; IMPACT	Objectives In a district hospital in conflict-torn Somalia, we assessed (i) the impact of introducing telemedicine on the quality of paediatric care, and (ii) the added value as perceived by local clinicians. Methods A real-time audio-visual exchange of information on paediatric cases (Audiosoft Technologies, Quebec, Canada) took place between clinicians in Somalia and a paediatrician in Nairobi. The study involved a retrospective analysis of programme data, and a perception study among the local clinicians. Results Of 3920 paediatric admissions, 346 (9%) were referred for telemedicine. In 222 (64%) children, a significant change was made to initial case management, while in 88 (25%), a life-threatening condition was detected that had been initially missed. There was a progressive improvement in the capacity of clinicians to manage complicated cases as demonstrated by a significant linear decrease in changes to initial case management for meningitis and convulsions (9229%, P = 0.001), lower respiratory tract infection (7545%, P = 0.02) and complicated malnutrition (8640%, P = 0.002). Adverse outcomes (deaths and lost to follow-up) fell from 7.6% in 2010 (without telemedicine) to 5.4% in 2011 with telemedicine (30% reduction, odds ratio 0.70, 95% CI: 0.570.88, P = -0.001). The number needed to be treated through telemedicine to prevent one adverse outcome was 45. All seven clinicians involved with telemedicine rated it to be of high added value. Conclusion The introduction of telemedicine significantly improved quality of paediatric care in a remote conflict setting and was of high added value to distant clinicians.	[Zachariah, R.; Manzi, M.; Engy, E.; Reid, T.] Medecins Sans Frontieres, Brussels Operat Ctr, Luxembourg, Belgium; [Bienvenue, B.; Maalim, A.] Medecins Sans Frontieres, Somalia Mission Coordinat, Nairobi, Kenya; [Ayada, L.; Jemmy, J. P.; Bseiso, J.; Michalski, D.; Oberreit, J.; Draguez, B.; Stokes, C.] Medecins Sans Frontieres, Brussels Operat Ctr, Brussels, Belgium; [Said, A. Ibrahim; Hassan, A.; Abdulrahaman, F.; Abdulrahman, O.; Amin, H.] Medecins Sans Frontieres, Guirel Hosp, Galgadud, Somalia; [Harries, A. D.] Int Union TB & Lung Dis, Ctr Operat Res, Paris, France; [Harries, A. D.] London Sch Hyg & Trop Med, London WC1, England	Zachariah, R (reprint author), Medecins Sans Frontieres, Operat Res Unit, Brussels Operat Ctr, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu			MSF-Brussels operational centre, Belgium	We thank health workers, support staff in the Guir'el hospital for their valuable work. We are grateful to the caretakers of children and community elders who agreed to be involved with telemedicine and for their support in this study. We are also very grateful to our donors who support our programmes in Somalia. This study was funded by MSF-Brussels operational centre, Belgium.	Aaudiosoft, 2008, AUDISOFT TECHN 2101, P646; ALLEN A, 1994, AM J PUBLIC HEALTH, V84, P1693, DOI 10.2105/AJPH.84.10.1693; Ermer DJ, 1999, PSYCHIATR SERV, V50, P260, DOI 10.1176/ps.50.2.260; Fraser HSF, 2000, BRIT MED J, V321, P465, DOI 10.1136/bmj.321.7259.465; Geissbuhler A, 2003, AMIA ANN S P, V24, P9; Jennett PA, 2003, J TELEMED TELECARE, V9, P311, DOI 10.1258/135763303771005207; Karp WB, 2000, PEDIATRICS, V105, P843, DOI 10.1542/peds.105.4.843; Marcin JP, 2004, J PEDIATR-US, V144, P375, DOI 10.1016/j.jpeds.2003.12.017; McConnochie K, 2010, TELEMED J E-HEALTH, V16, P280, DOI 10.1089/tmj.2009.0112; MSF, 2010, CLIN GUID DIAGN TREA; Mupela Evans N, 2011, Philos Ethics Humanit Med, V6, P9, DOI 10.1186/1747-5341-6-9; Romano MJ, 2001, TELEMED J E-HEALTH, V7, P281, DOI 10.1089/15305620152814683; Sable CA, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e3; Smith AC, 2007, EXPERT REV MED DEVIC, V4, P5, DOI 10.1586/17434440.4.1.5; Sood S, 2007, TELEMED J E-HEALTH, V13, P573, DOI 10.1089/tmj.2006.0073; Spooner SA, 2004, PEDIATRICS, V113, pE639, DOI 10.1542/peds.113.6.e639; Strehle EM, 2006, ARCH DIS CHILD, V91, P956, DOI 10.1136/adc.2006.099622; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wootton Richard, 2010, JRSM Short Rep, V1, P37, DOI 10.1258/shorts.2010.010045	19	21	21	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2012	17	9					1156	1162		10.1111/j.1365-3156.2012.03047.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	994OQ	WOS:000307940800016	22845678				2019-03-26	
J	Jansen, O; Tits, M; Angenot, L; Nicolas, JP; De Mol, P; Nikiema, JB; Frederich, M				Jansen, Olivia; Tits, Monique; Angenot, Luc; Nicolas, Jean-Pierre; De Mol, Patrick; Nikiema, Jean-Baptiste; Frederich, Michel			Anti-plasmodial activity of Dicoma tomentosa (Asteraceae) and identification of urospermal A-15-O-acetate as the main active compound	MALARIA JOURNAL			English	Article						Antiplasmodial; Asteraceae; Melampolide; Burkina Faso; Dicoma tomentosa; Natural compound	SESQUITERPENE LACTONES; NATURAL-PRODUCTS; IN-VITRO; ANTIPLASMODIAL ACTIVITY; QUANTITATIVE STRUCTURE; PLANT-EXTRACTS; DRUG DISCOVERY; BURKINA-FASO; MALARIA; ARTEMISININ	Background: Natural products could play an important role in the challenge to discover new anti-malarial drugs. In a previous study, Dicoma tomentosa (Asteraceae) was selected for its promising anti-plasmodial activity after a preliminary screening of several plants traditionally used in Burkina Faso to treat malaria. The aim of the present study was to further investigate the anti-plasmodial properties of this plant and to isolate the active anti-plasmodial compounds. Methods: Eight crude extracts obtained from D. tomentosa whole plant were tested in vitro against two Plasmodium falciparum strains (3D7 and W2) using the p-LDH assay (colorimetric method). The Peters' four-days suppressive test model (Plasmodium berghei-infected mice) was used to evaluate the in vivo anti-plasmodial activity. An in vitro bioguided fractionation was undertaken on a dichloromethane extract, using preparative HPLC and TLC techniques. The identity of the pure compound was assessed using UV, MS and NMR spectroscopic analysis. In vitro cytotoxicity against WI38 human fibroblasts (WST-1 assay) and haemolytic activity were also evaluated for extracts and pure compounds in order to check selectivity. Results: The best in vitro anti-plasmodial results were obtained with the dichloromethane, diethylether, ethylacetate and methanol extracts, which exhibited a high activity (IC50 <= 5 mu g/ml). Hot water and hydroethanolic extracts also showed a good activity (IC50 <= 15 mu g/ml), which confirmed the traditional use and the promising anti-malarial potential of the plant. The activity was also confirmed in vivo for all tested extracts. However, most of the active extracts also exhibited cytotoxic activity, but no extract was found to display any haemolytic activity. The bioguided fractionation process allowed to isolate and identify a sesquiterpene lactone (urospermal A-15-O-acetate) as the major anti-plasmodial compound of the plant (IC50 <= 1 mu g/ml against both 3D7 and W2 strains). This was also found to be the main cytotoxic compound (SI = 3.3). While this melampolide has already been described in the plant, this paper is the first report on the biological properties of this compound. Conclusions: The present study highlighted the very promising anti-plasmodial activity of D. tomentosa and enabled to identify its main active compound, urospermal A-15-O-acetate. The high anti-plasmodial activity of this compound merits further study about its anti-plasmodial mechanism of action. The active extracts of D. tomentosa, as well as urospermal A 15-O-acetate, displayed only a moderate selectivity, and further studies are needed to assess the safety of the use of the plant by the local population.	[Jansen, Olivia; Tits, Monique; Angenot, Luc; Frederich, Michel] Univ Liege, CIRM, Lab Pharmacognosie, B-4000 Liege, Belgium; [Nicolas, Jean-Pierre] Associat Jardins Monde, F-29190 Brasparts, France; [De Mol, Patrick] Univ Liege, Lab Microbiol Med, B-4000 Liege, Belgium; [Nikiema, Jean-Baptiste] Univ Ouagadougou, Unite Format & Rech Sci Sante, Ouagadougou 7021 03, Burkina Faso	Jansen, O (reprint author), Univ Liege, CIRM, Lab Pharmacognosie, Av Hop 1,CHU-B36, B-4000 Liege, Belgium.	ojansen@ulg.ac.be		FREDERICH, Michel/0000-0002-0770-9990			[Anonymous], 2010, GUID REG TRAD MED WH; Aqil M., 2001, Global Journal of Pure and Applied Sciences, V7, P273; Aqil M, 1999, ULTRA SCI PHYS SCI, V11, P378; Aqil M, 1999, GLOBAL J PURE APPL S, V5, P357; Aquil M, 1998, GLOBAL J PURE APPL S, V4, P135; Batista R, 2009, MOLECULES, V14, P3037, DOI 10.3390/molecules14083037; Becker JVW, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-295; Bero J, 2011, PLANTA MED, V77, P631, DOI 10.1055/s-0030-1250405; Bero J, 2009, J PHARM PHARMACOL, V61, P1401, DOI [10.1211/jpp.61.11.0001, 10.1211/jpp/61.11.0001]; BOHLMANN F, 1982, PHYTOCHEMISTRY, V21, P2122, DOI 10.1016/0031-9422(82)83062-8; Catalan CAN, 1996, BIOCHEM SYST ECOL, V24, P659, DOI 10.1016/S0305-1978(97)81209-4; Deharo E, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S5; Dondorp AM, 2010, NAT REV MICROBIOL, V8, P272, DOI 10.1038/nrmicro2331; Egan TJ, 2009, FUTURE MICROBIOL, V4, P637, DOI [10.2217/fmb.09.42, 10.2217/FMB.09.42]; Ferreira JFS, 2010, MOLECULES, V15, P3135, DOI 10.3390/molecules15053135; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Frederich M, 2004, PLANTA MED, V70, P520, DOI 10.1055/s-2004-827151; Frederich M, 2002, J NAT PROD, V65, P1381, DOI 10.1021/np020070e; Ganfon H, 2012, J ETHNOPHARMACOL, V141, P411, DOI 10.1016/j.jep.2012.03.002; Ginsburg H, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S1; Goffin E, 2002, PLANTA MED, V68, P543, DOI 10.1055/s-2002-32552; Graz B, 2010, T ROY SOC TROP MED H, V104, P33, DOI 10.1016/j.trstmh.2009.07.005; Jansen O., 2008, ETHNOPHARMACOLOGIA, V41, P74; Jansen O, 2010, J ETHNOPHARMACOL, V130, P143, DOI 10.1016/j.jep.2010.04.032; Kaur K, 2009, BIOORGAN MED CHEM, V17, P3229, DOI 10.1016/j.bmc.2009.02.050; Kenmogne M, 2006, PHYTOCHEMISTRY, V67, P433, DOI 10.1016/j.pytochem.2005.10.015; Krishna V, 2003, J INDIAN CHEM SOC, V80, P971; MAKLER MT, 1993, AM J TROP MED HYG, V48, P739, DOI 10.4269/ajtmh.1993.48.739; MEHTA R, 1981, INDIAN J CHEM B, V20, P834; Nogueira CR, 2011, MOLECULES, V16, P2146, DOI 10.3390/molecules16032146; Phillipson DJ, 1991, J ETHNOPHARMACOL, V32, P155; Phyo AP, 2012, LANCET, V379, P1960, DOI 10.1016/S0140-6736(12)60484-X; Pink R, 2005, NAT REV DRUG DISCOV, V4, P727, DOI 10.1038//nrd1824; Rasoanaivo P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S4; Robert S, 2010, J ETHNOPHARMACOL, V128, P641, DOI 10.1016/j.jep.2010.02.007; Schmidt TJ, 2009, MOLECULES, V14, P2062, DOI 10.3390/molecules14062062; Scotti MT, 2007, BIOORGAN MED CHEM, V15, P2927, DOI 10.1016/j.bmc.2007.02.005; Willcox M, 2004, TRA HERB, V4, P187; Willcox ML, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S8; Willcox ML, 2004, BMJ-BRIT MED J, V329, P1156, DOI 10.1136/bmj.329.7475.1156; World Health Organization, 2010, GUID TREATM MAL; World Health Organization (WHO), 2008, TRAD MED FACT SHEET; Yerbanga RS, 2012, J ETHNOPHARMACOL, V140, P255, DOI 10.1016/j.jep.2012.01.014; ZDERO C, 1990, PHYTOCHEMISTRY, V29, P183, DOI 10.1016/0031-9422(90)89034-7	44	28	28	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	AUG 21	2012	11								289	10.1186/1475-2875-11-289				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	033IC	WOS:000310786600001	22909422	DOAJ Gold, Green Published			2019-03-26	
J	Mens, PF; Moers, APHA; de Bes, LM; Flint, J; Sak, JRS; Keereecharoen, L; van Overmeir, C; Verweij, JJ; Hallett, RL; Wihokhoen, B; Proux, S; Schallig, HDFH; van Amerongen, A				Mens, Petra F.; Moers, Antoine P. H. A.; de Bes, Laura M.; Flint, Jonathan; Sak, Jathee R. S.; Keereecharoen, Lily; van Overmeir, Chantal; Verweij, Jaco J.; Hallett, Rachel L.; Wihokhoen, Benchawan; Proux, Stephane; Schallig, Henk D. F. H.; van Amerongen, Aart			Development, validation and evaluation of a rapid PCR-nucleic acid lateral flow immuno-assay for the detection of Plasmodium and the differentiation between Plasmodium falciparum and Plasmodium vivax	MALARIA JOURNAL			English	Article							MALARIA DIAGNOSIS; AMPLIFICATION; PARASITE; MICROSCOPY; ACCURACY; TESTS; CARE	Background: Molecular tools are very sensitive and specific and could be an alternative for the diagnosis of malaria. The complexity and need for expensive equipment may hamper implementation and, therefore, simplifications to current protocols are warranted. Methods: A PCR detecting the different Plasmodium species and differentiating between Plasmodium falciparum and Plasmodium vivax was developed and combined with a nucleic acid lateral flow immuno-assay (PCR-NALFIA) for amplicon detection. The assay was thoroughly evaluated for the analytical sensitivity and specificity in the laboratory, the robustness and reproducibility in a ring trial and accuracy and predictive value in a field trial. Results: The analytical sensitivity and specificity were 0.978 (95% CI: 0.932-0.994) and 0.980 (95% CI: 0.924-0.997), respectively, and were slightly less sensitive for the detection of P. vivax than for P. falciparum. The reproducibility tested in three laboratories was very good (k = 0.83). This evaluation showed that the PCR machine used could influence the results. Accuracy was evaluated in Thailand and compared to expert microscopy and rapid diagnostic tests (RDTs). The overall and P. falciparum-specific sensitivity and specificity was good ranging from 0.86-1 and 0.95-0.98 respectively, compared to microscopy. Plasmodium vivax detection was better than the sensitivity of RDT, but slightly less than microscopy performed in this study. Conclusion: PCR-NALFIA is a sensitive, specific and robust assay able to identify Plasmodium species with good accuracy. Extensive testing including a ring trial can identify possible bottlenecks before implementation and is therefore essential to perform in additon to other evaluations.	[Mens, Petra F.; de Bes, Laura M.; Schallig, Henk D. F. H.] Royal Trop Inst, Koninklijk Inst Tropen, NL-1105 AZ Amsterdam, Netherlands; [Moers, Antoine P. H. A.; van Amerongen, Aart] Wageningen UR Food & Biobased Res, Biomol Sensing & Diagnost, Wageningen, Netherlands; [Flint, Jonathan] Forsite Diagnost Ltd, York YO41 1LZ, N Yorkshire, England; [Sak, Jathee R. S.; Keereecharoen, Lily; Wihokhoen, Benchawan; Proux, Stephane] Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand; [Sak, Jathee R. S.; Keereecharoen, Lily; Wihokhoen, Benchawan; Proux, Stephane] Shoklo Malaria Res Unit, Mae Sot, Thailand; [van Overmeir, Chantal] Inst Trop Geneeskunde, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Verweij, Jaco J.] Leiden Univ, Dept Parasitol, Med Ctr, NL-2300 RC Leiden, Netherlands; [Hallett, Rachel L.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England	Mens, PF (reprint author), Royal Trop Inst, Koninklijk Inst Tropen, Meibergdreef 39, NL-1105 AZ Amsterdam, Netherlands.	p.mens@kit.nl			EU [201889]; Wellcome Trust (UK)	This project was financially supported by the EU funded FP7 project MALACTRES (Multi-drug resistance in malaria under combination therapy: Assessment of specific markers and development of innovative, rapid and simple diagnostics) grant nr 201889. We thank all collaborators of the MALACTRES project for their contribution. We want to specifically thank Dr Colin Sutherland of the London School of Hygiene and Tropical Medicine (UK) and Malaria Reference Laboratory (UK) and Dr Bakri Nour from Wad Medani Teaching Hospital (Sudan) for their kind provision of the blood samples for the laboratory and ring trial evaluation. We are also grateful to the staff and patients of Mae Khon Ken, and Wang Pa malaria clinics and the Shoklo Malaria Research Unit (Thailand) part of Mahidol-Oxford Tropical Medicine Research Unit (MORU) supported by the Wellcome Trust (UK) for their willingness to participate in this trial. We thank Dr Masja Straetmans (Royal Tropical Institute, The Netherlands) for her support in the analysis of the ring trial data.	Altman DG, 1991, PRACTICAL STAT MED R, P611; Ansah EK, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c930; Bossuyt PM, 2006, BRIT MED J, V332, P1089, DOI 10.1136/bmj.332.7549.1089; Fleiss JL, 2003, STAT METHODS RATES P; Harris I, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-254; Hawkes M, 2007, EXPERT REV ANTI-INFE, V5, P485, DOI 10.1586/14787210.5.3.485; Kahama-Maro J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-332; Kyabayinze DJ, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-200; Lucchi NW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013733; malERA consultative group on diagnoses and diagnostics, 2011, PLOS MED, V8, DOI DOI 10.1371/JOURNAL.PMED.1000396; Meena M, 2009, T ROY SOC TROP MED H, V103, P1237, DOI 10.1016/j.trstmh.2009.04.011; Mens P, 2007, TROP MED INT HEALTH, V12, P238, DOI 10.1111/j.1365-3165.2006.01779.x; Noguera P, 2011, ANAL BIOANAL CHEM, V399, P831, DOI 10.1007/s00216-010-4334-z; Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2; Proux S, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-323; Saah AJ, 1997, ANN INTERN MED, V126, P91, DOI 10.7326/0003-4819-126-1-199701010-00026; Schneider P, 2005, J CLIN MICROBIOL, V43, P402, DOI 10.1128/JCM.43.1.402-405.2005; Sirichaisinthop J, 2011, AM J TROP MED HYG, V85, P594, DOI 10.4269/ajtmh.2011.10-0676; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B; Weinstein S, 2005, AM J ROENTGENOL, V184, P14, DOI 10.2214/ajr.184.1.01840014; World Health Organization, 2010, BAS MAL MICR 1; World Health Organization, 2010, GUID TREATM MAL; World Organization of Animal Health, 2010, TERR MAN, pp1	23	12	12	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	AUG 17	2012	11								279	10.1186/1475-2875-11-279				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	012ZM	WOS:000309275300001	22900750	DOAJ Gold, Green Published			2019-03-26	
J	Yewhalaw, D; Asale, A; Tushune, K; Getachew, Y; Duchateau, L; Speybroeck, N				Yewhalaw, Delenasaw; Asale, Abebe; Tushune, Kora; Getachew, Yehenew; Duchateau, Luc; Speybroeck, Niko			Bio-efficacy of selected long-lasting insecticidal nets against pyrethroid resistant Anopheles arabiensis from South-Western Ethiopia	PARASITES & VECTORS			English	Article						Bio-efficacy; Long-lasting insecticidal nets; Insecticide resistance; Anopheles arabiensis; Ethiopia	CULEX-QUINQUEFASCIATUS; MALARIA VECTORS; TREATED NETS; IMPREGNATED BEDNETS; FIELD EFFICACY; MOSQUITO NETS; GAMBIAE S.S.; SUSCEPTIBILITY; CULICIDAE; DIPTERA	Background: The emergence and spread of insecticide resistance in the major African malaria vectors Anopheles gambiae s.s. and Anopheles arabiensis may compromise control initiatives based on insecticide-treated nets (ITNs) or indoor residual spraying (IRS), and thus threaten the global malaria elimination strategy. Methods: We investigated pyrethroid resistance in four populations of An. arabiensis from south-western Ethiopia and then assessed the bio-efficacy of six World Health Organization recommended long lasting insecticidal nets (LLINs) using these populations. Results: For all four populations of An. arabiensis, bottle bioassays indicated low to moderate susceptibility to deltamethrin (mortality at 30 minutes ranged between 43 and 80%) and permethrin (mortality ranged between 16 and 76%). Pre-exposure to the synergist piperonylbutoxide (PBO) significantly increased the susceptibility of all four populations to both deltamethrin (mortality increased between 15.3 and 56.8%) and permethrin (mortality increased between 11.6 and 58.1%), indicating the possible involvement of metabolic resistance in addition to the previously identified kdr mutations. There was reduced susceptibility of all four An. arabiensis populations to the five standard LLINs tested (maximum mortality 81.1%; minimum mortality 13.9%). Bio-efficacy against the four populations varied by net type, with the largest margin of difference observed with the Jimma population (67.2% difference). Moreover, there were differences in the bio-efficacy of each individual standard LLIN against the four mosquito populations; for example there was a difference of 40% in mortality of Yorkool against two populations. Results from standard LLINs indicated reduced susceptibility to new, unused nets that was likely due to observed pyrethroid resistance. The roof of the combination LLIN performed optimally (100% mortality) against all the four populations of An. arabiensis, indicating that observed reductions in susceptibility could be ameliorated with the combination of PBO with deltamethrin, as used in PermaNet (R) 3.0. Conclusion: Our results suggest that bio-efficacy evaluations using local mosquito populations should be conducted where possible to make evidence-based decisions on the most suitable control products, and that those combining multiple chemicals such as PBO and deltamethrin should be considered for maintaining a high level of efficacy in vector control programmes.	[Yewhalaw, Delenasaw; Asale, Abebe] Jimma Univ, Dept Biol, Coll Nat Sci, Jimma, Ethiopia; [Tushune, Kora] Jimma Univ, Dept Hlth Serv Management, Coll Publ Hlth & Med Sci, Jimma, Ethiopia; [Getachew, Yehenew] Jimma Univ, Dept Hort, Coll Agr & Vet Med, Jimma, Ethiopia; [Duchateau, Luc] Univ Ghent, Fac Vet Med, Dept Physiol & Biometr, B-9000 Ghent, Belgium; [Speybroeck, Niko] Catholic Univ Louvain, Sch Publ Hlth, Inst Hlth & Soc, B-1200 Brussels, Belgium	Yewhalaw, D (reprint author), Jimma Univ, Dept Biol, Coll Nat Sci, Jimma, Ethiopia.	delenasaw.yewhwlaw@ju.edu.et		asale, abebe/0000-0003-0143-5762	VestergaardFrandsenSA, Switzerland	We are grateful to Dr Tessa B. Knox for providing technical assistance. Vincent Were is acknowledged with appreciation for analysing the data. We thank AbdoJemal, WorkinehJaleta, Miftah A/Gidi, Nasir A/Raya and Abdo A/Gidi for their support in field mosquito collection. Financial support for this study was obtained from VestergaardFrandsenSA, Switzerland.	Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; Ahmed M, 2006, PEST MANAG SCI, V62, P805; [Anonymous], 2011, TECHN BAS COORD ACT; [Anonymous], 2011, GUID ENT MON INS RES, P7; Berticat C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-104; Brogdon WG, 1998, EMERG INFECT DIS, V4, P605, DOI 10.3201/eid0404.980410; Center for Disease Control and Prevention, 2012, EV MOSQ INS RES; Coleman M, 2006, J MED ENTOMOL, V43, P663, DOI 10.1603/0022-2585(2006)43[663:DAEDSS]2.0.CO;2; Corbel V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-113; Djouaka RF, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-538; Etang J, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-46; Fane M, 2011, ACTA TROP, V22, P1; Gillies MT, 1987, SUPPLEMENT ANOPHELIN, P55; Gu WD, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-256; Guillet P, 2001, MED VET ENTOMOL, V15, P105, DOI 10.1046/j.1365-2915.2001.00288.x; Gunasekaran K, 2008, ACTA TROP, V105, P154, DOI 10.1016/j.actatropica.2007.10.008; Hardstone MC, 2009, J EVOLUTION BIOL, V22, P416, DOI 10.1111/j.1420-9101.2008.01661.x; Hemingway J, 2000, ANNU REV ENTOMOL, V45, P371, DOI 10.1146/annurev.ento.45.1.371; Hougard JM, 2003, B ENTOMOL RES, V93, P491, DOI 10.1079/BER2003261; Hunt RH, 2010, PARASITVECTORS, V3, P12; Hunt RH, 2011, PARASITVECTORS, V16, P107; Kolaczinski JH, 2000, B ENTOMOL RES, V90, P125; Kulkarni MA, 2007, TROP MED INT HEALTH, V12, P1061, DOI 10.1111/j.1365-3156.2007.01883.x; Lengeler C., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; Mathias DK, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-10; Moores G., 2005, Outlooks on Pest Management, V16, P7, DOI 10.1564/16feb03; Muller P, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000286; Rafinejad J., 2008, Journal of Vector Borne Diseases, V45, P143; Ranson H, 2011, TRENDS PARASITOL, V27, P91, DOI 10.1016/j.pt.2010.08.004; Ranson H, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-299; Trape GF, 2011, LANCET INFECT DIS, V11, P925; van den Berg H, 2012, ENVIRON HEALTH PERSP, V120, P577, DOI 10.1289/ehp.1104340; Vezenegho SB, 2009, MED VET ENTOMOL, V23, P326, DOI 10.1111/j.1365-2915.2009.00840.x; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization, 2005, GUID CONTR SHIG INCL, P11; World Health Organization, 2005, MAL CONTR TOD CURR W, P75; Yewhalaw D., 2011, PLOS ONE, V6, P1, DOI DOI 10.1371/JOURNAL.PONE.0016066; Yewhalaw D, 2010, AM J TROP MED HYG, V83, P122, DOI 10.4269/ajtmh.2010.09-0738	39	21	21	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	AUG 7	2012	5								159	10.1186/1756-3305-5-159				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	028XV	WOS:000310459900001	22871143	DOAJ Gold, Green Published			2019-03-26	
J	Gryseels, S; Amissah, D; Durnez, L; Vandelannoote, K; Leirs, H; De Jonckheere, J; Silva, MT; Portaels, F; Ablordey, A; Eddyani, M				Gryseels, Sophie; Amissah, Diana; Durnez, Lies; Vandelannoote, Koen; Leirs, Herwig; De Jonckheere, Johan; Silva, Manuel T.; Portaels, Francoise; Ablordey, Anthony; Eddyani, Miriam			Amoebae as Potential Environmental Hosts for Mycobacterium ulcerans and Other Mycobacteria, but Doubtful Actors in Buruli Ulcer Epidemiology	PLOS NEGLECTED TROPICAL DISEASES			English	Article							FREE-LIVING AMEBAS; REAL-TIME PCR; ACANTHAMOEBA-POLYPHAGA; LEGIONELLA-PNEUMOPHILA; INTRACELLULAR GROWTH; NAUCORIS-CIMICOIDES; COCULTURE PROCEDURE; ENHANCES VIRULENCE; HUMAN MACROPHAGES; CAUSATIVE AGENT	Background: The reservoir and mode of transmission of Mycobacterium ulcerans, the causative agent of Buruli ulcer, remain unknown. Ecological, genetic and epidemiological information nonetheless suggests that M. ulcerans may reside in aquatic protozoa. Methodology/Principal Findings: We experimentally infected Acanthamoeba polyphaga with M. ulcerans and found that the bacilli were phagocytised, not digested and remained viable for the duration of the experiment. Furthermore, we collected 13 water, 90 biofilm and 45 detritus samples in both Buruli ulcer endemic and non-endemic communities in Ghana, from which we cultivated amoeboid protozoa and mycobacteria. M. ulcerans was not isolated, but other mycobacteria were as frequently isolated from intracellular as from extracellular sources, suggesting that they commonly infect amoebae in nature. We screened the samples as well as the amoeba cultures for the M. ulcerans markers IS2404, IS2606 and KR-B. IS2404 was detected in 2% of the environmental samples and in 4% of the amoeba cultures. The IS2404 positive amoeba cultures included up to 5 different protozoan species, and originated both from Buruli ulcer endemic and non-endemic communities. Conclusions/Significance: This is the first report of experimental infection of amoebae with M. ulcerans and of the detection of the marker IS2404 in amoeba cultures isolated from the environment. We conclude that amoeba are potential natural hosts for M. ulcerans, yet remain sceptical about their implication in the transmission of M. ulcerans to humans and their importance in the epidemiology of Buruli ulcer.	[Gryseels, Sophie; Leirs, Herwig] Univ Antwerp, Evolutionary Ecol Grp, B-2020 Antwerp, Belgium; [Amissah, Diana; Ablordey, Anthony] Univ Ghana, Noguchi Mem Inst Med Res, Legon, Ghana; [Durnez, Lies; Vandelannoote, Koen; Portaels, Francoise; Eddyani, Miriam] Inst Trop Med, B-2000 Antwerp, Belgium; [Leirs, Herwig] Aarhus Univ, Danish Pest Infestat Lab, Dept Agroecol, Slagelse, Denmark; [De Jonckheere, Johan] Catholic Univ Louvain, Trop Dis Res Unit, de Duve Inst, B-1200 Brussels, Belgium; [De Jonckheere, Johan] Sci Inst Publ Hlth, Brussels, Belgium; [Silva, Manuel T.] Univ Porto, Inst Mol & Cell Biol IBMC, P-4100 Oporto, Portugal	Gryseels, S (reprint author), Univ Antwerp, Evolutionary Ecol Grp, B-2020 Antwerp, Belgium.	sophie.gryseels@ua.ac.be	Leirs, Herwig/B-8197-2008	Leirs, Herwig/0000-0002-7612-5024; Gryseels, Sophie/0000-0002-4851-9384	Flemish Interuniversity Council - University Development Cooperation (VLIR-UOS); Stop Buruli Initiative; UBS Optimus Foundation (Zurich, Switzerland); FWO [1.1.671.10.N.00]	This study was supported by the Flemish Interuniversity Council - University Development Cooperation (VLIR-UOS) and by the Stop Buruli Initiative funded by the UBS Optimus Foundation (Zurich, Switzerland). S. Gryseels is currently an FWO PhD fellow (FWO grant nr 1.1.671.10.N.00). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adekambi T, 2006, APPL ENVIRON MICROB, V72, P5974, DOI 10.1128/AEM.03075-05; Astarie-Dequeker C, 1999, INFECT IMMUN, V67, P469; Benbow ME, 2008, EMERG INFECT DIS, V14, P1247, DOI 10.3201/eid1408.071503; Bermudez LE, 1997, INFECT IMMUN, V65, P3768; BOOM R, 1990, J CLIN MICROBIOL, V28, P495; CIANCIOTTO NP, 1992, P NATL ACAD SCI USA, V89, P5188, DOI 10.1073/pnas.89.11.5188; Cirillo JD, 1997, INFECT IMMUN, V65, P3759; Cirillo JD, 1999, INFECT IMMUN, V67, P4427; Cloud JL, 2006, INT J SYST EVOL MICR, V56, P1413, DOI 10.1099/ijs.0.64194-0; Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033; De Jonckheere JF, 1998, PROTIST, V149, P221, DOI 10.1016/S1434-4610(98)70030-6; De Jonckheerea JF, 2005, PROTIST, V156, P89, DOI 10.1016/j.protis.2004.11.001; DRAPER P, 1970, NATURE, V228, P860, DOI 10.1038/228860a0; Durnez L, 2009, J MICROBIOL METH, V76, P152, DOI 10.1016/j.mimet.2008.10.002; Eddyani M, 2008, APPL ENVIRON MICROB, V74, P6547, DOI 10.1128/AEM.01066-08; Eddyani M, 2008, J CLIN MICROBIOL, V46, P69, DOI 10.1128/JCM.00301-07; Falkinham JO, 2002, CLIN CHEST MED, V23, P529, DOI 10.1016/S0272-5231(02)00014-X; Fyfe JAM, 2007, APPL ENVIRON MICROB, V73, P4733, DOI 10.1128/AEM.02971-06; Fyfe JAM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000791; Gao LY, 2004, MOL MICROBIOL, V53, P1677, DOI 10.1111/j.1365-2958.2004.04261.x; Greub G, 2004, CLIN MICROBIOL REV, V17, P413, DOI 10.1128/CMR.17.2.413-433.2004; Grosset J, 2003, ANTIMICROB AGENTS CH, V47, P833, DOI 10.1128/AAC.47.3.833-836.2003; Krishna Prasad B.N., 1978, Current Science (Bangalore), V47, P245; La Scola B, 2001, J CLIN MICROBIOL, V39, P365, DOI 10.1128/JCM.39.1.365-366.2001; Loytynoja A, 2005, P NATL ACAD SCI USA, V102, P10557, DOI 10.1073/pnas.0409137102; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Marion E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000731; Marsollier L, 2005, CELL MICROBIOL, V7, P935, DOI 10.1111/j.1462-5822.2005.00521.x; Marsollier L, 2004, APPL ENVIRON MICROB, V70, P1097, DOI 10.1128/AEM.70.2.1097-1103.2004; Marsollier L, 2002, APPL ENVIRON MICROB, V68, P4623, DOI 10.1128/AEM.68.9.4623-4628.2002; Marsollier L, 2007, CELL MICROBIOL, V9, P347, DOI 10.1111/j.1462-5822.2006.00790.x; Menashe O, 2008, ANTIMICROB AGENTS CH, V52, P920, DOI 10.1128/AAC.00382-07; Merritt RW, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000911; Miltner EC, 2000, ANTIMICROB AGENTS CH, V44, P1990, DOI 10.1128/AAC.44.7.1990-1994.2000; Mosi L, 2008, APPL ENVIRON MICROB, V74, P7036, DOI 10.1128/AEM.01234-08; PAGE FC, 1976, ILLUSTRATED KEY FRES; Pagnier I, 2008, ENVIRON MICROBIOL, V10, P1135, DOI 10.1111/j.1462-2920.2007.01530.x; PORTAELS F, 1995, CLIN DERMATOL, V13, P207, DOI 10.1016/0738-081X(95)00004-Y; Portaels F, 1996, J CLIN MICROBIOL, V34, P962; PORTAELS F, 1988, J GEN MICROBIOL, V134, P849; Portaels F, 2001, REV SCI TECH OIE, V20, P252, DOI 10.20506/rst.20.1.1270; Portaels F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000178; R Development Core Team, 2009, R LANG ENV STAT COMP; Salah IB, 2009, CLIN MICROBIOL INFEC, V15, P894, DOI 10.1111/j.1469-0691.2009.03011.x; Schinsky MF, 2000, INT J SYST EVOL MICR, V50, P575, DOI 10.1099/00207713-50-2-575; Schroeder JM, 2001, J CLIN MICROBIOL, V39, P1903, DOI 10.1128/JCM.39.5.1903-1911.2001; Silva MT, 2009, LANCET INFECT DIS, V9, P699, DOI 10.1016/S1473-3099(09)70234-8; SILVA MT, 1984, J GEN MICROBIOL, V130, P369; SILVA MT, 1990, TROP MED PARASITOL, V41, P339; Singh RD, 2000, MOL CELL BIOCHEM, V215, P39, DOI 10.1023/A:1026545630773; Steinert M, 1998, APPL ENVIRON MICROB, V64, P2256; Stinear TP, 2007, GENOME RES, V17, P192, DOI 10.1101/gr.5942807; Strahl ED, 2001, APPL ENVIRON MICROB, V67, P4432, DOI 10.1128/AEM.67.10.4432-4439.2001; Stuart AE, 1977, J CLIN PATHOL, V30, P592; Thomas V, 2007, LETT APPL MICROBIOL, V45, P349, DOI 10.1111/j.1472-765X.2007.02206.x; Thomas V, 2004, J APPL MICROBIOL, V97, P950, DOI 10.1111/j.1365-2672.2004.02391.x; Torrado E, 2007, INFECT IMMUN, V75, P977, DOI 10.1128/IAI.00889-06; van Ingen J, 2012, INFECT GENET EVOL, V12, P832, DOI 10.1016/j.meegid.2011.10.006; Vandelannoote K, 2010, FEMS MICROBIOL LETT, V304, P191, DOI 10.1111/j.1574-6968.2010.01902.x; Wallace RJ, 2004, J CLIN MICROBIOL, V42, P5689, DOI 10.1128/JCM.42.12.5689-5697.2004; WHO World Health Organization, BUR ULC NUMB NEW CAS; Wilson M, 2011, J PETROL, V52, P1, DOI 10.1093/petrology/egq092; Yip MJ, 2007, J BACTERIOL, V189, P2021, DOI 10.1128/JB.01442-06	63	24	24	3	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	AUG	2012	6	8							e1764	10.1371/journal.pntd.0001764				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	001YS	WOS:000308497100011	22880141	DOAJ Gold, Green Published			2019-03-26	
J	Conlan, JV; Vongxay, K; Khamlome, B; Dorny, P; Sripa, B; Elliot, A; Blacksell, SD; Fenwick, S; Thompson, RCA				Conlan, James V.; Vongxay, Khamphouth; Khamlome, Boualam; Dorny, Pierre; Sripa, Banchob; Elliot, Aileen; Blacksell, Stuart D.; Fenwick, Stanley; Thompson, R. C. Andrew			A Cross-Sectional Study of Taenia solium in a Multiple Taeniid-Endemic Region Reveals Competition May be Protective	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							LAO PDR; SOUTHEAST-ASIA; SAGINATA CYSTICERCOSIS; INTESTINAL PARASITE; HELMINTH INFECTIONS; NORTH VIETNAM; EPIDEMIOLOGY; PREVALENCE; HEALTH; ECHINOCOCCOSIS	We conducted cross-sectional surveys for taeniasis and cysticercosis in humans, pigs, and dogs in four northern provinces of Laos. Human cysticercosis and taeniasis prevalence was 2.2% (95% confidence interval [CI] = 1.4-3.0%) and 8.4% (95% CI = 6.9-9.9%), respectively. Eating uncooked beef, being male, province of residence, age, and ethnicity were significant risk factors for taeniasis and only province of residence was a significant risk factor for cystiercosis. Thirty-five human tapeworms were recovered during the survey and 33 (94.3%) and 2 (5.7%) were identified as Taenia saginata and T. solium, respectively. Maximum-likelihood adjusted prevalence of T solium and T. hydatigena in pigs was 4.2% (95% CI = 0.5-7.9%) and 55.9% (95% CI = 47.5-64.3%), respectively, and T hydatigena taeniasis in dogs was 4.8% (95% CI = 0.0-11.3%). Taenia hydatigena and T saginata were the most prevalent taeniids in the respective pig and human populations and together may suppress T solium transmission.	[Conlan, James V.; Elliot, Aileen; Fenwick, Stanley; Thompson, R. C. Andrew] Murdoch Univ, Sch Vet & Biomed Sci, Murdoch, WA 6150, Australia; [Vongxay, Khamphouth] Minist Agr & Forestry, Dept Livestock & Fisheries, Natl Anim Hlth Ctr, Viangchan, Laos; [Khamlome, Boualam] Minist Hlth, Dept Hyg & Prevent, Viangchan, Laos; [Dorny, Pierre] Inst Trop Med, B-2000 Antwerp, Belgium; [Sripa, Banchob] Khon Kaen Univ, Fac Med, Dept Pathol, Trop Dis Res Lab,Div Expt Pathol, Khon Kaen 40002, Thailand; [Blacksell, Stuart D.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England	Conlan, JV (reprint author), Food Stand Australia New Zealand, 55 Blackall St, Barton, ACT 2600, Australia.	james.conlan@foodstandards.gov.au; kamputvongxay@yahoo.com; drboualam2004@yahoo.com.au; pdorny@itg.be; banchob@kku.ac.th; a.elliot@murdoch.edu.au; stuart@tropmeclres.ac; stanley_fenwick@dai.com; a.thompson@murdoch.edu.au	blacksell, stuart/D-5530-2018	blacksell, stuart/0000-0001-6576-726X	Australian Centre for International Agricultural Research [AH2006/161]; Murdoch University	This study was supported by the Australian Centre for International Agricultural Research (project no. AH2006/161). James V. Conlan was supported by a Murdoch University Research Studentship award.	Allan JC, 2003, ACTA TROP, V87, P87, DOI 10.1016/S0001-706X(03)00059-7; Allan JC, 1996, AM J TROP MED HYG, V54, P352, DOI 10.4269/ajtmh.1996.54.352; Anantaphruti MT, 2007, EMERG INFECT DIS, V13, P1413, DOI 10.3201/eid1309.061148; Boa ME, 2002, VET PARASITOL, V106, P155, DOI 10.1016/S0304-4017(02)00037-7; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Chai JY, 2009, KOREAN J PARASITOL, V47, P243, DOI 10.3347/kjp.2009.47.3.243; Chai Jong-Yil, 1998, Korean Journal of Parasitology, V36, P55; Chen YD, 2004, SE ASIAN J TROP MED, V35, P231; Conlan J, 2008, PARASITOL INT, V57, P252, DOI 10.1016/j.parint.2008.04.002; Conlan JV, 2009, TRENDS PARASITOL, V25, P398, DOI 10.1016/j.pt.2009.06.005; Deckers N, 2010, TRENDS PARASITOL, V26, P137, DOI 10.1016/j.pt.2009.12.008; DEPLAZES P, 1990, VET PARASITOL, V36, P91, DOI 10.1016/0304-4017(90)90097-U; Dorny P, 2004, TRENDS PARASITOL, V20, P259, DOI 10.1016/j.pt.2004.04.001; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Dorny P, 2002, VET PARASITOL, V104, P211, DOI 10.1016/S0304-4017(01)00634-3; Dorny P, 2000, VET PARASITOL, V88, P43, DOI 10.1016/S0304-4017(99)00196-X; Eom KS, 2009, KOREAN J PARASITOL, V47, pS115, DOI 10.3347/kjp.2009.47.S.S115; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Erlanger TE, 2008, INT J ENVIRON HEAL R, V18, P223, DOI 10.1080/09603120701757815; Flisser A, 2006, PARASITOL INT, V55, pS117, DOI 10.1016/j.parint.2005.11.018; Flisser A, 2005, AM J TROP MED HYG, V72, P510, DOI 10.4269/ajtmh.2005.72.510; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; GarciaNoval J, 1996, AM J TROP MED HYG, V55, P282, DOI 10.4269/ajtmh.1996.55.282; GEMMELL MA, 1987, INT J PARASITOL, V17, P465, DOI 10.1016/0020-7519(87)90122-6; GEMMELL MA, 1987, PARASITOLOGY, V94, P161, DOI 10.1017/S0031182000053543; GIBODA M, 1991, B SOC PATHOL EXOT, V84, P184; Giboda M, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P56; Handali S, 2010, CLIN VACCINE IMMUNOL, V17, P631, DOI 10.1128/CVI.00511-09; Jeri C, 2004, LANCET, V363, P949, DOI 10.1016/S0140-6736(04)15791-7; McManus DP, 2010, ADV PARASIT, V72, P267, DOI 10.1016/S0065-308X(10)72010-8; OIE, 2010, CYST MAN DIAGN TESTS; Pawlowski Zbigniew S., 2002, P1, DOI 10.1079/9780851996288.0001; Phengsavanh P, 2010, TROP ANIM HEALTH PRO, V42, P1627, DOI 10.1007/s11250-010-9612-4; PHOLSENA K, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P137; Rahme E, 1998, J ROY STAT SOC D-STA, V47, P149; Raso G, 2005, TROP MED INT HEALTH, V10, P42, DOI 10.1111/j.1365-3156.2004.01352.x; Rim HJ, 2003, PARASITOL RES, V91, P267, DOI 10.1007/s00436-003-0963-x; Salim L, 2009, AM J TROP MED HYG, V80, P384, DOI 10.4269/ajtmh.2009.80.384; Sanchez AL, 1997, ANN TROP MED PARASIT, V91, P163, DOI 10.1080/00034983.1997.11813126; Sayasone S, 2007, T ROY SOC TROP MED H, V101, P40, DOI 10.1016/j.trstmh.2006.02.018; Sayasone S, 2009, T ROY SOC TROP MED H, V103, P247, DOI 10.1016/j.trstmh.2008.10.011; Sciutto E, 1998, VET PARASITOL, V79, P299, DOI 10.1016/S0304-4017(98)00180-0; Sithithaworn Paiboon, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P1083; Somers R, 2006, TROP MED INT HEALTH, V11, P65, DOI 10.1111/j.1365-3156.2005.01537.x; Somers R, 2007, T ROY SOC TROP MED H, V101, P275, DOI 10.1016/j.trstmh.2006.04.007; Statistical Center of Iran, 2006, POPULATION HOUSING C; Steinmann P, 2007, ACTA TROP, V104, P38, DOI 10.1016/j.actatropica.2007.07.003; Tran Duc Si, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P537; Vannachone Bouakham, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P717; Vongxay K, 2012, VECTOR-BORNE ZOONOT, V12, P861, DOI 10.1089/vbz.2011.0850; Willingham A Lee 3rd, 2003, Southeast Asian J Trop Med Public Health, V34 Suppl 1, P35; Willingham AL, 2010, ADV PARASIT, V72, P235, DOI 10.1016/S0065-308X(10)72009-1; Yamasaki H, 2004, J CLIN MICROBIOL, V42, P548, DOI 10.1128/JCM.42.2.548-553.2004	53	20	20	0	12	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2012	87	2					281	291		10.4269/ajtmh.2012.11-0106				11	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	984QA	WOS:000307204900016	22855759	Green Published, Bronze			2019-03-26	
J	Gundi, VAKB; Kosoy, MY; Makundi, RH; Laudisoit, A				Gundi, Vijay A. K. B.; Kosoy, Michael Y.; Makundi, Rhodes H.; Laudisoit, Anne			Identification of Diverse Bartonella Genotypes among Small Mammals from Democratic Republic of Congo and Tanzania	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							CITRATE SYNTHASE GENE; MOLECULAR-DETECTION; RICKETTSIA-FELIS; SOUTHERN CHINA; B-HENSELAE; SP. NOV.; RODENTS; SPP.; WILD; PREVALENCE	Small mammals from the Democratic Republic (DR) of the Congo and Tanzania were tested to determine the prevalence and genetic diversity of Bartonella species. The presence of Bartonella DNA was assessed in spleen samples of the animals by rpoB- and gltA-polymerase chain reactions (PCRs). By rpoB-PCR, Bartonella was detected in 8 of 59 animals of DR Congo and in 16 of 39 Tanzanian animals. By gltA-PCR, Bartonella was detected in 5 and 15 animals of DR Congo and Tanzania, respectively. The gene sequences from Arvicanthis neumanni were closely related to Bartonella elizabethae. The genotypes from Lophuromys spp. and from Praomys delectorum were close to Bartonella tribocorum. Five genogroups were not genetically related to any known Bartonella species. These results suggest the need to conduct further studies to establish the zoonotic risks linked with those Bartonella species and, in particular, to verify whether these agents might be responsible for human cases of febrile illness of unknown etiology in Africa.	[Kosoy, Michael Y.] Ctr Dis Control & Prevent, Bartonella Lab, Div Vector Borne Dis, Ft Collins, CO 80521 USA; [Makundi, Rhodes H.] Sokoine Univ Agr, Morogoro, Tanzania; [Laudisoit, Anne] Vet & Agrochem Res Ctr, Brussels, Belgium; [Laudisoit, Anne] Univ Antwerp, B-2020 Antwerp, Belgium; [Laudisoit, Anne] Univ Liege, Liege, Belgium	Kosoy, MY (reprint author), Ctr Dis Control & Prevent, Bartonella Lab, Div Vector Borne Dis, 3150 Rampart Rd,Foothills Res Campus, Ft Collins, CO 80521 USA.	mck3@cdc.gov	Laudisoit, Anne/F-2646-2017	Laudisoit, Anne/0000-0001-7626-9426	Centers for Disease and Control and Prevention (CDC); Belgium fund for Scientific Research (FNRS); Belgium fund for Scientific Research (FRIA); University of Antwerp (Belgium); Sokoine University of Agriculture, Morogoro, Tanzania	This research was supported in part by an appointment to the Emerging Infectious Diseases (EID) Fellowship Program administered by the Association of Public Health Laboratories (APHL) and funded by the Centers for Disease and Control and Prevention (CDC). We wish to acknowledge the financial support from the Belgium funds for Scientific Research (FNRS and FRIA), the University of Antwerp (Belgium), the Sokoine University of Agriculture, Morogoro, Tanzania, and the logistical support from the Pest Management Centre that enabled the scientific expedition to the Rift Valley District of Mbulu in northern Tanzania.	Bai Y, 2007, AM J TROP MED HYG, V77, P567, DOI 10.4269/ajtmh.2007.77.567; Birtles RJ, 1996, INT J SYST BACTERIOL, V46, P891, DOI 10.1099/00207713-46-4-891; Birtles RJ, 2001, EPIDEMIOL INFECT, V126, P323, DOI 10.1017/S095026880100526X; Breitschwerdt EB, 2000, CLIN MICROBIOL REV, V13, P428, DOI 10.1128/CMR.13.3.428-438.2000; Castle KT, 2004, AM J TROP MED HYG, V70, P429, DOI 10.4269/ajtmh.2004.70.429; Chang CC, 2000, EMERG INFECT DIS, V6, P306, DOI 10.3201/eid0603.000313; Chomel BB, 2006, EMERG INFECT DIS, V12, P389, DOI 10.3201/eid1203.050931; de Sousa R, 2006, AM J TROP MED HYG, V75, P727, DOI 10.4269/ajtmh.2006.75.727; Ellis BA, 1999, J INFECT DIS, V180, P220, DOI 10.1086/314824; Engbaek K, 2004, APMIS, V112, P336, DOI 10.1111/j.1600-0463.2004.apm1120603.x; FELSENSTEIN J, 1992, GENET RES, V60, P209, DOI 10.1017/S0016672300030962; Fournier PE, 2002, J CLIN MICROBIOL, V40, P3620, DOI 10.1128/JCM.40.10.3620-3624.2002; Gundi VAKB, 2004, EMERG INFECT DIS, V10, P2261; Gundi VAKB, 2004, J CLIN MICROBIOL, V42, P3816, DOI 10.1128/JCM.42.8.3816-3818.2004; Gundi VAKB, 2010, APPL ENVIRON MICROB, V76, P8247, DOI 10.1128/AEM.01180-10; Gundi VAKB, 2009, INT J SYST EVOL MICR, V59, P2956, DOI 10.1099/ijs.0.002865-0; Heller R, 1999, INT J SYST BACTERIOL, V49, P283, DOI 10.1099/00207713-49-1-283; Heller R, 1998, INT J SYST BACTERIOL, V48, P1333, DOI 10.1099/00207713-48-4-1333; Hofmeister EK, 1998, J INFECT DIS, V177, P409, DOI 10.1086/514201; Holmberg M, 2003, EPIDEMIOL INFECT, V130, P149, DOI 10.1017/S0950268802008075; Inoue K, 2008, APPL ENVIRON MICROB, V74, P5086, DOI 10.1128/AEM.00071-08; Jardine C, 2005, VECTOR-BORNE ZOONOT, V5, P402, DOI 10.1089/vbz.2005.5.402; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Knap N, 2007, FEMS IMMUNOL MED MIC, V50, P45, DOI 10.1111/j.1574-695X.2007.00226.x; Koehler J E, 1996, Adv Pediatr Infect Dis, V11, P1; Kordick DL, 1996, INT J SYST BACTERIOL, V46, P704, DOI 10.1099/00207713-46-3-704; Kosoy MY, 1997, AM J TROP MED HYG, V57, P578, DOI 10.4269/ajtmh.1997.57.578; La Scola B, 2003, TRENDS MICROBIOL, V11, P318, DOI 10.1016/S0966-842X(03)00143-4; Marie JL, 2006, AM J TROP MED HYG, V74, P436, DOI 10.4269/ajtmh.2006.74.436; Marquez FJ, 2008, VECTOR-BORNE ZOONOT, V8, P695, DOI 10.1089/vbz.2007.0257; Mogollon-Pasapera E, 2009, INT J INFECT DIS, V13, P3, DOI 10.1016/j.ijid.2008.04.002; NORMAN AF, 1995, J CLIN MICROBIOL, V33, P1797; Pretorius AM, 2004, INT J SYST EVOL MICR, V54, P1959, DOI 10.1099/ijs.0.03033-0; Renesto P, 2001, J CLIN MICROBIOL, V39, P430, DOI 10.1128/JCM.39.2.430-437.2001; Sackal C, 2008, EMERG INFECT DIS, V14, P1972, DOI 10.3201/eid1412.080610; SAITOU N, 1987, MOL BIOL EVOL, V4, P406; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Tea A, 2004, EMERG INFECT DIS, V10, P963, DOI 10.3201/eid1005.030430; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Welc-Faleciak R, 2008, VECTOR-BORNE ZOONOT, V8, P467, DOI 10.1089/vbz.2007.0217; Ying B, 2002, AM J TROP MED HYG, V66, P622, DOI 10.4269/ajtmh.2002.66.622	41	14	15	0	7	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2012	87	2					319	326		10.4269/ajtmh.2012.11-0555				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	984QA	WOS:000307204900022	22855765	Bronze, Green Published			2019-03-26	
J	Devleesschauwer, B; Aryal, A; Joshi, DD; Rijal, S; Sherchand, JB; Praet, N; Speybroeck, N; Duchateau, L; Vercruysse, J; Dorny, P				Devleesschauwer, Brecht; Aryal, Arjun; Joshi, Durga Datt; Rijal, Suman; Sherchand, Jeevan Bahadur; Praet, Nicolas; Speybroeck, Niko; Duchateau, Luc; Vercruysse, Jozef; Dorny, Pierre			Epidemiology of Taenia solium in Nepal: is it influenced by the social characteristics of the population and the presence of Taenia asiatica?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						epidemiology; Nepal; social composition; Taenia asiatica; Taenia solium; epidemiologie; Nepal; composition sociale; Taenia asiatica; Taenia solium; epidemiologia; Nepal; composicion social; Taenia asiatica; Taenia solium	TRANSMISSION DYNAMICS; NORTH VIETNAM; CYSTICERCOSIS	The transmission of the zoonotic pork tapeworms Taenia solium and T.similar to asiatica depends on a combination of specific risk factors, such as open defecation, backyard pig raising and the consumption of raw or undercooked pork and viscera. A community-based survey was conducted among 289 households in southeastern Nepal to study the heterogeneity of these risk factor frequencies as a function of the social composition of the population. The frequency of open defecation, backyard pig raising and pork consumption differed significantly (P < 0.005) among the different coexisting caste and ethnic groups. In the same survey, the taeniosis prevalence was examined among the different groups. Tapeworm carriers were identified at a high prevalence among the Dum, one of the most disadvantaged communities of Nepal. A PCR-RFLP assay revealed that all collected tapeworm specimens were T.similar to asiatica, a species thus far not known to occur in South Asia. These results can help to understand the epidemiology of T.similar to solium in Nepal, which appears to be more complex than thought so far.	[Devleesschauwer, Brecht; Vercruysse, Jozef; Dorny, Pierre] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, B-9820 Merelbeke, Belgium; [Devleesschauwer, Brecht; Speybroeck, Niko] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium; [Aryal, Arjun] Cent Vet Hosp, Kathmandu, Nepal; [Joshi, Durga Datt] Natl Zoonoses & Food Hyg Res Ctr, Kathmandu, Nepal; [Rijal, Suman] BP Koirala Inst Hlth Sci, Dept Internal Med, Dharan, Nepal; [Sherchand, Jeevan Bahadur] Tribhuvan Univ, Inst Med, Dept Clin Microbiol & Hlth Res Lab, Kathmandu, Nepal; [Praet, Nicolas; Dorny, Pierre] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Duchateau, Luc] Univ Ghent, Dept Comparat Physiol & Biometr, Fac Vet Med, B-9820 Merelbeke, Belgium	Devleesschauwer, B (reprint author), Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Salisburylaan 133, B-9820 Merelbeke, Belgium.	brecht.devleesschauwer@ugent.be	Devleesschauwer, Brecht/A-5301-2013; Devleesschauwer, Brecht/G-9895-2018	Devleesschauwer, Brecht/0000-0002-2867-6892	Flemish Interuniversity Council, Belgium	We are very grateful to the people of Mrigauliya and adjacent areas for their willingness to participate in our study. We would like to thank Mr Tej Raj Karki, Mr Keshab Karki and Mrs Bimala Poudel for their technical assistance in the field, and Mr Bjorn Victor and Ms Inne Pauwels of the Institute of Tropical Medicine for performing the molecular analyses. This study was supported by the Flemish Interuniversity Council, Belgium.	Carabin H, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000555; Conlan JV, 2009, TRENDS PARASITOL, V25, P398, DOI 10.1016/j.pt.2009.06.005; Dorny P, 2009, VET PARASITOL, V163, P196, DOI 10.1016/j.vetpar.2009.05.026; Eom KS, 2009, KOREAN J PARASITOL, V47, pS115, DOI 10.3347/kjp.2009.47.S.S115; Joshi DD, 2004, SE ASIAN J TROPIC S1, V34, pS252; Morales J, 2006, ANN TROP MED PARASIT, V100, P123, DOI 10.1179/136485906x86275; Pandey TR, 2005, OCCASIONAL PAPERS SO, V9, P63; Somers R, 2006, TROP MED INT HEALTH, V11, P65, DOI 10.1111/j.1365-3156.2005.01537.x; Somers R, 2007, T ROY SOC TROP MED H, V101, P275, DOI 10.1016/j.trstmh.2006.04.007	9	17	17	0	18	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2012	17	8					1019	1022		10.1111/j.1365-3156.2012.03017.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	981GT	WOS:000306955700025	22643112	Bronze			2019-03-26	
J	Li, S; Heyman, P; Cochez, C; Simons, L; Vanwambeke, SO				Li, Sen; Heyman, Paul; Cochez, Christel; Simons, Leopold; Vanwambeke, Sophie O.			A multi-level analysis of the relationship between environmental factors and questing Ixodes ricinus dynamics in Belgium	PARASITES & VECTORS			English	Article						Ixodes ricinus; Spatio-temporal dynamics; Multi-level analysis; Environment; Belgium	BURGDORFERI SENSU-LATO; CLIMATE-BASED MODEL; LYME-DISEASE RISK; UNITED-STATES; POPULATION-DYNAMICS; SATURATION DEFICIT; DEER; LANDSCAPE; ABUNDANCE; SCAPULARIS	Background: Ticks are the most important pathogen vectors in Europe. They are known to be influenced by environmental factors, but these links are usually studied at specific temporal or spatial scales. Focusing on Ixodes ricinus in Belgium, we attempt to bridge the gap between current "single-sided" studies that focus on temporal or spatial variation only. Here, spatial and temporal patterns of ticks are modelled together. Methods: A multi-level analysis of the Ixodes ricinus patterns in Belgium was performed. Joint effects of weather, habitat quality and hunting on field sampled tick abundance were examined at two levels, namely, sampling level, which is associated with temporal dynamics, and site level, which is related to spatial dynamics. Independent variables were collected from standard weather station records, game management data and remote sensing-based land cover data. Results: At sampling level, only a marginally significant effect of daily relative humidity and temperature on the abundance of questing nymphs was identified. Average wind speed of seven days prior to the sampling day was found important to both questing nymphs and adults. At site level, a group of landscape-level forest fragmentation indices were highlighted for both questing nymph and adult abundance, including the nearest-neighbour distance, the shape and the aggregation level of forest patches. No cross-level effects or spatial autocorrelation were found. Conclusions: Nymphal and adult ticks responded differently to environmental variables at different spatial and temporal scales. Our results can advise spatio-temporal extents of environment data collection for continuing empirical investigations and potential parameters for biological tick models.	[Li, Sen; Vanwambeke, Sophie O.] Catholic Univ Louvain, Earth & Life Inst, Georges Lemaitre Ctr Earth & Climate Res, B-1348 Louvain, Belgium; [Heyman, Paul; Cochez, Christel; Simons, Leopold] Queen Astrid Mil Hosp, Res Lab Vector Borne Dis, B-1120 Brussels, Belgium	Li, S (reprint author), Catholic Univ Louvain, Earth & Life Inst, Georges Lemaitre Ctr Earth & Climate Res, B-1348 Louvain, Belgium.	sen.li@uclouvain.be		Vanwambeke, Sophie/0000-0001-6620-6173; Li, Sen/0000-0002-1177-7339			Allan BF, 2003, CONSERV BIOL, V17, P267, DOI 10.1046/j.1523-1739.2003.01260.x; Bacon Rendi Murphree, 2008, Morbidity and Mortality Weekly Report, V57, P1; Beck DL, 2011, J VECTOR ECOL, V36, P135, DOI 10.1111/j.1948-7134.2011.00150.x; Brownstein JS, 2003, ENVIRON HEALTH PERSP, V111, P1152, DOI 10.1289/ehp.6052; Clarke P, 2008, J EPIDEMIOL COMMUN H, V62, P752, DOI 10.1136/jech.2007.060798; Daniel M, 2003, EUR J CLIN MICROBIOL, V22, P327, DOI 10.1007/s10096-003-0918-2; DEARDORFF JW, 1978, J GEOPHYS RES-OCEANS, V83, P1889, DOI 10.1029/JC083iC04p01889; Despommier D, 2006, ECOHEALTH, V3, P281, DOI 10.1007/s10393-006-0063-3; Diuk-Wasser MA, 2010, GLOBAL ECOL BIOGEOGR, V19, P504, DOI 10.1111/j.1466-8238.2010.00526.x; Estrada-Pena A, 2003, ECOGRAPHY, V26, P661, DOI 10.1034/j.1600-0587.2003.03530.x; Estrada-Pena A, 2002, EXP APPL ACAROL, V28, P239, DOI 10.1023/A:1025362903620; Fournier DA, 2011, OPTIM METHOD SOFTW, V27, P1; GARCIA RICHARD, 1962, ANN ENTOMOL SOC AMER, V55, P605; Gilbert L, 2012, ECOL APPL, V22, P658, DOI 10.1890/11-0458.1; Guerra M, 2002, EMERG INFECT DIS, V8, P289, DOI 10.3201/eid0803.010166; Herrmann C, 2010, J MED ENTOMOL, V47, P1196, DOI 10.1603/ME10111; Heyman P, 2003, J INFECTION, V47, P129, DOI 10.1016/S0163-4453(03)00056-2; Hillyard PD, 1996, TICKS N W EUROPE; Hoch T, 2010, ECOL MODEL, V221, P1798, DOI 10.1016/j.ecolmodel.2010.04.008; Hubalek Z, 2003, J VECTOR ECOL, V28, P159; Jensen ME, 1990, EVAPOTRANSPIRATION I; Johnson JB, 2004, TRENDS ECOL EVOL, V19, P101, DOI 10.1016/j.tree.2003.10.013; Jouda F, 2004, VECTOR-BORNE ZOONOT, V4, P23, DOI 10.1089/153036604773082960; KIKKAWA J, 1964, J ANIM ECOL, V33, P259, DOI 10.2307/2631; Killilea ME, 2008, ECOHEALTH, V5, P167, DOI 10.1007/s10393-008-0171-3; Kozakiewicz M, 2007, ACTA THERIOL, V52, P339, DOI 10.1007/BF03194231; Kurtenbach K, 2006, NAT REV MICROBIOL, V4, P660, DOI 10.1038/nrmicro1475; Lambin EF, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-54; LEES AD, 1948, J EXP BIOL, V25, P145; Linard C, 2007, INT J HEALTH GEOGR, V6, DOI 10.1186/1476-072X-6-15; Moser D, 2002, LANDSCAPE ECOL, V17, P657, DOI 10.1023/A:1021513729205; Ostfeld RS, 2006, PLOS BIOL, V4, P1058, DOI 10.1371/journal.pbio.0040145; Perkins SE, 2006, ECOLOGY, V87, P1981, DOI 10.1890/0012-9658(2006)87[1981:LDALTT]2.0.CO;2; Perret JL, 2003, J EXP BIOL, V206, P1809, DOI 10.1242/jeb.00345; Putman R., 1988, NATURAL HIST DEER; Ruiz-Fons F, 2010, INT J PARASITOL, V40, P1013, DOI 10.1016/j.ijpara.2010.02.006; SELLERS PJ, 1986, J ATMOS SCI, V43, P505, DOI 10.1175/1520-0469(1986)043<0505:ASBMFU>2.0.CO;2; Tack W, 2012, FOREST ECOL MANAG, V265, P30, DOI 10.1016/j.foreco.2011.10.028; Tagliapietra V, 2011, VET PARASITOL, V183, P114, DOI 10.1016/j.vetpar.2011.07.022; Theall KP, 2011, J EPIDEMIOL COMMUN H, V65, P688, DOI 10.1136/jech.2009.097956; Vanwambeke Sophie O, 2006, Int J Health Geogr, V5, P5, DOI 10.1186/1476-072X-5-5; Wagenmakers EJ, 2004, PSYCHON B REV, V11, P192, DOI 10.3758/BF03206482; Watts EJ, 2009, PARASITOLOGY, V136, P1221, DOI 10.1017/S0031182009990424	43	22	24	1	44	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	JUL 25	2012	5								149	10.1186/1756-3305-5-149				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	993DT	WOS:000307836700001	22830528	DOAJ Gold, Green Published			2019-03-26	
J	Muhindo, HM; Ilombe, G; Meya, R; Mitashi, PM; Kutekemeni, A; Gasigwa, D; Lutumba, P; Van Geertruyden, JP				Muhindo, Hypolite Mavoko; Ilombe, Gillon; Meya, Ruth; Mitashi, Patrick M.; Kutekemeni, Albert; Gasigwa, Didier; Lutumba, Pascal; Van Geertruyden, Jean-Pierre			Accuracy of malaria rapid diagnosis test Optimal-IT (R) in Kinshasa, the Democratic Republic of Congo	MALARIA JOURNAL			English	Article						Rapid Diagnostic Test; Malaria; Optimal-IT (R); Paracheck-Pf (R); Democratic Republic of Congo	PLASMODIUM-FALCIPARUM MALARIA; LACTATE-DEHYDROGENASE; CASE-MANAGEMENT; MICROSCOPY; PERFORMANCE; KENYA; AFRICA; UGANDA	Background: Despite some problems related to accuracy and applicability, malaria rapid diagnostic tests (RDTs), are currently considered the best option in areas with limited laboratory services for improving case management and reducing over-treatment. However, their performance must be established taking into the account the particularities of each endemic area. In the Democratic Republic of Congo, the validity of Optimal-IT (R) and Paracheck-Pf (R), respectively based on the detection of lactate dehydrogenase and histidine-rich protein-2, was assessed at primary health care level (PHC). Methods: This was a two-stage cluster randomized survey, conducted in one health centre in 12 health zones in Kinshasa city. All patients with malaria presumptive diagnosis were eligible. Gold standard was microscopy performed by experts from the parasitology unit, Kinshasa University. Results: 624 patients were enrolled. 53.4% (95% CI: 49.4-57.3) owed a bed net, obtained in 74.5% of cases (95% CI: 69.4-79.1) through community-based distribution by the National Malaria Control Programme. Microscopy expert reading confirmed 123 malaria cases (19.7%; 95% CI: 16.7-23.1). Overall sensitivity were 79.7% (95% CI: 72.4-86.8), 87.8% (95% CI: 81.9-93.6) and 86.2% (95% CI: 79.9-92.3), respectively, for Optimal-IT (R), Paracheck-Pf (R) and microscopy performed at PHC. Specificity was 97.0% (95% CI: 95.5-98.5), 91.6% (95% CI: 89.1-94.0) and 49.1% (95% CI: 44.7-53.4). The proportion of confirmed cases seemed similar in under-fives compared to others. Any treatment prior to the current visit was a predictor for malaria (AOR: 2.3; 95% CI: 1.5-3.5), but not malaria treatment (AOR: 0.87; 95% CI: 0.4-1.8). Bed net ownership tended to protect against malaria (AOR: 0.67; 95% CI: 0.45-0.99). Conclusion: Although microscopy is considered as the "gold standard" for malaria diagnosis at point of care level, this study showed that its accuracy may not always be satisfactory when performed in health centres.	[Muhindo, Hypolite Mavoko; Ilombe, Gillon; Meya, Ruth; Mitashi, Patrick M.; Lutumba, Pascal] Univ Kinshasa, Dept Trop Med, Kin Xi, Zaire; [Kutekemeni, Albert; Gasigwa, Didier] Minist Sante Publ, Programme Natl Lutte Paludisme, Kinshasa, Zaire; [Van Geertruyden, Jean-Pierre] Univ Antwerp, Dept Epidemiol, Int Hlth Unit, B-2610 Antwerp, Belgium	Muhindo, HM (reprint author), Univ Kinshasa, Dept Trop Med, BP 747, Kin Xi, Zaire.	mavoko@yahoo.com	Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364	VLIR-UOS [ZRDC2008MP053]	This study was funded by VLIR-UOS through project number ZRDC2008MP053, which aimed to create a clinical research unit and the capacity building at the Tropical Medicine Deparment, Kinshasa University. We thank all key persons for that project: Marleen Boelaert, Odio Wobin and Marc Van Sprundel. We thank the study participants and the staff of involved health centres. Many thanks to the study team: Jean Lokombe, Ernest Makengo, Rodin Mukele, Bolive Liandja, Nancy Mwema, Aurelie Tshambu, Bulere Kavughe, Jean-Claude Fwankenda, Bibiche Ekoko, Benjamin Banjanga, Laurent nzengu and Simon Mukandila. We would like to aknowledge the contribution of Halidou Tinto and Flory Muanda to the conception of the idea.	[Anonymous], 2009, WORLD MAL REP 2009; Ansah EK, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c930; Ashley EA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-241; Atieli HE, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-113; BELL D, 2006, NAT REV MICROBIOL S, V4, pS7, DOI DOI 10.1038/NRMICO1525; COENE J, 1993, MED VET ENTOMOL, V7, P127, DOI 10.1111/j.1365-2915.1993.tb00665.x; de Macedo OA, 2010, MALARIA J, V9, P222; de Oliveira AM, 2009, AM J TROP MED HYG, V80, P470, DOI 10.4269/ajtmh.2009.80.470; Haditsch M, 2004, Travel Med Infect Dis, V2, P149, DOI 10.1016/j.tmaid.2004.03.001; Hamer DH, 2007, JAMA-J AM MED ASSOC, V297, P2227, DOI 10.1001/jama.297.20.2227; Hance P, 2005, Med Trop (Mars), V65, P389; Kiggundu M, 2011, AM J TROP MED HYG, V84, P820, DOI 10.4269/ajtmh.2011.10-0597; Kyabayinze DJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-221; Mayxay M, 2001, T ROY SOC TROP MED H, V95, P179, DOI 10.1016/S0035-9203(01)90156-7; McKenzie FE, 2003, AM J TROP MED HYG, V69, P372, DOI 10.4269/ajtmh.2003.69.372; Moody A, 2000, BRIT J HAEMATOL, V109, P891, DOI 10.1046/j.1365-2141.2000.01974.x; Mukadi P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-308; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Ndjinga JK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-279; Oduola AMJ, 1997, EXP PARASITOL, V87, P283, DOI 10.1006/expr.1997.4251; PAYNE D, 1988, B WORLD HEALTH ORGAN, V66, P621; Piper R, 1999, AM J TROP MED HYG, V60, P109, DOI 10.4269/ajtmh.1999.60.109; Rafael Maria E, 2006, Nature, V444 Suppl 1, P39, DOI 10.1038/nature05445; Rosenthal PJ, 2012, AM J TROP MED HYG, V86, P192, DOI 10.4269/ajtmh.2012.11-0619; Shillcutt S, 2008, B WORLD HEALTH ORGAN, V86, P101, DOI 10.2471/BLT.07.042259; Singh N, 2002, AM J TROP MED HYG, V66, P314, DOI 10.4269/ajtmh.2002.66.314; Swarthout TD, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-58; Tarimo DS, 2001, ANN TROP MED PARASIT, V95, P437, DOI 10.1080/13648590120068971; Tjitra Emiliana, 2001, American Journal of Tropical Medicine and Hygiene, V65, P593; Valea I, 2009, TROP MED INT HEALTH, V14, P338, DOI 10.1111/j.1365-3156.2009.02228.x; White N. J., 1999, Parassitologia (Rome), V41, P301; *WHO, 1991, BAS MAL MICR 1; WHO, 2000, NEW PERSP MAL DIAGN; *WHO, 2003, MAL RAP DIAGN MAK IT; World Health Organization, 2006, ROL LAB DIAGN SUPP M, P1; World Health Organization, 2011, MAL RAP DIAGN TEST P; World Health Organization, 2009, MAL MICR QUAL ASS MA; World Health Organization, 2010, GUID TREATM MAL; World Health Organization, 1991, BAS MAL MICR 2; Zurovac D, 2006, TROP MED INT HEALTH, V11, P432, DOI 10.1111/j.1365-3156.2006.01587.x	40	12	13	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JUL 6	2012	11								224	10.1186/1475-2875-11-224				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	019LL	WOS:000309741000001	22770130	DOAJ Gold, Green Published			2019-03-26	
J	Odiwuor, S; Muia, A; Magiri, C; Maes, I; Kirigi, G; Dujardin, JC; Wasunna, M; Mbuchi, M; Van der Auwera, G				Odiwuor, Samwel; Muia, Alfred; Magiri, Charles; Maes, Ilse; Kirigi, George; Dujardin, Jean-Claude; Wasunna, Monique; Mbuchi, Margaret; Van der Auwera, Gert			Identification of Leishmania tropica from micro-foci of cutaneous leishmaniasis in the Kenyan Rift Valley	PATHOGENS AND GLOBAL HEALTH			English	Article						Diagnosis; Kenya; Leishmania tropica; PCR; Molecular typing	PHLEBOTOMUS-GUGGISBERGI; VISCERAL LEISHMANIASIS; DONOVANI; DISTRICT; VECTOR; PCR	We performed diagnosis and species identification of parasites in lesion samples from suspected cutaneous leishmaniasis patients in four villages, three of which are in a known Leishmania tropica endemic region in Kenya. Samples were analyzed both by microscopy and PCR for Leishmania, and typed by an assay using four ribosomal DNA-based species-identification PCRs. The lesions were demonstrated to be caused by L. tropica, which confirms the re-emergence of cutaneous leishmaniasis from this species after a period of reduced incidence in the endemic zone. Our report highlights the importance of an intervention and sustained Leishmania control program.	[Odiwuor, Samwel; Maes, Ilse; Dujardin, Jean-Claude; Van der Auwera, Gert] Inst Trop Med Antwerp, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Odiwuor, Samwel; Muia, Alfred; Magiri, Charles; Kirigi, George; Wasunna, Monique; Mbuchi, Margaret] Kenya Govt Med Res Ctr, Clin Res Ctr, Nairobi, Kenya; [Odiwuor, Samwel; Dujardin, Jean-Claude] Univ Antwerp, Dept Biomed Sci, Antwerp, Belgium	Van der Auwera, G (reprint author), Inst Trop Med, Dept Biomed Sci, Natl Str 155, B-2000 Antwerp, Belgium.	gvdauwera@itg.be			European Union [INCO-CT-2005-015379]; Belgian Directorate General for Development Cooperation (DGDC); Institute of Tropical Medicine Antwerp; TRYLEIDIAG; DGDC	We thank Simonne De Doncker for technical assistance. The study was supported by funds from the European Union's sixth Framework Program INCO-CT-2005-015379 (TRYLEIDIAG project) and the Belgian Directorate General for Development Cooperation (DGDC) through the third framework agreement with the Institute of Tropical Medicine Antwerp. TRYLEIDIAG funded the research while DGDC provided salary (GVDA) and scholarship (SO) support.	Basiye FL, 2011, DIAGN MICR INFEC DIS, V69, P66, DOI 10.1016/j.diagmicrobio.2010.08.018; BOOM R, 1990, J CLIN MICROBIOL, V28, P495; CHULAY JD, 1983, T ROY SOC TROP MED H, V77, P717, DOI 10.1016/0035-9203(83)90213-4; Deborggraeve S, 2008, TROP MED INT HEALTH, V13, P1378, DOI 10.1111/j.1365-3156.2008.02154.x; Elamin EM, 2005, T ROY SOC TROP MED H, V99, P803, DOI 10.1016/j.trstmh.2005.04.009; Jafari S., 2010, Eastern Mediterranean Health Journal, V16, P340; JOHNSON RN, 1993, MED VET ENTOMOL, V7, P216, DOI 10.1111/j.1365-2915.1993.tb00679.x; Khandelwal K, 2011, AM J TROP MED HYG, V85, P64, DOI 10.4269/ajtmh.2011.10-0649; Kolaczinski JH, 2008, INT J EPIDEMIOL, V37, P344, DOI 10.1093/ije/dym275; LAWYER PG, 1991, AM J TROP MED HYG, V44, P290, DOI 10.4269/ajtmh.1991.44.290; Massamba NN, 1998, ACTA TROP, V71, P293, DOI 10.1016/S0001-706X(98)00071-0; MEBRAHTU Y, 1988, AM J TROP MED HYG, V39, P267, DOI 10.4269/ajtmh.1988.39.267; MEBRAHTU Y, 1987, T ROY SOC TROP MED H, V81, P923, DOI 10.1016/0035-9203(87)90352-X; MEBRAHTU YB, 1993, T ROY SOC TROP MED H, V87, P598, DOI 10.1016/0035-9203(93)90101-U; MEBRAHTU YB, 1992, AM J TROP MED HYG, V47, P852, DOI 10.4269/ajtmh.1992.47.852; MEBRAHTU YB, 1992, T ROY SOC TROP MED H, V86, P381, DOI 10.1016/0035-9203(92)90230-A; Odiwuor SOC, 2011, EUR J CLIN MICROBIOL, V30, P209, DOI 10.1007/s10096-010-1071-3; PERKINS PV, 1988, T ROY SOC TROP MED H, V82, P695, DOI 10.1016/0035-9203(88)90204-0; SANG DK, 1993, T ROY SOC TROP MED H, V87, P629, DOI 10.1016/0035-9203(93)90265-R; SANG DK, 1994, T ROY SOC TROP MED H, V88, P35, DOI 10.1016/0035-9203(94)90486-3; SANG DK, 1993, ANN TROP MED PARASIT, V87, P349, DOI 10.1080/00034983.1993.11812778; Soni P, 2011, INDIAN J DERMATOL VE, V77, DOI 10.4103/0378-6323.77484; Tonui Willy Kiprotich, 2006, Afr J Health Sci, V13, P7	23	7	7	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2047-7724	2047-7732		PATHOG GLOB HEALTH	Pathog. Glob. Health	JUL	2012	106	3					159	165		10.1179/2047773212Y.0000000015				7	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	011MV	WOS:000309170000009	23265373	Green Published			2019-03-26	
J	Moens, B; Decanine, D; Menezes, SM; Khouri, R; Silva-Santos, G; Lopez, G; Alvarez, C; Talledo, M; Gotuzzo, E; Kruschewsky, RD; Galvao-Castro, B; Vandamme, AM; Van Weyenbergh, J				Moens, Britta; Decanine, Daniele; Menezes, Soraya Maria; Khouri, Ricardo; Silva-Santos, Gilvaneia; Lopez, Giovanni; Alvarez, Carolina; Talledo, Michael; Gotuzzo, Eduardo; Kruschewsky, Ramon de Almeida; Galvao-Castro, Bernardo; Vandamme, Anne-Mieke; Van Weyenbergh, Johan			Ascorbic Acid Has Superior Ex Vivo Antiproliferative, Cell Death-Inducing and Immunomodulatory Effects over IFN-alpha in HTLV-1-Associated Myelopathy	PLOS NEGLECTED TROPICAL DISEASES			English	Article							I-ASSOCIATED MYELOPATHY; SPASTIC PARAPARESIS HAM/TSP; LEUKEMIA-VIRUS TYPE-1; CD4(+) T-CELLS; HTLV-I; CEREBROSPINAL-FLUID; PROVIRAL LOAD; DIETARY ANTIOXIDANTS; NEUROLOGICAL-DISEASE; IMMUNE-RESPONSE	Background: Clear therapeutic guidelines for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) are missing due to the lack of randomized double-blind controlled clinical trials. Moderate yet similar clinical benefit has been demonstrated for IFN-alpha and high-dose ascorbic acid (AA) monotherapy in a large open clinical trial. However, there is a lack of in vivo and in vitro studies exploring and comparing the effects of high-dose AA and IFN-alpha treatment in the context of HAM/TSP. Therefore, we performed the first comparative analysis of the ex vivo and in vitro molecular and cellular mechanisms of action of IFN-alpha and high-dose AA in HAM/TSP. Principal Findings: Through thymidine incorporation and quantification of Th1/Th2/Th17 cytokines, we demonstrate that high-dose AA displays differential and superior antiproliferative and immunomodulatory effects over IFN-alpha in HAM/TSP PBMCs ex vivo. In addition, high-dose AA, but not IFN-alpha, induced cell death in both HAM/TSP PBMCs and HTLV-1-infected T-cell lines MT-2 and MT-4. Microarray data combined with pathway analysis of MT-2 cells revealed AA-induced regulation of genes associated with cell death, including miR-155. Since miR-155 has recently been demonstrated to up-regulate IFN-gamma, this microRNA might represent a novel therapeutic target in HAM/TSP, as recently demonstrated in multiple sclerosis, another neuroinflammatory disease. On the other hand, IFN-alpha selectively up-regulated antiviral and immune-related genes. Conclusions: In comparison to IFN-alpha, high-dose AA treatment has superior ex vivo and in vitro cell death-inducing, antiproliferative and immunomodulatory anti-HTLV-1 effects. Differential pathway activation by both drugs opens up avenues for targeted treatment in specific patient subsets.	[Moens, Britta; Menezes, Soraya Maria; Khouri, Ricardo; Alvarez, Carolina; Vandamme, Anne-Mieke; Van Weyenbergh, Johan] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium; [Decanine, Daniele; Khouri, Ricardo; Silva-Santos, Gilvaneia; Galvao-Castro, Bernardo; Van Weyenbergh, Johan] Oswaldo Cruz Fdn FIOCRUZ, Goncalo Moniz Res Ctr, Salvador, BA, Brazil; [Lopez, Giovanni; Alvarez, Carolina; Talledo, Michael; Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Dept Med, Fac Med, Lima, Peru; [Kruschewsky, Ramon de Almeida; Galvao-Castro, Bernardo] Bahia Sch Med & Publ Hlth, Salvador, BA, Brazil; [Vandamme, Anne-Mieke] Univ Nova Lisboa, Ctr Malaria & Outras Doencas Tropicais, Inst Higiene & Med Trop, P-1200 Lisbon, Portugal	Moens, B (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium.	moensbritta@gmail.com	Vandamme, Anne-Mieke/I-4127-2012; santos, sofia/I-1637-2012; Van Weyenbergh, Johan/B-4187-2009	Vandamme, Anne-Mieke/0000-0002-6594-2766; Van Weyenbergh, Johan/0000-0003-3234-8426	Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen); FWO [G.0778.10]; CNPq; Impulsfinanciering K.U. Leuven; Leerstoel voor Wetenschappelijk onderzoek over infectieziekten in ontwikkelingslanden	Britta Moens is supported by a Ph.D. grant of the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen). This research was supported by FWO G.0778.10, CNPq, "Impulsfinanciering K.U. Leuven" and "Leerstoel voor Wetenschappelijk onderzoek over infectieziekten in ontwikkelingslanden." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Araujo A, 2004, ANN NEUROL, V56, P10, DOI 10.1002/ana.20126; Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182/blood-2008-04-154286; Azimi N, 1999, J IMMUNOL, V163, P4064; Bellon M, 2009, BLOOD, V113, P4914, DOI 10.1182/blood-2008-11-189845; Best I, 2006, CLIN EXP IMMUNOL, V146, P226, DOI 10.1111/j.1365-2249.2006.03208.x; CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538; Feng X, 2003, J VIROL, V77, P13389, DOI 10.1128/JVI.77.24.13389-13395.2003; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Fromberg A, 2011, CANCER CHEMOTH PHARM, V67, P1157, DOI 10.1007/s00280-010-1418-6; Fukushima N, 2007, INTERNAL MED, V46, P347, DOI 10.2169/internalmedicine.46.6118; Gartel AL, 2008, SEMIN CANCER BIOL, V18, P103, DOI 10.1016/j.semcancer.2008.01.008; Goon PKC, 2003, J VIROL, V77, P9716, DOI 10.1128/JVI.77.17.9716-9722.2003; Goon PKC, 2002, BLOOD, V99, P3335, DOI 10.1182/blood.V99.9.3335; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Grever MR, 2010, BLOOD, V115, P21, DOI 10.1182/blood-2009-06-195370; Hagiya K, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-19; Hanon E, 2000, AIDS RES HUM RETROV, V16, P1711, DOI 10.1089/08892220050193191; Harakeh S, 2007, ANTICANCER RES, V27, P289; Hoffer LJ, 2008, ANN ONCOL, V19, P1969, DOI 10.1093/annonc/mdn377; Hughes DA, 1999, P NUTR SOC, V58, P79, DOI 10.1079/PNS19990012; Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016; Jacobson S, 2002, J INFECT DIS, V186, pS187, DOI 10.1086/344269; Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825; Junker A, 2009, BRAIN, V132, P3342, DOI 10.1093/brain/awp300; Kataoka A, 1993, Rinsho Shinkeigaku, V33, P282; Kchour G, 2008, LEUKEMIA LYMPHOMA, V49, P265, DOI 10.1080/10428190701760060; Kendall EA, 2009, J PEDIATR-US, V155, P700, DOI 10.1016/j.jpeds.2009.05.027; KURODA Y, 1993, J NEUROIMMUNOL, V42, P223, DOI 10.1016/0165-5728(93)90014-P; Maloney EM, 1998, J ACQ IMMUN DEF SYND, V17, P167, DOI 10.1097/00042560-199802010-00011; Mandl J, 2009, BRIT J PHARMACOL, V157, P1097, DOI 10.1111/j.1476-5381.2009.00282.x; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; MIYOSHI I, 1981, GANN, V72, P978; MIYOSHI I, 1981, GANN, V72, P997; Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952; Nagai M, 2001, ANN NEUROL, V50, P807, DOI 10.1002/ana.10065; Nakagawa M, 1996, J NEUROVIROL, V2, P345, DOI 10.3109/13550289609146899; NAKAMURA S, 1993, J NEUROIMMUNOL, V42, P127, DOI 10.1016/0165-5728(93)90001-F; NISHIMOTO N, 1990, J NEUROL SCI, V97, P183, DOI 10.1016/0022-510X(90)90217-B; O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009; Osame M, 2002, J NEUROVIROL, V8, P359, DOI 10.1080/13550280290100860; Paraboschi EM, 2011, INT J MOL SCI, V12, P8695, DOI 10.3390/ijms12128695; Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100; Primo JRL, 2005, CLIN INFECT DIS, V41, P535, DOI 10.1086/432058; Puertollano MA, 2011, CURR TOP MED CHEM, V11, P1752; RICHARDSON JH, 1990, J VIROL, V64, P5682; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Saito M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-19; Santos SB, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-7; Santos SB, 2006, NEUROIMMUNOMODULAT, V13, P145, DOI 10.1159/000097259; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Trinchieri G, 2010, J EXP MED, V207, P2053, DOI 10.1084/jem.20101664; Trotta R, 2012, BLOOD; UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P72, DOI 10.1097/00005072-199401000-00009; Vajente N, 2009, APOPTOSIS, V14, P153, DOI 10.1007/s10495-008-0289-3; Wang L, 2011, J VIROL, V85, P8328, DOI 10.1128/JVI.00570-11; Washiyama M, 2007, FEBS LETT, V581, P5207, DOI 10.1016/j.febslet.2007.10.008	56	11	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUL	2012	6	7							e1729	10.1371/journal.pntd.0001729				15	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	983ES	WOS:000307101900022	22848768	DOAJ Gold, Green Published			2019-03-26	
J	Ngudi, DD; Kuo, YH; Van Montagu, M; Lambein, F				Ngudi, Delphin Diasolua; Kuo, Yu-Haey; Van Montagu, Marc; Lambein, Fernand			Research on Motor Neuron Diseases Konzo and Neurolathyrism: Trends from 1990 to 2010	PLOS NEGLECTED TROPICAL DISEASES			English	Article							SYMPTOMATIC TREATMENT; EPIDEMIC	Konzo (caused by consumption of improperly processed cassava, Manihot esculenta) and neurolathyrism (caused by prolonged overconsumption of grass pea, Lathyrus sativus) are two distinct non-infectious upper motor neurone diseases with identical clinical symptoms of spastic paraparesis of the legs. They affect many thousands of people among the poor in the remote rural areas in the central and southern parts of Africa afflicting them with konzo in Ethiopia and in the Indian sub-continent with neurolathyrism. Both diseases are toxico-nutritional problems due to monotonous consumption of starchy cassava roots or protein-rich grass pea seeds as a staple, especially during drought and famine periods. Both foods contain toxic metabolites (cyanogenic glycosides in cassava and the neuro-excitatory amino acid beta-ODAP in grass pea) that are blamed for theses diseases. The etiology is also linked to the deficiency in the essential sulfur amino acids that protect against oxidative stress. The two diseases are not considered reportable by the World Health Organization (WHO) and only estimated numbers can be found. This paper analyzes research performance and determines scientific interest in konzo and neurolathyrism. A literature search of over 21 years (from 1990 to 2010) shows that in terms of scientific publications there is little interest in these neglected motorneurone diseases konzo and neurolathyrism that paralyze the legs. Comparison is made with HTLV-1/TSP, an infectious disease occurring mainly in Latin America of which the clinical manifestation is similar to konzo and neurolathyrism and requires a differential diagnosis. Our findings emphasize the multidisciplinary nature of studies on these neglected diseases, which however have not really captured the attention of decision makers and project planners, especially when compared with the infectious HTLV-1/TSP. Konzo and neurolathyrism can be prevented by a balanced diet.	[Ngudi, Delphin Diasolua] Programme Natl Nutr PRONANUT, Kinshasa, Zaire; [Ngudi, Delphin Diasolua; Kuo, Yu-Haey; Van Montagu, Marc; Lambein, Fernand] Univ Ghent, Inst Plant Biotechnol Outreach IPBO, B-9000 Ghent, Belgium	Ngudi, DD (reprint author), Programme Natl Nutr PRONANUT, Kinshasa, Zaire.	Fernand.Lambein@ugent.be					Banea JP, 2012, FOOD CHEM TOXICOL, V50, P1517, DOI 10.1016/j.fct.2012.02.001; Bradbury HL, 2011, FOOD CHEM TOXICOL, V49, P537; Bradbury JH, 2011, FOOD CHEM, V127, P1755, DOI 10.1016/j.foodchem.2011.02.053; Diasolua Ngudi D, 2010, CCDN NEWS, V16, P1; Enneking D, 2011, FOOD CHEM TOXICOL, V49, P694, DOI 10.1016/j.fct.2010.11.029; Getahun H, 2003, LANCET, V362, P1808, DOI 10.1016/S0140-6736(03)14902-1; Getahun H, 1999, LANCET, V354, P306, DOI 10.1016/S0140-6736(99)02532-5; Girma D, 2012, PLANT BREEDING; HAQUE A, 1994, PARAPLEGIA, V32, P193, DOI 10.1038/sc.1994.35; Hillocks RJ, 2012, EUPHYTICA, V186, P647, DOI 10.1007/s10681-012-0702-4; HOWLETT WP, 1990, BRAIN, V113, P223, DOI 10.1093/brain/113.1.223; Ikegami F, 1994, PHYTOCHEMISTRY, V23, P1567; Kuo YH, 2003, PHYTOCHEMISTRY, V62, P1087, DOI 10.1016/S0031-9422(02)00658-1; Lan G, 2011, COMPOSITIONS METHODS; Melka A, 1997, ETHIOPIAN MED J, V35, P77; Nunn PB, 2011, FOOD CHEM TOXICOL, V49, P662, DOI 10.1016/j.fct.2010.08.037; Rao SLN, 2011, FOOD CHEM TOXICOL, V49, P620, DOI 10.1016/j.fct.2010.06.054; Teklehaimanot R, 2005, ETHIOP J HLTH DEV, V19, P230; WHO, 1996, WKLY EPIDEMIOL REC, V71, P225; Zaninovic V, 1999, Int J Infect Dis, V3, P168, DOI 10.1016/S1201-9712(99)90041-3; Zaninovic V, 2001, LATHYRUS LATHYRISM N, V2, P11	21	5	5	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUL	2012	6	7							e1759	10.1371/journal.pntd.0001759				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	983ES	WOS:000307101900043	22860149	DOAJ Gold, Green Published			2019-03-26	
J	Riveau, G; Deplanque, D; Remoue, F; Schacht, AM; Vodougnon, H; Capron, M; Thiry, M; Martial, J; Libersa, C; Capron, A				Riveau, Gilles; Deplanque, Dominique; Remoue, Franck; Schacht, Anne-Marie; Vodougnon, Hubert; Capron, Monique; Thiry, Michel; Martial, Joseph; Libersa, Christian; Capron, Andre			Safety and Immunogenicity of rSh28GST Antigen in Humans: Phase 1 Randomized Clinical Study of a Vaccine Candidate against Urinary Schistosomiasis	PLOS NEGLECTED TROPICAL DISEASES			English	Article							GLUTATHIONE-S-TRANSFERASE; PROTECTIVE ANTIGEN; MANSONI; PRAZIQUANTEL; IMMUNIZATION; VIABILITY; INFECTION; FECUNDITY; ALUMINUM; MATTHEEI	Background: Treatment of urinary schistosomiasis by chemotherapy remains challenging due to rapid re-infection and possibly to limited susceptibility to praziquantel treatment. Therefore, therapeutic vaccines represent an attractive alternative control strategy. The objectives of this study were to assess the safety and tolerability profile of the recombinant 28 kDa glutathione S-transferase of Schistosoma haematobium (rSh28GST) in healthy volunteers, and to determine its immunogenicity. Methodology: Volunteers randomly received 100 mu g rSh28GST together with aluminium hydroxide (Alum) as adjuvant (n = 8), or Alum alone as a comparator (n = 8), twice with a 28-day interval between doses. A third dose of rSh28GST or Alum alone was administered to this group at day 150. In view of the results obtained, another group of healthy volunteers (n = 8) received two doses of 300 mu g of rSh28GST, again with a 28-day interval. A six-month follow-up was performed with both clinical and biological evaluations. Immunogenicity of the vaccine candidate was evaluated in terms of specific antibody production, the capacity of sera to inhibit enzymatic activity of the antigen, and in vitro cytokine production. Principal Findings: Among the 24 healthy male participants no serious adverse events were reported in the days or weeks after administration. Four subjects under rSh28GST reported mild reactions at the injection site while a clinically insignificant increase in bilirubin was observed in 8/24 subjects. No hematological nor biochemical evidence of toxicity was detected. Immunological analysis showed that rSh28GST was immunogenic. The induced Th2-type response was characterized by antibodies capable of inhibiting the enzymatic activity of rSh28GST. Conclusions: rSh28GST in Alum did not induce any significant toxicity in healthy adults and generated a Th2-type immune response. Together with previous preclinical results, the data of safety, tolerability and quality of the specific immune response provide evidence that clinical trials with rSh28GST could be continued in humans as a potential vaccine candidate against urinary schistosomiasis.	[Riveau, Gilles; Remoue, Franck; Schacht, Anne-Marie; Capron, Monique; Capron, Andre] Univ Lille 2, INSERM, Inst Pasteur Lille, Lille, France; [Deplanque, Dominique; Libersa, Christian] Univ Lille Nord France, Dept Med Pharmacol, Fac Med, Lille, France; [Thiry, Michel; Martial, Joseph] Eurogentec, Seraing, Belgium; [Deplanque, Dominique; Vodougnon, Hubert; Libersa, Christian] CHRU, Inserm CIC CRB 9301, Lille, France	Riveau, G (reprint author), Univ Lille 2, INSERM, Inst Pasteur Lille, Lille, France.	gilles.riveau@gmail.com	Deplanque, Dominique/E-4901-2015	Deplanque, Dominique/0000-0002-4995-584X	Institut National de la Sante et de la Recherche Medicale (Inserm) [97CICLIL01]	Research was supported by Institut National de la Sante et de la Recherche Medicale (Inserm) contract 97CICLIL01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1995, WHO TECHN REP SER, V850, P97; BALLOUL JM, 1987, NATURE, V326, P149, DOI 10.1038/326149a0; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; BOULANGER D, 1991, PARASITE IMMUNOL, V13, P473, DOI 10.1111/j.1365-3024.1991.tb00545.x; BOULANGER D, 1995, PARASITE IMMUNOL, V17, P361, DOI 10.1111/j.1365-3024.1995.tb00903.x; Capron A, 2005, TRENDS PARASITOL, V21, P143, DOI 10.1016/j.pt.2005.01.003; Capron A, 1998, PARASITOL TODAY, V14, P379, DOI 10.1016/S0169-4758(98)01322-2; Capron Andre, 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P281, DOI 10.2174/1568008023340587; DeBont J, 1997, PARASITOLOGY, V115, P249, DOI 10.1017/S0031182097001352; DUNNE DW, 1995, LANCET, V345, P1488; Dupre L, 1999, J INFECT DIS, V180, P454, DOI 10.1086/314875; FALLON PG, 1995, AM J TROP MED HYG, V53, P61, DOI 10.4269/ajtmh.1995.53.61; FDA, 2007, GUID IND TOX GRAD SC; Fiejka M, 1996, PHARMACOL TOXICOL, V78, P123, DOI 10.1111/j.1600-0773.1996.tb00192.x; GRZYCH JM, 1993, J IMMUNOL, V150, P527; Grzych JM, 1998, INFECT IMMUN, V66, P1142; Gupta R K, 1995, Pharm Biotechnol, V6, P229; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; Redman CA, 1996, PARASITOL TODAY, V12, P14, DOI 10.1016/0169-4758(96)80640-5; Remoue F, 2000, J INFECT DIS, V181, P1855, DOI 10.1086/315454; Riveau G, 1996, CONCEPTS VACCINE DES; Romagnani S, 1996, INT J CLIN LAB RES, V26, P83, DOI 10.1007/BF02592350; Romagnani S, 1997, INT ARCH ALLERGY IMM, V113, P153, DOI 10.1159/000237532; Sabra ANA, 2008, J PARASITOL, V94, P537, DOI 10.1645/GE-1297.1; STELMA FF, 1995, AM J TROP MED HYG, V53, P167, DOI 10.4269/ajtmh.1995.53.167; TROTTEIN F, 1992, J MOL BIOL, V224, P515, DOI 10.1016/0022-2836(92)91013-F; [WHO Committee ICHS], 1996, ICH HARM TRIP GUID; XU CB, 1993, J IMMUNOL, V150, P940	28	59	60	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUL	2012	6	7							e1704	10.1371/journal.pntd.0001704				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	983ES	WOS:000307101900008	22802974	DOAJ Gold, Green Published			2019-03-26	
J	Martini, J; Mongo, R; Kalambay, H; Fromont, A; Ribesse, N; Dujardin, B				Martini, Jessica; Mongo, Roch; Kalambay, Hyppolite; Fromont, Anne; Ribesse, Nathalie; Dujardin, Bruno			Aid effectiveness from Rome to Busan: some progress but lacking bottom-up approaches or behaviour changes	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						development; health policies; bottom-up approaches; behaviour change; aid effectiveness; developpement; politiques de sante; approches ascendantes; changement de comportement; efficacite de l'aide; desarrollo; politicas sanitarias; enfoque ascendente; cambios en el comportamiento; efectividad de la ayuda		The Busan partnership adopted at the 4th High Level Forum on Aid Effectiveness at the end of last year is a significant step forward towards the improvement of aid quality and the promotion of development. In particular, the inclusiveness achieved in Busan and the shift in discourse from aid effectiveness to development effectiveness are emblematic. However, key challenges still remain. Firstly, decision-making should be more bottom-up, finding ways to take into account the populations needs and experiences and to enhance self-learning dynamics during the policy process. Today, it is particularly necessary to define what development means at country level, according to the aspirations of particular categories of people and meeting operational and local expectations. Secondly, changes in language should be followed by a real change in mindset. Development stakeholders should further adapt their procedures to the reality of complex systems in which development interventions are being dealt with.	[Martini, Jessica; Fromont, Anne; Dujardin, Bruno] Univ Libre Brussels, Ecole Sante Publ, GRAP PA Sante, Brussels, Belgium; [Mongo, Roch] Univ Abomey Calavi, Lab Social Dynam & Dev, LADYD, Abomey Calavi, Benin; [Kalambay, Hyppolite] Minist Publ Hlth, Direct Studies & Planning, Kinshasa, Zaire; [Ribesse, Nathalie] Catholic Univ Louvain, Fac Publ Hlth, GRAP PA Sante, B-1200 Brussels, Belgium	Martini, J (reprint author), Univ Libre Brussels, Ecole Sante Publ, GRAP PA Sante, Brussels, Belgium.	jmartini@ulb.ac.be					Commission Sud, 1990, DEF SUD RAPP COMM SU; de Renzio P, 2011, PRINC COMM WELC BRAV; Martini J, 2011, TROPICAL MED INT S1, V16, P330; OECD, 2005, HIGH LEV FOR 2 AID E; OECD, 2011, 4 HIGH LEV FOR AID E; OECD, 2008, HIGH LEV FOR 3 AID E; OECD, 2003, HIGH LEV FOR 1 AID E; Paul E, 2010, 1 GLOB S HLTH SYST R; PAUL E, 2011, TROP MED INT HEAL S1, V16, P42; Rihani S., 2002, COMPLEX SYSTEMS THEO; Rist Gilbert, 2007, DEV HIST CROYANCE OC; Wood B, 2011, EVALUATION PARIS DEC	12	3	3	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2012	17	7					931	933		10.1111/j.1365-3156.2012.02995.x				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	962BH	WOS:000305513700017	22583911	Bronze			2019-03-26	
J	Bouchaud, O; Muhlberger, N; Parola, P; Calleri, G; Matteelli, A; Peyerl-Hoffmann, G; Mechai, F; Gautret, P; Clerinx, J; Kremsner, PG; Jelinek, T; Kaiser, A; Beltrame, A; Schmid, ML; Kern, P; Probst, M; Bartoloni, A; Weinke, T; Grobusch, MP				Bouchaud, Olivier; Muehlberger, Nikolai; Parola, Philippe; Calleri, Guido; Matteelli, Alberto; Peyerl-Hoffmann, Gabriele; Mechai, Frederic; Gautret, Philippe; Clerinx, Jan; Kremsner, Peter G.; Jelinek, Tomas; Kaiser, Annette; Beltrame, Anna; Schmid, Matthias L.; Kern, Peter; Probst, Meike; Bartoloni, Alessandro; Weinke, Thomas; Grobusch, Martin P.			Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study	MALARIA JOURNAL			English	Article						Imported falciparum malaria; Uncomplicated; Therapy; Treatment change; Parasite clearance time; Fever clearance time; Adverse events; Europe	PLASMODIUM-FALCIPARUM; ATOVAQUONE-PROGUANIL; ARTEMETHER-LUMEFANTRINE; IMPORTED MALARIA; QUININE-CLINDAMYCIN; NONIMMUNE PATIENTS; CLINICAL-EFFICACY; RANDOMIZED-TRIAL; COMBINATION; MEFLOQUINE	Background: Malaria continues to be amongst the most frequent infectious diseases imported to Europe. Whilst European treatment guidelines are based on data from studies carried out in endemic areas, there is a paucity of original prospective treatment data. The objective was to summarize data on treatments to harmonize and optimize treatment for uncomplicated malaria in Europe. Methods: A prospective observational multicentre study was conducted, assessing tolerance and efficacy of treatment regimens for imported uncomplicated falciparum malaria in adults amongst European centres of tropical and travel medicine. Results: Between December 2003 and 2009, 504 patients were included in 16 centres from five European countries. Eighteen treatment regimens were reported, the top three being atovaquone-proguanil, mefloquine, and artemether-lumefantrine. Treatments significantly differed with respect to the occurrence of treatment changes (p = 0.005) and adverse events (p = 0.001), parasite and fever clearance times (p < 0.001), and hospitalization rates (p = 0.0066) and durations (p = 0.001). Four recrudescences and two progressions to severe disease were observed. Compared to other regimens, quinine alone was associated with more frequent switches to second line treatment, more adverse events and longer inpatient stays. Parasite and fever clearance times were shortest with artemether-mefloquine combination treatment. Vomiting was the most frequent cause of treatment change, occurring in 5.5% of all patients but 9% of the atovaquone-proguanil group. Conclusions: This study highlights the heterogeneity of standards of care within Europe. A consensus discussion at European level is desirable to foster a standardized management of imported falciparum malaria.	[Kremsner, Peter G.; Grobusch, Martin P.] Univ Tubingen, Inst Trop Med, Tubingen, Germany; [Bouchaud, Olivier; Mechai, Frederic] Univ Paris 13, Bobigny, France; [Bouchaud, Olivier; Mechai, Frederic] Hop Avicenne, AP HP, Infect & Trop Dis Dept, F-93009 Bobigny, France; [Muehlberger, Nikolai] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria; [Parola, Philippe; Gautret, Philippe] N Univ Hosp, Infect & Trop Med Unit, F-13015 Marseille, France; [Calleri, Guido] Osped Amedeo di Savoia, Div Malattie Infett & Tropicali, Turin, Italy; [Matteelli, Alberto] Univ Hosp, Inst Infect & Trop Dis, Brescia, Italy; [Peyerl-Hoffmann, Gabriele] Univ Hosp Freiburg, Ctr Infect Dis & Travel Med, Freiburg, Germany; [Clerinx, Jan] Inst Trop Med, B-2000 Antwerp, Belgium; [Jelinek, Tomas] Berlin Ctr Travel & Trop Med, Berlin, Germany; [Kaiser, Annette] Univ Bonn, Inst Med Microbiol & Parasitol, Bonn, Germany; [Beltrame, Anna] AOU Udine, Clin Malattie Infett, Udine, Italy; [Schmid, Matthias L.] Royal Victoria Infirm, Dept Infect & Trop Med, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Kern, Peter] Univ Hosp, Comprehens Infect Dis Ctr, Ulm, Germany; [Probst, Meike] Charite, Med Klin MS Infektiol, Berlin, Germany; [Bartoloni, Alessandro] Univ Florence, Infect & Trop Dis Unit, AOU Careggi, Florence, Italy; [Bartoloni, Alessandro] Univ Florence, Dept Crit Care Med & Surg, Florence, Italy; [Weinke, Thomas] Klinikum Ernst Von Bergmann, Dept Gastroenterol & Infect Dis, Potsdam, Germany; [Grobusch, Martin P.] Univ Amsterdam, Acad Med Ctr, Ctr Trop & Travel Med, Dept Infect Dis,Div Internal Med, NL-1105 AZ Amsterdam, Netherlands	Grobusch, MP (reprint author), Univ Tubingen, Inst Trop Med, Tubingen, Germany.	m.p.grobusch@amc.uva.nl	BARTOLONI, ALESSANDRO/K-3403-2018; Matteelli, Alberto/M-8784-2015	BARTOLONI, ALESSANDRO/0000-0001-9758-1523; Matteelli, Alberto/0000-0001-5109-9248; Kaiser, Annette/0000-0001-7873-3958	GSK Germany, Munich	We thank all site staff for their contribution. This work was supported by GSK Germany, Munich, which contributed in part to study initiation cost coverage.	Adjei GO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-127; Alecrim MG, 2006, AM J TROP MED HYG, V74, P20, DOI 10.4269/ajtmh.2006.74.20; Alkadi HO, 2007, CHEMOTHERAPY, V53, P385, DOI 10.1159/000109767; Borrmann S, 2003, CLIN INFECT DIS, V37, P1441, DOI 10.1086/379014; Bottieau E, 2007, EUR J CLIN MICROBIOL, V26, P181, DOI 10.1007/s10096-007-0264-x; Bouchaud O, 2000, AM J TROP MED HYG, V63, P274; BOUCHAUD O, 1994, AM J TROP MED HYG, V51, P204, DOI 10.4269/ajtmh.1994.51.204; Briand V, 2007, J TRAVEL MED, V14, P306, DOI 10.1111/j.1708-8305.2007.00143.x; BUNNAG D, 1995, T ROY SOC TROP MED H, V89, P213, DOI 10.1016/0035-9203(95)90500-6; Bustos DG, 1999, J INFECT DIS, V179, P587; D'Acremont V, 2002, BRIT MED J, V324, P875, DOI 10.1136/bmj.324.7342.875; Djimde A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-S1-S4; Durand R, 2008, EMERG INFECT DIS, V14, P320, DOI 10.3201/eid1402.070945; Gautret P, 2009, EMERG INFECT DIS, V15, P1783, DOI 10.3201/eid1511.091147; Giao PT, 2004, TROP MED INT HEALTH, V9, P209, DOI 10.1046/j.1365-3156.2003.01180.x; Grobusch MP, 2005, CURR TOP MICROBIOL, V295, P83; Hatz C, 2008, AM J TROP MED HYG, V78, P241, DOI 10.4269/ajtmh.2008.78.241; Hitani Akihiro, 2006, Journal of Infection and Chemotherapy, V12, P277, DOI 10.1007/s10156-006-0465-8; Hussein Z, 1997, CLIN PHARMACOL THER, V61, P518, DOI 10.1016/S0009-9236(97)90132-6; Jelinek T, 2002, CLIN INFECT DIS, V34, P572, DOI 10.1086/338235; Karbwang J, 1995, J ANTIMICROB CHEMOTH, V36, P1079, DOI 10.1093/jac/36.6.1079; Kockaerts Y, 2001, Eur J Emerg Med, V8, P287, DOI 10.1097/00063110-200112000-00007; KREMSNER PG, 1995, ANTIMICROB AGENTS CH, V39, P1603, DOI 10.1128/AAC.39.7.1603; Lalloo DG, 2007, J INFECTION, V54, P111, DOI 10.1016/j.jinf.2006.12.003; Looareesuwan S, 1997, AM J TROP MED HYG, V56, P613, DOI 10.4269/ajtmh.1997.56.613; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P533, DOI 10.4269/ajtmh.1999.60.533; Makanga M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-S1-S5; Malvy D, 2002, Med Trop (Mars), V62, P229; Nosten F, 2007, AM J TROP MED HYG, V77, P181, DOI 10.4269/ajtmh.2007.77.181; OSEIAKOTO A, 2005, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD004529.PUB2; Owusu-Agyei S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002530; Parola P, 2005, MED MALADIES INFECT, V35, P482, DOI 10.1016/j.medmal.2005.05.006; Parola P, 2001, ANTIMICROB AGENTS CH, V45, P932, DOI 10.1128/AAC.45.3.932-935.2001; Pistone T, 2008, HEALTH POLICY, V88, P186, DOI 10.1016/j.healthpol.2008.03.002; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Ramharter M, 2005, CLIN INFECT DIS, V40, P1777, DOI 10.1086/430309; Societe de Pathologie Infectieuse de Langue Francaise; College des Universitaires de Maladies Infectieuses et Tropicales; Societe Francaise de Medecine des Armees; Societe Francaise de Parasitologie; Societe Francaise de Pediatrie; Societe de Medecine des Voyages; Societe de Pathologie Exotique; Societe de Reanimation de Langue Francaise, 2008, MED MALADIES INFECT, V38, P39; Thybo SR, 2004, J TRAVEL MED, V11, P220; van Agtmael M, 1999, INT J ANTIMICROB AG, V12, P159, DOI 10.1016/S0924-8579(99)00070-9; Vatan R, 2006, PRESSE MED, V35, P571, DOI 10.1016/S0755-4982(06)74642-5	40	21	22	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JUN 22	2012	11								212	10.1186/1475-2875-11-212				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	023GR	WOS:000310021400001	22720832	DOAJ Gold, Green Published			2019-03-26	
J	Heutmekers, M; Gillet, P; Maltha, J; Scheirlinck, A; Cnops, L; Bottieau, E; Van Esbroeck, M; Jacobs, J				Heutmekers, Marloes; Gillet, Philippe; Maltha, Jessica; Scheirlinck, Annelies; Cnops, Lieselotte; Bottieau, Emmanuel; Van Esbroeck, Marjan; Jacobs, Jan			Evaluation of the rapid diagnostic test CareStart pLDH Malaria (Pf-pLDH/pan-pLDH) for the diagnosis of malaria in a reference setting	MALARIA JOURNAL			English	Article						Malaria; Plasmodium; Diagnostic; Evaluation; RDT; Rapid diagnostic tests; pLDH; Lactate dehydrogenase; CareStart	FALCIPARUM; ACCURACY; TRAVELERS; PROZONE; QUALITY	Background: The present study evaluated CareStart pLDH Malaria, a three-band rapid diagnostic test detecting Plasmodium falciparum-specific parasite lactate dehydrogenase (Pf-pLDH) and pan Plasmodium-specific pLDH (pan-pLDH) in a reference setting. Methods: CareStart pLDH was retrospectively and prospectively assessed with a panel of stored (n = 498) and fresh (n = 77) blood samples obtained in international travelers suspected of malaria. Both panels comprised all four Plasmodium species; the retrospective panel comprised also Plasmodium negative samples. The reference method was microscopy corrected by PCR. The prospective panel was run side-to-side with OptiMAL (Pf-pLDH/pan-pLDH) and SDFK60 (histidine-rich protein-2 (HRP-2)/pan-pLDH). Results: In the retrospective evaluation, overall sensitivity for P. falciparum samples (n = 247) was 94.7%, reaching 98.7% for parasite densities >1,000/mu l. Most false negative results occurred among samples with pure gametocytaemia (2/12, 16.7%) and at parasite densities = 100/mu l (7/12, 58.3%). None of the Plasmodium negative samples (n = 96) showed visible test lines. Sensitivities for Plasmodium vivax (n = 70), Plasmodium ovale (n = 69) and Plasmodium malariae (n = 16) were 74.3%, 31.9% and 25.0% respectively. Wrong species identification occurred in 10 (2.5%) samples and was mainly due to P. vivax samples reacting with the Pf-pLDH test line. Overall, Pf-pLDH test lines showed higher line intensities compared to the pan-pLDH lines (67.9% and 23.0% medium and strong line intensities for P. falciparum). In the prospective panel (77 Plasmodium-positive samples), CareStart pLDH showed higher sensitivities for P. falciparum compared to OptiMAL (p = 0.008), lower sensitivities for P. falciparum as compare to SDFK60 (although not reaching statistical significance, p = 0.08) and higher sensitivities for P. ovale compared to both OptiMAL (p = 0.03) and SDFK60 (p = 0.01). Inter-observer and test reproducibility were good to excellent. Conclusion: CareStart pLDH performed excellent for the detection of P. falciparum, well for P. vivax, but poor for P. ovale and P. malariae.	[Gillet, Philippe; Maltha, Jessica; Scheirlinck, Annelies; Cnops, Lieselotte; Bottieau, Emmanuel; Van Esbroeck, Marjan; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Heutmekers, Marloes] Maastricht Univ, Fac Hlth Med & Life Sci FHML, Maastricht, Netherlands	Gillet, P (reprint author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	pgillet@itg.be	Heutmekers, Marloes/P-6140-2015	Heutmekers, Marloes/0000-0003-0880-409X; gillet, philippe/0000-0001-5878-6446	Unit of Tropical Laboratory Medicine	The malaria RDTs used in this study were purchased through the core funding of the Unit of Tropical Laboratory Medicine. We would like to thank the staff of the Central Laboratory of Clinical Biology for technical support.	Ashley EA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-241; Bossuyt PM, 2003, CROAT MED J, V44, P639; Chiodini PL, 2007, T ROY SOC TROP MED H, V101, P331, DOI 10.1016/j.trstmh.2006.09.007; Cnops L, 2010, CLIN MICROBIOL INFEC; Drakeley C, 2009, T ROY SOC TROP MED H, V103, P333, DOI 10.1016/j.trstmh.2008.10.003; Gamboa D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008091; Gerstl S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-28; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-166; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-39; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-271; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-129; Grobusch MP, 2002, EUR J CLIN MICROBIOL, V21, P818, DOI 10.1007/s10096-002-0831-0; Makler MT, 2009, AM J TROP MED HYG, V81, P921, DOI 10.4269/ajtmh.2009.09-0202; Maltha J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-7; Maltha J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-171; Marx A, 2005, ANN INTERN MED, V142, P836, DOI 10.7326/0003-4819-142-10-200505170-00009; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Piper RC, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-213; Ratsimbasoa A, 2007, AM J TROP MED HYG, V76, P481, DOI 10.4269/ajtmh.2007.76.481; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; van Dijk DPJ, 2010, EUR J CLIN MICROBIOL, V29, P577, DOI 10.1007/s10096-010-0898-y; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO (World Health Organization), 2010, INT TRAV HLTH; World Health Organisation, 2010, BAS MAL MICR 2; World Health Organization, 2011, MAL RAP DIAGN TEST P; World Health Organization, 2010, BAS MAL MICR 1	27	14	18	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JUN 18	2012	11								204	10.1186/1475-2875-11-204				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	008IA	WOS:000308949400001	22704733	DOAJ Gold, Green Published			2019-03-26	
J	Jamonneau, V; Ilboudo, H; Kabore, J; Kaba, D; Koffi, M; Solano, P; Garcia, A; Courtin, D; Laveissiere, C; Lingue, K; Buscher, P; Bucheton, B				Jamonneau, Vincent; Ilboudo, Hamidou; Kabore, Jacques; Kaba, Dramane; Koffi, Mathurin; Solano, Philippe; Garcia, Andre; Courtin, David; Laveissiere, Claude; Lingue, Kouakou; Buscher, Philippe; Bucheton, Bruno			Untreated Human Infections by Trypanosoma brucei gambiense Are Not 100% Fatal	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HUMAN AFRICAN TRYPANOSOMIASIS; APARASITEMIC SEROLOGICAL SUSPECTS; SLEEPING SICKNESS DIAGNOSIS; COTE-DIVOIRE; LEISHMANIA-INFANTUM; BLOOD-DONORS; FOLLOW-UP; POPULATION; HOST; CATT	The final outcome of infection by Trypanosoma brucei gambiense, the main agent of sleeping sickness, has always been considered as invariably fatal. While scarce and old reports have mentioned cases of self-cure in untreated patients, these studies suffered from the lack of accurate diagnostic tools available at that time. Here, using the most specific and sensitive tools available to date, we report on a long-term follow-up (15 years) of a cohort of 50 human African trypanosomiasis (HAT) patients from the Ivory Coast among whom 11 refused treatment after their initial diagnosis. In 10 out of 11 subjects who continued to refuse treatment despite repeated visits, parasite clearance was observed using both microscopy and polymerase chain reaction (PCR). Most of these subjects (7/10) also displayed decreasing serological responses, becoming progressively negative to trypanosome variable antigens (LiTat 1.3, 1.5 and 1.6). Hence, in addition to the "classic" lethal outcome of HAT, we show that alternative natural progressions of HAT may occur: progression to an apparently aparasitaemic and asymptomatic infection associated with strong long-lasting serological responses and progression to an apparently spontaneous resolution of infection (with negative results in parasitological tests and PCR) associated with a progressive drop in antibody titres as observed in treated cases. While this study does not precisely estimate the frequency of the alternative courses for this infection, it is noteworthy that in the field national control programs encounter a significant proportion of subjects displaying positive serologic test results but negative results in parasitological testing. These findings demonstrate that a number of these subjects display such infection courses. From our point of view, recognising that trypanotolerance exists in humans, as is now widely accepted for animals, is a major step forward for future research in the field of HAT.	[Jamonneau, Vincent; Solano, Philippe; Laveissiere, Claude; Bucheton, Bruno] Inst Rech Dev, Unite Mixte Rech IRD CIRAD 177, Montpellier, France; [Jamonneau, Vincent; Ilboudo, Hamidou; Kabore, Jacques; Solano, Philippe] Ctr Int Rech Dev Elevage Zones Subhumides CIRDES, Unite Rech Bases Biol Lutte Integree, Bobo Dioulasso, Burkina Faso; [Kaba, Dramane] Inst Pierre Richet, Unite Rech Trypanosomoses, Abidjan, Cote Ivoire; [Koffi, Mathurin] Univ Abobo Adjame, URES Daloa, Lab Genet Mol & Evolut Malad Infect Trop, Daloa, Cote Ivoire; [Garcia, Andre; Courtin, David] Inst Rech Dev, Unite Rech 010, Fac Pharm, Paris, France; [Lingue, Kouakou] Programme Natl Eliminat Trypanosomose Humaine Afr, Abidjan, Cote Ivoire; [Buscher, Philippe] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium	Jamonneau, V (reprint author), Inst Rech Dev, Unite Mixte Rech IRD CIRAD 177, Campus Int Baillarguet, Montpellier, France.	vincent.jamonneau@ird.fr	Buscher, Philippe/B-9956-2012; Jamonneau, Vincent/K-1124-2016	Buscher, Philippe/0000-0002-1926-7472; solano, philippe/0000-0002-4351-3506; Courtin, David/0000-0002-5263-4430	Institut de Recherche pour le Developpement (IRD); Ministere Francais des Affaires Etrangeres (Fonds de Solidarite Prioritaire "Recherches en Entomologie, Formation et Strategies de formation, le cas du paludisme et de la Trypanosomose Humaine Africaine")	This study was funded by the Institut de Recherche pour le Developpement (IRD) and the Ministere Francais des Affaires Etrangeres (Fonds de Solidarite Prioritaire "Recherches en Entomologie, Formation et Strategies de formation, le cas du paludisme et de la Trypanosomose Humaine Africaine"). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1998, WHO TECHN REP SER, V881; Barlovatz A, 1933, ANN TROP MED PARASIT, V28, P1; Brun R, 2010, LANCET, V375, P148, DOI 10.1016/S0140-6736(09)60829-1; Bucheton B, 2011, PARASITE IMMUNOL, V33, P438, DOI 10.1111/j.1365-3024.2011.01287.x; Buscher P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000471; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Checchi F, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000303; Checchi F, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-16; Cooke WE, 1937, T R SOC TROP MED HYG, V30; Courtin D, 2006, INFECT GENET EVOL, V6, P123, DOI 10.1016/j.meegid.2005.03.002; Courtin D, 2007, INFECT GENET EVOL, V7, P60, DOI 10.1016/j.meegid.2006.04.001; Deborggraeve S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000972; DYLEFF P., 1932, Bulletin de la Societe de Pathologie Exotique, V25, P956; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; Garcia A, 2006, TRENDS PARASITOL, V22, P405, DOI 10.1016/j.pt.2006.06.011; Giroud C, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000509; Hanotte O, 2003, P NATL ACAD SCI USA, V100, P7443, DOI 10.1073/pnas.1232392100; HARDING RD, 1948, T ROY SOC TROP MED H, V41, P481, DOI 10.1016/S0035-9203(48)90747-0; Holzmuller P, 2008, MICROBES INFECT, V10, P79, DOI 10.1016/j.micinf.2007.10.008; Ilboudo H, 2011, MICROBES INFECT, V13, P943, DOI 10.1016/j.micinf.2011.05.007; Iraqi F, 2000, MAMM GENOME, V11, P645, DOI 10.1007/s003350010133; Jamonneau J, 2000, ANN TROP MED PARASIT, V94, P643, DOI 10.1080/00034983.2000.11813587; Jamonneau V, 2004, ANN TROP MED PARASIT, V98, P329, DOI 10.1179/000349804225003406; Jamonneau V, 2002, TROP MED INT HEALTH, V7, P610, DOI 10.1046/j.1365-3156.2002.00905.x; Jamonneau V, 2000, ANN TROP MED PARASIT, V94, P831, DOI 10.1080/00034980020028004; Jamonneau V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000917; Kaba D, 2006, TROP MED INT HEALTH, V11, P136, DOI 10.1111/j.1365-3156.2005.01549.x; Kabore J, 2011, INFECT GENET EVOL, V11, P1250, DOI 10.1016/j.meegid.2011.04.014; Kabore J, 2011, INFECT GENET EVOL, V11, P1129, DOI 10.1016/j.meegid.2011.04.011; Kemp SJ, 1997, NAT GENET, V16, P194, DOI 10.1038/ng0697-194; Koffi M, 2006, ACTA TROP, V98, P183, DOI 10.1016/j.actatropica.2006.04.001; Koffi M, 2009, P NATL ACAD SCI USA, V106, P209, DOI 10.1073/pnas.0811080106; le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953; Lejon V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000590; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Morrison LJ, 2011, PARASITE IMMUNOL, V33, P448, DOI 10.1111/j.1365-3024.2011.01286.x; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; Nikolskaia OV, 2006, INT J PARASITOL, V36, P513, DOI 10.1016/j.ijpara.2006.01.011; PAQUET C, 1992, LANCET, V340, P250, DOI 10.1016/0140-6736(92)90524-7; RASEROKA B H, 1986, Parasitology Today, V2, P147, DOI 10.1016/0169-4758(86)90182-1; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; Riera C, 2008, TRANSFUSION, V48, P1383, DOI 10.1111/j.1537-2995.2008.01708.x; Simarro PP, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001007; Simarro PP, 1999, TROP MED INT HEALTH, V4, P858, DOI 10.1046/j.1365-3156.1999.00494.x; Solano P, 2003, Med Trop (Mars), V63, P577; Sternberg JM, 2010, PARASITOLOGY, V137, P2007, DOI 10.1017/S0031182010000946; Steverding D, 2008, PARASITE VECTOR, V1, DOI 10.1186/1756-3305-1-3; Toukam CMW, 2011, PARASITE, V18, P295; Van den Bossche P, 2005, TROP MED INT HEALTH, V10, P833, DOI 10.1111/j.1365-3156.2005.01467.x; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; Zimmermann S, 2012, PLANTA MED, V78, P553, DOI 10.1055/s-0031-1298241	51	78	78	5	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUN	2012	6	6							e1691	10.1371/journal.pntd.0001691				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	967YY	WOS:000305945300032	22720107	DOAJ Gold, Green Published			2019-03-26	
J	Valencia, C; Arevalo, J; Dujardin, JC; Llanos-Cuentas, A; Chappuis, F; Zimic, M				Valencia, Cristian; Arevalo, Jorge; Dujardin, Jean Claude; Llanos-Cuentas, Alejandro; Chappuis, Francois; Zimic, Mirko			Prediction Score for Antimony Treatment Failure in Patients with Ulcerative Leishmaniasis Lesions	PLOS NEGLECTED TROPICAL DISEASES			English	Article							AMERICAN CUTANEOUS LEISHMANIASIS; VISCERAL LEISHMANIASIS; RISK-FACTORS; TEGUMENTARY LEISHMANIASIS; MEGLUMINE ANTIMONIATE; BRAZIL; INFECTION; CHILDREN; DEATH	Background: Increased rates for failure in leishmaniasis antimony treatment have been recently recognized worldwide. Although several risk factors have been identified there is no clinical score to predict antimony therapy failure of cutaneous leishmaniasis. Methods: A case control study was conducted in Peru from 2001 to 2004. 171 patients were treated with pentavalent antimony and followed up to at least 6 months to determine cure or failure. Only patients with ulcerative cutaneous leishmaniasis (N = 87) were considered for data analysis. Epidemiological, demographical, clinical and laboratory data were analyzed to identify risk factors for treatment failure. Two prognostic scores for antimonial treatment failure were tested for sensitivity and specificity to predict antimony therapy failure by comparison with treatment outcome. Results: Among 87 antimony-treated patients, 18 (21%) failed the treatment and 69 (79%) were cured. A novel risk factor for treatment failure was identified: presence of concomitant distant lesions. Patients presenting concomitant-distant lesions showed a 30.5-fold increase in the risk of treatment failure compared to other patients. The best prognostic score for antimonial treatment failure showed a sensitivity of 77.78% and specificity of 95.52% to predict antimony therapy failure. Conclusions: A prognostic score including a novel risk factor was able to predict antimonial treatment failure in cutaneous leishmaniasis with high specificity and sensitivity. This prognostic score presents practical advantages as it relies on clinical and epidemiological characteristics, easily obtained by physicians or health workers, and makes it a promising clinical tool that needs to be validated before their use for developing countries.	[Valencia, Cristian; Arevalo, Jorge; Llanos-Cuentas, Alejandro] UPCH, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Zimic, Mirko] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Lab Invest & Desarrollo, Unidad Bioinformat, Lima, Peru; [Dujardin, Jean Claude] Inst Trop Med, B-2000 Antwerp, Belgium; [Chappuis, Francois] Univ Hosp Geneva, Geneva, Switzerland	Valencia, C (reprint author), UPCH, Inst Med Trop Alexander von Humboldt, Lima, Peru.	mzimic@jhsph.edu			European Community [INCO-CT2005-015407]; Directorate-General for Development Cooperation of the Belgian Government [95502]	This study was funded by European Community (INCO-Dev program "Control strategies for visceral leishmaniasis (VL) and mucocutaneous leishmaniasis (MCL) in South America: applications of molecular epidemiology" [contract INCO-CT2005-015407]), and Directorate-General for Development Cooperation of the Belgian Government (Framework Agreement 03 - project 95502). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Sampaio MJAD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000877; Arevalo J, 2007, J INFECT DIS, V195, P1846, DOI 10.1086/518041; Bermudez H, 2006, ANN TROP MED PARASIT, V100, P591, DOI 10.1179/136485906X118495; BERTHO AL, 1994, J PARASITOL, V80, P93, DOI 10.2307/3283351; CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]; DAVIES CR, 1995, EPIDEMIOL INFECT, V114, P297, DOI 10.1017/S0950268800057964; Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135; HADI AS, 1994, J ROY STAT SOC B MET, V56, P393; Keane VP, 1997, INT J EPIDEMIOL, V26, P1115, DOI 10.1093/ije/26.5.1115; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Llanos-Cuentas A, 2008, CLIN INFECT DIS, V46, P223, DOI 10.1086/524042; Modabber Farrokh, 2007, Kinetoplastid Biol Dis, V6, P3, DOI 10.1186/1475-9292-6-3; Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5; Oliveira-Neto MP, 1997, AM J TROP MED HYG, V57, P651, DOI 10.4269/ajtmh.1997.57.651; Palacios R, 2001, AM J TROP MED HYG, V64, P187, DOI 10.4269/ajtmh.2001.64.187; Peters W, 1987, CLIN ASPECT IN PRESS; Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8; Romero GAS, 2001, AM J TROP MED HYG, V65, P456, DOI 10.4269/ajtmh.2001.65.456; Unger A, 2009, AM J TROP MED HYG, V80, P574, DOI 10.4269/ajtmh.2009.80.574; WEIGLE KA, 1993, J INFECT DIS, V168, P699, DOI 10.1093/infdis/168.3.699; Werneck GL, 2003, INFECTION, V31, P174, DOI 10.1007/s15010-003-3139-9; World Health Organization, 2004, WORLD HLTH REP 2004; Zulueta AM, 1999, AM J TROP MED HYG, V61, P945, DOI 10.4269/ajtmh.1999.61.945	24	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUN	2012	6	6							e1656	10.1371/journal.pntd.0001656				6	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	967YY	WOS:000305945300009	22720098	DOAJ Gold, Green Published			2019-03-26	
J	Van Nieuwenhove, L; Buscher, P; Balharbi, F; Humbert, M; Dieltjens, T; Guisez, Y; Lejon, V				Van Nieuwenhove, Liesbeth; Buscher, Philippe; Balharbi, Fatima; Humbert, Michael; Dieltjens, Tessa; Guisez, Yves; Lejon, Veerle			Identification of Mimotopes with Diagnostic Potential for Trypanosoma brucei gambiense Variant Surface Glycoproteins Using Human Antibody Fractions	PLOS NEGLECTED TROPICAL DISEASES			English	Article							OPERATING CHARACTERISTIC CURVES; SLEEPING SICKNESS; AFRICAN TRYPANOSOMIASIS; SEROLOGICAL DIAGNOSIS; CEREBROSPINAL-FLUID; ANTIGENIC VARIATION; AGGLUTINATION-TEST; PEPTIDE LIBRARIES; SERUM; DISPLAY	Background: At present, screening of the population at risk for gambiense human African trypanosomiasis (HAT) is based on detection of antibodies against native variant surface glycoproteins (VSGs) of Trypanosoma brucei (T.b.) gambiense. Drawbacks of these native VSGs include culture of infective T.b. gambiense trypanosomes in laboratory rodents, necessary for production, and the exposure of non-specific epitopes that may cause cross-reactions. We therefore aimed at identifying peptides that mimic epitopes, hence called "mimotopes," specific to T.b. gambiense VSGs and that may replace the native proteins in antibody detection tests. Methodology/Principal Findings: A Ph.D.-12 peptide phage display library was screened with polyclonal antibodies from patient sera, previously affinity purified on VSG LiTat 1.3 or LiTat 1.5. The peptide sequences were derived from the DNA sequence of the selected phages and synthesised as biotinylated peptides. Respectively, eighteen and twenty different mimotopes were identified for VSG LiTat 1.3 and LiTat 1.5, of which six and five were retained for assessment of their diagnostic performance. Based on alignment of the peptide sequences on the original protein sequence of VSG LiTat 1.3 and 1.5, three additional peptides were synthesised. We evaluated the diagnostic performance of the synthetic peptides in indirect ELISA with 102 sera from HAT patients and 102 endemic negative controls. All mimotopes had areas under the curve (AUCs) of >= 0.85, indicating their diagnostic potential. One peptide corresponding to the VSG LiTat 1.3 protein sequence also had an AUC of >= 0.85, while the peptide based on the sequence of VSG LiTat 1.5 had an AUC of only 0.79. Conclusions/Significance: We delivered the proof of principle that mimotopes for T.b. gambiense VSGs, with diagnostic potential, can be selected by phage display using polyclonal human antibodies.	[Van Nieuwenhove, Liesbeth; Buscher, Philippe; Balharbi, Fatima; Dieltjens, Tessa; Lejon, Veerle] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Humbert, Michael] Harvard Univ, Sch Med, Boston, MA USA; [Humbert, Michael] Dana Farber Canc Inst, Boston, MA 02115 USA; [Guisez, Yves] Univ Antwerp, Dept Biol, B-2020 Antwerp, Belgium	Van Nieuwenhove, L (reprint author), Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium.	pbuscher@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472; Lejon, Veerle/0000-0002-6795-0962	Belgian Directorate General for Development Cooperation (DGDC); Research Foundation of Flanders (FWO) [1.5.169.07N, 1.5.074.09.N]; FWO [1.1.270.07.N.00, 1.1.270.09.N.01]	The project was funded by the Belgian Directorate General for Development Cooperation (DGDC) and the Research Foundation of Flanders (FWO, 1.5.169.07N and 1.5.074.09.N). Liesbeth Van Nieuwenhove is supported by a PhD scholarship of the FWO (1.1.270.07.N.00 and 1.1.270.09.N.01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Berberof M, 2001, MOL BIOCHEM PARASIT, V113, P127, DOI 10.1016/S0166-6851(01)00208-0; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Bewick V, 2004, CRIT CARE, V8, P508, DOI 10.1186/cc3000; BRUN R, 2009, LANCET, V375, P148, DOI DOI 10.1016/S0140-6736(09)60829-1; Burri C., 2009, MANSONS TROPICAL DIS, P1307; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; Carrington M, 1991, J MOL BIOL, V221; Casey JL, 2009, PROTEIN ENG DES SEL, V22, P85, DOI 10.1093/protein/gzn076; da Silva Ribeiro V, 2010, IMMUNOL LETT, V129, P94; DEGREEF C, 1989, MOL BIOCHEM PARASIT, V36, P169, DOI 10.1016/0166-6851(89)90189-8; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Dieltjens T, 2010, J VIROL METHODS, V169, P95, DOI 10.1016/j.jviromet.2010.07.004; FREYMANN DM, 1984, NATURE, V311, P167, DOI 10.1038/311167a0; Gershoni JM, 2007, BIODRUGS, V21, P145, DOI 10.2165/00063030-200721030-00002; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; Herwaldt BL, 2001, CLIN MICROBIOL REV, V14, P659, DOI 10.1128/CMR.14.3.659-688.2001; Hutchinson OC, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-234; Hutchinson OC, 2004, TRENDS PARASITOL, V20, P519, DOI 10.1016/j.pt.2004.08.007; Jamonneau V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000917; Kiefer F, 2009, NUCLEIC ACIDS RES, V37, pD387, DOI 10.1093/nar/gkn750; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; Lejon V, 2006, TROP MED INT HEALTH, V11, P620, DOI 10.1111/j.1365-3156.2006.01620.x; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Mandava S, 2004, PROTEOMICS, V4, P1439, DOI 10.1002/pmic.200300680; Marcello L, 2007, GENOME RES, V17, P1344, DOI 10.1101/gr.6421207; Minenkova O, 2001, EUR J BIOCHEM, V268, P4758, DOI 10.1046/j.1432-1327.2001.02402.x; Muller N, 1996, INFECT IMMUN, V64, P4593; MULLER N, 1992, PARASITOLOGY, V104, P111; New England Biolabs, 2009, PH D PHAG DISPL LIB; Ngoyi DM, 2010, J INFECT DIS, V201, P453, DOI 10.1086/649917; Schreiber A, 2005, J COMPUT CHEM, V26, P879, DOI 10.1002/jcc.20229; Schwede A, 2011, MOL BIOCHEM PARASIT, V175, P201, DOI 10.1016/j.molbiopara.2010.11.004; Schwede A, 2010, PARASITOLOGY, V137, P2029, DOI 10.1017/S0031182009992034; Tang SS, 2003, CLIN DIAGN LAB IMMUN, V10, P1078, DOI 10.1128/CDLI.10.6.1078-1084.2003; Taylor JE, 2006, TRENDS GENET, V22, P614, DOI 10.1016/j.tig.2006.08.003; Ullman CG, 2011, BRIEF FUNCT GENOMICS, V10, P125, DOI 10.1093/bfgp/elr010; Van Nieuwenhove LC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001189; VINCENDEAU P, 1999, PROGR HUMAN AFRICAN, P137; Yang WJ, 2005, J IMMUNOL METHODS, V304, P15, DOI 10.1016/j.jim.2005.05.009; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791	42	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUN	2012	6	6							e1682	10.1371/journal.pntd.0001682				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	967YY	WOS:000305945300024	22720103	DOAJ Gold, Green Published			2019-03-26	
J	Lunguya, O; Phoba, MF; Mundeke, SA; Bonebe, E; Mukadi, P; Muyembe, JJ; Verhaegen, J; Jacobs, J				Lunguya, Octavie; Phoba, Marie-France; Mundeke, Steve Ahuka; Bonebe, Edmonde; Mukadi, Pierre; Muyembe, Jean-Jacques; Verhaegen, Jan; Jacobs, Jan			The diagnosis of typhoid fever in the Democratic Republic of the Congo	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Typhoid fever; Widal test; Salmonella Typhi	WIDAL TEST; AGGLUTINATION-TEST; BLOOD-DONORS; ENDEMIC AREA; SPECIFICITY; CHALLENGES; CAMEROON; CHILDREN; MALARIA; AFRICA	The diagnosis of typhoid fever (TF) in Kinshasa (DR Congo) was assessed by on-site surveys, external quality assessment (EQA) of the Widal test and a microbiological blood culture surveillance study. In 331/536 (61.8%) health facilities, clinicians diagnosed TF by clinical picture and the Widal test. An EQA on the Widal test consisting of three samples revealed correct scores by respectively 27.1%, 65.6% and 3.1% of 125 participating laboratories. Most (80.9% of 152 laboratories) performed <100 Widal tests per month, with a median sample positivity rate of 32.6% (range 0-90.7%). The Widal test was mostly performed on a single sample and by slide agglutination (89.5% and 97.0% respectively); errors in cold chain and procedures were recorded (not making serial dilutions, estimating titres by the intensity of agglutination). Among 293 prescribers, 52.2% and 40.8% requested the Widal test for treatment follow-up and detection of chronic carriers respectively. Salmonella Typhi was recovered from the blood in 2.4% of 3820 patients suspected as having TF, with non-typhoid Salmonellae and other Enterobacteriaceae accounting for the majority of organisms. In conclusion, clinicians rely highly on the Widal test for the diagnosis of IF and the Widal test is poorly performed and interpreted. (C) 2012 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Jacobs, Jan] Inst Trop Med, B-2000 Antwerp, Belgium; [Lunguya, Octavie; Phoba, Marie-France; Mundeke, Steve Ahuka; Bonebe, Edmonde; Mukadi, Pierre; Muyembe, Jean-Jacques] Natl Inst Biomed Res, Kinshasa, Zaire; [Lunguya, Octavie; Phoba, Marie-France; Mundeke, Steve Ahuka; Muyembe, Jean-Jacques] Univ Hosp Kinshasa, Kinshasa, Zaire; [Verhaegen, Jan] Katholieke Univ Leuven Hosp, Louvain, Belgium	Jacobs, J (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	jjacobs@itg.be			Directorate General of Development Cooperation of the Belgian government through the Institutional Collaboration INRB - ITM (Network Program on Laboratory Quality Management) [3.21]	Studies were funded by Directorate General of Development Cooperation of the Belgian government through the Institutional Collaboration INRB - ITM (Network Program on Laboratory Quality Management; Project 3.21).	Adias TC, 2010, BLOOD TRANSFUS-ITALY, V8, P163, DOI [10.2450/2009-0115-09, 10.2450/2009.0115-09]; Archibald LK, 2001, J CLIN MICROBIOL, V39, P1960, DOI 10.1128/JCM.39.5.1960-1962.2001; Bhutta ZA, 2006, BMJ-BRIT MED J, V333, P78, DOI 10.1136/bmj.333.7558.78; CLEGG A, 1994, ACTA TROP, V57, P255, DOI 10.1016/0001-706X(94)90071-X; Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; HARRIES AD, 1995, J INFECTION, V31, P149, DOI 10.1016/S0163-4453(95)92210-5; House D, 2001, J CLIN MICROBIOL, V39, P1002, DOI 10.1128/JCM.39.3.1002-1007.2001; Itah Alfred Young, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P673; Kariuki S, 2008, J INFECT DEV COUNTR, V2, P443; Keddy KH, 2011, B WORLD HEALTH ORGAN, V89, P640, DOI 10.2471/BLT.11.087627; Kumar A, 2002, INFECT GENET EVOL, V2, P107, DOI 10.1016/S1567-1348(02)00090-4; Ley B, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-180; Massi Muhammad Nasrum, 2003, Journal of Infection and Chemotherapy, V9, P233, DOI 10.1007/s10156-003-0256-4; Ministry of Health Provincial Health Inspection Kinshasa Democratic Republic of the Congo, 2009, MIN HLTH ANN REP; Muyembe-Tamfum JJ, 2009, TRAVEL MED INFECT DI, V7, P40, DOI 10.1016/j.tmaid.2008.12.006; Mweu E, 2008, TROP MED INT HEALTH, V13, P532, DOI 10.1111/j.1365-3156.2008.02031.x; Nsutebu EF, 2003, TROP MED INT HEALTH, V8, P575, DOI 10.1046/j.1365-3156.2003.01012.x; Nsutebu EF, 2002, T ROY SOC TROP MED H, V96, P64, DOI 10.1016/S0035-9203(02)90243-9; Okeke IN, 2007, EMERG INFECT DIS, V13, P1610; Olopoenia LA, 2000, POSTGRAD MED J, V76, P80, DOI 10.1136/pmj.76.892.80; PANG T, 1983, J CLIN PATHOL, V36, P471, DOI 10.1136/jcp.36.4.471; Parry CM, 1999, J CLIN MICROBIOL, V37, P2882; Parry CM, 2002, NEW ENGL J MED, V347, P1770, DOI 10.1056/NEJMra020201; Srikantiah P, 2006, AM J TROP MED HYG, V74, P114, DOI 10.4269/ajtmh.2006.74.114; Steele D, 2008, J INFECT DEV COUNTR, V2, P250, DOI 10.3855/jidc.217; Uneke C. J., 2008, Journal of Vector Borne Diseases, V45, P133; WICKS ACB, 1974, S AFR MED J, V48, P1368; World Health Organization, 2003, BACKGR DOC DIAGN TRE	29	22	22	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUN	2012	106	6					348	355		10.1016/j.trstmh.2012.03.006				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	966RH	WOS:000305854600004	22551639				2019-03-26	
J	Levecke, B; Vercruysse, J				Levecke, Bruno; Vercruysse, Jozef			Reply to comment on: The impact of baseline faecal egg counts on the efficacy of single-dose albendazole against Trichuris trichiura	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Letter									[Levecke, Bruno; Vercruysse, Jozef] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, B-9820 Merelbeke, Belgium	Levecke, B (reprint author), Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Salisburylaan 133, B-9820 Merelbeke, Belgium.	bruno.levecke@ugent.be					Levecke B, 2012, T ROY SOC TROP MED H, V106, P128, DOI 10.1016/j.trstmh.2011.09.007; Vercruysse J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000948; Verhoef H, 2005, AM J CLIN NUTR, V81, P835, DOI 10.1093/ajcn/81.4.835	3	0	0	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUN	2012	106	6					390	392		10.1016/j.trstmh.2012.03.009				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	966RH	WOS:000305854600012					2019-03-26	
J	Desimmie, B				Desimmie, B.			The LEDGINs: first-in-class allosteric HIV-1 integrase inhibitors	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Desimmie, B.] Katholieke Univ Leuven, Louvain, Belgium								0	0	0	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2012	17			1	SI		14	14						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	945AB	WOS:000304244000040					2019-03-26	
J	D'Alessandro, U				D'Alessandro, U.			A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomised trial	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[D'Alessandro, U.] Inst Trop Med, B-2000 Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015; Van geertruyden, Jean-Pierre/K-6425-2014	D'Alessandro, Umberto/0000-0001-6341-5009; Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2012	17			1	SI		40	40						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	945AB	WOS:000304244000128					2019-03-26	
J	Sariego, I; Kanobana, K; Junco, R; Vereecken, K; Nunez, FA; Polman, K; Bonet, M; Rojas, L				Sariego, I.; Kanobana, K.; Junco, R.; Vereecken, K.; Nunez, F. A.; Polman, K.; Bonet, M.; Rojas, L.			Frequency of antibodies to Toxocara in Cuban schoolchildren	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Toxocara; toxocariasis; antibody; prevalence; enzyme-linked immunosorbent assays; Cuba; Toxocara; toxocarose; anticorps; prevalence; ELISA; Cuba; Toxocara; toxocariasis; anticuerpos; prevalencia; ELISA; Cuba	RISK-FACTORS; SEROPREVALENCE; INFECTION; PREVALENCE; CHILDREN; BRAZIL; AREAS; AGE	Objective The aim of the study was to determine the frequency of antibodies to Toxocara in Cuban schoolchildren. Methods The frequency of antibodies to Toxocara canis was assessed with a commercial enzyme-linked immunosorbent assays kit in school-aged children from two municipalities of Cuba. Univariate analysis and a multivariable logistic regression analysis adjusted for age, sex, municipality and co-infection with helminth and/or protozoa were conducted. Results The percentage of children with antibodies to Toxocara was 38.8% (392/1011; 95% CI = 36.842.8). Antibody positivity was significantly associated with gender and co-infections with intestinal parasites, but not with age or municipality. Conclusion Cuban children are highly exposed to the Toxocara parasite, corresponding well with reported environmental contamination with Toxocara parasite eggs and T. canis prevalences in dogs in Cuba. Relevant policy makers and the Cuban population need to be better informed about this preventable infection.	[Sariego, I.; Nunez, F. A.; Rojas, L.] Inst Trop Med Pedro Kouri, Havana, Cuba; [Kanobana, K.; Vereecken, K.; Polman, K.] Inst Trop Med, B-2000 Antwerp, Belgium; [Junco, R.; Bonet, M.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba	Sariego, I (reprint author), Inst Med Trop Pedro Kouri, Dept Parasitol, Apartado Postal 601,Marianao 13, Havana, Cuba.	idalia@ipk.sld.cu					Alderete JMS, 2003, MEM I OSWALDO CRUZ, V98, P593, DOI 10.1590/S0074-02762003000500002; Alonso JM, 2000, MEMORIAS I O CRUZ, V44, P303; Baboolal S, 2002, T ROY SOC TROP MED H, V96, P139, DOI 10.1016/S0035-9203(02)90281-6; Berrocal J, 1980, T AM OPHTHALMOLOGICA, VLXXCVIII, P376; BUNDY DAP, 1987, TROP MED PARASITOL, V38, P309; Colli CM, 2010, REV INST MED TROP SP, V52, P69, DOI [10.1590/S0036-46652010000200003, 10.1590/S0036-46652010000200002]; Dumenigo B, 1994, Rev Cubana Med Trop, V46, P99; Dumenigo Blanca, 1995, Revista Cubana de Medicina Tropical, V47, P178; Hernandez Merlo R, 2007, REV CUBANA MED TROPI, V59, P234; Jarosz W, 2010, PARASITOLOGY, V137, P53, DOI 10.1017/S0031182009990874; LAIRD RM, 1995, REV CUBANA HIG EPIDE, V58, P116; Magnaval Jean-Francois, 2001, Korean Journal of Parasitology, V39, P1; MAGNAVAL JF, 1994, T ROY SOC TROP MED H, V88, P531, DOI 10.1016/0035-9203(94)90148-1; Montalvo A M, 1994, Rev Cubana Med Trop, V46, P156; Pinelli E, 2009, EUR J CLIN MICROBIOL, V28, P1327, DOI 10.1007/s10096-009-0785-6; Roldan WH, 2009, REV INST MED TROP SP, V51, P67, DOI 10.1590/S0036-46652009000200002; Rubinsky-Elefant G, 2010, ANN TROP MED PARASIT, V104, P3, DOI 10.1179/136485910X12607012373957; Smith H, 2009, TRENDS PARASITOL, V25, P182, DOI 10.1016/j.pt.2009.01.006; Stensvold CR, 2009, CLIN VACCINE IMMUNOL, V16, P1372, DOI 10.1128/CVI.00234-09; THOMPSON DE, 1986, B WORLD HEALTH ORGAN, V64, P283; Wordemann M, 2006, TROP MED INT HEALTH, V11, P1813, DOI 10.1111/j.1365-3156.2006.01745.x; Won KY, 2008, AM J TROP MED HYG, V79, P552, DOI 10.4269/ajtmh.2008.79.552	22	5	7	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2012	17	6					711	714		10.1111/j.1365-3156.2012.02996.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	945ZE	WOS:000304316100005	22943301	Bronze			2019-03-26	
J	Deroost, K; Lays, N; Noppen, S; Martens, E; Opdenakker, G; Van den Steen, PE				Deroost, Katrien; Lays, Natacha; Noppen, Sam; Martens, Erik; Opdenakker, Ghislain; Van den Steen, Philippe E.			Improved methods for haemozoin quantification in tissues yield organ- and parasite-specific information in malaria-infected mice	MALARIA JOURNAL			English	Article						Chemo-luminescence; Densitometry; Haemozoin quantification; Malaria pigment; Plasmodium	RESPIRATORY-DISTRESS-SYNDROME; CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; VIVAX MALARIA; LUNG INJURY; HEMOZOIN; PIGMENT; ERYTHROCYTES; SEQUESTRATION; CHILDREN	Background: Despite intensive research, malaria remains a major health concern for non-immune residents and travelers in malaria-endemic regions. Efficient adjunctive therapies against life-threatening complications such as severe malarial anaemia, encephalopathy, placental malaria or respiratory problems are still lacking. Therefore, new insights into the pathogenesis of severe malaria are imperative. Haemozoin (Hz) or malaria pigment is produced during intra-erythrocytic parasite replication, released in the circulation after schizont rupture and accumulates inside multiple organs. Many in vitro and ex vivo immunomodulating effects are described for Hz but in vivo data are limited. This study aimed to improve methods for Hz quantification in tissues and to investigate the accumulation of Hz in different organs from mice infected with Plasmodium parasites with a varying degree of virulence. Methods: An improved method for extraction of Hz from tissues was elaborated and coupled to an optimized, quantitative, microtiter plate-based luminescence assay with a high sensitivity. In addition, a technique for measuring Hz by semi-quantitative densitometry, applicable on transmitted light images, was developed. The methods were applied to measure Hz in various organs of C57BL/6 J mice infected with Plasmodium berghei ANKA, P. berghei NK65 or Plasmodium chabaudi AS. The used statistical methods were the Mann-Whitney U test and Pearsons correlation analysis. Results: Most Hz was detected in livers and spleens, lower levels in lungs and kidneys, whereas sub-nanomolar amounts were observed in brains and hearts from infected mice, irrespectively of the parasite strain used. Furthermore, total Hz contents correlated with peripheral parasitaemia and were significantly higher in mice with a lethal P. berghei ANKA or P. berghei NK65-infection than in mice with a self-resolving P. chabaudi AS-infection, despite similar peripheral parasitaemia levels. Conclusions: The developed techniques were useful to quantify Hz in different organs with a high reproducibility and sensitivity. An organ-specific Hz deposition pattern was found and was independent of the parasite strain used. Highest Hz levels were identified in mice infected with lethal parasite strains suggesting that Hz accumulation in tissues is associated with malaria-related mortality.	[Deroost, Katrien; Lays, Natacha; Martens, Erik; Opdenakker, Ghislain; Van den Steen, Philippe E.] Katholieke Univ Leuven, Rega Inst, Immunol Lab, Louvain, Belgium; [Noppen, Sam] Katholieke Univ Leuven, Rega Inst, Lab Mol Immunol, Louvain, Belgium	Van den Steen, PE (reprint author), Katholieke Univ Leuven, Rega Inst, Immunol Lab, Louvain, Belgium.	Philippe.VandenSteen@rega.kuleuven.be	Noppen, Sam/F-8681-2018; Martens, Erik/F-9214-2015; Opdenakker, Ghislain/Q-3130-2017; Van den Steen, Philippe/K-5132-2012	Noppen, Sam/0000-0002-2831-5042; Martens, Erik/0000-0002-7947-6567; Opdenakker, Ghislain/0000-0003-1714-2294; Van den Steen, Philippe/0000-0002-7334-9145; Deroost, Katrien/0000-0001-7580-2479	IWT; "Fonds voor Wetenschappelijk Onderzoek in Vlaanderen (FWO-Vlaanderen)"; Geconcerteerde OnderzoeksActies (GOA); Rega Centre of Excellence [EF/05/015]; Research Fund KU Leuven [CREA/09/023]	KD is a research assistant of the "Instituut voor Wetenschap en Technologie (IWT)", Belgium. This study was supported by the IWT, the "Fonds voor Wetenschappelijk Onderzoek in Vlaanderen (FWO-Vlaanderen)", the "Geconcerteerde OnderzoeksActies (GOA 2007-2011)", the Rega Centre of Excellence (EF/05/015) and the Research Fund KU Leuven (CREA/09/023).	Amodu OK, 1998, T ROY SOC TROP MED H, V92, P54, DOI 10.1016/S0035-9203(98)90952-X; Anstey NM, 2007, J INFECT DIS, V195, P589, DOI 10.1086/510756; Arese P, 1997, ANN TROP MED PARASIT, V91, P501, DOI 10.1080/00034983.1997.11813168; Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815; Coban C, 2007, INT IMMUNOL, V19, P67, DOI 10.1093/intimm/dxl123; Craig AG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002401; Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204; Dorovini-Zis K, 2011, AM J PATHOL, V178, P2146, DOI 10.1016/j.ajpath.2011.01.016; Fonager J, 2012, J EXP MED, V209, P93, DOI 10.1084/jem.20110762; Geurts N, 2008, BIOCHEMISTRY-US, V47, P2689, DOI 10.1021/bi702260q; Goldberg DE, 2005, CURR TOP MICROBIOL, V295, P275; Grau GE, 2003, J INFECT DIS, V187, P461, DOI 10.1086/367960; Hanscheid T, 2007, LANCET INFECT DIS, V7, P675, DOI 10.1016/S1473-3099(07)70238-4; Hanscheid T, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-109; Haque A, 2011, J IMMUNOL, V186, P6148, DOI 10.4049/jimmunol.1003955; Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8; Janse CJ, 2006, NAT PROTOC, V1, P346, DOI 10.1038/nprot.2006.53; LAWRENCE C, 1986, AM J CLIN PATHOL, V86, P360, DOI 10.1093/ajcp/86.3.360; Levesque MA, 1999, J PARASITOL, V85, P570, DOI 10.2307/3285800; Mohan Alladi, 2008, Journal of Vector Borne Diseases, V45, P179; Muehlenbachs A, 2010, J INFECT DIS, V202, P1608, DOI 10.1086/656723; Ncokazi KK, 2005, ANAL BIOCHEM, V338, P306, DOI 10.1016/j.ab.2004.11.022; Noland GS, 2003, MOL BIOCHEM PARASIT, V130, P91, DOI 10.1016/S0166-6851(03)00163-4; ORJIH AU, 1993, BIOCHIM BIOPHYS ACTA, V1157, P270, DOI 10.1016/0304-4165(93)90109-L; PHU NH, 1995, T ROY SOC TROP MED H, V89, P200; Rosenthal PJ, 1996, MOL BIOCHEM PARASIT, V83, P131, DOI 10.1016/S0166-6851(96)02763-6; Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686; Schwarzer E., 2008, Parassitologia (Rome), V50, P143; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; SCHWARZER E, 1994, BRIT J HAEMATOL, V88, P740, DOI 10.1111/j.1365-2141.1994.tb05112.x; Scorza T, 1999, PARASITE IMMUNOL, V21, P545, DOI 10.1046/j.1365-3024.1999.00254.x; Shio MT, 2010, MICROBES INFECT, V12, P889, DOI 10.1016/j.micinf.2010.07.001; Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X; Spaccapelo R, 2010, AM J PATHOL, V176, P205, DOI 10.2353/ajpath.2010.090504; Stephens R, 2012, TRENDS PARASITOL, V28, P73, DOI 10.1016/j.pt.2011.10.006; Sullivan AD, 2000, PLACENTA, V21, P417, DOI 10.1053/plac.1999.0479; Sullivan AD, 1996, PARASITOLOGY, V112, P285, DOI 10.1017/S003118200006580X; Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986; Valecha N, 2009, AM J TROP MED HYG, V81, P758, DOI 10.4269/ajtmh.2009.09-0348; Van den Steen PE, 2010, AM J RESP CRIT CARE, V181, P957, DOI 10.1164/rccm.200905-0786OC; Yuan JC, 1999, ANAL CHEM, V71, P1975, DOI 10.1021/ac981357c	41	13	13	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAY 14	2012	11								166	10.1186/1475-2875-11-166				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	021FD	WOS:000309869800001	22583751	DOAJ Gold, Green Published			2019-03-26	
J	Manyando, C; Kayentao, K; D'Alessandro, U; Okafor, HU; Juma, E; Hamed, K				Manyando, Christine; Kayentao, Kassoum; D'Alessandro, Umberto; Okafor, Henrietta U.; Juma, Elizabeth; Hamed, Kamal			A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy	MALARIA JOURNAL			English	Review						Artemether-lumefantrine; Artemisinin-based combination therapy (ACT); Pregnancy; Malaria; Plasmodium falciparum	POPULATION PHARMACOKINETICS; DEVELOPMENTAL TOXICITY; RETICULOCYTE COUNT; INTERACTION TRIAL; WOMEN; ARTESUNATE; ARTEMISININS; ANTIMALARIALS; UGANDA; ARTEMETHER/LUMEFANTRINE	Malaria during pregnancy, particularly Plasmodium falciparum malaria, has been linked to increased morbidity and mortality, which must be reduced by both preventive measures and effective case management. The World Health Organization (WHO) recommends artemisinin-based combination therapy (ACT) to treat uncomplicated falciparum malaria during the second and third trimesters of pregnancy, and quinine plus clindamycin during the first trimester. However, the national policies of many African countries currently recommend quinine throughout pregnancy. Therefore, the aim of this article is to provide a summary of the available data on the safety and efficacy of artemether-lumefantrine (AL) in pregnancy. An English-language search identified 16 publications from 1989 to October 2011 with reports of artemether or AL exposure in pregnancy, including randomized clinical trials, observational studies and systematic reviews. Overall, there were 1,103 reports of AL use in pregnant women: 890 second/third trimester exposures; 212 first trimester exposures; and one case where the trimester of exposure was not reported. In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine. There is evidence to suggest that the pharmacokinetics of antimalarial drugs may change in pregnancy, although the impact on efficacy and safety needs to be studied further, especially since the majority of studies report high cure rates and adequate tolerability. As there are fewer reports of AL safety in the first trimester, additional data are required to assess the potential to use AL in the first trimester. Though the available safety and efficacy data support the use of AL in the second and third trimesters, there is still a need for further information. These findings reinforce the WHO recommendation to treat uncomplicated falciparum malaria with quinine plus clindamycin in early pregnancy and ACT in later pregnancy.	[Manyando, Christine] Trop Dis Res Ctr, Ndola, Zambia; [Kayentao, Kassoum] Malaria Res & Training Ctr, Bamako, Mali; [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium; [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia; [Okafor, Henrietta U.] Univ Nigeria, Dept Paediat, Coll Med, Enugu, Nigeria; [Juma, Elizabeth] Kenya Govt Med Res Ctr, Kisumu, Kenya; [Hamed, Kamal] Novartis Pharmaceut, E Hanover, NJ USA	Manyando, C (reprint author), Trop Dis Res Ctr, Ndola, Zambia.	cmanyando@yahoo.com	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Hamed, Kamal/0000-0003-1896-9736	Novartis Pharma AG	The authors would like to thank Kirstin Stricker for her critical review of the manuscript. Dr Lisa Redrup of PreScript Communications provided editorial support sponsored by Novartis Pharma AG.	Adam I, 2004, T ROY SOC TROP MED H, V98, P509, DOI 10.1016/j.trstmh.2003.11.008; Adam I, 2009, ANN TROP MED PARASIT, V103, P205, DOI 10.1179/136485909X398285; [Anonymous], 2010, GUID TREATM MAL S AF; [Anonymous], PHARM STUD; Ashley EA, 2007, TROP MED INT HEALTH, V12, P201, DOI 10.1111/j.1365-3165.2006.01785.x; Azairwe R., 2011, Southern Sudan Medical Journal, V4, P30; Bardaji A, 2011, J INFECT DIS, V203, P691, DOI 10.1093/infdis/jiq049; Birku Y, 2002, ETHIOPIAN MED J, V40, P17; Byakika-Kibwika P, 2010, THER CLIN RISK MANAG, V6, P11; Chi BH, 2011, INT J GYNECOL OBSTET, V113, P131, DOI [10.1016/j.ijgo.2010.11.013, 10.1016/j.ijgo.2010.11.1313]; Clark RL, 2008, BIRTH DEFECTS RES B, V83, P397, DOI 10.1002/bdrb.20165; Clark RL, 2012, BIRTH DEFECTS RES A, V94, P61, DOI 10.1002/bdra.22868; Dellicour S, 2008, PLOS MED, V5, P1310, DOI 10.1371/journal.pmed.0050187; Dellicour S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-15; Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Djimde A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-S1-S4; Ezzet F, 2000, ANTIMICROB AGENTS CH, V44, P697, DOI 10.1128/AAC.44.3.697-704.2000; German P, 2009, JAIDS-J ACQ IMM DEF, V51, P424, DOI 10.1097/QAI.0b013e3181acb4ff; Kaye DK, 2008, J INFECT DEV COUNTR, V2, P135, DOI 10.3855/T2.2.135; Lefevre G, 2000, EUR J PHARM SCI, V10, P141, DOI 10.1016/S0928-0987(00)00060-9; Lefevre G, 2002, J CLIN PHARMACOL, V42, P1147, DOI 10.1177/009127002237995; Lefevre G, 2001, AM J TROP MED HYG, V64, P247, DOI 10.4269/ajtmh.2001.64.247; Makanga M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-S1-S5; Manyando C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-249; McGready R, 2012, LANCET INFECT DIS, V12, P388, DOI 10.1016/S1473-3099(11)70339-5; McGready R, 2011, BJOG-INT J OBSTET GY, V118, P123, DOI 10.1111/j.1471-0528.2010.02810.x; McGready R, 1999, ANN TROP MED PARASIT, V93, pS19, DOI 10.1080/00034989957709; McGready R, 1998, T ROY SOC TROP MED H, V92, P430, DOI 10.1016/S0035-9203(98)91081-1; McGready R, 2001, CLIN INFECT DIS, V33, P2009, DOI 10.1086/324349; McGready R, 2008, PLOS MED, V5, P1699, DOI 10.1371/journal.pmed.0050253; McGready R, 2006, EUR J CLIN PHARMACOL, V62, P1021, DOI 10.1007/s00228-006-0199-7; Menendez C, 2008, PLOS MED, V5, P220, DOI 10.1371/journal.pmed.0050044; Morris CA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-114; Nosten F, 2007, LANCET INFECT DIS, V7, P118, DOI 10.1016/S1473-3099(07)70023-3; Onyamboko MA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-49; Orton LC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004912.pub3; Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1; Piola P, 2010, LANCET INFECT DIS, V10, P762, DOI 10.1016/S1473-3099(10)70202-4; Poespoprodjo JR, 2011, AM J TROP MED HYG S6, V85; President's Malaria Initiative, MAL OP PLAN MOP FY20; Roll Back Malaria Partnership, 2005 THAIL COUNTR PR; Roll Back Malaria Partnership, 2005 CHIN COUNTR PRO; Sangare LR, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-152; Sinclair D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007483.pub2; Sowunmi A., 1998, Journal of Obstetrics and Gynaecology (Abingdon), V18, P322; Tarning J, 2009, ANTIMICROB AGENTS CH, V53, P3837, DOI 10.1128/AAC.00195-09; Ter Kuile FO, 2004, AM J TROP MED HYG, V71, P41, DOI 10.4269/ajtmh.2004.71.41; Ugandan Malaria Control Programme, UG NAT POL MAL 2005; Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/ajtmh.2004.71.35; WANG T, 1989, Journal of Traditional Chinese Medicine, V9, P28; White TEK, 2008, BIRTH DEFECTS RES B, V83, P407, DOI 10.1002/bdrb.20157; Whitty CJM, 2005, BJOG-INT J OBSTET GY, V112, P1189, DOI 10.1111/j.1471-0528.2005.00714.x; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, ANT CHLORPR DAPS LAP; Wilby KJ, 2011, CLIN PHARMACOKINET, V50, P705, DOI 10.2165/11594550-000000000-00000; World Health Organization, COUNTR ANT DRUG POL; World Health Organization, GLOB REP ANT DRUG EF; World Health Organization, 2006, ASS SAF ART COMP PRE; World Health Organization, 2010, GUID TREATM MAL	60	36	36	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAY 1	2012	11								141	10.1186/1475-2875-11-141				13	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	982CU	WOS:000307020100001	22548983	DOAJ Gold, Green Published			2019-03-26	
J	Hendrickx, S; da Luz, RAI; Bhandari, V; Kuypers, K; Shaw, CD; Lonchamp, J; Salotra, P; Carter, K; Sundar, S; Rijal, S; Dujardin, JC; Cos, P; Maes, L				Hendrickx, Sarah; da Luz, Raquel Andrea Inocencio; Bhandari, Vasundhra; Kuypers, Kristel; Shaw, Craig D.; Lonchamp, Julien; Salotra, Poonam; Carter, Katharine; Sundar, Shyam; Rijal, Suman; Dujardin, Jean-Claude; Cos, Paul; Maes, Louis			Experimental Induction of Paromomycin Resistance in Antimony-Resistant Strains of L. donovani: Outcome Dependent on In Vitro Selection Protocol	PLOS NEGLECTED TROPICAL DISEASES			English	Article							VISCERAL LEISHMANIASIS; SODIUM STIBOGLUCONATE; COMBINATION THERAPY; HOST-CELLS; OPEN-LABEL; KALA-AZAR; PROMASTIGOTES; SUDAN; MITOCHONDRIAL; EXPRESSION	Paromomycin (PMM) has recently been introduced for treatment of visceral leishmaniasis in India. Although no clinical resistance has yet been reported, proactive vigilance should be warranted. The present in vitro study compared the outcome and stability of experimental PMM-resistance induction on promastigotes and intracellular amastigotes. Cloned antimony-resistant L. donovani field isolates from India and Nepal were exposed to stepwise increasing concentrations of PMM (up to 500 mu M), either as promastigotes or intracellular amastigotes. One resulting resistant strain was cloned and checked for stability of resistance by drug-free in vitro passage as promastigotes for 20 weeks or a single in vivo passage in the golden hamster. Resistance selection in promastigotes took about 25 weeks to reach the maximal 97 mu M inclusion level that did not affect normal growth. Comparison of the IC50 values between the parent and the selected strains revealed a 9 to 11-fold resistance for the Indian and 3 to 5-fold for the Nepalese strains whereby the resistant phenotype was also maintained at the level of the amastigote. Applying PMM pressure to intracellular amastigotes produced resistance after just two selection cycles (IC50 = 199 mu M) compared to the parent strain (IC50= 45 mu M). In the amastigote-induced strains/clones, lower PMM susceptibilities were seen only in amastigotes and not at all in promastigotes. This resistance phenotype remained stable after serial in vitro passage as promastigote for 20 weeks and after a single in vivo passage in the hamster. This study clearly demonstrates that a different PMM-resistance phenotype is obtained whether drug selection is applied to promastigotes or intracellular amastigotes. These findings may have important relevance to resistance mechanism investigations and the likelihood of resistance development and detection in the field.	[Hendrickx, Sarah; da Luz, Raquel Andrea Inocencio; Kuypers, Kristel; Cos, Paul; Maes, Louis] Univ Antwerp, Lab Microbiol Parasitol & Hyg, B-2020 Antwerp, Belgium; [Bhandari, Vasundhra; Salotra, Poonam] Natl Inst Pathol, New Delhi, India; [Shaw, Craig D.; Lonchamp, Julien; Carter, Katharine] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland; [Sundar, Shyam] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Rijal, Suman] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Dujardin, Jean-Claude] Inst Trop Med Antwerp, Antwerp, Belgium	Hendrickx, S (reprint author), Univ Antwerp, Lab Microbiol Parasitol & Hyg, B-2020 Antwerp, Belgium.	louis.maes@ua.ac.be	Inocencio da Luz, Raquel/L-9676-2016; Cos, Paul/L-9717-2015; Maes, Louis/A-2384-2017	Inocencio da Luz, Raquel/0000-0002-2870-0311; Cos, Paul/0000-0003-4361-8911; Maes, Louis/0000-0002-2324-9509; Salotra, Poonam/0000-0002-4057-4872	European Commission [ICA4-CT-2001-10076, 222895]	This work was financially supported by the European Commission's Specific International Scientific Cooperation Activities (LeishNatDrug-R project, grant number ICA4-CT-2001-10076), and the European Commission's Seventh Framework Programme (Kaladrug-R project, grant number 222895). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brotherton MC, 2010, J PROTEOME RES, V9, P3842, DOI 10.1021/pr100048m; Chakraborty B, 2010, BIOCHEMISTRY-MOSCOW+, V75, P494, DOI 10.1134/S0006297910040140; Coelho AC, 2012, PLOS NEGL TROP DIS; Cos P, 2010, CURR PHARM DESIGN, V16, P2279, DOI 10.2174/138161210791792868; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]; da Luz RI, 2009, ANTIMICROB AGENTS CH, V53, P5197, DOI 10.1128/AAC.00866-09; Davidson RN, 2009, T ROY SOC TROP MED H, V103, P653, DOI 10.1016/j.trstmh.2008.09.008; Dhillon G P S, 2008, J Indian Med Assoc, V106, P666; Holzer TR, 2006, MOL BIOCHEM PARASIT, V146, P198, DOI 10.1016/j.molbiopara.2005.12.009; Jha TK, 2006, INDIAN J MED RES, V123, P389; Jhingran A, 2009, MOL BIOCHEM PARASIT, V164, P111, DOI 10.1016/j.molbiopara.2008.12.007; Kulshrestha A, 2011, ANTIMICROB AGENTS CH, V55, P2916, DOI 10.1128/AAC.00812-10; Maarouf M, 1998, PARASITE, V5, P167, DOI 10.1051/parasite/1998052167; Maarouf M, 1997, EXP CELL RES, V232, P339, DOI 10.1006/excr.1997.3500; Maes L, 2004, ANTIMICROB AGENTS CH, V48, P130, DOI 10.1128/AAC.48.1.130-136.2004; Melaku Y, 2007, AM J TROP MED HYG, V77, P89, DOI 10.4269/ajtmh.2007.77.89; Mukhopadhyay R, 2011, INT J PARASITOL, V41, P1311, DOI 10.1016/j.ijpara.2011.07.013; Murray HW, 2010, FUTURE MICROBIOL, V5, P1301, DOI 10.2217/FMB.10.92; Musa AM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000855; Sundar S, 2008, EXPERT OPIN INV DRUG, V17, P787, DOI [10.1517/13543784.17.5.787 , 10.1517/13543780802030168]; Sundar S, 2007, NEW ENGL J MED, V356, P2571, DOI 10.1056/NEJMoa066536; Sundar S, 2006, INDIAN J MED RES, V123, P345; t'Kindt R, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000904; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P429, DOI 10.1016/S0035-9203(00)90130-5; Thornton SJ, 2010, DRUG DEV IND PHARM, V36, P1312, DOI 10.3109/03639041003796648; Tintaya KWQ, 2004, J INFECT DIS, V189, P1035, DOI 10.1086/382049; van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6; Vermeersch M, 2009, ANTIMICROB AGENTS CH, V53, P3855, DOI 10.1128/AAC.00548-09; Zheng LA, 2010, RAPID COMMUN MASS SP, V24, P2074, DOI 10.1002/rcm.4618	29	26	26	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2012	6	5							e1664	10.1371/journal.pntd.0001664				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	951ZG	WOS:000304758900041	22666513	DOAJ Gold, Green Published			2019-03-26	
J	Castro, M; Sanchez, L; Perez, D; Carbonell, N; Lefevre, P; Vanlerberghe, V; Van der Stuyft, P				Castro, Marta; Sanchez, Lizet; Perez, Dennis; Carbonell, Nestor; Lefevre, Pierre; Vanlerberghe, Veerle; Van der Stuyft, Patrick			A community empowerment strategy embedded in a routine dengue vector control programme: a cluster randomised controlled trial	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Aedes aegypti; Dengue; Empowerment; Community participation; Randomised controlled trial; Cuba	AEDES-AEGYPTI CONTROL; INTERSECTORAL COORDINATION; COST-EFFECTIVENESS; CUBA; PARTICIPATION; HAVANA; INTERVENTIONS; PREVENTION; SANTIAGO; HEALTH	The non-sustainability of vertically organised dengue vector control programmes led to pleas for changing the emphasis towards community-based strategies. We conducted a cluster randomised controlled trial with 16 intervention and 16 control clusters to test the effectiveness of a community empowerment strategy intertwined with the routine dengue vector control programme in La Lisa, Havana City, Cuba. The intervention included four components on top of routine control: organisation and management; entomological risk surveillance; capacity building; and community work for vector control. In the control clusters, routine activities continued without interference. The community participation score increased from 1.4 to 3.4. Good knowledge of breeding sites increased by 52.8% and 27.5% in the intervention and control clusters, respectively. There were no changes in adequate Aedes aegypti control practices at household level in the control clusters, but in the intervention clusters adequacy increased by 36.2%. At baseline, the Breteau indices (BI) were approximately 0.1 and were comparable; they fluctuated over time but became different with the launch of the community-based dengue control activities in the intervention clusters. Over the intervention period, the BI remained 53% (95% Cl 22-92%) lower in these clusters than in the control clusters. The empowerment strategy increased community involvement and added effectiveness to routine A. aegypti control. (C) 2012 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Castro, Marta; Sanchez, Lizet; Perez, Dennis] Inst Trop Med Pedro Kouri, Div Epidemiol, Havana, Cuba; [Carbonell, Nestor] Univ Sancti Spiritus, Dept Math, Sancti Spiritus, Cuba; [Lefevre, Pierre; Vanlerberghe, Veerle; Van der Stuyft, Patrick] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium	Castro, M (reprint author), Inst Trop Med Pedro Kouri, Div Epidemiol, Km 6,AP 601,Marianao 13, Havana, Cuba.	martac@ipk.sld.cu			Cuban Ministry of Health; Institute of Tropical Medicine 'Pedro Kouri' (Havana City, Cuba); Institute of Tropical Medicine (Antwerp, Belgium); Belgium Directorate-General for Development Cooperation	This research was funded by the Cuban Ministry of Health and through a framework agreement between the Institute of Tropical Medicine 'Pedro Kouri' (Havana City, Cuba), the Institute of Tropical Medicine (Antwerp, Belgium) and the Belgium Directorate-General for Development Cooperation.	Ballenger-Browning KK, 2009, TROP MED INT HEALTH, V14, P1542, DOI 10.1111/j.1365-3156.2009.02396.x; Baly A, 2007, T ROY SOC TROP MED H, V101, P578, DOI 10.1016/j.trstmh.2007.01.002; Baly A, 2009, AM J TROP MED HYG, V81, P88, DOI 10.4269/ajtmh.2009.81.88; Castro M, 2008, REV CUBANA MED TROPI, V60, P83; de Oliveira R M, 2001, Cad Saude Publica, V17 Suppl, P77, DOI 10.1590/S0102-311X2001000700016; Elder JP, 2005, EVALUATION COMMUNICA; Farrar J, 2007, TROP MED INT HEALTH, V12, P695, DOI 10.1111/j.1365-3156.2007.01838; Freire P, 1970, PEDAGOGY OPPRESSED; Gubler DJ, 1996, ACTA TROP, V61, P169, DOI 10.1016/0001-706X(95)00103-L; Guzman MG, 2005, SCIENCE, V309, P1495, DOI 10.1126/science.1115177; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Heintze C, 2007, T ROY SOC TROP MED H, V101, P317, DOI 10.1016/j.trstmh.2006.08.007; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Kay BH, 2010, AM J TROP MED HYG, V82, P822, DOI 10.4269/ajtmh.2010.09-0503; KOURI GP, 1989, B WORLD HEALTH ORGAN, V67, P375; Kroeger A, 2006, BRIT MED J, V332, P1247, DOI 10.1136/bmj.332.7552.1247; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Marquetti Fernández María del Carmen, 2009, Rev Cubana Med Trop, V61, P232; Marquetti Maria del Carmen, 2000, Revista Cubana de Medicina Tropical, V52, P170; Marquetti MC, 2008, REV CUBA MED TROP, V60, P62; Pelaez O, 2004, EMERG INFECT DIS, V10, P719, DOI 10.3201/eid1004.030271; Perez D, 2007, TROP MED INT HEALTH, V12, P664, DOI 10.1111/j.1365-3156.2007.01833.x; Perez D, 2011, HEALTH POLICY PLANN, V26, P413, DOI 10.1093/heapol/czq077; Rebchook GM, 2006, AIDS EDUC PREV, V18, P119, DOI 10.1521/aeap.2006.18.supp.119; RIFKIN SB, 1988, SOC SCI MED, V26, P931, DOI 10.1016/0277-9536(88)90413-3; Rogers E. M, 2003, DIFFUSION INNOVATION; Romani MET, 2007, SOC SCI MED, V64, P976, DOI 10.1016/j.socscimed.2006.10.033; Ruppert D., 2003, SEMIPARAMETRIC REGRE; Sanchez L, 2005, TROP MED INT HEALTH, V10, P82, DOI 10.1111/j.1365-3156.2004.01347.x; Sanchez L, 2009, TROP MED INT HEALTH, V14, P1356, DOI 10.1111/j.1365-3156.2009.02379.x; Sanchez L, 2008, REV PANAM SALUD PUBL, V24, P61, DOI 10.1590/S1020-49892008000700008; *TDR, 2006, SCI WORK GROUP M DEN; Toledo ME, 2007, T ROY SOC TROP MED H, V101, P56, DOI 10.1016/j.trstmh.2006.03.006; Toledo ME, 2011, TROP MED INT HEALTH, V16, P744, DOI 10.1111/j.1365-3156.2011.02762.x; Vanlerberghe V, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1959	35	29	31	0	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAY	2012	106	5					315	321		10.1016/j.trstmh.2012.01.013				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	937WA	WOS:000303692500007	22465423				2019-03-26	
J	Martinez, FP; Picado, A; Roddy, P; Palma, P				Pascual Martinez, F.; Picado, A.; Roddy, P.; Palma, P.			Low castes have poor access to visceral leishmaniasis treatment in Bihar, India	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Kala azar; visceral leishmaniasis; caste; Bihar; Mushar; Kala-azar; leishmaniose viscerale; caste; Bihar; Mushar; Kala azar; leishmaniasis visceral; casta; Bihar; Mushar	AMPHOTERICIN-B; KALA-AZAR; MALNUTRITION; RISK; MANAGEMENT; POVERTY; PROGRAM	Objectives Bihar, the poorest state in India, concentrates most of the visceral leishmaniasis (VL) cases in the country. A large proportion of the poor rural communities where VL is endemic are marginalized by their socio-economic status, intrinsically related to the caste system. In this study, we evaluated whether people from low socio-economic strata had difficulties accessing VL treatment in Bihar. As a secondary outcome, we evaluated whether people delaying their VL treatment had poorer clinical indicators at admission. methods Data on 2187 patients with VL treated by Me ' decins Sans Frontie` res ( MSF) in Vaishali district from July 2007 to December 2008 were analysed. Patients who reported having onset of symptoms 8 weeks before admission were defined as ` late presenters'. Logistic regression models were used to evaluate whether low castes had higher risk to be ` late presenters' compared to the rest of castes and whether ` late presenters' had poorer indicators at admission ( i. e. haemoglobin level, spleen size). results After adjusting for age, gender and distance to VL treatment facility, Mushars ( the lowest caste in Bihar) had twice the odds to be ` late presenters' compared to the rest of castes ( OR 2.05, 95% CI: 1.24-2.38). Subjects that had VL symptoms for 8 weeks had a larger spleen and lower haemoglobin level than those that were treated earlier. conclusion Low castes have poor access to VL treatment in Bihar, and late presenters have poorer clinical indicators at admission. These findings have implications at individual and community levels and should stimulate targeted VL control programmes to ensure that marginalized communities in Bihar are properly treated.	[Pascual Martinez, F.; Roddy, P.; Palma, P.] Med Sans Frontieres Operat Ctr Barcelona, Barcelona 08001, Spain; [Picado, A.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Picado, A.] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England	Martinez, FP (reprint author), Med Sans Frontieres Operat Ctr Barcelona, Nou Rambla 26, Barcelona 08001, Spain.	fernando.pascual@barcelona.msf.org		Picado, Albert/0000-0001-7344-628X			Alvar J, 2006, TRENDS PARASITOL, V22, P552, DOI 10.1016/j.pt.2006.09.004; Babu BV, 2001, J HLTH MANAGEMENT, V3, P1, DOI DOI 10.1177/097206340100300101; Barratt G, 2005, CURR OPIN INFECT DIS, V18, P527, DOI 10.1097/01.qco.0000191508.48481.f4; Boelaert M, 2009, TROP MED INT HEALTH, V14, P639, DOI 10.1111/j.1365-3156.2009.02279.x; CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030; Collin S, 2004, CLIN INFECT DIS, V38, P612, DOI 10.1086/381203; de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497; Dedet J, 2008, MANSONS TROPICAL DIS, P1341, DOI [10.1016/j.trstmh.2009.09.003, DOI 10.1016/J.TRSTMH.2009.09.003]; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; DYE C, 1993, P ROY SOC B-BIOL SCI, V254, P33, DOI 10.1098/rspb.1993.0123; Hasker E, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02562.x; Heymann DL, 2008, CONTROL COMMUNICABLE; India. G.o, 2001, CENS IND; India. M.o.H.a.F.W.G.o, 2009, ANN REP 2008 2009, P88; Mondal D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000355; Ostyn B, 2008, TROP MED INT HEALTH, V13, P1073, DOI 10.1111/j.1365-3156.2008.02110.x; Ranjan A, 2005, AM J TROP MED HYG, V73, P74, DOI 10.4269/ajtmh.2005.73.74; Sinha PK, 2010, AM J TROP MED HYG, V83, P357, DOI 10.4269/ajtmh.2010.10-0156; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P156, DOI 10.1016/S0035-9203(00)90255-4; Van de Poel E, 2009, ETHNIC HEALTH, V14, P271, DOI 10.1080/13557850802609931; Watch HR, 2007, HIDD APARTH CAST DIS, P13; WHO, 2005, REP WHO INF CONS LIP, P13; *WHO, 2005, 1 M MAN HAR 20 23 DE; WHO/UNICEF, 2009, WHO CHILD GROWTH STA; World Health Organization, 2009, WHO GLOB DAT VIT A D, P1; World Health Organization, 2004, WORLD HLTH REP 2004	26	16	16	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2012	17	5					666	673		10.1111/j.1365-3156.2012.02960.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	928RU	WOS:000303001900017	22385129	Bronze			2019-03-26	
J	Falisse, JB; Meessen, B; Ndayishimiye, J; Bossuyt, M				Falisse, Jean-Benoit; Meessen, Bruno; Ndayishimiye, Juvenal; Bossuyt, Michel			Community participation and voice mechanisms under performance-based financing schemes in Burundi	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						community participation; performance-based financing; primary health care; health systems; rural health centres; Burundi; participation communautaire; financement base sur la performance; soins de sante primaires; systemes de sante; centres de sante ruraux; Burundi; participacion comunitaria; financiamiento basado en el desempeno; atencion primaria; sistemas sanitarios; centro de salud rural; Burundi	DEVELOPING-COUNTRIES; HEALTH SYSTEMS; LESSONS; REALITY; RWANDA; REFORM; POLICY; CARE	Objective Community participation is often described as a key for primary health care in low-income countries. Recent performance-based financing (PBF) initiatives have renewed the interest in this strategy by questioning the accountability of those in charge at the health centre (HC) level. We analyse the place of two downward accountability mechanisms in a PBF scheme: health committees elected among the communities and community-based organizations (CBOs) contracted as verifiers of health facilities performance. method We evaluated 100 health committees and 79 CBOs using original data collected in six Burundi provinces (2009-2010) and a framework based on the literature on community participation in health and New Institutional Economics. results Health committees appear to be rather ineffective, focusing on supporting the medical staff and not on representing the population. CBOs do convey information about the concerns of the population to the health authorities; yet, they represent only a few users and lack the ability to force changes. PBF does not automatically imply more ` voice' from the population, but introduces an interesting complement to health committees with CBOs. However, important efforts remain necessary to make both mechanisms work. More experiments and analysis are needed to develop truly efficient ` downward' mechanisms of accountability at the HC level.	[Falisse, Jean-Benoit] Univ Oxford, Dept Int Dev, Oxford, England; [Meessen, Bruno] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Falisse, JB (reprint author), Oxford Dept Int Dev, Queen Elizabeth House,3 Mansfield Rd, Oxford OX1 3TB, England.	jean-benoit.falisse@qeh.ox.ac.uk	Falisse, Jean-Benoit/J-9815-2015	Falisse, Jean-Benoit/0000-0002-0291-731X; Meessen, Bruno/0000-0002-0359-8621	European Union	We dedicate this article to the memory of our colleague and friend Pierre-Antoine Cavert. As the Health Programme Officer of the European Union in Burundi between 2006 and 2010, he strongly supported this research and provided us with insightful comments. We also thank the European Union that funded the research as well as Cordaid, the Swiss Tropical Institute Office in Ngozi and the Ministry of Public Health of Burundi for their cooperation during the field research. We are grateful to Maria Paola Bertone and Kristof Decoster for their careful proofreading and comments on this paper.	Basenya O, 2011, PBF COP WORKING PAPE, V4, P1; Basinga P, 2011, B WORLD HEALTH ORGAN, V89, P698, DOI 10.2471/BLT.11.089912; Berlan D, 2012, HEALTH POLICY PLANN, V27, P271, DOI 10.1093/heapol/czr036; Bertone MP, 2011, 3 INT C HLTH FIN DEV; Bjorkman M, 2009, Q J ECON, V124, P735; Bjorkman M, 2010, J EUR ECON ASSOC, V8, P571, DOI 10.1111/j.1542-4774.2010.tb00527.x; Brinkerhoff DW, 2004, HEALTH POLICY PLANN, V19, P371, DOI 10.1093/heapol/czh052; Brinkerhoff DW, 2009, GOOD GOVERNANCE HLTH; Busogoro JF, 2010, PAY PERFORMANCE IMPR; Cooke B., 2001, PARTICIPATION NEW TY; Deheneffe J-C, 2008, RAPPORT MISSION ETUD; Evans D, 2010, J PUBLIC HEALTH-UK, V32, P418, DOI 10.1093/pubmed/fdq014; Falisse J-B, 2010, PARTICIPATION COMMUN; Falisse J-B, 2011, PBF COP WORKING PAPE, P1; Hirschman A. O., 1970, EXIT VOICE LOYALTY R; Ireland M, 2011, B WORLD HEALTH ORGAN, V89, P695, DOI 10.2471/BLT.11.087379; Jacobs B, 2003, HEALTH POLICY PLANN, V18, P399, DOI 10.1093/heapol/czg048; Kahssay HM, 1999, PUBLIC HLTH ACTION, V5; Macq J, 2007, B WORLD HEALTH ORGAN, V85, P699; McCoy DC, 2012, HEALTH POLICY PLANN, V27, P449, DOI 10.1093/heapol/czr077; Meessen B., 2009, I EC ANAL PUBLIC HLT; Meessen B, 2011, B WORLD HEALTH ORGAN, V89, P153, DOI 10.2471/BLT.10.077339; Meessen B, 2006, TROP MED INT HEALTH, V11, P1303, DOI 10.1111/j.1365-3156.2006.01680.x; Ministry of Public Health of Burundi & WHO, 2007, GUID ORG COM SANT BU; Misra V, 2007, SOCIAL ACCOUNTABILIT, V1, P1; Mitchell SM, 2000, MILBANK Q, V78, P241, DOI 10.1111/1468-0009.00170; Molyneux S, 2012, HEALTH POLICY PLANN, V27, P541, DOI 10.1093/heapol/czr083; Morgan LM, 2001, HEALTH POLICY PLANN, V16, P221, DOI 10.1093/heapol/16.3.221; Musembi F, 2000, IDS BULL-I DEV STUD, V31, P64, DOI 10.1111/j.1759-5436.2000.mp31001010.x; Musgrove P, 2010, FINANCIAL OTHER REWA; Nimpagaritse M, 2011, HLTH POLICY PLAN S2, V26, pii63, DOI DOI 10.1093/HEAP0L/CZR061; Rifkin S. B., 2000, PARTICIPATORY APPROA; Rifkin S. B., 1986, HLTH POLICY PLANNING, V1, P240, DOI DOI 10.1093/HEAP0L/1.3.240; Rifkin SB, 1996, ACTA TROP, V61, P79, DOI 10.1016/0001-706X(95)00105-N; RIFKIN SB, 1988, SOC SCI MED, V26, P931, DOI 10.1016/0277-9536(88)90413-3; Rosato M, 2008, LANCET, V372, P962, DOI 10.1016/S0140-6736(08)61406-3; Rusa L, 2009, PERFORMANCE INCENTIV, P189; Soeters R, 2006, B WORLD HEALTH ORGAN, V84, P884; Soeters R, 2011, B WORLD HEALTH ORGAN, V89, P700, DOI 10.2471/BLT.11.089987; Tizio S, 1997, TIERS MONDE, V38, P837; Toonen J., 2009, LEARNING LESSONS IMP; Wakabi W, 2007, LANCET, V369, P1847, DOI 10.1016/S0140-6736(07)60832-0; WHO, 2008, WORLD HLTH REP 2008; WHO, 2009, BUR DAT; World Bank, 2011, WOR BANK STUD, P1, DOI 10.1596/978-0-8213-8800-6; World Bank, 2003, WORLD BANK DEV REP 2; Zachus ZD, 1998, HLTH POLICY PLANNING, V13, P1	47	29	29	2	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2012	17	5					674	682		10.1111/j.1365-3156.2012.02973.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	928RU	WOS:000303001900018	22487362	Bronze			2019-03-26	
J	Bhandari, V; Kulshrestha, A; Deep, DK; Stark, O; Prajapati, VK; Ramesh, V; Sundar, S; Schonian, G; Dujardin, JC; Salotra, P				Bhandari, Vasundhra; Kulshrestha, Arpita; Deep, Deepak Kumar; Stark, Olivia; Prajapati, Vijay Kumar; Ramesh, V.; Sundar, Shyam; Schonian, Gabriele; Dujardin, Jean Claude; Salotra, Poonam			Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis	PLOS NEGLECTED TROPICAL DISEASES			English	Article							ORAL MILTEFOSINE; INDIA; DONOVANI; TRANSLOCATION; ANTIMONY	Background: With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of Leishmania donovani is vital to preserve it and support the VL elimination program. Methodology and Principal Findings: We measured in vitro susceptibility towards MIL and paromomycin (PMM) in L. donovani isolated from VL and PKDL, pre- and post-treatment cases, using an amastigote-macrophage model. MIL susceptibility of post-treatment isolates from cured VL cases (n = 13, mean IC50 +/- SD = 2.43 +/- 1.44 mu M), was comparable (p>0.05) whereas that from relapses (n = 3, mean IC50 = 4.72 +/- 1.99 mu M) was significantly higher (p = 0.04) to that of the pre-treatment group (n = 6, mean IC50 = 1.86 +/- 0.75 mu M). In PKDL, post-treatment isolates (n = 3, mean IC50 = 16.13 +/- 2.64 mu M) exhibited significantly lower susceptibility (p = 0.03) than pre-treatment isolates (n = 5, mean IC50 = 8.63 +/- 0.94 mu M). Overall, PKDL isolates (n = 8, mean IC50 = 11.45 +/- 4.19 mu M) exhibited significantly higher tolerance (p<0.0001) to MIL than VL isolates (n = 22, mean IC50 = 2.58 +/- 1.58 mu M). Point mutations in the miltefosine transporter (LdMT) and its beta subunit (LdRos3) genes previously reported in parasites with experimentally induced MIL resistance were not present in the clinical isolates. Further, the mRNA expression profile of these genes was comparable in the pre- and post-treatment isolates. Parasite isolates from VL and PKDL cases were uniformly susceptible to PMM with respective mean IC50 = 7.05 +/- 2.24 mu M and 6.18 +/- 1.51 mu M. Conclusion: The in vitro susceptibility of VL isolates remained unchanged at the end of MIL treatment; however, isolates from relapsed VL and PKDL cases had lower susceptibility than the pre-treatment isolates. PKDL isolates were more tolerant towards MIL in comparison with VL isolates. All parasite isolates were uniformly susceptible to PMM. Mutations in the LdMT and LdRos3 genes as well as changes in the expression of these genes previously correlated with experimental resistance to MIL could not be verified for the field isolates.	[Bhandari, Vasundhra; Kulshrestha, Arpita; Deep, Deepak Kumar; Salotra, Poonam] Indian Council Med Res, Natl Inst Pathol, New Delhi, India; [Stark, Olivia; Schonian, Gabriele] Charite, Inst Microbiol & Hyg, D-13353 Berlin, Germany; [Prajapati, Vijay Kumar; Sundar, Shyam] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Ramesh, V.] Safdarjang Hosp, Dept Dermatol, New Delhi, India; [Dujardin, Jean Claude] Inst Trop Med, Dept Parasitol, Unit Mol Parasitol, B-2000 Antwerp, Belgium	Bhandari, V (reprint author), Indian Council Med Res, Natl Inst Pathol, Safdarjung Hosp Campus, New Delhi, India.	salotra@vsnl.com		Salotra, Poonam/0000-0002-4057-4872	Kaladrug-R [EC-FP7-222895]	This work was funded by Kaladrug-R (grant number EC-FP7-222895, www.leishrisk.net/kaladrug). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], CHROMAS CHROMAS PROS; Berman J, 2005, EXPERT OPIN PHARMACO, V6, P1381, DOI 10.1517/14656566.6.8.1381; Chrusciak-Talhari A, 2011, AM J TROP MED HYG, V84, P255, DOI 10.4269/ajtmh.2011.10-0155; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; Control of the leishmaniasis, 2010, WHO TECHN REP SER; Downing T, 2011, GENOME RES, V21, P2143, DOI 10.1101/gr.123430.111; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Jha TK, 2005, AM J TROP MED HYG, V73, P1005, DOI 10.4269/ajtmh.2005.73.1005; Joshi A., 2008, Journal of Vector Borne Diseases, V45, P105; Kulshrestha A, 2011, ANTIMICROB AGENTS CH, V55, P2916, DOI 10.1128/AAC.00812-10; Kumar D, 2009, ANTIMICROB AGENTS CH, V53, P835, DOI 10.1128/AAC.01233-08; Kumar R, 2007, AM J TROP MED HYG, V76, P896, DOI 10.4269/ajtmh.2007.76.896; Olliaro PL, 2005, LANCET INFECT DIS, V5, P763, DOI 10.1016/S1473-3099(05)70296-6; Pandey BD, 2009, AM J TROP MED HYG, V80, P580, DOI 10.4269/ajtmh.2009.80.580; Perez-Victoria FJ, 2006, J BIOL CHEM, V281, P23766, DOI 10.1074/jbc.M605214200; Perez-Victoria FJ, 2003, ANTIMICROB AGENTS CH, V47, P2397, DOI 10.1128/AAC.47.8.2397-2403.2003; Ramesh V, 2011, BRIT J DERMATOL, V165, P411, DOI 10.1111/j.1365-2133.2011.10402.x; ROZEN S, 1998, PRIMER3; Sanchez-Canete MP, 2009, ANTIMICROB AGENTS CH, V53, P1305, DOI 10.1128/AAC.01694-08; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; Sindermann H, 2004, CLIN INFECT DIS, V39, P1520, DOI 10.1086/425359; Singh R, 2006, J INFECT DIS, V194, P302, DOI 10.1086/505079; Sinha PK, 2011, J TROP MED, DOI 10.1155/2011/645203; Sundar S, 2005, B WORLD HEALTH ORGAN, V83, P394; Sundar S, 2005, EXPERT OPIN PHARMACO, V6, P2821, DOI 10.1517/14656566.6.16.2821; Sundar S, 2002, CURR OPIN INFECT DIS, V15, P593, DOI 10.1097/01.qco.0000044778.05458.f9; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 2007, NEW ENGL J MED, V356, P2571, DOI 10.1056/NEJMoa066536; Sundar S, 2006, INDIAN J MED RES, V123, P345; Sundar S, 2006, T ROY SOC TROP MED H, V100, P698, DOI 10.1016/j.trstmh.2005.09.015; Troya J, 2008, SCAND J INFECT DIS, V40, P78, DOI 10.1080/00365540701466215; WHO, 2005, EXP COMM REG STRAT F	32	49	49	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2012	6	5							e1657	10.1371/journal.pntd.0001657				6	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	951ZG	WOS:000304758900036	22629478	DOAJ Gold, Green Published			2019-03-26	
J	Van Malderen, C; Van Geertruyden, JP; Machevo, S; Gonzalez, R; Bassat, Q; Talisuna, A; Yeka, A; Nabasumba, C; Piola, P; Daniel, A; Turyakira, E; Forret, P; Van Overmeir, C; van Loen, H; Robert, A; D'Alessandro, U				Van Malderen, Carine; Van Geertruyden, Jean-Pierre; Machevo, Sonia; Gonzalez, Raquel; Bassat, Quique; Talisuna, Ambrose; Yeka, Adoke; Nabasumba, Carolyn; Piola, Patrice; Daniel, Atwine; Turyakira, Eleanor; Forret, Pascale; Van Overmeir, Chantal; van Loen, Harry; Robert, Annie; D'Alessandro, Umberto			Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria	MALARIA JOURNAL			English	Article						Malaria; Artemisinin-based combination therapy; Chlorproguanil-dapsone; Artesunate; Glucose-6-phosphate dehydrogenase deficiency; Uganda; Mozambique; Restriction fragment length polymorphisms; Conditional logistic regression	PLASMODIUM-FALCIPARUM MALARIA; PHASE-III TRIAL; G6PD DEFICIENCY; DOUBLE-BLIND; DEHYDROGENASE-DEFICIENCY; DIHYDROFOLATE-REDUCTASE; PLUS ARTESUNATE; PYRIMETHAMINE; ADOLESCENTS; POPULATION	Background: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy (ACT), but its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. The objective of the study was to assess whether CDA treatment and G6PD deficiency are risk factors for a post-treatment haemoglobin drop in African children <5 years of age with uncomplicated malaria. Methods: This case-control study was performed in the context of a larger multicentre randomized clinical trial comparing safety and efficacy of four different ACT in children with uncomplicated malaria. Children, who after treatment experienced a haemoglobin drop >= 2 g/dl (cases) within the first four days (days 0, 1, 2, and 3), were compared with those without an Hb drop (controls). Cases and controls were matched for study site, sex, age and baseline haemoglobin measurements. Data were analysed using a conditional logistic regression model. Results: G6PD deficiency prevalence, homo- or hemizygous, was 8.5% (10/117) in cases and 6.8% (16/234) in controls (p = 0.56). The risk of a Hb drop >= 2 g/dl was not associated with either G6PD deficiency (adjusted odds ratio (AOR): 0.81; p = 0.76) or CDA treatment (AOR: 1.28; p = 0.37) alone. However, patients having both risk factors tended to have higher odds (AOR: 11.13; p = 0.25) of experiencing a Hb drop = 2 g/dl within the first four days after treatment, however this finding was not statistically significant, mainly because G6PD deficient patients treated with CDA were very few. In non-G6PD deficient individuals, the proportion of cases was similar between treatment groups while in G6PD-deficient individuals, haemolytic anaemia occurred more frequently in children treated with CDA (56%) than in those treated with other ACT (29%), though the difference was not significant (p = 0.49). Conclusion: The use of CDA for treating uncomplicated malaria may increase the risk of haemolytic anaemia in G6PD-deficient children.	[Van Malderen, Carine] Catholic Univ Louvain, Fac Pharm & Sci Biomed, B-1200 Brussels, Belgium; [Van Geertruyden, Jean-Pierre] Univ Antwerp, Int Hlth Unit, B-2020 Antwerp, Belgium; [Machevo, Sonia; Gonzalez, Raquel; Bassat, Quique] CISM, Maputo, Mozambique; [Gonzalez, Raquel; Bassat, Quique] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain; [Talisuna, Ambrose; Yeka, Adoke] Makerere Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Kampala, Uganda; [Talisuna, Ambrose] Univ Oxford, KEMRI Wellcome Trust Res Program, Malaria Publ Hlth & Epidemiol Grp MPHEG, Nairobi, Kenya; [Nabasumba, Carolyn; Piola, Patrice; Daniel, Atwine; Turyakira, Eleanor] Epictr Mbarara Res Base, Mbarara, Uganda; [Forret, Pascale; Van Overmeir, Chantal; van Loen, Harry; D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium; [Robert, Annie] Catholic Univ Louvain, Brussels Hlth Sect, Inst Rech Expt, B-1200 Brussels, Belgium; [Robert, Annie] Catholic Univ Louvain, Brussels Hlth Sect, Clin Pole Epidemiol & Biostat, B-1200 Brussels, Belgium	Van Malderen, C (reprint author), Catholic Univ Louvain, Fac Pharm & Sci Biomed, B-1200 Brussels, Belgium.	carine.vanmalderen@uclouvain.be	Gonzalez, Raquel/J-3604-2017; D'Alessandro, Umberto/D-3457-2015; Bassat, Quique/P-2341-2016; Van geertruyden, Jean-Pierre/K-6425-2014	Gonzalez, Raquel/0000-0001-5487-801X; D'Alessandro, Umberto/0000-0001-6341-5009; Bassat, Quique/0000-0003-0875-7596; Van geertruyden, Jean-Pierre/0000-0001-5006-6364	sanofi Aventis; sigma tau; Novartis	UDA has received travel grants from sanofi Aventis, sigma tau and Novartis. He has also received research funds from sanofi Aventis and sigma tau.	Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2; Bardsley B, 2011, J PHARMACEUT BIOMED, V54, P610, DOI 10.1016/j.jpba.2010.09.033; BEUTLER E, 1968, BLOOD, V32, P816; BEUTLER E, 1994, BLOOD, V84, P3613; Beutler E, 2007, AM J TROP MED HYG, V77, P779, DOI 10.4269/ajtmh.2007.77.779; Cappellini MD, 2008, LANCET, V371, P64, DOI 10.1016/S0140-6736(08)60073-2; Carrazza MZN, 2000, REV SAUDE PUBL, V34, P396, DOI 10.1590/S0034-89102000000400013; De Araujo C, 2006, HAEMATOL-HEMATOL J, V91, P262; Fanello CI, 2008, T ROY SOC TROP MED H, V102, P412, DOI 10.1016/j.trstmh.2008.01.013; Fanello CI, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004031; Jalloh A, 2008, J HUM GENET, V53, P675, DOI 10.1007/s10038-008-0294-y; Kotea R, 1999, BRIT J HAEMATOL, V104, P849, DOI 10.1046/j.1365-2141.1999.01230.x; Krudsood S, 2005, T ROY SOC TROP MED H, V99, P142, DOI 10.1016/j.trstmh.2004.07.001; Looareesuwan S, 2004, LANCET, V363, P1838, DOI 10.1016/S0140-6736(04)16390-3; Mason PJ, 2007, BLOOD REV, V21, P267, DOI 10.1016/j.blre.2007.05.002; Meissner PE, 2005, BRIT J HAEMATOL, V131, P395, DOI 10.1111/j.1365-2141.2005.05778.x; Mockenhaupt FP, 2003, TROP MED INT HEALTH, V8, P118, DOI 10.1046/j.1365-3156.2003.01008.x; Mutabingwa T, 2001, LANCET, V358, P1218, DOI 10.1016/S0140-6736(01)06344-9; NIEUWENHUIS F, 1986, TROP GEOGR MED, V38, P183; Ochong E, 2008, ANTIMICROB AGENTS CH, V52, P3883, DOI 10.1128/AAC.00431-08; Owusu-Agyei S, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0006682, 10.1371/journal.pone.0007302]; Parikh S, 2004, AM J TROP MED HYG, V71, P750, DOI 10.4269/ajtmh.2004.71.750; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Ruwende C, 1998, J MOL MED, V76, P581, DOI 10.1007/s001090050253; Saunders MA, 2005, GENETICS, V171, P1219, DOI 10.1534/genetics.105.048140; The 4ABC Study Group, 2011, PLOS MED, DOI DOI 10.1371/J0URNAL.PMED.1001119; Tiono AB, 2009, AM J TROP MED HYG, V81, P969, DOI 10.4269/ajtmh.2009.09-0351; *WHO, 1990, T R SOC TROP MED S2, V84, pS1; *WHO, 2008, ANT CHLORPR DAPS LAP; Wootton DG, 2008, PLOS ONE, V3, P1779	30	6	7	1	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	APR 30	2012	11								139	10.1186/1475-2875-11-139				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	973QZ	WOS:000306376200001	22546009	DOAJ Gold, Green Published			2019-03-26	
J	Jahfari, S; Fonville, M; Hengeveld, P; Reusken, C; Scholte, EJ; Takken, W; Heyman, P; Medlock, JM; Heylen, D; Kleve, J; Sprong, H				Jahfari, Setareh; Fonville, Manoj; Hengeveld, Paul; Reusken, Chantal; Scholte, Ernst-Jan; Takken, Willem; Heyman, Paul; Medlock, Jolyon M.; Heylen, Dieter; Kleve, Jenny; Sprong, Hein			Prevalence of Neoehrlichia mikurensis in ticks and rodents from North-west Europe	PARASITES & VECTORS			English	Article						Vector-borne disease; Emerging zoonoses; Candidatus N. mikurensis; I. ricinus; Anaplasma phagocytophylum	IXODES-RICINUS TICKS; RACCOONS PROCYON-LOTOR; ANAPLASMA-PHAGOCYTOPHILUM; BORRELIA-BURGDORFERI; BORNE DISEASES; TRANSOVARIAL TRANSMISSION; FAMILY ANAPLASMATACEAE; SMALL MAMMALS; PCR DETECTION; WILD RODENTS	Background: Neoehrlichia mikurensis s an emerging and vector-borne zoonosis: The first human disease cases were reported in 2010. Limited information is available about the prevalence and distribution of Neoehrlichia mikurensis in Europe, its natural life cycle and reservoir hosts. An Ehrlichia-like schotti variant has been described in questing Ixodes ricinus ticks, which could be identical to Neoehrlichia mikurensis. Methods: Three genetic markers, 16S rDNA, gltA and GroEL, of Ehrlichia schotti-positive tick lysates were amplified, sequenced and compared to sequences from Neoehrlichia mikurensis. Based on these DNA sequences, a multiplex real-time PCR was developed to specifically detect Neoehrlichia mikurensis in combination with Anaplasma phagocytophilum in tick lysates. Various tick species from different life-stages, particularly Ixodes ricinus nymphs, were collected from the vegetation or wildlife. Tick lysates and DNA derived from organs of wild rodents were tested by PCR-based methods for the presence of Neoehrlichia mikurensis. Prevalence of Neoehrlichia mikurensis was calculated together with confidence intervals using Fisher's exact test. Results: The three genetic markers of Ehrlichia schotti-positive field isolates were similar or identical to Neoehrlichia mikurensis. Neoehrlichia mikurensis was found to be ubiquitously spread in the Netherlands and Belgium, but was not detected in the 401 tick samples from the UK. Neoehrlichia mikurensis was found in nymphs and adult Ixodes ricinus ticks, but neither in their larvae, nor in any other tick species tested. Neoehrlichia mikurensis was detected in diverse organs of some rodent species. Engorging ticks from red deer, European mouflon, wild boar and sheep were found positive for Neoehrlichia mikurensis. Conclusions: Ehrlichia schotti is similar, if not identical, to Neoehrlichia mikurensis. Neoehrlichia mikurensis is present in questing Ixodes ricinus ticks throughout the Netherlands and Belgium. We propose that Ixodes ricinus can transstadially, but not transovarially, transmit this microorganism, and that different rodent species may act as reservoir hosts. These data further imply that wildlife and humans are frequently exposed to Neoehrlichia mikurensis-infected ticks through tick bites. Future studies should aim to investigate to what extent Neoehrlichia mikurensis poses a risk to public health.	[Jahfari, Setareh; Fonville, Manoj; Hengeveld, Paul; Sprong, Hein] Natl Inst Publ Hlth & Environm RIVM, Lab Zoonoses & Environm Microbiol, Bilthoven, Netherlands; [Reusken, Chantal] Natl Inst Publ Hlth & Environm RIVM, Lab Infect Dis & Screening, Bilthoven, Netherlands; [Takken, Willem] Wageningen Univ, Entomol Lab, Wageningen, Netherlands; [Heyman, Paul] Queen Astrid Mil Hosp, Res Lab Vector Borne Dis, B-1120 Brussels, Belgium; [Medlock, Jolyon M.] Hlth Protect Agcy, Emergency Response Dept, Microbial Risk Assessment, Med Entomol & Zoonoses Ecol Grp, Porton Down, Wilts, England; [Heylen, Dieter] Univ Antwerp, Evolutionary Ecol Grp, B-2020 Antwerp, Belgium; [Kleve, Jenny] Natl Hedgehog & Squirrel Asylum, Naarden, Netherlands	Jahfari, S (reprint author), Natl Inst Publ Hlth & Environm RIVM, Lab Zoonoses & Environm Microbiol, Antonie van Leeuwenhoeklaan 9,POB 1, Bilthoven, Netherlands.	Setareh.Jahfari@rivm.nl		Sprong, Hein/0000-0002-0218-4320	Dutch Food and Consumer Product Safety Authority (VWA); Wageningen University and Research Centre; Ministry of Health, Welfare and Sport (VWS); FWO	The authors are very grateful to the volunteers and co-workers of the Central Veterinary Institute of Wageningen University and Research Centre, particularly Cor Gaasenbeek Fred Borgsteede and Kitty Maassen who have dedicated much time and effort to monthly collections of ticks. We thank Francine Pacillij, Annette Benning and Frans Jacobs for having collected ticks on large herbivores. We are grateful to Ellen Tijsse-Klasen, Joke van der Giessen, Marieke Opsteegh and Ankje de Vries for collecting rodent samples, support and technical assistance. This study was financially supported by the Dutch Food and Consumer Product Safety Authority (VWA), Wageningen University and Research Centre and by the Ministry of Health, Welfare and Sport (VWS). Dieter Heylen was supported by a FWO postdoctoral fellowship.	Alekseev AN, 2001, J CLIN MICROBIOL, V39, P2237, DOI 10.1128/JCM.39.6.2237-2242.2001; Andersson M, 2011, EMERG INFECT DIS, V17, P1716, DOI 10.3201/eid1709.101058; Baldridge GD, 2009, J MED ENTOMOL, V46, P625, DOI 10.1603/033.046.0330; Beninati T, 2006, Eur J Clin Microbiol Infect Dis, V25, P677, DOI 10.1007/s10096-006-0196-x; BLACK WC, 1994, P NATL ACAD SCI USA, V91, P10034, DOI 10.1073/pnas.91.21.10034; Bown KJ, 2006, VECTOR-BORNE ZOONOT, V6, P404, DOI 10.1089/vbz.2006.6.404; Bown KJ, 2009, EMERG INFECT DIS, V15, P1948, DOI 10.3201/eid1512.090178; Brouqui P, 2003, ANN NY ACAD SCI, V990, P134, DOI 10.1111/j.1749-6632.2003.tb07352.x; Courtney JW, 2004, J CLIN MICROBIOL, V42, P3164, DOI 10.1128/JCM.42.7.3164-3168.2004; de Greeff SC, 2008, EUR J CLIN MICROBIOL, V27, P985, DOI 10.1007/s10096-008-0535-1; Diniz PPVP, 2011, J CLIN MICROBIOL, V49, P2059, DOI 10.1128/JCM.02327-10; Dugan VG, 2005, VECTOR-BORNE ZOONOT, V5, P162, DOI 10.1089/vbz.2005.5.162; Fehr JS, 2010, EMERG INFECT DIS, V16, P1127, DOI 10.3201/eid1607.091907; Groen J, 2002, EUR J CLIN MICROBIOL, V21, P46, DOI 10.1007/s10096-001-0659-z; Heyman P, 2010, EXPERT REV ANTI-INFE, V8, P33, DOI 10.1586/ERI.09.118; Hillyard P.D., 1996, SYNOPSES BRIT FAUNA, V52; Hofhuis A, 2006, EUROSURVEILLANCE, V11, P2; Hubalek Zdenek, 2009, V37, P31, DOI 10.1159/000213069; Ismail N, 2010, CLIN LAB MED, V30, P261, DOI 10.1016/j.cll.2009.10.004; Kawahara M, 2004, INT J SYST EVOL MICR, V54, P1837, DOI 10.1099/ijs.0.63260-0; Liz JS, 2000, J CLIN MICROBIOL, V38, P1002; Long SW, 2003, J MED ENTOMOL, V40, P1000, DOI 10.1603/0022-2585-40.6.1000; Naitou H, 2006, MICROBIOL IMMUNOL, V50, P45, DOI 10.1111/j.1348-0421.2006.tb03769.x; Pan H, 2003, ANN NY ACAD SCI, V990, P107, DOI 10.1111/j.1749-6632.2003.tb07346.x; Pekova S, 2011, DIAGN MICR INFEC DIS, V69, P266, DOI 10.1016/j.diagmicrobio.2010.10.004; Polin H, 2004, J CLIN MICROBIOL, V42, P2285, DOI 10.1128/JCM.42.5.2285-2286.2004; Rar VA, 2010, TICKS TICK-BORNE DIS, V1, P57, DOI 10.1016/j.ttbdis.2010.01.002; Sanogo YO, 2003, ANN NY ACAD SCI, V990, P182, DOI 10.1111/j.1749-6632.2003.tb07360.x; Schouls LM, 1999, J CLIN MICROBIOL, V37, P2215; Shpynov S, 2006, ANN NY ACAD SCI, V1078, P378, DOI 10.1196/annals.1374.075; Skotarczak B, 2006, ANN AGR ENV MED, V13, P21; Spitalska E, 2008, ACTA VIROL, V52, P175; Sprong H, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-41; Tijsse-Klasen E, 2011, EPIDEMIOL INFECT, V139, P524, DOI 10.1017/S0950268810002608; Tijsse-Klasen E, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-61; Tijsse-Klasen E, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-17; Tijsse-Klasen E, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-42; van Dobbenburgh A, 1999, NEW ENGL J MED, V340, P1214, DOI 10.1056/NEJM199904153401517; von Loewenich FD, 2003, J CLIN MICROBIOL, V41, P5033, DOI 10.1128/JCM.41.11.5033-5040.2003; von Loewenich FD, 2010, J CLIN MICROBIOL, V48, P2630, DOI 10.1128/JCM.00588-10; Welinder-Olsson C, 2010, J CLIN MICROBIOL, V48, P1956, DOI 10.1128/JCM.02423-09; Wielinga PR, 2006, APPL ENVIRON MICROB, V72, P7594, DOI 10.1128/AEM.01851-06; Yabsley MJ, 2008, INT J SYST EVOL MICR, V58, P2794, DOI 10.1099/ijs.0.65836-0	43	75	78	2	31	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	APR 19	2012	5								74	10.1186/1756-3305-5-74				10	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	973ZI	WOS:000306399000001	22515314	DOAJ Gold, Green Published			2019-03-26	
J	Lustigman, S; Geldhof, P; Grant, WN; Osei-Atweneboana, MY; Sripa, B; Basanez, MG				Lustigman, Sara; Geldhof, Peter; Grant, Warwick N.; Osei-Atweneboana, Mike Y.; Sripa, Banchob; Basanez, Maria-Gloria			A Research Agenda for Helminth Diseases of Humans: Basic Research and Enabling Technologies to Support Control and Elimination of Helminthiases	PLOS NEGLECTED TROPICAL DISEASES			English	Review							TAENIA-SOLIUM CYSTICERCOSIS; ENDOSYMBIOTIC WOLBACHIA-BACTERIA; NEGLECTED TROPICAL DISEASES; POST-PRAZIQUANTEL TREATMENT; HOST-PARASITE INTERACTIONS; INTERFERON-GAMMA RECEPTOR; CARCINOGENIC LIVER FLUKE; NEMATODE BRUGIA-MALAYI; SCHISTOSOMA-MANSONI; ONCHOCERCA-VOLVULUS	Successful and sustainable intervention against human helminthiases depends on optimal utilisation of available control measures and development of new tools and strategies, as well as an understanding of the evolutionary implications of prolonged intervention on parasite populations and those of their hosts and vectors. This will depend largely on updated knowledge of relevant and fundamental parasite biology. There is a need, therefore, to exploit and apply new knowledge and techniques in order to make significant and novel gains in combating helminthiases and supporting the sustainability of current and successful mass drug administration (MDA) programmes. Among the fields of basic research that are likely to yield improved control tools, the Disease Reference Group on Helminth Infections (DRG4) has identified four broad areas that stand out as central to the development of the next generation of helminth control measures: 1) parasite genetics, genomics, and functional genomics; 2) parasite immunology; 3) (vertebrate) host-parasite interactions and immunopathology; and 4) (invertebrate) host-parasite interactions and transmission biology. The DRG4 was established in 2009 by the Special Programme for Research and Training in Tropical Diseases (TDR). The Group was given the mandate to undertake a comprehensive review of recent advances in helminthiases research in order to identify notable gaps and highlight priority areas. This paper summarises recent advances and discusses challenges in the investigation of the fundamental biology of those helminth parasites under the DRG4 Group's remit according to the identified priorities, and presents a research and development agenda for basic parasite research and enabling technologies that will help support control and elimination efforts against human helminthiases.	[Lustigman, Sara] New York Blood Ctr, Lindsley F Kimball Res Inst, Mol Parasitol Lab, New York, NY 10021 USA; [Geldhof, Peter] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Merelbeke, Belgium; [Grant, Warwick N.] La Trobe Univ, Nematode Funct Genom Lab, Bundoora, Vic 3086, Australia; [Osei-Atweneboana, Mike Y.] Water Res Inst, Council Sci & Ind Res, Dept Environm Biol & Hlth, Accra, Ghana; [Sripa, Banchob] Khon Kaen Univ, Dept Pathol, Trop Dis Res Lab, Div Expt Pathol,Fac Med, Khon Kaen, Thailand; [Basanez, Maria-Gloria] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, Sch Publ Hlth, Fac Med, London, England	Lustigman, S (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, Mol Parasitol Lab, New York, NY 10021 USA.	slustigman@nybloodcenter.org			New York Blood Center; NIAID/NIH [R01AI078314, U01AI065871]; European Foundation Initiative for African Research into Neglected Tropical Diseases (EFINTD); Career Development Fellowship award from the Special Programme for Research and Training in Tropical Diseases (TDR); National Research University, Office of the Higher Education Commission, Thailand; Wellcome Trust [085133/Z/08/Z, 092677/Z/10/Z]; Royal Society-Leverhulme Trust; European Commission [PP-AP/2008/160-163]; UNICEF; UNDP; World Bank; WHO; Special Programme for Research and Training in Tropical Diseases (TDR)	SL received intramural funding from the New York Blood Center and a research grant from the NIAID/NIH (R01AI078314). MYO-A is funded by the European Foundation Initiative for African Research into Neglected Tropical Diseases (EFINTD) and a Career Development Fellowship award from the Special Programme for Research and Training in Tropical Diseases (TDR). BS was funded by the National Research University Project, Office of the Higher Education Commission, Thailand and NIAID/NIH (U01AI065871). M-GB thanks the Wellcome Trust, http://www.wellcome.ac.uk (Grants 085133/Z/08/Z and 092677/Z/10/Z). MGB and MYO-A also thank the Royal Society-Leverhulme Trust (http://www.royalsociety.org) for a Capacity Building Africa Award. The Special Programme for Research and Training in Tropical Diseases (TDR) provided both technical and financial support to the Disease Reference Group on Helminth Infections (DRG4), and the European Commission provided financial support under Agreement PP-AP/2008/160-163. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This review was prepared following deliberations of the Disease Reference Group on Helminth Infections (DRG4), which forms part of an independent "think tank'' of international experts, established and funded by the Special Programme for Research and Training in Tropical Diseases (TDR) to identify key research priorities through the review of research evidence and input from stakeholder consultations. The authors wish to thank all remaining members of the DRG4, namely, Boakye A. Boatin (Co-Chair), Roger K. Prichard, Rashida M. Barakat, Hector Hugo Garcia, Eliezer N'Goran, Guo-Jing Yang and Andrea Gazzinelli. Poppy Lamberton at Imperial College London helped to draft the snail-schistosome interaction section. The DRG4 thanks Ayoade Oduola, Michael Wilson, Arve Lee Willingham, Deborah W. Kioy, and other TDR staff for facilitation. TDR is a programme executed by the World Health Organization (WHO) and co-sponsored by UNICEF, UNDP, the World Bank, and the WHO. Further information on all the Disease and Thematic Reference Groups, as well as on the related Global Report on Research for Infectious Diseases of Poverty, can be found on the TDR website at http://www.who.int/tdr/stewardship/research-think-tank/en/.	Abraham D, 2002, TRENDS PARASITOL, V18, P164, DOI 10.1016/S1471-4922(02)02245-6; Aguilar-Diaz H, 2006, PARASITOL INT, V55, pS127, DOI 10.1016/j.parint.2005.11.020; Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; Andrade ZA, 2009, PARASITE IMMUNOL, V31, P656, DOI 10.1111/j.1365-3024.2009.01157.x; Appleton CC, 2009, ANN TROP MED PARASIT, V103, P249, DOI 10.1179/136485909X398212; Ayuk MA, 2011, INT J PARASITOL, V41, P783, DOI 10.1016/j.ijpara.2011.02.004; Babayan SA, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000525; Bandi C, 2001, VET PARASITOL, V98, P215, DOI 10.1016/S0304-4017(01)00432-0; Basanez MG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001548; Basanez MG, 2009, ADV PARASIT, V68, P263, DOI 10.1016/S0065-308X(08)00611-8; Beech RN, 2011, PARASITOLOGY, V138, P160, DOI 10.1017/S0031182010001198; Bennuru S, 2011, P NATL ACAD SCI USA, V108, P9649, DOI 10.1073/pnas.1011481108; Bennuru S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000688; Berriman M, 2009, NATURE, V460, P352, DOI 10.1038/nature08160; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Bhardwaj R, 2011, INFECT IMMUN, V79, P4276, DOI 10.1128/IAI.05431-11; Bhardwaj R, 2011, METHODS MOL BIOL, V764, P223, DOI 10.1007/978-1-61779-188-8_15; Bhardwaj R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001011; Blanton RE, 2005, EUR J HUM GENET, V13, P660, DOI 10.1038/sj.ejhg.5201388; Boatin BA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001547; Botelho M, 2009, INT J PARASITOL, V39, P1083, DOI 10.1016/j.ijpara.2009.02.016; Botros S, 2005, INT J PARASITOL, V35, P787, DOI 10.1016/j.ijpara.2005.02.005; Brattig NW, 2000, MICROBES INFECT, V2, P1147, DOI 10.1016/S1286-4579(00)01269-7; Brattig NW, 2004, J IMMUNOL, V173, P437, DOI 10.4049/jimmunol.173.1.437; Brattig NW, 2001, MICROBES INFECT, V3, P439, DOI 10.1016/S1286-4579(01)01399-5; Brindley PJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000538; Brindley PJ, 2005, TRENDS PARASITOL, V21, P533, DOI 10.1016/j.pt.2005.08.015; Britton C, 2011, EXP PARASITOL; Burke ML, 2009, PARASITE IMMUNOL, V31, P163, DOI 10.1111/j.1365-3024.2009.01098.x; Campbell G, 2006, PARASITOL INT, V55, pS121, DOI 10.1016/j.parint.2005.11.019; Campino S, 2006, SEMIN IMMUNOL, V18, P411, DOI 10.1016/j.smim.2006.07.011; Cantacessi C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000684; Churcher TS, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000211; Colley DG, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000032; Cooper PJ, 2000, J INFECT DIS, V182, P1207, DOI 10.1086/315830; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; Cooper PJ, 2001, INFECT IMMUN, V69, P1574, DOI 10.1128/IAI.69.3.1574-1580.2001; Criscione CD, 2007, P ROY SOC B-BIOL SCI, V274, P2669, DOI 10.1098/rspb.2007.0877; Cross HF, 2001, LANCET, V358, P1873, DOI 10.1016/S0140-6736(01)06899-4; Dalzell JJ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001176; Davies CM, 2002, PARASITOLOGY, V124, P31, DOI 10.1017/S0031182001008873; Delcroix M, 2006, J BIOL CHEM, V281, P39316, DOI 10.1074/jbc.M607128200; Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526; Dillon GP, 2007, PARASITOLOGY, V134, P1589, DOI 10.1017/S0031182007002995; Dissous C, 2011, TRENDS PARASITOL, V27, P59, DOI 10.1016/j.pt.2010.09.001; Druilhe P, 2005, TRENDS PARASITOL, V21, P359, DOI 10.1016/j.pt.2005.06.011; Duerr HP, 2008, TRENDS PARASITOL, V24, P350, DOI 10.1016/j.pt.2008.04.005; DUKE BOL, 1968, T ROY SOC TROP MED H, V62, P22, DOI 10.1016/0035-9203(68)90026-6; Faghiri Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010451; Fenton A, 2008, PARASITOLOGY, V135, P841, DOI 10.1017/S0031182008000310; Foster J, 2005, PLOS BIOL, V3, P599, DOI 10.1371/journal.pbio.0030121; FREEDMAN DO, 1988, J INFECT DIS, V158, P556, DOI 10.1093/infdis/158.3.556; French MD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000897; Garcia HH, 2005, LANCET NEUROL, V4, P653, DOI 10.1016/S1474-4422(05)70194-0; GARRETTJ.C, 1964, B WORLD HEALTH ORGAN, V31, P71; Geary TG, 2010, INT J PARASITOL, V40, P1, DOI 10.1016/j.ijpara.2009.11.001; Geldhof P, 2007, PARASITOLOGY, V134, P609, DOI 10.1017/S0031182006002071; Ghedin E, 2007, SCIENCE, V317, P1756, DOI 10.1126/science.1145406; Gobert GN, 2006, EXP PARASITOL, V114, P160, DOI 10.1016/j.exppara.2006.03.003; Gobert GN, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000600; Gower CM, 2004, EVOLUTION, V58, P1178; Gower CM, 2011, PARASITOLOGY, P1; Griffin JT, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000324; HAAS W, 1995, PARASITOLOGY, V110, P133, DOI 10.1017/S0031182000063897; Han ZG, 2009, ANNU REV GENOM HUM G, V10, P211, DOI 10.1146/annurev-genom-082908-150036; Hansen RDE, 2011, P ROY SOC B-BIOL SCI, V278, P2293, DOI 10.1098/rspb.2010.2367; Harnett W, 2004, IMMUNOL LETT, V94, P27, DOI 10.1016/j.imlet.2004.04.008; Hartmann S, 2003, INT J PARASITOL, V33, P1291, DOI 10.1016/S0020-7519(03)00163-2; Hassan AHM, 2003, J PARASITOL, V89, P1248, DOI 10.1645/GE-85R; Hatherill M, 2009, VACCINE, V27, P4743, DOI 10.1016/j.vaccine.2009.05.021; Hewitson JP, 2009, MOL BIOCHEM PARASIT, V167, P1, DOI 10.1016/j.molbiopara.2009.04.008; Higazi TB, 2005, MOL BIOCHEM PARASIT, V141, P109, DOI 10.1016/j.molbiopara.2005.02.006; Hoerauf A, 2002, TRENDS PARASITOL, V18, P25, DOI 10.1016/S1471-4922(01)02173-0; Hotez PJ, 2006, VACCINE, V24, P5787, DOI 10.1016/j.vaccine.2006.05.008; Hotez PJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000718; Hotez PJ, 2009, LANCET, V373, P1570, DOI 10.1016/S0140-6736(09)60233-6; Jex AR, 2011, NATURE, V479, P529, DOI 10.1038/nature10553; Jiang DJ, 2008, INT J PARASITOL, V38, P503, DOI 10.1016/j.ijpara.2007.09.010; Kalbe M, 1996, PARASITOL RES, V82, P8, DOI 10.1007/s004360050059; Kalbe M, 2004, PARASITOLOGY, V128, P635, DOI 10.1017/S0031182004005037; Keiser PB, 2002, J INFECT DIS, V185, P805, DOI 10.1086/339344; Kim YJ, 2008, PARASITOL RES, V102, P411, DOI 10.1007/s00436-007-0778-2; Kirch AK, 2003, PARASITOLOGY, V127, P327, DOI 10.1017/S0031182003003834; Koukounari A, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-227; Krautz-Peterson G, 2010, PARASITOLOGY, V137, P485, DOI 10.1017/S0031182009991168; Leenstra T, 2006, INFECT IMMUN, V74, P6398, DOI 10.1128/IAI.00757-06; Li BW, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000947; Lima C., 2002, Clinical and Experimental Allergy, V32, P1659, DOI 10.1046/j.1365-2222.2002.01506.x; Lok JB, 2011, PARASITOLOGY, P1; Lu DB, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000781; Lu DB, 2009, INT J PARASITOL, V39, P1581, DOI 10.1016/j.ijpara.2009.06.003; Lustigman S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001582; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; malERA Consultative Group on Basic Science and Enabling Technologies, 2011, PLOS MED, V8, DOI DOI 10.1371/JOURNAL.PMED.1000399; Mann VH, 2010, PARASITOLOGY, V137, P451, DOI 10.1017/S0031182009991211; Marquet S, 1999, EUR J HUM GENET, V7, P88, DOI 10.1038/sj.ejhg.5200243; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Mas-Coma S, 2009, ADV PARASIT, V69, P41, DOI 10.1016/S0065-308X(09)69002-3; Maule AG, 2011, TRENDS PARASITOL, V27, P505, DOI 10.1016/j.pt.2011.07.004; McCarthy JS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001601; Michael E, 2009, J MED ENTOMOL, V46, P873, DOI 10.1603/033.046.0420; Morales ME, 2008, MOL BIOCHEM PARASIT, V157, P160, DOI 10.1016/j.molbiopara.2007.10.009; Mwangi TW, 2006, ANN TROP MED PARASIT, V100, P551, DOI 10.1179/136485906X118468; Nacher M, 2004, CLIN REV ALLERG IMMU, V26, P85, DOI 10.1385/CRIAI:26:2:085; Nacher M, 2001, TRENDS PARASITOL, V17, P563, DOI 10.1016/S1471-4922(01)02117-1; Nacher M, 2002, J PARASITOL, V88, P55, DOI 10.2307/3285390; Narain K., 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P512; Nash TE, 1999, NEUROLOGY, V53, P777, DOI 10.1212/WNL.53.4.777; Njongmeta LM, 2004, INT J PARASITOL, V34, P1069, DOI 10.1016/j.ijpara.2004.04.011; Norton A, 2008, PARASITE VECTOR, V1, DOI 10.1186/1756-3305-1-43; Norton AJ, 2010, AM J TROP MED HYG, V83, P951, DOI 10.4269/ajtmh.2010.10-0283; Ohnmacht C, 2009, BLOOD, V113, P2816, DOI 10.1182/blood-2008-05-154773; Ottesen EA, 2004, AM J TROP MED HYG, V71, P1; Piao XY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018267; Poeschl P, 2006, AM J NEURORADIOL, V27, P653; Prasad KN, 2008, J BIOSCIENCES, V33, P571, DOI 10.1007/s12038-008-0075-y; Prichard RK, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001549; Rajan TV, 2007, TRENDS PARASITOL, V23, P459, DOI 10.1016/j.pt.2007.08.009; Reis EAG, 2006, AM J TROP MED HYG, V75, P904, DOI 10.4269/ajtmh.2006.75.904; Rim HJ, 2005, J HELMINTHOL, V79, P269, DOI 10.1079/JOH2005300; Rinaldi G, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001348; Robinson MW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002042; Robinson MW, 2009, MOL CELL PROTEOMICS, V8, P1891, DOI 10.1074/mcp.M900045-MCP200; Rudge JW, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000340; Rudge JW, 2009, MOL ECOL, V18, P2134, DOI 10.1111/j.1365-294X.2009.04181.x; Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269; Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732; Satayathum SA, 2006, AM J TROP MED HYG, V75, P83, DOI 10.4269/ajtmh.2006.75.83; Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5; Schnoeller C, 2008, J IMMUNOL, V180, P4265, DOI 10.4049/jimmunol.180.6.4265; Sciutto E, 2007, PARASITE IMMUNOL, V29, P621, DOI 10.1111/j.1365-3024.2007.00967.x; Shrivastava J, 2005, MOL ECOL, V14, P839, DOI 10.1111/j.1365-294X.2005.02443.x; Singh G, 2010, NEUROLOGY, V75, P2236, DOI 10.1212/WNL.0b013e31820202dc; Sinha S, 2009, J CLIN NEUROSCI, V16, P867, DOI 10.1016/j.jocn.2008.10.030; Smout MJ, 2011, PROTEIN EXPRES PURIF, V79, P263, DOI 10.1016/j.pep.2011.06.018; Smout MJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000611; Snow LC, 2006, MED VET ENTOMOL, V20, P261, DOI 10.1111/j.1365-2915.2006.00629.x; Song CZ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001239; Spiliotis M, 2008, INT J PARASITOL, V38, P1025, DOI 10.1016/j.ijpara.2007.11.002; Sripa B, 2003, ACTA TROP, V88, P209, DOI 10.1016/j.actatropica.2003.08.002; Sripa B, 2009, HEPATOLOGY, V50, P1273, DOI 10.1002/hep.23134; Stolk WA, 2004, MED VET ENTOMOL, V18, P57, DOI 10.1111/j.0269-283X.2004.0470.x; Sukhdeo MVK, 2004, CAN J ZOOL, V82, P292, DOI [10.1139/z03-212, 10.1139/Z03-212]; Takayanagui OM, 2006, PARASITOL INT, V55, pS111, DOI 10.1016/j.parint.2005.11.016; Taylor MJ, 2010, LANCET, V376, P1175, DOI 10.1016/S0140-6736(10)60586-7; Taylor MJ, 2005, ADV PARASIT, V60, P245, DOI 10.1016/S0065-308X(05)60004-8; Taylor MJ, 2000, J EXP MED, V191, P1429, DOI 10.1084/jem.191.8.1429; Taylor MJ, 1999, PARASITOL TODAY, V15, P437, DOI 10.1016/S0169-4758(99)01533-1; Taylor MJ, 2003, ANN NY ACAD SCI, V990, P444, DOI 10.1111/j.1749-6632.2003.tb07409.x; Tchoubrieva EB, 2010, CELL MOL LIFE SCI, V67, P3739, DOI 10.1007/s00018-010-0345-3; Terrazas LI, 2008, CURR TOP MED CHEM, V8, P383, DOI 10.2174/156802608783790848; Thuwajit C, 2004, PARASITOLOGY, V129, P455, DOI 10.1017/S0031182004005815; Cruz-Chan JV, 2010, EXPERT REV VACCINES, V9, P707, DOI 10.1586/ERV.10.63; Webster JP, 2010, TRENDS PARASITOL, V26, P103, DOI 10.1016/j.pt.2009.12.006; White AC, 1997, CHEM IMMUNOL, V66, P209; WHITE AC, 1992, INFECT AGENT DIS, V1, P185; WHO, 2003, CONTR DIS DUE HELM I; Williams-Blangero S, 2008, J INFECT DIS, V197, P1198, DOI 10.1086/533493; Williams-Blangero S, 2008, J INFECT DIS, V197, P66, DOI 10.1086/524060; Wylie T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-525; Xu SL, 2011, INT J PARASITOL, V41, P355, DOI 10.1016/j.ijpara.2010.10.005; Yoo WG, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001208; Yosry A, 2006, INFECT INFLAMMATION, P81; Young ND, 2010, BIOTECHNOL ADV, V28, P859, DOI 10.1016/j.biotechadv.2010.07.006; Young ND, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000719; Zerlotini A, 2009, NUCLEIC ACIDS RES, V37, pD579, DOI 10.1093/nar/gkn681; Zhou Y, 2009, NATURE, V460, P345, DOI 10.1038/nature08140	167	26	28	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	APR	2012	6	4							e1445	10.1371/journal.pntd.0001445				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	935CP	WOS:000303496800001	22545160	DOAJ Gold, Green Published			2019-03-26	
J	Das, M; Roy, L; Picado, A; Kroeger, A; Rijal, S; Boelaert, M				Das, Murari; Roy, Lalita; Picado, Albert; Kroeger, Axel; Rijal, Suman; Boelaert, Marleen			Deltamethrin and permethrin residue on long-lasting insecticidal nets after 18 months of use in a visceral leishmaniasis-endemic area in Nepal	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Insecticide-treated nets; Insecticide residue; Permethrin; Deltamethrin; Visceral leishmaniasis; Nepal	TREATED NETS; SANDFLY VECTOR; ANOPHELES-CULICIFACIES; PHLEBOTOMUS-ARGENTIPES; INDIAN SUBCONTINENT; WASH-RESISTANCE; KALA-AZAR; BED NETS; FIELD; ELIMINATION	The insecticide residue on two types of long-lasting insecticidal nets (LLIN), Olyset Net and PermaNet 2.0, used in a visceral leishmaniasis-endemic village in eastern Nepal was quantified using HPLC. After two washes during 18 months of use the mean insecticide residues on PermaNet 2.0 and Olyset Net were 53.5 mg/m(2) (97.3% of the target dose) of deltamethrin and 911.8 mg/m(2) (91.2% of the target dose) of permethrin, respectively. These residues were close to the insecticide loads specified by the manufacturers of the two LLINs. The use of LLINs has been postulated as an alternative or complementary method to indoor residual spraying. Our results suggest that LLINs should be washed 4-5 times each year throughout their lifespan by specifically requesting villagers to wash nets on certain dates. The insecticide residue on the nets and their bioefficacy against sand fly vectors should be monitored after each wash, in various cultural settings, to assess their durability and long-term retention of the insectide. (C) 2012 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Das, Murari; Roy, Lalita; Rijal, Suman] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Picado, Albert] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Picado, Albert; Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Kroeger, Axel] World Hlth Org, Special Programme Res & Training Trop Dis, CH-1211 Geneva 27, Switzerland; [Kroeger, Axel] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Das, M (reprint author), BP Koirala Inst Hlth Sci, Dharan, Nepal.	mldas_29@yahoo.com	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Kroeger, Axel/0000-0001-8438-2904; Das, Murari/0000-0001-6816-2389; Picado, Albert/0000-0001-7344-628X	UNICEF/UNDP/World Bank/ WHO; European Union	This investigation received financial support from the UNICEF/UNDP/World Bank/ WHO Special Programme for Research and Training in Tropical Diseases (TDR). The European Union FP6 INCODEV-funded KALANET project supported the purchase and the distribution of the LLINs.	Ansari MA, 2006, J AM MOSQUITO CONTR, V22, P102, DOI 10.2987/8756-971X(2006)22[102:BOONAM]2.0.CO;2; Atieli FK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-248; Banek K, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-84; Bern C, 2000, AM J TROP MED HYG, V63, P184, DOI 10.4269/ajtmh.2000.63.184; Chowdhury R, 2011, ANN TROP MED PARASIT, V105, P31, DOI 10.1179/136485911X12899838683124; Courtenay O, 2007, MED VET ENTOMOL, V21, P168, DOI 10.1111/j.1365-2915.2007.00678.x; Das M, 2008, ANN TROP MED PARASIT, V102, P729, DOI 10.1179/136485908X355274; Das ML, 2009, ACTA TROP, V113, P162; Das ML, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000100; Dev V, 2010, VECTOR-BORNE ZOONOT, P403; Dinesh DS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000859; Graham K, 2005, MED VET ENTOMOL, V19, P72, DOI 10.1111/j.0269-283X.2005.00543.x; Jalouk L, 2007, T ROY SOC TROP MED H, V101, P360, DOI 10.1016/j.trstmh.2006.07.011; Joshi AB, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-54; Kasili S, 2010, J VECTOR DIS, V47, P1; Kayedi MH, 2008, T ROY SOC TROP MED H, V102, P811, DOI 10.1016/j.trstmh.2008.05.025; Kilian A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-49; Koirala S, 1998, B WORLD HEALTH ORGAN, V76, P485; Kroeger A, 2004, T ROY SOC TROP MED H, V98, P152, DOI 10.1016/S0035-9203(03)00038-5; KULKARNI M, 2006, MALARIA MATTERS, V15, P1; Lindblade KA, 2005, TROP MED INT HEALTH, V10, P1141, DOI 10.1111/j.1365-3156.2005.01501.x; Mondal D, 2010, TROP MED INT HEALTH, V15, P1382, DOI 10.1111/j.1365-3156.2010.02635.x; Moosa-Kazemi SH, 2009, IRAN J ARTHROPOD-BOR, V3, P1; N'Guessan R, 2010, T ROY SOC TROP MED H, V104, P758, DOI 10.1016/j.trstmh.2010.08.008; Niraula SR, 2007, INDIAN J PRACTICIN 1, V4; Picado A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000587; Sharma SK, 2009, J MED ENTOMOL, V46, P342, DOI 10.1603/033.046.0220; Sreehari U, 2009, TROP MED INT HEALTH, V14, P597, DOI 10.1111/j.1365-3156.2009.02252.x; Tami A, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-19; *WHO, 2001, 5 WHOPES WORK GROUP; WHO, 2003, 7 WHOPES WORK GROUP; WHO, 2007, 2 M KATHM NEP 30 OCT; WHO, 2011, WHOPES WORK GROUP M; Yaghoobi-Ershadi M R, 2006, Bull Soc Pathol Exot, V99, P43, DOI 10.3185/pathexo2818	34	5	5	0	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	APR	2012	106	4					230	234		10.1016/j.trstmh.2012.01.007				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	921TH	WOS:000302500000004	22381627				2019-03-26	
J	De Vos, P; Garcia-Farinas, A; Alvarez-Perez, A; Rodriguez-Salva, A; Bonet-Gorbea, M; Van der Stuyft, P				De Vos, Pol; Garcia-Farinas, Anai; Alvarez-Perez, Adolfo; Rodriguez-Salva, Armando; Bonet-Gorbea, Mariano; Van der Stuyft, Patrick			Public health services, an essential determinant of health during crisis. Lessons from Cuba, 1989-2000	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						public health; determinants of health; health services; economic crisis; Cuba; international health; sante publique; determinants de la sante; services de sante; crise economique; Cuba; sante internationale; Salud publica; determinantes de salud; servicios sanitarios; crisis economica; Cuba; salud internacional	ECONOMIC-CRISIS; US EMBARGO; CARE; IMPACT; SYSTEM; 1990S; TRANSITION; MORTALITY; REFORM	During the 1990s, Cuba was able to overcome a severe crisis, almost without negative health impacts. This national retrospective study covering the years 19892000 analyses the countrys strategy through essential social, demographic, health process and health outcome indicators. Gross domestic product (GDP) diminished by 34.76% between 1989 and 1993. In 1994 slow recuperation started. During the crisis, public health expenses increased. The number of family doctors rose from 9.22 to 27.03 per 104 inhabitants between 1989 and 2000. Infant mortality rate and life expectancy exemplify a series of health indicators that continued to improve during the crisis years, whereas low birth weight and tuberculosis incidence are among the few indicators that suffered deterioration. GDP is inversely related to tuberculosis incidence, whereas the average salary is inversely related to low birth weight. Infant mortality rate has a strong negative correlation with the health expenses per inhabitant, the number of maternal homes, the number of family doctors and the proportion of pregnant women receiving care in maternal homes. Life expectancy has a strong positive correlation with health expenses, the number of nursing personnel and the number of medical contacts per inhabitant. The Cuban strategy effectively resolved health risks during the crisis. In times of serious socio-economic constraints, a well conceptualized public health policy can play an important role in maintaining the overall well-being of a population.	[De Vos, Pol; Van der Stuyft, Patrick] Inst Trop Med, B-2000 Antwerp, Belgium; [Garcia-Farinas, Anai; Alvarez-Perez, Adolfo; Rodriguez-Salva, Armando; Bonet-Gorbea, Mariano] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba	De Vos, P (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	pdevos@itg.be	De Vos, Pol/D-3370-2009				Abel-Smith B, 1986, Health Policy Plan, V1, P202, DOI 10.1093/heapol/1.3.202; Almeida Celia, 2002, Cad. Saúde Pública, V18, P905, DOI 10.1590/S0102-311X2002000400002; Almirall P, 1995, NEUROPATIA EPIDEMICA; Alvarez-Perez AG, 2008, REV CUB HIG EPIDEMIO, V46, P1; Alvarez-Perez AG, 2007, REV CUB HIG EPIDEMIO, V45, P1; Alvarez-Perez AG, 2007, REV CUB SALUD PUBLIC, V33, P1; American Association for World Health, 1997, DEN FOOD MED IMP US; [Anonymous], 1999, LANCET, V353, P337; AYCAGUER L C S, 1990, Revista de Saude Publica, V24, P473; Utra IMB, 2007, REV PANAM SALUD PUBL, V21, P85; Brainerd E, 1998, WORLD DEV, V26, P2013, DOI 10.1016/S0305-750X(98)00096-5; BRENNER MH, 1987, SOC SCI MED, V25, P183, DOI 10.1016/0277-9536(87)90387-X; Campbell A, 1999, GLOBAL DEV STUDIES, V1, P150; Castro F, 1994, INTERVENCION CLAUSUR; Chiara M, 2008, 8 C INT CLAD REF EST; CIP, 2008, PER ESP BIBL VIRT; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Cutler DM, 2002, J PUBLIC ECON, V84, P279, DOI 10.1016/S0047-2727(01)00127-X; De Broeck M, 2000, WP0032 IMF; De Vos P, 2005, INT J HEALTH SERV, V35, P189, DOI 10.2190/M72R-DBKD-2XWV-HJWB; De Vos P, 2005, SOC SCI MED, V60, P609, DOI 10.1016/j.socscimed.2004.05.022; De Vos P, 2008, HEALTH POLICY, V85, P94, DOI 10.1016/j.healthpol.2007.07.001; De Vos P, 2010, HEALTH POLICY, V96, P64, DOI 10.1016/j.healthpol.2010.01.005; De Vos P, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-76; Deere CD, 1991, MON REV, V43, P3; Evans Robert G, 2008, Healthc Policy, V3, P21; Garcia Farinas A, 2006, REV CUB SALUD PUBLIC, V32, P1; Garcia-Farinas A, 2008, REV CUB SALUD PUBLIC, V34, P1; Garfield R, 1997, AM J PUBLIC HEALTH, V87, P15, DOI 10.2105/AJPH.87.1.15; Gonzalez-Ochoa E, 2007, TUBERCULOSIS INCIDEN; Gwatkin Davidson R., 2002, Rev Panam Salud Publica, V11, P310; Herman DL, 2005, CONTROL ENFERMEDADES; Hopkins S, 2006, HEALTH POLICY, V75, P347, DOI 10.1016/j.healthpol.2005.04.002; Ibarra D, 1997, EC CUBANA REFORMAS E; Infomed, 2006, DISC MIN SAL PUBL CU; Keskimaki I, 2003, SOC SCI MED, V56, P1517, DOI 10.1016/S0277-9536(02)00153-3; Knowledge Network on Health Systems, 2007, CHALL IN HLTH SYST; KUNTZ D, 1994, INT J HEALTH SERV, V24, P161, DOI 10.2190/L6VN-57RR-AFLK-XW90; Lobe J, 2001, LEARN CUBA SAYS WORL; Lopez-Acuna D, 2000, Rev Panam Salud Publica, V8, P147, DOI 10.1590/S1020-49892000000700020; Maddison A, 2009, 12006 GDP AD; Mann R, 1998, EC CRISIS INDONESIA; Marmot M, 2010, FAIR SOC HLTH LIVES; Mesa-Lago C, 1998, WORLD DEV, V26, P857, DOI 10.1016/S0305-750X(98)00020-5; Minsap, 1996, CARP MET MINSAP; Minsap, 1998, SIST NAC SAL POL EST; Minsap/OPS, 1996, AN SECT SAL CUB; Mroz TA, 2004, MONITORING EC CONDIT; MUSGROVE P, 1987, INT J HEALTH SERV, V17, P411, DOI 10.2190/7EC9-PM6N-6LLJ-X2PC; Nayeri K, 2005, INT J HEALTH SERV, V35, P797, DOI 10.2190/C1QG-6Y0X-CJJA-863H; Notzon FC, 1998, JAMA-J AM MED ASSOC, V279, P793, DOI 10.1001/jama.279.10.793; PAHO, 2003, CHOL NUMB CAS DEATHS; Paxton C, 2004, N3260 WORLD BANK; Phua KaiLit, 2011, Open Public Health Journal, V4, P1, DOI 10.2174/1874944501004011001; ROMAN GC, 1994, NEUROLOGY, V44, P1784, DOI 10.1212/WNL.44.10.1784; Romero D E, 2000, Cad Saude Publica, V16, P799, DOI 10.1590/S0102-311X2000000300028; Rozenfeld BA, 1996, RAND CONF PROC, P163; Sainz P, 2006, 22 DESA; Santiesteban R, 1997, EPIDEMIAS ENDEMIAS N; Shkolnikov VM, 1998, WORLD DEV, V26, P1995, DOI 10.1016/S0305-750X(98)00102-8; Shkolnikov VM, 1996, RAND C P, P163; Spiegel JM, 2004, J PUBLIC HEALTH POL, V25, P85, DOI 10.1057/palgrave.jphp.3190007; Stuckler D., 2010, BMJ-BRIT MED J, V341, P77; Stuckler D, 2009, LANCET, V373, P399, DOI 10.1016/S0140-6736(09)60005-2; Stuckler D, 2009, LANCET, V374, P315, DOI 10.1016/S0140-6736(09)61124-7; Sussangkarn C, 1999, TDRI Q REV, V14, P3; UNCTAD, 1991, HDB INT TRAD DEV STA; UND UNCTAD and World Bank, 1997, DEBT MAN REP JOINT P; *UNDP, 2003, HUM DEV REP 2003 MIL; UNICEF and CEPAL, 2006, EF CRIS ARG POL EST; United Nations Development Programme (UNDP), 1992, HUM DEV REP 1992; Uriarte-Gaston M, 2004, CUBAN STUDIES, V35, P105; US Department of Agrculture, 2008, OFF GLOB AN FOR AGR; Waters H, 2003, HEALTH POLICY PLANN, V18, P172, DOI 10.1093/heapol/czg022; WHO, 2008, CLOS GAP GEN HLTH EQ; World Health Organization, 2009, FIN CRIS GLOB HLTH R	76	12	12	1	36	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2012	17	4					469	479		10.1111/j.1365-3156.2011.02941.x				11	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	915EA	WOS:000302005600011	22296108	Bronze			2019-03-26	
J	Purchase, SE; Van der Linden, DJ; McKerrow, NH				Purchase, Susan E.; Van der Linden, Dimitri J.; McKerrow, Neil H.			Feasibility and Effectiveness of Early Initiation of Combination Antiretroviral Therapy in HIV-infected Infants in a Government Clinic of Kwazulu-Natal, South Africa	JOURNAL OF TROPICAL PEDIATRICS			English	Article						HIV; antiretroviral therapy; infants; paediatric	RESOURCE-LIMITED SETTINGS; CALMETTE-GUERIN; FOLLOW-UP; CHILDREN; LESS; AGE; TUBERCULOSIS; MORTALITY; EFFICACY; PHARMACOKINETICS	A recent randomized trial showed dramatic improvement in survival of HIV-infected infants receiving early combination antiretroviral therapy (cART). However, few data are available for resource-limited settings. Therefore we conducted a chart review of HIV-infected infants initiated on cART between 2005 and 2008. Of 129 treated infants, 94 completed 6 months, 62 completed 12 months, and 39 completed 18 months of cART. Median age at initiation of cART was 8.6 months (range 2.1-11.9) and 77.2% had advanced disease. Undetectable VL was found in 78.8% of children who reached 18 months of treatment. CD4% increased from a median of 15.4% at baseline to 33.1% at 18 months. Weight for age Z-score increased from a mean +/- SD of -2.7 +/- 1.97 to 0.02 +/- 1.10 at 18 months. Findings show favourable response to cART in HIV-infected infants outside a research environment, despite initial advanced disease. Efforts should be made to initiate cART as early as possible.	[Van der Linden, Dimitri J.] Clin Univ St Luc, Dept Paediat, B-1200 Brussels, Belgium; [Purchase, Susan E.] Pietermarizburg Metropolitan Hosp Complex, Dept Paediat, ZA-3200 Pietermaritzburg, South Africa; [Van der Linden, Dimitri J.] CHU St Justine, Dept Paediat, Div Infect Dis, Montreal, PQ H3T 1C5, Canada; [McKerrow, Neil H.] Pietermaritzburg Metropolitan Hosp Complex, Dept Paediat & Child Hlth, ZA-3200 Pietermaritzburg, South Africa; [McKerrow, Neil H.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, ZA-4013 Durban, South Africa	Van der Linden, DJ (reprint author), Clin Univ St Luc, Dept Paediat, 10 Ave Hippocrate, B-1200 Brussels, Belgium.	dimitri.vanderlinden@uclouvain.be		Van der Linden, Dimitri/0000-0002-2696-4559			Aboulker JP, 2004, AIDS, V18, P237, DOI 10.1097/01.aids.0000111388.02002.6b; [Anonymous], 2010, NIH GUID US ANT AG P; Castro H, 2010, AIDS, V24, P231, DOI 10.1097/QAD.0b013e328333d343; Chadwick EG, 2008, AIDS, V22, P249, DOI 10.1097/QAD.0b013e3282f2be1d; Chiappini E, 2006, AIDS, V20, P207, DOI 10.1097/01.aids.0000200529.64113.3e; Eley B, 2006, SAMJ S AFR MED J, V96, P988; Faye A, 2004, CLIN INFECT DIS, V39, P1692, DOI 10.1086/425739; Fetzer BC, 2009, TROP MED INT HEALTH, V14, P862, DOI 10.1111/j.1365-3156.2009.02315.x; Goetghebuer T, 2009, AIDS, V23, P597, DOI 10.1097/QAD.0b013e328326ca37; Hesseling AC, 2007, VACCINE, V25, P14, DOI 10.1016/j.vaccine.2006.07.020; Inwani I, 2009, JAIDS-J ACQ IMM DEF, V50, P492, DOI 10.1097/QAI.0b013e318198a8a4; Luzuriaga K, 2004, NEW ENGL J MED, V350, P2471, DOI 10.1056/NEJMoa032706; MCILLERON H, 2009, 16 C RETR OPP INF MO; Meyer-Rath G, 2010, 13 INT AIDS C VIENN; Mphatswe W, 2007, AIDS, V21, P1253, DOI 10.1097/QAD.0b013e3281a3bec2; Nachman SA, 2005, PEDIATR INFECT DIS J, V24, P352, DOI 10.1097/01.inf.0000157095.75081.43; National Department of Health, 2005, GUID MAN HIV INF CHI; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; O'Brien DP, 2007, CLIN INFECT DIS, V44, P1245, DOI 10.1086/513433; Poerksen G, 2010, ANTIVIR THER, V15, P343, DOI 10.3851/IMP1544; Prendergast A, 2008, AIDS, V22, P1333, DOI 10.1097/QAD.0b013e32830437df; Puthanakit T, 2005, CLIN INFECT DIS, V41, P100, DOI 10.1086/430714; Puthanakit T, 2005, CLIN INFECT DIS, V41, P1049, DOI 10.1086/433177; Puthanakit T, 2009, PEDIATR INFECT DIS J, V28, P246, DOI 10.1097/INF.0b013e31818dd72b; RABIE H, 2008, 15 C RETR OPP INF BO; Reitz C, 2010, J INFECT DIS, V201, P1121, DOI 10.1086/651454; Ren Y, 2008, JAIDS-J ACQ IMM DEF, V47, P566, DOI 10.1097/QAI.0b013e3181642257; Sauvageot D, 2010, PEDIATRICS, V125, pE1039, DOI 10.1542/peds.2009-1062; Smith K, 2009, AIDS, V23, P1097, DOI 10.1097/QAD.0b013e32832afefc; Van der Linden D, 2007, PEDIATR INFECT DIS J, V26, P359, DOI 10.1097/01.inf.0000258626.34984.eb; van Rossum AMC, 2000, J PEDIATR-US, V136, P780, DOI 10.1067/mpd.2000.106234; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; Welch S, 2009, HIV MED, V10, P591, DOI 10.1111/j.1468-1293.2009.00759.x; World Health Organization, 2006, ANT THER HIV INF INF; [World Health Organization UNAIDS], 2009, AIDS EP UPD 2009 WHO; World Health Organization, 2010, WHO PUBL; Zanoni BC, 2011, AIDS, V25, P49, DOI 10.1097/QAD.0b013e32833f9e04; Zhang C, 2010, 10 INT C DRUG THER H	38	6	6	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0142-6338			J TROP PEDIATRICS	J. Trop. Pediatr.	APR	2012	58	2					114	119		10.1093/tropej/fmr053				6	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	919DH	WOS:000302300800006	21705764	Bronze			2019-03-26	
J	Kreeftmeijer-Vegter, AR; van Genderen, PJ; Visser, LG; Bierman, WFW; Clerinx, J; van Veldhuizen, CKW; de Vries, PJ				Kreeftmeijer-Vegter, Annemarie R.; van Genderen, Perry J.; Visser, Leo G.; Bierman, Wouter F. W.; Clerinx, Jan; van Veldhuizen, Cees K. W.; de Vries, Peter J.			Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium	MALARIA JOURNAL			English	Article						Intravenous artesunate; Severe malaria; Parasite clearance; Named patient program; European traveller	SEVERE FALCIPARUM-MALARIA; HEMOLYTIC-ANEMIA; RANDOMIZED-TRIAL; QUININE; ARTEMISININ; TRAVELERS; EFFICACY	Background: Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, however, no GMP-manufactured product is available and treatment data in European travellers are scarce. Fortunately, artesunate became available in the Netherlands and Belgium through a named patient programme. This is the largest case series of artesunate treated patients with severe malaria in Europe. Methods: Hospitalized patients treated with IV artesunate between November 2007 and December 2010 in the Netherlands and Belgium were retrospectively evaluated. Patient characteristics, treatment and clinical outcome were recorded on a standardized form and mortality, parasite clearance times and the occurrence of adverse events were evaluated. Results: Of the 68 treated patients, including 55 with severe malaria, two patients died (2/55 = 3.6%). The mean time to 50% parasite clearance (PCT50), 90% and 99% were 4.4 hours (3.9 - 5.2), 14.8 hours (13.0 - 17.2), and 29.5 hours (25.9 - 34.4) respectively. Artesunate was well tolerated. However, an unusual form of haemolytic anaemia was observed in seven patients. The relationship with artesunate remains uncertain. Conclusions: Data from the named patient programme demonstrate that IV artesunate is effective and well-tolerated in European travellers lacking immunity. However, increased attention needs to be paid to the possible development of haemolytic anaemia 2-3 weeks after start of treatment. Treatment of IV artesunate should be limited to the period that IV treatment is required and should be followed by a full oral course of an appropriate anti-malarial drug.	[Kreeftmeijer-Vegter, Annemarie R.; de Vries, Peter J.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis, NL-1105 AZ Amsterdam, Netherlands; [Kreeftmeijer-Vegter, Annemarie R.; van Veldhuizen, Cees K. W.] ACE Pharmaceut BV, NL-3891 ZK Zeewolde, Netherlands; [van Genderen, Perry J.] Harbour Hosp, Dept Internal Med, NL-3011 TG Rotterdam, Netherlands; [van Genderen, Perry J.] Inst Trop Dis, NL-3011 TG Rotterdam, Netherlands; [Visser, Leo G.] Leiden Univ, Med Ctr, Sect Travel Med, Dept Infect Dis, NL-2333 ZA Leiden, Netherlands; [Bierman, Wouter F. W.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9713 GZ Groningen, Netherlands; [Clerinx, Jan] Inst Trop Med Antwerp, Dept Clin Med, B-2000 Antwerp, Belgium	Kreeftmeijer-Vegter, AR (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	a.r.vegter@amc.uva.nl		van Genderen, Perry/0000-0001-8892-7596; Visser, Leo/0000-0002-3600-9782			Aloni N M, 2010, Bull Soc Pathol Exot, V103, P296, DOI 10.1007/s13149-010-0076-6; Berdelle N, 2011, MOL CANCER THER, V10, P2224, DOI 10.1158/1535-7163.MCT-11-0534; Bruneel F, 2001, CLIN INFECT DIS, V32, P1133, DOI 10.1086/319743; Bruneel F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013236; Camacho LH, 1998, ANN TROP MED PARASIT, V92, P525, DOI 10.1080/00034983.1998.11813310; Cramer JP, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-256; de Vries PJ, 2000, ANTIMICROB AGENTS CH, V44, P1302, DOI 10.1128/AAC.44.5.1302-1308.2000; Dhaliwal G, 2004, AM FAM PHYSICIAN, V69, P2599; Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1; Faiz MA, 2005, LANCET, V366, P717; Garratty G, 2010, BLOOD REV, V24, P143, DOI 10.1016/j.blre.2010.06.004; Ghosh K, 2001, BRIT J BIOMED SCI, V58, P20; Hale V, 2007, AM J TROP MED HYG, V77, P198, DOI 10.4269/ajtmh.2007.77.198; Levesque F, 2012, ANGEW CHEM INT EDIT, V51, P1706, DOI 10.1002/anie.201107446; Longo M, 2006, REPROD TOXICOL, V21, P83, DOI 10.1016/j.reprotox.2005.05.005; Morch K, 2008, EMERG INFECT DIS, V14, P1816, DOI 10.3201/eid1411.080636; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Newton PN, 2006, EUR J CLIN PHARMACOL, V62, P1003, DOI 10.1007/s00228-006-0203-2; Newton PN, 2001, BLOOD, V98, P450, DOI 10.1182/blood.V98.2.450; RITTER K, 1993, LANCET, V342, P1333, DOI 10.1016/0140-6736(93)92248-R; SCHNITZER B, 1972, SCIENCE, V177, P175, DOI 10.1126/science.177.4044.175; van Genderen PJJ, 2010, TRANSFUSION, V50, P787, DOI 10.1111/j.1537-2995.2009.02488.x; White NJ, 2008, SCIENCE, V320, P330, DOI 10.1126/science.1155165; WHO, 2011, WHO LIST PREQ MED PR; World Health Organization, 2006, GUID TREATM MAL; World Health Organization, 2010, GUID TREATM MAL; Zoller T, 2011, EMERG INFECT DIS, V17, P771, DOI 10.3201/eid1705.101229	27	58	59	1	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAR 31	2012	11								102	10.1186/1475-2875-11-102				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	952AA	WOS:000304760900001	22462806	DOAJ Gold, Green Published			2019-03-26	
J	Cook, J; Speybroeck, N; Sochanta, T; Somony, H; Sokny, M; Claes, F; Lemmens, K; Theisen, M; Soares, IS; D'Alessandro, U; Coosemans, M; Erhart, A				Cook, Jackie; Speybroeck, Nico; Sochanta, Tho; Somony, Heng; Sokny, Mao; Claes, Filip; Lemmens, Kristel; Theisen, Michael; Soares, Irene S.; D'Alessandro, Umberto; Coosemans, Marc; Erhart, Annette			Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in Cambodia	MALARIA JOURNAL			English	Article						Malaria; Serology; Classification and regression tree; Elimination; Cambodia	MALARIA TRANSMISSION; RISK-FACTORS; ANTIBODY-RESPONSES; CENTRAL VIETNAM; CIRCUMSPOROZOITE PROTEIN; FOREST MALARIA; ANTIGENS; INFECTION; ELIMINATION; LONGEVITY	Background: In Cambodia, malaria transmission is low and most cases occur in forested areas. Seroepidemiological techniques can be used to identify both areas of ongoing transmission and high-risk groups to be targeted by control interventions. This study utilizes repeated cross-sectional data to assess the risk of being malaria sero-positive at two consecutive time points during the rainy season and investigates who is most likely to sero-convert over the transmission season. Methods: In 2005, two cross-sectional surveys, one in the middle and the other at the end of the malaria transmission season, were carried out in two ecologically distinct regions in Cambodia. Parasitological and serological data were collected in four districts. Antibodies to Plasmodium falciparum Glutamate Rich Protein (GLURP) and Plasmodium vivax Merozoite Surface Protein-119 (MSP-119) were detected using Enzyme Linked Immunosorbent Assay (ELISA). The force of infection was estimated using a simple catalytic model fitted using maximum likelihood methods. Risks for sero-converting during the rainy season were analysed using the Classification and Regression Tree (CART) method. Results: A total of 804 individuals participating in both surveys were analysed. The overall parasite prevalence was low (4.6% and 2.0% for P. falciparum and 7.9% and 6.0% for P. vivax in August and November respectively). P. falciparum force of infection was higher in the eastern region and increased between August and November, whilst P. vivax force of infection was higher in the western region and remained similar in both surveys. In the western region, malaria transmission changed very little across the season (for both species). CART analysis for P. falciparum in the east highlighted age, ethnicity, village of residence and forest work as important predictors for malaria exposure during the rainy season. Adults were more likely to increase their antibody responses to P. falciparum during the transmission season than children, whilst members of the Charay ethnic group demonstrated the largest increases. Discussion: In areas of low transmission intensity, such as in Cambodia, the analysis of longitudinal serological data enables a sensitive evaluation of transmission dynamics. Consecutive serological surveys allow an insight into spatio-temporal patterns of malaria transmission. The use of CART enabled multiple interactions to be accounted for simultaneously and permitted risk factors for exposure to be clearly identified.	[Cook, Jackie; Claes, Filip; Lemmens, Kristel; D'Alessandro, Umberto; Coosemans, Marc; Erhart, Annette] Inst Trop Med, B-2000 Antwerp, Belgium; [Speybroeck, Nico] Catholic Univ Louvain, Ecole Sante Publ, B-1200 Brussels, Belgium; [Sochanta, Tho; Somony, Heng; Sokny, Mao] Natl Ctr Malaria Control Parasitol & Entomol, Phnom Penh, Cambodia; [Theisen, Michael] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, Denmark; [Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil; [D'Alessandro, Umberto] MRC Unit, Fajara, Gambia	Cook, J (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	jcook@itg.be	D'Alessandro, Umberto/D-3457-2015; Vacinas, Inct/J-9431-2013; Soares, Irene/C-5974-2012	D'Alessandro, Umberto/0000-0001-6341-5009; Soares, Irene/0000-0002-3336-6856; Theisen, Michael/0000-0003-4412-1392	Institute of Tropical Medicine of Antwerp; National Center for Malaria Control, Parasitology and Entomology (CNM); Belgium Cooperation (Directorate-General for Development Co-operation)	We would like to thank the study population for all their support and contributions to the project. We are also grateful to Vincent Sluydts for designing the map in Figure 1. This study was funded by the Framework Agreement II (2003-2007) for capacity strengthening between the Institute of Tropical Medicine of Antwerp and the National Center for Malaria Control, Parasitology and Entomology (CNM) and supported by the Belgium Cooperation (Directorate-General for Development Co-operation).	Abe T, 2009, SE ASIAN J TROP MED, V40, P18; Achtman AH, 2005, CURR TOP MICROBIOL, V297, P71; Agak GW, 2008, VACCINE, V26, P1963, DOI 10.1016/j.vaccine.2008.02.020; Ak Mucide, 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P685; Bousema T, 2010, J INFECT DIS, V201, P1764, DOI 10.1086/652456; Bousema T, 2010, EMERG INFECT DIS, V16, P392, DOI 10.3201/eid1603.090732; BRUCECHWATT LJ, 1975, J TROP MED HYG, V78, P194; BRUCECHWATT LJ, 1973, LANCET, V2, P547; Chowell G, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-142; Cook J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025137; Corran P, 2007, TRENDS PARASITOL, V23, P575, DOI 10.1016/j.pt.2007.08.023; Corran PH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-195; DELGIUDICE G, 1990, B WORLD HEALTH ORGAN, V68, P191; Drakeley C, 2009, ADV PARASIT, V69, P299, DOI 10.1016/S0065-308X(09)69005-9; Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102; Durnez L, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-195; Dysoley L, 2008, ACTA TROP, V106, P207, DOI 10.1016/j.actatropica.2007.01.007; Erhart A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-58; Incardona S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-37; John CC, 2003, INFECT IMMUN, V71, P4320, DOI 10.1128/IAI.71.8.4320-4325.2003; Kinyanjui SM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-82; Maitland K, 1996, T ROY SOC TROP MED H, V90, P614, DOI 10.1016/S0035-9203(96)90406-X; Maitland K, 1997, PARASITOL TODAY, V13, P227, DOI 10.1016/S0169-4758(97)01061-2; Mehrizi AA, 2009, ACTA TROP, V112, P1, DOI 10.1016/j.actatropica.2009.05.016; Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97; Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X; Okell LC, 2009, J INFECT DIS, V200, P1509, DOI 10.1086/644781; Perraut R, 2000, AM J TROP MED HYG, V62, P746, DOI 10.4269/ajtmh.2000.62.746; Protopopoff N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008022; Snounou G, 2004, TRENDS PARASITOL, V20, P333, DOI 10.1016/j.pt.2004.05.004; Soares IS, 1999, AM J TROP MED HYG, V60, P357, DOI 10.4269/ajtmh.1999.60.357; Steenkeste N, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-108; Taylor RR, 1996, INT IMMUNOL, V8, P905, DOI 10.1093/intimm/8.6.905; Thang ND, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-28; THEISEN M, 1995, CLIN DIAGN LAB IMMUN, V2, P30; Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x; Turner L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029025; Van Bortel W, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-373; Weiss GE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000912	39	36	36	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAR 25	2012	11								86	10.1186/1475-2875-11-86				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	951ZZ	WOS:000304760800001	22443375	DOAJ Gold, Green Published			2019-03-26	
J	Valea, I; Tinto, H; Drabo, MK; Huybregts, L; Sorgho, H; Ouedraogo, JB; Guiguemde, RT; van Geertruyden, JP; Kolsteren, P; D'Alessandro, U				Valea, Innocent; Tinto, Halidou; Drabo, Maxime K.; Huybregts, Lieven; Sorgho, Hermann; Ouedraogo, Jean-Bosco; Guiguemde, Robert T.; van Geertruyden, Jean Pierre; Kolsteren, Patrick; D'Alessandro, Umberto		FSP MISAME Study Grp	An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso	MALARIA JOURNAL			English	Article						Malaria infection; Pregnancy; First trimester; Sulphadoxine-pyrimethamine; IPT	INTERMITTENT PREVENTIVE TREATMENT; SULFADOXINE-PYRIMETHAMINE; KOUPELA DISTRICT; AFRICA; BURDEN; PATHOGENESIS; IMMUNITY; PROGRAM; IMPACT	Background: A prospective study aiming at assessing the effect of adding a third dose sulphadoxine-pyrimethamine (SP) to the standard two-dose intermittent preventive treatment for pregnant women was carried out in Hounde, Burkina Faso, between March 2006 and July 2008. Pregnant women were identified as earlier as possible during pregnancy through a network of home visitors, referred to the health facilities for inclusion and followed up until delivery. Methods: Study participants were enrolled at antenatal care (ANC) visits and randomized to receive either two or three doses of SP at the appropriate time. Women were visited daily and a blood slide was collected when there was fever (body temperature > 37.5 degrees C) or history of fever. Women were encouraged to attend ANC and deliver in the health centre, where the new-born was examined and weighed. The timing and frequency of malaria infection was analysed in relation to the risk of low birth weight, maternal anaemia and perinatal mortality. Results: Data on birth weight and haemoglobin were available for 1,034 women. The incidence of malaria infections was significantly lower in women having received three instead of two doses of SP. Occurrence of first malaria infection during the first or second trimester was associated with a higher risk of low birth weight: incidence rate ratios of 3.56 (p < 0.001) and 1.72 (p = 0.034), respectively. After adjusting for possible confounding factors, the risk remained significantly higher for the infection in the first trimester of pregnancy (adjusted incidence rate ratio = 2.07, p = 0.002). The risk of maternal anaemia and perinatal mortality was not associated with the timing of first malaria infection. Conclusion: Malaria infection during first trimester of pregnancy is associated to a higher risk of low birth weight. Women should be encouraged to use long-lasting insecticidal nets before and throughout their pregnancy.	[Valea, Innocent; Tinto, Halidou; Ouedraogo, Jean-Bosco; Guiguemde, Robert T.] Ctr Muraz, Lab Parasitol & Entomol, Bobo Dioulasso, Burkina Faso; [Tinto, Halidou; Drabo, Maxime K.; Sorgho, Hermann; Ouedraogo, Jean-Bosco] Direct Reg Ouest, Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso; [Huybregts, Lieven; Kolsteren, Patrick] Univ Ghent, Dept Food Safety & Food Qual, B-9000 Ghent, Belgium; [van Geertruyden, Jean Pierre] Univ Antwerp, Dept Int Hlth, B-2020 Antwerp, Belgium; [Kolsteren, Patrick] Prince Leopold Inst Trop Med, Dept Publ Hlth, Unit Nutr & Child Hlth, Antwerp, Belgium; [D'Alessandro, Umberto] Prince Leopold Inst Trop Med, Dept Parasitol, Unit Epidemiol & Control Parasit Dis, Antwerp, Belgium	Valea, I (reprint author), Ctr Muraz, Lab Parasitol & Entomol, Bobo Dioulasso, Burkina Faso.	valinno@yahoo.fr	Van geertruyden, Jean-Pierre/K-6425-2014; D'Alessandro, Umberto/D-3457-2015; Huybregts, Lieven/B-9578-2009	Van geertruyden, Jean-Pierre/0000-0001-5006-6364; D'Alessandro, Umberto/0000-0001-6341-5009; Huybregts, Lieven/0000-0002-3068-2853; Tinto, Halidou/0000-0002-0472-3586	Nutrition Third Word, The Belgium ministry of development, Flemish Interuniversity Council; French Ministry of Development	The FSP/MISAME Study Group thanks the community and especially the women from Karaba and Koho and the families who participated in the study, the health staff of the Hounde district, and the staff of Center Muraz for their great support.; The FSP/MISAME Study Group also acknowledges the study funding organizations (Nutrition Third Word, The Belgium ministry of development, Flemish Interuniversity Council, and French Ministry of Development) for their financial support to the study.	Huynh BT, 2011, AM J TROP MED HYG, V85, P214, DOI 10.4269/ajtmh.2011.11-0103; Bourgoing R, 1997, Glob Impacts, P14; Brabin BJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S6; Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019; Briand V, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-160; COT M, 1993, AM J TROP MED HYG, V48, P358, DOI 10.4269/ajtmh.1993.48.358; Cottrell G, 2007, AM J TROP MED HYG, V76, P849, DOI 10.4269/ajtmh.2007.76.849; Coulibaly SO, 2007, AM J TROP MED HYG, V77, P56, DOI 10.4269/ajtmh.2007.77.56; D'Alessandro U, 2001, BRIT MED J, V322, P249, DOI 10.1136/bmj.322.7281.249; Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Gies S, 2009, TROP MED INT HEALTH, V14, P174, DOI 10.1111/j.1365-3156.2008.02215.x; Grietens KP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012013; Guyatt HL, 2004, CLIN MICROBIOL REV, V17, P760, DOI 10.1128/CMR.17.4.760-769.2004; Huybregts L, 2009, AM J CLIN NUTR, V90, P1593, DOI 10.3945/ajcn.2009.28253; Kalilani L, 2010, T ROY SOC TROP MED H, V104, P416, DOI 10.1016/j.trstmh.2010.01.013; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9; Ministere de la Sante/ Programme National de Lutte contre le Paludisme, 2006, DIR NAT PRIS CHARG P; Noor AM, 2009, LANCET, V373, P58, DOI 10.1016/S0140-6736(08)61596-2; Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003; Piola P, 2010, LANCET INFECT DIS, V10, P762, DOI 10.1016/S1473-3099(10)70202-4; Rogerson SJ, 2007, AM J TROP MED HYG, V77, P14; Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8; Sirima SB, 2003, CLIN INFECT DIS, V36, P1374, DOI 10.1086/375077; Sirima SB, 2006, AM J TROP MED HYG, V75, P205, DOI 10.4269/ajtmh.2006.75.205; Smith LA, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-18; Tagbor H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014425; Tiono AB, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-224; Uneke Chigozie J, 2007, Yale J Biol Med, V80, P39; Valea I, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-324; Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/ajtmh.2004.71.35; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; White NJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-9; *WHO AFRO, 2004, STRAT FRAM MAL PREV	36	34	34	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAR 16	2012	11								71	10.1186/1475-2875-11-71				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	933IJ	WOS:000303353800001	22433778	DOAJ Gold, Green Published			2019-03-26	
J	Declercq, E				Declercq, Etienne			Leprosy figures: no time for self-complacency	LEPROSY REVIEW			English	Editorial Material									Damien Fdn, B-1081 Brussels, Belgium	Declercq, E (reprint author), Damien Fdn, Blvd Leopold 2,263, B-1081 Brussels, Belgium.	etienne.declercq@damien-foundation.be					[Anonymous], 2011, WEEKLY EPIDEMIOLOGIC, V86, P389	1	3	3	0	3	LEPRA	COLCHESTER	28 MIDDLEBOROUGH, COLCHESTER CO1 1TG, ESSEX, ENGLAND	0305-7518			LEPROSY REV	Lepr. Rev.	MAR	2012	83	1					3	5						3	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	945NK	WOS:000304283000003	22655464				2019-03-26	
J	Mwape, KE; Phiri, IK; Praet, N; Muma, JB; Zulu, G; Van den Bossche, P; de Deken, R; Speybroeck, N; Dorny, P; Gabriel, S				Mwape, Kabemba E.; Phiri, Isaac K.; Praet, Nicolas; Muma, John B.; Zulu, Gideon; Van den Bossche, Peter; de Deken, Reginald; Speybroeck, Niko; Dorny, Pierre; Gabriel, Sarah			Taenia solium Infections in a Rural Area of Eastern Zambia-A Community Based Study	PLOS NEGLECTED TROPICAL DISEASES			English	Article							PORCINE CYSTICERCOSIS; RISK-FACTORS; HUMAN NEUROCYSTICERCOSIS; SOUTHERN PROVINCES; PREVALENCE; SEROPREVALENCE; EPILEPSY; ECUADOR; TOOLS; HETEROGENEITY	Background: Taenia solium taeniosis/cysticercosis is a parasitic infection occurring in many developing countries. Data on the status of human infections in Zambia is largely lacking. We conducted a community-based study in Eastern Zambia to determine the prevalence of human taeniosis and cysticercosis in a rural community. Methods and Findings: Stool and serum samples were collected from willing participants. Geographical references of the participants' households were determined and household questionnaires administered. Taeniosis was diagnosed in stool samples by coprology and by the polyclonal antibody-based copro-antigen enzyme-linked immunosorbent assay (copro-Ag ELISA), while cysticercosis was diagnosed in serum by the B158/B60 monoclonal antibody-based antigen ELISA (sero-Ag ELISA). Identification of the collected tapeworm after niclosamide treatment and purgation was done using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A total of 255 households from 20 villages participated in the study, 718 stool and 708 serum samples were collected and examined. Forty-five faecal samples (6.3%) were found positive for taeniosis on copro-Ag ELISA while circulating cysticercus antigen was detected in 5.8% (41/708) individuals. The tapeworm recovered from one of the cases was confirmed to be T. solium on PCR-RFLP. Seropositivity (cysticercosis) was significantly positively related to age (p = 0.00) and to copro-Ag positivity (taeniosis) (p = 0.03) but not to gender. Change point analysis revealed that the frequency of cysticercus antigens increased significantly in individuals above the age of 30. Copro-Ag positivity was not related to age or gender. The following risk factors were noted to be present in the study community: free-range pig husbandry system and poor sanitation with 47.8% of the households visited lacking latrines. Conclusions: This study has recorded high taeniosis and cysticercosis prevalences and identified the need for further studies on transmission dynamics and impact of the disease on the local people.	[Mwape, Kabemba E.; Phiri, Isaac K.] Univ Zambia, Sch Vet Med, Dept Clin Studies, Lusaka, Zambia; [Praet, Nicolas; Van den Bossche, Peter; de Deken, Reginald; Dorny, Pierre; Gabriel, Sarah] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Muma, John B.] Univ Zambia, Sch Vet Med, Dept Dis Control, Lusaka, Zambia; [Zulu, Gideon] Petauke Dist Hosp, Petauke, Zambia; [Speybroeck, Niko] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium; [Dorny, Pierre] Univ Ghent, Fac Vet Med, Parasitol Lab, B-9000 Ghent, Belgium	Mwape, KE (reprint author), Univ Zambia, Sch Vet Med, Dept Clin Studies, Lusaka, Zambia.	sgabriel@itg.be			Flemish Inter University Council, Zambia [VLIR-UOS.ZIUS2008RIP-8961]; Belgian Directorate for Development Co-operation; ITM	This work was funded by the Flemish Inter University Council, Research Initiative Programme, Zambia (VLIR-UOS.ZIUS2008RIP-8961), with the Belgian Directorate for Development Co-operation through the 3rd Framework Agreement with ITM. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afonso S. M. S., 2011, Animal Health Research Reviews, V12, P123, DOI 10.1017/S1466252311000077; ALBRIGHT JW, 1994, IMMUNOL LETT, V40, P279, DOI 10.1016/0165-2478(94)00066-2; Allan JC, 1996, ANN TROP MED PARASIT, V90, P157, DOI 10.1080/00034983.1996.11813039; Allan JC, 2006, PARASITOL INT, V55, pS75, DOI 10.1016/j.parint.2005.11.010; ALLAN JC, 1990, PARASITOLOGY, V101, P473, DOI 10.1017/S0031182000060686; Allan JC, 2003, ACTA TROP, V87, P87, DOI 10.1016/S0001-706X(03)00059-7; [Anonymous], 2010, NED LEV CRIMESTAT; Boa ME, 2006, VET PARASITOL, V139, P249, DOI 10.1016/j.vetpar.2006.02.012; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Carpio A, 1998, EPILEPSIA, V39, P1025, DOI 10.1111/j.1528-1157.1998.tb01287.x; Cavellani CL, 2007, ANN DIAGN PATHOL, V11, P330, DOI 10.1016/j.anndiagpath.2006.12.008; Cruz M, 1999, B WORLD HEALTH ORGAN, V67, P401; Dorny P, 2004, TRENDS PARASITOL, V20, P259, DOI 10.1016/j.pt.2004.04.001; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Dorny P, 2002, VET PARASITOL, V104, P211, DOI 10.1016/S0304-4017(01)00634-3; Field CJ, 2002, J LEUKOCYTE BIOL, V71, P16; Fleury A, 2004, J NEUROL, V251, P830, DOI 10.1007/s00415-004-0437-9; Fleury A, 2010, T ROY SOC TROP MED H, V104, P243, DOI 10.1016/j.trstmh.2010.01.005; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; Garcia HH, 2003, AM J TROP MED HYG, V68, P268, DOI 10.4269/ajtmh.2003.68.268; Garcia HH, 1998, AM J TROP MED HYG, V59, P902, DOI 10.4269/ajtmh.1998.59.902; Horne R, 1997, HLTH SURVIVAL 21 CEN, P63; Jayaraman T, 2011, T ROY SOC TROP MED H, V105, P153, DOI 10.1016/j.trstmh.2010.10.007; Jeri C, 2004, LANCET, V363, P949, DOI 10.1016/S0140-6736(04)15791-7; Kagira JM, 2010, J HELMINTHOL, V84, P398, DOI 10.1017/S0022149X10000076; Kandala NB, 2008, AIDS CARE, V20, P812, DOI 10.1080/09540120701742292; Kanobana K, 2011, INT J PARASITOL, V41, P1015, DOI 10.1016/j.ijpara.2011.06.004; Mafojane NA, 2003, ACTA TROP, V87, P25, DOI 10.1016/S0001-706X(03)00052-4; MoH, 2006, ZAMB MAL IND SURV RE; Mwape KE, 2011, T ROY SOC TROP MED H, V105, P574, DOI 10.1016/j.trstmh.2011.05.010; Nakao M, 2002, PARASITOLOGY, V124, P657, DOI 10.1017/S0031182002001725; Ndimubanzi PC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000870; Ngowi HA, 2004, VET PARASITOL, V120, P275, DOI 10.1016/j.vetpar.2004.01.015; Nguekam JP, 2003, TROP MED INT HEALTH, V8, P144, DOI 10.1046/j.1365-3156.2003.01000.x; Phiri IK, 2003, ACTA TROP, V87, P13, DOI [10.1016/S0001-706X(03)00051-2, 10.1016/S0001-706X(03)00202-X]; Phiri IK, 2002, VET PARASITOL, V108, P31, DOI 10.1016/S0304-4017(02)00165-6; Pondja A, 2009, PLOS NEGLECT TROP D, V4, pe594; Praet N, 2010, INT J PARASITOL, V40, P85, DOI 10.1016/j.ijpara.2009.07.007; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; Rodriguez-Hidalgo R, 2006, MEM I OSWALDO CRUZ, V101, P779, DOI 10.1590/S0074-02762006000700012; Rodriguez-Hidalgo R, 2003, VET PARASITOL, V118, P51, DOI 10.1016/j.vetpar.2003.09.019; Rodriguez-Hidalgo R, 2002, J PARASITOL, V88, P1007, DOI 10.2307/3285546; Rodriquez-Canul R, 1999, TROPICAL MED PARASIT, V93; Sacks L V, 1990, Trop Gastroenterol, V11, P30; Sanchez AL, 1999, ANN TROP MED PARASIT, V93, P247, DOI 10.1080/00034983.1999.11813420; Serpa Jose A, 2006, Expert Rev Anti Infect Ther, V4, P1051, DOI 10.1586/14787210.4.6.1051; Sikasunge CS, 2008, VET PARASITOL, V158, P57, DOI 10.1016/j.vetpar.2008.08.014; Sikasunge CS, 2007, VET PARASITOL, V143, P59, DOI 10.1016/j.vetpar.2006.07.023; Sikasunge CS, 2008, VET J, V176, P240, DOI 10.1016/j.tvjl.2007.02.030; Somers R, 2006, TROP MED INT HEALTH, V11, P65, DOI 10.1111/j.1365-3156.2005.01537.x; Speybroeck N, 2006, ENVIRON ECOL STAT, V13, P69, DOI 10.1007/s10651-005-5691-1; UNDP, 2007, HUM DEV REP 2007 200, P238; Vilhena M, 1999, AM J TROP MED HYG, V61, P59, DOI 10.4269/ajtmh.1999.61.59; Wohlgemut J, 2010, AM J TROP MED HYG, V82, P634, DOI 10.4269/ajtmh.2010.09-0404	54	28	28	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAR	2012	6	3							e1594	10.1371/journal.pntd.0001594				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	916VU	WOS:000302132100035	22479664	DOAJ Gold, Green Published			2019-03-26	
J	Likwela, JL; D'Alessandro, U; Lokwa, BL; Meuris, S; Dramaix, MW				Likwela, Joris L.; D'Alessandro, Umberto; Lokwa, Bernard L.; Meuris, Sylvain; Dramaix, Michele W.			Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC)	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						malaria; intermittent preventive treatment; sulfadoxine-pyrimethamine; pregnancy; birth weight; Democratic Republic of Congo	FALCIPARUM-MALARIA; AFRICA; EFFICACY; BURDEN; CHLOROQUINE; MORTALITY; AREAS	Objective To assess the effect of intermittent preventive treatment with sulfadoxinepyrimethamine (IPTp-SP) on birth weight in sites with varying degrees of drug resistance. METHODS Birth weight data from three regions in Democratic Republic of Congo with varying degrees of sulfadoxine-pyrimethamine (SP) resistance (1.6% in Mikalayi, 21.7% in Kisangani and 60.6% in Rutshuru) were analysed retrospectively by means of a logistic model that included the number of SP doses taken by the mother and other potentials confounding factors. results The IPTp-SP reduced the risk of low birth weight (LBW) in Kisangani (adjusted OR, 0.15; IC95%, 0.05-0.46) and in Mikalayi (adjusted OR, 0.12; IC95%, 0.01-0.89). In both sites, the average birth weight was higher for mothers having received two rather than one or no SP doses (P < 0.001). In Rutshuru, IPTp-SP had an effect in primigravidae but not in multigravidae. However, after adjustment for other LBW risk factors, there was no difference in the proportion of LBW (adjusted OR 0.92; IC95%, 0.37-2.25) between women having taken at least 2 SP doses and those with only one dose or none. conclusion IPT-SP remains an effective strategy in Kisangani and Mikalayi where the therapeutic failure to SP in children with clinical malaria was 21.7% and 1.6%, respectively, while IPTp-SP effect seems lower in Rutshuru where the therapeutic failure to SP was 60.6%. The threshold value of SP resistance at which IPTp-SP fails to have a significant impact on birth weight and LBW is unknown. Considering that no alternative is currently available, additional studies on the efficacy of IPTp-SP in the areas of high SP resistance such as Rutshuru are needed so that the threshold at which this intervention fails to provide any benefit is determined with some precision.	[Likwela, Joris L.; Meuris, Sylvain] Univ Libre Bruxelles, Fac Med, Lab Hormonol Expt, Campus Erasme CP598,808 Route Lennik, B-1070 Brussels, Belgium; [D'Alessandro, Umberto] Inst Trop Med, Epidemiol & Control Parasit Dis Unit, B-2000 Antwerp, Belgium; [Lokwa, Bernard L.] Univ Kisangani, Fac Med, Dept Obstet Gynecol, Kisangani, DEM REP CONGO; [Dramaix, Michele W.] Univ Libre Bruxelles, Ecole Sante Publ, Dept Biostat, B-1070 Brussels, Belgium	Likwela, JL (reprint author), Univ Libre Bruxelles, Fac Med, Lab Hormonol Expt, Campus Erasme CP598,808 Route Lennik, B-1070 Brussels, Belgium.	losimba@ulb.ac.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009	Belgian Technical Cooperation	We thank the Belgian Technical Cooperation for financial support.	Alker AP, 2008, TROP MED INT HEALTH, V13, P1384, DOI 10.1111/j.1365-3156.2008.02150.x; Brabin BJ, 1999, ANN TROP MED PARASIT, V93, pS43, DOI 10.1080/00034983.1999.11813503; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Breslow NE, 1987, IARC SCI PUBLICATION, VII; Briand V, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-160; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Kazadi WM, 2003, TROP MED INT HEALTH, V8, P868, DOI 10.1046/j.1365-3156.2003.01098.x; Lagerberg RE, 2008, J MIDWIFERY WOM HEAL, V53, P209, DOI 10.1016/j.jmwh.2008.02.012; Lukuka KA, 2006, B SOC PATHOL EXOT, V99, P1; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; Menendez C, 2008, PLOS MED, V5, P220, DOI 10.1371/journal.pmed.0050044; Menendez C, 2007, LANCET INFECT DIS, V7, P126, DOI 10.1016/S1473-3099(07)70024-5; MEURIS S, 1993, AM J TROP MED HYG, V48, P603, DOI 10.4269/ajtmh.1993.48.603; *MIN PLAN MACR, 2008, ENQ DEM SANT REP DEM; Ministere de la Sante Republique Democratique du Congo Programme Nationale de Lutte contre le Paludisme, 2007, FAIR RECU PAL PLAN 2; Mita T, 2003, AM J TROP MED HYG, V68, P413, DOI 10.4269/ajtmh.2003.68.413; Mutabingwa TK, 2005, PLOS MED, V2, P1260, DOI 10.1371/journal.pmed.0020407; Newman RD, 2003, TROP MED INT HEALTH, V8, P488, DOI 10.1046/j.1365-3156.2003.01066.x; Odio W, 2005, RAPPORT REV RESULTAT; Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1; Sirima SB, 2006, AM J TROP MED HYG, V75, P205, DOI 10.4269/ajtmh.2006.75.205; Steketee RW, 2003, J NUTR, V133, p1661S, DOI 10.1093/jn/133.5.1661S; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; Taylor SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016420; ter Kuile FO, 2007, JAMA-J AM MED ASSOC, V297, P2603, DOI 10.1001/jama.297.23.2603; Vallely A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-16; Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/ajtmh.2004.71.35; White NJ, 2005, PLOS MED, V2, P28, DOI 10.1371/journal.pmed.0020003; WHO, 2008, WORLD MAL REP 2008; WHO, 2003, ANT CAR DEV COUNTR P; WHO, 2004, STRAT FRAM MAL PREV; World Health Organization, 2006, AFR MAL REP 2006; World Health Organization, 2008, TECHN EXP GROUP M IN; World Health Organization, 2005, WORLD HLTH REP 2005, P68; World Health Organization, 2005, REC US SULF PIR SP I	37	15	15	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAR	2012	17	3					322	329		10.1111/j.1365-3156.2011.02935.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	897VG	WOS:000300686600009	22212628	Bronze			2019-03-26	
J	Picado, A; Singh, SP; Vanlerberghe, V; Uranw, S; Ostyn, B; Kaur, H; Das, ML; Sundar, S; Rijal, S; Tungu, P; Boelaert, M; Rowland, M				Picado, Albert; Singh, Shri Prakash; Vanlerberghe, Veerle; Uranw, Surendra; Ostyn, Bart; Kaur, Harparkash; Das, Murari Lal; Sundar, Shyam; Rijal, Suman; Tungu, Patrick; Boelaert, Marleen; Rowland, Mark			Residual activity and integrity of PermaNet (R) 2.0 after 24 months of household use in a community randomised trial of long lasting insecticidal nets against visceral leishmaniasis in India and Nepal	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Deltamethrin; Long lasting insecticidal net; PermaNet 2.0; Visceral leishmaniasis; WHOPES	VECTORS ANOPHELES-CULICIFACIES; WASH-RESISTANCE; TREATED NETS; MALARIA VECTORS; FIELD-EVALUATION; ENDEMIC AREAS; MOSQUITO NET; TRIBAL AREA; DELTAMETHRIN; SUBCONTINENT	The World Health Organization (WHO) recommends several brands of long lasting insecticidal net (LN) for protection against insect vectors but also advises national programmes to monitor and evaluate performance under local conditions to help them select the most suitable LN for their setting. During the course of a community randomised trial of LNs against visceral leishmaniasis in northern India and Nepal, opportunity arose to assess the efficacy of PermaNet 2.0 (Vestergaard-Frandsen, Denmark) after two years of use against sandfly vectors. Between 63% (India) and 78% (Nepal) of LNs became holed over the course of two years, deltamethrin residues fell from 55 mg/m(2) to an average of 11.6 mg/m(2) (India) and 27.9 mg/m(2) (Nepal), but on the basis of bioassay criteria all LNs tested still met the WHO Pesticide Evaluation Scheme standard for LN effectiveness. Nets had on average only been washed 2.5 times (India) and 0.6 times (Nepal) by householders over the course of two years. The loss of insecticide was attributed to factors which had little or nothing to do with washing, such as handling, friction and torsion during daily use. Under conditions pertaining in this region of south Asia, and for two years at least, this brand of net continues to meet the criteria established by WHO for LNs. (C) 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Picado, Albert; Vanlerberghe, Veerle; Ostyn, Bart; Boelaert, Marleen] Inst Trop Med, Dept Publ Heath, B-2000 Antwerp, Belgium; [Picado, Albert; Kaur, Harparkash; Rowland, Mark] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England; [Singh, Shri Prakash; Sundar, Shyam] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Uranw, Surendra; Das, Murari Lal; Rijal, Suman] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Tungu, Patrick] Natl Inst Med Res, Muheza, Tanzania	Picado, A (reprint author), Inst Trop Med, Dept Publ Heath, B-2000 Antwerp, Belgium.	albert.picado@lshtm.ac.uk	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	European Union, INCO-DEV [015374]; Fonds Wetenschappelijk Onderzoek - Vlaanderen (FWO) [1511309]	Funding: European Union, INCO-DEV (FP-6 contract no 015374) and Fonds Wetenschappelijk Onderzoek - Vlaanderen (FWO contract 1511309).	[Anonymous], 2009, 12 WHOPES WORK GROUP; Atieli FK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-248; Das ML, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000100; Dev V, 2010, T ROY SOC TROP MED H, V104, P273, DOI 10.1016/j.trstmh.2009.08.010; Dev V, 2010, VECTOR-BORNE ZOONOT, V10, P403, DOI 10.1089/vbz.2008.0191; Dhingra N, 2010, LANCET, V376, P1768, DOI 10.1016/S0140-6736(10)60831-8; Dinesh DS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000859; Fettene M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-114; Graham K, 2005, MED VET ENTOMOL, V19, P72, DOI 10.1111/j.0269-283X.2005.00543.x; Green MD, 2009, TROP MED INT HEALTH, V14, P381, DOI 10.1111/j.1365-3156.2009.02247.x; Joshi AB, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-54; Kayedi MH, 2007, ANN TROP MED PARASIT, V101, P519, DOI 10.1179/136485907X193815; Kilian A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-49; Lindblade KA, 2005, TROP MED INT HEALTH, V10, P1141, DOI 10.1111/j.1365-3156.2005.01501.x; Ostyn B, 2008, TROP MED INT HEALTH, V13, P1073, DOI 10.1111/j.1365-3156.2008.02110.x; Picado A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6760; Picado A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000587; Sharma SK, 2006, J MED ENTOMOL, V43, P884, DOI 10.1603/0022-2585(2006)43[884:WRABOO]2.0.CO;2; Sharma SK, 2009, J MED ENTOMOL, V46, P342, DOI 10.1603/033.046.0220; Sharma SK, 2010, ACTA TROP, V116, P24, DOI 10.1016/j.actatropica.2010.05.002; Smith SC, 2007, AM J TROP MED HYG, V77, P243, DOI 10.4269/ajtmh.2007.77.243; Tungu P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-21; Vanlerberghe V, 2010, TROP MED INT HEALTH, V15, P60, DOI 10.1111/j.1365-3156.2009.02433.x; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, 2008, 11 WHOPES WORK GROUP; WHO (World Health Organization), 2005, WHOCDSWHOPESGCDPP200; World Health Organization, 2009, 13 WHOPES WORK GROUP; Yates A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-52	28	12	12	1	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAR	2012	106	3					150	159		10.1016/j.trstmh.2011.10.014				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	910HD	WOS:000301626900003	22137191	Bronze			2019-03-26	
J	Albonico, M; Ame, SM; Vercruysse, J; Levecke, B				Albonico, M.; Ame, S. M.; Vercruysse, J.; Levecke, B.			Comparison of the Kato-Katz thick smear and McMaster egg counting techniques for monitoring drug efficacy against soil-transmitted helminths in schoolchildren on Pemba Island, Tanzania	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Soil-transmitted helminths; Faecal egg count; Kato-Katz thick smear technique; McMaster egg counting technique; Drug efficacy; Albendazole		The Kato-Katz thick smear technique is widely used to assess prevalence and intensity in soil-transmitted helminth (STH) control programmes, but its usefulness in monitoring anthelminthic drug efficacy needs to be validated and compared with other methods. A promising alternative is the McMaster egg counting technique. In the present study, the efficacy of single-dose albendazole against STH infections in 430 schoolchildren on Pemba Island was assessed using both the Kato-Katz and McMaster techniques. The study revealed comparable drug efficacy results for both methods and confirmed the potency of the McMaster technique as an alternative method for monitoring large-scale deworming programmes. (C) 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Albonico, M.; Ame, S. M.] Publ Hlth Lab, Pemba Isl, Zanzibar, Tanzania; [Albonico, M.] Ivo de Carneri Fdn, Milan, Italy; [Vercruysse, J.; Levecke, B.] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium	Albonico, M (reprint author), Fdn Ivo de Carneri, Via 4 Marzo 14, I-10122 Turin, Italy.	albonico@tin.it		ALBONICO, Marco/0000-0002-7805-2391; Levecke, Bruno/0000-0001-8912-5595	World Health Organization, Geneva, Switzerland [2008/12964/0, P2-APW002]; Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) [G.0853.09]	The fieldwork was supported by the World Health Organization, Geneva, Switzerland (Reference No. 2008/12964/0; Registration File No. P2-APW002). BL is funded by the Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen; Reference No. G.0853.09).	Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Knopp S, 2009, T ROY SOC TROP MED H, V103, P1190, DOI 10.1016/j.trstmh.2009.05.012; Levecke B, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000366; Levecke B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001201; Vercruysse J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000948; WHO, 1999, WHOCDSCPCSIP991, P8; World Health Organization, 2006, PREV CHEM HUM HELM	7	12	12	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAR	2012	106	3					199	201		10.1016/j.trstmh.2011.11.006				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	910HD	WOS:000301626900011	22261186				2019-03-26	
J	Bentley, SD; Comas, I; Bryant, JM; Walker, D; Smith, NH; Harris, SR; Thurston, S; Gagneux, S; Wood, J; Antonio, M; Quail, MA; Gehre, F; Adegbola, RA; Parkhill, J; de Jong, BC				Bentley, Stephen D.; Comas, Inaki; Bryant, Josephine M.; Walker, Danielle; Smith, Noel H.; Harris, Simon R.; Thurston, Scott; Gagneux, Sebastien; Wood, Jonathan; Antonio, Martin; Quail, Michael A.; Gehre, Florian; Adegbola, Richard A.; Parkhill, Julian; de Jong, Bouke C.			The Genome of Mycobacterium Africanum West African 2 Reveals a Lineage-Specific Locus and Genome Erosion Common to the M. tuberculosis Complex	PLOS NEGLECTED TROPICAL DISEASES			English	Article							EFFLUX PUMP; PULMONARY TUBERCULOSIS; CODING SEQUENCES; TUBERCLE-BACILLI; DRUG-RESISTANCE; BACTERIAL GENES; GUINEA-BISSAU; BOVIS BCG; VIRULENCE; EVOLUTION	Background: M. africanum West African 2 constitutes an ancient lineage of the M. tuberculosis complex that commonly causes human tuberculosis in West Africa and has an attenuated phenotype relative to M. tuberculosis. Methodology/Principal Findings: In search of candidate genes underlying these differences, the genome of M. africanum West African 2 was sequenced using classical capillary sequencing techniques. Our findings reveal a unique sequence, RD900, that was independently lost during the evolution of two important lineages within the complex: the "modern" M. tuberculosis group and the lineage leading to M. bovis. Closely related to M. bovis and other animal strains within the M. tuberculosis complex, M. africanum West African 2 shares an abundance of pseudogenes with M. bovis but also with M. africanum West African clade 1. Comparison with other strains of the M. tuberculosis complex revealed pseudogenes events in all the known lineages pointing toward ongoing genome erosion likely due to increased genetic drift and relaxed selection linked to serial transmission-bottlenecks and an intracellular lifestyle. Conclusions/Significance: The genomic differences identified between M. africanum West African 2 and the other strains of the Mycobacterium tuberculosis complex may explain its attenuated phenotype, and pave the way for targeted experiments to elucidate the phenotypic characteristic of M. africanum. Moreover, availability of the whole genome data allows for verification of conservation of targets used for the next generation of diagnostics and vaccines, in order to ensure similar efficacy in West Africa.	[Bentley, Stephen D.; Bryant, Josephine M.; Walker, Danielle; Harris, Simon R.; Thurston, Scott; Wood, Jonathan; Quail, Michael A.; Parkhill, Julian] Wellcome Trust Sanger Inst, Hinxton, Cambs, England; [Comas, Inaki] Ctr Publ Hlth Res, Genom & Hlth Unit, Valencia, Spain; [Comas, Inaki] Natl Inst Med Res, MRC, Div Mycobacterial Res, London NW7 1AA, England; [Smith, Noel H.] VLA, TB Res Grp, Addlestone, Surrey, England; [Smith, Noel H.] Univ Sussex, Ctr Study Evolut, Brighton, E Sussex, England; [Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Dept Med Parasitol & Infect Biol, Basel, Switzerland; [Gagneux, Sebastien] Univ Basel, Basel, Switzerland; [Antonio, Martin; Gehre, Florian; Adegbola, Richard A.; de Jong, Bouke C.] MRC Unit, Banjul, Gambia; [Gehre, Florian; de Jong, Bouke C.] Inst Trop Med, B-2000 Antwerp, Belgium; [de Jong, Bouke C.] NYU, New York, NY USA	Bentley, SD (reprint author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton, Cambs, England.	bdejong@itg.be	Harris, Simon/K-1318-2013; Parkhill, Julian/G-4703-2011; de Jong, Bouke/A-3636-2013; Smith, Noel/C-6708-2011; Comas, Inaki/F-1185-2011; APHA, Staff publications/E-6082-2010	Harris, Simon/0000-0003-1512-6194; Parkhill, Julian/0000-0002-7069-5958; de Jong, Bouke/0000-0002-1017-4675; Comas, Inaki/0000-0001-5504-9408; Bryant, Josephine/0000-0002-0149-5768	Wellcome Trust through the Sanger Institute core budget; Medical Research Council [MC_U190074190, MC_U190071468, MC_UP_A900_1122, MC_U190081991, MC_U190085850, MC_U190081982]	The genome sequencing of M. africanum strain GM041182 was funded by the Wellcome Trust through the Sanger Institute core budget. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Affolabi D, 2009, INT J TUBERC LUNG D, V13, P317; Agarwal N, 2009, NATURE, V460, P98, DOI 10.1038/nature08123; Alexander KA, 2010, EMERG INFECT DIS, V16, P1296, DOI 10.3201/eid1608.100314; Balganesh M, ANTIMICROB AGENTS CH, V54, P5167; Berriman Matt, 2003, Briefings in Bioinformatics, V4, P124, DOI 10.1093/bib/4.2.124; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; Bold TD, J INFECT DI IN PRESS; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553; Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179; Chain PSG, 2009, SCIENCE, V326, P236, DOI 10.1126/science.1180614; Colangeli R, 2005, MOL MICROBIOL, V55, P1829, DOI 10.1111/j.1365-2958.2005.04510.x; Comas I, 2010, NAT GENET, V42, P498, DOI 10.1038/ng.590; Comas I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007815; Coscolla Mireilla, 2010, Drug Discov Today Dis Mech, V7, pe43, DOI 10.1016/j.ddmec.2010.09.004; Cubillos-Ruiz A, 2008, MC RES NOTES, V1, P110; Dasgupta A, PLOS ONE, V5; de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977; de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41; de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504; de Jong BC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000744; de Jong BC, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-11; De Smet KAL, 2000, MICROBIOL-UK, V146, P199, DOI 10.1099/00221287-146-1-199; Delcher AL, 2007, BIOINFORMATICS, V23, P673, DOI 10.1093/bioinformatics/btm009; Deshayes C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-78; Desmond E, 2004, EMERG INFECT DIS, V10, P921; Diop S, 1976, Bull Soc Med Afr Noire Lang Fr, V21, P50; Domenech P, 2005, INFECT IMMUN, V73, P3492, DOI 10.1128/IAI.73.6.3492-3501.2005; Durnez L, 2010, APPL ENVIRON MICROB, V76, P4574, DOI 10.1128/AEM.00199-10; Fang Z, 1999, J BACTERIOL, V181, P1014; Frothingham R, 1999, J CLIN MICROBIOL, V37, P1921; Gao LY, 2004, MOL MICROBIOL, V53, P1677, DOI 10.1111/j.1365-2958.2004.04261.x; Gioffre A, 2005, MICROBES INFECT, V7, P325, DOI 10.1016/j.micinf.2004.11.007; Goossens B, 1998, VET REC, V142, P277, DOI 10.1136/vr.142.11.277; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311; Honaker RW, 2008, INFECT IMMUN, V76, P2587, DOI 10.1128/IAI.01235-07; Huard RC, 2006, J BACTERIOL, V188, P4271, DOI 10.1128/JB.01783-05; Intemann CD, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000577; Joshi SM, 2006, P NATL ACAD SCI USA, V103, P11760, DOI 10.1073/pnas.0603179103; Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872; Kalscheuer R, 2010, P NATL ACAD SCI US; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907; Karboul A, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-107; Koivula T, 2004, MICROBES INFECT, V6, P272, DOI 10.1016/j.micinf.2003.12.006; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li XZ, 2004, ANTIMICROB AGENTS CH, V48, P2415, DOI 10.1128/AAC.48.7.2415-2423.2004; Maurelli AT, 2007, FEMS MICROBIOL LETT, V267, P1, DOI 10.1111/j.1574-6968.2006.00526.x; McLean KJ, 2008, J BIOL CHEM, V283, P33406, DOI 10.1074/jbc.M802115200; Meyer CG, 2008, TUBERCULOSIS, V88, P482, DOI 10.1016/j.tube.2008.05.004; Miller BH, 2000, INFECT IMMUN, V68, P387, DOI 10.1128/IAI.68.1.387-390.2000; Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004; Mostowy S, 2002, J INFECT DIS, V186, P74, DOI 10.1086/341068; Newton SM, 2006, P NATL ACAD SCI USA, V103, P15594, DOI 10.1073/pnas.0604283103; Niemann S, 2004, J CLIN MICROBIOL, V42, P3958, DOI 10.1128/JCM.42.9.3958-3962.2004; Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003; Parsons S, 2008, TUBERCULOSIS, V88, P80, DOI 10.1016/j.tube.2007.08.012; Pollock JM, 2003, J CLIN MICROBIOL, V41, P1856, DOI 10.1128/JCM.41.5.1856.1860.2003; Raghavan S, 2008, NATURE, V454, P717, DOI 10.1038/nature07219; Ramon-Garcia S, 2007, J ANTIMICROB CHEMOTH, V59, P544, DOI 10.1093/jac/dkl510; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Smith NH, 2006, J THEOR BIOL, V239, P220, DOI 10.1016/j.jtbi.2005.08.036; Sohaskey CD, 2003, J BACTERIOL, V185, P7247, DOI 10.1128/JB.185.24.7247-7256.2003; Stinear TP, 2008, GENOME RES, V18, P729, DOI 10.1101/gr.075069.107; Tamura K, 2011, MOL BIOL EVOL; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Thye T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020908; Unger F, 2003, RISK ASS MYCOBACTERI, P1; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406; Veyrier FJ, 2011, TRENDS MICROBIOL, V19, P156, DOI 10.1016/j.tim.2010.12.008	73	37	40	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	FEB	2012	6	2							e1552	10.1371/journal.pntd.0001552				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	901FX	WOS:000300949200051	22389744	DOAJ Gold, Green Published			2019-03-26	
J	Decuypere, S; Vanaerschot, M; Brunker, K; Imamura, H; Muller, S; Khanal, B; Rijal, S; Dujardin, JC; Coombs, GH				Decuypere, Saskia; Vanaerschot, Manu; Brunker, Kirstyn; Imamura, Hideo; Mueller, Sylke; Khanal, Basudha; Rijal, Suman; Dujardin, Jean-Claude; Coombs, Graham H.			Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background	PLOS NEGLECTED TROPICAL DISEASES			English	Article							INDIAN KALA-AZAR; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; VISCERAL LEISHMANIASIS; PENTAVALENT ANTIMONY; TRYPANOTHIONE REDUCTASE; SODIUM STIBOGLUCONATE; IN-VITRO; MYCOBACTERIUM-TUBERCULOSIS; EXPRESSION ANALYSIS; TRIVALENT ANTIMONY	The evolution of drug-resistance in pathogens is a major global health threat. Elucidating the molecular basis of pathogen drug-resistance has been the focus of many studies but rarely is it known whether a drug-resistance mechanism identified is universal for the studied pathogen; it has seldom been clarified whether drug-resistance mechanisms vary with the pathogen's genotype. Nevertheless this is of critical importance in gaining an understanding of the complexity of this global threat and in underpinning epidemiological surveillance of pathogen drug resistance in the field. This study aimed to assess the molecular and phenotypic heterogeneity that emerges in natural parasite populations under drug treatment pressure. We studied lines of the protozoan parasite Leishmania (L.) donovani with differential susceptibility to antimonial drugs; the lines being derived from clinical isolates belonging to two distinct genetic populations that circulate in the leishmaniasis endemic region of Nepal. Parasite pathways known to be affected by antimonial drugs were characterised on five experimental levels in the lines of the two populations. Characterisation of DNA sequence, gene expression, protein expression and thiol levels revealed a number of molecular features that mark antimonial-resistant parasites in only one of the two populations studied. A final series of in vitro stress phenotyping experiments confirmed this heterogeneity amongst drug-resistant parasites from the two populations. These data provide evidence that the molecular changes associated with antimonial-resistance in natural Leishmania populations depend on the genetic background of the Leishmania population, which has resulted in a divergent set of resistance markers in the Leishmania populations. This heterogeneity of parasite adaptations provides severe challenges for the control of drug resistance in the field and the design of molecular surveillance tools for widespread applicability.	[Decuypere, Saskia; Vanaerschot, Manu; Imamura, Hideo; Dujardin, Jean-Claude] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Decuypere, Saskia; Brunker, Kirstyn; Coombs, Graham H.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland; [Decuypere, Saskia; Mueller, Sylke] Univ Glasgow, Wellcome Trust Ctr Mol Parasitol, Inst Infect Immun & Inflammat, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Imamura, Hideo] Wellcome Trust Sanger Inst, Hinxton, England; [Khanal, Basudha; Rijal, Suman] BP Koirala Inst Hlth Sci, Ghopa, Dharan, Nepal; [Dujardin, Jean-Claude] Univ Antwerp, Dept Biomed Sci, B-2020 Antwerp, Belgium	Decuypere, S (reprint author), Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium.	jcdujardin@itg.be	Vanaerschot, Manu/B-6812-2013	Vanaerschot, Manu/0000-0002-9141-2347; Decuypere, Saskia/0000-0001-5036-4601; Brunker, Kirstyn/0000-0001-9990-6299; Imamura, Hideo/0000-0002-3282-1319	European Commission [FP5-ICA4-CT-2001-10076, FP6 -DonNA-R - 041465, FP7-222895]; Baillet-Latour Foundation; Wellcome Trust [WT061173MA-SM, 085349]	This work received financial support from the European Commission (INCO-Dev project LeishNatDrug-R contract FP5-ICA4-CT-2001-10076, Marie Curie IEF contract FP6 -DonNA-R - 041465, and INCO-Dev project Kaladrug-R contract FP7-222895) and the Baillet-Latour Foundation. This work was also supported by the Wellcome Trust (WT061173MA-SM). The Wellcome Trust Centre for Molecular Parasitology is supported by core funding from the Wellcome Trust (085349). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adaui V, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001021; Ait-Oudhia K, 2011, TRENDS PARASITOL, V27, P141, DOI 10.1016/j.pt.2010.12.003; Alcolea PJ, 2010, INT J PARASITOL, V40, P1497, DOI [10.1016/j.ijpara2010.05.013, 10.1016/j.ijpara.2010.05.013]; Alvar J, 2006, ADV PARASIT, V61, P223, DOI 10.1016/S0065-308X(05)61006-8; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Ashutosh, 2007, J MED MICROBIOL, V56, P143, DOI 10.1099/jmm.0.46841-0; Baiocco P, 2009, J MED CHEM, V52, P2603, DOI 10.1021/jm900185q; Basu JM, 2006, ANTIMICROB AGENTS CH, V50, P1788, DOI [10.1128/AAC.50.5.1788-1797.2006, 10.1128/AAC.50.5.1768-1797.2006]; Beerenwinkel N, 2011, STAT APPL G IN PRESS, P10; Borrell S, 2011, CLIN MICROBIOL INFEC, V17, P815, DOI 10.1111/j.1469-0691.2011.03556.x; Brochu C, 2003, ANTIMICROB AGENTS CH, V47, P3073, DOI 10.1128/AAC.47.10.3073-3079.2003; Carter KC, 2005, PARASITOLOGY, V131, P747, DOI 10.1017/S0031182005008486; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Coelho AC, 2003, MOL BIOCHEM PARASIT, V130, P83, DOI 10.1016/S0166-6851(03)00162-2; CUNNINGHAM ML, 1995, EUR J BIOCHEM, V230, P460; da Luz RI, 2009, ANTIMICROB AGENTS CH, V53, P5197, DOI 10.1128/AAC.00866-09; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; Decuypere S, 2008, PARASITOLOGY, V135, P183, DOI 10.1017/S0031182007003782; Denton H, 2004, BIOCHEM J, V381, P405, DOI 10.1042/BJ20040283; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; Downing T, 2012, INFECT GENET EVOL, V12, P149, DOI 10.1016/j.meegid.2011.11.005; Downing T, 2011, GENOME RES, V21, P2143, DOI 10.1101/gr.123430.111; Dube A, 2005, PARASITOL RES, V96, P216, DOI 10.1007/s00436-005-1339-1; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.mi.46.100192.003403; Ferreira CD, 2003, BIOMETALS, V16, P441; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Frezard F, 2001, ANTIMICROB AGENTS CH, V45, P913, DOI 10.1128/AAC.45.3.913-916.2001; Gagneux S, 2006, SCIENCE, V312, P1944, DOI 10.1126/science.1124410; Gourbal B, 2004, J BIOL CHEM, V279, P31010, DOI 10.1074/jbc.M403959200; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Hadighi R, 2007, PARASITOL RES, V101, P1319, DOI 10.1007/s00436-007-0638-0; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; KELLY JM, 1993, EUR J BIOCHEM, V218, P29, DOI 10.1111/j.1432-1033.1993.tb18348.x; Krauth-Siegel RL, 2005, ANGEW CHEM INT EDIT, V44, P690, DOI 10.1002/anie.200300639; Krauth-Siegel RL, 2003, BIOL CHEM, V384, P539, DOI 10.1515/BC.2003.062; Laurent T, 2007, INFECT GENET EVOL, V7, P206, DOI 10.1016/j.meegid.2006.08.005; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Lira R, 1999, J INFECT DIS, V180, P564, DOI 10.1086/314896; Maharjan M, 2008, AM J TROP MED HYG, V79, P69, DOI 10.4269/ajtmh.2008.79.69; Mandal G, 2007, PARASITOLOGY, V134, P1679, DOI 10.1017/S0031182007003150; Mandal S, 2010, J ANTIMICROB CHEMOTH, V65, P496, DOI 10.1093/jac/dkp468; Mehta A, 2006, FREE RADICAL BIO MED, V40, P1857, DOI 10.1016/j.freeradbiomed.2006.01.024; Mikus Judith, 2000, Parasitology International, V48, P265, DOI 10.1016/S1383-5769(99)00020-3; Mittal MK, 2007, AM J TROP MED HYG, V76, P681, DOI 10.4269/ajtmh.2007.76.681; MOTTRAM JC, 1992, MOL MICROBIOL, V6, P1925, DOI 10.1111/j.1365-2958.1992.tb01365.x; Mukherjee A, 2007, J ANTIMICROB CHEMOTH, V59, P204, DOI 10.1093/jac/dkl494; Mukhopadhyay R, 2011, INT J PARASITOL, V41, P1311, DOI 10.1016/j.ijpara.2011.07.013; Muller S, 2003, TRENDS PARASITOL, V19, P320, DOI 10.1016/S1471-4922(03)00141-7; Munday JC, 2008, THESIS U GLASGOW UK; Murray Henry W, 2004, Expert Rev Anti Infect Ther, V2, P279, DOI 10.1586/14787210.2.2.279; Nozaki T, 2001, J BIOL CHEM, V276, P6516, DOI 10.1074/jbc.M009774200; Perry MR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001227; Rais S, 2000, ANTIMICROB AGENTS CH, V44, P2406, DOI 10.1128/AAC.44.9.2406-2410.2000; Rijal S, 2007, MICROBES INFECT, V9, P529, DOI 10.1016/j.micinf.2007.01.009; Rojas R, 2006, J INFECT DIS, V193, P1375, DOI 10.1086/503371; Romao PRT, 1999, PARASITOLOGY, V118, P559, DOI 10.1017/S0031182099004278; Samant M, 2007, PARASITOLOGY, V134, P1175, DOI 10.1017/S0031182007002569; SHIM H, 1988, J GEN MICROBIOL, V134, P807; Sidhu ABS, 2005, MOL MICROBIOL, V57, P913, DOI 10.1111/j.1365-2958.2005.04729.x; Singh N, 2007, PARASITOLOGY, V134, P777, DOI 10.1017/S0031182007002284; Singh R, 2010, INT J ANTIMICROB AG, V36, P50, DOI 10.1016/j.ijantimicag.2010.03.012; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Tintaya KWQ, 2004, J INFECT DIS, V189, P1035, DOI 10.1086/382049; Tovar J, 1998, MOL MICROBIOL, V29, P653, DOI 10.1046/j.1365-2958.1998.00968.x; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P25; Vanaerschot M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023120; Vergnes B, 2007, MOL CELL PROTEOMICS, V6, P88, DOI 10.1074/mcp.M600319-MCP200; Weinreich DM, 2005, EVOLUTION, V59, P1165; Williams RAM, 2003, J BIOL CHEM, V278, P1480, DOI 10.1074/jbc.M209395200; Wyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200; Wyllie S, 2010, MOL BIOCHEM PARASIT, V173, P162, DOI 10.1016/j.molbiopara.2010.05.015; Yan SC, 2003, CHEM COMMUN, P266, DOI 10.1039/b210240d; Yan SC, 2003, J BIOL INORG CHEM, V8, P689, DOI 10.1007/s00775-003-0468-1; Yardley V, 2006, J INFECT DIS, V194, P1168, DOI 10.1086/507710; Zhou Y, 2004, J BIOL CHEM, V279, P37445, DOI 10.1074/jbc.M404383200	76	48	49	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	FEB	2012	6	2							e1514	10.1371/journal.pntd.0001514				16	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	901FX	WOS:000300949200026	22389733	DOAJ Gold, Green Published			2019-03-26	
J	Sariego, I; Kanobana, K; Rojas, L; Speybroeck, N; Polman, K; Nunez, FA				Sariego, Idalia; Kanobana, Kirezi; Rojas, Lazara; Speybroeck, Niko; Polman, Katja; Nunez, Fidel A.			Toxocariasis in Cuba: A Literature Review	PLOS NEGLECTED TROPICAL DISEASES			English	Review							EPIDEMIOLOGIC CHARACTERISTICS; SEROPREVALENCE; ENVIRONMENT; PREVALENCE; INFECTION; EGGS	Human toxocariasis (HT) is a zoonotic disease caused by infection with the larval stage of Toxocara canis, the intestinal roundworm of dogs. Infection can be associated with a wide clinical spectrum varying from asymptomatic to severe organ injury. While the incidence of symptomatic human toxocariasis appears to be low, infection of the human population is widespread. In Cuba, a clear overview on the status of the disease is lacking. Here, we review the available information on toxocariasis in Cuba as a first step to estimate the importance of the disease in the country. Findings are discussed and put in a broader perspective. Data gaps are identified and suggestions on how to address these are presented. The available country data suggest that Toxocara infection of the definitive dog host and environmental contamination with Toxocara spp. eggs is substantial, but information on HT is less conclusive. The availability of adequate diagnostic tools in the country should be guaranteed. Dedicated studies are needed for a reliable assessment of the impact of toxocariasis in Cuba and the design of prevention or control strategies.	[Sariego, Idalia; Rojas, Lazara; Nunez, Fidel A.] Inst Trop Med Pedro Kouri, Havana, Cuba; [Kanobana, Kirezi; Polman, Katja] Inst Trop Med, B-2000 Antwerp, Belgium; [Speybroeck, Niko] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium	Sariego, I (reprint author), Inst Trop Med Pedro Kouri, Havana, Cuba.	idalia@ipk.sld.cu			Belgian Program of Cooperation and Development with Cuba	This work was financially supported by the Belgian Program of Cooperation and Development with Cuba. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baboolal S, 2002, T ROY SOC TROP MED H, V96, P139, DOI 10.1016/S0035-9203(02)90281-6; Beck K, 1991, ATLAS COLORES LAPARA; Berrocal J, 1980, Trans Am Ophthalmol Soc, V78, P376; BUNDY DAP, 1987, TROP MED PARASITOL, V38, P309; Curbelo MJ, 2008, MEDISUR, V6, P99; de la Fe Rodriguez PY, 2004, THESIS HAVANA I TROP; Delgado M, 2009, MEDICIEGO S2, V15; Despommier D, 2003, CLIN MICROBIOL REV, V16, P265, DOI 10.1128/CMR.16.2.265-272.2003; Dumenigo B, 1994, Rev Cubana Med Trop, V46, P99; Dumenigo Blanca, 1995, Revista Cubana de Medicina Tropical, V47, P178; DUNSMORE JD, 1984, VET PARASITOL, V16, P303, DOI 10.1016/0304-4017(84)90048-7; Epe C, 2006, TOXOCARA: THE ENIGMATIC PARASITE, P239; Fernandez JE, 1974, REV CUBANA MED TROP, V26, P1; Fisher M, 2003, TRENDS PARASITOL, V19, P167, DOI 10.1016/S1471-4922(03)00027-8; GLICKMAN LT, 1979, T ROY SOC TROP MED H, V73, P254, DOI 10.1016/0035-9203(79)90077-4; Hernandez Merlo Roberto, 2007, Rev Cubana Med Trop, V59, P234; Jimenez M, 2008, MEDISUR, V6, P5; LAIRD RM, 1995, REV CUBANA HIG EPIDE, V58, P116; Luis MC, 2003, REV CUBANA PEDIAT, V75; Magnaval Jean-Francois, 2001, Korean Journal of Parasitology, V39, P1; MAGNAVAL JF, 1994, T ROY SOC TROP MED H, V88, P531, DOI 10.1016/0035-9203(94)90148-1; Millan Marcelo J C, 1985, Rev Cubana Med Trop, V37, P26; Mizgajska H, 2001, J HELMINTHOL, V75, P147; Mizgajska-Wiktor H, 2006, TOXOCARA: THE ENIGMATIC PARASITE, P211; Montalvo A M, 1994, Rev Cubana Med Trop, V46, P156; Pena Pereiro A, 1978, Rev Cubana Med Trop, V30, P59; Rey S, 1987, REV CUBA MED, V26, P1269; Rodriguez de la Vega A, 1969, REV CUBA MED, V8, P1; Rubinsky-Elefant G, 2010, ANN TROP MED PARASIT, V104, P3, DOI 10.1179/136485910X12607012373957; Schantz PM, 2006, TOXOCARA: THE ENIGMATIC PARASITE, P253; Smith H, 2009, TRENDS PARASITOL, V25, P182, DOI 10.1016/j.pt.2009.01.006; Stensvold CR, 2009, CLIN VACCINE IMMUNOL, V16, P1372, DOI 10.1128/CVI.00234-09; THOMPSON DE, 1986, B WORLD HEALTH ORGAN, V64, P283	33	7	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	FEB	2012	6	2							e1382	10.1371/journal.pntd.0001382				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	901FX	WOS:000300949200001	22389726	DOAJ Gold, Green Published			2019-03-26	
J	Levecke, B; Mekonnen, Z; Albonico, M; Vercruysse, J				Levecke, B.; Mekonnen, Z.; Albonico, M.; Vercruysse, J.			The impact of baseline faecal egg counts on the efficacy of single-dose albendazole against Trichuris trichiura	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Trichuris trichiura; Albendazole; Anthelminthics; Drug resistance; Treatment outcome; Confounding factor		There is considerable variation in the efficacy of single-dose albendazole (400 mg) against Trichuris trichiura across human trials. Factors contributing to this variation have not yet been identified. We assessed the impact of mean baseline faecal egg counts (FEC) on the efficacy of single-dose albendazole against T. trichiura in five previously conducted trials. Our results suggest that efficacy measured by reduction in mean FECs decreased significantly (p < 0.0001) When mean baseline FECs increased, highlighting that this parameter should be considered as an important confounding factor for drug efficacy. [ClinicalTrials.gov Identifiers: NCT01087099 and NCT01327469] Crown Copyright (C) 2011 Published by Elsevier Ltd on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.	[Levecke, B.; Mekonnen, Z.; Vercruysse, J.] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium; [Mekonnen, Z.] Jimma Univ, Coll Publ Hlth & Med Sci, Dept Med Lab Sci & Pathol, Jimma, Ethiopia; [Albonico, M.] Fdn Ivo Carneri, Milan, Italy	Levecke, B (reprint author), Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium.	bruno.levecke@ugent.be		ALBONICO, Marco/0000-0002-7805-2391; Levecke, Bruno/0000-0001-8912-5595	World Health Organization; Flemish Interuniversity Council (Institutional University Cooperation of the Council of Flemish Universities, VLIR-IUC); Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen)	The fieldwork received financial support from the World Health Organization and the Flemish Interuniversity Council (Programme of Institutional University Cooperation of the Council of Flemish Universities, VLIR-IUC). BL is funded by the Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) and ZM is funded by the Flemish Interuniversity Council (Programme of Institutional University Cooperation of the Council of Flemish Universities, VLIR-IUC).	Bennett A, 2000, PARASITOL TODAY, V16, P71, DOI 10.1016/S0169-4758(99)01544-6; Diawara A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000397; Kotze AC, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000297; Sanchez C., 2006, J VET PHARMACOL THER, V23, P193; Vercruysse J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000948; WHO, 1999, WHOCDSCPCSIP991, P8	6	26	26	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	FEB	2012	106	2					128	130		10.1016/j.trstmh.2011.09.007				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	895WS	WOS:000300528000009	22189084				2019-03-26	
J	Carlier, Y; Truyens, C; Deloron, P; Peyron, F				Carlier, Yves; Truyens, Carine; Deloron, Philippe; Peyron, Francois			Congenital parasitic infections: A review	ACTA TROPICA			English	Review						Congenital toxoplasmosis; Congenital Chagas disease; Congenital malaria; Placenta; Immune responses	TRYPANOSOMA-CRUZI INFECTION; UMBILICAL-CORD-BLOOD; INTERMITTENT PREVENTIVE TREATMENT; PLASMODIUM-FALCIPARUM MALARIA; TOXOPLASMA-GONDII INFECTION; POLYMERASE-CHAIN-REACTION; MEDIATED IMMUNE-RESPONSES; TOLL-LIKE RECEPTORS; CHAGAS-DISEASE; VERTICAL TRANSMISSION	This review defines the concepts of maternal-fetal (congenital) and vertical transmissions (mother-to-child) of pathogens and specifies the human parasites susceptible to be congenitally transferred. It highlights the epidemiological features of this transmission mode for the three main congenital parasitic infections due to Toxoplasma gondii, Trypanosoma cruzi and Plasmodium sp. Information on the possible maternal-fetal routes of transmission, the placental responses to infection and timing of parasite transmission are synthesized and compared. The factors susceptible to be involved in parasite transmission and development of congenital parasitic diseases, such as the parasite genotypes, the maternal co-infections and parasitic load, the immunological features of pregnant women and the capacity of some fetuses/neonates to overcome their immunological immaturity to mount an immune response against the transmitted parasites are also discussed and compared. Analysis of clinical data indicates that parasitic congenital infections are often asymptomatic, whereas symptomatic newborns generally display non-specific symptoms. The long-term consequences of congenital infections are also mentioned, such as the imprinting of neonatal immune system and the possible trans-generational transmission. The detection of infection in pregnant women is mainly based on standard serological or parasitological investigations. Amniocentesis and cordocentesis can be used for the detection of some fetal infections. The neonatal infection can be assessed using parasitological, molecular or immunological methods; the place of PCR in such neonatal diagnosis is discussed. When such laboratory diagnosis is not possible at birth or in the first weeks of life, standard serological investigations can also be performed 8-10 months after birth, to avoid detection of maternal transmitted antibodies. The specific aspects of treatment of T. gondii, T. cruzi and Plasmodium congenital infections are mentioned. The possibilities of primary and secondary prophylaxes, as well as the available WHO corresponding recommendations are also presented. (C) 2011 Elsevier B.V. All rights reserved.	[Carlier, Yves; Truyens, Carine] Univ Libre Bruxelles, Fac Med, Parasitol Lab, B-1070 Brussels, Belgium; [Carlier, Yves] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA 70112 USA; [Deloron, Philippe] Univ Paris 05, Fac Pharm, IRD, UMR 216, F-75006 Paris, France; [Peyron, Francois] Hop Croix Rousse, Serv Parasitol, F-69317 Lyon, France	Carlier, Y (reprint author), Univ Libre Bruxelles, Fac Med, Parasitol Lab, CP 616,Route Lennik 808, B-1070 Brussels, Belgium.	ycarlier@ulb.ac.be; ctruyens@ulb.ac.be; philippe.deloron@ird.fr; francois.peyron@chu-lyon.fr		DELORON, Philippe/0000-0003-4705-2484			Abbasi M, 2003, J INFECT DIS, V188, P608, DOI 10.1086/377132; Abrahams VM, 2005, PLACENTA, V26, P540, DOI 10.1016/j.placenta.2004.08.010; Adam I, 2009, ANN TROP MED PARASIT, V103, P205, DOI 10.1179/136485909X398285; AGARWAL M, 1986, Indian Pediatrics, V23, P169; Ajzenberg D, 2002, J INFECT DIS, V186, P684, DOI 10.1086/342663; Akinbi HT, 2004, AM J OBSTET GYNECOL, V191, P2090, DOI 10.1016/j.ajog.2004.05.002; Altcheh J, 2011, PEDIATRICS, V127, pE212, DOI 10.1542/peds.2010-1172; Altemani AM, 2000, AM J TROP MED HYG, V62, P319, DOI 10.4269/ajtmh.2000.62.319; ALTSHULER G, 1975, AM J OBSTET GYNECOL, V121, P351, DOI 10.1016/0002-9378(75)90011-3; Amaratunga C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014798; Carlier Yves, 2003, Rev. Soc. Bras. Med. Trop., V36, P767, DOI 10.1590/S0037-86822003000600024; ANOSIKE JC, 1993, J HELMINTHOL, V67, P83, DOI 10.1017/S0022149X00012906; Apt W, 2010, BIOL RES, V43, P269, DOI [/S0716-97602010000300002, 10.4067/S0716-97602010000300002]; ASPOCK H, 1992, SCAND J INFECT DIS, P32; AZOGUE E, 1985, T ROY SOC TROP MED H, V79, P176, DOI 10.1016/0035-9203(85)90328-1; Benard A., 2008, EURO SURVEILL, V13; Benirschke K, 2006, PATHOLOGY HUMAN PLAC; Bern C, 2009, CLIN INFECT DIS, V49, P1667, DOI 10.1086/648070; Berrebi A, 2007, EUR J OBSTET GYN R B, V135, P53, DOI 10.1016/j.ejogrb.2006.11.002; Biggar RJ, 2008, AIDS, V22, P2251, DOI 10.1097/QAD.0b013e328314e36b; Billot C, 2005, REV SOC BRAS MED TRO, V38, P108; BITTENCOURT AL, 1992, REV I MED TROP, V34, P403, DOI 10.1590/S0036-46651992000500006; BITTENCOURT AL, 1976, AM J DIS CHILD, V130, P97, DOI 10.1001/archpedi.1976.02120020099020; BITTENCOURT AL, 1981, AM J TROP MED HYG, V30, P38, DOI 10.4269/ajtmh.1981.30.38; Blanco SB, 2000, TROP MED INT HEALTH, V5, P293, DOI 10.1046/j.1365-3156.2000.00548.x; Boehme CC, 2006, EMERG INFECT DIS, V12, P359, DOI 10.3201/eid1202.050449d; Bogdan C, 2001, CLIN INFECT DIS, V32, P302, DOI 10.1086/318476; Boughattas S, 2010, AM J TROP MED HYG, V82, P1041, DOI 10.4269/ajtmh.2010.09-0691; Breugelmans M, 2004, J PERINAT MED, V32, P211, DOI 10.1515/JPM.2004.039; Briand V, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-160; Brutus L, 2007, T ROY SOC TROP MED H, V101, P1159, DOI 10.1016/j.trstmh.2007.03.015; Brutus L, 2010, AM J TROP MED HYG, V83, P1044, DOI [10.4269/ajtmh.2010.10.0326, 10.4269/ajtmh.2010.10-0326]; Buekens P, 2008, MATERN CHILD HLTH J, V12, P283, DOI 10.1007/s10995-007-0246-8; Burgos JM, 2007, INT J PARASITOL, V37, P1319, DOI 10.1016/j.ijpara.2007.04.015; Burgos JM, 2009, DIAGN MICR INFEC DIS, V65, P58, DOI 10.1016/j.diagmicrobio.2009.04.010; Burke J., 2000, FOMETRO ASBL FONDS M, P39; Candolfi E, 2007, DIAGN MICR INFEC DIS, V58, P83, DOI 10.1016/j.diagmicrobio.2006.12.010; Carlier Y, 2005, REV SOC BRAS MED TRO, V38, P105; CARLIER Y, 1995, PARASITOL TODAY, V11, P94, DOI 10.1016/0169-4758(95)80165-0; Carlier Y., 2002, ENCY MED CHIR MALADI, P8; Carlier Y, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001250; Carlier Y, 2010, ELSEV INSIGHT, P539, DOI 10.1016/B978-0-12-384876-5.00022-8; Chapey E, 2010, J CLIN MICROBIOL, V48, P41, DOI 10.1128/JCM.01903-09; CHATURVEDI P, 1991, Indian Journal of Pediatrics, V58, P378, DOI 10.1007/BF02754974; Chippaux JP, 2010, TROP MED INT HEALTH, V15, P87, DOI 10.1111/j.1365-3156.2009.02431.x; Ciardelli L, 2008, PEDIATR INFECT DIS J, V27, P125, DOI 10.1097/INF.0b013e3181586052; Coll O, 2008, J PERINAT MED, V36, P15, DOI 10.1515/JPM.2008.002; Conroy AL, 2011, TRENDS PARASITOL, V27, P294, DOI 10.1016/j.pt.2011.02.005; Conway DJ, 2007, CLIN MICROBIOL REV, V20, P188, DOI 10.1128/CMR.00021-06; Cook AJC, 2000, BRIT MED J, V321, P142, DOI 10.1136/bmj.321.7254.142; Corrales RM, 2009, INFECT GENET EVOL, V9, P278, DOI 10.1016/j.meegid.2008.12.008; Correa D, 2007, PARASITE IMMUNOL, V29, P651, DOI 10.1111/j.1365-3024.2007.00982.x; Cumberland P, 2007, J INFECT DIS, V196, P550, DOI 10.1086/519845; CZEIZEL E, 1966, AM J OBSTET GYNECOL, V96, P264, DOI 10.1016/0002-9378(66)90324-3; Dauby N, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000571; Del Punta V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-63; Deloron P, 2010, EMERG INFECT DIS, V16, P1666, DOI 10.3201/eid1611.101064; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Di Mario S, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006171.pub2; Diez CN, 2008, AM J TROP MED HYG, V78, P624, DOI 10.4269/ajtmh.2008.78.624; Dolcini GL, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-53; Duaso J, 2010, PLACENTA, V31, P705, DOI 10.1016/j.placenta.2010.05.007; Egan CE, 2009, CLIN EXP IMMUNOL, V156, P17, DOI 10.1111/j.1365-2249.2009.03876.x; Elbez-Rubinstein A, 2009, J INFECT DIS, V199, P280, DOI 10.1086/595793; ELTOUM IA, 1992, AM J TROP MED HYG, V46, P57, DOI 10.4269/ajtmh.1992.46.57; Evengard B, 2001, EPIDEMIOL INFECT, V127, P121, DOI 10.1017/S0950268801005775; Falade C, 2007, TROP MED INT HEALTH, V12, P1279, DOI 10.1111/j.1365-3156.2007.01931.x; Falla A, 2009, ACTA TROP, V110, P15, DOI 10.1016/j.actatropica.2008.12.003; Fatoohi AF, 2003, EUR J CLIN MICROBIOL, V22, P181, DOI 10.1007/s10096-003-0903-9; Fernandez-Aguilar S, 2005, REV SOC BRAS MED TRO, V38, P84; Figueiro-Filho Ernesto Antonio, 2004, Infect Dis Obstet Gynecol, V12, P31, DOI 10.1080/1064744042000210384; Filisetti D, 2010, PEDIATR INFECT DIS J, V29, P665, DOI 10.1097/INF.0b013e3181d7a725; FONTICIELLA M, 1995, PEDIATR RADIOL, V25, P171, DOI 10.1007/BF02021524; Foulon W, 1999, AM J OBSTET GYNECOL, V181, P843, DOI 10.1016/S0002-9378(99)70311-X; Foulon W, 1999, AM J OBSTET GYNECOL, V180, P410, DOI 10.1016/S0002-9378(99)70224-3; Freeman K, 2005, BJOG-INT J OBSTET GY, V112, P31, DOI 10.1111/j.1471-0528.2004.00299.x; FREILIJ H, 1995, CLIN INFECT DIS, V21, P551, DOI 10.1093/clinids/21.3.551; FREILIJ H, 1995, PEDIATR INFECT DIS J, V14, P161; Fricker-Hidalgo H, 2007, PEDIATR INFECT DIS J, V26, P845, DOI 10.1097/INF.0b013e318123e8d3; Fuentes I, 2001, J CLIN MICROBIOL, V39, P1566, DOI 10.1128/JCM.39.4.1566-1570.2001; Schijman AG, 2007, PERSP MED V, V13, P223, DOI 10.1016/S0168-7069(06)13012-8; Gamble C, 2007, PLOS MED, V4, P506, DOI 10.1371/journal.pmed.0040107; Garcia-Lloret MI, 2000, J LEUKOCYTE BIOL, V68, P903; Garner P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000169.pub2; Garweg JG, 2005, BJOG-INT J OBSTET GY, V112, P241, DOI 10.1111/j.1471-0528.2004.00302.x; Gilbert R, 2006, ARCH DIS CHILD, V91, P629, DOI 10.1136/adc.2006.094870; Gilbert RE, 2002, J MED SCREEN, V9, P135, DOI 10.1136/jms.9.3.135; Gollub EL, 2008, EUR J OBSTET GYN R B, V136, P137, DOI 10.1016/j.ejogrb.2007.09.010; Gras L, 2005, ACTA PAEDIATR, V94, P1721, DOI 10.1080/08035250500251999; Gratzl R, 2002, EUR J CLIN MICROBIOL, V21, P12, DOI 10.1007/s10096-001-0644-6; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; Guglietta S, 2007, MICROBES INFECT, V9, P127, DOI 10.1016/j.micinf.2006.10.017; Gurtler RE, 2003, EMERG INFECT DIS, V9, P29; Scapellato PG, 2009, REV SOC BRAS MED TRO, V42, P107, DOI 10.1590/S0037-86822009000200002; Hafalla JC, 2011, IMMUNOL REV, V240, P297, DOI 10.1111/j.1600-065X.2010.00988.x; Hartgers FC, 2008, INFECT IMMUN, V76, P5149, DOI 10.1128/IAI.01579-07; Hermann E, 2004, J INFECT DIS, V189, P1274, DOI 10.1086/382511; Hermann E, 2002, BLOOD, V100, P2153; Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8; Jackson Y, 2009, EMERG INFECT DIS, V15, P601, DOI 10.3201/eid1504.080438; Jafari-Guemouri S, 2005, J CLIN MICROBIOL, V43, P2980, DOI 10.1128/JCM.43.6.2980-2983.2005; Jauniaux E, 2003, PLACENTA, V24, pS86, DOI 10.1053/plac.2002.0932; Jenum PA, 1998, J CLIN MICROBIOL, V36, P2900; Jercic MI, 2010, J CLIN MICROBIOL, V48, P3824, DOI 10.1128/JCM.00048-10; Jonsson AM, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.09.047; Juliano PB, 2006, PLACENTA, V27, P750, DOI 10.1016/j.placenta.2005.07.008; Kamwendo DD, 2002, T ROY SOC TROP MED H, V96, P145, DOI 10.1016/S0035-9203(02)90284-1; Kasper DC, 2009, DIAGN MICR INFEC DIS, V63, P10, DOI 10.1016/j.diagmicrobio.2008.09.009; Kassberger F, 2002, PARASITOL RES, V88, P1073, DOI 10.1007/s00436-002-0715-3; Khonde N, 1997, T ROY SOC TROP MED H, V91, P521, DOI 10.1016/S0035-9203(97)90008-0; Kieffer F, 2011, PEDIATR INFECT DIS J, V30, P813, DOI 10.1097/INF.0b013e31821b8dfe; Koga K, 2010, AM J REPROD IMMUNOL, V63, P587, DOI 10.1111/j.1600-0897.2010.00848.x; Kudo Y, 2004, J REPROD IMMUNOL, V61, P87, DOI 10.1016/j.jri.2003.11.004; Lago EG, 2007, PAEDIATR PERINAT EP, V21, P525, DOI 10.1111/j.1365-3016.2007.00869.x; Leiby DA, 1999, TRANSFUSION, V39, P310, DOI 10.1046/j.1537-2995.1999.39399219290.x; Lesko CR, 2007, ARCH PEDIAT ADOL MED, V161, P1062, DOI 10.1001/archpedi.161.11.1062; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Lindner AK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000783; Lujan CD, 2004, EXP PARASITOL, V108, P176, DOI 10.1016/j.exppara.2004.07.013; Luquetti AO, 2005, REV SOC BRAS MED TRO, V38, P24; Macedo AM, 2010, ELSEV INSIGHT, P489, DOI 10.1016/B978-0-12-384876-5.00020-4; Machado AS, 2010, MEM I OSWALDO CRUZ, V105, P757, DOI 10.1590/S0074-02762010000600005; Magi B, 2011, NEW MICROBIOL, V34, P93; Malhotra I, 2006, J INFECT DIS, V194, P176, DOI 10.1086/505150; Marchant A, 2005, CLIN EXP IMMUNOL, V141, P10, DOI 10.111/j.1365.2249.2005.02799.x; De Rissio AM, 2010, AM J TROP MED HYG, V82, P838, DOI 10.4269/ajtmh.2010.08-0383; Mayengue PI, 2004, TROP MED INT HEALTH, V9, P949, DOI 10.1111/j.1365-3156.2004.01294.x; Mayer JP, 2010, ANN TROP MED PARASIT, V104, P485, DOI 10.1179/136485910X12786389891362; McCall MBB, 2007, J IMMUNOL, V179, P162, DOI 10.4049/jimmunol.179.1.162; McLeod R, 2006, CLIN INFECT DIS, V42, P1383, DOI 10.1086/501360; MCLEOD R, 1990, J LAB CLIN MED, V116, P623; McLeod R, 2009, MEM I OSWALDO CRUZ, V104, P320, DOI 10.1590/S0074-02762009000200029; Melamed J, 2010, EYE, V24, P528, DOI 10.1038/eye.2009.140; Melis G.B., 2007, J CHEMOTHER, V19, P17; Menendez C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001934; Menendez C, 2007, SEMIN FETAL NEONAT M, V12, P207, DOI 10.1016/j.siny.2007.01.018; Montoya JG, 2002, J INFECT DIS, V185, pS73, DOI 10.1086/338827; Montoya JG, 2008, CLIN INFECT DIS, V47, P554, DOI 10.1086/590149; Mora MC, 2005, J PARASITOL, V91, P1468, DOI 10.1645/GE-549R.1; Moretti E, 2005, REV SOC BRAS MED TRO, V38, P53, DOI 10.1590/S0037-86822005000100010; Moya P R, 1979, Rev Fac Cien Med Univ Nac Cordoba, V37, P21; Munoz J, 2009, CLIN INFECT DIS, V48, P1736, DOI 10.1086/599223; Mwaniki MK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-313; Mwapasa V, 2004, AIDS, V18, P1051, DOI [10.1097/00002030-200404300-00014, 10.1097/01.aids.0000125924.10668.14]; Myatt L, 2004, HISTOCHEM CELL BIOL, V122, P369, DOI 10.1007/s00418-004-0677-x; Naessens A, 2003, Arch Pediatr, V10 Suppl 1, P18; Nanaev AK, 2000, PLACENTA, V21, P122, DOI 10.1053/plac.1999.0455; Negrette OS, 2005, PEDIATRICS, V115, pE668, DOI 10.1542/peds.2004-1732; Nisida Isabelle Vera Vichr, 1999, Revista do Instituto de Medicina Tropical de Sao Paulo, V41, P305, DOI 10.1590/S0036-46651999000500007; Nowakowska D, 2006, J CLIN MICROBIOL, V44, P1382, DOI 10.1128/JCM.44.4.1382-1389.2006; Oduwole OA, 2011, AM J TROP MED HYG, V84, P386, DOI 10.4269/ajtmh.2011.10-0253; Okafor U H, 2006, J Obstet Gynaecol, V26, P612, DOI 10.1080/09638280600902893; Okumura M, 2004, PRENATAL DIAG, V24, P179, DOI 10.1002/pd.813; Oliveira JG, 2006, PLACENTA, V27, P691, DOI 10.1016/j.placenta.2005.06.006; OPS, 2006, OPSHDMCD42506 PAN AM; Orton LC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004912.pub3; OUAISSI MA, 1984, NATURE, V308, P380, DOI 10.1038/308380a0; Pagliano P, 2005, J ANTIMICROB CHEMOTH, V55, P229, DOI 10.1093/jac/dkh538; Pappas G, 2009, INT J PARASITOL, V39, P1385, DOI 10.1016/j.ijpara.2009.04.003; Parazzini F, 1999, LANCET, V353, P1035; Paul M, 2001, J CLIN MICROBIOL, V39, P1912, DOI 10.1128/JCM.39.5.1912-1916.2001; Pepin J, 1989, Med Trop (Mars), V49, P83; PEREIRA LH, 1972, T ROY SOC TROP MED H, V66, P802, DOI 10.1016/0035-9203(72)90103-4; Perrault SD, 2009, AM J TROP MED HYG, V80, P119, DOI 10.4269/ajtmh.2009.80.119; Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003; Petersen E, 2007, PARASITOLOGY, V134, P1855, DOI 10.1017/S0031182007000182; Peyron F., 2011, PEDIAT INFECT DIS J; Peyron F, 2006, MICROBES INFECT, V8, P2333, DOI 10.1016/j.micinf.2006.03.023; Pfaff AW, 2005, INT J PARASITOL, V35, P1569, DOI 10.1016/j.ijpara.2005.08.003; Pfaff AW, 2005, IMMUNOL CELL BIOL, V83, P483, DOI 10.1111/j.1440-1711.2005.01356.x; Phan L, 2008, OPHTHALMOLOGY, V115, P553, DOI 10.1016/j.ophtha.2007.06.022; PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189; Prigione I, 2006, MICROBES INFECT, V8, P552, DOI 10.1016/j.micinf.2005.08.008; Rabilloud M, 2010, PEDIATR INFECT DIS J, V29, P421, DOI 10.1097/INF.0b013e3181c80493; Raimundo SM, 2010, BIOSYSTEMS, V99, P215, DOI 10.1016/j.biosystems.2009.11.005; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; Redline RW, 2006, SEMIN FETAL NEONAT M, V11, P296, DOI 10.1016/j.siny.2006.02.011; Remigton JS, 2006, INFECT DIS FETUS NEW, V31, P947, DOI [DOI 10.1016/B0-72-160537-0/50033-5, 10.1016/B0-72-160537-0/50033-5]; Robert-Gangneux F, 1999, EUR J CLIN MICROBIOL, V18, P648, DOI 10.1007/s100960050366; Robert-Gangneux F, 2010, PEDIATR INFECT DIS J, V29, P33, DOI 10.1097/INF.0b013e3181b20ed1; Rocha G, 2004, LANCET, V363, P247, DOI 10.1016/S0140-6736(03)15345-7; Rogerson SJ, 2007, AM J TROP MED HYG, V77, P14; Rogerson Stephen J, 2006, Expert Rev Anti Infect Ther, V4, P687, DOI 10.1586/14787210.4.4.687; Romero R, 2007, NUTR REV, V65, pS194, DOI 10.1301/nr.2007.dec.S194-S202; Roser D, 2010, J INHERIT METAB DIS, V33, pS241, DOI 10.1007/s10545-010-9124-4; Russomando G, 2005, REV SOC BRAS MED TRO, V38, P49; Russomando G, 1998, AM J TROP MED HYG, V59, P487, DOI 10.4269/ajtmh.1998.59.487; Rutherford RAD, 1995, BRIT J PHARMACOL, V116, P3099, DOI 10.1111/j.1476-5381.1995.tb15111.x; Sartori AMC, 2007, ANN TROP MED PARASIT, V101, P31, DOI 10.1179/136485907X154629; Schijman AG, 2003, J ANTIMICROB CHEMOTH, V52, P441, DOI 10.1093/jac/dkg338; SCHOONDERMARKVANDEVEN E, 1994, ANTIMICROB AGENTS CH, V38, P1922, DOI 10.1128/AAC.38.9.1922; Schwandt A, 2008, J REPROD MED, V53, P59; Shear HL, 1998, BLOOD, V92, P2520; Shi Y. E., 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P323; Shippey SH, 2005, AM J OBSTET GYNECOL, V192, P586, DOI 10.1016/j.ajog.2004.07.079; Sibley LD, 2009, PHILOS T R SOC B, V364, P2749, DOI 10.1098/rstb.2009.0087; Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004; Signorell LM, 2006, PEDIATR INFECT DIS J, V25, P123, DOI 10.1097/01.inf.0000195542.43369.96; Silveira C, 2003, AM J OPHTHALMOL, V136, P370, DOI 10.1016/S0002-9394(03)00191-0; Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7; Singh N, 2003, ANN TROP MED PARASIT, V97, P875, DOI 10.1179/000349803225002688; Sosa-Estani S, 2005, PLOS MED, V2, P1194, DOI 10.1371/journal.pmed.0020387; Sosa-Estani S, 2009, REV SOC BRAS MED TRO, V42, P484, DOI 10.1590/S0037-86822009000500002; Soulard V, 2011, INFECT IMMUN, V79, P2801, DOI 10.1128/IAI.00203-11; Stagni L, 2009, MEM I OSWALDO CRUZ, V104, P374, DOI 10.1590/S0074-02762009000200035; Storino R, 2002, REV SAUDE PUBL, V36, P755, DOI 10.1590/s0034-89102002000700016; Svoboda M, 2011, MOLECULAR MICROBIOLOGY: DIAGNOSTIC PRINCIPLES AND PRACTICE, SECOND EDITION, P713; Tarleton RL, 2007, CURR OPIN IMMUNOL, V19, P430, DOI 10.1016/j.coi.2007.06.003; Temesvari P, 2004, PEDIATR INFECT DIS J, V23, P282, DOI 10.1097/01.inf.0000115952.43192.cf; Thiebaut R, 2007, LANCET, V369, P115; Tobian AAR, 2000, J INFECT DIS, V182, P558, DOI 10.1086/315729; Torrico F, 2006, TROP MED INT HEALTH, V11, P628, DOI 10.1111/j.1365-3156.2006.01623.x; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; TRAUB N, 1978, E AFR MED J, V55, P477; Triolo N, 1985, Med Trop (Mars), V45, P251; Truyens C, 2005, REV SOC BRAS MED TRO, V38, P96; Truyens C, 2010, ELSEV INSIGHT, P601, DOI 10.1016/B978-0-12-384876-5.00024-1; Uneke CJ, 2007, PARASITOL RES, V101, P835, DOI 10.1007/s00436-007-0577-9; Uneke Chigozie J, 2007, Yale J Biol Med, V80, P95; Vekemans J, 2000, INFECT IMMUN, V68, P5430, DOI 10.1128/IAI.68.9.5430-5434.2000; Ferro EAV, 2008, AM J PATHOL, V172, P50, DOI 10.2353/ajpath.2008.070432; Villena I., 2010, EURO SURVEILL, V15; Viotti R, 2009, EXPERT REV ANTI-INFE, V7, P157, DOI 10.1586/14787210.7.2.157; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; Virreira M, 2007, AM J TROP MED HYG, V77, P102, DOI 10.4269/ajtmh.2007.77.102; Virreira M, 2006, AM J TROP MED HYG, V75, P871, DOI 10.4269/ajtmh.2006.75.871; Virreira M, 2006, AM J TROP MED HYG, V75, P1082, DOI 10.4269/ajtmh.2006.75.1082; Vottier G, 2008, ACTA PAEDIATR, V97, P505, DOI 10.1111/j.1651-2227.2008.00690.x; Wallon M, 2004, PEDIATRICS, V113, P1567, DOI 10.1542/peds.113.6.1567; Wallon M, 1999, BRIT MED J, V318, P1511, DOI 10.1136/bmj.318.7197.1511; Wallon M, 2010, OBSTET GYNECOL, V115, P727, DOI 10.1097/AOG.0b013e3181d57b09; Wilczynski JR, 2005, EUR J OBSTET GYN R B, V122, P136, DOI 10.1016/j.ejorb.2005.03.008; Willems F, 2009, EUR J IMMUNOL, V39, P26, DOI 10.1002/eji.200838391; Pavia PX, 2009, BIOMEDICA, V29, P513; Yadon ZE, 2009, AM J TROP MED HYG, V81, P927, DOI 10.4269/ajtmh.2009.09-0257; YANG YP, 1993, J IMMUNOL, V150, P5614; Yavuz E, 2006, PLACENTA, V27, P780, DOI 10.1016/j.placenta.2005.07.002; Zaghouani H, 2009, TRENDS IMMUNOL, V30, P585, DOI 10.1016/j.it.2009.09.002; ZAROU DM, 1964, AM J OBSTET GYNECOL, V88, P565, DOI 10.1016/0002-9378(64)90881-6; Zinchuk A, 2010, ANN TROP PAEDIATR, V30, P161, DOI 10.1179/146532810X12703902516400; Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021	241	67	68	0	33	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	FEB	2012	121	2					55	70		10.1016/j.actatropica.2011.10.018				16	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	890GJ	WOS:000300132800001	22085916				2019-03-26	
J	Quinet, Y; Vieira, RHSF; Sousa, MR; Evangelista-Barreto, NS; Carvalho, FCT; Guedes, MIF; Alves, CR; de Biseau, JC; Heredia, A				Quinet, Y.; Vieira, R. H. S. F.; Sousa, M. R.; Evangelista-Barreto, N. S.; Carvalho, F. C. T.; Guedes, M. I. F.; Alves, C. R.; de Biseau, J. C.; Heredia, A.			Antibacterial properties of contact defensive secretions in neotropical Crematogaster ants	JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES			English	Article						Hymenoptera; Formicidae; Crematogaster; sting apparatus; contact venoms	ANTIMICROBIAL PEPTIDES; BIOLOGICAL CHARACTERIZATION; SCUTELLARIS HYMENOPTERA; BREVISPINOSA-ROCHAI; DUFOUR GLAND; VENOM; MYRMICINAE; FORMICIDAE; NASUTITERMES; BRAZIL	Crematogaster ants use their contact venoms to compete with other ants. Although those venoms are used primarily as repellent and toxic secretions, they may have other functions. The present study aimed to test the antibacterial property of abdominal venom of three neotropical Crematogaster ant species (C. distans, C. pygmaea and C. rochai) against gram-negative (Escherichia coli and Pseudomonas aeruginosa) and gram-positive (Enterococcus faecalis and Staphylococcus aureus) bacteria. Sterile filter paper was soaked with C. distans, C. pygmaea or C. rochai crude venom and placed on an agar dish that was inoculated with bacterial suspensions. The agar dish was incubated overnight at 37 C and examined for zones of growth inhibition. For each tested venom and bacterial strain, three venom concentrations were used, with six replicates for each concentration: 1, 2 and 4 DGE (Dufour's gland equivalent). The venom of C. pygmaea, but not those of C. rochai and C. distans, inhibited the growth of all tested gram-positive and gram-negative bacterial strains. This is the first evidence of antibacterial properties of contact venoms in Crematogaster ants and it supports the claim that ant venoms are multifunctional. It is hypothesized that only C. pygmaea venom showed antibacterial activities due to its nesting habits.	[Quinet, Y.; Heredia, A.] Univ Estadual Ceara, Super Inst Biomed Sci, Fortaleza, Ceara, Brazil; [Vieira, R. H. S. F.; Carvalho, F. C. T.] Univ Fed Ceara, Inst Marine Sci, Fortaleza, Ceara, Brazil; [Sousa, M. R.; Evangelista-Barreto, N. S.; Guedes, M. I. F.; Alves, C. R.] Univ Estadual Ceara, Lab Human Biochem, Fortaleza, Ceara, Brazil; [de Biseau, J. C.] Free Univ Brussels, Brussels, Belgium	Quinet, Y (reprint author), Av Paranjana 1700, BR-60740000 Fortaleza, CE, Brazil.	yvesq@terra.com.br	Heredia, Ana/D-8926-2018; Quinet, Yves/H-9525-2012; Guedes, Maria Izabel/C-3755-2016	Heredia, Ana/0000-0001-7862-8955; Alves, Carlucio Roberto/0000-0001-7164-7467; Vieira, Regine/0000-0001-5768-400X	DCR-CNPq; National Council for Scientific and Technological Development (CNPq) [473939/2004-5]	Ana Heredia was supported by a fellowship (DCR-CNPq) and Yves Quinet by a grant from the National Council for Scientific and Technological Development (CNPq), project n. 473939/2004-5.	ATTYGALLE AB, 1989, J CHEM ECOL, V15, P317, DOI 10.1007/BF02027793; BEATTIE AJ, 1986, ANN ENTOMOL SOC AM, V79, P448, DOI 10.1093/aesa/79.3.448; Blum MS, 1996, ANNU REV ENTOMOL, V41, P353, DOI 10.1146/annurev.en.41.010196.002033; BOLTON B, 1995, J NAT HIST, V29, P1037, DOI 10.1080/00222939500770411; Budnik BA, 2004, J MASS SPECTROM, V39, P193, DOI 10.1002/jms.577; BUREN WILLIAM F., 1958, JOUR NEW YORK ENT SOC, V66, P119; Buschinger A., 1984, P95; Corzo G, 2001, BIOCHEM J, V359, P35, DOI 10.1042/0264-6021:3590035; DALOZE D, 1991, EXPERIENTIA, V47, P1082, DOI 10.1007/BF01923348; Daloze D, 1998, TETRAHEDRON LETT, V39, P4671, DOI 10.1016/S0040-4039(98)00875-2; Heredia A, 2005, CHEMOECOLOGY, V15, P235, DOI 10.1007/s00049-005-0317-5; Hindler AH, 1985, TXB DIAGNOSTIC MICRO, P69; HOlldobler B, 1990, ANTS; Holldobler B., 1984, PSYCHE, V91, P201, DOI DOI 10.1155/1984/70141; Inagaki H, 2004, ARCH BIOCHEM BIOPHYS, V428, P170, DOI 10.1016/j.abb.2004.05.013; Laurent P, 2003, TETRAHEDRON LETT, V44, P1383, DOI 10.1016/S0040-4039(02)02870-8; Leclercq S, 1997, J NAT PROD, V60, P1143, DOI 10.1021/np970202h; Leclercq S, 2000, TETRAHEDRON LETT, V41, P633, DOI 10.1016/S0040-4039(99)02127-9; Leclercq S, 2000, TETRAHEDRON, V56, P2037, DOI 10.1016/S0040-4020(00)00113-7; Longino John T., 2003, Zootaxa, V151, P1; Marlier JF, 2004, BEHAV PROCESS, V67, P427, DOI 10.1016/j.beproc.2004.07.003; Mendes MA, 2004, TOXICON, V44, P67, DOI 10.1016/j.toxicon.2004.04.009; Orivel J, 2001, J BIOL CHEM, V276, P17823, DOI 10.1074/jbc.M100216200; PASTEELS JM, 1989, J CHEM ECOL, V15, P1501, DOI 10.1007/BF01012379; Quinet Y, 2005, J INSECT BEHAV, V18, P1, DOI 10.1007/s10905-005-9343-y; Quinet Y, 2009, ZOOTAXA, P45; Rosengaus RB, 2000, J CHEM ECOL, V26, P21, DOI 10.1023/A:1005481209579; VANDERMEER RK, 1995, NATURWISSENSCHAFTEN, V82, P93, DOI 10.1007/BF01140150; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059	29	7	7	0	19	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1678-9199			J VENOM ANIM TOXINS	J. Venom. Anim. Toxins Trop. Dis.		2012	18	4					441	445		10.1590/S1678-91992012000400013				5	Toxicology; Tropical Medicine; Zoology	Toxicology; Tropical Medicine; Zoology	052LT	WOS:000312199900013		DOAJ Gold			2019-03-26	
J	Mpanya, A; Hendrickx, D; Vuna, M; Kanyinda, A; Lumbala, C; Tshilombo, V; Mitashi, P; Luboya, O; Kande, V; Boelaert, M; Lefevre, P; Lutumba, P				Mpanya, Alain; Hendrickx, David; Vuna, Mimy; Kanyinda, Albert; Lumbala, Crispin; Tshilombo, Valery; Mitashi, Patrick; Luboya, Oscar; Kande, Victor; Boelaert, Marleen; Lefevre, Pierre; Lutumba, Pascal			Should I Get Screened for Sleeping Sickness? A Qualitative Study in Kasai Province, Democratic Republic of Congo	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HUMAN AFRICAN TRYPANOSOMIASIS; BRUCEI-GAMBIENSE; MELARSOPROL; THERAPY; DISEASE; SUDAN	Background: Control of human African trypanosomiasis (sleeping sickness) in the Democratic Republic of Congo is based on mass population active screening by mobile teams. Although generally considered a successful strategy, the community participation rates in these screening activities and ensuing treatment remain low in the Kasai-Oriental province. A better understanding of the reasons behind this observation is necessary to improve regional control activities. Methods: Thirteen focus group discussions were held in five health zones of the Kasai-Oriental province to gain insights in the regional perceptions regarding sleeping sickness and the national control programme's activities. Principal Findings: Sleeping sickness is well known among the population and is considered a serious and life-threatening disease. The disease is acknowledged to have severe implications for the individual (e. g., persistence of manic periods and trembling hands, even after treatment), at the family level (e. g., income loss, conflicts, separations) and for communities (e. g., disruption of community life and activities). Several important barriers to screening and treatment were identified. Fear of drug toxicity, lack of confidentiality during screening procedures, financial barriers and a lack of communication between the mobile teams and local communities were described. Additionally, a number of regionally accepted prohibitions related to sleeping sickness treatment were described that were found to be a strong impediment to disease screening and treatment. These prohibitions, which do not seem to have a rational basis, have far-reaching socio-economic repercussions and severely restrict the participation in day-to-day life. Conclusions/Significance: A mobile screening calendar more adapted to the local conditions with more respect for privacy, the use of less toxic drugs, and a better understanding of the origin as well as better communication about the prohibitions related to treatment would facilitate higher participation rates among the Kasai-Oriental population in sleeping sickness screening and treatment activities organized by the national HAT control programme.	[Mpanya, Alain; Lumbala, Crispin; Kande, Victor] PNLTHA, Kinshasa, Zaire; [Hendrickx, David; Boelaert, Marleen; Lefevre, Pierre] Inst Trop Med, B-2000 Antwerp, Belgium; [Vuna, Mimy; Lutumba, Pascal] Inst Natl Rech Biomed, Kinshasa, Zaire; [Kanyinda, Albert] Bur Diocesain OEuvres Med, Mbuji Mayi, Zaire; [Tshilombo, Valery] Univ Mbuji Mayi, Mbuji Mayi, Zaire; [Mitashi, Patrick; Lutumba, Pascal] Univ Kinshasa, Kinshasa, Zaire; [Luboya, Oscar] Univ Lubumbashi, Lubumbashi, Zaire	Mpanya, A (reprint author), PNLTHA, Kinshasa, Zaire.	dhendrickx@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	Belgian Directorate-General for Development Cooperation; Institute of Tropical Medicine, Antwerp, Belgium	This study was financed within the Framework Agreement between the Belgian Directorate-General for Development Cooperation and the Institute of Tropical Medicine, Antwerp, Belgium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2006, Wkly Epidemiol Rec, V81, P71; ASONGANYI T, 1994, J CAMEROUNAIS MED, V3, P30; Bailey EJ, 2000, MED ANTHR AFRICAN AM; Barrett MP, 2007, BRIT J PHARMACOL, V152, P1155, DOI 10.1038/sj.bjp.0707354; Beardsworth Alan, 1997, SOCIOLOGY MENU INVIT; Blum J, 2001, TROP MED INT HEALTH, V6, P390, DOI 10.1046/j.1365-3156.2001.00710.x; *BUR CENTR TRYP, 1995, GUID TECHN PROGR NAT; Burke J, 2000, TRYPANOSOMIASE HUMAI; BURKE J, 1992, MED HYGIENE AFRIQUE, P1489; BURRI C, 2003, MANSONS TROPICAL DIS, P1303; CTB PNLTHA, 2004, DOSS TECHN FIN APP L; Lutumba P, 2005, EMERG INFECT DIS, V11, P1382; MANDERSON L, 1987, SOC SCI MED, V25, P329, DOI 10.1016/0277-9536(87)90270-X; Moore A, 1999, AM J TROP MED HYG, V61, P315, DOI 10.4269/ajtmh.1999.61.315; Moore A, 2001, TROP MED INT HEALTH, V6, P342, DOI 10.1046/j.1365-3156.2001.00714.x; PAQUET C, 1995, B SOC PATHOL EXOT, V88, P38; Pepin J, 2005, EMERG INFECT DIS, V11, P921; Pepin J, 2002, T ROY SOC TROP MED H, V96, P421, DOI 10.1016/S0035-9203(02)90380-9; PNLTHA, 2007, RAPP ANN PROGR NAT L; Robays J, 2007, TROP MED INT HEALTH, V12, P290, DOI 10.1111/j.1365-3165.2006.01768.x; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; Robays J, 2008, EMERG INFECT DIS, V14, P966, DOI 10.3201/eid1406.071266; Simarro PP, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-57; SIMARRO PP, 1991, B WORLD HEALTH ORGAN, V69, P451; STANGHELLINI A, 1999, PROGR HUMAN AFRICAN, P301; WHO, 1998, TRYP AFR LUT SURV; Yun O, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000720	27	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JAN	2012	6	1							e1467	10.1371/journal.pntd.0001467				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	894GW	WOS:000300416100018	22272367	DOAJ Gold, Green Published			2019-03-26	
J	Mugasa, CM; Adams, ER; Boer, KR; Dyserinck, HC; Buscher, P; Schallig, HDHF; Leeflang, MMG				Mugasa, Claire M.; Adams, Emily R.; Boer, Kimberly R.; Dyserinck, Heleen C.; Buscher, Philippe; Schallig, Henk D. H. F.; Leeflang, Mariska M. G.			Diagnostic Accuracy of Molecular Amplification Tests for Human African Trypanosomiasis-Systematic Review	PLOS NEGLECTED TROPICAL DISEASES			English	Article							POLYMERASE-CHAIN-REACTION; SEQUENCE-BASED AMPLIFICATION; SLEEPING SICKNESS DIAGNOSIS; BRUCEI-GAMBIENSE; CEREBROSPINAL-FLUID; STAGE DETERMINATION; CLINICAL-SAMPLES; RAPID DETECTION; BLOOD-SAMPLES; FOLLOW-UP	Background: A range of molecular amplification techniques have been developed for the diagnosis of Human African Trypanosomiasis (HAT); however, careful evaluation of these tests must precede implementation to ensure their high clinical accuracy. Here, we investigated the diagnostic accuracy of molecular amplification tests for HAT, the quality of articles and reasons for variation in accuracy. Methodology: Data from studies assessing diagnostic molecular amplification tests were extracted and pooled to calculate accuracy. Articles were included if they reported sensitivity and specificity or data whereby values could be calculated. Study quality was assessed using QUADAS and selected studies were analysed using the bivariate random effects model. Results: 16 articles evaluating molecular amplification tests fulfilled the inclusion criteria: PCR (n = 12), NASBA (n = 2), LAMP (n = 1) and a study comparing PCR and NASBA (n = 1). Fourteen articles, including 19 different studies were included in the meta-analysis. Summary sensitivity for PCR on blood was 99.0% (95% CI 92.8 to 99.9) and the specificity was 97.7% (95% CI 93.0 to 99.3). Differences in study design and readout method did not significantly change estimates although use of satellite DNA as a target significantly lowers specificity. Sensitivity and specificity of PCR on CSF for staging varied from 87.6% to 100%, and 55.6% to 82.9% respectively. Conclusion: Here, PCR seems to have sufficient accuracy to replace microscopy where facilities allow, although this conclusion is based on multiple reference standards and a patient population that was not always representative. Future studies should, therefore, include patients for which PCR may become the test of choice and consider well designed diagnostic accuracy studies to provide extra evidence on the value of PCR in practice. Another use of PCR for control of disease could be to screen samples collected from rural areas and test in reference laboratories, to spot epidemics quickly and direct resources appropriately.	[Mugasa, Claire M.; Adams, Emily R.; Boer, Kimberly R.; Schallig, Henk D. H. F.] Royal Trop Inst, KIT Biomed Res, NL-1105 AZ Amsterdam, Netherlands; [Mugasa, Claire M.] Makerere Univ, Dept Vet Parasitol & Microbiol, Fac Vet Med, Kampala, Uganda; [Boer, Kimberly R.] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands; [Dyserinck, Heleen C.] Univ Amsterdam, Acad Med Ctr, Acad Med Ctr Lib, NL-1105 AZ Amsterdam, Netherlands; [Buscher, Philippe] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium; [Leeflang, Mariska M. G.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1105 AZ Amsterdam, Netherlands	Mugasa, CM (reprint author), Royal Trop Inst, KIT Biomed Res, NL-1105 AZ Amsterdam, Netherlands.	e.adams@kit.nl	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472; Adams, Emily/0000-0002-0816-2835; Leeflang, Mariska/0000-0001-5960-0471	commission of the European Communities', INCO-DEV [015379]	This study was financed by the commission of the European Communities' Sixth Framework Programme, priority INCO-DEV, project TRYLEIDIAG, contract 015379. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAILEY JW, 1994, TROP DOCT, V24, P54, DOI 10.1177/004947559402400204; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; Becker S, 2004, DIAGN MICR INFEC DIS, V50, P193, DOI 10.1016/j.diagmicrobio.2004.07.001; Brun R, 2010, LANCET, V375, P148, DOI 10.1016/S0140-6736(09)60829-1; Buscher P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000471; CATTAND P, 1988, B WORLD HEALTH ORGAN, V66, P83; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Deborggraeve S, 2006, J CLIN MICROBIOL, V44, P2884, DOI 10.1128/JCM.02594-05; Deborggraeve S, 2008, DIAGN MICR INFEC DIS, V61, P428, DOI 10.1016/j.diagmicrobio.2008.03.006; Deborggraeve S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000972; Deborggraeve S, 2010, LANCET INFECT DIS, V10, P433, DOI 10.1016/S1473-3099(10)70077-3; Jamonneau V, 2003, TROP MED INT HEALTH, V8, P589, DOI 10.1046/j.1365-3156.2003.01079.x; Kabiri M, 1999, TROP MED INT HEALTH, V4, P658, DOI 10.1046/j.1365-3156.1999.00465.x; Koffi M, 2006, ACTA TROP, V98, P183, DOI 10.1016/j.actatropica.2006.04.001; Kyambadde JW, 2000, B WORLD HEALTH ORGAN, V78, P119; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Leeflang MMG, 2008, ANN INTERN MED, V149, P889, DOI 10.7326/0003-4819-149-12-200812160-00008; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; MATHIEUDAUDE F, 1994, AM J TROP MED HYG, V50, P13, DOI 10.4269/ajtmh.1994.50.13; Matovu E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000737; MOSER DR, 1989, PARASITOLOGY, V99, P57, DOI 10.1017/S0031182000061023; Mugasa CM, 2008, DIAGN MICR INFEC DIS, V61, P440, DOI 10.1016/j.diagmicrobio.2008.03.019; Mugasa CM, 2009, J CLIN MICROBIOL, V47, P630, DOI 10.1128/JCM.01430-08; Njiru ZK, 2008, INT J PARASITOL, V38, P589, DOI 10.1016/j.ijpara.2007.09.006; Njiru ZK, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000147; Penchenier L, 2000, T ROY SOC TROP MED H, V94, P392, DOI 10.1016/S0035-9203(00)90116-0; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; Picozzi K, 2005, BMJ-BRIT MED J, V331, P1238, DOI 10.1136/bmj.331.7527.1238; Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X; Radwanska M, 2002, AM J TROP MED HYG, V67, P289, DOI 10.4269/ajtmh.2002.67.289; Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; Rutjes A W S, 2007, Health Technol Assess, V11, pix; Rutjes Anne W S, 2006, CMAJ, V174, P469, DOI 10.1503/cmaj.050090; Rutjes AWS, 2005, CLIN CHEM, V51, P1335, DOI 10.1373/clinchem.2005.048595; Simarro PP, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-57; Solano P, 2002, ACTA TROP, V82, P349, DOI 10.1016/S0001-706X(02)00029-3; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Truc P, 1999, B WORLD HEALTH ORGAN, V77, P745; Whiting P, 2004, ANN INTERN MED, V140, P189, DOI 10.7326/0003-4819-140-3-200402030-00010; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Woo P. T. K., 1970, Acta trop., V27, P384	42	17	17	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JAN	2012	6	1							e1438	10.1371/journal.pntd.0001438				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	894GW	WOS:000300416100004	22253934	DOAJ Gold, Green Published			2019-03-26	
J	Baly, A; Toledo, ME; Rodriguez, K; Benitez, JR; Rodriguez, M; Boelaert, M; Vanlerberghe, V; Van der Stuyft, P				Baly, Alberto; Toledo, Maria E.; Rodriguez, Karina; Benitez, Juan R.; Rodriguez, Maritza; Boelaert, Marleen; Vanlerberghe, Veerle; Van der Stuyft, Patrick			Costs of dengue prevention and incremental cost of dengue outbreak control in Guantanamo, Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Aedes aegypti control; dengue outbreak control; economic cost; Cuba; controle de l'Aedes aegypti; controle de l'epidemie de la dengue; cout economique; Cuba; control de Aedes aegypti; control de un brote de dengue; coste economico; Cuba	VECTOR CONTROL; AEDES-AEGYPTI; AMERICA; SURVEILLANCE; STRATEGIES; HEALTH; TRANSMISSION; SANTIAGO; LIFE; ASIA	Objective To assess the economic cost of routine Aedes aegypti control in an at-risk environment without dengue endemicity and the incremental costs incurred during a sporadic outbreak. methods The study was conducted in 2006 in the city of Guantanamo, Cuba. We took a societal perspective to calculate costs in months without dengue transmission (January-July) and during an outbreak (August-December). Data sources were bookkeeping records, direct observations and interviews. results The total economic cost per inhabitant (p. i.) per month. (p. m.) increased from 2.76 USD in months without dengue transmission to 6.05 USD during an outbreak. In months without transmission, the routine Aedes control programme cost 1.67 USD p. i. p. m. Incremental costs during the outbreak were mainly incurred by the population and the primary / secondary level of the healthcare system, hardly by the vector control programme (1.64, 1.44 and 0.21 UDS increment p. i. p. m., respectively). The total cost for managing a hospitalized suspected dengue case was 296.60 USD (62.0% direct medical, 9.0% direct non-medical and 29.0% indirect costs). In both periods, the main cost drivers for the Aedes control programme, the healthcare system and the community were the value of personnel and volunteer time or productivity losses. conclusions Intensive efforts to keep A. aegypti infestation low entail important economic costs for society. When a dengue outbreak does occur eventually, costs increase sharply. In-depth studies should assess which mix of activities and actors could maximize the effectiveness and cost-effectiveness of routine Aedes control and dengue prevention.	[Baly, Alberto; Toledo, Maria E.] Inst Med Trop Pedro Kouri, Havana, Cuba; [Rodriguez, Karina; Benitez, Juan R.; Rodriguez, Maritza] Unidad Prov Vigilancia & Lucha Antivectorial, Guantanamo, Cuba; [Boelaert, Marleen; Vanlerberghe, Veerle; Van der Stuyft, Patrick] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium	Baly, A (reprint author), Inst Med Trop Pedro Kouri, Havana, Cuba.	baly@ipk.sld.cu	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	Institute of Tropical Medicine, Antwerp; Belgium Directorate - General for Development Co-operation [95900]	We gratefully acknowledge the role played by the health sector and provincial vector control programme staff involved in the dengue prevention and control activities. The study was partially funded through the framework agreement between the Institute of Tropical Medicine, Antwerp, and the Belgium Directorate - General for Development Co-operation (project 95900).	ARIAS DY, 2009, THESIS FACULTAD SALU; Armien B, 2008, AM J TROP MED HYG, V79, P364, DOI 10.4269/ajtmh.2008.79.364; Baly A, 2011, AM J TROP MED HYG, V84, P747, DOI 10.4269/ajtmh.2011.10-0532; Baly A, 2009, AM J TROP MED HYG, V81, P88, DOI 10.4269/ajtmh.2009.81.88; Beatty ME, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000890; BEATTY ME, 2008, 2 INT C DENG DENG HA, P198; Eisen L, 2009, J MED ENTOMOL, V46, P1245, DOI 10.1603/033.046.0601; FLESSA S, 2009, COSTING HLTH CARE SE, P33; Gold M.R., 1996, COST EFFECTIVENESS H; Guzman MG, 2011, DRUG FUTURE, V36, P45, DOI 10.1358/dof.2011.36.1.1583182; Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6; HADDIX A, 2003, PRACTICAL GUIDE PREV; Johns B, 2003, COST EFF RESOUR ALLO, V1, P1; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; *OF NAC EST, 2009, PROD INT BRUT CLAS A; *OF NAC EST, 2007, GUANT POPL RES MUN S; Orellano PW, 2008, REV PANAM SALUD PUBL, V24, P113; *PAHO, 2006, BROT DENG CUB; Romani MET, 2007, SOC SCI MED, V64, P976, DOI 10.1016/j.socscimed.2006.10.033; Scott TW, 2010, CURR TOP MICROBIOL, V338, P115, DOI 10.1007/978-3-642-02215-9_9; SUAYA JA, 2006, TDR SCI WORK GROUP M, P35; Suaya JA, 2007, TROP MED INT HEALTH, V12, P1026, DOI 10.1111/j.1365-3156.2007.01889.x; Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846; *TDR, 2006, SCI WORK GROUP M DEN; Toledo ME, 2007, T ROY SOC TROP MED H, V101, P56, DOI 10.1016/j.trstmh.2006.03.006; Toledo ME, 2009, TROP MED INT HEALTH, V14, P168; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Torres JR, 2007, CAD SAUDE PUBLICA, V23, pS23, DOI 10.1590/S0102-311X2007001300004; Tun-Lin W, 2009, TROP MED INT HEALTH, V14, P1143, DOI 10.1111/j.1365-3156.2009.02341.x; Valdés G Luis, 2002, Rev Cubana Med Trop, V54, P220; Vanlerberghe V, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1959; Vazquez-Prokopec GM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000858; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; World Health Organization, 2009, DENG GUID DIAGN TREA	34	21	22	0	15	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2012	17	1					123	132		10.1111/j.1365-3156.2011.02881.x				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	865RO	WOS:000298328200014	21906216				2019-03-26	
J	Alen, MMF; Schols, D				Alen, Marijke M. F.; Schols, Dominique			Dengue Virus Entry as Target for Antiviral Therapy	JOURNAL OF TROPICAL MEDICINE			English	Review								Dengue virus (DENV) infections are expanding worldwide and, because of the lack of a vaccine, the search for antiviral products is imperative. Four serotypes of DENV are described and they all cause a similar disease outcome. It would be interesting to develop an antiviral product that can interact with all four serotypes, prevent host cell infection and subsequent immune activation. DENV entry is thus an interesting target for antiviral therapy. DENV enters the host cell through receptor-mediated endocytosis. Several cellular receptors have been proposed, and DC-SIGN, present on dendritic cells, is considered as the most important DENV receptor until now. Because DENV entry is a target for antiviral therapy, various classes of compounds have been investigated to inhibit this process. In this paper, an overview is given of all the putative DENV receptors, and the most promising DENV entry inhibitors are discussed.	[Alen, Marijke M. F.; Schols, Dominique] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, B-3000 Leuven, Belgium	Schols, D (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, B-3000 Leuven, Belgium.	dominique.schols@rega.kuleuven.be	Schols, Dominique/S-9057-2017	Schols, Dominique/0000-0003-3256-5850	Katholieke Universiteit Leuven (GOA) [10/014, PF/10/018]; FWO [G.485.08]	The work of the authors was supported by the Katholieke Universiteit Leuven (GOA no. 10/014 and PF/10/018) and the FWO (no. G.485.08).	Acosta EG, 2008, J GEN VIROL, V89, P474, DOI 10.1099/vir.0.83357-0; Acosta EG, 2009, CELL MICROBIOL, V11, P1533, DOI 10.1111/j.1462-5822.2009.01345.x; Alen MMF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021658; Alen MMF, 2009, VIROLOGY, V387, P67, DOI 10.1016/j.virol.2009.01.043; Aoki C, 2006, J BIOCHEM, V139, P607, DOI 10.1093/jb/mvj067; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Avirutnan P, 1998, J IMMUNOL, V161, P6338; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Bryant JE, 2007, VIROLOGY, V366, P415, DOI 10.1016/j.virol.2007.05.007; Chang JH, 2011, ANTIVIR RES, V89, P26, DOI 10.1016/j.antiviral.2010.11.002; Chang JH, 2009, ANTIMICROB AGENTS CH, V53, P1501, DOI 10.1128/AAC.01457-08; Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013; Chen YC, 1999, J VIROL, V73, P2650; Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002; Chen YL, 2010, ANTIMICROB AGENTS CH, V54, P3255, DOI 10.1128/AAC.00397-10; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Chu JJH, 2004, J VIROL, V78, P10543, DOI [10.1128/JVI.78.19.10543-10555.2004, 10.1128/JVI.78.19.1053-10555.2004]; Costin JM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000721; Courageot MP, 2000, J VIROL, V74, P564, DOI 10.1128/JVI.74.1.564-572.2000; Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7; Crill WD, 2001, J VIROL, V75, P7769, DOI 10.1128/JVI.75.16.7769-7773.2001; DAUGHADAY CC, 1981, INFECT IMMUN, V32, P469; Davis CW, 2006, J VIROL, V80, P1290, DOI 10.1128/JVI.80.3.1290-1301.2006; Diamond MS, 2002, VIROLOGY, V304, P211, DOI 10.1006/viro.2002.1685; Durbin AP, 2008, VIROLOGY, V376, P429, DOI 10.1016/j.virol.2008.03.028; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Germi R, 2002, VIROLOGY, V292, P162, DOI 10.1006/viro.2001.1232; Gu Baohua, 2007, Antiviral Chemistry & Chemotherapy, V18, P49; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; GUIRAKHOO F, 1993, VIROLOGY, V194, P219, DOI 10.1006/viro.1993.1252; Hacker K, 2009, J GEN VIROL, V90, P2097, DOI 10.1099/vir.0.012120-0; HALSTEAD SB, 1977, J EXP MED, V146, P218, DOI 10.1084/jem.146.1.218; Halstead SB, 2008, ANNU REV ENTOMOL, V53, P273, DOI 10.1146/annurev.ento.53.103106.093326; Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0; HASE T, 1989, ARCH VIROL, V104, P129, DOI 10.1007/BF01313814; Hidari KIPJ, 2008, BIOCHEM BIOPH RES CO, V376, P91, DOI 10.1016/j.bbrc.2008.08.100; Hilgard P, 2000, HEPATOLOGY, V32, P1069, DOI 10.1053/jhep.2000.18713; Ho LJ, 2001, J IMMUNOL, V166, P1499, DOI 10.4049/jimmunol.166.3.1499; Hrobowski YM, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-49; Hung JJ, 2004, J VIROL, V78, P378, DOI 10.1128/JVI.78.1.378-388.2004; Hung SL, 1999, VIROLOGY, V257, P156, DOI 10.1006/viro.1999.9633; Jindadamrongwech S, 2004, ARCH VIROL, V149, P915, DOI 10.1007/s00705-003-0263-x; JOHNSON AJ, 1994, VIROLOGY, V203, P241, DOI 10.1006/viro.1994.1481; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; Kaptein SJF, 2010, ANTIMICROB AGENTS CH, V54, P5269, DOI 10.1128/AAC.00686-10; KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444; Klimstra WB, 2003, J VIROL, V77, P12022, DOI 10.1128/JVI.77.22.12022-12032.2003; Kou Z, 2008, J MED VIROL, V80, P134, DOI 10.1002/jmv.21051; Kuadkitkan A, 2010, VIROLOGY, V406, P149, DOI 10.1016/j.virol.2010.07.015; Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8; Lee E, 2006, ANTIVIR RES, V69, P31, DOI 10.1016/j.antiviral.2005.08.006; Lee E, 1997, VIROLOGY, V232, P281, DOI 10.1006/viro.1997.8570; Lee E, 2010, J VIROL, V84, P5171, DOI 10.1128/JVI.01900-09; Leyssen P, 2000, CLIN MICROBIOL REV, V13, P67, DOI 10.1128/CMR.13.1.67-82.2000; Liang PH, 2006, CHEMBIOCHEM, V7, P165, DOI 10.1002/cbic.200500321; Libraty DH, 2001, J VIROL, V75, P3501, DOI 10.1128/JVI.75.8.3501-3508.2001; Lin YL, 2002, ANTIVIR RES, V56, P93, DOI 10.1016/S0166-3542(02)00095-5; Lin YL, 2000, J MED VIROL, V60, P425, DOI 10.1002/(SICI)1096-9071(200004)60:4<425::AID-JMV10>3.0.CO;2-A; Lozach PY, 2005, J BIOL CHEM, V280, P23698, DOI 10.1074/jbc.M504337200; Mairuhu ATA, 2004, EUR J CLIN MICROBIOL, V23, P425, DOI 10.1007/s10096-004-1145-1; Marks RM, 2001, J MED CHEM, V44, P2178, DOI 10.1021/jm000412i; Marovich M, 2001, J INVEST DERM SYMP P, V6, P219, DOI 10.1046/j.0022-202x.2001.00037.x; Martin CSS, 2009, TRENDS MICROBIOL, V17, P514, DOI 10.1016/j.tim.2009.08.002; Martinez-Barragan JD, 2001, J VIROL, V75, P7818, DOI 10.1128/JVI.75.17.7818-7827.2001; Marzi A, 2007, J INFECT DIS, V196, pS237, DOI 10.1086/520607; Mehta Anand, 2002, Antivir Chem Chemother, V13, P299; Mercado-Curiel RF, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-85; Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100; Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165; Mondotte JA, 2007, J VIROL, V81, P7136, DOI 10.1128/JVI.00116-07; Murrell S, 2011, BIOTECHNOL ADV, V29, P239, DOI 10.1016/j.biotechadv.2010.11.008; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Nawa M, 2003, J GEN VIROL, V84, P1737, DOI 10.1099/vir.0.18883-0; Nicholson CO, 2011, ANTIVIR RES, V89, P71, DOI 10.1016/j.antiviral.2010.11.008; Ono L, 2003, ANTIVIR RES, V60, P201, DOI 10.1016/S0166-3542(03)00175-X; Perera R, 2008, ANTIVIR RES, V80, P11, DOI 10.1016/j.antiviral.2008.05.004; Poh MK, 2009, ANTIVIR RES, V84, P260, DOI 10.1016/j.antiviral.2009.09.011; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Pokidysheva E, 2006, CELL, V124, P485, DOI 10.1016/j.cell.2005.11.042; Pujol C A, 2002, Antivir Chem Chemother, V13, P83; Qiu H, 2007, CARBOHYD RES, V342, P2230, DOI 10.1016/j.carres.2007.06.021; Rajamanonmani R, 2009, J GEN VIROL, V90, P799, DOI 10.1099/vir.0.006874-0; RANDOLPH VB, 1990, J GEN VIROL, V71, P1845, DOI 10.1099/0022-1317-71-8-1845; Rees CR, 2008, ANTIVIR RES, V80, P135, DOI 10.1016/j.antiviral.2008.05.007; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7; Rogers KM, 2009, J INNATE IMMUN, V1, P405, DOI 10.1159/000226422; Sakoonwatanyoo P, 2006, INTERVIROLOGY, V49, P161, DOI 10.1159/000089377; Salas-Benito J, 2007, AM J TROP MED HYG, V77, P283, DOI 10.4269/ajtmh.2007.77.283; SalasBenito JS, 1997, J VIROL, V71, P7246; Sayce AC, 2010, TRENDS MICROBIOL, V18, P323, DOI 10.1016/j.tim.2010.04.003; Scherret JH, 2001, ANN NY ACAD SCI, V951, P361, DOI 10.1111/j.1749-6632.2001.tb02719.x; Schul W, 2007, J INFECT DIS, V195, P665, DOI 10.1086/511310; Seneviratne SL, 2006, T ROY SOC TROP MED H, V100, P608, DOI 10.1016/j.trstmh.2005.10.007; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SHIBUYA N, 1986, ARCH BIOCHEM BIOPHYS, V249, P215, DOI 10.1016/0003-9861(86)90577-1; Solomon T, 2001, J INFECTION, V42, P104, DOI 10.1053/jinf.2001.0802; Stiasny K, 2011, AMINO ACIDS, V41, P1159, DOI 10.1007/s00726-009-0370-4; Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405; Takhampunya R, 2006, J GEN VIROL, V87, P1947, DOI 10.1099/vir.0.81655-0; Talarico LB, 2007, VIROLOGY, V363, P473, DOI 10.1016/j.virol.2007.01.043; Talarico LB, 2005, ANTIVIR RES, V66, P103, DOI 10.1016/j.antiviral.2005.02.001; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Taweechaisupapong S, 1996, J MED MICROBIOL, V45, P138, DOI 10.1099/00222615-45-2-138; Thepparit C, 2004, J VIROL, V78, P12647, DOI 10.1128/JVI.78.22.12647-12656.2004; Thepparit C, 2004, INTERVIROLOGY, V47, P78, DOI 10.1159/000077830; Tong XK, 2010, ACTA PHARMACOL SIN, V31, P585, DOI 10.1038/aps.2010.29; Valle JRD, 2005, J VIROL, V79, P4557, DOI 10.1128/JVI.79.8.4557-4567.2005; van der Schaar HM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000244; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003; Wang QY, 2009, ANTIMICROB AGENTS CH, V53, P1823, DOI 10.1128/AAC.01148-08; Wati S, 2009, J VIROL, V83, P12871, DOI 10.1128/JVI.01419-09; Watson AA, 2011, J BIOL CHEM, V286, P24208, DOI 10.1074/jbc.M111.226142; Whitby K, 2005, J VIROL, V79, P8698, DOI [10.1128/JVI.79.14.8698-8706.2005, 10.1128/JVI.79.14.8690.8706.2005]; Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690; Wichit S, 2011, MICROBIOL IMMUNOL, V55, P135, DOI 10.1111/j.1348-0421.2010.00293.x; Wu SF, 2002, J VIROL, V76, P3596, DOI 10.1128/JVI.76.8.3596-3604.2002; Wu SJL, 2000, NAT MED, V6, P816; Yang JM, 2007, PLOS ONE, V5, pe428; Zhang JL, 2007, BIOCHEM BIOPH RES CO, V356, P763, DOI 10.1016/j.bbrc.2007.03.051; Zhang Y, 2004, STRUCTURE, V12, P1607, DOI 10.1016/j.str.2004.06.019	127	10	10	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-9686	1687-9694		J TROP MED	J. Trop. Med.		2012									UNSP 628475	10.1155/2012/628475				13	Tropical Medicine	Tropical Medicine	V15ZF	WOS:000214585800043	22529868	DOAJ Gold, Green Published			2019-03-26	
J	van Olmen, J; Schellevis, F; Van Damme, W; Kegels, G; Rasschaert, F				van Olmen, Josefien; Schellevis, Francois; Van Damme, Wim; Kegels, Guy; Rasschaert, Freya			Management of Chronic Diseases in Sub-Saharan Africa: Cross-Fertilisation between HIV/AIDS and Diabetes Care	JOURNAL OF TROPICAL MEDICINE			English	Review								There is growing attention for chronic diseases in sub-Saharan Africa (SSA) and for bridges between the management of HIV/AIDS and other (noncommunicable) chronic diseases. This becomes more urgent with increasing numbers of people living with both HIV/AIDS and other chronic conditions. This paper discusses the commonalities between chronic diseases by reviewing models of care, focusing on the two most dominant ones, diabetes mellitus type 2 (DM2) and HIV/AIDS. We argue that in order to cope with care for HIV patients and diabetes patients, health systems in SSA need to adopt new strategies taking into account essential elements of chronic disease care. We developed a "chronic dimension framework," which analyses the " disease dimension," the " health provider dimension," the patient or " person dimension," and the " environment dimension" of chronic diseases. Applying this framework to HIV/AIDS and DM2 shows that it is useful to think about management of both in tandem, comparing care delivery platforms and self-management strategies. A literature review on care delivery models for diabetes and HIV/AIDS in SSA revealed potential elements for cross-fertilisation: rapid scale-up approaches through the public health approach by simplification and decentralisation; community involvement, peer support, and self-management strategies; and strengthening health services.	[van Olmen, Josefien; Van Damme, Wim; Kegels, Guy; Rasschaert, Freya] Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium; [Schellevis, Francois] Netherlands Inst Hlth Serv Res NIVEL, NL-3513 CR Utrecht, Netherlands; [Schellevis, Francois] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Dept Gen Practice & Elderly Care Med, Med Ctr, NL-1081 BT Amsterdam, Netherlands	van Olmen, J (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	jvanolmen@itg.be		van Olmen, Josefien/0000-0001-9724-1887			Abaasa AM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-241; Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Alemu S, 2004, DIAB VOICE, V49, P8; Assal JP, 1999, PATIENT EDUC COUNS, V37, P99, DOI 10.1016/S0738-3991(98)00109-8; AVERT, 2011, HIV AIDS STIGM DISCR; Beaglehole R, 2008, LANCET, V372, P940, DOI 10.1016/S0140-6736(08)61404-X; Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0; Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Behforouz HL, 2004, CLIN INFECT DIS, V38, pS429, DOI 10.1086/421408; Bekker LG, 2006, SAMJ S AFR MED J, V96, P315; Bemelmans M, 2010, TROP MED INT HEALTH, V15, P1413, DOI 10.1111/j.1365-3156.2010.02649.x; Beran D, 2006, LANCET, V368, P1689, DOI 10.1016/S0140-6736(06)69704-3; Bermejo R, 2011, LANCET, V377, P2004, DOI 10.1016/S0140-6736(11)60863-5; Bischoff A, 2009, INT J ENV RES PUB HE, V6, P2258, DOI 10.3390/ijerph6082258; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7; Bussmann H, 2008, AIDS, V22, P2303, DOI 10.1097/QAD.0b013e3283129db0; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Chan AK, 2010, TROP MED INT HEALTH, V15, P90, DOI 10.1111/j.1365-3156.2010.02503.x; Cohen R, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-23; Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75; Coleman R, 1998, B WORLD HEALTH ORGAN, V76, P633; De Maeseneer J, 2012, LANCET, V379, P1860, DOI 10.1016/S0140-6736(11)61135-5; de-Graft Aikins Ama, 2010, Global Health, V6, P6, DOI 10.1186/1744-8603-6-6; Decroo T, 2011, JAIDS-J ACQ IMM DEF, V56, pE39, DOI 10.1097/QAI.0b013e3182055138; Deeks Steven G, 2009, Top HIV Med, V17, P118; Dixon-Woods Mary, 2006, BMC Med Res Methodol, V6, P35, DOI 10.1186/1471-2288-6-35; Dohrn J, 2009, JAIDS-J ACQ IMM DEF, V52, pS27, DOI 10.1097/QAI.0b013e3181bbc9e4; El-Sadr WM, 2007, AIDS, V21, pS65, DOI 10.1097/01.aids.0000298105.79484.62; Elema Riekje, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P60, DOI 10.1177/1545109709331472; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Fisher EB, 2010, FAM PRACT, V27, pI6, DOI 10.1093/fampra/cmp013; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Funnell MM, 2010, DIABETES CARE, V33, pS89, DOI 10.2337/dc10-S089; Funnell MM, 2010, FAM PRACT, V27, pI17, DOI 10.1093/fampra/cmp027; Funnell MM, 2005, DIABETES EDUCATOR, V31, P53, DOI 10.1177/0145721704273166; Gale EAM, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5675; Genberg BL, 2009, SOC SCI MED, V68, P2279, DOI 10.1016/j.socscimed.2009.04.005; Glasgow RE, 2001, MILBANK Q, V79, P579, DOI 10.1111/1468-0009.00222; Glazier RH, 2006, DIABETES CARE, V29, P1675, DOI 10.2337/dc05-1942; Grubb Ian, 2003, PUBLIC HLTH APPROACH; Harries AD, 2004, T ROY SOC TROP MED H, V98, P695, DOI 10.1016/j.trstmh.2004.05.002; Harries AD, 2009, JAIDS-J ACQ IMM DEF, V52, pS14, DOI 10.1097/QAI.0b013e3181bbc99e; Holman H, 2004, PUBLIC HEALTH REP, V119, P239, DOI 10.1016/j.phr.2004.04.002; Hunt LM, 2001, MED ANTHROPOL Q, V15, P347, DOI 10.1525/maq.2001.15.3.347; International Diabetes Federation, 2007, DIABETES ATLAS; Ir P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010930; Isenhower W., 2011, P CHRON CAR DES M HL; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; Janssens B, 2007, B WORLD HEALTH ORGAN, V85, P880, DOI 10.2471/BLT.06.036574; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)17741-1; Kipp W, 2010, CURR HIV RES, V8, P179, DOI 10.2174/157016210790442722; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Krebs DW, 2008, AIDS CARE, V20, P311, DOI 10.1080/09540120701594776; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lowrance DW, 2008, JAIDS-J ACQ IMM DEF, V49, P287, DOI 10.1097/QAI.0b013e3181893ef0; Luseno WK, 2010, AIDS PATIENT CARE ST, V24, P257, DOI 10.1089/apc.2009.0213; Maher D, 2010, TROP MED INT HEALTH, V15, P176, DOI 10.1111/j.1365-3156.2009.02438.x; Mak WWS, 2007, SOC SCI MED, V64, P1549, DOI 10.1016/j.socscimed.2006.12.003; Mamo Y, 2007, CLIN MED, V7, P228, DOI 10.7861/clinmedicine.7-3-228; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mays Nicholas, 2005, J Health Serv Res Policy, V10 Suppl 1, P6, DOI 10.1258/1355819054308576; Mdee A., 2011, 4 JEFCAS; Merten S, 2010, TROP MED INT HEALTH, V15, P16, DOI 10.1111/j.1365-3156.2010.02510.x; National Diabetes Education Program, 2009, GUID PRINC DIAB CAR; Nglazi MD, 2011, JAIDS-J ACQ IMM DEF, V56, pE1, DOI 10.1097/QAI.0b013e3181ff0bdc; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Nuno R, 2012, HEALTH POLICY, V105, P55, DOI 10.1016/j.healthpol.2011.10.006; Pearson ML, 2005, HEALTH SERV RES, V40, P978, DOI 10.1111/j.1475-6773.2005.00397.x; Rasschaert Freya, 2011, J Int AIDS Soc, V14 Suppl 1, pS3, DOI 10.1186/1758-2652-14-S1-S3; SCHELLEVIS FG, 1993, J CLIN EPIDEMIOL, V46, P469, DOI 10.1016/0895-4356(93)90024-U; Selke HM, 2010, JAIDS-J ACQ IMM DEF, V55, P483, DOI 10.1097/QAI.0b013e3181eb5edb; Smith JH, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-47; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Su TT, 2006, B WORLD HEALTH ORGAN, V84, P21; The NCD Alliance, 2013, PROP OUTC DOC UN HIG; Turner J, 2000, WESTERN J MED, V172, P124, DOI 10.1136/ewjm.172.2.124; UNAIDS, 2011, CHRON CAR HIV NONC D; Vallabhaneni S, 2012, AIDS CARE, V24, P687, DOI 10.1080/09540121.2011.630370; van Olmen J., 2011, P 7 EUR C TROP MED I; van Olmen J., 2009, WORKSH I TROP MED AN; van Olmen J, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-38; Wagner EH, 2001, BMJ-BRIT MED J, V323, P945, DOI 10.1136/bmj.323.7319.945; Windisch R, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-25; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea; Wools-Kaloustian KK, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-22; World Diabetes Federation, 2006, TYP 2 DIAB CLIN PRAC; World Health Organization, 2011, GLOB HLTH OBS; World Health Organization, 2011, PACK ESS NONC PEN DI; World Health Organization, 2011, GLOB HIV AIDS RESP E; World Health Organization, 2007, INN CAR CHRON COND; World Health Organization, 2006, TUB FACTSH WHAT IS D; World Health Organization Maximizing Positive Synergies Collaborative Group, 2000, LANCET, V373, P2137; Zachariah R, 2007, T ROY SOC TROP MED H, V101, P79, DOI 10.1016/j.trstmh.2006.05.010; Zachariah R, 2009, T ROY SOC TROP MED H, V103, P549, DOI 10.1016/j.trstmh.2008.09.019	96	10	10	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1687-9686	1687-9694		J TROP MED	J. Trop. Med.		2012									UNSP 349312	10.1155/2012/349312				10	Tropical Medicine	Tropical Medicine	V15ZF	WOS:000214585800022	23209477	DOAJ Gold, Green Published			2019-03-26	
J	Hercot, D; Keugoung, B; Zerbo, A; Appelmans, A; Van Damme, W				Hercot, D.; Keugoung, B.; Zerbo, A.; Appelmans, A.; Van Damme, W.			The Emerging Voices for Global Health Initiative: an intensive capacity-building effort for young researchers from the South	MEDECINE ET SANTE TROPICALES			French	Article						capacity building; researcher; professional development; global health; developing countries		Researchers from developing countries, French-speaking nations in particular, are underrepresented in the international biomedical and health literature. Various initiatives seek to address this problem. This article presents the experience of the Emerging Voices for Global Health (EV4GH) program. This initiative provided 52 young researchers from developing countries with intensive skills and content training, with an assortment of complementary components: training in scientific writing and presenting skills, immersion in global health and health systems research, an innovative presentation of their work at the 52nd colloquium of the Institute of Tropical Medicine in Antwerp, and an active role in the first Global Symposium on Health Systems Research, supervised by a team of experienced researchers/coaches who supported them in the publication of a scientific essay. This approach targeting researchers in developing countries and combining the development of skills and knowledge through the publication process, merits reproduction and encouragement. Young researchers from developing countries should not miss out on the second version of this program in October 2012 in Beijing, China.	[Hercot, D.; Keugoung, B.; Appelmans, A.; Van Damme, W.] Inst Med Trop, Dept Sante Publ, Antwerp, Belgium; [Keugoung, B.] Minist Sante Publ, Yaounde, Cameroon	Hercot, D (reprint author), Inst Med Trop, Dept Sante Publ, Antwerp, Belgium.	dhercot@itg.be	yan, liu/A-1822-2015	yan, liu/0000-0001-8517-1084; Hercot, David/0000-0002-0457-0663			Abimbola S, 2011, MEDICC REV, V13, P43; [Anonymous], 2010, LANCET, V375, P1496, DOI 10.1016/S0140-6736(10)60640-X; Daivadanam M., 2011, DESSERT ARRIVED GLOB; Hercot D, 2012, INT HLTH POLICIES 20; ITM, 2012, EM VOIC GLOB HLTH; ITM, 2010, ITG COLL 2010 ANTW; Kajja V., 2010, TAKE HIV AIDS AWAREN; Katikireddi SV, 2004, BRIT MED J, V328, P1190, DOI 10.1136/bmj.328.7449.1190; Keugoung B, 2012, POLITIQUES INT SANTE; Keugoung B, 2011, TROP MED INT HEALTH, V16, P478, DOI 10.1111/j.1365-3156.2010.02716.x; Klein A, 2012, PECHA KUCHA; Masanja IM, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-322; Meda Ziemle Clement, 2011, Sante, V21, P178, DOI 10.1684/san.2011.0268; Narayan L, 2010, ITM EM VOIC PECH KUC; Ngo AD, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-237; Nkonki L, 2011, B WORLD HEALTH ORGAN, V89, P919, DOI 10.2471/BLT.11.087825; Shafik A, 2011, B WORLD HEALTH ORGAN, V89, P622, DOI 10.2471/BLT.11.089755; WHO, 2012, GLOB S HLTH SYST RES	18	2	2	0	1	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	2261-3684	2261-2211		MED SANTE TROP	Med. Sante Trop.	JAN-MAR	2012	22	1					9	11		10.1684/mst.2012.0018				3	Tropical Medicine	Tropical Medicine	VD2WQ	WOS:000436570600003	22868718				2019-03-26	
J	Namululi, BA; Guerrieri, C; Dramaix, M				Namululi, B. A.; Guerrieri, C.; Dramaix, M.			Impact of method of recruitment of blood donors on the prevalence of HIV and HBV in Bukavu, DR Congo	MEDECINE ET SANTE TROPICALES			French	Article						Prevalence; Blood donations; HIV; HBV; Congo DR		Objectives. To determine the impact of the mode of recruitment of blood donors on the prevalence of blood-borne infections (HIV and HBV). Methodology. Retrospective cohort study, conducted in Bukavu (eastern DR Congo) 2001-2005. HBsAg and HIV tests were analyzed according to age, sex, type, and category of donors. Proportions were compared with Pearson Chi2 or Fisher's exact tests and Chi2 trend tests, and the strength of associations measured by odds ratios (and their 95% CI). Results. Men accounted for 70.2% of the donors, and 88.3% were volunteers (n = 3292). Regular donors (n = 7442) provided 75% of the donations. The proportion of family donors decreased over time, from 14.3% in 2001 to 5.1% in 2005. HIV prevalence was 1% and that of HBsAg 3.7%. Prevalence rates were higher among new donors than among regular donors (HIV 1.9% versus 0.2% and HBsAg 7.3% versus 0.5%), among family donors than among volunteers (4.2% versus 1.6% for HIV and 9.9% versus 7% for HBs Ag, and among women than among men (2.8% versus 1.6%, OR = 1.79 [ 1.08-2.96]). Thus new women family donors were 3.75 times more likely to be HIV-positive as new volunteers who were women (OR = 3.75 [1.65-8.55]). The prevalence of HBsAg among new women donors was 5.8%, lower than among their male counterparts, 7.9% (OR = 0.71 [0.51-0.98]). Conclusion. Risk of contamination by seropositive donors was lowest for regular and volunteer blood donors.	[Namululi, B. A.] Hop Prov Gen Reference Bukavu, Bukavu, Rep Congo; [Guerrieri, C.] Clin Univ St Luc Bruxelles, Banque Sang, B-1200 Brussels, Belgium; [Guerrieri, C.] Inst Paul Lambin, B-1200 Brussels, Belgium; [Dramaix, M.] Univ Libre Bruxelles, Ecole Sante Publ, B-1070 Brussels, Belgium	Namululi, BA (reprint author), Hop Prov Gen Reference Bukavu, Bukavu, Rep Congo.	aimenamululi@yahoo.fr					AbouZahr C, 2004, MATERNAL MORBILITY 2, P39; Ampofo W, 2002, J CLIN MICROBIOL, V40, P3523, DOI 10.1128/JCM.40.9.3523-3525.2002; Batina A, 2007, Rev Med Brux, V28, P145; Elira-Dokekias A, 2002, GAZETTE TRANSFUSION, V177, P4; Heyns AD, 2006, JAMA-J AM MED ASSOC, V295, P519, DOI 10.1001/jama.295.5.519; Loua A, 2004, TRANSFUS CLIN BIOL, V11, P98, DOI 10.1016/j.tracli.2004.01.004; Matee MIN, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-21; Mbanya DN, 2005, TRANSFUSION MED, V15, P395, DOI 10.1111/j.1365-3148.2005.00608.x; Mbanya DN, 2003, TRANSFUSION MED, V13, P267, DOI 10.1046/j.1365-3148.2003.00453.x; Mbendi Nlombi C, 2001, Med Trop (Mars), V61, P139; ONUSIDA, 2004, 4 ONUSIDA, P18; Tapko J., 2002, 4 AR C 3 AFR C BLOOD, P67; *WHO, 2004, GLOB STAT REP ALC CO, P29; WHO, 2009, BLOOD SAF AV FACTS F; WHO, 2002, IARC MON EV CARC RIS, P51	15	5	5	0	0	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	2261-3684	2261-2211		MED SANTE TROP	Med. Sante Trop.	JAN-MAR	2012	22	1					69	74		10.1684/mst.2012.0028				6	Tropical Medicine	Tropical Medicine	VD2WQ	WOS:000436570600020	22868730				2019-03-26	
J	Elongi, JP; Tandu-Umba, B; Spitz, B; Verdonck, F; Kashitu, D; Buassa, B; Dikamba, N				Elongi, J. P.; Tandu-Umba, B.; Spitz, B.; Verdonck, F.; Kashitu, D.; Buassa, B.; Dikamba, N.			Seasonal variations in hematocrit in Kinshasa, Democratic Republic of Congo	MEDECINE ET SANTE TROPICALES			French	Letter						seasonal variation; blood concentration; democratic Republic of Congo		The aim of the present study was to determine whether the concentration of blood cells in plasma varies seasonally in Kinshasa, DR Congo. Changes in hematocrit of 104 volunteer blood donors in good health were followed during the two seasons of the year-rainy and dry. Hematocrit was higher during the rainy season than during the dry season.	[Elongi, J. P.] Hop Gen Kinshasa, Dept Gynecol Obstet, Kinshasa, DEM REP CONGO; [Tandu-Umba, B.] Univ Kinshasa, Dept Gynecol Obstet, Kinshasa, DEM REP CONGO; [Spitz, B.] Katholieke Univ Leuven, UZ Gasthuisberg, Dept Gynecol Obstet, Leuven, Belgium; [Verdonck, F.] Katholieke Univ Leuven, Dept Physiol, Leuven, Belgium; [Kashitu, D.] Hop Gen Kinshasa, Serv Banque Sang, Kinshasa, DEM REP CONGO; [Buassa, B.] Hop Gen Kinshasa, Dept Biol Clin, Kinshasa, DEM REP CONGO; [Dikamba, N.] Univ Kinshasa, Ecole Sante Publ, Kinshasa, DEM REP CONGO	Elongi, JP (reprint author), Hop Gen Kinshasa, Dept Gynecol Obstet, Kinshasa, DEM REP CONGO.	elongi2002@yahoo.fr					Bazett H., 1945, JAMA-J AM MED ASSOC, V111, P1841; Bazett HC, 1940, AM J PHYSIOL, V129, P0069; Elongi J, 2011, MED AFR NOIRE, V58, P115; Elongi JP, 2011, GYNECOL OBSTET FERTI, V39, P132, DOI 10.1016/j.gyobfe.2010.12.010; HEILMANN L, 1981, ARCH GYNECOL, V231, P7, DOI 10.1007/BF02110019; KACEM NH, 1987, AQUACULTURE, V64, P325	6	0	0	0	0	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	2261-3684	2261-2211		MED SANTE TROP	Med. Sante Trop.	JAN-MAR	2012	22	1					102	103						3	Tropical Medicine	Tropical Medicine	VD2WQ	WOS:000436570600032	22868742				2019-03-26	
J	Chitanga, S; Marcotty, T; Namangala, B; Van den Bossche, P; Van den Abbeele, J; Delespaux, V				Chitanga, Simbarashe; Marcotty, Tanguy; Namangala, Boniface; Van den Bossche, Peter; Van den Abbeele, Jan; Delespaux, Vincent			High Prevalence of Drug Resistance in Animal Trypanosomes without a History of Drug Exposure	PLOS NEGLECTED TROPICAL DISEASES			English	Article							EASTERN PROVINCE; PCR-RFLP; MOLECULAR TOOLS; DIMINAZENE; CONGOLENSE; CATTLE; ZAMBIA; ISOMETAMIDIUM; TRANSPORTER; MALARIA	Background: Trypanosomosis caused by Trypanosoma congolense is a major constraint to animal health in sub-Saharan Africa. Unfortunately, the treatment of the disease is impaired by the spread of drug resistance. Resistance to diminazene aceturate (DA) in T. congolense is linked to a mutation modifying the functioning of a P2-type purine-transporter responsible for the uptake of the drug. Our objective was to verify if the mutation was linked or not to drug pressure. Methodology/Principal Findings: Thirty-four T. congolense isolates sampled from tsetse or wildlife were screened for the DA-resistance linked mutation using DpnII-PCR-RFLP. The results showed 1 sensitive, 12 resistant and 21 mixed DpnII-PCR-RFLP profiles. This suggests that the mutation is present on at least one allele of each of the 33 isolates. For twelve of the isolates, a standard screening method in mice was used by (i) microscopic examination, (ii) trypanosome-specific 18S-PCR after 2 months of observation and (iii) weekly trypanosome-specific 18S-PCR for 8 weeks. The results showed that all mice remained microscopically trypanosome-positive after treatment with 5 mg/kg DA. With 10 and 20 mg/kg, 8.3% (n = 72) and 0% (n = 72) of the mice became parasitologically positive after treatment. However, in these latter groups the trypanosome-specific 18S-PCR indicated a higher degree of trypanosome-positivity, i.e., with a unique test, 51.4% (n = 72) and 38.9% (n = 72) and with the weekly tests 79.2% (n = 24) and 66.7% (n = 24) for 10 and 20 mg/kg respectively. Conclusion/Significance: The widespread presence of the DA-resistance linked mutation in T. congolense isolated from wildlife suggests that this mutation is favourable to parasite survival and/or its dissemination in the host population independent from the presence of drug. After treatment with DA, those T. congolense isolates cause persisting low parasitaemias even after complete elimination of the drug and with little impact on the host's health.	[Chitanga, Simbarashe; Marcotty, Tanguy; Van den Bossche, Peter; Van den Abbeele, Jan; Delespaux, Vincent] Inst Trop Med Antwerp, Antwerp, Belgium; [Chitanga, Simbarashe; Namangala, Boniface] Univ Zambia, Dept Paraclin Studies, Sch Vet Med, Lusaka, Zambia; [Marcotty, Tanguy; Van den Bossche, Peter] Univ Pretoria, Dept Vet Trop Dis, Onderstepoort, South Africa	Chitanga, S (reprint author), Inst Trop Med Antwerp, Antwerp, Belgium.	vdelespaux@itg.be		Van Den Abbeele, Jan/0000-0002-4533-4480	Belgian Development Cooperation	This work was funded by the Belgian Development Cooperation - Framework Agreement ITM-DGD (http://diplomatie.belgium.be/en/policy/development_cooperation/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babiker HA, 2009, EXPERT REV ANTI-INFE, V7, P581, DOI 10.1586/ERI.09.29; Delespaux V, 2006, ACTA TROP, V100, P96, DOI 10.1016/j.actatropica.2006.10.001; Delespaux V, 2002, VET PARASITOL, V110, P117, DOI 10.1016/S0304-4017(02)00316-3; Delespaux V, 2008, TRENDS PARASITOL, V24, P236, DOI 10.1016/j.pt.2008.02.006; Delespaux V, 2007, DRUG RESIST UPDATE, V10, P30, DOI 10.1016/j.drup.2007.02.004; Delespaux V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000828; Delespaux V, 2008, DRUG RESIST UPDATE, V11, P205, DOI 10.1016/j.drup.2008.10.002; Eisler MC, 2001, VET PARASITOL, V97, P171, DOI 10.1016/S0304-4017(01)00415-0; GEERTS S, 1998, PAAT TECHNICAL SCI S, V1; Geysen D, 2003, VET PARASITOL, V110, P171, DOI 10.1016/S0304-4017(02)00313-8; Hargrove JW, 1990, B ENTOMOL RES, V80, P1468; Hastings IM, 2004, TRENDS PARASITOL, V20, P512, DOI 10.1016/j.pt.2004.08.006; Hastings IM, 2001, TROP MED INT HEALTH, V6, P883, DOI 10.1046/j.1365-3156.2001.00800.x; Jones-Davies WJ, 1968, B EPIZOOT DIS AFR, P65; JONESDAVIES WJ, 1967, VET REC, V81, P567, DOI 10.1136/vr.81.22.567; Kaur G, 2000, ACTA VET HUNG, V48, P187; Lloyd LL, 1924, B ENTOMOL RES, V14, P225; Mackinnon MJ, 2005, ACTA TROP, V94, P207, DOI 10.1016/j.actatropica.2005.04.006; Mamoudou A, 2008, ACTA TROP, V106, P115, DOI 10.1016/j.actatropica.2008.02.003; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Mattioli RC, 2004, FOOD AGR ENV FOOD AG, P310; McKenzie FE, 2006, PLOS MED, V3, pe141, DOI [10.1371/journal.pmed.0030141, DOI 10.1371/JOURNAL.PMED.0030141]; PEREGRINE AS, 1993, ACTA TROP, V54, P185, DOI 10.1016/0001-706X(93)90092-P; Sinyangwe L, 2004, VET PARASITOL, V119, P125, DOI 10.1016/j.vetpar.2003.11.007; Van den Bossche P, 2000, ACTA TROP, V75, P247, DOI 10.1016/S0001-706X(00)00059-0; Van den Bossche P, 2011, PARASITE IMMUNOL, V33, P456, DOI 10.1111/j.1365-3024.2010.01277.x; Vitouley HS, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001223; Whiteside EF, 1962, E AFR AGR J, P6773	28	20	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2011	5	12							e1454	10.1371/journal.pntd.0001454				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	870KI	WOS:000298667700048	22206039	DOAJ Gold, Green Published			2019-03-26	
J	Levecke, B; Speybroeck, N; Dobson, RJ; Vercruysse, J; Charlier, J				Levecke, Bruno; Speybroeck, Niko; Dobson, Robert J.; Vercruysse, Jozef; Charlier, Johannes			Novel Insights in the Fecal Egg Count Reduction Test for Monitoring Drug Efficacy against Soil-Transmitted Helminths in Large-Scale Treatment Programs	PLOS NEGLECTED TROPICAL DISEASES			English	Article							KATO-KATZ; ANTHELMINTIC RESISTANCE; PUBLIC-HEALTH; DIAGNOSIS; INFECTIONS; HOOKWORM; FLOTAC; ALBENDAZOLE; SENSITIVITY; TRICHURIS	Background: The fecal egg count reduction test (FECRT) is recommended to monitor drug efficacy against soil-transmitted helminths (STHs) in public health. However, the impact of factors inherent to study design (sample size and detection limit of the fecal egg count (FEC) method) and host-parasite interactions (mean baseline FEC and aggregation of FEC across host population) on the reliability of FECRT is poorly understood. Methodology/Principal Findings: A simulation study was performed in which FECRT was assessed under varying conditions of the aforementioned factors. Classification trees were built to explore critical values for these factors required to obtain conclusive FECRT results. The outcome of this analysis was subsequently validated on five efficacy trials across Africa, Asia, and Latin America. Unsatisfactory (<85.0%) sensitivity and specificity results to detect reduced efficacy were found if sample sizes were small (<10) or if sample sizes were moderate (10-49) combined with highly aggregated FEC (k<0.25). FECRT remained inconclusive under any evaluated condition for drug efficacies ranging from 87.5% to 92.5% for a reduced-efficacy-threshold of 90% and from 92.5% to 97.5% for a threshold of 95%. The most discriminatory study design required 200 subjects independent of STH status (including subjects who are not excreting eggs). For this sample size, the detection limit of the FEC method and the level of aggregation of the FEC did not affect the interpretation of the FECRT. Only for a threshold of 90%, mean baseline FEC <150 eggs per gram of stool led to a reduced discriminatory power. Conclusions/Significance: This study confirms that the interpretation of FECRT is affected by a complex interplay of factors inherent to both study design and host-parasite interactions. The results also highlight that revision of the current World Health Organization guidelines to monitor drug efficacy is indicated. We, therefore, propose novel guidelines to support future monitoring programs.	[Levecke, Bruno; Vercruysse, Jozef; Charlier, Johannes] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium; [Speybroeck, Niko] Catholic Univ Louvain, Inst Hlth & Soc, B-1348 Louvain, Belgium; [Dobson, Robert J.] Murdoch Univ, Sch Vet & Biomed Sci, Div Hlth Sci, Murdoch, WA 6150, Australia	Levecke, B (reprint author), Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium.	Bruno.Levecke@UGent.be	Charlier, Johannes/A-6487-2009	Charlier, Johannes/0000-0002-1332-1458; Levecke, Bruno/0000-0001-8912-5595	Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine (Ghent University); Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) [G.0853.09]; agency for Innovation by Science and Technology of Flanders (IWT Vlaanderen) [OZM090697]	This investigation was supported by the Department of Virology, Parasitology and Immunology, Faculty of Veterinary Medicine (Ghent University). BL is funded by the Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) (www.fwo.be, Ref Nr G.0853.09). JC is supported by the agency for Innovation by Science and Technology of Flanders (IWT Vlaanderen, www.iwt.be, projectOZM090697). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albonico M, 2004, INT J PARASITOL, V34, P1205, DOI 10.1016/j.ijpara.2004.08.001; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Bogoch II, 2006, EUR J CLIN MICROBIOL, V25, P344, DOI 10.1007/s10096-006-0135-x; Breiman L, 1984, CLASSIFICATION REGRE; COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U; Cringoli G, 2004, VET PARASITOL, V123, P121, DOI 10.1016/j.vetpar.2004.05.021; Cringoli G, 2010, NAT PROTOC, V5, P503, DOI 10.1038/nprot.2009.235; DeClercq D, 1997, AM J TROP MED HYG, V57, P25, DOI 10.4269/ajtmh.1997.57.25; Diawara A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000397; Dobson RJ, 2009, VET PARASITOL, V161, P162, DOI 10.1016/j.vetpar.2008.12.007; El-Abdellati A, 2010, VET PARASITOL, V169, P352, DOI 10.1016/j.vetpar.2010.01.015; Engels D, 1997, TROP MED INT HEALTH, V2, P265, DOI 10.1046/j.1365-3156.1997.d01-264.x; Geerts S, 2001, TROP MED INT HEALTH, V6, P915, DOI 10.1046/j.1365-3156.2001.00774.x; Habib I, 2008, J APPL MICROBIOL, V105, P2002, DOI 10.1111/j.1365-2672.2008.03902.x; Humphries D, 2011, AM J TROP MED HYG, V84, P792, DOI 10.4269/ajtmh.2011.11-0003; Keiser J, 2008, JAMA-J AM MED ASSOC, V299, P1937, DOI 10.1001/jama.299.16.1937; Knopp S, 2009, T ROY SOC TROP MED H, V103, P1190, DOI 10.1016/j.trstmh.2009.05.012; Kotze AC, 2009, PLOS NEGLECT TROP D, V2, pe297; Levecke B, 2011, T R SOC MED IN PRESS; Levecke B, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000366; Levecke B, 2011, PARASITOL RES, V109, P953, DOI 10.1007/s00436-011-2338-z; Levecke B, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001201; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; *MIN AGR FISH FOOD, 1986, MAN VET PAR LAB TECH; Pereckiene A, 2007, VET PARASITOL, V149, P111, DOI 10.1016/j.vetpar.2007.04.014; Saegerman C, 2004, J CLIN MICROBIOL, V42, P172, DOI 10.1128/JCM.42.1.172-178.2004; Speich B, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-71; Tsai CL, 2010, AM J EMERG MED, V28, P803, DOI 10.1016/j.ajem.2009.04.009; Vercruysse J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000948; WHO, 2005, WHOCDSCPEPVC200514, P14; WHO, 1999, WHOCDSCPCSIP991, P8; WHO, 1991, BAS LAB METH MED PAR, P25; World Health Organization, 2006, PREV CHEM HUM HELM; World Health Organization (WHO), 2010, WHOHTMNTD20101	34	13	13	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2011	5	12							e1427	10.1371/journal.pntd.0001427				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	870KI	WOS:000298667700032	22180801	DOAJ Gold, Green Published			2019-03-26	
J	Nwaka, S; Besson, D; Ramirez, B; Maes, L; Matheeussen, A; Bickle, Q; Mansour, NR; Yousif, F; Townson, S; Gokool, S; Cho-Ngwa, F; Samje, M; Misra-Bhattacharya, S; Murthy, PK; Fakorede, F; Paris, JM; Yeates, C; Ridley, R; Van Voorhis, WC; Geary, T				Nwaka, Solomon; Besson, Dominique; Ramirez, Bernadette; Maes, Louis; Matheeussen, An; Bickle, Quentin; Mansour, Nuha R.; Yousif, Fouad; Townson, Simon; Gokool, Suzanne; Cho-Ngwa, Fidelis; Samje, Moses; Misra-Bhattacharya, Shailja; Murthy, P. K.; Fakorede, Foluke; Paris, Jean-Marc; Yeates, Clive; Ridley, Robert; Van Voorhis, Wesley C.; Geary, Timothy			Integrated Dataset of Screening Hits against Multiple Neglected Disease Pathogens	PLOS NEGLECTED TROPICAL DISEASES			English	Article							DRUG DISCOVERY; IN-VITRO; PLASMODIUM-FALCIPARUM; CHAGAS-DISEASE; MALARIA; IDENTIFICATION; CHALLENGES; ASSAY; SCHISTOSOMIASIS; LEISHMANIASIS	New chemical entities are desperately needed that overcome the limitations of existing drugs for neglected diseases. Screening a diverse library of 10,000 drug-like compounds against 7 neglected disease pathogens resulted in an integrated dataset of 744 hits. We discuss the prioritization of these hits for each pathogen and the strong correlation observed between compounds active against more than two pathogens and mammalian cell toxicity. Our work suggests that the efficiency of early drug discovery for neglected diseases can be enhanced through a collaborative, multi-pathogen approach.	[Nwaka, Solomon; Besson, Dominique; Ramirez, Bernadette; Fakorede, Foluke; Ridley, Robert] World Hlth Org, Special Programme Res & Training Trop Dis, Geneva, Switzerland; [Nwaka, Solomon; Fakorede, Foluke] United Nations Econ Commiss Africa, African Network Drugs & Diagnost Innovat, Addis Ababa, Ethiopia; [Maes, Louis; Matheeussen, An] Univ Antwerp, B-2020 Antwerp, Belgium; [Bickle, Quentin; Mansour, Nuha R.] London Sch Hyg & Trop Med, London WC1, England; [Yousif, Fouad] Theodor Bilharz Res Inst, Cairo, Egypt; [Townson, Simon; Gokool, Suzanne] Northwick Pk Inst Med Res, Harrow, Middx, England; [Cho-Ngwa, Fidelis; Samje, Moses] Univ Buea, Buea, Cameroon; [Misra-Bhattacharya, Shailja; Murthy, P. K.] Cent Drug Res Inst, Lucknow 226001, Uttar Pradesh, India; [Paris, Jean-Marc] Ecole Natl Super Chim Paris, F-75231 Paris 05, France; [Yeates, Clive] InPharma Consultancy, Welwyn Garden City, Herts, England; [Van Voorhis, Wesley C.] Univ Washington, Seattle, WA 98195 USA; [Geary, Timothy] McGill Univ, Montreal, PQ, Canada	Nwaka, S (reprint author), World Hlth Org, Special Programme Res & Training Trop Dis, Geneva, Switzerland.	nwakas@who.int			WHO	Work produced was entirely supported by WHO public funds; no grants or external funding was used to maintain activities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Sattar E, 2010, PHYTOTHER RES, V24, P1322, DOI 10.1002/ptr.3108; Aguero F, 2008, NAT REV DRUG DISCOV, V7, P900, DOI 10.1038/nrd2684; Baniecki ML, 2007, ANTIMICROB AGENTS CH, V51, P716, DOI 10.1128/AAC.01144-06; Bin L, 2010, J AGR FOOD CHEM, V58, P2673, DOI 10.1021/jf902639x; Bost F, 2010, CURR OPIN DRUG DISC, V13, P286; BUCKNER FS, ADV EXPT MED BIOL, V625, pCH6; Caffrey CR, 2008, EXPERT OPIN DRUG DIS, V3, P173, DOI 10.1517/17460441.3.2.173; Charman SA, 2011, P NATL ACAD SCI USA, V108, P4400, DOI 10.1073/pnas.1015762108; Cos P, 2006, J ETHNOPHARMACOL, V106, P290, DOI 10.1016/j.jep.2006.04.003; Crowther GJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000804; Ekins S, 2010, MOL BIOSYST, V6, P2316, DOI 10.1039/c0mb00104j; Engel JC, 2010, ANTIMICROB AGENTS CH, V54, P3326, DOI 10.1128/AAC.01777-09; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Gamo FJ, 2010, NATURE, V465, P305, DOI 10.1038/nature09107; Geary TG, 2009, DRUG DISCOV INFEC DI, V1, P3; Geary TG, 2010, INT J PARASITOL, V40, P1, DOI 10.1016/j.ijpara.2009.11.001; GREENWOOD D, 1995, J ANTIMICROB CHEMOTH, V36, P857, DOI 10.1093/jac/36.5.857; Guiguemde WA, 2010, NATURE, V465, P311, DOI 10.1038/nature09099; Gutteridge WE, 2006, T ROY SOC TROP MED H, V100, pS21, DOI 10.1016/j.trstmh.2006.02.013; Hudson A, 2007, EXPERT OPIN DRUG DIS, V2, pS3, DOI 10.1517/17460441.2.S1.S3; JAKOBSEN P, 2011, PLOS NEGL TROP DIS, V5; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lucumi E, 2010, ANTIMICROB AGENTS CH, V54, P3597, DOI 10.1128/AAC.00431-10; Maes L, 2004, ANTIMICROB AGENTS CH, V48, P130, DOI 10.1128/AAC.48.1.130-136.2004; Mansour NR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000795; Murray HW, 2010, FUTURE MICROBIOL, V5, P1301, DOI 10.2217/FMB.10.92; Nwaka S, 2003, NAT REV DRUG DISCOV, V2, P919, DOI 10.1038/nrd.1230; Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144; Nwaka S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000293; Nwaka S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000440; PicaMattoccia L, 1997, PARASITOL RES, V83, P687, DOI 10.1007/s004360050320; Plouffe D, 2008, P NATL ACAD SCI USA, V105, P9059, DOI 10.1073/pnas.0802982105; Ramirez B, 2007, EXPERT OPIN DRUG DIS, V2, pS53, DOI 10.1517/17460441.2.S1.S53; Ridley R, 2007, B WORLD HEALTH ORGAN, V85, P509; Rottmann M, 2010, SCIENCE, V329, P1175, DOI 10.1126/science.1193225; Sayed AA, 2008, NAT MED, V14, P407, DOI 10.1038/nm1737; Townson S, 2007, EXPERT OPIN DRUG DIS, V2, pS63, DOI 10.1517/17460441.2.S1.S63; Valdes AFC, 2008, MEM I OSWALDO CRUZ, V103, P615, DOI 10.1590/S0074-02762008000600019; Vik A, 2009, MOLECULES, V14, P279, DOI 10.3390/molecules14010279; *WHO, 2009, WHO ANN REP 2009 DRU	40	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2011	5	12							e1412	10.1371/journal.pntd.0001412				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	870KI	WOS:000298667700018	22247786	DOAJ Gold, Green Published			2019-03-26	
J	Phanzu, DM; Suykerbuyk, P; Imposo, DBB; Lukanu, PN; Minuku, JBM; Lehman, LF; Saunderson, P; de Jong, BC; Lutumba, PT; Portaels, F; Boelaert, M				Phanzu, Delphin Mavinga; Suykerbuyk, Patrick; Imposo, Desire Bofunga B.; Lukanu, Philippe Ngwala; Minuku, Jean-Bedel Masamba; Lehman, Linda F.; Saunderson, Paul; de Jong, Bouke C.; Lutumba, Pascal Tshindele; Portaels, Francoise; Boelaert, Marleen			Effect of a Control Project on Clinical Profiles and Outcomes in Buruli Ulcer: A Before/After Study in Bas-Congo, Democratic Republic of Congo	PLOS NEGLECTED TROPICAL DISEASES			English	Article							MYCOBACTERIUM-ULCERANS; SOUTHERN BENIN; DISEASE; GHANA; INFECTION	Background: Buruli ulcer (BU) is a necrotizing bacterial infection of skin, subcutaneous tissue and bone caused by Mycobacterium ulcerans. Although the functional impairment caused by BU results in severe suffering and in socioeconomic problems, the disease remains largely neglected in Africa. The province of Bas-Congo in Democratic Republic of Congo contains one of the most important BU foci of the country, i.e. the Songololo Territory in the District of Cataractes. This study aims to assess the impact of a BU control project launched in 2004 in the Songololo Territory. Methods: We used a comparative non-randomized study design, comparing clinical profiles and outcomes of the group of patients admitted at the General Reference Hospital (GRH) of the "Institut Medical Evangelique" (IME) of Kimpese 3 years before the start of the project (2002-2004) with those admitted during the 3 years after the start of the project (2005-2007). Results: The BU control project was associated with a strong increase in the number of admitted BU cases at the GRH of IME/Kimpese and a fundamental change in the profile of those patients; more female patients presented with BU, the proportion of relapse cases amongst all admissions reduced, the proportion of early lesions and simple ulcerative forms increased, more patients healed without complications and the case fatality rate decreased substantially. The median duration since the onset of first symptoms however remained high, as well as the proportion of patients with osteomyelitis or limitations of joint movement, suggesting that the diagnostic delay remains substantial. Conclusion: Implementing a specialized program for BU may be effective in improving clinical profiles and outcomes in BU. Despite these encouraging results, our study highlights the need of considering new strategies to better improve BU control in a low resources setting.	[Phanzu, Delphin Mavinga; Imposo, Desire Bofunga B.] Gen Reference Hosp Kimpese, Inst Med Evangel, Kimpese, Bas Congo, DEM REP CONGO; [Suykerbuyk, Patrick; de Jong, Bouke C.; Portaels, Francoise] Inst Trop Med, Mycobacteriol Unit, Dept Microbiol, B-2000 Antwerp, Belgium; [Lukanu, Philippe Ngwala] Cent Off Rural Hlth Zone Kimpese, Bas Congo, DEM REP CONGO; [Minuku, Jean-Bedel Masamba] Cent Off Rural Hlth Zone Nsona Mpangu, Bas Congo, DEM REP CONGO; [Lehman, Linda F.; Saunderson, Paul] Amer Leprosy Missions, Greenville, SC USA; [Lutumba, Pascal Tshindele] Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO; [Phanzu, Delphin Mavinga; Boelaert, Marleen] Inst Trop Med, Unit Epidemiol & Dis Control, Dept Publ Hlth, B-2000 Antwerp, Belgium	Phanzu, DM (reprint author), Gen Reference Hosp Kimpese, Inst Med Evangel, Kimpese, Bas Congo, DEM REP CONGO.	portaels@itg.be	de Jong, Bouke/A-3636-2013; Boelaert, Marleen/E-2698-2012	de Jong, Bouke/0000-0002-1017-4675; Boelaert, Marleen/0000-0001-8051-6776	American Leprosy Missions (Greenville, South Carolina, United States of America); European Commission [INCO-CT-2005-05-051476-BURULICO]	This study was supported by the American Leprosy Missions (Greenville, South Carolina, United States of America), the European Commission (International Science and Technology Cooperation Development Program), Project No. INCO-CT-2005-05-051476-BURULICO and the Directorate General for Development and Cooperation (Brussels, Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSEN F O, 1965, Cent Afr J Med, V11, P131; Asiedu K, 1998, AM J TROP MED HYG, V59, P1015, DOI 10.4269/ajtmh.1998.59.1015; ASIEDU K, 2000, WHOCDSCPEGBUI20011; Aujoulat I, 2003, TROP MED INT HEALTH, V8, P750, DOI 10.1046/j.1365-3156.2003.01089.x; AUJOULAT I, 1996, DEV SANTE, V125, P22; Debacker M, 2004, EMERG INFECT DIS, V10, P1391, DOI 10.3201/eid1008.030886; Eddyani M, 2008, J CLIN MICROBIOL, V46, P69, DOI 10.1128/JCM.00301-07; Etuaful S, 2005, ANTIMICROB AGENTS CH, V49, P3182, DOI 10.1128/AAC.49.8.3182-3186.; Grietens KP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000321; Habicht JP, 1999, INT J EPIDEMIOL, V28, P10, DOI 10.1093/ije/28.1.10; Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142; Johnson PDR, 2005, PLOS MED, V2, P282, DOI 10.1371/journal.pmed.00201108; Johnson R C, 2004, Med Trop (Mars), V64, P145; KIBADI K, 2003, CAHIERS SANTE, V13, P39; Kibadi K, 2009, TROP MED INT HEALTH, V14, P1110, DOI 10.1111/j.1365-3156.2009.02324.x; Meyers W M, 1974, Ann Soc Belg Med Trop, V54, P147; Mulder AA, 2008, T ROY SOC TROP MED H, V102, P912, DOI 10.1016/j.trstmh.2008.05.026; Nienhuis WA, 2010, LANCET, V375, P664, DOI 10.1016/S0140-6736(09)61962-0; Noeske J, 2004, AM J TROP MED HYG, V70, P520, DOI 10.4269/ajtmh.2004.70.520; Phanzu DM, 2006, AM J TROP MED HYG, V75, P311, DOI 10.4269/ajtmh.2006.75.311; PORTAELS F, 1989, ANN SOC BELG MED TR, V69, P91; Portaels F., 2001, WHOCDSCPEGBUI20014; PORTAELS F, 2008, B ALLF, V23, P48; Portaels F, 2009, CLIN DERMATOL, V27, P291, DOI 10.1016/j.clindermatol.2008.09.021; Renzaho AMN, 2007, TROP MED INT HEALTH, V12, P445, DOI 10.1111/j.1365-3156.2006.01795.x; Sizaire V, 2006, LANCET INFECT DIS, V6, P288, DOI 10.1016/S1473-3099(06)70464-9; SMITH JH, 1970, AM J TROP MED HYG, V19, P657, DOI 10.4269/ajtmh.1970.19.657; Stienstra Y, 2002, AM J TROP MED HYG, V67, P207, DOI 10.4269/ajtmh.2002.67.207; *WHO, 2004, WHOCDSCPEGBUI200410; WHO, 2008, WKLY EPIDEMIOL REC, V83, P145	30	15	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2011	5	12							e1402	10.1371/journal.pntd.0001402				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	870KI	WOS:000298667700012	22216362	DOAJ Gold, Green Published			2019-03-26	
J	Uranw, S; Ostyn, B; Rijal, A; Devkota, S; Khanal, B; Menten, J; Boelaert, M; Rijal, S				Uranw, Surendra; Ostyn, Bart; Rijal, Arpana; Devkota, Saru; Khanal, Basudha; Menten, Joris; Boelaert, Marleen; Rijal, Suman			Post-Kala-azar Dermal Leishmaniasis in Nepal: A Retrospective Cohort Study (2000-2010)	PLOS NEGLECTED TROPICAL DISEASES			English	Article							VISCERAL LEISHMANIASIS; DIAGNOSIS; PKDL; TRANSMISSION; ELIMINATION; BANGLADESH; SUDAN	Introduction: Post-kala-azar dermal leishmaniasis (PKDL) is a cutaneous complication appearing after treatment of visceral leishmaniasis, and PKDL patients are considered infectious to sand flies and may therefore play a role in the transmission of VL. We estimated the risk and risk factors of PKDL in patients with past VL treatment in south-eastern Nepal. Methods: Between February and May 2010 we traced all patients who had received VL treatment during 2000-2009 in five high-endemic districts and screened them for PKDL-like skin lesions. Suspected cases were referred to a tertiary care hospital for confirmation by parasitology (slit skin smear (SSS)) and/or histopathology. We calculated the risk of PKDL using Kaplan-Meier survival curves and exact logistic regression for risk factors. Results: Out of 680 past-treated VL patients, 37(5.4%) presented active skin lesions suspect of PKDL during the survey. Thirty-three of them underwent dermatological assessment, and 16 (2.4%) were ascertained as probable (2) or confirmed (14) PKDL. Survival analysis showed a 1.4% risk of PKDL within 2 years of VL treatment. All 16 had been previously treated with sodium stibogluconate (SSG) for their VL. In 5, treatment had not been completed (<= 21 injections). Skin lesions developed after a median time interval of 23 months [interquartile range (IQR) 16-40]. We found a higher PKDL rate (29.4%) in those inadequately treated compared to those who received a full SSG course (2.0%). In the logistic regression model, unsupervised treatment [odds ratio (OR) = 8.58, 95% CI 1.21-374.77], and inadequate SSG treatment for VL in the past (OR = 11.68, 95% CI 2.71-45.47) were significantly associated with PKDL. Conclusion: The occurrence of PKDL after VL treatment in Nepal is low compared to neighboring countries. Supervised and adequate treatment of VL seems essential to reduce the risk of PKDL development and active surveillance for PKDL is needed.	[Uranw, Surendra; Devkota, Saru; Rijal, Suman] BP Koirala Inst Hlth Sci, Dept Internal Med, Ghopa, Dharan, Nepal; [Uranw, Surendra; Ostyn, Bart; Menten, Joris; Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Rijal, Arpana] BP Koirala Inst Hlth Sci, Dept Dermatol, Ghopa, Dharan, Nepal; [Khanal, Basudha] BP Koirala Inst Hlth Sci, Dept Microbiol, Ghopa, Dharan, Nepal	Uranw, S (reprint author), BP Koirala Inst Hlth Sci, Dept Internal Med, Ghopa, Dharan, Nepal.	bostyn@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	European Union, Belgium [93040]	The study was supported by the European Union funded Visceral Leishmaniasis Control Project (Proposal Contract number 93040; FP6/INCO-DEV), Belgium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADDY M, 1992, B WORLD HEALTH ORGAN, V70, P341; Bern C, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000313; Bern C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000599; Croft SL, 2008, INDIAN J MED RES, V128, P10; Das M. L., 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P619; Das VNR, 2009, AM J TROP MED HYG, V80, P336, DOI 10.4269/ajtmh.2009.80.336; Desjeux P, 2001, T ROY SOC TROP MED H, V95, P239, DOI 10.1016/S0035-9203(01)90223-8; Desjeux P, 2011, POSTKALAAZAR DERMAL, P111, DOI [10.1007/978-94-007-0277-6_11, DOI 10.1007/978-94-007-0277-6_11]; El Hassan AM, 2001, TROP MED INT HEALTH, V6, P743, DOI 10.1046/j.1365-3156.2001.00776.x; Ganguly S, 2010, INT J DERMATOL, V49, P921, DOI 10.1111/j.1365-4632.2010.04558.x; Garg VK, 2001, INT J DERMATOL, V40, P179, DOI 10.1046/j.1365-4362.2001.01198.x; Karki P., 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P22; Mondal D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000355; Mondal D, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000832; Mubayi A, 2010, J THEOR BIOL, V262, P177, DOI 10.1016/j.jtbi.2009.09.012; Musa AM, 2002, ANN TROP MED PARASIT, V96, P765, DOI 10.1179/000349802125002211; Rahman KM, 2010, CLIN INFECT DIS, V50, P73, DOI 10.1086/648727; RAMESH V, 1995, INT J DERMATOL, V34, P85, DOI 10.1111/j.1365-4362.1995.tb03584.x; Rijal A, 2005, INT J DERMATOL, V44, P494, DOI 10.1111/j.1365-4632.2004.02433.x; Salotra P, 2006, INDIAN J MED RES, V123, P295; World Health Organization, 2005, 1 M MAN HAAR 20 23 D; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6; Zijlstra EE, 2000, BRIT J DERMATOL, V143, P136, DOI 10.1046/j.1365-2133.2000.03603.x; ZIJLSTRA EE, 1995, AM J TROP MED HYG, V52, P299, DOI 10.4269/ajtmh.1995.52.299	24	18	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2011	5	12							e1433	10.1371/journal.pntd.0001433				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	870KI	WOS:000298667700036	22206030	DOAJ Gold, Green Published			2019-03-26	
J	Phanzu, DM; Mahema, RL; Suykerbuyk, P; Imposo, DHB; Lehman, LF; Nduwamahoro, E; Meyers, WM; Boelaert, M; Portaels, F				Phanzu, Delphin M.; Mahema, Roger L.; Suykerbuyk, Patrick; Imposo, Desire-Hubert B.; Lehman, Linda F.; Nduwamahoro, Elie; Meyers, Wayne M.; Boelaert, Marleen; Portaels, Francoise			Mycobacterium ulcerans Infection (Buruli Ulcer) on the Face: A Comparative Analysis of 13 Clinically Suspected Cases from the Democratic Republic of Congo	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							RISK-FACTORS; DISEASE; GHANA; CAMEROON; EPIDEMIOLOGY; UGANDA; BENIN	We report our experience in managing 13 consecutive clinically suspected cases of Buruli ulcer on the face treated at the hospital of the Institut Medical Evangelique at Kimpese, Democratic Republic of Congo diagnosed during 2003-2007. During specific antibiotherapy, facial edema diminished, thus minimizing the subsequent extent of surgery and severe disfigurations. The following complications were observed: 1) lagophthalmos from scarring in four patients and associated ectropion in three of them; 2) blindness in one eye in one patient; 3) disfiguring exposure of teeth and gums resulting from excision of the left labial commissure that affected speech, drinking, and eating in one patient; and 4) dissemination of Mycobacterium ulcerans infection in three patients. Our study highlights the importance of this clinical presentation of Buruli ulcer, and the need for health workers in disease-endemic areas to be aware of the special challenges management of Buruli ulcer on the face presents.	[Suykerbuyk, Patrick; Nduwamahoro, Elie; Portaels, Francoise] Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, B-2000 Antwerp, Belgium; [Phanzu, Delphin M.; Boelaert, Marleen] Inst Trop Med, Epidemiol & Dis Control Unit, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Phanzu, Delphin M.; Mahema, Roger L.; Imposo, Desire-Hubert B.] Kimpese Hosp, Inst Med Evangel, Kimpese, Bas Congo, Zaire; [Lehman, Linda F.] Amer Leprosy Missions, Greenville, SC USA; [Meyers, Wayne M.] Armed Forces Inst Pathol, Dept Environm & Infect Dis Sci, Washington, DC 20306 USA	Portaels, F (reprint author), Inst Trop Med, Dept Microbiol, Mycobacteriol Unit, Natl Str 155, B-2000 Antwerp, Belgium.	dmavingaphanzu@yahoo.fr; mahemalut@yahoo.fr; psuykerbuyk.acolson@gmail.com; imposodesire@yahoo.fr; lehman@uaigiga.com.br; enduwamahoro@itg.br; wmekmeyers@comcast.net; mboelaert@itg.be; portaels@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	American Leprosy Missions (Greenville, SC); European Commission [INCO-CT-2005-05-051476-BURULICO]	This study was supported by the American Leprosy Missions (Greenville, SC) and the European Commission (International Science and Technology Cooperation Development Program), Project No. INCO-CT-2005-05-051476-BURULICO.	Addo HA, 1995, GHANA MED J, V29, P595; Aguiar J, 1997, B SEANCES ACAD R SCI, V3, P325; Amofah G, 2002, EMERG INFECT DIS, V8, P167, DOI 10.3201/eid0802.010119; [Anonymous], 2008, Wkly Epidemiol Rec, V83, P145; [Anonymous], 2004, Wkly Epidemiol Rec, V79, P194; Asiedu K, 1998, AM J TROP MED HYG, V59, P1015, DOI 10.4269/ajtmh.1998.59.1015; ASIEDU K, 2000, BURULI ULCER MYCOBAC; AUJOULAT I, 1996, DEV SANTE, V125, P22; Bafende AE, 2004, TROP DOCT, V34, P82, DOI 10.1177/004947550403400207; BARKER DJP, 1971, J TROP MED HYG, V74, P260; BARKER DJP, 1972, T ROY SOC TROP MED H, V66, P867, DOI 10.1016/0035-9203(72)90121-6; CONNOR DH, 1966, ARCH PATHOL, V81, P183; DARIE H, 1993, B SOC PATHOL EXOT, V86, P272; Debacker M, 2004, TROP MED INT HEALTH, V9, P1297, DOI 10.1111/j.1365-3156.2004.01339.x; Eddyani M, 2008, J CLIN MICROBIOL, V46, P69, DOI 10.1128/JCM.00301-07; Eddyani M, 2009, J CLIN MICROBIOL, V47, P1700, DOI 10.1128/JCM.00197-09; En J, 2008, INFECT IMMUN, V76, P2002, DOI 10.1128/IAI.01588-07; Hospers IC, 2005, T ROY SOC TROP MED H, V99, P196, DOI 10.1016/j.trstmh.2004.05.004; James K, 2003, CAH SANTE, V13, P43; Janssens P, 2005, B SEANCES ACAD R SCI, V51, P265; Johnson ND, 2007, EMERG INFECT DIS, V11, P1653; JOSSE R, 1994, B SOC PATHOL EXOT, V87, P170; Kibadi Kapay, 2003, Sante, V13, P39; Kibadi K, 2009, TROP MED INT HEALTH, V14, P1110, DOI 10.1111/j.1365-3156.2009.02324.x; Kouame K, 2008, Med Trop (Mars), V68, P643; Meyers W M, 1974, Ann Soc Belg Med Trop, V54, P147; MEYERS WM, 1995, TROPICAL PATHOLOGY, P291; Noeske J, 2004, AM J TROP MED HYG, V70, P520, DOI 10.4269/ajtmh.2004.70.520; OLUWASANMI JO, 1976, AM J TROP MED HYG, V25, P122, DOI 10.4269/ajtmh.1976.25.122; Ouattara D, 2003, Rev Stomatol Chir Maxillofac, V104, P231; Ouoba K, 1998, NOUV DERMATOL, V17, P358; Phanzu DM, 2006, AM J TROP MED HYG, V75, P311, DOI 10.4269/ajtmh.2006.75.311; Phanzu MD, 2007, AM J TROP MED HYG, V77, P1099; PORTAELS F, 1989, ANN SOC BELG MED TR, V69, P91; Portaels F, 2001, BURULI ULCER DIAGNOS; Portaels F, 2009, CLIN DERMATOL, V27, P291, DOI 10.1016/j.clindermatol.2008.09.021; Pouillot R, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000101; Raghunathan PL, 2005, CLIN INFECT DIS, V40, P1445, DOI 10.1086/429623; RAVISSE P, 1977, B SOC PATHOL EXOT, V70, P109; Reid I S, 1967, Med J Aust, V1, P427; Schierle HP, 2002, PLAST RECONSTR SURG, V109, P2608, DOI 10.1097/00006534-200206000-00088; Silva MT, 2009, LANCET INFECT DIS, V9, P699, DOI 10.1016/S1473-3099(09)70234-8; SMITH JH, 1970, AM J TROP MED HYG, V19, P657, DOI 10.4269/ajtmh.1970.19.657; Sopoh GE, 2007, EMERG INFECT DIS, V13, P1374, DOI 10.3201/eid1309.061338; Uganda Buruli Group, 1971, T R SOC TROP MED HYG, V65, P763; VANDERWERF TS, 1989, T ROY SOC TROP MED H, V83, P410, DOI 10.1016/0035-9203(89)90521-X; Vincent QB, 2014, BURULI ULCER PREVENT, V2, pe422; *WHO, 2004, WHOCDSCPEGBUI200410	48	5	5	0	3	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2011	85	6					1100	1105		10.4269/ajtmh.2011.10-0530				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	858FJ	WOS:000297781000026	22144452	Green Published, Bronze			2019-03-26	
J	van Griensven, J; Thai, S				van Griensven, Johan; Thai, Sopheak			Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						HIV; CD4 cell; Antiretroviral treatment; Predictors; Mortality; Cambodia	SUB-SAHARAN AFRICA; LOW-INCOME COUNTRIES; SOUTH-AFRICA; COLLABORATIVE ANALYSIS; HIV-1-INFECTED PATIENTS; INITIAL TREATMENT; HIV-1 INFECTION; SCALE-UP; THERAPY; PROGRAM	The objectives of this study were to examine the association of the on-treatment CD4 cell count with late mortality (after >6 months of antiretroviral treatment [ART]) and to identify the determinants of the long-term CD4 cell count evolution after treatment initiation. We conducted a retrospective analysis including all antiretroviral (ARV)-naive adults initiating ART in a tertiary hospital in Phnom Penh, Cambodia from 2003-2010. We used Cox proportional hazards modelling (mortality analysis), including time-updated CD4 counts, and mixed-effects modelling (CD4 response over time). Overall, 2840 patients were included (47% male, median age: 34 years, median baseline CD4 count: 78 cells/mu L). The median time on ART was 2.5 years (IQR 1.1-4.3); 71 patients died after >6 months of ART. The baseline CD4 count was the main determinant of the on-treatment CD4 cell count. Time-updated CD4 cell counts was the strongest determinant of late mortality with a HR of 0.32 (95% CI 0.16-0.63) and 0.29 (95% CI 0.11-0.71) for CD4 values of 200-350 cells/mu L and 350-500 cells/mu L respectively. We conclude that baseline CD4 counts strongly determine the long-term immune recovery, which critically affects late mortality. This calls for increased efforts for early ART initiation and availability of CD4 count testing in low-income countries. (C) 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[van Griensven, Johan] Inst Trop Med, B-2000 Antwerp, Belgium; [van Griensven, Johan; Thai, Sopheak] Sihanouk Hosp Ctr Hope, Phnom Penh, Cambodia	van Griensven, J (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	jvangriensven@itg.be			Belgian Directorate General of Development Cooperation; Institute of Tropical Medicine; Antwerp; Global Fund to fight AIDS; Tuberculosis and Malaria; Hope World Wide; Inbev-Baillet Latour Fund	The treatment program was supported by the Belgian Directorate General of Development Cooperation through the framework agreement with the Institute of Tropical Medicine, Antwerp, the Global Fund to fight AIDS, Tuberculosis and Malaria, and Hope World Wide. JvG is supported by the Inbev-Baillet Latour Fund.	Achhra AC, 2010, AIDS, V24, P1877, DOI 10.1097/QAD.0b013e32833b1b26; Althoff KN, 2010, AIDS; Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7; Braitstein P, 2006, LANCET, V367, P817; Carael M, 2009, JAIDS-J ACQ IMM DEF, V52, pS111, DOI 10.1097/QAI.0b013e3181baeec2; Cornell M, 2010, AIDS, V24, P2263, DOI 10.1097/QAD.0b013e32833d45c5; Engels EA, 2010, JAIDS-J ACQ IMM DEF, V54, P78, DOI 10.1097/01.qai.0000371677.48743.8d; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Falster K, 2009, AIDS, V23, P2323, DOI 10.1097/QAD.0b013e328331910c; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Justice Amy C, 2010, Curr HIV/AIDS Rep, V7, P69, DOI 10.1007/s11904-010-0041-9; Keiser O, 2008, PLOS MED, V5, P1102, DOI 10.1371/journal.pmed.0050148; Kipp W, 2010, AIDS CARE, V22, P271, DOI 10.1080/09540120903193625; Kirk JB, 2009, J AM GERIATR SOC, V57, P2129, DOI 10.1111/j.1532-5415.2009.02494.x; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095; Lawn SD, 2009, AIDS, V23, P335, DOI 10.1097/QAD.0b013e328321823f; Lynen L, 2009, JAIDS-J ACQ IMM DEF, V52, P40, DOI 10.1097/QAI.0b013e3181af6705; Marin B, 2009, AIDS, V23, P1743, DOI 10.1097/QAD.0b013e32832e9b78; May M, 2010, LANCET, V376, P449, DOI 10.1016/S0140-6736(10)60666-6; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Monforte AD, 2008, AIDS, V22, P2143, DOI 10.1097/QAD.0b013e3283112b77; Moore AL, 2003, JAIDS-J ACQ IMM DEF, V32, P452, DOI 10.1097/00126334-200304010-00017; Nachega JB, 2010, CURR OPIN HIV AIDS, V5, P70, DOI 10.1097/COH.0b013e328333ad61; Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9; Nicastri E, 2007, J ANTIMICROB CHEMOTH, V60, P724, DOI 10.1093/jac/dkm302; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Schechter M, 2006, J ANTIMICROB CHEMOTH, V58, P506, DOI 10.1093/jac/dkl263; Squires KE, 2000, AIDS, V14, P1591, DOI 10.1097/00002030-200007280-00015; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Thai S, 2009, TROP MED INT HEALTH, V14, P1048, DOI 10.1111/j.1365-3156.2009.02334.x; Toro PL, 2010, AIDS, V24, P515, DOI 10.1097/QAD.0b013e3283350ecd; Tuboi SH, 2010, JAIDS-J ACQ IMM DEF, V53, P70, DOI 10.1097/QAI.0b013e3181c22d19; UNAIDS, 2009, AIDS EP UPD DEC 2009; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; *WHO, 2003, SCAL ANT THER RES LT; *WHO, 2006, ANT THER HIV INF AD; World Health Organization, 2010, ANT THER HIV INF AD; Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0; Zachariah R, 2009, TROP MED INT HEALTH, V14, P713, DOI 10.1111/j.1365-3156.2009.02291.x	46	23	23	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	DEC	2011	105	12					694	703		10.1016/j.trstmh.2011.08.007				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	862DK	WOS:000298069800003	21962614				2019-03-26	
J	Levecke, B; Dreesen, L; Barrionuevo-Samaniego, M; Ortiz, WB; Praet, N; Brandt, J; Dorny, P				Levecke, B.; Dreesen, L.; Barrionuevo-Samaniego, M.; Ortiz, W. Benitez; Praet, N.; Brandt, J.; Dorny, P.			Molecular differentiation of Entamoeba spp. in a rural community of Loja province, South Ecuador	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Entamoeba histolytica; Ecuador; PCR-reverse line hybridization blot	HISTOLYTICA	Although previous epidemiological surveys in Ecuador indicate the presence of Entamoeba histolytica, prevalence data of this parasite remain scarce. Most of the studies were based on microscopic examination, which does not allow a morphological differentiation from the non-pathogenic Ent. dispar and Ent. moshkovskii. In the present study, 674 stool samples from a South Ecuadorian rural community were screened for Entamoeba spp. Subsequently, molecular identification was performed on 101 samples containing Ent. histolytica/Ent. dispar/Ent. moshkovskii cysts. The study indicated the absence of Ent. histolytica in this South Ecuadorian community and confirmed the difficulty of differentiating Entamoeba spp. based on morphological features. (C), 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Levecke, B.; Dreesen, L.] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, B-9820 Salisburylaan, Merelbeke, Belgium; [Barrionuevo-Samaniego, M.; Ortiz, W. Benitez] Univ Cent Ecuador, Ctr Int Zoonosis, Quito, Ecuador; [Praet, N.; Brandt, J.; Dorny, P.] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium	Levecke, B (reprint author), Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Salisburylaan 133, B-9820 Salisburylaan, Merelbeke, Belgium.	Bruno.Levecke@Ugent.be		Levecke, Bruno/0000-0001-8912-5595	Institute of Tropical Medicine in Antwerp; Centro Internacional de Zoonosis in Quito; Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen)	The fieldwork was supported by the Belgian Cooperation in the framework of the Institutional Collaboration between the Institute of Tropical Medicine in Antwerp and the Centro Internacional de Zoonosis in Quito. The work of BL has been financially supported by the Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen).	Gatti S, 2002, AM J TROP MED HYG, V67, P123, DOI 10.4269/ajtmh.2002.67.123; Kebede A, 2004, TROP MED INT HEALTH, V9, P651, DOI 10.1111/j.1365-3156.2004.01236.x; Levecke B, 2010, J Clin Microbiol, V48, P2988, DOI 10.1128/JCM.00013-10; Praet N, 2010, INT J PARASITOL, V40, P85, DOI 10.1016/j.ijpara.2009.07.007; Stauffer W, 2003, CURR OPIN INFECT DIS, V16, P479, DOI 10.1097/01.qco.0000092821.42392.ca	5	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	DEC	2011	105	12					737	739		10.1016/j.trstmh.2011.08.010				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	862DK	WOS:000298069800009	21981992				2019-03-26	
J	Peeters, E; Verhulst, S; Wojciechowski, M; Vlieghe, E; Jorens, P; Van Marck, V; Ramet, J; De Dooy, J				Peeters, Ellen; Verhulst, Stijn; Wojciechowski, Marek; Vlieghe, Erika; Jorens, Philippe; Van Marck, Veerle; Ramet, Jose; De Dooy, Jozef			Visceral Leishmaniasis in a Child Infected with the Human Immunodeficiency Virus in a Non-endemic Region	JOURNAL OF TROPICAL PEDIATRICS			English	Article						HIV; visceral leishmaniasis; amphotericin B; septic shock		We reported the case of a boy who fled from Chechnya to Belgium. He was diagnosed with a human immune deficiency virus (HIV)/Visceral leishmaniasis (VL) coinfection. In both countries, the prevalence of HIV-infected children is low and VL is not endemic. Migration of people results in confrontation with diseases that are not frequent in the countries of destination and becomes a challenge for pediatricians.	[Peeters, Ellen; Verhulst, Stijn; Jorens, Philippe; De Dooy, Jozef] Univ Antwerp, Dept Pediat Intens Care, Univ Antwerp Hosp, B-2020 Antwerp, Belgium; [Wojciechowski, Marek; Vlieghe, Erika] Univ Antwerp, Dept Trop Med, Univ Antwerp Hosp, B-2020 Antwerp, Belgium; [Wojciechowski, Marek; Ramet, Jose] Univ Antwerp, Dept Pediat, Univ Antwerp Hosp, B-2020 Antwerp, Belgium; [Van Marck, Veerle] Univ Antwerp, Dept Pathol, Univ Antwerp Hosp, B-2020 Antwerp, Belgium	De Dooy, J (reprint author), Univ Antwerp Hosp, Dept Pediat Intens Care, Wilrijkstr 10, B-2650 Edegem, Belgium.	jozef.de.dooy@uza.be	Verhulst, Stijn/B-1702-2008	Verhulst, Stijn/0000-0002-1922-9716			Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07; Cruz I, 2006, INDIAN J MED RES, V123, P357; Desjeux P, 2001, Med Trop (Mars), V61, P187; MASTROIANNI A, 2004, INFEZ MED, V3, P197; McIntosh N, 2008, FORFAR ARNEILS TXB P; Mofenson LM, 2005, CLIN INFECT DIS, V40, pS1, DOI 10.1086/427295; Paredes R, 2003, J Postgrad Med, V49, P39; Vecsei AKW, 2001, WIEN KLIN WOCHENSCHR, V113, P102; VIDYASHANKAR C, LEISHMANIASIS; *WHO EXP COMM CONT, PROGR PROJ	10	1	1	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0142-6338			J TROP PEDIATRICS	J. Trop. Pediatr.	DEC	2011	57	6					493	495		10.1093/tropej/fmr024				3	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	855OL	WOS:000297574000020	21367850	Bronze			2019-03-26	
J	Sinka, ME; Rubio-Palis, Y; Manguin, S; Patil, AP; Temperley, WH; Gething, PW; Van Boeckel, T; Kabaria, CW; Harbach, RE; Hay, SI				Sinka, Marianne E.; Rubio-Palis, Yasmin; Manguin, Sylvie; Patil, Anand P.; Temperley, Will H.; Gething, Peter W.; Van Boeckel, Thomas; Kabaria, Caroline W.; Harbach, Ralph E.; Hay, Simon I.			The dominant Anopheles vectors of human malaria in the Americas: occurrence data, distribution maps and bionomic precis (vol 3, pg 72, 2010)	PARASITES & VECTORS			English	Correction									[Sinka, Marianne E.; Patil, Anand P.; Temperley, Will H.; Gething, Peter W.; Van Boeckel, Thomas; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England; [Rubio-Palis, Yasmin] Univ Carabobo, BIOMED, Maracay 2101A, Venezuela; [Rubio-Palis, Yasmin] Minist Poder Popular Salud, Direcc Control Vectores & Fauna Nociva, Lab Ecol Vectores, Maracay, Venezuela; [Manguin, Sylvie] Univ Montpellier 1, Fac Pharm, Lab Immunophysiopathol Virale & Mol, Inst Rech Dev,UMR MD3, F-34093 Montpellier, France; [Van Boeckel, Thomas] Univ Libre Bruxelles, B-1050 Brussels, Belgium; [Kabaria, Caroline W.; Hay, Simon I.] Univ Oxford, Wellcome Trust Collaborat Programme, Kenyatta Natl Hosp Grounds,KEMRI, Malaria Publ Hlth & Epidemiol Grp,Ctr Geog Med, Nairobi, Kenya; [Harbach, Ralph E.] Nat Hist Museum, Dept Entomol, London SW7 5BD, England	Sinka, ME (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Tinbergen Bldg,S Parks Rd, Oxford OX1 3PS, England.	marianne.sinka@zoo.ox.ac.uk; simon.hay@zoo.ox.ac.uk	Manguin, Sylvie/G-1787-2015	Manguin, Sylvie/0000-0002-5925-7164; Gething, Peter/0000-0001-6759-5449			Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-72	1	0	0	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	NOV 3	2011	4								210	10.1186/1756-3305-4-210				2	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	849BU	WOS:000297101100001		DOAJ Gold, Green Published			2019-03-26	
J	Hermans, V; Monzote, L; Van den Sande, B; Mukadi, P; Sopheak, T; Gillet, P; Jacobs, J				Hermans, Veerle; Monzote, Lianet; Van den Sande, Bjorn; Mukadi, Pierre; Sopheak, Thai; Gillet, Philippe; Jacobs, Jan			Assessment of the knowledge of graphical symbols labelled on malaria rapid diagnostic tests in four international settings	MALARIA JOURNAL			English	Article						Graphical symbols; in vitro diagnostics; ISO 15223; malaria rapid diagnostic tests	COMPREHENSION; INSTRUCTIONS; PICTOGRAMS	Background: Graphical symbols on in vitro diagnostics (IVD symbols) replace the need for text in different languages and are used on malaria rapid diagnostic tests (RDTs) marketed worldwide. The present study assessed the comprehension of IVD symbols labelled on malaria RDT kits among laboratory staff in four different countries. Methods: Participants (n = 293) in Belgium (n = 96), the Democratic Republic of the Congo (DRC, n = 87), Cambodia (n = 59) and Cuba (n = 51) were presented with an anonymous questionnaire with IVD symbols extracted from ISO 15223 and EN 980 presented as stand-alone symbols (n = 18) and in context (affixed on RDT packages, n = 16). Responses were open-ended and scored for correctness by local professionals. Results: Presented as stand-alone, three and five IVD symbols were correctly scored for comprehension by 67% and 50% of participants; when contextually presented, five and seven symbols reached the 67% and 50% correct score respectively. 'Batch code' scored best (correctly scored by 71.3% of participants when presented as stand-alone), 'Authorized representative in the European Community' scored worst (1.4% correct). Another six IVD symbols were scored correctly by less than 10% of participants: 'Do not reuse', 'In vitro diagnostic medical device', 'Sufficient for', 'Date of manufacture', 'Authorised representative in EC', and 'Do not use if package is damaged'. Participants in Belgium and Cuba both scored six symbols above the 67% criterion, participants from DRC and Cambodia scored only two and one symbols above this criterion. Low correct scores were observed for safety-related IVD symbols, such as for 'Biological Risk' (42.7%) and 'Do not reuse' (10.9%). Conclusion: Comprehension of IVD symbols on RDTs among laboratory staff in four international settings was unsatisfactory. Administrative and outreach procedures should be undertaken to assure their acquaintance by endusers.	[Hermans, Veerle; Gillet, Philippe; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, Unit Trop Lab Med, B-2000 Antwerp, Belgium; [Monzote, Lianet] Inst Trop Med Pedro Kouri, Havana, Cuba; [Mukadi, Pierre] Inst Natl Rech Biomed, Kinshasa, Zaire; [Sopheak, Thai] Sihanouk Hosp Ctr HOPF, Phnom Penh, Cambodia; [Jacobs, Jan] Univ Maastricht, Fac Med & Hlth Sci, Dept Med Microbiol, Maastricht, Netherlands	Gillet, P (reprint author), Inst Trop Med, Dept Clin Sci, Unit Trop Lab Med, Natl Str 155, B-2000 Antwerp, Belgium.	pgillet@itg.be		gillet, philippe/0000-0001-5878-6446	Strategic Network on Laboratory Quality Management through the Belgian Directorate of Development Cooperation [SN3.21]	The research for this manuscript was funded by the Strategic Network on Laboratory Quality Management through the Belgian Directorate of Development Cooperation (Project SN3.21). The authors would like to thank the participants who volunteered their time for completing the questionnaires.	[Anonymous], 2007, 1522312007 ISO; Banda SF, 2006, SCI TOTAL ENVIRON, V363, P22, DOI 10.1016/j.scitotenv.2005.10.011; COWGILL J, 2003, SYMBOL USAGE HLTH CA; Dowse R, 2001, PATIENT EDUC COUNS, V45, P87, DOI 10.1016/S0738-3991(00)00197-X; Dowse R, 2004, S AFR J SCI, V100, P687; Dowse R, 2003, INT J PHARM PRACTICE, V11, P11, DOI DOI 10.1211/002235702810]; *EDMA, 2009, EDMA SYMB IVD REAG C; *EN, 2011, 9802008 EN; *FDA, 2004, US SYMB LAB LAB IN V; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-39; Hara K, 2007, J OCCUP HEALTH, V49, P260, DOI 10.1539/joh.49.260; Houts PS, 2006, PATIENT EDUC COUNS, V64, P393, DOI [10.1016/j.pec.2006.06.023, 10.1016/j.pec.2005.05.004]; *ISO, 2007, 9186 ISO; *ISO, 1984, 38641984 ISO; Kassam R, 2004, INT J PHARM PRACT, V12, P199; Katz MG, 2006, AM J HEALTH-SYST PH, V63, P2391, DOI 10.2146/ajhp060162; LIU H, 2005, WIEN OESTERREICHISCH, V81, P7; Morrow DG, 1998, J GERONTOL B-PSYCHOL, V53, pP240, DOI 10.1093/geronb/53B.4.P240; Smith-Jackson Tonya L, 2002, Int J Occup Saf Ergon, V8, P37; WOLFF JS, 1991, GEORGIA I TECHNOLOGY, V30	20	6	6	0	9	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	NOV 2	2011	10								331	10.1186/1475-2875-10-331				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	847PD	WOS:000296984000001	22047089	DOAJ Gold, Green Published			2019-03-26	
J	Stauch, A; Sarkar, RR; Picado, A; Ostyn, B; Sundar, S; Rijal, S; Boelaert, M; Dujardin, JC; Duerr, HP				Stauch, Anette; Sarkar, Ram Rup; Picado, Albert; Ostyn, Bart; Sundar, Shyam; Rijal, Suman; Boelaert, Marleen; Dujardin, Jean-Claude; Duerr, Hans-Peter			Visceral Leishmaniasis in the Indian Subcontinent: Modelling Epidemiology and Control	PLOS NEGLECTED TROPICAL DISEASES			English	Article							AZAR DERMAL LEISHMANIASIS; KALA-AZAR; DONOVANI INFECTION; VECTOR CONTROL; SAND FLIES; NEPAL; BANGLADESH; DIAGNOSIS; BIHAR; NETS	Background: In the Indian subcontinent, about 200 million people are at risk of developing visceral leishmaniasis (VL). In 2005, the governments of India, Nepal and Bangladesh started the first regional VL elimination program with the aim to reduce the annual incidence to less than 1 per 10,000 by 2015. A mathematical model was developed to support this elimination program with basic quantifications of transmission, disease and intervention parameters. This model was used to predict the effects of different intervention strategies. Methods and Findings: Parameters on the natural history of Leishmania infection were estimated based on a literature review and expert opinion or drawn from a community intervention trial (the KALANET project). The transmission dynamic of Leishmania donovani is rather slow, mainly due to its long incubation period and the potentially long persistence of parasites in infected humans. Cellular immunity as measured by the Leishmanin skin test (LST) lasts on average for roughly one year, and re-infection occurs in intervals of about two years, with variation not specified. The model suggests that transmission of L. donovani is predominantly maintained by asymptomatically infected hosts. Only patients with symptomatic disease were eligible for treatment; thus, in contrast to vector control, the treatment of cases had almost no effect on the overall intensity of transmission. Conclusions: Treatment of Kala-azar is necessary on the level of the individual patient but may have little effect on transmission of parasites. In contrast, vector control or exposure prophylaxis has the potential to efficiently reduce transmission of parasites. Based on these findings, control of VL should pay more attention to vector-related interventions. Cases of PKDL may appear after years and may initiate a new outbreak of disease; interventions should therefore be long enough, combined with an active case detection and include effective treatment.	[Stauch, Anette; Duerr, Hans-Peter] Univ Tubingen, Dept Med Biometry, Tubingen, Germany; [Sarkar, Ram Rup] Ctr Cellular & Mol Biol CSIR, Hyderabad, Andhra Pradesh, India; [Picado, Albert; Ostyn, Bart; Boelaert, Marleen; Dujardin, Jean-Claude] Inst Trop Med, B-2000 Antwerp, Belgium; [Sundar, Shyam] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Rijal, Suman] Koirala Inst Med Sci, Dharan, Nepal; [Dujardin, Jean-Claude] Univ Antwerp, Dept Biomed Sci, Lab Microbiol Parasitol & Hyg, B-2020 Antwerp, Belgium	Stauch, A (reprint author), Univ Tubingen, Dept Med Biometry, Tubingen, Germany.	hans-peter.duerr@uni-tuebingen.de	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Picado, Albert/0000-0001-7344-628X; Duerr, Hans-Peter/0000-0001-7289-6019	EU [EC-FP7-222895]	This investigation was funded by the EU project KalaDrug-R (EC-FP7-222895). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Martin Eichner for helpful discussions while developing this model, and Helmut Pitters for assistance in programming with Matlab.	ADDY M, 1992, B WORLD HEALTH ORGAN, V70, P341; ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; Ashford RW, 2000, INT J PARASITOL, V30, P1269, DOI 10.1016/S0020-7519(00)00136-3; Azzalini A, 1996, STAT INFERENCE BASED, P105; Bern C, 2007, AM J TROP MED HYG, V76, P909; Bern C, 2006, AM J TROP MED HYG, V75, P744, DOI 10.4269/ajtmh.2006.75.744; Bhattarai NR, 2009, T ROY SOC TROP MED H, V103, P1087, DOI 10.1016/j.trstmh.2009.03.008; Boelaert M, 2009, TROP MED INT HEALTH, V14, P639, DOI 10.1111/j.1365-3156.2009.02279.x; Brahmachari U N, 1922, Ind Med Gaz, V57, P125; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]; Das ML, 2010, ACTA TROP, V113, P162, DOI 10.1016/j.actatropica.2009.10.012; Deborggraeve S, 2008, TROP MED INT HEALTH, V13, P1378, DOI 10.1111/j.1365-3156.2008.02154.x; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; DYE C, 1992, PARASITOLOGY, V105, P35, DOI 10.1017/S0031182000073662; Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125; DYE C, 1992, PARASITOLOGY, V104, pS7, DOI 10.1017/S0031182000075211; DYE C, 1988, T ROY SOC TROP MED H, V82, P843, DOI 10.1016/0035-9203(88)90013-2; Gidwani K, 2011, CLIN VACCINE IMMUNOL, V18, P346, DOI 10.1128/CVI.00473-10; Gidwani K, 2009, AM J TROP MED HYG, V80, P345, DOI 10.4269/ajtmh.2009.80.345; Hailu A, 2009, ANN TROP MED PARASIT, V103, P659, DOI 10.1179/000349809X12554106963555; HATI AK, 1991, INDIAN J MED RES-A, V93, P388; Hurissa Z, 2010, TROP MED INT HEALTH, V15, P848, DOI 10.1111/j.1365-3156.2010.02550.x; Joshi AB, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-54; Lukes J, 2007, P NATL ACAD SCI USA, V104, P9375, DOI 10.1073/pnas.0703678104; Molina R, 1999, AM J TROP MED HYG, V60, P51, DOI 10.4269/ajtmh.1999.60.51; Mondal D, 2010, TROP MED INT HEALTH, V15, P1382, DOI 10.1111/j.1365-3156.2010.02635.x; Moreno J, 2000, T ROY SOC TROP MED H, V94, P328, DOI 10.1016/S0035-9203(00)90345-6; Mubayi A, 2010, J THEOR BIOL, V262, P177, DOI 10.1016/j.jtbi.2009.09.012; Murray HW, 1999, AIDS PATIENT CARE ST, V13, P459, DOI 10.1089/108729199318183; Ostyn B, 2008, TROP MED INT HEALTH, V13, P1073, DOI 10.1111/j.1365-3156.2008.02110.x; Pandey K, 2008, PARASITOL RES, V103, P293, DOI 10.1007/s00436-008-0967-7; Picado A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6760; Rahman KM, 2010, CLIN INFECT DIS, V50, P73, DOI 10.1086/648727; RAMESH V, 1995, INT J DERMATOL, V34, P85, DOI 10.1111/j.1365-4362.1995.tb03584.x; SACKS DL, 1985, AM J TROP MED HYG, V34, P456, DOI 10.4269/ajtmh.1985.34.456; Schenkel K, 2006, TROP MED INT HEALTH, V11, P1792, DOI 10.1111/j.1365-3156.2006.01735.x; Sharma Umakant, 2008, Journal of Vector Borne Diseases, V45, P255; Srinivasan R., 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P536; Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627; van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6; Verma S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010107; WHO, 2009, WHO LEISHM; WHO, 1996, TDRGEN96 WHO AD HOC; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R; ZIJLSTRA EE, 1995, AM J TROP MED HYG, V52, P299, DOI 10.4269/ajtmh.1995.52.299	47	70	73	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	NOV	2011	5	11							e1405	10.1371/journal.pntd.0001405				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	863AA	WOS:000298134000029	22140589	DOAJ Gold, Green Published			2019-03-26	
J	Alexander, A; John, KR; Jayaraman, T; Oommen, A; Raghava, MV; Dorny, P; Rajshekhar, V				Alexander, Anu; John, K. R.; Jayaraman, T.; Oommen, Anna; Raghava, M. Venkata; Dorny, Pierre; Rajshekhar, Vedantam			Economic implications of three strategies for the control of taeniasis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						taeniasis; screening; mass therapy; costs	SOLIUM TAENIASIS; HUMAN CYSTICERCOSIS; RURAL VILLAGE; INDIA; PREVALENCE; NEUROCYSTICERCOSIS; INFECTION; ANTIGENS; EPILEPSY; HUMANS	OBJECTIVE To evaluate the cost-effectiveness of three strategies for the control of taeniasis in a community, in terms of cost per case treated. METHODS A study was conducted in South India to determine the prevalence of taeniasis by screening stool samples from 653 randomly chosen subjects, for coproantigens. The costs incurred in the project were used to estimate the cost per case screened and treated. A one-way sensitivity analysis was carried out for varying rates of taeniasis, different screening strategies and mass therapy. Further sensitivity analysis was carried out with different manpower and test costs. RESULTS The rate of taeniasis as detected by ELISA for coproantigen was 3 per 1000 (2 of 653 samples). Our study showed that mass therapy without screening for taeniasis would be the most economical strategy in terms of cost per case treated if field workers are employed exclusively for either mass therapy or screening. For each strategy, costs per case treated are higher at low prevalence of taeniasis, with a sharp rise below 15%. CONCLUSIONS In places that are endemic for taeniasis and neurocysticercosis, mass therapy or screening for taeniasis should be considered. Screening by stool microscopy is not cost-effective in terms of cost per case of taeniasis treated owing to its low sensitivity. Although the cost per case of taeniasis treated is high at low prevalence of taeniasis for all options, incorporating mass therapy into existing mass drug distribution programmes might prove to be the most cost-effective control strategy.	[Jayaraman, T.; Oommen, Anna; Rajshekhar, Vedantam] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632004, Tamil Nadu, India; [Alexander, Anu; John, K. R.; Raghava, M. Venkata] Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632004, Tamil Nadu, India; [Dorny, Pierre] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Dorny, Pierre] Univ Ghent, Fac Vet Med, Parasitol Lab, B-9000 Ghent, Belgium	Rajshekhar, V (reprint author), Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632004, Tamil Nadu, India.	rajshekhar@cmcvellore.ac.in	Tharmalingam, Jayaraman/G-2542-2013	Tharmalingam, Jayaraman/0000-0002-7071-2797; Mohan, Venkata Raghava/0000-0001-5787-7223	Flemish Interuniversity Council, Belgium	This study was funded by a grant from the Flemish Interuniversity Council, Belgium.	Allan JC, 1997, T ROY SOC TROP MED H, V91, P595, DOI 10.1016/S0035-9203(97)90042-0; ALLAN JC, 1993, PARASITOLOGY, V107, P79, DOI 10.1017/S0031182000079439; Allan JC, 1996, AM J TROP MED HYG, V54, P352, DOI 10.4269/ajtmh.1996.54.352; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Drummond M, 2005, METHODS EC EVALUATIO, P42; FLISSER A, 1993, LANCET, V342, P748, DOI 10.1016/0140-6736(93)91743-6; Garcia HH, 2003, AM J TROP MED HYG, V68, P268, DOI 10.4269/ajtmh.2003.68.268; Gonzalez Armando E., 2002, P437, DOI 10.1079/9780851996288.0437; Prabhakaran V, 2004, T ROY SOC TROP MED H, V98, P478, DOI 10.1016/j.trstmh.2003.12.006; Prasad KN, 2007, T ROY SOC TROP MED H, V101, P1241, DOI 10.1016/j.trstmh.2007.04.019; Rajshekhar V, 2006, NEUROLOGY, V67, P2135, DOI 10.1212/01.wnl.0000249113.11824.64; Rodriguez-Canul R, 1999, ANN TROP MED PARASIT, V93, P57; Sabesan S, 2000, ANN TROP MED PARASIT, V94, P591, DOI 10.1080/00034983.2000.11813582; Sarti E, 2003, ACTA TROP, V87, P137, DOI [10.1016/S0001-706X(03)00034-2, 10.1016/S0001-706X(03)00197-9]; SARTI E, 1994, T ROY SOC TROP MED H, V88, P49, DOI 10.1016/0035-9203(94)90493-6; Sarti E, 2000, T ROY SOC TROP MED H, V94, P85, DOI 10.1016/S0035-9203(00)90451-6; Somers R, 2006, TROP MED INT HEALTH, V11, P65, DOI 10.1111/j.1365-3156.2005.01537.x; Thomas SV, 2001, EPILEPSIA, V42, P1052, DOI 10.1046/j.1528-1157.2001.0420081052.x; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Vora S. H., 2008, Journal of Communicable Diseases, V40, P147; WHO, 2001, WEEKLY EPIDEMIOLOGIC, V76, P149; WILSON M. B., 1978, IMMUNOFLUORESCENCE R, P215; YOUNG KH, 1979, J CLIN MICROBIOL, V10, P852	23	5	5	0	8	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2011	16	11					1410	1416		10.1111/j.1365-3156.2011.02850.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832VP	WOS:000295837600009	21790912				2019-03-26	
J	Mori, M; Ravinetto, R; Jacobs, J				Mori, Marcella; Ravinetto, Raffaella; Jacobs, Jan			Quality of medical devices and in vitro diagnostics in resource-limited settings	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						medical devices; in vitro diagnostics; quality problems; regulatory surveillance; poor countries	VISCERAL LEISHMANIASIS; LABORATORY DIAGNOSIS; POOR SETTINGS; TESTS; MICROSCOPY; MEDICINES; COUNTRIES; ACCURACY; DISEASE; AFRICA	The phenomenon of poor-quality medicines in resource-limited settings is well documented, and field observations reveal similar problems with medical devices (MDs) and in vitro diagnostics (IVDs). In scientific literature, however, there are only scarce reports and documents providing evidence of quality problems of MDs or IVDs in resource-limited settings. This discrepancy may be ascribed to (i) the poor regulatory oversight of MDs/IVDs in resource-limited settings, (ii) a general lack of awareness of the problem of poor-quality MDs/IVDs amongst the scientific community and decision-makers, and (iii) poor quality assurance in diagnostic laboratories in resource-poor settings, precluding tracing quality problems of IVDs from the other potential causes of diagnostic inaccuracy. The problem of poor-quality MDs/IVDs in resource-limited settings is a complex one to address. Firstly, operational definitions for substandard and counterfeit MDs/IVDs are required, as well as ad hoc field surveys, to ensure proper appraisal of the real extent of the problem. Investments are needed to reinforce the national regulatory oversights on MDs/IVDs in resource-limited settings, and to encourage a proactive and transparent exchange of information between Northern and Southern regulatory authorities. Industrialized countries can play a role by expanding and strengthening their regulatory oversight and quality labels to those MDs/IVDs that are frequently used in resource-poor settings. Hopefully, the combination of these measures will result in better protection of patients in resource-poor countries from the effects of being exposed to poor-quality MDs and IVDs.	[Mori, Marcella; Jacobs, Jan] Prince Leopold Inst Trop Med, Unit Trop Lab Med, Antwerp, Belgium; [Ravinetto, Raffaella] Prince Leopold Inst Trop Med, Clin Trials Unit, Antwerp, Belgium; [Jacobs, Jan] Fac Hlth Med & Life Sci, Dept Med Microbiol, Maastricht, Netherlands; [Mori, Marcella] Vet & Agrochem Res Ctr, Operat Unit Genitopathol, Operat Directorate Bacterial Dis, Brussels, Belgium	Mori, M (reprint author), Prince Leopold Inst Trop Med ITM, Unit Trop Lab Med, Natl Str 155, B-2000 Antwerp, Belgium.	marcellamori@gmail.com	Mori, Marcella/U-3810-2018	Mori, Marcella/0000-0002-7191-9191			BAKER ME, 1991, AM J ROENTGENOL, V157, P195, DOI 10.2214/ajr.157.1.2048520; Banoo S, 2006, NAT REV MICROBIOL, pS21, DOI 10.1038/nrmico1523; Bates I, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-38; *BBC NEWS, 2006, 2 ACC FAK HIV TESTS; Bell D, 2006, NAT REV MICROBIOL, pS34, DOI 10.1038/nrmico1524; Bimenya Gabriel S, 2003, Afr Health Sci, V3, P23; *BLOOMB, 2007, CHIN COUNT DIAB TEST; Boelaert M, 2004, AM J TROP MED HYG, V70, P72, DOI 10.4269/ajtmh.2004.70.72; Bonnet M, 2009, INT J TUBERC LUNG D, V13, P1112; Bretzel G, 2006, TROP MED INT HEALTH, V11, P1688, DOI 10.1111/j.1365-3156.2006.01722.x; Caudron JM, 2008, TROP MED INT HEALTH, V13, P1062, DOI 10.1111/j.1365-3156.2008.02106.x; *CHENN ONL, 2008, NACO PULL SUBST HIV; Day JN, 2004, LANCET, V363, P172, DOI 10.1016/S0140-6736(03)15286-5; Dini L, 2003, T ROY SOC TROP MED H, V97, P675, DOI 10.1016/S0035-9203(03)80101-3; *EC TIM, 2008, NACO PULL SUBST HIV; El-Safi S H, 2003, East Mediterr Health J, V9, P844; *EM, 2011, WORLDW MED DEV REG; *EM, 2011, MED DEV REG REQ EG; *EUR COMM, 2011, MED DEV CURR LEG; *EUR COMM, 2011, REV MED DEV DIR; *FDA, SIGN DAT US FOOD DRU; *FDA, 2011, OV IVD REG; *GHTF, 2008, PRINC INV DIAGN IVD; *GHTF, 2008, PRINC CONF ASS INV D; Gidwani K, 2009, AM J TROP MED HYG, V80, P566, DOI 10.4269/ajtmh.2009.80.566; Gillet P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-39; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; Gordon C, 2009, INT J TUBERC LUNG D, V13, P130; *GOV ACC PROJ, 2007, WORLD BANK FUND US D; Herring A, 2006, NAT REV MICROBIOL, pS41, DOI 10.1038/nrmicro1562; Herring A, 2006, NAT REV MICROBIOL, pS33, DOI 10.1038/nrmicro1563; *IND EXPR, 2009, HOUSE; Joshi A, 2008, INDIAN J MED MICROBI, V26, P160; *LIF, 2009, COUNT ON TEST STRIP; Liu KY, 2001, J CATARACT REFR SURG, V27, P924, DOI 10.1016/S0886-3350(01)00767-2; *LUDH TRIB, 2008, DENG OUTBR BEN DOCS; Lumb R, 2006, INT J TUBERC LUNG D, V10, P227; Martin R, 2005, AIDS, V19, pS59, DOI 10.1097/01.aids.0000172878.20628.a8; Mbembati Naboth A, 2008, East Afr J Public Health, V5, P13; Mfinanga G S, 2007, Tanzan Health Res Bull, V9, P164; Mfinanga G S, 2007, Tanzan Health Res Bull, V9, P44; *MHRA, 2006, MDA2006070LIFESPAN; *MON, 2007, COUNT MON TEST KITS; Moore A, 2001, LANCET, V358, P657, DOI 10.1016/S0140-6736(01)05783-X; MORI M, 2010, FDA SEEKS MODIFY REG; Mundy C, 2000, T ROY SOC TROP MED H, V94, P583, DOI 10.1016/S0035-9203(00)90098-1; Newton PN, 2006, LANCET INFECT DIS, V6, P602, DOI 10.1016/S1473-3099(06)70581-3; Otani MM, 2009, TRANSFUSION, V49, P1076, DOI 10.1111/j.1537-2995.2009.02107.x; *OUTL IND, 2008, NACO PULL SUBST HIV; Pardeshi Geeta S, 2005, Indian J Med Sci, V59, P13; PEELING RW, 2006, NATURE REV MICRO S12, V8, pS2; *PEOPL BETT TREATM, 2009, MED NEGL AN KIND US; Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363; Ravinetto RM, 2009, LANCET INFECT DIS, V9, P267, DOI 10.1016/S1473-3099(09)70090-8; Roehr B, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4415; Ruder Kate, 2007, Diabetes Forecast, V60, P29; *S AS POST, 2007, FAK DIAB KIT AL; Antunes ALS, 2007, MEM I OSWALDO CRUZ, V102, P719, DOI 10.1590/S0074-02762007000600010; Stevens W, 2008, NAT REV MICROBIOL, V6, pS29, DOI 10.1038/nrmicro2000; SUBHASH CA, 2006, CURRENT THERAPEUTIC, V67, P151; *TIM IND, 2009, ROW SUPPL PREV KIT; *TIM IND, 2009, DIAGN KITS CLEAR TES; *TIM IND, 2002, NO TESTS SEE PATH LA; US Food and Drug Administration, REC MARK WITHDR SAF; Van Rie A, 2008, J CLIN MICROBIOL, V46, P897, DOI 10.1128/JCM.01553-07; Volkow P, 2006, AM J INFECT CONTROL, V34, P335, DOI 10.1016/j.ajic.2005.10.011; *WHO, 2011, EXP COMM BIOL STAND; *WHO, 2011, COUNT MED FREQ ASK Q; *WHO, 2010, FACT SHEET N 275; WHO, 2010, ASS MED REG SYST SUB; *WHO, 2001, DIAGN TB GLOB DEM MA; WHO, 2011, WHO PREQ DIAGN PROGR; World Health Organization, 2003, MED DEV REG GLOB OV; Zarocostas J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c5052	74	15	15	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2011	16	11					1439	1449		10.1111/j.1365-3156.2011.02852.x				11	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832VP	WOS:000295837600013	21955331	Bronze			2019-03-26	
J	Casas, EC; Decroo, T; Mahoudo, JAB; Baltazar, JM; Das Dores, C; Cumba, L; De Weggheleire, A; Huyst, V; Bottieau, E				Casas, Esther Carrillo; Decroo, Tom; Mahoudo, Jules Aime Bonou; Baltazar, Jesus Maria; Das Dores, Carla; Cumba, Luisa; De Weggheleire, Anja; Huyst, Veerle; Bottieau, Emmanuel			Burden and outcome of HIV infection and other morbidities in health care workers attending an Occupational Health Program at the Provincial Hospital of Tete, Mozambique	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						occupational health; health care workers; HIV; tuberculosis	HIV/AIDS PREVALENCE; SOUTHERN AFRICA; MORTALITY; ACCESS; CRISIS; ZAMBIA	OBJECTIVES To investigate the burden and outcome of HIV infection and other morbidities amongst a Mozambican hospital staff. METHODS Within an occupational health service set up in April 2008 in the provincial hospital of Tete, Mozambique, we offered to all staff members an initial clinical, laboratory and radiological screening and followed them up prospectively until April 2010. RESULTS A total of 47.5% of 423 health workers attended the program. The cohort (female-to-male ratio: 2.2; mean age: 39 years) consisted mostly of auxiliary staff (43%) and nurses (29.8%). At initial screening, 71% were asymptomatic. HIV infection (28.4%) and tuberculosis (TB) (21%) were the main reported antecedent illnesses. Laboratory screening revealed anaemia (haemoglobin level <10 mg/dl) in 9% participants, abnormal liver enzymes in 23.9% and a reactive non-treponemal syphilis test in 5%. Of 145 performed chest X-rays, 13% showed abnormalities. All 113 health workers not recently tested for HIV were screened, and 31 were newly diagnosed with HIV infection (resulting in an overall HIV prevalence of 43.8%). Nine cases of TB were diagnosed at screening/during follow-up. In April 2010, all but one of the participants were alive. All HIV-infected health workers under antiretroviral therapy were actively followed-up. CONCLUSION Serious conditions were frequently diagnosed in health workers, in particular HIV infection. Mid-term outcome was favourable within this program. Creation of screening and care services dedicated to caregivers should be of highest priority in similar African settings.	[Casas, Esther Carrillo; Mahoudo, Jules Aime Bonou; De Weggheleire, Anja; Huyst, Veerle; Bottieau, Emmanuel] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Decroo, Tom] Med Sans Frontiers, Tete, Mozambique; [Baltazar, Jesus Maria] Prov Hosp Tete, Tete, Mozambique; [Das Dores, Carla; Cumba, Luisa] Prov Hlth Directorate Tete, Tete, Mozambique	Casas, EC (reprint author), Med Sans Frontieres Operat Cell Amsterdam, Middenlaan,14, Amsterdam, Netherlands.	esther.casas@msf.org	De Weggheleire, Anja/C-7345-2018	De Weggheleire, Anja/0000-0001-9377-4766; Decroo, Tom/0000-0002-1205-1484	Flemish International Cooperation Agency	Most sincere thanks to all HCW of the provincial hospital of Tete. Special thanks to the nurse-counselors Loria and Eva; without their inestimable work and professionalism the program could not have been successfully implemented. This study was conducted within a collaborative health project financed by the Flemish International Cooperation Agency.	Bemelmans M, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-1; BUVE A, 1994, AIDS, V8, P396, DOI 10.1097/00002030-199403000-00023; Connelly D, 2007, SAMJ S AFR MED J, V97, P115; Feeley FG, 2007, INT J OCCUP ENV HEAL, V13, P99, DOI 10.1179/107735207800244910; *INT LAB ORG, 2010, JOINT WHO ILO UNAIDS; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Kruse GR, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-55; MANN JM, 1986, JAMA-J AM MED ASSOC, V256, P3099, DOI 10.1001/jama.256.22.3099; Marchal B, 2005, TROP MED INT HEALTH, V10, P300, DOI 10.1111/j.1365-3156.2005.01397.x; Marchal B, 2004, LANCET, V363, P2191, DOI 10.1016/S0140-6736(04)16518-5; *MIN HLTH, 2009, INQUERITO NAC PREV R; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; Nyblade L, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-15; O'Donnell MR, 2010, ANN INTERN MED, V153, P516, DOI 10.7326/0003-4819-153-8-201010190-00008; Shisana O, 2004, SAMJ S AFR MED J, V94, P846; Shisana O, 2007, SAMJ S AFR MED J, V97, P108; Uebel KE, 2007, J INFECT DIS, V196, pS500, DOI 10.1086/521113; Uebel KE, 2010, SAMJ S AFR MED J, V100, P589, DOI 10.7196/SAMJ.3897; World Health Organization (WHO), 2010, GLOB TUB CONTR WHO R	19	2	2	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2011	16	11					1450	1456		10.1111/j.1365-3156.2011.02853.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832VP	WOS:000295837600014	21848576				2019-03-26	
J	Masanja, IM; de Bethune, X; Jacobs, J				Masanja, Irene M.; de Bethune, Xavier; Jacobs, Jan			Implementing ideal health policy in a fragile health system: the example of expanding the use of malaria rapid diagnostic tests in mainland Tanzania	MALARIA JOURNAL			English	Editorial Material						Malaria rapid diagnostic tests; health systems; Tanzania		Malaria confirmation before treatment provides an opportunity for improving the quality of malaria case management in endemic regions. However, increased coverage of this strategy is facing many organizational, logistical and technical challenges that threaten its success. Introducing an intervention with system-wide effect, such as the use of malaria rapid diagnostic tests in areas where malaria is still a public health problem, should be accompanied by system strengthening measures to better attain the goal of improving quality of care.	[Masanja, Irene M.] Ifakara Hlth Inst, Hlth Syst Grp, Dar Es Salaam, Tanzania; [Masanja, Irene M.] Inst Trop Med, Emerging Voices Programme 2010, B-2000 Antwerp, Belgium; [de Bethune, Xavier] Christian Sickness Fund, B-1031 Brussels, Belgium; [Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium	Masanja, IM (reprint author), Ifakara Hlth Inst, Hlth Syst Grp, Kiko Ave Mikocheni,POB 78373, Dar Es Salaam, Tanzania.	imasanja@ihi.or.tz					Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1; Bell D, 2008, T ROY SOC TROP MED H, V102, P1064, DOI 10.1016/j.trstmh.2008.05.007; D'Acremont V, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-107; de Savigny D, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-27; DeSavigny D, 2009, SYSTEMS THINKING FOR HEALTH SYSTEMS STRENGTHENING, P1; ETTLING M, 1994, TROP MED PARASITOL, V45, P74; Graz B, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-136; Harvey SA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-160; Masanja MI, 2010, AM J TROP MED HYG, V83, P1238, DOI 10.4269/ajtmh.2010.10-0194; Mayxay M, 2004, TROP MED INT HEALTH, V9, P325, DOI 10.1111/j.1365-3156.2004.01199.x; *MIN HLTH SOC WELF, 2006, MAL CONTR SER MIN HL, V11; Ministry of Health, 2006, ANN HLTH STAT ABSTR; RENNIE W, 2001, T R SOC TROP MED HYG, V101, P9; Reyburn H, 2007, BRIT MED J, V334, P403, DOI 10.1136/bmj.39073.496829.AE; *TACAIDS, 2008, TANZ HIV AIDS MAL IN, P148	15	9	9	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	OCT 28	2011	10								322	10.1186/1475-2875-10-322				4	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	845UZ	WOS:000296850600001	22035466	DOAJ Gold, Green Published			2019-03-26	
J	Kyabayinze, DJ; Tibenderana, JK; Nassali, M; Tumwine, LK; Riches, C; Montague, M; Counihan, H; Hamade, P; Van Geertruyden, JP; Meek, S				Kyabayinze, Daniel J.; Tibenderana, James K.; Nassali, Mercy; Tumwine, Lynette K.; Riches, Clare; Montague, Mark; Counihan, Helen; Hamade, Prudence; Van Geertruyden, Jean-Pierre; Meek, Sylvia			Placental Plasmodium falciparum malaria infection: Operational accuracy of HRP2 rapid diagnostic tests in a malaria endemic setting	MALARIA JOURNAL			English	Article							INTERMITTENT PREVENTIVE TREATMENT; POLYMERASE-CHAIN-REACTION; SULFADOXINE-PYRIMETHAMINE; MOLECULAR MARKERS; LIKELIHOOD RATIOS; CASE-MANAGEMENT; PREGNANT-WOMEN; MICROSCOPY; BLOOD; TIME	Background: Malaria has a negative effect on the outcome of pregnancy. Pregnant women are at high risk of severe malaria and severe haemolytic anaemia, which contribute 60-70% of foetal and perinatal losses. Peripheral blood smear microscopy under-estimates sequestered placental infections, therefore malaria rapid diagnostic tests (RDTs) detecting histidine rich protein-2 antigen (HRP-2) in peripheral blood are a potential alternative. Methods: HRP-2 RDTs accuracy in detecting malaria in pregnancy (MIP >28 weeks gestation) and placental Plasmodium falciparum malaria (after childbirth) were conducted using Giemsa microscopy and placental histopathology respectively as the reference standard. The study was conducted in Mbale Hospital, using the midwives to perform and interpret the RDT results. Discordant results samples were spot checked using PCR techniques. Results: Among 433 febrile women tested, RDTs had a sensitivity of 96.8% (95% CI 92-98.8), specificity of 73.5% (95% CI 67.8-78.6), a positive predictive value (PPV) of 68.0% (95% CI 61.4-73.9), and negative predictive value (NPV) of 97.5% (95% CI 94.0-99.0) in detecting peripheral P. falciparum malaria during pregnancy. At delivery, in non-symptomatic women, RDTs had a 80.9% sensitivity (95% CI 57.4-93.7) and a 87.5% specificity (95% CI 80.9-92.1), PPV of 47.2% (95% CI 30.7-64.2) and NPV of 97.1% (95% CI 92.2-99.1) in detecting placental P. falciparum infections among 173 samples. At delivery, 41% of peripheral infections were detected by microscopy without concurrent placental infection. The combination of RDTs and microscopy improved the sensitivity to 90.5% and the specificity to 98.4% for detecting placental malaria infection (McNemar's X-2 > 3.84). RDTs were not superior to microscopy in detecting placental infection (McNemar's X-2 < 3.84). Presence of malaria in pregnancy and active placental malaria infection were 38% and 12% respectively. Placental infections were associated with poor pregnancy outcome [pre-term, still birth and low birth weight] (aOR = 37.9) and late pregnancy malaria infection (aOR = 20.9). Mosquito net use (aOR 2.1) and increasing parity (aOR 2.7) were associated with lower risk for malaria in pregnancy. Conclusion: Use of HRP-2 RDTs to detect malaria in pregnancy in symptomatic women was accurate when performed by midwives. A combination of RDTs and microscopy provided the best means of detecting placental malaria. RDTs were not superior to microscopy in detecting placental infection. With a high sensitivity and specificity, RDTs could be a useful tool for assessing malaria in pregnancy, with further (cost-) effectiveness studies.	[Kyabayinze, Daniel J.; Tibenderana, James K.; Riches, Clare] Malaria Consortium, Kampala, Uganda; [Kyabayinze, Daniel J.; Van Geertruyden, Jean-Pierre] Univ Antwerp, Fac Med, ESOC Dept, Unit Int Hlth, BE-2610 Antwerp, Belgium; [Tibenderana, James K.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Nassali, Mercy] Mbale Reg Referral Hosp, Minist Hlth, Mbale, Uganda; [Tumwine, Lynette K.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda; [Montague, Mark; Counihan, Helen; Hamade, Prudence; Meek, Sylvia] Malaria Consortium, London EC2A 4LT, England	Kyabayinze, DJ (reprint author), Malaria Consortium, Upper Naguru E Rd,POB 8045, Kampala, Uganda.	drdjkyabayinze@yahoo.com	Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364; TIBENDERANA, JAMES/0000-0002-0755-4597	United Kingdom Department for International Development (DFID)	The authors thank all the patients who participated in this study. They recognize the contributions of S Takali, I Otim, M Adeke, B Namwase, Dr A Diaz, Moses Kiggundu and C Apio. Special thanks to Drs P Mufubega, D Chandamohan, A Talisuna and D Nakanjako for reviewing the proposal and manuscript. The research was funded by United Kingdom Department for International Development (DFID) through COMDIS Research Programme Consortium	Abba K, 2011, COCHRANE DB SYST REV, V7; Adam I, 2005, ANN TROP MED PARASIT, V99, P339, DOI 10.1179/136485905X36244; ADAM I, 2008, J VECTOR DIS, V45, P79; Adam Ishag, 2008, J Vector Borne Dis, V45, P78; Adebami OJ, 2007, AM J TROP MED HYG, V77, P209, DOI 10.4269/ajtmh.2007.77.209; Akobeng AK, 2007, ACTA PAEDIATR, V96, P487, DOI 10.1111/j.1651-2227.2006.00179.x; Anchang-Kimbi JK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-126; Bardaji A, 2011, J INFECT DIS, V203, P691, DOI 10.1093/infdis/jiq049; BELL D, 2006, NAT REV MICROBIOL, V4, pS34, DOI DOI 10.1038/NRMICO1524; Bell DR, 2005, AM J TROP MED HYG, V73, P199, DOI 10.4269/ajtmh.2005.73.199; Bertin G, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-196; Campos IM, 2011, AM J TROP MED HYG, V84, P929, DOI 10.4269/ajtmh.2011.10-0507; Carley S, 2005, EMERG MED J, V22, P180, DOI 10.1136/emj.2003.011148; Cattamanchi A, 2003, AM J TROP MED HYG, V68, P133, DOI 10.4269/ajtmh.2003.68.133; Chico RM, 2011, TROP MED INT HEALTH, V16, P774, DOI 10.1111/j.1365-3156.2011.02765.x; Cottrell G, 2005, AM J TROP MED HYG, V73, P1112, DOI 10.4269/ajtmh.2005.73.1112; Cottrell G, 2006, ACTA TROP, V98, P255, DOI 10.1016/j.actatropica.2006.05.009; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Feng GA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012012; Halkin A, 1998, QJM-INT J MED, V91, P247, DOI 10.1093/qjmed/91.4.247; Hawass NED, 1997, BRIT J RADIOL, V70, P360, DOI 10.1259/bjr.70.832.9166071; Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8; Kyabayinze D, 2003, AM J TROP MED HYG, V69, P247, DOI 10.4269/ajtmh.2003.69.247; Kyabayinze DJ, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-200; Kyabayinze DJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-221; Leke RFG, 1999, J CLIN MICROBIOL, V37, P2992; Malhotra I, 2005, J CLIN MICROBIOL, V43, P3630, DOI 10.1128/JCM.43.8.3630-3635.2005; Mankhambo L, 2002, J CLIN MICROBIOL, V40, P155, DOI 10.1128/JCM.40.1.155-158.2002; Mockenhaupt FP, 2000, TROP MED INT HEALTH, V5, P167, DOI 10.1046/j.1365-3156.2000.00532.x; Mockenhaupt FP, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-119; Mokuolu OA, 2009, INFECT DIS OBSTET GY, V2009; Msellem MI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000070; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Ndyomugyenyi R, 2010, T ROY SOC TROP MED H, V104, P536, DOI 10.1016/j.trstmh.2010.02.003; Nosten F, 2007, LANCET INFECT DIS, V7, P118, DOI 10.1016/S1473-3099(07)70023-3; Pang T, 2007, T ROY SOC TROP MED H, V101, P856, DOI 10.1016/j.trstmh.2007.04.014; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Reyburn H, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-4; Reyburn H, 2007, BRIT MED J, V334, P403, DOI 10.1136/bmj.39073.496829.AE; Shulman CE, 2003, T ROY SOC TROP MED H, V97, P30, DOI 10.1016/S0035-9203(03)90012-5; Swarthout TD, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-58; Uganda Bureau of Statistics & ICF Macro, 2010, UG MAL IND SURV 2009; Uneke CJ, 2008, PARASITOL RES, V102, P333, DOI 10.1007/s00436-007-0782-6; Uneke CJ, 2008, HAEMATOL-HEMATOL J, V93, P143, DOI 10.3324/haematol.11695; Uneke Chigozie J, 2008, Yale J Biol Med, V81, P1; *US CDC, 2009, MAL RAP DIAG TEST PE; VALENTE B, 2011, TROP MED INT HLTH; Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35, DOI 10.4269/ajtmh.2004.71.35; Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119, DOI 10.4269/ajtmh.2007.77.119; World Health Organization, 2010, GUID TREATM MAL; Zwetyenga J, 1998, AM J TROP MED HYG, V59, P726, DOI 10.4269/ajtmh.1998.59.726	51	18	19	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	OCT 18	2011	10								306	10.1186/1475-2875-10-306				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	843YG	WOS:000296712900001	22004666	DOAJ Gold, Green Published			2019-03-26	
J	Mukadi, P; Gillet, P; Lukuka, A; Atua, B; Kahodi, S; Lokombe, J; Muyembe, JJ; Jacobs, J				Mukadi, Pierre; Gillet, Philippe; Lukuka, Albert; Atua, Ben; Kahodi, Simelo; Lokombe, Jean; Muyembe, Jean-Jacques; Jacobs, Jan			External quality assessment of malaria microscopy in the Democratic Republic of the Congo	MALARIA JOURNAL			English	Article							RAPID DIAGNOSTIC-TESTS; LABORATORY DIAGNOSIS; ASSESSMENT-SCHEME; UNITED-KINGDOM; PERFORMANCE; MANAGEMENT; PROGRAMS; AFRICA; FILMS	Background: External quality assessments (EQA) are an alternative to cross-checking of blood slides in the quality control of malaria microscopy. This study reports the findings of an EQA of malaria microscopy in the Democratic Republic of the Congo (DRC). Methods: After validation, an EQA slide panel and a questionnaire were delivered to diagnostic laboratories in four provinces of DRC. The panel included three samples for diagnosis (sample 1: Plasmodium falciparum, 177,000/mu l, sample 2: P. falciparum, 2,500/mu l, sample 3: no parasites seen), one didactic sample (Howell-Jolly bodies) and one sample for assessing the quality of staining. Participating laboratories were addressed and selected through the network of the National Tuberculosis Control Programme. Participants were asked to return the responses together with a stained thin and thick blood film for evaluation of Giemsa stain quality. Results: Among 174 participants (response rate 95.1%), 26.2% scored samples 1, 2 and 3 correctly and 34.3%, 21.5% and 5.8% of participants reported major errors in one, two or three samples respectively. Major errors included reporting "no malaria" or "non-falciparum malaria" for Plasmodium falciparum-positive samples 1 and 2 (16.1% and 34.9% of participants respectively) and "P. falciparum" for Plasmodium negative sample 3 (24.0%). Howell-Jolly bodies (didactic sample) were not recognized by any of the participants but reported as "P. falciparum" by 16.7% of participants. With parasite density expressed according to the "plus system", 16.1% and 21.5% of participants scored one "+"different from the reference score for samples 1 and 2 respectively and 9.7% and 2.9% participants scored more than two "+" different. When expressed as counts of asexual parasites/mu l, more than two-thirds of results were outside the mean +/- 2SD reference values. The quality of the Giemsa stain was poor, with less than 20% slides complying with all criteria assessed. Only one quarter of participants purchase Giemsa stain from suppliers of documented reliability and half of participants use a buffered staining solution. One third of participants had participated in a formal training about malaria diagnosis, half of them earlier than 2007. Conclusion: The present EQA revealed a poor quality of malaria microscopy in DRC.	[Gillet, Philippe; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Mukadi, Pierre; Lukuka, Albert; Lokombe, Jean; Muyembe, Jean-Jacques] Inst Natl Rech Biomed, Kinshasa, Zaire; [Lukuka, Albert; Atua, Ben] PNLP, Kinshasa, Zaire; [Kahodi, Simelo] PNLT, Kinshasa, Zaire; [Lokombe, Jean; Muyembe, Jean-Jacques] Univ Kinshasa, Fac Med, Kinshasa, Zaire; [Jacobs, Jan] Maastricht Univ, Med Ctr, Dept Med Microbiol, Sch Publ Hlth & Primary Care,CAPHRI, Maastricht, Netherlands	Gillet, P (reprint author), Inst Trop Med, Dept Clin Sci, Natl Str 155 B, B-2000 Antwerp, Belgium.	pgillet@itg.be		gillet, philippe/0000-0001-5878-6446			Alonso PL, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000396; [Anonymous], 2003, MAN BAS TECHN HLTH L; Batwala V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-349; Cnops L, 2010, CLIN MICROBIOL INFEC; Cnops L, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-370; de Oliveira AM, 2009, AM J TROP MED HYG, V80, P470, DOI 10.4269/ajtmh.2009.80.470; Dini L, 2003, T ROY SOC TROP MED H, V97, P675, DOI 10.1016/S0035-9203(03)80101-3; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; Jensen TP, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-213; Kettelhut MM, 2003, J CLIN PATHOL, V56, P927, DOI 10.1136/jcp.56.12.927; Libeer JC, 2002, ACCREDIT QUAL ASSUR, V7, P320, DOI 10.1007/s00769-002-0492-9; MILNE LM, 1994, J CLIN PATHOL, V47, P740, DOI 10.1136/jcp.47.8.740; MULUMBA M, 1999, CONGO MED, V11, P759; Petti CA, 2006, CLIN INFECT DIS, V42, P377, DOI 10.1086/499363; *PNLP, 2010, MAN FORM DIAGN LAB P; Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Sarkinfada F, 2009, J INFECT DEV COUNTR, V3, P20; SNELL JJS, 1992, B WORLD HEALTH ORGAN, V70, P605; SNELL JJS, 1985, EUR J CLIN MICROBIOL, V4, P464, DOI 10.1007/BF02014425; Tholen DW, 2002, ACCREDIT QUAL ASSUR, V7, P146, DOI 10.1007/s00769-002-0450-6; Thomson S, 2000, ARCH PATHOL LAB MED, V124, P57; TRUDEL L, 2008, RAPPORT ACTIVITES 20; *WHO, 2009, TRANP STOR HANDL MAL; WHO, 2010, INF NOT INT SEL CRIT; *WHO, 2010, LOT TEST US QUAL CON; *WHO, 2009, MAL RAP DIAGN TEST P; *WHO, 2010, OV PREQ DIAGN ASS PR; World Health Organisation, 2010, BAS MAL MICR 2; World Health Organization, 2011, GOOD PRACT SEL PROC; World Health Organization, 2008, US RAP DIAGN TEST RD; World Health Organization, 2010, BAS MAL MICR 1; World Health Organization, 2009, MAL MICR QUAL ASS MA; World Health Organization -Regional office for Ihe Western Pacific, 2005, MAL LIGHT MICR CREAT	33	23	24	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	OCT 18	2011	10								308	10.1186/1475-2875-10-308				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	843YH	WOS:000296713100001	22008378	DOAJ Gold, Green Published			2019-03-26	
J	van Gool, T; van Wolfswinkel, ME; Koelewijn, R; van Thiel, PPAM; Jacobs, J; van Hellemond, JJ; van Genderen, PJJ				van Gool, Tom; van Wolfswinkel, Marlies E.; Koelewijn, Rob; van Thiel, Pieter P. A. M.; Jacobs, Jan; van Hellemond, Jaap J.; van Genderen, Perry J. J.			A simple and fast method to exclude high Plasmodium falciparum parasitaemia in travellers with imported malaria	MALARIA JOURNAL			English	Article						malaria; traveller; imported disease; aldolase; severe malaria; rapid diagnostic test	RAPID DIAGNOSTIC-TESTS; RETURNED TRAVELERS; PERFORMANCE; PFHRP2	Background: Counts of malaria parasites in peripheral blood are important to assess severity of Plasmodium falciparum malaria. Thin and thick smears are routinely used for this purpose. Methods: In this study the Binax NOW (R) Malaria Test, an easy-to-perform rapid diagnostic test, with Histidine Rich Protein-2 (HRP-2) and aldolase as diagnostic markers, was used for semi-quantitative assessment of parasitaemia of P. faciparum. Results: In 257 patients with imported P. falciparum malaria, reactivity of aldolase increased with higher parasitaemia. In all patients with a parasitaemia above 50,000 asexual parasites/mu l (> 1%) co-reactivity of HRP-2 and aldolase was observed. Absence of aldolase reactivity in the presence of HRP-2 was a reliable predictive marker to exclude high (> 1%) parasitaemia in P. falciparum malaria. Conclusions: Assessment of HRP-2 and aldolase co-reactivity can be of help in clinical decision making in the acute care setting of returning travellers suspected of having malaria.	[van Gool, Tom] Univ Amsterdam, Acad Med Ctr, Dept Parasitol, NL-1105 AZ Amsterdam, Netherlands; [van Wolfswinkel, Marlies E.; van Genderen, Perry J. J.] Harbour Hosp, Dept Internal Med, Rotterdam, Netherlands; [van Gool, Tom; Koelewijn, Rob; van Hellemond, Jaap J.] Harbour Hosp, Dept Parasitol, Rotterdam, Netherlands; [van Thiel, Pieter P. A. M.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; [Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [van Hellemond, Jaap J.] Erasmus Univ Hosp, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands; [van Genderen, Perry J. J.] Harbour Hosp, Inst Trop Dis, Rotterdam, Netherlands	van Gool, T (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Parasitol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	vangool@amc.uva.nl	Van Gool, Tom/H-6750-2012	van Genderen, Perry/0000-0001-8892-7596	AMC, Amsterdam; Harbour Hospital, Rotterdam; ITG, Antwerp	Carla Wassenaar and Leny Nieuwendijk at the AMC, Amsterdam, Henk Hofwegen and Yvonne Kuhn at the Harbour Hospital, Rotterdam, and Jessica Maltha at the ITG, Antwerp, are acknowledged for technical assistance during the study. All authors were funded by their respective institutes.	Baker J, 2005, J INFECT DIS, V192, P870, DOI 10.1086/432010; Bruneel F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013236; Durand F, 2005, CLIN MICROBIOL INFEC, V11, P903, DOI 10.1111/j.1469-0691.2005.01253.x; Gamboa D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008091; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-271; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Richter J, 2004, PARASITOL RES, V94, P384, DOI 10.1007/s00436-004-1213-6; SERINGE E, 2001, EMERG INFECT DIS, V17, P807; Stauffer WM, 2009, CLIN INFECT DIS, V49, P908, DOI 10.1086/605436; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; van Genderen PJJ, 2010, TRANSFUSION, V50, P787, DOI 10.1111/j.1537-2995.2009.02488.x; van Genderen PJJ, 2005, J TRAVEL MED, V12, P261; van Hellemond JJ, 2009, EMERG INFECT DIS, V15, P1478, DOI 10.3201/eid1509.090358; van Rijckevorsel GGC, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-300; World Health Organization, WORLD MAL REP 2010	15	4	5	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	OCT 14	2011	10								300	10.1186/1475-2875-10-300				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	843YD	WOS:000296712600001	21999570	DOAJ Gold, Green Published			2019-03-26	
J	Kilian, A; Byamukama, W; Pigeon, O; Gimnig, J; Atieli, F; Koekemoer, L; Protopopoff, N				Kilian, Albert; Byamukama, Wilson; Pigeon, Olivier; Gimnig, John; Atieli, Francis; Koekemoer, Lizette; Protopopoff, Natacha			Evidence for a useful life of more than three years for a polyester-based long-lasting insecticidal mosquito net in Western Uganda	MALARIA JOURNAL			English	Article							WASH-RESISTANCE; TREATED NETS; MALARIA PREVENTION; ANOPHELES-GAMBIAE; HOUSEHOLD USE; BED NETS; FIELD; BEDNETS; PERMETHRIN; EFFICACY	Background: Long-lasting insecticidal nets (LLIN) are now standard for the prevention of malaria. However, only products with recommendation for public use from the World Health Organization should be used and this evaluation includes the assessment of net effectiveness after three years of field use. Results for one of the polyester-based products, Interceptor (R) is presented. Methods: In five villages, 190 LLIN and 90 nets conventionally treated with the insecticide alpha-cypermethrin at 25 mg/m(2) were distributed randomly and used by the families. Following a baseline household survey a net survey was carried out every six months to capture use, washing habits and physical condition of the nets. Randomly selected nets were collected after 6, 12, 24, 36 and 42 months and tested for remaining insecticide content and ability to knock-down and kill malaria transmitting mosquitoes. Results: During the three and a half years of observation only 16 nets were lost to follow-up resulting in an estimated attrition rate of 12% after three and 20/% after 3.5 years. Nets were used regularly and washed on average 1.5 times per year. After three and a half years 29% of the nets were still in good condition while 13% were seriously torn with no difference between the LLIN and control nets. The conventionally treated nets quickly lost insecticide and after 24 months only 7% of the original dose remained (1.6 mg/m(2)). Baseline median concentration of alpha-cypermethrin for LLIN was 194.5 mg/m(2) or 97% of the target dose with between and within net variation of 11% and 4% respectively (relative standard deviation). On the LLIN 73.8 mg/m(2) alphacypermethrin remained after three years of use and 56.2 mg/m(2) after three and a half and 94% and 81% of the LLIN still had > 15 mg/m(2) left respectively. Optimal effectiveness in bio-assays (>= 95% 60 minute knock-down or >= 80% 24 hour mortality) was found in 83% of the sampled LLIN after three and 71% after three and a half years. Conclusions: Under conditions in Western Uganda the tested long-lasting insecticidal net Interceptor (R) fulfilled the criteria for phase III of WHO evaluations and, based on preliminary criteria of the useful life, this product is estimated to last on average between three and four years.	[Kilian, Albert] Malaria Consortium Int, London, England; [Byamukama, Wilson; Protopopoff, Natacha] Africa Reg Off, Malaria Consortium, Kampala, Uganda; [Pigeon, Olivier] Walloon Agr Res Ctr CRA W, Agr & Nat Environm Dept, Gembloux, Belgium; [Gimnig, John] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA; [Atieli, Francis] Kenya Govt Med Res Ctr, Ctr Vector Biol & Control Res, Kisumu, Kenya; [Koekemoer, Lizette] NHLS, Vector Control Reference Unit, Natl Inst Communicable Dis, Sandringham, England; [Koekemoer, Lizette] Univ Witwatersrand, Malaria Entomol Res Unit, Sch Pathol, ZA-2000 Johannesburg, South Africa	Kilian, A (reprint author), Malaria Consortium Int, London, England.	a.kilian@malariaconsortium.org		Protopopoff, Natacha/0000-0001-6698-4936	BASF Corporation	The study was financially supported by the BASF Corporation. Special thanks go to Bob Farlow and James Austin from BASF for their technical support and inputs. We also wish to acknowledge and thank the village health workers and participating villagers in Kyenjojo District, Uganda.	Adams KJ, 2002, MED VET ENTOMOL, V16, P106, DOI 10.1046/j.0269-283x.2002.00341.x; [Anonymous], 2011, WHO REC LONG LAST IN; Banek K, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-84; CARNEVALE P, 1992, T ROY SOC TROP MED H, V86, P362, DOI 10.1016/0035-9203(92)90219-3; Dev V, 2010, T ROY SOC TROP MED H, V104, P273, DOI 10.1016/j.trstmh.2009.08.010; Doannio J M, 1999, Med Trop (Mars), V59, P349; Erlanger TE, 2004, MED VET ENTOMOL, V18, P153, DOI 10.1111/j.0269-283X.2004.00491.x; FAO/WHO, 2010, MAN DEV US FAO WHO S; *GLOB MAL PROGR, 2007, INS TREAT MOSQ NETS; Graham K, 2005, MED VET ENTOMOL, V19, P72, DOI 10.1111/j.0269-283X.2005.00543.x; Guillet P, 2001, B WORLD HEALTH ORGAN, V79, P998; Jawara M, 1998, MED VET ENTOMOL, V12, P60; Jawara M, 2001, TROP MED INT HEALTH, V6, P309, DOI 10.1046/j.1365-3156.2001.00706.x; Jima D, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-58; KILIAN A, 2011, 6 RBM VECT WORK GROU; Kilian A, 2010, PUBLIC HLTH J, V<IT>21</IT>, P43; Kilian A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-49; Kroeger A, 2004, T ROY SOC TROP MED H, V98, P152, DOI 10.1016/S0035-9203(03)00038-5; Lindblade KA, 2005, TROP MED INT HEALTH, V10, P1141, DOI 10.1111/j.1365-3156.2005.01501.x; Malima RC, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-38; Maxwell CA, 2002, TROP MED INT HEALTH, V7, P1003, DOI 10.1046/j.1365-3156.2002.00966.x; Miller JE, 1999, TROP MED INT HEALTH, V4, P167, DOI 10.1046/j.1365-3156.1999.43378.x; MILLER JE, 1991, MED VET ENTOMOL, V5, P465, DOI 10.1111/j.1365-2915.1991.tb00575.x; MILLER JE, 1995, MED VET ENTOMOL, V9, P43, DOI 10.1111/j.1365-2915.1995.tb00115.x; Muller O, 2002, T ROY SOC TROP MED H, V96, P483, DOI 10.1016/S0035-9203(02)90411-6; PORT GR, 1982, B ENTOMOL RES, V72, P483, DOI 10.1017/S0007485300013663; Sharma SK, 2010, ACTA TROP, V116, P24, DOI 10.1016/j.actatropica.2010.05.002; Smith SC, 2007, AM J TROP MED HYG, V77, P243, DOI 10.4269/ajtmh.2007.77.243; Spencer S, 2004, T ROY SOC TROP MED H, V98, P719, DOI 10.1016/j.trstmh.2004.01.012; Vatandoost H., 2006, Journal of Vector Borne Diseases, V43, P133; *WHO, 2006, 10 WHOPES WORK GROUP; WHO, GUID MON DUR LONG LA; WHO, 2005, GUID LAB FIELD TEST; WHO-World Health Organization, 2009, SPEC EV PUBL HLTH PE	34	47	47	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	OCT 13	2011	10								299	10.1186/1475-2875-10-299				13	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	845UP	WOS:000296849300001	21992483	DOAJ Gold, Green Published			2019-03-26	
J	Akue, JP; Nkoghe, D; Padilla, C; Moussavou, G; Moukana, H; Mbou, RA; Ollomo, B; Leroy, EM				Akue, Jean Paul; Nkoghe, Dieudonne; Padilla, Cindy; Moussavou, Ghislain; Moukana, Hubert; Mbou, Roger Antoine; Ollomo, Benjamin; Leroy, Eric Maurice			Epidemiology of Concomitant Infection Due to Loa loa and Mansonella perstans in Gabon	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TEST REACTIVITY; ENDEMIC AREA; PREVALENCE; MICROFILAREMIA; FILARIASIS; LOIASIS; IVERMECTIN; CULICOIDES; INTENSITY; RESIDENTS	Background: The filarial parasites Loa loa and Mansonnella perstans are endemic in the central and western African forest block. Loa loa is pathogenic and represents a major obstacle to the control of co-endemic filariae because its treatment can cause fatal complications such as encephalitis. Methodology/Principal Findings: 4392 individuals aged over 15 years were studied both by direct examination and a concentration technique. The overall prevalence rates were 22.4% for Loa loa microfilaremia, 10.2% for M. perstans microfilaremia, and 3.2% for mixed infection. The prevalence of both filariae was higher in the forest ecosystem than in savannah and lakeland (p<0.0001). The intensity of microfilariae (mf) was also higher in the forest ecosystem for both parasites. The prevalence and intensity of microfilaria were both influenced by age and gender. Correlations were found between the prevalence and intensity of Loa loa microfilariae (r = 0.215 p = 0.036), and between the prevalence of Loa loa and the prevalence of individuals with microfilaria >8000 mf/ml (r = 0.624; p<0.0001) and microfilariae >30 000 mf/ml (r = 0.319, p = 0.002). In contrast, the prevalence of pruritis and Calabar swellings correlated negatively with the prevalence of Loa loa microfilaria (r = -0.219, p = 0.032; r = -0.220; p = 0.031, respectively). Pruritis, Calabar swellings and eye worm were not associated with L. loa mf intensity (r = -0.144, p = 0.162; r-0.061, p = 0.558; and r = 0.051, p = 0.624, respectively), or with the prevalence or intensity of M. perstans microfilariae. Conclusions/Significance: This map of the distribution of filariae in Gabon should prove helpful for control programs. Our findings confirm the spatial uniformity of the relationship between parasitological indices. Clinical manifestations point to a relationship between filariae and allergy.	[Akue, Jean Paul; Moukana, Hubert; Mbou, Roger Antoine; Ollomo, Benjamin] CIRMF, Dept Med Parasitol, Franceville, Gabon; [Nkoghe, Dieudonne; Padilla, Cindy; Moussavou, Ghislain; Leroy, Eric Maurice] Ctr Int Rech Med Franceville, Unite Malad Virales Emergentes, Franceville, Gabon; [Nkoghe, Dieudonne] Minist Hlth, Libreville, Gabon; [Nkoghe, Dieudonne] Univ Liege, Dept Immunodeficiency & Infect Dis, Liege, Belgium; [Leroy, Eric Maurice] MIVEGEC IRD 224 CNRS 5290 UM1 UM2, Montpellier, France	Akue, JP (reprint author), CIRMF, Dept Med Parasitol, Franceville, Gabon.	jpakue@yahoo.fr	LEROY, Eric/I-4347-2016	LEROY, Eric/0000-0003-0022-0890	Government of Gabon; Total Gabon; Ministere des Affaires Etrangeres de la France; Fonds de Solidarite Prioritaire [2002005700]; Global Viral Forecasting Initiative, San Francisco, United States of America	Centre International de Recherches Medicales de Franceville (CIRMF) is supported by the Government of Gabon, Total Gabon, and Ministere des Affaires Etrangeres de la France. This work was supported by Fonds de Solidarite Prioritaire n<SUP>o</SUP> 2002005700 (Ministere des Affaires Etrangeres de la France) and Global Viral Forecasting Initiative, San Francisco, United States of America. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agbolade OM, 2005, AFR J BIOTECHNOL, V4, P1554; Akue JP, 1996, T ROY SOC TROP MED H, V90, P115, DOI 10.1016/S0035-9203(96)90105-4; Anosike JC, 2005, ANN AGR ENV MED, V12, P35; Asio SM, 2009, T ROY SOC TROP MED H, V103, P274, DOI 10.1016/j.trstmh.2008.10.038; Asio Santa Maria, 2009, T ROY SOC TROP MED H, V103, P266; Baird Kevin J, 1988, AM J TROP MED HYG, V38, P553; Bodiwala D, 2003, CANCER LETT, V192, P145, DOI 10.1016/S0304-3835(02)00710-3; BOULESTEIX G, 1986, B SOC PATHOL EXOT, V79, P649; Boussinesq M, 1997, ANN TROP MED PARASIT, V91, P573, DOI 10.1080/00034983.1997.11813176; Boussinesq M, 2006, ANN TROP MED PARASIT, V100, P715, DOI 10.1179/136485906X112194; Boussinesq M, 2001, ANN TROP MED PARASIT, V95, P495, DOI 10.1080/00034980120073184; Bregani E. R., 2007, Parassitologia (Rome), V49, P23; Bregani ER, 2002, T ROY SOC TROP MED H, V96, P654, DOI 10.1016/S0035-9203(02)90343-3; Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175; Chippaux JP, 1996, PARASITOL TODAY, V12, P448, DOI 10.1016/0169-4758(96)40006-0; Collectif, 2004, GRANDS ENS VEG GAB A; DAY KP, 1991, PARASITE IMMUNOL, V13, P277, DOI 10.1111/j.1365-3024.1991.tb00282.x; Diggle PJ, 2007, ANN TROP MED PARASIT, V101, P499, DOI 10.1179/136485907X229121; Duong TH, 1997, T ROY SOC TROP MED H, V91, P592, DOI 10.1016/S0035-9203(97)90040-7; FAIN A, 1981, ANN SOC BELG MED TR, V61, P277; Fux Christoph A, 2006, Travel Med Infect Dis, V4, P275, DOI 10.1016/j.tmaid.2005.07.001; Garcia A, 1999, TROP MED INT HEALTH, V4, P565, DOI 10.1046/j.1365-3156.1999.00442.x; Gardon J, 1997, LANCET, V350, P18, DOI 10.1016/S0140-6736(96)11094-1; GOLDSMID JM, 1970, J CLIN PATHOL, V23, P632, DOI 10.1136/jcp.23.7.632; Kamgno J, 2001, B SOC PATHOL EXOT, V94, P342; Keiser PB, 2003, AM J TROP MED HYG, V69, P331, DOI 10.4269/ajtmh.2003.69.331; LANGUILLAT G, 1978, REV EPIDEMIOL SANTE, V26, P273; LUBEGA R, 1976, B ENTOMOL RES, V66, P421, DOI 10.1017/S0007485300006829; Mpairwe H, 2008, T ROY SOC TROP MED H, V102, P367, DOI 10.1016/j.trstmh.2008.01.017; Mullens BA, 2004, VETER ITAL SER, V40, P160; Narladkar B. W., 2006, Journal of Veterinary Parasitology, V20, P7; PINDER M, 1992, PARASITE IMMUNOL, V14, P541, DOI 10.1111/j.1365-3024.1992.tb00027.x; PINDER M, 1988, PARASITOL TODAY, V4, P279, DOI 10.1016/0169-4758(88)90019-1; Richard Lenoble D, 1985, B SOC PATHOL EXOT, V78, P485; RICHARDLENOBLE D, 1980, B SOC PATHOL EXOT, V73, P192; Takougang I, 2002, B WORLD HEALTH ORGAN, V80, P852; Thomson MC, 2004, FILARIA J, V3, P7, DOI DOI 10.1186/1475-2883-3-7; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2001, INT ARCH ALLERGY IMM, V126, P231, DOI 10.1159/000049519; VOORS AW, 1979, J CHRON DIS, V32, P157, DOI 10.1016/0021-9681(79)90044-4; Wanji S, 2003, T ROY SOC TROP MED H, V97, P182, DOI 10.1016/S0035-9203(03)90114-3; Wanji S, 2003, MED MICROBIOL IMMUN, V192, P15, DOI 10.1007/s00430-002-0154-x	42	24	26	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	OCT	2011	5	10							e1329	10.1371/journal.pntd.0001329				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	842FR	WOS:000296579700010	22022623	DOAJ Gold, Green Published			2019-03-26	
J	Carlier, Y; Torrico, F; Sosa-Estani, S; Russomando, G; Luquetti, A; Freilij, H; Vinas, PA				Carlier, Yves; Torrico, Faustino; Sosa-Estani, Sergio; Russomando, Graciela; Luquetti, Alejandro; Freilij, Hector; Vinas, Pedro Albajar			Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TRYPANOSOMA-CRUZI INFECTION; TRANSMISSION; BENZNIDAZOLE; BOLIVIA; BLOOD		[Carlier, Yves] Univ Libre Brussels, Fac Med, Lab Parasitol, Brussels, Belgium; [Torrico, Faustino] Univ Mayor de San Simon, Fac Med, Cochabamba, Bolivia; [Sosa-Estani, Sergio] Ctr Nacl Diagnost & Invest Endemoepidemias, Buenos Aires, DF, Argentina; [Russomando, Graciela] Univ Nacl Asuncion, Inst Invest Ciencias Salud, Asuncion, Paraguay; [Luquetti, Alejandro] Univ Fed Goias, Hosp Clin, Lab Pesquisa Doenca Chagas, Goiania, Go, Brazil; [Freilij, Hector] Hosp Ninos Dr Ricardo Gutierrez, Serv Parasitol & Chagas, Buenos Aires, DF, Argentina; [Freilij, Hector] Minist Salud Publ, Programa Nacl Chagas, Buenos Aires, DF, Argentina; [Vinas, Pedro Albajar] WHO, Dept Control Neglected Trop Dis, CH-1211 Geneva, Switzerland	Carlier, Y (reprint author), Univ Libre Brussels, Fac Med, Lab Parasitol, Brussels, Belgium.	ycarlier@ulb.ac.be					Altcheh J, 2011, PEDIATRICS, V127, pE212, DOI 10.1542/peds.2010-1172; Bern C, 2009, CLIN INFECT DIS, V49, P1667, DOI 10.1086/648070; Carlier Y, 2003, REV SOC BRAS MED TRO, V6, P767; Carlier Y, 2010, ELSEV INSIGHT, P539, DOI 10.1016/B978-0-12-384876-5.00022-8; Freilij H., 1983, Journal of Clinical Microbiology, V18, P327; FREILIJ H, 1995, CLIN INFECT DIS, V21, P551, DOI 10.1093/clinids/21.3.551; Jackson Y, 2009, EMERG INFECT DIS, V15, P601, DOI 10.3201/eid1504.080438; Munoz J, 2009, CLIN INFECT DIS, V48, P1736, DOI 10.1086/599223; Otani MM, 2009, TRANSFUSION, V49, P1076, DOI 10.1111/j.1537-2995.2009.02107.x; Pan American Health Organization, 2006, OPSHDMCD42506I PAN A; Reithinger R, 2010, J CLIN MICROBIOL, V48, P3003, DOI 10.1128/JCM.02474-09; Remesar MC, 2009, TRANSFUSION, V49, P2352, DOI 10.1111/j.1537-2995.2009.02301.x; Schijman AG, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000931; Sosa-Estani S, 2008, AM J TROP MED HYG, V79, P755, DOI 10.4269/ajtmh.2008.79.755; Sosa-Estani S, 2009, REV SOC BRAS MED TRO, V42, P484, DOI 10.1590/S0037-86822009000500002; Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201; Viotti R, 2009, EXPERT REV ANTI-INFE, V7, P157, DOI 10.1586/14787210.7.2.157; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; *WHO, 2002, 905 WHO	19	86	90	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	OCT	2011	5	10							e1250	10.1371/journal.pntd.0001250				3	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	842FR	WOS:000296579700002	22039554	DOAJ Gold, Green Published			2019-03-26	
J	Ostyn, B; Gidwani, K; Khanal, B; Picado, A; Chappuis, F; Singh, SP; Rijal, S; Sundar, S; Boelaert, M				Ostyn, Bart; Gidwani, Kamlesh; Khanal, Basudha; Picado, Albert; Chappuis, Francois; Singh, Shri Prakash; Rijal, Suman; Sundar, Shyam; Boelaert, Marleen			Incidence of Symptomatic and Asymptomatic Leishmania donovani Infections in High-Endemic Foci in India and Nepal: A Prospective Study	PLOS NEGLECTED TROPICAL DISEASES			English	Article							DIRECT AGGLUTINATION-TEST; HIGH-TRANSMISSION FOCI; VISCERAL LEISHMANIASIS; KALA-AZAR; SKIN-TEST; BARINGO DISTRICT; EASTERN SUDAN; RISK-FACTORS; RIFT-VALLEY; EPIDEMIOLOGY	Incidence of Leishmania donovani infection and Visceral Leishmaniasis (VL) was assessed in a prospective study in Indian and Nepalese high-endemic villages. DAT-seroconversion was used as marker of incident infection in 3 yearly surveys. The study population was followed up to month 30 to identify incident clinical cases. In a cohort of 9034 DAT-negative individuals with neither active signs nor history of VL at baseline, 42 VL cases and 375 asymptomatic seroconversions were recorded in the first year, giving an infection: disease ratio of 8.9 to 1. In the 18 months' follow-up, 7 extra cases of VL were observed in the seroconverters group (N = 375), against 14 VL cases among the individuals who had not seroconverted in the first year (N = 8570) (RR = 11.5(4.5<RR<28.3)). Incident asymptomatic L. donovani infection in VL high-endemic foci in India and Nepal is nine times more frequent than incident VL disease. About 1 in 50 of these new but latent infections led to VL within the next 18 months.	[Ostyn, Bart; Picado, Albert; Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Khanal, Basudha; Rijal, Suman] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Gidwani, Kamlesh; Singh, Shri Prakash; Sundar, Shyam] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Picado, Albert] London Sch Hyg & Trop Med, London WC1, England; [Chappuis, Francois] Univ Hosp Geneva, Geneva, Switzerland; [Chappuis, Francois] Univ Geneva, Geneva, Switzerland	Ostyn, B (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	bostyn@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Picado, Albert/0000-0001-7344-628X	European Union [015374]	The Kalanet project received financial support from the European Union (Proposal Contract No.: 015374, FP6/INCO-DEV, http://ec.europa.eu/research/fp6/index_en.cfm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALI A, 1994, ANN TROP MED PARASIT, V88, P289, DOI 10.1080/00034983.1994.11812869; ALI A, 1993, ANN TROP MED PARASIT, V87, P157, DOI 10.1080/00034983.1993.11812749; BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; Bern C, 2005, EMERG INFECT DIS, V11, P655, DOI 10.3201/eid1105.040718; Bern C, 2007, AM J TROP MED HYG, V76, P909; Bern C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000599; Bhattarai NR, 2009, TROP MED INT HEALTH, V14, P404, DOI 10.1111/j.1365-3156.2009.02242.x; Bimal S, 2005, ANN TROP MED PARASIT, V99, P743, DOI 10.1179/136485905X65107; Boelaert M, 1999, TROP MED INT HEALTH, V4, P31, DOI 10.1046/j.1365-3156.1999.00348.x; CHOWDHURY MS, 1993, PARASITOL RES, V79, P444, DOI 10.1007/BF00931580; Costa CHN, 2002, AM J TROP MED HYG, V66, P334, DOI 10.4269/ajtmh.2002.66.334; Davies CR, 1999, PARASITOLOGY, V119, P247, DOI 10.1017/S0031182099004680; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; DHIMAN RC, 1991, INDIAN J MED RES-A, V93, P155; ELHARITH A, 1988, J CLIN MICROBIOL, V26, P1321; ELHARITH A, 1987, T R SOC TROP MED HYG, V81, P603; EVANS TG, 1992, J INFECT DIS, V166, P1124, DOI 10.1093/infdis/166.5.1124; Gidwani K, 2009, AM J TROP MED HYG, V80, P345, DOI 10.4269/ajtmh.2009.80.345; Gidwani K, 2009, AM J TROP MED HYG, V80, P566, DOI 10.4269/ajtmh.2009.80.566; Hailu A, 2009, ANN TROP MED PARASIT, V103, P659, DOI 10.1179/000349809X12554106963555; Hailu A, 1996, ETHIOPIAN MED J, V34, P11; Jacquet D, 2006, TROP MED INT HEALTH, V11, P1777, DOI 10.1111/j.1365-3156.2006.01743.x; Khalil EAG, 2002, TROP MED INT HEALTH, V7, P35, DOI 10.1046/j.1365-3156.2002.00832.x; Khanal B, 2010, TROP MED INT HEALTH, V15, P1390, DOI 10.1111/j.1365-3156.2010.02631.x; Koirala S, 2004, TROP MED INT HEALTH, V9, P533, DOI 10.1111/j.1365-3156.2004.01212.x; Liese J, 2008, IMMUNOBIOLOGY, V213, P377, DOI 10.1016/j.imbio.2007.12.005; NANDY A, 1987, ANN TROP MED PARASIT, V81, P693, DOI 10.1080/00034983.1987.11812172; Picado A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6760; Rijal S, 2010, TROP MED INT HEALTH, V15, P21, DOI 10.1111/j.1365-3156.2010.02518.x; Romero HD, 2009, AM J TROP MED HYG, V81, P27; Saha S, 2009, T ROY SOC TROP MED H, V103, P737, DOI 10.1016/j.trstmh.2008.10.006; SCHAEFER KU, 1994, AM J TROP MED HYG, V50, P78, DOI 10.4269/ajtmh.1994.50.78; SCHAEFER KU, 1995, T ROY SOC TROP MED H, V89, P471, DOI 10.1016/0035-9203(95)90070-5; Schenkel K, 2006, TROP MED INT HEALTH, V11, P1792, DOI 10.1111/j.1365-3156.2006.01735.x; Singh S, 2002, CLIN DIAGN LAB IMMUN, V9, P568, DOI 10.1128/CDLI.9.3.568-572.2002; Singh SP, 2006, TROP MED INT HEALTH, V11, P899, DOI 10.1111/j.1365-3156.2006.01647.x; Singh SP, 2010, TROP MED INT HEALTH, V15, P12, DOI 10.1111/j.1365-3156.2010.02519.x; Singh VP, 2010, AM J TROP MED HYG, V82, P9, DOI 10.4269/ajtmh.2010.09-0235; Sinha PK, 2008, ANN TROP MED PARASIT, V102, P119, DOI 10.1179/136485908X252278; Topno RK, 2010, AM J TROP MED HYG, V83, P502, DOI 10.4269/ajtmh.2010.09-0345; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826; Zijlstra EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717	43	75	78	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	OCT	2011	5	10							e1284	10.1371/journal.pntd.0001284				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	842FR	WOS:000296579700004	21991397	DOAJ Gold, Green Published			2019-03-26	
J	De Smedt, S; Nkurikiye, J; Fonteyne, Y; Hogewoning, A; Van Esbroeck, M; De Bacquer, D; Tuft, S; Gilbert, C; Delanghe, J; Kestelyn, P				De Smedt, Stefan; Nkurikiye, John; Fonteyne, Yannick; Hogewoning, Arjan; Van Esbroeck, Marjan; De Bacquer, Dirk; Tuft, Stephen; Gilbert, Clare; Delanghe, Joris; Kestelyn, Philippe			Vernal Keratoconjunctivitis in School Children in Rwanda and Its Association with Socio-Economic Status: A Population-Based Survey	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							NORTHERN NIGERIA; ALLERGIC DISEASES; BRONCHIAL-ASTHMA; IGE; PREVALENCE; PARASITES; URBAN; ATOPY; CONJUNCTIVITIS; INFECTION	Vernal keratoconjunctivitis (VKC) is an allergic eye disease and an important cause of hospital referral among children in Africa and Asia. Hospital-based studies have suggested a role for parasites in its pathogenesis. To determine the prevalence and risk factors for VKC in Central Africa, we conducted a nested population-based case control study in Rwanda, involving randomly selected primary schools from different environments (rural/urban) and climate. A prevalence of VKC of 4.0% (95% confidence interval 3.3-4.7%) was found among 3,041 children studied (participation rate 94.7%). The intestinal parasitic burden was not related to VKC. Besides hot dry climate (odds ratio [OR] = 1.5, P = 0.05) and male gender (OR = 1.7, P = 0.005), multivariate analysis identified higher economic status as a risk for VKC (OR = 1.4, P = 0.005). The effect on VKC of higher economic status appears not to act through differences in parasitic intestinal load.	[De Smedt, Stefan; Kestelyn, Philippe] Ghent Univ Hosp, Dept Ophthalmol, Ghent, Belgium; [Nkurikiye, John; Hogewoning, Arjan] King Faisal Hosp, Dept Ophthalmol, Kigali, Rwanda; [Van Esbroeck, Marjan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [De Bacquer, Dirk] Univ Ghent, Dept Publ Hlth, Ghent, Belgium; [Tuft, Stephen] Natl Hlth Serv Fdn Trust, Moorfields Eye Hosp, London, England; [Gilbert, Clare] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London, England; [Delanghe, Joris] Ghent Univ Hosp, Dept Biol Clin, Ghent, Belgium	De Smedt, S (reprint author), Leopoldstr 34, B-2800 Mechelen, Belgium.	dr.stefan.desmedt@gmail.com; jeankur@yahoo.co.uk; stds@telenet.be; arjanhogewoning@yahoo.com; mvesbroeck@itg.be; dirk.debacquer@ugent.be; s.tuft@ucl.ac.uk; clare.gilbert@Ishtm.ac.uk; joris.delanghe@ugent.be; philippe.kestelyn@ugent.be		De Smedt, Stefaan/0000-0002-8653-2598	FRO (Belgian Funds for Research in Ophthalmology); Light for the World Belgium; CBM-International; PHADIA NV/SA (Brussels, Belgium)	This study was possible thanks to financial support from FRO (Belgian Funds for Research in Ophthalmology), Light for the World Belgium, CBM-International, and PHADIA NV/SA (Brussels, Belgium) and the active participation in the field work of the Kabgayi Eye Unit personnel.	ABDURRAHMAN MB, 1982, CLIN ALLERGY, V12, P379, DOI 10.1111/j.1365-2222.1982.tb02542.x; Ajaiyeoba Ayotunde, 2005, J Natl Med Assoc, V97, P1529; ALSHISHTAWY MM, 1991, INT ARCH ALLER A IMM, V96, P348, DOI 10.1159/000235520; BENEZRA D, 1986, AM J OPHTHALMOL, V101, P278, DOI 10.1016/0002-9394(86)90819-6; Bonini S, 2000, OPHTHALMOLOGY, V107, P1157, DOI 10.1016/S0161-6420(00)00092-0; Bremond-Gignac D, 2008, BRIT J OPHTHALMOL, V92, P1097, DOI 10.1136/bjo.2007.117812; CAMERON JA, 1995, OPHTHALMOLOGY, V102, P985, DOI 10.1016/S0161-6420(95)30925-6; CARSWELL F, 1977, CLIN ALLERGY, V7, P445, DOI 10.1111/j.1365-2222.1977.tb01475.x; Chenge B, 2003, Bull Soc Belge Ophtalmol, P9; DAHAN E, 1983, BRIT J OPHTHALMOL, V67, P688, DOI 10.1136/bjo.67.10.688; Diallo J S, 1976, Rev Int Trach Pathol Ocul Trop Subtrop, V53, P71; DiVall SA, 2009, CURR OPIN ENDOCRINOL, V16, P1, DOI 10.1097/MED.0b013e3283207937; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; Everaerts M C, 1993, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, V70, P199; Glewwe P, 2000, DESIGNING HOUSEHOLD; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hodges MG, 2007, CURR OPIN ALLERGY CL, V7, P424, DOI 10.1097/ACI.0b013e3282ef6937; Hugg T, 2008, EUR J EPIDEMIOL, V23, P123, DOI 10.1007/s10654-007-9217-z; JOUBERT JR, 1979, S AFR MED J, V56, P599; Khan MD, 1986, PAK J OPHTHALMOL, V2, P111; Kocabeyoglu S, 2008, EUR J OPHTHALMOL, V18, P675; Lambiase A, 2009, OPHTHAL EPIDEMIOL, V16, P38, DOI 10.1080/09286580802573177; LEE TH, 1985, THORAX, V40, P481, DOI 10.1136/thx.40.7.481; LOUGHLIN EH, 1949, JAMA-J AM MED ASSOC, V139, P997, DOI 10.1001/jama.1949.02900320027008; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; MACFARLANE JT, 1979, CLIN ALLERGY, V9, P333, DOI 10.1111/j.1365-2222.1979.tb02491.x; McConchie BW, 2006, INFECT IMMUN, V74, P6632, DOI 10.1128/IAI.00720-06; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; Mitchell H S, 1970, East Afr Med J, V47, P142; MUMCUOGLU YK, 1988, OPHTHALMOLOGICA, V196, P175, DOI 10.1159/000309896; Munyakazi A, 2005, ATLAS RWANDA; NEUMANN E, 1959, AM J OPHTHALMOL, V47, P166, DOI 10.1016/S0002-9394(14)76417-7; Nicolaou N, 2005, ALLERGY, V60, P1357, DOI 10.1111/j.1398-9995.2005.00961.x; ORREN A, 1975, INT ARCH ALLER A IMM, V49, P814, DOI 10.1159/000231465; Resnikoff S, 1988, REV INT TRACHOME, V3, P53; Rischewski D, 2008, T ROY SOC TROP MED H, V102, P608, DOI 10.1016/j.trstmh.2008.02.023; SANDFORDSMITH JH, 1979, TROP GEOGR MED, V31, P321; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Tabbara KF, 1999, CAN J OPHTHALMOL, V34, P88; The Government of Rwanda K, 2003, 3 GEN CENS POP HOUS; TUFT SJ, 1989, EYE, V3, P420, DOI 10.1038/eye.1989.63; Tuft SJ, 1998, OPHTHALMOLOGY, V105, P1489, DOI 10.1016/S0161-6420(98)98034-4; TURTON JA, 1976, LANCET, V2, P686; Ukponmwan CU, 2003, TROP DOCT, V33, P242, DOI 10.1177/004947550303300419; Viinanen A, 2007, ALLERGY, V62, P272, DOI 10.1111/j.1398-9995.2006.01279.x; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; WARRELL DA, 1975, Q J MED, V44, P325; WEINBERG EG, 1977, LANCET, V2, P500; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Zeyrek CD, 2006, J INVEST ALLERG CLIN, V16, P290	51	15	15	0	5	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	OCT	2011	85	4					711	717		10.4269/ajtmh.2011.11-0291				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	833QB	WOS:000295898900025	21976577	Green Published, Bronze			2019-03-26	
J	Mwape, KE; Praet, N; Benitez-Ortiz, W; Muma, JB; Zulu, G; Celi-Erazo, M; Phiri, IK; Rodriguez-Hidalgo, R; Dorny, P; Gabriel, S				Mwape, K. E.; Praet, N.; Benitez-Ortiz, W.; Muma, J. B.; Zulu, G.; Celi-Erazo, M.; Phiri, I. K.; Rodriguez-Hidalgo, R.; Dorny, P.; Gabriel, S.			Field evaluation of urine antigen detection for diagnosis of Taenia solium cysticercosis	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Cysticercosis; Taenia solium; Diagnosis; Urine; Antigen; ELISA	PORCINE CYSTICERCOSIS; PREVALENCE; NEUROCYSTICERCOSIS; DISEASE; LEISHMANIASIS; INFECTION; PROVINCES; FRAMEWORK; SOUTHERN; EASTERN	(Neuro)cysticercosis is an important zoonotic disease caused by infection with Taenia solium metacestode larvae. Existing immunodiagnostic techniques detect antibodies and circulating antigens (Ag) in serum and cerebrospinal fluid (CSF). Blood/CSF collection is an invasive procedure associated with blood-borne infections and is often not well accepted by communities. Detection of circulating Ag in urine has been suggested as an alternative, however this has been evaluated in clinical settings only. The aim of the present study was to evaluate the performance of a urine Ag-ELISA under field conditions. Paired serum and urine samples were obtained from participants in endemic areas of Ecuador (n = 748) and Zambia (n = 690) and were subjected to a monoclonal antibody-based Ag-ELISA. Calculation of positive and negative agreement indices (AI) showed better agreement in the negative direction both for Ecuadorian and Zambian samples (AI of 93.1 and 86.8, respectively). Using a Bayesian approach to determine the test characteristics, similar sensitivities were obtained for serum and urine Ag detection, whereas a decreased specificity was determined for the urine Ag-ELISA with a lower specificity (78.6%) for Zambian samples than for Ecuadorian samples (88.4%). This study indicates a higher specificity for the serum test under field conditions and promotes further research to improve the urine test. (C) 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Praet, N.; Dorny, P.; Gabriel, S.] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Mwape, K. E.; Phiri, I. K.] Univ Zambia, Dept Clin Studies, Sch Vet Med, Lusaka, Zambia; [Benitez-Ortiz, W.; Celi-Erazo, M.] Univ Cent Ecuador, Ctr Int Zoonosis CIZ, Quito, Ecuador; [Muma, J. B.] Univ Zambia, Dept Dis Control, Sch Vet Med, Lusaka, Zambia; [Zulu, G.] Petauke Dist Hosp, Petauke, Zambia; [Rodriguez-Hidalgo, R.] Univ Cent Ecuador, Fac Med Vet & Zootecnia, Ctr Int Zoonosis, Hosp Dia, Quito, Ecuador	Gabriel, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	sgabriel@itg.be	Rodriguez-Hidalgo, Richar/P-8877-2015	Rodriguez-Hidalgo, Richar/0000-0002-9338-1062; GABRIEL, SARAH/0000-0002-2523-233X	Institute of Tropical Medicine (Antwerp, Belgium); Centro Internacional de Zoonosis (Quito, Ecuador); University of Pretoria (Pretoria, South Africa); Flemish Interuniversity Cooperation, Zambia; Research Initiative Programme, Zambia [VLIR-UOS.ZIUS2008RIP-8961]	This study received financial support from the Belgian Cooperation in the framework of the institutional collaboration between the Institute of Tropical Medicine (Antwerp, Belgium) and the Centro Internacional de Zoonosis (Quito, Ecuador) and the University of Pretoria (Pretoria, South Africa). Support was also obtained from the Flemish Interuniversity Cooperation, Research Initiative Programme, Zambia (VLIR-UOS.ZIUS2008RIP-8961).	Adel A, 2010, VET PARASITOL, V172, P204, DOI 10.1016/j.vetpar.2010.05.009; Berkvens D, 2006, EPIDEMIOLOGY, V17, P145, DOI 10.1097/01.ede.0000198422.64801.8d; Bhattarai NR, 2009, TROP MED INT HEALTH, V14, P404, DOI 10.1111/j.1365-3156.2009.02242.x; Castillo Y, 2009, AM J TROP MED HYG, V80, P379, DOI 10.4269/ajtmh.2009.80.379; Deckers N, 2010, TRENDS PARASITOL, V26, P137, DOI 10.1016/j.pt.2009.12.008; Del Brutto OH, 2005, SEMIN NEUROL, V25, P243, DOI 10.1055/s-2005-917661; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Dorny P, 2003, ACTA TROP, V87, P79, DOI 10.1016/S0001-706X(03)00058-5; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; FREILIJ HL, 1987, J CLIN MICROBIOL, V25, P133; Graham P, 1998, J CLIN EPIDEMIOL, V51, P763, DOI 10.1016/S0895-4356(98)00048-1; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713; KATZIN AM, 1991, AM J TROP MED HYG, V45, P453, DOI 10.4269/ajtmh.1991.45.453; KOHANTEB J, 1987, T ROY SOC TROP MED H, V81, P578, DOI 10.1016/0035-9203(87)90414-7; KREMSNER PG, 1993, T ROY SOC TROP MED H, V87, P167, DOI 10.1016/0035-9203(93)90474-5; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Murrell KD, 2005, WHO FAO OIE GUIDELIN, P27; Parija M, 2004, ACTA TROP, V92, P253, DOI 10.1016/j.actatropica.2004.08.007; Parija SC, 1997, J CLIN MICROBIOL, V35, P1571; Phiri IK, 2002, VET PARASITOL, V108, P31, DOI 10.1016/S0304-4017(02)00165-6; Praet N, 2010, INT J PARASITOL, V40, P85, DOI 10.1016/j.ijpara.2009.07.007; Praet N, 2010, AM J TROP MED HYG, V83, P413, DOI 10.4269/ajtmh.2010.10-0121; Roman G, 2000, B WORLD HEALTH ORGAN, V78, P399; Sikasunge CS, 2008, VET J, V176, P240, DOI 10.1016/j.tvjl.2007.02.030; Simarro PP, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-57; SOKAL R, 1981, BIOMETRY PRINCIPALS; ZHENG HJ, 1987, AM J TROP MED HYG, V36, P554	27	6	6	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	OCT	2011	105	10					574	578		10.1016/j.trstmh.2011.05.010				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832AD	WOS:000295771300006	21862093				2019-03-26	
J	Cook, J				Cook, J.			Measuring malaria transmission using serology	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Cook, J.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		12	12						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100016					2019-03-26	
J	Colebunders, R				Colebunders, R.			Tuberculosis associated to Immune Reconstruction Inflammatory Syndrome (IRIS)	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Colebunders, R.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		15	15						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100026					2019-03-26	
J	Diro, E; Hailu, A; Lynen, L; Boelaert, M; Van Griensven, J				Diro, E.; Hailu, A.; Lynen, L.; Boelaert, M.; Van Griensven, J.			VL-HIV co-infection in East-Africa: current challenges and perspectives	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Diro, E.] Univ Gondar, Gondar, Ethiopia; [Hailu, A.; Boelaert, M.; Van Griensven, J.] Inst Trop Med, B-2000 Antwerp, Belgium; [Lynen, L.] Univ Addis Ababa, Fac Med, Addis Ababa, Ethiopia			Boelaert, Marleen/E-2698-2012; Lynen, Lutgarde/A-1212-2014	Boelaert, Marleen/0000-0001-8051-6776; Lynen, Lutgarde/0000-0001-7183-4895				0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		17	17						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100033					2019-03-26	
J	van Griensven, J; Diro, E; Hailu, A; Ritmeijer, K; Zijlstra, E; Balasegaram, M				van Griensven, J.; Diro, E.; Hailu, A.; Ritmeijer, K.; Zijlstra, E.; Balasegaram, M.			Recent HIV-VL clinical research initiatives in East Africa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[van Griensven, J.] Inst Trop Med, B-2000 Antwerp, Belgium; [Diro, E.] Univ Gondar, Gondar, Ethiopia; [Hailu, A.] Addis Abeba Univ, Addis Ababa, Ethiopia; [Ritmeijer, K.] Med Sans Frontiers, Amsterdam, Netherlands; [Zijlstra, E.; Balasegaram, M.] Drugs Neglected Dis Initiat, Geneva, Switzerland								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		18	18						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100035					2019-03-26	
J	Dubourg, D; Richard, F				Dubourg, D.; Richard, F.			Female Genital Mutilation in Europe	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Dubourg, D.; Richard, F.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		37	38						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100098					2019-03-26	
J	Schirvel, C; Gyselinck, K; Van de Roost, D				Schirvel, C.; Gyselinck, K.; Van De Roost, D.			Be-Cause health, Belgian initiative for international health!	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Schirvel, C.; Gyselinck, K.; Van De Roost, D.] Because Hlth, Brussels, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		41	42						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100112					2019-03-26	
J	Paul, E; Ireland, M; Martini, J; Zinnen, V; Ronse, I; Samake, S; Dujardin, B				Paul, E.; Ireland, M.; Martini, J.; Zinnen, V.; Ronse, I.; Samake, S.; Dujardin, B.			What results can be expected from the agenda for aid effectiveness? Analysis and application to Mali	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Paul, E.] Univ Liege, Liege, Belgium; [Paul, E.] GRAP PA Sante, Brussels, Belgium; [Ireland, M.; Dujardin, B.] Univ Libre Bruxelles, Ecole Sante Publ, Brussels, Belgium; [Martini, J.] Catholic Univ Louvain, Fac Sante Publ, B-3000 Louvain, Belgium; [Ronse, I.; Samake, S.] Hlth Sector, Planning & Stat Unit, Bamako, Mali								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		42	42						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100114					2019-03-26	
J	Paul, E; Berthe, I; Samake, S				Paul, E.; Berthe, I.; Samake, S.			Comparative analysis of two approaches to putting IHP+ into practice: Mali and Benin	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Paul, E.] Univ Liege, GRAP PA Sante, Liege, Belgium; [Berthe, I.; Samake, S.] Cellule Planificat & Stat Secteur Sante, Bamako, Mali								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		42	42						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100113					2019-03-26	
J	Zinnen, V; Macq, J; Robert, A				Zinnen, V.; Macq, J.; Robert, A.			Getting knowledge from relationship between Sector Wide Approach and Health Service Delivery: a multiple-case study approach in Tanzania	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Zinnen, V.; Macq, J.; Robert, A.] Catholic Univ Louvain, Louvain GRAP PA Sante, Louvain, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		42	43						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100115					2019-03-26	
J	Hoofmann, A; Gerstel, L; van Heusden, G; Peterhans, B; Zwanikken, P; Valladares, LM				Hoofmann, A.; Gerstel, L.; van Heusden, G.; Peterhans, B.; Zwanikken, P.; Magana Valladares, L.			tropEd - learning together for better health worldwide	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Hoofmann, A.; Peterhans, B.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Gerstel, L.; Zwanikken, P.] Royal Trop Inst, NL-1105 AZ Amsterdam, Netherlands; [van Heusden, G.] Inst Trop Med, B-2000 Antwerp, Belgium; [Magana Valladares, L.] Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		47	47						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100126					2019-03-26	
J	De Smet, M; Van Herp, M; Stassijns, J				De Smet, M.; Van Herp, M.; Stassijns, J.			The challenge of timely identification of malaria outbreaks - the intervention of Medecins Sans Frontieres in Burundi, 2010	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[De Smet, M.; Van Herp, M.; Stassijns, J.] Med Sans Frontieres, Brussels, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		58	58						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100159					2019-03-26	
J	Kirakoya-Samadoulougou, F; Sanou, M; Kiba-Koumare, ARTC; Kienou, K; Bationo, F; Robert, A				Kirakoya-Samadoulougou, F.; Sanou, M.; Kiba-Koumare, A. R. T. C.; Kienou, K.; Bationo, F.; Robert, Annie			Seroepidemiology of transfusion-transmissible infections in blood donors of Burkina Faso	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Kirakoya-Samadoulougou, F.; Bationo, F.; Robert, Annie] Catholic Univ Louvain, Fac Sante Publ, IREC, B-3000 Louvain, Belgium; [Sanou, M.; Kiba-Koumare, A. R. T. C.; Kienou, K.] Ctr Natl Transfus Sanguine, Ouagadougou, Burkina Faso								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		64	64						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100177					2019-03-26	
J	Gidwani, K; Picado, A; Rijal, S; Singh, SP; Roy, L; Volf, P; Sudarshan, M; Sundar, S; Boelaert, M; Rogers, M				Gidwani, K.; Picado, A.; Rijal, S.; Singh, S. P.; Roy, L.; Volf, P.; Sudarshan, M.; Sundar, S.; Boelaert, M.; Rogers, M.			Antibody response to sand fly saliva to evaluate human visceral leishmaniasis vector exposure in India and Nepal: effect of long-lasting insecticidal nets	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Gidwani, K.; Singh, S. P.; Sudarshan, M.; Sundar, S.] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Picado, A.; Rogers, M.] London Sch Hyg & Trop Med, London WC1, England; [Rijal, S.; Roy, L.] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Volf, P.] Charles Univ Prague, Prague, Czech Republic; [Boelaert, M.] Inst Trop Med, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012; Volf, Petr/C-4300-2012	Boelaert, Marleen/0000-0001-8051-6776; Volf, Petr/0000-0003-1790-1123				0	1	1	1	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		66	66						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100183					2019-03-26	
J	Perry, M; Wyllie, S; Prajapati, VK; Feldmann, J; Sundar, S; Boelaert, M; Fairlamb, AH				Perry, M.; Wyllie, S.; Prajapati, V. K.; Feldmann, J.; Sundar, S.; Boelaert, M.; Fairlamb, A. H.			Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Perry, M.; Wyllie, S.; Fairlamb, A. H.] Univ Dundee, Dundee, Scotland; [Prajapati, V. K.; Sundar, S.] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Feldmann, J.] Univ Aberdeen, Aberdeen, Scotland; [Boelaert, M.] Inst Trop Med, B-2000 Antwerp, Belgium			Fairlamb, Alan/A-5272-2009; Boelaert, Marleen/E-2698-2012	Fairlamb, Alan/0000-0001-5134-0329; Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		66	67						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100185					2019-03-26	
J	Malaviya, P; Picado, A; Singh, SP; Hasker, E; Singh, RP; Boelaert, M; Sundar, S				Malaviya, P.; Picado, A.; Singh, S. P.; Hasker, E.; Singh, R. P.; Boelaert, M.; Sundar, S.			Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Malaviya, P.; Singh, S. P.; Singh, R. P.; Sundar, S.] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Picado, A.; Hasker, E.; Boelaert, M.] Inst Trop Med, Epidemiol & Dis Control Unit, Dept Publ Hlth, B-2000 Antwerp, Belgium			Malaviya, Paritosh/B-1819-2012; Boelaert, Marleen/E-2698-2012	Malaviya, Paritosh/0000-0002-7558-152X; Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		67	67						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100187					2019-03-26	
J	Gabriel, S; Blocher, J; Dorny, P; Abatih, E; Schmutzhard, E; Winkler, A				Gabriel, S.; Blocher, J.; Dorny, P.; Abatih, E.; Schmutzhard, E.; Winkler, A.			Re-visiting the 'Del Brutto diagnostic criteria' for the diagnosis of neurocysticercosis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Gabriel, S.; Dorny, P.; Abatih, E.] Inst Trop Med, B-2000 Antwerp, Belgium; [Blocher, J.] Med Univ Innsbruck, Innsbruck, Austria; [Schmutzhard, E.] Univ Med Ctr Gottingen, Gottingen, Germany; [Winkler, A.] Tech Univ Munich, Munich, Germany				GABRIEL, SARAH/0000-0002-2523-233X				0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		68	68						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100189					2019-03-26	
J	van Lieshout, L; Brienen, E; Ziem, J; Mendes, F; Benitez, W; Kaisar, M; Canales, M; Ramarokoto, CE; Downs, J; Polman, K; Verweij, JJ				van Lieshout, L.; Brienen, E.; Ziem, J.; Mendes, F.; Benitez, W.; Kaisar, M.; Canales, M.; Ramarokoto, C. E.; Downs, J.; Polman, K.; Verweij, J. J.			Multiplex real-time PCR demonstrates focal distribution of Strongyloides stercoralis in endemic countries	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[van Lieshout, L.; Brienen, E.; Verweij, J. J.] Leiden Univ, Dept Parasitol, Med Ctr, B-2000 Leiden, Netherlands; [Ziem, J.] Univ Dev Studies, Tamale, Ghana; [Mendes, F.] Catholic Univ Mozambique, Beira, Mozambique; [Benitez, W.] Cent Univ Ecuador, Quito, Ecuador; [Kaisar, M.] Univ Indonesia, Jakarta, Indonesia; [Canales, M.] Univ Peruana Cayetano Heredia, Lima, Peru; [Ramarokoto, C. E.] Inst Pasteur Madagascar, Antananarivo, Madagascar; [Downs, J.] Weill Cornell Med Coll, Mwanza, Tanzania; [Downs, J.] Bugando Med Ctr, Mwanza, Tanzania; [Polman, K.] Inst Trop Med Prince Leopold, Antwerp, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		70	70						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100197					2019-03-26	
J	Vanlerberghe, V; Trongtokit, Y; Jirarojwatana, S; Jirarojwatana, R; Apiwathnasorn, C; Van der Stuyft, P				Vanlerberghe, V.; Trongtokit, Y.; Jirarojwatana, S.; Jirarojwatana, R.; Apiwathnasorn, C.; Van der Stuyft, P.			The effectiveness of insecticide treated curtains in combination with other Aedes control actions	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Vanlerberghe, V.; Van der Stuyft, P.] Inst Trop Med, B-2000 Antwerp, Belgium; [Trongtokit, Y.; Apiwathnasorn, C.] Mahidol Univ, Bangkok 10700, Thailand; [Jirarojwatana, S.; Jirarojwatana, R.] Reg Off Dis Prevent & Control, Chon Buri, Thailand								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		72	72						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100202					2019-03-26	
J	Sanchez, L; Sebrango, C; Abad, Y; Pelaez, O; Shkedy, Z; Van der Stuyft, P				Sanchez, L.; Sebrango, C.; Abad, Y.; Pelaez, O.; Shkedy, Z.; Van der Stuyft, P.			Reproduction number, turning point, total number of cases and impact of interventions during dengue outbreak in Playa municipality, La Habana city	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Sanchez, L.; Abad, Y.; Pelaez, O.] Inst Pedro Kouri, Havana, Cuba; [Sebrango, C.] Univ Sancti Spiritus, Sancti Spiritus, Cuba; [Shkedy, Z.] Hasselt Univ, Hasselt, Belgium; [Van der Stuyft, P.] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		73	73						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100205					2019-03-26	
J	Duysburgh, E; Temmerman, M; Ye, M; Williams, A; Massawe, S				Duysburgh, E.; Temmerman, M.; Ye, M.; Williams, A.; Massawe, S.			Improving quality of maternal and newborn care in selected districts in 3 sub-saharan countries: baseline quality assessment	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Duysburgh, E.; Temmerman, M.] Univ Ghent, Int Ctr Reprod Hlth, Ghent, Belgium; [Massawe, S.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania								0	0	0	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		81	81						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100228					2019-03-26	
J	Philips, MM; Ponsar, F; Gerard, S				Philips, M. M.; Ponsar, F.; Gerard, S.			Lessons learned from an organisation-wide policy change within an international non-governmental organisation: process and issues linked to the removal of user fees within MSF supported health services	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Philips, M. M.; Ponsar, F.; Gerard, S.] Med Sans Frontieres, Brussels, Belgium								0	0	0	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		90	90						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100253					2019-03-26	
J	Philips, MM; Jouquet, G; Ponsar, F; Vanoverloop, C; Lambert, D				Philips, M. M.; Jouquet, G.; Ponsar, F.; Vanoverloop, C.; Lambert, D.			Simulation of running cost needs for a rural district hospital in DRC: based on real life cost data, collected during post-conflict restart of health services in the District Hospital of Lubutu	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Philips, M. M.; Jouquet, G.; Ponsar, F.; Vanoverloop, C.; Lambert, D.] Med Sans Frontieres, Brussels, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		90	90						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100252					2019-03-26	
J	Berthe, A; Berthe, L; Konate, B; Drabo, M; Badini, FK; Macq, J				Berthe, A.; Berthe, L.; Konate, B.; Drabo, M.; Badini, F. Kinda; Macq, J.			Identification of elders with functional disability in Bobo-Dioulasso Burkina Faso	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Berthe, A.] Ctr Muraz, Bobo Dioulasso, Burkina Faso; [Badini, F. Kinda] Univ Ouagadougou, Ouagadougou, Burkina Faso; [Macq, J.] Catholic Univ Louvain, B-1348 Louvain, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		91	91						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100255					2019-03-26	
J	Rodriguez-Salva, A; Diaz-Pinera, A; Garcia-Roche, R; Guerra-Chang, M; Balcindes-Acosta, S; Jova-Morel, R; De Vos, P; Van der Stuyft, P				Rodriguez-Salva, A.; Diaz-Pinera, A.; Garcia-Roche, R.; Guerra-Chang, M.; Balcindes-Acosta, S.; Jova-Morel, R.; De Vos, P.; Van der Stuyft, P.			Health seeking behavior in Centro Habana, Cuba: the family doctor as entry point to the health care system	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Rodriguez-Salva, A.; Diaz-Pinera, A.; Garcia-Roche, R.; Balcindes-Acosta, S.; Jova-Morel, R.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; [Guerra-Chang, M.] Ctr Habana, Municipal Hlth Direct, Havana, Cuba; [De Vos, P.; Van der Stuyft, P.] Inst Trop Med, Epidemiol & Dis Control Unit, Dept Publ Hlth, B-2000 Antwerp, Belgium			De Vos, Pol/D-3370-2009					0	0	0	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		91	91						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100254					2019-03-26	
J	van Olmen, J; Criel, B; Van Damme, W; Marchal, B; Hoeree, T; Pirard, M; Kegels, G				van Olmen, J.; Criel, B.; Van Damme, W.; Marchal, B.; Hoeree, T.; Pirard, M.; Kegels, G.			Analysing health systems to make them stronger	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[van Olmen, J.; Criel, B.; Van Damme, W.; Marchal, B.; Hoeree, T.; Pirard, M.; Kegels, G.] Inst Trop Med, B-2000 Antwerp, Belgium			Van Damme, Wim/F-7404-2011					0	1	1	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		93	93						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100261					2019-03-26	
J	Keygnaert, I; Anastasiou, A; Camilleri, K; Degomme, O; Devile, W; Dias, S; Field, CA; Kovats, A; Vettenburg, N; Temmerman, M				Keygnaert, I.; Anastasiou, A.; Camilleri, K.; Degomme, O.; Devile, W.; Dias, S.; Field, C. -A.; Kovats, A.; Vettenburg, N.; Temmerman, M.			Senperforto: determinants for effective prevention and response actions of SGBV perpetration and victimization in the European asylum reception system	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Keygnaert, I.; Degomme, O.; Devile, W.; Temmerman, M.] Univ Ghent, ICRH, B-9000 Ghent, Belgium; [Anastasiou, A.] Univ Ghent, Greek Refugee Council, B-9000 Ghent, Belgium; [Camilleri, K.] Univ Ghent, Jesuit Refugee Serv Malta, B-9000 Ghent, Belgium; [Dias, S.] NI VEL, Utrecht, Netherlands; [Field, C. -A.] Univ Nova Lisboa, IHMT, P-1200 Lisbon, Portugal; [Kovats, A.] Univ Coll Dublin, Sch Social Policy, Dublin 2, Ireland; [Vettenburg, N.] Hungarian Assoc Migrat, Budapest, Hungary; Univ Ghent, Dept Social Welf Studies, B-9000 Ghent, Belgium			Dias, Sonia/I-7876-2012; santos, sofia/I-1637-2012	Dias, Sonia/0000-0001-5085-0685; 				0	0	0	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		96	96						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100268					2019-03-26	
J	Mens, P; de Bes, L; Moers, A; Hallett, R; Verweij, J; Overmeir, C; Leeflang, M; van Amerongen, A; Tinto, H; Schallig, H				Mens, P.; de Bes, L.; Moers, A.; Hallett, R.; Verweij, J.; Overmeir, C.; Leeflang, M.; van Amerongen, A.; Tinto, H.; Schallig, H.			Development and evaluation of simplified molecular diagnostic devices for malaria	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Mens, P.; de Bes, L.; Schallig, H.] Royal Trop Inst, NL-1105 AZ Amsterdam, Netherlands; [Moers, A.; van Amerongen, A.] Wageningen Univ, Res Ctr, Wageningen, Netherlands; [Hallett, R.] London Sch Hyg & Trop Med, London WC1, England; [Verweij, J.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Overmeir, C.] Inst Trop Med, B-2000 Antwerp, Belgium; [Leeflang, M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Tinto, H.] IRSS Ctr Muraz, Bobo Dioulasso, Burkina Faso								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		98	98						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100275					2019-03-26	
J	Schallig, H; Consortium, M				Schallig, H.; Consortium, M.			Introducing the EU funded consortium to tackle multi-drug resistance in malaria under combination therapy and to develop innovative simplified diagnostics: Malactres	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Schallig, H.; Consortium, M.] Royal Trop Inst, NL-1105 AZ Amsterdam, Netherlands; [Consortium, M.] Inst Trop Med, B-2000 Antwerp, Belgium; [Consortium, M.] London Sch Hyg & Trop Med, London WC1, England; [Consortium, M.] Wageningen Univ, Res Ctr, Wageningen, Netherlands; [Consortium, M.] Univ Benin, Benin, Nigeria; [Consortium, M.] IRSS Ctr Muraz, Bobo Dioulasso, Burkina Faso; [Consortium, M.] Kilimanjaro Christian Med Ctr, Moshi, Tanzania								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		98	98						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100274					2019-03-26	
J	Maketa, V; Matangila, J; Muhindo, H; Lutumba, P				Maketa, V.; Matangila, J.; Muhindo, H.; Lutumba, P.			Impact of IPTi-sp in protective acquired immunity in infant living in Kinshasa a hyper endemic level of transmission area for malaria	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Maketa, V.; Matangila, J.; Muhindo, H.; Lutumba, P.] UNIKIN, Dept Trop Med, Kinshasa, Zaire; [Lutumba, P.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		103	104						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100292					2019-03-26	
J	Matangila, J; Maketa, V; Muhindo, H; Lutumba, P				Matangila, J.; Maketa, V.; Muhindo, H.; Lutumba, P.			Profile of IL 10 throughout human gestation and pregnancy outcomes in Kinshasa a high level of transmission area for malaria	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Matangila, J.; Maketa, V.; Muhindo, H.; Lutumba, P.] UNIKIN, Dept Trop Med, Kinshasa, Zaire; [Lutumba, P.] Trop Med Inst Antwerp, Antwerp, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		103	103						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100290					2019-03-26	
J	Bauwens, I				Bauwens, I.			Earth observation in malaria vector control and management	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bauwens, I.] Urosense, Mechelen, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		107	108						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100304					2019-03-26	
J	Bisoffi, Z; Sirima, BS; Meheus, F; Lodesani, C; Gobbi, F; Angheben, A; Tinto, H; Bouma, N; Van den Ende, K; Romeo, A; Van den Ende, J				Bisoffi, Z.; Sirima, B. Sodiomon; Meheus, F.; Lodesani, C.; Gobbi, F.; Angheben, A.; Tinto, H.; Bouma, N.; Van den Ende, K.; Romeo, A.; Van den Ende, J.			A cost benefit analysis of malaria rapid diagnostic tests for adults and children in Burkina Faso	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bisoffi, Z.; Gobbi, F.; Angheben, A.] S Cuore Hosp, Ctr Trop Dis, Verona, Italy; [Sirima, B. Sodiomon] Minist Hlth, Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso; [Meheus, F.; Lodesani, C.; Bouma, N.; Van den Ende, K.; Romeo, A.; Van den Ende, J.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Tinto, H.] Projet AnKaHeresso, Bobo Dioulasso, Burkina Faso								0	1	1	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		107	107						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100303					2019-03-26	
J	Sauboin, C; Van Vlaenderen, I; Laure-Anne, VB; Baudouin, S				Sauboin, C.; Van Vlaenderen, I.; Laure-Anne, V. B.; Baudouin, S.			Can a static cohort model predict a vaccine effectiveness against malaria of children in different transmission areas? comparing the results with a dynamic population model	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Sauboin, C.] CHESS Consulting Hlth Econ Simulatios & Strategie, Ternat, Belgium; [Van Vlaenderen, I.] GSK Biol, Wavre, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		114	114						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100323					2019-03-26	
J	D'Alessandro, U; Tinto, H; Kalilani-Phiri, L; Tagbor, H; Nambozi, M; Mutabingwa, T				D'Alessandro, U.; Tinto, H.; Kalilani-Phiri, L.; Tagbor, H.; Nambozi, M.; Mutabingwa, T.			Artemisinin-based combination treatments for African pregnant women with malaria	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[D'Alessandro, U.] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Tinto, H.] Ctr Muraz, IRSS, Muraz, Burkina Faso; [Kalilani-Phiri, L.] Univ Malawi, Coll Med, Blantyre, Malawi; [Tagbor, H.] Wame Nkrumah Univ, Ndola, Zambia; [Nambozi, M.] Trop Dis Res Ctr, Dept Clin Sci, Ndola, Zambia; [Mutabingwa, T.] Muheza Designated Dist Hosp, Natl Inst Med Res, Tanga, Tanzania			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		115	116						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100328					2019-03-26	
J	Jansen, FH; Lesaffre, E				Jansen, F. Herwig; Lesaffre, E.			A meta-analysis of artemisinin-based combination therapies (ACTs) reveals changes in therapeutic efficacy	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Jansen, F. Herwig] Action Afrique, Oud Turnhout, Oud, Belgium; [Lesaffre, E.] Erasmus Univ, Dept Biostat, Med Ctr, NL-3000 DR Rotterdam, Netherlands; [Lesaffre, E.] Katholieke Univ Leuven, Interunive Inst Biostat & Stat Bioinformat, Louvain, Belgium; [Lesaffre, E.] Univ Hasselt, Diepenbeek, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		116	117						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100331					2019-03-26	
J	De Weggheleire, A; Gillet, P; Scheirlinck, A; Stokx, J; Mahoudo, JAB; Baltazar, JM; Mosse, CDD; Jacobs, J; Bottieau, E				De Weggheleire, A.; Gillet, P.; Scheirlinck, A.; Stokx, J.; Mahoudo, J. A. Bonou; Baltazar, J. M.; Dores Mosse, C. D.; Jacobs, J.; Bottieau, E.			Effect of malaria test results on treatment practices in the provincial hospital of Tete, Mozambique	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[De Weggheleire, A.; Gillet, P.; Scheirlinck, A.; Stokx, J.; Mahoudo, J. A. Bonou; Jacobs, J.; Bottieau, E.] Inst Trop Med, B-2000 Antwerp, Belgium; [Baltazar, J. M.] Prov Hosp Tete, Tete, Mozambique; [Dores Mosse, C. D.] Direcao Prov Saude, Tete, Mozambique								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		126	127						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100361					2019-03-26	
J	De Weggheleire, A; Gillet, P; Scheirlinck, A; Stokx, J; Mahoudo, JAB; Baltazar, JM; Mosse, CDD; Jacobs, J; Bottieau, E				De Weggheleire, A.; Gillet, P.; Scheirlinck, A.; Stokx, J.; Mahoudo, J. A. Bonou; Baltazar, J. M.; Dores Mosse, C. D.; Jacobs, J.; Bottieau, E.			Management of severe illness due to malaria in the provincial hospital of Tete-Mozambique	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[De Weggheleire, A.; Gillet, P.; Scheirlinck, A.; Stokx, J.; Mahoudo, J. A. Bonou; Jacobs, J.; Bottieau, E.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Dores Mosse, C. D.] Direcao Prov Saude, Tete, Mozambique								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		126	126						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100360					2019-03-26	
J	Nahum, A; Erhart, A; Maye, A; Ahounou, D; van Overmeir, C; Menten, J; van Loen, H; Akogbeto, M; Coosemans, M; Massougbodji, A; D'Alessandro, U				Nahum, A.; Erhart, A.; Maye, A.; Ahounou, D.; van Overmeir, C.; Menten, J.; van Loen, H.; Akogbeto, M.; Coosemans, M.; Massougbodji, A.; D'Alessandro, U.			Malaria incidence and prevalence among children living in a peri-urban area on the coast of Benin, West Africa: a longitudinal study	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Nahum, A.; Ahounou, D.; Akogbeto, M.] Ctr Rech Entomol Cotonou, Cotonou, Benin; [Erhart, A.; van Overmeir, C.; Menten, J.; van Loen, H.; Coosemans, M.; D'Alessandro, U.] Prince Leopold Inst Trop Med, Antwerp, Belgium; [Maye, A.] Hop Zone, Abomey Calavi, Benin; [Massougbodji, A.] Univ Natl Benin, Parasitol Lab, Fac Sci Sante, Cotonou, Benin			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	1	1	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		131	131						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100374					2019-03-26	
J	Bahizire, E; Mitangala, P; Schirvel, C; Zozo, D; Hennart, P; Dramaix, M				Bahizire, E.; Mitangala, P.; Schirvel, C.; Zozo, D.; Hennart, P.; Dramaix, M.			Malaria and malnutrition: risk factors of anemia in young children hospitalized in rural hospital in Kivu Province, DR Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bahizire, E.; Mitangala, P.; Dramaix, M.] ULB, Dept Biostat, Ecole Sante Publ, Brussels, Belgium; [Bahizire, E.; Mitangala, P.; Schirvel, C.; Hennart, P.; Dramaix, M.] Univ Libre Bruxelles Activ Cooperat, CEMUBAC, Ctr Sci & Med, Brussels, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		137	137						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100394					2019-03-26	
J	Briet, O; N'Guessan, R; Hardy, D; Chitnis, N; Rowland, M				Briet, O.; N'Guessan, R.; Hardy, D.; Chitnis, N.; Rowland, M.			Epidemiological effectiveness of insecticide treated nets in the presence of pyrethroid resistance	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Briet, O.; Hardy, D.; Chitnis, N.] Swiss Trop & Publ Hlth Inst, Basel, Belgium; [Briet, O.; Hardy, D.; Chitnis, N.] Univ Basel, Basel, Switzerland; [N'Guessan, R.; Rowland, M.] London Sch Hyg & Trop Med, London, England			Chitnis, Nakul/B-3105-2013					0	1	1	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		140	140						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100403					2019-03-26	
J	Penali, LK; Jansen, FH				Penali, L. K.; Jansen, F. H.			Pharmacokinetics of artemether and dihydroartemisinin for two commercially available artemether intramuscular injections in a black adult population affected with uncomplicated malaria	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Penali, L. K.] Inst Pasteur dAbidjan, Unite Paludol, Abidjan, Cote Ivoire; [Jansen, F. H.] Dafra Pharma, Turnhout, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		148	148						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100428					2019-03-26	
J	Barletta, F; Collantes, J; Arevalo, J; Rigouts, L				Barletta, F.; Collantes, J.; Arevalo, J.; Rigouts, L.			Standardization of in-house real time PCR for the identification of Mycobacterium tuberculosis in sputum	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract						real time PCR; Mycobacterium tuberculosis; element IS6110			[Barletta, F.; Collantes, J.; Arevalo, J.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander Von Humboldt, Lima, Peru; [Rigouts, L.] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; [Rigouts, L.] Univ Antwerp, Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		151	151						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100438					2019-03-26	
J	Mesfin, N; Deribew, A; Yami, A; Solomon, T; Vangeertruyden, JP; Colebunders, R				Mesfin, N.; Deribew, A.; Yami, A.; Solomon, T.; Vangeertruyden, J. P.; Colebunders, R.			Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case-control study	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Mesfin, N.] Hawassa Univ, Dept Internal Med, Awasa, Ethiopia; [Deribew, A.; Vangeertruyden, J. P.; Colebunders, R.] Univ Antwerp, Dept Epidemiol & Social Med, B-2020 Antwerp, Belgium; [Deribew, A.] Jimma Univ, Dept Epidemiol, Jimma, Ethiopia; [Mesfin, N.; Yami, A.] Jimma Univ, Dept Internal Med, Jimma, Ethiopia; [Solomon, T.] Hannover Med Sch, Inst Virol, D-3000 Hannover, Germany; [Colebunders, R.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		152	152						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100441					2019-03-26	
J	Gonzalez-Ochoa, E; Portuondo, AIM; Diaz, AG; Matthys, F; Vargas, LR; Morales, MAM; Riveron, BV; Perez, LA; Valdes, LS; Van der Stuyft, P				Gonzalez-Ochoa, E.; Martinez Portuondo, A. I.; Diaz, A. G.; Matthys, F.; Vargas, L. R.; Martinez Morales, M. A.; Riveron, B. V.; Perez, L. A.; Valdes, L. S.; Van der Stuyft, P.			Towards a sustained reduction of tuberculosis case fatality in La Habana, Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract						tuberculosis; mortality; case fatality; surveillance; Cuba			[Gonzalez-Ochoa, E.; Diaz, A. G.; Perez, L. A.] Pedro Kouri Inst, TB Leprosy & Acute Resp Infect Surveillance & Res, Havana, Cuba; [Martinez Portuondo, A. I.] Univ Med Sci Havana, Dept Publ Hlth, Finlay Albarran Fac, Havana, Cuba; [Matthys, F.; Van der Stuyft, P.] Inst Trop Med, Epidermiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Vargas, L. R.] Prov Ctr Hyg & Epidermiol, Havana, Cuba; [Martinez Morales, M. A.] Minist Publ Hlth Cuba, Natl Board Med Records & Hlth Stat, Havana, Cuba; [Riveron, B. V.; Valdes, L. S.] Pedro Kouri Inst, Grp Math Models, Dept Epidemiol, Havana, Cuba								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		155	156						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100451					2019-03-26	
J	Bulabula, A; Shindano, T; Mulema, PP; Rene, RF				Bulabula, A.; Shindano, T.; Mulema, P. P.; Rene, R. F.			Modified ziehl neelsen staining and prevalence of coccidian parasites in HIV patients with diarrhea; a series of 12 cases, Bukavu, DRCongo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bulabula, A.; Shindano, T.] Catholic Univ Bukavu, Sch Med, Bukavu, DEM REP CONGO; [Mulema, P. P.] Catholic Univ Louvain, Sch Med, B-3000 Louvain, Belgium								0	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		157	157						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100457					2019-03-26	
J	De Weggheleire, A; Mahoudo, JAB; Bande, NJ; Casas, EC; Baltazar, JM; Mosse, CDD; Bottieau, E				De Weggheleire, A.; Mahoudo, J. A. B.; Bande, N. J.; Casas, E. C.; Baltazar, J. M.; Mosse, C. D. D.; Bottieau, E.			Short-term tolerability of doxorubicin-based chemotherapy in patients with advanced hiv-related Kaposi's sarcoma in the provincial Hospital of Tete, Mozambique	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[De Weggheleire, A.; Mahoudo, J. A. B.; Casas, E. C.; Bottieau, E.] Inst Trop Med Clin Sci, Antwerp, Belgium; [Mosse, C. D. D.] Direccao Prov Saude, Tete, Mozambique								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		162	163						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100473					2019-03-26	
J	De Weggheleire, A; N'Zeth, KN; Akpome, F; Biot, M; Casas, EC; Bottieau, E				De Weggheleire, A.; N'Zeth, K. N.; Akpome, F.; Biot, M.; Casas, E. C.; Bottieau, E.			Outcome of severe AIDS-related kaposi's sarcoma treated with two-weekly bleomycin/vincristine and antiretroviral treatment in the district Hospital of Buhera, Zimbabwe	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[De Weggheleire, A.; Casas, E. C.; Bottieau, E.] Inst Trop Med Clin Sci, Antwerp, Belgium; [N'Zeth, K. N.; Akpome, F.; Biot, M.] Med Sans Frontieres Operat Cell Brussels, Brussels, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		162	162						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100472					2019-03-26	
J	Schallig, H; Migchelsen, S; Busscher, P; Hoepelman, A; Adams, E				Schallig, H.; Migchelsen, S.; Busscher, P.; Hoepelman, A.; Adams, E.			Human African trypanosomiasis: a review of non-endemic cases in the past 20 years	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Schallig, H.; Migchelsen, S.; Adams, E.] Royal Trop Inst, NL-1105 AZ Amsterdam, Netherlands; [Migchelsen, S.; Hoepelman, A.] Utrecht Med Ctr, Utrecht, Netherlands; [Busscher, P.] Inst Trop Med, B-2000 Antwerp, Belgium								0	1	1	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		167	168						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100489					2019-03-26	
J	Deborggraeve, S; Lejon, V; Ekangu, RA; Ngoyi, DM; Pyana, P; Mulunda, JP; Buscher, P				Deborggraeve, S.; Lejon, V.; Ekangu, R. Ali; Ngoyi, D. M.; Pyana, P.; Mulunda, J. P.; Buscher, P.			How reliable is PCR for diagnosis, staging and follow-up of gambiense sleeping sickness?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Deborggraeve, S.; Lejon, V.; Ngoyi, D. M.; Pyana, P.; Buscher, P.] Inst Trop Med Antwerp, Antwerp, Belgium; [Deborggraeve, S.] Katholieke Univ Leuven, Rega Inst, Louvain, Belgium; [Ekangu, R. Ali; Ngoyi, D. M.; Pyana, P.] Inst Natl Rech Biomed, Kinshasa, Zaire; [Mulunda, J. P.] Programme Natl Lutte Trypanosomiase Humaine Afric, Mbuji Dayi, Zaire			Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472				0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		168	168						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100492					2019-03-26	
J	Gidwani, K; Jones, S; Kumar, R; Boelart, M; Sundar, S				Gidwani, K.; Jones, S.; Kumar, R.; Boelart, M.; Sundar, S.			Interferon-gamma release assay (modified quantiferon) as a potential marker of infection for Leishmania donovani, a proof of concept study	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Gidwani, K.; Kumar, R.; Sundar, S.] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Jones, S.] Cellestis Ltd, Chadstone, Vic, Australia; [Boelart, M.] Inst Trop Med, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		168	168						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100491					2019-03-26	
J	Adaui, V; Castillo, D; Zimic, M; Gutierrez, A; Decuypere, S; Vanaerschot, M; De Doncker, S; Schnorbusch, K; Maes, I; Van der Auwera, G; Llanos-Cuentas, A; Arevalo, J; Dujardin, JC				Adaui, V.; Castillo, D.; Zimic, M.; Gutierrez, A.; Decuypere, S.; Vanaerschot, M.; De Doncker, S.; Schnorbusch, K.; Maes, I.; Van der Auwera, G.; Llanos-Cuentas, A.; Arevalo, J.; Dujardin, J. -C.			Comparative gene expression analysis throughout the life cycle of Leishmania braziliensis: diversity of expression profiles among clinical isolates	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Adaui, V.; Castillo, D.; Llanos-Cuentas, A.; Arevalo, J.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Adaui, V.; Decuypere, S.; Vanaerschot, M.; De Doncker, S.; Schnorbusch, K.; Maes, I.; Van der Auwera, G.; Dujardin, J. -C.] Inst Trop Med, Unit Mol Parasitol, Dept Parasitol, B-2000 Antwerp, Belgium; [Castillo, D.; Zimic, M.; Gutierrez, A.; Arevalo, J.] Univ Peruana Cayetano Heredia, Lab Invest & Desarrollo, Fac Ciencias & Filosofia, Lima, Peru; [Vanaerschot, M.; Schnorbusch, K.; Dujardin, J. -C.] Univ Antwerp, Dept Biomed Sci, Fac Pharmaceut Biomed & Vet Sci, Antwerp, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		169	169						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100493					2019-03-26	
J	Praet, N; Coral-Almeida, M; Benitez-Ortiz, W; Rodriguez-Hidalgo, R; Celi, M; Gabriel, S; Speybroeck, N; Dorny, P				Praet, N.; Coral-Almeida, M.; Benitez-Ortiz, W.; Rodriguez-Hidalgo, R.; Celi, M.; Gabriel, S.; Speybroeck, N.; Dorny, P.			Incidence of Taenia solium cysticercosis in southern Ecuador: a longitudinal community-based study	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Praet, N.; Coral-Almeida, M.; Gabriel, S.; Dorny, P.] Inst Trop Med, B-2000 Antwerp, Belgium; [Coral-Almeida, M.; Benitez-Ortiz, W.; Rodriguez-Hidalgo, R.; Celi, M.] Univ Cent Ecuador, Ctr Int Zoonosis, Quito, Ecuador; [Speybroeck, N.] Catholic Univ Louvain, Res Inst Hlth & Soc IRSS, B-1200 Brussels, Belgium				GABRIEL, SARAH/0000-0002-2523-233X				0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		170	170						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100496					2019-03-26	
J	Picado, A; Aditya, PD; Bhattacharya, S; Boelaert, M				Picado, A.; Aditya, P. D.; Bhattacharya, S.; Boelaert, M.			Vector control interventions for the visceral leishmaniasis elimination initiative in South Asia, 2005-2010	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Picado, A.; Boelaert, M.] Inst Trop Med, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		171	171						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100499					2019-03-26	
J	Matangila, J; Maketa, V; Muhindo, H; Lutumba, P				Matangila, J.; Maketa, V.; Muhindo, H.; Lutumba, P.			Assessment of immunologic salivary proteins of Glossina sp as an epidemiological tool, comparedto entomological method	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Matangila, J.; Maketa, V.; Muhindo, H.; Lutumba, P.] UNIKIN, Dept Trop Med, Kinshasa, DEM REP CONGO; [Lutumba, P.] Trop Med Inst Antwerp, Antwerp, Belgium								0	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		176	176						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100517					2019-03-26	
J	van der Werff, SD; Twisk, JWR; Ponce, MC; Diaz, RJ; Wordemann, M; Gorbea, MB; Polman, K				van der Werff, S. D.; Twisk, J. W. R.; Ponce, M. C.; Diaz, R. J.; Wordemann, M.; Gorbea, M. B.; Polman, K.			Deworming improves asthma and temporarily deteriorates atopy: longitudinal anthelminthic treatment study in Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[van der Werff, S. D.; Twisk, J. W. R.; Ponce, M. C.; Polman, K.] Vrije Univ Amsterdam, Dept Hlth Sci, Amsterdam, Netherlands; [Diaz, R. J.; Gorbea, M. B.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; [Wordemann, M.; Polman, K.] Prince Leopold Inst Trop Med, Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		177	177						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100522					2019-03-26	
J	Vereecken, K; Kanobana, K; Wordemann, M; Diaz, RJ; Heredia, LM; Espinosa, AR; Nunez, FA; Rivero, LR; Gorbea, MB; Polman, K; Polman, K				Vereecken, K.; Kanobana, K.; Wordemann, M.; Diaz, R. J.; Heredia, L. M.; Espinosa, A. R.; Nunez, F. A.; Rivero, L. R.; Gorbea, M. B.; Polman, K.; Polman, K.			Associations between atopic markers in asthma and intestinal helminth infections in Cuban schoolchildren	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Vereecken, K.; Kanobana, K.; Wordemann, M.; Polman, K.] Inst Trop Med, B-2000 Antwerp, Belgium; [Diaz, R. J.; Heredia, L. M.; Gorbea, M. B.] Natl Inst Hyg Epidemiol & Microbiol, Antwerp, Belgium; [Espinosa, A. R.; Nunez, F. A.; Rivero, L. R.] Inst Pedro Kouri, Havana, Cuba; [Polman, K.] Vrije Univ Amsterdam, Amsterdam, Netherlands								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		179	179						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100527					2019-03-26	
J	Cunningham, J; Hasker, E; Das, P; El Safi, S; Goto, H; Mondal, D; Mbuchi, M; Mukhtar, M; Rabello, A; Rijal, S; Sundar, S; Menten, J; Peeling, R; Boelaert, M				Cunningham, J.; Hasker, E.; Das, P.; El Safi, S.; Goto, H.; Mondal, D.; Mbuchi, M.; Mukhtar, M.; Rabello, A.; Rijal, S.; Sundar, S.; Menten, J.; Peeling, R.; Boelaert, M.			A global comparative evaluation of commercially available rapid diagnostic tests for visceral leishmaniasis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Cunningham, J.] WHO, Geneva, Switzerland; [Hasker, E.; Menten, J.; Boelaert, M.] Inst Trop Med, B-2000 Antwerp, Belgium; [Das, P.] Rajendra Mem Res Inst Med Sci, Patna, Bihar, India; [El Safi, S.; Mukhtar, M.] Univ Khartoum, Khartoum, Sudan; [Goto, H.] Inst Med Trop Sao Paulo, Sao Paulo, Brazil; [Mbuchi, M.] Med Res Inst KEMRI, Nairobi, Kenya; [Rabello, A.] Fiocruz MS, Ctr Pesquisas Rene Rachou, Rio De Janeiro, Brazil; [Rijal, S.] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Sundar, S.] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Peeling, R.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		180	180						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100531					2019-03-26	
J	Ponce, MC; Incani, RN; Pinelli, E; ten Kulve, N; Ramak, R; Polman, K; Doak, CM				Ponce, M. C.; Incani, R. N.; Pinelli, E.; ten Kulve, N.; Ramak, R.; Polman, K.; Doak, C. M.			Are intestinal parasites fuelling the rise in dual burden households in Venezuela?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Ponce, M. C.; ten Kulve, N.; Ramak, R.; Polman, K.; Doak, C. M.] Vrije Univ Amsterdam, Dept Hlth Sci, Amsterdam, Netherlands; [Incani, R. N.] Univ Carabobo, Fac Hlth Sci, Dept Parasitol, Valencia, Venezuela; [Polman, K.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		180	181						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100533					2019-03-26	
J	Uranw, S; Ostyn, B; Rijal, A; Devkota, S; Khanal, B; Boelaert, M; Rijal, S				Uranw, S.; Ostyn, B.; Rijal, A.; Devkota, S.; Khanal, B.; Boelaert, M.; Rijal, S.			Risk factors for post-kala-azar dermal leishmaniasis in Nepal, a retrospective cohort study	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Uranw, S.; Rijal, A.; Devkota, S.; Khanal, B.; Rijal, S.] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Ostyn, B.; Boelaert, M.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		180	180						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100532					2019-03-26	
J	Uranw, S; Hasker, E; Roy, L; Meheus, F; Das, ML; Bhattarai, NR; Boelaert, M; Rijal, S				Uranw, S.; Hasker, E.; Roy, L.; Meheus, F.; Das, M. Lal; Bhattarai, N. R.; Boelaert, M.; Rijal, S.			An outbreak investigation of visceral leishmaniasis among urban residents of Dharan town, eastern Nepal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Uranw, S.; Roy, L.; Das, M. Lal; Bhattarai, N. R.; Rijal, S.] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Hasker, E.; Meheus, F.; Boelaert, M.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		182	182						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100538					2019-03-26	
J	Uranw, S; Meheus, F; Boelaert, M; Rijal, S				Uranw, S.; Meheus, F.; Boelaert, M.; Rijal, S.			The economic burden of visceral leishmaniasis on households in south-eastern Nepal	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Uranw, S.; Rijal, S.] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Meheus, F.; Boelaert, M.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	1	1	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		183	183						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100540					2019-03-26	
J	van der Werff, S; Vereecken, K; van der Laan, K; Ponce, MC; Diaz, RJ; Nunez, FA; Rivero, LR; Gorbea, MB; Polman, K				van der Werff, S.; Vereecken, K.; van der Laan, K.; Ponce, M. C.; Diaz, R. J.; Nunez, F. A.; Rivero, L. R.; Gorbea, M. B.; Polman, K.			Evaluation of selective periodic mebendazole treatment against soil-transmitted helminth infections in Cuban schoolchildren	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[van der Werff, S.; van der Laan, K.; Ponce, M. C.; Polman, K.] Vrije Univ Amsterdam, Amsterdam, Netherlands; [Vereecken, K.; Polman, K.] Inst Trop Med, B-2000 Antwerp, Belgium; [Diaz, R. J.; Gorbea, M. B.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; [Nunez, F. A.; Rivero, L. R.] Inst Pedro Kouri, Havana, Cuba								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		183	184						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100542					2019-03-26	
J	Hasker, E; Singh, SP; Malaviya, P; Picado, A; Gidwani, K; Singh, RP; Sundar, S; Boelaert, M				Hasker, E.; Singh, S. P.; Malaviya, P.; Picado, A.; Gidwani, K.; Singh, R. P.; Sundar, S.; Boelaert, M.			Risk factors for visceral leishmaniasis in a rural district of Bihar, India, a multilevel analysis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Hasker, E.; Picado, A.; Boelaert, M.] ITM Antwerp, Antwerp, Belgium; [Singh, S. P.; Malaviya, P.; Gidwani, K.; Singh, R. P.; Sundar, S.] BHU Varanasi, Varanasi, Uttar Pradesh, India			Malaviya, Paritosh/B-1819-2012; Boelaert, Marleen/E-2698-2012	Malaviya, Paritosh/0000-0002-7558-152X; Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		187	187						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100552					2019-03-26	
J	Sinha, K; van Griensven, J; Pandey, K; Kumar, N; Verma, N; Mahajan, R; Kumar, P; Kumar, R; Das, P; Mitra, G; Flevaud, L; Ferreyra, C; Remartinez, D; Pece, M; Palma, PP				Sinha, K.; van Griensven, J.; Pandey, K.; Kumar, N.; Verma, N.; Mahajan, R.; Kumar, P.; Kumar, R.; Das, P.; Mitra, G.; Flevaud, L.; Ferreyra, C.; Remartinez, D.; Pece, M.; Palma, P. P.			Liposomal amphotericin B for visceral leishmaniasis in HIV-coinfected patients: 2-year treatment outcomes in Bihar, India	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Sinha, K.; Pandey, K.; Kumar, N.; Verma, N.; Das, P.] Rajendra Mem Res Inst Med Sci, Patna, Bihar, India; [van Griensven, J.; Mahajan, R.; Kumar, P.; Kumar, R.; Mitra, G.] Medecins Sans Frontieres India, Operat Ctr Barcelona Athens, New Delhi, India; [van Griensven, J.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		189	189						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100559					2019-03-26	
J	Maes, L; Yardley, V; Cos, P; Jansen, H; Fortin, A				Maes, L.; Yardley, V.; Cos, P.; Jansen, H.; Fortin, A.			In vivo efficacy and tolerability of oleylphosphocholine (OLPC) in laboratory models of visceral leishmaniasis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Maes, L.; Cos, P.] Univ Antwerp, B-2020 Antwerp, Belgium; [Yardley, V.] London Inst Hyg & Trop Med, London, England; [Jansen, H.; Fortin, A.] Dafra Pharma Res & Dev, Turnhout, Belgium			Maes, Louis/A-2384-2017; Cos, Paul/L-9717-2015	Maes, Louis/0000-0002-2324-9509; Cos, Paul/0000-0003-4361-8911				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		190	190						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100561					2019-03-26	
J	Kanobana, K; Polman, K; Sariego, I; Nunez, F; Rojas, L; Speybroeck, N				Kanobana, K.; Polman, K.; Sariego, I.; Nunez, F.; Rojas, L.; Speybroeck, N.			Rule-based modeling to simulate exposure to toxocariasis in children	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Kanobana, K.; Polman, K.] Inst Trop Med, B-2000 Antwerp, Belgium; [Sariego, I.; Nunez, F.; Rojas, L.] Inst Pedro Kouri, Havana, Cuba; [Speybroeck, N.] Catholic Univ Louvain, B-1348 Louvain, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		200	201						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100594					2019-03-26	
J	Kirezi, K; Kim, V; Idalia, SR; Raquel, JD; Fidel, N; Lazara, R; Mariano, BG; Katja, P				Kirezi, K.; Kim, V.; Idalia, S. R.; Raquel, J. D.; Fidel, N.; Lazara, R.; Mariano, B. G.; Katja, P.			Toxocara seropositivity and atopy in Cuban children with asthma	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Kirezi, K.; Kim, V.; Katja, P.] Inst Trop Med, B-2000 Antwerp, Belgium; [Idalia, S. R.; Fidel, N.; Lazara, R.] Inst Pedro Kouri, Havana, Cuba; [Raquel, J. D.; Mariano, B. G.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		200	200						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100592					2019-03-26	
J	Bhattacharyya, T; Franzen, O; Falconar, A; Baleela, R; Mauricio, I; Yeo, M; Luquetti, A; Andersson, B; Carlier, Y; Miles, M				Bhattacharyya, T.; Franzen, O.; Falconar, A.; Baleela, R.; Mauricio, I.; Yeo, M.; Luquetti, A.; Andersson, B.; Carlier, Y.; Miles, M.			Genetic diversity and diagnostics development for trypanosomatid protozoa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bhattacharyya, T.; Falconar, A.; Baleela, R.; Mauricio, I.; Yeo, M.; Miles, M.] London Sch Hyg & Trop Med, London, England; [Franzen, O.; Andersson, B.] Karolinska Inst, Stockholm, Sweden; [Luquetti, A.] Univ Fed Goias, Goiania, Go, Brazil; [Carlier, Y.] Univ Libre Bruxelles, Brussels, Belgium			Mauricio, Isabel/H-5272-2011; santos, sofia/I-1637-2012; Andersson, Bjorn/G-9832-2013	Mauricio, Isabel/0000-0002-7748-4643; Andersson, Bjorn/0000-0002-4624-0259				0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		213	214						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100633					2019-03-26	
J	van Lieshout, L; Brienen, E; Aryeetey, Y; Mendes, F; Kahama, A; Ramarokoto, CE; Downs, J; Meurs, L; Verweij, JJ				van Lieshout, L.; Brienen, E.; Aryeetey, Y.; Mendes, F.; Kahama, A.; Ramarokoto, C. E.; Downs, J.; Meurs, L.; Verweij, J. J.			Specific detection of schistosoma DNA in stool and urine samples illustrates shortcomings of microscopy in population based surveys	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[van Lieshout, L.; Brienen, E.; Verweij, J. J.] Leiden Univ, Dept Parasitol, Med Ctr, NL-2300 RA Leiden, Netherlands; [Aryeetey, Y.] Univ Ghana, Noguchi Mem Inst Med Res, Accra, Ghana; [Mendes, F.] Catholic Univ Mozamb, Beira, Mozambique; [Kahama, A.] Minist Hlth, Div Vector Borne Dis, Nairobi, Kenya; [Ramarokoto, C. E.] Inst Pasteur, Epidemiol Unit, Antananarivo, Madagascar; [Downs, J.] Weill Cornell Med Coll, Mwanza, Tanzania; [Downs, J.] Bugando Med Ctr, Mwanza, Tanzania; [Meurs, L.] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		216	216						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100640					2019-03-26	
J	Veland, N; Boggild, A; Valencia, C; Valencia, B; Llanos-Cuentas, A; Van der Auwera, G; Dujardin, JC; Arevalo, J				Veland, N.; Boggild, A.; Valencia, C.; Valencia, B.; Llanos-Cuentas, A.; Van der Auwera, G.; Dujardin, J. -C.; Arevalo, J.			Leishmania (Viannia) species identification on clinical samples from cutaneous leishmaniasis in Peru: assessment of a PCR step-wise approach	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Veland, N.; Valencia, C.; Valencia, B.; Llanos-Cuentas, A.; Arevalo, J.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Boggild, A.] Toronto Gen Hosp, Div Infect Dis, Trop Dis Unit, Toronto, ON, Canada; [Van der Auwera, G.; Dujardin, J. -C.] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Dujardin, J. -C.] Univ Antwerp, Dept Biomed Sci, Fac Pharmaceut Biomed & Vet Sci, B-2020 Antwerp, Belgium; [Arevalo, J.] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Bioquim, Lab Invest & Desarrollo, Lima, Peru; Hosp Nacl Cayetano Heredia, Lima, Peru								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		217	217						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100644					2019-03-26	
J	Mueller, Y; Nackers, F; Ahmed, K; Boelaert, M; Eltigani, R; Gorashi, H; Hammam, O; Ritmeijer, K; Salih, N; Etard, JF; Chappuis, F				Mueller, Y.; Nackers, F.; Ahmed, K.; Boelaert, M.; Eltigani, R.; Gorashi, H.; Hammam, O.; Ritmeijer, K.; Salih, N.; Etard, J. -F.; Chappuis, F.			Burden of Kala-azar in highly endemic villages of Gedaref state, Sudan	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Ahmed, K.; Hammam, O.; Salih, N.; Chappuis, F.] Operat Ctr, Geneva, Switzerland; [Boelaert, M.] Inst Trop Med Antwerp, Antwerp, Belgium; [Gorashi, H.] Univ Gedaref, Dept Community Med, Gedaref, Sudan; [Ritmeijer, K.] Operat Ctr Amsterdam, Amsterdam, Netherlands			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		218	219						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100649					2019-03-26	
J	Portocarero, MJ; Adaui, V; Cruz, M; Dujardin, JC; Arevalo, J				Portocarero, M. J.; Adaui, V.; Cruz, M.; Dujardin, J-C; Arevalo, J.			SYBR green-based quantitation of Leishmania parasite load in lesion biopsies from Peruvian patients with tegumentary leishmaniasis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Portocarero, M. J.; Adaui, V.; Arevalo, J.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Cruz, M.] Hosp Nacl Adolfo Guevara Velasco, Lima, Peru; [Dujardin, J-C] Inst Trop Med, Unit Mol Parasitol, Dept Parasitol, B-2000 Antwerp, Belgium; [Dujardin, J-C] Univ Antwerp, Dept Biomed Sci, Fac Pharmaceut Biomed & Vet Sci, B-2020 Antwerp, Belgium; [Arevalo, J.] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Labs Invest & Desarrollo, Lima, Peru								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		220	220						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100654					2019-03-26	
J	Gonzalez, L; Sanchez, L; Castro, M; Lefevre, P; Perez, D				Gonzalez, L.; Sanchez, L.; Castro, M.; Lefevre, P.; Perez, D.			Learning to draw cartoons: an educational intervention to improve communication skills of students involved in Aedes aegypti control in Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Gonzalez, L.; Sanchez, L.; Castro, M.; Perez, D.] Inst Med Trop Pedro Kouri, Havana, Cuba; [Lefevre, P.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		234	234						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100700					2019-03-26	
J	Van Esbroeck, M; Verschueren, J; Cnops, L				Van Esbroeck, M.; Verschueren, J.; Cnops, L.			Significant increase in imported dengue infections in 2010 and an overview of 10 years of dengue surveillance in Belgium	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Van Esbroeck, M.; Verschueren, J.; Cnops, L.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium								0	1	1	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		236	236						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100708					2019-03-26	
J	Lefevre, P; Chacon, D; Zabala, MD; Van der Stuyft, P				Lefevre, P.; Chacon, D.; del Carmen Zabala, M.; Van der Stuyft, P.			An adapted theoretical framework to assess implementation fidelity of participatory health strategies	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Lefevre, P.; Van der Stuyft, P.] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Chacon, D.] Inst Med Trop Pedro Kouri, Vicedirecc Epidemiol, Havana, Cuba; [del Carmen Zabala, M.] Univ La Habana, Fac Latinoamer Ciencias Soci, Havana, Cuba								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		238	238						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100715					2019-03-26	
J	Baly, A; Toledo, ME; Rodriguez, K; Benitez, JR; Rodriguez, M; Boelaert, M; Vanlerbrghe, V; Van der Stuyft, P				Baly, A.; Toledo, M. E.; Rodriguez, K.; Benitez, J. R.; Rodriguez, M.; Boelaert, M.; Vanlerbrghe, V.; Van der Stuyft, P.			Incremental cost of dengue outbreak control in Guantanamo, Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Baly, A.; Toledo, M. E.] Inst Medidina Trop Pedro Kouri, Havana, Cuba; [Rodriguez, K.; Benitez, J. R.; Rodriguez, M.] Unidad Prov Vigilancia & Lucha Antivectorial, Guantanamo, Cuba; [Boelaert, M.; Vanlerbrghe, V.; Van der Stuyft, P.] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium			Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		239	239						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100717					2019-03-26	
J	Toledo, ME; Lambert, I; Popa, JC; Baly, A; Vanlerberghe, V; Abad, Y; Van der Stuyft, P				Toledo, M. E.; Lambert, I.; Popa, J. C.; Baly, A.; Vanlerberghe, V.; Abad, Y.; Van der Stuyft, P.			Effectiveness of insecticide treated curtains in a setting with low Aedes aegypti infestation levels and an intensive routine vector control programme	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Toledo, M. E.; Baly, A.; Abad, Y.] Inst Med Trop Pedro Kouri, Havana, Cuba; [Lambert, I.] Unidad Prov Vigilancia & Lucha Antivectorial, Guantanamo, Cuba; [Popa, J. C.] Unidad Prov Vigilancia & Lucha Antivectorial, Santiago De Cuba, Cuba; [Vanlerberghe, V.; Van der Stuyft, P.] Inst Trop Med, Unit Epidemiol & Dis Control, B-2000 Antwerp, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		240	240						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100720					2019-03-26	
J	Castro, M; Sanchez, L; Perez, D; Carbonell, N; Vanlerberghe, V; Van der Stuyft, P				Castro, M.; Sanchez, L.; Perez, D.; Carbonell, N.; Vanlerberghe, V.; Van der Stuyft, P.			A community empowerment strategy embedded in a routine dengue vector control programme: a cluster randomized controlled trial	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Castro, M.; Sanchez, L.; Perez, D.] Trop Med Inst Pedro Kouri, Havana, Cuba; [Carbonell, N.] Univ Sancti Spiritus, Sancti Spiritus, Cuba; [Vanlerberghe, V.; Van der Stuyft, P.] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium								0	0	0	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		242	243						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100729					2019-03-26	
J	Sanchez, L; Sebrango, C; Abad, Y; Pelaez, O; Shked, Z; Van der Stuyft, P				Sanchez, L.; Sebrango, C.; Abad, Y.; Pelaez, O.; Shked, Z.; Van der Stuyft, P.			Reproduction number, turning point and total number of cases during a dengue outbreak in playa municipality, Havana city	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Sanchez, L.; Abad, Y.; Pelaez, O.] Inst Pedro Kouri, Havana, Cuba; [Sebrango, C.] Univ Sancti Spiritus, Sancti Spiritus, Cuba; [Shked, Z.] Hasselt Univ, Hasselt, Belgium; [Van der Stuyft, P.] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		243	244						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100732					2019-03-26	
J	Perez, K; Sanchez, L; Iniguez, L; Castro, M; Alfonso, L; Van der Stuyft, P				Perez, K.; Sanchez, L.; Iniguez, L.; Castro, M.; Alfonso, L.; Van der Stuyft, P.			An incidence hotspot, associated with ecological factors, during a dengue outbreak in Havana city	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Perez, K.; Sanchez, L.; Castro, M.; Alfonso, L.] Inst Pedro Kouri, Div Epidemiol, Havana, Cuba; [Van der Stuyft, P.] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		244	245						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100735					2019-03-26	
J	Paul, M; Stefaniak, J; Kacprzak, E; Van Esbroeck, M; Geysen, D; Clerinx, J				Paul, M.; Stefaniak, J.; Kacprzak, E.; Van Esbroeck, M.; Geysen, D.; Clerinx, J.			Successful treatment of rhodesian trypanosomiasis with pentamidine in a polish tourist returning from equatorial Africa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Paul, M.; Stefaniak, J.; Kacprzak, E.] Univ Med Sci, Dept & Clin Trop & Parasit Dis, Poznan, Poland; [Van Esbroeck, M.; Clerinx, J.] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Geysen, D.] Inst Trop Med, Dept Vet Sci, B-2000 Antwerp, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		245	246						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100737					2019-03-26	
J	Cats, MM; Tempia, S; Naidoo, D; Somwe, SW; Blumberg, L				Cats, M. M.; Tempia, S.; Naidoo, D.; Somwe, S. Wa; Blumberg, L.			Disease control programmes and strengthening public health care services: experience from pandemic influenza preparedness in Southern Africa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Cats, M. M.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		265	265						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100801					2019-03-26	
J	Versteynen, L				Versteynen, L.			Improvement of global access to life-saving medicines-facing the future	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Versteynen, L.] Tibotec Virco Virol BVBA, Beerse, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		268	268						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100810					2019-03-26	
J	Carod, JF; Rakotondrazaka, M; Ramahefarisoa, RM; Menard, D; Soares, JL; Dorny, P; Wilkins, P				Carod, J-F.; Rakotondrazaka, M.; Ramahefarisoa, R. M.; Menard, D.; Soares, J-L.; Dorny, P.; Wilkins, P.			Updated epidemiology of cysticercosis in Madagascar	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Dorny, P.] Inst Trop, Antwerp, Belgium; [Wilkins, P.] CDC, Atlanta, GA 30333 USA			Menard, Didier/O-3294-2013	Menard, Didier/0000-0003-1357-4495				0	0	0	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		270	270						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100815					2019-03-26	
J	Nejoua, B; Abdelali, AB; Amina, S; Bruno, D; Ulrich, K				Nejoua, B.; Abdelali, A. B.; Amina, S.; Bruno, D.; Ulrich, K.			Systemic quality improvement - Moroccan case scaling up to improve access to care	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Nejoua, B.; Abdelali, A. B.; Amina, S.] Minist Healh Morocco, Morocco, Belgium; [Bruno, D.] Univ Libre Bruxelles, Brussels, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		276	277						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100837					2019-03-26	
J	Kyabayinze, D; Nassali, M; Tibenderana, J; Tumwine, L; Riches, C; Montangue, M; Homade, P; Van Geertruyden, JP; Meek, S				Kyabayinze, D.; Nassali, M.; Tibenderana, J.; Tumwine, L.; Riches, C.; Montangue, M.; Homade, P.; Van Geertruyden, J. P.; Meek, S.			Diagnosis of placental Plasmodium falciparum malaria infection using HRP, 2 rapid diagnostic tests in an endemic setting in Uganda	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Kyabayinze, D.; Tibenderana, J.; Riches, C.; Montangue, M.; Homade, P.; Meek, S.] Malaria Consortium, Kampala, Uganda; [Nassali, M.] Mbale Hosp, Uganda Minist Hlth, Mbale, Uganda; [Tumwine, L.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda; [Van Geertruyden, J. P.] Univ Antwerp, Fac Med, Unit Int Hlth, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		281	281						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100850					2019-03-26	
J	Wilunda, C; Putoto, G; Azzimonti, G; Castiglioni, M; Manenti, F; Criel, B				Wilunda, C.; Putoto, G.; Azzimonti, G.; Castiglioni, M.; Manenti, F.; Criel, B.			Measuring equity in access to emergency obstetric care at Wolisso hospital in Oromiya, Ethiopia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Wilunda, C.; Putoto, G.; Azzimonti, G.; Manenti, F.] Doctors Africa CUAMM, Padua, Italy; [Castiglioni, M.] Univ Padua, Dept Stat, I-35100 Padua, Italy; [Criel, B.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		288	289						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519100877					2019-03-26	
J	Kayumba, EK; Donnen, P; Simbi, JBL; Kabange, ET; Habimana, L; Okolonken, JO; Denayer, P; Mwenze, KK; Robert, A				Kayumba, E. K.; Donnen, P.; Simbi, J. -B. L.; Kabange, E. T.; Habimana, L.; Okolonken, J. O.; Denayer, P.; Mwenze, K. K.; Robert, A.			Iodine content of household salt in Lubumbashi, DR Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Kayumba, E. K.; Simbi, J. -B. L.; Kabange, E. T.; Okolonken, J. O.; Mwenze, K. K.] Univ Lubumbashi, DR, Lubumbashi, DEM REP CONGO; [Donnen, P.] Univ Libre Bruxelles, Brussels, Belgium; [Habimana, L.; Denayer, P.; Robert, A.] Univ Catholique Louvain UCL, Inst Rech Expet & Clin, Brussels, Belgium								0	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		292	+						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101007					2019-03-26	
J	Twite, E; Habimana, L; Bernard, P; Denayer, P; Donnen, P; Mpoyo, E; Kalwaba, K; Gruson, D; Mutamba, G; Kalenga, P; Robert, A				Twite, E.; Habimana, L.; Bernard, P.; Denayer, P.; Donnen, P.; Mpoyo, E.; Kalwaba, K.; Gruson, D.; Mutamba, G.; Kalenga, P.; Robert, A.			Ultrasonographical thyroid features in pregnant women in Lubumbashi, DR Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Twite, E.; Mpoyo, E.; Kalwaba, K.; Mutamba, G.; Kalenga, P.; Robert, A.] Univ Lubumbashi, Lubumbashi, DEM REP CONGO; [Habimana, L.; Bernard, P.; Denayer, P.; Gruson, D.] Catholic Univ Louvain, Louvain, Belgium; [Donnen, P.] Univ Libre Bruxelles, Brussels, Belgium								0	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		292	292						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101006					2019-03-26	
J	Bigirindavyi, D; Ndikubagenzi, J; Van Geertruyden, JP				Bigirindavyi, D.; Ndikubagenzi, J.; Van Geertruyden, J. -P.			Young domestic staff represent a vulnerable population in relation to reproductive health and HIV prevention in Bujumbura, Burundi	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Van Geertruyden, J. -P.] Univ Antwerp, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		300	300						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101029					2019-03-26	
J	Ntukamazina, D; Ndikubagenzi, J; Van Geertruyden, JP				Ntukamazina, D.; Ndikubagenzi, J.; Van Geertruyden, J. -P.			Obstetric fistulae is still a major and stigmatizing public health problem in rural Burundi	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Van Geertruyden, J. -P.] Univ Antwerp, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		301	301						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101032					2019-03-26	
J	Geelhoed, D; Lafort, Y; Candrinho, B; Chissale, E; Temmerman, M; Degomme, O				Geelhoed, D.; Lafort, Y.; Candrinho, B.; Chissale, E.; Temmerman, M.; Degomme, O.			The effect of integrated mother-and-child health services on the follow-up of HIV exposed infants in Mozambique	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Lafort, Y.; Temmerman, M.; Degomme, O.] UGent, Int Ctr Reprod Hlth, Ghent, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		302	303						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101037					2019-03-26	
J	Truong, H; The, DN; Gillerot, Y; Reding, R; Robert, A				Truong, H.; The, D. N.; Gillerot, Y.; Reding, R.; Robert, A.			External birth defects in south of Vietnam: a population-based study	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Truong, H.; Gillerot, Y.; Reding, R.; Robert, A.] Catholic Univ Louvain, UCL Brussels, Inst Rech Expt & Clin, Louvain, Belgium; [Truong, H.; The, D. N.] Pham Ngoc Thach Univ Med, Ho Chi Minh City, Vietnam								0	0	0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		303	303						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101039					2019-03-26	
J	Habimana, L; Twite, E; Kitwa, E; Ozoza, J; Gruson, D; Wallemacq, P; Denayer, P; Donnen, P; Kalenga, M; Robert, A				Habimana, L.; Twite, E.; Kitwa, E.; Ozoza, J.; Gruson, D.; Wallemacq, P.; Denayer, P.; Donnen, P.; Kalenga, M.; Robert, A.			Iodine status of pregnant women in Lubumbashi, Dr Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Habimana, L.; Gruson, D.; Wallemacq, P.; Denayer, P.; Robert, A.] Catholic Univ Louvain, Louvain, Belgium; [Twite, E.; Kitwa, E.; Ozoza, J.; Kalenga, M.] Univ Lubumbashi, Lubumbashi, Zaire; [Donnen, P.] Univ Libre Bruxelles, Brussels, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		314	314						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101074					2019-03-26	
J	Jansen, FH; Adoubi, I; Musibi, A; De Cnodder, T; Efferth, T				Jansen, F. H.; Adoubi, I.; Musibi, A.; De Cnodder, T.; Efferth, T.			Artenimol-R in advanced cervical cancer	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Jansen, F. H.; De Cnodder, T.] Dafra Pharma R&D, Turnhout, Belgium; [Adoubi, I.] CHU Treichville, Serv Cancerol, Cote Divoire, Turnhout, Belgium; [Musibi, A.] KEMRI, Clin Res Ctr, Nairobi, Kenya; [Efferth, T.] Johannes Gutenberg Univ Mainz, Dept Pharmaceut Biol, Inst Pharm & Biochem, D-6500 Mainz, Germany								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		319	319						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101090					2019-03-26	
J	Nikubagenzi, J; Marerwa, G; Niragira, S; van Geertruyden, JP				Nikubagenzi, J.; Marerwa, G.; Niragira, S.; van Geertruyden, J. -P.			Cancer, a neglected disease in Burundi, a low income country	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[van Geertruyden, J. -P.] Univ Antwerp, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	14	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		319	319						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101092					2019-03-26	
J	Havyarimana, C; Ndikubagenzi, J; Van Geertruyden, JP				Havyarimana, C.; Ndikubagenzi, J.; Van Geertruyden, J. -P.			Popular restaurants, a potential source of transmission of food borne and infectious diseases in Bujumbura town, Burundi	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Van Geertruyden, J. -P.] Univ Antwerp, Antwerp, Belgium			Van geertruyden, Jean-Pierre/K-6425-2014	Van geertruyden, Jean-Pierre/0000-0001-5006-6364				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		323	324						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101106					2019-03-26	
J	Martini, J; Tijou-Traore, A; Dujardin, B; Macq, J; Gobatto, I				Martini, J.; Tijou-Traore, A.; Dujardin, B.; Macq, J.; Gobatto, I.			Patient involvement in care strategies for chronic diseases: the cases of diabetes and HIV/AIDS care in Mali. What lessons can be learned?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Martini, J.; Dujardin, B.] Univ Libre Bruxelles, Sch Publ Hlth, Brussels, Belgium; [Tijou-Traore, A.] Univ Bordeaux Segalen, Lab ADES SSD, CNRS, UMR 5185, Bordeaux, France; [Macq, J.] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium; [Gobatto, I.] Univ Bordeaux Segalen, Dept Social Anthropol Ethnol, Bordeaux, France								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		326	326						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101115					2019-03-26	
J	Van, PNN; Hong, TK; The, DN; Robert, A				Van, P. N. Ngoc; Hong, T. Kim; The, D. Nguyen; Robert, A.			Overweight and obesity among secondary high school students in Ho Chi Minh city, Vietnam	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Van, P. N. Ngoc; Robert, A.] Univ Catholique Louvain UCL Brussels, Inst Rech Expt & Clin, Louvain, Belgium; [Hong, T. Kim; The, D. Nguyen] Pham Ngoc Thach Univ Med, Ho Chi Minh City, Vietnam								0	0	0	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		326	326						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101113					2019-03-26	
J	van Olmen, J; Kalobu, JC; Bewa, E; Mencarini, P; De Clerck, M; Criel, B				van Olmen, J.; Kalobu, J. -C.; Bewa, E.; Mencarini, P.; De Clerck, M.; Criel, B.			An analysis of diabetes care in first line health facilities in Kinshasa, DR Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[van Olmen, J.; Criel, B.] Inst Trop Med Antwerpen, Antwerp, Belgium			Mencarini, Paola/B-7137-2017	Mencarini, Paola/0000-0001-8928-8183				0	0	0	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		329	329						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101123					2019-03-26	
J	Jessica, M; Paul, E; Ireland, M; Dujardin, B				Jessica, M.; Paul, E.; Ireland, M.; Dujardin, B.			The evaluation of the Paris declaration on aid effectiveness: what does it tell us? What results for the health sector?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Jessica, M.; Ireland, M.; Dujardin, B.] Univ Libre Bruxelles GRAP PA Sante, Sch Publ Hlth, Brussels, Belgium; [Paul, E.] Univ Liege GRAP PA Sante, Liege, Belgium								0	0	0	0	11	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		331	331						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101129					2019-03-26	
J	Ravinetto, R; Jacobs, J; Luyckx, C				Ravinetto, R.; Jacobs, J.; Luyckx, C.			Substandard medicines: a neglected plague?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Ravinetto, R.; Jacobs, J.; Luyckx, C.] Inst Trop Med Antwerp, Antwerp, Belgium								0	0	0	1	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		332	332						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101132					2019-03-26	
J	Claeys, Y; Ouedraogo, S; Battarai, A; Kalonji, H; Meester, R; Mwakazanga, D; Smedley, J; Sopheak, S; Thiongo, M; Woukeu, A; Gondol, G; Ravinetto, R; van Loen, H				Claeys, Y.; Ouedraogo, S.; Battarai, A.; Kalonji, H.; Meester, R.; Mwakazanga, D.; Smedley, J.; Sopheak, S.; Thiongo, M.; Woukeu, A.; Gondol, G.; Ravinetto, R.; van Loen, H.			Data management in tropical medicine: a call for uniformity	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Claeys, Y.; Gondol, G.; Ravinetto, R.; van Loen, H.] Inst Trop Med ITM Prince Leopold, Antwerp, Belgium; [Kalonji, H.] Univ Kinshasa, Kinshasa, DEM REP CONGO; [Meester, R.] Amsterdam Med Ctr, Amsterdam, Netherlands; [Smedley, J.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Woukeu, A.] London Sch Hyg & Trop Med, London, England								0	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		333	333						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101138					2019-03-26	
J	Malaviya, P; Singh, RP; Singh, SP; Hasker, E; Ostyn, B; Shankar, R; Boelaert, M; Sundar, S				Malaviya, P.; Singh, R. P.; Singh, S. P.; Hasker, E.; Ostyn, B.; Shankar, R.; Boelaert, M.; Sundar, S.			Monitoring drug effectiveness in Kala-azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting system	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Malaviya, P.; Singh, R. P.; Singh, S. P.; Shankar, R.; Sundar, S.] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Hasker, E.; Ostyn, B.; Boelaert, M.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium			Malaviya, Paritosh/B-1819-2012; Boelaert, Marleen/E-2698-2012	Malaviya, Paritosh/0000-0002-7558-152X; Boelaert, Marleen/0000-0001-8051-6776				0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		337	338						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101151					2019-03-26	
J	Tejerina, H; de Paepe, P; Van Dessel, P; Unger, JP; Closon, MC				Tejerina, H.; de Paepe, P.; Van Dessel, P.; Unger, J. -P.; Closon, M. -C.			Are integrated services networks of privately delivered health care a good option for lmic? The prosalud experience in Bolivia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Tejerina, H.] Catholic Univ Louvain, La Paz, Bolivia; [de Paepe, P.; Van Dessel, P.; Unger, J. -P.; Closon, M. -C.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		338	338						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101152					2019-03-26	
J	Maketa, V; Vuna, M; Baloji, S; Lubanza, S; Mpanya, A; Lutumba, P				Maketa, V.; Vuna, M.; Baloji, S.; Lubanza, S.; Mpanya, A.; Lutumba, P.			Perception and expectation of poor urban communities of Kinshasa/DRC on health care services	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Maketa, V.; Lutumba, P.] UNIKIN, Dept Trop Med, Kinshasa, Zaire; [Vuna, M.; Lutumba, P.] Inst Natl Rech Biomed, Kinshasa, Zaire; [Baloji, S.] Inst Super Tech Med, Kinshasa, Zaire; [Lubanza, S.] UNIKIN, Dept Anthropol, Kinshasa, Zaire; [Lutumba, P.] Inst Trop Med Antwerp, Antwerp, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		339	340						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101157					2019-03-26	
J	Laokri, S; Olivier, W; Maxime, D; Bruno, D				Laokri, S.; Olivier, W.; Maxime, D.; Bruno, D.			Catastrophic out-of-pocket health costs due to inefficient management of the health-care system: an evidence-based case study of tuberculosis control program in rural Burkina Faso	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract						cost-of-illness; out-of-pocket expenses; tuberculosis; households; Burkina Faso			[Laokri, S.; Bruno, D.] Univ Libre Bruxelles, Ecole Sante Publ, Brussels, Belgium; [Olivier, W.] HLSP Inst, London, England; [Maxime, D.] IRSS CNRST, Ouagadougou, Burkina Faso								0	2	2	1	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		340	340						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101159					2019-03-26	
J	Sosa, I; Guerra, M; De Vos, P; Rodriguez, A; Bonet, M; Lefevre, P; Van der Stuyft, P				Sosa, I.; Guerra, M.; De Vos, P.; Rodriguez, A.; Bonet, M.; Lefevre, P.; Van der Stuyft, P.			Community empowerment in the planning, implementation and evaluation of health interventions in four Cuban health areas	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Sosa, I.; Rodriguez, A.; Bonet, M.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; [Guerra, M.] Ctr Havana, Municipal Hlth Direct, Havana, Cuba; [De Vos, P.; Lefevre, P.; Van der Stuyft, P.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium			De Vos, Pol/D-3370-2009					0	0	0	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		341	341						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101161					2019-03-26	
J	Eggermont, N; Van Damme, W; Van Olmen, J				Eggermont, N.; Van Damme, W.; Van Olmen, J.			Evaluation of a peer-education program for diabetes and hypertension in rural Cambodia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Eggermont, N.] Univ Ghent, Fac Med, Ghent, Belgium; [Van Damme, W.; Van Olmen, J.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium			Van Damme, Wim/F-7404-2011					0	0	0	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		343	344						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101169					2019-03-26	
J	Alvarez-Perez, A; Maldonado, G; Luis, I; Alegret, M; Bonet-Gorbea, M; Rodriguez-Salva, A; De Vos, P; Van der Stuyft, P				Alvarez-Perez, A.; Maldonado, G.; Luis, I.; Alegret, M.; Bonet-Gorbea, M.; Rodriguez-Salva, A.; De Vos, P.; Van der Stuyft, P.			Population health and its determinants in Cuba: disparities study 1989-2010	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Alvarez-Perez, A.; Maldonado, G.; Luis, I.; Bonet-Gorbea, M.; Rodriguez-Salva, A.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; [Alegret, M.] Prov Direct, Minist Hlth, Santa Clara, CA, Cuba; [De Vos, P.; Van der Stuyft, P.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium			De Vos, Pol/D-3370-2009					0	0	0	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		344	345						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101172					2019-03-26	
J	Rodriguez-Salva, A; Diaz-Pinera, A; Garcia-Roche, R; Guerra-Chang, M; Balcindes-Acosta, S; Jova-Morel, R; De Vos, P; Van der Stuyft, P				Rodriguez-Salva, A.; Diaz-Pinera, A.; Garcia-Roche, R.; Guerra-Chang, M.; Balcindes-Acosta, S.; Jova-Morel, R.; De Vos, P.; Van der Stuyft, P.			Determinants of health service utilization in Centro Habana, Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Rodriguez-Salva, A.; Diaz-Pinera, A.; Garcia-Roche, R.; Balcindes-Acosta, S.; Jova-Morel, R.] Natl Inst Hyg Epidemiol & Microbiol, Havana, Cuba; [Guerra-Chang, M.] Ctr Habana, Municipal Hlth Direct, Havana, Cuba; [De Vos, P.; Van der Stuyft, P.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium			De Vos, Pol/D-3370-2009					0	0	0	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		344	344						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101171					2019-03-26	
J	Bhojani, U; Thriveni, BS; Devadasan, R; Munegowda, MS; AnthonyAmma, C; Soors, W; Devadasan, N; Criel, B; Kolsteren, P				Bhojani, U.; Thriveni, B. S.; Devadasan, R.; Munegowda, M. S.; AnthonyAmma, C.; Soors, W.; Devadasan, N.; Criel, B.; Kolsteren, P.			Health systems obstacles in the delivery of quality care to people with chronic diseases (PWCD): a case study from urban India	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Bhojani, U.; Thriveni, B. S.; Devadasan, R.; Munegowda, M. S.; AnthonyAmma, C.; Devadasan, N.] Inst Publ Hlth, Bengaluru, India; [Soors, W.; Criel, B.; Kolsteren, P.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		346	347						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101178					2019-03-26	
J	Kahindo, JB; Bonami, M; Godelet, E; Fonteyne, G; Wodon, A; Schirvel, C				Kahindo, J. -B.; Bonami, M.; Godelet, E.; Fonteyne, G.; Wodon, A.; Schirvel, C.			Reorganization of provincial level of health system in North Kivu and oriental Kasai, democratic Republic of Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Kahindo, J. -B.; Bonami, M.; Godelet, E.; Fonteyne, G.; Wodon, A.; Schirvel, C.] CEMUBAC, Brussels, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		346	346						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101177					2019-03-26	
J	Philips, MM; Ponsar, F; Gerard, S				Philips, M. M.; Ponsar, F.; Gerard, S.			Lessons learned from an organisation-wide policy change within an international non-governmental organisation: process and issues linked to the removal of user fees within msf supported health services	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Philips, M. M.; Ponsar, F.; Gerard, S.] Med Sans Frontieres, Brussels, Belgium			yan, liu/A-1822-2015	yan, liu/0000-0001-8517-1084				0	0	0	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		346	346						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101176					2019-03-26	
J	Berthe, A; Berthe, L; Konate, B; Drabo, M; Badini, FK; Macq, J				Berthe, A.; Berthe, L.; Konate, B.; Drabo, M.; Badini, F. Kinda; Macq, J.			Functional disability among elderly people in Bobo-Dioulasso (Burkina Faso)	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Berthe, A.; Konate, B.] Ctr Muraz, Bobo Dioulasso, Burkina Faso; [Badini, F. Kinda] Univ Ouagadougou, Ouagadougou, Burkina Faso; [Macq, J.] Catholic Univ Louvain, B-3000 Louvain, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		348	348						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101183					2019-03-26	
J	Berthe, A; Berthe, L; Konate, B; Drabo, M; Kinda-Badini, F; Macq, J				Berthe, A.; Berthe, L.; Konate, B.; Drabo, M.; Kinda-Badini, F.; Macq, J.			The influence of social networks on the health of older people: review of literature and research opportunities in Africa	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Berthe, A.; Konate, B.] Ctr Muraz, Bobo Dioulasso, Burkina Faso; [Kinda-Badini, F.] Univ Ouagadougou, Ouagadougou, Burkina Faso; [Macq, J.] Catholic Univ Louvain, B-3000 Louvain, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		348	348						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101182					2019-03-26	
J	Schirvel, C; Byamungu, T; Kahindo, JB; Fonteyne, G; Khomba, P; Wodon, A				Schirvel, C.; Byamungu, T.; Kahindo, J. -B.; Fonteyne, G.; Khomba, P.; Wodon, A.			Adding a reference wing to an unstructured public urban hospital: impact on the organization of health district in Kintambo, DR Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Schirvel, C.; Byamungu, T.; Kahindo, J. -B.; Fonteyne, G.; Khomba, P.; Wodon, A.] Univ Libre Bruxelles, CEMUBAC, Ctr Sci & Med, Brussels, Belgium								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		348	348						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101181					2019-03-26	
J	Philips, M; Benazeh, C; Camara, C; Van Overloop, C; Akerfeldt, K				Philips, M.; Benazeh, C.; Camara, C.; Van Overloop, C.; Akerfeldt, K.			Access barriers to effective hiv treatment linked to integrated service delivery through inequitable health services: the case of rationing arv initiation through patient payments for health care in Kinshasa, DRC	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Philips, M.] Med Sans Frontieres, Anal & Advocacy Unit, Brussels, Belgium; [Akerfeldt, K.] Med Sans Frontieres, Stockholm, Sweden								0	1	1	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		351	352						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101193					2019-03-26	
J	Philips, M; Lambert, D; Ponsar, F				Philips, M.; Lambert, D.; Ponsar, F.			The question of adequate utilisation rates for outpatient and inpatient activities in DRC for planning and resource allocation: a lack of standards?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Philips, M.; Lambert, D.] Anal & AdvocacyUnit, Med Sans Frontieres, Brussels, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		352	352						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101194					2019-03-26	
J	De Weggheleire, A; Chilengue, HJ; Botao, CF; Mbofana, F; Mahoudo, JAB; Casas, EC; Decroo, T; Baltazar, JM; Mosse, CDD; Bottieau, E				De Weggheleire, A.; Chilengue, H. J.; Botao, C. F.; Mbofana, F.; Mahoudo, J. A. Bonou; Casas, E. Carillo; Decroo, T.; Baltazar, J. M.; Mosse, C. Das Dores; Bottieau, E.			Perception of a new occupational health service by the health care workers of the provincial hospital of Tete, Mozambique	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[De Weggheleire, A.; Mahoudo, J. A. Bonou; Casas, E. Carillo; Bottieau, E.] Inst Trop Med, B-2000 Antwerp, Belgium; [Mosse, C. Das Dores] Direccao Prov Saude, Tete, Mozambique								0	0	0	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		355	356						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101205					2019-03-26	
J	Mukaji, B; Zinnen, V; Ribesse, N; Iyeti, A; Acq, J				Mukaji, B.; Zinnen, V.; Ribesse, N.; Iyeti, A.; Acq, J.			Health system strengthening and disease specific programs in Democratic Republic of Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Mukaji, B.] UNIKIN, Ecole Sante Publ, Kinshsa, Zaire; [Zinnen, V.; Ribesse, N.; Acq, J.] IRSS UCL, Brussels, Belgium								0	0	0	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		355	355						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101204					2019-03-26	
J	Ribesse, N; Iyeti, A; Zinnen, V; Mukaji, B; Macq, J				Ribesse, N.; Iyeti, A.; Zinnen, V.; Mukaji, B.; Macq, J.			Technical assistance for health system strengthening in fragile state: learning from experiences through systemic approach	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Ribesse, N.; Zinnen, V.; Mukaji, B.; Macq, J.] Catholic Univ Louvain, B-1200 Brussels, Belgium								0	0	0	1	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		357	357						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101209					2019-03-26	
J	Derderian, K				Derderian, K.			Humanitarian aid and health care when development goes 'backward': MSF field-based perspectives from Ivory Coast and Liberia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Meeting Abstract									[Derderian, K.] Med Sans Frontieres, Brussels, Belgium								0	0	0	1	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2011	16			1	SI		376	376						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	828RC	WOS:000295519101268					2019-03-26	
J	Marchal, B; Van Dormael, M; Pirard, M; Cavalli, A; Kegels, G; Polman, K				Marchal, Bruno; Van Dormael, Monique; Pirard, Marjan; Cavalli, Anna; Kegels, Guy; Polman, Katja			Neglected tropical disease (NTD) control in health systems: The interface between programmes and general health services	ACTA TROPICA			English	Article						Neglected tropical disease (NTD) control; Health systems; Integration; Health system strengthening	SUB-SAHARAN AFRICA; SOIL-TRANSMITTED HELMINTHIASIS; SCHISTOSOMIASIS CONTROL; LATIN-AMERICA; CARE SERVICES; INTEGRATION; ELIMINATION; COMMUNITY; FRAMEWORK; WORLD	Disease control programmes are an intrinsic part of health systems. Neglected tropical disease (NTD) control is a clear case in point. While there is a growing consensus that NTD control and health services are linked, with important mutual impacts, little is known of what actually happens at the interface between the two entities. Here, we review the rationale, viewpoints and experiences of NTD control programmes regarding general health services, and vice versa, and compare their respective arguments. We discuss the interactions and interface between disease control and health systems, and present possible scenarios for health system strengthening by NTD- and other disease-specific programmes. Focusing on countries in sub-Saharan Africa, we suggest a number of principles that could pave the way for fruitful discussions and development of synergies. (C) 2011 Elsevier B.V. All rights reserved.	[Polman, Katja] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Marchal, Bruno; Van Dormael, Monique; Pirard, Marjan; Cavalli, Anna; Kegels, Guy] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Polman, K (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	kpolman@itg.be					Albonico M, 2006, ADV PARASIT, V61, P311, DOI 10.1016/S0065-308X(05)61008-1; Amazigo UV, 2002, ANN TROP MED PARASIT, V96, P75, DOI 10.1179/00349802125000664; Atun R, 2010, HEALTH POLICY PLANN, V25, P104, DOI 10.1093/heapol/czp055; Baker MC, 2010, LANCET, V375, P231, DOI 10.1016/S0140-6736(09)61458-6; Baker MC, 2007, INT J HEALTH PLAN M, V22, P337, DOI 10.1002/hpm.900; Bitran R, 2009, HEALTH AFFAIR, V28, P1707, DOI 10.1377/hlthaff.28.6.1707; Blackburn BG, 2006, AM J TROP MED HYG, V75, P650, DOI 10.4269/ajtmh.2006.75.650; Brady MA, 2006, TRENDS PARASITOL, V22, P285, DOI 10.1016/j.pt.2006.05.007; BURKE J, 1971, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V51, P465; Claeson M, 2003, LANCET, V362, P323; Coulibaly Y, 2008, TROP MED INT HEALTH, V13, P1430, DOI 10.1111/j.1365-3156.2008.02174.x; Criel B, 2004, TROP MED INT HEALTH, V9, pA1, DOI 10.1111/j.1365-3156.2004.01257.x; Criel B, 1997, INTEGRATION VERTICAL; Crompton W.T., 2010, 1 WHO REPORT NEGLECT; CSDH (Commission on Social Determinants of Health), 2008, CLOS GAP GEN HLTH EQ; Daumerie D., 2006, STRAT TECHN M INT CO; DE SCHEITZ L, 1953, Ann Soc Belg Med Trop (1920), V33, P33; DEBROUWERE V, 1989, ANN SOC BELG MED TR, V69, P221; DeSavigny D, 2009, SYSTEMS THINKING FOR HEALTH SYSTEMS STRENGTHENING, P1; Diawara L, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000497; Esterre P, 2005, Bull Soc Pathol Exot, V98, P41; Feenstra P., 1993, LEP REV, P64; Fenwick A, 2009, PARASITOLOGY, V136, P1719, DOI 10.1017/S0031182009990400; Gabrielli AF, 2006, ACTA TROP, V99, P234, DOI 10.1016/j.actatropica.2006.08.008; Garba A, 2006, TRENDS PARASITOL, V22, P322, DOI 10.1016/j.pt.2006.04.007; Gbangbadthore S., 2006, SYSTEMWIDE EFFECTS G; Gilson L, 2003, SOC SCI MED, V56, P1453, DOI 10.1016/S0277-9536(02)00142-9; GNNTD, 2010, OUR HIST; Grepin KA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000174; Gyapong JO, 2010, LANCET, V375, P160, DOI 10.1016/S0140-6736(09)61249-6; Harries AD, 2009, INT J TUBERC LUNG D, V13, P1194; Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142; Hotez PJ, 2010, ADV PARASIT, V72, P31, DOI 10.1016/S0065-308X(10)72002-9; Hotez PJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000718; Hotez PJ, 2009, LANCET, V373, P1570, DOI 10.1016/S0140-6736(09)60233-6; Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000300; HOTEZ PJ, 2006, PLOS MED, V3, P102, DOI DOI 10.1371/J0URNAL.PMED.0030102; Kabatereine NB, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000755; Koblinsky M, 2006, LANCET, V368, P1377, DOI 10.1016/S0140-6736(06)69382-3; Kolaczinski JH, 2007, TRENDS PARASITOL, V23, P485, DOI 10.1016/j.pt.2007.08.007; Kolaczinski JH, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000745; Lammie PJ, 2006, TRENDS PARASITOL, V22, P313, DOI 10.1016/j.pt.2006.05.009; Loevinsohn B, 2002, AM J PUBLIC HEALTH, V92, P19, DOI 10.2105/AJPH.92.1.19; Marchal B., 2009, PLOS MED; Marmot M, 2006, LANCET, V368, P2081, DOI 10.1016/S0140-6736(06)69746-8; Men B., 2005, INT J HLTH PLAN MANA, P20; Mercenier P., 1983, GUIDELINES RES PROTO; MILLS A, 1983, SOC SCI MED, V17, P1971, DOI 10.1016/0277-9536(83)90137-5; Mills A, 2005, B WORLD HEALTH ORGAN, V83, P315; Moerman F, 2003, LANCET INFECT DIS, V3, P99, DOI 10.1016/S1473-3099(03)00518-8; Mogedal S., 2000, DIS ERADICATION FRIE; Molyneux DH, 2008, T ROY SOC TROP MED H, V102, P509, DOI 10.1016/j.trstmh.2008.02.024; Molyneux DH, 2005, PLOS MED, V2, P1064, DOI 10.1371/journal.pmed.0020336; Narain JP, 2010, B WORLD HEALTH ORGAN, V88, P206, DOI 10.2471/BLT.09.072322; Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4; OECD, 2005, PAR DECL AID EFF; Oliveira-Cruz V, 2004, TROP MED INT HEALTH, V9, P292, DOI 10.1046/j.1365-3156.2003.01188.x; Ooms G, 2008, GLOBALIZATION HEALTH, V4, DOI 10.1186/1744-8603-4-6; Pandey A, 2006, LEPROSY REV, V77, P210; Parker M, 2008, J BIOSOC SCI, V40, P161, DOI 10.1017/S0021932007002301; Perez D, 2009, HEALTH POLICY PLANN, V24, P335, DOI 10.1093/heapol/czp028; Potter C, 2004, HEALTH POLICY PLANN, V19, P336, DOI 10.1093/heapol/czh038; Rasanathan K., 2010, J EPIDEMIOL COMMUN H, P27; Reich MR, 2008, LANCET, V371, P865, DOI 10.1016/S0140-6736(08)60384-0; Richards FO, 2006, B WORLD HEALTH ORGAN, V84, P673, DOI 10.2471/BLT.06.029652; Rifkin SB, 1996, ACTA TROP, V61, P79, DOI 10.1016/0001-706X(95)00105-N; Rumunu J, 2009, TRENDS PARASITOL, V25, P301, DOI 10.1016/j.pt.2009.03.011; Savioli L, 2009, PARASITOLOGY, V136, P1677, DOI 10.1017/S0031182009991181; Segall M, 2003, INT J HEALTH PLAN M, V18, pS5, DOI 10.1002/hpm.719; Sepulveda J, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, pXIII; Shiffman J, 2008, HEALTH POLICY PLANN, V23, P95, DOI 10.1093/heapol/czm045; Singh A, 2006, HEALTH POLICY PLANN, V21, P326, DOI 10.1093/heapol/czl008; Spiegel JM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000255; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Talisuna AO, 2004, CLIN MICROBIOL REV, V17, P235, DOI 10.1128/CMR.17.1.235-254.2004; The NTD Initiative, 2010, AB NEGL TROP DIS IN; Thomas S, 2007, HEALTH POLICY, V83, P180, DOI 10.1016/j.healthpol.2007.01.002; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; UNGER JP, 1995, INT J HEALTH PLAN M, V10, P113, DOI 10.1002/hpm.4740100205; Unger JP, 2006, TROP MED INT HEALTH, V11, P314, DOI 10.1111/j.1365-3156.2006.01576.x; Unger JP, 2003, INT J HEALTH PLAN M, V18, pS27, DOI 10.1002/hpm.723; Uplekar M, 2007, B WORLD HEALTH ORGAN, V85, P413, DOI 10.2471/BLT.07.041756; Utzinger J, 2009, PARASITOLOGY, V136, P1859, DOI 10.1017/S0031182009991600; van Hoof L., 1946, ANN SOC BEIGE MED TROP, V26, P371; Van Olmen J., 2010, ANAL HLTH SYST MAK T; WHO, 2006, 4 WHO; WHO, 2009, MAX POS SYN BETW HLT; WHO, 2006, NEGL TROP DIS HIDD S; WHO, 2008, PRIM HLTH CAR NOW MO; WHO, 2007, EV BUS STRENGTH HLTH; *WHO, 2002, WHO TECH REP SER, V912, P1; World Health Organization, 2006, PREV CHEM HUM HELM C; World Health Organization, 2000, WORLD HLTH REP 2000; World Health Organization, 1978, DECL ALM AT INT C PR; World Health Organization The London School of Hygiene & Tropical Medicine and the International Trachoma Initiative, 2006, TRACH CONTR GUID PRO; World Health Organization (WHO), 2003, WORLD HLTH REP 2003	96	22	22	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	SEP	2011	120			1	SI		S177	S185		10.1016/j.actatropica.2011.02.017				9	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	847DZ	WOS:000296953400024	21439930	Other Gold			2019-03-26	
J	Gidwani, K; Picado, A; Rijal, S; Singh, SP; Roy, L; Volfova, V; Andersen, EW; Uranw, S; Ostyn, B; Sudarshan, M; Chakravarty, J; Volf, P; Sundar, S; Boelaert, M; Rogers, ME				Gidwani, Kamlesh; Picado, Albert; Rijal, Suman; Singh, Shri Prakash; Roy, Lalita; Volfova, Vera; Andersen, Elisabeth Wreford; Uranw, Surendra; Ostyn, Bart; Sudarshan, Medhavi; Chakravarty, Jaya; Volf, Petr; Sundar, Shyam; Boelaert, Marleen; Rogers, Matthew Edward			Serological Markers of Sand Fly Exposure to Evaluate Insecticidal Nets against Visceral Leishmaniasis in India and Nepal: A Cluster-Randomized Trial	PLOS NEGLECTED TROPICAL DISEASES			English	Article							LUTZOMYIA-LONGIPALPIS SALIVA; PHLEBOTOMUS-ARGENTIPES; ANTIBODY-RESPONSE; VECTOR CONTROL; DONOVANI INFECTION; TREATED NETS; BIHAR; SANDFLIES; SUBCONTINENT; PROTEINS	Background: Visceral leishmaniasis is the world' second largest vector-borne parasitic killer and a neglected tropical disease, prevalent in poor communities. Long-lasting insecticidal nets (LNs) are a low cost proven vector intervention method for malaria control; however, their effectiveness against visceral leishmaniasis (VL) is unknown. This study quantified the effect of LNs on exposure to the sand fly vector of VL in India and Nepal during a two year community intervention trial. Methods: As part of a paired-cluster randomized controlled clinical trial in VL-endemic regions of India and Nepal we tested the effect of LNs on sand fly biting by measuring the antibody response of subjects to the saliva of Leishmania donovani vector Phlebotomus argentipes and the sympatric (non-vector) Phlebotomus papatasi. Fifteen to 20 individuals above 15 years of age from 26 VL endemic clusters were asked to provide a blood sample at baseline, 12 and 24 months post-intervention. Results: A total of 305 individuals were included in the study, 68 participants provided two blood samples and 237 gave three samples. A random effect linear regression model showed that cluster-wide distribution of LNs reduced exposure to P. argentipes by 12% at 12 months (effect 0.88; 95% CI 0.83-0.94) and 9% at 24 months (effect 0.91; 95% CI 0.80-1.02) in the intervention group compared to control adjusting for baseline values and pair. Similar results were obtained for P. papatasi. Conclusions: This trial provides evidence that LNs have a limited effect on sand fly exposure in VL endemic communities in India and Nepal and supports the use of sand fly saliva antibodies as a marker to evaluate vector control interventions.	[Gidwani, Kamlesh; Singh, Shri Prakash; Sudarshan, Medhavi; Chakravarty, Jaya; Sundar, Shyam] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Picado, Albert; Andersen, Elisabeth Wreford; Rogers, Matthew Edward] London Sch Hyg & Trop Med, London WC1, England; [Picado, Albert; Ostyn, Bart; Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium; [Rijal, Suman; Roy, Lalita; Uranw, Surendra] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Volfova, Vera; Volf, Petr] Charles Univ Prague, Prague, Czech Republic; [Andersen, Elisabeth Wreford] Univ Copenhagen, Copenhagen, Denmark	Gidwani, K (reprint author), Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India.	matthew.rogers@lshtm.ac.uk	Volf, Petr/C-4300-2012; Volfova, Vera/H-1055-2017; Boelaert, Marleen/E-2698-2012	Volf, Petr/0000-0003-1790-1123; Volfova, Vera/0000-0002-7189-1483; Boelaert, Marleen/0000-0001-8051-6776; Picado, Albert/0000-0001-7344-628X; Rogers, Matthew/0000-0002-6542-6438	European Union [015374]; Czech Ministry of Education [MSM 0021620828]; Wellcome Trust [WT078223/Z/05/Z]; Biotechnology and Biological Sciences Research Council, UK [BB/H022406/1]; Biotechnology and Biological Sciences Research Council [BB/H022406/1]	This work was supported by the European Union under its 6th Framework Program (KALANET/INCODEV/Project 015374); the Czech Ministry of Education (MSM 0021620828 to V.V. and P.V.), the Wellcome Trust (Advanced Training Fellowship: WT078223/Z/05/Z to M.E.R.) and the Biotechnology and Biological Sciences Research Council, UK (David Phillips Fellowship: BB/H022406/1 to M.R.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Basak Basab, 1995, Journal of Communicable Diseases, V27, P122; Billingsley PF, 2006, PARASITE IMMUNOL, V28, P143, DOI 10.1111/j.1365-3024.2006.00805.x; Clements MF, 2010, AM J TROP MED HYG, V82, P801, DOI 10.4269/ajtmh.2010.09-0336; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; Dinesh DS, 2008, MED VET ENTOMOL, V22, P120, DOI 10.1111/j.1365-2915.2008.00724.x; Dinesh DS, 2008, TROP MED INT HEALTH, V13, P953, DOI 10.1111/j.1365-3156.2008.02096.x; Dinesh DS, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000859; Dinesh DS, 2001, ANN TROP MED PARASIT, V95, P197, DOI 10.1080/00034980120041071; Drame PM, 2010, AM J TROP MED HYG, V83, P115, DOI 10.4269/ajtmh.2010.09-0684; Ghosh K, 1982, J INDIAN ASS COMMUNI, V5, P14; GHOSH K N, 1990, Journal of Communicable Diseases, V22, P67; Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733; HATI AK, 1981, WHOVBC81801; Hostomska J, 2008, VECTOR-BORNE ZOONOT, V8, P443, DOI 10.1089/vbz.2007.0214; Joshi AB, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-54; MONDAL D, 2010, TROP MED INT HEALTH, V11, P1382; MUKHOPADHYAY AK, 1987, INDIAN J MED RES, V86, P475; Ostyn B, 2008, TROP MED INT HEALTH, V13, P1073, DOI 10.1111/j.1365-3156.2008.02110.x; PICADO A, 2010, PLOS NEGLECT TROP D, V1, pE587; Picado A, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6760; Picado A, 2009, MEM I OSWALDO CRUZ, V104, P1183, DOI 10.1590/S0074-02762009000800018; Poche D, 2011, J VECTOR ECOL, V36, pS106, DOI 10.1111/j.1948-7134.2011.00119.x; Poinsignon A, 2010, TROP MED INT HEALTH, V15, P1198, DOI 10.1111/j.1365-3156.2010.02611.x; RAHMAN S J, 1986, Journal of Communicable Diseases, V18, P35; READY PD, 1988, MED VET ENTOMOL, V2, P109, DOI 10.1111/j.1365-2915.1988.tb00060.x; Remoue F, 2006, T ROY SOC TROP MED H, V100, P363, DOI 10.1016/j.trstmh.2005.06.032; Rohousova I, 2005, PARASITOLOGY, V130, P493, DOI 10.1017/S00311200400681X; SCHWARTZ BS, 1991, AM J EPIDEMIOL, V134, P86, DOI 10.1093/oxfordjournals.aje.a115996; Schwarz A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000532; Singh R, 2008, ACTA TROP, V107, P117, DOI 10.1016/j.actatropica.2008.04.025; Singh SP, 2010, TROP MED INT HEALTH, V15, P12, DOI 10.1111/j.1365-3156.2010.02519.x; Souza AP, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000649; SRINIVASAN R, 1992, INDIAN J MED RES-A, V95, P301; SRINIVASAN R, 1995, ACTA TROP, V54, P125; STAUCH A, 2010, PLOS NEGL TROP UNPUB; SWAMINATH CS, 1942, INDIAN J MED RES, V30, P47; Volf P, 2001, PARASITOLOGY, V122, P37, DOI 10.1017/S0031182000007046	37	40	40	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	SEP	2011	5	9							e1296	10.1371/journal.pntd.0001296				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	842FM	WOS:000296578900010	21931871	DOAJ Gold, Green Published			2019-03-26	
J	Perry, MR; Wyllie, S; Prajapati, VK; Feldmann, J; Sundar, S; Boelaert, M; Fairlamb, AH				Perry, Meghan R.; Wyllie, Susan; Prajapati, Vijay Kumar; Feldmann, Joerg; Sundar, Shyam; Boelaert, Marleen; Fairlamb, Alan H.			Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent?	PLOS NEGLECTED TROPICAL DISEASES			English	Article							KALA-AZAR; SODIUM STIBOGLUCONATE; TRYPAREDOXIN PEROXIDASE; DRUG-RESISTANCE; DONOVANI; BIHAR; BANGLADESH; TARENTOLAE; NEPAL; PGPA		[Perry, Meghan R.; Wyllie, Susan; Fairlamb, Alan H.] Univ Dundee, Coll Life Sci, Div Biol Chem & Drug Discovery, Dundee, Scotland; [Prajapati, Vijay Kumar; Sundar, Shyam] Banaras Hindu Univ, Inst Med Sci, Dept Med, Infect Dis Res Lab, Varanasi 221005, Uttar Pradesh, India; [Feldmann, Joerg] Univ Aberdeen, Trace Element Speciat Lab, Coll Phys Sci Chem, Aberdeen, Scotland; [Boelaert, Marleen] Inst Trop Med Prince Leopold, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium	Perry, MR (reprint author), Univ Dundee, Coll Life Sci, Div Biol Chem & Drug Discovery, Dundee, Scotland.	a.h.fairlamb@dundee.ac.uk	Boelaert, Marleen/E-2698-2012; Fairlamb, Alan/A-5272-2009	Boelaert, Marleen/0000-0001-8051-6776; Fairlamb, Alan/0000-0001-5134-0329; Feldmann, Joerg/0000-0002-0524-8254; Wyllie, Susan/0000-0001-8810-5605	Wellcome Trust [090665, 079838]		Argos M, 2010, LANCET, V376, P252, DOI 10.1016/S0140-6736(10)60481-3; Ashutosh, 2007, J MED MICROBIOL, V56, P143, DOI 10.1099/jmm.0.46841-0; BERMAN JD, 1987, EXP PARASITOL, V64, P127, DOI 10.1016/0014-4894(87)90018-X; Bern C, 2006, INDIAN J MED RES, V123, P275; Bhattacharjee H, 2004, BIOCHEM BIOPH RES CO, V322, P836, DOI 10.1016/j.bbrc.2004.08.002; Brochu C, 2003, ANTIMICROB AGENTS CH, V47, P3073, DOI 10.1128/AAC.47.10.3073-3079.2003; Central Ground Water Board, 2010, GROUNDW QUAL SHALL A; Chakraborti D, 2003, ENVIRON HEALTH PERSP, V111, P1194, DOI 10.1289/ehp.5966; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI [10.1128/CMR.19.1.111-126.2006, 10.4103/0974-777X.62887]; Das S, 2005, TOXICOL APPL PHARM, V204, P18, DOI 10.1016/j.taap.2004.08.010; Deshingkar P, 2006, ROLE MIGRATION REMIT; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1994, MOL BIOCHEM PARASIT, V67, P49, DOI 10.1016/0166-6851(94)90095-7; El Fadili K, 2005, ANTIMICROB AGENTS CH, V49, P1988, DOI 10.1128/AAC.49.5.1988-1993.2005; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0; Hasker E, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02562.x; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Lira R, 1999, J INFECT DIS, V180, P564, DOI 10.1086/314896; Mazumder DNG, 2005, TOXICOL APPL PHARM, V206, P169, DOI 10.1016/j.taap.2004.08.025; Mittal MK, 2007, AM J TROP MED HYG, V76, P681, DOI 10.4269/ajtmh.2007.76.681; Mondal D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000355; Mubayi A, 2010, J THEOR BIOL, V262, P177, DOI 10.1016/j.jtbi.2009.09.012; Mukhopadhyay R, 2002, FEMS MICROBIOL REV, V26, P311, DOI 10.1016/S0168-6445(02)00112-2; Olliaro PL, 2005, LANCET INFECT DIS, V5, P763, DOI 10.1016/S1473-3099(05)70296-6; PAYNE D, 1988, PARASITOL TODAY, V4, P112, DOI 10.1016/0169-4758(88)90042-7; PETERS W, 1981, INDIAN J MED RES, V73, P1; Raab A, 2005, ANAL BIOANAL CHEM, V381, P332, DOI 10.1007/s00216-004-2796-6; Ravenscroft P., 2009, ARSENIC POLLUTION GL; Rijal S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2; Rijal S, 2007, MICROBES INFECT, V9, P529, DOI 10.1016/j.micinf.2007.01.009; Seifert K, 2010, J ANTIMICROB CHEMOTH, V65, P508, DOI 10.1093/jac/dkp500; Singh RK, 2006, INDIAN J MED RES, V123, P331; Sohel N, 2009, EPIDEMIOLOGY, V20, P824, DOI 10.1097/EDE.0b013e3181bb56ec; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; Sundar S, 2008, TROP MED INT HEALTH, V13, P2, DOI 10.1111/j.1365-3156.2007.01974.x; Thakur CP, 2004, INDIAN J MED RES, V120, P166; THAKUR CP, 1988, BRIT MED J, V296, P1557, DOI 10.1136/bmj.296.6636.1557; THAKUR CP, 1984, T ROY SOC TROP MED H, V78, P391, DOI 10.1016/0035-9203(84)90131-7; Vahter Marie, 1999, Science Progress, V82, P69; Vanaerschot M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012211; Wyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200; Wyllie S, 2008, ANTIMICROB AGENTS CH, V52, P1359, DOI 10.1128/AAC.01563-07; Wyllie S, 2010, MOL BIOCHEM PARASIT, V173, P162, DOI 10.1016/j.molbiopara.2010.05.015; Yan S, 2005, METALLOTHERAPEUTIC D, P441	46	30	30	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	SEP	2011	5	9							e1227	10.1371/journal.pntd.0001227				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	842FM	WOS:000296578900003	21980542	DOAJ Gold, Green Published			2019-03-26	
J	Ford, NP; de Smet, M; Kolappa, K; White, NJ				Ford, Nathan P.; de Smet, Martin; Kolappa, Kavitha; White, Nicholas J.			Responding to the evidence for the management of severe malaria	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						severe malaria; quinine; artesunate; treatment	ARTESUNATE; QUININE		[Ford, Nathan P.; de Smet, Martin; Kolappa, Kavitha] Med Sans Frontieres, Brussels, Belgium; [Ford, Nathan P.] Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa; [Kolappa, Kavitha] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [White, Nicholas J.] Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand	Ford, NP (reprint author), Med Sans Frontieres, Brussels, Belgium.	nathan.ford@msf.org	White, Nicholas/I-4629-2012		Wellcome Trust [093956]		Amuasi JH, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-34; Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5; Butler AR, 2010, J ROY COLL PHYS EDIN, V40, P172, DOI 10.4997/JRCPE.2010.216; Council for International Organizations of Medical Sciences(CIOMS), 2002, COUNC INT ORG MED SC; DONDORP AM, 2010, LANCET, V376, P164; Faiz MA, 2005, LANCET, V366, P717; Guthmann JP, 2008, PLOS MED, V5, P1191, DOI 10.1371/journal.pmed.0050169; Lubell Y, 2009, TROP MED INT HEALTH, V14, P332, DOI 10.1111/j.1365-3156.2009.02227.x; LUBELL Y, 2011, B WHO IN PRESS; MSF, 2011, MAK SWITCH ENS ACC I; Sinclair D, 2011, COCHRANE DB SYST REV, V3; Snow RW, 2010, LANCET, V376, P1409, DOI 10.1016/S0140-6736(10)61340-2; WHO, 2010, WORLD MALARIA REPORT 2010, P1; *WHO, 2011, GUID TREATM SEV MAL	14	2	2	1	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2011	16	9					1085	1086		10.1111/j.1365-3156.2011.02810.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	804MY	WOS:000293659100006	21689220	Green Published, Bronze			2019-03-26	
J	Malaviya, P; Singh, RP; Singh, SP; Hasker, E; Ostyn, B; Shankar, R; Boelaert, M; Sundar, S				Malaviya, P.; Singh, R. P.; Singh, S. P.; Hasker, E.; Ostyn, B.; Shankar, R.; Boelaert, M.; Sundar, S.			Monitoring drug effectiveness in kala-azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting system	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; drug monitoring; drug effectiveness; public health system; recording and reporting; supervised treatment; patient follow up	VISCERAL LEISHMANIASIS; TUBERCULOSIS	OBJECTIVE In 2009, a random survey was conducted in Muzaffarpur district to document the clinical outcomes of visceral leishmaniasis patients (VL) treated by the public health care system in 2008, to assess the effectiveness of miltefosine against VL. We analysed the operational feasibility and cost of such periodic random surveys as compared with health facility-based routine monitoring. METHODS A random sample of 150 patients was drawn from registers kept at Primary Health Care centres. Patient records were examined, and the patients were located at their residence. Patients and physicians were interviewed with the help of two specifically designed questionnaires by a team of one supervisor, one physician and one field worker. Costs incurred during this survey were properly documented, and vehicle log books maintained for analysis. RESULTS Hundred and 39 (76.7%) of the patients could be located. Eleven patients were not traceable. Per patient, follow-up cost was US$ 15.51 and on average 2.27 patients could be visited per team-day. Human resource involvement constituted 75% of the total cost whereas involvement of physician costs 51% of the total cost. CONCLUSION A random survey to document clinical outcomes is costly and labour intensive but gives probably the most accurate information on drug effectiveness. A health service-based retrospective cohort reporting system modelled on the monitoring system developed by tuberculosis programmes could be a better alternative. Involvement of community health workers in such monitoring would offer the additional advantage of treatment supervision and support.	[Malaviya, P.; Singh, R. P.; Singh, S. P.; Shankar, R.; Sundar, S.] Banaras Hindu Univ, Inst Med Sci, Dept Med, Varanasi 221005, Uttar Pradesh, India; [Hasker, E.; Ostyn, B.; Boelaert, M.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium	Sundar, S (reprint author), Banaras Hindu Univ, Inst Med Sci, Dept Med, Varanasi 221005, Uttar Pradesh, India.	drshyamsundar@hotmail.com		Boelaert, Marleen/0000-0001-8051-6776	NIAID, NIH [1P50AI074321]	This work was supported by NIAID, NIH TMRC Grant No. 1P50AI074321.	ADDY M, 1992, B WORLD HEALTH ORGAN, V70, P341; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Hasker E, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02562.x; STYBLO K, 1976, INT J EPIDEMIOL, V5, P63, DOI 10.1093/ije/5.1.63; Styblo K, 1991, TUBERCULOSIS SURVEIL, V2, P60; Sundar S, 2001, AM J TROP MED HYG, V65, P193, DOI 10.4269/ajtmh.2001.65.193; van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6; Veen J, 1998, EUR RESPIR J, V12, P505, DOI 10.1183/09031936.98.12020505; *WHO, 1990, WHO TECH REP SER, V793, P1, DOI DOI 10.3201/EID1105.040718; WHO, 2005, REG STRAT FRAM EL KA	10	5	5	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2011	16	9					1159	1166		10.1111/j.1365-3156.2011.02803.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	804MY	WOS:000293659100016	21624015	Green Accepted, Bronze			2019-03-26	
J	De Ceukelaire, W; De Vos, P; Criel, B				De Ceukelaire, Wim; De Vos, Pol; Criel, Bart			Political will for better health, a bottom-up process	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						right to health; state; civil society; class analysis	CIVIL-SOCIETY; SOCIAL DETERMINANTS; PERSPECTIVE; COUNTRIES; POLICY	Lately, different voices in the global public health community have drawn attention to the interaction between the State and civil society in the context of reducing health inequities. A rights-based approach empowers people not only to claim their rights but also to demand accountability from the State. Lessons from history show that economic growth does not automatically have positive implications for population health. It may even be disruptive in the absence of strong stewardship and regulation by national and local public health authorities. The field research in which we have been involved over the past 20 years in the Philippines, Palestine, Cuba, and Europe confirms that organized communities and people's organizations can effectively pressure the state into action towards realizing the right to health. Class analysis, influencing power relations, and giving the State a central role have been identified as three key strategies of relevant social movements and NGOs. More interaction between academia and civil society organizations could contribute to enhance and safeguard the societal relevance of public health researches. Our own experience made us discover that social movements and public health researchers have a lot to learn from one another.	[De Vos, Pol; Criel, Bart] Inst Trop Med, B-2000 Antwerp, Belgium; [De Ceukelaire, Wim] INTAL, Brussels, Belgium	De Vos, P (reprint author), Inst Trop Med, Nationalestr 155, B-2000 Antwerp, Belgium.	pdevos@itg.be	De Vos, Pol/D-3370-2009				*3 WORLD REL FUND, 2010, MOST SIGN CHANG MON; Baldwin P., 1990, POLITICS SOCIAL SOLI; Bhan A, 2007, PLOS MED, V4, P1456, DOI 10.1371/journal.pmed.0040272; Blas E, 2008, LANCET, V372, P1684, DOI 10.1016/S0140-6736(08)61693-1; Borrel M, 2004, IND CONFLICT MASS DE; Chopra M, 2000, BRIT MED J, V321, P832, DOI 10.1136/bmj.321.7264.832; Commission on Social Determinants of Health, 2008, CSDH FIN REP CLOS GA; *COUNC HLTH DEV, 1998, COMM BAS HLTH PROGR; De Vos P, 2005, INT J HEALTH SERV, V35, P189, DOI 10.2190/M72R-DBKD-2XWV-HJWB; De Vos P, 2004, INT J HEALTH SERV, V34, P255, DOI 10.2190/PURT-1LY9-F0BG-RRUD; De Vos Pol, 2009, Health Hum Rights, V11, P23; Delisle Helene, 2005, Health Res Policy Syst, V3, P3, DOI 10.1186/1478-4505-3-3; Elias PEM, 2003, AM J PUBLIC HEALTH, V93, P44, DOI 10.2105/AJPH.93.1.44; Garfield Richard, 1992, HLTH CARE NICARAGUA; LUTTRELL C, 2007, LINKAGES HUMAN RIGHT; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; NAVARRO V, 1989, SOC SCI MED, V28, P887, DOI 10.1016/0277-9536(89)90313-4; Sanders D, 2004, B WORLD HEALTH ORGAN, V82, P757; SPIESSCHAERT F, 2005, METHODOLOGY EXPERIEN; Szreter S, 1997, POPUL DEV REV, V23, P693, DOI 10.2307/2137377; Szreter S, 2003, AM J PUBLIC HEALTH, V93, P421, DOI 10.2105/AJPH.93.3.421; Turiano Laura, 2008, Health Hum Rights, V10, P137; Unger JP, 2008, AM J PUBLIC HEALTH, V98, P636, DOI 10.2105/AJPH.2006.099598; WHO Regional Office for the Western Pacific, 2008, WORLD HLTH REP 2008, P35	24	5	5	0	18	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2011	16	9					1185	1189		10.1111/j.1365-3156.2011.02817.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	804MY	WOS:000293659100019	21707878	Bronze			2019-03-26	
J	Killeen, GF; Okumu, FO; N'Guessan, R; Coosemans, M; Adeogun, A; Awolola, S; Etang, J; Dabire, RK; Corbel, V				Killeen, Gerry F.; Okumu, Fredros O.; N'Guessan, Raphael; Coosemans, Marc; Adeogun, Adedapo; Awolola, Sam; Etang, Josiane; Dabire, Roch K.; Corbel, Vincent			The importance of considering community-level effects when selecting insecticidal malaria vector products	PARASITES & VECTORS			English	Article							RESISTANT ANOPHELES-GAMBIAE; CULEX-QUINQUEFASCIATUS MOSQUITOS; EXPERIMENTAL HUT EVALUATION; CONTROL INTERVENTIONS; PERMANET(R) 3.0; MEKONG REGION; WEST-AFRICA; BED NETS; TRANSMISSION; BENIN	Background: Insecticide treatment of nets, curtains or walls and ceilings of houses represent the primary means for malaria prevention worldwide. Direct personal protection of individuals and households arises from deterrent and insecticidal activities which divert or kill mosquitoes before they can feed. However, at high coverage, community-level reductions of mosquito density and survival prevent more transmission exposure than the personal protection acquired by using a net or living in a sprayed house. Methods: A process-explicit simulation of malaria transmission was applied to results of 4 recent Phase II experimental hut trials comparing a new mosaic long-lasting insecticidal net (LLIN) which combines deltamethrin and piperonyl butoxide with another LLIN product by the same manufacturer relying on deltamethrin alone. Results: Direct estimates of mean personal protection against insecticide-resistant vectors in Vietnam, Cameroon, Burkina Faso and Benin revealed no clear advantage for combination LLINs over deltamethrin-only LLINs (P = 0.973) unless both types of nets were extensively washed (Relative mean entomologic inoculation rate (EIR) +/- standard error of the mean (SEM) for users of combination nets compared to users of deltamethrin only nets = 0.853 +/- 0.056, P = 0.008). However, simulations of impact at high coverage (80% use) predicted consistently better impact for the combination net across all four sites (Relative mean EIR +/- SEM in communities with combination nets, compared with those using deltamethrin only nets = 0.613 +/- 0.076, P < 0.001), regardless of whether the nets were washed or not (P = 0.467). Nevertheless, the degree of advantage obtained with the combination varied substantially between sites and their associated resistant vector populations. Conclusion: Process-explicit simulations of community-level protection, parameterized using locally-relevant experimental hut studies, should be explicitly considered when choosing vector control products for large-scale epidemiological trials or public health programme procurement, particularly as growing insecticide resistance necessitates the use of multiple active ingredients.	[Killeen, Gerry F.; Okumu, Fredros O.] Ifakara Hlth Inst, Biomed & Environm Themat Grp, Morogoro, Tanzania; [Killeen, Gerry F.] Univ Liverpool, Liverpool Sch Trop Med, Vector Grp, Liverpool L3 5QA, Merseyside, England; [Okumu, Fredros O.; N'Guessan, Raphael] London Sch Hyg & Trop Med, Dis Control & Vector Biol Unit, London WC1E 7HT, England; [N'Guessan, Raphael; Corbel, Vincent] CREC, Lab Natl, Minist Sante, Cotonou, Benin; [Coosemans, Marc] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Coosemans, Marc] Univ Antwerp, Dept Biomed Sci, Fac Pharmaceut Vet & Biomed Sci, B-2610 Antwerp, Belgium; [Adeogun, Adedapo; Awolola, Sam] Nigerian Inst Med Res, Publ Hlth Div, Lagos, Nigeria; [Etang, Josiane] Org Coordinat lutte Endmies Afrique Ctr, Yaounde, Cameroon; [Etang, Josiane] Univ Douala, Fac Med & Pharmaceut Sci, Douala, Cameroon; [Dabire, Roch K.] CM, IRSS, Bobo Dioulasso, Burkina Faso; [Corbel, Vincent] CNRS, Inst Rech Dev IRD Malad Infect & Vecteurs Ecol, Genet Evolut & Controle MIVEGEC, UM1 5290,IRD 224,CREC, Cotonou, Benin	Killeen, GF (reprint author), Ifakara Hlth Inst, Biomed & Environm Themat Grp, POB 53, Morogoro, Tanzania.	gkilleen@ihi.or.tz	Corbel, VIncent/G-9576-2016		Vestergaard Frandsen SA	We thank Dr T Knox and Dr H Pates Jamet (Vestergaard Frandsen SA) and Dr G Devine (Liverpool School of Tropical Medicine and Ifakara Health Institute) for comments on the manuscript. This research and all the field studies described herein were funded entirely by Vestergaard Frandsen SA.	Akogbeto MC, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-204; Chitnis N, 2010, AM J TROP MED HYG, V83, P230, DOI 10.4269/ajtmh.2010.09-0179; Corbel V, 2007, ACTA TROP, V101, P207, DOI 10.1016/j.actatropica.2007.01.005; Corbel V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-113; Dabire KR, 2009, T ROY SOC TROP MED H, V103, P1113, DOI 10.1016/j.trstmh.2009.01.008; Etang J, 2003, J MED ENTOMOL, V40, P491, DOI 10.1603/0022-2585-40.4.491; Etang J, 2007, J VECTOR ECOL, V32, P123, DOI 10.3376/1081-1710(2007)32[123:SOMRTD]2.0.CO;2; GARRETTJONES C, 1964, NATURE, V204, P1173, DOI 10.1038/2041173a0; Grieco JP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000716; Griffin JT, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000324; Guillet P, 2001, B WORLD HEALTH ORGAN, V79, P998; Hawley WA, 2003, AM J TROP MED HYG, V68, P121, DOI 10.4269/ajtmh.2003.68.121; Killeen GF, 2007, PLOS MED, V4, P1246, DOI 10.1371/journal.pmed.0040229; Killeen GF, 2007, T ROY SOC TROP MED H, V101, P867, DOI 10.1016/j.trstmh.2007.04.022; Killeen GF, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-207; Killeen GF, 2004, AM J TROP MED HYG, V71, P87, DOI 10.4269/ajtmh.2004.71.2_suppl.0700087; Killeen GF, 2003, LANCET INFECT DIS, V3, P297, DOI 10.1016/S1473-3099(03)00611-X; Killeen GF, 2001, T ROY SOC TROP MED H, V95, P469, DOI 10.1016/S0035-9203(01)90005-7; Kleinschmidt I, 2009, AM J TROP MED HYG, V81, P519, DOI 10.4269/ajtmh.2009.81.519; Kouznetsov R L, 1977, Trop Doct, V7, P81; Lengeler C., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; LINES JD, 1991, MED VET ENTOMOL, V5, P261, DOI 10.1111/j.1365-2915.1991.tb00550.x; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; Malima RC, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-38; Molineaux L., 1980, GARKI PROJECT; Muller P, 2008, MOL ECOL, V17, P1145, DOI 10.1111/j.1365-294X.2007.03617.x; N'Guessan R, 2010, T ROY SOC TROP MED H, V104, P758, DOI 10.1016/j.trstmh.2010.08.008; N'Guessan R, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-44; N'Guessan R, 2009, TROP MED INT HEALTH, V14, P389, DOI 10.1111/j.1365-3156.2009.02245.x; Najera J. A., 2001, Parassitologia (Rome), V43, P1; Okumu FO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011573; Pluess B, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006657.pub2; Rajatileka S, 2011, T ROY SOC TROP MED H, V105, P247, DOI 10.1016/j.trstmh.2011.01.009; SAUL AJ, 1990, J APPL ECOL, V27, P123, DOI 10.2307/2403572; Scholte EJ, 2005, SCIENCE, V308, P1641, DOI 10.1126/science.1108639; Service MW, 2008, MOSQUITO ECOLOGY FIE, P1425; Trung HD, 2005, TROP MED INT HEALTH, V10, P251, DOI 10.1111/j.1365-3156.2004.01378.x; Van Bortel W, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-248; Van Bortel W, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-102; Verhaeghen K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-84; *WHO, 2008, WORLD MAL REP; *WHO, 2007, INS TREAT MOSQ NETS, V10; World Health Organization, 2006, GUID TEST MOSQ AD IN; Yakob L, 2011, J R SOC INTERFACE, V8, P799, DOI 10.1098/rsif.2010.0537	44	16	16	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	AUG 12	2011	4								160	10.1186/1756-3305-4-160				7	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	832VD	WOS:000295836100001	21838903	DOAJ Gold, Green Published			2019-03-26	
J	Swysen, C; Vekemans, J; Bruls, M; Oyakhirome, S; Drakeley, C; Kremsner, P; Greenwood, B; Ofori-Anyinam, O; Okech, B; Villafana, T; Carter, T; Savarese, B; Duse, A; Reijman, A; Ingram, C; Frean, J; Ogutu, B				Swysen, Christine; Vekemans, Johan; Bruls, Myriam; Oyakhirome, Sunny; Drakeley, Chris; Kremsner, Peter; Greenwood, Brian; Ofori-Anyinam, Opokua; Okech, Brenda; Villafana, Tonya; Carter, Terrell; Savarese, Barbara; Duse, Adriano; Reijman, Andrea; Ingram, Charlotte; Frean, John; Ogutu, Bernhards		Clinical Trials Partnership Comm	Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine	MALARIA JOURNAL			English	Article							MOZAMBICAN CHILDREN; SAFETY; IMMUNOGENICITY; BENEFITS; EFFICACY; INFANTS; TRIAL	Background: A pivotal phase III study of the RTS, S/AS01 malaria candidate vaccine is ongoing in several research centres across Africa. The development and establishment of quality systems was a requirement for trial conduct to meet international regulatory standards, as well as providing an important capacity strengthening opportunity for study centres. Methods: Standardized laboratory methods and quality assurance processes were implemented at each of the study centres, facilitated by funding partners. Results: A robust protocol for determination of parasite density based on actual blood cell counts was set up in accordance with World Health Organization recommendations. Automated equipment including haematology and biochemistry analyzers were put in place with standard methods for bedside testing of glycaemia, base excess and lactacidaemia. Facilities for X-rays and basic microbiology testing were also provided or upgraded alongside health care infrastructure in some centres. External quality assurance assessment of all major laboratory methods was established and method qualification by each laboratory demonstrated. The resulting capacity strengthening has ensured laboratory evaluations are conducted locally to the high standards required in clinical trials. Conclusion: Major efforts by study centres, together with support from collaborating parties, have allowed standardized methods and robust quality assurance processes to be put in place for the phase III evaluation of the RTS, S/AS01 malaria candidate vaccine. Extensive training programmes, coupled with continuous commitment from research centre staff, have been the key elements behind the successful implementation of quality processes. It is expected these activities will culminate in healthcare benefits for the subjects and communities participating in these trials.	[Swysen, Christine; Vekemans, Johan; Bruls, Myriam; Ofori-Anyinam, Opokua; Okech, Brenda] GlaxoSmithKline Biol, Rixensart, Belgium; [Oyakhirome, Sunny; Kremsner, Peter] Univ Tubingen, Inst Trop Med, Tubingen, Germany; [Oyakhirome, Sunny; Kremsner, Peter] Albert Schweitzer Hosp, Kumasi, Gabon; [Drakeley, Chris; Greenwood, Brian] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Villafana, Tonya; Carter, Terrell; Savarese, Barbara] PATH Malaria Vaccine Initiat, Washington, DC USA; [Duse, Adriano] Univ Witwatersrand, Sch Med, Johannesburg, South Africa; [Reijman, Andrea; Ingram, Charlotte] Contract Lab Serv, Johannesburg, South Africa; [Frean, John] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa; [Ogutu, Bernhards] Malaria Clin Trials Alliance, INDEPTH Network, Accra, Ghana	Swysen, C (reprint author), GlaxoSmithKline Biol, Rixensart, Belgium.	christine.swysen@gskbio.com		Tinto, Halidou/0000-0002-0472-3586	MVI; GSK Biologicals	CS, JV, MB, OOA, and BOk are employees of GSK Biologicals or were so during the writing of this manuscript. JV holds stock options in GSK Biologicals. CS, JV, MB, PK, BG, OOA, Bok, AR, CI, and JF declare their institution received a grant from MVI for the clinical trial described in this manuscript. JV, MB, and OOA declare their institution has received grants from MVI for previous clinical trials. BG, AD, AR, CI, and JF declare receiving travel funds from GSK Biologicals for travel related to this clinical trial. AR and CI declare their institution receiving financial support for lab support from GSK Biologicals. During the development of this manuscript, TV, TC, and BS were employed by MVI. SO and BOg declare no potential conflicts of interest.	Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773; Agnandji ST, 2010, J INFECT DIS, V202, P1076, DOI 10.1086/656190; Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; [Anonymous], 2002, SCIENCE, V298, P2133; [Anonymous], 2004, HASTINGS CENT REP, V34, P17; Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6; ASANTE KP, LANCET INFECT DIS; Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381; GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q; Mahon CR, 2000, TXB DIAGNOSTIC MICRO; Moorthy Vasee, 2007, Vaccine, V25, P5115, DOI 10.1016/j.vaccine.2007.01.085; Planche T, 2001, AM J TROP MED HYG, V65, P599, DOI 10.4269/ajtmh.2001.65.599; Sacarlal J, 2009, J INFECT DIS, V200, P329, DOI 10.1086/600119; Schluger N, 2007, PLOS MED, V4, P1726, DOI 10.1371/journal.pmed.0040302; Schulz-Baldes A, 2007, EMBO REP, V8, P8, DOI 10.1038/sj.embor.7400886; VEKEMANS J, MALAR J; W. H. Organization, 2006, INF CONS QUAL CONTR; WESTGARD JO, 2010, BASIC QC PRACTICES T, P3; Winn W, 2006, KONEMANS COLOR ATLAS	19	30	30	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	AUG 4	2011	10								223	10.1186/1475-2875-10-223				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	850OR	WOS:000297205500001	21816032	DOAJ Gold, Green Published			2019-03-26	
J	Vekemans, J; Marsh, K; Greenwood, B; Leach, A; Kabore, W; Soulanoudjingar, S; Asante, KP; Ansong, D; Evans, J; Sacarlal, J; Bejon, P; Kamthunzi, P; Salim, N; Njuguna, P; Hamel, MJ; Otieno, W; Gesase, S; Schellenberg, D				Vekemans, Johan; Marsh, Kevin; Greenwood, Brian; Leach, Amanda; Kabore, William; Soulanoudjingar, Solange; Asante, Kwaku Poku; Ansong, Daniel; Evans, Jennifer; Sacarlal, Jahit; Bejon, Philip; Kamthunzi, Portia; Salim, Nahya; Njuguna, Patricia; Hamel, Mary J.; Otieno, Walter; Gesase, Samwel; Schellenberg, David		Clinical Trials Partnership Comm	Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care	MALARIA JOURNAL			English	Article							ACUTE BACTERIAL-MENINGITIS; RANDOMIZED CONTROLLED-TRIAL; SEVERE FALCIPARUM-MALARIA; CLINICAL CASE-DEFINITIONS; LIFE-THREATENING MALARIA; PAPUA-NEW-GUINEA; AFRICAN CHILDREN; CEREBRAL MALARIA; PROGNOSTIC-SIGNIFICANCE; GAMBIAN CHILDREN	Background: An effective malaria vaccine, deployed in conjunction with other malaria interventions, is likely to substantially reduce the malaria burden. Efficacy against severe malaria will be a key driver for decisions on implementation. An initial study of an RTS, S vaccine candidate showed promising efficacy against severe malaria in children in Mozambique. Further evidence of its protective efficacy will be gained in a pivotal, multi-centre, phase III study. This paper describes the case definitions of severe malaria used in this study and the programme for standardized assessment of severe malaria according to the case definition. Methods: Case definitions of severe malaria were developed from a literature review and a consensus meeting of expert consultants and the RTS, S Clinical Trial Partnership Committee, in collaboration with the World Health Organization and the Malaria Clinical Trials Alliance. The same groups, with input from an Independent Data Monitoring Committee, developed and implemented a programme for standardized data collection. The case definitions developed reflect the typical presentations of severe malaria in African hospitals. Markers of disease severity were chosen on the basis of their association with poor outcome, occurrence in a significant proportion of cases and on an ability to standardize their measurement across research centres. For the primary case definition, one or more clinical and/or laboratory markers of disease severity have to be present, four major co-morbidities (pneumonia, meningitis, bacteraemia or gastroenteritis with severe dehydration) are excluded, and a Plasmodium falciparum parasite density threshold is introduced, in order to maximize the specificity of the case definition. Secondary case definitions allow inclusion of co-morbidities and/or allow for the presence of parasitaemia at any density. The programmatic implementation of standardized case assessment included a clinical algorithm for evaluating seriously sick children, improvements to care delivery and a robust training and evaluation programme for clinicians. Conclusions: The case definition developed for the pivotal phase III RTS, S vaccine study is consistent with WHO recommendations, is locally applicable and appropriately balances sensitivity and specificity in the diagnosis of severe malaria. Processes set up to standardize severe malaria data collection will allow robust assessment of the efficacy of the RTS, S vaccine against severe malaria, strengthen local capacity and benefit patient care for subjects in the trial.	[Vekemans, Johan; Leach, Amanda] GlaxoSmithKline Biol, Wavre, Belgium; [Marsh, Kevin; Bejon, Philip; Njuguna, Patricia; Schellenberg, David] KEMRI Wellcome Trust Res Programme, Kisumu, Kenya; [Greenwood, Brian] Univ London, London Sch Hyg & Trop Med, London, England; [Soulanoudjingar, Solange] Albert Schweitzer Hosp, Kumasi, Gabon; [Asante, Kwaku Poku] Ghana Hlth Serv, Kintampo Hlth Res Ctr, Kintampo, Ghana; [Ansong, Daniel] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Kumasi, Ghana; [Evans, Jennifer] Kumasi Ctr Collaborat Res, Kumasi, Ghana; [Sacarlal, Jahit] Ctr Invest Saude Manhica, Manhica, Mozambique; [Kamthunzi, Portia] Univ N Carolina UNC Project, Lilongwe, Malawi; [Salim, Nahya] Ifakara Hlth Inst, Ifakara, Tanzania; [Hamel, Mary J.; Otieno, Walter] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya; [Gesase, Samwel] Natl Inst Med Res, Dar Es Salaam, Tanzania; [Schellenberg, David] PATH Malaria Vaccine Initiat, Washington, DC USA	Vekemans, J (reprint author), GlaxoSmithKline Biol, Wavre, Belgium.	johan.vekemans@gskbio.com		masoud, nahya salim/0000-0002-3784-6478; ANSONG, Daniel/0000-0003-1328-9117	NIHR Biomedical research Centre in Oxford; PATH-MVI	We hereby would like to thank the following people for their critical scientific contribution: Bernards Ogutu, Jay Berkley, Kathrin Maitland, Quique Bassat, Vasee Moorthy, Santiago Ferro, Jackie Deen, Terrie Taylor and to the members of the RTS,S Independent Data Monitoring Committee for their continuous commitment: Malcolm Molyneux (chair), Kathryn O'Brien, Juanita Hatcher, Kwodjo Koram, Zul Premji, Tom Doherty. Philip Bejon is funded by the NIHR Biomedical research Centre in Oxford. Editorial assistance and manuscript coordination were provided by Julia Donnelly, Jarno Jansen, and Sarah Benns on behalf of GlaxoSmithKline Biologicals.; JV and AL are employees of GSK Biologicals and hold stock options in GSK Biologicals. JV, KM, BG, AL, KPA, DA, JE, JS, PB, NS, PN, and SG declare their institution received a grant from PATH-MVI for the clinical trial described in this manuscript. JV and AL declare their institution has received grants from PATH-MVI for previous clinical trials. PB and PN declare their institution has grants pending from PATH-MVI. KM, BG, KPA, JE, JS, PB, NS, PN, MJH, SG, and DS declare receiving travel funds from PATH-MVI for travel related to this clinical trial. KPA declares his institution receiving a consultancy fee from PATH-MVI. JE and SG declare they or their institution receive financial compensation from PATH-MVI for administrative support. DS is employed by PATH-MVI. WK, SS, PK, and WO declare no potential conflicts of interest.	Allen SJ, 1996, QJM-INT J MED, V89, P779, DOI 10.1093/qjmed/89.10.779; Alonso Pedro L, 2002, Methods Mol Med, V72, P607, DOI 10.1385/1-59259-271-6:607; Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; [Anonymous], 2009, WORLD MAL REP 2009; Anstey NM, 2007, PLOS MED, V4, P1291, DOI 10.1371/journal.pmed.0040267; Beare NA, 2004, ARCH OPHTHALMOL-CHIC, V122, P1141, DOI 10.1001/archopht.122.8.1141; Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381; Bejon P, 2007, PLOS MED, V4, P1333, DOI 10.1371/journal.pmed.0040251; Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X; Berkley JA, 2004, PEDIATRICS, V114, pE713, DOI 10.1542/peds.2004-0007; Berkley JA, 1999, QJM-INT J MED, V92, P151, DOI 10.1093/qjmed/92.3.151; Berkley JA, 2005, BRIT MED J, V330, P995, DOI 10.1136/bmj.38408.471991.8F; Berkley JA, 2001, LANCET, V357, P1753, DOI 10.1016/S0140-6736(00)04897-2; Binka FN, 2002, T ROY SOC TROP MED H, V96, P597, DOI 10.1016/S0035-9203(02)90321-4; Bojang KA, 1997, ANN TROP PAEDIATR, V17, P355, DOI 10.1080/02724936.1997.11747910; Brent AJ, 2006, LANCET, V367, P482, DOI 10.1016/S0140-6736(06)68180-4; Casals-Pascual C, 2006, CURR MOL MED, V6, P155, DOI 10.2174/156652406776055159; Day NPJ, 2000, CRIT CARE MED, V28, P1833, DOI 10.1097/00003246-200006000-00025; Dzeing-Ella A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-1; English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X; English M, 1997, QJM-INT J MED, V90, P263, DOI 10.1093/qjmed/90.4.263; English M, 1996, AM J TROP MED HYG, V55, P521, DOI 10.4269/ajtmh.1996.55.521; Evans JA, 2004, QJM-INT J MED, V97, P591, DOI [10.1093/qjmed/hch093, 10.1093/qjmed/hcho93]; Evans JA, 2006, J PEDIATR-US, V149, P676, DOI 10.1016/j.peds.2006.07.040; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6-5-723; Gwer S, 2007, AM J TROP MED HYG, V77, P6, DOI 10.4269/ajtmh.2007.77.6; Harding SP, 2006, TROP DOCT, V36, P1, DOI 10.1258/004947506776315781; Idro R, 2006, ARCH DIS CHILD, V91, P142, DOI 10.1136/adc.2005.077784; Idro R, 2004, ANN TROP PAEDIATR, V24, P17, DOI 10.1179/027249304225013240; Idro R, 2007, JAMA-J AM MED ASSOC, V297, P2232, DOI 10.1001/jama.297.20.2232; Jaffar S, 1997, AM J TROP MED HYG, V57, P20, DOI 10.4269/ajtmh.1997.57.20; KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5; Leach A, 2011, MALAR J; Lehmann D, 1999, ANN TROP PAEDIATR, V19, P21, DOI 10.1080/02724939992608; Lewallen S, 1996, T ROY SOC TROP MED H, V90, P144, DOI 10.1016/S0035-9203(96)90116-9; Maitland K, 2005, TRENDS PARASITOL, V21, P11, DOI 10.1016/j.pt.2004.10.010; *MAL VACC TECHN RO, 2006, EX SUMM; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9; Mockenhaupt FP, 2004, AM J TROP MED HYG, V71, P167, DOI 10.4269/ajtmh.2004.71.167; Molyneux E, 1998, TROP MED INT HEALTH, V3, P610, DOI 10.1046/j.1365-3156.1998.00278.x; MOLYNEUX ME, 1989, Q J MED, V71, P441; Moorthy Vasee, 2007, Vaccine, V25, P5115, DOI 10.1016/j.vaccine.2007.01.085; Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306; Mulholland K, 2005, INT J EPIDEMIOL, V34, P375, DOI 10.1093/ije/dyi028; Newton CRJC, 1997, TROP MED INT HEALTH, V2, P165, DOI 10.1046/j.1365-3156.1997.d01-238.x; Newton CRJC, 2005, CLIN INFECT DIS, V41, P948, DOI 10.1086/432941; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; Planche T, 2006, CURR MOL MED, V6, P141, DOI 10.2174/156652406776055177; Planche T, 2003, CLIN INFECT DIS, V37, P890, DOI 10.1086/377536; Ranque S, 2008, PEDIATR INFECT DIS J, V27, P130, DOI 10.1097/INF.0b013e31815988ed; REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O; Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Rogers WO, 2006, J INFECT DIS, V193, P467, DOI 10.1086/499314; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; Schemann JF, 2002, AM J TROP MED HYG, V67, P61, DOI 10.4269/ajtmh.2002.67.61; Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746; Taylor T, 2006, T ROY SOC TROP MED H, V100, P615, DOI 10.1016/j.trstmh.2005.09.021; Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986; TAYLOR TE, 1993, Q J MED, V86, P99; WALLER D, 1995, CLIN INFECT DIS, V21, P577, DOI 10.1093/clinids/21.3.577; White VA, 2001, T ROY SOC TROP MED H, V95, P618, DOI 10.1016/S0035-9203(01)90097-5; WHO, 2005, POCK BOOK HOSP CAR C; *WHO YOUNG INF STU, 1999, PEDIATR INFECT DIS J, V18, pS17, DOI DOI 10.1097/00006454-199910001-00004; World Health Organization, 2001, STAND INT CHEST RAD; [World Health Organization Severe falciparum malaria], 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6	67	18	18	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	AUG 4	2011	10								221	10.1186/1475-2875-10-221				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	850OP	WOS:000297205300001	21816031	DOAJ Gold, Green Published			2019-03-26	
J	Bisoffi, Z; Sirima, SB; Meheus, F; Lodesani, C; Gobbi, F; Angheben, A; Tinto, H; Neya, B; Van den Ende, K; Romeo, A; Van den Ende, J				Bisoffi, Zeno; Sirima, Sodiomon B.; Meheus, Filip; Lodesani, Claudia; Gobbi, Federico; Angheben, Andrea; Tinto, Halidou; Neya, Bouma; Van den Ende, Klara; Romeo, Annalisa; Van den Ende, Jef			Strict adherence to malaria rapid test results might lead to a neglect of other dangerous diseases: a cost benefit analysis from Burkina Faso	MALARIA JOURNAL			English	Article							DIAGNOSTIC-TESTS; RANDOMIZED-TRIAL; TANZANIA; MICROSCOPY; MANAGEMENT; CHILDREN; KENYA	Background: Malaria rapid diagnostic tests (RDTs) have generally been found reliable and cost-effective. In Burkina Faso, the adherence of prescribers to the negative test result was found to be poor. Moreover, the test accuracy for malaria-attributable fever (MAF) is not the same as for malaria infection. This paper aims at determining the costs and benefits of two competing strategies for the management of MAF: presumptive treatment for all or use of RDTs. Methods: A cost benefit analysis was carried out using a decision tree, based on data previously obtained, including a randomized controlled trial (RCT) recruiting 852 febrile patients during the dry season and 1,317 in the rainy season. Cost and benefit were calculated using both the real adherence found by the RCT and assuming an ideal adherence of 90% with the negative result. The main parameters were submitted to sensitivity analysis. Results and discussion: At real adherence, the test-based strategy was dominated. Assuming ideal adherence, at the value of 525 (sic) for a death averted, the total cost of managing 1,000 febrile children was 1,747 vs. 1,862 (sic) in the dry season and 1,372 vs. 2,138 in the rainy season for the presumptive vs. the test-based strategy. For adults it was 2,728 vs. 1,983 and 2,604 vs. 2,225, respectively. At the subsidized policy adopted locally, assuming ideal adherence, the RDT would be the winning strategy for adults in both seasons and for children in the dry season. At sensitivity analysis, the factors most influencing the choice of the better strategy were the value assigned to a death averted and the proportion of potentially severe NMFI treated with antibiotics in patients with false positive RDT results. The test-based strategy appears advantageous for adults if a satisfactory adherence could be achieved. For children the presumptive strategy remains the best choice for a wide range of scenarios. Conclusions: For RDTs to be preferred, a positive result should not influence the decision to treat a potentially severe NMFI with antibiotics. In the rainy season the presumptive strategy always remains the better choice for children.	[Bisoffi, Zeno; Gobbi, Federico; Angheben, Andrea] S Cuore Hosp, Ctr Trop Dis, I-37024 Verona, Italy; [Bisoffi, Zeno; Gobbi, Federico; Neya, Bouma; Van den Ende, Klara; Romeo, Annalisa] Projet AnKaHeresso, Bobo Dioulasso, Burkina Faso; [Sirima, Sodiomon B.] Minist Hlth, Ctr Natl Rech & Format Paludisme, Ouagadougou 01, Burkina Faso; [Meheus, Filip] Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Lodesani, Claudia] Med Sans Frontieres, I-00185 Rome, Italy; [Tinto, Halidou] Ctr Muraz, Bobo Dioulasso 01, Burkina Faso; [Van den Ende, Jef] Inst Trop Med Prince Leopold, Dept Clin Sci, B-2000 Antwerp, Belgium	Bisoffi, Z (reprint author), S Cuore Hosp, Ctr Trop Dis, I-37024 Verona, Italy.	zeno.bisoffi@sacrocuore.it	Bisoffi, Zeno/B-6438-2013	Tinto, Halidou/0000-0002-0472-3586	UNIDEA - UNICREDIT Foundation	The authors thank the patients who accepted to participate in the study, the personnel of the health centres involved and all the research assistants, as well as all the following health staff of the "An Ka Heresso" Project (Progetto Mondo - MLAL) at the time of the field survey: Giuseppe Baracca (who first suggested a study on RDT), Mamadou Traore and Rosalie Midjour. This study was funded by UNIDEA - UNICREDIT Foundation.	Ansah EK, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c930; Bisoffi Z, 2008, BRIT MED J, V336, P168, DOI 10.1136/bmj.39401.486655.80; Bisoffi Z, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-192; Bisoffi Z, 2009, TROP MED INT HEALTH, V14, P491, DOI 10.1111/j.1365-3156.2009.02246.x; Bjorkman A, 2010, CLIN INFECT DIS, V51, P512, DOI 10.1086/655689; Bualombai P., 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P322; Chanda Pascalina, 2009, Cost Eff Resour Alloc, V7, P5, DOI 10.1186/1478-7547-7-5; d'Acremont V, 2010, CLIN INFECT DIS, V51, P506, DOI 10.1086/655688; GREENBERG AE, 1989, B WORLD HEALTH ORGAN, V67, P189; Hamer DH, 2007, JAMA-J AM MED ASSOC, V297, P2227, DOI 10.1001/jama.297.20.2227; *IDA FDN, 2010, WEB CAT; Lubell Y, 2008, BRIT MED J, V336, P202, DOI 10.1136/bmj.39395.696065.47; Mosha JF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008707; Msellem MI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000070; Njama-Meya D, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-7; Rafael Maria E, 2006, Nature, V444 Suppl 1, P39, DOI 10.1038/nature05445; Reyburn H, 2007, BRIT MED J, V334, P403, DOI 10.1136/bmj.39073.496829.AE; Rolland E, 2006, TROP MED INT HEALTH, V11, P398, DOI 10.1111/j.1365-3156.2006.01580.x; Rushby JF, 2001, HEALTH POLICY PLANN, V16, P326, DOI 10.1093/heapol/16.3.326; Shillcutt S, 2008, B WORLD HEALTH ORGAN, V86, P101, DOI 10.2471/BLT.07.042259; Skarbinski J, 2009, AM J TROP MED HYG, V80, P919; United Nations, 2010, WORLD POP PROSP 2008; Uzochukwu BSC, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-265; Williams HA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-239; World Health Organization, 2006, GUID TREATM MAL; World Health Organization, 2010, MAL RAP DIAGN TEST P; World Health Organization, 2010, GUID TREATM MAL; Yukich J, 2010, AM J TROP MED HYG, V83, P61, DOI 10.4269/ajtmh.2010.09-0632; Zurovac D, 2008, TROP MED INT HEALTH, V13, P784, DOI 10.1111/j.1365-3156.2008.02072.x	29	13	13	1	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	AUG 4	2011	10								226	10.1186/1475-2875-10-226				13	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	815CX	WOS:000294504800001	21816087	DOAJ Gold, Green Published			2019-03-26	
J	Leach, A; Vekemans, J; Lievens, M; Ofori-Anyinam, O; Cahill, C; Owusu-Agyei, S; Abdulla, S; Macete, E; Njuguna, P; Savarese, B; Loucq, C; Ballou, WR				Leach, Amanda; Vekemans, Johan; Lievens, Marc; Ofori-Anyinam, Opokua; Cahill, Conor; Owusu-Agyei, Seth; Abdulla, Salim; Macete, Eusebio; Njuguna, Patricia; Savarese, Barbara; Loucq, Christian; Ballou, W. Ripley		Clinical Trials Partnership Comm	Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa	MALARIA JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; TREATED BED NETS; CASE-DEFINITION; WEST-AFRICA; MOZAMBICAN CHILDREN; CLINICAL MALARIA; ENDEMIC AREA; DOUBLE-BLIND; RURAL AREA; SAFETY	Background: GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative are working in partnership to develop a malaria vaccine to protect infants and children living in malaria endemic regions of sub-Saharan Africa, which can be delivered through the Expanded Programme on Immunization. The RTS, S/AS candidate vaccine has been evaluated in multiple phase I/II studies and shown to have a favourable safety profile and to be well-tolerated in both adults and children. This paper details the design of the phase III multicentre efficacy trial of the RTS, S/AS01 malaria vaccine candidate, which is pivotal for licensure and policy decision-making. Methods: The phase III trial is a randomized, controlled, multicentre, participant-and observer-blind study ongoing in 11 centres associated with different malaria transmission settings in seven countries in sub-Saharan Africa. A minimum of 6,000 children in each of two age categories (6-12 weeks, 5-17 months) have been enrolled. Children were randomized 1: 1: 1 to one of three study groups: (1) primary vaccination with RTS, S/AS01 and booster dose of RTS, S/AS01; (2) primary vaccination with RTS, S/AS01 and a control vaccine at time of booster; (3) primary vaccination with control vaccine and a control vaccine at time of booster. Primary vaccination comprises three doses at monthly intervals; the booster dose is administered at 18 months post-primary course. Subjects will be followed to study month 32. The co-primary objectives are the evaluation of efficacy over one year post-dose 3 against clinical malaria when primary immunization is delivered at: (1) 6-12 weeks of age, with co-administration of DTPwHepB/Hib antigens and OPV; (2) 5-17 months of age. Secondary objectives include evaluation of vaccine efficacy against severe malaria, anaemia, malaria hospitalization, fatal malaria, all-cause mortality and other serious illnesses including sepsis and pneumonia. Efficacy of the vaccine against clinical malaria under different transmission settings, the evolution of efficacy over time and the potential benefit of a booster will be evaluated. In addition, the effect of RTS, S/AS01 vaccination on growth, and the safety and immunogenicity in HIV-infected and malnourished children will be assessed. Safety of the primary course of immunization and the booster dose will be documented in both age categories. Conclusions: This pivotal phase III study of the RTS, S/AS01 candidate malaria vaccine in African children was designed and implemented by the Clinical Trials Partnership Committee. The study will provide efficacy and safety data to fulfil regulatory requirements, together with data on a broad range of endpoints that will facilitate the evaluation of the public health impact of the vaccine and will aid policy and implementation decisions.	[Leach, Amanda; Vekemans, Johan; Lievens, Marc; Ofori-Anyinam, Opokua; Cahill, Conor; Ballou, W. Ripley] GlaxoSmithKline Biol, Wavre, Belgium; [Owusu-Agyei, Seth] Kintampo Hlth Res Ctr, Ghana Hlth Serv, Kintampo, Ghana; [Abdulla, Salim] Ifakara Hlth Inst, Ifakara, Tanzania; [Macete, Eusebio] Ctr Invest Saude Manhica, Manhica, Mozambique; [Njuguna, Patricia] KEMRI Wellcome Trust Res Programme, Kisumu, Kenya; [Savarese, Barbara; Loucq, Christian] PATH Malaria Vaccine Initiat, Washington, DC USA	Leach, A (reprint author), GlaxoSmithKline Biol, Wavre, Belgium.	amanda.leach@gskbio.com			NIHR Biomedical research Centre in Oxford; PATH-MVI	The authors would particularly like to acknowledge the consistent support and scientific input in the development of the trial design of these experts: Bernhards Ogutu (Malaria Clinical Trials Alliance), Jessica Milman (Bill and Melinda Gates Foundation), Vasee Moorthy (WHO), Lorenz von-Seidlein, Alice Grasset, Anne Walsh, Didier Lapierre, Patricia Atkinson. Lorenz von-Seidlein, Alice Grasset, Anne Walsh, Didier Lapierre, Patricia Atkinson. Philip Bejon is funded by the NIHR Biomedical research Centre in Oxford. Editorial assistance and manuscript coordination were provided by Julia Donnelly, Jarno Jansen, Mary Greenacre and Sarah Benns on behalf of GlaxoSmithKline Biologicals.; GSK and all participating institutions declare to have received a grant and travel funds from PATH-MVI for/relating to the clinical trial described in this manuscript. Employees of PATH-MVI (BS, CL, AB, FD, SF, CH, MM, JM, CP, DP, and MS) report their institute received a grant by the Bill and Melinda Gates foundation for this trial. All GSK employees, SA, PB, and PN declare their institution has received grants or has grants pending from PATH-MVI for previous clinical trials. CSS, JFT declare no potential conflicts of interest.	Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773; Agnandji ST, 2010, J INFECT DIS, V202, P1076, DOI 10.1086/656190; Alonso Pedro L, 2002, Methods Mol Med, V72, P607, DOI 10.1385/1-59259-271-6:607; ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O; [Anonymous], 2008, LANCET, V372, P1193; Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6; Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7; ASANTE KP, LANCET INFECT DIS; Beigel J, 2007, VACCINE, V25, P5697, DOI 10.1016/j.vaccine.2007.02.066; Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381; Bonhoeffer J, 2004, VACCINE, V22, P557, DOI 10.1016/j.vaccine.2003.09.008; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Breman JG, 2007, AM J TROP MED HYG S6, V77; BROOME CV, 1983, B WORLD HEALTH ORGAN, V61, P325; Carneiro I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008988; Dicko A, 2005, TROP MED INT HEALTH, V10, P550, DOI 10.1111/j.1365-3156.2005.01418.x; Dodet B, 2009, VACCINE, V27, P5027, DOI [10.1016/j.vaccine.2009.06.030, 10.1016/j.vaccine.2009.02.012]; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6-5-723; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120; Knobel DL, 2005, B WORLD HEALTH ORGAN, V83, P360; Kwara A, 1998, TROP MED INT HEALTH, V3, P742, DOI 10.1046/j.1365-3156.1998.00300.x; LIEVENS M, MALAR J; McGuinness D, 1998, T ROY SOC TROP MED H, V92, P527, DOI 10.1016/S0035-9203(98)90902-6; Milstien J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-182; Moorthy Vasee, 2007, Vaccine, V25, P5115, DOI 10.1016/j.vaccine.2007.01.085; Mulholland K, 2005, INT J EPIDEMIOL, V34, P375, DOI 10.1093/ije/dyi028; Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006; O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; Plotkin Stanley A., 2004, VACCINES; Polhemus ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006465; Sacarlal J, 2008, VACCINE, V26, P174, DOI 10.1016/j.vaccine.2007.11.003; Saute F, 2003, T ROY SOC TROP MED H, V97, P661, DOI 10.1016/S0035-9203(03)80098-6; Smith T, 1994, STAT MED; SWYSEN C, MALAR J; VEKEMANS J, MALAR J; Whittle H C, 1976, Trop Doct, V6, P99; WHO, 2010, WORLD MALARIA REPORT 2010, P1; World Health Organization, 2007, VERB AUT STAND ASC A; World Health Organization, 2001, STAND INT CHEST RAD	45	41	41	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	AUG 4	2011	10								224	10.1186/1475-2875-10-224				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	815CW	WOS:000294504700001	21816029	DOAJ Gold, Green Published			2019-03-26	
J	Lievens, M; Aponte, JJ; Williamson, J; Mmbando, B; Mohamed, A; Bejon, P; Leach, A				Lievens, Marc; Aponte, John J.; Williamson, John; Mmbando, Bruno; Mohamed, Ali; Bejon, Philip; Leach, Amanda			Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children	MALARIA JOURNAL			English	Article							PLASMODIUM-FALCIPARUM MALARIA; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; SYMPATRIC ETHNIC-GROUPS; ROUTINE VACCINATIONS; PUBLIC-HEALTH; INFANTS; ANEMIA; SUSCEPTIBILITY; MOZAMBIQUE	Background: There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. Methods: The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. Conclusions: The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy. Trial registration: Clinicaltrials.gov NCT00866619	[Lievens, Marc; Leach, Amanda] GlaxoSmithKline Biol, Wavre, Belgium; [Aponte, John J.] Univ Barcelona, Hosp Clin Barcelona, CRESIB, E-08007 Barcelona, Spain; [Williamson, John] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya; [Mohamed, Ali] Ifakara Hlth Inst, Ifakara, Tanzania; [Mmbando, Bruno] Natl Inst Med Res, Dar Es Salaam, Tanzania; [Bejon, Philip] KEMRI Wellcome Trust Res Program, Kilifi, Kenya	Lievens, M (reprint author), GlaxoSmithKline Biol, Wavre, Belgium.	marc.lievens@gskbio.com			MVI; NIHR Biomedical research Centre in Oxford	ML and AL are employees of GSK Biologicals. AL holds stock options in GSK Biologicals. ML, JA, JW, BM, PB, and AL declare their institution received a grant from MVI for the clinical trial described in this manuscript. ML and AL declare their institution has received grants from MVI for previous clinical trials. PB declares his institution has grants pending from MVI. JA, JW, and PB declare receiving travel funds from MVI for travel related to this clinical trial. JA declares his institution received financial compensation from MVI for administrative support. AM declares no potential conflicts of interest.; The authors would like to acknowledge the participants of the Investigator Working Group on statistics for their valuable input: Seth Owusu-Agyei, Daniel Ansong, Juergen May, Bertrand Lell, Greg Fegan, Jahit Sacarlal, Lorenz Von Seidlein, Christophe Rogier, Cheikh Tidjane Ndao, Salim Abdulla, Marcel Tanner, and Honorati Masanja. The authors are also grateful to Didier Leboulleux and Yuxiao Tang at PATH-MVI and Marc Fourneau at GSK for supporting the Statistical Working Group and Lode Schuerman for his review and suggestions. Philip Bejon is funded by the NIHR Biomedical research Centre in Oxford. Writing assistance and editorial support were provided by Aurelie Olivier and Jarno Jansen.	Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6; Bassat Q, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-37; Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381; Caulfield LE, 2004, AM J CLIN NUTR, V80, P193; Dolo A, 2005, AM J TROP MED HYG, V72, P243, DOI 10.4269/ajtmh.2005.72.243; Eisele TP, 2009, AM J TROP MED HYG, V80, P209, DOI 10.4269/ajtmh.2009.80.209; Fegan GW, 2007, LANCET, V370, P1035, DOI 10.1016/S0140-6736(07)61477-9; Fillol F, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-116; Gosoniu L, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-356; LEACH A, MALAR J; Macete E, 2006, J INFECT DIS, V194, P276, DOI 10.1086/505431; Menendez C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009438; Modiano D, 1996, P NATL ACAD SCI USA, V93, P13206, DOI 10.1073/pnas.93.23.13206; Moorthy VS, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-23; Moorthy VS, 2009, VACCINE, V27, P624, DOI 10.1016/j.vaccine.2008.11.034; Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306; Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57; O'Meara WP, 2009, PARASITE IMMUNOL, V31, P574, DOI 10.1111/j.1365-3024.2009.01144.x; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; Sacarlal J, 2009, J INFECT DIS, V200, P329, DOI 10.1086/600119; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; Schellenberg JA, 1998, INT J EPIDEMIOL, V27, P323, DOI 10.1093/ije/27.2.323; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; Taylor T, 2006, T ROY SOC TROP MED H, V100, P615, DOI 10.1016/j.trstmh.2005.09.021; Valim C, 2008, PHILOS T R SOC A, V366, P2347, DOI 10.1098/rsta.2008.0044; VEKEMANS J, MALAR J; Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0; *WHO, 1997, GUID EV PLASM FALC V	30	16	16	1	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	AUG 4	2011	10								222	10.1186/1475-2875-10-222				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	816KY	WOS:000294599600001	21816030	DOAJ Gold, Green Published			2019-03-26	
J	Mumba, D; Bohorquez, E; Messina, J; Kande, V; Taylor, SM; Tshefu, AK; Muwonga, J; Kashamuka, MM; Emch, M; Tidwell, R; Buscher, P; Meshnick, SR				Mumba, Dieudonne; Bohorquez, Elaine; Messina, Jane; Kande, Victor; Taylor, Steven M.; Tshefu, Antoinette K.; Muwonga, Jeremie; Kashamuka, Melchior M.; Emch, Michael; Tidwell, Richard; Buscher, Philippe; Meshnick, Steven R.			Prevalence of Human African Trypanosomiasis in the Democratic Republic of the Congo	PLOS NEGLECTED TROPICAL DISEASES			English	Article							SEROLOGICAL TESTS; BLOOD-SAMPLES; BRUCEI; GAMBIENSE	Human African Trypanosomiasis (HAT) is a major public health problem in the Democratic Republic of the Congo (DRC). Active and passive surveillance for HAT is conducted but may underestimate the true prevalence of the disease. We used ELISA to screen 7,769 leftover dried blood spots from a nationally representative population-based survey, the 2007 Demographic and Health Survey. 26 samples were positive by ELISA. Three of these were also positive by trypanolysis and/or PCR. From these data, we estimate that there were 18,592 people with HAT (95% confidence interval, 4,883-32,302) in the DRC in 2007, slightly more than twice as many as were reported.	[Mumba, Dieudonne] Inst Natl Rech Biomed, Kinshasa, Zaire; [Bohorquez, Elaine; Taylor, Steven M.; Kashamuka, Melchior M.; Meshnick, Steven R.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Messina, Jane; Emch, Michael] Univ N Carolina, Dept Geog, Chapel Hill, NC USA; [Kande, Victor] Programme Natl Lutte Trypanosomiase Humaine Afric, Kinshasa, Zaire; [Tshefu, Antoinette K.] Univ Kinshasa, Kinshasa Sch Publ Hlth, Kinshasa, Zaire; [Muwonga, Jeremie] Programme Natl Lutte SIDA, Kinshasa, Zaire; [Tidwell, Richard] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Buscher, Philippe] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Mumba, D (reprint author), Inst Natl Rech Biomed, Kinshasa, Zaire.	meshnick@unc.edu	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472	Gillings Innovative Lab; Consortium for Parasitic Drug Disease Development; European Community; Belgian Directorate General for Development Cooperation	This work was supported by the Gillings Innovative Lab fund, the Consortium for Parasitic Drug Disease Development, the European Communities' 6th Framework Programme, and the Belgian Directorate General for Development Cooperation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2006, Wkly Epidemiol Rec, V81, P71; Becker S, 2004, DIAGN MICR INFEC DIS, V50, P193, DOI 10.1016/j.diagmicrobio.2004.07.001; Boerma JT, 2007, LANCET, V369, P779, DOI 10.1016/S0140-6736(07)60364-X; Brun R, 2010, LANCET, V375, P148, DOI 10.1016/S0140-6736(09)60829-1; Chappuis F, 2010, EMERG INFECT DIS, V16, P354, DOI 10.3201/eid1602.090967; Fevre EM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000333; Hasker E, 2010, AM J TROP MED HYG, V83, P374, DOI 10.4269/ajtmh.2010.09-0735; Holland WG, 2002, ACTA TROP, V81, P159, DOI 10.1016/S0001-706X(01)00211-X; Lutumba P, 2005, EMERG INFECT DIS, V11, P1382; *MIN PLAN MACR, 2008, ENQ DEM SANT REP DEM; Mugasa CM, 2008, DIAGN MICR INFEC DIS, V61, P440, DOI 10.1016/j.diagmicrobio.2008.03.019; Taylor SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016420; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; 2008, 0300213 RDC; 2010, DEMOGRAPHIC HLTH HIG; 2007, LANCET, V370, P1802	16	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	AUG	2011	5	8							e1246	10.1371/journal.pntd.0001246				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	814TJ	WOS:000294479800008	21829736	DOAJ Gold, Green Published			2019-03-26	
J	Secka, A; Grimm, F; Marcotty, T; Geysen, D; Niang, AM; Ngale, V; Boutche, L; Van Marck, E; Geerts, S				Secka, Arss; Grimm, Felix; Marcotty, Tanguy; Geysen, Dirk; Niang, Alassane M.; Ngale, Victoire; Boutche, Laurent; Van Marck, Eric; Geerts, Stanny			Old focus of cysticercosis in a senegalese village revisited after half a century	ACTA TROPICA			English	Article						Neurocysticercosis; Taenia solium; Ag-ELISA; EITB; CT-scan; Senegal	TAENIA-SOLIUM TAENIASIS; SEROPREVALENCE; ASSAY; ANTIGENS; SAGINATA; MEXICO; ELISA	The objective of this epidemiological study was to determine whether cysticercosis and especially neurocysticercosis is endemic in Soutou village about half a century after the 1962 outbreak. This study was carried out from September 2009 to February 2010. It involved a questionnaire administration, serology, treatment, coproscopy and neuro-imaging. Four hundred and three serum samples were collected from the village people, which covered 94% of the village population. By using a parallel combination of the antigen-detection ELISA and the enzyme-linked immunoelectrotransfer blot (EITB) a cysticercosis seroprevalence of 11.9% (95% Cl: 8.9-15.4%) was found. Cerebral CT-scans showed that 23.3% (10/43) of the seropositives were affected by neurocysticercosis. Four out of these 43 (9.3%) were tapeworm carriers. Seropositivity was significantly associated to older age groups (41-60 years old; p = 0.001 and 61-91 years old: p = 0.028) and absence of a household toilet (p = 0.001). It can be concluded that Soutou village is an active focus of Taenia solium cysticercosis about 50 years after the first reported epidemic outbreak. (C) 2011 Elsevier B.V. All rights reserved.	[Marcotty, Tanguy; Geysen, Dirk; Geerts, Stanny] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Secka, Arss] Int Trypanotolerance Ctr, Banjul, Gambia; [Grimm, Felix] Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland; [Marcotty, Tanguy] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0002 Pretoria, South Africa; [Van Marck, Eric] Univ Antwerp, Pathol Lab, B-2020 Antwerp, Belgium; [Niang, Alassane M.] Bignona Hosp, Bignona, Senegal; [Ngale, Victoire; Boutche, Laurent] Ziguinchor Reg Hosp, Ziguinchor, Senegal	Geerts, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	geerts.demedts@gmail.com		Geerts, Stanny/0000-0001-9885-8846	Flemish Interuniversity Council (VLIR, Brussels); Epidemiology and Control of Zoonotic Infections in The Gambia and Senegal implemented in collaboration with the International Trypanotolerance Centre (ITC) in The Gambia	This study was financed by the Flemish Interuniversity Council (VLIR, Brussels) within the framework of a project entitled Epidemiology and Control of Zoonotic Infections in The Gambia and Senegal implemented in collaboration with the International Trypanotolerance Centre (ITC) in The Gambia. Contributions from the technical and administrative staff of ITC, the medical personnel of Soutou Health Centre, the administrative staff of Bignona hospital, radiologists and laboratory staff of Ziguinchor hospital are greatly appreciated. We would also like to thank all the inhabitants of Soutou village, especially the village chief and the village committee.	[Anonymous], 1989, EPILEPSIA, V30, P389; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Collomb H, 1964, B MEMOIRE FACULTE MI, V12, P148; Dorny P, 2004, TRENDS PARASITOL, V20, P259, DOI 10.1016/j.pt.2004.04.001; DUMAS M, 1989, Acta Leidensia, V57, P191; Dumas M, 1976, Bull Soc Med Afr Noire Lang Fr, V21, P203; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; GarciaNoval J, 1996, AM J TROP MED HYG, V55, P282, DOI 10.4269/ajtmh.1996.55.282; Geerts S, 2004, SE ASIAN J TROP MED, V35, P262; Houinato D, 1998, T ROY SOC TROP MED H, V92, P621, DOI 10.1016/S0035-9203(98)90785-4; Nguekam JP, 2003, TROP MED INT HEALTH, V8, P144, DOI 10.1046/j.1365-3156.2003.01000.x; Prado-Jean A, 2007, TROP MED INT HEALTH, V12, P895, DOI 10.1111/j.1365-3156.2007.01860.x; RITCHIE LAWRENCE S., 1948, BULL U S ARMY MED DEPT, V8, P326; Rodriguez-Hidalgo R, 2002, J PARASITOL, V88, P1007, DOI 10.2307/3285546; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; SARTI E, 1994, T ROY SOC TROP MED H, V88, P49, DOI 10.1016/0035-9203(94)90493-6; Secka Arss, 2010, J Parasitol Res, V2010, P823892, DOI 10.1155/2010/823892; SOKOL RR, 1981, BIOMETRY; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Vanderick F X, 1972, Ann Soc Belg Med Trop, V52, P153	21	12	12	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	AUG	2011	119	2-3					199	202		10.1016/j.actatropica.2011.05.003				4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	805HJ	WOS:000293717200022	21605539				2019-03-26	
J	Zachariah, R; Tayler-Smith, K; Manzi, M; Massaquoi, M; Mwagomba, B; van Griensven, J; van Engelgem, I; Arnould, L; Schouten, EJ; Chimbwandira, FM; Harries, AD				Zachariah, R.; Tayler-Smith, K.; Manzi, M.; Massaquoi, M.; Mwagomba, B.; van Griensven, J.; van Engelgem, I.; Arnould, L.; Schouten, E. J.; Chimbwandira, F. M.; Harries, A. D.			Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes?	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Attrition; Retention; Preparation phase; ART; Reporting; Kenya; Malawi	SUB-SAHARAN AFRICA; EARLY MORTALITY; RURAL DISTRICT; SOUTH-AFRICA; FOLLOW-UP; TREATMENT OUTCOMES; THERAPY; SERVICE; DELIVERY; LOST	Among adults eligible for antiretroviral therapy (ART) in Thyolo (rural Malawi) and Kibera (Nairobi, Kenya), this study (a) reports on retention and attrition during the preparation phase and after starting ART and (b) identifies risk factors associated with attrition. 'Retention' implies being alive and on follow-up, whilst 'attrition' implies loss to follow-up, death or stopping treatment (if on ART). There were 11 309 ART-eligible patients from Malawi and 3633 from Kenya, of whom 8421 (74%) and 2792 (77%), respectively, went through the preparation phase and started ART. In Malawi, 2649 patients (23%) were lost to attrition in the preparation phase and 2189 (26%) after starting ART. Similarly, in Kenya 546 patients (15%) were lost to attrition in the ART preparation phase and 647(23%) while on ART. Overall programme attrition was 43% (4838/11 309) for Malawi and 33% (1193/3633) for Kenya. Restricting cohort evaluation to 'on ART' (as is usually done) underestimates overall programme attrition by 38% in Malawi and 36% in Kenya. Risk factors associated with attrition in the preparation phase included male sex, age < 35 years, advanced HIV/AIDS disease and increasing malnutrition. Considerable attrition occurs during the preparation phase of ART, and programme evaluations confined to on-treatment analysis significantly underestimate attrition. This has important operational implications, which are discussed here. (C) 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Zachariah, R.; Tayler-Smith, K.; Manzi, M.] Medecins Sans Frontieres, Brussels Operat Ctr, Med Dept Operat Res, L-1617 Luxembourg, Luxembourg; [Massaquoi, M.] Medecins Sans Frontieres, Thyolo, Malawi; [Mwagomba, B.] Minist Hlth, Thyolo, Malawi; [van Griensven, J.] Inst Trop Med, B-2000 Antwerp, Belgium; [van Engelgem, I.] Medecins Sans Frontieres, Nairobi, Kenya; [Arnould, L.] MSF Brussels Operat Ctr, Dept Med, Brussels, Belgium; [Schouten, E. J.; Chimbwandira, F. M.] Minist Hlth, Dept HIV AIDS, Lilongwe, Malawi; [Schouten, E. J.] Management Sci Hlth, Lilongwe, Malawi; [Harries, A. D.] Int Union TB & Lung Dis, Paris, France; [Harries, A. D.] London Sch Hyg & Trop Med, London WC1, England	Zachariah, R (reprint author), Medecins Sans Frontieres, Brussels Operat Ctr, Med Dept Operat Res, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu			Ministries of Health of Malawi and Kenya; InBev-Baillet Latour Fund; Medecins Sans Frontieres [09_NAT_ERB_001]	The authors are grateful to the Ministries of Health of Malawi and Kenya for excellent collaboration and support in implementing HIV/AIDS-related activities. They are particularly grateful to the Thyolo and Kibera database teams and all the health workers, patient support groups and associations. They also thank the database teams of Thyolo and Kibera for their work with data collection and support. The authors are particularly grateful to Tony Reid and Nathan Ford for their comments on this paper.; JvG is supported by the InBev-Baillet Latour Fund.	Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290; Braitstein P, 2006, LANCET, V367, P817; Fox MP, 2010, TROP MED INT HEALTH, V15, P405, DOI 10.1111/j.1365-3156.2010.02473.x; Harries AD, 2009, INT J TUBERC LUNG D, V13, P801; INGLE S, 1917, 17 C RETR OPP INF CR; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095; *MOHP, 2006, GUID US ANT THER MAL; *NASCOP, 2005, GUID ANT DRUG THER K; Philips M, 2008, LANCET, V371, P682, DOI 10.1016/S0140-6736(08)60307-4; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Unge C, 2009, JAIDS-J ACQ IMM DEF, V50, P397, DOI 10.1097/QAI.0b013e318194618e; von Elm E, 2008, INTERNIST, V49, P688, DOI 10.1007/s00108-008-2138-4; Weller I, 2006, CLIN INFECT DIS, V43, P777, DOI 10.1086/507113; WHO, 2006, PAT MON GUID HIV CAR; WHO, 2009, RAP ADV ANT THER HIV; *WHO, 2006, ANT THER HIV INF AD; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739; Yu JKL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002065; Zachariah R, 2007, T ROY SOC TROP MED H, V101, P79, DOI 10.1016/j.trstmh.2006.05.010; Zachariah R, 2005, INT J TUBERC LUNG D, V9, P238; Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0; Zachariah R, 2009, TROP MED INT HEALTH, V14, P713, DOI 10.1111/j.1365-3156.2009.02291.x	23	35	35	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	AUG	2011	105	8					421	430		10.1016/j.trstmh.2011.04.014				10	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	804UC	WOS:000293678500001	21724219				2019-03-26	
J	Verma, A; Manchanda, S; Kumar, N; Sharma, A; Goel, M; Banerjee, PS; Garg, R; Singh, BP; Balharbi, F; Lejon, V; Deborggraeve, S; Rana, UVS; Puliyel, J				Verma, Archana; Manchanda, Samiksha; Kumar, Nirmal; Sharma, Archna; Goel, Masha; Banerjee, Partha Sarathi; Garg, Rajat; Singh, Brahma Pal; Balharbi, Fatima; Lejon, Veerle; Deborggraeve, Stijn; Rana, Udai Veer Singh; Puliyel, Jacob			Case Report: Trypanosoma lewisi or T. lewisi-like Infection in a 37-Day-Old Indian Infant	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							EVANSI; DIAGNOSIS	Trypanosomes were observed in the peripheral blood smear of a 37-day-old Indian infant admitted off feeds, with fever and convulsions. Trypanosoma (Herpetosoma) lewisi was identified in the blood. The species identification was confirmed by morphometry, polymerase chain reaction, and sequencing. Human infection with this organism is rare. Only seven cases of this infection have been reported previously in humans. The cases reported are reviewed to develop a composite picture of this disease.	[Verma, Archana; Manchanda, Samiksha; Kumar, Nirmal] St Stephens Hosp, Dept Paediat, Delhi 110054, India; [Sharma, Archna; Goel, Masha] St Stephens Hosp, Dept Pathol, Delhi 110054, India; [Balharbi, Fatima; Lejon, Veerle; Deborggraeve, Stijn] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Rana, Udai Veer Singh] Natl Ctr Dis Control, Delhi, India	Puliyel, J (reprint author), St Stephens Hosp, Dept Paediat, Delhi 110054, India.	dr_archanaverma@yahoo.com; manchandasami@yahoo.com; nsk9_2000@yahoo.com; drarchna_sharma@yahoo.com; Mashagoel86@gmail.com; banerjeeparth62@gmail.com; rajatgarg_2000@yahoo.com; bpsingh_para@yahoo.co.in; fbalharbi@itg.be; vlejon@itg.be; sdeborggraeve@itg.be; druvsrana@gmail.com; puliyel@gmail.com		Lejon, Veerle/0000-0002-6795-0962			Banerjee P.S., 2008, 40 AS PAC AC CONS PU; Brun R, 2005, AM J TROP MED HYG, V73, P484, DOI 10.4269/ajtmh.2005.73.484; CLAES F, 2004, KINETOPLASTID BIOL D, V3, P3; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Deborggraeve S, 2008, DIAGN MICR INFEC DIS, V61, P428, DOI 10.1016/j.diagmicrobio.2008.03.006; Deborggraeve S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000972; DESQUESNES M, 2002, KINETOPLASTID BIOL D, V1, P2, DOI DOI 10.1186/1475-9292-1-2 12234387; Howie S, 2006, PLOS MED, V3, P1508, DOI 10.1371/journal.pmed.0030355; JOHNSON P. D., 1933, TRANS ROY SOC TROP MED AND HYG [LONDON], V26, P467, DOI 10.1016/S0035-9203(33)90105-4; Joshi PP, 2005, AM J TROP MED HYG, V73, P491, DOI 10.4269/ajtmh.2005.73.491; Kaur Raminder, 2007, J Commun Dis, V39, P71; Sarataphan N, 2007, J MED MICROBIOL, V56, P1118, DOI 10.1099/jmm.0.47222-0; Shegokar VR, 2006, AM J TROP MED HYG, V75, P869, DOI 10.4269/ajtmh.2006.75.869; SHRIVASTAVA KK, 1974, T ROY SOC TROP MED H, V68, P3, DOI 10.1016/0035-9203(74)90217-X; Truc P, 2007, INFECT GENET EVOL, V7, P305, DOI 10.1016/j.meegid.2006.07.004	15	24	28	0	10	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2011	85	2					221	224		10.4269/ajtmh.2011.11-0002				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	803WN	WOS:000293613000007	21813838	Bronze, Green Published			2019-03-26	
J	Watanaveeradej, V; Simasathien, S; Nisalak, A; Endy, TP; Jarman, RG; Innis, BL; Thomas, SJ; Gibbons, RV; Hengprasert, S; Samakoses, R; Kerdpanich, A; Vaughn, DW; Putnak, JR; Eckels, KH; De la Barrera, R; Mammen, MP				Watanaveeradej, Veerachai; Simasathien, Sriluck; Nisalak, Ananda; Endy, Timothy P.; Jarman, Richard G.; Innis, Bruce L.; Thomas, Stephen J.; Gibbons, Robert V.; Hengprasert, Sumetha; Samakoses, Rudiwilai; Kerdpanich, Angkool; Vaughn, David W.; Putnak, J. Robert; Eckels, Kenneth H.; De la Barrera, Rafael; Mammen, Mammen P., Jr.			Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							VIRUS-VACCINE; ANTIBODIES; COUNTRIES; DISEASE; PCR	A Phase I/II observer-blind, randomized, controlled trial evaluated the safety and immunogenicity of a dengue virus (DENV) vaccine candidate in healthy Thai infants (aged 12-15 months) without measurable pre-vaccination neutralizing antibodies to DENV and Japanese encephalitis virus. Fifty-one subjects received two doses of either DENV (N = 34; four received 1/10th dose) or control vaccine (N = 17; dose 1, live varicella; dose 2, Haemophilus influenzue type b). After each vaccine dose, adverse events (AEs) were solicited for 21 days, and non-serious AEs were solicited for 30 days; serious AEs (SAEs) were recorded throughout the study. Laboratory safety assessments were performed at 10 and 30 days; neutralizing antibodies were measured at 30 days. The DENV vaccine was well-tolerated without any related SAEs. After the second dose, 85.7% of full-dose DENV vaccinees developed at least trivalent and 53.6% developed tetravalent neutralizing antibodies >= 1:10 to DENV (control group = 0%). This vaccine candidate, therefore, warrants continued development in this age group (NCT00322049; clinicaltrials.gov).	[Mammen, Mammen P., Jr.] US Army Med Mat Dev Act, Pharmaceut Syst Program Management Off, Ft Detrick, MD 21702 USA; Phramongkutklao Hosp PMK, Dept Pediat, Bangkok, Thailand; [Nisalak, Ananda; Jarman, Richard G.; Thomas, Stephen J.; Gibbons, Robert V.; Hengprasert, Sumetha] AFRIMS, Dept Virol, Bangkok, Thailand; GlaxoSmithKline Biol, King Of Prussia, PA USA; GlaxoSmithKline Biol, Rixensart, Belgium; GlaxoSmithKline Biol, Bangkok, Thailand; [Putnak, J. Robert] Walter Reed Army Inst Res, Div Viral Dis, Silver Spring, MD USA; [Eckels, Kenneth H.; De la Barrera, Rafael] Walter Reed Army Inst Res, Div Regulated Act, Pilot Bioprod Facil, Silver Spring, MD USA; [Watanaveeradej, Veerachai; Simasathien, Sriluck; Samakoses, Rudiwilai; Kerdpanich, Angkool] Phramongkutklao Hosp, Dept Pediat, Bangkok, Thailand; [Endy, Timothy P.] SUNY Upstate Med Univ, Div Infect Dis, Dept Med, Syracuse, NY USA; [Innis, Bruce L.; Vaughn, David W.] GlaxoSmithKline, King Of Prussia, PA USA	Mammen, MP (reprint author), US Army Med Mat Dev Act, Pharmaceut Syst Program Management Off, 1430 Vet Dr, Ft Detrick, MD 21702 USA.	veerachaiw@yahoo.com; ssriluck@hotmail.com; ananda.nisalak@afrims.org; endyt@upstate.edu; richard.jarman@afrims.org; bruce.2.innis@gsk.com; Stephen.thomas@afrims.org; Robert.gibbons@afrims.org; sumethah@afrims.org; rudiwilai_samakoses@hotmail.com; akpmk@yahoo.com; david.w.vaughn@gsk.com; robert.putnak@amedd.army.mil; kenneth.eckels@amedd.army.mil; rafael.delabarreral@us.army.mil; mammen.mammen@us.army.mil		Innis, Bruce/0000-0002-1753-7248	US Army Medical Research and Materiel Command (Fort Detrick, MD); GlaxoSmithKline (Rixensart, Belgium)	This work was funded by US Army Medical Research and Materiel Command (Fort Detrick, MD) and GlaxoSmithKline (Rixensart, Belgium).	DeRoeck D, 2003, VACCINE, V22, P121, DOI 10.1016/S0264-410X(03)00533-4; Eckels KH, 2003, AM J TROP MED HYG, V69, P12, DOI 10.4269/ajtmh.2003.69.12; Forattini O. P., 2003, Dengue Bulletin, V27, P91; Innis BL, 2003, AM J TROP MED HYG, V69, P1; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), 2011, MED DICT REG ACT MAI; Klungthong C, 2007, J CLIN MICROBIOL, V45, P2480, DOI 10.1128/JCM.00305-07; [Ministry of Environment and Tourism CRIAA-SADC], 1999, NAT GROWTH REF THAI, P28; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Nisalak A, 2003, AM J TROP MED HYG, V68, P191, DOI 10.4269/ajtmh.2003.68.191; *PDVI, 2010, GLOB BURD DENG; RUSSELL PK, 1967, J IMMUNOL, V99, P285; Sadon N, 2008, J VIROL METHODS, V153, P1, DOI 10.1016/j.jviromet.2008.06.023; Simasathien S, 2008, AM J TROP MED HYG, V78, P426, DOI 10.4269/ajtmh.2008.78.426; Suchita Chaudhry, 2006, Dengue Bulletin, V30, P121; Sun W, 2009, HUM VACCINES, V5, P33, DOI 10.4161/hv.5.1.6348; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215; Watanaveeradej V, 2003, AM J TROP MED HYG, V69, P123, DOI 10.4269/ajtmh.2003.69.123; Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690; *WHO, 2009, FACT SHEET 117	20	34	37	0	2	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2011	85	2					341	351		10.4269/ajtmh.2011.10-0501				11	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	803WN	WOS:000293613000026	21813857	Green Published, Bronze			2019-03-26	
J	Rossi, G; Mesia, D				Rossi, G.; Mesia, D.			Management of harlequin ichthyosis in low-income countries	ANNALS OF TROPICAL PAEDIATRICS			English	Article							ABCA12; FETUS; MUTATIONS	Harlequin ichthyosis (HI) is a very rare severe form of autosomal recessive congenital ichthyosis, usually associated with stillbirth and early neonatal death. A newborn girl with HI is described. She presented in a critical condition with severe universalis hyperkeratosis, diffuse scales and deep erythematous fissures. She received preventive systemic antibiotics and hygienic nursing with skin and eye care, feeding and appropriate hydration. She was discharged at 28 days in good general condition.	[Rossi, G.] Med Sans Frontieres, Rome, Italy; [Mesia, D.] Med Sans Frontieres, Brussels, Belgium	Rossi, G (reprint author), Med Sans Frontieres, Via Como 17, I-20095 Cusano Milanino, Italy.	gab.rossi@tiscali.it					Akiyama M, 2005, J CLIN INVEST, V115, P1777, DOI 10.1172/JCI14834; Akiyama M, 2007, J INVEST DERMATOL, V127, P568, DOI 10.1038/sj.jid.5700617; Bongain A, 2002, ULTRASOUND OBST GYN, V20, P82, DOI 10.1046/j.1469-0705.2002.00708.x; Kelsell DP, 2005, AM J HUM GENET, V76, P794; KOUSKOUKIS C, 1982, INT J DERMATOL, V21, P347, DOI 10.1111/j.1365-4362.1982.tb03144.x; LAWLOR F, 1985, BRIT J DERMATOL, V112, P585; Singh S, 2001, INT J DERMATOL, V40, P472, DOI 10.1046/j.1365-4362.2001.01173.x	7	1	2	0	5	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0272-4936			ANN TROP PAEDIATR	Ann. Trop. Paediatr.	AUG	2011	31	3					247	249		10.1179/1465328111Y.0000000020				3	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	793NC	WOS:000292829200010	21781420				2019-03-26	
J	Meessen, B; Kouanda, S; Musango, L; Richard, F; Ridde, V; Soucat, A				Meessen, Bruno; Kouanda, Seni; Musango, Laurent; Richard, Fabienne; Ridde, Valery; Soucat, Agnes			Communities of practice: the missing link for knowledge management on implementation issues in low-income countries?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						knowledge management; user fee; community of practice; implementation science	HEALTH-CARE; USER FEES; PUBLIC-HEALTH; POLICY; RESEARCHERS; MORTALITY; AFRICA	The implementation of policies remains a huge challenge in many low-income countries. Several factors play a role in this, but improper management of existing knowledge is no doubt a major issue. In this article, we argue that new platforms should be created that gather all stakeholders who hold pieces of relevant knowledge for successful policies. To build our case, we capitalize on our experience in our domain of practice, health care financing in sub-Saharan Africa. We recently adopted a community of practice strategy in the region. More in general, we consider these platforms as the way forward for knowledge management of implementation issues.	[Meessen, Bruno; Richard, Fabienne] Inst Trop Med, B-2000 Antwerp, Belgium; [Kouanda, Seni; Ridde, Valery] IRSS, Ouagadougou, Burkina Faso; [Musango, Laurent] WHO AFRO, Libreville, Gabon; [Ridde, Valery] Univ Montreal, Montreal, PQ, Canada; [Soucat, Agnes] African Dev Bank, Tunis, Tunisia	Meessen, B (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	bmeessen@itg.be		Ridde, Valery/0000-0001-9299-8266; Meessen, Bruno/0000-0002-0359-8621	European Commission [261449]	This publication is an output of the FEMHealth project, supported by the Seventh Framework Programme of the European Commission [contract 261449].	Agyepong IA, 2011, TROP MED INT HEALTH, V16, P105, DOI 10.1111/j.1365-3156.2010.02639.x; Agyepong IA, 2011, HEALTH POLICY, V99, P226, DOI 10.1016/j.healthpol.2010.09.018; Barrett M., 2005, KM4D J, V1, P31; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; CHOI BC, 2005, LANCET, V368, P954; Frenk J, 2006, LANCET, V368, P954, DOI 10.1016/S0140-6736(06)69376-8; Gertler PJ, 2011, IMPACT EVALUATION IN PRACTICE, P1, DOI 10.1596/978-0-8213-8541-8; GRODOS D, 2000, STUDIES HLTH SERVICE, V15; *HARM HLTH AFR, 2010, TECHN WORKSH SHAR EX; Hyder AA, 2011, HEALTH POLICY PLANN, V26, P73, DOI 10.1093/heapol/czq020; Innvaer Simon, 2002, J Health Serv Res Policy, V7, P239, DOI 10.1258/135581902320432778; Ir P, 2010, HEALTH POLICY, V96, P200, DOI 10.1016/j.healthpol.2010.02.003; James C, 2005, BRIT MED J, V331, P747, DOI 10.1136/bmj.331.7519.747; Jansen MWJ, 2010, HEALTH RES POLICY SY, V8, DOI 10.1186/1478-4505-8-37; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Landry R, 2006, B WORLD HEALTH ORGAN, V84, P597, DOI 10.2471/BLT.06.031724; Lavis JN, 2010, CAN MED ASSOC J, V182, pE350, DOI 10.1503/cmaj.081164; Li LC, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-27; Lipsky Michael, 1980, STREET LEVEL BUREAUC; Madon T, 2007, SCIENCE, V318, P1728, DOI 10.1126/science/1150009; McGrath S, 2004, INT J EDUC DEV, V24, P167, DOI 10.1016/j.ijedudev.2003.10.008; Meessen B, 2009, REMOVING USER FEES H; MEESSEN B, 2011, PERFORMANCE BASED FI; Meessen B, 2011, B WORLD HEALTH ORGAN, V89, P153, DOI 10.2471/BLT.10.077339; Orlikowski WJ, 2002, ORGAN SCI, V13, P249, DOI 10.1287/orsc.13.3.249.2776; Parkhurst J, 2010, LANCET, V375, P1414, DOI 10.1016/S0140-6736(10)60585-5; Pawson R., 2006, EVIDENCE BASED POLIC; Peters DH, 2009, DIR DEV, P1, DOI 10.1596/978-0-8213-7888-5; Polanyi M, 1962, PERSONAL KNOWLEDGE P; Pressman J. L, 1984, IMPLEMENTATION GREAT; Ranmuthugala G, 2010, COMMUNITIES PRACTICE; Remme JHF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1001000; Richard F, 2010, AM J PUBLIC HEALTH, V100, P1845, DOI 10.2105/AJPH.2009.179689; Ridde V, 2011, HEALTH POLICY PLANN, V26, P1, DOI 10.1093/heapol/czq021; Ridde Valery, 2009, Glob Health Promot, V16, P3, DOI 10.1177/1757975909339768; Ridde V, 2009, PLOS MED, V6, P12, DOI 10.1371/journal.pmed.1000008; Sachs JD, 2005, LANCET, V365, P347, DOI 10.1016/S0140-6736(05)17791-5; Saetren H, 2005, POLICY STUD J, V33, P559, DOI 10.1111/j.1541-0072.2005.00133.x; The Global Campaign for the Health Millennium Development Goals, 2009, LEAD EX PROT MOST VU; Thomas AU, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-25; Walker L, 2004, SOC SCI MED, V59, P1251, DOI 10.1016/j.socscimed.2003.12.020; WENGER E, 2002, GUID MANAGING KNOWLE; WHO, 2010, WOR HEALT REP, P1; Witter S, 2010, HEALTH POLICY PLANN, V25, P384, DOI 10.1093/heapol/czq013; *WORLD BANK, 1998, WORLD DEV REP 1998 9; Yates R, 2010, B WORLD HEALTH ORGAN, V88, P474, DOI 10.2471/BLT.09.074401; Yates R, 2009, LANCET, V373, P2078, DOI 10.1016/S0140-6736(09)60258-0; YOUNG R, 2008, KNOWLEDGE MANAGEMENT; Zachariah R, 2010, INT HEALTH, V2, P1, DOI 10.1016/j.inhe.2009.12.008; Zachariah R, 2009, LANCET INFECT DIS, V9, P711, DOI 10.1016/S1473-3099(09)70229-4; 2007, LANCET, V369, P1833	51	23	23	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2011	16	8					1007	1014		10.1111/j.1365-3156.2011.02794.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	791EM	WOS:000292647200013	21564426	Bronze			2019-03-26	
J	Cox, JA; Lukande, RL; Kateregga, A; Mayanja-Kizza, H; Manabe, YC; Colebunders, R				Cox, Janneke A.; Lukande, Robert L.; Kateregga, Alice; Mayanja-Kizza, Harriet; Manabe, Yukari C.; Colebunders, Robert			Autopsy acceptance rate and reasons for decline in Mulago Hospital, Kampala, Uganda	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						autopsy; post-mortem; acceptance; sub-Saharan Africa; Uganda	VERBAL AUTOPSY; DEATH; DIAGNOSES; ADULTS; KENYA	OBJECTIVE To determine the autopsy acceptance rate and reasons for decline at Mulago Hospital, Kampala, Uganda. METHODS The next of kin of patients who died in a combined infectious diseases and gastro-enterology ward of Mulago Hospital were approached to answer a questionnaire concerning characteristics of their deceased relative. During the interview their consent was asked to perform a complete autopsy. If autopsy was declined, the next of kin were asked to provide their reason for the decline. RESULTS Permission to perform an autopsy was requested in 158 (54%) of the 290 deaths that occurred during the study period. In 60 (38%) cases autopsy was accepted. Fifty-nine autopsies were performed. For 82% of refusals a reason was listed; mainly 'not wanting to delay the burial' (58%), 'no use to know the cause of death' (16%) and 'being satisfied with the clinical cause of death' (10%). CONCLUSION The autopsy rate achieved under study conditions was 38% compared to rates of 5% in Mulago Hospital over the past decade. Timely request and rapid performance of autopsies appear to be important determinants of autopsy acceptance. A motivated team of pathologists and clinicians is required to increase autopsy acceptance.	[Cox, Janneke A.; Colebunders, Robert] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Lukande, Robert L.] Makerere Univ, Dept Pathol, Kampala, Uganda; [Kateregga, Alice; Mayanja-Kizza, Harriet] Mulago Hosp, Dept Internal Med, Kampala, Uganda; [Manabe, Yukari C.] Makerere Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda; [Colebunders, Robert] Univ Antwerp, Dept Epidemiol & Social Med, B-2020 Antwerp, Belgium	Colebunders, R (reprint author), Inst Trop Med, Dept Clin Sci, Natl Str 155, B-2000 Antwerp, Belgium.	bcoleb@itg.be		Mayanja-Kizza, Harriet/0000-0002-9297-6208	Directorate General for Development Cooperation (DGDC) through the Flemish Interuniversity council (VLIR-UOS)	The authors would like to thank all the staff of the study ward in particular Dr Pauline Byakika and Dr Kenneth Opio for facilitating the study and Dr Martin Opio for collecting data. We also want to thank the staff of the Pathology Department of Mulago Hospital in particular Dr Sam Kalungi and the mortuary staff of Mulago Hospital. The study received funding from the Directorate General for Development Cooperation (DGDC) through the Flemish Interuniversity council (VLIR-UOS).	Beadsworth MBJ, 2009, INT J STD AIDS, V20, P84, DOI 10.1258/ijsa.2008.008271; Burton JL, 2007, LANCET, V369, P1471, DOI 10.1016/S0140-6736(07)60376-6; Cox JA, 2010, AIDS REV, V12, P183; Ekanem V J, 2007, Niger Postgrad Med J, V14, P8; Lishimpi K, 2001, ARCH DIS CHILD, V84, P463, DOI 10.1136/adc.84.6.463; Lopman B, 2010, J EPIDEMIOL COMMUN H, V64, P330, DOI 10.1136/jech.2008.081554; Martinson NA, 2007, AIDS, V21, P2043, DOI 10.1097/QAD.0b013e3282eea47f; Nelson Ann Marie, 1994, P283; Oluwasola OA, 2009, ARCH PATHOL LAB MED, V133, P78, DOI 10.1043/1543-2165-133.1.78; Rana FS, 2000, J ACQ IMMUN DEF SYND, V24, P23; Setel PW, 2006, PLOS MED, V3, P1282, DOI 10.1371/journal.pmed.0030268; Sheikh A, 1998, J ROY SOC MED, V91, P138, DOI 10.1177/014107689809100307; *UG BUR STAT, 2002, 2002 UG POP HOUS CEN; van Eijk AM, 2008, TROP MED INT HEALTH, V13, P1314, DOI 10.1111/j.1365-3156.2008.02136.x; World Health Organization, 2007, VERB AUT STAND	15	12	12	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2011	16	8					1015	1018		10.1111/j.1365-3156.2011.02798.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	791EM	WOS:000292647200014	21564428	Bronze			2019-03-26	
J	Durnez, L; Van Bortel, W; Denis, L; Roelants, P; Veracx, A; Trung, HD; Sochantha, T; Coosemans, M				Durnez, Lies; Van Bortel, Wim; Denis, Leen; Roelants, Patricia; Veracx, Aurelie; Ho Dinh Trung; Sochantha, Tho; Coosemans, Marc			False positive circumsporozoite protein ELISA: a challenge for the estimation of the entomological inoculation rate of malaria and for vector incrimination	MALARIA JOURNAL			English	Article							LINKED-IMMUNOSORBENT-ASSAY; POLYMERASE-CHAIN-REACTION; PLASMODIUM-VIVAX SPOROZOITES; MOLECULAR-IDENTIFICATION; MOSQUITOS DIPTERA; ANOPHELES DIPTERA; FIELD-EVALUATION; SOUTHEAST-ASIA; FALCIPARUM; TRANSMISSION	Background: The entomological inoculation rate (EIR) is an important indicator in estimating malaria transmission and the impact of vector control. To assess the EIR, the enzyme-linked immunosorbent assay (ELISA) to detect the circumsporozoite protein (CSP) is increasingly used. However, several studies have reported false positive results in this ELISA. The false positive results could lead to an overestimation of the EIR. The aim of present study was to estimate the level of false positivity among different anopheline species in Cambodia and Vietnam and to check for the presence of other parasites that might interact with the anti-CSP monoclonal antibodies. Methods: Mosquitoes collected in Cambodia and Vietnam were identified and tested for the presence of sporozoites in head and thorax by using CSP-ELISA. ELISA positive samples were confirmed by a Plasmodium specific PCR. False positive mosquitoes were checked by PCR for the presence of parasites belonging to the Haemosporidia, Trypanosomatidae, Piroplasmida, and Haemogregarines. The heat-stability and the presence of the cross-reacting antigen in the abdomen of the mosquitoes were also checked. Results: Specimens (N = 16,160) of seven anopheline species were tested by CSP-ELISA for Plasmodium falciparum and Plasmodium vivax (Pv210 and Pv247). Two new vector species were identified for the region: Anopheles pampanai (P. vivax) and Anopheles barbirostris (Plasmodium malariae). In 88% (155/176) of the mosquitoes found positive with the P. falciparum CSP-ELISA, the presence of Plasmodium sporozoites could not be confirmed by PCR. This percentage was much lower (28% or 5/18) for P. vivax CSP-ELISAs. False positive CSP-ELISA results were associated with zoophilic mosquito species. None of the targeted parasites could be detected in these CSP-ELISA false positive mosquitoes. The ELISA reacting antigen of P. falciparum was heat-stable in CSP-ELISA true positive specimens, but not in the false positives. The heat-unstable cross-reacting antigen is mainly present in head and thorax and almost absent in the abdomens (4 out of 147) of the false positive specimens. Conclusion: The CSP-ELISA can considerably overestimate the EIR, particularly for P. falciparum and for zoophilic species. The heat-unstable cross-reacting antigen in false positives remains unknown. Therefore it is highly recommended to confirm all positive CSP-ELISA results, either by re-analysing the heated ELISA lysate (100 degrees C, 10 min), or by performing Plasmodium specific PCR followed if possible by sequencing of the amplicons for Plasmodium species determination.	[Durnez, Lies; Van Bortel, Wim; Denis, Leen; Roelants, Patricia; Coosemans, Marc] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Veracx, Aurelie] Univ Mediterranee, Fac Med, Unite Rech Malad Infect & Trop Emergentes, CNRS,IRD,UMR 6236, F-13385 Marseille 5, France; [Ho Dinh Trung] Natl Inst Malariol Parasitol & Entomol, Dept Entomol, Hanoi, Vietnam; [Sochantha, Tho] Natl Ctr Malaria Control Parasitol & Entomol, Phnom, Penh, Cambodia	Durnez, L (reprint author), Inst Trop Med, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	ldurnez@itg.be		Van Bortel, Wim/0000-0002-6644-518X	NIMPE; Institute of Tropical Medicine, Belgium; Belgian Co-operation (Directorate-General for Development Co-operation)	The current study was financially supported by the Institutional Collaboration between NIMPE and the Institute of Tropical Medicine, Belgium, supported by the Belgian Co-operation (Directorate-General for Development Co-operation).	Alam MS, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-15; ARNOT DE, 1985, SCIENCE, V230, P815, DOI 10.1126/science.2414847; BEEBE NW, 1995, AM J TROP MED HYG, V53, P478, DOI 10.4269/ajtmh.1995.53.478; BEIER JC, 1990, J MED ENTOMOL, V27, P377, DOI 10.1093/jmedent/27.3.377; BEIER JC, 1987, AM J TROP MED HYG, V36, P459, DOI 10.4269/ajtmh.1987.36.459; BENEDICT MQ, 2007, MR4; Bigoga JD, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-5; Birkenheuer AJ, 2007, PARASITOLOGY, V134, P631, DOI 10.1017/S0031182006002095; Brennan JDG, 2000, P NATL ACAD SCI USA, V97, P13859, DOI 10.1073/pnas.250472597; BURKOT TR, 1984, AM J TROP MED HYG, V33, P783, DOI 10.4269/ajtmh.1984.33.783; BURKOT TR, 1991, PARASITE IMMUNOL, V13, P161, DOI 10.1111/j.1365-3024.1991.tb00272.x; Cooper RD, 2009, INT J PARASITOL, V39, P1495, DOI 10.1016/j.ijpara.2009.05.009; Cuong DM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-259; Deborggraeve S, 2008, DIAGN MICR INFEC DIS, V61, P428, DOI 10.1016/j.diagmicrobio.2008.03.006; Duval L, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-157; Elmore SA, 2010, TRENDS PARASITOL, V26, P190, DOI 10.1016/j.pt.2010.01.009; Fontenille D, 2001, J MED ENTOMOL, V38, P451, DOI 10.1603/0022-2585-38.3.451; Gutierrez LA, 2009, MEM I OSWALDO CRUZ, V104, P1117, DOI 10.1590/S0074-02762009000800008; *IMPE, 1987, KEY ID AN VIETN AD P; Koekemoer LL, 2001, J AM MOSQUITO CONTR, V17, P160; Lochouarn L, 1999, T ROY SOC TROP MED H, V93, P101, DOI 10.1016/S0035-9203(99)90198-0; Mangold KA, 2005, J CLIN MICROBIOL, V43, P2435, DOI 10.1128/JCM.43.5.2435-2440.2005; Mouatcho JC, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-30; Perkins SL, 2001, J PARASITOL, V87, P870, DOI 10.2307/3285147; Plassmeyer ML, 2009, J BIOL CHEM, V284, P26951, DOI 10.1074/jbc.M109.013706; Povoa MM, 2000, T ROY SOC TROP MED H, V94, P106, DOI 10.1016/S0035-9203(00)90457-7; Prakash A, 2004, ANN TROP MED PARASIT, V98, P559, DOI 10.1179/000349804225021361; QARI SH, 1994, AM J TROP MED HYG, V50, P45, DOI 10.4269/ajtmh.1994.50.45; Ross AGP, 2002, NEW ENGL J MED, V346, P1212, DOI 10.1056/NEJMra012396; Shaukat AM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-122; SOMBOON P, 1993, T ROY SOC TROP MED H, V87, P322, DOI 10.1016/0035-9203(93)90148-J; Sylla EHK, 2000, T ROY SOC TROP MED H, V94, P652, DOI 10.1016/S0035-9203(00)90219-0; TASSANAKAJON A, 1993, T ROY SOC TROP MED H, V87, P273, DOI 10.1016/0035-9203(93)90124-9; Trung HD, 2005, TROP MED INT HEALTH, V10, P251, DOI 10.1111/j.1365-3156.2004.01378.x; Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x; Van Bortel W, 2000, INSECT MOL BIOL, V9, P335, DOI 10.1046/j.1365-2583.2000.00192.x; Van Bortel W, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-373; Verzberger-Epshtein I, 2008, VET PARASITOL, V151, P53, DOI 10.1016/j.vetpar.2007.09.028; Vilmos P, 1998, IMMUNOL LETT, V62, P59, DOI 10.1016/S0165-2478(98)00023-6; Walton C, 1999, MED VET ENTOMOL, V13, P24, DOI 10.1046/j.1365-2915.1999.00142.x; Walton C, 2007, INFECT GENET EVOL, V7, P93, DOI 10.1016/j.meegid.2006.05.001; Wide Albina, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P327, DOI 10.1590/S0036-46652006000600005; WIRTZ RA, 1987, J MED ENTOMOL, V24, P433, DOI 10.1093/jmedent/24.4.433; WIRTZ RA, 1992, J MED ENTOMOL, V29, P854, DOI 10.1093/jmedent/29.5.854; WIRTZ RA, 1985, AM J TROP MED HYG, V34, P1048, DOI 10.4269/ajtmh.1985.34.1048; BLAST BASIC LOCAL AL	46	61	61	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JUL 18	2011	10								195	10.1186/1475-2875-10-195				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	810VJ	WOS:000294155500001	21767376	DOAJ Gold, Green Published			2019-03-26	
J	Vitouley, HS; Mungube, EO; Allegye-Cudjoe, E; Diall, O; Bocoum, Z; Diarra, B; Randolph, TF; Bauer, B; Clausen, PH; Geysen, D; Sidibe, I; Bengaly, Z; Van den Bossche, P; Delespaux, V				Vitouley, Herve Sena; Mungube, Erick Ouma; Allegye-Cudjoe, Emmanuel; Diall, Oumar; Bocoum, Zakaria; Diarra, Boucader; Randolph, Thomas F.; Bauer, Burkhard; Clausen, Peter-Henning; Geysen, Dirk; Sidibe, Issa; Bengaly, Zakaria; Van den Bossche, Peter; Delespaux, Vincent			Improved PCR-RFLP for the Detection of Diminazene Resistance in Trypanosoma congolense under Field Conditions Using Filter Papers for Sample Storage	PLOS NEGLECTED TROPICAL DISEASES			English	Editorial Material							DRUG-RESISTANCE; MOLECULAR TOOLS; CATTLE		[Vitouley, Herve Sena; Sidibe, Issa; Bengaly, Zakaria] CIRDES, Bobo Dioulasso, Burkina Faso; [Mungube, Erick Ouma; Bauer, Burkhard; Clausen, Peter-Henning] Free Univ Berlin, Inst Parasitol & Trop Vet Med, D-1000 Berlin, Germany; [Allegye-Cudjoe, Emmanuel] Cent Vet Labs, Pong Tamale, Tamale, Ghana; [Diall, Oumar] ILRI, Bamako, Mali; [Bocoum, Zakaria] LCV, Bamako, Mali; [Diarra, Boucader] Pan African Tsetse & Typanosomosis Eradicat Progr, Bamako, Mali; [Randolph, Thomas F.] ILRI, Nairobi, Kenya; [Geysen, Dirk; Van den Bossche, Peter; Delespaux, Vincent] Inst Trop Med, B-2000 Antwerp, Belgium; [Van den Bossche, Peter] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa	Vitouley, HS (reprint author), CIRDES, Bobo Dioulasso, Burkina Faso.	vdelespaux@itg.be			German Federal Ministry of Economic Cooperation and Development (BMZ); Institute of Tropical Medicine Antwerp	We acknowledge the German Federal Ministry of Economic Cooperation and Development (BMZ) and the Institute of Tropical Medicine Antwerp for funding this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Clausen PH, 2010, TRANSBOUND EMERG DIS, V57, P28, DOI 10.1111/j.1865-1682.2010.01129.x; Delespaux V, 2006, ACTA TROP, V100, P96, DOI 10.1016/j.actatropica.2006.10.001; Delespaux V, 2008, TRENDS PARASITOL, V24, P236, DOI 10.1016/j.pt.2008.02.006; Eisler MC, 2001, VET PARASITOL, V97, P171, DOI 10.1016/S0304-4017(01)00415-0; EISLER MC, 2000, P 9 S INT SOC VET EP; Geysen D, 2003, VET PARASITOL, V110, P171, DOI 10.1016/S0304-4017(02)00313-8; Mamoudou A, 2008, ACTA TROP, V106, P115, DOI 10.1016/j.actatropica.2008.02.003; MATTIOLI RC, 2004, FOOD AGR ENV, V2, P310	8	6	7	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUL	2011	5	7							e1223	10.1371/journal.pntd.0001223				4	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	797YN	WOS:000293166300008	21814586	DOAJ Gold, Green Published			2019-03-26	
J	Hasker, E; Lumbala, C; Mbo, F; Mpanya, A; Kande, V; Lutumba, P; Boelaert, M				Hasker, E.; Lumbala, C.; Mbo, F.; Mpanya, A.; Kande, V.; Lutumba, P.; Boelaert, M.			Health care-seeking behaviour and diagnostic delays for Human African Trypanosomiasis in the Democratic Republic of the Congo	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Human African Trypanosomiasis; patients delay; health systems delay	SLEEPING-SICKNESS; EASTERN UGANDA	OBJECTIVE About half of the patients with Human African trypanosomiasis (HAT) reported in the Democratic Republic of the Congo (DRC) are currently detected by fixed health facilities and not by mobile teams. Given the recent policy to integrate HAT control into general health services, we studied health seeking behaviour in these spontaneously presenting patients. METHODS We took a random sample from all patients diagnosed with a first-time HAT episode through passive case finding between 1 October 2008 and 30 September 2009 in the two most endemic provinces of the DRC. Patients were approached at their homes for a structured interview. We documented patient delay (i.e. time between onset of symptoms and contacting a health centre) and health system delay (i.e. time between first contact and correct diagnosis of HAT). RESULTS Median patient delay was 4 months (IQR 1-10 months, n = 66); median health system delay was 3 months (IQR 0.5-11 months). Those first presenting to public health centres had a median systems delay of 7 months (IQR 2-14 months, n = 23). On median, patients were diagnosed upon the forth visit to a health facility (IQR 3rd-7th visit). CONCLUSIONS Substantial patient as well as health system delays are incurred in HAT cases detected passively. Public health centres are performing poorly in the diagnostic work-up for HAT, mainly because HAT is a relatively rare disease with few and non-specific early symptoms. Integration of HAT diagnosis and treatment into general health services requires strong technical support and well-organized supervision and referral mechanisms.	[Hasker, E.; Boelaert, M.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Lumbala, C.; Mbo, F.; Mpanya, A.; Kande, V.] Natl Program Control Human African Trypanosomiasi, Kinshasa, Zaire; [Lutumba, P.] Univ Kinshasa, Fac Med, Kinshasa, Zaire	Hasker, E (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, Nationalestr 155, B-2000 Antwerp, Belgium.	ehasker@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Bukachi SA, 2009, ANN TROP MED PARASIT, V103, P211, DOI 10.1179/136485909X398230; Burri C., 2009, MANSONS TROPICAL DIS, P1307; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Checchi F, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-16; *FIND, 2010, FIND FDN INN DIAGN F; Hasker E, 2010, TROP MED INT HEALTH, V15, P263, DOI 10.1111/j.1365-3156.2009.02446.x; Hasker E, 2010, AM J TROP MED HYG, V83, P374, DOI 10.4269/ajtmh.2010.09-0735; Lockwood DNI, 2006, LEPROSY REV, V77, P1; Odiit M, 2004, ANN TROP MED PARASIT, V98, P339, DOI 10.1179/000349804225003389; Robays J, 2007, TROP MED INT HEALTH, V12, P290, DOI 10.1111/j.1365-3165.2006.01768.x; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Wembonyama S, 2007, Med Trop (Mars), V67, P447; *WHO, 2006, LEPROSY REV, V77, P9; *WHO, 2006, LEPROSY REV, V77, P10; *WHO, 2006, LEPROSY REV, V77, P50; *WORLD BANK, 2006, POV HEADC RAT 2 DAY; World Health Organization, 2005, MAN TUB TRAIN DISTR	18	23	23	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUL	2011	16	7					869	874		10.1111/j.1365-3156.2011.02772.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	786GB	WOS:000292290300014	21447063				2019-03-26	
J	Alemu, A; Tsegaye, W; Golassa, L; Abebe, G				Alemu, Abebe; Tsegaye, Wondewosen; Golassa, Lemu; Abebe, Gemeda			Urban malaria and associated risk factors in Jimma town, south-west Ethiopia	MALARIA JOURNAL			English	Article							SUB-SAHARAN AFRICA; TREATED BED NETS; PLASMODIUM-FALCIPARUM; TRANSMISSION; URBANIZATION; AREA; EPIDEMIOLOGY; INFECTION; EPISODES; CHILDREN	Background: Malaria kills millions around the world. Until recently it was believed to be a disease of rural areas, since the Anopheles mosquito, which transmits Plasmodium species breeds in rural areas. Urban malaria is emerging as a potential, but "avertable" crisis, in Africa. In view of the rapidly growing number of small and medium-sized towns in Ethiopia there is a pressing need to improve the understanding of the epidemiology of malaria. Therefore, the aim of this study was to determine malaria prevalence and associated risk factors in Jimma town. Methods: A cross-sectional study was carried out in Jimma town from April 1 to May 28, 2010. 804 study participants were included from 291 households for microscopic examination of malaria parasites. Socio-demography data and risk factors were collected using structured questionnaires. Logistic regression analysis was done using SPSS 15.0 statistical software. Results: From a total of 804 study participants in current survey only 42 (5.2%) were positive for malaria parasites. Plasmodium vivax, Plasmodium falciparum and mixed infection accounted 71.4%, 26.2% and 2.4%, respectively. Higher malaria prevalence rate was observed among under-five children (11%). Those who do not use insecticide-treated bed nets (ITN) were more likely to be infected with malaria (OR = 13.6; 95% CI 4.9-37.2, p < 0.001) compared with those who use the ITN. Living in areas where stagnant water existed (OR = 2.1; 95% CI 1.00-4.2, p = 0.047) and its distance of existence < 1 km from the house(OR = 2.1; 95% CI 2.0-15.8, p = 0.001) were more likely to be infected with malaria parasite compared with those who live away from stagnant at a distance greater than 1 km. Conclusion: Malaria is a major health problem with P. vivax becoming a predominant species in the town. The prevalence was strongly associated with proximity of residence to potential mosquito breeding sites. Malaria is affecting significant proportions of the urban settlers and human activities nevertheless play an important role in bringing the mosquito breeding sites closer to residences.	[Alemu, Abebe; Tsegaye, Wondewosen; Golassa, Lemu; Abebe, Gemeda] Jimma Univ, Dept Med Lab Sci & Pathol, Jimma, Ethiopia; [Alemu, Abebe] Univ Gondar, Coll Med & Hlth Sci, Dept Med Lab Sci, Gondar 6543, Ethiopia; [Abebe, Gemeda] Univ Antwerp, Dept Epidemiol & Social Med, B-2020 Antwerp, Belgium	Alemu, A (reprint author), Jimma Univ, Dept Med Lab Sci & Pathol, Jimma, Ethiopia.	yanbule@gmail.com		Abebe, Gemeda/0000-0002-7172-9136	Jimma university; anti malaria association (AMA)/Climate and Health Working Group of Ethiopia	We are grateful to Jimma university and anti malaria association (AMA)/Climate and Health Working Group of Ethiopia for funding this study. The authors appreciate the study participants for their cooperation in providing the necessary information and blood sample.	Achidi EA, 1996, AM J TROP MED HYG, V55, P138, DOI 10.4269/ajtmh.1996.55.138; Alemu A, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-30; ALEMU G, 2006, THESIS ADDIS ABABA U; ALONSO PL, 1993, T R SOC TROP MED H S, V2, P13; AMEYU G, 2008, THESIS ADDIS ABABA U; [Anonymous], 2005, DEMOGRAPHIC HLTH SUR; Batega DW, 2004, KNOWLEDGE ATTITUDES; CAMBEL CC, 1991, J INFECT DIS, V163, P1207; Carlson J, 2004, J VECTOR ECOL, V29, P331; *CTR NAT HLTH DEV, 2003, PROP GLOB FUND FIGHT; De Castro MC, 2004, AM J TROP MED HYG, V71, P103, DOI 10.4269/ajtmh.2004.71.103; Deressa W., 2003, ETHIOP J HEALTH DEV, V17, P9; Donnelly MJ, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-12; Giha HA, 2000, T ROY SOC TROP MED H, V94, P645, DOI 10.1016/S0035-9203(00)90218-9; Hay SI, 2005, NAT REV MICROBIOL, V3, P81, DOI 10.1038/nrmicro1069; Keating Joseph, 2004, Int J Health Geogr, V3, P9, DOI 10.1186/1476-072X-3-9; Keiser J, 2004, AM J TROP MED HYG, V71, P118, DOI 10.4269/ajtmh.2004.71.118; KIDANE G, 1998, 24 ANN MED C ETH HLT, P62; KLINKENBERG P, 2005, EMERG INFECT DIS, V11, P1290; Koram KA, 2003, TROP MED INT HEALTH, V8, P793, DOI 10.1046/j.1365-3156.2003.01092.x; LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L; Martens P, 2000, EMERG INFECT DIS, V6, P103, DOI 10.3201/eid0602.000202; *MIN HLTH, 2001, NAT 5 YEARS STRAT PL; Muller DA, 2001, ACTA TROP, V78, P155, DOI 10.1016/S0001-706X(01)00067-5; Oesterholt MJAM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-98; Okafor Emeka Emmanuel, 2007, Journal of Human Ecology, V21, P155; Robert V, 2003, AM J TROP MED HYG, V68, P169, DOI 10.4269/ajtmh.2003.68.169; Rosendaal JA, 2003, TROP DIS B, V86, P1; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9; Staedke SG, 2003, AM J TROP MED HYG, V69, P244, DOI 10.4269/ajtmh.2003.69.244; Tilaye Tesfaye, 2007, Ethiop Med J, V45, P151; United Nations, 2002, WORLD URB PROSP 2001; Utzinger J, 2006, ANN TROP MED PARASIT, V100, P517, DOI 10.1179/136485906X97372; VLALUAL D, 2003, LANCET, V362, P1091; Wakgari D, 2008, J BIOSOC SCI, V40, P1; Wakgari Deressa, 2005, Ethiopian Journal of Health Development, V19, P3; Wang SJ, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-29; WHO, 2008, WORLD MAL REP 2008; World Health Organization, 2004, WHO M BRAT SLOV 9 10, P15; *WORLD POP PROSP, 2006 REV WORLD URB P; Woyessa A, 2004, ETHIOP J HEALTH DEV, V18, P2; Yewhalaw D, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-47	42	41	42	0	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JUN 24	2011	10								173	10.1186/1475-2875-10-173				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	786PL	WOS:000292320300001	21699741	DOAJ Gold, Green Published			2019-03-26	
J	Gillet, P; Scheirlinck, A; Stokx, J; De Weggheleire, A; Chauque, HS; Canhanga, ODJV; Tadeu, BT; Mosse, CDD; Tiago, A; Mabunda, S; Bruggeman, C; Bottieau, E; Jacobs, J				Gillet, Philippe; Scheirlinck, Annelies; Stokx, Jocelijn; De Weggheleire, Anja; Chauque, Helder S.; Canhanga, Oreana D. J. V.; Tadeu, Benvindo T.; Mosse, Carla D. D.; Tiago, Armindo; Mabunda, Samuel; Bruggeman, Cathrien; Bottieau, Emmanuel; Jacobs, Jan			Prozone in malaria rapid diagnostics tests: how many cases are missed?	MALARIA JOURNAL			English	Article							PLASMODIUM-FALCIPARUM MALARIA; DIFFERENT EPIDEMIOLOGIC SETTINGS; POLYMERASE-CHAIN-REACTION; RETURNED TRAVELERS; CHILDREN; FEVER; MANAGEMENT; ACCURACY; INSTRUCTIONS; PERFORMANCE	Background: Prozone means false-negative or false-low results in antigen-antibody reactions, due to an excess of either antigen or antibody. The present study prospectively assessed its frequency for malaria rapid diagnostic tests (RDTs) and Plasmodium falciparum samples in an endemic field setting. Methods: From January to April 2010, blood samples with P. falciparum high parasitaemia (>= 4% red blood cells infected) were obtained from patients presenting at the Provincial Hospital of Tete (Mozambique). Samples were tested undiluted and 10-fold diluted in saline with a panel of RDTs and results were scored for line intensity (no line visible, faint, weak, medium and strong). Prozone was defined as a sample which showed no visible test line or a faint or weak test line when tested undiluted, and a visible test line of higher intensity when tested 10-fold diluted, as observed by two blinded observers and upon duplicate testing. Results: A total of 873/7,543 (11.6%) samples showed P. falciparum, 92 (10.5%) had high parasitaemia and 76 were available for prozone testing. None of the two Pf-pLDH RDTs, but all six HRP-2 RDTs showed prozone, at frequencies between 6.7% and 38.2%. Negative and faint HRP-2 lines accounted for four (3.8%) and 15 (14.4%) of the 104 prozone results in two RDT brands. For the most affected brand, the proportions of prozone with no visible or faint HRP-2 lines were 10.9% (CI: 5.34-19.08), 1.2% (CI: 0.55-2.10) and 0.1% (CI: 0.06-0.24) among samples with high parasitaemia, all positive samples and all submitted samples respectively. Prozone occurred mainly, but not exclusively, among young children. Conclusion: Prozone occurs at different frequency and intensity in HRP-2 RDTs and may decrease diagnostic accuracy in the most affected RDTs.	[Gillet, Philippe; Scheirlinck, Annelies; Stokx, Jocelijn; De Weggheleire, Anja; Bottieau, Emmanuel; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, Unit Trop Lab Med, B-2000 Antwerp, Belgium; [Tadeu, Benvindo T.; Mosse, Carla D. D.] Prov Hlth Author, Tete, Mozambique; [Tiago, Armindo; Mabunda, Samuel] Natl Malaria Programme, Maputo, Mozambique; [Bruggeman, Cathrien] Maastricht Univ Med Ctr, Dept Med Microbiol, Sch Publ Hlth & Primary Care CAPHRI, Maastricht, Netherlands	Gillet, P (reprint author), Inst Trop Med, Dept Clin Sci, Unit Trop Lab Med, Natl Str 155, B-2000 Antwerp, Belgium.	pgillet@itg.be	De Weggheleire, Anja/C-7345-2018	De Weggheleire, Anja/0000-0001-9377-4766; gillet, philippe/0000-0001-5878-6446	Flemish International Cooperation Agency	This study has been conducted within a collaborative health project financed by the Flemish International Cooperation Agency. The authors would like to thank all patients and their parents/guardians for their participation. The authors are also grateful to the medical, paramedical and laboratory staff of the Provincial Hospital of Tete for their clinical and laboratory assistance.	Batwala V, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-349; Bell D, 2006, NAT REV MICROBIOL, pS34, DOI 10.1038/nrmico1524; Bisoffi Z, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-192; Bjorkman A, 2010, CLIN INFECT DIS, V51, P512, DOI 10.1086/655689; Bruneel F, 2003, AM J RESP CRIT CARE, V167, P684, DOI 10.1164/rccm.200206-631OC; Bruneel F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013236; Butch AW, 2000, CLIN CHEM, V46, P1719; Chiodini PL, 2007, T ROY SOC TROP MED H, V101, P331, DOI 10.1016/j.trstmh.2006.09.007; D'Acremont V, 2009, PLOS MED, V6, P4, DOI 10.1371/journal.pmed.0050252; Drakeley C, 2009, T ROY SOC TROP MED H, V103, P333, DOI 10.1016/j.trstmh.2008.10.003; Farcas GA, 2006, CLIN INFECT DIS, V42, P622, DOI 10.1086/500134; Fogg C, 2008, T ROY SOC TROP MED H, V102, P25, DOI 10.1016/j.trstmh.2007.09.014; Forney JR, 2001, J CLIN MICROBIOL, V39, P2884, DOI 10.1128/JCM.39.8.2884-2890.2001; Gerstl S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-28; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-271; Harvey SA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-160; Heidelberger M, 1935, J EXP MED, V62, P467, DOI 10.1084/jem.62.4.467; Mabunda S, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-216; Mabunda S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-74; Makler MT, 2009, AM J TROP MED HYG, V81, P921, DOI 10.4269/ajtmh.2009.09-0202; Marx A, 2005, ANN INTERN MED, V142, P836, DOI 10.7326/0003-4819-142-10-200505170-00009; Mawili-Mboumba DP, 2010, DIAGN MICR INFEC DIS, V66, P162, DOI 10.1016/j.diagmicrobio.2009.09.011; Mayxay M, 2004, TROP MED INT HEALTH, V9, P325, DOI 10.1111/j.1365-3156.2004.01199.x; *MIN SAUD REP MOC, 2009, MAN FORM MAN CAS MAL; Msellem MI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000070; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Ochola LB, 2006, LANCET INFECT DIS, V6, P582, DOI 10.1016/S1473-3099(06)70579-5; Ohrt C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-79; Olliaro P, 2009, TROP MED INT HEALTH, V14, P488, DOI 10.1111/j.1365-3156.2009.02272.x; Pieroni P, 1998, T ROY SOC TROP MED H, V92, P166, DOI 10.1016/S0035-9203(98)90730-1; Rennie W, 2007, T ROY SOC TROP MED H, V101, P9, DOI 10.1016/j.trstmh.2006.03.011; Risch L, 1999, SCHWEIZ MED WSCHR, V129, P1002; Stow NW, 1999, T ROY SOC TROP MED H, V93, P519, DOI 10.1016/S0035-9203(99)90359-0; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; WHO, 2010, WORLD MALARIA REPORT 2010, P1; WHO, 2010, INF NOT INT SEL CRIT; WHO, 2009, LIST KNOWN COMM AV A; *WHO, 2009, MAL RAP DIAGN TEST P; Wiese L, 2006, SCAND J INFECT DIS, V38, P1063, DOI 10.1080/00365540600818011; *WORLD FOOD PROGR, 2011, TRMM PREC DAT AN; World Health Organization, 2010, MAL RAP DIAGN TEST P; World Health Organization, 2010, GUID TREATM MAL	43	44	45	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JUN 15	2011	10								166	10.1186/1475-2875-10-166				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	794DN	WOS:000292875800001	21676264	DOAJ Gold, Green Published			2019-03-26	
J	Paladini, G; Huyse, T; Shinn, AP				Paladini, Giuseppe; Huyse, Tine; Shinn, Andrew P.			Gyrodactylus salinae n. sp (Platyhelminthes: Monogenea) infecting the south European toothcarp Aphanius fasciatus (Valenciennes) (Teleostei, Cyprinodontidae) from a hypersaline environment in Italy	PARASITES & VECTORS			English	Article							FRESH-WATER FISHES; VON-NORDMANN; TREMATODA-MONOGENEA; VECTOR COMPETENCE; AEDES-ALBOPICTUS; DNA-SEQUENCES; SP-NOV; MEXICO; SWORDTAILS; KILLIFISH	Background: Historically, non-native species of Gambusia (Poeciliidae) have been used to control larval stages of the Asian tiger mosquito, Stegomyia albopicta Reinert, Harbach et Kitching, 2004 throughout Italy. The potential utility of indigenous populations of Aphanius fasciatus (Valenciennes) (Teleostei: Cyprinodontidae) as an appropriate alternative biological control is currently being explored. A sub-sample of ten fish collected from Cervia Saline, Italy (salinity 65 ppt; 30 degrees C) to assess their reproductive capability in captivity, harboured a moderate infection of Gyrodactylus von Nordmann, 1832 (Platyhelminthes, Monogenea). A subsequent morphological and molecular study identified this as being a new species. Results: Gyrodactylus salinae n. sp. is described from the skin, fins and gills of A. fasciatus. Light and scanning electron microscopical (SEM) examination of the opisthaptoral armature and their comparison with all other recorded species suggested morphological similarities to Gyrodactylus rugiensoides Huyse et Volckaert, 2002 from Pomatoschistus minutus (Pallas). Features of the ventral bar, however, permit its discrimination from G. rugiensoides. Sequencing of the nuclear ribosomal DNA internal transcribed spacers 1 and 2 and the 5.8S rRNA gene and a comparison with all species listed in GenBank confirmed they are unique and represent a new species (most similar to Gyrodactylus anguillae Ergens, 1960, 8.3% pair-wise distance based on 5.8S+ITS2). This represents the first species of Gyrodactylus to be described from Aphanius and, to date, has the longest ITS1 (774 bp) sequenced from any Gyrodactylus. Additional sampling of Cervia Saline throughout the year, found G. salinae n. sp. to persist in conditions ranging from 35 ppt and 5 degrees C in December to 65 ppt and 30 degrees C in July, while in captivity a low level of infection was present, even in freshwater conditions (0 ppt). Conclusions: The ability of G. salinae n. sp. to tolerate a wide range of salinities and temperatures shows its potential to readily adapt to several environmental conditions. These findings, together with the fact that A. fasciatus is a protected species and is considered as a biological control organism, necessitate further studies on the ecology and virulence of G. salinae n. sp.	[Paladini, Giuseppe; Shinn, Andrew P.] Univ Stirling, Inst Aquaculture, Stirling FK9 4LA, Scotland; [Huyse, Tine] Katholieke Univ Leuven, Lab Anim Divers & Systemat, B-3000 Louvain, Belgium	Paladini, G (reprint author), Univ Stirling, Inst Aquaculture, Stirling FK9 4LA, Scotland.	paladini2000@yahoo.it		Paladini, Giuseppe/0000-0003-4944-0499; Shinn, Andrew/0000-0002-5434-2685	Department of the Environment, Food and Rural Affairs (Defra), UK [FC1183]	The authors would like to thank Mr Antonio Casalini, Mr Giuseppe Bastone and Dr Oliviero Mordenti (Faculty of Veterinary Medicine, University of Bologna, Italy) for providing literature and moribund fish for study; Mr Linton Brown (Institute of Aquaculture, University of Stirling, UK) for technical assistance with the acquisition of scanning electron photomicrographs; Mrs Eileen Harris (The Natural History Museum, London, UK) and Mrs Patricia Pilitt (United States National Parasite Collection, Beltsville, Maryland, USA) for the loan of type material from international collections. This study was conducted during the tenure of a PhD scholarship from the Department of the Environment, Food and Rural Affairs (Defra), UK (project no. FC1183) awarded to APS and conducted by GP. TH is currently a Postdoctoral Fellow of the Research Foundation - Flanders (FWO-Vlaanderen).	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AN LG, 1991, CAN J ZOOL, V69, P1199, DOI 10.1139/z91-171; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Cable J, 1999, CAN J ZOOL, V77, P1439, DOI 10.1139/cjz-77-9-1439; Cable J, 2005, SYST PARASITOL, V60, P159, DOI 10.1007/s11230-004-6348-4; CINTI S, 2009, INFECT DIS CLIN PRAC, V17, P6; CRIVELLI AJ, 2006, APHANIUS FASICATUS; Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443; DECHTIAR AO, 1988, PARASITES FISHES CAN, P66; Dove ADM, 1998, INT J PARASITOL, V28, P1755, DOI 10.1016/S0020-7519(98)00134-9; Garcia-Berthou E, 2005, CAN J FISH AQUAT SCI, V62, P453, DOI 10.1139/F05-017; GRANOMALDONADO MI, 2011, VET PARASITOL; HARGIS WJ, 1955, BIOL BULL, V108, P125, DOI 10.2307/1538429; HARRIS PD, 1986, J NAT HIST, V20, P183, DOI 10.1080/00222938600770151; Harris PD, 2000, SYST PARASITOL, V47, P79, DOI 10.1023/A:1006413804061; HARRIS PD, 1993, B FR PECHE PISCIC, P47, DOI 10.1051/kmae:1993011; Hayward CJ, 2001, DIS AQUAT ORGAN, V44, P53, DOI 10.3354/dao044053; Huyse T, 2004, SYST PARASITOL, V59, P103, DOI 10.1023/B:SYPA.0000044427.81580.33; Huyse T, 2002, INT J PARASITOL, V32, P907, DOI 10.1016/S0020-7519(02)00026-7; King SD, 2009, J PARASITOL, V95, P846, DOI 10.1645/GE-1901.1; Kritsky DC, 2005, SOUTHWEST NAT, V50, P312, DOI 10.1894/0038-4909(2005)050[0312:NSOGMG]2.0.CO;2; KRITSKY DC, 1970, P HELM SOC WASH, V37, P63; KRITSKY DC, 1977, EXCERTA PARASITOL ME, V4, P53; Leyse KE, 2004, BIOL CONSERV, V118, P57, DOI 10.1016/j.biocon.2003.07.008; Lucky Z., 1973, Veterinarni Med Praha, V18, P647; MALMBERG G, 1970, ARK ZOOL, V23, P1; Matejusova I, 2001, INT J PARASITOL, V31, P738, DOI 10.1016/S0020-7519(01)00176-X; MAYES MA, 1977, J PARASITOL, V63, P805, DOI 10.2307/3279882; Mendoza-Palmero CA, 2009, J PARASITOL, V95, P315, DOI 10.1645/GE-1761.1; MILLER BR, 1988, T ROY SOC TROP MED H, V82, P476, DOI 10.1016/0035-9203(88)90168-X; MIZELLE JD, 1967, CALIF FISH GAME, V53, P264; Mordenti O., 2007, Biologia Marina Mediterranea, V14, P276; MORDENTI O, 2009, P 22 C NAZ IT ENT 15; Mordenti O, 2008, BIOL MAR MEDIT, V15, P306; Mueller J. F., 1937, American Midland Naturalist, V18, P207, DOI 10.2307/2420497; PALADINI G, 1957, 1 REPORT GYRODACTYLU; Paladini G, 2010, FOLIA PARASIT, V57, P17, DOI 10.14411/fp.2010.004; PAPERNA I, 1968, Bamidgeh, V20, P88; Pauly D., 2010, FISHBASE; Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083; Reichard M, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-89; ROGERS WA, 1965, J PARASITOL, V51, P977, DOI 10.2307/3275887; Rosenfield JA, 2003, J EVOLUTION BIOL, V16, P595, DOI 10.1046/j.1420-9101.2003.00557.x; Rubio-Godoy M, 2010, ZOOTAXA, P1; RUKMINI C, 1989, INDIAN J HELMINTHOL, V6, P17; RYAN MJ, 1987, SCIENCE, V236, P595, DOI 10.1126/science.236.4801.595; Sardelis MR, 2002, J AM MOSQUITO CONTR, V18, P284; Shinn A. P., 2011, GYRODB; Shinn A. P., 2011, MONODB WEB HOST MONO; Shinn AP, 2004, FOLIA PARASIT, V51, P239, DOI 10.14411/fp.2004.029; TAMURA K, 1993, MOL BIOL EVOL, V10, P512; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Triantafyllidis A, 2007, MAR BIOL, V152, P1159, DOI 10.1007/s00227-007-0760-7; TURNBULL ELEANOR RAE, 1956, CANADIAN JOUR ZOOL, V34, P583, DOI 10.1139/z56-061; WILLIAMS EH, 1971, J PARASITOL, V57, P845, DOI 10.2307/3277811; Wong BBM, 2005, BEHAV ECOL, V16, P818, DOI 10.1093/beheco/ari058; Zietara MS, 2002, EVOLUTION, V56, P2445, DOI 10.1111/j.0014-3820.2002.tb00170.x; Zietara MS, 2002, PARASITOLOGY, V124, P39, DOI 10.1017/S0031182001008939; 2009, VET PARASITOL, V165, P290	59	20	20	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	JUN 9	2011	4								100	10.1186/1756-3305-4-100				12	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	792ET	WOS:000292724000001	21658217	DOAJ Gold, Green Published			2019-03-26	
J	Ramos, PL; Moreira, CA; Van Trappen, S; Swings, J; De Vos, P; Barbosa, HR; Thompson, CC; Vasconcelos, ATR; Thompson, FL				Ramos, Patricia Locosque; Moreira-Filho, Carlos Alberto; Van Trappen, Stefanie; Swings, Jean; De Vos, Paul; Barbosa, Heloiza Ramos; Thompson, Cristiane Carneiro; Ribeiro Vasconcelos, Ana Tereza; Thompson, Fabiano Lopes			An MLSA-based online scheme for the rapid identification of Stenotrophomonas isolates	MEMORIAS DO INSTITUTO OSWALDO CRUZ			English	Article						Stenotrophomonas; MLSA; online scheme	MULTILOCUS SEQUENCE-ANALYSIS; SP-NOV.; GENUS STENOTROPHOMONAS; MALTOPHILIA INFECTIONS; DRUG-RESISTANCE; BACTERIA; PHYLOGENY; PATHOGEN; STRAINS; PLANT	An online scheme to assign Stenotrophomonas isolates to genomic groups was developed using the multilocus sequence analysis (MLSA), which is based on the DNA sequencing of selected fragments of the housekeeping genes ATP synthase alpha subunit (atpA), the recombination repair protein (recA), the RNA polymerase alpha subunit (rpoA) and the excision repair beta subunit (uvrB). This MLSA-based scheme was validated using eight of the 10 Stenotrophomonas species that have been previously described. The environmental and nosocomial Stenotrophomonas strains were characterised using MLSA, 16S rRNA sequencing and DNA-DNA hybridisation (DDH) analyses. Strains of the same species were found to have greater than 95% concatenated sequence similarity and specific strains formed cohesive readily recognisable phylogenetic groups. Therefore, MLSA appeared to be an effective alternative methodology to amplified fragment length polymorphism fingerprint and DDH techniques. Strains of Stenotrophomonas can be readily assigned through the open database resource that was developed in the current study (www.steno.lncc.br/).	[Ramos, Patricia Locosque; Moreira-Filho, Carlos Alberto] Univ Sao Paulo, Fac Med, Dept Pediat, BR-01246903 Sao Paulo, Brazil; [Ramos, Patricia Locosque; Moreira-Filho, Carlos Alberto] Univ Sao Paulo, Ctr Pesquisas Biotecnol, Sao Paulo, Brazil; [Barbosa, Heloiza Ramos] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508 Sao Paulo, Brazil; [Van Trappen, Stefanie; Swings, Jean; De Vos, Paul] Univ Ghent, Microbiol Lab, B-9000 Ghent, Belgium; [Thompson, Cristiane Carneiro; Thompson, Fabiano Lopes] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, Brazil; [Ribeiro Vasconcelos, Ana Tereza] Lab Nacl Comp Cient, Dept Matemat Aplicada & Computac, Petropolis, RJ, Brazil	Ramos, PL (reprint author), Univ Sao Paulo, Fac Med, Dept Pediat, Av Dr Eneas Carvalho Aguiar 647, BR-01246903 Sao Paulo, Brazil.	locosque@usp.br	Thompson, Cristiane/I-5783-2016; De Vos, Paul/J-5392-2013; FAPESP, BIOEN/H-6149-2012	Locosque Ramos, Patricia/0000-0003-2726-4949; Vasconcelos, Ana Tereza/0000-0002-4632-2086	CNPq [300996/2006-7]; FAPESP [2004/00814-9]; IFS	Financial support: CNPq (300996/2006-7), FAPESP (2004/00814-9), CNPq and IFS (to FLT), FAPESP (Biota Program) (to CAMF)	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Araoka H, 2010, EUR J CLIN MICROBIOL, V29, P605, DOI 10.1007/s10096-010-0882-6; Assih EA, 2002, INT J SYST EVOL MICR, V52, P559, DOI 10.1099/ijs.0.01869-0; Bishop CJ, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-3; Brady C, 2008, SYST APPL MICROBIOL, V31, P447, DOI 10.1016/j.syapm.2008.09.004; Coenye T, 2004, INT J SYST EVOL MICR, V54, P1235, DOI 10.1099/ijs.0.63093-0; Coenye T, 2004, FEMS IMMUNOL MED MIC, V40, P181, DOI 10.1016/S0928-8244(03)00307-9; Crossman LC, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-4-r74; Drancourt M, 1997, INT J SYST BACTERIOL, V47, P160, DOI 10.1099/00207713-47-1-160; EZAKI B, 1989, MOL GEN GENET, V218, P183, DOI 10.1007/BF00331267; Falagas ME, 2008, J ANTIMICROB CHEMOTH, V62, P889, DOI 10.1093/jac/dkn301; Finkmann W, 2000, INT J SYST EVOL MICR, V50, P273, DOI 10.1099/00207713-50-1-273; Hanage WP, 2006, PHILOS T R SOC B, V361, P1917, DOI 10.1098/rstb.2006.1917; Hauben L, 1999, INT J SYST BACTERIOL, V49, P1749, DOI 10.1099/00207713-49-4-1749; Heylen K, 2007, INT J SYST EVOL MICR, V57, P2056, DOI 10.1099/ijs.0.65044-0; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Jolley KA, 2001, BIOINFORMATICS, V17, P1230, DOI 10.1093/bioinformatics/17.12.1230; Juhasz AL, 2000, J APPL MICROBIOL, V89, P642, DOI 10.1046/j.1365-2672.2000.01161.x; Kaparullina E, 2009, SYST APPL MICROBIOL, V32, P157, DOI 10.1016/j.syapm.2008.12.003; Kim HB, 2010, INT J SYST EVOL MICR, V60, P1522, DOI 10.1099/ijs.0.014662-0; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Minkwitz A, 2001, J CLIN MICROBIOL, V39, P139, DOI 10.1128/JCM.39.1.139-145.2001; Naser SM, 2005, MICROBIOL-SGM, V151, P2141, DOI 10.1099/mic.0.27840-0; Nicodemo AC, 2007, EUR J CLIN MICROBIOL, V26, P229, DOI 10.1007/s10096-007-0279-3; Nyc O, 2010, FOLIA MICROBIOL, V55, P286, DOI 10.1007/s12223-010-0043-4; PALLERONI NJ, 1993, INT J SYST BACTERIOL, V43, P606, DOI 10.1099/00207713-43-3-606; Ramos PL, 2011, INT J SYST EVOL MICR, V61, P926, DOI 10.1099/ijs.0.019372-0; Ryan RP, 2009, NAT REV MICROBIOL, V7, P514, DOI 10.1038/nrmicro2163; SAITOU N, 1987, MOL BIOL EVOL, V4, P406; Sanchez MB, 2009, FUTURE MICROBIOL, V4, P655, DOI [10.2217/fmb.09.45, 10.2217/FMB.09.45]; Thompson FL, 2005, APPL ENVIRON MICROB, V71, P5107, DOI 10.1128/AEM.71.9.5107-5115.2005; Turner KME, 2007, INT J ANTIMICROB AG, V29, P129, DOI 10.1016/j.ijantimicag.2006.11.002; Vega FE, 2005, J BASIC MICROB, V45, P371, DOI 10.1002/jobm.200410551; WAYNE LG, 1987, INT J SYST BACTERIOL, V37, P463, DOI 10.1099/00207713-37-4-463; Willems A, 2001, INT J SYST EVOL MICR, V51, P1315, DOI 10.1099/00207713-51-4-1315; Wolf A, 2002, INT J SYST EVOL MICR, V52, P1937, DOI 10.1099/ijs.0.02135-0; Yang HC, 2006, INT J SYST EVOL MICR, V56, P81, DOI 10.1099/ijs.0.63826-0	37	7	7	0	6	FUNDACO OSWALDO CRUZ	RIO DE JANEIRO, RJ	AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL	0074-0276			MEM I OSWALDO CRUZ	Mem. Inst. Oswaldo Cruz	JUN	2011	106	4					394	399		10.1590/S0074-02762011000400003				6	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	787UN	WOS:000292402300003	21739025	DOAJ Gold			2019-03-26	
J	Zachariah, R; Mwagomba, B; Misinde, D; Mandere, BC; Bemeyani, A; Ginindza, T; Cortier, H; Bissel, K; Jahn, A; Harries, AD				Zachariah, R.; Mwagomba, B.; Misinde, D.; Mandere, B. C.; Bemeyani, A.; Ginindza, T.; Cortier, H.; Bissel, K.; Jahn, A.; Harries, A. D.			Vital registration in rural Africa: is there a way forward to report on health targets of the Millennium Development Goals?	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Review						Vital registration; Millennium Development Goals; Deaths; Village; Malawi	VERBAL AUTOPSY; GLOBAL HEALTH; SOUTH-AFRICA; MORTALITY; DEATH; COUNTS; IMPACT; NEEDS	Vital registration - the systematic recording of births and deaths - has both legal and health significance. In particular, accurate recording and reporting of vital statistics are public goods to enable the monitoring of progress towards achieving health related targets of the 2015 United Nations Millennium Development Goals (MDG). The reality in Africa is that most births and deaths cannot be traced in legal records or official statistics and as such, there is currently no way of assessing progress towards achieving MDG targets and this applies particularly to rural settings in Africa. From the context of a rural district in Malawi, we describe an informal traditional system for the reporting of deaths at village level, and discuss the potential opportunities, challenges and ways forward in the wider implementation and interpretation of vital data generated by such a system. Such a system might provide an interim solution for accelerating the production and use of district level vital statistics for legal, administrative, statistical purposes and to report on the MDG in rural Africa while waiting for more comprehensive national systems to become a reality. (C) 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Zachariah, R.] Brussels Operat Ctr, Med Dept Operat Res, L-1617 Luxembourg, Luxembourg; [Mwagomba, B.] Minist Hlth & Populat, Thyolo Dist Hlth Serv, Thyolo, Malawi; [Misinde, D.; Ginindza, T.] Med Sans Frontieres, Thyolo, Malawi; [Cortier, H.] Brussels Operat Ctr, Maternal & Child Hlth Serv, Brussels, Belgium; [Bissel, K.; Harries, A. D.] Int Union TB & Lung Dis, Paris, France; [Jahn, A.] Int Training & Educ Ctr, Seattle, WA USA; [Harries, A. D.] London Sch Hyg & Trop Med, London WC1, England	Zachariah, R (reprint author), Brussels Operat Ctr, Med Dept Operat Res, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu					AbouZahr C, 2010, LANCET, V375, P619, DOI 10.1016/S0140-6736(09)60004-0; Baiden F, 2007, B WORLD HEALTH ORGAN, V85, P570, DOI 10.2471/BLT.07.043745; CHET N, 2005, HLTH POLICY PLAN, V20, P375; CHINNOCK P, MALARIA DIAGNOSIS TR; Diaz T, 2005, AIDS, V19, pS31, DOI 10.1097/01.aids.0000172875.67262.21; G8 Health Experts Group, 2008, TOY FRAM ACT GLOB HL; Hill K, 2007, LANCET, V370, P1726, DOI 10.1016/S0140-736(07)61309-9; Kahn K, 2000, TROP MED INT HEALTH, V5, P824, DOI 10.1046/j.1365-3156.2000.00638.x; KING MB, 1989, BRIT MED J, V298, P734, DOI 10.1136/bmj.298.6675.734; Lee JW, 2003, LANCET, V362, P2083, DOI 10.1016/S0140-6736(03)15107-0; Mathers CD, 2005, B WORLD HEALTH ORGAN, V83, P171; MDG Africa Steering Group, 2008, ACH MILL DEV GOALS A; Nannan N, 2007, J BIOSOC SCI, V39, P613, DOI 10.1017/S0021932006001702; *NSO, MAL 2004 DEM HLTH SU; Okonofua F, 2006, J OBSTET GYNAECOL CA, V28, P974, DOI 10.1016/S1701-2163(16)32307-6; Philips M, 2008, LANCET, V371, P682, DOI 10.1016/S0140-6736(08)60307-4; RUZICKA L T, 1990, World Health Statistics Quarterly, V43, P249; Setel PW, 2007, LANCET, V370, P1569, DOI 10.1016/S040-6736(07)61307-5; Setel PW, 2005, B WORLD HEALTH ORGAN, V83, P611; Stover J, 2008, SEX TRANSM INFECT, V84, pI24, DOI 10.1136/sti.2008.029868; Takemi K, 2008, LANCET, V372, P13, DOI 10.1016/S0140-6736(08)60971-X; Todd J, 1997, AIDS, V11, P801, DOI 10.1097/00002030-199706000-00013; Todres Jonathan, 2003, HUM RTS BRIEF, V10, p[32, 32]; *UM, WHO WE WORK HLTH SUR; *UN, MILL DEV GOALS; United Nations, 1989, CONV RIGHTS CHILD; *WHO, 1992, CLASS INT CLASS DIS; CABLEG24949	28	8	8	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUN	2011	105	6					301	309		10.1016/j.trstmh.2011.03.002				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	780IS	WOS:000291848500001	21511318	Green Published			2019-03-26	
J	Thomson, KA; Cheti, EO; Reid, T				Thomson, Kerry A.; Cheti, Erastus O.; Reid, Tony			Implementation and outcomes of an active defaulter tracing system for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB patients in Kibera, Nairobi, Kenya	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Loss to follow-up; Defaulting; Retention; HIV/AIDS; ART; TB	ANTIRETROVIRAL THERAPY PROGRAMS; SUB-SAHARAN AFRICA; RESOURCE-LIMITED SETTINGS; FOLLOW-UP; SOUTH-AFRICA; INFECTED PATIENTS; PATIENTS LOST; DRUG-RESISTANCE; RURAL MALAWI; RETENTION	Retention of patients in long term care and adherence to treatment regimens are a constant challenge for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB programmes in sub-Saharan Africa. This study describes the implementation and outcomes of an active defaulter tracing system used to reduce loss to follow-up (LTFU) among HIV, PMTCT, TB, and HIV/TB co-infected patients receiving treatment at three Medecins Sans Frontieres clinics in the informal settlement of Kibera, Nairobi, Kenya. Patients are routinely contacted by a social worker via telephone, in-person visit, or both very soon after they miss an appointment. Patient outcomes identified through 1066 tracing activities conducted between 1 April 2008 and 31 March 2009 included: 59.4% returned to the clinic, 9.0% unable to return to clinic, 6.3% died, 4.7% refused to return to clinic, 4.5% went to a different clinic, and 0.8% were hospitalized. Fifteen percent of patients identified for tracing could not be contacted. LTFU among all HIV patients decreased from 21.2% in 2006 to 11.5% in 2009. An active defaulter tracing system is feasible in a resource poor setting, solicits feedback from patients, retains a mobile population of patients in care, and reduces LTFU among HIV, PMTCT, and TB patients. (C) 2011 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Thomson, Kerry A.; Cheti, Erastus O.] Med Sans Frontieres MSF Operat Ctr Brussels, Nairobi 00623, Kenya; [Reid, Tony] Med Sans Frontieres MSF Operat Ctr Brussels, B-1090 Brussels, Belgium	Thomson, KA (reprint author), 2343 Lowell Blvd, Denver, CO 80211 USA.	thomson.kerry@gmail.com			Europe Aid; Norwegian Agency for Development Cooperation (NORAD); Directorate-General for Development Cooperation (DGDC); Medecins Sans Frontieres [09_MSF_ERB_009]	The MSF-OCB Kibera Project is funded in part by Europe Aid, The Norwegian Agency for Development Cooperation (NORAD) and The Directorate-General for Development Cooperation (DGDC).	Assefa Y, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000056; Bennett DE, 2008, ANTIVIR THER, V13, P1; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Dalal RP, 2008, JAIDS-J ACQ IMM DEF, V47, P101; Deventer C. van, 2009, Southern African Journal of HIV Medicine, V10, P50; Ekouevi DK, 2010, TROP MED INT HEALTH, V15, P34, DOI 10.1111/j.1365-3156.2010.02505.x; Forster M, 2008, B WORLD HEALTH ORGAN, V86, P939, DOI 10.2471/BLT.07.049908; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Fraser HSF, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.4.e29; Geng EH, 2010, TROP MED INT HEALTH, V15, P63, DOI 10.1111/j.1365-3156.2010.02507.x; Ginsburg AS, 2007, AIDS, V21, P2529, DOI 10.1097/QAD.0b013e3282f155f4; Harries AD, 2010, TROP MED INT HEALTH, V15, P70, DOI 10.1111/j.1365-3156.2010.02506.x; Hedt BL, 2008, ANTIVIR THER, V13, P69; Jones SA, 2005, AIDS CARE, V17, P466, DOI 10.1080/09540120412331319723; Kizito KW, 2011, T ROY SOC TROP MED H, V105, P52, DOI 10.1016/j.trstmh.2010.08.015; Kruyt ML, 1999, B WORLD HEALTH ORGAN, V77, P386; MacPherson P, 2009, T ROY SOC TROP MED H, V103, P588, DOI 10.1016/j.trstmh.2008.10.001; Manzi M, 2005, TROP MED INT HEALTH, V10, P1242, DOI 10.1111/j.1365-3156.2005.01526.x; McGuire M, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02504.x; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Myer L, 2004, SAMJ S AFR MED J, V94, P273; Painter TM, 2004, BMJ-BRIT MED J, V329, P543, DOI 10.1136/bmj.329.7465.543; Reid Tony, 2008, Confl Health, V2, P15, DOI 10.1186/1752-1505-2-15; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Rosen S, 2010, TROP MED INT HEALTH, V15, P98, DOI 10.1111/j.1365-3156.2010.02512.x; Tweya H, 2010, TROP MED INT HEALTH, V15, P82, DOI 10.1111/j.1365-3156.2010.02509.x; Unge C, 2009, JAIDS-J ACQ IMM DEF, V50, P397, DOI 10.1097/QAI.0b013e318194618e; *WHO, 2006, ANT DRUGS TREAT PREG; Yiannoutsos CT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003843; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739; ZACARIAH R, 2005, T R SOC TROP MED HYG, V101, P79	32	28	28	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JUN	2011	105	6					320	326		10.1016/j.trstmh.2011.02.011				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	780IS	WOS:000291848500004	21511317	Green Published			2019-03-26	
J	Gelanew, T; Hurissa, Z; Diro, E; Kassahun, A; Kuhls, K; Schonian, G; Hailu, A				Gelanew, Tesfaye; Hurissa, Zewdu; Diro, Ermias; Kassahun, Aysheshm; Kuhls, Katrin; Schoenian, Gabriele; Hailu, Asrat			Case Report: Disseminated Cutaneous Leishmaniasis Resembling Post-Kala-Azar Dermal Leishmaniasis Caused by Leishmania donovani in Three Patients Co-Infected with Visceral Leishmaniasis and Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in Ethiopia	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; RECONSTITUTION INFLAMMATORY SYNDROME; HIV-INFECTION; SODIUM STIBOGLUCONATE; AIDS PATIENT; INFANTUM; LESIONS; VIRUS; STRAINS; FEATURES	We report paired strains of Leishmania parasites, one from the viscera and the other from skin lesions that were isolated from three patients with visceral leishmaniasis and disseminated cutaneous leishmaniasis that were co-infected with human immunodeficiency virus. The causative parasites were characterized by polymerase chain reaction restriction length polymorphism of the ribosomal DNA internal transcribed spacer 1 and by a panel of multilocus microsatellite markers. We demonstrated that the causative agent was Leishmania donovani in all cases, irrespective of the phenotype of the disease. The paired strains from viscera and skin lesions of the same patients showed genetic identity across the 14 microsatellite markers investigated. These findings demonstrate that the skin lesions in these human immunodeficiency virus positive patients with visceral leishmaniasis were caused by dissemination of viscerotropic L. donovani parasites as a consequence of severe immunosuppression. However, in all three patients, rapid clearance of the skin lesions was observed after antimonial therapy.	[Gelanew, Tesfaye; Kuhls, Katrin; Schoenian, Gabriele] Charite, Inst Mikrobiol & Hyg, D-10117 Berlin, Germany; [Gelanew, Tesfaye; Kassahun, Aysheshm; Hailu, Asrat] Univ Addis Ababa, Fac Med, Addis Ababa, Ethiopia; [Hurissa, Zewdu; Diro, Ermias] Univ Gondar, Coll Med & Hlth Sci, Gondar, Ethiopia; [Diro, Ermias] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium	Gelanew, T (reprint author), Charite, Inst Mikrobiol & Hyg, Dorotheenstr 96, D-10117 Berlin, Germany.	tesfayegela2002@yahoo.com			Prince Leopold Instutue of Tropical Medicine; Belgian Development Cooperation	Tesfaye Gelanew is a recipient of PhD fellowship from the German Academic Exchange Service. Ermias Diro is a recipient of a PhD scholarship in the Individual PhD Scholarship Programme of the Prince Leopold Instutue of Tropical Medicine, which is supported by the Belgian Development Cooperation.	Agostoni C, 1998, INFECTION, V26, P93, DOI 10.1007/BF02767767; Alam MZ, 2009, INFECT GENET EVOL, V9, P24, DOI 10.1016/j.meegid.2008.09.005; ALJASER M, 1995, ANTIMICROB AGENTS CH, V39, P516, DOI 10.1128/AAC.39.2.516; Alvar J, 1996, CLIN DERMATOL, V14, P541, DOI 10.1016/0738-081X(96)00046-6; Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07; Antinori S, 2007, BRIT J DERMATOL, V157, P1032, DOI 10.1111/j.1365-2133.2007.08157.x; Ara M, 1998, BRIT J DERMATOL, V139, P114; Barro-Traore F, 2008, ANN DERMATOL VENER, V135, P380, DOI 10.1016/j.annder.2007.10.005; Bittencourt Achiléa, 2002, Braz J Infect Dis, V6, P313, DOI 10.1590/S1413-86702002000600008; Blackwell JM, 2004, TRENDS PARASITOL, V20, P268, DOI 10.1016/j.pt.2004.04.003; Bosch RJ, 2002, INT J DERMATOL, V41, P670, DOI 10.1046/j.1365-4362.2002.01610.x; Boumis E, 2006, INT J STD AIDS, V17, P351, DOI 10.1258/095646206776790132; Chaudhary RG, 2008, INDIAN J DERMATOL VE, V74, P641, DOI 10.4103/0378-6323.45111; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; Colebunders R, 1999, J AM ACAD DERMATOL, V41, P847, DOI 10.1016/S0190-9622(99)70342-7; Couppie P, 2004, BRIT J DERMATOL, V151, P1165, DOI 10.1111/j.1365-2133.2004.06226.x; Dieringer D, 2003, MOL ECOL NOTES, V3, P167, DOI 10.1046/j.1471-8286.2003.00351.x; El Tai NO, 2001, EXP PARASITOL, V97, P35, DOI 10.1006/expr.2001.4592; ELHASSAN AM, 1992, T ROY SOC TROP MED H, V86, P245, DOI 10.1016/0035-9203(92)90294-M; Gasim S, 2000, CLIN EXP IMMUNOL, V119, P523, DOI 10.1046/j.1365-2249.2000.01163.x; Gelanew T, 2010, BRIT J DERMATOL, V163, P870, DOI 10.1111/j.1365-2133.2010.09768.x; Gelanew T, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000889; Gonzalez-Beato MJ, 2000, BRIT J DERMATOL, V143, P1316, DOI 10.1046/j.1365-2133.2000.03909.x; Haile T, 2006, East Afr Med J, V83, P389; Hurissa Z, 2010, TROP MED INT HEALTH, V15, P848, DOI 10.1111/j.1365-3156.2010.02550.x; Ismail A, 1999, J PATHOL, V189, P615, DOI 10.1002/(SICI)1096-9896(199912)189:4<615::AID-PATH466>3.0.CO;2-Z; Jafari S, 2010, MEDITERRANEAN HLTH J, V16, P3041; Kallel K, 2008, ACTA TROP, V106, P132, DOI 10.1016/j.actatropica.2008.02.006; Kuhls K, 2007, MICROBES INFECT, V9, P334, DOI 10.1016/j.micinf.2006.12.009; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Lawn SD, 2006, PARASITE IMMUNOL, V28, P625, DOI 10.1111/j.1365-3024.2006.00900.x; Lewin S, 2002, INT J PARASITOL, V32, P1267, DOI 10.1016/S0020-7519(02)00091-7; Lyons S, 2003, TROP MED INT HEALTH, V8, P733, DOI 10.1046/j.1365-3156.2003.01088.x; Mandi M, 2005, INFECT GENET EVOL, V5, P29; Mengistu G, 2007, ETHIOP J HEALTH DEV, V21, P53; Mohamed HS, 2003, GENES IMMUN, V4, P351, DOI 10.1038/sj.gene.6363977; Postigo C, 1997, J INFECTION, V35, P265, DOI 10.1016/S0163-4453(97)93080-2; Pratlong F, 2004, J CLIN MICROBIOL, V42, P4077, DOI 10.1128/JCM.42.9.4077-4082.2004; Ridolfo AL, 2000, J INFECTION, V40, P199, DOI 10.1053/jinf.1999.0630; Rihl Markus, 2006, J Infect, V53, pe25, DOI 10.1016/j.jinf.2005.09.015; Ritmeijer K, 2001, T ROY SOC TROP MED H, V95, P668, DOI 10.1016/S0035-9203(01)90110-5; Schonian G, 1996, MOL BIOCHEM PARASIT, V77, P19, DOI 10.1016/0166-6851(96)02572-8; Schonian G, 2003, DIAGN MICR INFEC DIS, V47, P349, DOI 10.1016/S0732-8893(03)00093-2; Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306; Shelburne SA, 2005, AIDS, V19, P399, DOI 10.1097/01.aids.0000161769.06158.8a; Stark D, 2006, J CLIN MICROBIOL, V44, P1178, DOI 10.1128/JCM.44.3.1178-1180.2006; ter Horst R, 2008, CLIN INFECT DIS, V46, P1702, DOI 10.1086/587899; Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6	49	14	14	1	4	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUN	2011	84	6					906	912		10.4269/ajtmh.2011.11-0055				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	773TI	WOS:000291333200013	21633027	Green Published, Bronze			2019-03-26	
J	Muvunyi, CM; Masaisa, F; Bayingana, C; Mutesa, L; Musemakweri, A; Muhirwa, G; Claeys, G				Muvunyi, Claude Mambo; Masaisa, Florence; Bayingana, Claude; Mutesa, Leon; Musemakweri, Andre; Muhirwa, Gregoire; Claeys, Geert (W.)			Decreased Susceptibility to Commonly Used Antimicrobial Agents in Bacterial Pathogens Isolated from Urinary Tract Infections in Rwanda: Need for New Antimicrobial Guidelines	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							SPECTRUM BETA-LACTAMASES; ESCHERICHIA-COLI STRAINS; ANTIBIOTIC-RESISTANCE; KLEBSIELLA-PNEUMONIAE; RISK-FACTORS; ECO.SENS PROJECT; PREVALENCE; CYSTITIS; ENTEROBACTERIACEAE; EPIDEMIOLOGY	The aim of this study was to obtain data on susceptibility patterns of pathogens responsible for both community and hospital urinary tract infections (UTIs); and analyzed risk factors for infection caused by ciprofloxacin-resistant Escherichia coli and extended-spectrum beta-lactamace (ESBL)-producing strains in Rwanda. Of 1,012 urine cultures prospectively studied, a total of 196 (19.3%) yielded significant growth of a single organism. The most common isolate (60.7%) was Escherichia coli. The antibiotics commonly used in UTIs are less effective except Fosfomycin-trometamol and imipinem. The use of ciprofloxacin in the previous 6 months (odds ratio [OR] = 7.59 [1.75-32.74]), use of other antibiotics in the previous 6 months (OR = 1.02 [1.02-2.34]), and production of ESBL (OR = 19.32 [2.62-142.16]) were found to be associated with ciprofloxacin resistance among the E. coli isolates. Risk factors for ESBL positivity were the use of ciprofloxacin and third-generation cephalosporin in the preceding 6 months (OR = 3.05 [1.42-6.58] and OR = 9.78 [2.71-35.25], respectively); and being an inpatient (OR = 2.27 [1.79-2.89]). Fosfomycin-trometamol could be included as a reasonable alternative for the therapy of uncomplicated UTI in Rwanda.	[Muvunyi, Claude Mambo; Masaisa, Florence; Bayingana, Claude; Mutesa, Leon; Musemakweri, Andre; Muhirwa, Gregoire] NUR, Fac Med, Huye, Rwanda; [Claeys, Geert (W.)] Ghent Univ Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium; Natl Univ Rwanda, Ctr Hosp Univ Butare, Dept Biol Clin, Butare, Rwanda; Natl Univ Rwanda, Ctr Hosp Univ Butare, Dept Internal Med, Butare, Rwanda	Muvunyi, CM (reprint author), NUR, Fac Med, POB 217, Huye, Rwanda.	cmuvunyi@nur.ac.rw; kabasius@yahoo.fr; cbayingana@nur.ac.rw; lmutesa@nur.ac.rw; amusemakweri@nur.ac.rw; gmuhirwa@nur.ac.rw; geert.claeys@ugent.be			Ghent University, Ghent, Belgium [VLIR-UOS ZEIN2007PR342-19878]	This study was financially supported by a PhD grant from the Ghent University, Ghent, Belgium through its VLIR (Flemish Interuniversity Council) own initiative project number VLIR-UOS ZEIN2007PR342-19878.	Aboderin OA, 2009, J NATL MED ASSOC, V101, P1268, DOI 10.1016/S0027-9684(15)31138-X; Akram Mohammed, 2007, Ann Clin Microbiol Antimicrob, V6, P4, DOI 10.1186/1476-0711-6-4; Alos JI, 2005, CLIN MICROBIOL INFEC, V11, P199, DOI 10.1111/j.1469-0691.2004.01057.x; Andrade SS, 2006, MEM I OSWALDO CRUZ, V101, P741, DOI 10.1590/S0074-02762006000700006; Arslan H, 2005, J ANTIMICROB CHEMOTH, V56, P914, DOI 10.1093/jac/dki344; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; *CLIN LAB STAND I, 2008, 100S18 CLIN LAB STAN; Dromigny JA, 2005, J ANTIMICROB CHEMOTH, V56, P236, DOI 10.1093/jac/dki158; Echols RM, 1999, CLIN INFECT DIS, V29, P113, DOI 10.1086/520138; Edelstein M, 2003, ANTIMICROB AGENTS CH, V47, P3724, DOI 10.1128/AAC.47.12.3724-3732.2003; Gangoue-Pieboji J, 2005, J CLIN MICROBIOL, V43, P3273, DOI 10.1128/JCM.43.7.3273-3277.2005; Goettsch W, 2000, J ANTIMICROB CHEMOTH, V46, P223, DOI 10.1093/jac/46.2.223; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; Hooton Thomas M, 2003, Int J Antimicrob Agents, V22 Suppl 2, P65, DOI 10.1016/S0924-8579(03)00238-3; Howard AJ, 2001, J ANTIMICROB CHEMOTH, V47, P305, DOI 10.1093/jac/47.3.305; Hryniewicz K, 2001, J ANTIMICROB CHEMOTH, V47, P773, DOI 10.1093/jac/47.6.773; Jacoby GA, 2005, NEW ENGL J MED, V352, P380, DOI 10.1056/NEJMra041359; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V52, P128, DOI 10.1093/jac/dkg280; Kahlmeter G, 2003, J ANTIMICROB CHEMOTH, V51, P69, DOI 10.1093/jac/dkg028; Karlowsky JA, 2002, ANTIMICROB AGENTS CH, V46, P2540, DOI 10.1128/AAC.46.8.2540-2545.2002; Lobel B, 2003, Int J Antimicrob Agents, V22 Suppl 2, P85, DOI 10.1016/S0924-8579(03)00237-1; Mulvey MR, 2004, ANTIMICROB AGENTS CH, V48, P1204, DOI 10.1128/AAC.48.4.1204-1214.2004; Nicoletti J, 2010, SWISS MED WKLY, V140, DOI 10.4414/smw.2010.13059; Nijssen S, 2004, INT J ANTIMICROB AG, V24, P585, DOI 10.1016/j.ijantimicag.2004.08.008; Paterson DL, 2005, CLIN MICROBIOL REV, V18, P657, DOI 10.1128/CMR.18.4.657-686.2005; Raka L, 2004, INT J ANTIMICROB AG, V23, pS2, DOI 10.1016/j.ijantimicag.2003.09.009; Randrianirina F, 2007, J ANTIMICROB CHEMOTH, V59, P309, DOI 10.1093/jac/dkl466; Reinert RR, 2007, J ANTIMICROB CHEMOTH, V60, P1018, DOI 10.1093/jac/dkm310; Ryoo NH, 2005, J ANTIMICROB CHEMOTH, V56, P698, DOI 10.1093/jac/dki324; Schaeffer AJ, 2001, INT J ANTIMICROB AG, V17, P245, DOI 10.1016/S0924-8579(01)00302-8; Schito G C, 2003, Int J Antimicrob Agents, V22 Suppl 2, P79, DOI 10.1016/S0924-8579(03)00231-0; Sire JM, 2007, J INFECT DEV COUNTR, V1, P263, DOI 10.3855/jidc.362; Skippen I, 2006, J HOSP INFECT, V64, P115, DOI 10.1016/j.jhin.2006.05.010; Smaoui Hanene, 2003, Tunis Med, V81, P390; Smith RD, 2002, B WORLD HEALTH ORGAN, V80, P126; Ullah F, 2009, BURNS, V35, P1020, DOI 10.1016/j.burns.2009.01.005; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; Yilmaz E, 2008, J CHEMOTHERAPY, V20, P581, DOI 10.1179/joc.2008.20.5.581; Zhanel GG, 2006, INT J ANTIMICROB AG, V27, P468, DOI 10.1016/j.ijantimicag.2006.02.009	40	32	35	1	7	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	JUN	2011	84	6					923	928		10.4269/ajtmh.2011.11-0057				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	773TI	WOS:000291333200015	21633029	Bronze, Green Published			2019-03-26	
J	Cencig, S; Coltel, N; Truyens, C; Carlier, Y				Cencig, Sabrina; Coltel, Nicolas; Truyens, Carine; Carlier, Yves			Parasitic Loads in Tissues of Mice Infected with Trypanosoma cruzi and Treated with AmBisome	PLOS NEGLECTED TROPICAL DISEASES			English	Article							LIPOSOMAL AMPHOTERICIN-B; CHRONIC CHAGAS-DISEASE; SERUM AMYLOID-P; VISCERAL LEISHMANIASIS; LIPID FORMULATIONS; IN-VIVO; BENZNIDAZOLE; DIAGNOSIS; TRYPOMASTIGOTES; CHEMOTHERAPY	Background: Chagas disease is one of the most important public health problems and a leading cause of cardiac failure in Latin America. The currently available drugs to treat T. cruzi infection (benznidazole and nifurtimox) are effective in humans when administered during months. AmBisome (liposomal amphotericin B), already shown efficient after administration for some days in human and experimental infection with Leishmania, has been scarcely studied in T. cruzi infection. Aims: This work investigates the effect of AmBisome treatment, administered in 6 intraperitoneal injections at various times during acute and/or chronic phases of mouse T. cruzi infection, comparing survival rates and parasitic loads in several tissues. Methodology: Quantitative PCR was used to determine parasitic DNA amounts in tissues. Immunosuppressive treatment with cyclophosphamide was used to investigate residual infection in tissues. Findings: Administration of AmBisome during the acute phase of infection prevented mice from fatal issue. Parasitaemias (microscopic examination) were reduced in acute phase and undetectable in chronic infection. Quantitative PCR analyses showed significant parasite load reductions in heart, liver, spleen, skeletal muscle and adipose tissues in acute as well as in chronic infection. An earlier administration of AmBisome (one day after parasite inoculation) had a better effect in reducing parasite loads in spleen and liver, whereas repetition of treatment in chronic phase enhanced the parasite load reduction in heart and liver. However, whatever the treatment schedule, cyclophosphamide injections boosted infection to parasite amounts comparable to those observed in acutely infected and untreated mice. Conclusions: Though AmBisome treatment fails to completely cure mice from T. cruzi infection, it impedes mortality and reduces significantly the parasitic loads in most tissues. Such a beneficial effect, obtained by administrating it over a short time, should stimulate studies on using AmBisome in association with other drugs in order to shorten recovery from T. cruzi infection.	[Cencig, Sabrina; Coltel, Nicolas; Truyens, Carine; Carlier, Yves] Univ Libre Bruxelles, Parasitol Lab, Fac Med, Brussels, Belgium	Cencig, S (reprint author), Univ Libre Bruxelles, Parasitol Lab, Fac Med, Brussels, Belgium.	ycarlier@ulb.ac.be			European Community [223034]	This study was supported by the European Community's Seventh Framework Programme [FP7] under grant agreement No. 223034 (fellowship and disposal), the "Fonds Emile Defay 2007" (disposal, ULB) and the "Fondation Van Buuren 2007" (equipment, ULB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABITBOL H., 1960, REV SOC ARGENTINA BIOL, V36, P41; ANDRADE SG, 1985, B WORLD HEALTH ORGAN, V63, P721; Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530; Bern C, 2009, CLIN INFECT DIS, V49, pE52, DOI 10.1086/605091; Bickerstaff MCM, 1999, NAT MED, V5, P694; BRAJTBURG J, 1990, ANTIMICROB AGENTS CH, V34, P381, DOI 10.1128/AAC.34.3.381; Buekens P, 2008, MATERN CHILD HLTH J, V12, P283, DOI 10.1007/s10995-007-0246-8; Bustamante JM, 2008, NAT MED, V14, P542, DOI 10.1038/nm1744; CARLIER Y, 1987, AM J TROP MED HYG, V37, P534, DOI 10.4269/ajtmh.1987.37.534; CARLIER Y, 1987, INFECT IMMUN, V55, P2496; CARLIER Y, 2002, TRYPANOSOMIASE AM MA, P1; Carlier Y, 2010, ELSEV INSIGHT, P539, DOI 10.1016/B978-0-12-384876-5.00022-8; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Chen SCA, 2007, MED J AUSTRALIA, V187, P404; Combs TP, 2005, J BIOL CHEM, V280, P24085, DOI 10.1074/jbc.M412802200; Coura JR, 2010, NATURE, V465, pS6, DOI 10.1038/nature09221; Croft SL, 2005, TRENDS PARASITOL, V21, P508, DOI 10.1016/j.pt.2005.08.026; CROFT SL, 1988, TROP MED PARASITOL, V39, P145; Cruz I, 2006, J CLIN MICROBIOL, V44, P2343, DOI 10.1128/JCM.02297-05; Cummings KL, 2003, MOL BIOCHEM PARASIT, V129, P53, DOI 10.1016/S0166-6851(03)00093-8; DECASTRO SL, 1993, BRAZ J MED BIOL RES, V26, P1219; GASCON J, 2009, ACTA TROP; HAIDO RMT, 1989, CHEM-BIOL INTERACT, V71, P91, DOI 10.1016/0009-2797(89)90092-6; HAIDO RMT, 1992, J PROTOZOOL, V39, P609, DOI 10.1111/j.1550-7408.1992.tb04859.x; Hiemenz JW, 1996, CLIN INFECT DIS, V22, pS133, DOI 10.1093/clinids/22.Supplement_2.S133; HORVATH AE, 1974, J TROP MED HYG, V77, P144; HUNT RC, 1974, BIOCHIM BIOPHYS ACTA, V339, P173, DOI 10.1016/0005-2736(74)90316-2; HUTCHINSON WL, 1994, J CLIN INVEST, V94, P1390, DOI 10.1172/JCI117474; JANKNEGT R, 1992, CLIN PHARMACOKINET, V23, P279, DOI 10.2165/00003088-199223040-00004; Kiserud T, 2005, SEMIN FETAL NEONAT M, V10, P493, DOI 10.1016/j.siny.2005.08.007; Lescure FX, 2008, EMERG INFECT DIS, V14, P644, DOI 10.3201/eid1404.070489; Minodier P, 2005, ARCH PEDIATRIE, V12, P1102, DOI 10.1016/j.arcped.2005.01.009; Moen MD, 2009, DRUGS, V69, P361, DOI 10.2165/00003495-200969030-00010; Mondal S, 2010, EXPERT REV ANTI-INFE, V8, P919, DOI 10.1586/ERI.10.78; Ramos H, 1996, J MEMBRANE BIOL, V152, P65, DOI 10.1007/s002329900086; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; Ribeiro I, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000484; Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3; Rolon M, 2006, INT J ANTIMICROB AG, V28, P104, DOI 10.1016/j.ijantimicag.2006.02.025; Sardinha LR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000578; SCHARFSTEIN J, 1982, INFECT IMMUN, V35, P46; Sosa-Estani S, 2006, CURR OPIN INFECT DIS, V19, P583, DOI 10.1097/01.qco.0000247592.21295.a5; Takemoto K, 2006, MICROBIOL IMMUNOL, V50, P579, DOI 10.1111/j.1348-0421.2006.tb03832.x; TALIAFERRO WH, 1955, J INFECT DIS, V96, P199, DOI 10.1093/infdis/96.3.199; Urbina JA, 2010, ACTA TROP, V115, P55, DOI 10.1016/j.actatropica.2009.10.023; Urbina JA, 2009, MEM I OSWALDO CRUZ, V104, P311, DOI 10.1590/S0074-02762009000900041; Viotti R, 2006, ANN INTERN MED, V144, P724, DOI 10.7326/0003-4819-144-10-200605160-00006; Viotti R, 2009, EXPERT REV ANTI-INFE, V7, P157, DOI 10.1586/14787210.7.2.157; Virreira M, 2007, AM J TROP MED HYG, V77, P102, DOI 10.4269/ajtmh.2007.77.102; Virreira M, 2006, AM J TROP MED HYG, V75, P1082, DOI 10.4269/ajtmh.2006.75.1082; Yardley V, 1999, AM J TROP MED HYG, V61, P193, DOI 10.4269/ajtmh.1999.61.193; Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393; Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021	53	33	33	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUN	2011	5	6							e1216	10.1371/journal.pntd.0001216				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	784EZ	WOS:000292139600048	21738811	DOAJ Gold, Green Published			2019-03-26	
J	Levecke, B; Behnke, JM; Ajjampur, SSR; Albonico, M; Ame, SM; Charlier, J; Geiger, SM; Hoa, NTV; Ngassam, RIK; Kotze, AC; McCarthy, JS; Montresor, A; Periago, MV; Roy, S; Tchuente, LAT; Thach, DTC; Vercruysse, J				Levecke, Bruno; Behnke, Jerzy M.; Ajjampur, Sitara S. R.; Albonico, Marco; Ame, Shaali M.; Charlier, Johannes; Geiger, Stefan M.; Hoa, Nguyen T. V.; Ngassam, Romuald I. Kamwa; Kotze, Andrew C.; McCarthy, James S.; Montresor, Antonio; Periago, Maria V.; Roy, Sheela; Tchuente, Louis-Albert Tchuem; Thach, D. T. C.; Vercruysse, Jozef			A Comparison of the Sensitivity and Fecal Egg Counts of the McMaster Egg Counting and Kato-Katz Thick Smear Methods for Soil-Transmitted Helminths	PLOS NEGLECTED TROPICAL DISEASES			English	Article							MONITORING DRUG EFFICACY; ASCARIS-LUMBRICOIDES; TRICHURIS-TRICHIURA; SCHOOL-CHILDREN; PUBLIC-HEALTH; INFECTIONS; ALBENDAZOLE; FECES; RESISTANCE; NEMATODES	Background: The Kato-Katz thick smear (Kato-Katz) is the diagnostic method recommended for monitoring large-scale treatment programs implemented for the control of soil-transmitted helminths (STH) in public health, yet it is difficult to standardize. A promising alternative is the McMaster egg counting method (McMaster), commonly used in veterinary parasitology, but rarely so for the detection of STH in human stool. Methodology/Principal Findings: The Kato-Katz and McMaster methods were compared for the detection of STH in 1,543 subjects resident in five countries across Africa, Asia and South America. The consistency of the performance of both methods in different trials, the validity of the fixed multiplication factor employed in the Kato-Katz method and the accuracy of these methods for estimating 'true' drug efficacies were assessed. The Kato-Katz method detected significantly more Ascaris lumbricoides infections (88.1% vs. 75.6%, p < 0.001), whereas the difference in sensitivity between the two methods was nonsignificant for hookworm (78.3% vs. 72.4%) and Trichuris trichiura (82.6% vs. 80.3%). The sensitivity of the methods varied significantly across trials and magnitude of fecal egg counts (FEC). Quantitative comparison revealed a significant correlation (Rs > 0.32) in FEC between both methods, and indicated no significant difference in FEC, except for A. lumbricoides, where the Kato-Katz resulted in significantly higher FEC (14,197 eggs per gram of stool (EPG) vs. 5,982 EPG). For the Kato-Katz, the fixed multiplication factor resulted in significantly higher FEC than the multiplication factor adjusted for mass of feces examined for A. lumbricoides (16,538 EPG vs. 15,396 EPG) and T. trichiura (1,490 EPG vs. 1,363 EPG), but not for hookworm. The McMaster provided more accurate efficacy results (absolute difference to 'true' drug efficacy: 1.7% vs. 4.5%). Conclusions/Significance: The McMaster is an alternative method for monitoring large-scale treatment programs. It is a robust (accurate multiplication factor) and accurate (reliable efficacy results) method, which can be easily standardized.	[Levecke, Bruno; Charlier, Johannes; Vercruysse, Jozef] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Merelbeke, Belgium; [Behnke, Jerzy M.] Univ Nottingham, Sch Biol, Nottingham NG7 2RD, England; [Ajjampur, Sitara S. R.; Roy, Sheela] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore, Tamil Nadu, India; [Albonico, Marco; Ame, Shaali M.] Publ Hlth Lab, Pemba Isl, Zanzibar, Tanzania; [Geiger, Stefan M.; Periago, Maria V.] Fundacao Oswaldo Cruz, Inst Rene Rachou, Belo Horizonte, MG, Brazil; [Hoa, Nguyen T. V.; Thach, D. T. C.] Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam; [Ngassam, Romuald I. Kamwa; Tchuente, Louis-Albert Tchuem] Univ Yaounde 1, Ctr Schistosomiasis & Parasitol, Fac Sci, Yaounde, Cameroon; [Kotze, Andrew C.] Commonwealth Sci & Ind Res Org, Div Livestock Ind, Brisbane, Qld, Australia; [McCarthy, James S.] Univ Queensland, Queensland Inst Med Res, Herston, Qld, Australia; [Montresor, Antonio] WHO, Dept Neglected Trop Dis, CH-1211 Geneva, Switzerland	Levecke, B (reprint author), Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Merelbeke, Belgium.	Bruno.Levecke@UGent.be	Periago, Maria/H-1054-2013; Kotze, andrew/B-5995-2012; Geiger, Stefan/E-6748-2016	Periago, Maria Victoria/0000-0002-1470-5146; Charlier, Johannes/0000-0002-1332-1458; ALBONICO, Marco/0000-0002-7805-2391; Levecke, Bruno/0000-0001-8912-5595; Geiger, Stefan/0000-0002-9741-2727	WHO [2008/12964/0, P2-APW002]; Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) [G.0853.09]; agency for Innovation by Science and Technology of Flanders [OZM090697]	The study was funded in part by the WHO (www.who.int; Reference Number 2008/12964/0; Registration File Number P2-APW002). BL is funded by the Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) (www.fwo.be; Reference Number G.0853.09). The research of JC was supported by the agency for Innovation by Science and Technology of Flanders (www.IWT.be; IWT Vlaanderen, projectOZM090697). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albonico M, 2004, INT J PARASITOL, V34, P1205, DOI 10.1016/j.ijpara.2004.08.001; Albonico M, 1997, E AFR MED J, V74, P294; Albonico M, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000126; Albonico M, 2007, T ROY SOC TROP MED H, V101, P454, DOI 10.1016/j.trstmh.2006.09.003; Bennett A, 2000, PARASITOL TODAY, V16, P71, DOI 10.1016/S0169-4758(99)01544-6; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Bogoch II, 2006, EUR J CLIN MICROBIOL, V25, P344, DOI 10.1007/s10096-006-0135-x; Brooker S, 2007, T ROY SOC TROP MED H, V101, P146, DOI 10.1016/j.trstmh.2006.05.012; COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U; Diawara A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000397; Dohoo I., 2003, VET EPIDEMIOLOGIC RE, P706; Engels D, 1997, TROP MED INT HEALTH, V2, P265, DOI 10.1046/j.1365-3156.1997.d01-264.x; FOREYT WJ, 1986, J AM VET MED ASSOC, V189, P1065; GEERTS S, 2000, CLIN MICROBIOL REV, V13, P202; Hall A, 2000, PARASITOL TODAY, V16, P540, DOI 10.1016/S0169-4758(00)01779-8; Kang G, 1998, TROP MED INT HEALTH, V3, P70, DOI 10.1046/j.1365-3156.1998.00175.x; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Keiser J, 2008, JAMA-J AM MED ASSOC, V299, P1937, DOI 10.1001/jama.299.16.1937; Knopp S, 2009, T ROY SOC TROP MED H, V103, P1190, DOI 10.1016/j.trstmh.2009.05.012; Levecke B, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000366; Ministry of Agriculture Fisheries and Food, 1986, MAN VET PAR LAB TECH, V418; Montresor A, 1998, WHOCTDSIP981; ODOS SC, 2002, REV SOC BRAS MED TRO, V35, P597; Pereckiene A, 2007, VET PARASITOL, V149, P111, DOI 10.1016/j.vetpar.2007.04.014; Ramsan M, 1999, TROP MED INT HEALTH, V4, P46, DOI 10.1046/j.1365-3156.1999.00356.x; SINNIAH B, 1982, PARASITOLOGY, V84, P167, DOI 10.1017/S0031182000051763; Speich B, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-71; Tchuem Tchuente LA, 2003, TROP MED INT HEALTH, V8, P975, DOI 10.1046/j.1360-2276.2003.01120.x; van der Hoek Wim, 2003, Southeast Asian J Trop Med Public Health, V34 Suppl 1, P1; Vercruysse J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000948; WHO, 1991, BAS LAB METH MED PAR, P25; *WHO, 2007, WHO GLOB DAT BANK SC; Ye XP, 1997, TROP MED INT HEALTH, V2, P261, DOI 10.1046/j.1365-3156.1997.d01-259.x	33	69	70	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUN	2011	5	6							e1201	10.1371/journal.pntd.0001201				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	784EZ	WOS:000292139600037	21695104	DOAJ Gold, Green Published			2019-03-26	
J	Van Nieuwenhove, LC; Roge, S; Balharbi, F; Dieltjens, T; Laurent, T; Guisez, Y; Buscher, P; Lejon, V				Van Nieuwenhove, Liesbeth Carolien; Roge, Stijn; Balharbi, Fatima; Dieltjens, Tessa; Laurent, Thierry; Guisez, Yves; Buscher, Philippe; Lejon, Veerle			Identification of Peptide Mimotopes of Trypanosoma brucei gambiense Variant Surface Glycoproteins	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HUMAN AFRICAN TRYPANOSOMIASIS; SEROLOGICAL DIAGNOSIS; CEREBROSPINAL-FLUID; AGGLUTINATION-TEST; SLEEPING-SICKNESS; EPITOPE DISCOVERY; ANTIBODIES; SERUM; PHAGE; INFECTIONS	Background: The current antibody detection tests for the diagnosis of gambiense human African trypanosomiasis (HAT) are based on native variant surface glycoproteins (VSGs) of Trypanosoma brucei (T.b.) gambiense. These native VSGs are difficult to produce, and contain non-specific epitopes that may cause cross-reactions. We aimed to identify mimotopic peptides for epitopes of T.b. gambiense VSGs that, when produced synthetically, can replace the native proteins in antibody detection tests. Methodology/Principal Findings: PhD.-12 and PhD.-C7C phage display peptide libraries were screened with mouse monoclonal antibodies against the predominant VSGs LiTat 1.3 and LiTat 1.5 of T.b. gambiense. Thirty seven different peptide sequences corresponding to a linear LiTat 1.5 VSG epitope and 17 sequences corresponding to a discontinuous LiTat 1.3 VSG epitope were identified. Seventeen of 22 synthetic peptides inhibited the binding of their homologous monoclonal to VSG LiTat 1.5 or LiTat 1.3. Binding of these monoclonal antibodies to respectively six and three synthetic mimotopic peptides of LiTat 1.5 and LiTat 1.3 was significantly inhibited by HAT sera (p < 0.05). Conclusions/Significance: We successfully identified peptides that mimic epitopes on the native trypanosomal VSGs LiTat 1.5 and LiTat 1.3. These mimotopes might have potential for the diagnosis of human African trypanosomiasis but require further evaluation and testing with a large panel of HAT positive and negative sera.	[Van Nieuwenhove, Liesbeth Carolien; Roge, Stijn; Balharbi, Fatima; Buscher, Philippe; Lejon, Veerle] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Dieltjens, Tessa] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium; [Laurent, Thierry] CorisBioConcept, Dept Res & Dev, Gembloux, Belgium; [Guisez, Yves] Univ Antwerp, Lab Mol Plant Physiol & Biotechnol, Dept Biol, B-2020 Antwerp, Belgium	Van Nieuwenhove, LC (reprint author), Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium.	lvnieuwenhove@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472; Lejon, Veerle/0000-0002-6795-0962	Belgian Directorate General for International Cooperation (DGIC); Research Foundation of Flanders (FWO) [1.5.169.07N, 1.5.074.09.N, 1.1.270.07.N.00, 1.1.270.09.N.01]	The project was funded by the Belgian Directorate General for International Cooperation (DGIC, http://diplomatie.belgium.be/en/policy/development_cooperation/index.jsp) and the Research Foundation of Flanders (http://www.fwo.be/Default.aspx) (FWO, 1.5.169.07N and 1.5.074.09.N). Liesbeth Van Nieuwenhove is supported by a PhD scholarship of the FWO (1.1.270.07.N.00 and 1.1.270.09.N.01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbas III C. F., 2001, PHAGE DISPLAY LAB MA; Barenholz A, 2007, J MED MICROBIOL, V56, P579, DOI 10.1099/jmm.0.46920-0; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; Buscher P., 2004, The trypanosomiases, P203, DOI 10.1079/9780851994758.0203; Carrington M, 1991, J MOL BIOL, V221; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; De Bolle X, 1999, J MOL BIOL, V294, P181, DOI 10.1006/jmbi.1999.3248; DUKES P, 1992, ACTA TROP, V51, P123, DOI 10.1016/0001-706X(92)90054-2; Enyaru JCK, 1998, ANN TROP MED PARASIT, V92, P845; Ferguson MAJ, 1997, PHILOS T ROY SOC B, V352, P1295, DOI 10.1098/rstb.1997.0113; Goulart LR, 2010, CRIT REV IMMUNOL, V30, P201, DOI 10.1615/CritRevImmunol.v30.i2.70; Herwaldt BL, 2001, CLIN MICROBIOL REV, V14, P659, DOI 10.1128/CMR.14.3.659-688.2001; KAZYUMBA G, 1986, CLIN EXP IMMUNOL, V65, P10; Kouzmitcheva GA, 2001, CLIN DIAGN LAB IMMUN, V8, P150, DOI 10.1128/CDLI.8.1.150-160.2001; LAMBERT PH, 1981, J CLIN INVEST, V67, P77, DOI 10.1172/JCI110035; Lejon V, 2006, TROP MED INT HEALTH, V11, P620, DOI 10.1111/j.1365-3156.2006.01620.x; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Mandava S, 2004, PROTEOMICS, V4, P1439, DOI 10.1002/pmic.200300680; Minenkova O, 2001, EUR J BIOCHEM, V268, P4758, DOI 10.1046/j.1432-1327.2001.02402.x; New England Biolabs, 2009, PH D PHAG DISPL LIB; Ribeiro VD, 2010, IMMUNOL LETT, V129, P94, DOI 10.1016/j.imlet.2010.01.008; Schreiber A, 2005, J COMPUT CHEM, V26, P879, DOI 10.1002/jcc.20229; SIMARRO PP, 2008, Sci Med, V5, P174; Smith PG, 1997, CHEM REV, V97, P391; Tang SS, 2003, CLIN DIAGN LAB IMMUN, V10, P1078, DOI 10.1128/CDLI.10.6.1078-1084.2003; Urbanelli L, 2000, J IMMUNOL METHODS, V236, P167, DOI 10.1016/S0022-1759(99)00238-0; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; Wang LF, 2004, CURR DRUG TARGETS, V5, P1, DOI 10.2174/1389450043490668; Yang DC, 2011, VIRUS RES, V155, P291, DOI 10.1016/j.virusres.2010.10.024	33	10	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JUN	2011	5	6							e1189	10.1371/journal.pntd.0001189				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	784EZ	WOS:000292139600028	21695105	DOAJ Gold, Green Published			2019-03-26	
J	Toledo, ME; Rodriguez, A; Valdes, L; Carrion, R; Cabrera, G; Banderas, D; Ceballos, E; Domeqc, M; Pena, C; Baly, A; Vanlerberghe, V; Van der Stuyft, P				Toledo, Maria E.; Rodriguez, Adriana; Valdes, Luis; Carrion, Rigoberto; Cabrera, Georgina; Banderas, Digna; Ceballos, Enrique; Domeqc, Mireya; Pena, Carilda; Baly, Alberto; Vanlerberghe, Veerle; Van der Stuyft, Patrick			Evidence on impact of community-based environmental management on dengue transmission in Santiago de Cuba	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						dengue; vector control; community-based strategies; outbreak; Cuba	COST-EFFECTIVENESS; VECTOR CONTROL; AEDES-AEGYPTI; CONTROL PROGRAMS	P>During the dengue outbreak that struck Santiago de Cuba in 2006-2007, we conducted an observational study in the Mariana Grajales district, the former setting of a community trial for Aedes aegypti control. In the trial, community working groups (CWG) had been created in 29 randomly selected intervention house blocks, and routine vector control activities alone were conducted in the remaining 30 control blocks. The CWG elaborated and implemented with the population plans and activities to reduce Aedes infestation. They were still functional in 2006 and continued organizing community-based environmental management activities. The attack rate of dengue fever during the outbreak was 8.5 per 1000 inhabitants in the former intervention blocks and 38.1 per 1000 inhabitants in the control blocks, which corresponds to a relative risk of 4.5 (95% CI 3.1-6.5). There was a significantly higher proportion of unaffected intervention blocks, and affected blocks had on average substantially less cases than affected control blocks. This study indicates that community-based environmental management inserted in the routine A. aegypti control programme can not only sustainably curb vector infestation but also have an impact on dengue transmission.	[Toledo, Maria E.; Baly, Alberto] Inst Med Trop Pedro Kouri, Havana, Cuba; [Rodriguez, Adriana; Valdes, Luis; Pena, Carilda] Ctr Prov Higiene & Epidemiol, Santiago De Cuba, Cuba; [Carrion, Rigoberto; Cabrera, Georgina; Domeqc, Mireya] Policlin Univ Jose Marti, Santiago De Cuba, Cuba; [Banderas, Digna; Ceballos, Enrique] Unidad Prov Vigilancia & Lucha Antivectorial, Santiago De Cuba, Cuba; [Vanlerberghe, Veerle; Van der Stuyft, Patrick] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium	Toledo, ME (reprint author), Inst Med Trop Pedro Kouri, Havana, Cuba.	mariaeugenia@ipk.sld.cu			Institute of Tropical Medicine [95900]; Belgium Directorate-General for Development Co-operation [95900]	We gratefully acknowledge the role played by the health sector and provincial vector control programme staff involved in the dengue prevention and control activities. We also thank the people of Santiago de Cuba who participated in the study. The study was partially funded through the framework agreement between the Institute of Tropical Medicine and the Belgium Directorate-General for Development Co-operation, project 95900.	Baly A, 2007, T ROY SOC TROP MED H, V101, P578, DOI 10.1016/j.trstmh.2007.01.002; Baly A, 2009, AM J TROP MED HYG, V81, P88, DOI 10.4269/ajtmh.2009.81.88; Guzman MG, 2006, REV PANAM SALUD PUBL, V19, P282, DOI 10.1590/S1020-49892006000400014; Heintze C, 2007, T ROY SOC TROP MED H, V101, P317, DOI 10.1016/j.trstmh.2006.08.007; Kay B, 2005, LANCET, V365, P613, DOI 10.1016/S0140-6736(05)17913-6; Kittayapong P, 2008, AM J TROP MED HYG, V78, P70, DOI 10.4269/ajtmh.2008.78.70; *PAHO, 2006, BROT DENG CUB; Parks W., 2004, WHOCDSWMC20042; Romani MET, 2007, SOC SCI MED, V64, P976, DOI 10.1016/j.socscimed.2006.10.033; Suaya JA, 2007, TROP MED INT HEALTH, V12, P1026, DOI 10.1111/j.1365-3156.2007.01889.x; Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846; Toledo ME, 2007, T ROY SOC TROP MED H, V101, P56, DOI 10.1016/j.trstmh.2006.03.006; Toledo ME, 2008, TROP MED INT HEALTH, V13, P728, DOI 10.1111/j.1365-3156.2008.02046.x; Vanlerberghe V, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1959	14	14	16	0	9	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JUN	2011	16	6					744	747		10.1111/j.1365-3156.2011.02762.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	762EQ	WOS:000290456100014	21418448				2019-03-26	
J	Gething, PW; Van Boeckel, TP; Smith, DL; Guerra, CA; Patil, AP; Snow, RW; Hay, SI				Gething, Peter W.; Van Boeckel, Thomas P.; Smith, David L.; Guerra, Carlos A.; Patil, Anand P.; Snow, Robert W.; Hay, Simon I.			Modelling the global constraints of temperature on transmission of Plasmodium falciparum and P. vivax	PARASITES & VECTORS			English	Article							DOMINANT ANOPHELES VECTORS; MALARIA TRANSMISSION; CLIMATE-CHANGE; AFRICAN HIGHLANDS; DISTRIBUTION MAPS; BIONOMIC PRECIS; SOUTH-AFRICA; HUMAN HEALTH; RISK; POPULATIONS	Background: Temperature is a key determinant of environmental suitability for transmission of human malaria, modulating endemicity in some regions and preventing transmission in others. The spatial modelling of malaria endemicity has become increasingly sophisticated and is now central to the global scale planning, implementation, and monitoring of disease control and regional efforts towards elimination, but existing efforts to model the constraints of temperature on the malaria landscape at these scales have been simplistic. Here, we define an analytical framework to model these constraints appropriately at fine spatial and temporal resolutions, providing a detailed dynamic description that can enhance large scale malaria cartography as a decision-support tool in public health. Results: We defined a dynamic biological model that incorporated the principal mechanisms of temperature dependency in the malaria transmission cycle and used it with fine spatial and temporal resolution temperature data to evaluate time-series of temperature suitability for transmission of Plasmodium falciparum and P. vivax throughout an average year, quantified using an index proportional to the basic reproductive number. Time-series were calculated for all 1 km resolution land pixels globally and were summarised to create high-resolution maps for each species delineating those regions where temperature precludes transmission throughout the year. Within suitable zones we mapped for each pixel the number of days in which transmission is possible and an integrated measure of the intensity of suitability across the year. The detailed evaluation of temporal suitability dynamics provided by the model is visualised in a series of accompanying animations. Conclusions: These modelled products, made available freely in the public domain, can support the refined delineation of populations at risk; enhance endemicity mapping by offering a detailed, dynamic, and biologically driven alternative to the ubiquitous empirical incorporation of raw temperature data in geospatial models; and provide a rich spatial and temporal platform for future biological modelling studies.	[Gething, Peter W.; Van Boeckel, Thomas P.; Guerra, Carlos A.; Patil, Anand P.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England; [Van Boeckel, Thomas P.] Univ Libre Bruxelles, B-1050 Brussels, Belgium; [Smith, David L.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32610 USA; [Smith, David L.] Univ Florida, Dept Biol, Gainesville, FL 32610 USA; [Snow, Robert W.] Univ Oxford, Malaria Publ Hlth & Epidemiol Grp, Ctr Geog Med, KEMRI,Wellcome Trust Collaborat Programme, Nairobi, Kenya; [Snow, Robert W.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, CCVTM, Oxford OX3 9DS, England	Gething, PW (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Tinbergen Bldg,S Parks Rd, Oxford OX1 3PS, England.	peter.gething@zoo.ox.ac.uk	Smith, David/L-8850-2013; Hay, Simon/F-8967-2015	Smith, David/0000-0003-4367-3849; Hay, Simon/0000-0002-0611-7272; Gething, Peter/0000-0001-6759-5449; Snow, Robert/0000-0003-3725-6088	Wellcome Trust [079091, 079080]; Bill and Melinda Gates Foundation [49446]; Directorate, Department of Homeland Security; Fogarty International Center, National Institutes of Health; Belgian Fond National pour la Recherche Scientifique; Fondation Wiener-Anspach; Kenyan Medical Research Institute (KEMRI); Wellcome Trust, UK	We thank Anja Bibby and Katherine Battle for proof reading this manuscript. SIH is funded by a Senior Research Fellowship from the Wellcome Trust (#079091), which also supports CAG and PWG. DLS is supported by a grant from the Bill and Melinda Gates Foundation (#49446). DLS and SIH also acknowledge funding support from the RAPIDD program of the Science & Technology Directorate, Department of Homeland Security, and the Fogarty International Center, National Institutes of Health. RWS is funded by a Wellcome Trust Principal Research Fellowship (#079080), which also supports APP. TPVB is funded by a grant from the Belgian Fond National pour la Recherche Scientifique and the Fondation Wiener-Anspach. The authors acknowledge the support of the Kenyan Medical Research Institute (KEMRI) and this paper is published with the permission of the director of KEMRI. This work forms part of the output of the Malaria Atlas Project (MAP, http://www.map.ox.ac.uk), principally funded by the Wellcome Trust, UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahumada JA, 2004, J MED ENTOMOL, V41, P1157, DOI 10.1603/0022-2585-41.6.1157; Anderson RM, 1991, INFECT DIS HUMANS; Bayoh MN, 2003, B ENTOMOL RES, V93, P375, DOI 10.1079/BER2003259; Boyd MF, 1949, MALARIOLOGY, V1, P608; CLEMENTS AN, 1981, J APPL ECOL, V18, P373, DOI 10.2307/2402401; Clements ACA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-180; Craig MH, 2004, TROP MED INT HEALTH, V9, P1247, DOI 10.1111/j.1365-3156.2004.01340.x; Craig MH, 1999, PARASITOL TODAY, V15, P105, DOI 10.1016/S0169-4758(99)01396-4; DAVIDSON G, 1953, T ROY SOC TROP MED H, V47, P522, DOI 10.1016/S0035-9203(53)80005-2; DAVIDSON G., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P339, DOI 10.1016/0035-9203(55)90056-0; Depinay J. M. O., 2004, MALARIA J, V3; Detinova TS, 1962, AGE GROUPING METHODS; Dietz K, 1993, Stat Methods Med Res, V2, P23, DOI 10.1177/096228029300200103; DIETZ K, 1988, PRINCIPLES PRACTICE, P1091; Diggle PJ, 2007, SPRINGER SER STAT, P1, DOI 10.1007/978-0-387-48536-2; GARNHAM PCC, 1945, BRIT MED J, V2, P45, DOI 10.1136/bmj.2.4410.45; GARRETTJONES C, 1964, NATURE, V204, P1173, DOI 10.1038/2041173a0; Gemperli A, 2006, TROP MED INT HEALTH, V11, P1032, DOI 10.1111/j.1365-3156.2006.01640.x; Gething PW, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000724; Gething PW, 2010, NATURE, V465, P342, DOI 10.1038/nature09098; Gosoniu L, 2006, GEOSPATIAL HEALTH, V1, P127, DOI 10.4081/gh.2006.287; Gosoniu L, 2009, COMPUT STAT DATA AN, V53, P3358, DOI 10.1016/j.csda.2009.02.022; Gray EM, 2005, AM J TROP MED HYG, V73, P553, DOI 10.4269/ajtmh.2005.73.553; Guerra CA, 2007, MALARIA J, V6, DOI 10.1186/1475-2575-6-17; Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038; Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774; Hay SI, 1998, PARASITOL TODAY, V14, P306, DOI 10.1016/S0169-4758(98)01285-X; Hay SI, 2003, LANCET, V361, P1705, DOI 10.1016/S0140-6736(03)13366-1; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000290; Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; Horstall W.R., 1955, MOSQUITOES THEIR BIO; Hoshen MB, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-32; Kazembe Lawrence N, 2006, Int J Health Geogr, V5, P41, DOI 10.1186/1476-072X-5-41; Kiszewski A, 2004, AM J TROP MED HYG, V70, P486, DOI 10.4269/ajtmh.2004.70.486; Kleinschmidt I, 2000, INT J EPIDEMIOL, V29, P355, DOI 10.1093/ije/29.2.355; Kleinschmidt I, 2001, AM J EPIDEMIOL, V153, P1213, DOI 10.1093/aje/153.12.1213; Kleinschmidt I, 2001, TROP MED INT HEALTH, V6, P779, DOI 10.1046/j.1365-3156.2001.00790.x; Koenraadt CJM, 2006, TROP MED INT HEALTH, V11, P1195, DOI 10.1111/j.1365-3156.2006.01675.x; Lindsay SW, 1998, B WORLD HEALTH ORGAN, V76, P33; Lysenko A. J., 1968, ITOGI NAUKI MEDICINS, P25; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; MAHMOOD F, 1981, MOSQ NEWS, V41, P41; *MALERA CONS GROUP, 2011, PLOS MED, V0008; Martens P, 1999, GLOBAL ENVIRON CHANG, V9, pS89, DOI 10.1016/S0959-3780(99)00020-5; Martens P., 1998, HLTH CLIMATE CHANGE; Martens WJM, 1996, CLIMATE RES, V6, P107, DOI 10.3354/cr006107; MARTENS WJM, 1995, ENVIRON HEALTH PERSP, V103, P458, DOI 10.2307/3432584; Martens WJM, 1997, CLIMATIC CHANGE, V35, P145, DOI 10.1023/A:1005365413932; MARTENS WJM, 1995, GLOBAL ENVIRON CHANG, V5, P195, DOI 10.1016/0959-3780(95)00051-O; Nikolaev B.P., 1935, LENINGRAD PASTEUR I, V2, P108; Noor AM, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-180; Noor AM, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-159; Paaijmans KP, 2010, P NATL ACAD SCI USA, V107, P15135, DOI 10.1073/pnas.1006422107; Paaijmans KP, 2009, P NATL ACAD SCI USA, V106, P13844, DOI 10.1073/pnas.0903423106; Parham P E., 2009, ENV HLTH PERSPECT, V118, P620, DOI DOI 10.1289/EHP.0901256; Pascual M, 2006, P NATL ACAD SCI USA, V103, P5829, DOI 10.1073/pnas.0508929103; Patz JA, 2005, NATURE, V438, P310, DOI 10.1038/nature04188; Piel FB, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1104; Ross R., 1911, PREVENTION MALARIA; Shililu JI, 2004, J AM MOSQUITO CONTR, V20, P243; Sinka ME, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-89; Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-117; Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-72; Smith DL, 2007, PLOS BIOL, V5, P531, DOI 10.1371/journal.pbio.0050042; Smith DL, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-13; Snow RW, 2008, PLOS MED, V5, P1068, DOI 10.1371/journal.pmed.0050142; Snow RW, 2010, LANCET, V376, P1409, DOI 10.1016/S0140-6736(10)61340-2; Tatem AJ, 2010, LANCET, V376, P1579, DOI 10.1016/S0140-6736(10)61301-3; van Lieshout M, 2004, GLOBAL ENVIRON CHANG, V14, P87, DOI 10.1016/j.gloenvcha.2003.10.009; WHITE GB, 1989, GEOGRAPHICAL DISTRIB; YE Y, 2009, GLOBAL HLTH ACTION, V2	72	89	89	0	19	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	MAY 26	2011	4								92	10.1186/1756-3305-4-92				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	780PA	WOS:000291869200001	21615906	DOAJ Gold, Green Published			2019-03-26	
J	Achan, J; Talisuna, AO; Erhart, A; Yeka, A; Tibenderana, JK; Baliraine, FN; Rosenthal, PJ; D'Alessandro, U				Achan, Jane; Talisuna, Ambrose O.; Erhart, Annette; Yeka, Adoke; Tibenderana, James K.; Baliraine, Frederick N.; Rosenthal, Philip J.; D'Alessandro, Umberto			Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria	MALARIA JOURNAL			English	Review							UNCOMPLICATED FALCIPARUM-MALARIA; RANDOMIZED CLINICAL-TRIAL; HUMAN-IMMUNODEFICIENCY-VIRUS; CHILDHOOD CEREBRAL MALARIA; IN-VITRO SUSCEPTIBILITY; PLASMODIUM-FALCIPARUM; INTRAVENOUS QUININE; ARTEMETHER-LUMEFANTRINE; COMBINATION THERAPY; HEALTHY-VOLUNTEERS	Quinine remains an important anti-malarial drug almost 400 years after its effectiveness was first documented. However, its continued use is challenged by its poor tolerability, poor compliance with complex dosing regimens, and the availability of more efficacious anti-malarial drugs. This article reviews the historical role of quinine, considers its current usage and provides insight into its appropriate future use in the treatment of malaria. In light of recent research findings intravenous artesunate should be the first-line drug for severe malaria, with quinine as an alternative. The role of rectal quinine as pre-referral treatment for severe malaria has not been fully explored, but it remains a promising intervention. In pregnancy, quinine continues to play a critical role in the management of malaria, especially in the first trimester, and it will remain a mainstay of treatment until safer alternatives become available. For uncomplicated malaria, artemisinin-based combination therapy (ACT) offers a better option than quinine though the difficulty of maintaining a steady supply of ACT in resource-limited settings renders the rapid withdrawal of quinine for uncomplicated malaria cases risky. The best approach would be to identify solutions to ACT stock-outs, maintain quinine in case of ACT stock-outs, and evaluate strategies for improving quinine treatment outcomes by combining it with antibiotics. In HIV and TB infected populations, concerns about potential interactions between quinine and antiretroviral and anti-tuberculosis drugs exist, and these will need further research and pharmacovigilance.	[Achan, Jane] Makerere Univ, Dept Pediat & Child Hlth, Coll Hlth Sci, Kampala, Uganda; [Talisuna, Ambrose O.] Makerere Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Kampala, Uganda; [Erhart, Annette; D'Alessandro, Umberto] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Yeka, Adoke] Uganda Malaria Surveillance Project, Epidemiol Unit, Kampala, Uganda; [Tibenderana, James K.] Malaria Consortium Africa, Communicable Dis Control Dept, Kampala, Uganda; [Baliraine, Frederick N.; Rosenthal, Philip J.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Achan, J (reprint author), Makerere Univ, Dept Pediat & Child Hlth, Coll Hlth Sci, POB 7475, Kampala, Uganda.	achanj@yahoo.co.uk	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; TIBENDERANA, JAMES/0000-0002-0755-4597			Aceng JR, 2005, BMJ-BRIT MED J, V330, P334, DOI 10.1136/bmj.330.7487.334; Achan J, 2007, CLIN INFECT DIS, V45, P1446, DOI 10.1086/522972; Achan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017053; Achan J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2763; Adam I, 2004, East Mediterr Health J, V10, P554; Adegnika AA, 2005, AM J TROP MED HYG, V73, P263, DOI 10.4269/ajtmh.2005.73.263; ADENABDI OEY, 1995, HDB DRUGS TROPICAL P, V2; Alecrim MG, 2006, AM J TROP MED HYG, V74, P20, DOI 10.4269/ajtmh.2006.74.20; [Anonymous], 2009, WORLD MAL REP 2009; [Anonymous], 1931, CHEM NEWS, V142, P129; [Anonymous], 2010, MAL TREATM GUID; Barennes H, 2006, BRIT MED J, V332, P1055, DOI 10.1136/bmj.332.7549.1055; Barennes H, 2001, Sante, V11, P145; Barennes H, 1995, Med Trop (Mars), V55, P91; BARENNES H, 1995, T ROY SOC TROP MED H, V89, P418, DOI 10.1016/0035-9203(95)90036-5; Barennes H, 1998, T ROY SOC TROP MED H, V92, P437, DOI 10.1016/S0035-9203(98)91083-5; Basco LK, 2004, AM J TROP MED HYG, V70, P474, DOI 10.4269/ajtmh.2004.70.474; BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B; Chongsuphajaisiddhi T, 1981, Ann Trop Paediatr, V1, P21; COLEBUNDERS R, 1990, J INFECTION, V21, P167, DOI 10.1016/0163-4453(90)91701-E; David B., 2005, ENCY FAMILY HLTH; de Vries PJ, 2000, ANTIMICROB AGENTS CH, V44, P1302, DOI 10.1128/AAC.44.5.1302-1308.2000; DESOUZA JM, 1985, B WORLD HEALTH ORGAN, V63, P603; Di Perri G, 1998, ACTA TROP, V70, P25, DOI 10.1016/S0001-706X(98)00010-2; Dobson S. M., 2001, ANTIMALARIAL CHEMOTH, P15; DONDORP AM, LANCET, V376, P1647; Esamai F, 2000, E AFR MED J, V77, P273; Esamai F, 2005, J TROP PEDIATRICS, V51, P17, DOI 10.1093/tropej/fmh069; Faiz MA, 2005, LANCET, V366, P717; Fungladda W, 1998, Bull World Health Organ, V76 Suppl 1, P59; Gasasira AF, 2008, CLIN INFECT DIS, V46, P985, DOI 10.1086/529192; Gaudiano MC, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-22; German P, 2009, JAIDS-J ACQ IMM DEF, V51, P424, DOI 10.1097/QAI.0b013e3181acb4ff; Gomes MF, 2009, LANCET, V373, P557, DOI 10.1016/S0140-6736(08)61734-1; GREENBERG AE, 1991, NEW ENGL J MED, V325, P105, DOI 10.1056/NEJM199107113250206; HARINASUTA T, 1984, MOSQUITO BORNE DIS B, V1, P23; Huttinger F, 2010, WIEN KLIN WOCHENSCHR, V122, P52, DOI 10.1007/s00508-010-1438-6; Ibrahim MH, 2004, ANN TROP MED PARASIT, V98, P441, DOI 10.1179/000349804225003488; JAMALUDIN A, 1988, Acta Leidensia, V57, P39; JONES KL, 2007, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD005967.PUB2; Kangwana BB, 2009, AM J TROP MED HYG, V80, P737, DOI 10.4269/ajtmh.2009.80.737; KARLSSON KK, 1990, T ROY SOC TROP MED H, V84, P765, DOI 10.1016/0035-9203(90)90069-Q; Kayumba PC, 2004, J CLIN PHARM THER, V29, P331, DOI 10.1111/j.1365-2710.2004.00568.x; Khoo S, 2005, AIDS, V19, P995, DOI 10.1097/01.aids.0000174445.40379.e0; Kofoed PE, 1997, T ROY SOC TROP MED H, V91, P462, DOI 10.1016/S0035-9203(97)90286-8; KREMSNER PG, 1994, J INFECT DIS, V169, P467, DOI 10.1093/infdis/169.2.467; Le Jouan M, 2005, ANTIMICROB AGENTS CH, V49, P3658, DOI 10.1128/AAC.49.9.3658-3662.2005; Legrand E, 2008, ANTIMICROB AGENTS CH, V52, P288, DOI 10.1128/AAC.00263-07; Lell B, 2002, ANTIMICROB AGENTS CH, V46, P2315, DOI 10.1128/AAC.46.8.2315-2320.2002; LESI A, 2004, COCHRANE DB SYST REV, V3; Lon CT, 2006, T ROY SOC TROP MED H, V100, P1019, DOI 10.1016/j.trstmh.2006.01.003; LOOAREESUWAN S, 1994, ACTA TROP, V57, P47, DOI 10.1016/0001-706X(94)90092-2; LOOAREESUWAN S, 1990, J INFECT DIS, V161, P577, DOI 10.1093/infdis/161.3.577; LOOAREESUWAN S, 1985, LANCET, V2, P4, DOI 10.1016/S0140-6736(85)90056-X; Manyando C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-249; Mayxay M, 2007, AM J TROP MED HYG, V76, P245, DOI 10.4269/ajtmh.2007.76.245; McGready R, 2005, J INFECT DIS, V192, P846, DOI 10.1086/432551; McGready R, 2001, T ROY SOC TROP MED H, V95, P651, DOI 10.1016/S0035-9203(01)90106-3; McGready R, 2000, T ROY SOC TROP MED H, V94, P689, DOI 10.1016/S0035-9203(00)90235-9; MEEK SR, 1986, AM J TROP MED HYG, V35, P246, DOI 10.4269/ajtmh.1986.35.246; METZGER W, 1995, ANTIMICROB AGENTS CH, V39, P245, DOI 10.1128/AAC.39.1.245; MIHALY GW, 1987, BRIT J CLIN PHARMACO, V24, P769, DOI 10.1111/j.1365-2125.1987.tb03244.x; Miller RS, 2006, AM J TROP MED HYG, V74, P401, DOI 10.4269/ajtmh.2006.74.401; Mutanda LN, 1999, E AFR MED J, V76, P421; Myint HY, 2004, T ROY SOC TROP MED H, V98, P73, DOI 10.1016/S0035-9203(03)00014-2; Ndiaye JLA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-152; Newton PN, 2006, T ROY SOC TROP MED H, V100, P184, DOI 10.1016/j.trstmh.2005.01.008; Noedl H, 2006, CLIN INFECT DIS, V43, P1264, DOI 10.1086/508175; OKITOLONDA W, 1987, BRIT MED J, V295, P716, DOI 10.1136/bmj.295.6600.716; Onwujekwe O, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-22; Parola P, 2001, ANTIMICROB AGENTS CH, V45, P932, DOI 10.1128/AAC.45.3.932-935.2001; PETERS W, 1982, BRIT MED BULL, V38, P187, DOI 10.1093/oxfordjournals.bmb.a071757; PHILIPSON A, 1976, CLIN PHARMACOL THER, V19, P68; Piola P, 2010, LANCET INFECT DIS, V10, P762, DOI 10.1016/S1473-3099(10)70202-4; Pradines B, 1998, PARASITOLOGY, V117, P541, DOI 10.1017/S0031182098003400; Pukrittayakamee S, 2000, ANTIMICROB AGENTS CH, V44, P2395, DOI 10.1128/AAC.44.9.2395-2398.2000; Pukrittayakamee S, 2003, ANTIMICROB AGENTS CH, V47, P3458, DOI 10.1128/AAC.47.11.3458-3463.2003; Pukrittayakamee S, 2003, ANTIMICROB AGENTS CH, V47, P1509, DOI 10.1128/AAC.47.5.1509-1513.2003; Quashie NB, 2007, ANN TROP MED PARASIT, V101, P391, DOI 10.1179/136485907X176553; Roche J, 2003, AM J TROP MED HYG, V68, P598, DOI 10.4269/ajtmh.2003.68.598; ROCHE J, 1993, ANN TROP MED PARASIT, V87, P443, DOI 10.1080/00034983.1993.11812794; Rogier C, 1996, T ROY SOC TROP MED H, V90, P175, DOI 10.1016/S0035-9203(96)90128-5; SABCHAREON A, 1988, B WORLD HEALTH ORGAN, V66, P347; SALAKO LA, 1992, EUR J CLIN PHARMACOL, V42, P171, DOI 10.1007/BF00278479; Sayang C, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-174; Soyinka JO, 2010, BRIT J CLIN PHARMACO, V69, P262, DOI 10.1111/j.1365-2125.2009.03566.x; Soyinka JO, 2009, J PHARM PHARMACOL, V61, P439, DOI [10.1211/jpp.61.04.0004, 10.1211/jpp/61.04.0004]; Taylor TE, 1998, TROP MED INT HEALTH, V3, P3, DOI 10.1046/j.1365-3156.1998.00166.x; Thera MA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-68; Tinto H, 2006, T ROY SOC TROP MED H, V100, P509, DOI 10.1016/j.trstmh.2005.09.018; Toure Andre Offianan, 2008, Sante, V18, P43, DOI 10.1684/san.2008.0103; TRACY WLA, GOODMAN GILMANS PHAR, V97, P978; UMSP, 2010, UMSP SENT SIT MAL SU; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WANWIMOLRUK S, 1995, BRIT J CLIN PHARMACO, V40, P87, DOI 10.1111/j.1365-2125.1995.tb04541.x; Wasunna B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-29; WERNSDORFER WH, 1995, T ROY SOC TROP MED H, V89, P90, DOI 10.1016/0035-9203(95)90672-X; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; WHITE NJ, 1992, BRIT J CLIN PHARMACO, V34, P1; WHITE NJ, 1983, BRIT J CLIN PHARMACO, V16, P399, DOI 10.1111/j.1365-2125.1983.tb02184.x; WHITE NJ, 1982, AM J MED, V73, P564, DOI 10.1016/0002-9343(82)90337-0; *WHO, 2000, T R SOC TROP MED S1, V94, P1; World Health Organization, 2009, GLOB ANT DRUG POL DA; Yeka A, 2009, LANCET INFECT DIS, V9, P448, DOI 10.1016/S1473-3099(09)70109-4; QUININE; 2001, T R SOC TROP MED HYG, V95, P637; 1993, ANTIMALARIAL MARTIND, P30; CINCHONA BARK; WA QUININE DISCOVERE	109	170	173	3	65	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAY 24	2011	10								144	10.1186/1475-2875-10-144				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	782EB	WOS:000291989700001	21609473	DOAJ Gold, Green Published			2019-03-26	
J	Mombo-Ngoma, G; Oyakhirome, S; Ord, R; Gabor, JJ; Greutelaers, KC; Profanter, K; Greutelaers, B; Kurth, F; Lell, B; Kun, JFJ; Issifou, S; Roper, C; Kremsner, PG; Grobusch, MP				Mombo-Ngoma, Ghyslain; Oyakhirome, Sunny; Ord, Rosalynn; Gabor, Julian J.; Greutelaers, Katja C.; Profanter, Katharina; Greutelaers, Benedikt; Kurth, Florian; Lell, Bertrand; Kun, Juergen F. J.; Issifou, Saadou; Roper, Cally; Kremsner, Peter G.; Grobusch, Martin P.			High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children	MALARIA JOURNAL			English	Article							PLASMODIUM-FALCIPARUM MALARIA; RANDOMIZED CONTROLLED-TRIAL; DIHYDROFOLATE-REDUCTASE; DIHYDROPTEROATE SYNTHASE; DOUBLE-BLIND; UNCOMPLICATED MALARIA; AFRICAN CHILDREN; POINT MUTATION; RESISTANCE; AMODIAQUINE	Background: Drug resistance contributes to the global malaria burden. Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) polymorphisms confer resistance to sulphadoxine-pyrimethamine (SP). Methods: The study assessed the frequency of SP resistance-conferring polymorphisms in Plasmodium falciparum-positive samples from two clinical studies in Lambarene. Their role on treatment responses and transmission potential was studied in an efficacy open-label clinical trial with a 28-day follow-up in 29 children under five with uncomplicated malaria. Results: SP was well tolerated by all subjects in vivo. Three subjects were excluded from per-protocol analysis. PCR-corrected, 12/26 (46%) achieved an adequate clinical and parasitological response, 13/26 (50%) were late parasitological failures, while 1/26 (4%) had an early treatment failure, resulting in early trial discontinuation. Of 106 isolates, 98 (92%) carried the triple mutant dhfr haplotype. Three point mutations were found in dhps in a variety of haplotypic configurations. The 437G + 540E double mutant allele was found for the first time in Gabon. Conclusions: There is a high prevalence of dhfr triple mutant with some dhps point mutations in Gabon, in line with treatment failures observed, and molecular markers of SP resistance should be closely monitored.	[Mombo-Ngoma, Ghyslain; Oyakhirome, Sunny; Gabor, Julian J.; Greutelaers, Katja C.; Profanter, Katharina; Greutelaers, Benedikt; Kurth, Florian; Lell, Bertrand; Issifou, Saadou; Kremsner, Peter G.; Grobusch, Martin P.] Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon; [Mombo-Ngoma, Ghyslain; Oyakhirome, Sunny; Gabor, Julian J.; Greutelaers, Katja C.; Profanter, Katharina; Greutelaers, Benedikt; Kurth, Florian; Lell, Bertrand; Kun, Juergen F. J.; Issifou, Saadou; Kremsner, Peter G.; Grobusch, Martin P.] Univ Tubingen, Inst Trop Med, Tubingen, Germany; [Mombo-Ngoma, Ghyslain] Univ Sci Sante, Dept Parasitol, Libreville, Gabon; [Ord, Rosalynn] NYU, Sch Med, New York, NY USA; [Ord, Rosalynn; Roper, Cally] London Sch Hyg & Trop Med, Dept Infect Trop Dis, London WC1, England; [Grobusch, Martin P.] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa; [Grobusch, Martin P.] Univ Amsterdam, Acad Med Ctr, Div Internal Med, NL-1012 WX Amsterdam, Netherlands; [Oyakhirome, Sunny] Glaxo Smith Kline Biol, Rixensart, Belgium; [Kurth, Florian] Univ Hosp Carl Gustav Carus, Dept Neonatol & Pediat Intens Care, Dresden, Germany; [Ord, Rosalynn] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA	Grobusch, MP (reprint author), Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.	m.p.grobusch@amc.uva.nl	Roper, Cally/K-2989-2013	Roper, Cally/0000-0002-6545-309X; Greutelaers, Benedikt/0000-0002-7198-505X			Abacassamo F, 2004, TROP MED INT HEALTH, V9, P200, DOI 10.1046/j.1365-3156.2003.01182.x; Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2; Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7; Aubouy A, 2003, J ANTIMICROB CHEMOTH, V52, P43, DOI 10.1093/jac/dkg294; Bousema JT, 2003, TROP MED INT HEALTH, V8, P427, DOI 10.1046/j.1365-3156.2003.01047.x; BROOKS DR, 1994, EUR J BIOCHEM, V224, P397, DOI 10.1111/j.1432-1033.1994.00397.x; Bwijo B, 2003, ACTA TROP, V85, P363, DOI 10.1016/S0001-706X(02)00264-4; Cattamanchi A, 2003, AM J TROP MED HYG, V68, P133, DOI 10.4269/ajtmh.2003.68.133; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; Deloron P, 2000, T ROY SOC TROP MED H, V94, P188, DOI 10.1016/S0035-9203(00)90272-4; Dzinjalamala FK, 2005, AM J TROP MED HYG, V72, P267, DOI 10.4269/ajtmh.2005.72.267; Ehrhardt S, 2002, ANN TROP MED PARASIT, V96, P239, DOI 10.1179/000349802125000772; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Grobusch MP, 2007, CURR OPIN INFECT DIS, V20, P613, DOI 10.1097/QCO.0b013e3282f1ae3b; Grobusch MP, 2007, J INFECT DIS, V196, P1595, DOI 10.1086/522160; Grobusch MP, 2009, J INFECT DIS, V200, P1658, DOI 10.1086/647990; Kremsner PG, 2004, LANCET, V364, P285, DOI 10.1016/S0140-6736(04)16680-4; KUN FJK, 1999, ANTIMICROB AGENTS CH, V43, P2205; Lell B, 1998, AM J TROP MED HYG, V58, P619, DOI 10.4269/ajtmh.1998.58.619; Mawili-Mboumba DP, 2001, ACTA TROP, V78, P231, DOI 10.1016/S0001-706X(01)00084-5; Mendez F, 2002, AM J EPIDEMIOL, V156, P230, DOI 10.1093/aje/kwf030; METZGER W, 1995, J ANTIMICROB CHEMOTH, V36, P723, DOI 10.1093/jac/36.4.723; Mockenhaupt FP, 2005, TROP MED INT HEALTH, V10, P512, DOI 10.1111/j.1365-3156.2005.01427.x; Nsimba B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-31; Oduro AR, 2005, TROP MED INT HEALTH, V10, P279, DOI 10.1111/j.1365-3156.2004.01382.x; Oyakhirome S, 2007, ANTIMICROB AGENTS CH, V51, P1869, DOI 10.1128/AAC.01448-06; Pearce RJ, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000055; Pearce RJ, 2003, ANTIMICROB AGENTS CH, V47, P1347, DOI 10.1128/AAC.47.4.1347-1354.2003; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; Planche T, 2001, AM J TROP MED HYG, V65, P599, DOI 10.4269/ajtmh.2001.65.599; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; RAMHARTER M, 2007, WIEN KLIN WOCHENS S3, V11, P8; Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0; Schellenberg D, 2002, AM J TROP MED HYG, V67, P17, DOI 10.4269/ajtmh.2002.67.17; TRIGLIA T, 1994, P NATL ACAD SCI USA, V91, P7149, DOI 10.1073/pnas.91.15.7149; vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7; Wernsdorfer WH, 2003, CURR OPIN INFECT DIS, V16, P553, DOI [10.1097/00001432-200312000-00007, 10.1097/01.qco.0000104295.87920.fd]; WHO, 2010, POL REC INT PREV TRE; *WHO, 2005, CLASS TREATM OUTC; WINKLER S, 1994, TROP MED PARASITOL, V45, P214	40	22	23	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAY 14	2011	10								123	10.1186/1475-2875-10-123				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	777ES	WOS:000291599200001	21569596	DOAJ Gold, Green Published			2019-03-26	
J	Adaui, V; Castillo, D; Zimic, M; Gutierrez, A; Decuypere, S; Vanaerschot, M; De Doncker, S; Schnorbusch, K; Maes, I; Van der Auwera, G; Maes, L; Llanos-Cuentas, A; Arevalo, J; Dujardin, JC				Adaui, Vanessa; Castillo, Denis; Zimic, Mirko; Gutierrez, Andres; Decuypere, Saskia; Vanaerschot, Manu; De Doncker, Simonne; Schnorbusch, Kathy; Maes, Ilse; Van der Auwera, Gert; Maes, Louis; Llanos-Cuentas, Alejandro; Arevalo, Jorge; Dujardin, Jean-Claude			Comparative Gene Expression Analysis throughout the Life Cycle of Leishmania braziliensis: Diversity of Expression Profiles among Clinical Isolates	PLOS NEGLECTED TROPICAL DISEASES			English	Article							AXENIC AMASTIGOTES; IN-VITRO; DONOVANI; DIFFERENTIATION; SUSCEPTIBILITY; INFANTUM; REVEALS	Background: Most of the Leishmania genome is reported to be constitutively expressed during the life cycle of the parasite, with a few regulated genes. Inter-species comparative transcriptomics evidenced a low number of species-specific differences related to differentially distributed genes or the differential regulation of conserved genes. It is of uppermost importance to ensure that the observed differences are indeed species-specific and not simply specific of the strains selected for representing the species. The relevance of this concern is illustrated by current study. Methodology/Principal Findings: We selected 5 clinical isolates of L. braziliensis characterized by their diversity of clinical and in vitro phenotypes. Real-time quantitative PCR was performed on promastigote and amastigote life stages to assess gene expression profiles at seven time points covering the whole life cycle. We tested 12 genes encoding proteins with roles in transport, thiol-based redox metabolism, cellular reduction, RNA poly(A)-tail metabolism, cytoskeleton function and ribosomal function. The general trend of expression profiles showed that regulation of gene expression essentially occurs around the stationary phase of promastigotes. However, the genes involved in this phenomenon appeared to vary significantly among the isolates considered. Conclusion/Significance: Our results clearly illustrate the unique character of each isolate in terms of gene expression dynamics. Results obtained on an individual strain are not necessarily representative of a given species. Therefore, extreme care should be taken when comparing the profiles of different species and extrapolating functional differences between them.	[Adaui, Vanessa; Castillo, Denis; Llanos-Cuentas, Alejandro; Arevalo, Jorge] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Adaui, Vanessa; Decuypere, Saskia; Vanaerschot, Manu; De Doncker, Simonne; Schnorbusch, Kathy; Maes, Ilse; Van der Auwera, Gert] Inst Trop Med, Dept Parasitol, Unit Mol Parasitol, B-2000 Antwerp, Belgium; [Zimic, Mirko; Gutierrez, Andres; Arevalo, Jorge] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Lab Invest & Desarrollo, Lima, Peru; [Vanaerschot, Manu; Schnorbusch, Kathy; Dujardin, Jean-Claude] Univ Antwerp, Dept Biomed Sci, Fac Pharmaceut Biomed & Vet Sci, B-2020 Antwerp, Belgium	Adaui, V (reprint author), Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.	jcdujardin@itg.be	Maes, Louis/A-2384-2017; Vanaerschot, Manu/B-6812-2013	Maes, Louis/0000-0002-2324-9509; Vanaerschot, Manu/0000-0002-9141-2347; Gutierrez, Andres/0000-0002-6127-8327; Decuypere, Saskia/0000-0001-5036-4601	European Commission [LeishNatDrug-R - ICA4-CT-2001-10076, LeishEpiNetSA - INCO-CT2005-015407]; Directorate-General for Development Cooperation of the Belgian Government [95501, 95502]	This work was supported by the European Commission (INCO-DEV contracts LeishNatDrug-R - ICA4-CT-2001-10076, and LeishEpiNetSA - INCO-CT2005015407), and the Directorate-General for Development Cooperation of the Belgian Government (framework agreement 02 - project 95501, and framework agreement 03 - project 95502). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adaui V, 2011, PARASITOLOGY, V138, P183, DOI 10.1017/S0031182010001095; Alcolea PJ, 2010, INT J PARASITOL, V40, P1497, DOI [10.1016/j.ijpara2010.05.013, 10.1016/j.ijpara.2010.05.013]; Ashutosh, 2007, J MED MICROBIOL, V56, P143, DOI 10.1099/jmm.0.46841-0; Barak E, 2005, MOL BIOCHEM PARASIT, V141, P99, DOI 10.1016/j.molbiopara.2005.02.004; da Silva LA, 2010, INFECT GENET EVOL, V10, P77, DOI 10.1016/j.meegid.2009.11.001; Decuypere S, 2008, PARASITOLOGY, V135, P183, DOI 10.1017/S0031182007003782; Decuypere S, 2005, ANTIMICROB AGENTS CH, V49, P4616, DOI 10.1128/AAC.49.11.4616-4621.2005; Depledge DP, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000476; Fraga J, 2010, INFECT GENET EVOL, V10, P238, DOI 10.1016/j.meegid.2009.11.007; Gamboa D, 2008, PARASITOLOGY, V135, P319, DOI 10.1017/S0031182007003848; Garcia L, 2004, J CLIN MICROBIOL, V42, P2294, DOI 10.1128/JCM.42.5.2294-2297.2004; Haile S, 2007, CURR OPIN MICROBIOL, V10, P569, DOI 10.1016/j.mib.2007.10.001; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Holzer TR, 2006, MOL BIOCHEM PARASIT, V146, P198, DOI 10.1016/j.molbiopara.2005.12.009; McCarthy DJ, 2009, BIOINFORMATICS, V25, P765, DOI 10.1093/bioinformatics/btp053; Montalvo AM, 2010, PARASITOLOGY, V137, P1159, DOI 10.1017/S0031182010000089; Puentes F, 2000, AM J TROP MED HYG, V63, P102, DOI 10.4269/ajtmh.2000.63.102; Rochette Annie, 2008, BMC Genomics, V9, P255, DOI 10.1186/1471-2164-9-255; Rochette A, 2009, MOL BIOCHEM PARASIT, V165, P32, DOI 10.1016/j.molbiopara.2008.12.012; Saxena A, 2007, MOL BIOCHEM PARASIT, V152, P53, DOI 10.1016/j.molbiopara.2006.11.011; t'Kindt R, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000904; Teixeira MCA, 2002, PARASITOL RES, V88, P963, DOI 10.1007/s00436-002-0695-3; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Yardley V, 2006, J INFECT DIS, V194, P1168, DOI 10.1086/507710	24	13	13	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2011	5	5							e1021	10.1371/journal.pntd.0001021				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	770OZ	WOS:000291099100003	21572980	DOAJ Gold, Green Published			2019-03-26	
J	Dione, MM; Ikumapayi, UN; Saha, D; Mohammed, NI; Geerts, S; Ieven, M; Adegbola, RA; Antonio, M				Dione, Michel M.; Ikumapayi, Usman N.; Saha, Debasish; Mohammed, Nuredin I.; Geerts, Stanny; Ieven, Margareta; Adegbola, Richard A.; Antonio, Martin			Clonal Differences between Non-Typhoidal Salmonella (NTS) Recovered from Children and Animals Living in Close Contact in The Gambia	PLOS NEGLECTED TROPICAL DISEASES			English	Article							AGED 2-29 MONTHS; TYPHIMURIUM INFECTION; ENTERITIDIS; SEROVAR; AFRICA; BACTEREMIA; CHICKENS; STRAIN; SHEEP; DAKAR	Background: Non-Typhoidal Salmonella (NTS) is an important cause of invasive bacterial disease and associated with mortality in Africa. However, little is known about the environmental reservoirs and predominant modes of transmission. Our study aimed to study the role of domestic animals in the transmission of NTS to humans in rural area of The Gambia. Methodology: Human NTS isolates were obtained through an active population-based case-control surveillance study designated to determine the aetiology and epidemiology of enteric infections covering 27,567 Gambian children less than five years of age in the surveillance area. Fourteen children infected with NTS were traced back to their family compounds and anal swabs collected from 210 domestic animals present in their households. Identified NTSs were serotyped and genotyped by multi-locus sequencing typing. Principal Findings: NTS was identified from 21/210 animal sources in the households of the 14 infected children. Chickens carried NTS more frequently than sheep and goats; 66.6%, 28.6% and 4.8% respectively. The most common NTS serovars were S. Colindale in humans (21.42%) and S. Poona in animals (14.28%). MLST on the 35 NTS revealed four new alleles and 24 sequence types (ST) of which 18 (75%) STs were novel. There was no overlap in serovars or genotypes of NTS recovered from humans or animal sources in the same household. Conclusion: Our results do not support the hypothesis that humans and animals in close contact in the same household carry genotypically similar Salmonella serovars. These findings form an important baseline for future studies of transmission of NTS in humans and animals in Africa.	[Dione, Michel M.] Int Trypanotolerance Ctr, Banjul, Gambia; [Ikumapayi, Usman N.; Saha, Debasish; Mohammed, Nuredin I.; Adegbola, Richard A.; Antonio, Martin] Med Res Council UK Labs, Banjul, Gambia; [Dione, Michel M.; Geerts, Stanny] Inst Trop Med, B-2000 Antwerp, Belgium; [Dione, Michel M.; Ieven, Margareta] Univ Antwerp, B-2020 Antwerp, Belgium	Dione, MM (reprint author), Int Trypanotolerance Ctr, Banjul, Gambia.	mantonio@mrc.gm		Dione, Michel/0000-0001-7812-5776; Geerts, Stanny/0000-0001-9885-8846	Flemish Interuniversity Council (VLIR-UOS, Brussels, Belgium); Medical Research Council, United Kingdom; Science Foundation of Ireland [05/FE1/B882]; Medical Research Council [MC_U190074190, MC_U190081991]	This work was supported by the Flemish Interuniversity Council (VLIR-UOS, Brussels, Belgium) and the Medical Research Council, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We acknowledge Kebba Touray for technical assistance with GIS and Mark Achtman for the use of the Salmonella MLST database [30], which is hosted at the University College Cork and funded by the Science Foundation of Ireland (05/FE1/B882).	Aanensen DM, 2005, NUCLEIC ACIDS RES, V33, pW728, DOI 10.1093/nar/gki415; Alvseike O, 2002, PREV VET MED, V52, P277, DOI 10.1016/S0167-5877(01)00252-5; BARROW PA, 1987, RES VET SCI, V42, P194, DOI 10.1016/S0034-5288(18)30685-4; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Braden CR, 2006, CLIN INFECT DIS, V43, P512, DOI 10.1086/505973; Cardinale E, 2005, INT J FOOD MICROBIOL, V103, P157, DOI 10.1016/j.ijfoodmicro.2004.12.023; Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5; Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146; Graham SM, 2000, PEDIATR INFECT DIS J, V19, P1189, DOI 10.1097/00006454-200012000-00016; Grimont P. A., 2007, ANTIGENIC FORMULAE S; Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2; Ikumapayi UN, 2007, J MED MICROBIOL, V56, P1479, DOI 10.1099/jmm.0.47416-0; Kariuki S, 2002, FEMS IMMUNOL MED MIC, V33, P165, DOI 10.1016/S0928-8244(02)00309-7; Kotetishvili M, 2002, J CLIN MICROBIOL, V40, P1626, DOI 10.1128/JCM.40.5.1626-1635.2002; Mandomando I, 2009, TROP MED INT HEALTH, V14, P1467, DOI 10.1111/j.1365-3156.2009.02399.x; Morpeth SC, 2009, CLIN INFECT DIS, V49, P606, DOI 10.1086/603553; Mulholland EK, 1999, PEDIATR INFECT DIS J, V18, pS35, DOI 10.1097/00006454-199910001-00007; Sadeyen JR, 2004, MICROBES INFECT, V6, P1278, DOI 10.1016/j.micinf.2004.07.005; Sow AI, 2000, MED MALADIES INFECT, V30, P657, DOI 10.1016/S0399-077X(00)80037-2; Spratt Brian G, 2004, Methods Mol Biol, V266, P323; Suerbaum S, 2004, INT J MED MICROBIOL, V294, P133, DOI 10.1016/j.ijmm.2004.06.014; Torpdahl M, 2005, J MICROBIOL METH, V63, P173, DOI 10.1016/j.mimet.2005.03.006; Uzzau S, 2001, INFECT IMMUN, V69, P3092, DOI 10.1128/IAI.69.5.3092-3099.2001; Van Immerseel F, 2002, DEV COMP IMMUNOL, V26, P355, DOI 10.1016/S0145-305X(01)00084-2; Wall PG, 1996, LANCET, V348, P471, DOI 10.1016/S0140-6736(96)24033-4	25	20	20	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2011	5	5							e1148	10.1371/journal.pntd.0001148				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	770OZ	WOS:000291099100026	21655353	DOAJ Gold, Green Published			2019-03-26	
J	Grolla, A; Jones, SM; Fernando, L; Strong, JE; Stroher, U; Moller, P; Paweska, JT; Burt, F; Palma, PP; Sprecher, A; Formenty, P; Roth, C; Feldmann, H				Grolla, Allen; Jones, Steven M.; Fernando, Lisa; Strong, James E.; Stroeher, Ute; Moeller, Peggy; Paweska, Janusz T.; Burt, Felicity; Pablo Palma, Pedro; Sprecher, Armand; Formenty, Pierre; Roth, Cathy; Feldmann, Heinz			The Use of a Mobile Laboratory Unit in Support of Patient Management and Epidemiological Surveillance during the 2005 Marburg Outbreak in Angola	PLOS NEGLECTED TROPICAL DISEASES			English	Article							EBOLA HEMORRHAGIC-FEVER; SANS-FRONTIERES INTERVENTION; VIRUS DISEASE; DIAGNOSIS; UIGE; CONGO; PCR	Background: Marburg virus (MARV), a zoonotic pathogen causing severe hemorrhagic fever in man, has emerged in Angola resulting in the largest outbreak of Marburg hemorrhagic fever (MHF) with the highest case fatality rate to date. Methodology/Principal Findings: A mobile laboratory unit (MLU) was deployed as part of the World Health Organization outbreak response. Utilizing quantitative real-time PCR assays, this laboratory provided specific MARV diagnostics in Uige, the epicentre of the outbreak. The MLU operated over a period of 88 days and tested 620 specimens from 388 individuals. Specimens included mainly oral swabs and EDTA blood. Following establishing on site, the MLU operation allowed a diagnostic response in,4 hours from sample receiving. Most cases were found among females in the child-bearing age and in children less than five years of age. The outbreak had a high number of paediatric cases and breastfeeding may have been a factor in MARV transmission as indicated by the epidemiology and MARV positive breast milk specimens. Oral swabs were a useful alternative specimen source to whole blood/serum allowing testing of patients in circumstances of resistance to invasive procedures but limited diagnostic testing to molecular approaches. There was a high concordance in test results between the MLU and the reference laboratory in Luanda operated by the US Centers for Disease Control and Prevention. Conclusions/Significance: The MLU was an important outbreak response asset providing support in patient management and epidemiological surveillance. Field laboratory capacity should be expanded and made an essential part of any future outbreak investigation.	[Grolla, Allen; Jones, Steven M.; Fernando, Lisa; Strong, James E.; Stroeher, Ute; Feldmann, Heinz] Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB, Canada; [Jones, Steven M.; Strong, James E.; Stroeher, Ute; Feldmann, Heinz] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada; [Jones, Steven M.] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada; [Strong, James E.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Moeller, Peggy] Univ Marburg, Inst Virol, D-3550 Marburg, Hessen, Germany; [Paweska, Janusz T.; Burt, Felicity] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Special Pathogens Unit, Johannesburg, South Africa; [Pablo Palma, Pedro] Med Sans Frontieres, Barcelona, Spain; [Sprecher, Armand] Med Sans Frontieres, Brussels, Belgium; [Formenty, Pierre; Roth, Cathy] WHO, CH-1211 Geneva, Switzerland	Grolla, A (reprint author), Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB, Canada.	feldmannh@niaid.nih.gov			Public Health Agency of Canada	The Mobile Laboratory Unit (MLU) was supported by the Public Health Agency of Canada. The World Health Organization (WHO) provided on-site logistic support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1978, Bull World Health Organ, V56, P271; Bausch DG, 2006, NEW ENGL J MED, V355, P909, DOI 10.1056/NEJMoa051465; Colebunders R, 2007, J INFECT DIS, V196, pS148, DOI 10.1086/520543; Feldmann H, 1996, ADV VIRUS RES, V47, P1, DOI 10.1016/S0065-3527(08)60733-2; Feldmann H, 2005, VIRUS TAXONOMY, P645, DOI DOI 10.1086/503836; Feldmann H, 2006, NEW ENGL J MED, V355, P866, DOI 10.1056/NEJMp068160; Formenty P, 2006, CLIN INFECT DIS, V42, P1521, DOI 10.1086/503836; Fujita N., 2009, Morbidity and Mortality Weekly Report, V58, P1377; GEAR JSS, 1975, BRIT MED J, V4, P489, DOI 10.1136/bmj.4.5995.489; Grolla A, 2005, Bull Soc Pathol Exot, V98, P205; Ignatyev GM, P 1996 ERDEC SCI C C; Jeffs B, 2007, J INFECT DIS, V196, pS154, DOI 10.1086/520548; Johnson ED, 1996, ARCH VIROL, P101; Lee MA, 2002, J CLIN MICROBIOL, V40, P4343, DOI 10.1128/JCM.40.114343-4345.2002; Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a; Martini G.A., 1971, MARBURG VIRUS DIS; Niedrig M, 2004, J CLIN MICROBIOL, V42, P1753, DOI 10.1128/JCM.42.4.1753-1755.2004; Nikiforov V V, 1994, Zh Mikrobiol Epidemiol Immunobiol, P104; Onyango CO, 2007, J INFECT DIS, V196, pS193, DOI 10.1086/520609; Peters CJ, 2005, NEW ENGL J MED, V352, P2571, DOI 10.1056/NEJMp058109; Peters CJ, 1999, J INFECT DIS, V179, pIX; Peters CJ, 1996, ARCH VIROL, P141; Peterson AT, 2004, EMERG INFECT DIS, V10, P40, DOI 10.3201/eid1001.030125; Roddy P, 2007, J INFECT DIS, V196, pS162, DOI 10.1086/520544; Roddy P, 2010, J INFECT DIS, V201, P1909, DOI 10.1086/652748; Sanchez A., 2007, FIELDS VIROLOGY, P1409; SIEGERT R, 1967, DEUT MED WOCHENSCHR, V92, P2341, DOI 10.1055/s-0028-1106144; Slenczka WG, 1999, CURR TOP MICROBIOL, V235, P49; SMITH DH, 1982, LANCET, V1, P816; Stroher U, 2006, EXPERT OPIN INV DRUG, V15, P1523, DOI 10.1517/13543784.15.12.1523; Timen A, 2009, EMERG INFECT DIS, V15, P1171, DOI [10.3201/eid1508.090015, 10.3201/eid1508.090051]; Towner JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000764; Towner JS, 2006, J VIROL, V80, P6497, DOI 10.1128/JVI.00069-06; Towner JS, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000536; Towner JS, 2004, J VIROL, V78, P4330, DOI 10.1128/JVI.78.8.4330-4341.2004; Zaki SR, 1999, J INFECT DIS, V179, pS36, DOI 10.1086/514319	36	34	35	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2011	5	5							e1183	10.1371/journal.pntd.0001183				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	770OZ	WOS:000291099100044	21629730	DOAJ Gold, Green Published			2019-03-26	
J	Kariuki, T; Phillips, R; Njenga, S; Olesen, OF; Klatser, PR; Porro, R; Lock, S; Cabral, MH; Gliber, M; Hanne, D				Kariuki, Thomas; Phillips, Richard; Njenga, Sammy; Olesen, Ole F.; Klatser, Paul R.; Porro, Riccardo; Lock, Sarah; Cabral, Maria Herminia; Gliber, Martina; Hanne, Detlef			Research and Capacity Building for Control of Neglected Tropical Diseases: The Need for a Different Approach	PLOS NEGLECTED TROPICAL DISEASES			English	Article									[Kariuki, Thomas] Natl Museums Kenya, Inst Primate Res, Nairobi, Kenya; [Phillips, Richard] Komfo Anokye Teaching Hosp, KNUST Sch Med Sci, Kumasi, Ghana; [Njenga, Sammy] Ctr Microbiol Res, Kenya Med Res Inst, Nairobi, Kenya; [Olesen, Ole F.] European Commiss, DG Res, Neglected Infect Dis Infect Dis Unit, Brussels, Belgium; [Klatser, Paul R.] KIT Biomed Res, Royal Trop Inst KIT, Amsterdam, Netherlands; [Porro, Riccardo] Fdn Cariplo, Milan, Italy; [Lock, Sarah] Nuffield Fdn, London, England; [Cabral, Maria Herminia] Fundacao Calouste Gulbenkian, Lisbon, Portugal; [Gliber, Martina] Fdn Merieux, Lyon, France; [Hanne, Detlef] Volkswagen Fdn, Hanover, NH USA	Kariuki, T (reprint author), Natl Museums Kenya, Inst Primate Res, Nairobi, Kenya.	hanne@volkswagenstiftung.de		Phillips, Richard/0000-0001-8992-0222; Klatser, Paul/0000-0003-3868-2409; Klatser, Paul/0000-0003-2127-9138	EFINTD Initiatve	R. Porro, M. Gliber, M. H. Cabral, S. Lock and D. Hanne represent the foundations behind the EFINTD Initiative. T. Kariuki, R. Phillips and S. Njenga are receiving funding through the EFINTD Initiatve.	Molyneux DH, 2010, LANCET, V375, P3, DOI 10.1016/S0140-6736(09)61914-0; Molyneux DH, 2005, PLOS MED, V2, P1064, DOI 10.1371/journal.pmed.0020336	2	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAY	2011	5	5							e1020	10.1371/journal.pntd.0001020				2	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	770OZ	WOS:000291099100002	21655352	DOAJ Gold, Green Published			2019-03-26	
J	Baly, A; Flessa, S; Cote, M; Thiramanus, T; Vanlerberghe, V; Villegas, E; Jirarojwatana, S; Van der Stuyft, P				Baly, Alberto; Flessa, Steffen; Cote, Marilys; Thiramanus, Thirapong; Vanlerberghe, Veerle; Villegas, Elci; Jirarojwatana, Somchai; Van der Stuyft, Patrick			The Cost of Routine Aedes aegypti Control and of Insecticide-Treated Curtain Implementation	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							DENGUE VECTOR CONTROL; WATER CONTAINER COVERS; INTERVENTIONS; PREVENTION; CUBA; SANTIAGO; CAMBODIA	Insecticide-treated curtains (ITCs) are promoted for controlling the Dengue vector Aedes aegypti. We assessed the cost of the routine Aedes control program (RACP) and the cost of ITC implementation through the RACP and health committees in Venezuela and through health volunteers in Thailand. The yearly cost of the RACP per household amounted to US$2.14 and $1.89, respectively. The ITC implementation cost over three times more, depending on the channel used. In Venezuela the RACP was the most efficient implementation-channel. It spent US$1.90 (95% confidence interval [CI]: 1.83; 1.97) per curtain distributed, of which 76.9% for the curtain itself. Implementation by health committees cost significantly (P = 0.02) more: US$2.32 (95% CI:1.93;2.61) of which 63% for the curtain. For ITC implementation to be at least as cost-effective as the RACP, at equal effectiveness and actual ITC prices, the attained curtain coverage and the adulticiding effect should last for 3 years.	[Baly, Alberto] Inst Med Trop Pedro Kouri, Subdirecc Epidemiol, Havana, Cuba; [Flessa, Steffen] Ernst Moritz Arndt Univ Greifswald, Fac Law & Econ, Greifswald, Germany; [Cote, Marilys; Villegas, Elci] Univ Los Andes Nucleo Univ Rafael Rangel, Inst Witremundo Torrealba, Trujillo, Venezuela; [Thiramanus, Thirapong] Burapha Univ, Dept Publ Hlth Fundamentals, Fac Publ Hlth, Chon Buri, Thailand; [Vanlerberghe, Veerle; Van der Stuyft, Patrick] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Jirarojwatana, Somchai] Reg Off Dis Prevent & Control Reg 3, Chon Buri, Thailand; Inst Med Trop Pedro Kouri, Havana, Cuba; Univ Los Andes, Res Inst Witremundo Torrealba, Trujillo, Venezuela; Off Dis Prevent & Control, Chon Buri, Thailand	Baly, A (reprint author), Inst Med Trop Pedro Kouri, Subdirecc Epidemiol, Autopista Novia Mediodia Km 6 1-2 La Lisa, Havana, Cuba.	baly@ipk.sld.cu; Steffen.Flessa@uni-greifswald.de; cotema2003@yahoo.com; thirapon@buu.ac.th; vvanlerberghe@itg.be; elciv@ula.ve; rjiraroj@hotmail.com; pvds@itg.be			European Union [INCO-CT-2004-517708]	The study reports partial results of the project DENCO-Towards successful dengue prevention and control, financed by the European Union (INCO-CT-2004-517708).	Armien B, 2008, AM J TROP MED HYG, V79, P364, DOI 10.4269/ajtmh.2008.79.364; Ballenger-Browning KK, 2009, TROP MED INT HEALTH, V14, P1542, DOI 10.1111/j.1365-3156.2009.02396.x; Baly A, 2009, AM J TROP MED HYG, V81, P88, DOI 10.4269/ajtmh.2009.81.88; Eisen L, 2009, J MED ENTOMOL, V46, P1245, DOI 10.1603/033.046.0601; Erlanger TE, 2008, MED VET ENTOMOL, V22, P203, DOI 10.1111/j.1365-2915.2008.00740.x; Esu E, 2010, TROP MED INT HEALTH, V15, P619, DOI 10.1111/j.1365-3156.2010.02489.x; Gold MR, 2006, COST EFFECTIVENESS H; HADDIX A, 2003, PRACTICAL GUIDE PREV; JOHNS B, 2003, COST EFF RESOUR ALLO, V26, P1; Kroeger A, 2006, BRIT MED J, V332, P1247, DOI 10.1136/bmj.332.7552.1247; McCall PJ, 2008, LANCET INFECT DIS, V8, P7, DOI 10.1016/S1473-3099(07)70298-0; Parks W., 2004, WHOCDSWMC20042; Parks W. J., 2004, Dengue Bulletin, V28, P1; Romani MET, 2007, SOC SCI MED, V64, P976, DOI 10.1016/j.socscimed.2006.10.033; Sanchez L, 2009, TROP MED INT HEALTH, V14, P1356, DOI 10.1111/j.1365-3156.2009.02379.x; Seng CM, 2008, J VECTOR ECOL, V33, P333, DOI 10.3376/1081-1710-33.2.333; Suaya JA, 2007, TROP MED INT HEALTH, V12, P1026, DOI 10.1111/j.1365-3156.2007.01889.x; *TDR, 2006, REP SCI WORK GROUP M; Toledo ME, 2007, T ROY SOC TROP MED H, V101, P56, DOI 10.1016/j.trstmh.2006.03.006; Toledo ME, 2008, TROP MED INT HEALTH, V13, P728, DOI 10.1111/j.1365-3156.2008.02046.x; Tun-Lin W, 2009, TROP MED INT HEALTH, V14, P1143, DOI 10.1111/j.1365-3156.2009.02341.x; Vanlerberghe V, 2011, TROP MED INT HEALTH, V16, P162, DOI 10.1111/j.1365-3156.2010.02668.x; Vanlerberghe V, 2010, TROP MED INT HEALTH, V15, P1067, DOI 10.1111/j.1365-3156.2010.02582.x; VANLERBERGHE V, 2009, TROP MED INT HEALTH, V4, P169; VANLERBERGHE V, 2009, BRIT MED J, V338, P1640; *WHO, 2009, DENG GUID DEIG TREAT; 2010, EPIDEMIOLOGY DENGUE	27	21	23	0	5	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAY	2011	84	5					747	752		10.4269/ajtmh.2011.10-0532				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	760ZW	WOS:000290365100015	21540384	Green Published, Bronze			2019-03-26	
J	Tayler-Smith, K; Zachariah, R; Manzi, M; Kizito, W; Vandenbulcke, A; Dunkley, S; von Rege, D; Reid, T; Arnould, L; Suleh, A; Harries, AD				Tayler-Smith, K.; Zachariah, R.; Manzi, M.; Kizito, W.; Vandenbulcke, A.; Dunkley, S.; von Rege, D.; Reid, T.; Arnould, L.; Suleh, A.; Harries, A. D.			Demographic characteristics and opportunistic diseases associated with attrition during preparation for antiretroviral therapy in primary health centres in Kibera, Kenya	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						risk factors; attrition; pre-ART phase; facteurs de risque; attrition; phase pre-ART; factores de riesgo; perdida de pacientes; fase anterior al TAR	FREE STATE PROVINCE; SOUTH-AFRICA; EARLY MORTALITY; FOLLOW-UP; HIV; ADULTS; TUBERCULOSIS; INFECTIONS; PROGRAMS; OUTCOMES	Using routine data from HIV-positive adult patients eligible for antiretroviral therapy (ART), we report on routinely collected demographic characteristics and opportunistic diseases associated with pre-ART attrition (deaths and loss to follow-up). Among 2471 ART eligible patients, enrolled between January 2005 and November 2008, 446(18%) were lost to attrition pre-ART. Adjusted risk factors significantly associated with pre-ART attrition included age < 35 years (Odds Ratio, OR 1.4, 95% Confidence Interval, CI 1.1-1.8), severe malnutrition (OR 1.5, 95% CI 1.1-2.0), active pulmonary tuberculosis (OR 1.6, 95% CI 1.1-2.4), severe bacterial infections including severe bacterial pneumonia (OR 1.9, 95% CI 1.2-2.8) and prolonged unexplained fever (> 1 month), (OR 2.6, 95% CI 1.3-5.2). This study highlights a number of clinical markers associated with pre-ART attrition that could serve as 'pointers' or screening tools to identify patients who merit fast-tracking onto ART and/or closer clinical attention and follow-up.	[Tayler-Smith, K.; Zachariah, R.; Manzi, M.; Reid, T.] Brussels Operat Ctr, Med Dept Operat Res, Luxembourg, Luxembourg; [Kizito, W.; Vandenbulcke, A.; Dunkley, S.; von Rege, D.] Med Sans Frontieres, Nairobi, Kenya; [Arnould, L.] MSF Brussels Operat Ctr, Dept Med, Brussels, Belgium; [Suleh, A.] Minist Hlth, Nairobi, Kenya; [Harries, A. D.] Int Union TB & Lung Dis, Paris, France; [Harries, A. D.] London Sch Hyg & Trop Med, London WC1, England	Zachariah, R (reprint author), Med Sans Frontieres Brussels Operat Ctr, Med Dept Operat Res, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu					Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290; Anglaret X, 2002, AIDS, V16, P909, DOI 10.1097/00002030-200204120-00011; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Braitstein P, 2006, LANCET, V367, P817; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Fox MP, 2010, TROP MED INT HEALTH, V15, P405, DOI 10.1111/j.1365-3156.2010.02473.x; GILKS C, 1990, LANCET, V346, P545; Gilks CF, 1998, BRIT MED BULL, V54, P383; Grant A D, 1997, AIDS, V11 Suppl B, pS43; Ingle SM, 2010, AIDS, V24, P2717, DOI 10.1097/QAD.0b013e32833fb71f; Ingle SM, 2010, SAMJ S AFR MED J, V100, P675, DOI 10.7196/SAMJ.3952; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; Jones N, 1998, AIDS, V12, P2177, DOI 10.1097/00002030-199816000-00013; Larson BA, 2010, TROP MED INT HEALTH, V15, P43, DOI 10.1111/j.1365-3156.2010.02511.x; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; *NASCOP, 2005, GUID ANT DRUG THER K; Peters RPH, 2004, TROP MED INT HEALTH, V9, P928, DOI 10.1111/j.1365-3156.2004.01288.x; Scott JAG, 2000, LANCET, V355, P1225, DOI 10.1016/S0140-6736(00)02089-4; van Griensven J, 2010, T ROY SOC TROP MED H, V104, P690, DOI 10.1016/j.trstmh.2010.07.006; World Health Organization, 2009, WHO RAP ADV ANT THER; ZACHARIAH R, 2010, T ROY SOC TROP MED H, V104, P690	23	13	13	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	MAY	2011	16	5					579	584		10.1111/j.1365-3156.2011.02740.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	751PB	WOS:000289628900007	21306485				2019-03-26	
J	Thomson, A; Khogali, M; de Smet, M; Reid, T; Mukhtar, A; Peterson, S; von Schreeb, J				Thomson, Anna; Khogali, Mohammed; de Smet, Martin; Reid, Tony; Mukhtar, Ahmed; Peterson, Stefan; von Schreeb, John			Low referral completion of rapid diagnostic test-negative patients in community-based treatment of malaria in Sierra Leone	MALARIA JOURNAL			English	Article							HOME-BASED MANAGEMENT; HEALTH WORKERS; CHILDREN; CHLOROQUINE; CARETAKERS; EXPERIENCE; FACILITIES; PNEUMONIA; ADHERENCE; DISTRICT	Background: Malaria is hyper-endemic and a major public health problem in Sierra Leone. To provide malaria treatment closer to the community, Medecins Sans Frontieres (MSF) launched a community-based project where Community Malaria Volunteers (CMVs) tested and treated febrile children and pregnant women for malaria using rapid diagnostic tests (RDTs). RDT-negative patients and severely ill patients were referred to health facilities. This study sought to determine the referral rate and compliance of patients referred by the CMVs. Methods: In MSF's operational area in Bo and Pujehun districts, Sierra Leone, a retrospective analysis of referral records was carried out for a period of three months. All referral records from CMVs and referral health structures were reviewed, compared and matched for personal data. The eligible study population included febrile children between three and 59 months and pregnant women in their second or third trimester with fever who were noted as having received a referral advice in the CMV recording form. Results: The study results showed a total referral rate of almost 15%. During the study period 36 out of 2,459 (1.5%) referred patients completed their referral. There was a significant difference in referral compliance between patients with fever but a negative RDT and patients with signs of severe malaria. Less than 1% (21/2,442) of the RDT-negative patients with fever completed their referral compared to 88.2% (15/17) of the patients with severe malaria (RR = 0.010 95% CI 0.006 - 0.015). Conclusions: In this community-based malaria programme, RDT-negative patients with fever were referred to a health structure for further diagnosis and care with a disappointingly low rate of referral completion. This raises concerns whether use of CMVs, with referral as backup in RDT-negative cases, provides adequate care for febrile children and pregnant women. To improve the referral completion in MSF's community-based malaria programme in Sierra Leone, and in similar community-based programmes, a suitable strategy needs to be defined.	[Thomson, Anna; Peterson, Stefan; von Schreeb, John] Karolinska Inst, Div Global Hlt, Stockholm, Sweden; [Thomson, Anna; de Smet, Martin; Reid, Tony] Med Sans Frontieres Operat Ctr Brussels, Brussels, Belgium; [Khogali, Mohammed; Mukhtar, Ahmed] Med Sans Frontieres Operat Ctr Brussels, Bo, Sierra Leone	Thomson, A (reprint author), Karolinska Inst, Div Global Hlt, Stockholm, Sweden.	anna.thomson@stockholm.msf.org			Swedish National Board for Health and Welfare, Stockholm, Sweden; Medecins Sans Frontieres [09_MSF_ERB_016]	Acknowledgments to the MSF field team and in particular to the data encoders: Eric M. Yajo, Martha Konneh and Alim Barry. We also thank the CMVs in Bo and Pujehun districts, Sierra Leone, who carries out their work tirelessly. The study was supported by a grant from the Swedish National Board for Health and Welfare (project Kunskapscentrum for Katastrofmedicin) in Stockholm, Sweden.	Checchi F, 2005, TROP MED INT HEALTH, V10, P146, DOI 10.1111/j.1365-3156.2004.01367.x; Dawson P, 2008, B WORLD HEALTH ORGAN, V86, P339, DOI 10.2471/BLT.07.047688; Elmardi KA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-39; Haines A, 2007, LANCET, V369, P2121, DOI 10.1016/S0140-6736(07)60325-0; Hawkes M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-308; Hopkins H, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-134; Kallander K, 2006, T ROY SOC TROP MED H, V100, P956, DOI 10.1016/j.trstmh.2005.11.004; Kallander Karin, 2006, BMC Int Health Hum Rights, V6, P2, DOI 10.1186/1472-698X-6-2; Kalter HD, 2003, ACTA PAEDIATR, V92, P103; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; Lemma H, 2010, TROP MED INT HEALTH, V15, P241, DOI 10.1111/j.1365-3156.2009.02447.x; *MSF, 2009, SIERR LEON ANN MED R; MSF, 2008, FULL PRESCR BETT MAL; Okeke TA, 2010, J BIOSOC SCI, V42, P325, DOI 10.1017/S0021932009990484; Okeke TA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-260; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; Sievers Amy C, 2008, World Hosp Health Serv, V44, P28; Simba DO, 2009, TROP MED INT HEALTH, V14, P775, DOI 10.1111/j.1365-3156.2009.02299.x; Tiono AB, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-201; WHO, 2010, WORLD MALARIA REPORT 2010, P1; *WHOSIS, WHOSIS DET DAT SEARC; Winch PJ, 2003, T ROY SOC TROP MED H, V97, P481, DOI 10.1016/S0035-9203(03)80001-9; World Health Organisation, SIERR LEON HLTH PROF; World Health Organization, 2010, GUID TREATM MAL; Yasuoka J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-109; Yeboah-Antwi K, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000340	26	22	22	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	APR 17	2011	10								94	10.1186/1475-2875-10-94				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	770DE	WOS:000291066400001	21496333	DOAJ Gold, Green Published			2019-03-26	
J	Laudisoit, A; Iverson, J; Neerinckx, S; Shako, JC; Nsabimana, JMM; Kersh, G; Kosoy, M; Zeidner, N				Laudisoit, Anne; Iverson, Jennifer; Neerinckx, Simon; Shako, Jean-Christophe; Nsabimana, Jean-Marie Mafuko; Kersh, Gilbert; Kosoy, Michael; Zeidner, Nordin			Human seroreactivity against Bartonella species in the Democratic Republic of Congo	ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE			English	Article						Bartonella; Democratic Republic of Congo; Serology; Human	FLEAS; HENSELAE; SPP.	Objective: To assess the presence and identity of Bartonella species in a pool of human blood samples from DRC Congo. Methods: Blood ( 120 c L) was collected anonymously from Congolese patients and placed on calibrated filter papers. Bartonella serology determination was performed using an indirect immunofluorescence assay (IFA) against six specific Bartonella antigens and Coxiella burnetii (C. burnetii) antigen. The end cut off value for Bartonella sp. was a titre greater than 1:200. Results: None of the patients was positive for Bartonella elizabethae, Bartonella vinsonii subsp. vinsonii or Bartonella vinsonii subsp. arupensis nor for C. burnetti, but 4.5% of the 155 samples were positive for either Bartonella henselae, Bartonella quintana, or Bartonella clarridgeiae. Conclusions: This preliminary study presents the first report of Bartonella species in the DR Congo and the first report of antibodies to Bartonella clarridgeiae in an African human population. Although few experimental trials have established the link between fleas and Bartonella transmission, the repeated detection of similar Bartonella species in fleas and humans in several countries suggests that Bartonellosis could be another flea borne disease which specific reservoirs are still unknown.	[Laudisoit, Anne] Univ Liverpool, Inst Integrat Biol, Biosci Bldg, Liverpool L69 7ZB, Merseyside, England; [Laudisoit, Anne; Neerinckx, Simon] Univ Antwerp, B-2020 Antwerp, Belgium; [Iverson, Jennifer; Kosoy, Michael; Zeidner, Nordin] Ctr Dis Control & Prevent, Ft Collins, CO USA; [Neerinckx, Simon] Katholieke Univ Leuven, B-3001 Heverlee, Belgium; [Shako, Jean-Christophe] Med Reference Lab, Bunia, DEM REP CONGO; [Kersh, Gilbert] Ctr Dis Control & Prevent, Atlanta, GA USA	Laudisoit, A (reprint author), Univ Liverpool, Inst Integrat Biol, Biosci Bldg, Liverpool L69 7ZB, Merseyside, England.	Anne.Laudisoit@liverpool.ac.uk	Laudisoit, Anne/F-2646-2017	Laudisoit, Anne/0000-0001-7626-9426	Belgian Funds for Scientific Research (FNRS); Agriculture and Industry (FRIA)	This study was supported by a Belgian Funds for Scientific Research (FNRS) grant. The authors thank the Belgian Funds for research in Agriculture and Industry (FRIA) and Dr. Eric Bertherat (WHO), for financial assistance and logistical support in the field.	Breitschwerdt EB, 2000, CLIN MICROBIOL REV, V13, P428, DOI 10.1128/CMR.13.3.428-438.2000; Brinkerhoff RJ, 2010, ISME J, V4, P955, DOI 10.1038/ismej.2010.22; Brouqui P, 2005, AM J TROP MED HYG, V73, P1028, DOI 10.4269/ajtmh.2005.73.1028; Chomel BB, 1996, J CLIN MICROBIOL, V34, P1952; DALTON MJ, 1995, ARCH INTERN MED, V155, P1670, DOI 10.1001/archinte.155.15.1670; Houpikian P, 2001, FEMS MICROBIOL LETT, V200, P1, DOI 10.1016/S0378-1097(01)00198-7; LaScola B, 1996, J CLIN MICROBIOL, V34, P2270; Morick D, 2010, APPL ENVIRON MICROB, V76, P6864, DOI 10.1128/AEM.00879-10; Osahon Adesuwa I., 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P150, DOI 10.1016/S2221-1691(11)60015-4; Perez-Martinez L, 2009, EMERG INFECT DIS, V15, P1150, DOI 10.3201/eid1507.081570; Sackal C, 2008, EMERG INFECT DIS, V14, P1972, DOI 10.3201/eid1412.080610	11	8	8	0	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	1995-7645	2352-4146		ASIAN PAC J TROP MED	Asian Pac. J. Trop. Med.	APR	2011	4	4					320	322		10.1016/S1995-7645(11)60094-1				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	809SU	WOS:000294077800014	21771478	DOAJ Gold			2019-03-26	
J	Gidwani, K; Jones, S; Kumar, R; Boelaert, M; Sundar, S				Gidwani, Kamlesh; Jones, Stephen; Kumar, Rajiv; Boelaert, Marleen; Sundar, Shyam			Interferon-Gamma Release Assay (Modified QuantiFERON) as a Potential Marker of Infection for Leishmania donovani, a Proof of Concept Study	PLOS NEGLECTED TROPICAL DISEASES			English	Article							AZAR DERMAL LEISHMANIASIS; VISCERAL LEISHMANIASIS; KALA-AZAR; SKIN-TEST; BANGLADESH	Background: In areas endemic for visceral leishmaniasis (VL), a large number of infected individuals mount a protective cellular immune response and remain asymptomatic carriers. We propose an interferon-gamma release assay (IFN-gamma RA) as a novel marker for latent L. donovani infection. Methods and Findings: We modified a commercial kit (QuantiFERON) evaluating five different leishmania-specific antigens; H2B, H2B-PSA2, H2B-Lepp12, crude soluble antigen (CSA) and soluble leishmania antigen (SLA) from L. donovani with the aim to detect the cell-mediated immune response in VL. We evaluated the assay on venous blood samples of active VL patients (n = 13), cured VL patients (n = 15), non-endemic healthy controls (n = 11) and healthy endemic controls (n = 19). The assay based on SLA had a sensitivity of 80% (95% CI = 54.81-92.95) and specificity of 100% (95% CI = 74.12-100). Conclusion: Our findings suggest that a whole-blood SLA-based QuantiFERON assay can be used to measure the cell-mediated immune response in L. donovani infection. The positive IFN-gamma response to stimulation with leishmania antigen in patients with active VL was contradictory to the conventional finding of a non-proliferative antigen-specific response of peripheral blood mononuclear cells and needs further research.	[Gidwani, Kamlesh; Kumar, Rajiv; Sundar, Shyam] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Jones, Stephen] Cellestis Ltd, Chadstone, Vic, Australia; [Boelaert, Marleen] Inst Trop Med, B-2000 Antwerp, Belgium	Gidwani, K (reprint author), Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India.	drshyamsundar@hotmail.com	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Kumar, Rajiv/0000-0003-2338-1494	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Tropical Medicine Research Centers [1P50AI074321]; Sitaram Memorial Trust, Muzaffarpur, India	This work was supported by National Institute of Allergy and Infectious Diseases, National Institutes of Health, Tropical Medicine Research Centers Grant No. 1P50AI074321. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank the hospital staffs at the Kala-azar Medical Research Centre, Muzaffarpur for their assistance in the collection of blood samples and Mr. Om Prakash Singh for his scientific comments during preparation of manuscript. The care of the patients was supported by Sitaram Memorial Trust, Muzaffarpur, India.	Bern C, 2005, EMERG INFECT DIS, V11, P655, DOI 10.3201/eid1105.040718; Bern C, 2007, AM J TROP MED HYG, V76, P909; Bern C, 2006, AM J TROP MED HYG, V75, P744, DOI 10.4269/ajtmh.2006.75.744; CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209; Costa CHN, 2002, AM J TROP MED HYG, V66, P334, DOI 10.4269/ajtmh.2002.66.334; Gidwani K, 2009, AM J TROP MED HYG, V80, P566, DOI 10.4269/ajtmh.2009.80.566; HALDAR JP, 1983, INFECT IMMUN, V42, P702; HOLADAY BJ, 1993, J CLIN INVEST, V92, P2626, DOI 10.1172/JCI116878; Kumar D, 2008, T ROY SOC TROP MED H, V102, P167, DOI 10.1016/j.trstmh.2007.11.003; le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953; Mol Christopher J, 2006, AAOHN J, V54, P245; Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC; Ostyn B, 2009, TROP MED INT HEALTH, V14, P60; Pai M, 2006, J OCCUP MED TOXICOL, V1, DOI 10.1186/1745-6673-1-7; SCOTT P, 1987, J IMMUNOL, V139, P221; Sundar S, 2002, CLIN DIAGN LAB IMMUN, V9, P951, DOI 10.1128/CDLI.9.5.951-958.2002; Turgay N, 2010, AM J TROP MED HYG, V83, P822, DOI 10.4269/ajtmh.2010.09-0605; ZHOU XH, 2002, STASTICAL METHODS DI; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826	19	28	28	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	APR	2011	5	4							e1042	10.1371/journal.pntd.0001042				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	755MY	WOS:000289937400013	21526219	DOAJ Gold, Green Published			2019-03-26	
J	Oduor, RO; Ojo, KK; Williams, GP; Bertelli, F; Mills, J; Maes, L; Pryde, DC; Parkinson, T; Van Voorhis, WC; Holler, TP				Oduor, Richard O.; Ojo, Kayode K.; Williams, Gareth P.; Bertelli, Francois; Mills, James; Maes, Louis; Pryde, David C.; Parkinson, Tanya; Van Voorhis, Wesley C.; Holler, Tod P.			Trypanosoma brucei Glycogen Synthase Kinase-3, A Target for Anti-Trypanosomal Drug Development: A Public-Private Partnership to Identify Novel Leads	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HUMAN AFRICAN TRYPANOSOMIASIS; PROTEIN-KINASES; BETA-CATENIN; INHIBITORS; GSK-3; GLYCOGEN-SYNTHASE-KINASE-3; CHEMOTHERAPY; INFLAMMATION; MUSCLE; ASSAYS	Background: Trypanosoma brucei, the causative agent of Human African Trypanosomiasis (HAT), expresses two proteins with homology to human glycogen synthase kinase 3 beta (HsGSK-3) designated TbruGSK-3 short and TbruGSK-3 long. TbruGSK-3 short has previously been validated as a potential drug target and since this enzyme has also been pursued as a human drug target, a large number of inhibitors are available for screening against the parasite enzyme. A collaborative industrial/academic partnership facilitated by the World Health Organisation Tropical Diseases Research division (WHO TDR) was initiated to stimulate research aimed at identifying new drugs for treating HAT. Methodology/Principal Findings: A subset of over 16,000 inhibitors of HsGSK-3 beta from the Pfizer compound collection was screened against the shorter of two orthologues of TbruGSK-3. The resulting active compounds were tested for selectivity versus HsGSK-3 beta and a panel of human kinases, as well as in vitro anti-trypanosomal activity. Structural analysis of the human and trypanosomal enzymes was also performed. Conclusions/Significance: We identified potent and selective compounds representing potential attractive starting points for a drug discovery program. Structural analysis of the human and trypanosomal enzymes also revealed hypotheses for further improving selectivity of the compounds.	[Oduor, Richard O.; Parkinson, Tanya; Holler, Tod P.] Pfizer Global Res & Dev, Opportun Partnering Med, Sandwich, Kent, England; [Ojo, Kayode K.; Van Voorhis, Wesley C.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA; [Williams, Gareth P.; Bertelli, Francois] Pfizer Global Res & Dev, High Throughput Screening Ctr Emphasis, Sandwich, Kent, England; [Mills, James; Pryde, David C.] Pfizer Global Res & Dev, Worldwide Med Chem, Sandwich, Kent, England; [Maes, Louis] Univ Antwerp, Lab Microbiol Parasitol & Hyg, B-2020 Antwerp, Belgium	Oduor, RO (reprint author), Kenyatta Univ, Dept Biochem & Biotechnol, Nairobi, Kenya.	tanya.parkinson@pfizer.com	Maes, Louis/A-2384-2017	Maes, Louis/0000-0002-2324-9509	UNICEF/UNDP/World Bank/WHO; United States [NIH5R01AI80625]	The authors would like to acknowledge UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) for supporting this work. The work at the University of Washington was supported by United States NIH grant #5R01AI80625. Richard Odour is a training fellow at Pfizer funded by WHO TDR. WHO TDR also funded the parasite enzyme production and whole parasite and MRC5 cell screening. The funders had no role in study design, data collection or analysis. The funders were consulted regarding the decision to publish and had the opportunity to review the manuscript before submission.	Balde ES, 2010, J ETHNOPHARMACOL, V130, P529, DOI 10.1016/j.jep.2010.05.042; Bertrand JA, 2003, J MOL BIOL, V333, P393, DOI 10.1016/j.jmb.2003.08.031; Bouteille B, 2003, FUND CLIN PHARMACOL, V17, P171, DOI 10.1046/j.1472-8206.2003.00167.x; Burchmore RJS, 2002, CURR PHARM DESIGN, V8, P257, DOI 10.2174/1381612023396159; Card A, 2009, J BIOMOL SCREEN, V14, P31, DOI 10.1177/1087057108326663; Cos P, 2006, J ETHNOPHARMACOL, V106, P290, DOI 10.1016/j.jep.2006.04.003; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Doerig C, 2004, BBA-PROTEINS PROTEOM, V1697, P155, DOI 10.1016/j.bbapap.2003.11.021; Henriksen EJ, 2003, AM J PHYSIOL-ENDOC M, V284, pE892, DOI 10.1152/ajpendo.00346.2002; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kaidanovich-Beilin O, 2006, J PHARMACOL EXP THER, V316, P17, DOI 10.1124/jpet.105.090266; Kennedy PGE, 2008, ANN NEUROL, V64, P116, DOI 10.1002/ana.21429; Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Liao JJL, 2007, J MED CHEM, V50, P409, DOI 10.1021/jm0608107; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martinez A, 2002, MED RES REV, V22, P373, DOI 10.1002/med.10011; Naula C, 2005, BBA-PROTEINS PROTEOM, V1754, P151, DOI 10.1016/j.bbapap.2005.08.018; Ojo KK, 2008, ANTIMICROB AGENTS CH, V52, P3710, DOI 10.1128/AAC.00364-08; Ojo KK, 2010, NAT STRUCT MOL BIOL, V17, P602, DOI 10.1038/nsmb.1818; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; Rodgers J, 2009, BRAIN, V132, P1259, DOI 10.1093/brain/awp074; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Weinmann H, 2005, CHEMBIOCHEM, V6, P455, DOI 10.1002/cbic.200500034; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	30	20	20	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	APR	2011	5	4							e1017	10.1371/journal.pntd.0001017				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	755MY	WOS:000289937400029	21483717	DOAJ Gold, Green Published			2019-03-26	
J	Pyana, PP; Lukusa, IN; Ngoyi, DM; Van Reet, N; Kaiser, M; Bin Shamamba, SK; Buscher, P				Pyana, Patient Pati; Lukusa, Ipos Ngay; Ngoyi, Dieudonne Mumba; Van Reet, Nick; Kaiser, Marcel; Bin Shamamba, Stomy Karhemere; Buscher, Philippe			Isolation of Trypanosoma brucei gambiense from Cured and Relapsed Sleeping Sickness Patients and Adaptation to Laboratory Mice	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HUMAN AFRICAN TRYPANOSOMIASIS; GENETIC-CHARACTERIZATION; ADENOSINE TRANSPORTER; SOUTH SUDAN; MELARSOPROL; RESISTANCE; FAILURE; SITUATION; THERAPY; UGANDA	Background: Sleeping sickness due to Trypanosoma brucei (T.b.) gambiense is still a major public health problem in some central African countries. Historically, relapse rates around 5% have been observed for treatment with melarsoprol, widely used to treat second stage patients. Later, relapse rates of up to 50% have been recorded in some isolated foci in Angola, Sudan, Uganda and Democratic Republic of the Congo (DRC). Previous investigations are not conclusive on whether decreased sensitivity to melarsoprol is responsible for these high relapse rates. Therefore we aimed to establish a parasite collection isolated from cured as well as from relapsed patients for downstream comparative drug sensitivity profiling. A major constraint for this type of investigation is that T.b. gambiense is particularly difficult to isolate and adapt to classical laboratory rodents. Methodology/Principal Findings: From 360 patients treated in Dipumba hospital, Mbuji-Mayi, D.R. Congo, blood and cerebrospinal fluid (CSF) was collected before treatment. From patients relapsing during the 24 months follow-up, the same specimens were collected. Specimens with confirmed parasite presence were frozen in liquid nitrogen in a mixture of Triladyl, egg yolk and phosphate buffered glucose solution. Isolation was achieved by inoculation of the cryopreserved specimens in Grammomys surdaster, Mastomys natalensis and SCID mice. Thus, 85 strains were isolated from blood and CSF of 55 patients. Isolation success was highest in Grammomys surdaster. Forty strains were adapted to mice. From 12 patients, matched strains were isolated before treatment and after relapse. All strains belong to T.b. gambiense type I. Conclusions and Significance: We established a unique collection of T.b. gambiense from cured and relapsed patients, isolated in the same disease focus and within a limited period. This collection is available for genotypic and phenotypic characterisation to investigate the mechanism behind abnormally high treatment failure rates in Mbuji-Mayi, D.R. Congo.	[Pyana, Patient Pati; Lukusa, Ipos Ngay; Ngoyi, Dieudonne Mumba; Bin Shamamba, Stomy Karhemere] Inst Natl Rech Biomed, Kinshasa, Zaire; [Pyana, Patient Pati; Ngoyi, Dieudonne Mumba; Van Reet, Nick; Buscher, Philippe] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Kaiser, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Kaiser, Marcel] Univ Basel, Basel, Switzerland	Pyana, PP (reprint author), Inst Natl Rech Biomed, Kinshasa, Zaire.	pbuscher@itg.be	Van Reet, Nick/D-8406-2011; Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472; Kaiser, Marcel/0000-0003-1785-7302	Belgian Directorate-General for Development Cooperation; Atlanta Research and Education Foundation; World Health Organization Control of Neglected Tropical Diseases; Innovative and Intensified Disease Management; Swiss Tropical and Public Health Institute; Institute of Tropical Medicine	This study received financial support from the Belgian Directorate-General for Development Cooperation, the Atlanta Research and Education Foundation, World Health Organization Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, and the Swiss Tropical and Public Health Institute. PP and DMG benefit from, respectively, a PhD and Post PhD grant from the Institute of Tropical Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AERTS D, 1992, T ROY SOC TROP MED H, V86, P394, DOI 10.1016/0035-9203(92)90234-4; Brun R, 2001, TROP MED INT HEALTH, V6, P906, DOI 10.1046/j.1365-3156.2001.00775.x; Brun R, 2010, LANCET, V375, P148, DOI 10.1016/S0140-6736(09)60829-1; Buscher P, 2005, TROP MED INT HEALTH, V10, P850, DOI 10.1111/j.1365-3156.2005.01468.x; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; de Koning HP, 2008, TRENDS PARASITOL, V24, P345, DOI 10.1016/j.pt.2008.04.006; DUKES P, 1989, T ROY SOC TROP MED H, V83, P636, DOI 10.1016/0035-9203(89)90379-9; Giroud C, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000509; HERBERT WJ, 1976, EXP PARASITOL, V40, P427, DOI 10.1016/0014-4894(76)90110-7; Jamonneau V, 2002, TROP MED INT HEALTH, V7, P610, DOI 10.1046/j.1365-3156.2002.00905.x; Koffi M, 2007, INFECT GENET EVOL, V7, P675, DOI 10.1016/j.meegid.2007.07.001; Legros D, 2002, LANCET INFECT DIS, V2, P437, DOI 10.1016/S1473-3099(02)00321-3; Likeufack ACL, 2006, ACTA TROP, V100, P11, DOI 10.1016/j.actatropica.2006.09.003; Maina N, 2007, ACTA TROP, V104, P84, DOI 10.1016/j.actatropica.2007.07.007; Maina NWN, 2007, T ROY SOC TROP MED H, V101, P540, DOI 10.1016/j.trstmh.2006.11.008; Maina NWN, 2006, ACTA TROP, V98, P207, DOI 10.1016/j.actatropica.2005.11.011; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Matovu E, 2001, MOL BIOCHEM PARASIT, V117, P73, DOI 10.1016/S0166-6851(01)00332-2; Matovu E, 2001, TROP MED INT HEALTH, V6, P407, DOI 10.1046/j.1365-3156.2001.00712.x; Moore A, 2001, TROP MED INT HEALTH, V6, P342, DOI 10.1046/j.1365-3156.2001.00714.x; Morrison LJ, 2008, INFECT GENET EVOL, V8, P847, DOI 10.1016/j.meegid.2008.08.005; Ngoyi DM, 2010, J INFECT DIS, V201, P453, DOI 10.1086/649917; PEPIN J, 1994, T ROY SOC TROP MED H, V88, P447, DOI 10.1016/0035-9203(94)90430-8; Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X; Radwanska M, 2002, AM J TROP MED HYG, V67, P684, DOI 10.4269/ajtmh.2002.67.684; Robays J, 2008, EMERG INFECT DIS, V14, P966, DOI 10.3201/eid1406.071266; Schmid C, 2005, J INFECT DIS, V191, P1922, DOI 10.1086/429929; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Stanghellini A, 2001, TROP MED INT HEALTH, V6, P330, DOI 10.1046/j.1365-3156.2001.00724.x; Welburn SC, 2001, LANCET, V358, P2017, DOI 10.1016/S0140-6736(01)07096-9	30	17	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	APR	2011	5	4							e1025	10.1371/journal.pntd.0001025				6	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	755MY	WOS:000289937400011	21526217	DOAJ Gold, Green Published			2019-03-26	
J	Dhont, N; van de Wijgert, J; Vyankandondera, J; Busasa, R; Gasarabwe, A; Temmerman, M				Dhont, Nathalie; van de Wijgert, Janneke; Vyankandondera, Joseph; Busasa, Rosette; Gasarabwe, Ammiel; Temmerman, Marleen			Results of infertility investigations and follow-up among 312 infertile women and their partners in Kigali, Rwanda	TROPICAL DOCTOR			English	Article							SUB-SAHARAN AFRICA; NIGERIA; HEALTH	The objectives of this study were to assess the outcome of infertility investigations and an 18-month follow-up of 312 infertile women and their partners in Rwanda. Between November 2007 and May 2009, an infertility research clinic was opened. Infertile couples received basic infertility investigations, the available treatment was provided and couples were followed up over an 18-month period. The infertility remained unexplained in 3%, was due to a female factor in 31%, due to a male factor in 16% or due to a combination of male and female causes in 50% of fully investigated couples (n = 224). A tubal factor was found in 69% of women, a male factor in 64% of men. Predictors for tubal infertility in women included a history of high-risk sexual behaviour, HIV infection and a history of sexually transmitted infection (STI) symptoms in the male partner. After 12-18 months of follow-up, 40 pregnancies (16%) had occurred in 244 women. Our study shows high rates of tubal and male factor infertility in Rwanda. Pregnancy rates were low after conventional therapy. In order to provide effective and affordable treatment for infertility in resource-poor countries the development of low-cost assisted reproductive technologies are needed.	[Dhont, Nathalie; Busasa, Rosette; Gasarabwe, Ammiel] Projet Ubuzima, Kiyovu, Kigali, Rwanda; [Dhont, Nathalie; Temmerman, Marleen] Univ Ghent, Int Ctr Reprod Hlth, Ghent, Belgium; [van de Wijgert, Janneke] Univ Amsterdam, Dept Internal Med, Amsterdam, Netherlands; [van de Wijgert, Janneke] Inst Global Hlth & Dev, Amsterdam, Netherlands; [Vyankandondera, Joseph] Belgian Tech Cooperat, Kigali, Rwanda	Dhont, N (reprint author), Projet Ubuzima, Rue Akagera 715, Kiyovu, Kigali, Rwanda.	dhontnathalie@gmail.com			Flemish Interuniversity Council (VLIR-UOS); European and Developing Countries Clinical Trials Partnership (EDCTP); Walking Egg NPO	This study was funded by a PhD grant from the Flemish Interuniversity Council (VLIR-UOS) and by the European and Developing Countries Clinical Trials Partnership (EDCTP) through a project entitled: 'Preparing for Phase III vaginal microbicide trials in Rwanda and Kenya: preparedness studies, capacity building, and strengthening of medical referral systems'. EDCTP cannot accept any responsibility for the information or views expressed in this report. The project also received funding from the 'Walking Egg NPO', Genk 2000.	Bove R, 2009, SOC SCI MED, V68, P21, DOI 10.1016/j.socscimed.2008.09.045; Bukar M, 2009, J OBSTET GYNAECOL, V29, P536, DOI 10.1080/01443610903039146; CATES W, 1985, LANCET, V2, P596; Chigumadzi PT, 1998, TROP DOCT, V28, P168, DOI 10.1177/004947559802800314; COLLET M, 1988, INT J GYNECOL OBSTET, V26, P423, DOI 10.1016/0020-7292(88)90340-2; Cooper TG, 2010, HUM REPROD UPDATE, V16, P231, DOI 10.1093/humupd/dmp048; Dhont N, 2010, HUM REPROD, V25, P2024, DOI 10.1093/humrep/deq161; FIANDER A, 1990, TROP DOCT, V20, P137, DOI 10.1177/004947559002000319; Kiguli-Malwadde Elsie, 2004, Afr Health Sci, V4, P178; Kurewa NE, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-127; Larsen U, 2006, East Afr Med J, V83, P10; Larsen U, 2000, INT J EPIDEMIOL, V29, P285, DOI 10.1093/ije/29.2.285; Mgbor S O, 2005, J Obstet Gynaecol, V25, P504, DOI 10.1080/01443610500171300; Ombelet W, 2007, REPROD BIOMED ONLINE, V15, P257, DOI 10.1016/S1472-6483(10)60337-9; Orhue A, 2008, INT J GYNECOL OBSTET, V101, P11, DOI 10.1016/j.ijgo.2007.09.034; Pritts EA, 2009, FERTIL STERIL, V91, P1215, DOI 10.1016/j.fertnstert.2008.01.051; Stewart-Smythe GW, 2003, SAMJ S AFR MED J, V93, P141; van Balen F, 2009, FACTS VIEWS VIS OBGY, V1, P106; Yahya-Malima KI, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-75	19	7	7	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0049-4755	1758-1133		TROP DOCT	Trop. Dr.	APR	2011	41	2					96	101		10.1258/td.2011.100410				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	757XG	WOS:000290121300009	21421887	Bronze			2019-03-26	
J	Soto, A; Solari, L; Gotuzzo, E; Acinelli, R; Vargas, D; Van der Stuyft, P				Soto, Alonso; Solari, Lely; Gotuzzo, Eduardo; Acinelli, Roberto; Vargas, Dante; Van der Stuyft, Patrick			Performance of an algorithm based on WHO recommendations for the diagnosis of smear-negative pulmonary tuberculosis in patients without HIV infection	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						tuberculosis; pulmonary; algorithms; validation studies; Peru; tuberculose; pulmonaire; algorithmes; etudes de validation; Perou; Tuberculosis; Pulmonar; algoritmos; estudios de validacion; Peru	GROWTH INDICATOR TUBE; TB SUSPECTS; SPUTUM; PREVALENCE; COUGH; TRIAL; MYCOBACTERIA; EPIDEMIOLOGY; MICROSCOPY; COUNTRIES	Objective To evaluate the performance of an algorithm based on WHO recommendations for diagnosis of smear-negative pulmonary tuberculosis in HIV-negative patients. Methods We recruited HIV-negative patients with clinical suspicion of tuberculosis who had had three negative sputum smears in Lima, Peru. All included subjects underwent a complete anamnesis, physical examination and chest X-ray, and had a sputum specimen cultured in Ogawa, Middlebrook 7H9 media and MGIT (R). We applied an algorithm based on WHO recommendations to classify patients as having tuberculosis or not. The diagnostic performance of the algorithm was evaluated comparing its results against the reference standard of a positive culture for M. tuberculosis in either of the media used. Results A total of 264 of the 285 patients included (92.6%) completed evaluation and follow up. Of these, 70 (26.5%) had a positive culture for M. tuberculosis. Clinical response to a broad spectrum course of antibiotics was good in 32 of these 70 patients (45.7; 95%CI 34.0-57.4%). Overall, the algorithm attained a sensitivity of 22.9% (95% CI 13.1-32.7%) and a specificity of 95.4 % (95% CI 92.4-98.3%) compared to culture results. The positive likelihood ratio was 4.93 and the negative likelihood ratio was 0.81. Conclusions The sensitivity and negative likelihood ratio of the algorithm is poor. It should be re-evaluated, and possibly adapted to local circumstances before further use. The clinical response to an antibiotic trial is the most important component to reassess. We also suggest considering performing chest X-ray earlier in the diagnostic work-up.	[Soto, Alonso; Vargas, Dante] Hosp Nacl Hipolito Unanue, Lima 33, Santiago Surco, Peru; [Solari, Lely] Inst Nacl Salud, Lima, Peru; [Gotuzzo, Eduardo] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Van der Stuyft, Patrick] Inst Trop Med, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium	Soto, A (reprint author), Hosp Nacl Hipolito Unanue, Luis Galvani 249, Lima 33, Santiago Surco, Peru.	sotosolari@yahoo.com		Soto, Alonso/0000-0001-8648-8032; Solari, Lely/0000-0002-8041-8807	Damian Foundation	We are grateful to Dr Alberto Mantilla for facilitating the recruitment of patients and to Dr. Marie-Laurence Lambert for participating in the design of the study. The study was funded by the Damian Foundation.	[Anonymous], 1997, TREATM TUB GUID NAT; Apers L, 2003, INT J TUBERC LUNG D, V7, P376; Bah B, 2002, INT J TUBERC LUNG D, V6, P592; Bernabe-Ortiz A, 2008, REV CHIL INFECTOL, V25, P104, DOI [/S0716-10182008000300002, 10.4067/S0716-10182008000200002]; Bruchfeld J, 2000, T ROY SOC TROP MED H, V94, P677, DOI 10.1016/S0035-9203(00)90230-X; Cohen T, 2008, AM J RESP CRIT CARE, V177, P1302, DOI 10.1164/rccm.200801-175PP; Colebunders R, 2000, INT J TUBERC LUNG D, V4, P97; DUJARDIN B, 1994, EUR J EPIDEMIOL, V10, P29, DOI 10.1007/BF01717448; *ESTR SAN NAC PREV, 2008, SIT TUB PER INF GEST; *ESTR SAN NAC PREV, 2006, NORM TECN CONTR TUB; Foulds J, 1998, INT J TUBERC LUNG D, V2, P778; Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0; Goetghebeur E, 2000, STAT METHODS MED RES, V9, P231, DOI 10.1191/096228000701555127; Kanaya AM, 2001, CHEST, V120, P349, DOI 10.1378/chest.120.2.349; Katamba A, 2007, INT J TUBERC LUNG D, V11, P659; Kent PT, 1985, PUBLIC HLTH MYCOBACT; Kim WJ, 2006, RESPIROLOGY, V11, P805, DOI 10.1111/j.1440-1843.2006.00929.x; Kudjawu Y, 2006, INT J TUBERC LUNG D, V10, P441; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Lonnroth K, 2008, SEMIN RESP CRIT CARE, V29, P481, DOI 10.1055/s-0028-1085700; Mase SR, 2007, INT J TUBERC LUNG D, V11, P485; Matthys F, 2009, T ROY SOC TROP MED H, V103, P52, DOI 10.1016/j.trstmh.2008.07.021; Mello FCD, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-43; O'Brien RJ, 2003, INT J TUBERC LUNG D, V7, P198; Otero L, 2010, TROP MED INT HEALTH, V15, P1475, DOI 10.1111/j.1365-3156.2010.02645.x; Siddiqi K, 2006, TROP MED INT HEALTH, V11, P323, DOI 10.1111/j.1365-3156.2006.01559.x; Siddiqi K, 2003, LANCET INFECT DIS, V3, P288, DOI 10.1016/S1473-3099(03)00609-1; Solari L, 2008, INT J TUBERC LUNG D, V12, P619; Somi GR, 1999, INT J TUBERC LUNG D, V3, P231; Somoskovi A, 1999, J CLIN MICROBIOL, V37, P1366; Soto A, 2008, INT J INFECT DIS, V13, P40, DOI DOI 10.1016/J.IJID.2008.03.023; Soto A, 2008, BRAZ J INFECT DIS, V12, P128, DOI 10.1590/S1413-86702008000200006; Van den Ende J, 2007, J EVAL CLIN PRACT, V13, P374, DOI 10.1111/j.1365-2753.2006.00710.x; Vincent JM, 2000, CLIN INFECT DIS, V30, P534, DOI 10.1086/313707; WHO, 2007, IMPR DIAGN TREATM SM; Wilkinson D, 2000, INT J TUBERC LUNG D, V4, P513; Wilkinson D, 1997, T ROY SOC TROP MED H, V91, P422, DOI 10.1016/S0035-9203(97)90264-9; World Health Organisation, 2003, WHOCDSTB2003313	38	13	13	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2011	16	4					424	430		10.1111/j.1365-3156.2010.02715.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	736QP	WOS:000288509500004	21208352	Bronze			2019-03-26	
J	Keugoung, B; Macq, J; Buve, A; Meli, J; Criel, B				Keugoung, Basile; Macq, Jean; Buve, Anne; Meli, Jean; Criel, Bart			The interface between health systems and vertical programmes in Francophone Africa: the managers' perceptions	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						vertical programme; general health service; interface; sub-Saharan Africa	MASS CAMPAIGNS; DEVELOPING-COUNTRIES; IMMUNIZATION; INITIATIVES; SERVICES; CARE; MALI	Objective To explores the interface between vertical programmes (VPs) and general health services (GHS) in sub-Saharan Africa. Methods Using semi-structured interviews, we analysed the perceptions of a selection of experienced mid-level managers of health systems and of VP originating in francophone Africa on the nature and quality of this interface. Results The respondents acknowledged that VPs lead to both positive and negative effects on the functioning of GHS. The overall result, however, cannot be viewed as a simple summation of the positive effects possibly compensating for the negative ones. Indeed, some of the negative effects have a profound impact on the management and operation of the health care delivery system and may undermine the long-term institutional capacity of the general health systems. The quality and the nature of the interface between VP and GHS strongly vary in time, between settings and programmes. Conclusion We argue for more systematic monitoring of the interface between VP and GHS, so as to identify and address, in a timely manner, significant disruptive effects and deficiencies in a perspective of systemic capacity building of health systems.	[Keugoung, Basile] Minist Publ Hlth, Yaounde, Cameroon; [Macq, Jean] Catholic Univ Louvain, B-1200 Brussels, Belgium; [Buve, Anne; Criel, Bart] Inst Trop Med, B-2000 Antwerp, Belgium; [Meli, Jean] Yaounde I Univ, Fac Med & Biomed Sci, Yaounde, Cameroon	Keugoung, B (reprint author), Minist Publ Hlth, Yaounde, Cameroon.	bkeugoung@itg.be					[Anonymous], 2005, PARIS DECLARATION AI; ATUN R, 2010, HLTH POLICY PLANNING, V15, P1; Cavalli A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000798; De Maeseneer J, 2008, BRIT J GEN PRACT, V58, P3, DOI 10.3399/bjgp08X263721; Dietz V, 1997, INT J HEALTH SERV, V27, P767, DOI 10.2190/QPCQ-FBF8-6ABX-2TB5; Gething PW, 2006, PLOS MED, V3, P825, DOI 10.1371/journal.pmed.0030271; Gonzalez C., 1965, MASS CAMPAIGNS GEN H; Hsiao W., 2007, 0713 IMF; Kertesz DA, 2003, J INFECT DIS, V187, pS69, DOI 10.1086/368025; Keugoung B, 2009, LANCET INFECT DIS, V9, P586, DOI 10.1016/S1473-3099(09)70239-7; KOMATSU R, 2006, B WORLD HEALTH ORGAN, V85, P805; Mate KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005483; Mills A, 2005, B WORLD HEALTH ORGAN, V83, P315; Mills A, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P87; Oliveira-Cruz V, 2003, J INT DEV, V15, P67, DOI DOI 10.1002/JID.966; Ooms G, 2008, GLOBALIZATION HEALTH, V4, DOI 10.1186/1744-8603-4-6; Organisation for Economic and Cultural Develepment (OECD), 1991, DAC PRINC EV DEV ASS; PAUL S, 1995, 5 WHO FOR HLTH SECT; Potter C, 2004, HEALTH POLICY PLANN, V19, P336, DOI 10.1093/heapol/czh038; Reerink IH, 1996, INT J QUAL HEALTH C, V8, P131, DOI 10.1093/intqhc/8.2.131; Ricketts T C 3rd, 1990, J Rural Health, V6, P119, DOI 10.1111/j.1748-0361.1990.tb00195.x; Samb B, 2009, LANCET, V373, P2137, DOI 10.1016/S0140-6736(09)60919-3; Swanson RC, 2009, LANCET, V374, P433, DOI 10.1016/S0140-6736(09)61212-5; Szlezak NA, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000183; Unger JP, 2007, EDUC HEALTH, V20, P63; UNGER JP, 1991, SOC SCI MED, V32, P249, DOI 10.1016/0277-9536(91)90101-H; World Health Organization, 2010, KEY COMP WELL FUNCT	27	12	12	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2011	16	4					478	485		10.1111/j.1365-3156.2010.02716.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	736QP	WOS:000288509500010	21219552				2019-03-26	
J	Ravinetto, R; Buve, A; Halidou, T; Lutumba, P; Talisuna, A; Juffrie, M; D'Alessandro, U; Boelaert, M				Ravinetto, Raffaella; Buve, Anne; Halidou, Tinto; Lutumba, Pascal; Talisuna, Ambrose; Juffrie, Mohammad; D'Alessandro, Umberto; Boelaert, Marleen			Double ethical review of North-South collaborative clinical research: hidden paternalism or real partnership?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						clinical trials; ethical review; vulnerability; developing countries; protection of study subjects	COUNTRIES	Despite their universal character, the ethical principles governing clinical research need to be translated into procedures and practices, which will vary among countries and regions because of differences in local cultural norms and in the available resources. Double ethical review, by which a research protocol is submitted for ethical clearance both in the country or countries where the research takes place and in the country of the sponsor or funding agency, will then help ensure that all relevant perspectives are taken into account. In addition, a geographically and culturally close ethics committee can do a much better informed and comprehensive assessment of the respective skills of the clinical sites and of the sponsor. But the practical implementation of double ethical review can bring significant difficulties and delays, especially in multi-site and multi-country researches. Currently, most ethics committees do not proactively seek communication with others evaluating the same research protocol in different socio-economical and cultural contexts, so in practice there is no mutual learning process. Proactive communication would help to build collaborative partnership among ethical bodies, promoting common practices and resolving conflicting opinions.	[Ravinetto, Raffaella] Inst Trop Med Prince Leopold, Clin Trials Unit, B-2000 Antwerp, Belgium; [Buve, Anne] Inst Trop Med Prince Leopold, Dept Microbiol, B-2000 Antwerp, Belgium; [Halidou, Tinto; Lutumba, Pascal] Inst Rech Sci Sante IRSS Ctr Muraz, Bobo Dioulasso, Burkina Faso; [Talisuna, Ambrose] Uganda Infect Dis Res Collaborat, Kampala, Uganda; [Juffrie, Mohammad] Gadjahmada Univ, Fac Med, Dept Pediat, Yogyakarta, Indonesia; [D'Alessandro, Umberto] Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium; [Boelaert, Marleen] Inst Trop Med Prince Leopold, Dept Publ Hlth, B-2000 Antwerp, Belgium	Ravinetto, R (reprint author), Inst Trop Med Prince Leopold, Clin Trials Unit, B-2000 Antwerp, Belgium.	rravinetto@itg.be	Boelaert, Marleen/E-2698-2012; D'Alessandro, Umberto/D-3457-2015	Boelaert, Marleen/0000-0001-8051-6776; D'Alessandro, Umberto/0000-0001-6341-5009; Tinto, Halidou/0000-0002-0472-3586			Ateudjieu J, 2010, DEV WORLD BIOETH, V10, P88, DOI 10.1111/j.1471-8847.2009.00266.x; Benatar SR, 2010, J MED ETHICS, V36, P194, DOI 10.1136/jme.2009.032672; Bompart F, 2008, THERAPIE, V63, P83, DOI [10.2515/therapie:2008023, 10.2515/therapie:2008022]; Council for International Organization of Medical Sciences, 2002, INT ETH GUID BIOM RE; *EMA, 2010, REFL PAP ETH GCP ASP; EZEKIEL J, 2004, J INFECT DIS, V189, P930; Garrafa V, 2008, CAD SAUDE PUBLICA, V24, P2219, DOI 10.1590/S0102-311X2008001000003; Glickman SW, 2009, NEW ENGL J MED, V360, P816, DOI 10.1056/NEJMsb0803929; Hyder AA, 2004, J MED ETHICS, V30, P68, DOI 10.1136/jme.2002.001933; Hyder AA, 2009, LANCET, V373, P862, DOI 10.1016/S0140-6736(09)60488-8; Kass NE, 2007, PLOS MED, V4, P26, DOI 10.1371/journal.pmed.0040003; Kirigia JM, 2005, BMC MED ETHICS, V6, P10, DOI DOI 10.1186/1472-6939-6-10; Lang TA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000619; MACKLIN R, 2008, OXFORD TXB CLIN RES, pCH64; Milford Cecilia, 2006, IRB, V28, P1; National Bioethics Advisory Commission, 2001, ETH POL ISS INT RES, V1; [New Technologies to the European Commission European Group on Ethics in Science], 2003, OP ETH ASP CLIN RES; NKIYA A, 2010, MALARIA J, V9, P86; Nuffield Council on Bioethics, 2002, ETH RES REL HEALTHC; RAVINETTO R, 2010, ITALIAN J TROPICAL M, V15, P15; RAVINETTO R, 2010, ITALIAN J TROPICAL M, V15, P1; RAVINETTO R, 2010, 59 ANN M AM IN PRESS; Rwabihama JP, 2010, J MED ETHICS, V36, P243, DOI 10.1136/jme.2009.033142; *TDR SPEC PROGR RE, 2007, SPEC TOP, V5; *TDR WHO, 2002, SURV EV ETH REV PRAC; *TDR WHO, 2000, OP GUID ETH COMM REV; The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979, BELM REP ETH PRINC G; World Medical Association, 2008, DECL HELS ETH PRINC; 1996, JAMA, V276, P1691	29	11	11	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	APR	2011	16	4					527	530		10.1111/j.1365-3156.2011.02732.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	736QP	WOS:000288509500017	21410849	Bronze			2019-03-26	
J	Jansen, FH				Jansen, Frans Herwig			Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination	MALARIA JOURNAL			English	Editorial Material							PLASMODIUM-FALCIPARUM MALARIA; SULFADOXINE-PYRIMETHAMINE; PREGNANT-WOMEN; RESISTANCE; CHILDREN; TRIAL	Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi). Recommendations for other therapies are being made. By using a different and better sulphonamide (sulphamethoxypyrazine), it is possible to manufacture fixed dose combination pills with artesunate and pyrimethamine. This combination permits a full therapy over 24 hours (dosing interval being 12 hours). It is recommended that this combination should be tested in future field studies of IPTi.	ACT Ion Afrique, Brussels, Belgium	Jansen, FH (reprint author), ACT Ion Afrique, Brussels, Belgium.	fhjansen@actionafrique.com					Adam Ishag, 2006, Ann Clin Microbiol Antimicrob, V5, P18, DOI 10.1186/1476-0711-5-18; Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7; Cairns M, 2009, T ROY SOC TROP MED H, V103, P1199, DOI 10.1016/j.trstmh.2009.06.007; Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0; DEVRIENDT A, 1973, MEDIKON, V2, P185; Gosling RD, 2010, EXPERT REV ANTI-INFE, V8, P589, DOI [10.1586/eri.10.36, 10.1586/ERI.10.36]; Gosling RD, 2009, LANCET, V374, P1521, DOI 10.1016/S0140-6736(09)60997-1; Harrington WE, 2009, P NATL ACAD SCI USA, V106, P9027, DOI 10.1073/pnas.0901415106; McGready R, 2009, LANCET, V374, P1478, DOI 10.1016/S0140-6736(09)61629-9; Menendez C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001934; Mockenhaupt FP, 2008, J INFECT DIS, V198, P1545, DOI 10.1086/592455; Molineaux L., 1980, GARKI PROJECT RES EP; Penali LK, 2008, INT J INFECT DIS, V12, P430, DOI 10.1016/j.ijid.2007.12.006; Peters W., 1984, ANTIMALARIAL DRUGS; Rulisa S, 2007, AM J TROP MED HYG, V77, P612, DOI 10.4269/ajtmh.2007.77.612; Sagara I, 2006, AM J TROP MED HYG, V75, P630, DOI 10.4269/ajtmh.2006.75.630; Sagara I, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-63	17	0	0	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAR 29	2011	10								70	10.1186/1475-2875-10-70				3	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	751VH	WOS:000289645300001	21443809	DOAJ Gold, Green Published			2019-03-26	
J	Cnops, L; Boderie, M; Gillet, P; Van Esbroeck, M; Jacobs, J				Cnops, Lieselotte; Boderie, Merel; Gillet, Philippe; Van Esbroeck, Marjan; Jacobs, Jan			Rapid diagnostic tests as a source of DNA for Plasmodium species-specific real-time PCR	MALARIA JOURNAL			English	Article							POLYMERASE-CHAIN-REACTION; MALARIA PARASITES; QUALITY; BLOOD; ASSAY; IDENTIFICATION; AMPLIFICATION; PERFORMANCE; MICROSCOPY; FALCIPARUM	Background: This study describes the use of malaria rapid diagnostic tests (RDTs) as a source of DNA for Plasmodium species-specific real-time PCR. Methods: First, the best method to recover DNA from RDTs was investigated and then the applicability of this DNA extraction method was assessed on 12 different RDT brands. Finally, two RDT brands (OptiMAL Rapid Malaria Test and SDFK60 malaria Ag Plasmodium falciparum/Pan test) were comprehensively evaluated on a panel of clinical samples submitted for routine malaria diagnosis at ITM. DNA amplification was done with the 18S rRNA real-time PCR targeting the four Plasmodium species. Results of PCR on RDT were compared to those obtained by PCR on whole blood samples. Results: Best results were obtained by isolating DNA from the proximal part of the nitrocellulose component of the RDT strip with a simple DNA elution method. The PCR on RDT showed a detection limit of 0.02 asexual parasites/mu l, which was identical to the same PCR on whole blood. For all 12 RDT brands tested, DNA was detected except for one brand when a low parasite density sample was applied. In RDTs with a plastic seal covering the nitrocellulose strip, DNA extraction was hampered. PCR analysis on clinical RDT samples demonstrated correct identification for single species infections for all RDT samples with asexual parasites of P. falciparum (n = 60), Plasmodium vivax (n = 10), Plasmodium ovale (n = 10) and Plasmodium malariae (n = 10). Samples with only gametocytes were detected in all OptiMAL and in 10 of the 11 SDFK60 tests. None of the negative samples (n = 20) gave a signal by PCR on RDT. With PCR on RDT, higher Ct-values were observed than with PCR on whole blood, with a mean difference of 2.68 for OptiMAL and 3.53 for SDFK60. Mixed infections were correctly identified with PCR on RDT in 4/5 OptiMAL tests and 2/5 SDFK60 tests. Conclusions: RDTs are a reliable source of DNA for Plasmodium real-time PCR. This study demonstrates the best method of RDT fragment sampling for a wide range of RDT brands in combination with a simple and low cost extraction method, allowing RDT quality control.	[Cnops, Lieselotte; Gillet, Philippe; Van Esbroeck, Marjan; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Boderie, Merel; Jacobs, Jan] Fac Hlth Med & Life Sci FHML, Maastricht, Netherlands	Cnops, L (reprint author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	lcnops@itg.be		gillet, philippe/0000-0001-5878-6446			[Anonymous], 2009, WORLD MAL REP 2009; Bell D, 2008, T ROY SOC TROP MED H, V102, P1064, DOI 10.1016/j.trstmh.2008.05.007; Bell D, 2006, NAT REV MICROBIOL, V4, P682, DOI 10.1038/nrmicro1474; Brown  T., 2001, CURR PROTOC IMMUNOL, DOI 10.1002/0471142735.im1006as06; Chilton D, 2006, J CLIN PATHOL, V59, P862, DOI 10.1136/jcp.2005.032904; Chinkhumba J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-209; Chiodini PL, 2007, T ROY SOC TROP MED H, V101, P331, DOI 10.1016/j.trstmh.2006.09.007; CNOPS L, 2010, CLIN MICROBIOL INF; Cnops L, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-370; de Oliveira AM, 2009, AM J TROP MED HYG, V80, P470, DOI 10.4269/ajtmh.2009.80.470; Drakeley C, 2009, T ROY SOC TROP MED H, V103, P333, DOI 10.1016/j.trstmh.2008.10.003; GILLET P, 2010, MALARIA J, V13, P359; Hanscheid T, 2002, TRENDS PARASITOL, V18, P395, DOI 10.1016/S1471-4922(02)02348-6; Hoorfar J, 2004, APMIS, V112, P808, DOI 10.1111/j.1600-0463.2004.apm11211-1207.x; Ishengoma DS, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-6; KAIN KC, 1991, J CLIN MICROBIOL, V29, P1171; Kaltenboeck B, 2005, ADV CLIN CHEM, V40, P219, DOI 10.1016/S0065-2423(05)40006-2; KIMURA M, 1995, MOL BIOCHEM PARASIT, V70, P193, DOI 10.1016/0166-6851(95)00006-M; Kube DM, 1997, NUCLEIC ACIDS RES, V25, P3375, DOI 10.1093/nar/25.16.3375; Mas S, 2007, BASIC CLIN PHARMACOL, V101, P132, DOI 10.1111/j.1742-7843.2007.00089.x; McMorrow ML, 2008, AM J TROP MED HYG, V79, P385, DOI 10.4269/ajtmh.2008.79.385; Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Neumaier M, 1998, CLIN CHEM, V44, P12; Osman MMM, 2010, TROP MED INT HEALTH, V15, P1442, DOI 10.1111/j.1365-3156.2010.02659.x; Scolpel KKG, 2004, MALARIA J, V3, P8; Shokoples SE, 2009, J CLIN MICROBIOL, V47, P975, DOI 10.1128/JCM.01858-08; Singh B, 1999, AM J TROP MED HYG, V60, P687, DOI 10.4269/ajtmh.1999.60.687; Swan H, 2005, AM J TROP MED HYG, V73, P850, DOI 10.4269/ajtmh.2005.73.850; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; Veron V, 2006, AM J TROP MED HYG, V74, P941, DOI 10.4269/ajtmh.2006.74.941; Volpini AC, 2006, CLIN MICROBIOL INFEC, V12, P815, DOI 10.1111/j.1469-0691.2006.01422.x; WHO, 2009, LIST KNOWN COMM AV A; *WHO, 2009, MAL RAP DIAGN TEST P; Wiese L, 2006, SCAND J INFECT DIS, V38, P1063, DOI 10.1080/00365540600818011; Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119, DOI 10.4269/ajtmh.2007.77.119; World Health Organization, 2010, MAL RAP DIAGN TEST P; Xiao Fang-zhen, 2006, Chinese Journal of Parasitology and Parasitic Diseases, V24, P290	38	22	22	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAR 24	2011	10								67	10.1186/1475-2875-10-67				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	748YS	WOS:000289429800001	21435256	DOAJ Gold, Green Published			2019-03-26	
J	Addae-Mensah, I; Fakorede, F; Holtel, A; Nwaka, S				Addae-Mensah, Ivan; Fakorede, Foluke; Holtel, Andreas; Nwaka, Solomon			Traditional medicines as a mechanism for driving research innovation in Africa	MALARIA JOURNAL			English	Review								The outcomes from recent high profile deliberations concerning African health research and economic development all point towards the need for a mechanism to support health innovation on the continent. The mission of the African Network for Drugs and Diagnostics Innovation (ANDI), is to promote and sustain African-led health product innovation to address African public health needs through the assembly of research networks, and building of capacity to support human and economic development. ANDI is widely viewed as the vehicle to implementing some of these recommendations. There is tremendous opportunity for Africa, to leverage the expertise in natural products and traditional medicines in support of this objective to kick-start innovation. This report highlights key recommendations that have emerged through expert forums convened by ANDI on the challenges, opportunities and prospects for investing in this important area of research.	[Fakorede, Foluke; Nwaka, Solomon] WHO, WHO Special Programme Res & Training Trop Dis TDR, World Bank, UNDP,UNICEF, CH-1211 Geneva, Switzerland; [Addae-Mensah, Ivan] Univ Ghana, Dept Chem, Legon, Ghana; [Holtel, Andreas] Commiss European Communities, DG Res Hlth Res Unit, B-1049 Brussels, Belgium	Nwaka, S (reprint author), WHO, WHO Special Programme Res & Training Trop Dis TDR, World Bank, UNDP,UNICEF, CH-1211 Geneva, Switzerland.	nwakas@who.int					Mboya-Okeyo T, 2009, LANCET, V373, P1507, DOI 10.1016/S0140-6736(09)60838-2; NWAKA S, 2010, PLOS MED, V7; Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144; Wambebe CO, 2001, CURR THER RES CLIN E, V62, P26, DOI 10.1016/S0011-393X(01)80039-4; *WHO, 2002, TRAD MED GROW NEEDS, P2; NEW AFRICAN LED HLTH	6	8	8	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	MAR 15	2011	10			1					S9	10.1186/1475-2875-10-S1-S9				4	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	759GW	WOS:000290229700009	21411020	DOAJ Gold, Green Published			2019-03-26	
J	Alemu, A; Abebe, G; Tsegaye, W; Golassa, L				Alemu, Abebe; Abebe, Gemeda; Tsegaye, Wondewossen; Golassa, Lemu			Climatic variables and malaria transmission dynamics in Jimma town, South West Ethiopia	PARASITES & VECTORS			English	Article							EL-NINO; EPIDEMICS; AFRICA	Background:-: In Ethiopia, malaria is seasonal and unstable, causing frequent epidemics. It usually occurs at altitudes < 2,000 m above sea level. Occasionally, transmission of malaria occurs in areas previously free of malaria, including areas > 2,000 m above sea level. For transmission of malaria parasite, climatic factors are important determinants as well as non-climatic factors that can negate climatic influences. Indeed, there is a scarcity of information on the correlation between climatic variability and malaria transmission risk in Ethiopia in general and in the study area in particular. Therefore, the aim of this study was to determine the level of correlation between meteorological variables and malaria cases. Methods: -: Time-series analysis was conducted using data on monthly meteorological variables and monthly total malaria in Jimma town, south west Ethiopia, for the period 2000-2009. All the data were entered and analyzed using SPSS-15 database program. Spearman correlation and linear regression analysis were used to asses association between the variables. Results: -: During last ten years (2000-2009), a fluctuating trend of malaria transmission was observed with P. vivax becoming predominant species. Spearman correlation analysis showed that monthly minimum temperature, total rainfall and two measures of relative humidity were positively related with malaria but monthly maximum temperature negatively related. Also regression analysis suggested that monthly minimum (p = 0.008), monthly maximum temperature (p = 0.013) and monthly total rainfall (p = 0.040), at one month lagged effect, were significant meteorological factors for transmission of malaria in the study area. Conclusion: -: Malaria incidences in the last decade seem to have a significant association with meteorological variables. In future, prospective and multidisciplinary cooperative research involving researchers from the fields of parasitology, epidemiology, botany, agriculture and climatology is necessary to identify the real effect of meteorological factors on vector-borne diseases like malaria.	[Alemu, Abebe; Abebe, Gemeda; Tsegaye, Wondewossen; Golassa, Lemu] Jimma Univ, Dept Med Lab Sci & Pathol, Jimma, Ethiopia; [Alemu, Abebe] Univ Gondar, Coll Med & Hlth Sci, Dept Med Lab Sci, Gondar, Ethiopia; [Abebe, Gemeda] Univ Antwerp, Dept Epidemiol & Social Med, B-2020 Antwerp, Belgium	Alemu, A (reprint author), Jimma Univ, Dept Med Lab Sci & Pathol, Jimma, Ethiopia.	yanbule@gmail.com		Abebe, Gemeda/0000-0002-7172-9136	Jimma University; Anti Malaria Association (AMA)/Climate and Health Working Group of Ethiopia	We are grateful to Jimma University and Anti Malaria Association (AMA)/Climate and Health Working Group of Ethiopia for funding this study. We would also like to extend our heartiest appreciation to Jimma town and zone health bureau for providing malaria data. Also we would like to extend our gratitude to National Meteorological Agency of Ethiopia for providing all necessary meteorological data of the study.	Abeku T, 2004, PARASITOLOGY, V128, P85; ANTHONY J, 2000, LOND SCH HYG TROP ME, V25, P34; Bouma MJ, 2003, T ROY SOC TROP MED H, V97, P133, DOI 10.1016/S0035-9203(03)90099-X; *CDC, LIF CYCL PLASM SPEC; Craig MH, 2004, TROP MED INT HEALTH, V9, P1247, DOI 10.1111/j.1365-3156.2004.01340.x; Craig MH, 1999, PARASITOL TODAY, V15, P105, DOI 10.1016/S0169-4758(99)01396-4; DONALD K, 2000, PUBLIC HLTH REPORT, V118, P65; *FED REP ETH, 2004, MAL DIAGN TREATM GUI; Federal Ministry of Health Ethiopia and World Health Organization, 2007, ENT PROF MAL ETH; GEBEREMARIAM N, 1984, HIGHLIGHTS MALARIA S; HIWOT T, 2008, MALARIA J, V7, P220; ISHAG A, 2005, MALARIA J, V4, P2875; JENNIFER S, 2003, CLIMATIC SUITABILITY, P1911; Jima D, 2005, East Afr Med J, V82, P391; JONATHAN A, 2006, MALARIA RISK TEMPERA, V103, P5635; Kilian AHD, 1999, T ROY SOC TROP MED H, V93, P22, DOI 10.1016/S0035-9203(99)90165-7; Lindsay SW, 2000, LANCET, V355, P989, DOI 10.1016/S0140-6736(00)90022-9; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; Martens P, 2000, EMERG INFECT DIS, V6, P28; Mbogo CM, 2003, AM J TROP MED HYG, V68, P734; *MIN HLTH, 2007, MAL DIAGN TREATM GUI; *MIN HLTH, HLTH HLTH REL IND; Ministry of Health, 2002, GUID MAL VECT CONTR; MMV website, 2008, CUR MAL TOG; REITER P, 2001, CLIM CHANGE MOSQUITO, V109, P223; Rogers DJ, 2000, SCIENCE, V289, P1763; Rowe AK, 2006, INT J EPIDEMIOL, V35, P691, DOI 10.1093/ije/dy1027; Shanks GD, 2002, EMERG INFECT DIS, V8, P1404, DOI 10.3201/eid0812.020077; TSIGE K, 2009, MALARIA J, V8, P177; WHO, 2003, ASS MON ANT DRUG EFF; *WHO, 2000, WHO TECHN REP SER, V892; Woube Mengistu, 1997, Indian Journal of Malariology, V34, P140; Woyessa A, 2004, ETHIOP J HEALTH DEV, V18, P2; Zhou G, 2004, P NATL ACAD SCI USA, V101, P2375, DOI 10.1073/pnas.0308714100; 2005, GLOBAL MALARIA SITUA	35	61	62	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	MAR 2	2011	4								30	10.1186/1756-3305-4-30				11	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	733MS	WOS:000288267400001	21366906	DOAJ Gold, Green Published			2019-03-26	
J	Vanlerberghe, V; Villegas, E; Oviedo, M; Baly, A; Lenhart, A; McCall, PJ; Van der Stuyft, P				Vanlerberghe, Veerle; Villegas, Elci; Oviedo, Milagros; Baly, Alberto; Lenhart, Audrey; McCall, P. J.; Van der Stuyft, Patrick			Evaluation of the Effectiveness of Insecticide Treated Materials for Household Level Dengue Vector Control	PLOS NEGLECTED TROPICAL DISEASES			English	Article							CLUSTER-RANDOMIZED-TRIALS; WATER CONTAINER COVERS; AEDES-AEGYPTI; MESOCYCLOPS COPEPODA; CENTRAL VIETNAM; CUBA; SUSTAINABILITY; INTERVENTIONS; SURVEILLANCE; CURTAINS	Objective: To assess the operational effectiveness of long-lasting insecticide treated materials (ITMs), when used at household level, for the control of Aedes aegypti in moderately infested urban and suburban areas. Methods: In an intervention study, ITMs consisting of curtains and water jar-covers (made from PermaNet) were distributed under routine field conditions in 10 clusters (5 urban and 5 suburban), with over 4000 houses, in Trujillo, Venezuela. Impact of the interventions were determined by comparing pre- and post-intervention measures of the Breteau index (BI, number of positive containers/100 houses) and pupae per person index (PPI), and by comparison with indices from untreated areas of the same municipalities. The effect of ITM coverage was modeled. Results: At distribution, the proportion of households with >= 1 ITM curtain was 79.7% in urban and 75.2% in suburban clusters, but decreased to 32.3% and 39.0%, respectively, after 18 months. The corresponding figures for the proportion of jars using ITM covers were 34.0% and 50.8% at distribution and 17.0% and 21.0% after 18 months, respectively. Prior to intervention, the BI was 8.5 in urban clusters and 42.4 in suburban clusters, and the PPI was 0.2 and 0.9, respectively. In both urban and suburban clusters, the BI showed a sustained 55% decrease, while no discernable pattern was observed at the municipal level. After controlling for confounding factors, the percentage ITM curtain coverage, but not ITM jar-cover coverage, was significantly associated with both entomological indices (Incidence Rate Ratio = 0.98; 95% CI 0.97-0.99). The IRR implied that ITM curtain coverage of at least 50% was necessary to reduce A. aegypti infestation levels by 50%. Conclusion: Deployment of insecticide treated window curtains in households can result in significant reductions in A. aegypti levels when dengue vector infestations are moderate, but the magnitude of the effect depends on the coverage attained, which itself can decline rapidly over time.	[Vanlerberghe, Veerle; Van der Stuyft, Patrick] Inst Trop Med, B-2000 Antwerp, Belgium; [Villegas, Elci; Oviedo, Milagros] Los Andes Univ, Inst Jose Witremundo Torrealba, Trujillo, Venezuela; [Baly, Alberto] Inst Trop Med Pedro Kouri, Havana, Cuba; [Lenhart, Audrey; McCall, P. J.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Vanlerberghe, V (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	vvanlerberghe@itg.be		McCall, Philip/0000-0002-0007-3985	European Union [NCO-CT-2004-517708]; Institute of Tropical Medicine; Belgian Directorate-General for Development Cooperation	The authors received funding from the European Union, DENCO project, Towards successful dengue prevention and control (INCO-CT-2004-517708). The insecticide treated materials were donated by Vestergaard Frandsen, Lausanne, Switzerland. A. Baly was partly supported by the framework agreement between the Institute of Tropical Medicine and the Belgian Directorate-General for Development Cooperation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arredondo-Jimenez JI, 2006, ANN TROP MED PARASIT, V100, pS17, DOI 10.1179/136485906X105480; BALY A, 2008, 2 INT C DENG DENG HA; Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5; Erlanger TE, 2008, MED VET ENTOMOL, V22, P203, DOI 10.1111/j.1365-2915.2008.00740.x; Farrar J, 2007, TROP MED INT HEALTH, V12, P695, DOI 10.1111/j.1365-3156.2007.01838; Focks DA, 1997, AM J TROP MED HYG, V56, P159, DOI 10.4269/ajtmh.1997.56.159; Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Kay B, 2005, LANCET, V365, P613, DOI 10.1016/S0140-6736(05)17913-6; Kay BH, 2002, AM J TROP MED HYG, V66, P40, DOI 10.4269/ajtmh.2002.66.40; Kay BH, 2010, AM J TROP MED HYG, V82, P822, DOI 10.4269/ajtmh.2010.09-0503; KINDHAUSER MK, 2003, GLOBAL DEFENSE INFEC, P140; Kittayapong P, 2008, AM J TROP MED HYG, V78, P70, DOI 10.4269/ajtmh.2008.78.70; Kroeger A, 2006, BRIT MED J, V332, P1247, DOI 10.1136/bmj.332.7552.1247; Lenhart A, 2008, TROP MED INT HEALTH, V13, P56, DOI 10.1111/j.1365-3156.2007.01966.x; MENDEZCASTELLAN.H, 1994, SOC ESTRATIFICACION; Nam VS, 2005, AM J TROP MED HYG, V72, P67, DOI 10.4269/ajtmh.2005.72.67; Perich MJ, 2003, MED VET ENTOMOL, V17, P205, DOI 10.1046/j.1365-2915.2003.00427.x; Phuanukoonnon S, 2005, TROP MED INT HEALTH, V10, P755, DOI 10.1111/j.1365-3156.2005.01452.x; Romani MET, 2007, SOC SCI MED, V64, P976, DOI 10.1016/j.socscimed.2006.10.033; Sanchez L, 2009, TROP MED INT HEALTH, V14, P1356, DOI 10.1111/j.1365-3156.2009.02379.x; Seng CM, 2008, J VECTOR ECOL, V33, P139, DOI 10.3376/1081-1710(2008)33[139:CUOTLF]2.0.CO;2; Seng CM, 2008, J VECTOR ECOL, V33, P333, DOI 10.3376/1081-1710-33.2.333; *TDR, 2006, SCI WORK GROUP M DEN; Toledo ME, 2007, T ROY SOC TROP MED H, V101, P56, DOI 10.1016/j.trstmh.2006.03.006; Toledo ME, 2008, TROP MED INT HEALTH, V13, P728, DOI 10.1111/j.1365-3156.2008.02046.x; Vanlerberghe V, 2010, TROP MED INT HEALTH, V15, P1067, DOI 10.1111/j.1365-3156.2010.02582.x; Vanlerberghe V, 2010, TROP MED INT HEALTH, V15, P60, DOI 10.1111/j.1365-3156.2009.02433.x; Vanlerberghe V, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1959	29	40	40	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAR	2011	5	3							e994	10.1371/journal.pntd.0000994				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	742KI	WOS:000288940800025	21468313	DOAJ Gold, Green Published			2019-03-26	
J	Jayaraman, T; Prabhakaran, V; Babu, P; Raghava, MV; Rajshekhar, V; Dorny, P; Muliyil, J; Oommen, A				Jayaraman, T.; Prabhakaran, V.; Babu, P.; Raghava, M. Venkata; Rajshekhar, V.; Dorny, P.; Muliyil, J.; Oommen, A.			Relative seroprevalence of cysticercus antigens and antibodies and antibodies to Taenia ova in a population sample in south India suggests immunity against neurocysticercosis	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Host immunity; Cysticercus antibodies; Neurocysticercosis; Taenia antigens; Taenia solium ova antibodies; India	SOLIUM ONCOSPHERE ANTIGENS; LINKED-IMMUNOSORBENT-ASSAY; PORCINE CYSTICERCOSIS; VELLORE DISTRICT; INFECTION; EPILEPSY; FIELD; PIGS; IMMUNIZATION; VACCINATION	We evaluated the exposure of a community in Vellore district of south India to Taenia solium infection and its relationship to the prevalence of neurocysticercosis (NCC) causing active epilepsy. Seroprevalence of Taenia cysticercus antigens and antibodies were determined in 1064 randomly chosen asymptomatic individuals, antibodies to T. solium ova in 197 selected sera, and prevalence of taeniasis by a coproantigen test in 729 stool samples. The prevalence of NCC causing active epilepsy in Vellore district was determined in a population of 50 617. Coproantigens were detected in 0.8% (6 samples), Taenia cysticercus antigens in 4.5% (48 sera) and cysticercus IgG antibodies in 15.9% (169 sera) of the population. Cysticercus antibodies were directed against relatively low molecular weight cyst glycoprotein antigens in 14.9% (158 sera) of the population. IgG antibodies to Taenia ova were found in 81(41.1%) of the selected samples. Prevalence of NCC causing active epilepsy was 1.3 per 1000 population. These results show high exposure of the population to the parasite and a relatively high prevalence of active infections (4.5% antigen positives) but a low prevalence of NCC causing active epilepsy (0.13%). These findings may indicate that the population is protected against developing neurocysticercosis. IgG antibodies directed against Taenia ova and low molecular weight cyst antigens may contribute to protection. (C) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Jayaraman, T.; Prabhakaran, V.; Babu, P.; Rajshekhar, V.; Oommen, A.] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632004, Tamil Nadu, India; [Raghava, M. Venkata; Muliyil, J.] Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632004, Tamil Nadu, India; [Dorny, P.] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Dorny, P.] Univ Ghent, Fac Vet Med, Parasitol Lab, Ghent, Belgium	Oommen, A (reprint author), Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632004, Tamil Nadu, India.	anna@cmcvellore.ac.in	Vasudevan, prabhakaran/C-7240-2012; Tharmalingam, Jayaraman/G-2542-2013	Tharmalingam, Jayaraman/0000-0002-7071-2797; Mohan, Venkata Raghava/0000-0001-5787-7223	Indian Council of Medical Research, New Delhi (DO) [SWG/Neuro/3/2001-NCD]; Flemish Interuniversity Council (VLIR), Belgium	This study was funded in part by a Task Force grant from The Indian Council of Medical Research, New Delhi (DO No SWG/Neuro/3/2001-NCD). Research fellowships of TJ and MVR are funded by The Flemish Interuniversity Council (VLIR), Belgium.	Allan JC, 1996, AM J TROP MED HYG, V54, P352, DOI 10.4269/ajtmh.1996.54.352; BOGH HO, 1988, PARASITE IMMUNOL, V10, P255, DOI 10.1111/j.1365-3024.1988.tb00219.x; Cai XP, 2008, INFECT IMMUN, V76, P767, DOI 10.1128/IAI.00444-07; Conlan JV, 2009, TRENDS PARASITOL, V25, P398, DOI 10.1016/j.pt.2009.06.005; deAluja AS, 1996, VET PARASITOL, V61, P49, DOI 10.1016/0304-4017(95)00817-9; Dorny P, 2000, VET PARASITOL, V88, P43, DOI 10.1016/S0304-4017(99)00196-X; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Fleury A, 2006, T ROY SOC TROP MED H, V100, P551, DOI 10.1016/j.trstmh.2005.08.008; Fleury A, 2004, J NEUROL, V251, P830, DOI 10.1007/s00415-004-0437-9; Flisser A, 2004, INFECT IMMUN, V72, P5292, DOI 10.1128/IAI.72.9.5292-5297.2004; FLISSER A, 1979, B WORLD HEALTH ORGAN, V57, P839; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; GARCIA HH, 1993, LANCET, V341, P197, DOI 10.1016/0140-6736(93)90064-N; GEMMELL MA, 1972, AUST VET J, V48, P26, DOI 10.1111/j.1751-0813.1972.tb02204.x; Lightowlers MW, 2003, VET PARASITOL, V115, P83, DOI 10.1016/S0304-4017(03)00202-4; Madigubba S, 2007, Indian J Med Microbiol, V25, P214; MOLINARI JL, 1993, AM J TROP MED HYG, V49, P502, DOI 10.4269/ajtmh.1993.49.502; MOLINARI JL, 1993, J PARASITOL, V79, P124, DOI 10.2307/3283291; Murthy JMK, 1999, SEIZURE-EUR J EPILEP, V8, P162, DOI 10.1053/seiz.1998.0251; Pawlowski Zbigniew S., 2002, P1, DOI 10.1079/9780851996288.0001; Prabhakaran V, 2008, T ROY SOC TROP MED H, V102, P246, DOI 10.1016/j.trstmh.2007.10.010; Prabhakaran V, 2004, T ROY SOC TROP MED H, V98, P478, DOI 10.1016/j.trstmh.2003.12.006; Prado-Jean A, 2007, TROP MED INT HEALTH, V12, P895, DOI 10.1111/j.1365-3156.2007.01860.x; Prasad KN, 2009, T ROY SOC TROP MED H, V103, P144, DOI 10.1016/j.trstmh.2008.07.015; Rajshekhar V, 2006, NEUROLOGY, V67, P2135, DOI 10.1212/01.wnl.0000249113.11824.64; Rodriguez-Hidalgo R, 2006, MEM I OSWALDO CRUZ, V101, P779, DOI 10.1590/S0074-02762006000700012; SCIUTTO E, 1995, VET PARASITOL, V60, P53, DOI 10.1016/0304-4017(94)00781-7; Singh G, 2006, ACTA NEUROL SCAND, V113, P233, DOI 10.1111/j.1600-0404.2005.00575.x; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Verastegui M, 2003, AM J TROP MED HYG, V69, P438, DOI 10.4269/ajtmh.2003.69.438; Verastegui M, 2002, VET PARASITOL, V108, P49, DOI 10.1016/S0304-4017(02)00182-6; Zhang WB, 2001, PARASITOL INT, V50, P279, DOI 10.1016/S1383-5769(01)00086-1	32	10	10	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	MAR	2011	105	3					153	159		10.1016/j.trstmh.2010.10.007				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	740DG	WOS:000288771200006	21216417				2019-03-26	
J	Masaisa, F; Gahutu, JB; Mukiibi, J; Delanghe, J; Philippe, J				Masaisa, Florence; Gahutu, Jean Bosco; Mukiibi, Joshua; Delanghe, Joris; Philippe, Jan			Anemia in Human Immunodeficiency Virus-Infected and Uninfected Women in Rwanda	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; RECOMBINANT-HUMAN-ERYTHROPOIETIN; QUALITY-OF-LIFE; PULMONARY TUBERCULOSIS; HIV-INFECTION; RISK-FACTORS; PREVALENCE; ADULTS; INDIVIDUALS; DIAGNOSIS	To determine the prevalence and risk factors of anemia among human immunodeficiency virus (HIV)-infected women in Rwanda and the influence of highly active antiretroviral therapy (HAART) on anemia, we analyzed 200 HIV-positive women and 50 HIV-negative women in a cross-sectional study. Clinical examinations and iron and vitamin B-12 assays were performed, and complete blood counts, serum folic acid levels, and CD4 cell count determined. The prevalence of anemia was significantly higher among HIV-positive women (29%) than among HIV-negative women (8%) (P < 0.001). Risk factors for anemia were lower body mass index (odds ratio [OR] = 3.4,95% confidence interval [CI] = 2.4-4.1), zidovudine use (OR = 1.14, 95% CI = 1.01-1.29), lack of HAART (OR = 1.44, 95% CI = 1.21-1.67), oral candidiasis (OR = 1.4,95% CI = 1.2-1.6), pulmonary tuberculosis (OR = 1.8, 95% CI = 1.7-2.2), cryptococcal meningitis (OR = 1.6, 95% CI = 1.21-1.8), Pneumocystis jiroveci pneumonia (OR = 1.41, 95% CI = 1.20-1.65) and CD4 lymphocyte count < 200 cells/mu L (OR = 2.41,95% CI = 2.01-3.07). The mean +/- SD hemoglobin level of 10.9 +/- 1.6 g/dL at HAART initiation significantly increased to 12.3 +/- 1.5 g/dL in 8 months (P < 0.001). Anemia increases with HIV stage, and HAART is associated with a significant improvement in hemoglobin levels.	[Gahutu, Jean Bosco] Natl Univ Rwanda, Fac Med, Dept Internal Med, Huye, Rwanda; [Delanghe, Joris; Philippe, Jan] Ghent Univ Hosp, B-9000 Ghent, Belgium; Natl Univ Rwanda, Fac Med, Dept Med Biol, Huye, Rwanda; Univ Ghent, Dept Clin Chem Microbiol & Immunol, Ghent, Belgium	Gahutu, JB (reprint author), Natl Univ Rwanda, Fac Med, Dept Internal Med, POB 30, Huye, Rwanda.	kabasius@yahoo.fr; jgahutu@nur.ac.rw; jmukiibi@nur.ac.rw; joris.delanghe@ugent.be; jan.philippe@ugent.be	Philippe, Jan/A-1027-2008; Gahutu, Jean Bosco/I-3994-2016	Philippe, Jan/0000-0003-4857-5746; Gahutu, Jean Bosco/0000-0002-7969-867X	Flemish Inter-University Council; National University of Rwanda, Faculty of Medicine [ZEIN2007PR342]	This study was supported by the Flemish Inter-University Council in cooperation with the National University of Rwanda, Faculty of Medicine, Project reference: ZEIN2007PR342.	Abrams DI, 2000, INT J STD AIDS, V11, P659, DOI 10.1258/0956462001915020; Belperio PS, 2004, AM J MED, V116, P27, DOI 10.1016/j.amjmed.2003.12.010; Beutler E, 2006, BLOOD, V107, P1747, DOI 10.1182/blood-2005-07-3046; Claster S, 2002, J INFECT DIS, V185, pS105, DOI 10.1086/340202; HENRY DH, 1992, ANN INTERN MED, V117, P739, DOI 10.7326/0003-4819-117-9-739; Jam S, 2009, ARCH IRAN MED, V12, P145; Lewis DK, 2005, T ROY SOC TROP MED H, V99, P561, DOI 10.1016/j.trstmh.2005.01.002; Miller MF, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-1; Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010; Moore RD, 1998, J ACQ IMMUN DEF SYND, V19, P29, DOI 10.1097/00042560-199809010-00004; Moore RD, 2002, J ACQ IMMUN DEF SYND, V29, P54; Morelli P, 2007, EUR J CLIN MICROBIOL, V26, P833, DOI 10.1007/s10096-007-0360-y; Moyle G, 2004, CLIN THER, V26, P92, DOI 10.1016/S0149-2918(04)90009-4; Mugisha JO, 2008, TROP MED INT HEALTH, V13, P788, DOI 10.1111/j.1365-3156.2008.02069.x; NADLER JP, 2004, AIDS READ, V14, P305; O'Brien ME, 2005, JAIDS-J ACQ IMM DEF, V40, P219, DOI 10.1097/01.qai.0000166374.16222.a2; ONYEKACHI I, 2001, CLEV CLIN J MED, V68, P643; REVICKI DA, 1994, J ACQ IMMUN DEF SYND, V7, P474; Semba RD, 2005, ARCH INTERN MED, V165, P2229, DOI 10.1001/archinte.165.19.2229; Semba RD, 2003, CLIN INFECT DIS, V37, pS105, DOI 10.1086/375892; Semba RD, 2001, AIDS PATIENT CARE ST, V15, P473, DOI 10.1089/108729101753145466; Semba RD, 2001, J ACQ IMMUN DEF SYND, V26, P315; Semba RD, 2001, J INVEST MED, V49, P225, DOI 10.2310/6650.2001.33967; Semba RD, 2002, CLIN INFECT DIS, V34, P260, DOI 10.1086/338151; Shah Ira, 2005, Indian Journal of Pediatrics, V72, P359, DOI 10.1007/BF02724022; Shah S, 2001, J NUTR, V131, P2843; Spiga MG, 1999, ANTIVIR RES, V44, P167, DOI 10.1016/S0166-3542(99)00065-0; Sullivan PS, 1998, BLOOD, V91, P301; van Lettow M, 2005, EUR J CLIN NUTR, V59, P526, DOI 10.1038/sj.ejcn.1602116; WHO, 1992, PREV AN WOM TAB AV I	30	16	16	0	5	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR	2011	84	3					456	460		10.4269/ajtmh.2011.10.0519				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	730AK	WOS:000287995600017	21363986				2019-03-26	
J	Beatty, ME; Beutels, P; Meltzer, MI; Shepard, DS; Hombach, J; Hutubessy, R; Dessis, D; Coudeville, L; Dervaux, B; Wichmann, O; Margolis, HS; Kuritsky, JN				Beatty, Mark E.; Beutels, Philippe; Meltzer, Martin I.; Shepard, Donald S.; Hombach, Joachim; Hutubessy, Raymond; Dessis, Damien; Coudeville, Laurent; Dervaux, Benoit; Wichmann, Ole; Margolis, Harold S.; Kuritsky, Joel N.			Health Economics of Dengue: A Systematic Literature Review and Expert Panel's Assessment	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							ADJUSTED LIFE-YEARS; FEVER/DENGUE HEMORRHAGIC-FEVER; AEGYPTI CONTROL PROGRAMS; COST-EFFECTIVENESS; AEDES-AEGYPTI; PUERTO-RICO; CONTINGENT VALUATION; VIRUS-INFECTION; VECTOR CONTROL; PRIMARY-SCHOOL	Dengue vaccines are currently in development and policymakers need appropriate economic studies to determine their potential financial and public health impact. We searched five databases (PubMed, EMBASE, LILAC, EconLit, and WHOLIS) to identify health economics studies of dengue. Forty-three manuscripts were identified that provided primary data: 32 report economic burden of dengue and nine are comparative economic analyses assessing various interventions. The remaining two were a willingness-to-pay study and a policymaker survey. An expert panel reviewed the existing dengue economic literature and recommended future research to fill information gaps. Although dengue is an important vector-borne disease, the economic literature is relatively sparse and results have often been conflicting because of use of inconsistent assumptions. Health economic research specific to dengue is urgently needed to ensure informed decision making on the various options for controlling and preventing this disease.	[Beatty, Mark E.] Int Vaccine Inst, Pediat Dengue Vaccine Initiat, Seoul, South Korea; Univ Antwerp, Ctr Hlth Econ Res & Modeling Infect Dis, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst, B-2020 Antwerp, Belgium; [Beutels, Philippe] Univ Antwerp, Ctr Hlth Econ Res & Modeling Infect Dis CHERMID, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst VAXINFECTIO, B-2020 Antwerp, Belgium; Ctr Dis Control & Prevent, Atlanta, GA USA; [Meltzer, Martin I.] US Ctr Dis Control & Prevent, CDC CCID NCPDCID DEISS, Atlanta, GA USA; [Shepard, Donald S.] Brandeis Univ, Heller Sch, Schneider Inst Hlth Policy, Waltham, MA 02254 USA; [Hombach, Joachim; Hutubessy, Raymond] World Hlth Org, Initiat Vaccine Res, Geneva, Switzerland; [Dessis, Damien] GlaxoSmithKline Biol, Wavre, Belgium; [Coudeville, Laurent] Sanofi Pasteur, Lyon, France; [Dervaux, Benoit] Univ Catholique Lille, Lille, France; [Wichmann, Ole] Robert Koch Inst, D-1000 Berlin, Germany; [Margolis, Harold S.] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR USA; [Kuritsky, Joel N.] US Agcy Int Dev, Washington, DC 20523 USA	Beatty, ME (reprint author), Int Vaccine Inst, Pediat Dengue Vaccine Initiat, San 4-8 Bongcheon 7 Dong, Seoul, South Korea.	mbeatty@pdvi.org; philippe.beutels@ua.ac.be; qzm4@CDC.GOV; shepard@brandeis.edu; hombachj@who.int; hutubessyr@who.int; damien.dessis@gskbio.com; laurent.coudeville@sanofipasteur.com; benoit.dervaux@univ-lille2.fr; WichmannO@rki.de; hsm1@cdc.gov; jkuritsky@usaid.gov	Beutels, Philippe/A-1919-2010; Dervaux, Benoit/A-7161-2014; Calmette, Albert/Q-2318-2016; Dervaux, Benoit/O-6002-2016	Beutels, Philippe/0000-0001-5034-3595; Calmette, Albert/0000-0002-1852-0122; Wichmann, Ole/0000-0003-2353-7188; Dervaux, Benoit/0000-0002-8429-2404	Bill and Melinda Gates Foundation	PDVI is funded solely by The Bill and Melinda Gates Foundation (www.gatesfoundation.org). The systematic review was completed as part of the routine work of PDVI. The donor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam T, 2003, COST EFFECTIVENESS R, V1, P3, DOI DOI 10.1186/1478-7547-1-3; *ADV COMM IMM PRAC, 2004, MMWR RECOMM REP, V49, P13; Anderson KB, 2007, LANCET, V369, P1452, DOI 10.1016/S0140-6736(07)60671-0; Anez G, 2006, REV PANAM SALUD PUBL, V19, P314, DOI 10.1590/S1020-49892006000500004; Armien B, 2008, AM J TROP MED HYG, V79, P364, DOI 10.4269/ajtmh.2008.79.364; ARTHUR D, 1992, PREVENTION DIS TRANS; Baly A, 2007, T ROY SOC TROP MED H, V101, P578, DOI 10.1016/j.trstmh.2007.01.002; Beutels P, 2008, LANCET INFECT DIS, V8, P727, DOI 10.1016/S1473-3099(08)70258-5; Canyon Deon V., 2008, Journal of Vector Borne Diseases, V45, P245; Chareonsook O, 1999, EPIDEMIOL INFECT, V122, P161, DOI 10.1017/S0950268898001617; Clark DV, 2005, AM J TROP MED HYG, V72, P786, DOI 10.4269/ajtmh.2005.72.786; Dechant EJ, 1999, AM J TROP MED HYG, V61, P574, DOI 10.4269/ajtmh.1999.61.574; Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5; DeRoeck D, 2003, VACCINE, V22, P121, DOI 10.1016/S0264-410X(03)00533-4; Egger JR, 2007, EMERG INFECT DIS, V13, P924, DOI 10.3201/eid1306.070008; Endy TP, 2002, AM J EPIDEMIOL, V156, P40, DOI 10.1093/aje/kwf005; Ferrando J, 1995, ESTIMATE COSTS DENGU; Flores G, 2008, HEALTH ECON, V17, P1393, DOI 10.1002/hec.1338; Garg P, 2008, T ROY SOC TROP MED H, V102, P570, DOI 10.1016/j.trstmh.2008.02.015; Graham RR, 1999, AM J TROP MED HYG, V61, P412, DOI 10.4269/ajtmh.1999.61.412; Griebsch I, 2005, PEDIATRICS, V115, pE600, DOI 10.1542/peds.2004-2127; Griffiths UK, 2005, HEALTH POLICY PLANN, V20, P50, DOI 10.1093/heapol/czi006; Gubler DJ, 1999, ADV VIRUS RES, V53, P35, DOI 10.1016/S0065-3527(08)60342-5; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; Gupta E, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-92; Guy B, 2008, VACCINE, V26, P5712, DOI 10.1016/j.vaccine.2008.08.019; Guzman M G, 1992, Rev Cubana Med Trop, V44, P13; Guzman MG, 2003, J CLIN VIROL, V27, P1, DOI 10.1016/S1386-6532(03)00010-6; HANEMANN WM, 1994, J ECON PERSPECT, V8, P19, DOI 10.1257/jep.8.4.19; HARLING R, 1999, J INFECTION, V48, P139; Harving ML, 2007, DAN MED BULL, V54, P170; Huy R, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-155; Jacobs B, 2004, HEALTH POLICY PLANN, V19, P310, DOI 10.1093/heapol/czh036; Johns B, 2003, COST EFF RESOUR ALLO, V1, P1; Kabilan Lalitha, 2004, Indian Journal of Pediatrics, V71, P707, DOI 10.1007/BF02730659; Khun S, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-262; Kim SY, 2008, PHARMACOECONOMICS, V26, P191, DOI 10.2165/00019053-200826030-00004; Kittigul L, 2007, J CLIN VIROL, V39, P76, DOI 10.1016/j.jcv.2007.04.006; LEDUC JL, 2004, GLOBAL BURDEN DIS IN, V4; Lian CW, 2006, TROP BIOMED, V23, P85; Lok C, 1985, SINGAPORES DENGUE HA; Lum LCS, 2008, AM J TROP MED HYG, V78, P862, DOI 10.4269/ajtmh.2008.78.862; Luz PM, 2009, TROP MED INT HEALTH, V14, P237, DOI 10.1111/j.1365-3156.2008.02203.x; Mahoney RT, 1999, VACCINE, V17, P646, DOI 10.1016/S0264-410X(98)00246-1; Mathers CD, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000114; McConnell K. John, 2003, Rev Panam Salud Publica, V14, P9, DOI 10.1590/S1020-49892003000600003; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; Meltzer MI, 1998, AM J TROP MED HYG, V59, P265, DOI 10.4269/ajtmh.1998.59.265; *MIN HLTH BRAZ, 2002, NAT PROGR CONTR DENG; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P481; NAING CM, 2000, SE ASIAN J TROP MED, V31, P636; NATHAN MB, 1993, J AM MOSQUITO CONTR, V9, P1; NEFF JM, 1967, AM J EPIDEMIOL, V86, P162, DOI 10.1093/oxfordjournals.aje.a120722; Nisalak A, 2003, AM J TROP MED HYG, V68, P191, DOI 10.4269/ajtmh.2003.68.191; Okanurak K, 1997, Southeast Asian J Trop Med Public Health, V28, P711; Orellano PW, 2008, REV PANAM SALUD PUBL, V24, P113; Osaka Ken, 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P484; Palanca-Tan R, 2008, VACCINE, V26, P914, DOI 10.1016/j.vaccine.2007.12.011; *PAN AM HLTH ORG, 1997, OPSHCPHCT9097 PAN AM; *PAN AM HLTH ORG, 1997, DENGU DENG HEM FEV A; *PAN AM HLTH ORG, 1997, PAN AM J PUB HLTH, V1, P68; *PED DEN VACC IN, 2006, PED DENG VACC IN; PICKFORDGORDON L, 2008, YEAR DENGUE OUTBREAK; Porter KR, 2005, AM J TROP MED HYG, V72, P60, DOI 10.4269/ajtmh.2005.72.60; Sackett D., 2000, EVIDENCE BASED MED P; Sanchez L, 2006, EMERG INFECT DIS, V12, P800; Sauerborn R, 1996, SOC SCI MED, V43, P281, DOI 10.1016/0277-9536(95)00374-6; *SCI WORK GROUP DE, 2007, REP SCI WORK GROUP D; SCOTT TW, 2004, ECOLOGICAL ASPECTS A; Sharma S. K., 1998, Dengue Bulletin, V22, P36; Shepard DS, 2004, VACCINE, V22, P1275, DOI 10.1016/j.vaccine.2003.09.019; SHEPARD DS, 1993, DIS CONTROL PRIORITI; SIANG LK, 2003, WORST DENGUE EPIDEMI; Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091; Suaya JA, 2007, TROP MED INT HEALTH, V12, P1026, DOI 10.1111/j.1365-3156.2007.01889.x; Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846; Sun W, 2009, HUM VACCINES, V5, P33, DOI 10.4161/hv.5.1.6348; Thiry N, 2004, VACCINE, V22, P3546, DOI 10.1016/j.vaccine.2004.03.043; Torres MI, 1997, HUM ORGAN, V56, P19, DOI 10.17730/humo.56.1.gw72125m546701wh; Tun-Lin W, 2009, TROP MED INT HEALTH, V14, P1143, DOI 10.1111/j.1365-3156.2009.02341.x; Valdés G Luis, 2002, Rev Cubana Med Trop, V54, P220; Van Damme W, 2004, TROP MED INT HEALTH, V9, P273, DOI 10.1046/j.1365-3156.2003.01194.x; VONALLMEN SD, 1979, AM J TROP MED HYG, V28, P1040, DOI 10.4269/ajtmh.1979.28.1040; Welte R, 2005, PHARMACOECONOMICS, V23, P855, DOI 10.2165/00019053-200523090-00001; *WHO, 2009, WHO GUID IND EC CONS; *WHO, 1996, GLOB BURD DIS INJ SE, V2; WHO, 2009, WHOHTMNTDDEN20091; WHO, 2008, GLOB BURD DIS; *WHO, 2005, WORLD HLTH SURV; *WHO, 1996, GLOB BURD DIS INJ SE, V1; *WHO, 2009, YELL FEV; WHO, 1997, DENG HEM FEV DIAGN T; Widdus R, 2005, T ROY SOC TROP MED H, V99, pS1, DOI 10.1016/j.trstmh.2005.06.005; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; WINCH PJ, 1994, SOC SCI MED, V39, P63, DOI 10.1016/0277-9536(94)90166-X; Wong C. Y., 2007, SMJ Singapore Medical Journal, V48, P16; World Health Organization, 2008, WHOIVB0814; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5; York Centre for Reviews and Dissemination, 2001, REP UND SYST REV RES; 2007, TOP TAINAN CHINA HLT; 2007, PARAGUAY DENGUE OFFI; 2007, DENGUE OFFICIALS MAY	102	91	91	0	22	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	MAR	2011	84	3					473	488		10.4269/ajtmh.2011.10-0521				16	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	730AK	WOS:000287995600020	21363989	Green Published, Bronze			2019-03-26	
J	Declercq, E				Declercq, Etienne			Reflections on the new WHO leprosy indicator: The rate of new cases with grade 2 disabilities per 100,000 population per year	LEPROSY REVIEW			English	Editorial Material									Damien Fdn, B-1081 Brussels, Belgium	Declercq, E (reprint author), Damien Fdn, Blvd Leopold II 263, B-1081 Brussels, Belgium.	Etienne.declercq@damien-foundation.be					WHO. World Health Organization, 2009, ENH GLOB STRAT FURTH, P28	1	5	5	0	3	LEPRA	COLCHESTER	28 MIDDLEBOROUGH, COLCHESTER CO1 1TG, ESSEX, ENGLAND	0305-7518			LEPROSY REV	Lepr. Rev.	MAR	2011	82	1					3	5						3	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	864FY	WOS:000298223600002	21644466				2019-03-26	
J	Declercq, E				Declercq, Etienne			Leprosy statistics 2009: some thoughts	LEPROSY REVIEW			English	Editorial Material									Damien Fdn, B-1080 Brussels, Belgium	Declercq, E (reprint author), Damien Fdn, Blvd Leopold II 263, B-1080 Brussels, Belgium.	etienne.declercq@damien-foundation.be					[Anonymous], 2010, WEEKLY EPIDEMIOLOGIC, V85, P337; [Anonymous], 2009, SEAGLP20093 WHO, P28; Declercq E, 2009, LEPROSY REV, V80, P350	3	4	4	0	2	LEPRA	COLCHESTER	28 MIDDLEBOROUGH, COLCHESTER CO1 1TG, ESSEX, ENGLAND	0305-7518			LEPROSY REV	Lepr. Rev.	MAR	2011	82	1					87	89						3	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	Dermatology; Infectious Diseases; Pathology; Tropical Medicine	864FY	WOS:000298223600015	21644478				2019-03-26	
J	Vercruysse, J; Behnke, JM; Albonico, M; Ame, SM; Angebault, C; Bethony, JM; Engels, D; Guillard, B; Hoa, NTV; Kang, G; Kattula, D; Kotze, AC; McCarthy, JS; Mekonnen, Z; Montresor, A; Periago, MV; Sumo, L; Tchuente, LAT; Thach, DTC; Zeynudin, A; Levecke, B				Vercruysse, Jozef; Behnke, Jerzy M.; Albonico, Marco; Ame, Shaali Makame; Angebault, Cecile; Bethony, Jeffrey M.; Engels, Dirk; Guillard, Bertrand; Nguyen Thi Viet Hoa; Kang, Gagandeep; Kattula, Deepthi; Kotze, Andrew C.; McCarthy, James S.; Mekonnen, Zeleke; Montresor, Antonio; Periago, Maria Victoria; Sumo, Laurentine; Tchuente, Louis-Albert Tchuem; Dang Thi Cam Thach; Zeynudin, Ahmed; Levecke, Bruno			Assessment of the Anthelmintic Efficacy of Albendazole in School Children in Seven Countries Where Soil-Transmitted Helminths Are Endemic	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HUMAN HOOKWORM INFECTIONS; ANCYLOSTOMA-DUODENALE; VETERINARY IMPORTANCE; NECATOR-AMERICANUS; DRUG-RESISTANCE; SOUTHERN REGION; MEBENDAZOLE; NEMATODES; ASCARIS; PARASITOLOGY	Background: The three major soil-transmitted helminths (STH) Ascaris lumbricoides, Trichuris trichiura and Necator americanus/Ancylostoma duodenale are among the most widespread parasites worldwide. Despite the global expansion of preventive anthelmintic treatment, standard operating procedures to monitor anthelmintic drug efficacy are lacking. The objective of this study, therefore, was to define the efficacy of a single 400 milligram dose of albendazole (ALB) against these three STH using a standardized protocol. Methodology/Principal Findings: Seven trials were undertaken among school children in Brazil, Cameroon, Cambodia, Ethiopia, India, Tanzania and Vietnam. Efficacy was assessed by the Cure Rate (CR) and the Fecal Egg Count Reduction (FECR) using the McMaster egg counting technique to determine fecal egg counts (FEC). Overall, the highest CRs were observed for A. lumbricoides (98.2%) followed by hookworms (87.8%) and T. trichiura (46.6%). There was considerable variation in the CR for the three parasites across trials (country), by age or the pre-intervention FEC (pre-treatment). The latter is probably the most important as it had a considerable effect on the CR of all three STH. Therapeutic efficacies, as reflected by the FECRs, were very high for A. lumbricoides (99.5%) and hookworms (94.8%) but significantly lower for T. trichiura (50.8%), and were affected to different extents among the 3 species by the pre-intervention FEC counts and trial (country), but not by sex or age. Conclusions/Significance: Our findings suggest that a FECR (based on arithmetic means) of >95% for A. lumbricoides and >90% for hookworms should be the expected minimum in all future surveys, and that therapeutic efficacy below this level following a single dose of ALB should be viewed with concern in light of potential drug resistance. A standard threshold for efficacy against T. trichiura has yet to be established, as a single-dose of ALB is unlikely to be satisfactory for this parasite.	[Vercruysse, Jozef; Levecke, Bruno] Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Merelbeke, Belgium; [Behnke, Jerzy M.] Univ Nottingham, Sch Biol, Nottingham NG7 2RD, England; [Albonico, Marco; Ame, Shaali Makame] Publ Hlth Lab, Pemba Isl, Zanzibar, Tanzania; [Angebault, Cecile; Guillard, Bertrand] Inst Pasteur Cambodia, Clin Pathol Unit, Phnom Penh, Cambodia; [Bethony, Jeffrey M.; Periago, Maria Victoria] Fundacao Oswaldo Cruz, Inst Rene Rachou, Belo Horizonte, MG, Brazil; [Engels, Dirk; Montresor, Antonio] WHO, Dept Neglected Trop Dis, CH-1211 Geneva, Switzerland; [Nguyen Thi Viet Hoa; Dang Thi Cam Thach] Natl Inst Malariol Parasitol & Entomol, Hanoi, Vietnam; [Kang, Gagandeep; Kattula, Deepthi] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore, Tamil Nadu, India; [Kotze, Andrew C.] Commonwealth Sci & Ind Res Org, Div Livestock Ind, Brisbane, Qld, Australia; [McCarthy, James S.] Univ Queensland, Queensland Inst Med Res, Herston, Qld, Australia; [Mekonnen, Zeleke; Zeynudin, Ahmed] Jimma Univ, Coll Publ Hlth & Med Sci, Dept Med Lab Sci & Pathol, Jimma, Ethiopia; [Sumo, Laurentine; Tchuente, Louis-Albert Tchuem] Univ Yaounde 1, Fac Sci, Ctr Schistosomiasis & Parasitol, Yaounde, Cameroon	Vercruysse, J (reprint author), Univ Ghent, Dept Virol Parasitol & Immunol, Fac Vet Med, Merelbeke, Belgium.	Jozef.Vercruysse@ugent.be	Periago, Maria/H-1054-2013; Kotze, andrew/B-5995-2012	Kang, Gagandeep/0000-0002-3656-564X; Periago, Maria Victoria/0000-0002-1470-5146; Levecke, Bruno/0000-0001-8912-5595; ALBONICO, Marco/0000-0002-7805-2391	WHO [2008/12964/0, P2-APW002]; Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) [G.0853.09]	The study was funded in part by the WHO (www.who.int; Ref Nr 2008/12964/0; Reg File Nr P2-APW002). BL is funded by the Fund for Scientific Research-Flanders (Belgium) (F.W.O.-Vlaanderen) (www.fwo.be; Ref Nr G. 0853.09). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albonico M, 2004, INT J PARASITOL, V34, P1205, DOI 10.1016/j.ijpara.2004.08.001; Albonico M, 2003, B WORLD HEALTH ORGAN, V81, P343; ALBONICO M, 1994, T ROY SOC TROP MED H, V88, P585, DOI 10.1016/0035-9203(94)90174-0; Albonico M, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000126; Bennett A, 2000, PARASITOL TODAY, V16, P71, DOI 10.1016/S0169-4758(99)01544-6; Coles GC, 2006, VET PARASITOL, V136, P167, DOI 10.1016/j.vetpar.2005.11.019; COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U; Crawley M, 1993, GLIM ECOLOGISTS; Dayan AD, 2003, ACTA TROP, V86, P141, DOI 10.1016/S0001-706X(03)00031-7; DeClercq D, 1997, AM J TROP MED HYG, V57, P25, DOI 10.4269/ajtmh.1997.57.25; Diawara A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000397; Dobson RJ, 2009, VET PARASITOL, V161, P162, DOI 10.1016/j.vetpar.2008.12.007; ELMASRY NA, 1983, T ROY SOC TROP MED H, V77, P160, DOI 10.1016/0035-9203(83)90056-1; Geerts S, 2001, TROP MED INT HEALTH, V6, P915, DOI 10.1046/j.1365-3156.2001.00774.x; HOAGLAND KE, 1978, EXP PARASITOL, V44, P36, DOI 10.1016/0014-4894(78)90078-4; Hu M, 2003, INT J PARASITOL, V33, P955, DOI 10.1016/S0020-7519(03)00129-2; Keiser J, 2008, JAMA-J AM MED ASSOC, V299, P1937, DOI 10.1001/jama.299.16.1937; Kopp SR, 2008, VET PARASITOL, V152, P284, DOI 10.1016/j.vetpar.2007.12.020; Kotze AC, 2009, PLOS NEGLECT TROP D, V2, pe297; Leles D, 2009, VET PARASITOL, V163, P167, DOI 10.1016/j.vetpar.2009.03.050; Levecke B, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000366; Marti H, 1996, AM J TROP MED HYG, V55, P477, DOI 10.4269/ajtmh.1996.55.477; MCKELLAR QA, 1990, J VET PHARMACOL THER, V13, P223, DOI 10.1111/j.1365-2885.1990.tb00773.x; *MIN AGR FISH FOOD, 1986, MAN VET PAR LAB TECH; Montresor A, 1998, WHOCTDSIP981; Sacko M, 1999, T ROY SOC TROP MED H, V93, P195, DOI 10.1016/S0035-9203(99)90306-1; SANCHEZ SF, 1996, XENOBIOTICA, V25, P307; WHO, 2005, WHOCDSCPEPVC200514, P14; *WHO, 1961, CCTA WHO AFR C ANC B; WHO, 1999, WHOCDSCPCSIP991, P8; Wolstenholme AJ, 2004, TRENDS PARASITOL, V20, P469, DOI 10.1016/j.pt.2004.07.010	31	83	85	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	MAR	2011	5	3							e948	10.1371/journal.pntd.0000948				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	742KI	WOS:000288940800004	21468309	DOAJ Gold, Green Published			2019-03-26	
J	Nambozi, M; Van Geertruyden, JP; Hachizovu, S; Chaponda, M; Mukwamataba, D; Mulenga, M; Ubben, D; D'Alessandro, U				Nambozi, Michael; Van Geertruyden, Jean-Pierre; Hachizovu, Sebastian; Chaponda, Mike; Mukwamataba, Doreen; Mulenga, Modest; Ubben, David; D'Alessandro, Umberto			Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children	MALARIA JOURNAL			English	Article							CHLOROQUINE; PHARMACOKINETICS; PYRIMETHAMINE; RESISTANCE; AFRICA	Background: Malaria in Zambia remains a public health and developmental challenge, affecting mostly children under five and pregnant women. In 2002, the first-line treatment for uncomplicated malaria was changed to artemether-lumefantrine (AL) that has proved to be highly efficacious against multidrug resistant Plasmodium falciparum. Objective: The study objective was to determine whether dihydroartemisinin-piperaquine (DHA/PQP) had similar efficacy, safety and tolerability as AL for the treatment of children with uncomplicated P. falciparum malaria in Ndola, Zambia. Methods: Between 2005 and 2006, 304 children (6-59 months old) with uncomplicated P. falciparum were enrolled, randomized to AL (101) or DHA/PQP (203) and followed up for 42 days. Outcome of treatment was defined according to the standard WHO classification, i.e. early treatment failure (ETF), late clinical failure (LCF, late parasitological failure (LPF) and adequate clinical and parasitological response (ACPR). Recurrent infections were genotyped to distinguish between recrudescence and new infection. Results: No ETF was observed. At day 28, PCR-uncorrected ACPR was 92% in the DHA/PQP and 74% in the AL arm (OR: 4.05; 95% CI: 1.89-8.74; p < 0.001). Most failure were new infections and PCR-corrected ACPR was similar in the two study arms (OR: 0.69; 95% CI: 0.22-2.26; p = 0.33). Similar results were observed for day 42, i.e. higher PCR-uncorrected ACPR for DHA/PQP, mainly due to the difference observed up to day 28, while the PCR-corrected ACPR was similar: DHA/PQP: 93% (179/192), AL: 93% (84/90), (OR: 0.92; 95% CI: 0.30-2.64; p = 0.85). Except for cough, more frequent in the DHA/PQP arm (p = 0.04), there were no differences between treatment arms in the occurrence of adverse events. Two serious adverse events were probably associated to AL treatment. Conclusion: DHA/PQP was as efficacious, safe and well tolerated in treatment of uncomplicated malaria as AL, though in the latter group more new infections during the follow up were observed. DHA/PQP seems a potential candidate to be used as an alternative first-line or rescue treatment in Zambia.	[Nambozi, Michael; Hachizovu, Sebastian; Chaponda, Mike; Mukwamataba, Doreen; Mulenga, Modest] Trop Dis Res Ctr, Dept Clin Sci, Ndola, Zambia; [Van Geertruyden, Jean-Pierre] Int Hlth Unit, BE-2610 Antwerp, Belgium; [Van Geertruyden, Jean-Pierre] Univ Antwerp, B-2020 Antwerp, Belgium; [Ubben, David] Med Malaria Venture, CH-1215 Geneva 15, Switzerland; [D'Alessandro, Umberto] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Nambozi, M (reprint author), Trop Dis Res Ctr, Dept Clin Sci, POB 71769, Ndola, Zambia.	michaelnambozi@yahoo.com	Van geertruyden, Jean-Pierre/K-6425-2014; D'Alessandro, Umberto/D-3457-2015	Van geertruyden, Jean-Pierre/0000-0001-5006-6364; D'Alessandro, Umberto/0000-0001-6341-5009	MMV	The first gratitude goes to the mothers/guardians and children from Ndola district who participated in the study without whom, we would not have reached our goals. Special thanks to TDRC clinical sciences department staff for being able help in data collection. Other staffs in the study were Dr Ignatius Gashongore, Daniel Mutale, Millie Chisenga, Diffie Gondwe, Beth Malunga, and laboratory staff in biochemistry department. We also would like pay our gratitude to the MDC Pharma Services for monitoring the study and MMV for funding it.	Barat LM, 1998, TROP MED INT HEALTH, V3, P535, DOI 10.1046/j.1365-3156.1998.00271.x; Bassat Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007871; Bijl HM, 2000, TROP MED INT HEALTH, V5, P692, DOI 10.1046/j.1365-3156.2000.00629.x; EKUE JMK, 1983, BRIT MED J, V286, P1315, DOI 10.1136/bmj.286.6374.1315-a; Ezzet F, 2000, ANTIMICROB AGENTS CH, V44, P697, DOI 10.1128/AAC.44.3.697-704.2000; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607; Hung TY, 2004, BRIT J CLIN PHARMACO, V57, P253, DOI [10.1046/j.1365-2125.2003.02004.x, 10.1111/j.1365-2125.2003.02004.x]; Kamya MR, 2007, PLOS CLIN TRIALS, V2, DOI 10.1371/journal.pctr.0020020; Karema C, 2006, T ROY SOC TROP MED H, V100, P1105, DOI 10.1016/j.trstmh.2006.01.001; KHAN AA, 1978, BRIT MED J, V1, P1669, DOI 10.1136/bmj.1.6128.1669; Martensson A, 2005, CLIN INFECT DIS, V41, P1079, DOI 10.1086/444460; *MIN FIN, 2010, MILL DEV GOALS STAT; *MIN HLTH NAT MAL, 2010, NDOL DISTR HLTH MAN; Mulenga M, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-73; *NAT MAL CONTR CTR, 2006, NAT ACT PLAN ACT SCA; *NAT MAL CONTR CTR, 2000, NAT MAL SIT AN; *NAT MAL CONTR CTR, 2006, ZAMB NAT MAL IND SUR; Piola P, 2005, LANCET, V365, P1467, DOI 10.1016/S0140-6736(05)66416-1; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Ratcliff A, 2007, LANCET, V369, P757, DOI 10.1016/S0140-6736(07)60160-3; Sipilanyambe N, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-25; Smithuis F, 2006, LANCET, V367, P2075, DOI 10.1016/S0140-6736(06)68931-9; Whitty CJM, 2005, CLIN INFECT DIS, V41, P1087, DOI 10.1086/444464; WHO, 2003, ASS MON ANT DRUG EFF; World Health Organization, 2010, GUID TREATM MAL; World Health Organization, 2006, WHO CHILD GROWTH STA; World Health Organization (WHO), 2001, ANT DRUG COMB THER R; Zurovac D, 2005, BRIT MED J, V331, P734, DOI 10.1136/bmj.331.7519.734	28	36	37	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	FEB 28	2011	10								50	10.1186/1475-2875-10-50				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	740SI	WOS:000288814300003	21352609	DOAJ Gold, Green Published			2019-03-26	
J	Verbeken, M; Suleman, S; Baert, B; Vangheluwe, E; Van Dorpe, S; Burvenich, C; Duchateau, L; Jansen, FH; De Spiegeleer, B				Verbeken, Mathieu; Suleman, Sultan; Baert, Bram; Vangheluwe, Elien; Van Dorpe, Sylvia; Burvenich, Christian; Duchateau, Luc; Jansen, Frans H.; De Spiegeleer, Bart			Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine	MALARIA JOURNAL			English	Article							FALCIPARUM-MALARIA; ARTEMETHER-LUMEFANTRINE; MASS-SPECTROMETRY; CGP 56697; BENFLUMETOL; CHILDREN; EFFICACY; TABLETS; SAFETY	Background: Lumefantrine (benflumetol) is a fluorene derivative belonging to the aryl amino alcohol class of antimalarial drugs and is commercially available in fixed combination products with beta-artemether. Impurity characterization of such drugs, which are widely consumed in tropical countries for malaria control programmes, is of paramount importance. However, until now, no exhaustive impurity profile of lumefantrine has been established, encompassing process-related and degradation impurities in active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs). Methods: Using HPLC-DAD/UV-ESI/ion trap/MS, a comprehensive impurity profile was established based upon analysis of market samples as well as stress, accelerated and long-term stability results. In-silico toxicological predictions for these lumefantrine related impurities were made using Toxtree(R) and Derek(R). Results: Several new impurities are identified, of which the desbenzylketo derivative (DBK) is proposed as a new specified degradant. DBK and the remaining unspecified lumefantrine related impurities are predicted, using Toxtree(R) and Derek(R), to have a toxicity risk comparable to the toxicity risk of the API lumefantrine itself. Conclusions: From unstressed, stressed and accelerated stability samples of lumefantrine API and FPPs, nine compounds were detected and characterized to be lumefantrine related impurities. One new lumefantrine related compound, DBK, was identified and characterized as a specified degradation impurity of lumefantrine in real market samples (FPPs). The in-silico toxicological investigation (Toxtree(R) and Derek(R)) indicated overall a toxicity risk for lumefantrine related impurities comparable to that of the API lumefantrine itself.	[Verbeken, Mathieu; Suleman, Sultan; Baert, Bram; Vangheluwe, Elien; Van Dorpe, Sylvia; De Spiegeleer, Bart] Univ Ghent, Fac Pharmaceut Sci, Drug Qual & Registrat DruQuaR Grp, B-9000 Ghent, Belgium; [Burvenich, Christian; Duchateau, Luc] Univ Ghent, Fac Vet Med, Dept Physiol & Biometr, B-9820 Merelbeke, Belgium; [Suleman, Sultan] Jimma Univ, Sch Pharm, Jimma, Ethiopia; [Jansen, Frans H.] Fdn ACT Ion Afrique, B-1000 Brussels, Belgium	De Spiegeleer, B (reprint author), Univ Ghent, Fac Pharmaceut Sci, Drug Qual & Registrat DruQuaR Grp, Harelbekestr 72, B-9000 Ghent, Belgium.	Bart.Despiegeleer@UGent.be	De Spiegeleer, Bart/A-2001-2008	De Spiegeleer, Bart/0000-0001-6794-3108	(Jimma University) of VLIR; Dafra	The authors would like to thank Dafra Pharmaceuticals (Turnhout, Belgium) for the provision of the reference substances, as well as their interest and support in this investigation. Moreover, one of the authors (SS) is supported by the Epidemiology and Modeling Project within the Institutional University Cooperation Programme (Jimma University) of VLIR.; The authors, MV, BB, EVG and BDS would like to acknowledge that Dafra sponsored the analytical development. However, these authors do not work for, or represent in any way, Dafra. FHJ is partly working for Dafra.	[Anonymous], 2006, CPMPICH273799; Ballereau F, 1997, AM J TROP MED HYG, V57, P31, DOI 10.4269/ajtmh.1997.57.31; Bari SB, 2007, EURASIAN J ANAL CHEM, V2, P32, DOI 10.12973/ejac.2007.00009a; Cesar ID, 2008, J PHARMACEUT BIOMED, V48, P951, DOI 10.1016/j.jpba.2008.05.022; Cesar ID, 2008, J PHARMACEUT BIOMED, V48, P223, DOI 10.1016/j.jpba.2008.05.006; De Spiegeleer B, 2008, ANAL BIOCHEM, V376, P229, DOI 10.1016/j.ab.2008.02.014; de Villiers KA, 2009, MOLECULES, V14, P2868, DOI 10.3390/molecules14082868; Ellison CM, 2010, MOL INFORM, V29, P97, DOI 10.1002/minf.200900006; Falade C, 2005, T ROY SOC TROP MED H, V99, P459, DOI 10.1016/j.trstmh.2004.09.013; Hatz C, 1998, TROP MED INT HEALTH, V3, P498, DOI 10.1046/j.1365-3156.1998.00250.x; ICH Q1A(R2), 2003, STAB TEST NEW DRUG S; KRISTIANSEN E, 1995, TOXICOL LETT, V80, P147, DOI 10.1016/0378-4274(95)03390-7; Lee H, 2005, J LIQ CHROMATOGR R T, V28, P1161, DOI 10.1081/JLC-200053022; Mohan CG, 2007, MINI-REV MED CHEM, V7, P499; Munjal V, 2010, CHROMATOGRAPHIA, V71, P505, DOI 10.1365/s10337-009-1446-8; Munro IC, 2008, TOXICOL LETT, V180, P151, DOI 10.1016/j.toxlet.2008.05.006; Nicolas EC, 1998, J PHARMACEUT BIOMED, V16, P813, DOI 10.1016/S0731-7085(97)00131-3; Patil KR, 2009, CHROMATOGRAPHIA, V69, P375, DOI 10.1365/s10337-008-0894-x; Pirker-Krassnig DK, 2004, WIEN KLIN WOCHENSCHR, V116, P47; ROY J, 2002, AAPS PHARMSCITECH, V3; Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003; van Vugt M, 2000, T ROY SOC TROP MED H, V94, P545, DOI 10.1016/S0035-9203(00)90082-8; Van Vugt M, 1997, SOC PSYCHOL QUART, V60, P355; Vergote V, 2009, J PEPT SCI, V15, P697, DOI 10.1002/psc.1167; vonSeidlein L, 1997, J INFECT DIS, V176, P1113, DOI 10.1086/516524; Wernsdorfer WH, 1998, ACTA TROP, V70, P9, DOI 10.1016/S0001-706X(97)00141-1; 2010, LABVIEW; 2009, APREPITANT INTERVIEW	28	12	12	2	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	FEB 28	2011	10								51	10.1186/1475-2875-10-51				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	740SI	WOS:000288814300004	21356068	DOAJ Gold, Green Published			2019-03-26	
J	Aregawi, MW; Ali, AS; Al-Mafazy, AW; Molteni, F; Katikiti, S; Warsame, M; Njau, RJ; Komatsu, R; Korenromp, E; Hosseini, M; Low-Beer, D; Bjorkman, A; D'Alessandro, U; Coosemans, M; Otten, M				Aregawi, Maru W.; Ali, Abdullah S.; Al-Mafazy, Abdul-Wahiyd; Molteni, Fabrizio; Katikiti, Samson; Warsame, Marian; Njau, Ritha Ja; Komatsu, Ryuichi; Korenromp, Eline; Hosseini, Mehran; Low-Beer, Daniel; Bjorkman, Anders; D'Alessandro, Umberto; Coosemans, Marc; Otten, Mac			Reductions in malaria and anaemia case and death burden at hospitals following scale-up of malaria control in Zanzibar, 1999-2008	MALARIA JOURNAL			English	Article							CHILD SURVIVAL; MORTALITY; AFRICA; IMPACT	Background: In Zanzibar, the Ministry of Health and partners accelerated malaria control from September 2003 onwards. The impact of the scale-up of insecticide-treated nets (ITN), indoor-residual spraying (IRS) and artemisinin-combination therapy (ACT) combined on malaria burden was assessed at six out of seven in-patient health facilities. Methods: Numbers of outpatient and inpatient cases and deaths were compared between 2008 and the pre-intervention period 1999-2003. Reductions were estimated by segmented log-linear regression, adjusting the effect size for time trends during the pre-intervention period. Results: In 2008, for all age groups combined, malaria deaths had fallen by an estimated 90% (95% confidence interval 55-98%)(p < 0.025), malaria in-patient cases by 78% (48-90%), and parasitologically-confirmed malaria outpatient cases by 99.5% (92-99.9%). Anaemia in-patient cases decreased by 87% (57-96%); anaemia deaths and outpatient cases declined without reaching statistical significance due to small numbers. Reductions were similar for children under-five and older ages. Among under-fives, the proportion of all-cause deaths due to malaria fell from 46% in 1999-2003 to 12% in 2008 (p < 0.01) and that for anaemia from 26% to 4% (p < 0.01). Cases and deaths due to other causes fluctuated or increased over 1999-2008, without consistent difference in the trend before and after 2003. Conclusions: Scaling-up effective malaria interventions reduced malaria-related burden at health facilities by over 75% within 5 years. In high-malaria settings, intensified malaria control can substantially contribute to reaching the Millennium Development Goal 4 target of reducing under-five mortality by two-thirds between 1990 and 2015.	[Aregawi, Maru W.; Warsame, Marian; Otten, Mac] WHO, Global Malaria Programme, CH-1211 Geneva 27, Switzerland; [Katikiti, Samson] WHO, Intercountry Support Team So & Eastern Africa, Reg Off Africa AFRO, Harare, Zimbabwe; [Komatsu, Ryuichi; Korenromp, Eline; Hosseini, Mehran; Low-Beer, Daniel] Global Fund AIDS TB & Malaria, Geneva, Switzerland; [Korenromp, Eline] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Njau, Ritha Ja] WHO, Country Off, Dar Es Salaam, Tanzania; [D'Alessandro, Umberto; Coosemans, Marc] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Bjorkman, Anders] Karolinska Univ Hosp, Dept Med, Solna, Sweden	Aregawi, MW (reprint author), WHO, Global Malaria Programme, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	aregawim@who.int	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009	Global Fund	We thank the Zanzibar Malaria Control Programme for their full support in availing field staff and providing all data and information used in this study. The Global Fund for their funding to cover all costs related to this study. Dr R. Newman, Director of Global Malaria Programme (GMP) of WHO revised it critically for important intellectual content.	Akech SO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-256; [Anonymous], 2008, GLOB MAL ACT PLAN MA; Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2; Craig MH, 1999, PARASITOL TODAY, V15, P105, DOI 10.1016/S0169-4758(99)01396-4; Government of the Republic of Zambia Ministry of Health. Zambia M of H Government of the Republic of, 2010, ZAMB NAT MAL IND SUR; IJUMBA JN, 2007, VECTORIAL CAPACITY E; Kahigwa E, 2002, TROP MED INT HEALTH, V7, P823, DOI 10.1046/j.1365-3156.2002.00938.x; Kleinschmidt I, 2009, AM J TROP MED HYG, V80, P882, DOI 10.4269/ajtmh.2009.80.882; Korenromp EL, 2004, TROP MED INT HEALTH, V9, P1050, DOI 10.1111/j.1365-3156.2004.01317.x; Lemnge MM, 2005, AM J TROP MED HYG, V73, P681, DOI 10.4269/ajtmh.2005.73.681; MATOLA YG, 1984, CENT AFR J MED, V30, P91; MATOLA YG, 1984, CENT AFR J MED, V30, P95; Otten M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-14; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; Rowe AK, 2006, INT J EPIDEMIOL, V35, P691, DOI 10.1093/ije/dy1027; Rowe AK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-209; Schellenberg JRA, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-194; Teklehaimanot HD, 2009, AM J TROP MED HYG, V80, P133, DOI 10.4269/ajtmh.2009.80.133; Thomson M, 2003, LANCET, V362, P580, DOI 10.1016/S0140-6736(03)14135-9; *UN GEN ASS, 2000, MILL DEV GOALS CHIL; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; *WHO, 2010, WORLD MAL REP 2010, P39; *WHO, 2010, GUID TREATM MAL, P12; WHO UNICEF, 2009, WORLD MAL REP, P32; *ZANZ MAL CONTR PR, 2009, BIANN REP YEAR END 2, P42; *ZANZ REV GOV, 2008, ROLL MAL IND SURV MA	28	61	61	1	8	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	FEB 18	2011	10								46	10.1186/1475-2875-10-46				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	740SG	WOS:000288814100001	21332989	DOAJ Gold, Green Published			2019-03-26	
J	Gillet, P; Maltha, J; Hermans, V; Ravinetto, R; Bruggeman, C; Jacobs, J				Gillet, Philippe; Maltha, Jessica; Hermans, Veerle; Ravinetto, Raffaella; Bruggeman, Cathrien; Jacobs, Jan			Malaria rapid diagnostic kits: quality of packaging, design and labelling of boxes and components and readability and accuracy of information inserts	MALARIA JOURNAL			English	Article							TESTS; INSTRUCTIONS; EDUCATION; DISTRICT; MONITOR	Background: The present study assessed malaria RDT kits for adequate and correct packaging, design and labelling of boxes and components. Information inserts were studied for readability and accuracy of information. Methods: Criteria for packaging, design, labelling and information were compiled from Directive 98/79 of the European Community (EC), relevant World Health Organization (WHO) documents and studies on end-users' performance of RDTs. Typography and readability level (Flesch-Kincaid grade level) were assessed. Results: Forty-two RDT kits from 22 manufacturers were assessed, 35 of which had evidence of good manufacturing practice according to available information (i.e. CE-label affixed or inclusion in the WHO list of ISO13485:2003 certified manufacturers). Shortcomings in devices were (i) insufficient place for writing sample identification (n = 40) and (ii) ambiguous labelling of the reading window (n = 6). Buffer vial labels were lacking essential information (n = 24) or were of poor quality (n = 16). Information inserts had elevated readability levels (median Flesch-Kincaid grade 8.9, range 7.1 - 12.9) and user-unfriendly typography (median font size 8, range 5 - 10). Inadequacies included (i) no referral to biosafety (n = 18), (ii) critical differences between depicted and real devices (n = 8), (iii) figures with unrealistic colours (n = 4), (iv) incomplete information about RDT line interpretations (n = 31) and no data on test characteristics (n = 8). Other problems included (i) kit names that referred to Plasmodium vivax although targeting a pan-species Plasmodium antigen (n = 4), (ii) not stating the identity of the pan-species antigen (n = 2) and (iii) slight but numerous differences in names displayed on boxes, device packages and information inserts. Three CE labelled RDT kits produced outside the EC had no authorized representative affixed and the shape and relative dimensions of the CE symbol affixed did not comply with the Directive 98/79/EC. Overall, RDTs with evidence of GMP scored better compared to those without but inadequacies were observed in both groups. Conclusion: Overall, malaria RDTs showed shortcomings in quality of construction, design and labelling of boxes, device packages, devices and buffers. Information inserts were difficult to read and lacked relevant information.	[Gillet, Philippe; Hermans, Veerle; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, Unit Trop Lab Med, B-2000 Antwerp, Belgium; [Maltha, Jessica; Jacobs, Jan] Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Ravinetto, Raffaella] Inst Trop Med, Clin Trials Unit, B-2000 Antwerp, Belgium; [Bruggeman, Cathrien] Maastricht Univ Med Ctr, Dept Med Microbiol, Sch Publ Hlth & Primary Care CAPHRI, Maastricht, Netherlands	Gillet, P (reprint author), Inst Trop Med, Dept Clin Sci, Unit Trop Lab Med, Natl Str 155, B-2000 Antwerp, Belgium.	pgillet@itg.be		gillet, philippe/0000-0001-5878-6446			Arnold CL, 2006, PEDIATRICS, V117, pS320, DOI 10.1542/peds.2005-2633L; Bell D, 2008, T ROY SOC TROP MED H, V102, P1064, DOI 10.1016/j.trstmh.2008.05.007; Chiodini PL, 2007, T ROY SOC TROP MED H, V101, P331, DOI 10.1016/j.trstmh.2006.09.007; Doak L G, 1996, Oncol Nurs Forum, V23, P1305; European Commission, 1998, EUR STAND IN VITR DI; FLESCH R, 2004, WRITE PLAIN ENGLISH; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-215; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-271; Grobusch MP, 2002, EUR J CLIN MICROBIOL, V21, P818, DOI 10.1007/s10096-002-0831-0; Harvey SA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-160; Hashizume M, 2006, PUBLIC HEALTH, V120, P444, DOI 10.1016/j.puhe.2005.11.007; Hawkes M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-308; Jorgensen P, 2006, AM J TROP MED HYG, V74, P750, DOI 10.4269/ajtmh.2006.74.750; Kaphingst KA, 2004, HEALTH AFFAIR, V23, P143, DOI 10.1377/hlthaff.23.4.143; Knebel E, 2000, USE MANUAL JOB AIDS; Maltha J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-198; Maltha J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-171; Mayxay M, 2004, TROP MED INT HEALTH, V9, P325, DOI 10.1111/j.1365-3156.2004.01199.x; McMorrow ML, 2008, AM J TROP MED HYG, V79, P385, DOI 10.4269/ajtmh.2008.79.385; Moonasar D, 2009, SAMJ S AFR MED J, V99, P810; Murray CK, 2003, TROP MED INT HEALTH, V8, P876, DOI 10.1046/j.1365-3156.2003.01115.x; RENNIE W, 2004, DEV TESTING GENERIC; Rennie W, 2007, T ROY SOC TROP MED H, V101, P9, DOI 10.1016/j.trstmh.2006.03.011; Seidahmed OME, 2008, TROP MED INT HEALTH, V13, P406, DOI 10.1111/j.1365-3156.2008.02015.x; Tavrow P, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-10; Taylor H A, 1999, Semin Oncol Nurs, V15, P89, DOI 10.1016/S0749-2081(99)80066-7; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; van Dijk DPJ, 2010, EUR J CLIN MICROBIOL, V29, P577, DOI 10.1007/s10096-010-0898-y; van Dijk DPJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-293; Wallace LS, 2008, DIABETES TECHNOL THE, V10, P11, DOI 10.1089/dia.2007.0258; Wallace LS, 2008, BLOOD PRESS MONIT, V13, P219, DOI 10.1097/MBP.0b013e3283057b0a; Wallace LS, 2008, PATIENT EDUC COUNS, V70, P420, DOI 10.1016/j.pec.2007.11.017; Wallace LS, 2010, ACAD PEDIATR, V10, P224, DOI 10.1016/j.acap.2010.04.001; Wallace LS, 2009, J WOMENS HEALTH, V18, P363, DOI 10.1089/jwh.2008.0985; Wallace LS, 2006, J ASTHMA, V43, P375, DOI 10.1080/02770900600709856; White LJ, 1996, ACAD EMERG MED, V3, P745, DOI 10.1111/j.1553-2712.1996.tb03509.x; WHO, 2009, LIST KNOWN COMM AV A; *WHO, 2010, LOT TEST US QUAL CON; *WHO, 2010, OV PREQ DIAGN ASS PR; *WHO, 2006, NOT JOB AIDS MAL RAP; WHO, 2009, 16 WHO; World Health Organization, 2008, US RAP DIAGN TEST RD; World Health Organization, 2010, MAL RAP DIAGN TEST P; World Health Organization, 2006, US RAP MAL DIAGN TES; World Health Organization, MAL RAP DIAGN TEST P; World Health Organization, 2010, GUID TREATM MAL; World Health Organization (WHO), 2004, 1 WHO; TESTS DOCUMENT READA	49	22	22	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	FEB 13	2011	10								39	10.1186/1475-2875-10-39				15	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	740RY	WOS:000288813300001	21314992	DOAJ Gold, Green Published			2019-03-26	
J	Nkoghe, D; Akue, JP; Gonzalez, JP; Leroy, EM				Nkoghe, Dieudonne; Akue, Jean-Paul; Gonzalez, Jean-Paul; Leroy, Eric M.			Prevalence of Plasmodium falciparum infection in asymptomatic rural Gabonese populations	MALARIA JOURNAL			English	Article							MALARIA; ADULTS	Background: Malaria may be perennial or epidemic in sub-Saharan Africa, and its transmission may be stable or unstable, depending on the region. The prevalence of asymptomatic Plasmodium falciparum carriage is poorly documented in Gabon. A large survey of P. falciparum infection was conducted in asymptomatic individuals living in rural Gabon. Methods: Two hundred and twenty-two villages were randomly selected in the nine administrative regions. With the participants' informed consent, blood samples were collected for thick and thin blood film examination after 20% Giemsa staining. Prevalence rates were calculated per village, per region and per ecosystem, and nationwide. Demographic risk factors were identified with STATA software version 9.0. Significance was assumed at p < 0.05. Results and discussion: The prevalence of P. falciparum in adults was 6.2% (269/4342) nationwide, with a maximum of 37.2% in one village; a linear decrease was observed with increasing age (p = 0.045). Only 5% of the 399 children from forest areas tested positive. The prevalence was significantly higher in forest areas (7%) than in savannah (4%) and lakeland (2.5%). Within the forest region, the prevalence was significantly higher in forest grassland (10.9%) than in the mountain forest (3.5%), interior forest (6.8%) and north-eastern forest (4.5%). Conclusion: Plasmodium falciparum carriage remains high among adults in rural Gabon. Control measures must be adapted to the region and ecosystem. Routine treatment of asymptomatic individuals should be considered.	[Nkoghe, Dieudonne; Akue, Jean-Paul; Gonzalez, Jean-Paul; Leroy, Eric M.] CIRMF, Franceville, Gabon; [Nkoghe, Dieudonne] Minist Hlth, Libreville, Gabon; [Nkoghe, Dieudonne] Univ Liege, Dept Immunodeficiency & Infect Dis, B-4000 Liege, Belgium; [Leroy, Eric M.] Univ Aix Marseille 2, UMR Emergences Pathol Virales 190, Inst Rech Dev, F-13284 Marseille 07, France	Nkoghe, D (reprint author), CIRMF, Franceville, Gabon.	dnkoghe@hotmail.com	LEROY, Eric/I-4347-2016	LEROY, Eric/0000-0003-0022-0890; Gonzalez, Jean-Paul/0000-0003-3063-1770	Gabonese State; Total Gabon; Ministere Francais de la Cooperation	We thank Benjamin Ollomo, Philippe Yaba, Andre Delicat, Paul Ngari, Patrick Yangari and Xavier Pourrut from Centre International de Recherches Medicales de Franceville (CIRMF), Gabon, for their technical assistance. CIRMF is supported by the Gabonese State, Total Gabon, and Ministere Francais de la Cooperation.	[Anonymous], 2009, WORLD MAL REP 2009; Bouyou-Akotet MK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-300; Dal-Bianco MP, 2007, AM J TROP MED HYG, V77, P939, DOI 10.4269/ajtmh.2007.77.939; Dzeing-Ella A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-1; Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560; Mayor A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-3; PERRET JL, 1991, B SOC PATHOL EXOT, V84, P323; Pullan RL, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-2; RICHARDLENOBLE D, 1987, B SOC PATHOL EXOT, V80, P532; WILDLING E, 1995, TROP MED PARASITOL, V46, P77	10	27	27	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1475-2875			MALARIA J	Malar. J.	FEB 9	2011	10								33	10.1186/1475-2875-10-33				4	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	740RU	WOS:000288812900001	21306636	DOAJ Gold, Green Published			2019-03-26	
J	Vanlerberghe, V; Villegas, E; Jirarojwatana, S; Santana, N; Trongtorkit, Y; Jirarojwatana, R; Srisupap, W; Lefevre, P; Van der Stuyft, P				Vanlerberghe, V.; Villegas, E.; Jirarojwatana, S.; Santana, N.; Trongtorkit, Y.; Jirarojwatana, R.; Srisupap, W.; Lefevre, P.; Van der Stuyft, P.			Determinants of uptake, short-term and continued use of insecticide-treated curtains and jar covers for dengue control	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						dengue; Aedes aegypti; insecticide-treated material; insecticide-treated curtain; use; vector control	WATER CONTAINER COVERS; AEDES-AEGYPTI; VISCERAL LEISHMANIASIS; IMPREGNATED BEDNETS; CHILD-MORTALITY; NETS; SUSTAINABILITY; ACCEPTABILITY; INTERVENTIONS; IMMUNIZATION	OBJECTIVE To evaluate the acceptance and long-term use of insecticide-treated (IT) materials for dengue vector control. METHODS In 2007, IT jar covers and/or curtains (PermaNet (R)) were distributed under routine conditions to 4101 households (10 clusters) in Venezuela and to 2032 households (22 clusters) in Thailand. The use of IT tools was measured at distribution (uptake), at 5/6 months (short-term use) and at 18/22 months (continued use) after distribution. Determinants of use were assessed with logistic regression analysis. RESULTS The uptake of IT curtains was 76.7% in Venezuela and 92.3% in Thailand. It was associated with being a resident for > 5 years (OR Venezuela 3.0 95% CI 2.0-4.4; OR Thailand 3.5 95% CI 1.7-7.3) and with pre-intervention use of ordinary curtains (OR Venezuela 2.2 95% CI 1.4-3.6). The continued use decreased significantly to 38.4% of households in Venezuela and 59.7% in Thailand and was, conditional on short-term use, only determined by the perceived effectiveness of IT curtains (OR Venezuela 13.0 95%CI 8.7-19.5; OR Thailand 4.9 95% CI 3.1-7.8). Disease knowledge and pre-intervention perception of mosquito nuisance were not associated with IT curtains' uptake or use. The uptake of IT jar covers in Venezuela was 21.5% and essentially determined by the presence of uncovered jars in the household (OR 32.5 95% CI 14.5-72.6). Their continued use, conditional on short-time use, was positively associated with the household use of Abate (R) (OR 7.8 95% CI 2.1-28.9). CONCLUSION The use of IT curtains rapidly declines over time. Continued use is mainly determined by the perceived effectiveness of the tool. This poses a real challenge if IT curtains are to be introduced in dengue control programmes.	[Vanlerberghe, V.; Lefevre, P.; Van der Stuyft, P.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Villegas, E.; Santana, N.] Univ Los Andes, Res Inst Jose Witremundo Torrealba, Trujillo, Venezuela; [Jirarojwatana, S.; Jirarojwatana, R.; Srisupap, W.] Reg Off Dis Prevent & Control, Chon Buri, Thailand; [Trongtorkit, Y.] Mahidol Univ, Fac Trop Med, Dept Med Entomol, Bangkok 10700, Thailand	Vanlerberghe, V (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, Natl Str 155, B-2000 Antwerp, Belgium.	vvanlerberghe@itg.be			European Union [INCO-CT-2004-517708]	We are grateful to the populations, the municipal authorities, the routine vector control programme and the health committees who accepted to participate in the study. We are indebted to the field research teams for the many hours they spent with the communities and for conducting the household surveys. We thank Vestergaard-Frandsen for providing the IT tools free of charge for the purpose of the study. The study reports partial results of Workpackage 4 of the project DENCO-Towards successful dengue prevention and control, financed by the European Union (INCO-CT-2004-517708).	Atkinson JA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-119; BALY A, 2010, THESIS I TROPICAL ME; Brieger WR, 1996, HEALTH EDUC RES, V11, P133, DOI 10.1093/her/11.2.133-a; Diallo DA, 2004, B WORLD HEALTH ORGAN, V82, P85; Donner A, 2000, DESIGN ANAL CLUSTER; Erlanger TE, 2008, MED VET ENTOMOL, V22, P203, DOI 10.1111/j.1365-2915.2008.00740.x; Farrar J, 2007, TROP MED INT HEALTH, V12, P695, DOI 10.1111/j.1365-3156.2007.01838; Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563; Gyapong M, 1996, TROP MED INT HEALTH, V1, P328, DOI 10.1046/j.1365-3156.1996.d01-41.x; Habluetzel A, 1999, TROP MED INT HEALTH, V4, P557, DOI 10.1046/j.1365-3156.1999.00455.x; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; HERNAN MC, 1994, SOC ESTRATIFICACION; Kachur SP, 1999, TROP MED INT HEALTH, V4, P728, DOI 10.1046/j.1365-3156.1999.00481.x; Kay BH, 2010, AM J TROP MED HYG, V82, P822, DOI 10.4269/ajtmh.2010.09-0503; Kleinbaum DG, 1998, APPL REGRESSION ANAL; Kroeger A, 2006, BRIT MED J, V332, P1247, DOI 10.1136/bmj.332.7552.1247; Kulkarni MA, 2007, TROP MED INT HEALTH, V12, P1061, DOI 10.1111/j.1365-3156.2007.01883.x; Phuanukoonnon S, 2005, TROP MED INT HEALTH, V10, P755, DOI 10.1111/j.1365-3156.2005.01452.x; Renganathan E., 2003, Dengue Bulletin, V27, P6; Ritchie SA, 2009, MED VET ENTOMOL, V23, P295, DOI 10.1111/j.1365-2915.2009.00833.x; Ritmeijer K, 2007, TROP MED INT HEALTH, V12, P404, DOI 10.1111/j.1365-3156.2006.01807.x; Romani MET, 2007, SOC SCI MED, V64, P976, DOI 10.1016/j.socscimed.2006.10.033; Rubardt M, 1999, HEALTH POLICY PLANN, V14, P313, DOI 10.1093/heapol/14.4.313; Sanchez L, 2009, TROP MED INT HEALTH, V14, P1356, DOI 10.1111/j.1365-3156.2009.02379.x; Seng CM, 2008, J VECTOR ECOL, V33, P333, DOI 10.3376/1081-1710-33.2.333; Severy LJ, 2005, AIDS BEHAV, V9, P121, DOI 10.1007/s10461-005-1687-y; Tami A, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-19; *TDR, 2006, SCI WORK GROUP M DEN; Toledo ME, 2008, TROP MED INT HEALTH, V13, P728, DOI 10.1111/j.1365-3156.2008.02046.x; Vanlerberghe V, 2010, TROP MED INT HEALTH, V15, P1067, DOI 10.1111/j.1365-3156.2010.02582.x; Vanlerberghe V, 2010, TROP MED INT HEALTH, V15, P60, DOI 10.1111/j.1365-3156.2009.02433.x; Vanlerberghe V, 2009, TROP MED INT HEALTH, V14, P169; Vanlerberghe V, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1959; Webster J, 2005, LANCET INFECT DIS, V5, P709, DOI 10.1016/S1473-3099(05)70269-3	34	14	14	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2011	16	2					162	173		10.1111/j.1365-3156.2010.02668.x				12	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	705GI	WOS:000286116500005	21044236	Bronze			2019-03-26	
J	Smit, J; Chersich, MF; Beksinska, M; Kunene, B; Manzini, N; Hilber, AM; Scorgie, F				Smit, J.; Chersich, M. F.; Beksinska, M.; Kunene, B.; Manzini, N.; Hilber, A. Martin; Scorgie, F.			Prevalence and self-reported health consequences of vaginal practices in KwaZulu-Natal, South Africa: findings from a household survey	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						vaginal hygiene; sexual behaviour; prevalence; intravaginal administration; women's health; South Africa	DRY SEX; MICROBICIDE ACCEPTABILITY; INTRAVAGINAL PRACTICES; WOMENS HEALTH; HIV; RISK; INFECTION; TRIAL; USERS	OBJECTIVES To investigate population-level prevalence of vaginal practices, their frequency and self-reported health consequences in KwaZulu-Natal, South Africa. METHODS A household survey using multi-stage cluster sampling was conducted in 2007. Women aged 18-60 (n = 867) were interviewed on demographics, sexual behaviours and vaginal practices, focusing on intravaginal practices. Design-based analysis used multivariate logistic regression to identify factors associated with intravaginal or any practice. RESULTS Most women currently perform vaginal practices (90.2%), with 34.8% reporting two and 16.3% >= 3 practices. Internal cleansing, the commonest practice (63.3% of women), is undertaken frequently (61.6% cleansing twice daily; 20.0% using >= 2 products). Fewer report application (10.1%), insertion (11.6%) or ingestion (14.3%) practices. Hygiene is a common motivation, even for the 23.2% of women reporting intravaginal practices around the time of sex. Prevalence of any practice was lower among women with tertiary education than those without primary education (AOR = 0.26, 95% CI = 0.08-0.85), nearly twice as common in sexually active women (95% CI = 1.05-3.56) and increased as overall health status declined. Adjusted odds of intravaginal practices were 1.8-fold higher in women reporting unprotected sex (95% CI = 1.11-2.90). Few reported health problems with current practices (0.6%); though, 12.6% had ever-experienced adverse effects. CONCLUSIONS Vaginal practices are common in KwaZulu-Natal. Although self-reported health problems with current practices are rare, high lifetime risk of adverse events and potential for asymptomatic but clinically important damage make continued research important.	[Smit, J.; Beksinska, M.] Univ Witwatersrand, Dept Obstet & Gynaecol, Reprod Hlth & HIV Res Unit, ZA-4091 Durban, South Africa; [Chersich, M. F.] Univ Witwatersrand, Sch Publ Hlth, Ctr Hlth Policy, Johannesburg, South Africa; [Chersich, M. F.] Univ Ghent, Dept Obstet & Gynaecol, Int Ctr Reprod Hlth, B-9000 Ghent, Belgium; [Kunene, B.] Program Appropriate Technol Hlth, Johannesburg, South Africa; [Manzini, N.] Lovelife, Johannesburg, South Africa; [Hilber, A. Martin] Inst Trop & Prevent Med, Bern, Switzerland	Smit, J (reprint author), Univ Witwatersrand, Dept Obstet & Gynaecol, Reprod Hlth & HIV Res Unit, 151 Juniper Rd, ZA-4091 Durban, South Africa.	jsmit@match.org.za					Bagnol B, 2008, CULT HEALTH SEX, V10, P573, DOI 10.1080/13691050801999071; Baird DD, 1996, AM J PUBLIC HEALTH, V86, P844, DOI 10.2105/AJPH.86.6.844; Baleta A, 1998, LANCET, V352, P1292, DOI 10.1016/S0140-6736(05)70507-9; Beksinska ME, 1999, SEX TRANSM INFECT, V75, P178, DOI 10.1136/sti.75.3.178; Braunstein S, 2005, J WOMENS HEALTH, V14, P424, DOI 10.1089/jwh.2005.14.424; Brown JE, 2000, SEX TRANSM DIS, V27, P183, DOI 10.1097/00007435-200004000-00001; CHERSICH MF, 2009, 5 IAS C HIV PATH TRE; *DEP HLTH MEAS DHS, 2007, S AFR DEM HLTH SURV; Department of Health, 2009, NAT HIV SYPH ANT SER; Hilber AM, 2007, SEX TRANSM INFECT, V83, P505, DOI 10.1136/sti.2007.028597; Hilber AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009119; HULL T, 2010, PREVALENCE IN PRESS; Joesoef MR, 1996, AM J OBSTET GYNECOL, V174, P115, DOI 10.1016/S0002-9378(96)70382-4; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; KISH L, 1949, J AM STAT ASSOC, V44, P380, DOI 10.2307/2280236; KORN E, 1999, WILEY SERIES PROBABI; MANN JM, 1988, AIDS, V2, P249, DOI 10.1097/00002030-198808000-00002; Martino JL, 2002, EPIDEMIOL REV, V24, P109, DOI 10.1093/epirev/mxf004; Mbikusita-Lewanika M, 2009, PSYCHOL HEALTH MED, V14, P227, DOI 10.1080/13548500802270364; Montgomery CM, 2010, CULT HEALTH SEX, V12, P649, DOI 10.1080/13691051003736261; Morar NS, 1998, S AFR MED J, V88, P470; Myer L, 2006, AM J EPIDEMIOL, V163, P552, DOI 10.1093/aje/kwj071; Pettifor AE, 2005, AIDS, V19, P1525, DOI 10.1097/01.aids.0000183129.16830.06; Poynten IM, 2009, AIDS, V23, P1245, DOI 10.1097/QAD.0b013e32832b4271; RAO JNK, 1984, ANN STAT, V12, P46, DOI 10.1214/aos/1176346391; RUNGANGA A, 1992, SOC SCI MED, V35, P1037, DOI 10.1016/0277-9536(92)90243-J; Scorgie F, 2009, CULT HEALTH SEX, V11, P267, DOI 10.1080/13691050802395915; Shisana O., 2009, S AFRICAN NATL HIV P; Smit J, 2002, SOC SCI MED, V55, P1511, DOI 10.1016/S0277-9536(01)00284-2; *STAT S AFR, 2003, CENS 2001; Tsai CS, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.06.026; van der Straten A, 2010, AIDS BEHAV, V14, P590, DOI 10.1007/s10461-010-9690-3; *WHO, 2002, WHOHIV200207 UNAIDS	33	9	9	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2011	16	2					245	256		10.1111/j.1365-3156.2010.02687.x				12	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	705GI	WOS:000286116500017	21091859				2019-03-26	
J	Deborggraeve, S; Lejon, V; Ekangu, RA; Ngoyi, DM; Pyana, PP; Ilunga, M; Mulunda, JP; Buscher, P				Deborggraeve, Stijn; Lejon, Veerle; Ekangu, Rosine Ali; Ngoyi, Dieudonne Mumba; Pyana, Patient Pati; Ilunga, Medard; Mulunda, Jean Pierre; Buscher, Philippe			Diagnostic Accuracy of PCR in gambiense Sleeping Sickness Diagnosis, Staging and Post-Treatment Follow-Up: A 2-year Longitudinal Study	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HUMAN AFRICAN TRYPANOSOMIASIS; POLYMERASE-CHAIN-REACTION; CEREBROSPINAL-FLUID; BRUCEI-GAMBIENSE; THERAPEUTIC DECISION; COTE-DIVOIRE; PENTAMIDINE; INFECTION; FAILURE; PATIENT	Background: The polymerase chain reaction (PCR) has been proposed for diagnosis, staging and post-treatment follow-up of sleeping sickness but no large-scale clinical evaluations of its diagnostic accuracy have taken place yet. Methodology/Principal Findings: An 18S ribosomal RNA gene targeting PCR was performed on blood and cerebrospinal fluid (CSF) of 360 T. brucei gambiense sleeping sickness patients and on blood of 12(endemic controls from the Democratic Republic of Congo. Sensitivity and specificity (with 95% confidence intervals) of PCR for diagnosis, disease staging and treatment failure over 2 years follow-up post-treatment were determined. Reference standard tests were trypanosome detection for diagnosis and trypanosome detection and/or increased white blood cell concentration in CSF for staging and detection of treatment failure. PCR on blood showed a sensitivity of 88.4% (84.4-92.5%) and a specificity of 99.2% (97.7-100%) for diagnosis, while for disease staging the sensitivity and specificity of PCR on cerebrospinal fluid were 88.4% (84.8-91.9%) and 82.9% (71.2-94.6%), respectively. During follow-up after treatment, PCR on blood had low sensitivity to detect treatment failure. In cerebrospinal fluid, PCR positivity vanished slowly and was observed until the end of the 2 year follow-up in around 20% of successfully treated patients. Conclusions/Significance: For T.b. gambiense sleeping sickness diagnosis and staging, PCR performed better than, or similar to, the current parasite detection techniques but it cannot be used for post-treatment follow-up. Continued PCR positivity in one out of five cured patients points to persistence of living or dead parasites or their DNA after successful treatment and may necessitate the revision of some paradigms about the pathophysiology of sleeping sickness.	[Deborggraeve, Stijn; Lejon, Veerle; Ekangu, Rosine Ali; Ngoyi, Dieudonne Mumba; Pyana, Patient Pati; Buscher, Philippe] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Deborggraeve, Stijn] Katholieke Univ Leuven, Rega Inst, B-3000 Louvain, Belgium; [Ekangu, Rosine Ali; Ngoyi, Dieudonne Mumba; Pyana, Patient Pati] Inst Natl Rech Biomed, Dept Parasitol, Kinshasa, Zaire; [Ilunga, Medard; Mulunda, Jean Pierre] Programme Natl Lutte Trypanosomiase Humaine Afric, Mbuji Mayi, Zaire	Deborggraeve, S (reprint author), Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium.	vlejon@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472; Deborggraeve, Stijn/0000-0003-1501-5355; Lejon, Veerle/0000-0002-6795-0962	European Community [015379]; Belgian Technical Cooperation; Belgian Ministry of Foreign Affairs, Directorate General for Development Cooperation; Fund for Scientific Research Flanders (FWO-Vlaanderen); Ministry of Health of DRC; Programme National de Lutte contre la Trypanosomiase Humaine Africaine; Dipumba Hospital; Miabi Mobile Team; Institut National de Recherche Biomedical; Minieres Bakwanga	Part of the study was supported by the European Community Sixth Framework Programme, priority INCO-DEV, project TRYLEIDIAG (contract 015379) and by the Belgian Technical Cooperation. Stijn Deborggraeve is a post-doctoral fellow of the Fund for Scientific Research Flanders (FWO-Vlaanderen, http://www.fwo.be/). Dieudonne Mumba Ngoyi and Patient Pati Pyana have received a PhD grant from the Belgian Ministry of Foreign Affairs, Directorate General for Development Cooperation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The support of the Ministry of Health of DRC, the Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Dipumba Hospital, Miabi Mobile Team, Institut National de Recherche Biomedical and Minieres Bakwanga is gratefully acknowledged. We thank Profs. Marleen Boelaert and Jean-Claude Dujardin for critical reading of the paper and Prof. Michael Barrett for language advice.	[Anonymous], 2007, WHOCDSNTDIDM20071; Brun R, 2010, LANCET, V375, P148, DOI 10.1016/S0140-6736(09)60829-1; Buscher P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000471; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Claes F, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000486; DEALMEIDA PJL, 1999, THESIS U LIBRE BRUXE, P195; Deborggraeve S, 2010, LANCET INFECT DIS, V10, P433, DOI 10.1016/S1473-3099(10)70077-3; Doua F, 1996, AM J TROP MED HYG, V55, P586, DOI 10.4269/ajtmh.1996.55.586; Gall Y, 2004, ACTA TROP, V92, P7, DOI 10.1016/j.actctropica.2004.04.003; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; Giroud C, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000509; Hecht MM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009181; Jamonneau V, 2003, TROP MED INT HEALTH, V8, P589, DOI 10.1046/j.1365-3156.2003.01079.x; Jamonneau V, 2001, Med Trop (Mars), V61, P347; JENNINGS FW, 1979, INT J PARASITOL, V9, P381, DOI 10.1016/0020-7519(79)90089-4; Kamei S, 2004, INTERNAL MED, V43, P796, DOI 10.2169/internalmedicine.43.796; Kirchhoff L. V., 1998, Central African Journal of Medicine, V44, P134; Kyambadde JW, 2000, B WORLD HEALTH ORGAN, V78, P119; Lejon V, 2005, TROP MED INT HEALTH, V10, P395, DOI 10.1111/j.1365-3156.2005.01403.x; Lejon V, 2003, J NEUROIMMUNOL, V144, P132, DOI 10.1016/j.jneuroim.2003.08.033; Lutumba P, 2007, EMERG INFECT DIS, V13, P1484, DOI 10.3201/eid1310.060358; Matovu E, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000737; Mbati Peter A., 1999, Korean Journal of Parasitology, V37, P289; Miezan TW, 2000, T ROY SOC TROP MED H, V94, P293, DOI 10.1016/S0035-9203(00)90327-4; Miezan TW, 2003, B SOC PATHOL EXOT, V95, P362; NGAMPO S, 1992, THESIS I TROPISCHE G, P45; Ngoyi DM, 2010, J INFECT DIS, V201, P453, DOI 10.1086/649917; Nikolskaia OV, 2006, INT J PARASITOL, V36, P513, DOI 10.1016/j.ijpara.2006.01.011; Njiru ZK, 2008, INT J PARASITOL, V38, P589, DOI 10.1016/j.ijpara.2007.09.006; PENTREATH VW, 1992, ANN TROP MED PARASIT, V86, P29, DOI 10.1080/00034983.1992.11812627; Radwanska M, 2002, AM J TROP MED HYG, V67, P289, DOI 10.4269/ajtmh.2002.67.289; Robays J, 2007, TROP MED INT HEALTH, V12, P290, DOI 10.1111/j.1365-3165.2006.01768.x; SCHIFFERLI JA, 1989, KIDNEY INT, V35, P993, DOI 10.1038/ki.1989.83; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Stoppini L, 2000, INT J MED MICROBIOL, V290, P105; Truc P, 1999, B WORLD HEALTH ORGAN, V77, P745; Woo P. T. K., 1970, Acta trop., V27, P384; World Health Organization, 1998, WHO TECH REP SER, P1	38	33	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	FEB	2011	5	2							e972	10.1371/journal.pntd.0000972				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	726CQ	WOS:000287696700019	21364966	DOAJ Gold, Green Published			2019-03-26	
J	Vanwambeke, SO; Bennett, SN; Kapan, DD				Vanwambeke, Sophie O.; Bennett, Shannon N.; Kapan, Durrell D.			Spatially disaggregated disease transmission risk: land cover, land use and risk of dengue transmission on the island of Oahu	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Aedes albopictus; dengue; basic reproductive rate; spatial analysis; land cover; land use	AEDES-ALBOPICTUS; HAWAII; AEGYPTI; VIRUS; MALARIA; DIPTERA; EPIDEMIOLOGY; DISPERSAL; LANDSCAPE; CULICIDAE	Vector-borne diseases persist in transmission systems that usually comprise heterogeneously distributed vectors and hosts leading to a highly heterogeneous case distribution. In this study, we build on principles of classical mathematical epidemiology to investigate spatial heterogeneity of disease risk for vector-borne diseases. Land cover delineates habitat suitability for vectors, and land use determines the spatial distribution of humans. We focus on the risk of exposure for dengue transmission on the Hawaiian island of Oahu, where the vector Aedes albopictus is well established and areas of dense human population exist. In Hawai'i, dengue virus is generally absent, but occasionally flares up when introduced. It is therefore relevant to investigate risk, but difficult to do based on disease incidence data. Based on publicly available data (land cover, land use, census data, surveillance mosquito trapping), we map the spatial distribution of vectors and human hosts and finally overlay them to produce a vector-to-host ratio map. The resulting high-resolution maps indicate a high spatial variability in vector-to-host ratio suggesting that risk of exposure is spatially heterogeneous and varies according to land cover and land use.	[Vanwambeke, Sophie O.] Catholic Univ Louvain, Earth & Life Inst, Georges Lemaitre Ctr Earth & Climate Res, B-1348 Louvain, Belgium; [Bennett, Shannon N.] Univ Hawaii Manoa, Asia Pacific Inst Trop Med & Infect Dis, Dept Trop Med, Honolulu, HI 96822 USA; [Kapan, Durrell D.] Univ Hawaii Manoa, Pacific Biosci Res Ctr, Ctr Conservat Res & Training, Honolulu, HI 96822 USA	Vanwambeke, SO (reprint author), Catholic Univ Louvain, Earth & Life Inst, Georges Lemaitre Ctr Earth & Climate Res, Pl Pasteur 3, B-1348 Louvain, Belgium.	sophie.vanwambeke@uclouvain.be		Vanwambeke, Sophie/0000-0001-6620-6173	University of Hawai'i; National Science Foundation [NSF IGERT 0549514]; NSF-EPSCoR IMUA II [05546557]; U.S. National Institutes of Health [P20RR018727, U54AI065359, G12RR003061]; U.S. Department of Defense [06187000]	The authors thank Pingjun Yang from the Hawai'i Department of Health for providing the mosquito trapping data and Jon Winchester for helping with retrieving the data, providing historical references as well as comments on this manuscript. Thanks also go to Bruce Wilcox and Hilary Ranson for comments on a previous version of the manuscript. SOV was a Fulbright scholar at the University of Hawai'i at Manoa. This research was partly funded by University of Hawai'i, National Science Foundation Graduate Education and Research Traineeship Program in Ecology, Conservation and Pathogen Biology (see http://www2.jabsom.hawaii.edu/igert/) (NSF IGERT 0549514). Support also came from NSF-EPSCoR IMUA II (05546557), U.S. National Institutes of Health (P20RR018727, U54AI065359, G12RR003061) and U.S. Department of Defense (06187000).	Adams B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006763; Anderson R.M., 1991, INFECT DIS HUMAN DYN; Aron J.L., 1982, P139; Barker CM, 2003, J MED ENTOMOL, V40, P403, DOI 10.1603/0022-2585-40.4.403; BONNET DD, 1946, AM J TROP MED, V26, P465, DOI 10.4269/ajtmh.1946.s1-26.465; Chung YK, 2002, TROP MED INT HEALTH, V7, P322, DOI 10.1046/j.1365-3156.2002.00873.x; Effler PV, 2005, EMERG INFECT DIS, V11, P742; Eisen L, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000411; FOCKS DA, 1993, J MED ENTOMOL, V30, P1003, DOI 10.1093/jmedent/30.6.1003; Gratz NG, 2004, MED VET ENTOMOL, V18, P215, DOI 10.1111/j.0269-283X.2004.00513.x; Gubler DJ, 2007, FIELDS VIROLOGY, V1, P1153; Gubler Duane J., 1997, P1; Hartemink NA, 2009, EPIDEMICS-NETH, V1, P153, DOI 10.1016/j.epidem.2009.05.004; HARTEMINK NA, 2009, VECTOR BORNE DIS BAS, P111; Hayes JM, 2006, T ROY SOC TROP MED H, V100, P559, DOI 10.1016/j.trstmh.2005.08.013; Herbreteau V., 2005, Parassitologia (Rome), V47, P63; Herbreteau V, 2007, HEALTH PLACE, V13, P400, DOI 10.1016/j.healthplace.2006.03.003; Honorio NA, 2003, MEM I OSWALDO CRUZ, V98, P191, DOI 10.1590/S0074-02762003000200005; Imrie A, 2006, ANN TROP MED PARASIT, V100, P327, DOI 10.1179/136485906X105589; Jelinek T, 1998, J Travel Med, V5, P44, DOI 10.1111/j.1708-8305.1998.tb00458.x; Jetten TH, 1997, AM J TROP MED HYG, V57, P285, DOI 10.4269/ajtmh.1997.57.285; JOYCE C. R., 1961, PROC HAWAIIAN ENT SOC, V17, P403; Kirkwood B. R., 2003, ESSENTIAL MED STAT; Kolivras KN, 2006, PROF GEOGR, V58, P139, DOI 10.1111/j.1467-9272.2006.00521.x; Larish LB, 2009, PAN-PAC ENTOMOL, V85, P169, DOI 10.3956/2009-17.1; Linard C, 2009, ECOHEALTH, V6, P135, DOI 10.1007/s10393-009-0236-y; Linard C, 2007, INT J HEALTH GEOGR, V6, DOI 10.1186/1476-072X-6-15; McGarigal K., 1994, FRAGSTATS SPATIAL PA; Mennis J, 2003, PROF GEOGR, V55, P31; Moffett A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000824; NAKAGAWA PATRICK Y., 1959, MOSQUITO NEWS, V19, P64; NAPIER M, 2003, INT S REM SENS ENV H; NIEBYLSKI ML, 1994, J AM MOSQUITO CONTR, V10, P339; Norris DE, 2004, ECOHEALTH, V1, P19, DOI DOI 10.1007/S10393-004-0008-7; PERKINS RCL, 1913, FAUNA HAWAIIENSIS, pR15; Peterson AT, 2008, NATURWISSENSCHAFTEN, V95, P483, DOI 10.1007/s00114-008-0352-5; Peterson AT, 2005, T ROY SOC TROP MED H, V99, P647, DOI 10.1016/j.trstmh.2005.02.004; *QMARK, 2005, NON VAL HAW COR REEF; Reiter P, 2003, EMERG INFECT DIS, V9, P86; RINDFUSS RR, 2003, PEOPLE ENV APPROACHE, P1; ROGERS DJ, 1988, PHILOS T R SOC B, V321, P513, DOI 10.1098/rstb.1988.0106; Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a; Smith CE, 2005, EMERG INFECT DIS, V11, P750, DOI 10.3201/eid1105.041064; SNOW RW, 2002, ESSENTIAL MALARIOLOG, P85; Stoddard ST, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000481; Usinger Robert L., 1944, PUBL HEALTH REPTS, V59, P423, DOI 10.2307/4584829; Vanwambeke SO, 2007, ECOHEALTH, V4, P37, DOI 10.1007/s10393-007-0085-5; Vanwambeke Sophie O, 2006, Int J Health Geogr, V5, P5, DOI 10.1186/1476-072X-5-5; Vanwambeke SO, 2007, J MED ENTOMOL, V44, P133, DOI 10.1603/0022-2585(2007)44[133:LALCFI]2.0.CO;2; Vanwambeke SO, 2010, VECTOR-BORNE ZOONOT, V10, P497, DOI 10.1089/vbz.2009.0116; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143; *WHO, 1997, DENG HAEM FEV DIAG T; WILSON GW, 1904, PUBLIC HLTH REP, V19, P67; WRIGLEY N, 1985, CATEGORICAL DATA ANA	54	19	19	0	23	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	FEB	2011	16	2					174	185		10.1111/j.1365-3156.2010.02671.x				12	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	705GI	WOS:000286116500006	21073638	Bronze, Green Accepted			2019-03-26	
J	Holtel, A; Troye-Blomberg, M; Penas-Jimenez, I				Holtel, Andreas; Troye-Blomberg, Marita; Penas-Jimenez, Inmaculada			EU-funded malaria research under the 6(th) and 7(th) Framework Programmes for research and technological development	MALARIA JOURNAL			English	Editorial Material								While malaria research has traditionally been strong in Europe, targeted and sustained support for cooperative malaria research at EU level, namely through the EU's 6th and 7th Framework Programmes for research and technological development, FP6 (2002-2006) and FP7 (2007-2013), has boosted both impact and visibility of European malaria research. Most of the European malaria research community is now organized under a number of comprehensive and complementary research networks and projects, assembled around four key areas: (1) fundamental research on the malaria parasite and the disease, (2) development of new malaria drugs, (3) research and development of a malaria vaccine, and (4) research to control the malaria-transmitting mosquito vector. Considerable efforts were undertaken to ensure adequate participation of research groups from disease-endemic countries, in particular from Africa, with the long-term aim to strengthen cooperative links and research capacities in these countries. The concept of organizing European research through major strategic projects to form a "European Research Area" (ERA) was originally developed in the preparation of FP6, and ERA formation has now turned into a major EU policy objective explicitly inscribed into the Lisbon Treaty. EU-funded malaria research may serve as a showcase to demonstrate how ERA formation can successfully be implemented in a given area of science when several surrounding parameters converge to support implementation of this strategic concept: timely coincidence of political stimuli, responsive programming, a clearly defined - and well confined - area of research, and the readiness of the targeted research community who is well familiar with transnational cooperation at EU level. Major EU-funded malaria projects have evolved into thematic and organizational platforms that can collaborate with other global players. Europe may thus contribute more, and better, to addressing the global research agenda for malaria.	[Holtel, Andreas; Penas-Jimenez, Inmaculada] Commiss European Communities, Hlth Directorate, Directorate Gen Res & Innovat, B-1050 Brussels, Belgium; [Troye-Blomberg, Marita] Stockholm Univ, Dept Immunol, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Holtel, A (reprint author), Commiss European Communities, Hlth Directorate, Directorate Gen Res & Innovat, Rue Champ Mars 21, B-1050 Brussels, Belgium.	andreas.holtel@ec.europa.eu	Troye-Blomberg, Marita/B-9210-2016	Troye-Blomberg, Marita/0000-0002-2804-0325			[Anonymous], 2003, OFFICIAL J EUROPEAN, V46, P1; Eckart W. U., 1998, Parassitologia (Rome), V40, P83; Garcia LS, 2010, CLIN LAB MED, V30, P93, DOI 10.1016/j.cll.2009.10.001; *HUDS I, REV PHARM COMP CONTR; Kurdova R. I., 2001, GLOBAL NEST J, V3, P153; M Watson, 1953, AFRICAN HIGHWAY BATT; MISSIROLI A, 1948, P 4 INT C TROP MED M, P1566; Opinel A, 2008, MED HIST, V52, P387, DOI 10.1017/S0025727300002696; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; *WHO, 2010, WHO FACT SHEET N 24; FP7 BRIEF; GLOBAL MALARIA ACTIO; INFRAVEC; 6 FRAMEWORK PROGRAMM; EUROPEAN RES AREA ER; BIOMALPAR FP6 MALARI; ANTIMAL DEV NEW DRUG; BOOK ABSTRACT PROJEC	18	0	0	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JAN 14	2011	10								11	10.1186/1475-2875-10-11				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	740QT	WOS:000288810200004	21235784	DOAJ Gold, Green Published			2019-03-26	
J	Maltha, J; Gillet, P; Cnops, L; Bottieau, E; Van Esbroeck, M; Bruggeman, C; Jacobs, J				Maltha, Jessica; Gillet, Philippe; Cnops, Lieselotte; Bottieau, Emmanuel; Van Esbroeck, Marjan; Bruggeman, Cathrien; Jacobs, Jan			Evaluation of the rapid diagnostic test SDFK40 (Pf-pLDH/pan-pLDH) for the diagnosis of malaria in a non-endemic setting	MALARIA JOURNAL			English	Article							PARASITE LACTATE-DEHYDROGENASE; EXPERT MICROSCOPY; FIELD; PERFORMANCE; ACCURACY; AREA	Background: The present study evaluated the SD Bioline Malaria Ag 05FK40 (SDFK40), a three-band RDT detecting Plasmodium falciparum-specific parasite lactate dehydrogenase (Pf-pLDH) and pan Plasmodium-specific pLDH (pan-pLDH), in a reference setting. Methods: The SDFK40 was retrospectively and prospectively tested against a panel of stored (n = 341) and fresh (n = 181) whole blood samples obtained in international travelers suspected of malaria, representing the four Plasmodium species as well as Plasmodium negative samples, and compared to microscopy and PCR results. The prospective panel was run together with OptiMAL (Pf-pLDH/pan-pLDH) and SDFK60 (histidine-rich protein-2 (HRP-2)/pan-pLDH). Results: Overall sensitivities for P. falciparum tested retrospectively and prospectively were 67.9% and 78.8%, reaching 100% and 94.6% at parasite densities >1,000/mu l. Sensitivity at parasite densities <= 100/mu l was 9.1%. Overall sensitivities for Plasmodium vivax and Plasmodium ovale were 86.7% and 80.0% (retrospectively) and 92.9% and 76.9% (prospectively), reaching 94.7% for both species (retrospective panel) at parasite densities >500/mu l. Sensitivity for Plasmodium malariae was 21.4%. Species mismatch occurred in 0.7% of samples (3/411) and was limited to non-falciparum species erroneously identified as P. falciparum. None of the Plasmodium negative samples in the retrospective panel reacted positive. Compared to OptiMAL and SDFK60, SDFK40 showed lower sensitivities for P. falciparum, but better detection of P. ovale. Inter-observer agreement and test reproducibility were excellent, but lot-to-lot variability was observed for pan-pLDH results in case of P. falciparum. Conclusion: SDFK40 performance was poor at low (<= 100/mu l) parasite densities, precluding its use as the only diagnostic tool for malaria diagnosis. SDFK40 performed excellent for P. falciparum samples at high (> 1,000/mu l) parasite densities as well as for detection of P. vivax and P. ovale at parasite densities > 500/mu l.	[Maltha, Jessica; Jacobs, Jan] Med & Life Sci FHML, Fac Hlth, Maastricht, Netherlands; [Maltha, Jessica; Gillet, Philippe; Cnops, Lieselotte; Bottieau, Emmanuel; Van Esbroeck, Marjan; Jacobs, Jan] Inst Trop Med ITM, Dept Clin Sci, Unit Trop Lab Med, Antwerp, Belgium; [Bruggeman, Cathrien] Maastricht Infect Ctr, Sch Publ Hlth & Primary Care, Dept Med Microbiol, Maastricht, Netherlands; [Bruggeman, Cathrien] Maastricht Univ, Med Ctr, CAPHRI, Maastricht, Netherlands	Maltha, J (reprint author), Med & Life Sci FHML, Fac Hlth, Maastricht, Netherlands.	j.maltha@student.maastrichtuniversity.nl		gillet, philippe/0000-0001-5878-6446			[Anonymous], 2009, WORLD MAL REP 2009; Baker J, 2005, J INFECT DIS, V192, P870, DOI 10.1086/432010; Bell D, 2006, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmico1525; Bossuyt PM, 2003, AM J CLIN PATHOL, V119, P18, DOI 10.1092/LXQQG66PNT4HHJV8; Chiodini PL, 2007, T ROY SOC TROP MED H, V101, P331, DOI 10.1016/j.trstmh.2006.09.007; Cnops L, 2010, CLIN MICROBIOL INFEC; Coleman RE, 2002, AM J TROP MED HYG, V66, P379, DOI 10.4269/ajtmh.2002.66.379; Craig MH, 2002, T ROY SOC TROP MED H, V96, P258, DOI 10.1016/S0035-9203(02)90092-1; Fogg C, 2008, T ROY SOC TROP MED H, V102, P25, DOI 10.1016/j.trstmh.2007.09.014; Gamboa D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008091; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-359; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-271; Grobusch MP, 2002, EUR J CLIN MICROBIOL, V21, P818, DOI 10.1007/s10096-002-0831-0; Harvey SA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-160; Iqbal J, 2004, J CLIN MICROBIOL, V42, P4237, DOI 10.1128/JCM.42.9.4237-4241.2004; Maltha J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-171; Mariette N, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-219; Marx A, 2005, ANN INTERN MED, V142, P836, DOI 10.7326/0003-4819-142-10-200505170-00009; Mason DP, 2002, ACTA TROP, V82, P51, DOI 10.1016/S0001-706X(02)00031-1; Mayxay M, 2004, TROP MED INT HEALTH, V9, P325, DOI 10.1111/j.1365-3156.2004.01199.x; Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002; Mueller I, 2007, J CLIN MICROBIOL, V45, P627, DOI 10.1128/JCM.00816-06; MURRAY CK, 2009, INTERDISCIP PERSPECT; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Ratsimbasoa A, 2007, AM J TROP MED HYG, V76, P481, DOI 10.4269/ajtmh.2007.76.481; Rennie W, 2007, T ROY SOC TROP MED H, V101, P9, DOI 10.1016/j.trstmh.2006.03.011; Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004; Talman AM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-140; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; van Dijk DPJ, 2010, EUR J CLIN MICROBIOL, V29, P577, DOI 10.1007/s10096-010-0898-y; van Dijk DPJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-293; *WHO, 2010, RES WHO PROD TEST MA; *WHO, 2009, RES WHO PROD TEST MA; Wiese L, 2006, SCAND J INFECT DIS, V38, P1063, DOI 10.1080/00365540600818011; World Health Organization, 2010, GUID TREATM MAL; MALARIA RAPID DIAGNO	36	20	21	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	JAN 12	2011	10								7	10.1186/1475-2875-10-7				10	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	740QS	WOS:000288810100002	21226920	DOAJ Gold, Green Published			2019-03-26	
J	Nguyen, TGT; Le, TH; Dao, THT; Tran, TLH; Praet, N; Speybroeck, N; Vercruysse, J; Dorny, P				Nguyen, T. G. T.; Le, T. H.; Dao, T. H. T.; Tran, T. L. H.; Praet, N.; Speybroeck, N.; Vercruysse, J.; Dorny, P.			Bovine fasciolosis in the human fasciolosis hyperendemic Binh Dinh province in Central Vietnam	ACTA TROPICA			English	Article						Fasciolosis; Prevalence; Cattle; ELISA; Binh Dinh; Vietnam	LINKED-IMMUNOSORBENT-ASSAY; CATTLE; INFECTIONS; EPIDEMIOLOGY; GIGANTICA; DIAGNOSIS	A cross-sectional survey on bovine fasciolosis was conducted in the Binh Dinh province of Central Vietnam that was previously identified as hyperendemic for human fasciolosis. In Vietnam, both pure Fasciola gigantica and hybrid and/or introgressed populations of liverflukes bearing genetic material from both Fasciola hepatica and F. gigantica infect humans and animals. In this study, 825 cattle were randomly selected from 8 of the 11 provincial districts for faecal collection; blood samples were taken from 400 of these animals. Fasciola eggs and antibodies against Fasciola were detected by a quantitative sedimentation method and an Enzyme Linked Immunosorbent Assay, respectively. Overall, 54.9% of the animals were shedding Fasciola eggs while 72.2% were Fasciola seropositive. Animals under two years showed lower Fasciola infection rates than older animals. There were no differences in infection rates between districts. These results indicate a very high prevalence of Fasciola infections in cattle in Binh Dinh province. It is concluded that a fasciolosis control programme should be designed in this region aiming at reducing infection in both cattle and humans. (C) 2010 Elsevier B.V. All rights reserved.	[Dorny, P.] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Nguyen, T. G. T.; Dao, T. H. T.] Natl Inst Vet Res, Hanoi, Vietnam; [Le, T. H.] Inst Biotechnol, Dept Immunol, Hanoi, Vietnam; [Speybroeck, N.] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium; [Vercruysse, J.] Univ Ghent, Parasitol Lab, Fac Vet Med, Merelbeke, Belgium	Dorny, P (reprint author), Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium.	pdorny@itg.be			Flemish Inter-University Council (VLIR), Belgium	This study was financially supported by the Flemish Inter-University Council (VLIR) PhD programme, Belgium. The authors wish to thank the staff of the Parasitology Department of NIVR, Binh Dinh Animal Health Department, the Department of Animal Health of ITM and the Laboratory of Parasitology, Faculty of Veterinary Medicine, Ghent University, for technical help.	Anderson N, 1999, VET PARASITOL, V83, P15, DOI 10.1016/S0304-4017(99)00026-6; BUI KL, 2003, JAPAN AGR RES Q, V37, P201; Charlier J, 2008, VET PARASITOL, V153, P44, DOI 10.1016/j.vetpar.2008.01.035; Daryani A., 2006, Journal of Animal and Veterinary Advances, V5, P408; DE NV, 2006, P 5 SEM FOOD WAT BOR; DE NV, 2005, J MALARIA PARASITIC, V6, P54; FAO, 1994, DIS DOM AN CAUS FLUK; Geurden T, 2008, VET PARASITOL, V153, P384, DOI 10.1016/j.vetpar.2008.01.031; HIEN TV, 2002, VIETNAM MED RES, V1, P13; HILLYER GV, 1992, AM J TROP MED HYG, V46, P603, DOI 10.4269/ajtmh.1992.46.603; Holland WG, 2000, VET PARASITOL, V93, P141, DOI 10.1016/S0304-4017(00)00363-0; Le TH, 2008, INT J PARASITOL, V38, P725, DOI 10.1016/j.ijpara.2007.10.003; Le TH, 2007, J CLIN MICROBIOL, V45, P648, DOI 10.1128/JCM.01151-06; Martin TG, 2005, ECOL LETT, V8, P1235, DOI 10.1111/j.1461-0248.2005.00826.x; Mas-Coma S, 2005, INT J PARASITOL, V35, P1255, DOI 10.1016/j.ijpara.2005.07.010; Mas-Coma S, 1999, B WORLD HEALTH ORGAN, V77, P340; Nguyen TGT, 2010, TROP MED INT HEALTH, V15, P462, DOI 10.1111/j.1365-3156.2010.02468.x; PHOLPAK M, 1989, P INT SEM AN HLTH PR; Soliman MFM, 2008, J INFECT DEV COUNTR, V2, P182; StataCorp, 2009, STAT STAT SOFTW REL; Thanh GTN, 2009, EXP PARASITOL, V123, P354, DOI 10.1016/j.exppara.2009.09.001; The D. T., 2005, ASIA PARASITOL, V1, P57; THU LT, 1996, VET SCI TECHNOL, V3, P74; *WHO, 2007, WHOCDSPCT20071	24	16	16	1	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	JAN	2011	117	1					19	22		10.1016/j.actatropica.2010.09.003				4	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	687NQ	WOS:000284785600005	20920452				2019-03-26	
J	Ganaba, R; Praet, N; Carabin, H; Millogo, A; Tarnagda, Z; Dorny, P; Hounton, S; Sow, A; Nitiema, P; Cowan, LD				Ganaba, Rasmane; Praet, Nicolas; Carabin, Helene; Millogo, Athanase; Tarnagda, Zekiba; Dorny, Pierre; Hounton, Sennen; Sow, Adama; Nitiema, Pascal; Cowan, Linda D.			Factors Associated with the Prevalence of Circulating Antigens to Porcine Cysticercosis in Three Villages of Burkina Faso	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TAENIA-SOLIUM CYSTICERCOSIS; RISK-FACTORS; SWINE CYSTICERCOSIS; SOUTHERN PROVINCES; WEST-CAMEROON; EASTERN; ZAMBIA; DISEASE; AFRICA	Background: Little is known about porcine cysticercosis in Burkina Faso. We conducted a pilot study to estimate the prevalence of antigens of Taenia solium cysticercosis and to identify associated factors in pigs of three villages in Burkina Faso, selected to represent different pig management practices: one village where pigs are allowed to roam freely (Batondo), one village where pigs are penned part of the time (Pabre) and one village with limited pig farming (Nyonyogo). Methods/Principal Findings: A clustered random sampling design was used. Data on socio-demographic characteristics (source of drinking water, presence of latrines in the household, type and number of breeding animals) and pig management practices were collected using a standardized questionnaire. Blood samples were collected from one pig per household to determine the presence of antigens of the larval stages of T. solium by the B158/B60 Ag-ELISA. The associations between seropositivity and socio-demographic and pig management practices were estimated using logistic regression. Proportions of 32.5% (95%CI 25.4-40.3), 39.6% (31.9-47.8), and 0% of pigs, were found positive for the presence of circulating antigens of T. solium in Batondo, Pabre, and Nyonyogo, respectively. The results of the logistic regression analyses suggested that people acquire knowledge on porcine cysticercosis following the contamination of their animals. The presence of antigens in the pigs' sera was not associated with the absence of latrines in the household, the source of drinking water or the status of infection in humans but was associated with pig rearing practices during the rainy season. Conclusions/Significance: The results suggest that education of pig farmers is urgently needed to reduce the prevalence of this infection.	[Ganaba, Rasmane] Agence Format Rech & Expertise & Sante Afrique AF, Bobo Dioulasso, Burkina Faso; [Praet, Nicolas; Dorny, Pierre] Inst Trop Med, B-2000 Antwerp, Belgium; [Carabin, Helene; Nitiema, Pascal; Cowan, Linda D.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Biostat & Epidemiol, Oklahoma City, OK USA; [Millogo, Athanase] Ctr Hosp Univ Souro Sanou, Bobo Dioulasso, Burkina Faso; [Tarnagda, Zekiba] Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso; [Hounton, Sennen] United Nations Populat Fund UNFPA, Tech Div, Sexual & Reprod Hlth Branch, New York, NY USA; [Sow, Adama] PATTEC, Bobo Dioulasso, Burkina Faso	Ganaba, R (reprint author), Agence Format Rech & Expertise & Sante Afrique AF, Bobo Dioulasso, Burkina Faso.	rganaba.muraz@fasonet.bf	Carabin, Helene/B-7600-2016		National Institute for Neurological Disorders and Stroke (NINDS); Fogarty International Center (FIC) of the US National Institutes of Health [R21 NS055353]	This study was funded by the National Institute for Neurological Disorders and Stroke (NINDS) and the Fogarty International Center (FIC) of the US National Institutes of Health (Epidemiology and Burden of Neurocysticercosis in Burkina Faso) (R21 NS055353) as part of the Brain Disorders in the Developing World: Research Across the Life-Span (BRAIN) grant program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carabin H, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000555; Coulibaly ND, 2000, ACTA TROP, V76, P53, DOI 10.1016/S0001-706X(00)00090-5; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Garcia HH, 2005, LANCET NEUROL, V4, P653, DOI 10.1016/S1474-4422(05)70194-0; Gwatkin DR, 2000, SOCIOECONOMIC DIFFER; JOSEPH L, 1995, AM J EPIDEMIOL, V141, P263, DOI 10.1093/oxfordjournals.aje.a117428; Krecek RC, 2008, VET PARASITOL, V154, P38, DOI 10.1016/j.vetpar.2008.03.005; Lescano AG, 2007, AM J TROP MED HYG, V76, P376, DOI 10.4269/ajtmh.2007.76.376; *MIN EC DEV, 2000, POL NAT POP BURK FAS; *MIN RESS AN SERV, 2006, STAT SECT EL BURK FA; MURRELL KD, 2005, GUIDELINES SURVEILLA; Ngowi HA, 2004, VET PARASITOL, V120, P275, DOI 10.1016/j.vetpar.2004.01.015; Phiri IK, 2002, VET PARASITOL, V108, P31, DOI 10.1016/S0304-4017(02)00165-6; Pondja A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000594; Pouedet MSR, 2002, VET PARASITOL, V106, P45, DOI 10.1016/S0304-4017(02)00035-3; Shey-Njila O, 2003, J HELMINTHOL, V77, P351, DOI 10.1079/JOH2003179; Sikasunge CS, 2007, VET PARASITOL, V143, P59, DOI 10.1016/j.vetpar.2006.07.023; Sikasunge CS, 2008, VET J, V176, P240, DOI 10.1016/j.tvjl.2007.02.030; UNDP (United Nations Development Program), 2010, HUM DEV IND; Widdowson MA, 2000, T ROY SOC TROP MED H, V94, P620, DOI 10.1016/S0035-9203(00)90209-8; Zoli A, 2003, ACTA TROP, V87, P35, DOI 10.1016/S0001-706X(02)00289-9	21	23	23	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JAN	2011	5	1							e927	10.1371/journal.pntd.0000927				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	711MP	WOS:000286596000005	21245913	DOAJ Gold, Green Published			2019-03-26	
J	Schijman, AG; Bisio, M; Orellana, L; Sued, M; Duffy, T; Jaramillo, AMM; Cura, C; Auter, F; Veron, V; Qvarnstrom, Y; Deborggraeve, S; Hijar, G; Zulantay, I; Lucero, RH; Velazquez, E; Tellez, T; Leon, ZS; Galvao, L; Nolder, D; Rumi, MM; Levi, JE; Ramirez, JD; Zorrilla, P; Flores, M; Jercic, MI; Crisante, G; Anez, N; Castro, AM; Gonzalez, CI; Viana, KA; Yachelini, P; Torrico, F; Robello, C; Diosque, P; Chavez, OT; Aznar, C; Russomando, G; Buscher, P; Assal, A; Guhl, F; Estani, SS; DaSilva, A; Britto, C; Luquetti, A; Ladzins, J				Schijman, Alejandro G.; Bisio, Margarita; Orellana, Liliana; Sued, Mariela; Duffy, Tomas; Mejia Jaramillo, Ana M.; Cura, Carolina; Auter, Frederic; Veron, Vincent; Qvarnstrom, Yvonne; Deborggraeve, Stijn; Hijar, Gisely; Zulantay, Ines; Horacio Lucero, Raul; Velazquez, Elsa; Tellez, Tatiana; Sanchez Leon, Zunilda; Galvao, Lucia; Nolder, Debbie; Monje Rumi, Maria; Levi, Jose E.; Ramirez, Juan D.; Zorrilla, Pilar; Flores, Maria; Jercic, Maria I.; Crisante, Gladys; Anez, Nestor; De Castro, Ana M.; Gonzalez, Clara I.; Viana, Karla Acosta; Yachelini, Pedro; Torrico, Faustino; Robello, Carlos; Diosque, Patricio; Triana Chavez, Omar; Aznar, Christine; Russomando, Graciela; Buscher, Philippe; Assal, Azzedine; Guhl, Felipe; Sosa Estani, Sergio; DaSilva, Alexandre; Britto, Constanca; Luquetti, Alejandro; Ladzins, Janis			International Study to Evaluate PCR Methods for Detection of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients	PLOS NEGLECTED TROPICAL DISEASES			English	Article							POLYMERASE-CHAIN-REACTION; KINETOPLAST MINICIRCLE DNA; FOLLOW-UP; REACTION AMPLIFICATION; HEART-TRANSPLANTATION; SATELLITE DNA; DIAGNOSIS; IDENTIFICATION; XENODIAGNOSIS; ASSAYS	Background: A century after its discovery, Chagas disease still represents a major neglected tropical threat. Accurate diagnostics tools as well as surrogate markers of parasitological response to treatment are research priorities in the field. The purpose of this study was to evaluate the performance of PCR methods in detection of Trypanosoma cruzi DNA by an external quality evaluation. Methodology/Findings: An international collaborative study was launched by expert PCR laboratories from 16 countries. Currently used strategies were challenged against serial dilutions of purified DNA from stocks representing T. cruzi discrete typing units (DTU) I, IV and VI (set A), human blood spiked with parasite cells (set B) and Guanidine Hidrochloride-EDTA blood samples from 32 seropositive and 10 seronegative patients from Southern Cone countries (set C). Forty eight PCR tests were reported for set A and 44 for sets B and C; 28 targeted minicircle DNA (kDNA), 13 satellite DNA (Sat-DNA) and the remainder low copy number sequences. In set A, commercial master mixes and Sat-DNA Real Time PCR showed better specificity, but kDNA-PCR was more sensitive to detect DTU I DNA. In set B, commercial DNA extraction kits presented better specificity than solvent extraction protocols. Sat-DNA PCR tests had higher specificity, with sensitivities of 0.05-0.5 parasites/mL whereas specific kDNA tests detected 5.10(-3) par/mL. Sixteen specific and coherent methods had a Good Performance in both sets A and B (10 fg/mu l of DNA from all stocks, 5 par/mL spiked blood). The median values of sensitivities, specificities and accuracies obtained in testing the Set C samples with the 16 tests determined to be good performing by analyzing Sets A and B samples varied considerably. Out of them, four methods depicted the best performing parameters in all three sets of samples, detecting at least 10 fg/mu l for each DNA stock, 0.5 par/mL and a sensitivity between 83.3-94.4%, specificity of 85-95%, accuracy of 86.8-89.5% and kappa index of 0.7-0.8 compared to consensus PCR reports of the 16 good performing tests and 63-69%, 100%, 71.4-76.2% and 0.4-0.5, respectively compared to serodiagnosis. Method LbD2 used solvent extraction followed by Sybr-Green based Real time PCR targeted to Sat-DNA; method LbD3 used solvent DNA extraction followed by conventional PCR targeted to Sat-DNA. The third method (LbF1) used glass fiber column based DNA extraction followed by TaqMan Real Time PCR targeted to Sat-DNA (cruzi 1/cruzi 2 and cruzi 3 TaqMan probe) and the fourth method (LbQ) used solvent DNA extraction followed by conventional hot-start PCR targeted to kDNA (primer pairs 121/122). These four methods were further evaluated at the coordinating laboratory in a subset of human blood samples, confirming the performance obtained by the participating laboratories. Conclusion/Significance: This study represents a first crucial step towards international validation of PCR procedures for detection of T. cruzi in human blood samples.	[Schijman, Alejandro G.; Bisio, Margarita; Duffy, Tomas; Cura, Carolina] Inst Invest Ingn Genet & Biol Mol INGEBI CONICET, Lab Biol Mol Enfermedad Chagas LabMECH, Buenos Aires, DF, Argentina; [Orellana, Liliana; Sued, Mariela] Univ Buenos Aires, Inst Calculo, Buenos Aires, DF, Argentina; [Mejia Jaramillo, Ana M.; Triana Chavez, Omar] Univ Antioquia, Grp Chagas, Medellin, Colombia; [Auter, Frederic; Assal, Azzedine] French Blood Serv, Paris, France; [Veron, Vincent; Aznar, Christine] Univ Parasitol, Lab Hosp, Cayene, French Guiana; [Qvarnstrom, Yvonne] Ctr Dis Control, Dept Parasit Dis, Atlanta, GA 30333 USA; [Deborggraeve, Stijn; Buscher, Philippe] Inst Trop Med, Antwerp, Belgium; [Hijar, Gisely] Inst Nacl Salud, Lima, Peru; [Horacio Lucero, Raul] Univ Nacl Nordeste, Chaco, Argentina; [Velazquez, Elsa] Inst Nacl Chagas, Buenos Aires, DF, Argentina; [Tellez, Tatiana; Torrico, Faustino] Univ Mayor San Simon, Ctr Univ Med Trop, Fac Med, Cochabamba, Bolivia; [Sanchez Leon, Zunilda; Russomando, Graciela] Univ Nacl Asuncion, Inst Invest Ciencias Salud, Asuncion, Paraguay; [Galvao, Lucia] Fac Farm, Natal, RN, Brazil; [Nolder, Debbie] Univ London London Sch Hyg & Trop Med, Hosp Trop Dis, Dept Clin Parasitol, London WC1E 7HT, England; [Monje Rumi, Maria] Univ Nacl Salta, Lab Patol Expt, Salta, Argentina; [Levi, Jose E.] Hosp Sirio Libanes, Blood Bank, Sao Paulo, Brazil; [Ramirez, Juan D.] Univ Los Andes, Ctr Invest Microbiol & Parasitol Trop, Bogota, Colombia; [Zorrilla, Pilar] Inst Pasteur, Montevideo, Uruguay; [Flores, Maria] Inst Salud Carlos III, Ctr Nacl Microbiol, Ctr Mahahonda, Madrid, Spain; [Jercic, Maria I.] Inst Nacl Salud, Secc Parasitol, Santiago, Chile; [Crisante, Gladys] Univ Los Andes, Ctr Invest Parasitol JF Torrealba, Merida, Venezuela; [De Castro, Ana M.] Univ Fed Goias, IPTSP, Goiania, Go, Brazil; [Gonzalez, Clara I.] Univ Ind Santander, Fac Salud, GIEM, Bucaramanga, Colombia; [Viana, Karla Acosta] Univ Autonoma Yucatan, Dept Biomed Enfermedades Infecciosas & Parasitari, Lab Biol Celular, Ctr Invest Reg CIR Dr Hideyo Noguchi, Yucatan, Mexico; [Yachelini, Pedro] Univ Catolica Santiago Estero, Inst Biomed, Santiago Del Estero, Argentina; [Sosa Estani, Sergio] CeNDIE ANLIS Dr Carlos G Malbran, Buenos Aires, DF, Argentina; [Britto, Constanca] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Mol & Doencas Endem, BR-21045900 Rio De Janeiro, Brazil; [Luquetti, Alejandro] Lab Pesquisa Doenca Chagas, Goiania, Go, Brazil; [Ladzins, Janis] WHO, Special Programme Res & Training Trop Dis TDR, CH-1211 Geneva, Switzerland	Schijman, AG (reprint author), Inst Invest Ingn Genet & Biol Mol INGEBI CONICET, Lab Biol Mol Enfermedad Chagas LabMECH, Buenos Aires, DF, Argentina.	schijman@dna.uba.ar	Ramirez, Juan David/F-3524-2016; Buscher, Philippe/B-9956-2012; FLORES-CHAVEZ, MARIA/M-5918-2015; Duffy, Tomas/S-6045-2017; Orellana, Liliana/I-5249-2013; Britto, Constanca/L-7658-2016	Ramirez, Juan David/0000-0002-1344-9312; Buscher, Philippe/0000-0002-1926-7472; FLORES-CHAVEZ, MARIA/0000-0003-2597-3100; Orellana, Liliana/0000-0003-3736-4337; Deborggraeve, Stijn/0000-0003-1501-5355; Britto, Constanca/0000-0003-0788-7030; Mejia-jaramillo, Ana/0000-0003-2125-9858	World Health Organization-Tropical Diseases Research, Panamerican Health Organization (WHO-TDR-PAHO); Universidad de las Naciones Unidas/Biotecnologia para America Latina y el Caribe (UNU-BIOLAC); Consejo Nacional de Ciencias y Tecnologia (CONICET) [PIP 112-200801-09215]; National Agency of Science and Technology, Buenos Aires, Argentina [PICT 33955]	Funding was provided by World Health Organization-Tropical Diseases Research, Panamerican Health Organization (WHO-TDR-PAHO), Universidad de las Naciones Unidas/Biotecnologia para America Latina y el Caribe (UNU-BIOLAC), Consejo Nacional de Ciencias y Tecnologia (CONICET) PIP 112-200801-09215, National Agency of Science and Technology, PICT 33955, Buenos Aires, Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	de Noya BA, 2010, J INFECT DIS, V201, P1308, DOI 10.1086/651608; AVILA HA, 1991, MOL BIOCHEM PARASIT, V48, P211, DOI 10.1016/0166-6851(91)90116-N; AVILA HA, 1993, J CLIN MICROBIOL, V31, P2421; Bisio M., 2009, REV BIOMED, V20, P166; Brener Z., 1962, REV INST MED TROP SP, V4, P389; Brisse S, 2001, INT J PARASITOL, V31, P1218, DOI 10.1016/S0020-7519(01)00238-7; BRITTO C, 1995, PARASITOLOGY, V110, P241, DOI 10.1017/S0031182000080823; BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030; Britto CC, 2009, MEM I OSWALDO CRUZ, V104, P122, DOI 10.1590/S0074-02762009000900018; Burgos JM, 2007, INT J PARASITOL, V37, P1319, DOI 10.1016/j.ijpara.2007.04.015; Burgos JM, 2010, CLIN INFECT DIS, V51, P485, DOI 10.1086/655680; CARDINAL MV, 2008, INT J PARASITOL; Carolina M, 2003, MOL BIOCHEM PARASIT, V129, P1, DOI 10.1016/S0166-6851(03)00054-9; Castro AM, 2002, PARASITOL RES, V88, P894, DOI 10.1007/s00436-002-0679-3; Chagas C., 1909, MEM I OSWALDO CRUZ, V1, P159, DOI DOI 10.1590/S0074-02761909000200008; Claes F, 2007, J CLIN MICROBIOL, V45, P3785, DOI 10.1128/JCM.01244-07; Coura JR, 2009, MEM I OSWALDO CRUZ, V104, P31, DOI 10.1590/S0074-02762009000900006; Cura C, 2010, INT J PARASITOL, DOI 10 1016/jupari 2010 06 006; Ramirez JD, 2009, J CLIN MICROBIOL, V47, P3945, DOI 10.1128/JCM.01601-09; de Freitas Jorge M., 2006, PLoS Pathogens, V2, P226, DOI 10.1371/journal.ppat.0020024; de Souza W., 2003, P13; Deborggraeve S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000450; Diez M, 2007, AM J TRANSPLANT, V7, P1633, DOI 10.1111/j.1600-6143.2007.01820.x; Duffy T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000419; EHRLICH GD, 1994, PCR BASED DIAGNOSTIC; Galvao LMC, 2003, J CLIN MICROBIOL, V41, P5066, DOI 10.1128/JCM.41.11.5066-5070.2003; Gomes YM, 2009, MEM I OSWALDO CRUZ, V104, P115, DOI 10.1590/S0074-02762009000900017; Herrera C, 2007, INFECT GENET EVOL, V7, P535, DOI 10.1016/j.meegid.2006.12.003; Hoorfar J, 2004, LETT APPL MICROBIOL, V38, P79, DOI 10.1046/j.1472-765X.2003.01456.x; Ienne S, 2010, INFECT GENET EVOL, V10, P601, DOI 10.1016/j.meegid.2010.04.007; Kirchhoff LV, 1996, J CLIN MICROBIOL, V34, P1171; Lewis MD, 2009, AM J TROP MED HYG, V81, P1041, DOI 10.4269/ajtmh.2009.09-0305; Lewis MD, 2009, INT J PARASITOL, V39, P1305, DOI 10.1016/j.ijpara.2009.04.001; Malorny B, 2003, APPL ENVIRON MICROB, V69, P290, DOI 10.1128/AEM.69.1.290-296.2003; Marcet PL, 2006, PARASITOLOGY, V132, P57, DOI 10.1017/S0031182005008772; Miyamoto CT, 2008, EXP PARASITOL, V120, P45, DOI 10.1016/j.exppara.2008.04.018; MOSER DR, 1989, J CLIN MICROBIOL, V27, P1477; Piron M, 2007, ACTA TROP, V103, P195, DOI 10.1016/j.actatropica.2007.05.019; Portela-Lindoso AAB, 2003, REV SAUDE PUBL, V37, P107, DOI 10.1590/S0034-89102003000100016; Russomando G, 1998, AM J TROP MED HYG, V59, P487, DOI 10.4269/ajtmh.1998.59.487; Sambrook J., 2001, MOL CLONING LAB MANU; Schijman AG, 2003, J ANTIMICROB CHEMOTH, V52, P441, DOI 10.1093/jac/dkg338; Solari A, 2001, J ANTIMICROB CHEMOTH, V48, P515, DOI 10.1093/jac/48.4.515; STURM NR, 1989, MOL BIOCHEM PARASIT, V33, P205, DOI 10.1016/0166-6851(89)90082-0; Taha MK, 2005, J CLIN MICROBIOL, V43, P144, DOI 10.1128/JCM.43.1.144-149.2005; Telleria J, 2006, EXP PARASITOL, V114, P279, DOI 10.1016/j.exppara.2006.04.005; Vargas N, 2004, MOL BIOCHEM PARASIT, V138, P131, DOI 10.1016/j.molbiopara.2004.08.005; Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574; *WHO, 2007, TDRGTC06 WHO; Wincker P, 1997, PARASITOLOGY, V114, P367, DOI 10.1017/S0031182096008554; Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021; Zulantay I, 2007, ANN TROP MED PARASIT, V101, P673, DOI 10.1179/136485907X241415; Zulantay I, 2004, DIAGN MICR INFEC DIS, V48, P253, DOI 10.1016/j.diagmicrobio.2003.10.011; 2002, 22174 ISODIS	54	161	166	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	JAN	2011	5	1							e931	10.1371/journal.pntd.0000931				13	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	711MP	WOS:000286596000009	21264349	DOAJ Gold, Green Published			2019-03-26	
J	Lim, FS; Phua, KB; Lee, BW; Quak, SH; Teoh, YL; Ramakrishnan, G; Han, HH; Van der Meeren, O; Jacquet, JM; Bock, HL				Lim, Fong Seng; Phua, Kong Boo; Lee, Bee Wah; Quak, Seng Hock; Teoh, Yee Leong; Ramakrishnan, Gunasekaran; Han, Htay-Htay; Van der Meeren, Olivier; Jacquet, Jeanne-Marie; Bock, Hans L.			SAFETY AND REACTOGENICITY OF DTPA-HBV-IPV/HIB AND DTPA-IPV/HIB VACCINES IN A POST-MARKETING SURVEILLANCE SETTING	SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH			English	Article						DTPa-HBV-IPV/Hib vaccine; DTPa-IPV/Hib vaccine; safety; reactogenicity	CELL PERTUSSIS-VACCINE; ACELLULAR PERTUSSIS; HEPATITIS-B; INACTIVATED POLIOVIRUS; COMBINATION VACCINE; INFANRIX HEXA(TM); CONJUGATE VACCINE; CHILDREN; IMMUNOGENICITY; IMMUNIZATION	Combination vaccines have been shown to improve the timeliness of vaccination and vaccine coverage. Safety and reactogenicity of combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b vaccine (DTPa-IPV/Hib, Infanrix (TM) IPV+Hib, GlaxoSmithKline Biologicals) was assessed in two clinical studies. In Study A, 2,590 subjects received DTPa-IPV/Hib at 3, 4 and 5 months of age with a booster at 18 months. In Study B, 702 subjects received the same schedule but with DTPa-hepatitis B-IPV/Hib (DTPa-HBV-IPV/Hib, Infanrix hexa (TM), GlaxoSmithKline Biologicals) vaccine administered at 5 months of age. Reactogenicity was assessed for four days after each dose using diary cards. Serious adverse events (SAEs) were assessed until 24 months of age. The vaccines were well tolerated. After primary vaccination, irritability was the most frequently reported grade 3 general symptom (0.8% of doses in both studies). Fever (axillary) >39 degrees C was infrequent (0.3% of doses in Study A; 0.5% of doses in Study B). After the booster dose, the most frequently reported grade 3 symptom was redness (5%) in Study A and pain (0.5%) in Study B. An axillary temperature >39 degrees C was reported in 1.1% of subjects. Throughout the study period, 646 SAEs were reported, of which 6 SAEs were considered to be vaccination-related. The reactogenicity and safety profile of the combined DTPa-IPV/Hib vaccine was good when used for primary and booster vaccinations in over 3,000 Singaporean infants. Substitution of DTPa-IPV/Hib with DTPa-HBV-IPV/Hib at Month 5 reduced the number of injections required at this age by one.	[Lim, Fong Seng; Teoh, Yee Leong] Natl Healthcare Grp Polyclin, Singapore 149547, Singapore; [Phua, Kong Boo] KK Womens & Childrens Hosp, Dept Pediat, Singapore, Singapore; [Lee, Bee Wah] Mt Elizabeth Med Ctr, Singapore, Singapore; [Quak, Seng Hock] Natl Univ Singapore, Dept Pediat, Singapore 117548, Singapore; [Teoh, Yee Leong; Ramakrishnan, Gunasekaran; Han, Htay-Htay; Van der Meeren, Olivier; Jacquet, Jeanne-Marie; Bock, Hans L.] GlaxoSmithKline Biol, Wavre, Belgium	Lim, FS (reprint author), Natl Healthcare Grp Polyclin, 6 Commonwealth Lane,Level 7,GMTI Bldg, Singapore 149547, Singapore.	Fong_Seng_LIM@nhgp.com.sg					Aristegui Javier, 2003, International Journal of Infectious Diseases, V7, P143, DOI 10.1016/S1201-9712(03)90011-7; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P1; CODY CL, 1981, PEDIATRICS, V68, P650; Curran MP, 2003, DRUGS, V63, P673, DOI 10.2165/00003495-200363070-00004; Dagan R, 1997, PEDIATR INFECT DIS J, V16, P1113, DOI 10.1097/00006454-199712000-00004; DELORIA MA, 1995, PEDIATRICS, V96, P592; Goh K. T., 1997, Annals Academy of Medicine Singapore, V26, P671; GOH KT, 1989, B WORLD HEALTH ORGAN, V67, P65; Happe LE, 2009, PEDIATR INFECT DIS J, V28, P98, DOI 10.1097/INF.0b013e318187d047; Jefferson T, 2003, VACCINE, V21, P2003, DOI 10.1016/S0264-410X(02)00770-3; Kalies H, 2006, PEDIATR INFECT DIS J, V25, P507, DOI 10.1097/01.inf.0000222413.47344.23; Lim FS, 2007, ANN ACAD MED SINGAP, V36, P801; Lin Tzou-Yien, 2003, Chang Gung Med J, V26, P315; Meyerhoff AS, 2005, PREV MED, V41, P540, DOI 10.1016/j.ypmed.2004.12.001; Peltola H, 2001, CLIN INFECT DIS, V32, P64, DOI 10.1086/317534; Phua KB, 2009, VACCINE, V27, P5936, DOI 10.1016/j.vaccine.2009.07.098; Phua KB, 2008, ANN ACAD MED SINGAP, V37, P546; Pichichero ME, 1997, PEDIATRICS, V100, P772, DOI 10.1542/peds.100.5.772; Rennels Margaret B, 2003, Semin Pediatr Infect Dis, V14, P196, DOI 10.1016/S1045-1870(03)00033-5; Scheifele DW, 2006, VACCINE, V24, P2057, DOI [10.1016/j.vaccine.2005.11.021, 10.1016//j.vaccine.2005.11.021]; TEE NW, 1996, ANN ACAD MED, V2, P184; *WHO, 2002, WHOVB0304 TCG; *WHO, 2007, WHO VACC PREV DIS MO; *WHO, 2004, WKLY EPIDEMIOL REC, V79, P255; *WHO, 2002, WHOVB0228; *WHO, 2006, WKLY EPIDEMIOL REC, V81, P445; Wong H B, 1982, Ann Acad Med Singapore, V11, P322; Woo EJ, 2003, CLIN INFECT DIS, V37, P351, DOI 10.1086/375820; Zepp F, 2004, VACCINE, V22, P2226, DOI 10.1016/j.vaccine.2003.11.044; Zepp F, 2009, EXPERT REV VACCINES, V8, P663, DOI 10.1586/ERV.09.32	30	4	4	0	0	SOUTHEAST ASIAN MINISTERS EDUC ORGANIZATION	BANGKOK	SEAMEO-TROPMED, 420-6 RAJVITHI RD,, BANGKOK 10400, THAILAND	0125-1562			SE ASIAN J TROP MED	Southeast Asian J. Trop. Med. Public Health	JAN	2011	42	1					138	147						10	Public, Environmental & Occupational Health; Infectious Diseases; Tropical Medicine	Public, Environmental & Occupational Health; Infectious Diseases; Tropical Medicine	720KF	WOS:000287278900019	21323176				2019-03-26	
J	Fernandez, MAL; Mason, PR; Gray, H; Bauernfeind, A; Fesselet, JF; Maes, P				Fernandez, Miguel Angel Luque; Mason, Peter R.; Gray, Henry; Bauernfeind, Ariane; Fesselet, Jean Francois; Maes, Peter			Descriptive spatial analysis of the cholera epidemic 2008-2009 in Harare, Zimbabwe: a secondary data analysis	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Cholera; Disease Outbreaks; Epidemiology; Zimbabwe; Africa	BANGLADESH	This ecological study describes the cholera epidemic in Harare during 2008-2009 and identifies patterns that may explain transmission. Rates ratios of cholera cases by suburb were calculated by a univariate regression Poisson model and then, through an Empirical Bayes modelling, smoothed rate ratios were estimated and represented geographically. Mbare and southwest suburbs of Harare presented higher rate ratios. Suburbs attack rates ranged from 1.2 (95% CI = 0.7-1.6) cases per 1000 people in Tynwald to 90.3 (95% CI = 82.8-98.2) in Hopley. The identification of this spatial pattern in the spread, characterised by low risk in low density residential housing, and a higher risk in high density south west suburbs and Mbare, could be used to advocate for improving water and sanitation conditions and specific preparedness measures in the most affected areas. (C) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Fernandez, Miguel Angel Luque; Bauernfeind, Ariane] Med Sans Frontieres, Brussels Operat Ctr, Dept Med, B-1090 Brussels, Belgium; [Mason, Peter R.] Univ Zimbabwe, Coll Hlth Sci, Biomed Res & Training Inst, Harare, Zimbabwe; [Gray, Henry; Maes, Peter] Med Sans Frontieres, Dept Med, Water Hyg & Sanitat Unit, Brussels Operat Ctr, B-1090 Brussels, Belgium; [Fesselet, Jean Francois] Med Sans Frontieres, Dept Publ Hlth, Water Hyg & Sanitat Unit, Amsterdam Operat Ctr, Holland, MI USA	Fernandez, MAL (reprint author), Med Sans Frontieres, Brussels Operat Ctr, Dept Med, 94 Rue Dupre, B-1090 Brussels, Belgium.	miguel.angel.luque@brussels.msf.org	LUQUE FERNANDEZ, MIGUEL ANGEL/L-4053-2015	LUQUE FERNANDEZ, MIGUEL ANGEL/0000-0001-6683-5164			Bauernfeind A, 2004, CHOLERA GUIDELINES; Bradley M, 1996, T ROY SOC TROP MED H, V90, P378, DOI 10.1016/S0035-9203(96)90512-X; Breslow N. E., 1987, STAT METHODS CANC RE, VII; Desenclos JC, 2007, MED MALADIES INFECT, V37, P77, DOI 10.1016/j.medmal.2006.09.008; Drakakis-Smith D.W., 1994, GEOGR ANN B, V76B, P3; DRAKAKISSMITH DW, 1984, INT MIGR REV, V18, P1278, DOI 10.2307/2546083; Dupont WD, 2002, STAT MODELING BIOMED; Emch M, 1999, SOC SCI MED, V49, P519, DOI 10.1016/S0277-9536(99)00146-X; Emch M, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-2; Feachem R G, 1982, Trop Dis Bull, V79, P1; Fisher D, 2009, ANN ACAD MED SINGAP, V38, P82; Fleiss JL, 2003, STAT METHODS RATES P; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; Gumbo B, 2000, Schriftenr Ver Wasser Boden Lufthyg, V105, P15; Hartley DM, 2006, PLOS MED, V3, P63, DOI 10.1371/journal.pmed.0030007; Hauri A M, 2005, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V48, P1013, DOI 10.1007/s00103-005-1119-1; Kapperud Georg, 1996, Tidsskrift for den Norske Laegeforening, V116, P3329; Mason PR, 2009, J INFECT DEV COUNTR, V3, P148, DOI 10.3855/jidc.62; Merrell DS, 2002, NATURE, V417, P642, DOI 10.1038/nature00778; Ncayiyana DJ, 2009, SAMJ S AFR MED J, V99, P7; Nelson EJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000187; Skronda A., 2008, MULTILEVEL LONGITUDI; Truscott R, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2942; Truscott R, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2710; *UN SECR DEP EC SO, 2008, WORLD POP PROSP 2008; Watts R, 1992, Afr Health, V15, P10; Zarocostas J, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b693; 2009, WKLY EPIDEMIOL REC, V84, P50; 2008, WKLY EPIDEMIOL REC, V83, P449; 1993, MMWR MORB MORTAL WKL, V42, P407; 1993, MMWR MORB MORTAL WKL, V42, P415	31	15	15	1	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN	2011	105	1					38	45		10.1016/j.trstmh.2010.10.001				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	702PM	WOS:000285906600006	21075411	Green Published			2019-03-26	
J	Kizito, KW; Dunkley, S; Kingori, M; Reid, T				Kizito, Kibango Walter; Dunkley, Sophie; Kingori, Magdalene; Reid, Tony			Lost to follow up from tuberculosis treatment in an urban informal settlement (Kibera), Nairobi, Kenya: what are the rates and determinants?	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Lost to follow up; Tuberculosis treatment	DOTS	Patients lost to follow up (LTFU) from treatment are a major concern for tuberculosis (TB) programmes. It is even more challenging in programmes in urban informal settlements (slums) with large, highly mobile, impoverished populations. Kibera, on the outskirts of Nairobi, Kenya is such a community with an estimated population of 500 000 to 700 000. Medecins Sans Frontieres (MSF), in collaboration with the Kenyan Ministry of Public Health and Sanitation (MPHS), operate three clinics providing integrated TB, HIV and primary health care. We undertook a retrospective study between July 2006 and December 2008 to determine the rate of LTFU from the TB programme in Kibera and to assess associated clinical and socio-demographic factors. Thanks to an innovative 'Defaulter Tracing Programme', patients who missed their appointments were routinely traced and encouraged to return for treatment. Where possible, reasons for missed appointments were recorded. LTFU occurred in 146 (13%) of the 1094 patients registered, with male gender, no salaried employment, lack of family support and positive TB smear at diagnosis found to be significant associations (P value <= 0.05). The most commonly cited reasons for LTFU were relocation from Kibera to 'up-country' rural homes and work commitments. (C) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Kizito, Kibango Walter; Dunkley, Sophie] Med Sans Frontieres, Operat Ctr Belgium, Nairobi, Kenya; [Kingori, Magdalene] Kenyatta Natl Hosp, Div Leprosy TB & Lung Dis, Govt Kenya Minist Publ Hlth & Sanitat, Nairobi, Kenya; [Reid, Tony] Med Sans Frontieres, Operat Ctr Belgium, Dept Operat Res, B-1090 Brussels, Belgium	Kizito, KW (reprint author), Med Sans Frontieres, Operat Ctr Belgium, Suguta Rd,Kileleshwa POB 38897-00623, Nairobi, Kenya.	kwalta@gmail.com			Centre for Operational Research, International Union Against Tuberculosis and Lung Disease; Operational Research Unit, MSF, Belgium; Medecins Sans Frontieres [09_MSF_ERB_015]	The authors would like to acknowledge the support provided by all the clinic and project office staff in Nairobi. This research was supported through an operational research course, which was jointly developed and run by the Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, and the Operational Research Unit, MSF, Belgium.	Bam TS, 2006, INT J TUBERC LUNG D, V10, P270; Comolet TM, 1998, INT J TUBERC LUNG D, V2, P891; Dodor EA, 2004, INT J TUBERC LUNG D, V8, P1337; *GOV KEN MIN PUBL, 2009, GUID TB LEPR CONTR; KEBEDE D, 1997, E AFR MED J, V74, P154; Munro SA, 2007, PLOS MED, V4, P1230, DOI 10.1371/journal.pmed.0040238; Okanurak K, 2008, INT J TUBERC LUNG D, V12, P1160; Reid Tony, 2008, Confl Health, V2, P15, DOI 10.1186/1752-1505-2-15; *REP KEN MIN PUBL, 2008, ANN REP 2008; Shargie EB, 2007, PLOS MED, V4, P280, DOI 10.1371/journal.pmed.0040037; Tekle B, 2002, INT J TUBERC LUNG D, V6, P573; *UN HAB, 2010, INT WAT SAN WAST MAN; World Health Organization, 2009, STOP TB PARTN TUB FA	13	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	JAN	2011	105	1					52	57		10.1016/j.trstmh.2010.08.015				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	702PM	WOS:000285906600008	20889176	Green Published			2019-03-26	
J	Zachariah, R; Reid, SD; Chaillet, P; Massaquoi, M; Schouten, EJ; Harries, AD				Zachariah, R.; Reid, S. D.; Chaillet, P.; Massaquoi, M.; Schouten, E. J.; Harries, A. D.			Viewpoint: Why do we need a point-of-care CD4 test for low-income countries?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						CD4 count; point-of-care; low-income countries; taux de CD4; lieu des soins; pays a faibles revenus; recuento de CD4; prueba rapida; paises en vias de desarrollo	ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; ADULTS; RESISTANCE	In this paper, we discuss the reasons why we urgently need a point-of-care (POC) CD4 test, elaborate the problems we have experienced with the current technology which hampers CD4-count coverage and highlight the ideal characteristics of a universal CD4 POC test. It is high-time that CD4 technology is simplified and adapted for wider use in low-income countries to change the current paradigm of restricted access once and for all.	[Zachariah, R.] MSF, Operat Ctr Brussels, Operat Res Unit, Dept Med, Luxembourg, Luxembourg; [Reid, S. D.] Univ London Imperial Coll Sci Technol & Med, Inst Global Hlth, Initiat CD4, London, England; [Chaillet, P.] Operat Ctr, Lab Serv, Brussels, Belgium; [Massaquoi, M.] Clinton Hlth Access Initiat, Monrovia, Liberia; [Schouten, E. J.] Minist Hlth, Dept HIV AIDS, Lilongwe, Malawi; [Schouten, E. J.] Management Sci Hlth, Lilongwe, Malawi; [Harries, A. D.] Int Union TB & Lung Dis, Paris, France; [Harries, A. D.] London Sch Hyg & Trop Med, London, England	Zachariah, R (reprint author), Med Sans Frontieres Brussels Operat Ctr, Med Dept Operat Res, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu		Reid, Steven/0000-0002-8585-4894			Bassett IV, 2010, AIDS, V24, pS37, DOI 10.1097/01.aids.0000366081.91192.1c; Carter RJ, 2010, JAIDS-J ACQ IMM DEF, V55, P404, DOI 10.1097/QAI.0b013e3181e73f4b; Gupta RK, 2009, LANCET INFECT DIS, V9, P409, DOI 10.1016/S1473-3099(09)70136-7; *IN AW, 2010, CD4 IN ZYOM CD4 POC, P45959; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; Maldonado F, 2009, T ROY SOC TROP MED H, V103, P607, DOI 10.1016/j.trstmh.2008.07.014; Malkin R, 2010, MED BIOL ENG COMPUT, V48, P721, DOI 10.1007/s11517-010-0630-1; Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8; *MOHP, 2010, Q REP ANT TREATM MAL, P45959; Mtapuri-Zinyowera S, 2010, JAIDS-J ACQ IMM DEF, V55, P1, DOI 10.1097/QAI.0b013e3181e93071; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Philips M, 2008, LANCET, V371, P682, DOI 10.1016/S0140-6736(08)60307-4; Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370; Tayler-Smith K, 2010, T ROY SOC TROP MED H, V104, P313, DOI 10.1016/j.trstmh.2010.01.007; World Health Organization, 2009, UN ACC SCAL PRIOR HI; World Health Organization, 2010, ANT THER HIV INF AD; Zachariah R, 2009, T ROY SOC TROP MED H, V103, P549, DOI 10.1016/j.trstmh.2008.09.019	17	50	50	0	5	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2011	16	1					37	41		10.1111/j.1365-3156.2010.02669.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	695RF	WOS:000285389600006	21371207	Bronze			2019-03-26	
J	Agyepong, IA; Orem, JN; Hercot, D				Agyepong, Irene Akua; Orem, Juliet Nabyonga; Hercot, David			Viewpoint: When the 'non-workable ideological best' becomes the enemy of the 'imperfect but workable good'	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						National Health Programs; Ghana; National Health Insurance; non-US; International Cooperation; programmes nationaux de sante; Ghana; assurance-maladie nationale; non Etats-Unis; cooperation internationale; Programas nacionales de salud; Ghana; seguro nacional de salud; no estadounidense; Cooperacion Internacional	HEALTH-INSURANCE; GHANA; POLICY; CARE; EXEMPTIONS; COUNTRIES; AFRICA; FEES	This brief paper addresses some of the difficulties inherent in international ideological approaches to solving the complex problems of health care financing and delivery in poor countries using Ghana as an example. It concludes with an appeal for problem solving approaches involving informed debate as to optimal ways forward to solve low income country health financing woes that are open minded about possible options rather than vested in particular positions.	[Hercot, David] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Orem, Juliet Nabyonga] WHO Uganda Country Off, Kampala, Uganda; [Agyepong, Irene Akua] Univ Utrecht Greater Accra Reg Hlth Directorate, Ghana Hlth Serv, Accra, Ghana	Hercot, D (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	dhercot@itg.be	Hercot, David/F-5444-2011	Hercot, David/0000-0002-0457-0663; Agyepong, Irene Akua/0000-0002-0193-5882			AGYEPONG IA, 2007, ASSESSMENT EFF UNPUB; Agyepong IA, 2008, HEALTH POLICY PLANN, V23, P150, DOI 10.1093/heapol/czn002; ANSAH EK, 2009, PLOS MED, V62; Ansah EK, 2009, PLOS MED, V6, P48, DOI 10.1371/journal.pmed.1000007; ASANTE F, 2007, DOES NHIS COVER POOR; Atim C, 1999, SOC SCI MED, V48, P881, DOI 10.1016/S0277-9536(98)00390-6; Baltussen R, 2006, TROP MED INT HEALTH, V11, P654, DOI 10.1111/j.1365-3156.2006.01621.x; BITRAN R, 2003, WORLD BANK SOCIAL PR, V308; BOATENG R, 2008, 2008 HLTH SUMM ACCR; BOSU WK, 2004, ANN HLTH SECT REV 20; Carrin G, 2005, TROP MED INT HEALTH, V10, P799, DOI 10.1111/j.1365-3156.2005.01455.x; CULYER AJ, 1992, J HEALTH POLIT POLIC, V17, P667, DOI 10.1215/03616878-17-4-667; EVANS RG, 1992, YALE L POLY REV, V10, P362; GARSHONG B, 2001, STUDY FACTORS AFFECT; GARSHONG B, 2001, WE ARE STILL P UNPUB; Gilson L, 2005, BRIT MED J, V331, P762, DOI 10.1136/bmj.331.7519.762; IKEGAMI N, 1992, J HEALTH POLIT POLIC, V17, P689, DOI 10.1215/03616878-17-4-689; Kivumbi GW, 2002, HEALTH POLICY PLANN, V17, P64, DOI 10.1093/heapol/17.suppl_1.64; McIntyre D, 2008, B WORLD HEALTH ORGAN, V86, P871, DOI 10.2471/BLT.08.053413; *MOH, 2006, REV EX POL REP ANN H; *MOH, 2009, PULL TOG AC IN PRESS; Mubyazi G. M., 2004, East African Journal of Public Health, V1, P11; NYONATOR F, 1996, CARING HLTH POOR POL; Palmer N, 2004, LANCET, V364, P1365, DOI 10.1016/S0140-6736(04)17195-X; PRICHARD W, 2009, TAXATION DEV GHANA F; SAVEDOFF W, 2004, TAX BASED FINANCING; *SEND GHAN, 2010, BAL ACC QUAL HLTH CA; van Doorslaer E, 2006, LANCET, V368, P1357, DOI 10.1016/S0140-6736(06)69560-3; VANDERSCHULENBU.JM, 1992, POLITICS, V17, P715; VIROJ T, 2004, POLICY IMPLEMENTATIO; WAHAB H, 2008, WORKSH POL THEOR POL; Witter S, 2007, REPROD HEALTH MATTER, V15, P61, DOI 10.1016/S0968-8080(07)30325-X; Witter S, 2007, INT J HEALTH PLAN M, V22, P133, DOI 10.1002/hpm.867; Witter S, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-20; World Bank, 2010, WORLD DEV IND DAT; 2010, WHO PAYS HLTH CARE G	36	10	10	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2011	16	1					105	109		10.1111/j.1365-3156.2010.02639.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	695RF	WOS:000285389600015	21371211	Bronze			2019-03-26	
J	Hainard, A; Tiberti, N; Robin, X; Ngoyi, DM; Matovu, E; Enyaru, JCK; Muller, M; Turck, N; Ndung'u, JM; Lejon, V; Sanchez, JC				Hainard, Alexandre; Tiberti, Natalia; Robin, Xavier; Ngoyi, Dieudonne M.; Matovu, Enock; Enyaru, John C. K.; Mueller, Markus; Turck, Natacha; Ndung'u, Joseph M.; Lejon, Veerle; Sanchez, Jean-Charles			Matrix metalloproteinase-9 and intercellular adhesion molecule 1 are powerful staging markers for human African trypanosomiasis	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						human African trypanosomiasis; stage determination; MMP-9; ICAM-1; cerebrospinal fluid; trypanosomiase humaine africaine; determination du stade; MMP-9; ICAM-1; liquide cephalo-rachidien; tripanosomiasis humana africana; determinacion de estadios; MMP-9; ICAM-1; liquido cefalorraquideo	BLOOD-BRAIN-BARRIER; GAMBIENSE SLEEPING SICKNESS; CENTRAL-NERVOUS-SYSTEM; MATRIX METALLOPROTEINASES; TISSUE INHIBITORS; CEREBRAL MALARIA; CELL-MIGRATION; MENINGITIS	Objectives A critical step before treatment of human African trypanosomiasis (HAT) is the correct staging of the disease. As late stage is established when trypanosomes cross the blood-brain barrier and invade the central nervous system, we hypothesized that matrix metalloproteinases and cell adhesion molecules could indicate, alone or in combination, the disease progression from the first to the second stage of HAT. Methods We measured the levels of MMP-2, MMP-9, ICAM-1, VCAM-1 and E-selectin in the cerebrospinal fluid (CSF) of 63 Trypanosoma brucei gambiense-infected patients (15 stage 1 and 48 stage 2). Staging was based on counting of white blood cells (WBC) and/or parasite detection in CSF. Concentrations were obtained either by ELISA or multiplex bead suspension assays, and results were compared with three known HAT staging markers (CXCL10, CXCL8 and H-FABP). Results ICAM-1 and MMP-9 accurately discriminated between stage 1 and stage 2 patients with HAT with 95% sensitivity (SE) for 100% specificity (SP), which was better than CXCL10 (93% SE for 100% SP), one of the most promising known markers. Combination of ICAM-1 and MMP-9 with H-FABP provided a panel that resulted in 100% of SE and SP for staging HAT. Conclusions ICAM-1 and MMP-9, alone or in combination, appeared as powerful CSF staging markers of HAT. Final validation of all newly discovered staging markers on a large multi-centric cohort including both forms of the disease as well as patients with others infections should be performed.	[Sanchez, Jean-Charles] Med Univ Ctr, Struct Biol & Bioinformat Dept, Biomed Prote Res Grp, 1 Rue Michel Servet, Geneva, Switzerland; [Ngoyi, Dieudonne M.] Inst Natl Rech Biomed, Kinshasa, DEM REP CONGO; [Matovu, Enock] Makerere Univ, Fac Vet Med, Dept Vet Parasitol & Microbiol, Kampala, Uganda; [Enyaru, John C. K.] Makerere Univ, Fac Sci, Dept Biochem, Kampala, Uganda; [Mueller, Markus] Med Univ Ctr, Swiss Inst Bioinformat, Geneva, Switzerland; [Ndung'u, Joseph M.] FIND, Geneva, Switzerland; [Lejon, Veerle] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Sanchez, JC (reprint author), Med Univ Ctr, Struct Biol & Bioinformat Dept, Biomed Prote Res Grp, 1 Rue Michel Servet, Geneva, Switzerland.	jean-charles.sanchez@unige.ch	Robin, Xavier/A-1680-2009; Tiberti, Natalia/I-7928-2018	Robin, Xavier/0000-0002-6813-3200; Tiberti, Natalia/0000-0002-2981-5233; Matovu, Enock/0000-0003-0714-7032; Lejon, Veerle/0000-0002-6795-0962	Foundation for Innovative New Diagnostics (FIND); Belgian Directorate General for International Cooperation	The authors thank Catherine Fouda, Noemie Roze-Fumaux and Nadia Walter for technical assistance. This work was supported with funds from the Foundation for Innovative New Diagnostics (FIND). The THARSAT study and D. Mumba Ngoyi received financial support from the Belgian Directorate General for International Cooperation.	AGRAWAL S, 2006, MEDICINE, V203, P1007; Amin DN, 2009, J INFECT DIS, V200, P1556, DOI 10.1086/644597; Brown HC, 2000, NEUROLOGY, V55, P104, DOI 10.1212/WNL.55.1.104; Brun R, 2010, LANCET, V375, P148, DOI 10.1016/S0140-6736(09)60829-1; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Courtioux B, 2009, TROP MED INT HEALTH, V14, P529, DOI 10.1111/j.1365-3156.2009.02263.x; Enanga B, 2002, CELL MOL LIFE SCI, V59, P845, DOI 10.1007/s00018-002-8472-0; Girard M, 2005, MOL BIOCHEM PARASIT, V139, P41, DOI 10.1016/j.molbiopara.2004.09.008; Grab DJ, 2008, J NEUROVIROL, V14, P344, DOI 10.1080/13550280802282934; Hainard A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000459; Jaber SM, 2009, J PEDIATR NEUROSCI, V4, P76, DOI 10.4103/1817-1745.57326; Kennedy PGE, 2008, ANN NEUROL, V64, P116, DOI 10.1002/ana.21429; Kristensson K, 2010, PROG NEUROBIOL, V91, P152, DOI 10.1016/j.pneurobio.2009.12.001; Leib SL, 2000, INFECT IMMUN, V68, P615, DOI 10.1128/IAI.68.2.615-620.2000; Lejon V, 2002, T ROY SOC TROP MED H, V96, P329, DOI 10.1016/S0035-9203(02)90115-X; Liuzzi GM, 2002, MULT SCLER, V8, P222, DOI 10.1191/1352458502ms800oa; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Man SM, 2007, BRAIN PATHOL, V17, P243, DOI 10.1111/j.1750-3639.2007.00067.x; MCCLISH DK, 1989, MED DECIS MAKING, V9, P190, DOI 10.1177/0272989X8900900307; Mulenga C, 2001, NEUROPATH APPL NEURO, V27, P77, DOI 10.1046/j.0305-1846.2001.00306.x; Ngoyi DM, 2010, J INFECT DIS, V201, P453, DOI 10.1086/649917; Petruzzelli L, 1999, AM J MED, V106, P467, DOI 10.1016/S0002-9343(99)00058-3; Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015<0516:CAMLTA>2.3.CO;2; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; Rodgers J, 2009, J NEUROIMMUNOL, V211, P16, DOI 10.1016/j.jneuroim.2009.02.007; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Tsai HC, 2008, AM J TROP MED HYG, V78, P20, DOI 10.4269/ajtmh.2008.78.20; Van den Steen PE, 2006, LAB INVEST, V86, P873, DOI 10.1038/labinvest.3700454; World Health Organization, 1998, WHO TECH REP SER, P1	29	22	22	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	JAN	2011	16	1					119	126		10.1111/j.1365-3156.2010.02642.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	695RF	WOS:000285389600017	20958893	Bronze			2019-03-26	
J	Ayede, IA; Falade, AG; Sowunmi, A; Jansen, FH				Ayede, Idowu Adejumoke; Falade, Adegoke Gbadegesin; Sowunmi, Akintunde; Jansen, Frans Herwig			An open randomized clinical trial in comparing two artesunate-based combination treatments on Plasmodium falciparum malaria in Nigerian children: artesunate/sulphamethoxypyrazine/pyrimethamine (fixed dose over 24 hours) versus artesunate/amodiaquine (fixed dose over 48 hours)	MALARIA JOURNAL			English	Article							ARTEMETHER-LUMEFANTRINE; SULFADOXINE-PYRIMETHAMINE; AMODIAQUINE; CHLOROQUINE; EFFICACY	Background: Several studies have demonstrated the efficacy of artemisinin-combination therapy (ACT) across malaria zones of the world. Fixed dose ACT with shorter courses and fewer tablets may be key determinants to ease of administration and compliance. Methods: Children aged one year to 13 years presenting with uncomplicated Plasmodium falciparum malaria were recruited in Ibadan, south-western Nigeria. A total of 250 children each were randomly assigned to receive three doses of artesunate/sulphamethoxypyrazine/pyrimethamine (AS + SMP) (12 hourly doses over 24 hours) or three doses of artesunate/amodiaquine (AS + AQ) (daily doses over 48 hours). Efficacy and safety of the two drugs were assessed using a 28-day follow-up and the primary outcome was PCR-corrected parasitological cure rate and clinical response. Results: There were two (0.4%) early treatment failures, one in each treatment arm. The PCR corrected cure rates for day 28 was 97.9% in the AS + AQ arm and 95.6% in the AS + SMP arm (p = 0.15). The re-infection rate was 1.7% in the AS + AQ arm and 5.7% in the AS + SMP arm (p = 0.021). The fever clearance time was similar in the two treatment groups: 1 - 2 days for both AS + SMP and AS + AQ (p = 0.271). The parasite clearance time was also similar in the two treatment groups with 1 - 7 days for AS + SMP and 1 - 4 days for AS + AQ (p = 0.941). The proportion of children with gametocytes over the follow-up period was similar in both treatment groups. Serious Adverse Events were not reported in any of the patients and in all children, laboratory values (packed cell volume, liver enzymes, bilirubin) remained within normal levels during the follow-up period but the packed cell volume was significantly lower in the AS + SMP group. Conclusions: This study demonstrates that AS + SMP FDC given as three doses over 24 hours (12-hour intervals) has similar efficacy as AS + AQ FDC given as three doses over 48 hours (24-hour interval) for the treatment of uncomplicated Plasmodium falciparum malaria in children in Nigeria. Both drugs also proved to be safe. Therefore, AS + SMP could be an alternative to currently recommended first-line ACT with continuous resistance surveillance.	[Ayede, Idowu Adejumoke; Falade, Adegoke Gbadegesin] Univ Coll Hosp, Coll Med, Dept Paediat, Ibadan, Nigeria; [Sowunmi, Akintunde] Univ Coll Hosp, Coll Med, Dept Pharmacol & Therapeut, Ibadan, Nigeria; [Jansen, Frans Herwig] Dafra Pharma, Turnhout, Belgium	Ayede, IA (reprint author), Univ Coll Hosp, Coll Med, Dept Paediat, Ibadan, Nigeria.	idayede@yahoo.co.uk			Dafra Pharma Belgium	The Authors acknowledge the contribution of all the field workers that participated in the study and typesetting of the manuscript. The study was sponsored by Dafra Pharma Belgium.	Adam Ishag, 2006, Ann Clin Microbiol Antimicrob, V5, P18, DOI 10.1186/1476-0711-5-18; Ademowo O G, 2002, East Afr Med J, V79, P42; *FED MIN HLTH NAT, 2005, NAT ANT TREATM POL; Federal Ministry of Health and National Malaria Control Programme, 2009, STRAT PLAN 2009 2013; Happi CT, 2004, AM J TROP MED HYG, V70, P20, DOI 10.4269/ajtmh.2004.70.20; Kim KS, 2010, LANCET INFECT DIS, V10, P32, DOI 10.1016/S1473-3099(09)70306-8; Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140-6736(05)66417-3; Ndiaye JL, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-125; Noutcha MAE, 2009, J VECTOR DIS, V46, P43; Penali LK, 2008, INT J INFECT DIS, V12, P430, DOI 10.1016/j.ijid.2007.12.006; Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Rulisa S, 2007, AM J TROP MED HYG, V77, P612, DOI 10.4269/ajtmh.2007.77.612; Sagara I, 2006, AM J TROP MED HYG, V75, P630, DOI 10.4269/ajtmh.2006.75.630; Sagara I, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-63; Sowunmi A, 2005, TROP MED INT HEALTH, V10, P1161, DOI 10.1111/j.1365-3156.2005.01503.x; SOWUNMI A, 1989, LANCET, V2, P213; Sowunmi A, 2007, AM J TROP MED HYG, V77, P235, DOI 10.4269/ajtmh.2007.77.235; VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85; *WHO, 2003, WHOHTMRBM200350; World Health Organization, 2010, GUID TREATM MAL; Zwang J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-203	21	8	8	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	DEC 31	2010	9								378	10.1186/1475-2875-9-378				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	724VW	WOS:000287605300001	21194422	DOAJ Gold, Green Published			2019-03-26	
J	Van Bortel, W; Ho, DT; Le, XH; Nguyen, VH; Nguyen, VC; Nguyen, DL; Roelants, P; Denis, L; Speybroeck, N; D'Alessandro, U; Coosemans, M				Van Bortel, Wim; Ho Dinh Trung; Le Xuan Hoi; Nguyen Van Ham; Nguyen Van Chut; Nguyen Dinh Luu; Roelants, Patricia; Denis, Leen; Speybroeck, Niko; D'Alessandro, Umberto; Coosemans, Marc			Malaria transmission and vector behaviour in a forested malaria focus in central Vietnam and the implications for vector control	MALARIA JOURNAL			English	Article							LINKED-IMMUNOSORBENT-ASSAY; POLYMERASE-CHAIN-REACTION; MOLECULAR-IDENTIFICATION; SOUTHEAST-ASIA; PLASMODIUM; COMPLEX; SPOROZOITES; CHALLENGE; MOSQUITOS; MEMBERS	Background: In Vietnam, malaria is becoming progressively restricted to specific foci where human and vector characteristics alter the known malaria epidemiology, urging for alternative or adapted control strategies. Long-lasting insecticidal hammocks (LLIH) were designed and introduced in Ninh Thuan province, south-central Vietnam, to control malaria in the specific context of forest malaria. An entomological study in this specific forested environment was conducted to assess the behavioural patterns of forest and village vectors and to assess the spatio-temporal risk factors of malaria transmission in the province. Methods: Five entomological surveys were conducted in three villages in Ma Noi commune and in five villages in Phuoc Binh commune in Ninh Thuan Province, south-central Vietnam. Collections were made inside the village, at the plot near the slash-and-burn fields in the forest and on the way to the forest. All collected mosquito species were subjected to enzyme-linked immunosorbent assay (ELISA) to detect Plasmodium in the head-thoracic portion of individual mosquitoes after morphological identification. Collection data were analysed by use of correspondence and multivariate analyses. Results: The mosquito density in the study area was low with on average 3.7 anopheline bites per man-night and 17.4 culicine bites per man-night. Plasmodium-infected mosquitoes were only found in the forest and on the way to the forest. Malaria transmission in the forested malaria foci was spread over the entire night, from dusk to dawn, but was most intense in the early evening as nine of the 13 Plasmodium positive bites occurred before 21H. The annual entomological inoculation rate of Plasmodium falciparum was 2.2 infective bites per person-year to which Anopheles dirus s.s. and Anopheles minimus s.s. contributed. The Plasmodium vivax annual entomological inoculation rate was 2.5 infective bites per person-year with Anopheles sawadwongporni, Anopheles dirus s.s. and Anopheles pampanai as vectors. Conclusion: The vector behaviour and spatio-temporal patterns of malaria transmission in Southeast Asia impose new challenges when changing objectives from control to elimination of malaria and make it necessary to focus not only on the known main vector species. Moreover, effective tools to prevent malaria transmission in the early evening and in the early morning, when the treated bed net cannot be used, need to be developed.	[Van Bortel, Wim; Roelants, Patricia; Denis, Leen; D'Alessandro, Umberto; Coosemans, Marc] Inst Trop Med Antwerp, Dept Parasitol, B-2000 Antwerp, Belgium; [Ho Dinh Trung; Le Xuan Hoi; Nguyen Dinh Luu] Natl Inst Malariol Parasitol & Entomol, Dept Entomol, Hanoi, Vietnam; [Nguyen Van Ham; Nguyen Van Chut] Ctr Malariol Parasitol & Entomol Ninh Thuan Prov, Ho Chi Minh City, Vietnam; [Speybroeck, Niko] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Speybroeck, Niko] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium; [Coosemans, Marc] Univ Antwerp, Dept Biomed Sci, Fac Pharmaceut Vet & Biomed Sci, B-2610 Antwerp, Belgium	Van Bortel, W (reprint author), Inst Trop Med Antwerp, Dept Parasitol, Natl Str 155, B-2000 Antwerp, Belgium.	wvbortel@itg.be	D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009; Van Bortel, Wim/0000-0002-6644-518X	UBS-Opitmus Foundation, Zurich (Switzerland); NIMPE; Institute of Tropical Medicine, Belgium; Belgian Co-operation	We are grateful to the staff of the Centre for Malariology, Parasitology & Entomology of Ninh Thuan province, the health staff of the districts and communes who were involved in the planning and implementation of the study. We acknowledge the inhabitants of the study villages who supported the study. This work was carried out in the framework of the study on LLIH efficacy supported by the UBS-Opitmus Foundation, Zurich (Switzerland). The current study was financially supported by the Institutional Collaboration between NIMPE and the Institute of Tropical Medicine, Belgium, supported by the Belgian Co-operation (Directorate-General for Development Co-operation).	Barat LM, 2006, AM J TROP MED HYG, V74, P12, DOI 10.4269/ajtmh.2006.74.12; BEEBE NW, 1995, AM J TROP MED HYG, V53, P478, DOI 10.4269/ajtmh.1995.53.478; Beier JC, 1999, AM J TROP MED HYG, V61, P109, DOI 10.4269/ajtmh.1999.61.109; BURKOT TR, 1984, AM J TROP MED HYG, V33, P227, DOI 10.4269/ajtmh.1984.33.227; Cook J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-169; Erhart A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-58; Erhart A, 2004, AM J TROP MED HYG, V70, P110, DOI 10.4269/ajtmh.2004.70.110; Erhart A, 2006, MALARIA CONTROL VIET; Grietens KP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-23; Hair J., 1998, MULTIVARIATE DATA AN; *IMPE, 1987, KEYS AN VIETN AD PUP; Konchom Supawadee, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P486; Mangold KA, 2005, J CLIN MICROBIOL, V43, P2435, DOI 10.1128/JCM.43.5.2435-2440.2005; Mayxay M, 2004, TRENDS PARASITOL, V20, P233, DOI 10.1016/j.pt.2004.03.006; Obsomer V, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-26; Okello PE, 2006, AM J TROP MED HYG, V75, P219, DOI 10.4269/ajtmh.2006.75.219; Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Sattabongkot J, 2004, TRENDS PARASITOL, V20, P192, DOI 10.1016/j.pt.2004.02.001; Shaukat AM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-122; Sochantha T, 2010, TROP MED INT HEALTH, V15, P336, DOI 10.1111/j.1365-3156.2009.02457.x; Thang Ngo Duc, 2009, PLoS One, V4, pe7369, DOI 10.1371/journal.pone.0007369; Trung HD, 2005, TROP MED INT HEALTH, V10, P251, DOI 10.1111/j.1365-3156.2004.01378.x; Trung HD, 2004, TROP MED INT HEALTH, V9, P230, DOI 10.1046/j.1365-3156.2003.01179.x; Van Bortel W, 2000, INSECT MOL BIOL, V9, P335, DOI 10.1046/j.1365-2583.2000.00192.x; Verle P., 1998, Research and Reviews in Parasitology, V58, P169; Walton C, 1999, MED VET ENTOMOL, V13, P24, DOI 10.1046/j.1365-2915.1999.00142.x; Walton C, 2007, INFECT GENET EVOL, V7, P93, DOI 10.1016/j.meegid.2006.05.001; WIRTZ RA, 1992, J MED ENTOMOL, V29, P854, DOI 10.1093/jmedent/29.5.854; WIRTZ RA, 1985, AM J TROP MED HYG, V34, P1048, DOI 10.4269/ajtmh.1985.34.1048	30	31	31	0	11	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	DEC 23	2010	9								373	10.1186/1475-2875-9-373				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	724VS	WOS:000287604900002	21182774	DOAJ Gold, Green Published			2019-03-26	
J	Cnops, L; Van Esbroeck, M; Bottieau, E; Jacobs, J				Cnops, Lieselotte; Van Esbroeck, Marjan; Bottieau, Emmanuel; Jacobs, Jan			Giemsa-stained thick blood films as a source of DNA for Plasmodium species-specific real-time PCR	MALARIA JOURNAL			English	Article							MALARIA DIAGNOSIS; SMEARS; FALCIPARUM; RNA; AMPLIFICATION; PARASITES	Background: This study describes the use of thick blood films (TBF) as specimens for DNA amplification with the Plasmodium species-specific real-time PCR that was recently validated on whole blood samples. Methods: The panel of 135 Giemsa-stained clinical TBFs represented single infections of the four Plasmodium species with varying parasite densities or only gametocytes, mixed infections, and negative samples and was stored for up to 12 years. Half of the Giemsa-stained TBF was scraped off by a sterile scalpel and collected into phosphate buffered saline. DNA was extracted with the Qiagen DNA mini kit with minor modifications. DNA was amplified with the 18S rRNA real-time PCR targeting the four Plasmodium species with four species-specific primers and probes in combination with one genus-specific reverse primer. Results of the PCR on TBF were compared to those of the PCR on whole blood and to microscopy. Results: Correct identification for single species infections was obtained for all TBF samples with Plasmodium falciparum (n = 50), Plasmodium vivax (n = 25), Plasmodium ovale (n = 25) and in all but one samples with Plasmodium malariae (n = 10). Compared to whole blood samples, higher Ct-values were observed by PCR on TBF with a mean difference of 5.93. Four out of five mixed infections were correctly identified with PCR on TBF. None of the negative samples (n = 20) gave a PCR signal. PCR on TBF showed a detection limit of 0.2 asexual parasites/mu l compared to 0.02/mu l for whole blood. Intra-run variation was higher for PCR on TBF (%CV 1.90) compared to PCR on whole blood (%CV 0.54). Compared to microscopy, PCR on TBF generated three more species identifications in samples containing a single species and detected the same four mixed-infections. Conclusions: Giemsa-stained TBFs are a reliable source of DNA for Plasmodium real-time PCR analysis, allowing applications in reference and research settings in case whole blood samples are not available.	[Cnops, Lieselotte; Van Esbroeck, Marjan; Bottieau, Emmanuel; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Jacobs, Jan] Fac Hlth Med & Life Sci FHML, Maastricht, Netherlands	Cnops, L (reprint author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	lcnops@itg.be					Alger J, 1996, MEM I OSWALDO CRUZ, V91, P589, DOI 10.1590/S0074-02761996000500009; Aubouy A, 2004, J INFECT DIS, V190, P1335, DOI 10.1086/424529; Bejon P, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-104; Berry A, 2005, Med Trop (Mars), V65, P176; Bronner U, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-15; CNOPS L, 2010, CLIN MICROBIOL INF; Cox-Singh J, 2008, CLIN INFECT DIS, V46, P165, DOI 10.1086/524888; Di Santi Silvia Maria, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P183, DOI 10.1590/S0036-46652004000400002; Edoh D, 1997, T ROY SOC TROP MED H, V91, P361, DOI 10.1016/S0035-9203(97)90109-7; EKALA MT, 1999, B SOC PATHOL EXOT, V93, P8; Erdman Laura K, 2008, Travel Med Infect Dis, V6, P82, DOI 10.1016/j.tmaid.2007.10.001; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-271; Hanscheid T, 2002, TRENDS PARASITOL, V18, P395, DOI 10.1016/S1471-4922(02)02348-6; Hawkes M, 2007, EXPERT REV ANTI-INFE, V5, P485, DOI 10.1586/14787210.5.3.485; KANTELE A, 2008, EMERG INFECT DIS, V14, P13434; Kawamoto F, 1996, J CLIN MICROBIOL, V34, P2287; Kettelhut MM, 2003, J CLIN PATHOL, V56, P927, DOI 10.1136/jcp.56.12.927; KIMURA M, 1995, MOL BIOCHEM PARASIT, V70, P193, DOI 10.1016/0166-6851(95)00006-M; Kirchgatter K, 2002, ACTA TROP, V84, P199, DOI 10.1016/S0001-706X(02)00181-X; Klein D, 2002, TRENDS MOL MED, V8, P257, DOI 10.1016/S1471-4914(02)02355-9; Li J, 1997, AM J TROP MED HYG, V57, P727, DOI 10.4269/ajtmh.1997.57.727; Mackay IM, 2004, CLIN MICROBIOL INFEC, V10, P190, DOI 10.1111/j.1198-743X.2004.00722.x; Maltha J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-171; MHARAKURWA S, MALAR J, V5, P103; MILNE LM, 1994, J CLIN PATHOL, V47, P740, DOI 10.1136/jcp.47.8.740; Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002; Scolpel KKG, 2004, MALARIA J, V3, P8; SCOLPEL KKG, 2004, ACTA TROP, V90, P61; Singh B, 2004, LANCET, V363, P1017, DOI 10.1016/S0140-6736(04)15836-4; Steenkeste N, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-86; Steinau M, 2006, J MOL DIAGN, V8, P113, DOI 10.2353/jmoldx.2006.050088; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; van Dijk DPJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-293; van Hellemond JJ, 2009, EMERG INFECT DIS, V15, P1478, DOI 10.3201/eid1509.090358; Volpini AC, 2006, CLIN MICROBIOL INFEC, V12, P815, DOI 10.1111/j.1469-0691.2006.01422.x; Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119, DOI 10.4269/ajtmh.2007.77.119; Xiao Fang-zhen, 2006, Chinese Journal of Parasitology and Parasitic Diseases, V24, P290	37	22	23	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	DEC 22	2010	9								370	10.1186/1475-2875-9-370				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	724VR	WOS:000287604800002	21176207	DOAJ Gold, Green Published			2019-03-26	
J	Gillet, P; Mukadi, P; Vernelen, K; Van Esbroeck, M; Muyembe, JJ; Bruggeman, C; Jacobs, J				Gillet, Philippe; Mukadi, Pierre; Vernelen, Kris; Van Esbroeck, Marjan; Muyembe, Jean-Jacques; Bruggeman, Cathrien; Jacobs, Jan			External quality assessment on the use of malaria rapid diagnostic tests in a non-endemic setting	MALARIA JOURNAL			English	Article							PERFORMANCE; TRAVELERS; CHAIN; AREA	Background: Malaria rapid diagnostic tests (RDTs) are increasingly used as a tool for the diagnosis of malaria, both in endemic and in non-endemic settings. The present study reports the results of an external quality assessment (EQA) session on RDTs in a non-endemic setting. Methods: After validation of antigen stability during shipment at room temperature, three clinical samples and a questionnaire were sent to clinical laboratories in Belgium and the Grand Duchy of Luxembourg using malaria RDTs. Participants were asked to report the results of the RDTs as observations (visibility of the RDT control and test lines) and interpretations (report as formulated to the clinician). In addition, participants were invited to fill in a questionnaire on the place of RDTs in the diagnostic strategy of malaria. Results: A total of 128/133 (96.2%) of clinical laboratories using RDTs participated. Six three-band and one four-band RDT brands were used. Analytical errors were rare and included (i) not recognizing invalid RDT results (1.6%) and (ii) missing the diagnosis of Plasmodium falciparum (0.8%). Minor errors were related to RDT test result interpretation and included (i) reporting "RDT positive" without species identification in the case of P. falciparum and non-falciparum species (16.9% and 6.5% respectively) and (ii) adding incorrect comments to the report (3.2%). Some of these errors were related to incorrect RDT package insert instructions such as (i) not reporting the possibility of mixed species infection in the case of P. falciparum and Plasmodium vivax (35.5% and 18.5% respectively) and (ii) the interpretation of P. vivax instead of non-falciparum species at the presence of a pan-species antigen line (4.0%). According to the questionnaire, 48.8% of participants processed <= 20 requests for malaria diagnosis in 2009. During opening hours, 93.6% of 125 participants used RDTs as an adjunct to microscopy but outside opening hours, nearly one third of 113 participants relied on RDTs as the primary (4.4%) or the single tool (25.7%) for malaria diagnosis. Conclusion: In this non-endemic setting, errors in RDT performance were mainly related to RDT test line interpretations, partly due to incorrect package insert instructions. The reliance on RDTs as the primary or the single tool for the diagnosis of malaria outside opening hours is of concern and should be avoided.	[Gillet, Philippe; Van Esbroeck, Marjan; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [Mukadi, Pierre; Muyembe, Jean-Jacques] INRB, Kinshasa, Zaire; [Vernelen, Kris] Inst Publ Hlth, Brussels, Belgium; [Bruggeman, Cathrien] Maastricht Univ Med Ctr, Sch Publ Hlth & Primary Care CAPHRI, Dept Med Microbiol, Maastricht, Netherlands	Gillet, P (reprint author), Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium.	pgillet@itg.be		gillet, philippe/0000-0001-5878-6446			Baker J, 2005, J INFECT DIS, V192, P870, DOI 10.1086/432010; Baker J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-129; Chilton D, 2006, J CLIN PATHOL, V59, P862, DOI 10.1136/jcp.2005.032904; Chiodini PL, 2007, T ROY SOC TROP MED H, V101, P331, DOI 10.1016/j.trstmh.2006.09.007; Cnops L, 2010, CLIN MICROBIOL INFEC; de Oliveira AM, 2009, AM J TROP MED HYG, V80, P470, DOI 10.4269/ajtmh.2009.80.470; Drakeley C, 2009, T ROY SOC TROP MED H, V103, P333, DOI 10.1016/j.trstmh.2008.10.003; Farcas GA, 2003, AM J TROP MED HYG, V69, P589, DOI 10.4269/ajtmh.2003.69.6.0690589; Forney JR, 2001, J CLIN MICROBIOL, V39, P2884, DOI 10.1128/JCM.39.8.2884-2890.2001; Gamboa D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008091; Gillet P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-215; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-271; Gillet P, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-262; Hanscheid T, 2003, CLIN MICROBIOL INFEC, V9, P497, DOI 10.1046/j.1469-0691.2003.00640.x; Jorgensen P, 2006, AM J TROP MED HYG, V74, P750, DOI 10.4269/ajtmh.2006.74.750; Kettelhut MM, 2003, J CLIN PATHOL, V56, P927, DOI 10.1136/jcp.56.12.927; Luchavez J, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-149; Maltha J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-171; Marx A, 2005, ANN INTERN MED, V142, P836, DOI 10.7326/0003-4819-142-10-200505170-00009; McMorrow ML, 2008, AM J TROP MED HYG, V79, P385, DOI 10.4269/ajtmh.2008.79.385; Moody A H, 2002, Br J Biomed Sci, V59, P228; Moulin F, 2009, ARCH PEDIATRIE, V16, pS89, DOI 10.1016/S0929-693X(09)75308-4; Mueller I, 2007, J CLIN MICROBIOL, V45, P627, DOI 10.1128/JCM.00816-06; Murray CK, 2008, CLIN MICROBIOL REV, V21, P97, DOI 10.1128/CMR.00035-07; Palmer CJ, 2003, J CLIN MICROBIOL, V41, P5178, DOI 10.1128/JCM.41.111.5178-5182.2003; Rennie W, 2007, T ROY SOC TROP MED H, V101, P9, DOI 10.1016/j.trstmh.2006.03.011; Seidahmed OME, 2008, TROP MED INT HEALTH, V13, P406, DOI 10.1111/j.1365-3156.2008.02015.x; Stauffer WM, 2009, CLIN INFECT DIS, V49, P908, DOI 10.1086/605436; Van der Palen M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-90; van Dijk DPJ, 2010, EUR J CLIN MICROBIOL, V29, P577, DOI 10.1007/s10096-010-0898-y; van Dijk DPJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-293; Versteeg I, 2009, DIAGN MICR INFEC DIS, V64, P256, DOI 10.1016/j.diagmicrobio.2009.03.012; WHO, 2010, PAR CONF MAL DIAGN; *WHO, 2008, RDT INSTR TRA; *WHO, 2010, LOT TEST US QUAL CON; *WHO, 2009, MAL RAP DIAGN TEST P; WHO Western Pacific Region., 2006, QUAL TEST MAL RAP DI; World Health Organization, 2008, US RAP DIAGN TEST RD; World Health Organization, 2010, MAL RAP DIAGN TEST P	39	26	26	0	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	DEC 13	2010	9								359	10.1186/1475-2875-9-359				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	724VK	WOS:000287604100001	21144034	DOAJ Gold, Green Published			2019-03-26	
J	Sinka, ME; Bangs, MJ; Manguin, S; Coetzee, M; Mbogo, CM; Hemingway, J; Patil, AP; Temperley, WH; Gething, PW; Kabaria, CW; Okara, RM; Van Boeckel, T; Godfray, HCJ; Harbach, RE; Hay, SI				Sinka, Marianne E.; Bangs, Michael J.; Manguin, Sylvie; Coetzee, Maureen; Mbogo, Charles M.; Hemingway, Janet; Patil, Anand P.; Temperley, Will H.; Gething, Peter W.; Kabaria, Caroline W.; Okara, Robi M.; Van Boeckel, Thomas; Godfray, H. Charles J.; Harbach, Ralph E.; Hay, Simon I.			The dominant Anopheles vectors of human malaria in Africa, Europe and the Middle East: occurrence data, distribution maps and bionomic precis	PARASITES & VECTORS			English	Article							GAMBIAE COMPLEX DIPTERA; MERUS DONITZ DIPTERA; PLASMODIUM-FALCIPARUM TRANSMISSION; ENTOMOLOGICAL INOCULATION RATES; PERMETHRIN-IMPREGNATED NETS; BLOOD-FEEDING BEHAVIOR; BAITED ENTRY TRAPS; WESTERN KENYA; INSECTICIDE RESISTANCE; ARABIENSIS DIPTERA	Background: This is the second in a series of three articles documenting the geographical distribution of 41 dominant vector species (DVS) of human malaria. The first paper addressed the DVS of the Americas and the third will consider those of the Asian Pacific Region. Here, the DVS of Africa, Europe and the Middle East are discussed. The continent of Africa experiences the bulk of the global malaria burden due in part to the presence of the An. gambiae complex. Anopheles gambiae is one of four DVS within the An. gambiae complex, the others being An. arabiensis and the coastal An. merus and An. melas. There are a further three, highly anthropophilic DVS in Africa, An. funestus, An. moucheti and An. nili. Conversely, across Europe and the Middle East, malaria transmission is low and frequently absent, despite the presence of six DVS. To help control malaria in Africa and the Middle East, or to identify the risk of its re-emergence in Europe, the contemporary distribution and bionomics of the relevant DVS are needed. Results: A contemporary database of occurrence data, compiled from the formal literature and other relevant resources, resulted in the collation of information for seven DVS from 44 countries in Africa containing 4234 geo-referenced, independent sites. In Europe and the Middle East, six DVS were identified from 2784 geo-referenced sites across 49 countries. These occurrence data were combined with expert opinion ranges and a suite of environmental and climatic variables of relevance to anopheline ecology to produce predictive distribution maps using the Boosted Regression Tree (BRT) method. Conclusions: The predicted geographic extent for the following DVS (or species/suspected species complex*) is provided for Africa: Anopheles (Cellia) arabiensis, An. (Cel.) funestus*, An. (Cel.) gambiae, An. (Cel.) melas, An. (Cel.) merus, An. (Cel.) moucheti and An. (Cel.) nili*, and in the European and Middle Eastern Region: An. (Anopheles) atroparvus, An. (Ano.) labranchiae, An. (Ano.) messeae, An. (Ano.) sacharovi, An. (Cel.) sergentii and An. (Cel.) superpictus*. These maps are presented alongside a bionomics summary for each species relevant to its control.	[Sinka, Marianne E.; Patil, Anand P.; Temperley, Will H.; Gething, Peter W.; Van Boeckel, Thomas; Godfray, H. Charles J.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England; [Bangs, Michael J.] PT Freeport Indonesia, Publ Hlth & Malaria Control Dept, Kuala Kencana, Papua, Indonesia; [Manguin, Sylvie] Univ Montpellier I, Inst Rech Dev,Fac Pharm, Lab Immunophysiopathol Mol Comparee, UMR MD3, F-34093 Montpellier, France; [Coetzee, Maureen] Univ Witwatersrand, Fac Hlth Sci, Malaria Entomol Res Unit, Sch Pathol, Johannesburg, South Africa; [Coetzee, Maureen] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Vector Control Reference Unit, ZA-2131 Johannesburg, South Africa; [Mbogo, Charles M.] Ctr Geog Med Res Coast, KEMRI Wellcome Trust Programme, Kilifi, Kenya; [Hemingway, Janet] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Kabaria, Caroline W.; Okara, Robi M.; Hay, Simon I.] Univ Oxford, Malaria Publ Hlth & Epidemiol Grp, Ctr Geog Med,Kenyatta Natl Hosp Grounds, KEMRI,Wellcome Trust Collaborat Programme, Nairobi, Kenya; [Van Boeckel, Thomas] Univ Libre Bruxelles, B-1050 Brussels, Belgium; [Harbach, Ralph E.] Nat Hist Museum, Dept Entomol, London SW7 5BD, England	Sinka, ME (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Tinbergen Bldg,S Parks Rd, Oxford OX1 3PS, England.	marianne.sinka@zoo.ox.ac.uk; simon.hay@zoo.ox.ac.uk	Manguin, Sylvie/G-1787-2015; Hay, Simon/F-8967-2015	Manguin, Sylvie/0000-0002-5925-7164; Hay, Simon/0000-0002-0611-7272; Hemingway, Janet/0000-0002-3200-7173; Coetzee, Maureen/0000-0003-2019-866X; Kabaria, Caroline/0000-0002-5641-5243; Gething, Peter/0000-0001-6759-5449	Wellcome Trust [083534, 079091, 079080]; Wellcome Trust, U.K.	We wish to thank Rosalind Howes, Edward Haynes, Philip Mbithi, Owen Yang, Carolynn Tago, and Elisabeth Thiveyrat for primary data abstraction. We also thank the Technical Advisory Group for extended support over the duration of the project (in addition to co-authors Michael Bangs, Sylvie Manguin, Maureen Coetzee, Ralph Harbach, Janet Hemingway and Charles M. Mbogo, these include, Theeraphap Chareonviriyaphap and Yasmin Rubio-Palis). MES is funded by a project grant from the Wellcome Trust (#083534) to SIH. SIH is funded by a Senior Research Fellowship from the Wellcome Trust (#079091) which also supports CWK and PWG. APP and WHT are funded by a Wellcome Trust Principal Research Fellowship (#079080) to Professor Robert Snow. This work forms part of the output of the Malaria Atlas Project (MAP, http://www.map.ox.ac.uk), principally funded by the Wellcome Trust, U.K.	Abdalla H, 2008, T ROY SOC TROP MED H, V102, P263, DOI 10.1016/j.trstmh.2007.10.008; ABDEL-MALEK ALBERT A., 1958, BULL SOC ENT EGYPTE, V42, P519; Abdoon A M M O, 2003, East Mediterr Health J, V9, P240; Abdullah M. A. R., 1995, Journal of the Egyptian Society of Parasitology, V25, P815; Abul-Hab J., 1986, Bulletin of Endemic Diseases, V27, P37; ADAMOVIC Z, 1984, ACTA VET-BEOGRAD, V34, P287; ADAMOVIC Z, 1980, ACTA VET-BEOGRAD, V30, P217; ADAMOVIC Z, 1988, ACTA VET-BEOGRAD, V38, P31; Adamovic ZR, 1982, B SERBIAN ACAD SCI A, V82, P97; Adja A M, 2006, Med Trop (Mars), V66, P449; Adugna N, 1996, ETHIOPIAN MED J, V34, P1; AITKEN THG, 1954, B ENTOMOL RES, V45, P437, DOI 10.1017/S0007485300029564; Akogbeto M, 1999, B SOC PATHOL EXOT, V92, P123; al-Maktari M T, 1999, East Mediterr Health J, V5, P698; Alphey L, 2002, SCIENCE, V298, P119, DOI 10.1126/science.1078278; Alten B, 2003, J VECTOR ECOL, V28, P97; Ameneshewa B, 1996, ANN TROP MED PARASIT, V90, P515, DOI 10.1080/00034983.1996.11813077; Ameneshewa B, 1995, BEHAV BIOL ANOPHELES; Amr ZS, 1997, J AM MOSQUITO CONTR, V13, P375; ANDREWES C H, 1956, J Hyg (Lond), V54, P478; ANIEDU I, 1993, ANZ SCHADLINGSKD PFL, V66, P72, DOI 10.1007/BF01903074; [Anonymous], 2009, WORLD MAL REP 2009; Antonio-Nkondjio C, 2005, T ROY SOC TROP MED H, V99, P347, DOI 10.1016/j.trstmh.2004.07.003; Antonio-Nkondjio C, 2002, J MED ENTOMOL, V39, P350, DOI 10.1603/0022-2585-39.2.350; Antonio-Nkondjio C, 2008, T R SOC TROP MED HYG; Antonio-Nkondjio C, 2007, ACTA TROP, V101, P61, DOI 10.1016/j.actatropica.2006.12.004; Antonio-Nkondjio C, 2006, J MED ENTOMOL, V43, P1215, DOI 10.1603/0022-2585(2006)43[1215:COTMVS]2.0.CO;2; Antonio-Nkondjio C, 2009, ACTA TROP, V112, P270, DOI 10.1016/j.actatropica.2009.08.009; Antonio-Nkondjio C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-120; Appawu M, 2004, TROP MED INT HEALTH, V9, P164, DOI 10.1046/j.1365-3156.2003.01162.x; Awolola T. S., 2007, Journal of Vector Borne Diseases, V44, P241; Awolola T. S., 2007, Journal of Vector Borne Diseases, V44, P181; Awolola TS, 2005, T ROY SOC TROP MED H, V99, P525, DOI 10.1016/j.trstmh.2004.12.003; Awolola TS, 2002, ANN TROP MED PARASIT, V96, P75, DOI 10.1179/000349802125000538; Awono-Ambene HP, 2006, AM J TROP MED HYG, V75, P656, DOI 10.4269/ajtmh.2006.75.656; Awono-Ambene Herman P., 2001, American Journal of Tropical Medicine and Hygiene, V64, P32; Awono-Ambene HP, 2004, J MED ENTOMOL, V41, P561, DOI 10.1603/0022-2585-41.4.561; Awono-Ambene HP, 1999, PARASITE, V6, P179, DOI 10.1051/parasite/1999062179; Ayala D, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-307; Baleta A, 2009, LANCET, V374, P1581, DOI 10.1016/S0140-6736(09)61933-4; Barber M., 1937, American Journal of Tropical Medicine, V17, P413; BARKAI A, 1968, B ENTOMOL RES, V58, P353, DOI 10.1017/S0007485300056881; BATES MARSTON, 1941, PROC ENT SOC WASHINGTON, V43, P37; Bayoh MN, 2001, MED VET ENTOMOL, V15, P267, DOI 10.1046/j.0269-283x.2001.00298.x; Becker N., 2003, MOSQUITOES THEIR CON; BEIER JC, 1990, J AM MOSQUITO CONTR, V6, P105; BEIER JC, 1987, J MED ENTOMOL, V24, P28, DOI 10.1093/jmedent/24.1.28; BEIER JC, 1986, J AM MOSQUITO CONTR, V2, P104; Berberian D. A., 1946, Journal of the Palestine Arab Medical Association Jerusalem, V1, P120; Betson M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-187; Bettini S, 1978, RICE CULTURE ANOPHEL, P1; Blackwell A, 2000, ANN TROP MED PARASIT, V94, P389, DOI 10.1080/00034983.2000.11813554; Bockarie M.J., 1993, Parassitologia (Rome), V35, P5; Bogh C, 1998, MED VET ENTOMOL, V12, P52, DOI 10.1046/j.1365-2915.1998.00091.x; Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239; Bogh C, 2001, J MED ENTOMOL, V38, P822, DOI 10.1603/0022-2585-38.6.822; BOREHAM PFL, 1973, B WORLD HEALTH ORGAN, V48, P605; Boyd DS, 2004, INT J REMOTE SENS, V25, P3343, DOI 10.1080/01431160310001654356; BRAACK LEO, 1994, J MED ENTOMOL, V31, P333, DOI 10.1093/jmedent/31.3.333; Brooke BD, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-74; BRUCECHWATT LJ, 1974, T ROY SOC TROP MED H, V68, P497, DOI 10.1016/0035-9203(74)90076-5; Bryan J.H., 1987, Parassitologia (Rome), V29, P221; BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1; Bublikova LI, 1998, ENTOMOL REV, V78, P398; Cambournac F. J. C., 1994, Parassitologia (Rome), V36, P215; Cano J, 2004, J MED ENTOMOL, V41, P158, DOI 10.1603/0022-2585-41.2.158; Capinha C, 2009, GEOSPATIAL HEALTH, V3, P177, DOI 10.4081/gh.2009.219; Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182; CARNEVALE P, 1978, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V16, P17; Carnevale P., 1975, Cahiers Off Rech scient tech Outre-Mer (Ent Med Parasit), V13, P69; Carnevale P, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P273; CEFALU M., 1961, Parassitologia, V3, P23; CHANDLER JA, 1975, J MED ENTOMOL, V12, P504, DOI 10.1093/jmedent/12.5.504; CHANDLER JA, 1976, J MED ENTOMOL, V13, P211, DOI 10.1093/jmedent/13.2.211; Chandre F, 1999, B WORLD HEALTH ORGAN, V77, P230; Charlwood JD, 1996, J MED ENTOMOL, V33, P202, DOI 10.1093/jmedent/33.2.202; Charlwood JD, 2003, ANN TROP MED PARASIT, V97, P751, DOI 10.1179/000349803225002345; CHARLWOOD JD, 1995, B ENTOMOL RES, V85, P29, DOI 10.1017/S0007485300051981; Chinayev PP, 1965, ENTOMOL REV, V4, P164; Chouaibou M, 2008, TROP MED INT HEALTH, V13, P476, DOI 10.1111/j.1365-3156.2008.02025.x; COENE J, 1993, MED VET ENTOMOL, V7, P127, DOI 10.1111/j.1365-2915.1993.tb00665.x; Coetzee M, 2000, PARASITOL TODAY, V16, P74, DOI 10.1016/S0169-4758(99)01563-X; COETZEE M, 1983, J ENTOMOL SOC S AFR, V46, P257; Coetzee M, 2004, INSECT BIOCHEM MOLEC, V34, P599, DOI 10.1016/j.ibmb.2004.03.012; Coetzee M, 2004, AM J TROP MED HYG, V70, P103, DOI 10.4269/ajtmh.2004.70.103; Cohuet A, 2004, J MED ENTOMOL, V41, P901, DOI 10.1603/0022-2585-41.5.901; Cohuet A, 2003, AM J TROP MED HYG, V69, P200, DOI 10.4269/ajtmh.2003.69.200; COLUZZI M, 1985, B ZOOL, V52, P45, DOI 10.1080/11250008509440343; COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; Coluzzi M, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P277; COLUZZI M, 1984, B WORLD HEALTH ORGAN, V62, P107; COLUZZI M, 1980, RIV PARASSITOLOGIA, V41, P117; COOSEMANS M, 1989, Parassitologia (Rome), V31, P113; Costantini C, 1996, MED VET ENTOMOL, V10, P220, DOI 10.1111/j.1365-2915.1996.tb00734.x; Costantini C., 2001, Parassitologia (Rome), V43, P179; Costantini C., 1999, Parassitologia (Rome), V41, P595; Costantini Carlo, 2009, BMC Ecology, V9, P16, DOI 10.1186/1472-6785-9-16; Cuamba N, 2009, J VECTOR DIS, V46, P157; CURTIS CF, 1984, J TROP MED HYG, V87, P101; D'Alessandro G, 1971, FURTHER STUDIES BIOL, P1; Dabire KR, 2008, J VECTOR ECOL, V33, P70, DOI 10.3376/1081-1710(2008)33[70:YTYASV]2.0.CO;2; DASKOVA NG, 1982, B WORLD HEALTH ORGAN, V60, P893; de Souza D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009927; de Zulueta J, 1990, Parassitologia, V32, P231; De'ath G, 2007, ECOLOGY, V88, P243, DOI 10.1890/0012-9658(2007)88[243:BTFEMA]2.0.CO;2; della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x; della Torre A, 2002, SCIENCE, V298, P115, DOI 10.1126/science.1078170; della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006; DEMIRHAN O, 1995, J AM MOSQUITO CONTR, V11, P11; Deredec A, 2008, GENETICS, V179, P2013, DOI 10.1534/genetics.108.089037; Di Luca M, 2004, J MED ENTOMOL, V41, P582, DOI 10.1603/0022-2585-41.4.582; Di Luca M, 2009, VECTOR-BORNE ZOONOT, V9, P703, DOI 10.1089/vbz.2008.0129; Dia I, 2005, J MED ENTOMOL, V42, P104, DOI 10.1603/0022-2585(2005)042[0104:COHCAO]2.0.CO;2; Dia I, 2003, J MED ENTOMOL, V40, P279, DOI 10.1603/0022-2585-40.3.279; Dia I, 2001, Bull Soc Pathol Exot, V94, P210; Diabate A, 2005, J MED ENTOMOL, V42, P548, DOI 10.1603/0022-2585(2005)042[0548:LDOTMF]2.0.CO;2; Diabate A, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-5; Diatta M, 1998, T ROY SOC TROP MED H, V92, P270, DOI 10.1016/S0035-9203(98)91005-7; Diop A, 2002, PARASITE, V9, P239, DOI 10.1051/parasite/2002093239; Djadid ND, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-6; Doannio JMC, 2002, B SOC PATHOL EXOT, V95, P11; Dossou-Yovo J, 1998, B SOC PATHOL EXOT, V91, P257; Dossou-Yovo J, 1999, B SOC PATHOL EXOT, V92, P198; Duchemin JB, 2001, MED VET ENTOMOL, V15, P50, DOI 10.1046/j.1365-2915.2001.00276.x; Edillo FE, 2002, J MED ENTOMOL, V39, P70, DOI 10.1603/0022-2585-39.1.70; Edillo FE, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-35; ELISSA N, 1993, ANN SOC BELG MED TR, V73, P291; Elith J, 2008, J ANIM ECOL, V77, P802, DOI 10.1111/j.1365-2656.2008.01390.x; Elith J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/j.2006.0906-7590.04596.x; Enayati A, 2010, ANNU REV ENTOMOL, V55, P569, DOI 10.1146/annurev-ento-112408-085423; Etang J, 2003, J MED ENTOMOL, V40, P491, DOI 10.1603/0022-2585-40.4.491; ETHERINGTON D, 1946, B ENTOMOL RES, V37, P191, DOI 10.1017/S0007485300022148; Fanello C, 2003, INSECT MOL BIOL, V12, P241, DOI 10.1046/j.1365-2583.2003.00407.x; Faraj C, 2009, ACTA TROP, V109, P70, DOI 10.1016/j.actatropica.2008.09.021; Farid MA, 1958, B WORLD HEALTH ORGAN, V15, P821; Fettene M, 2004, AFR ENTOMOL, V12, P83; Fontenille D, 1997, T ROY SOC TROP MED H, V91, P647, DOI 10.1016/S0035-9203(97)90506-X; Fontenille D, 1997, AM J TROP MED HYG, V56, P247, DOI 10.4269/ajtmh.1997.56.247; FONTENILLE D, 1990, Archives de l'Institut Pasteur de Madagascar, V57, P335; Fontenille D, 2004, COMP IMMUNOL MICROB, V27, P357, DOI 10.1016/j.cimid.2004.03.005; Fyodorova MV, 2006, J MED ENTOMOL, V43, P552, DOI 10.1603/0022-2585(2006)43[552:EOPWNV]2.0.CO;2; Gad A., 1982, JOURNAL OF THE EGYPTIAN PUBLIC HEALTH ASSOCIATION, V57, P541; Gad A.M., 1984, Journal of the Egyptian Society of Parasitology, V14, P1; Garros C, 2005, J MED ENTOMOL, V42, P522, DOI 10.1603/0022-2585(2005)042[0522:MAAMPO]2.0.CO;2; Garros C, 2004, AM J TROP MED HYG, V70, P260, DOI 10.4269/ajtmh.2004.70.260; GELFAND H. M., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P508, DOI 10.1016/0035-9203(55)90023-7; GIGLIOLI M E, 1964, Riv Malariol, V43, P245; GIGLIOLI M. E. C., 1965, ANN ENTOMOL SOC AMER, V58, P885; Gillies M, 1987, ANOPHELINAE AFRICA S; Gillies M, 1968, ANOPHELINAE AFRICA S; Gimnig JE, 2001, J MED ENTOMOL, V38, P282, DOI 10.1603/0022-2585-38.2.282; Girod R, 2006, J MED ENTOMOL, V43, P1082, DOI 10.1603/0022-2585(2006)43[1082:MTAIRO]2.0.CO;2; Githeko A. K., 1996, Parassitologia (Rome), V38, P481; GITHEKO AK, 1994, ACTA TROP, V58, P307, DOI 10.1016/0001-706X(94)90024-8; Githeko AK, 1996, EXP PARASITOL, V82, P306, DOI 10.1006/expr.1996.0038; GOKBERK C., 1961, Mosquito News, V21, P101; Govere J, 2000, AFR ENTOMOL, V8, P91; Gratz NG, 1987, EFFECT WATER DEV PRO; Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038; HACKETT L. W., 1934, TRANS ROY SOC TROP MED AND HYG, V28, P109, DOI 10.1016/S0035-9203(34)90135-8; Hackett L. W., 1937, Bull Hlth Organ League of Nations Geneva, V6, P1; HACKETT LW, 1935, RIV MALARIOLOGIA, V14, P1; HADJINICOLAOU J, 1973, B WORLD HEALTH ORGAN, V48, P699; Hadjinicolaou J, 1973, GAMBUSIA FISH MEANS, P1; Halcrow J. G., 1957, East African Medical Journal, V34, P133; HARBACH R E, 1988, Mosquito Systematics, V20, P317; Harbach RE, 2004, B ENTOMOL RES, V94, P537, DOI 10.1079/BER2004321; Hargreaves K, 2000, MED VET ENTOMOL, V14, P181, DOI 10.1046/j.1365-2915.2000.00234.x; Hay SI, 2005, NAT REV MICROBIOL, V3, P81, DOI 10.1038/nrmicro1069; Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3; Hay SI, 2000, ADV PARASIT, V47, P1, DOI 10.1016/S0065-308X(00)47005-3; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000290; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000209; Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; Himeidan Y.E., 2008, Eastern Mediterranean Health Journal, V14, P252; Himeidan YE, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-234; Howard AFV, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-199; Hunt RH, 1998, T ROY SOC TROP MED H, V92, P231, DOI 10.1016/S0035-9203(98)90761-1; Ijumba JN, 2002, MED VET ENTOMOL, V16, P28, DOI 10.1046/j.0269-283x.2002.00337.x; IYENGAR R, 1962, B WORLD HEALTH ORGAN, V27, P223; Jacob BG, 2007, AM J TROP MED HYG, V76, P73, DOI 10.4269/ajtmh.2007.76.73; Jacob BG, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-91; JAENSON TGT, 1991, MED VET ENTOMOL, V5, P243; Jawara M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-156; JEPSON WF, 1947, B ENTOMOL RES, V38, P177, DOI 10.1017/S0007485300030273; JETTEN TH, 1994, ANOPHELISM MALARIA E, P69; Kamau L, 2007, INFECT GENET EVOL, V7, P293, DOI 10.1016/j.meegid.2006.11.006; Kampen H, 2003, PARASITOL RES, V89, P252, DOI 10.1007/s00436-002-0746-9; KARANJA DMS, 1994, ACTA TROP, V56, P365, DOI 10.1016/0001-706X(94)90107-4; KASAP H, 1992, J AM MOSQUITO CONTR, V8, P47; Kasap H, 1995, ACTA PARASIT TURCICA, V19, P535; Kaufmann C, 2004, J VECTOR ECOL, V29, P140; KENAWY M, 1986, J MED ENTOMOL, V23, P576, DOI 10.1093/jmedent/23.5.576; KENAWY MA, 1986, J AM MOSQUITO CONTR, V2, P101; KENAWY MA, 1990, J AM MOSQUITO CONTR, V6, P446; Kiszewski A, 2004, AM J TROP MED HYG, V70, P486, DOI 10.4269/ajtmh.2004.70.486; KITRON U, 1989, REV INFECT DIS, V11, P391; Klinkenberg E, 2003, ACTA TROP, V85, P71, DOI 10.1016/S0001-706X(02)00254-1; Klinkenberg E, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-151; Kloke RG, 1997, AFR ENTOMOL, V5, P361; Koekemoer LL, 2006, J MED ENTOMOL, V43, P1178, DOI 10.1603/0022-2585(2006)43[1178:IOTRVO]2.0.CO;2; Koenraadt CJM, 2004, ACTA TROP, V90, P141, DOI 10.1016/j.actatropica.2003.11.007; Koudou BG, 2005, MED VET ENTOMOL, V19, P27, DOI 10.1111/j.0269-283X.2005.00530.x; Krafsur ES, 1970, B WORLD HEALTH ORGAN, V42, P1; Kristan M, 2003, MED VET ENTOMOL, V17, P326, DOI 10.1046/j.1365-2915.2003.00449.x; Kuhn KG, 2002, J MED ENTOMOL, V39, P621, DOI 10.1603/0022-2585-39.4.621; Kulkarni MA, 2006, J MED ENTOMOL, V43, P580, DOI 10.1603/0022-2585(2006)43[580:EEOMVA]2.0.CO;2; Kulkarni MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009396; Latyshev NL, 1929, ANIMAL PARASITES PAR, P41; LAVAGNINO A, 1983, T ROY SOC TROP MED H, V77, P883, DOI 10.1016/0035-9203(83)90326-7; Laventure S, 1996, Sante, V6, P79; Lemasson JJ, 1997, J MED ENTOMOL, V34, P396, DOI 10.1093/jmedent/34.4.396; Levine RS, 2004, AM J TROP MED HYG, V70, P105, DOI 10.4269/ajtmh.2004.70.105; LI ZL, 1993, REMOTE SENS ENVIRON, V43, P67, DOI 10.1016/0034-4257(93)90065-6; Linard C, 2009, ECOHEALTH, V6, P135, DOI 10.1007/s10393-009-0236-y; Lindsay SW, 1998, P ROY SOC B-BIOL SCI, V265, P847, DOI 10.1098/rspb.1998.0369; Linton YM, 2002, INSECT MOL BIOL, V11, P379, DOI 10.1046/j.1365-2583.2002.00338.x; Linton Yvonne-Marie, 2005, European Mosquito Bulletin, V19, P5; Lochouarn L, 1998, T ROY SOC TROP MED H, V92, P607, DOI 10.1016/S0035-9203(98)90782-9; MACDONALD G, 1957, EPIDEMIOLOGY CONTROL, P63; Macdonald W. W., 1982, Garyounis Medical Journal, V5, P72; MAGESA SM, 1991, ACTA TROP, V49, P97, DOI 10.1016/0001-706X(91)90057-Q; Mahande A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-100; MANGA L, 1995, ANN SOC BELG MED TR, V75, P43; Manguin S., 2008, BIODIVERSITY MALARIA; Manoukis NC, 2006, J MED ENTOMOL, V43, P820, DOI 10.1603/0022-2585(2006)43[820:IVBSTK]2.0.CO;2; MARCHI A, 1987, MED VET ENTOMOL, V1, P89, DOI 10.1111/j.1365-2915.1987.tb00327.x; Marrama L, 1995, Sante, V5, P415; Masendu HT, 2005, AFR ENTOMOL, V13, P25; Mathenge EM, 2001, J MED ENTOMOL, V38, P531, DOI 10.1603/0022-2585-38.4.531; Matthys B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-217; MATTINGLY PF, 1949, B ENTOMOL RES, V40, P387, DOI 10.1017/S0007485300022860; Midega JT, 2007, J MED ENTOMOL, V44, P923, DOI 10.1603/0022-2585(2007)44[923:EDASOA]2.0.CO;2; Minakawa N, 2005, AM J TROP MED HYG, V73, P157, DOI 10.4269/ajtmh.2005.73.157; Minakawa N, 2004, MED VET ENTOMOL, V18, P301, DOI 10.1111/j.0269-283X.2004.00503.x; Minakawa N, 2002, AM J TROP MED HYG, V67, P32, DOI 10.4269/ajtmh.2002.67.32; Minakawa N, 1999, AM J TROP MED HYG, V61, P1010, DOI 10.4269/ajtmh.1999.61.1010; Minakawa N, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-119; MNZAVA AEP, 1995, MED VET ENTOMOL, V9, P316, DOI 10.1111/j.1365-2915.1995.tb00140.x; Moffett A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000824; MOLINA R, 1993, J MED ENTOMOL, V30, P622, DOI 10.1093/jmedent/30.3.622; MOSHA FW, 1992, MED VET ENTOMOL, V6, P44, DOI 10.1111/j.1365-2915.1992.tb00033.x; MOSHA FW, 1982, B ENTOMOL RES, V72, P119, DOI 10.1017/S0007485300050331; Mouchet J, 1998, J AM MOSQUITO CONTR, V14, P121; MOUCHET J., 1966, Cahiers ORSTOM., V4, P71; Mouchet J, 2004, BIODIVERSITE PALUDIS; MUIRHEAD-THOMSON R C, 1956, J Hyg (Lond), V54, P472; Mulligan H. W., 1967, Journal of Helminthology Suppl, V2, P113; Munga S, 2009, AM J TROP MED HYG, V81, P1079, DOI 10.4269/ajtmh.2009.09-0156; Muriu SM, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-43; Mutero CM, 2000, ACTA TROP, V76, P253, DOI 10.1016/S0001-706X(00)00109-1; Mutero CM, 2004, ACTA TROP, V89, P187, DOI 10.1016/j.actatropica.2003.08.006; MUTERO CM, 1984, ANN TROP MED PARASIT, V78, P43, DOI 10.1080/00034983.1984.11811771; Mutuku FM, 2006, AM J TROP MED HYG, V74, P54, DOI 10.4269/ajtmh.2006.74.54; Muturi EJ, 2008, J VECTOR ECOL, V33, P56, DOI 10.3376/1081-1710(2008)33[56:EFAWTD]2.0.CO;2; Muturi EJ, 2007, J MED ENTOMOL, V44, P336, DOI 10.1603/0022-2585(2007)44[336:MSSAPF]2.0.CO;2; Muturi EJ, 2006, J VECTOR ECOL, V31, P129, DOI 10.3376/1081-1710(2006)31[129:MSDAAI]2.0.CO;2; Mwangangi JM, 2003, J AM MOSQUITO CONTR, V19, P371; Mwangangi J, 2006, J VECTOR ECOL, V31, P245, DOI 10.3376/1081-1710(2006)31[245:DOISOA]2.0.CO;2; Mwangangi Joseph M., 2007, Journal of Vector Borne Diseases, V44, P44; Mwangangi JM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-114; Mwangangi JM, 2007, J AM MOSQUITO CONTR, V23, P371, DOI 10.2987/5605.1; MYNENI RB, 1995, IEEE T GEOSCI REMOTE, V33, P481, DOI 10.1109/36.377948; Nicolescu G, 2004, B ENTOMOL RES, V94, P525, DOI 10.1079/BER2004330; Nigatu W, 1994, INSECT SCI APPL, V15, P371, DOI 10.1017/S1742758400017707; Noor AM, 2009, LANCET, V373, P58, DOI 10.1016/S0140-6736(08)61596-2; Odiere M, 2007, J MED ENTOMOL, V44, P14, DOI 10.1603/0022-2585(2007)44[14:SORAGA]2.0.CO;2; Okara RM, MALAR J, V9, P69; Okoye PN, 2007, B ENTOMOL RES, V97, P599, DOI 10.1017/S0007485307005317; Olayemi IK, 2009, J VECTOR DIS, V46, P295; Olayemi IK, 2008, ONLINE J HLTH ALLIED, P7; Omlin FX, 2007, AM J TROP MED HYG, V77, P264, DOI 10.4269/ajtmh.2007.77.264; Onyabe DY, 2001, MEM I OSWALDO CRUZ, V96, P1081, DOI 10.1590/S0074-02762001000800009; Oshaghi MA, 2007, ACTA TROP, V101, P241, DOI 10.1016/j.actatropica.2007.02.006; Oshaghi M.A., 2008, Bulletin de la Societe de Pathologie Exotique, V101, P429; Oyewole I. O., 2007, Journal of Vector Borne Diseases, V44, P56; Oyewole I. O., 2006, Journal of Vector Borne Diseases, V43, P173; PATERSON HE, 1962, NATURE, V195, P469, DOI 10.1038/195469a0; PATERSON HE, 1964, NATURE, V201, P524, DOI 10.1038/201524a0; PATERSON HE, 1964, B WORLD HEALTH ORGAN, V31, P635; Patsoula E, 2007, MED VET ENTOMOL, V21, P36, DOI 10.1111/j.1365-2915.2007.00669.x; PENER H, 1994, ISRAEL J MED SCI, V30, P287; PENER H, 1985, ISRAEL J MED SCI, V21, P850; PETRARCA V, 1991, J MED ENTOMOL, V28, P307, DOI 10.1093/jmedent/28.3.307; Petrarca V, 2000, MED VET ENTOMOL, V14, P149, DOI 10.1046/j.1365-2915.2000.00231.x; Pinto J, 2006, MED VET ENTOMOL, V20, P27, DOI 10.1111/j.1365-2915.2006.00611.x; Pinto J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001243; Pires C, 1982, DO I HIG MED TROP, V8, P79; Pluess B, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006657.pub2; Pombi Marco, 2008, BMC Evol Biol, V8, P309, DOI 10.1186/1471-2148-8-309; Poncon N, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-18; R: a language and environment for statistical computing, R LANG ENV STAT COMP; Rajaonarivelo V, 2004, PARASITE, V11, P75, DOI 10.1051/parasite/200411175; Ralisoa Randrianasolo B.O., 1987, Parassitologia (Rome), V29, P93; Ramphul U, 2009, T ROY SOC TROP MED H, V103, P1121, DOI 10.1016/j.trstmh.2009.02.014; RAMSDALE CD, 1978, T ROY SOC TROP MED H, V72, P570, DOI 10.1016/0035-9203(78)90005-6; RAMSDALE CD, 1983, J TROP MED HYG, V86, P51; Ranson H, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-299; Reiter P, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S3; Ribeiro H., 1989, Garcia De Orta Serie de Zoologia, V16, P137; Robert V, 1998, J MED ENTOMOL, V35, P948, DOI 10.1093/jmedent/35.6.948; Robert V, 2006, INT J PARASITOL, V36, P1273, DOI 10.1016/j.ijpara.2006.06.005; Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a; Roiz D, 2007, J VECTOR ECOL, V32, P10, DOI 10.3376/1081-1710(2007)32[10:ASOMBI]2.0.CO;2; ROMI R, 1993, J AM MOSQUITO CONTR, V9, P325; Romi R, 2004, MED VET ENTOMOL, V18, P14, DOI 10.1111/j.1365-2915.2004.0478.x; Romi R, 1997, J MED ENTOMOL, V34, P263, DOI 10.1093/jmedent/34.3.263; Rowland M, 2002, T ROY SOC TROP MED H, V96, P620, DOI 10.1016/S0035-9203(02)90331-7; SABATINI A, 1989, Parassitologia (Rome), V31, P69; Sainz-Elipe S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-221; Saliternik Z, 1974, HIST NOTES BIONOMICS, P1; Scharlemann JPW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001408; Sedaghat MM, 2003, SYST ENTOMOL, V28, P241, DOI 10.1046/j.1365-3113.2003.00211.x; Service M.W., 1993, P96; SERVICE MW, 1985, B ENT SOC AM     FAL, P8; SERVICE MW, 1993, BRUCECHWATTS ESSENTI, P305; Severini C, 2004, T ROY SOC TROP MED H, V98, P585, DOI 10.1016/j.trstmh.2004.01.003; SHARP BL, 1991, B ENTOMOL RES, V81, P107, DOI 10.1017/S000748530005330X; Shililu J, 2004, J AM MOSQUITO CONTR, V20, P155; Shililu J, 2003, J MED ENTOMOL, V40, P921, DOI 10.1603/0022-2585-40.6.921; Shililu JI, 2003, J AM MOSQUITO CONTR, V19, P251; Shililu J, 2007, AM J TROP MED HYG, V76, P103, DOI 10.4269/ajtmh.2007.76.103; Shute P. G., 1940, Journal of Tropical Medicine London, V43, P175; Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-72; Sinkins SP, 2004, P ROY SOC B-BIOL SCI, V271, P1421, DOI 10.1098/rspb.2004.2740; Snow Keith, 1998, European Mosquito Bulletin, V1, P9; Sogoba N, 2007, GEOSPATIAL HEALTH, V1, P213, DOI 10.4081/gh.2007.269; Sogoba N, 2007, ACTA TROP, V101, P232, DOI 10.1016/j.actatropica.2007.02.005; Soliman AA, 1961, 4 AR SCI C FEBR CAIR, P526; Sousa C, 2008, MALARIA VECTORIAL CA; Spillings BL, 2009, AM J TROP MED HYG, V81, P510, DOI 10.4269/ajtmh.2009.81.510; Takken W, 2002, AMBIO, V31, P212, DOI 10.1639/0044-7447(2002)031[0212:DADOLP]2.0.CO;2; Taye A, 2006, ACTA TROP, V97, P50, DOI 10.1016/j.actatropica.2005.08.002; Temu EA, 2007, ACTA TROP, V102, P119, DOI 10.1016/j.actatropica.2007.04.009; Temu EA, 1998, T ROY SOC TROP MED H, V92, P152, DOI 10.1016/S0035-9203(98)90724-6; THOMSON RCM, 1945, B ENTOMOL RES, V36, P185; THOMSON RCM, 1948, B ENTOMOL RES, V38, P527, DOI 10.1017/S0007485300023221; THOMSON RCM, 1951, B ENTOMOL RES, V41, P487; Tirados I, 2006, MED VET ENTOMOL, V20, P425, DOI 10.1111/j.1365-2915.2006.652.x; Toty C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-231; TRAPIDO H, 1953, AM J TROP MED HYG, V2, P658, DOI 10.4269/ajtmh.1953.2.658; Tshinaev PP, 1963, ENTOMOL REV, V42, P169; TSY JML, 2003, MALARIA J, V2, pNIL4; Tuno N, 2006, ECOL RES, V21, P476, DOI 10.1007/s11284-005-0131-0; Tuno N, 2010, J MED ENTOMOL, V47, P28, DOI 10.1603/033.047.0104; Utzinger J, 2002, NATURE, V419, P431, DOI 10.1038/419431a; Vulule JM, 1999, MED VET ENTOMOL, V13, P239, DOI 10.1046/j.1365-2915.1999.00177.x; Waka M, 2005, J VECTOR ECOL, V30, P27; Walton C, 1999, BIOL J LINN SOC, V68, P241, DOI 10.1006/bijl.1999.0340; Wanji S, 2003, TROP MED INT HEALTH, V8, P643, DOI 10.1046/j.1365-3156.2003.01070.x; WHITE GB, 1973, B ENTOMOL RES, V62, P613, DOI 10.1017/S0007485300005502; WHITE GB, 1972, T ROY SOC TROP MED H, V66, P572, DOI 10.1016/0035-9203(72)90302-1; WHITE GB, 1974, T ROY SOC TROP MED H, V68, P278, DOI 10.1016/0035-9203(74)90035-2; WHITE GB, 1985, SYST ENTOMOL, V10, P501, DOI 10.1111/j.1365-3113.1985.tb00155.x; White GB, 1989, MALARIA GEOGRAPHICAL, P7; Yaghoobi-Ershadi MR, 2001, ACTA TROP, V78, P207, DOI 10.1016/S0001-706X(01)00080-8; Ye-Ebiyo Y, 2000, AM J TROP MED HYG, V63, P90, DOI 10.4269/ajtmh.2000.63.90; Yohannes M, 2005, TROP MED INT HEALTH, V10, P1274, DOI 10.1111/j.1365-3156.2005.01512.x; Zahar A.R., 1990, VECTOR BIONOMICS E 2; Zamburlini R., 1998, Parassitologia (Rome), V40, P431; ZULUETA JD, 1975, B WORLD HEALTH ORGAN, V52, P109	362	225	231	0	61	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	DEC 3	2010	3								117	10.1186/1756-3305-3-117				34	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	702ZX	WOS:000285935500001	21129198	DOAJ Gold, Green Published			2019-03-26	
J	Poling, A; Weetjens, BJ; Cox, C; Mgode, G; Jubitana, M; Kazwala, R; Mfinanga, GS; in 't Veld, DH				Poling, Alan; Weetjens, Bart J.; Cox, Christophe; Mgode, Georgies; Jubitana, Maureen; Kazwala, Rudovic; Mfinanga, Godfrey S.; in 't Veld, Diana Huis			Short Report: Using Giant African Pouched Rats to Detect Tuberculosis in Human Sputum Samples: 2009 Findings	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							PULMONARY TUBERCULOSIS; DIAGNOSIS	In 2009, giant African pouched rats trained to detect tuberculosis (TB) evaluated sputum samples from 10,523 patients whose sputum had previously been evaluated by smear microscopy. Microscopists found 13.3% of the patients to be TB-positive. Simulated second-line screening by the rats revealed 620 new TB-positive patients, increasing the case detection rate by 44%. These data suggest that the rats may be useful for TB detection in developing countries, although further research is needed.	[Poling, Alan] Western Michigan Univ, Dept Psychol, Kalamazoo, MI 49008 USA; [Weetjens, Bart J.; Cox, Christophe; Mgode, Georgies; Jubitana, Maureen] APOPO, Morogoro, Tanzania; [Kazwala, Rudovic] Sokoine Univ Agr Morogoro, Morogoro, Tanzania; [Mfinanga, Godfrey S.] Natl Inst Med Res, Dar Es Salaam, Tanzania; [in 't Veld, Diana Huis] Univ Antwerp, FWO Aspirant Mandate, Antwerp, Belgium	Poling, A (reprint author), Western Michigan Univ, Dept Psychol, Kalamazoo, MI 49008 USA.	alan.poling@wmich.edu; bart.weetjens@gmail.com; christophe.cox@apopo.org; mgode@mpiib-berlin.mpg.de; maureen.jubitana@apopo.org; kazwala@suanet.ac.tz; gsmifanga@yahoo.com; dhuisintveld@itg.be		Mgode, Georgies/0000-0002-5618-5644	World Bank Development Marketplace (USA); UBS Optimus Foundation (Switzerland); National Institute of Health (USA)	Financial support has been provided by The World Bank Development Marketplace (USA), UBS Optimus Foundation (Switzerland), and National Institute of Health (USA). The contributions of all of these organizations, and the people who represent them, are greatly appreciated, as is the excellent performance of APOPO's staff.	Ani A, 2009, J INFECT DEV COUNTR, V3, P470, DOI 10.3855/jidc.420; Cambanis A, 2007, INT J TUBERC LUNG D, V11, P40; Mase SR, 2007, INT J TUBERC LUNG D, V11, P485; Organization WH, 2009, GLOB TUB CONTR EP ST; POLING A, PSYCHOL REC IN PRESS; RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515; Sarmiento OL, 2003, J CLIN MICROBIOL, V41, P3233, DOI 10.1128/JCM.41.7.3233-3240.2003; Weetjens BJ, 2009, INT J TUBERC LUNG D, V13, P737; Weetjens BJ, 2009, GLOBAL FORUM UPDATE, P6	9	33	33	2	10	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	DEC	2010	83	6					1308	1310		10.4269/ajtmh.2010.10-0180				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	697RX	WOS:000285534900025	21118940	Bronze, Green Published			2019-03-26	
J	Nackers, F; Broillet, F; Oumarou, D; Djibo, A; Gaboulaud, V; Guerin, PJ; Rusch, B; Grais, RF; Captier, V				Nackers, Fabienne; Broillet, France; Oumarou, Diakite; Djibo, Ali; Gaboulaud, Valerie; Guerin, Philippe J.; Rusch, Barbara; Grais, Rebecca F.; Captier, Valerie			Effectiveness of ready-to-use therapeutic food compared to a corn/soy-blend-based pre-mix for the treatment of childhood moderate acute malnutrition in Niger	JOURNAL OF TROPICAL PEDIATRICS			English	Article						child nutrition disorder; wasting; fortified blended flour; ready-to-use therapeutic food; Niger; randomized controlled trial	ROUTINE PROPHYLACTIC SUPPLEMENTATION; PLACEBO-CONTROLLED TRIAL; FORTIFIED SPREADS; MALAWIAN CHILDREN; FOLIC-ACID; MORTALITY; GROWTH; IRON	Standard nutritional treatment of moderate acute malnutrition (MAM) relies on fortified blended flours though their importance to treat this condition is a matter of discussion. With the newly introduced World Health Organization growth standards, more children at an early stage of malnutrition will be treated following the dietary protocols as for severe acute malnutrition, including ready-to-use therapeutic food (RUTF). We compared the effectiveness of RUTF and a corn/soy-blend (CSB)-based pre-mix for the treatment of MAM in the supplementary feeding programmes (SFPs) supported by Medecins Sans Frontieres, located in the Zinder region (south of Niger). Children measuring 65 to <110 cm, newly admitted with MAM [weight-for-height (WHM%) between 70% and <80% of the NCHS median] were randomly allocated to receive either RUTF (Plumpy'Nut (R), 1000 kcal day (1)) or a CSB pre-mix (1231 kcal day(-1)). Other interventions were similar in both groups (e. g. weekly family ration and ration at discharge). Children were followed weekly up to recovery (WHM% >= 85% for 2 consecutive weeks). In total, 215 children were recruited in the RUTF group and 236 children in the CSB pre-mix group with an overall recovery rate of 79.1 and 64.4%, respectively (p < 0.001). There was no evidence for a difference between death, defaulter and non-responder rates. More transfers to the inpatient Therapeutic Feeding Centre (I-TFC) were observed in the CSB pre-mix group (19.1%) compared to the RUTF group (9.3%) (p=0.003). The average weight gain up to discharge was 1.08 g kg(-1) day(-1) higher in the RUTF group [95% confidence interval: 0.46-1.70] and the length of stay was 2 weeks shorter in the RUTF group (p < 0.001). For the treatment of childhood MAM in Niger, RUTF resulted in a higher weight gain, a higher recovery rate, a shorter length of stay and a lower transfer rate to the I-TFC compared to a CSB pre-mix. This might have important implications on the efficacy and the quality of SFPs.	[Nackers, Fabienne; Oumarou, Diakite; Guerin, Philippe J.; Grais, Rebecca F.] Epictr, Paris, France; [Broillet, France; Oumarou, Diakite; Rusch, Barbara; Captier, Valerie] Med Sans Frontieres, Geneva, Switzerland; [Djibo, Ali] Minist Hlth, Niamey, Niger; [Gaboulaud, Valerie] Hop Avicenne, AP HP, F-93009 Bobigny, France	Nackers, F (reprint author), MSF, Epictr, Rue Dupre 94, B-1090 Brussels, Belgium.	fabienne.nackers@msf.be		Guerin, Philippe/0000-0002-6008-2963	Medecins Sans Frontrieres, Switzerland	This study was sponsored by Medecins Sans Frontrieres, Switzerland. The authors are grateful to the Ministry of Public Health in Niger for having authorized this study and to Dominique Van Beckhoven for her valuable advice. They would also like to thank the surveyors, the all MSF field team as well as the children and their caretakers who took part in this study.	Ciliberto MA, 2005, AM J CLIN NUTR, V81, P864, DOI 10.1093/ajcn/81.4.864; DEFOURNY I, 2007, FIELD EXCHANGE, V31, P2; *INS, 2007, DEM HLTH SURV MULT I; Isanaka S, 2009, PEDIATRICS, V123, pE54, DOI 10.1542/peds.2008-1375; Kuusipalo H, 2006, J PEDIATR GASTR NUTR, V43, P525, DOI 10.1097/01.mpg.0000235981.26700.d3; Matilsky DK, 2009, J NUTR, V139, P773, DOI 10.3945/jn.108.104018; NAVARROCOLORADO C, 2008, 63 HUM PRACT NETW; Patel MP, 2005, J HEALTH POPUL NUTR, V23, P351; Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; Tielsch JM, 2006, LANCET, V367, P144, DOI 10.1016/S0140-6736(06)67963-4; World Health Organization, 2006, ACTA PAEDIATR, V450, P76, DOI DOI 10.1080/08035320500495548	11	40	40	1	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0142-6338			J TROP PEDIATRICS	J. Trop. Pediatr.	DEC	2010	56	6					407	413		10.1093/tropej/fmq019				7	Pediatrics; Tropical Medicine	Pediatrics; Tropical Medicine	685RF	WOS:000284645100007	20332221	Green Published			2019-03-26	
J	Jamonneau, V; Bucheton, B; Kabore, J; Ilboudo, H; Camara, O; Courtin, F; Solano, P; Kaba, D; Kambire, R; Lingue, K; Camara, M; Baelmans, R; Lejon, V; Buscher, P				Jamonneau, Vincent; Bucheton, Bruno; Kabore, Jacques; Ilboudo, Hamidou; Camara, Oumou; Courtin, Fabrice; Solano, Philippe; Kaba, Dramane; Kambire, Roger; Lingue, Kouakou; Camara, Mamadou; Baelmans, Rudy; Lejon, Veerle; Buscher, Philippe			Revisiting the Immune Trypanolysis Test to Optimise Epidemiological Surveillance and Control of Sleeping Sickness in West Africa	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TRYPANOSOMA-BRUCEI-GAMBIENSE; COTE-DIVOIRE; AGGLUTINATION-TEST; CATT; TSETSE; SERODIAGNOSIS; INDIVIDUALS; POPULATION; INFECTIONS; DIAGNOSIS	Background: Because of its high sensitivity and its ease of use in the field, the card agglutination test for trypanosomiasis (CATT) is widely used for mass screening of sleeping sickness. However, the CATT exhibits false-positive results (i) raising the question of whether CATT-positive subjects who are negative in parasitology are truly exposed to infection and (ii) making it difficult to evaluate whether Trypanosoma brucei (T.b.) gambiense is still circulating in areas of low endemicity. The objective of this study was to assess the value of the immune trypanolysis test (TL) in characterising the HAT status of CATT-positive subjects and to monitor HAT elimination in West Africa. Methodology/Principal Findings: TL was performed on plasma collected from CATT-positive persons identified within medical surveys in several West African HAT foci in Guinea, Cote d'Ivoire and Burkina Faso with diverse epidemiological statuses (active, latent, or historical). All HAT cases were TL+. All subjects living in a nonendemic area were TL-. CATT prevalence was not correlated with HAT prevalence in the study areas, whereas a significant correlation was found using TL. Conclusion and Significance: TL appears to be a marker for contact with T.b. gambiense. TL can be a tool (i) at an individual level to identify nonparasitologically confirmed CATT-positive subjects as well as those who had contact with T.b. gambiense and should be followed up, (ii) at a population level to identify priority areas for intervention, and (iii) in the context of HAT elimination to identify areas free of HAT.	[Jamonneau, Vincent; Bucheton, Bruno; Ilboudo, Hamidou; Courtin, Fabrice; Solano, Philippe] IRD, Unite Mixte Rech IRD CIRAD 177, Montpellier, France; [Jamonneau, Vincent; Bucheton, Bruno; Kabore, Jacques; Ilboudo, Hamidou; Camara, Oumou; Courtin, Fabrice; Solano, Philippe] CIRDES, Unite Rech Bases Biol Lutte Integree, Bobo Dioulasso, Burkina Faso; [Kaba, Dramane] Inst Pierre Richet, Unite Rech Trypanosomoses, Abidjan, Cote Ivoire; [Kambire, Roger] Programme Natl Lutte Trypanosomose Humaine Africa, Ouagadougou, Burkina Faso; [Lingue, Kouakou] Programme Natl Eliminat Trypanosomose Humaine Afr, Abidjan, Cote Ivoire; [Baelmans, Rudy; Lejon, Veerle; Buscher, Philippe] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Jamonneau, V (reprint author), IRD, Unite Mixte Rech IRD CIRAD 177, Montpellier, France.	vincent.jamonneau@ird.fr	Buscher, Philippe/B-9956-2012; Solano, Philippe/B-2328-2010; Jamonneau, Vincent/K-1124-2016	Buscher, Philippe/0000-0002-1926-7472; solano, philippe/0000-0002-4351-3506; Lejon, Veerle/0000-0002-6795-0962	Institut de Recherche pour le Developpement (IRD); Ministere Francais des Affaires Etrangeres (Fonds de Solidarite Prioritaire "Recherches en Entomologie, Formation et Strategies de formation, le cas du paludisme et de la Trypanosomose Humaine Africaine"); World Health Organisation (WHO)	This study was supported by the Institut de Recherche pour le Developpement (IRD), the Ministere Francais des Affaires Etrangeres (Fonds de Solidarite Prioritaire "Recherches en Entomologie, Formation et Strategies de formation, le cas du paludisme et de la Trypanosomose Humaine Africaine") and the World Health Organisation (WHO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Buscher P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000471; Burri C., 2009, MANSONS TROPICAL DIS, P1307; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; Camara M, 2005, Med Trop (Mars), V65, P155; Cecchi G, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-15; Chappuis F, 2005, CLIN MICROBIOL REV, V18, P133, DOI 10.1128/CMR.18.1.133-146.2005; Courtin F, 2009, PARASITE, V16, P3, DOI 10.1051/parasite/2009161003; COURTIN F, 2006, TROP MED INT HEALTH, V13, P334; Dayo GK, 2010, RES VET SCI, V88, P470, DOI 10.1016/j.rvsc.2009.10.010; Deborggraeve S, 2010, LANCET INFECT DIS, V10, P433, DOI 10.1016/S1473-3099(10)70077-3; Dje NN, 2003, B SOC PATHOL EXOT, V95, P359; DUKES P, 1992, ACTA TROP, V51, P123, DOI 10.1016/0001-706X(92)90054-2; Garcia A, 2000, TROP MED INT HEALTH, V5, P786, DOI 10.1046/j.1365-3156.2000.00623.x; Garcia A, 2006, TRENDS PARASITOL, V22, P405, DOI 10.1016/j.pt.2006.06.011; Giroud C, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000509; Holland WG, 2002, ACTA TROP, V81, P159, DOI 10.1016/S0001-706X(01)00211-X; Jamonneau V, 2004, PARASITOLOGY, V129, P693, DOI 10.1017/S0031182004005876; Kaba D, 2006, TROP MED INT HEALTH, V11, P136, DOI 10.1111/j.1365-3156.2005.01549.x; Koffi M, 2006, ACTA TROP, V98, P183, DOI 10.1016/j.actatropica.2006.04.001; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MOSER DR, 1989, J CLIN MICROBIOL, V27, P1477; Pays E, 2004, CURR OPIN MICROBIOL, V7, P369, DOI 10.1016/j.mib.2004.05.001; Rayaisse JB, 2009, PARASITE, V16, P21, DOI 10.1051/parasite/2009161021; Semballa S, 2007, EXP PARASITOL, V115, P173, DOI 10.1016/j.exppara.2006.08.008; Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055; Simarro PP, 1999, TROP MED INT HEALTH, V4, P858, DOI 10.1046/j.1365-3156.1999.00494.x; Solano P, 2003, Med Trop (Mars), V63, P577; Stockdale C, 2008, PLOS BIOL, V6, P1386, DOI 10.1371/journal.pbio.0060185; Truc P, 2002, B WORLD HEALTH ORGAN, V80, P882; VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z; VANMEIRVENNE N, 1987, MED TROPICALE COOPER, V3, P98; *WHO, 2010, HUM AFR TRYP NUMB CA	32	44	44	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	DEC	2010	4	12							e917	10.1371/journal.pntd.0000917				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	697VI	WOS:000285547000016	21200417	DOAJ Gold, Green Published			2019-03-26	
J	van Griensven, J; Zachariah, R; Mugabo, J; Reid, T				van Griensven, Johan; Zachariah, Rony; Mugabo, Jules; Reid, Tony			Weight loss after the first year of stavudine-containing antiretroviral therapy and its association with lipoatrophy, virological failure, adherence and CD4 counts at primary health care level in Kigali, Rwanda	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						weight loss; antiretroviral treatment; lipoatrophy; Africa; stavudine; health center	EARLY MORTALITY; HIV; ADULTS; LIPODYSTROPHY; OUTCOMES; POPULATION; PREVALENCE; EFFICACY; CRITERIA; AFRICA	This study was conducted among 609 adults on stavudine-based antiretroviral treatment (ART) for at least one year at health center level in Kigali, Rwanda to (a) determine the proportion who manifest weight loss after one year of ART (b) examine the association between such weight loss and a number of variables, namely: lipoatrophy, virological failure, adherence and on-treatment CD4 count and (c) assess the validity and predictive values of weight loss to identify patients with lipoatrophy. Weight loss after the first year of ART was seen in 62% of all patients (median weight loss 3.1 kg/year). In multivariate analysis, weight loss was significantly associated with treatment-limiting lipoatrophy (adjusted effect/kg/year -2.0 kg, 95% confidence interval -0.6;-3.4 kg; P<0.01). No significant association was found with virological failure or adherence. Higher on-treatment CD4 cell counts were protective against weight loss. Weight loss that was persistent, progressive and/or chronic was predictive of lipoatrophy, with a sensitivity and specificity of 72% and 77%, and positive and negative predictive values of 30% and 95%. In low-income countries, measuring weight is a routine clinical procedure that could be used to filter out individuals with lipoatrophy on stavudine-based ART, after alternative causes of weight loss have been ruled out. (C) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[van Griensven, Johan; Zachariah, Rony; Reid, Tony] Medecins Sans Frontieres, Operat Ctr Brussels, Dept Med, B-1090 Brussels, Belgium; [van Griensven, Johan] Inst Trop Med, B-2000 Antwerp, Belgium; [Mugabo, Jules] Treatment & Res AIDS Ctr, Kigali 2717, Rwanda	van Griensven, J (reprint author), Medecins Sans Frontieres, Operat Ctr Brussels, Dept Med, Duprestr 94, B-1090 Brussels, Belgium.	jvgrie@yahoo.com			Inbev-Baillet Latour Fund; European Union; Belgian Development Cooperation (DGCD); Global Fund to fight AIDS, Tuberculosis and Malaria	We are grateful to all the staff of the Kimironko and Kininya health centres for their work on HIV/AIDS and the Ministry of Health of Rwanda for the fruitful collaboration. We are particularly grateful to all patients who participated in this assessment. JvG is supported by the Inbev-Baillet Latour Fund.; The MSF project received funding from the European Union, the Belgian Development Cooperation (DGCD) and the Global Fund to fight AIDS, Tuberculosis and Malaria.	Bisson GP, 2008, PLOS MED, V5, P777, DOI 10.1371/journal.pmed.0050109; Boulle A, 2007, ANTIVIR THER, V12, P753; Braitstein P, 2006, LANCET, V367, P817; Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073; Carr A, 2003, JAIDS-J ACQ IMM DEF, V33, P571, DOI 10.1097/00126334-200308150-00004; Colebunders R, 2006, LANCET INFECT DIS, V6, P53, DOI 10.1016/S1473-3099(05)70327-3; Fiscus SA, 2006, PLOS MED, V3, P1743, DOI 10.1371/journal.pmed.0030417; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Koethe JR, 2010, JAIDS-J ACQ IMM DEF, V53, P507, DOI 10.1097/QAI.0b013e3181b32baf; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lichtenstein KA, 2001, AIDS, V15, P1389, DOI 10.1097/00002030-200107270-00008; Lynen L, 2009, JAIDS-J ACQ IMM DEF, V52, P40, DOI 10.1097/QAI.0b013e3181af6705; Madec Y, 2009, AIDS, V23, P853, DOI 10.1097/QAD.0b013e32832913ee; MCCOMSEY G, 2006, 13 C RETR OPP INF 5; Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8; Mutimura E, 2007, JAIDS-J ACQ IMM DEF, V46, P451, DOI 10.1097/QAI.0b013e318158c0a6; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Tien PC, 2007, JAIDS-J ACQ IMM DEF, V44, P43, DOI 10.1097/01.qai.0000248353.56125.43; van Griensven J, 2008, JAIDS-J ACQ IMM DEF, V48, P631, DOI 10.1097/QAI.0b013e31817bec3e; van Griensven J, 2007, T ROY SOC TROP MED H, V101, P793, DOI 10.1016/j.trstmh.2007.02.020; van Griensven J, 2009, T ROY SOC TROP MED H, V103, P613, DOI 10.1016/j.trstmh.2008.08.015; van Oosterhout JJG, 2009, TROP MED INT HEALTH, V14, P856, DOI 10.1111/j.1365-3156.2009.02309.x; *WHO, 2006, ANT THER HIV INF AD; Zachariah R, 2009, TROP MED INT HEALTH, V14, P713, DOI 10.1111/j.1365-3156.2009.02291.x	26	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	DEC	2010	104	12					751	757		10.1016/j.trstmh.2010.08.016				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	694VG	WOS:000285326500001	20889179	Green Published			2019-03-26	
J	N'Guessan, R; Asidi, A; Boko, P; Odjo, A; Akogbeto, M; Pigeon, O; Rowland, M				N'Guessan, Raphael; Asidi, Alex; Boko, Pelagie; Odjo, Abibatou; Akogbeto, Martin; Pigeon, Olivier; Rowland, Mark			An experimental hut evaluation of PermaNet (R) 3.0, a deltamethrin-piperonyl butoxide combination net, against pyrethroid-resistant Anopheles gambiae and Culex quinquefasciatus mosquitoes in southern Benin	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Anopheles gambiae; Culex quinquefasciatus; Synergists; Pyrethroid resistance; Deltamethrin; Piperonyl butoxide	INSECTICIDE RESISTANCE; TREATED NETS; COTE-DIVOIRE; WEST-AFRICA; EFFICACY	PermaNet 3.0 is a long-lasting combination net with deltamethrin present on the sides and a mixture of deltamethrin and piperonyl butoxide (PBO), an oxidase synergist, on the top panel. An experimental hut trial comparing unwashed and 20 times washed PermaNet 3.0 and PermaNet 2.0, Olyset Net and a conventional deltamethrin-treated net washed three times was conducted in southern Benin. Anopheles gambiae and Culex quinquefasciatus from this area are highly resistant to pyrethroids through kdr and cytochrome P450 mechanisms. The unwashed PermaNet 3.0 killed slightly more A. gambiae (52%) than the unwashed PermaNet 2.0 (44%) (P=0.036), indicating only partial synergism of resistance. After washing there was significant loss of activity to a similar level, with PermaNet 3.0 killing 31%, PermaNet 2.0 killing 29% and the conventional net killing 26%. Blood-feeding rates were partially inhibited for unwashed PermaNet 3.0 and Olyset Net (27% inhibition). Personal protection against A. gambiae derived from PermaNet 3.0 was similar to that from PermaNet 2.0 before washing (50% vs. 47%), and after 20 washes it decreased to 30%. Against C. quinquefasciatus, no treatment killed >24% entering the huts. The synergism from unwashed PermaNet 3.0 was lower than expected, probably due to an unidentified resistance mechanism unaffected by PBO. (C) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[N'Guessan, Raphael; Asidi, Alex; Rowland, Mark] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [N'Guessan, Raphael; Asidi, Alex; Boko, Pelagie; Odjo, Abibatou; Akogbeto, Martin] Minist Sante, Lab Natl, CREC, Cotonou 06, Benin; [Pigeon, Olivier] Walloon Agr Res Ctr, Agr & Nat Environm Dept, Plant Protect Prod & Biocides Physicochem & Resid, B-5030 Gembloux, Belgium	N'Guessan, R (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	raphael.n'guessan@lshtm.ac.uk			Vestergaard Frandsen, Aarhus, Denmark	The study was financially supported by Vestergaard Frandsen, Aarhus, Denmark.	[Anonymous], 2009, 12 WHOPES WORK GROUP; Asidi AN, 2004, MED VET ENTOMOL, V18, P134, DOI 10.1111/j.0269-283X.2004.00485.x; Bingham G, 2007, PEST MANAG SCI, V63, P276, DOI 10.1002/ps.1336; Chandre F, 1998, MED VET ENTOMOL, V12, P359, DOI 10.1046/j.1365-2915.1998.00120.x; Corbel V, 2007, ACTA TROP, V101, P207, DOI 10.1016/j.actatropica.2007.01.005; Darriet F, 2000, Sante, V10, P413; DARRIET F, 1984, WHOVBC84899; DEVRIES DH, 1980, EXPERIENTIA, V36, P226, DOI 10.1007/BF01953747; Djouaka RF, 2008, BMC GENOMICS, V13, P538; Henry MC, 2005, AM J TROP MED HYG, V73, P859, DOI 10.4269/ajtmh.2005.73.859; N'Guessan R, 2001, MED VET ENTOMOL, V15, P97, DOI 10.1046/j.1365-2915.2001.00284.x; N'Guessan R, 2007, EMERG INFECT DIS, V13, P199, DOI 10.3201/eid1302.060631; PIGEON O, COLL INT PEST AN COU; Stump AD, 2004, AM J TROP MED HYG, V70, P591, DOI 10.4269/ajtmh.2004.70.591; Tungu P, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-21; *WHO, 2005, WHOCDSNTDWHOPESGCDPP; World Health Organization, 2009, 13 WHOPES WORK GROUP; World Health Organization, 2006, WHOCDSNTDWHOPESGCDPP	18	41	41	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	DEC	2010	104	12					758	765		10.1016/j.trstmh.2010.08.008				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	694VG	WOS:000285326500002	20956008				2019-03-26	
J	Alexander, AM; Prabhakaran, V; Rajshekhar, V; Muliyil, J; Dorny, P				Alexander, A. M.; Prabhakaran, V.; Rajshekhar, V.; Muliyil, J.; Dorny, P.			Long-term clinical evaluation of asymptomatic subjects positive for circulating Taenia solium antigens	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Cysticercosis; asymptomatic; Taenia solium; antigen; India	VELLORE DISTRICT; NEUROCYSTICERCOSIS; SEROPREVALENCE; CYSTICERCOSIS; INDIA	Although presence of cysticercal antigens in serum is presumed to indicate active cysticercosis not all positive persons are symptomatic. The significance of a positive antigen test in asymptomatic individuals, in predicting development of symptomatic cysticercosis on long-term follow up, is unknown. Forty two of 48 persons from Vellore district, India who were positive for circulating serum cysticercal antigens were followed up for four to five years. None of them developed clinical evidence of neurocysticercosis or subcutaneous cysts. We conclude that asymptomatic individuals with circulating cysticercal antigens have a low risk of developing symptomatic cysticercosis within four to five years. (C) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Prabhakaran, V.; Rajshekhar, V.] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore, Tamil Nadu, India; [Alexander, A. M.; Muliyil, J.] Christian Med Coll & Hosp, Dept Community Hlth, Vellore, Tamil Nadu, India; [Dorny, P.] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium	Rajshekhar, V (reprint author), Christian Med Coll & Hosp, Dept Neurol Sci, Vellore, Tamil Nadu, India.	rajshekhar@cmcvellore.ac.in			Indian Council of Medical Research, New Delhi; Flemish Interuniversity Council, Belgium	This study was funded in part by grants from the Indian Council of Medical Research, New Delhi and the Flemish Interuniversity Council, Belgium.	Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Garcia HH, 1997, J INFECT DIS, V175, P486, DOI 10.1093/infdis/175.2.486; Prabhakaran V, 2008, T ROY SOC TROP MED H, V102, P246, DOI 10.1016/j.trstmh.2007.10.010; Rajshekhar V, 2006, NEUROLOGY, V67, P2135, DOI 10.1212/01.wnl.0000249113.11824.64; Somers R, 2006, TROP MED INT HEALTH, V11, P65, DOI 10.1111/j.1365-3156.2005.01537.x	5	6	6	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	DEC	2010	104	12					809	810		10.1016/j.trstmh.2010.07.005				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	694VG	WOS:000285326500011	20801473				2019-03-26	
J	Harries, AD; Zachariah, R; Tayler-Smith, K; Schouten, EJ; Chimbwandira, F; Van Damme, W; El-Sadr, WM				Harries, Anthony D.; Zachariah, Rony; Tayler-Smith, Katie; Schouten, Erik J.; Chimbwandira, Frank; Van Damme, Wim; El-Sadr, Wafaa M.			Keeping health facilities safe: one way of strengthening the interaction between disease-specific programmes and health systems	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						health systems; disease-specific programmes; HINT/AIDS; tuberculosis; infection control	TUBERCULOSIS INFECTION; ANTIRETROVIRAL THERAPY; HUMAN-RESOURCES; CARE WORKERS; SCALE-UP; MALAWI; TRANSMISSION; SETTINGS; RATES; RISK	The debate on the interaction between disease-specific programmes and health system strengthening in the last few years has intensified as experts seek to tease out common ground and find solutions and synergies to bridge the divide. Unfortunately, the debate continues to be largely academic and devoid of specificity, resulting in the issues being irrelevant to health care workers on the ground. Taking the theme 'What would entice HIV- and tuberculosis (TB)-programme managers to sit around the table on a Monday morning with health system experts', this viewpoint focuses on infection control and health facility safety as an important and highly relevant practical topic for both disease-specific programmes and health system strengthening. Our attentions, and the examples and lessons we draw on, are largely aimed at sub-Saharan Africa where the great burden of TB and HIV/AIDS resides, although the principles we outline would apply to other parts of the world as well. Health care infections, caused for example by poor hand hygiene, inadequate testing of donated blood, unsafe disposal of needles and syringes, poorly sterilized medical and surgical equipment and lack of adequate airborne infection control procedures, are responsible for a considerable burden of illness amongst patients and health care personnel, especially in resource-poor countries, Effective infection control in a district hospital requires that all the components of a health system function well: governance and stewardship, financing, infrastructure, procurement and supply chain management, human resources, health information systems, service delivery and finally supervision. We argue in this article that proper attention to infection control and an emphasis on safe health facilities is a concrete first step towards strengthening the interaction between disease-specific programmes and health systems where it really matters for patients who are sick and for the health care workforce who provide the care and treatment,	[Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France; [Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England; [Zachariah, Rony; Tayler-Smith, Katie] MSF Luxembourg, Operat Res Unit, Operat Ctr Brussels, Luxembourg, Luxembourg; [Schouten, Erik J.; Chimbwandira, Frank] Minist Hlth, Dept HIV & AIDS, Lilongwe, Malawi; [Schouten, Erik J.] BASICS, Management Sci Hlth, Lilongwe, Malawi; [Van Damme, Wim] Inst Trop Med, Dept Publ Hlth, Antwerp, Belgium; [El-Sadr, Wafaa M.] Columbia Univ, Int Ctr AIDS Care & Treatment Programs, New York, NY USA	Harries, AD (reprint author), Vears Lane, Winchester SO21 1TQ, Hants, England.	adharries@theunion.org	chiu, takeung/A-2046-2013; Van Damme, Wim/F-7404-2011				Atun R, 2010, LANCET, V375, P2169, DOI 10.1016/S0140-6736(10)60493-X; Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661; Corbett EL, 2007, CLIN INFECT DIS, V44, P317, DOI 10.1086/509926; El-Sadr WM, 2009, JAIDS-J ACQ IMM DEF, V52, pS1, DOI 10.1097/QAI.0b013e3181bbcd7a; Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068; Harries AD, 2009, INT J TUBERC LUNG D, V13, P1194; Harries AD, 2002, T ROY SOC TROP MED H, V96, P34, DOI 10.1016/S0035-9203(02)90231-2; Hongoro C, 2004, LANCET, V364, P1451, DOI 10.1016/S0140-6736(04)17229-2; Libamba E, 2006, B WORLD HEALTH ORGAN, V84, P320, DOI 10.2471/BLT.05.023952; Makombe SD, 2007, B WORLD HEALTH ORGAN, V85, P851; Menzies D, 2007, INT J TUBERC LUNG D, V11, P593; Moore A, 2001, LANCET, V358, P657, DOI 10.1016/S0140-6736(01)05783-X; Morris K, 2008, LANCET, V372, P1941, DOI 10.1016/S0140-6736(08)61827-9; Newsom DH, 2002, ANN TROP MED PARASIT, V96, P517, DOI 10.1079/000349802125001186; Nyirenda TE, 1998, INT J TUBERC LUNG D, V2, P690; Ooms G, 2008, GLOBALIZATION HEALTH, V4, DOI 10.1186/1744-8603-4-6; Samb B, 2009, LANCET, V373, P2137, DOI 10.1016/S0140-6736(09)60919-3; Semmelweis I, 1861, ETIOLOGY CONCEPT PRO; Shenoi SV, 2010, CLIN INFECT DIS, V50, pS231, DOI 10.1086/651496; Van Oosterhout JJG, 2009, TROPICAL DOCTOR, V37, P4; WHO UNAIDS, 2009, WHOHTMTB2009414; World Health Organisation, 2009, WHOHTMTB2009419; World Health Organization, 2009, UN ACC SCAL PRIOR HI	23	21	21	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2010	15	12					1407	1412		10.1111/j.1365-3156.2010.02662.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	682BT	WOS:000284374600002	21137105	Bronze			2019-03-26	
J	Bemelmans, M; van den Akker, T; Ford, N; Philips, M; Zachariah, R; Harries, A; Schouten, E; Hermann, K; Mwagomba, B; Massaquoi, M				Bemelmans, Marielle; van den Akker, Thomas; Ford, Nathan; Philips, Mit; Zachariah, Rony; Harries, Anthony; Schouten, Erik; Hermann, Katharina; Mwagomba, Beatrice; Massaquoi, Moses			Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						universal access; task shifting; human resources; antiretroviral therapy scale-up; decentralization; Malawi	RURAL DISTRICT; AFRICA	OBIECTVE To describe how district-wide access to HIV/AIDS care was achieved and maintained in Thyolo District, Malawi, METHOD In mid-2003, the Ministry of Health and Medecims Sans Frontieres developed a model of care for Thyolo district (population 587 455) based on decentralization of care to health centres and community sites and task shifting. RESULTS After delegating HIV testing and Counseling to lay counsellors, uptake of testing increased from 1300 tests per month in 2003 to 6500 in 2009. Shifting responsibility for antiretroviral therapy (ART) initiations to non-physician clinicians almost doubled ART enrolment, with a majority of initiations performed in peripheral health centres. By the end 2009, 23 261 people had initiated ART of whom 11 042 received ART care at health-centre level. By the end of 2007, the universal access targets were achieved, with nearly 9000 patients alive and on ART. The average annual cost for achieving these targets was (sic)2.6 per inhabitant/year. CONCLUSION The Thyolo programme has demonstrated the feasibility of district-wide access to ART in a setting with limited resources for health. Expansion and decentralization of HINT/AIDS service-capacity to the primary care level, combined with task shifting, resulted in increased access to HIV services with good programme outcomes despite staff shortages.	[Bemelmans, Marielle; van den Akker, Thomas; Massaquoi, Moses] Med Sans Frontieres, Blantyre, Malawi; [Ford, Nathan] Med Sans Frontiers, Cape Town, South Africa; [Ford, Nathan] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7700 Rondebosch, South Africa; [Philips, Mit; Zachariah, Rony] Med Sans Frontieres, Brussels, Belgium; [Harries, Anthony] Int Union TB & Lung Dis, Paris, France; [Schouten, Erik] Minist Hlth, Lilongwe, Malawi; [Schouten, Erik] Management Sci Hlth, Lilongwe, Malawi; [Hermann, Katharina] Inst Trop Med, B-2000 Antwerp, Belgium; [Mwagomba, Beatrice] Dist Hlth Off, Thyolo, Malawi	Bemelmans, M (reprint author), Med Sans Frontieres Belgium, POB 30353, Blantyre 3, Malawi.	mariellebemelmans@hotmail.com					Adam MA, 2009, SAMJ S AFR MED J, V99, P661; Battegay M, 2006, LANCET INFECT DIS, V6, P280, DOI 10.1016/S1473-3099(06)70463-7; BEMELMANS M, 2009, 5 IAS C HIV PATH TRE; Braitstein P, 2006, LANCET, V367, P817; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; *GTZ MAL HLTH SWAP, 2007, HUM RES CAP DEV HLTH; Harries AD, 2002, T ROY SOC TROP MED H, V96, P34, DOI 10.1016/S0035-9203(02)90231-2; Hirschhorn Lisa R, 2006, Hum Resour Health, V4, P1, DOI 10.1186/1478-4491-4-1; JOUQUET G, 2009, 5 IAS C HIV PATH TRE; Libamba E, 2007, B WORLD HEALTH ORGAN, V85, P156; MASSAQUOI M, 2009, T ROY SOC TROP MED H, V104, P313; MASSAQUOI M, 2008, 17 INT AIDS C MEX 3; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; *MIN HLTH, 2009, Q REP ANT TREATM PRO; *MIN HLTH, 2010, HIV DEP HIV AIDS S N; *MIN HLTH, 2007, HUM RES HLTH CENS LI; *MIN HLTH, 2010, HIV DEP MAL; *MIN HLTH, 2008, HIV SUPH SER SURV NA; *MIN HLTH, 2010, MAL ANN HLTH SECT SW; *NAT AIDS COMM, 2010, OFF PRES CAB OPC MAL; *NAT STAT OFF, 2004, DEM HLTH SURV; *NAT STAT OFF, 2008, POP CENS; NKANDU P, 2005, MID TERM REV MALAWIS, V1; Philips M, 2008, LANCET, V371, P682, DOI 10.1016/S0140-6736(08)60307-4; The World Bank, 2006, MAL POV VULN ASS INV; Torpey KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002204; Weidle PJ, 2006, LANCET, V368, P1587, DOI 10.1016/S0140-6736(06)69118-6; WHO, 2009, RAP ADV ANT THER HIV; World Health Organization, 2008, TASK SHIFT GLOB REC; Zachariah R, 2007, T ROY SOC TROP MED H, V101, P79, DOI 10.1016/j.trstmh.2006.05.010	31	95	97	0	7	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2010	15	12					1413	1420		10.1111/j.1365-3156.2010.02649.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	682BT	WOS:000284374600003	20958897	Bronze			2019-03-26	
J	Otero, L; Ugaz, R; Dieltiens, G; Gonzalez, E; Verdonck, K; Seas, C; Van Deun, A; Gotuzzo, E; Van der Stuyft, P				Otero, L.; Ugaz, R.; Dieltiens, G.; Gonzalez, E.; Verdonck, K.; Seas, C.; Van Deun, A.; Gotuzzo, E.; Van der Stuyft, P.			Duration of cough, TB suspects' characteristics and service factors determine the yield of smear microscopy	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						tuberculosis; case detection; cough; Peru; smear positivity	ACID-FAST BACILLI; PULMONARY TUBERCULOSIS; PREVALENCE; STRATEGIES; COUNTRIES; SPUTUM; INDIA	OBJECTIVE To determine the efficiency of routine tuberculosis (TB) case detection by examining sputum smear positivity for acid-fast bacilli in relation to duration of cough, characteristics of TB suspects examined and health service factors. METHOD We combined patient interviews with routine data from laboratory registers in 6 health care facilities in San Juan de Lurigancho district, Lima, Peru. A TB case was defined as a TB suspect with at least one positive sputum smear. We calculated adjusted odds ratios with 95% confidence intervals for the association between smear positivity and health service and patient's characteristics. RESULTS Smear positivity was 7.3% (321/4376). Of the 4376 adults submitting sputa, 55.3% (2418) reported cough for <14 days. In this group, smear microscopy yielded 3.2% (78/2418) positive results vs. 12.4% (243/1958) in patients coughing for 14 or more days. Having cough for >2 weeks, being referred by health care staff, attending a secondary-level health care facility, male sex and age between 15 and 44 years were independent determinants of smear positivity. CONCLUSIONS Routine case detection yields a low proportion of smear-positive cases because of the inclusion of a high proportion of patients without cough or coughing for <2 weeks. Adherence to the national TB control programme guidelines on the selection of TB suspects would have a positive impact on the smear positivity rate, reduce laboratory costs and workload and possibly improve the reading quality of smear microscopy.	[Otero, L.; Ugaz, R.; Gonzalez, E.; Verdonck, K.; Seas, C.; Gotuzzo, E.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Dieltiens, G.; Van der Stuyft, P.] Inst Trop Med, Epidemiol & Dis Control Unit, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Verdonck, K.; Van Deun, A.] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium	Otero, L (reprint author), Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru.	larissaotero@gmail.com		Otero, Larissa/0000-0002-8348-4340; Seas, Carlos/0000-0001-7067-9141	European Commission - International Cooperation (INCO) grant	We thank Dr. Cesar Bonilla for revising the manuscript; Ms. Maribel Huayta and Ms. Elisa Sani for the data collection; and the staff at the health care facilities in San juan de Lurigancho district. This study was funded by a European Commission - International Cooperation (INCO) grant and received partial support from the Belgian Cooperation through a project of Institutional collaboration between the Institute of Tropical Medicine in Antwerp, Belgium and the Instituto de Medicina Tropical Alexander von Humboldt in Lima, Peru.	BAILY GVJ, 1967, B WORLD HEALTH ORGAN, V37, P875; Banda HT, 1998, T ROY SOC TROP MED H, V92, P161, DOI 10.1016/S0035-9203(98)90727-1; Bastos LGV, 2007, INT J TUBERC LUNG D, V11, P156; Currie CSM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-130; Gonzalez-Ochoa E, 2009, TROP MED INT HEALTH, V14, P131, DOI 10.1111/j.1365-3156.2008.02201.x; Harries AD, 1997, T ROY SOC TROP MED H, V91, P416, DOI 10.1016/S0035-9203(97)90262-5; Ipuge YAI, 1996, T ROY SOC TROP MED H, V90, P258, DOI 10.1016/S0035-9203(96)90239-4; Luelmo F, 2004, TOMANS TUBERCULOSIS, P7; Makunde W H, 2007, Tanzan Health Res Bull, V9, P87; *PER NAT TUB PROGR, 2005, AN SIT SAL 2005 DIR; *PER NAT TUB PROGR, 2006, NORM TECN ACT NORM P; *PER NAT TUB PROGR, 2004, INF OP 2004 ESTR SAN; *PER NAT TUB PROGR, 2006, INF OP 2006 ESTR SAN; Rieder HL, 1997, INT J TUBERC LUNG D, V1, P339; Santha T, 2005, INT J TUBERC LUNG D, V9, P61; SHARGIE EB, 2006, INT J TUBERC LUNG D, V10, P187; Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777; van Cleeff MRA, 2003, INT J TUBERC LUNG D, V7, P186; *WHO, 2009, WHOHTMTB2009426; World Health Organization, 1998, WHOTB98253; World Health Organization (WHO), 2009, WHOHTMTB2009420	21	7	9	0	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2010	15	12					1475	1480		10.1111/j.1365-3156.2010.02645.x				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	682BT	WOS:000284374600010	21087375	Bronze			2019-03-26	
J	Nelwan, EJ; van Crevel, R; Alisjahbana, B; Indrati, AK; Dwiyana, RF; Nuralam, N; Pohan, HT; Jaya, I; Meheus, A; van der Ven, A				Nelwan, Erni J.; van Crevel, Reinout; Alisjahbana, Bachti; Indrati, Agnes K.; Dwiyana, Reiva F.; Nuralam, Nisaa; Pohan, Herdiman T.; Jaya, Ilham; Meheus, Andre; van der Ven, Andre			Human immunodeficiency virus, hepatitis B and hepatitis C in an Indonesian prison: prevalence, risk factors and implications of HIV screening	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						prisons; HIV infections; epidemiology; therapy; hepatitis; viral; human; substance abuse; intravenous; Indonesia	INJECTING DRUG-USERS; ANTIRETROVIRAL THERAPY; INFECTED PRISONERS; EPIDEMIOLOGY; POPULATIONS; PREVENTION; WOMEN; USA	OBJECTIVE To determine the prevalence and behavioural correlates of HIV, HBV and HCV infections among Indonesian prisoners and to examine the impact of voluntary counselling and testing for all incoming prisoners on access to anti retroviral treatment (ART). METHODS In a non-anonymous survey in an Indonesian prison for drug-related offences, all incoming prisoners and symptomatic resident prisoners were counselled and offered testing for HIV, hepatitis B and C. RESULTS Screening was performed in 679 incoming prisoners, of whom 639 (94.1%) agreed to be tested, revealing a seroprevalence of 7.2% (95% CI 5.2-9.2) for HIV, 5.8% (95% CI 3.9-7.6) for HBsAg and 18.6% (95% CI 15.5-21.6) for HCV. Of 57 resident prisoners tested, 29.8% were HIV-positive. HIV infection was strongly associated with injecting drug use (IDU; P < 0.001), but not with a history of unsafe sex. Screening of incoming prisoners was responsible for diagnosing and treating HIV in 73.0%, respectively, and 68.0% of HIV-positive individuals. CONCLUSIONS HIV and HCV are highly prevalent among incoming Indonesian prisoners and almost entirely explained by IDU. Our study is the first to show that voluntary HIV counselling and testing during the intake process in prison may greatly improve access to ART in a developing country.	[Nelwan, Erni J.; Pohan, Herdiman T.] Univ Indonesia, Dept Internal Med, Div Trop & Infect Dis, Jakarta 10430, Indonesia; [Nelwan, Erni J.; Alisjahbana, Bachti; Indrati, Agnes K.; Dwiyana, Reiva F.] Padjadjaran State Univ, Hlth Res Unit, Fac Med, Hasan Sadikin Hosp, Bandung, Indonesia; [van Crevel, Reinout; van der Ven, Andre] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Alisjahbana, Bachti] Padjajaran Univ, Dept Internal Med, Fac Med, Hasan Sadikin Hosp, Bandung, Indonesia; [Indrati, Agnes K.] Padjajaran Univ, Dept Clin Pathol, Fac Med, Hasan Sadikin Hosp, Bandung, Indonesia; [Dwiyana, Reiva F.] Padjajaran Univ, Dept Dermatovenerol, Fac Med, Hasan Sadikin Hosp, Bandung, Indonesia; [Nuralam, Nisaa; Jaya, Ilham] Banceuy Narcot Prison, Bandung, Indonesia; [Meheus, Andre] Univ Antwerp, Dept Epidemiol & Social Med, B-2020 Antwerp, Belgium	Nelwan, EJ (reprint author), Univ Indonesia, Dept Internal Med, Div Trop & Infect Dis, Diponegoro 71, Jakarta 10430, Indonesia.	erninelwan@hotmail.com	van Crevel, reinout/A-6636-2010; Ven, A.J.A.M./H-8102-2014	van Crevel, reinout/0000-0002-6233-6410; Ven, A.J.A.M./0000-0003-1833-3391	'IMPACT' (Integrated Management of Prevention And Care and Treatment of HIV/AIDS), Padjadjaran University, Bandung, Indonesia; Maastricht University, the Netherlands; Radboud University Nijmegen, the Netherlands; Antwerpen University, Belgium; European Commission [SANTE/2005/105-033]; CORDAID	We thank Bambang Krishbanu, Ilham Djaja, Sambiyono, Iqbal Djamaris and Beni Benardi for allowing and assisting the study in Banceuy Narcotic Prison Bandung. We thank Prof. Cissy B. Sudjana Prawira, director of the Hasan Sadikin General Hospital, Bandung, Indonesia, and Dr. Eri Surahman, Dean of the Medical Faculty Universitas Padjajaran, for accommodating and encouraging research in their institutions. We highly value the assistance and companion of Harry Suherman, Fedri Rinawan, Aly Diana, Ahmad Isa, Aries Sulaiman, Nopi Susilawati, Irma Utama, Yanti Siti Rismayanti, Elfi Wulandari, Tuti Herawati, Nuning and Akhyar during the conduction of this study. This study was supported by 'IMPACT' (Integrated Management of Prevention And Care and Treatment of HIV/AIDS), a collaborative research and implementation program of Padjadjaran University, Bandung, Indonesia; Maastricht University and Radboud University Nijmegen, the Netherlands; and Antwerpen University, Belgium. IMPACT is funded by the European Commission (SANTE/2005/105-033) and contracted by CORDAID.	*AIDS AL INT, 2005, UNAIDS REP FOC AS CI; Akbar N, 1997, J GASTROEN HEPATOL, V12, P752, DOI 10.1111/j.1440-1746.1997.tb00365.x; Allwright S, 2000, BRIT MED J, V321, P78, DOI 10.1136/bmj.321.7253.78; Altice FL, 2005, J URBAN HEALTH, V82, P312, DOI 10.1093/jurban/jti055; Baillargeon J, 2009, JAMA-J AM MED ASSOC, V301, P848, DOI 10.1001/jama.2009.202; BEHRENDT C, 1994, AM J EPIDEMIOL, V139, P918, DOI 10.1093/oxfordjournals.aje.a117098; Butler T, 2007, AUST NZ J PUBL HEAL, V31, P44, DOI 10.1111/j.1753-6405.2007.00009.x; Celentano DD, 2001, AIDS, V15, P1707, DOI 10.1097/00002030-200109070-00015; Derlega VJ, 2008, INT J STD AIDS, V19, P259, DOI 10.1258/ijsa.2007.007141; *DIR JENDR PEM, 2007, PET PEL PET TEN LAY; Dolan K, 2007, LANCET INFECT DIS, V7, P32, DOI 10.1016/S1473-3099(06)70685-5; Ferreira RC, 2009, J MED VIROL, V81, P602, DOI 10.1002/jmv.21464; French AL, 2009, CLIN INFECT DIS, V49, P148, DOI 10.1086/599610; Freudenberg N, 2001, J URBAN HEALTH, V78, P214, DOI 10.1093/jurban/78.2.214; Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2; Mesquita Fabio, 2007, Harm Reduct J, V4, P9, DOI 10.1186/1477-7517-4-9; *MIN HLTH IND, 2007, REP HIV AIDS; Ministry of Health of Indonesia, 2008, MATH MOD HIV EP IND; Morrison D S, 2001, Health Bull (Edinb), V59, P114; NELWAN EJ, 2009, ACTA MEDICA INDON S1, V41, pS52; Pisani E, 2003, BRIT MED J, V326, P1384, DOI 10.1136/bmj.326.7403.1384; Samuel MC, 2001, EPIDEMIOL INFECT, V127, P475; Solomon SS, 2009, AIDS, V23, P997, DOI 10.1097/QAD.0b013e32832a594e; Spaulding A, 2002, CLIN INFECT DIS, V35, P305, DOI 10.1086/341418; Springer SA, 2007, HIV CLIN TRIALS, V8, P205, DOI 10.1310/hct0804-205; Stark K, 1996, AIDS, V10, P311, DOI 10.1097/00002030-199603000-00010; SULAIMAN HA, 1995, T ROY SOC TROP MED H, V89, P167, DOI 10.1016/0035-9203(95)90480-8; Thaisri H, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-25; Weinbaum CA, 2005, AIDS, V19, pS41, DOI 10.1097/01.aids.0000192069.95819.aa; Wilson D, 2007, PLOS MED, V4, P988, DOI 10.1371/journal.pmed.0040204; Zaller N, 2007, PUBLIC HEALTH REP, V122, P49, DOI 10.1177/003335490712200107	31	26	28	0	9	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2010	15	12					1491	1498		10.1111/j.1365-3156.2010.02655.x				8	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	682BT	WOS:000284374600012	20955370	Bronze			2019-03-26	
J	Vuylsteke, B; Vandenhoudt, H; Langat, L; Semde, G; Menten, J; Odongo, F; Anapapa, A; Sika, L; Buve, A; Laga, M				Vuylsteke, Bea; Vandenhoudt, Hilde; Langat, Lilian; Semde, Gisele; Menten, Joris; Odongo, Fredrick; Anapapa, Ayubu; Sika, Lazare; Buve, Anne; Laga, Marie			Capture recapture for estimating the size of the female sex worker population in three cities in Cote d'Ivoire and in Kisumu, western Kenya	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						female sex workers; size estimation; capture-recapture; mapping; AIDS prevention; Africa	SEXUALLY-TRANSMITTED DISEASES; HIV; ENUMERATION; PREVALENCE; INFECTION; DECLINE; NUMBER	OBJECTIVE To estimate the female sex worker population size in three cities in Cote d'Ivoire and in Kisumu, Kenya. METHODS Capture recapture was used, calculating size estimates by first 'tagging' a number of individuals and, through an independent recapture, calculating the proportion of overlap. The same procedures were used in all four cities. In the first phase, members of the target population were 'captured' and 'marked' by giving them a capture card, Six days later, in the same places and at the same time, a second sample was 'captured', which comprised a certain number of people who were captured in the first round. During the exercise, questions were asked to estimate the coverage of the sex worker clinics. RESULTS Using capture recapture, the estimated number of female sex workers was 1160 in Yamoussoukro (95% CI 1053-1287), 1202 in wBouake (95% CI 1128-1279), 1916 in San Pedro (95% CI 1809-2030) and 1350 in Kisumu (95% Cl 1261-1443). The proportion of female sex workers in Cote d'Ivoire who had visited the clinic ranged from 15% in Yamoussoukro to 30% in San Pedro and was 34% in Kisumu. CONCLUSIONS Capture recapture was successfully applied to estimate the population size of female sex workers. These estimations were urgently needed to help mobilize an increased response to HIV, to assess programme coverage and to estimate potential impact of the targeted intervention.	[Vuylsteke, Bea; Vandenhoudt, Hilde; Langat, Lilian; Menten, Joris; Buve, Anne] Inst Trop Med, B-2000 Antwerp, Belgium; [Vuylsteke, Bea; Semde, Gisele] Family Hlth Int, Abidjan, Cote Ivoire; [Odongo, Fredrick; Anapapa, Ayubu] Kenya Govt Med Res Ctr, Kisumu, Kenya; [Sika, Lazare] Natl Inst Stat & Appl Econ, Abidjan, Cote Ivoire	Vuylsteke, B (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	bvuylsteke@itg.be			Directorate-General for Development Cooperation (DGDC), Belgium; President's Emergency Plan for AIDS for AIDS Relief (PEPFAR), United States of America	The study was funded by the Directorate-General for Development Cooperation (DGDC), Belgium and the President's Emergency Plan for AIDS for AIDS Relief (PEPFAR), United States of America.	Alary M, 2002, AIDS, V16, P463, DOI 10.1097/00002030-200202150-00019; BUCKLAND ST, 1991, BIOMETRICS, V47, P225; Chao A, 2001, STAT MED, V20, P3123, DOI 10.1002/sim.996.abs; *FAM HLTH INT, 2003, UNAIDS0336E WHO WORK; Geibel S, 2007, AIDS, V21, P1349, DOI 10.1097/QAD.0b013e328017f843; Ghys PD, 2002, AIDS, V16, P251, DOI 10.1097/00002030-200201250-00015; Khan SI, 2004, J HEALTH POPUL NUTR, V22, P19; Kruse N, 2003, SEX TRANSM DIS, V30, P664, DOI 10.1097/01.OLQ.0000079523.04451.82; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MCKEGANEY N, 1992, BRIT MED J, V305, P801, DOI 10.1136/bmj.305.6857.801; Minh TT, 2004, AIDS EDUC PREV, V16, P389, DOI 10.1521/aeap.16.5.389.48740; *NASCOP, 2007, KAN AIDS IND SURV FI; Steen R, 2000, SEX TRANSM DIS, V27, P1, DOI 10.1097/00007435-200001000-00001; Vadivoo S, 2008, AIDS, V22, pS137, DOI 10.1097/01.aids.0000343772.82647.2d; VANDEPITTE J, 2006, SEX TRANSM INFECT S3, V82, P18, DOI DOI 10.1136/STI.2006.020081; VANVLIET C, 1998, CONFRONTING AIDS EVI, P39; VUYLSTEKE B, 2008, HIV PREVENTION, P376; Wi T, 2006, SEX TRANSM INFECT, V82, P386, DOI 10.1136/sti.2005.018283	18	18	18	0	8	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2010	15	12					1537	1543		10.1111/j.1365-3156.2010.02654.x				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	682BT	WOS:000284374600018	21054693				2019-03-26	
J	Yansouni, CP; Lynen, L; Colebunders, R				Yansouni, Cedric P.; Lynen, Lut; Colebunders, Robert			Challenges in the diagnosis of meningitis in low-resource settings	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Letter							AUTOPSY		[Yansouni, Cedric P.; Lynen, Lut; Colebunders, Robert] Inst Trop Med, B-2000 Antwerp, Belgium; [Colebunders, Robert] Univ Antwerp, Antwerp, Belgium	Yansouni, CP (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	cedric.yansouni@mail.mcgill.ca	Lynen, Lutgarde/A-1212-2014	Lynen, Lutgarde/0000-0001-7183-4895			Cohen DB, 2010, TROP MED INT HEALTH, V15, P910, DOI 10.1111/j.1365-3156.2010.02565.x; LUCAS SB, 1994, TUBERCLE LUNG DIS, V75, P301, DOI 10.1016/0962-8479(94)90137-6; Muller R, 2008, CLIN CHIM ACTA, V394, P1, DOI 10.1016/j.cca.2008.04.007; Murray J, 2007, AIDS, V21, pS97, DOI 10.1097/01.aids.0000299416.61808.24; Rana FS, 2000, J ACQ IMMUN DEF SYND, V24, P23	5	0	0	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	DEC	2010	15	12					1556	1557		10.1111/j.1365-3156.2010.02651.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	682BT	WOS:000284374600021	20958898	Bronze			2019-03-26	
J	Valea, I; Tinto, H; Drabo, MK; Huybregts, L; Henry, MC; Roberfroid, D; Guiguemde, RT; Kolsteren, P; D'Alessandro, U				Valea, Innocent; Tinto, Halidou; Drabo, Maxime K.; Huybregts, Lieven; Henry, Marie-Claire; Roberfroid, Dominique; Guiguemde, Robert T.; Kolsteren, Patrick; D'Alessandro, Umberto		FSP MISAME Study Grp	Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes	MALARIA JOURNAL			English	Article							CHLOROQUINE CHEMOPROPHYLAXIS; KOUPELA DISTRICT; WOMEN; EFFICACY; MALAWI; BURDEN; INFECTION; FAILURE; PROGRAM; IMPACT	Background: Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) is being implemented in most malaria endemic countries as a standard two-doses regimen as it reduces the risk of low birth weight (LBW) and the prevalence of maternal anaemia. Nevertheless, where the risk of infection close to delivery is high because of intense transmission, a third IPTp-SP dose may further reduce the negative effects of malaria on pregnancy outcome. Methods: Pregnant women in the 2(nd) or 3(rd) trimester were randomized to receive either 2 (SP2) or 3 doses (SP3) of SP. Trained field workers paid home visits to the women for drug administration according to a predefined drug delivery schedule. Women were encouraged to attend their scheduled ANC visits and to deliver at the health facilities where the new-born was weighed. The prevalence of LBW (<2500 g), severe anaemia (Hb < 8 g/dL) and premature birth was analysed using intention-to-treat (ITT) and per-protocol (PP) analysis. Results: Data from 1274 singleton pregnancies were analysed (641 in the SP3 and 633 in the SP2 group). The uptake of the intervention appeared to be low. Though the prevalence of LBW in both intervention groups was similar (adjusted Incident Rate Ratio, AIRR = 0.92, 95% CI: 0.69-1.24) in the ITT analysis, the risk of severe anaemia was significantly lower in the SP3 group compared to the SP2 group (AIRR = 0.38, 95% CI: 0.16 - 0.90). The PP analysis showed a trend of reduced risk of LBW, severe anaemia and premature delivery in the SP3 group, albeit the difference between two and three IPTp-SP did not reach statistical significance. Conclusion: The risk of LBW and severe anaemia tended to be lower in the SP3 group, though this was not statistically significant, probably due to the low uptake of the intervention which reduced the power of the study. Further studies are needed for establishing whether a third SP dose has a real benefit in preventing the negative effects of malaria in pregnancy in settings where transmission is markedly seasonal.	[Valea, Innocent; Tinto, Halidou; Henry, Marie-Claire; Guiguemde, Robert T.] Ctr Muraz, Lab Parasitol & Entomol, Bobo Dioulasso, Burkina Faso; [Tinto, Halidou; Drabo, Maxime K.] Inst Rech Sci Sante, Direct Reg Ouest, Bobo Dioulasso, Burkina Faso; [Huybregts, Lieven; Kolsteren, Patrick] Univ Ghent, Dept Food Safety & Food Qual, B-9000 Ghent, Belgium; [Roberfroid, Dominique; Kolsteren, Patrick] Inst Trop Med Prince Leopold, Dept Publ Hlth, Unit Nutr & Child Hlth, B-2000 Antwerp, Belgium; [D'Alessandro, Umberto] Inst Trop Med Prince Leopold, Dept Parasitol, Epidemiol Unit, B-2000 Antwerp, Belgium	Valea, I (reprint author), Ctr Muraz, Lab Parasitol & Entomol, Bobo Dioulasso, Burkina Faso.	innocentvalea@yahoo.fr	D'Alessandro, Umberto/D-3457-2015; Huybregts, Lieven/B-9578-2009	D'Alessandro, Umberto/0000-0001-6341-5009; Huybregts, Lieven/0000-0002-3068-2853; Tinto, Halidou/0000-0002-0472-3586	Nutrition Third Word; Belgium ministry of development; Flemish Interuniversity Council; French ministry of development	The MISAME/FSP Study Group thanks the community of Karaba and Koho and the families who participated in the study, the health staff of the Hounde district, and the staff of Center Muraz for their logistical and administrative support.; Funding organizations (Nutrition Third Word, The Belgium ministry of development, Flemish Interuniversity Council, and French ministry of development) are acknowledged for their financial support to the study. We acknowledge the MISAME/FSP field investigator team (J-P Ki and V Koudougbo/Valea, sociologists; L Toe and H Lanou, physicians; E Da, obstetrician-gynecologist; G Lougue, pharmacist; B Nagalo and O Guebe, nurses; and B Hien, laboratory technician), and the logistic team (S Ouattara, study coordinator; J Bicaba, administrative assistant; C Kouakou Yameogo; N Diallo, data clerk; M Sanou, driver; and A Hien, pharmacist).	BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P1; CHIMSUKU L, 1994, MEM I OSWALDO CRUZ, V89, P1; Coulibaly SO, 2007, AM J TROP MED HYG, V77, P56, DOI 10.4269/ajtmh.2007.77.56; Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Filler SJ, 2006, J INFECT DIS, V194, P286, DOI 10.1086/505080; Garner P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000169.pub2; Gies S, 2009, TROP MED INT HEALTH, V14, P174, DOI 10.1111/j.1365-3156.2008.02215.x; Guyatt HL, 2004, CLIN MICROBIOL REV, V17, P760, DOI 10.1128/CMR.17.4.760-769.2004; Hamer DH, 2007, J INFECT DIS, V196, P1585, DOI 10.1086/522142; HEYMANN DL, 1990, T ROY SOC TROP MED H, V84, P496, DOI 10.1016/0035-9203(90)90011-3; Huybregts L, 2009, AM J CLIN NUTR, V90, P1593, DOI 10.3945/ajcn.2009.28253; Kayentao K, 2005, J INFECT DIS, V191, P109, DOI 10.1086/426400; Lagerberg RE, 2008, J MIDWIFERY WOM HEAL, V53, P209, DOI 10.1016/j.jmwh.2008.02.012; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; *MIN SANT DIR ET P, 2008, ANN STAT SANT 2007; Parise ME, 1998, AM J TROP MED HYG, V59, P813, DOI 10.4269/ajtmh.1998.59.813; Rogerson SJ, 2007, AM J TROP MED HYG, V77, P14; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8; Sirima SB, 2003, CLIN INFECT DIS, V36, P1374, DOI 10.1086/375077; Sirima SB, 2006, AM J TROP MED HYG, V75, P205, DOI 10.4269/ajtmh.2006.75.205; Tinto H, 2007, AM J TROP MED HYG, V76, P608, DOI 10.4269/ajtmh.2007.76.608; van den Broek NR, 2000, AM J CLIN NUTR, V72, p247S, DOI 10.1093/ajcn/72.1.247S; Verhoeff FH, 1998, ANN TROP MED PARASIT, V92, P141, DOI 10.1080/00034983.1998.11813273; *WHO AFRO, 2004, STRAT FRAM MAL PREV	25	11	12	1	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1475-2875			MALARIA J	Malar. J.	NOV 12	2010	9								324	10.1186/1475-2875-9-324				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	724UB	WOS:000287600600002	24576068	DOAJ Gold, Green Published			2019-03-26	
J	Ouagal, M; Hendrikx, P; Saegerman, C; Berkvens, D				Ouagal, Mahamat; Hendrikx, Pascal; Saegerman, Claude; Berkvens, Dirk			Comparison between active and passive surveillance within the network of epidemiological surveillance of animal diseases in Chad	ACTA TROPICA			English	Article						Epidemiosurveillance; Active surveillance; Passive surveillance; REPIMAT; Rinderpest; Rift Valley Fever	RINDERPEST	A comparative study between passive and active surveillance based on herd visits (villages) was conducted over a period of 24 months. It included 106 surveillance stations of the animal disease epidemiological surveillance network in Chad distributed randomly into 52 stations of active surveillance and 54 stations of passive surveillance. Nine diseases of various vaccination and expected prevalence status were monitored. The active surveillance stations carried out four herd visits monthly to look for the diseases under surveillance and organised four farmers awareness-raising meetings to stimulate them to make disease notifications. The passive surveillance stations held each month four farmer awarenessraising meetings. The suspicions recorded by the stations were consigned to a suspicion form specific to each disease, indicating whether a call from the farmer, a visit to the herd or a awareness-raising meeting was the source. The results showed that, irrespective of surveillance type, all diseases under surveillance, except the rare diseases (Rinderpest and Rift Valley Fever) were reported by the surveillance agents. However, suspicions recorded following farmer calls are significantly more important than suspicions carried out during herd visits or meetings. Nevertheless, a considerable number of suspicions is recorded during awareness-raising meetings. Finally approximately 83% of the herd visits realised by the active surveillance stations showed negative results (no suspicion identified). Passive surveillance stimulated by awareness-raising meetings appears to be better adapted to Chads conditions and less expensive for the surveillance of existing diseases. However, for the rare diseases, other methods of specific active surveillance (such as for example sentinel herds) remain important to complete passive surveillance. (C) 2010 Elsevier B.V. All rights reserved.	[Ouagal, Mahamat; Berkvens, Dirk] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Hendrikx, Pascal] Direct Sci Afssa Lyon, F-69364 Lyon, France; [Ouagal, Mahamat; Saegerman, Claude] ULg, Fac Vet Med, Dept Infect & Parasit Dis, B-4000 Liege, Belgium; [Ouagal, Mahamat] Minist Elevage, Direct Serv Vet, Serv Epidemiol, Ndjamenca, Chad	Berkvens, D (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	dberkvens@itg.be					Bidjeh K, 1995, Rev Elev Med Vet Pays Trop, V48, P295; DABIS F, 1992, EPIDEMIOLOGIE INTERV, P109; Dufour B., 1998, EPIDEMIOL SANTE ANIM, V33, P133; Dufour B, 2005, SURVEILLANCE EPIDEMI; *IAEA, 2000, TECH REP IAEA; James AD, 1998, REV SCI TECH OIE, V17, P810; LEFEVRE PC, 2003, PRINCIPALES MALADIES, P775; Mariner JC, 2003, REV SCI TECH OIE, V22, P837, DOI 10.20506/rst.22.3.1439; Martrenchar A, 1994, Rev Elev Med Vet Pays Trop, V47, P19; *OIE, 1998, TECH REP OIE; OUAGAL M, 2004, EPIDEMIOL SANTE ANIM, V45, P101; PERREAU P., 1964, REV ELEVAGE MED VETERINAIRE PAYS TROP, V17, P587; Ringot D., 2003, EPIDEMIOLOGIE SANTE, V43, P43; Squarzoni C., 2005, EPIDEMIOL SANTE ANIM, V48, P69; Stata, 2007, STAT STAT SOFTW REL; THIAUCOURT F, 2003, PRINCIPALES MALADIES, P795; Toma B., 2001, EPIDEMIOLOGIE APPLIQ	17	9	9	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0001-706X	1873-6254		ACTA TROP	Acta Trop.	NOV	2010	116	2					147	151		10.1016/j.actatropica.2010.07.004				5	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	663FF	WOS:000282867700005	20655291				2019-03-26	
J	D'Alessandro, U				D'Alessandro, Umberto		4 Artemisinin Based Combinations S	ARTEMISININ-BASED COMBINATIONS FOR TREATING UNCOMPLICATED MALARIA IN AFRICAN CHILDREN: THE 4ABC TRIAL	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[D'Alessandro, Umberto] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		1	1	1						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819700002					2019-03-26	
J	Thera, MA; Coulibaly, D; Laurens, MB; Kone, AK; Guindo, AB; Diallo, D; Traore, K; Dolo, A; Tolo, Y; Sissoko, MS; Kouriba, B; Lyke, KE; Takala-Harrison, S; Blackwelder, WC; Vekemans, J; Cohen, J; Dube, T; Lanar, DE; Dutta, S; House, B; Diggs, CL; Soisson, L; Heppner, DG; Doumbo, OK; Plowe, CV; Traore, I; Diarra, I; Niangaly, A; Daou, M; Sissoko, M; Wu, YK; Godeaux, O; Dubois, MC; Ballou, R; Thompson, D; Bennett, JW				Thera, Mahamadou A.; Coulibaly, Drissa; Laurens, Matthew B.; Kone, Abdoulaye K.; Guindo, Ando B.; Diallo, Dapa; Traore, Karim; Dolo, Amagana; Tolo, Youssouf; Sissoko, Mahamadou S.; Kouriba, Bourema; Lyke, Kirsten E.; Takala-Harrison, Shannon; Blackwelder, William C.; Vekemans, Johan; Cohen, Joe; Dube, Tina; Lanar, David E.; Dutta, Sheetij; House, Brent; Diggs, Carter L.; Soisson, Lorraine; Heppner, D. Gray; Doumbo, Ogobara K.; Plowe, Christopher V.; Traore, Idrissa; Diarra, Issa; Niangaly, Amadou; Daou, Modibo; Sissoko, Mady; Wu, Yukun; Godeaux, Olivier; Dubois, Marie-Claude; Ballou, Ripley; Thompson, Darby; Bennett, Jason W.			EXTENDED SAFETY, IMMUNOGENICITY AND EFFICACY OF WALTER REED ARMY INSTITUTE OF RESEARCH'S AMA-1 MALARIA VACCINE (FMP2.1) ADJUVANTED IN GSK BIOLOGICALS' AS02A IN 1-6 YEAR OLD CHILDREN IN BANDIAGARA, MALI	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Thera, Mahamadou A.; Coulibaly, Drissa; Kone, Abdoulaye K.; Guindo, Ando B.; Diallo, Dapa; Traore, Karim; Dolo, Amagana; Tolo, Youssouf; Sissoko, Mahamadou S.; Kouriba, Bourema; Doumbo, Ogobara K.] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali; [Laurens, Matthew B.; Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Ctr Vaccine Dev, Baltimore, MD 21201 USA; [Vekemans, Johan; Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium; [Dube, Tina] EMMES Corp, Rockville, MD USA; [Lanar, David E.; Dutta, Sheetij; House, Brent; Heppner, D. Gray] Walter Reed Army Inst Res, Div Malaria Vaccine Dev, Silver Spring, MD USA; [Diggs, Carter L.; Soisson, Lorraine] US Agcy Int Dev, Malaria Vaccine Dev Program, Washington, DC 20523 USA								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		161	49	49						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819700162					2019-03-26	
J	Talledo, MJ; Lopez, G; Huyghe, JR; Verdonck, K; Gonzales, E; Clark, D; Vanharn, G; Gotuzzo, E; Van Camp, G; Van Laer, L				Talledo, Michael J.; Lopez, Giovanni; Huyghe, Jeroen R.; Verdonck, Kristien; Gonzales, Elsa; Clark, Daniel; Vanharn, Guido; Gotuzzo, Eduardo; Van Camp, Guy; Van Laer, Lut			HOST GENETIC FACTORS AND SUSCEPTIBILITY TO HTLV-1-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS IN PERUVIAN HTLV-1 INFECTED	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Talledo, Michael J.; Lopez, Giovanni; Verdonck, Kristien; Gonzales, Elsa; Gotuzzo, Eduardo] Alexander Von Humboldt Univ Peruana Cayetano Here, Inst Trop Med, Lima, Peru; [Huyghe, Jeroen R.; Van Camp, Guy; Van Laer, Lut] Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium; [Clark, Daniel] Univ Peruana Cayetano Heredia, Labs Invest & Desarrollo LID, Fac Ciencias & Filosofia, Lima, Peru; [Vanharn, Guido] Inst Trop Med, Dept Microbiol, Virol Unit, B-2000 Antwerp, Belgium			Van Camp, Guy/F-3386-2013	Van Camp, Guy/0000-0001-5105-9000				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		337	100	101						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819700337					2019-03-26	
J	Nahum, AM; Erhart, A; Maye, A; Ahounou, D; van Overmeir, C; Menten, J; van Loen, H; Akogbeto, M; Coosemans, M; Massougbodji, A; D'Alessandre, U				Nahum, Alain M.; Erhart, Annette; Maye, Ambroisine; Ahounou, Daniel; van Overmeir, Chantal; Menten, Joris; van Loen, Harry; Akogbeto, Martin; Coosemans, Marc; Massougbodji, Achille; D'Alessandre, Umberto			MALARIA INCIDENCE AND PREVALENCE AMONG CHILDREN LIVING IN A PERI-URBAN AREA ON THE COAST OF BENIN, WEST AFRICA: A LONGITUDINAL STUDY	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Nahum, Alain M.; Ahounou, Daniel; Akogbeto, Martin] Ctr Rech Entomol Cotonou, Cotonou, Benin; [Erhart, Annette; van Overmeir, Chantal; Menten, Joris; van Loen, Harry; Coosemans, Marc; D'Alessandre, Umberto] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; [Maye, Ambroisine] Hop Zone, Abomey Calavi, Benin; [Massougbodji, Achille] Fac Sci Sante, Parasitol Lab, Cotonou, Benin								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		495	148	148						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819700496					2019-03-26	
J	Ravinetto, RM; Talisuna, A; Tinto, H; D'Alessandro, U				Ravinetto, Raffaella M.; Talisuna, Ambrose; Tinto, Halidou; D'Alessandro, Umberto		4 Artemisinin-Based Combinations S	NORTH-SOUTH COLLABORATIONS IN NON-COMMERCIAL CLINICAL RESEARCH: OPEN CHALLENGES	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Ravinetto, Raffaella M.; D'Alessandro, Umberto] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; [Talisuna, Ambrose] Uganda Malaria Surveillance Project, Kampala, Uganda; [Tinto, Halidou] Ctr Muraz, Clin Res Unit, Nanoro, Burkina Faso			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		538	161	161						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819700539					2019-03-26	
J	Vekemans, J; Guerra, Y; Lievens, M; Benns, S; Lapierre, D; Leach, A; Verstraeten, T				Vekemans, Johan; Guerra, Yolanda; Lievens, Marc; Benns, Sarah; Lapierre, Didier; Leach, Amanda; Verstraeten, Tom			ANALYSIS OF AN EXTENSIVE INTEGRATED SAFETY DATABASE OF PEDIATRIC PHASE II CLINICAL TRIALS WITH THE RTS,S/AS CANDIDATE MALARIA VACCINE	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Vekemans, Johan; Guerra, Yolanda; Lievens, Marc; Benns, Sarah; Lapierre, Didier; Leach, Amanda; Verstraeten, Tom] GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		582	175	175						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819700583					2019-03-26	
J	Laurens, MB; Thera, MA; Coulibaly, D; Kone, AK; Guindo, AB; Diallo, DA; Traore, K; Niangaly, A; Dolo, A; Tolo, Y; Sissoko, MS; Kouriba, B; Lyke, KE; Takala-Harrison, S; Blackwelder, WC; Wu, YK; Vekemans, J; Cohen, J; Lanar, DE; Dutta, S; Diggs, CL; Soisson, L; Heppner, DG; Doumbo, OK; Plowe, CV; Traore, I; Diarra, I; Daou, M; Sissoko, M; Godeaux, O; Dubois, MC; Ballou, R; Thompson, D; Dube, T; House, B; Bennett, JW				Laurens, Matthew B.; Thera, Mahamadou A.; Coulibaly, Drissa; Kone, Abdoulaye K.; Guindo, Ando B.; Diallo, Dapa A.; Traore, Karim; Niangaly, Amadou; Dolo, Amagana; Tolo, Youssouf; Sissoko, Mahamadou S.; Kouriba, Bourema; Lyke, Kirsten E.; Takala-Harrison, Shannon; Blackwelder, William C.; Wu, Yukun; Vekemans, Johan; Cohen, Joe; Lanar, David E.; Dutta, Sheetij; Diggs, Carter L.; Soisson, Lorraine; Heppner, D. Gray; Doumbo, Ogobara K.; Plowe, Christopher V.; Traore, Idrissa; Diarra, Issa; Daou, Modibo; Sissoko, Mady; Godeaux, Olivier; Dubois, Marie-Claude; Ballou, Ripley; Thompson, Darby; Dube, Tina; House, Brent; Bennett, Jason W.			EFFICACY OF FMP2.1/AS02A AGAINST GAMETOCYTEMIA IN 1-6 YEAR OLD CHILDREN IN BANDIAGARA, MALI: IMPLICATIONS FOR MALARIA ELIMINATION	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Laurens, Matthew B.; Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Ctr Vaccine Dev, Baltimore, MD 21201 USA; [Thera, Mahamadou A.; Coulibaly, Drissa; Kone, Abdoulaye K.; Guindo, Ando B.; Diallo, Dapa A.; Traore, Karim; Niangaly, Amadou; Dolo, Amagana; Tolo, Youssouf; Sissoko, Mahamadou S.; Kouriba, Bourema; Doumbo, Ogobara K.] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali; [Vekemans, Johan; Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium; [Lanar, David E.; Dutta, Sheetij; Heppner, D. Gray] Walter Reed Army Inst Res, Div Malaria Vaccine Dev, Silver Spring, MD USA; [Diggs, Carter L.; Soisson, Lorraine] US Agcy Int Dev, Malaria Vaccine Dev Program, Washington, DC 20523 USA								0	0	0	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		590	177	177						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819700591					2019-03-26	
J	Adaui, VK; Schnorbusch, K; Zimic, M; Gutierrez, A; Decuypere, S; Vanaerschot, M; De Doncker, S; Maes, I; Llanos-Cuentas, A; Chappuis, F; Arevalo, J; Dujardin, JC				Adaui, Vanessa K.; Schnorbusch, Kathy; Zimic, Mirko; Gutierrez, Andres; Decuypere, Saskia; Vanaerschot, Manu; De Doncker, Simonne; Maes, Ilse; Llanos-Cuentas, Alejandro; Chappuis, Francois; Arevalo, Jorge; Dujardin, Jean-Claude			COMPARISON OF GENE EXPRESSION PATTERNS AMONG LEISHMANIA BRAZILIENSIS CLINICAL ISOLATES DIFFERING IN SUSCEPTIBILITY TO PENTAVALENT ANTIMONY	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Adaui, Vanessa K.; Llanos-Cuentas, Alejandro; Arevalo, Jorge] Univ Peruana Cayetano Heredia, Inst Trop Med Alexander von Humboldt, Lima, Peru; [Schnorbusch, Kathy; Decuypere, Saskia; Vanaerschot, Manu; De Doncker, Simonne; Maes, Ilse; Dujardin, Jean-Claude] Inst Trop Med, B-2000 Antwerp, Belgium; [Zimic, Mirko; Gutierrez, Andres] Univ Peruana Cayetano Heredia, Labs Invest & Desarrollo, Lima, Peru; [Chappuis, Francois] Hop Univ Geneve, Geneva, Switzerland								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		703	209	210						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701072					2019-03-26	
J	Van den Eede, P; Delgado, C; Soto-Calle, VE; Gamboa, D; Anne, J; Erhart, A; D'Alessandro, U				Van den Eede, Peter; Delgado, Christopher; Soto-Calle, Veronica E.; Gamboa, Dionicia; Anne, Jozef; Erhart, Annette; D'Alessandro, Umberto			RECURRENT AND SUB-PATENT INFECTIONS ARE A COMMON OCCURRENCE IN PLASMODIUM VIVAX PATIENTS TREATED WITH CHLOROQUINE AND PRIMAQUINE: A ONE-YEAR COHORT STUDY IN PERU	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Van den Eede, Peter; Erhart, Annette; D'Alessandro, Umberto] Inst Trop Med Antwerp, Antwerp, Belgium; [Delgado, Christopher; Soto-Calle, Veronica E.; Gamboa, Dionicia] Inst Med Trop Alexander Von Humboldt, Lima, Peru; [Anne, Jozef] Catholic Univ Louvain, B-3000 Louvain, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		784	232	232						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701152					2019-03-26	
J	Madrid, E; Dorny, P; Nash, TE; Mahanty, S				Madrid, Elise; Dorny, Pierre; Nash, Theodore E.; Mahanty, Siddhartha			IN VITRO EFFECTS OF ANTHELMINTICS ON TAENIA CRASSICEPS REVEAL LIMITATIONS OF ITS USE AS A MODEL FOR T. SOLIUM CYSTICERCOSIS	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Madrid, Elise; Nash, Theodore E.; Mahanty, Siddhartha] NIH, Bethesda, MD 20892 USA; [Dorny, Pierre] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		792	234	234						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701160					2019-03-26	
J	Ouattara, A; Takala-Harrison, S; Coulibaly, D; Thera, MA; Laurens, MB; Niangaly, A; Saye, R; Dutta, S; Heppner, GD; Soisson, L; Diggs, CL; Vekemans, J; Cohen, J; Leach, A; Blackwelder, WC; Doumbo, OK; Plowe, CV				Ouattara, Amed; Takala-Harrison, Shannon; Coulibaly, Drissa; Thera, Mahamadou A.; Laurens, Matthew B.; Niangaly, Amadou; Saye, Renion; Dutta, Sheetij; Heppner, D. Gray; Soisson, Lorraine; Diggs, Carter L.; Vekemans, Johan; Cohen, Joe; Leach, Amanda; Blackwelder, William C.; Doumbo, Ogobara K.; Plowe, Christopher V.			ALLELE-SPECIFIC EFFICACY OF THE MONOVALENT APICAL MEMBRANE ANTIGEN 1 (AMA1) MALARIA VACCINE FMP2.1/AS02A	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Laurens, Matthew B.; Plowe, Christopher V.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Howard Hughes Med Inst, Baltimore, MD 21201 USA; [Coulibaly, Drissa; Thera, Mahamadou A.; Niangaly, Amadou; Saye, Renion; Doumbo, Ogobara K.] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali; [Dutta, Sheetij; Heppner, D. Gray] Walter Reed Army Inst Res, Div Malaria Vaccine Dev, Silver Spring, MD USA; [Soisson, Lorraine; Diggs, Carter L.] US Agcy Int Dev, Malaria Vaccine Dev Program, Washington, DC 20523 USA; [Vekemans, Johan; Cohen, Joe; Leach, Amanda] GlaxoSmithKline Biol, Rixensart, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		803	238	238						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701171					2019-03-26	
J	Soto-Calle, VE; Contreras, JJ; Erhart, A; Llanos-Cuentas, A; Gamboa, D; Speybroeck, N; D'Alessandro, U				Soto-Calle, Veronica E.; Contreras, Juan J.; Erhart, Annette; Llanos-Cuentas, Alejandro; Gamboa, Dionicia; Speybroeck, Niko; D'Alessandro, Umberto			MALARIA EPIDEMIOLOGY IN A SUB-URBAN AREA OF THE PERUVIAN AMAZON REGION	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Soto-Calle, Veronica E.; Contreras, Juan J.; Llanos-Cuentas, Alejandro; Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru; [Erhart, Annette; D'Alessandro, Umberto] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Speybroeck, Niko] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		974	291	291						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701341					2019-03-26	
J							IRAC Public Hlth Team	THE INCREASE IN THE UTILITY AND IMPORTANCE OF BIOMOLECULAR TECHNIQUES IN RESISTANCE MONITORING IN INSECT VECTORS	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[IRAC Public Hlth Team] CropLife Int, Brussels, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		993	297	297						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701360					2019-03-26	
J	Jayaraman, T; Prabhakaran, V; Babu, P; Venkata, RM; Rajshekhar, V; Dorny, P; Muliyi, J; Oommen, A				Jayaraman, T.; Prabhakaran, V.; Babu, P.; Venkata, Raghava M.; Rajshekhar, V.; Dorny, P.; Muliyil, J.; Oommen, A.			EVIDENCE OF ANTIBODY-MEDIATED IMMUNITY AGAINST NEUROCYSTICERCOSIS IN INDIANS	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Jayaraman, T.; Prabhakaran, V.; Babu, P.; Venkata, Raghava M.; Rajshekhar, V.; Muliyil, J.; Oommen, A.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India; [Dorny, P.] Inst Trop Med, B-2000 Antwerp, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		1044	312	312						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701411					2019-03-26	
J	Mahanty, S; Paredes, A; Marzal, M; Dorny, P; Rodriguez, S; Gonzalez, E; Guerra, C; Garcia, H; Nash, T				Mahanty, Siddhartha; Paredes, Adriana; Marzal, Miguel; Dorny, Pierre; Rodriguez, Silvia; Gonzalez, Emico; Guerra, Cristina; Garcia, Hugo; Nash, Theodore		Cysticercosis Working Grp Peru	IN VITRO MORPHOLOGICAL AND BIOCHEMICAL EFFECTS OF PRAZIQUANTEL AND ALBENDAZOLE ON TAENIA SOLIUM CYSTS	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Mahanty, Siddhartha] NIH, Rockville, MD USA; [Paredes, Adriana; Marzal, Miguel; Rodriguez, Silvia; Guerra, Cristina; Garcia, Hugo] Univ Paruana Cayetano Heredia, Lab Expt Immunopathol, Lima, Peru; [Dorny, Pierre] Inst Trop Med, B-2000 Antwerp, Belgium; [Gonzalez, Emico] Univ Nacl Mayor San Marcos, Sch Vet Med, Lima 14, Peru; [Nash, Theodore] NIH, Bethesda, MD 20892 USA; [Cysticercosis Working Grp Peru] Cysticercosis Working Grp Peru, Lima, Peru								0	0	0	0	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		1046	312	313						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701413					2019-03-26	
J	Caljon, G; De Ridder, K; De Baetselier, P; Coosemans, M; Van Den Abbeele, J				Caljon, Guy; De Ridder, Karin; De Baetselier, Patrick; Coosemans, Marc; Van Den Abbeele, Jan			TRYPANOSOMA BRUCEI PARASITES FAVOR THEIR TRANSMISSION BY MODIFYING THE TSETSE FLY SALIVARY COMPOSITION	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Caljon, Guy; De Ridder, Karin; Coosemans, Marc; Van Den Abbeele, Jan] Inst Trop Med Antwerp, Antwerp, Belgium; [De Baetselier, Patrick] Free Univ Brussels, Brussels, Belgium			Caljon, Guy/E-1310-2017; De Baetselier, Patrick/D-3866-2014	Caljon, Guy/0000-0002-4870-3202; 				0	0	0	0	5	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		1082	323	323						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701449					2019-03-26	
J	Veland, N; Valencia, C; Boggild, AK; van der Auwera, G; Dujardin, JC; Arevalo, J				Veland, Nicolas; Valencia, Cristian; Boggild, Andrea K.; van der Auwera, Gert; Dujardin, Jean Claude; Arevalo, Jorge			ALGORITHM PERFORMANCE ASSESSMENT OF PCR AND PCR-RFLP ASSAYS FOR LEISHMANIA VIANNIA SPECIES IDENTIFICATION	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Veland, Nicolas; Valencia, Cristian; Arevalo, Jorge] Univ Peruana Cayetano Heredia, Lima, Peru; [Boggild, Andrea K.] Toronto Gen Hosp, Div Infect Dis, Trop Dis Unit, Toronto, ON, Canada; [van der Auwera, Gert; Dujardin, Jean Claude] Inst Trop Med Prince Leopold, Dept Parasitol, B-2000 Antwerp, Belgium								0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		1087	324	325						2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701454					2019-03-26	
J	Muok, EM; in't Veld, DH; Conesa-Botella, A; Nganga, ZW; Ogola, GOOO; Polman, K; Kestens, L; Karanja, DM; Colebunders, R; Mwinzi, PN				Muok, Erick M.; in't Veld, Diana Huis; Conesa-Botella, Anali; Nganga, Zipporah W.; Ogola, George O. Ogola O.; Polman, Katja; Kestens, Luc; Karanja, Diana M.; Colebunders, Robert; Mwinzi, Pauline N.			DIAGNOSIS OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN SCHISTOSOMIASIS PATIENTS UNDERGOING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN WESTERN KENYA	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Muok, Erick M.; Karanja, Diana M.; Mwinzi, Pauline N.] Kenya Govt Med Res Ctr, Kisumu, Kenya; [in't Veld, Diana Huis; Conesa-Botella, Anali; Polman, Katja; Kestens, Luc; Colebunders, Robert] Inst Trop Med, B-2000 Antwerp, Belgium; [Nganga, Zipporah W.] Jomo Kenyatta Univ, Nairobi, Kenya; [Ogola, George O. Ogola O.] Maseno Univ, Maseno, Kenya								0	0	0	1	1	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		1234	367	367						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701601					2019-03-26	
J	Achan, J; Tibenderana, J; Kyabayinze, D; Mawejje, H; Mujizi, R; Mpeka, B; Talisuna, A; D'Alessandro, U				Achan, Jane; Tibenderana, James; Kyabayinze, Daniel; Mawejje, Henry; Mujizi, Rukaaka; Mpeka, Betty; Talisuna, Ambrose; D'Alessandro, Umberto			SUBOPTIMAL MANAGEMENT OF SEVERE MALARIA CASES IN UGANDAN HEALTH FACILITIES: A CROSS SECTIONAL SURVEY	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Meeting Abstract	59th Annual Meeting of the American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)	NOV 03-07, 2010	Atlanta, GA	Amer Soc Trop Med & Hyg (ASTMH)					[Achan, Jane] Makerere Univ, Sch Med, Kampala, Uganda; [Tibenderana, James; Kyabayinze, Daniel; Mawejje, Henry; Mujizi, Rukaaka; Mpeka, Betty] Malaria Consortium, Kampala, Uganda; [Talisuna, Ambrose] Makerere Univ, Sch Publ Hlth, Kampala, Uganda; [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium			D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009				0	0	0	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2010	83	5		S		1315	391	391						1	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	832QF	WOS:000295819701682					2019-03-26	
J	t'Kindt, R; Scheltema, RA; Jankevics, A; Brunker, K; Rijal, S; Dujardin, JC; Breitling, R; Watson, DG; Coombs, GH; Decuypere, S				t'Kindt, Ruben; Scheltema, Richard A.; Jankevics, Andris; Brunker, Kirstyn; Rijal, Suman; Dujardin, Jean-Claude; Breitling, Rainer; Watson, David G.; Coombs, Graham H.; Decuypere, Saskia			Metabolomics to Unveil and Understand Phenotypic Diversity between Pathogen Populations	PLOS NEGLECTED TROPICAL DISEASES			English	Article							LEISHMANIA-DONOVANI PROMASTIGOTES; LC-MS DATA; PENTAMIDINE-RESISTANT LEISHMANIA; IN-VITRO SUSCEPTIBILITY; VISCERAL LEISHMANIASIS; MASS-SPECTROMETRY; AMPHOTERICIN-B; LIPID-METABOLISM; GENES; MILTEFOSINE	Leishmaniasis is a debilitating disease caused by the parasite Leishmania. There is extensive clinical polymorphism, including variable responsiveness to treatment. We study Leishmania donovani parasites isolated from visceral leishmaniasis patients in Nepal that responded differently to antimonial treatment due to differing intrinsic drug sensitivity of the parasites. Here, we present a proof-of-principle study in which we applied a metabolomics pipeline specifically developed for L. donovani to characterize the global metabolic differences between antimonial-sensitive and antimonial-resistant L. donovani isolates. Clones of drug-sensitive and drug-resistant parasite isolates from clinical samples were cultured in vitro and harvested for metabolomics analysis. The relative abundance of 340 metabolites was determined by ZIC-HILIC chromatography coupled to LTQ-Orbitrap mass spectrometry. Our measurements cover approximately 20% of the predicted core metabolome of Leishmania and additionally detected a large number of lipids. Drug-sensitive and drug-resistant parasites showed distinct metabolic profiles, and unsupervised clustering and principal component analysis clearly distinguished the two phenotypes. For 100 metabolites, the detected intensity differed more than three-fold between the 2 phenotypes. Many of these were in specific areas of lipid metabolism, suggesting that the membrane composition of the drug-resistant parasites is extensively modified. Untargeted metabolomics has been applied on clinical Leishmania isolates to uncover major metabolic differences between drug-sensitive and drug-resistant isolates. The identified major differences provide novel insights into the mechanisms involved in resistance to antimonial drugs, and facilitate investigations using targeted approaches to unravel the key changes mediating drug resistance.	[t'Kindt, Ruben; Dujardin, Jean-Claude; Decuypere, Saskia] Inst Trop Med, Dept Parasitol, Unit Mol Parasitol, B-2000 Antwerp, Belgium; [t'Kindt, Ruben; Brunker, Kirstyn; Watson, David G.; Coombs, Graham H.; Decuypere, Saskia] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland; [Scheltema, Richard A.; Jankevics, Andris; Breitling, Rainer] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Groningen Bioinformat Ctr, Haren, Netherlands; [Jankevics, Andris; Breitling, Rainer] Univ Glasgow, Fac Biomed & Life Sci, Glasgow, Lanark, Scotland; [Rijal, Suman] BP Koirala Inst Hlth Sci, Ghopa, Dharan, Nepal; [Dujardin, Jean-Claude] Univ Antwerp, Dept Biomed Sci, B-2020 Antwerp, Belgium	t'Kindt, R (reprint author), Inst Trop Med, Dept Parasitol, Unit Mol Parasitol, B-2000 Antwerp, Belgium.	sdecuypere@itg.be	Scheltema, Richard/I-3856-2016	Scheltema, Richard/0000-0002-1668-0253; Breitling, Rainer/0000-0001-7173-0922; Decuypere, Saskia/0000-0001-5036-4601; Brunker, Kirstyn/0000-0001-9990-6299	EC [ICA4-CT-2001-10076, 222895]; Genome and Metabolome Initiative of the Institute of Tropical Medicine Antwerp (GeMInI); Marie Curie Intra-European Fellowships (IEF) [DonNA-R-041465]; Baillet-Latour Foundation for Saskia Decuypere, a Netherlands Organisation for Scientific Research (NWO); NWO; Research Foundation Flanders	This work was supported by the EC project LeishNatDrug-R (programme INCO-Dev FP5: contract ICA4-CT-2001-10076), the EC project Kaladrug-R (programme INCO-Dev FP7: grant 222895), the Genome and Metabolome Initiative of the Institute of Tropical Medicine Antwerp (GeMInI, http://www.leishrisk.net/gemini/), FP6 Marie Curie Intra-European Fellowships (IEF) (contract DonNA-R-041465) and the Baillet-Latour Foundation for Saskia Decuypere, a Netherlands Organisation for Scientific Research (NWO)-Vidi grant for RB, an NWO-Vici grant to Ritsert Jansen (University of Groningen) for RAS, and a Research Foundation Flanders Grant for a long stay in Glasgow for RtK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam MZ, 2009, INFECT GENET EVOL, V9, P24, DOI 10.1016/j.meegid.2008.09.005; Alvar J, 2006, ADV PARASIT, V61, P223, DOI 10.1016/S0065-308X(05)61006-8; Atherton HJ, 2006, PHYSIOL GENOMICS, V27, P178, DOI 10.1152/physiolgenomics.00060.2006; Barratt G, 2009, CURR DRUG METAB, V10, P247, DOI 10.2174/138920009787846332; BASINGER MA, 1981, RES COMMUN CHEM PATH, V32, P355; Basselin M, 1998, PARASITOL RES, V84, P78; Basselin M, 1997, PARASITOL RES, V83, P413, DOI 10.1007/s004360050274; Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Breitling Rainer, 2005, Journal of Bioinformatics and Computational Biology, V3, P1171, DOI 10.1142/S0219720005001442; Breitling R, 2006, TRENDS BIOTECHNOL, V24, P543, DOI 10.1016/j.tibtech.2006.10.006; Cauchetier E, 2002, INT J PARASITOL, V32, P1043, DOI 10.1016/S0020-7519(02)00065-6; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Chavali AK, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.15; Christin C, 2008, ANAL CHEM, V80, P7012, DOI 10.1021/ac800920h; de Koning HP, 2005, FEMS MICROBIOL REV, V29, P987, DOI 10.1016/j.femsre.2005.03.004; Doyle MA, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-57; Dunn WB, 2008, PHYS BIOL, V5, DOI 10.1088/1478-3975/5/1/011001; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fahy E, 2007, NUCLEIC ACIDS RES, V35, pW606, DOI 10.1093/nar/gkm324; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; HSUCHEN CC, 1973, BIOCHEM BIOPH RES CO, V51, P972, DOI 10.1016/0006-291X(73)90022-3; Kamleh A, 2008, RAPID COMMUN MASS SP, V22, P1912, DOI 10.1002/rcm.3564; Kamleh MA, 2009, FEBS J, V276, P6798, DOI 10.1111/j.1742-4658.2009.07397.x; Kamleh Muhammad Anas, 2009, Briefings in Functional Genomics & Proteomics, V8, P28, DOI 10.1093/bfgp/eln052; Keller BO, 2008, ANAL CHIM ACTA, V627, P71, DOI 10.1016/j.aca.2008.04.043; Kumar D, 2009, ANTIMICROB AGENTS CH, V53, P835, DOI 10.1128/AAC.01233-08; Laurent T, 2007, INFECT GENET EVOL, V7, P206, DOI 10.1016/j.meegid.2006.08.005; Maltezou HC, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/617521; Mbongo N, 1998, ANTIMICROB AGENTS CH, V42, P352; MOTTRAM JC, 1992, MOL MICROBIOL, V6, P1925, DOI 10.1111/j.1365-2958.1992.tb01365.x; Murray Henry W, 2004, Expert Rev Anti Infect Ther, V2, P279, DOI 10.1586/14787210.2.2.279; Naderer T, 2008, CELL MICROBIOL, V10, P301, DOI 10.1111/j.1462-5822.2007.01096.x; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Olsen JV, 2005, MOL CELL PROTEOMICS, V4, P2010, DOI 10.1074/mcp.T500030-MCP200; Opperdoes FR, 2007, TRENDS PARASITOL, V23, P149, DOI 10.1016/j.pt.2007.02.004; Rakotomanga M, 2007, ANTIMICROB AGENTS CH, V51, P1425, DOI 10.1128/AAC.01123-06; Rijal S, 2007, MICROBES INFECT, V9, P529, DOI 10.1016/j.micinf.2007.01.009; Scalbert A, 2009, METABOLOMICS, V5, P435, DOI 10.1007/s11306-009-0168-0; Scheltema RA, 2009, BIOANALYSIS, V1, P1551, DOI 10.4155/BIO.09.146; Scheltema RA, 2010, PARASITOLOGY, V137, P1291, DOI 10.1017/S0031182009992022; Scheltema RA, 2008, PROTEOMICS, V8, P4647, DOI 10.1002/pmic.200800314; Shah V P, 2000, Pharm Res, V17, P1551, DOI 10.1023/A:1007669411738; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Tintaya KWQ, 2004, J INFECT DIS, V189, P1035, DOI 10.1086/382049; Trygg J, 2007, J PROTEOME RES, V6, P469, DOI 10.1021/pr060594q; van Meirvenne N., 1975, Annales Soc belge Med trop, V55, P25; VANDESOMPELE J, 2002, GENOME BIOL, V7; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; *WHO REG OFF SE AS, 2007, WHO M GUID STAND OP; Windig W, 2005, CHEMOMETR INTELL LAB, V77, P206, DOI 10.1016/j.chemolab.2004.10.008; Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923; Zhang K, 2007, EMBO J, V26, P1094, DOI 10.1038/sj.emboj.7601565; Zhang K, 2010, MOL BIOCHEM PARASIT, V170, P55, DOI 10.1016/j.molbiopara.2009.12.004	54	62	62	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	NOV	2010	4	11							e904	10.1371/journal.pntd.0000904				12	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	687GB	WOS:000284765900045	21152055	DOAJ Gold, Green Published			2019-03-26	
J	Zachariah, R; Tayler-Smith, K; Ngamvithayapong-Yanai, J; Ota, M; Murakami, K; Ohkado, A; Yamada, N; Van den Boogaard, W; Draguez, B; Ishikawa, N; Harries, AD				Zachariah, R.; Tayler-Smith, K.; Ngamvithayapong-Yanai, J.; Ota, M.; Murakami, K.; Ohkado, A.; Yamada, N.; Van den Boogaard, W.; Draguez, B.; Ishikawa, N.; Harries, A. D.			The published research paper: is it an important indicator of successful operational research at programme level?	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						publication; operational research; programme; knowledge	TUBERCULOSIS-CONTROL; COUNTRIES; CAPACITY	Is a published research paper an important indicator of successful operational research at programme level in low-income countries? In academia, publishing in peer-reviewed scientific journals is highly encouraged and strongly pursued for academic recognition and career progression. In contrast, for those who engage in operational research at programme level, there is often no necessity or reward for publishing the results of research studies; it may even be criticized as being an unnecessary detraction from programme-related work. We present arguments to support publishing operational research from low-income countries; we highlight some of the main reasons for failure of publication at programme level and suggest ways forward.	[Zachariah, R.; Tayler-Smith, K.] Med Sans Frontieres, Operat Ctr Brussels, Luxembourg, Luxembourg; [Ngamvithayapong-Yanai, J.; Ota, M.; Murakami, K.; Ohkado, A.; Yamada, N.; Ishikawa, N.] Japan Anti TB Assoc, Res Inst TB, Kiyose, Japan; [Van den Boogaard, W.] Med Sans Frontieres, Luxembourg, Luxembourg; [Harries, A. D.] Int Union TB & Lung Dis, Paris, France; [Harries, A. D.] London Sch Hyg & Trop Med, London WC1, England; [Draguez, B.] Med Sans Frontieres, Operat Ctr Brussels, Brussels, Belgium	Zachariah, R (reprint author), Med Sans Frontieres Brussels Operat Ctr, Med Dept Operat Res, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu					Haines A, 1998, BMJ-BRIT MED J, V317, P72, DOI 10.1136/bmj.317.7150.72; Harries AD, 2003, INT J TUBERC LUNG D, V7, P266; Man JP, 2004, EUR J EPIDEMIOL, V19, P811; *NAP, 2009, BEING SCI GUID RESP; Ohkado A, 2010, INT J TUBERC LUNG D, V14, P371; Ramos JM, 2008, INT J TUBERC LUNG D, V12, P1461; SCHERER RW, 2007, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.MR000005.PUB3; Wolffers I, 1998, LANCET, V351, P1652, DOI 10.1016/S0140-6736(97)10237-9; XUEREF S, 2009, OPERATIONS RES GLOBA; Zachariah R, 2010, INT HEALTH, V2, P1, DOI 10.1016/j.inhe.2009.12.008; Zachariah R, 2009, LANCET INFECT DIS, V9, P711, DOI 10.1016/S1473-3099(09)70229-4	11	17	17	0	8	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2010	15	11					1274	1277		10.1111/j.1365-3156.2010.02630.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	667CA	WOS:000283169000002	20976874	Bronze			2019-03-26	
J	Khanal, B; Rijal, S; Ostyn, B; Picado, A; Gidwani, K; Menten, J; Jacquet, D; Lejon, V; Chappuis, F; Boelaert, M				Khanal, Basudha; Rijal, Suman; Ostyn, Bart; Picado, Albert; Gidwani, Kamlesh; Menten, Joris; Jacquet, Diane; Lejon, Veerle; Chappuis, Francois; Boelaert, Marleen			Serological markers for Leishmania donovani infection in Nepal: agreement between direct agglutination test and rK39 ELISA	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						visceral leishmaniasis; kala-azar; Leishmania donovani; infection markers	LINKED-IMMUNOSORBENT-ASSAY; INDIAN VISCERAL LEISHMANIASIS; RECOMBINANT K-39 ANTIGEN; KALA-AZAR; DIAGNOSIS; ANTIBODY; EPIDEMIOLOGY; DISEASE	Visceral leishmaniasis (VL) is an important vector-borne disease caused by Leishmania donovani in the Indian subcontinent. The actual incidence and role of asymptomatic infections in the region are not well known. We used the direct agglutination test (DAT) and the rK39 ELISA as L. donovani infection markers in 10 VL endemic villages in Nepal. DAT titre distribution showed two subgroups in the population (infected and non-infected individuals), while rK39 did not. The agreement between both tests was moderate (kappa = 0.53; 95% CI 0.49-0.57). More research is needed to develop validated markers for Leishmania infection.	[Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Khanal, Basudha; Rijal, Suman] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Picado, Albert] London Sch Hyg & Trop Med, London WC1, England; [Gidwani, Kamlesh] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Chappuis, Francois] Univ Hosp Geneva, Geneva, Switzerland	Boelaert, M (reprint author), Inst Trop Med, Dept Publ Hlth, Natl Str 155, B-2000 Antwerp, Belgium.	mboelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Picado, Albert/0000-0001-7344-628X; Lejon, Veerle/0000-0002-6795-0962	EU [015374]	We thank Dr S. G. Reed, Infectious Disease Research Institute, Seattle, USA for kindly providing the rk39 antigen. The work was financially supported by EU-funded INCO-DEV KALANET project (EU contract no 015374).	Bern C, 2007, AM J TROP MED HYG, V76, P909; Bhattarai NR, 2009, TROP MED INT HEALTH, V14, P404, DOI 10.1111/j.1365-3156.2009.02242.x; BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775; Carvalho SFG, 2003, AM J TROP MED HYG, V68, P321; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Davis JC, 1999, OECOLOGIA, V119, P247, DOI 10.1007/s004420050783; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; ELHARITH A, 1988, J CLIN MICROBIOL, V26, P1321; HAILU A, 1990, T ROY SOC TROP MED H, V84, P673, DOI 10.1016/0035-9203(90)90141-Z; Jacquet D, 2006, TROP MED INT HEALTH, V11, P1777, DOI 10.1111/j.1365-3156.2006.01743.x; Joshi A., 2008, Journal of Vector Borne Diseases, V45, P105; Koirala S, 2004, TROP MED INT HEALTH, V9, P533, DOI 10.1111/j.1365-3156.2004.01212.x; Kumar R, 2001, CLIN DIAGN LAB IMMUN, V8, P1220, DOI 10.1128/CDLI.8.6.1220-1224.2001; Kurkjian KM, 2005, CLIN DIAGN LAB IMMUN, V12, P1410, DOI 10.1128/CDLI.12.12.1410-1415.2005; Moreno EC, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000536; Pedras MJ, 2008, T ROY SOC TROP MED H, V102, P172, DOI 10.1016/j.trstmh.2007.11.004; Rijal S, 2010, TROP MED INT HEALTH, V15, P21, DOI 10.1111/j.1365-3156.2010.02518.x; Romero HD, 2009, AM J TROP MED HYG, V81, P27; Saha S, 2009, T ROY SOC TROP MED H, V103, P737, DOI 10.1016/j.trstmh.2008.10.006; Schenkel K, 2006, TROP MED INT HEALTH, V11, P1792, DOI 10.1111/j.1365-3156.2006.01735.x; Sinha PK, 2008, ANN TROP MED PARASIT, V102, P119, DOI 10.1179/136485908X252278; Sundar S, 2006, T ROY SOC TROP MED H, V100, P533, DOI 10.1016/j.trstmh.2005.08.018; WESTGARD JO, 1981, CLIN CHEM, V27, P493; Wright P F, 1993, Rev Sci Tech, V12, P435; Zijlstra EE, 1998, CLIN DIAGN LAB IMMUN, V5, P717	25	13	13	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	NOV	2010	15	11					1390	1394		10.1111/j.1365-3156.2010.02631.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	667CA	WOS:000283169000017	21998875	Bronze			2019-03-26	
J	Boelaert, M; Meheus, F; Robays, J; Lutumba, P				Boelaert, M.; Meheus, F.; Robays, J.; Lutumba, P.			Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis	ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY			English	Review							HUMAN AFRICAN TRYPANOSOMIASIS; COST-EFFECTIVENESS ANALYSIS; HIGH-TRANSMISSION FOCI; SODIUM STIBOGLUCONATE; KALA-AZAR; GAMBIENSE TRYPANOSOMIASIS; DONOVANI INFECTION; ENDEMIC AREA; INDIA; BIHAR	Several tropical diseases that are essentially poverty-related have recently gained more attention under the label of 'neglected tropical diseases' or NTD. It is estimated that over 1000 million people currently suffer from one or more NTD. Here, the socio-economic aspects of two NTD - human African trypanosomiasis and human visceral leishmaniasis - are reviewed. Both of these diseases affect the poorest of the poor in endemic countries, cause considerable direct and indirect costs (even though the national control programmes tend to provide free care) and push affected households deeper into poverty.	[Boelaert, M.; Meheus, F.; Robays, J.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Lutumba, P.] Univ Kinshasa, Fac Med, Kinshasa, Zaire; [Lutumba, P.] Natl Inst Biomed Res, Kinshasa, Zaire	Boelaert, M (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, Natl Str 155, B-2000 Antwerp, Belgium.	mboelaert@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Adhikari SR, 2009, HEALTH POLICY PLANN, V24, P129, DOI 10.1093/heapol/czn052; ALI A, 1994, ANN TROP MED PARASIT, V88, P289, DOI 10.1080/00034983.1994.11812869; Alvar J, 2006, TRENDS PARASITOL, V22, P552, DOI 10.1016/j.pt.2006.09.004; Boelaert M, 2009, TROP MED INT HEALTH, V14, P639, DOI 10.1111/j.1365-3156.2009.02279.x; Chappuis F, 2010, EMERG INFECT DIS, V16, P354, DOI 10.3201/eid1602.090967; Das P, 2010, TROP MED INT HEALTH, V15, P4, DOI 10.1111/j.1365-3156.2010.02517.x; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; Dujardin JC, 2008, EMERG INFECT DIS, V14, P1013, DOI 10.3201/eid1407.071589; Gouteux J P, 1987, Med Trop (Mars), V47, P61; GOUTEUX JP, 1990, TROP MED PARASITOL, V41, P49; Griekspoor A, 1999, HEALTH POLICY PLANN, V14, P70, DOI 10.1093/heapol/14.1.70; Hasker E, 2010, TROP MED INT HEALTH, V15, P55, DOI 10.1111/j.1365-3156.2010.02562.x; Holveck JC, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-6; LANCIEN J, 1991, ANN SOC BELG MED TR, V71, P35; LAVEISSIERE C, 1986, Cahiers O.R.S.T.O.M. (Office de la Recherche Scientifique et Technique Outre-Mer) Serie Entomologie Medicale et Parasitologie, V24, P149; Lutumba P, 2005, EMERG INFECT DIS, V11, P1382; Lutumba P, 2007, EMERG INFECT DIS, V13, P248, DOI 10.3201/eid1302.060075; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; Marlet MVL, 2003, T ROY SOC TROP MED H, V97, P667, DOI 10.1016/S0035-9203(03)80099-8; MEHEUS F, 2010, PLOS NEGLEC IN PRESS; Meheus F, 2006, TROP MED INT HEALTH, V11, P1715, DOI 10.1111/j.1365-3156.2006.01732.x; Melaku Y, 2007, AM J TROP MED HYG, V77, P89, DOI 10.4269/ajtmh.2007.77.89; Moore A, 1999, AM J TROP MED HYG, V61, P315, DOI 10.4269/ajtmh.1999.61.315; Murray Christopher J. L., 1996, GLOBAL BURDEN DIS CO; Nightingale S L, 1991, JAMA, V265, P1229, DOI 10.1001/jama.265.10.1229; Olliaro P, 2009, TROP MED INT HEALTH, V14, P918, DOI 10.1111/j.1365-3156.2009.02306.x; Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X; Rijal S, 2006, T ROY SOC TROP MED H, V100, P838, DOI 10.1016/j.trstmh.2005.09.017; Rijal S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2; Rijal S, 2010, TROP MED INT HEALTH, V15, P21, DOI 10.1111/j.1365-3156.2010.02518.x; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; Sarnoff R, 2010, TROP MED INT HEALTH, V15, P42, DOI 10.1111/j.1365-3156.2010.02516.x; SCHAEFER KU, 1995, T ROY SOC TROP MED H, V89, P471, DOI 10.1016/0035-9203(95)90070-5; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; SHARMA AD, 2006, TROP MED INT HEALTH, V11, P757; Sharma BP, 2004, J NEPAL HLTH RES COU, V2, P35; Shaw A P, 2001, Med Trop (Mars), V61, P412; SHAW AP, 1989, SUPPL, V69, P237; Singh SP, 2006, TROP MED INT HEALTH, V11, P899, DOI 10.1111/j.1365-3156.2006.01647.x; Singh SP, 2010, TROP MED INT HEALTH, V15, P12, DOI 10.1111/j.1365-3156.2010.02519.x; Singh VP, 2010, AM J TROP MED HYG, V82, P9, DOI 10.4269/ajtmh.2010.09-0235; Stanghellini A, 2001, TROP MED INT HEALTH, V6, P330, DOI 10.1046/j.1365-3156.2001.00724.x; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Sundar S, 2010, TROP MED INT HEALTH, V15, P50, DOI 10.1111/j.1365-3156.2010.02520.x; Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P429, DOI 10.1016/S0035-9203(00)90130-5; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P156, DOI 10.1016/S0035-9203(00)90255-4; Trouiller P, 2001, TROP MED INT HEALTH, V6, P945, DOI 10.1046/j.1365-3156.2001.00803.x; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; Vanlerberghe V, 2007, TROP MED INT HEALTH, V12, P274, DOI 10.1111/j.1365-3156.2006.01782.x; Veeken H, 2000, TROP MED INT HEALTH, V5, P312, DOI 10.1046/j.1365-3156.2000.00555.x; Welburn S. C., 2004, The trypanosomiases, P219, DOI 10.1079/9780851994758.0219; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826	54	22	23	1	10	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0003-4983			ANN TROP MED PARASIT	Ann. Trop. Med. Parasitol.	OCT	2010	104	7					535	542		10.1179/136485910X12786389891641				8	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	Public, Environmental & Occupational Health; Parasitology; Tropical Medicine	684DU	WOS:000284529100001	21092391				2019-03-26	
J	Dinesh, DS; Das, ML; Picado, A; Roy, L; Rijal, S; Singh, SP; Das, P; Boelaert, M; Coosemans, M				Dinesh, Diwakar Singh; Das, Murari Lal; Picado, Albert; Roy, Lalita; Rijal, Suman; Singh, Shri Prakash; Das, Pradeep; Boelaert, Marleen; Coosemans, Marc			Insecticide Susceptibility of Phlebotomus argentipes in Visceral Leishmaniasis Endemic Districts in India and Nepal	PLOS NEGLECTED TROPICAL DISEASES			English	Article							HIGH-TRANSMISSION FOCI; DIPTERA PSYCHODIDAE; DONOVANI INFECTION; VECTOR-CONTROL; BIHAR INDIA; KALA-AZAR; NETS; EPIDEMIOLOGY; MANAGEMENT; BANGLADESH	Objectives: To investigate the DDT and deltamethrin susceptibility of Phlebotomus argentipes, the vector of Leishmania donovani, responsible for visceral leishmaniasis (VL), in two countries (India and Nepal) with different histories of insecticide exposure. Methods: Standard WHO testing procedures were applied using 4% DDT and 0.05% deltamethrin impregnated papers. The effect of the physiological status (fed and unfed) of females on the outcome of the bioassays was assessed and the optimal time of exposure for deltamethrin was evaluated on a colony population. Field populations from both countries were tested. Results: Fed and unfed females responded in a similar way. For exposure time on field samples 60 min was adopted for both DDT and deltamethrin. In Bihar, knockdown and mortality with DDT was respectively 20 and 43%. In Nepal almost all sand flies were killed, except at the border with Bihar (mortality 62%). With 0.05% deltamethrin, between 96 and 100% of the sand flies were killed in both regions. Conclusions: Based on literature and present data 4% DDT and 0.05% deltamethrin seem to be acceptable discriminating concentrations to separate resistant from susceptible populations. Resistance to DDT was confirmed in Bihar and in a border village of Nepal, but the sand flies were still susceptible in villages more inside Nepal where only synthetic pyrethroids are used for indoor spraying. The low effectiveness of indoor spraying with DDT in Bihar to control VL can be partially explained by this resistance hence other classes of insecticides should be tested. In both countries P. argentipes sand flies were susceptible to deltamethrin.	[Dinesh, Diwakar Singh; Das, Pradeep] Rajendra Mem Res Inst Med Sci, Patna, Bihar, India; [Das, Murari Lal; Roy, Lalita; Rijal, Suman] BP Koirala Inst Hlth Sci, Dharan, Nepal; [Picado, Albert; Boelaert, Marleen; Coosemans, Marc] Inst Trop Med, B-2000 Antwerp, Belgium; [Picado, Albert] London Sch Hyg & Trop Med, London WC1, England; [Singh, Shri Prakash] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India	Dinesh, DS (reprint author), Rajendra Mem Res Inst Med Sci, Patna, Bihar, India.	mcoosemans@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Das, Murari/0000-0001-6816-2389; Picado, Albert/0000-0001-7344-628X	European Union [015374]	The work was financially supported by European Union-funded 6th Framework/INCO-DEV KALANET project (EU contract no 015374). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander B, 2003, MED VET ENTOMOL, V17, P1, DOI 10.1046/j.1365-2915.2003.00420.x; Alexander B, 2009, TROP MED INT HEALTH, V14, P1272, DOI 10.1111/j.1365-3156.2009.02371.x; Amalraj D. Dominic, 1999, Journal of Communicable Diseases, V31, P177; Burniston I, 2010, J MED ENTOMOL, V47, P902, DOI 10.1603/ME09184; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; Dinesh DS, 2008, TROP MED INT HEALTH, V13, P953, DOI 10.1111/j.1365-3156.2008.02096.x; Donnelly MJ, 2009, TRENDS PARASITOL, V25, P213, DOI 10.1016/j.pt.2009.02.007; JOSHI AB, 2003, J NEPAL HLTH RES COU, V1, P1; Kishore K, 2004, Journal of Communicable Diseases, V36, P41; Koirala S, 2004, TROP MED INT HEALTH, V9, P533, DOI 10.1111/j.1365-3156.2004.01212.x; Kumar V, 2009, J VECTOR DIS, V46, P225; Mondal D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000355; Mondal D, 2008, HEALTH POLICY, V87, P369, DOI 10.1016/j.healthpol.2008.01.011; Ostyn B, 2008, TROP MED INT HEALTH, V13, P1073, DOI 10.1111/j.1365-3156.2008.02110.x; Picado A, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000587; Rijal S, 2010, TROP MED INT HEALTH, V15, P21, DOI 10.1111/j.1365-3156.2010.02518.x; Singh R, 2001, B WORLD HEALTH ORGAN, V79, P793; Singh SP, 2010, TROP MED INT HEALTH, V15, P12, DOI 10.1111/j.1365-3156.2010.02519.x; Surendran SN, 2005, B ENTOMOL RES, V95, P371, DOI 10.1079/BER2005368; Swaminath CS, 2006, INDIAN J MED RES, V123, pA473; *WHO TEST PROC INS, BIOEFF PERS INS TREA; *WHOPES, 2009, WHO REC LONG LAST IN	22	40	40	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	OCT	2010	4	10							e859	10.1371/journal.pntd.0000859				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	672CC	WOS:000283559600027	21049013	DOAJ Gold, Green Published			2019-03-26	
J	Dujardin, JC; Herrera, S; do Rosario, V; Arevalo, J; Boelaert, M; Carrasco, HJ; Correa-Oliveira, R; Garcia, L; Gotuzzo, E; Gyorkos, TW; Kalergis, AM; Kouri, G; Larraga, V; Lutumba, P; Garcia, MAM; Manrique-Saide, PC; Modabber, F; Nieto, A; Pluschke, G; Robello, C; de Arias, AR; Rumbo, M; Preciado, JIS; Sundar, S; Torres, J; Torrico, F; Van der Stuyft, P; Victoir, K; Olesen, OF				Dujardin, Jean-Claude; Herrera, Socrates; do Rosario, Virgilio; Arevalo, Jorge; Boelaert, Marleen; Carrasco, Hernan J.; Correa-Oliveira, Rodrigo; Garcia, Lineth; Gotuzzo, Eduardo; Gyorkos, Theresa W.; Kalergis, Alexis M.; Kouri, Gustavo; Larraga, Vicente; Lutumba, Pascal; Macias Garcia, Maria Angeles; Manrique-Saide, Pablo C.; Modabber, Farrokh; Nieto, Alberto; Pluschke, Gerd; Robello, Carlos; Rojas de Arias, Antonieta; Rumbo, Martin; Santos Preciado, Jose Ignacio; Sundar, Shyam; Torres, Jaime; Torrico, Faustino; Van der Stuyft, Patrick; Victoir, Kathleen; Olesen, Ole F.			Research Priorities for Neglected Infectious Diseases in Latin America and the Caribbean Region	PLOS NEGLECTED TROPICAL DISEASES			English	Article							TROPICAL DISEASES; PLASMODIUM-VIVAX; POPULATIONS; MALARIA; HEALTH		[Dujardin, Jean-Claude; Boelaert, Marleen; Van der Stuyft, Patrick] Inst Trop Med, B-2000 Antwerp, Belgium; [Herrera, Socrates] Univ Valle, Cali, Colombia; [do Rosario, Virgilio] Univ Nova Lisboa, Inst Higiene & Med Trop, P-1200 Lisbon, Portugal; [Arevalo, Jorge; Gotuzzo, Eduardo] Inst Med Trop A von Humboldt, Lima, Peru; [Carrasco, Hernan J.] Cent Univ Venezuela, Caracas, Venezuela; [Correa-Oliveira, Rodrigo] Fiocruz MS, Belo Horizonte, MG, Brazil; [Garcia, Lineth; Torrico, Faustino] Univ Mayor de San Simon, Cochabamba, Bolivia; [Gyorkos, Theresa W.] McGill Univ, Montreal, PQ, Canada; [Kalergis, Alexis M.] Pontificia Univ Catolica Chile, Santiago, Chile; [Kouri, Gustavo] Inst Pedro Kouri, Havana, Cuba; [Larraga, Vicente] Ctr Invest Biol CSIC, Madrid, Spain; [Lutumba, Pascal] Natl Inst Biomed Res, Kinshasa, Zaire; [Macias Garcia, Maria Angeles] EULARINET, Minist Ciencia & Innovac Espana, Madrid, Spain; [Manrique-Saide, Pablo C.] Univ Autonoma Yucatan, Yucatan, Mexico; [Modabber, Farrokh] Drugs Neglected Dis Initiat, Geneva, Switzerland; [Nieto, Alberto] Univ Republica, Montevideo, Uruguay; [Pluschke, Gerd] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Pluschke, Gerd] Univ Basel, Basel, Switzerland; [Robello, Carlos] Inst Pasteur Montevideo, Montevideo, Uruguay; [Robello, Carlos] Fac Med, Montevideo, Uruguay; [Rojas de Arias, Antonieta] Panamer Hlth Org, Ctr Desarrollo Invest Cient, Asuncion, Paraguay; [Rumbo, Martin] Univ Nacl La Plata, La Plata, Buenos Aires, Argentina; [Santos Preciado, Jose Ignacio] Univ Nacl Autonoma Mexico, Fac Med, Mexico City 04510, DF, Mexico; [Sundar, Shyam] Banaras Hindu Univ, Varanasi 221005, Uttar Pradesh, India; [Torres, Jaime] Univ Cent Caracas, Inst Med Trop, Caracas, Venezuela; [Victoir, Kathleen] Inst Pasteur, Paris, France; [Olesen, Ole F.] EU Commiss, Brussels, Belgium	Dujardin, JC (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	jcdujardin@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Rojas de Arias, Antonieta/0000-0002-6207-1870; Arevalo, Jorge/0000-0003-3837-2849; CARRASCO, HERNAN JOSE/0000-0001-7500-0927	Directorate-General for Development Cooperation of the Belgian Government [95502]; European Commission	This work was supported by the Directorate-General for Development Cooperation of the Belgian Government (framework agreement 03, project 95502) and the European Commission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ault SK, 2007, MEM I OSWALDO CRUZ, V102, P99, DOI 10.1590/S0074-02762007005000094; BARTEN F, 2008, INEQUIDAD SALUD HACI; Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059; Bochud PY, 2008, NEW ENGL J MED, V359, P1766, DOI 10.1056/NEJMoa0802629; Choi EH, 2003, J INFECT DIS, V187, P1153, DOI 10.1086/368345; Dujardin JC, 2009, INFECT GENET EVOL, V9, P290, DOI 10.1016/j.meegid.2008.11.007; ELLIS M, 2002, MOL IMMUNOL, V1096, P1; Franco-Paredes C, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-11; Galinski MR, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S9; Guhl F, 2009, MEM I OSWALDO CRUZ, V104, P71, DOI 10.1590/S0074-02762009000900012; Hall N, 2007, J EXP BIOL, V210, P1518, DOI 10.1242/jeb.001370; Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000300; Jimenez J, 2007, LANCET, V370, P1598, DOI 10.1016/S0140-6736(07)61672-9; Kalluri S, 2007, PLOS PATHOG, V3, P1361, DOI 10.1371/journal.ppat.0030116; Molyneux DH, 2010, LANCET, V375, P3, DOI 10.1016/S0140-6736(09)61914-0; Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X; Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79; Rabinowicz PD, 2001, GENOME RES, V11, P319, DOI 10.1101/gr.179501; RUPA DS, 1991, ENVIRON RES, V55, P123, DOI 10.1016/S0013-9351(05)80168-9; Sonoda IV, 2009, MEM I OSWALDO CRUZ, V104, P668, DOI 10.1590/S0074-02762009000400025; *TDR, 2010, TRAIN GUID PUBL; 2007, MEM I O CRUZ S1, V102, P1	22	18	18	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	OCT	2010	4	10							e780	10.1371/journal.pntd.0000780				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	672CC	WOS:000283559600004	21049009	DOAJ Gold, Green Published			2019-03-26	
J	van Griensven, J; Sopheak, T; Aseffa, Y; Van Damme, W; Lynen, L				van Griensven, Johan; Sopheak, Thai; Aseffa, Yibeltal; Van Damme, Wim; Lynen, Lutgarde			Attrition of HIV-infected individuals not yet eligible for antiretroviral treatment: do we care?	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Letter									[van Griensven, Johan; Van Damme, Wim; Lynen, Lutgarde] Inst Trop Med, B-2000 Antwerp, Belgium; [Sopheak, Thai] Sihanouk Hosp Ctr HOPE, Dept Infect Dis, Phnom Penh, Cambodia; [Aseffa, Yibeltal] Fed Minist Hlth, Med Serv Directorate, Addis Ababa, Ethiopia	van Griensven, J (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium.	jvangriensven@itg.be	Lynen, Lutgarde/A-1212-2014; Van Damme, Wim/F-7404-2011	Lynen, Lutgarde/0000-0001-7183-4895; 			Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Hallett TB, 2008, PLOS MED, V5, P403, DOI 10.1371/journal.pmed.0050053; IULIANO D, 2010, 17 C RETR OPP INF 16; Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d; Losina E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000173; Tayler-Smith K, 2010, T ROY SOC TROP MED H, V104, P313, DOI 10.1016/j.trstmh.2010.01.007; Thai S, 2009, TROP MED INT HEALTH, V14, P1048, DOI 10.1111/j.1365-3156.2009.02334.x; VANGRIENSVEN J, 2008, 4 ANN HIV AIDS RES E; World Health Organization, 2008, ESS PREV CAR INT AD	9	4	4	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	OCT	2010	104	10					690	692		10.1016/j.trstmh.2010.07.006				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	663AF	WOS:000282854700011	20800253				2019-03-26	
J	Ejara, ED; Lynen, L; Boelaert, M; van Griensven, J				Ejara, Ermias Diro; Lynen, Lutgarde; Boelaert, Marleen; van Griensven, Johan			Challenges in HIV and visceral Leishmania co-infection: future research directions	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Letter							NORTHWEST ETHIOPIA; DIAGNOSIS; THERAPY		[Ejara, Ermias Diro] Univ Gondar, Gondar, Ethiopia; [Lynen, Lutgarde; Boelaert, Marleen; van Griensven, Johan] Inst Trop Med, B-2000 Antwerp, Belgium	Ejara, ED (reprint author), Univ Gondar, Gondar, Ethiopia.	ermi_diro@yahoo.com	Boelaert, Marleen/E-2698-2012; Lynen, Lutgarde/A-1212-2014	Boelaert, Marleen/0000-0001-8051-6776; Lynen, Lutgarde/0000-0001-7183-4895			Barat C, 2007, J INFECT DIS, V195, P236, DOI 10.1086/510398; Diro E, 2007, T ROY SOC TROP MED H, V101, P908, DOI 10.1016/j.trstmh.2007.05.002; GELANEW T, 2010, BRIT J DERM IN PRESS; Hurissa Z, 2010, TROP MED INT HEALTH, V15, P848, DOI 10.1111/j.1365-3156.2010.02550.x; Izri MA, 1996, B WORLD HEALTH ORGAN, V74, P91; Laguna F, 2003, J ANTIMICROB CHEMOTH, V52, P464, DOI 10.1093/jac/dkg356; LEJON V, 2010, J CLIN MICR IN PRESS; RIBEIRO TT, 1992, J ACQ IMMUN DEF SYND, V6, P319; Trudel N, 2008, J INFECT DIS, V198, P1292, DOI 10.1086/592280; van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6; Waheed AA, 2008, J VIROL, V82, P9776, DOI 10.1128/JVI.00917-08; *WHO, 2007, WHO 5 CONS M LEISHM; Zolopa AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005575	13	6	6	1	2	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	OCT	2010	15	10					1266	1267		10.1111/j.1365-3156.2010.02612.x				2	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	649UC	WOS:000281798400022	20723183	Bronze			2019-03-26	
J	Reichard, M; Watters, BR; Wildekamp, RH; Sonnenberg, R; Nagy, B; Polacik, M; Valdesalici, S; Cellerino, A; Cooper, BJ; Hengstler, H; Rosenstock, J; Sainthouse, I				Reichard, Martin; Watters, Brian R.; Wildekamp, Rudolf H.; Sonnenberg, Rainer; Nagy, Bela; Polacik, Matej; Valdesalici, Stefano; Cellerino, Alessandro; Cooper, Barry J.; Hengstler, Holger; Rosenstock, John; Sainthouse, Ian			Potential negative impacts and low effectiveness in the use of African annual killifish in the biocontrol of aquatic mosquito larvae in temporary water bodies	PARASITES & VECTORS			English	Letter							NOTHOBRANCHIUS-KORTHAUSAE CYPRINODONTIFORMES; HETEROSPECIFIC MALES; SHEEPSHEAD MINNOW; SEXUAL SELECTION; PECOS PUPFISH; FRESH-WATER; FISH; POPULATIONS; HYBRIDIZATION; VARIEGATUS	Commentary and discussion on a recent paper promoting the use of Nothobranchius guentheri, a small African annual fish from the Island of Zanzibar as a tool to control mosquito larvae in temporary bodies of freshwater throughout Africa is presented. Arguments on major points; ( 1) expected low success of annual fish introductions, ( 2) low success of mosquito control in the field, ( 3) ecological threats, and ( 4) ethical issues are detailed. Despite serious problems with mosquito borne diseases in tropical Africa and elsewhere, we encourage responsible means of biological control of parasite vectors. We show that effectiveness of Nothobranchius translocations is low ( the previous attempts failed), likelihood of effective mosquito larvae control under field condition is negligible and ecological threats from Nothobranchius translocations from within and outside the naturally occurring range are serious. We advocate against the proposed next step of the project, i.e. field trials in Tanzania.	[Reichard, Martin; Polacik, Matej] Acad Sci Czech Republic, Inst Vertebrate Biol, CS-60365 Brno, Czech Republic; [Watters, Brian R.] Univ Regina, Dept Geol, Regina, SK S4S 0A2, Canada; [Wildekamp, Rudolf H.] Musee Royal Afr Cent, B-3080 Tervuren, Belgium; [Sonnenberg, Rainer] Zool Forsch Museum Alexander Koenig, D-53113 Bonn, Germany; [Cellerino, Alessandro] Fritz Lipmann Inst, Leibniz Inst Age Res, D-07745 Jena, Germany; [Cellerino, Alessandro] Scuola Normale Super Pisa, I-56100 Pisa, Italy; [Cooper, Barry J.] Cornell Univ, Coll Vet Med, Ithaca, NY 14853 USA; [Rosenstock, John] Scandinavian Killifish Assoc, Copenhagen, Denmark	Reichard, M (reprint author), Acad Sci Czech Republic, Inst Vertebrate Biol, Kvetna 8, CS-60365 Brno, Czech Republic.	reichard@ivb.cz	Polacik, Matej/A-8260-2010; Reichard, Martin/C-6563-2009; Cellerino, Alessandro/M-9380-2013; ASCR, IVB/A-9883-2011	Cellerino, Alessandro/0000-0003-3834-0097; 			BAHAR R, 1974, EMMAL124SOM2001 R; BLAUSTEIN L, 1992, HYDROBIOLOGIA, V232, P219, DOI 10.1007/BF00013707; Costa WJEM, 2009, ICHTHYOL EXPLOR FRES, V20, P111; Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443; DJELANTIK AAM, 1975, 137 EMMAL; Garcia-Berthou E, 2005, CAN J FISH AQUAT SCI, V62, P453, DOI 10.1139/F05-017; Ghosh SK, 2005, T ROY SOC TROP MED H, V99, P101, DOI 10.1016/j.trstmh.2004.03.009; HAAS R, 1976, EVOLUTION, V30, P614, DOI 10.1111/j.1558-5646.1976.tb00938.x; HAAS R, 1979, VBC18EMMAL164; Howard AFV, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-199; Kodric-Brown A, 2001, BIOL J LINN SOC, V74, P541, DOI 10.1006/bijl.2001.0598; Kodric-Brown A, 2004, BEHAV ECOL SOCIOBIOL, V56, P116, DOI 10.1007/s00265-004-0761-1; KOVCHAZOV G, 1974, EMMAL128, V128; Krkosek M, 2007, SCIENCE, V318, P1772, DOI 10.1126/science.1148744; Laufer G, 2009, NEOTROP ICHTHYOL, V7, P77, DOI 10.1590/S1679-62252009000100010; Leyse KE, 2004, BIOL CONSERV, V118, P57, DOI 10.1016/j.biocon.2003.07.008; LOM J, 1995, DIS AQUAT ORGAN, V21, P239, DOI 10.3354/dao021239; Louca V, 2009, J MED ENTOMOL, V46, P546, DOI 10.1603/033.046.0320; MARKOFSKY J, 1979, COLUMBIA U SEMINARS, V12, pH1; Matias JR, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-46; MATIAS JR, 1984, EXPERIENTIA, V40, P753, DOI 10.1007/BF01949761; MATIAS JR, 2009, POSEIDON SCI FDN GOV; Mooney HA, 2001, P NATL ACAD SCI USA, V98, P5446, DOI 10.1073/pnas.091093398; MYERS GS, 1952, AQUARIUM J, V22, P145; NEUMANN W, 2008, PRACHTGRUNDKRPFLINGE, V9; Polacik M, 2010, J FISH BIOL, V77, P754, DOI 10.1111/j.1095-8649.2010.02717.x; *POS OC SCI INC, POS SCI; Reichard M, 2009, J FISH BIOL, V74, P198, DOI 10.1111/j.1095-8649.2008.02129.x; Reichard M, 2010, BIOL J LINN SOC, V100, P62, DOI 10.1111/j.1095-8312.2010.01406.x; Roseman IJ, 2004, COGNITION EMOTION, V18, P1, DOI 10.1080/02699930244000390; Rosenfield JA, 2003, J EVOLUTION BIOL, V16, P595, DOI 10.1046/j.1420-9101.2003.00557.x; RYAN MJ, 1987, SCIENCE, V236, P595, DOI 10.1126/science.236.4801.595; TERZIBASI E, 2008, PLOS ONE, V3, P3866; Vanderplank F. L., 1967, New Scientist, V33, P42; VANDERPLANK FL, 1941, AFRICA, V17, P431; WATTERS B, 2009, J AM KILLIFISH ASS, V42, P58; WATTERS B, 2003, REPORT INVESTIGATION; WATTERS BR, 2006, J AM KILLIFISH ASS, V39, P14; WATTERS BR, 2006, DISPERSAL NOTHOBRANC, V39, P137; Wellborn GA, 1996, ANNU REV ECOL SYST, V27, P337, DOI 10.1146/annurev.ecolsys.27.1.337; Wildekamp R.H., 1992, Ichthyological Exploration of Freshwaters, V3, P1; WILDEKAMP RH, 1983, MAL198EMVBC41SOMMPD; WILDEKAMP RH, 2004, AMERICAN KILLIFISH A, V4; WILDEKAMP RH, 1990, ICHTHYOL EXPLOR FRES, V1, P16; Willems KJ, 2005, J VECTOR ECOL, V30, P87; Wong BBM, 2005, BEHAV ECOL, V16, P818, DOI 10.1093/beheco/ari058	46	6	9	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	SEP 16	2010	3								89	10.1186/1756-3305-3-89				6	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	658PF	WOS:000282501200002	20846414	DOAJ Gold, Green Published			2019-03-26	
J	Nahum, A; Erhart, A; Maye, A; Ahounou, D; van Overmeit, C; Menten, J; van Loen, H; Akogbeto, M; Coosemans, M; Massougbodji, A; D'Alessandro, U				Nahum, Alain; Erhart, Annette; Maye, Ambroisine; Ahounou, Daniel; van Overmeit, Chantal; Menten, Joris; van Loen, Harry; Akogbeto, Martin; Coosemans, Marc; Massougbodji, Achille; D'Alessandro, Umberto			Malaria Incidence and Prevalence Among Children Living in a Peri-Urban Area on the Coast of Benin, West Africa: A Longitudinal Study	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							URBAN MALARIA; PLASMODIUM-FALCIPARUM; APPRAISAL RUMA; UGANDAN CHILDREN; CLINICAL MALARIA; RISK-FACTORS; UNTREATED BEDNETS; FOREST MALARIA; EPIDEMIOLOGY; MORBIDITY	Clinical malaria incidence was determined over 18 months in a cohort of 553 children living in a pen-urban area near Cotonou Three cross-sectional surveys were also carried out Malaria incidence showed a marked seasonal distribution with two peaks the first corresponding to the long rainy season, and the second corresponding to the overflowing of Lake Nokoue. The overall Plasmodium falciparum incidence rate was estimated at 84/1,000 pet son-months, and its prevalence was estimated at over 40% in the two first surveys and 68 9% in the third survey. Multivariate analysis showed that girls and people living in closed houses had a lower risk of clinical malaria Bed net use was associated with a lower risk of malaria infection Conversely, children of families owing a pirogue were at higher risk of clinical malaria Considering the high pyrethroids resistance, indoor residual spraying with either a carbamate or an organophospate insecticide may have a major impact on the malaria burden	[Nahum, Alain] CREC, Cotonou, Benin; Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium; Hop Zone, Abomey Calavt, Benin; Univ Natl Benin, Fac Sci Sante, Parasitol Lab, Cotonou, Benin	Nahum, A (reprint author), CREC, 06 BP 2604, Cotonou, Benin.		D'Alessandro, Umberto/D-3457-2015	D'Alessandro, Umberto/0000-0001-6341-5009	Benin Ministry of Health	This study was funded by the Benin Ministry of Health through the Population Health Project	Akogbeto M, 1995, ANN SOC BELG MED TR, V75, P219; AKOGBETO M, 1992, REV EPIDEMIOL SANTE, V40, P233; Akogbeto M., 2000, Cahiers d'Etudes et de Recherches Francophones/Sante, V10, P267; Akogbeto M., 1992, Parassitologia (Rome), V34, P147; Baragatti M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-13; CHIPPAUX JP, 1992, REV EPIDEMIOL SANTE, V40, P240; Clark TD, 2008, J INFECT DIS, V198, P393, DOI 10.1086/589778; Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X; CUZICK J, 1990, J ROY STAT SOC B MET, V52, P73; Doannio J M C, 2006, Med Trop (Mars), V66, P45; Dolo A, 2005, AM J TROP MED HYG, V72, P243, DOI 10.4269/ajtmh.2005.72.243; Erhart A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-58; Erhart A, 2004, AM J TROP MED HYG, V70, P110, DOI 10.4269/ajtmh.2004.70.110; GENTON B, 1994, ANN TROP MED PARASIT, V88, P263, DOI 10.1080/00034983.1994.11812866; Global Malaria Programme, 2006, IND RES SPRAYING US; Greenwood B.M., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P25, DOI 10.1016/0035-9203(89)90599-3; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; Greenwood Brian, 2008, Travel Med Infect Dis, V6, P173, DOI 10.1016/j.tmaid.2007.11.003; Greenwood BM, 2008, J CLIN INVEST, V118, P1266, DOI 10.1172/JCI33996; GYAPONG M, 2007, WHO BEHALF SPECIAL P; Hopkins H, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-134; Konradsen F, 2003, AM J TROP MED HYG, V68, P177, DOI 10.4269/ajtmh.2003.68.177; Lautze J, 2007, TROP MED INT HEALTH, V12, P982, DOI 10.1111/j.1365-3156.2007.01878.x; Lindsay SW, 2003, TROP MED INT HEALTH, V8, P512, DOI 10.1046/j.1365-3156.2003.01059.x; Lindsay SW, 2002, TRENDS PARASITOL, V18, P510, DOI 10.1016/S1471-4922(02)02382-6; MACKINNON MJ, 2005, PLOS MED, V2, P340; Matthys B, 2006, AM J TROP MED HYG, V75, P1223, DOI 10.4269/ajtmh.2006.75.1223; *MIN SANT, 1992, PROGR NAT LUTT CONTR; *MIN TRANSP, 2003, REP DONN MET 2003; Ministerio de Agricultura y Desarrollo Rural Instituto Interamericano de Cooperacion para la Agricultura Banco Mundial, 2005, PHYS STRENGTH MOV AB, P1; N'Guessan R, 2007, EMERG INFECT DIS, V13, P199, DOI 10.3201/eid1302.060631; Nahum A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-37; Njama D, 2003, TROP MED INT HEALTH, V8, P685, DOI 10.1046/j.1365-3156.2003.01060.x; Omi K, 2003, AM J HUM GENET, V72, P364, DOI 10.1086/346091; *ORG MOND SANT, 2001, COLL DONN BAS MORB M; Parikh S, 2004, AM J TROP MED HYG, V71, P750, DOI 10.4269/ajtmh.2004.71.750; Peterson I, 2009, AM J TROP MED HYG, V80, P103, DOI 10.4269/ajtmh.2009.80.103; Phimpraphi W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003887; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; RANFORDCARTWRIGHT LC, 1993, PARASITOLOGY, V107, P11, DOI 10.1017/S003118200007935X; Rogier C, 2001, Med Trop (Mars), V61, P27; Saute F, 2003, T ROY SOC TROP MED H, V97, P655, DOI 10.1016/S0035-9203(03)80097-4; Snow RW, 1998, T ROY SOC TROP MED H, V92, P381, DOI 10.1016/S0035-9203(98)91056-2; Sokhna C, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-43; Staedke SG, 2003, AM J TROP MED HYG, V69, P244, DOI 10.4269/ajtmh.2003.69.244; Thera MA, 2000, TROP MED INT HEALTH, V5, P876, DOI 10.1046/j.1365-3156.2000.00652.x; VELEMA JP, 1991, T ROY SOC TROP MED H, V85, P430, DOI 10.1016/0035-9203(91)90206-E; Wang GS, 2005, THEOR APPL FRACT MEC, V43, P1, DOI 10.1016/j.tafmec.2004.12.001; Wang SJ, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-45; Wang SJ, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-29; Wang SJ, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-28; Wang SJ, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-40; WHO, 2003, ASS MON ANT DRUG EFF; *WHO, 2000, T R SOC TROP MED S1, V94, P1; Ye Y, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-8; Ye Y, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-46	56	14	14	0	5	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	SEP	2010	83	3					465	473		10.4269/ajtmh.2010.09-0611				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	645SZ	WOS:000281487800006	20810805	Green Published, Bronze			2019-03-26	
J	de Jong, BC; Antonio, M; Gagneux, S				de Jong, Bouke C.; Antonio, Martin; Gagneux, Sebastien			Mycobacterium africanum-Review of an Important Cause of Human Tuberculosis in West Africa	PLOS NEGLECTED TROPICAL DISEASES			English	Review							PULMONARY TUBERCULOSIS; GENETIC DIVERSITY; MOLECULAR EPIDEMIOLOGY; GENOMIC DELETIONS; TUBERCLE-BACILLI; DRUG-RESISTANCE; COMPLEX STRAINS; BURKINA-FASO; VIRULENCE; THIACETAZONE	Mycobacterium africanum consists of two phylogenetically distinct lineages within the Mycobacterium tuberculosis complex, known as M. africanum West African 1 and M. africanum West African 2. These lineages are restricted to West Africa, where they cause up to half of human pulmonary tuberculosis. In this review we discuss the definition of M. africanum, describe the prevalence and restricted geographical distribution of M. africanum West African 1 and 2, review the occurrence of M. africanum in animals, and summarize the phenotypic differences described thus far between M. africanum and M. tuberculosis sensu stricto.	[de Jong, Bouke C.; Antonio, Martin] Bacterial Dis Programme, MRC Labs, Fajara, Gambia; [de Jong, Bouke C.] NYU, Div Infect Dis, New York, NY USA; [de Jong, Bouke C.] Inst Trop Med, Mycobacteriol Unit, B-2000 Antwerp, Belgium; [Gagneux, Sebastien] MRC Natl Inst Med Res, London, England; [Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Basel, Switzerland	de Jong, BC (reprint author), Bacterial Dis Programme, MRC Labs, Fajara, Gambia.	bdejong@itg.be	de Jong, Bouke/A-3636-2013	de Jong, Bouke/0000-0002-1017-4675	Medical Research Council, United Kingdom; US National Institutes of Health [05TW006083, HHSN266200700022C, AI034238]; Medical Research Council [MC_U190074190, MC_U190081991, MC_U190081982, MC_U117588500]	This work was supported by the Medical Research Council, United Kingdom, and by US National Institutes of Health grants 05TW006083 awarded to BD, and HHSN266200700022C and AI034238 awarded to SG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abate G, 2002, INT J TUBERC LUNG D, V6, P933; Addo Kk, 2007, Ghana Med J, V41, P52; Affolabi D, 2009, INT J TUBERC LUNG D, V13, P317; Aldea M J, 1990, Enferm Infecc Microbiol Clin, V8, P64; BARIL L, 1995, CLIN INFECT DIS, V21, P653, DOI 10.1093/clinids/21.3.653; Bercion R, 1997, INT J TUBERC LUNG D, V1, P110; BHANOT N, 2008, INFECT DIS CLIN PRAC, V16, P327; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23; Cadmus S, 2006, J CLIN MICROBIOL, V44, P29, DOI 10.1128/JCM.44.1.29-34.2006; CADMUS SI, 2010, TROP ANIM HLTH PROD; CASTETS M, 1969, Bulletin de la Societe Medicale d'Afrique Noire de Langue Francaise, V14, P693; Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179; Castets M, 1979, Med Trop (Mars), V39, P145; Comas I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007815; Comas I, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000600; DAVID HL, 1978, INT J SYST BACTERIOL, V28, P467; de Jong BC, 2007, INT J TUBERC LUNG D, V11, P450; de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977; de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41; de Jong BC, 2009, J CLIN MICROBIOL; de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504; de Jong BC, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-11; de Jong BC, 2010, FEMS IMMUNOL MED MIC, V58, P102, DOI 10.1111/j.1574-695X.2009.00628.x; de Kantor I N, 1979, Bull Int Union Tuberc, V54, P173; de Medeiros D, 1974, Bull Soc Med Afr Noire Lang Fr, V19, P96; DEJONG BC, 2009, FEMS IMMUNO IN PRESS; DEKANTOR I, 1979, B ACAD VET FRANCE, V52, P499; DEMERS AM, 2010, TUBERCULOSIS EDINB; Desmond E, 2004, EMERG INFECT DIS, V10, P921; DIARRA B, 2009, KEYST C OV CRIS TB A; Diop S, 1976, Bull Soc Med Afr Noire Lang Fr, V21, P50; Esteras MAR, 2003, ARCH BRONCONEUMOL, V39, P376; Frothingham R, 1999, J CLIN MICROBIOL, V37, P1921; FROTTIER J, 1990, B ACAD NAT MED PARIS, V174, P29; Frottier J, 1990, B ACAD NATL MED, V174, P34; Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103; Gagneux S, 2007, LANCET INFECT DIS, V7, P328, DOI 10.1016/S1473-3099(07)70108-1; Gao LY, 2004, MOL MICROBIOL, V53, P1677, DOI 10.1111/j.1365-2958.2004.04261.x; Godreuil S, 2007, J CLIN MICROBIOL, V45, P921, DOI 10.1128/JCM.01918-06; Goossens B, 1998, VET REC, V142, P277, DOI 10.1136/vr.142.11.277; Goyal M, 1999, J INFECTION, V38, P171, DOI 10.1016/S0163-4453(99)90246-3; GRANGE JM, 1989, EPIDEMIOL INFECT, V87, P127; GROSSET J, 1971, Revue de Tuberculose et de Pneumologie, V35, P430; GROSSET J, 1974, B INT UNION TUBERC, V230, P177; Haas WH, 1997, J CLIN MICROBIOL, V35, P663; Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311; Homolka S, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-103; Huard RC, 2006, J BACTERIOL, V188, P4271, DOI 10.1128/JB.01783-05; HUET M, 1971, Revue de Tuberculose et de Pneumologie, V35, P413; Intemann CD, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000577; Inwald J, 2003, TUBERCULOSIS, V83, P387, DOI 10.1016/j.tube.2003.08.018; JANIER M, 1987, ANN DERMATOL VENER, V114, P1395; JUNGBLUTH H, 1978, PRAX KLIN PNEUMOL, V32, P306; Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872; KORSAK T, 1970, ACTA TUBERC PNEUMOL, V200, P388; Ledru S, 1996, TUBERCLE LUNG DIS, V77, P429, DOI 10.1016/S0962-8479(96)90116-1; MEISSNER G, 1969, ZENTBL BAKTERIOLOG P, V211, P69; Meyer CG, 2008, TUBERCULOSIS, V88, P482, DOI 10.1016/j.tube.2008.05.004; Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004; Mostowy S, 2002, J INFECT DIS, V186, P74, DOI 10.1086/341068; NERLICH AG, 2009, INTERDISCIP PERSPECT; Niang MN, 1999, MICROBES INFECT, V1, P1189, DOI 10.1016/S1286-4579(99)00243-9; Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003; NUNN P, 1991, LANCET, V337, P627; ONIPEDE AO, 2005, AFRICAN J CLIN EXPT, V6, P167; PARKHILL J, 2010, MYCOBACTERIUM GENOME; PATTYN S R, 1970, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V50, P211; PATTYN SR, 1978, ANN SOC BELG MED TR, V58, P59; PEREZDEPEDR, 2008, ENFERM INFEC MICR CL, V26, P600; PETIT JC, 1980, NOUV PRESSE MED, V9, P2845; Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859; Rahim Zeaur, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P706; Reparaz J, 1987, Rev Med Univ Navarra, V31, P103; Rey J L, 1979, Med Trop (Mars), V39, P149; SCHRODER KH, 1982, ZBL BAKT-INT J MED M, V251, P341, DOI 10.1016/S0174-3031(82)80103-0; Smith NH, 2009, NAT REV MICROBIOL, V7, P537, DOI 10.1038/nrmicro2165; Streicher EM, 2007, J CLIN MICROBIOL, V45, P237, DOI 10.1128/JCM.01429-06; THOREL MF, 1980, ANN INST PASTEUR MIC, VA131, P61; THOREL MF, 1980, TUBERCLE, V61, P101, DOI 10.1016/0041-3879(80)90018-5; Toure I M, 1982, Bull Int Union Tuberc, V57, P241; Tsolaki AG, 2004, P NATL ACAD SCI USA, V101, P4865, DOI 10.1073/pnas.0305634101; Unger F, 2003, RISK ASS MYCOBACTERI, P1; Van Der Groen G, 1975, Ann Soc Belg Med Trop, V55, P647; VANDERWERF TS, 1989, TUBERCLE, V70, P249, DOI 10.1016/0041-3879(89)90019-6; Vasconcellos SEG, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-80; Viana-Niero C, 2001, J CLIN MICROBIOL, V39, P57, DOI 10.1128/JCM.39.1.57-65.2001; Zink AR, 2003, J CLIN MICROBIOL, V41, P359, DOI 10.1128/JCM.41.1.359-367.2003	88	104	104	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	SEP	2010	4	9							e744	10.1371/journal.pntd.0000744				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	655TB	WOS:000282271300003	20927191	DOAJ Gold, Green Published			2019-03-26	
J	Delespaux, V; Vitouley, HS; Marcotty, T; Speybroeck, N; Berkvens, D; Roy, K; Geerts, S; Van den Bossche, P				Delespaux, Vincent; Vitouley, Herve Sena; Marcotty, Tanguy; Speybroeck, Niko; Berkvens, Dirk; Roy, Krisna; Geerts, Stanny; Van den Bossche, Peter			Chemosensitization of Trypanosoma congolense Strains Resistant to Isometamidium Chloride by Tetracyclines and Enrofloxacin	PLOS NEGLECTED TROPICAL DISEASES			English	Article							SSU-RDNA AMPLIFICATION; DRUG-RESISTANCE; MULTIDRUG-RESISTANCE; MOLECULAR TOOLS; CATTLE; EFFLUX; INHIBITION; DIAGNOSIS; INCREASE; ANALOGS	Background: Because of the development of resistance in trypanosomes to trypanocidal drugs, the livelihood of millions of livestock keepers in sub-Saharan Africa is threatened now more than ever. The existing compounds have become virtually useless and pharmaceutical companies are not keen on investing in the development of new trypanocides. We may have found a breakthrough in the treatment of resistant trypanosomal infections, through the combination of the trypanocide isometamidium chloride (ISM) with two affordable veterinary antibiotics. Methodology/Principal Findings: In a first experiment, groups of mice were inoculated with Trypanosoma congolense strains resistant to ISM and either left untreated or treated with (i) tetracycline, (ii) ISM or (iii) the combination of the antibiotic and the trypanocide. Survival analysis showed that there was a significant effect of treatment and resistance to treatment on the survival time. The groups treated with ISM (with or without antibiotic) survived significantly longer than the groups that were not treated with ISM (P < 0.01). The group treated with the combination trypanocide/antibiotic survived significantly longer than the group treated with ISM (P < 0.01). In a second experiment, groups of cattle were inoculated with the same resistant trypanosome strain and treated with (i) ISM, (ii) ISM associated with oxytetracycline or (iii) ISM associated with enrofloxacine. All animals treated with ISM became parasitaemic. In the groups treated with ISM-oxytetracycline and ISM-enrofloxacine, 50% of the animals were cured. Animals from the groups treated with a combination trypanocide/antibiotic presented a significantly longer prepatent period than animals treated with ISM (p < 0.001). The impact of the disease on the haematocrit was low in all ISM treated groups. Yet, it was lower in the groups treated with the combination trypanocide/antibiotic (p < 0.01). Conclusions/Significance: After optimization of the administration protocol, this new therapeutic combination could constitute a promising treatment for livestock infected with drug resistant T. congolense.	[Delespaux, Vincent; Marcotty, Tanguy; Speybroeck, Niko; Berkvens, Dirk; Geerts, Stanny; Van den Bossche, Peter] Inst Trop Med Antwerp, Dept Anim Hlth, Antwerp, Belgium; [Vitouley, Herve Sena] Ctr Int Rech Dev Elevage Zone Subhumide, Bobo Dioulasso, Burkina Faso; [Roy, Krisna] Chittagong Vet & Anim Sci Univ, Fac Vet Med, Pathol & Parasitol Dept, Khulshi, Chittagong, Bangladesh; [Van den Bossche, Peter] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa	Delespaux, V (reprint author), Inst Trop Med Antwerp, Dept Anim Hlth, Antwerp, Belgium.	vdelespaux@itg.be		Geerts, Stanny/0000-0001-9885-8846	General Direction of Development and Cooperation of Belgium (GDDC); Institute of Tropical Medicine of Antwerp (ITM)	This work was financially supported by the General Direction of Development and Cooperation of Belgium (GDDC) and by the Institute of Tropical Medicine of Antwerp (ITM). The funder GDDC had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder ITM paid the salaries of the ITM authors but had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ancelle T, 1997, Med Trop (Mars), V57, P245; Bailey AM, 2008, ANTIMICROB AGENTS CH, V52, P3604, DOI 10.1128/AAC.00661-08; Bhattacharjee AK, 2001, ANTIMICROB AGENTS CH, V45, P2655, DOI 10.1128/AAC.45.9.2655-2657.2001; Coustou V, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000618; Delespaux V, 2003, VET PARASITOL, V117, P185, DOI 10.1016/j.vetpar.2003.08.004; Delespaux V, 2008, TRENDS PARASITOL, V24, P236, DOI 10.1016/j.pt.2008.02.006; Delespaux V, 2007, DRUG RESIST UPDATE, V10, P30, DOI 10.1016/j.drup.2007.02.004; Delespaux V, 2008, DRUG RESIST UPDATE, V11, P205, DOI 10.1016/j.drup.2008.10.002; Eisler MC, 2001, VET PARASITOL, V97, P171, DOI 10.1016/S0304-4017(01)00415-0; Geerts S, 2001, TRENDS PARASITOL, V17, P25, DOI 10.1016/S1471-4922(00)01827-4; Geysen D, 2003, VET PARASITOL, V110, P171, DOI 10.1016/S0304-4017(02)00313-8; Helm JR, 2009, MOL BIOCHEM PARASIT, V168, P34, DOI 10.1016/j.molbiopara.2009.06.004; HERBERT WJ, 1976, EXP PARASITOL, V40, P427, DOI 10.1016/0014-4894(76)90110-7; HIRUMI H, 1984, ANN TROP MED PARASIT, V78, P327, DOI 10.1080/00034983.1984.11811824; Kabayo JP, 2002, TRENDS PARASITOL, V18, P473, DOI 10.1016/S1471-4922(02)02371-1; Knorre DA, 2009, ARCH MICROBIOL, V191, P675, DOI 10.1007/s00203-009-0493-8; LI XZ, 1994, ANTIMICROB AGENTS CH, V38, P1742, DOI 10.1128/AAC.38.8.1742; Mamoudou A, 2008, ACTA TROP, V106, P115, DOI 10.1016/j.actatropica.2008.02.003; Markham PN, 1999, ANTIMICROB AGENTS CH, V43, P988, DOI 10.1128/AAC.43.4.988; Masseno V, 2009, ANTIMICROB AGENTS CH, V53, P3131, DOI 10.1128/AAC.01689-08; Mazurkiewicz P, 2005, CURR ISSUES MOL BIOL, V7, P7; McDermott J, 2003, ACTA TROP, V86, P93, DOI 10.1016/S0001-706X(03)00019-6; Mullin S, 2004, ANTIMICROB AGENTS CH, V48, P4171, DOI 10.1128/AAC.48.11.4171-4176.2004; Olila D, 2002, ACTA TROP, V84, P19, DOI 10.1016/S0001-706X(02)00137-7; PAGES JM, 2009, PLOS ONE, V4; Peregrine A, 1997, ANTIMICROB AGENTS CH, V41, P1604, DOI 10.1128/AAC.41.7.1604; Roberts MC, 2005, FEMS MICROBIOL LETT, V245, P195, DOI 10.1016/j.femsle.2005.02.034; Sambrook J., 1989, MOL CLONING LAB MANU; Sangwan PL, 2008, BIOORGAN MED CHEM, V16, P9847, DOI 10.1016/j.bmc.2008.09.042; SHAW PMA, 2004, TRYPANOSOMIASES, P369; Sones K., 2001, ICPTV NEWSLETTER, V3, P19; TAO LY, 2001, CANCER CHEMOTH PHARM, V64, P961; Usui M, 2009, INT J ANTIMICROB AG, V34, P592, DOI 10.1016/j.ijantimicag.2009.07.009; Vale GA, 2009, ONDERSTEPOORT J VET, V76, P41; VANDENBOSSCH, 2008, REV SCI TECH OIE, V27, P551; Wong ILK, 2009, J ANTIMICROB CHEMOTH, V63, P1179, DOI 10.1093/jac/dkp130	36	9	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	SEP	2010	4	9							e828	10.1371/journal.pntd.0000828				8	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	655TB	WOS:000282271300004	20927189	DOAJ Gold, Green Published			2019-03-26	
J	Meheus, F; Balasegaram, M; Olliaro, P; Sundar, S; Rijal, S; Abul Faiz, M; Boelaert, M				Meheus, Filip; Balasegaram, Manica; Olliaro, Piero; Sundar, Shyam; Rijal, Suman; Abul Faiz, Md; Boelaert, Marleen			Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent	PLOS NEGLECTED TROPICAL DISEASES			English	Article							LIPOSOMAL AMPHOTERICIN-B; SODIUM ANTIMONY GLUCONATE; KALA-AZAR; ORAL MILTEFOSINE; PAROMOMYCIN AMINOSIDINE; INJECTABLE PAROMOMYCIN; PENTAVALENT ANTIMONY; BIHAR; SINGLE; STIBOGLUCONATE	Background: Visceral leishmaniasis is a systemic parasitic disease that is fatal unless treated. We assessed the cost and cost-effectiveness of alternative strategies for the treatment of visceral leishmaniasis in the Indian subcontinent. In particular we examined whether combination therapies are a cost-effective alternative compared to monotherapies. Methods and Findings: We assessed the cost-effectiveness of all possible mono-and combination therapies for the treatment of visceral leishmaniasis in the Indian subcontinent (India, Nepal and Bangladesh) from a societal perspective using a decision analytical model based on a decision tree. Primary data collected in each country was combined with data from the literature and an expert poll (Delphi method). The cost per patient treated and average and incremental cost-effectiveness ratios expressed as cost per death averted were calculated. Extensive sensitivity analysis was done to evaluate the robustness of our estimations and conclusions. With a cost of US$92 per death averted, the combination miltefosine-paromomycin was the most cost-effective treatment strategy. The next best alternative was a combination of liposomal amphotericin B with paromomycin with an incremental cost-effectiveness of $652 per death averted. All other strategies were dominated with the exception of a single dose of 10mg per kg of liposomal amphotericin B. While strategies based on liposomal amphotericin B (AmBisome) were found to be the most effective, its current drug cost of US$20 per vial resulted in a higher average cost-effectiveness. Sensitivity analysis showed the conclusion to be robust to variations in the input parameters over their plausible range. Conclusions: Combination treatments are a cost-effective alternative to current monotherapy for VL. Given their expected impact on the emergence of drug resistance, a switch to combination therapy should be considered once final results from clinical trials are available.	[Meheus, Filip; Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Balasegaram, Manica] Drugs Neglected Dis Initiat, Geneva, Switzerland; [Olliaro, Piero] WHO, United Nations Childrens Fund UNICEF, UNDP, World Bank,World Hlth Org WHO Special Programme R, CH-1211 Geneva, Switzerland; [Olliaro, Piero] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Ctr Trop Med & Vaccinol,Churchill Hosp, Oxford, England; [Sundar, Shyam] Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; [Rijal, Suman] BP Koirala Inst Med Sci, Dharan, Nepal; [Abul Faiz, Md] Sir Salimullah Med Coll, Dhaka, Bangladesh	Meheus, F (reprint author), Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.	fmeheus@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776			Anoopa SD, 2006, TROP MED INT HEALTH, V11, P757; Bern C, 2006, CLIN INFECT DIS, V43, P917, DOI 10.1086/507530; Bhattacharya SK, 2004, CLIN INFECT DIS, V38, P217, DOI 10.1086/380638; Bhattacharya SK, 2007, J INFECT DIS, V196, P591, DOI 10.1086/519690; Boelaert M, 2009, TROP MED INT HEALTH, V14, P639, DOI 10.1111/j.1365-3156.2009.02279.x; Bora D, 1999, NATL MED J INDIA, V12, P62; Bryceson A, 2001, TROP MED INT HEALTH, V6, P928, DOI 10.1046/j.1365-3156.2001.00795.x; Jha TK, 1998, BRIT MED J, V316, P1200, DOI 10.1136/bmj.316.7139.1200; Meheus F, 2006, TROP MED INT HEALTH, V11, P1715, DOI 10.1111/j.1365-3156.2006.01732.x; MULLIGAN J, 2003, 9 DCPP; Olliaro P, 2009, TROP MED INT HEALTH, V14, P88, DOI 10.1111/j.1365-3156.2008.02195.x; Olliaro P, 2009, TROP MED INT HEALTH, V14, P918, DOI 10.1111/j.1365-3156.2009.02306.x; Rijal S, 2006, T ROY SOC TROP MED H, V100, P838, DOI 10.1016/j.trstmh.2005.09.017; Rijal S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; Singh SP, 2006, TROP MED INT HEALTH, V11, P899, DOI 10.1111/j.1365-3156.2006.01647.x; Sundar S, 2005, B WORLD HEALTH ORGAN, V83, P394; Sundar S, 2000, CLIN INFECT DIS, V31, P1110, DOI 10.1086/318122; Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971; Sundar S, 2003, CLIN INFECT DIS, V37, P800, DOI 10.1086/377542; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 2002, AM J TROP MED HYG, V66, P143, DOI 10.4269/ajtmh.2002.66.143; Sundar S, 2001, BRIT MED J, V323, P419, DOI 10.1136/bmj.323.7310.419; Sundar S, 1997, J INFECT DIS, V176, P1117, DOI 10.1086/516526; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; SUNDAR S, 1921, CLIN INFECT DIS, V49, P914; Sundar S, 2008, CLIN INFECT DIS, V47, P1000, DOI 10.1086/591972; Sundar S, 2008, TROP MED INT HEALTH, V13, P2, DOI 10.1111/j.1365-3156.2007.01974.x; Sundar S, 2007, NEW ENGL J MED, V356, P2571, DOI 10.1056/NEJMoa066536; Sundar Shyam, 2003, Pediatric Infectious Disease Journal, V22, P434, DOI 10.1097/00006454-200305000-00009; Sundar S, 2010, NEW ENGL J MED, V362, P504, DOI 10.1056/NEJMoa0903627; TANTORRES T, 2003, MAKING CHOICES HLTH; Thakur CP, 2008, INDIAN J MED RES, V127, P582; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P429, DOI 10.1016/S0035-9203(00)90130-5; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P432, DOI 10.1016/S0035-9203(00)90131-7; Thakur CP, 1998, ANN TROP MED PARASIT, V92, P561, DOI 10.1080/00034983.1998.11813313; THAKUR CP, 1992, T ROY SOC TROP MED H, V86, P615, DOI 10.1016/0035-9203(92)90150-B; Thakur CP, 2000, T ROY SOC TROP MED H, V94, P156, DOI 10.1016/S0035-9203(00)90255-4; Thakur CP, 2004, ANN TROP MED PARASIT, V98, P129, DOI 10.1179/000349804225003154; Thakur CP, 2001, INT J ANTIMICROB AG, V17, P67, DOI 10.1016/S0924-8579(00)00312-5; Thakur CP, 1999, T ROY SOC TROP MED H, V93, P319, DOI 10.1016/S0035-9203(99)90037-8; van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6; Vanlerberghe V, 2007, TROP MED INT HEALTH, V12, P274, DOI 10.1111/j.1365-3156.2006.01782.x; *WHO, 2005, REG STRAG FRAM EL KA	44	54	54	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	SEP	2010	4	9							e818	10.1371/journal.pntd.0000818				9	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	655TB	WOS:000282271300021	20838649	DOAJ Gold, Green Published			2019-03-26	
J	Praet, N; Kanobana, K; Kabwe, C; Maketa, V; Lukanu, P; Lutumba, P; Polman, K; Matondo, P; Speybroeck, N; Dorny, P; Sumbu, J				Praet, Nicolas; Kanobana, Kirezi; Kabwe, Constantin; Maketa, Vivi; Lukanu, Philippe; Lutumba, Pascal; Polman, Katja; Matondo, Peter; Speybroeck, Niko; Dorny, Pierre; Sumbu, Julienne			Taenia solium Cysticercosis in the Democratic Republic of Congo: How Does Pork Trade Affect the Transmission of the Parasite?	PLOS NEGLECTED TROPICAL DISEASES			English	Article							NEGLECTED TROPICAL DISEASES; PORCINE CYSTICERCOSIS; PREVALENCE; AFRICA; PIGS; INFECTIONS; DIAGNOSIS; EASTERN; BURDEN; RISK	Background: Taenia solium, a zoonotic parasite that is endemic in most developing countries where pork is consumed, is recognised as the main cause of acquired epilepsy in these regions. T. solium has been reported in almost all of the neighboring countries of Democratic Republic of Congo (DRC) but data on the current prevalence of the disease in the country itself are lacking. This study, focusing on porcine cysticercosis (CC), makes part of a first initiative to assess whether cysticercosis is indeed actually present in DRC. Methods: An epidemiological study on porcine CC was conducted (1) on urban markets of Kinshasa where pork is sold and (2) in villages in Bas-Congo province where pigs are traditionally reared. Tongue inspection and ELISA for the detection of circulating antigen of the larval stage of T. solium were used to assess the prevalence of active CC in both study sites. Findings: The overall prevalence of pigs with active cysticercosis did not significantly differ between the market and the village study sites (38.8 [CI95%: 34-43] versus 41.2% [CI95%: 33-49], respectively). However, tongue cysticercosis was only found in the village study site together with a significantly higher intensity of infection (detected by ELISA). Interpretation: Pigs reared at village level are sold for consumption on Kinshasa markets, but it seems that highly infected animals are excluded at a certain level in the pig trade chain. Indeed, preliminary informal surveys on common practices conducted in parallel revealed that pig farmers and/or buyers select the low infected animals and exclude those who are positive by tongue inspection at village level. This study provides the only recent evidence of CC presence in DRC and gives the first estimates to fill an important gap on the African taeniasis/cysticercosis distribution map.	[Praet, Nicolas; Kanobana, Kirezi; Polman, Katja; Speybroeck, Niko; Dorny, Pierre] Inst Trop Med, B-2000 Antwerp, Belgium; [Praet, Nicolas] Univ Liege, Dept Infect & Parasit Dis, Res Unit Epidemiol & Risk Anal Appl Vet Sci, Fac Vet Med, Liege, Belgium; [Kabwe, Constantin; Lutumba, Pascal] Inst Natl Rech Biomed, Kinshasa, Zaire; [Maketa, Vivi] Kinshasa Univ, Dept Trop Med, Kinshasa, Zaire; [Lukanu, Philippe] Kimpese Hlth Zone, Kimpese, Zaire; [Matondo, Peter; Sumbu, Julienne] Lab Vet Kinshasa, Kinshasa, Zaire; [Speybroeck, Niko] Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium	Praet, N (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.	npraet@itg.be			Belgian Cooperation; Institute of Tropical Medicine of Antwerp, Belgium; Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of Congo	This work was supported by the Belgian Cooperation in the framework of the Institutional Collaboration between the Institute of Tropical Medicine of Antwerp, Belgium and the Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of Congo. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Budke CM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000319; Carabin H, 2006, TROP MED INT HEALTH, V11, P906, DOI 10.1111/j.1365-3156.2006.01627.x; Carpio A, 2002, NEUROLOGY, V59, P1730, DOI 10.1212/01.WNL.0000036320.69823.EA; Carpio A, 2009, CURR NEUROL NEUROSCI, V9, P319, DOI 10.1007/s11910-009-0048-z; CHARTIER C, 1990, ANN SOC BELG MED TR, V70, P213; *CIA, 2009, EC DEM REP CONG; Deckers N, 2008, INT J PARASITOL, V38, P1191, DOI 10.1016/j.ijpara.2008.01.005; DENISOFF N, 1958, Ann Soc Belg Med Trop (1920), V38, P529; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Eddi C, 2003, ACTA TROP, V87, P145, DOI 10.1016/S0001-706X(03)00037-8; FAIN A, 1997, HLTH CENTRAL AFRICA, P485; GONZALEZ AE, 1990, AM J TROP MED HYG, V43, P194, DOI 10.4269/ajtmh.1990.43.194; GONZALEZ AE, 1993, B WORLD HEALTH ORGAN, V71, P223; Hotez PJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000412; HOTEZ PJ, 2006, PLOS MED, V3, P102, DOI DOI 10.1371/J0URNAL.PMED.0030102; Martin TG, 2005, ECOL LETT, V8, P1235, DOI 10.1111/j.1461-0248.2005.00826.x; Morales J, 2006, ANN TROP MED PARASIT, V100, P123, DOI 10.1179/136485906x86275; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; Ngowi HA, 2004, TROP ANIM HEALTH PRO, V36, P335, DOI 10.1023/B:TROP.0000026663.07862.2a; Phiri IK, 2003, ACTA TROP, V87, P13, DOI [10.1016/S0001-706X(03)00051-2, 10.1016/S0001-706X(03)00202-X]; Praet N, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000406; SARTI E, 1992, AM J TROP MED HYG, V46, P677, DOI 10.4269/ajtmh.1992.46.677; World Health Organisation/Department for International Development-Animal Health Program, 2006, JOINT WHO DFID AHP M; Zoli A, 2003, ACTA TROP, V87, P35, DOI 10.1016/S0001-706X(02)00289-9	24	24	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	SEP	2010	4	9							e817	10.1371/journal.pntd.0000817				6	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	655TB	WOS:000282271300020	20838646	DOAJ Gold, Green Published			2019-03-26	
J	Chaillet, P; Tayler-Smith, K; Zachariah, R; Duclos, N; Moctar, D; Beelaert, G; Fransen, K				Chaillet, Pascale; Tayler-Smith, Katie; Zachariah, Rony; Duclos, Nanfack; Moctar, Diallo; Beelaert, Greet; Fransen, Katrien			Evaluation of four rapid tests for diagnosis and differentiation of HIV-1 and HIV-2 infections in Guinea-Conakry, West Africa	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Rapid tests; HIV-1; HIV-2; discrimination; Guinea-Conakry	POLYMERASE-CHAIN-REACTION; TYPE-2 SUBTYPE-A; REAL-TIME PCR; FIELD-EVALUATION; COTE-DIVOIRE; PROVIRAL LOAD; QUANTIFICATION; INDIVIDUALS; ALGORITHMS; BISSAU	With both HIV-1 and HV-2 prevalent in Guinea-Conakry, accurate diagnosis and differentiation is crucial for treatment purposes. Thus, four rapid HIV tests were evaluated for their HIV-1 and HIV-2 diagnostic and discriminative capacity for use in Guinea-Conakry. These included SD Bioline HIV 1/2 3.0 (Standard Diagnostics Inc.), Genie II HIV1/HIV2 (Bio-Rad), First Response HIV Card Test 1-2.0 (PMC Medical) and Immunoflow HIV1-HIV2 (Core Diagnostics). Results were compared with gold standard tests (INNO-LIA HIV-I/II Score) and NEW LAV BLOT II (Bio-Rad). Four hundred and forty three sequential stored HIV-positive serum samples, of known HIV-type, were evaluated. Genie II HIV1/HIV2, Immunoflow HIV1-HIV2 and SD Bioline HIV 1/2 3.0 had 100% sensitivity (95% CI, 98.9-100%) while for First Response HIV Card Test 1-2.0 this was 99.5% (95% CI, 98.2%-99.9%). In terms of discriminatory capacity, Genie II HIV1/HIV2 identified 382/ 384(99.5%) HIV-1 samples, 49/ 52(95%) HIV-2 and 7/7(100%) HIV-positive untypable samples. Immunoflow HIV1-HIV2 identified 99% HIV-1, 67% HIV-2 and all HIV-positive untypable samples. First Response HIV Card Test 1-2.0 identified 94% HIV-1, 64% HIV-2 and 57% HIV-positive untypable samples. SD-Bioline HIV 1/2 3.0 was the worst overall performer identifying 65% HIV-1, 69% HIV-2 and all HIV-positive untypable samples. The use of SD Bioline HIV 1/2 3.0 (the current standard in Guinea-Conakry) as a discriminatory HIV test is poor and may be best replaced by Immunoflow HIV1-HIV2. (c) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Tayler-Smith, Katie; Zachariah, Rony] Med San Frontieres, Dept Med, Brussels Operat Ctr, L-1617 Luxembourg, Luxembourg; [Chaillet, Pascale] Med San Frontieres, Dept Med, Brussels Operat Ctr, Brussels, Belgium; [Duclos, Nanfack] Med San Frontieres, Conakry, Guinea; [Moctar, Diallo] Minist Hlth, Conakry, Guinea; [Beelaert, Greet; Fransen, Katrien] Inst Trop Med, B-2000 Antwerp, Belgium	Zachariah, R (reprint author), Med San Frontieres, Brussels Operat Ctr Operat Res, 68 Rue Gasperich, L-1617 Luxembourg, Luxembourg.	zachariah@internet.lu			Medecins sans Frontieres	This study was funded as part of the routine operational and laboratory support package of Medecins sans Frontieres.	Ampofo W K, 1999, J Med Dent Sci, V46, P53; Andersson S, 1997, AIDS, V11, P1815, DOI 10.1097/00002030-199715000-00005; Chimirri A, 1999, ANTIVIR CHEM CHEMOTH, V10, P211, DOI 10.1177/095632029901000405; Constantine N T, 1997, J Hum Virol, V1, P45; Damond F, 2002, J CLIN MICROBIOL, V40, P3654, DOI 10.1128/JCM.40.10.3654-3659.2002; Damond F, 2001, J CLIN MICROBIOL, V39, P4264, DOI 10.1128/JCM.39.12.4264-4268.2001; Desire N, 2001, J CLIN MICROBIOL, V39, P1303, DOI 10.1128/JCM.39.4.1303-1310.2001; FURNHAM PG, 1996, PUBLIC HLTH REP, V111, P44; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; Ishikawa K, 1998, AIDS, V12, P1419, DOI 10.1097/00002030-199812000-00003; Kassler WJ, 1997, AIDS, V11, P1045, DOI 10.1097/00002030-199708000-00014; Kassler WJ, 1998, INT J STD AIDS, V9, P134, DOI 10.1258/0956462981921882; Koblavi-Deme S, 2001, J CLIN MICROBIOL, V39, P1808, DOI 10.1128/JCM.39.5.1808-1812.2001; Lyamuya EF, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-19; MCKENNA SL, 1997, AIDS S1, V11, P103; Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; PEETERS M, 1994, J VIROL METHODS, V48, P23, DOI 10.1016/0166-0934(94)90085-X; Rouet F, 2004, J CLIN MICROBIOL, V42, P4147, DOI 10.1128/JCM.42.9.4147-4153.2004; Sagoe Kwc, 2008, Ghana Med J, V42, P16; Stetler HC, 1997, AIDS, V11, P369, DOI 10.1097/00002030-199703110-00015; THEOPHILUSSUNDE.V, 2005, J CLIN MICROBIOL, V43, P4194; Walther-Jallow L, 1999, AIDS RES HUM RETROV, V15, P957, DOI 10.1089/088922299310467; WHO, 1997, WKLY EPIDEMIOL REC, V72, P81; *WHO, SCAL ANT THER RES LT; *WHO CDC, 2003, GUID APPR EV HIV TES; *WHO UNAIDS, 2004, 14 WHOUNAIDS; Witvrouw M, 2004, ANTIVIR THER, V9, P57; 1997, AIDS ALERT, V12, P3	29	16	16	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0035-9203	1878-3503		T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	SEP	2010	104	9					571	576		10.1016/j.trstmh.2010.05.007				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	645XM	WOS:000281499500001	20708123	Green Published			2019-03-26	
J	Raghava, MV; Prabhakaran, V; Jayaraman, T; Muliyil, J; Oommen, A; Dorny, P; Vercruysse, J; Rajshekhar, V				Raghava, M. Venkata; Prabhakaran, V.; Jayaraman, T.; Muliyil, J.; Oommen, A.; Dorny, P.; Vercruysse, J.; Rajshekhar, V.			Detecting spatial clusters of Taenia solium infections in a rural block in South India	TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE			English	Article						Cysticercosis; clusters; epilepsy; geographic information systems; taeniasis	GEOGRAPHIC INFORMATION-SYSTEMS; SAGINATA CYSTICERCOSIS; TAPEWORM CARRIERS; VELLORE DISTRICT; NEUROCYSTICERCOSIS; ANTIGENS; CANCER; SEROPREVALENCE; EPILEPSY; VILLAGES	Neurocysticercosis (NCC) is a major cause of seizures/epilepsy in countries endemic for the disease. The objectives of this study were to spatially map the burden of active epilepsy (AE), NCC, taeniasis, seroprevalence for cysticercal antibodies and positivity to circulating cysticercal antigens in Kaniyambadi block (approximately 100 villages comprising 100 000 population) of Vellore district and to detect spatial clusters of AE, NCC, taeniasis and seroprevalence. Using geographic information system (GIS) techniques, all 21 study villages with over 8000 houses (population of 38 105) were mapped. Clustering of different indices of Taenia solium infection was determined using a spatial scan statistic (SaTScan). There was a primary spatial cluster of AE with a log likelihood ratio (LLR) of 10.8 and relative risk (RR) of 22.4; however, no significant clustering for NCC was detected. Five significant spatial clusters of seropositivity for cysticercal antibodies, two clusters of seropositivity for cysticercal antigens and one for taeniasis were detected (LLR of 8.35 and RR of 36.67). Our study has demonstrated the use of GIS methods in mapping and identifying 'hot spots' of various indices of T. solium infection in humans. This spatial analysis has identified pockets with high transmission rates so that preventive measures could be focused on an intensive scale. (c) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.	[Raghava, M. Venkata; Muliyil, J.] Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632002, Tamil Nadu, India; [Prabhakaran, V.; Jayaraman, T.; Oommen, A.; Rajshekhar, V.] Christian Med Coll & Hosp, Dept Neurol Sci, Vellore 632002, Tamil Nadu, India; [Dorny, P.; Vercruysse, J.] Univ Ghent, Dept Virol Parasitol & Immunol, Ghent, Belgium; [Dorny, P.; Vercruysse, J.] Inst Trop Med, B-2000 Antwerp, Belgium	Raghava, MV (reprint author), Christian Med Coll & Hosp, Dept Community Hlth, Vellore 632002, Tamil Nadu, India.	venkat@cmcvellore.ac.in	Tharmalingam, Jayaraman/G-2542-2013	Tharmalingam, Jayaraman/0000-0002-7071-2797; Mohan, Venkata Raghava/0000-0001-5787-7223	Indian Council of Medical Research, New Delhi; Flemish Interuniversity Council, Belgium	The study was supported in part by a Task Force grant from the Indian Council of Medical Research, New Delhi and the Flemish Interuniversity Council, Belgium.	ALLAN JC, 1990, PARASITOLOGY, V101, P473, DOI 10.1017/S0031182000060686; Allan JC, 2003, ACTA TROP, V87, P87, DOI 10.1016/S0001-706X(03)00059-7; BECK LR, 1994, AM J TROP MED HYG, V51, P271, DOI 10.4269/ajtmh.1994.51.271; BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E; Chen Y, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-28; Coleman M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-68; Del Brutto OH, 2001, NEUROLOGY, V57, P177, DOI 10.1212/WNL.57.2.177; DelBrutto OH, 1997, CURR OPIN NEUROL, V10, P268, DOI 10.1097/00019052-199706000-00017; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Dorny P, 2000, VET PARASITOL, V88, P43, DOI 10.1016/S0304-4017(99)00196-X; Duker AA, 2004, INT J HEALTH GEOGR, V3, P19, DOI DOI 10.1186/1476-072X-3-19; Fischer EAJ, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-125; GARCIA HH, 1993, LANCET, V341, P197, DOI 10.1016/0140-6736(93)90064-N; Garcia HH, 2003, LANCET, V362, P547, DOI 10.1016/S0140-6736(03)14117-7; GLASS GE, 1995, AM J PUBLIC HEALTH, V85, P944, DOI 10.2105/AJPH.85.7.944; JOSEPH ST, 2004, INT J HLTH GEOGRAPHI, V3, P17; Kulldorff M, 1997, AM J EPIDEMIOL, V146, P161; Kulldorff M, 1997, COMMUN STAT-THEOR M, V26, P1481, DOI 10.1080/03610929708831995; Kulldorff M, 2006, SATSCAN USER GUIDE V; LAURA A, 2004, ENV HLTH PERSPECT, V112, pA896; Lescano AG, 2007, AM J TROP MED HYG, V76, P376, DOI 10.4269/ajtmh.2007.76.376; Lescano AG, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000371; MAZUMDAR S, 2008, GIS CLUSTER DETECTIO; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; ODOI A, 2004, INT J HEALTH GEOGR, V3, P11, DOI DOI 10.1186/1476-072X-3-11; Ozonoff Al, 2005, Environ Health, V4, P19, DOI 10.1186/1476-069X-4-19; Perez AM, 2002, PREV VET MED, V56, P63, DOI 10.1016/S0167-5877(02)00124-1; Prabhakaran V, 2008, T ROY SOC TROP MED H, V102, P246, DOI 10.1016/j.trstmh.2007.10.010; Prabhakaran V, 2004, T ROY SOC TROP MED H, V98, P478, DOI 10.1016/j.trstmh.2003.12.006; Rajshekhar V, 2006, NEUROLOGY, V67, P2135, DOI 10.1212/01.wnl.0000249113.11824.64; Rosenberg MS, 1999, EUR J EPIDEMIOL, V15, P15, DOI 10.1023/A:1007559728848; Sarkar R, 2007, T ROY SOC TROP MED H, V101, P587, DOI 10.1016/j.trstmh.2006.11.005; Schantz Peter M., 2002, P63, DOI 10.1079/9780851996288.0063; *SPSS INC, 2006, SPSS WIND REL 12 0 1; Tiwari Neeraj, 2006, Int J Health Geogr, V5, P33, DOI 10.1186/1476-072X-5-33; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Wheeler DC, 2007, INT J HEALTH GEOGR, V6, DOI 10.1186/1476-072X-6-13; *WHO, 1997, INF CONS TAEN CYST C; YOSHIHARU F, 2005, INT J HEALTH GEOGR, V4, P16; Zhou XN, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-10	40	16	16	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0035-9203			T ROY SOC TROP MED H	Trans. Roy. Soc. Trop. Med. Hyg.	SEP	2010	104	9					601	612		10.1016/j.trstmh.2010.06.002				12	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	645XM	WOS:000281499500006	20638091				2019-03-26	
J	Vanlerberghe, V; Trongtokit, Y; Cremonini, L; Jirarojwatana, S; Apiwathnasorn, C; Van der Stuyft, P				Vanlerberghe, V.; Trongtokit, Y.; Cremonini, L.; Jirarojwatana, S.; Apiwathnasorn, C.; Van der Stuyft, P.			Residual insecticidal activity of long-lasting deltamethrin-treated curtains after 1 year of household use for dengue control	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						dengue; vector control; insecticide-treated curtain; Thailand; Aedes aegypti; residual insecticidal activity; dengue; lutte antivectorielle; rideau traites a l''insecticide; Thailande; Aedes aegypti; activite insecticide residuelle; dengue; control vectorial; mosquitera impregnada con insecticida; Tailandia; Aedes aegypti; actividad insecticida residual	WATER CONTAINER COVERS; WASH-RESISTANCE; NETS; VENEZUELA; MOSQUITOS; VECTORS; TRIALS	P>Objective To evaluate the residual insecticidal activity of the PermaNet (R) curtains on Aedes aegypti after 1 year of use in Thai households and to assess the influence of sun and dust exposure, washing practices and detergent use. Methods We sampled UV-protected PermaNet (R) curtains made of a long-lasting deltamethrin-[55 mg/m2] treated polyester netting, before (10 curtains) and after 8 (10 curtains) and 12 months (66 curtains) of household use in a field site in Chon Buri, Thailand. We assessed the residual insecticidal activity of the curtains by standard WHO bioassay, using a deltamethrin-susceptible insectarium Aedes aegypti strain. Results Mosquito mortality was 100% before distribution, 100% at 8 months and 98.2% (95% CI 97.9-98.5) at 12 months of use. Sunlight, hand-washing and detergent use had no effect on the residual insecticidal activity after 12 months. However, the mosquito survival rate increased by a factor of 6.4 (95% CI 3.5-11.8) on machine-washed curtains and by a factor of 2.0 (95% CI 1.4-2.9) on curtains not covered by dust. Conclusion The residual insecticidal activity of PermaNet (R) curtains remains high after 12 months use under field conditions.	[Vanlerberghe, V.] Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, B-2000 Antwerp, Belgium; [Trongtokit, Y.; Apiwathnasorn, C.] Mahidol Univ, Dept Med Entomol, Bangkok 10700, Thailand; [Jirarojwatana, S.] Reg Off Dis Prevent & Control Reg 3, Chon Buri, Thailand	Vanlerberghe, V (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol & Dis Control Unit, Antionalestr 155, B-2000 Antwerp, Belgium.	vvanlerberghe@itg.be			European Union [INCO-CT-2004-517708]	We are grateful to the municipality and population of Laem Chabang who accepted to participate in the study and to use the IT curtains. We thank Vestergaard-Frandsen for providing the IT curtains free of charge for the purpose of the overall implementation study. The company was not involved in the study design, data collection, data analysis, interpretation of results or preparation of the manuscript. This study reports partial results of Workpackage 4 of the project DENCO-Towards successful dengue prevention and control, financed by the European Union (INCO-CT-2004-517708).	CUMMINGS DA, 2009, PLOS MED, V9; Farrar J, 2007, TROP MED INT HEALTH, V12, P695, DOI 10.1111/j.1365-3156.2007.01838; Graham K, 2005, MED VET ENTOMOL, V19, P72, DOI 10.1111/j.0269-283X.2005.00543.x; Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2; Kayedi MH, 2008, T ROY SOC TROP MED H, V102, P811, DOI 10.1016/j.trstmh.2008.05.025; Kayedi MH, 2009, ACTA TROP, V111, P192, DOI 10.1016/j.actatropica.2009.04.002; Kilian A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-49; Kroeger A, 2006, BRIT MED J, V332, P1247, DOI 10.1136/bmj.332.7552.1247; Lenhart A, 2008, TROP MED INT HEALTH, V13, P56, DOI 10.1111/j.1365-3156.2007.01966.x; Seng CM, 2008, J VECTOR ECOL, V33, P333, DOI 10.3376/1081-1710-33.2.333; Sreehari U, 2009, TROP MED INT HEALTH, V14, P597, DOI 10.1111/j.1365-3156.2009.02252.x; Vanlerberghe V, 2009, TROP MED INT HEALTH, V14, P169; VANLERBERGHE V, 2008, 2 INT C DENG DENG HA; Webster DP, 2009, LANCET INFECT DIS, V9, P678, DOI 10.1016/S1473-3099(09)70254-3; WHO (World Health Organization), 2005, WHOCDSWHOPESGCDPP200	15	20	20	1	8	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	SEP	2010	15	9					1067	1071		10.1111/j.1365-3156.2010.02582.x				5	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	635NP	WOS:000280662700011	20561312	Bronze			2019-03-26	
J	Sinka, ME; Rubio-Palis, Y; Manguin, S; Patil, AP; Temperley, WH; Gething, PW; Van Boeckel, T; Kabaria, CW; Harbach, RE; Hay, SI				Sinka, Marianne E.; Rubio-Palis, Yasmin; Manguin, Sylvie; Patil, Anand P.; Temperley, Will H.; Gething, Peter W.; Van Boeckel, Thomas; Kabaria, Caroline W.; Harbach, Ralph E.; Hay, Simon I.			The dominant Anopheles vectors of human malaria in the Americas: occurrence data, distribution maps and bionomic precis	PARASITES & VECTORS			English	Article							SOUTH-EASTERN BRAZIL; PLASMODIUM-FALCIPARUM TRANSMISSION; TAPACHULA FOOTHILLS AREA; HOST SELECTION PATTERNS; MARK-RELEASE-RECAPTURE; DIPTERA-CULICIDAE; WESTERN VENEZUELA; MOSQUITOS DIPTERA; LARVAL HABITATS; QUADRIMACULATUS COMPLEX	Background: An increasing knowledge of the global risk of malaria shows that the nations of the Americas have the lowest levels of Plasmodium falciparum and P. vivax endemicity worldwide, sustained, in part, by substantive integrated vector control. To help maintain and better target these efforts, knowledge of the contemporary distribution of each of the dominant vector species (DVS) of human malaria is needed, alongside a comprehensive understanding of the ecology and behaviour of each species. Results: A database of contemporary occurrence data for 41 of the DVS of human malaria was compiled from intensive searches of the formal and informal literature. The results for the nine DVS of the Americas are described in detail here. Nearly 6000 occurrence records were gathered from 25 countries in the region and were complemented by a synthesis of published expert opinion range maps, refined further by a technical advisory group of medical entomologists. A suite of environmental and climate variables of suspected relevance to anopheline ecology were also compiled from open access sources. These three sets of data were then combined to produce predictive species range maps using the Boosted Regression Tree method. The predicted geographic extent for each of the following species (or species complex*) are provided: Anopheles (Nyssorhynchus) albimanus Wiedemann, 1820, An. (Nys.) albitarsis*, An. (Nys.) aquasalis Curry, 1932, An. (Nys.) darlingi Root, 1926, An. (Anopheles) freeborni Aitken, 1939, An. (Nys.) marajoara Galvao & Damasceno, 1942, An. (Nys.) nuneztovari*, An. (Ano.) pseudopunctipennis* and An. (Ano.) quadrimaculatus Say, 1824. A bionomics review summarising ecology and behaviour relevant to the control of each of these species was also compiled. Conclusions: The distribution maps and bionomics review should both be considered as a starting point in an ongoing process of (i) describing the distributions of these DVS (since the opportunistic sample of occurrence data assembled can be substantially improved) and (ii) documenting their contemporary bionomics (since intervention and control pressures can act to modify behavioural traits). This is the first in a series of three articles describing the distribution of the 41 global DVS worldwide. The remaining two publications will describe those vectors found in (i) Africa, Europe and the Middle East and (ii) in Asia. All geographic distribution maps are being made available in the public domain according to the open access principles of the Malaria Atlas Project.	[Sinka, Marianne E.; Patil, Anand P.; Temperley, Will H.; Gething, Peter W.; Van Boeckel, Thomas; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England; [Rubio-Palis, Yasmin] Univ Carabobo, BIOMED, Maracay 2101A, Venezuela; [Rubio-Palis, Yasmin] Minist Poder Popular Salud, Lab Ecol Vectores, Direcc Control Vectores & Fauna Nociva, Maracay, Venezuela; [Manguin, Sylvie] Univ Montpellier I, Inst Rech Dev, Lab Immunophysiopathol Virale & Mol, UMR MD3,Fac Pharm, F-34093 Montpellier, France; [Van Boeckel, Thomas] Univ Libre Bruxelles, B-1050 Brussels, Belgium; [Kabaria, Caroline W.; Hay, Simon I.] Univ Oxford, Kenyatta Natl Hosp Grounds, Wellcome Trust Collaborat Programme,KEMRI, Malaria Publ Hlth & Epidemiol Grp,Ctr Geog Med, Nairobi, Kenya; [Harbach, Ralph E.] Nat Hist Museum, Dept Entomol, London SW7 5BD, England	Sinka, ME (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Tinbergen Bldg,S Parks Rd, Oxford OX1 3PS, England.	marianne.sinka@zoo.ox.ac.uk; simon.hay@zoo.ox.ac.uk	Manguin, Sylvie/G-1787-2015; Hay, Simon/F-8967-2015	Manguin, Sylvie/0000-0002-5925-7164; Hay, Simon/0000-0002-0611-7272; Kabaria, Caroline/0000-0002-5641-5243; Gething, Peter/0000-0001-6759-5449	Wellcome Trust, U.K.; Wellcome Trust [083534, 079091, 079080]	We wish to thank Philip Mbithi, Robi Okara, Rosalind Howes, Edward Haynes, Owen Yang, Carolynn Tago, and Elisabeth Thiveyrat for primary data abstraction and Anja Bibby and Rosalind Howes for proof-reading the manuscript. We also thank the Technical Advisory Group for extended support over the duration of the project (in addition to co-authors Ralph Harbach, Sylvie Manguin and Yasmin Rubio-Palis and these include Mike Bangs, Theeraphap Chareonviriyaphap, Janet Hemingway and Charles M. Mbogo). The following persons provided valuable unpublished information for the malaria vectors in the Americas: Marylin Aparicio (Bolivia), Mauricio Casas (Mexico), Roberto Fernandez (Peru), Ranulfo Gonzalez (Colombia), and Ricardo Lourenco-de-Oliveira (Brazil). MES is funded by a project grant from the Wellcome Trust (#083534) to SIH. SIH is funded by a Senior Research Fellowship from the Wellcome Trust (#079091) which also supports CWK and PWG. APP and WHT are funded by a Wellcome Trust Principal Research Fellowship (#079080) to Professor Robert Snow. This work forms part of the output of the Malaria Atlas Project (MAP, http://www.map.ox.ac.uk), principally funded by the Wellcome Trust, U.K.	Achee NL, 2007, J AM MOSQUITO CONTR, V23, P276, DOI 10.2987/8756-971X(2007)23[276:AMSTDT]2.0.CO;2; Achee NL, 2006, J VECTOR ECOL, V31, P45, DOI 10.3376/1081-1710(2006)31[45:BPASDO]2.0.CO;2; Achee NL, 2000, J VECTOR ECOL, V25, P203; Achee NL, 2005, J AM MOSQUITO CONTR, V21, P366, DOI 10.2987/8756-971X(2006)21[366:AMSUAN]2.0.CO;2; Achee NL, 2006, J MED ENTOMOL, V43, P382, DOI 10.1603/0022-2585(2006)043[0382:UORSAG]2.0.CO;2; Almiron WR, 1996, MEM I OSWALDO CRUZ, V91, P1; *ANOBASE, ANOBASE BIBL DAT; [Anonymous], VECTOR BORNE ZOONOTI; [Anonymous], WEB SCI; APPERSON CS, 1992, J INVERTEBR PATHOL, V60, P219, DOI 10.1016/0022-2011(92)90002-L; Arredondo-Jimenez JI, 2006, MED VET ENTOMOL, V20, P377, DOI 10.1111/j.1365-2915.2006.00656.x; ARREDONDOJIMENEZ JI, 1993, J AM MOSQUITO CONTR, V9, P210; ARREDONDOJIMENEZ JI, 1990, J AM MOSQUITO CONTR, V6, P300; ARREDONDOJIMENEZ JI, 1995, B WORLD HEALTH ORGAN, V73, P329; ASTAIZA R, 1988, REV SAUDE PUBL, V22, P101, DOI 10.1590/S0034-89101988000200005; BASSI DG, 1989, J AM MOSQUITO CONTR, V5, P264; BEACH RF, 1992, AM J TROP MED HYG, V47, P478, DOI 10.4269/ajtmh.1992.47.478; BENITEZ JA, 2004, B MALARIOL SALUD AMB, V44, P93; BERTI J, 1993, MEM I OSWALDO CRUZ, V88, P353, DOI 10.1590/S0074-02761993000300003; BERTI J, 1993, MEM I OSWALDO CRUZ, V88, P363, DOI 10.1590/S0074-02761993000300004; Bond JG, 2006, ENVIRON ENTOMOL, V35, P1561, DOI 10.1603/0046-225X(2006)35[1561:DAADRO]2.0.CO;2; Bond JG, 2007, J VECTOR ECOL, V32, P41, DOI 10.3376/1081-1710(2007)32[41:IOEMFA]2.0.CO;2; Bond JG, 2004, P ROY SOC B-BIOL SCI, V271, P2161, DOI 10.1098/rspb.2004.2826; BOWN DN, 1991, J AM MOSQUITO CONTR, V7, P180; BOWN DN, 1993, J AM MOSQUITO CONTR, V9, P321; Boyd DS, 2004, INT J REMOTE SENS, V25, P3343, DOI 10.1080/01431160310001654356; BRANQUINHO MS, 1993, T ROY SOC TROP MED H, V87, P391, DOI 10.1016/0035-9203(93)90008-E; Brochero Helena, 2006, Biomédica, V26, P269; Brochero HL, 2005, J AM MOSQUITO CONTR, V21, P182, DOI 10.2987/8756-971X(2005)21[182:BAABSO]2.0.CO;2; Butler WP, 2000, MIL MED, V165, P897; Calado DC, 2008, MEM I OSWALDO CRUZ, V103, P791, DOI 10.1590/S0074-02762008000800009; CARLSON DB, 1986, J AM MOSQUITO CONTR, V2, P516; Carreira-Alves JR, 2001, REV SAUDE PUBL, V35, P407, DOI 10.1590/S0034-89102001000400012; CASAS M, 1994, J AM MOSQUITO CONTR, V10, P348; CASAS M, 1994, J AM MOSQUITO CONTR, V10, P355; Casas M, 1998, J AM MOSQUITO CONTR, V14, P410; CHADEE DD, 1992, J MED ENTOMOL, V29, P567, DOI 10.1093/jmedent/29.3.567; Charlwood JD, 1996, MEM I OSWALDO CRUZ, V91, P391, DOI 10.1590/S0074-02761996000400001; Chefaoui RM, 2008, ECOL MODEL, V210, P478, DOI 10.1016/j.ecolmodel.2007.08.010; Clark GG, 2005, J AM MOSQUITO CONTR, V21, P412, DOI 10.2987/8756-971X(2006)21[412:MVCABI]2.0.CO;2; Coetzee M, 2004, AM J TROP MED HYG, V70, P103, DOI 10.4269/ajtmh.2004.70.103; Coetzee M, 1999, AM J TROP MED HYG, V60, P649, DOI 10.4269/ajtmh.1999.60.649; CONN J, 1993, J AM MOSQUITO CONTR, V9, P294; CONN J, 1990, J AM MOSQUITO CONTR, V6, P400; Conn JE, 2002, AM J TROP MED HYG, V66, P18, DOI 10.4269/ajtmh.2002.66.18; Correa TG, 2007, VET PARASITOL, V145, P181, DOI 10.1016/j.vetpar.2006.10.025; da Rocha JAM, 2008, AM J TROP MED HYG, V78, P872, DOI 10.4269/ajtmh.2008.78.872; da Silva-Vasconcelos A, 2002, MEM I OSWALDO CRUZ, V97, P151, DOI 10.1590/S0074-02762002000200002; Darsie R, 2005, IDENTIFICATION GEOGR; De Roa EZ, 2002, J AM MOSQUITO CONTR, V18, P47; De'ath G, 2007, ECOLOGY, V88, P243, DOI 10.1890/0012-9658(2007)88[243:BTFEMA]2.0.CO;2; DEARRUDA M, 1986, AM J TROP MED HYG, V35, P873, DOI 10.4269/ajtmh.1986.35.873; Dennett JA, 2001, J AM MOSQUITO CONTR, V17, P231; DEOLIVEIRAFERREIRA J, 1990, AM J TROP MED HYG, V43, P6; Diéguez Lorenzo, 2002, Rev Cubana Med Trop, V54, P118; *DIS VECT, DIS VECT DAT; Elith J, 2008, J ANIM ECOL, V77, P802, DOI 10.1111/j.1365-2656.2008.01390.x; Elith J, 2006, ECOGRAPHY, V29, P129, DOI 10.1111/j.2006.0906-7590.04596.x; ELLIOTT R, 1972, AM J TROP MED HYG, V21, P755, DOI 10.4269/ajtmh.1972.21.755; Estrada-Franco J G, 1993, Bull Pan Am Health Organ, V27, P26; FARAN M E, 1981, Mosquito Systematics, V13, P1; FERNANDEZSALAS I, 1994, J AM MOSQUITO CONTR, V10, P477; FERNANDEZSALAS I, 1994, J MED ENTOMOL, V31, P663, DOI 10.1093/jmedent/31.5.663; FERNANDEZSALAS I, 1993, J AM MOSQUITO CONTR, V9, P375; Ferrier S, 2002, BIODIVERS CONSERV, V11, P2275, DOI 10.1023/A:1021302930424; Fielding AH, 1997, ENVIRON CONSERV, V24, P38, DOI 10.1017/S0376892997000088; FloresMendoza C, 1996, REV SAUDE PUBL, V30, P129, DOI 10.1590/S0034-89101996000200003; Foley DH, 2008, ECOL ENTOMOL, V33, P12, DOI 10.1111/j.1365-2311.2007.00927.x; Forattini OP, 1996, REV SAUDE PUBL, V30, P299, DOI 10.1590/S0034-89101996000400002; FORATTINI OP, 1995, REV SAUDE PUBL, V29, P20, DOI 10.1590/S0034-89101995000100005; FORATTINI OP, 1993, REV SAUDE PUBL, V27, P313, DOI 10.1590/S0034-89101993000500001; Forattini OP, 1998, REV SAUDE PUBL, V32, P189, DOI 10.1590/S0034-89101998000200015; FORATTINI OP, 1994, REV SAUDE PUBL, V28, P329, DOI 10.1590/S0034-89101994000500003; Friedman J, 2000, ANN STAT, V28, P337, DOI 10.1214/aos/1016218223; FRITZ GN, 1994, MOL BIOL EVOL, V11, P406; Gething PW, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000724; Girod R, 2008, MEM I OSWALDO CRUZ, V103, P702, DOI 10.1590/S0074-02762008000700013; *GODD SPAC FLIGHT, GLOB LAND BIOSPH DAT; Grieco JP, 2002, J AM MOSQUITO CONTR, V18, P307; Grieco JP, 2005, J AM MOSQUITO CONTR, V21, P279, DOI 10.2987/8756-971X(2005)21[279:CSOTSO]2.0.CO;2; Grillet Maria Eugenia, 1998, Boletin de la Direccion de Malariologia y Saneamiento Ambiental, V38, P38; Grillet ME, 2000, J MED ENTOMOL, V37, P231, DOI 10.1603/0022-2585-37.2.231; Guerra CA, 2007, MALARIA J, V6, DOI 10.1186/1475-2575-6-17; Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038; Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774; Gutierrez LA, 2008, ACTA TROP, V107, P99, DOI 10.1016/j.actatropica.2008.04.019; Harris AF, 2006, T ROY SOC TROP MED H, V100, P45, DOI 10.1016/j.trstmh.2005.07.001; Hay SI, 2006, ADV PARASIT, V62, P37, DOI 10.1016/S0065-308X(05)62002-7; Hay SI, 2000, ADV PARASIT, V47, P1, DOI 10.1016/S0065-308X(00)47005-3; Hay SI, 2010, PLOS MED, V7; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000209; Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048; HAYES J, 1987, J AM MOSQUITO CONTR, V3, P418; Hernandez JE, 1997, J AM MOSQUITO CONTR, V13, P28; HERRERA S, 1987, COLOMB MEDICA, V18, P2; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; HOBBS JH, 1986, J AM MOSQUITO CONTR, V2, P150; Jensen J. R, 1996, INTRO DIGITAL IMAGE, P197; Jensen T, 1996, AM J TROP MED HYG, V54, P523, DOI 10.4269/ajtmh.1996.54.523; KAISER PE, 1988, J AM MOSQUITO CONTR, V4, P494; KAISER PE, 1988, J AM MOSQUITO CONTR, V4, P34; Killeen GF, 2002, LANCET INFECT DIS, V2, P618, DOI 10.1016/S1473-3099(02)00397-3; Kiszewski A, 2004, AM J TROP MED HYG, V70, P486, DOI 10.4269/ajtmh.2004.70.486; Klein T.A., 1991, Revista da Sociedade Brasileira de Medicina Tropical, V24, P13; KLEIN TA, 1990, J AM MOSQUITO CONTR, V6, P700; KOTTKAMP WB, 1985, J AM MOSQUITO CONTR, V1, P17; LACEY LA, 1985, J AM MOSQUITO CONTR, V1, P38; Lardeux F, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-8; Lardeux FJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-141; Levine RS, 2004, J MED ENTOMOL, V41, P607, DOI 10.1603/0022-2585-41.4.607; LI ZL, 1993, REMOTE SENS ENVIRON, V43, P67, DOI 10.1016/0034-4257(93)90065-6; LINTHICUM K J, 1988, Mosquito Systematics, V20, P98; Loaiza JR, 2008, J MED ENTOMOL, V45, P841, DOI 10.1603/0022-2585(2008)45[841:SCADOA]2.0.CO;2; LOURENCODEOLIVEIRA R, 1989, MEM I OSWALDO CRUZ, V84, P501, DOI 10.1590/S0074-02761989000400008; LourencodeOliveira R, 1996, MEM I OSWALDO CRUZ, V91, P687, DOI 10.1590/S0074-02761996000600005; LOYOLA EG, 1993, J MED ENTOMOL, V30, P518, DOI 10.1093/jmedent/30.3.518; LOYOLA EG, 1990, J AM MOSQUITO CONTR, V6, P635; LOYOLA EG, 1991, MED VET ENTOMOL, V5, P233, DOI 10.1111/j.1365-2915.1991.tb00546.x; LOYOLA EG, 1991, T ROY SOC TROP MED H, V85, P171, DOI 10.1016/0035-9203(91)90010-V; MACDONALD G, 1957, EPIDEMIOLOGY CONTROL, P63; Magris M, 2007, MEM I OSWALDO CRUZ, V102, P303, DOI 10.1590/S0074-02762007005000049; *MALARIAWORLD, MALARIAWORLD DAT; Manguin S, 1996, J AM MOSQUITO CONTR, V12, P619; MANGUIN S, 1995, AM J TROP MED HYG, V53, P362, DOI 10.4269/ajtmh.1995.53.362; MANGUIN S, 1993, J AM MOSQUITO CONTR, V9, P403; Manguin S, 1996, J MED ENTOMOL, V33, P205, DOI 10.1093/jmedent/33.2.205; Manguin S., 2008, BIODIVERSITY MALARIA; Marques GRAM, 2009, REV SAUDE PUBL, V43, P369, DOI 10.1590/s0034-89102009005000006; Marten GG, 2000, J VECTOR ECOL, V25, P1; MCHUGH CP, 1989, AM J TROP MED HYG, V41, P169, DOI 10.4269/ajtmh.1989.41.169; MCLAUGHLIN RE, 1988, J INVERTEBR PATHOL, V51, P172, DOI 10.1016/0022-2011(88)90078-X; MCLAUGHLIN RE, 1987, J AM MOSQUITO CONTR, V3, P574; MEKURIA Y, 1990, J AM MOSQUITO CONTR, V6, P651; MIAN LS, 1990, J AM MOSQUITO CONTR, V6, P64; Mijares AS, 1997, J MED ENTOMOL, V34, P1; MITCHELL CJ, 1985, AM J TROP MED HYG, V34, P945, DOI 10.4269/ajtmh.1985.34.945; Molez JF, 1998, B SOC PATHOL EXOT, V91, P334; de Barros FSM, 2007, MEM I OSWALDO CRUZ, V102, P299, DOI 10.1590/S0074-02762007005000024; Moore SJ, 2002, J AM MOSQUITO CONTR, V18, P107; Moreno JE, 2007, MED VET ENTOMOL, V21, P339, DOI 10.1111/j.1365-2915.2007.00704.x; Moreno JE, 2005, MED VET ENTOMOL, V19, P329, DOI 10.1111/j.1365-2915.2005.00572.x; Moreno Jorge, 2004, Entomotropica, V19, P55; Moreno Jorge, 2000, Boletin de la Direccion de Malariologia y Saneamiento Ambiental, V40, P21; Moser Jesus Berti, 2004, Entomotropica, V19, P79; Motoki MT, 2009, MEM I OSWALDO CRUZ, V104, P823, DOI 10.1590/S0074-02762009000600004; Mouchet J, 2004, BIODIVERSITE PALUDIS; MYNENI RB, 1995, IEEE T GEOSCI REMOTE, V33, P481, DOI 10.1109/36.377948; Nagm Lucy, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P309, DOI 10.1590/S0036-46652007000500007; NAYAR JK, 1992, J AM MOSQUITO CONTR, V8, P61; Olano V, 1997, Rev Panam Salud Publica, V1, P287, DOI 10.1590/S1020-49891997000400005; ORR BK, 1989, J AM MOSQUITO CONTR, V5, P579; Osborn Frances R., 2004, Boletin de Malariologia y Salud Ambiental, V44, P77; PALIS YR, 1991, VECTOR BIOL MALARIA; PERICH MJ, 1990, MED VET ENTOMOL, V4, P393, DOI 10.1111/j.1365-2915.1990.tb00456.x; *POSTGRESQL, POSTGRESQL OP DAT; Povoa MM, 2006, MEM I OSWALDO CRUZ, V101, P163, DOI 10.1590/S0074-02762006000200008; Povoa MM, 2001, MEM I OSWALDO CRUZ, V96, P179, DOI 10.1590/S0074-02762001000200008; Quinones ML, 2006, MEM I OSWALDO CRUZ, V101, P617, DOI 10.1590/S0074-02762006000600007; QUINONES ML, 1990, J AM MOSQUITO CONTR, V6, P602; *RBMP, 2008, GLOB MAL ACT PLAN MA; Reinert JF, 1997, J AM MOSQUITO CONTR, V13, P1; Reinert JF, 2003, J AM MOSQUITO CONTR, V19, P89; Rejmankova E, 1996, ENVIRON ENTOMOL, V25, P1058, DOI 10.1093/ee/25.5.1058; Rejmankova E, 1999, J VECTOR ECOL, V24, P130; Rejmankova E, 2000, J VECTOR ECOL, V25, P229; Galardo AKR, 2007, AM J TROP MED HYG, V76, P461, DOI 10.4269/ajtmh.2007.76.461; Richards F O Jr, 1994, Bull Pan Am Health Organ, V28, P112; Roberts D R, 1991, Bull Pan Am Health Organ, V25, P210; Roberts D. R., 2002, CONTEXTUAL DETERMINA, P35; Roberts DR, 1997, EMERG INFECT DIS, V3, P295, DOI 10.3201/eid0303.970305; Roberts DR, 2002, J VECTOR ECOL, V27, P21; ROBERTS DR, 1987, J AM MOSQUITO CONTR, V3, P433; ROBERTS DR, 1993, J AM MOSQUITO CONTR, V9, P456; ROBERTSON LC, 1993, J MED ENTOMOL, V30, P689, DOI 10.1093/jmedent/30.4.689; RODRIGUEZ AD, 1993, J AM MOSQUITO CONTR, V9, P46; Rodriguez M, 2009, J MED ENTOMOL, V46, P307, DOI 10.1603/033.046.0215; Rogers DJ, 2006, ADV PARASIT, V62, P1, DOI 10.1016/S0065-308X(05)62001-5; ROJAS E, 1992, REV SAUDE PUBL, V26, P336, DOI 10.1590/S0034-89101992000500007; Rojas W, 2001, Cad Saude Publica, V17 Suppl, P103; Root FM, 1938, AM J HYG, V27, P549, DOI 10.1093/oxfordjournals.aje.a118414; ROSAFREITAS MG, 1992, J AM MOSQUITO CONTR, V8, P357; ROZENDAAL JA, 1990, MEM I OSWALDO CRUZ, V85, P221, DOI 10.1590/S0074-02761990000200014; ROZENDAAL JA, 1992, MED VET ENTOMOL, V6, P16, DOI 10.1111/j.1365-2915.1992.tb00029.x; ROZENDAAL JA, 1989, J AM MOSQUITO CONTR, V5, P351; Rubio-Palis Y, 2003, J AM MOSQUITO CONTR, V19, P107; RubioPalis Y, 1997, J MED ENTOMOL, V34, P499, DOI 10.1093/jmedent/34.5.499; RUBIOPALIS Y, 1992, ACTA TROP, V52, P167, DOI 10.1016/0001-706X(92)90033-T; RUBIOPALIS Y, 1994, MED VET ENTOMOL, V8, P275, DOI 10.1111/j.1365-2915.1994.tb00509.x; RUBIOPALIS Y, 1992, MED VET ENTOMOL, V6, P325, DOI 10.1111/j.1365-2915.1992.tb00628.x; SAVAGE HM, 1990, J AM MOSQUITO CONTR, V6, P612; Scharlemann JPW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001408; SEAWRIGHT JA, 1992, J AGR ENTOMOL, V9, P289; Service M.W., 1993, P96; SERVICE MW, 1993, BRUCECHWATTS ESSENTI, P305; Shiff C, 2002, CLIN MICROBIOL REV, V15, P278, DOI 10.1128/CMR.15.2.278-293.2002; Sierra DM, 2004, J MED ENTOMOL, V41, P302, DOI 10.1603/0022-2585-41.3.302; Smith TW, 1998, J AM MOSQUITO CONTR, V14, P72; Snow RW, 2008, PLOS MED, V5, P1068, DOI 10.1371/journal.pmed.0050142; Solarte Y, 1996, MEM I OSWALDO CRUZ, V91, P141, DOI 10.1590/S0074-02761996000200002; Tadei Wanderli Pedro, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P87, DOI 10.1590/S0036-46652000000200005; Tadei WP, 1998, AM J TROP MED HYG, V59, P325, DOI 10.4269/ajtmh.1998.59.325; VanDerWal J, 2009, ECOL MODEL, V220, P589, DOI 10.1016/j.ecolmodel.2008.11.010; Vazquez-Martinez MG, 2002, J MED ENTOMOL, V39, P825, DOI 10.1603/0022-2585-39.6.825; Vittor AY, 2009, AM J TROP MED HYG, V81, P5; Vittor AY, 2006, AM J TROP MED HYG, V74, P3, DOI 10.4269/ajtmh.2006.74.3; Voorham J, 2002, REV SAUDE PUBL, V36, P75, DOI 10.1590/S0034-89102002000100012; WALKER ED, 1993, J MED ENTOMOL, V30, P1050, DOI 10.1093/jmedent/30.6.1050; Wallace JR, 2004, J MED ENTOMOL, V41, P853, DOI 10.1603/0022-2585-41.5.853; WASHINO RK, 1967, J MED ENTOMOL, V4, P311, DOI 10.1093/jmedent/4.3.311; Wekesa JW, 1997, J MED ENTOMOL, V34, P219, DOI 10.1093/jmedent/34.2.219; Wekesa JW, 1996, J MED ENTOMOL, V33, P344, DOI 10.1093/jmedent/33.3.344; White GB, 1989, MALARIA GEOGRAPHICAL, P7; WHO, 2004, GLOB STRAT FRAM INT; *WHO, 2007, GUID EL RES TOC MAL, P47; *WHO PAHO, 2006, REG STRAT PLAN MAL A, P71; WHO/PAHO (World Health Organization/Pan American Health Organization), 2008, MAL AM TIM SER EP DA; WILKERSON R C, 1991, Mosquito Systematics, V23, P110; Wilkerson RC, 1995, MEM I OSWALDO CRUZ, V90, P721, DOI 10.1590/S0074-02761995000600013; *WORLDCL, WORLDCL DAT; *WRBU, MOSQ CAT; Xavier MMD, 1999, REV SAUDE PUBL, V33, P535, DOI 10.1590/S0034-89101999000600003; ZIMMERMAN RH, 1992, MEM I OSWALDO CRUZ, V87, P371, DOI 10.1590/S0074-02761992000700064; Zimmerman RH, 2006, J MED ENTOMOL, V43, P947, DOI 10.1603/0022-2585(2006)43[947:BHOASD]2.0.CO;2; ENV HLTH USAID MALAR; INDIAN J MED RES	225	210	211	1	35	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	AUG 16	2010	3								72	10.1186/1756-3305-3-72				26	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	658OL	WOS:000282499200001	20712879	DOAJ Gold, Green Published			2019-03-26	
J	Bhullar, N; Maikere, J				Bhullar, Navneet; Maikere, Jacob			Challenges in mass drug administration for treating lymphatic filariasis in Papua, Indonesia	PARASITES & VECTORS			English	Article								Background: The World Health Organization (WHO) Global Program to Eliminate Lymphatic Filariasis relies on mass drug administration (MDA) of two drugs annually for 4 to 6 years. The goal is to reduce the reservoir of microfilariae in the blood to a level insufficient to maintain transmission by the mosquito vector. In 2008, the international medical aid organization Medecins Sans Frontieres (MSF) performed the first round of a MDA in the high-burden area of Asmat district, in Papua, Indonesia. We report the challenges faced in this MDA on a remote Indonesian island and propose solutions to overcome these hurdles in similar future contexts. Results: During the MDA, we encountered difficult challenges in accessing as well as persuading the patient population to take the antifilarial drugs. Health promotion activities supporting treatment need to be adapted and repetitive, with adequate time and resources allocated for accessing and communicating with local, seminomadic populations. Distribution of bednets resulted in an increase in MDA coverage, but it was still below the 80-85% target. Conclusions: MDA for lymphatic filariasis is how the WHO has planned to eliminate the disease from endemic areas. Our programmatic experience will hopefully help inform future campaign planning in difficult-to-access, high-burden areas of the world to achieve target MDA coverage for elimination of lymphatic filariasis.	[Bhullar, Navneet; Maikere, Jacob] Med Sans Frontieres Operat Ctr Brussels OCB, B-1090 Brussels, Belgium	Bhullar, N (reprint author), Med Sans Frontieres Operat Ctr Brussels OCB, Rue Dupre 94, B-1090 Brussels, Belgium.	nebhullar@gmail.com			MSF	Funding for clinical services was provided by MSF, which had no role in study design; collection, analysis, and interpretation of data; writing of the manuscript; or decision to submit the manuscript for publication.	Behbehani K, 1998, Bull World Health Organ, V76 Suppl 2, P64; Dreyer G., 1997, Cadernos de Saude Publica, V13, P537, DOI 10.1590/S0102-311X1997000300030; Ottesen EA, 1999, PARASITOL TODAY, V15, P382, DOI 10.1016/S0169-4758(99)01486-6; Ottesen EA, 1997, B WORLD HEALTH ORGAN, V75, P491; Sapak P, 2004, EVALUATION LYMPHATIC; *WHO, GLOB PROGR EL LYMPH; WHO, 2005, MON EP ASS PROGR EL; *WHO, 2004, WKLY EPIDEMIOL REC, V79, P417	8	19	19	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1756-3305			PARASITE VECTOR	Parasites Vectors	AUG 11	2010	3								70	10.1186/1756-3305-3-70				7	Parasitology; Tropical Medicine	Parasitology; Tropical Medicine	658ND	WOS:000282495800001	20701744	DOAJ Gold, Green Published			2019-03-26	
J	Sopoh, GE; Dossou, AD; Brun, LV; Barogui, YT; Houezo, JG; Affolabi, D; Anagonou, SY; Johnson, RC; Kestens, L; Portaels, F				Sopoh, Ghislain Emmanuel; Dossou, Ange Dodji; Brun, Luc Valere; Barogui, Yves Thierry; Houezo, Jean Gabin; Affolabi, Dissou; Anagonou, Severin Y.; Johnson, Roch Christian; Kestens, Luc; Portaels, Francoise			Case Report: Severe Multifocal Form of Buruli Ulcer after Streptomycin and Rifampin Treatment: Comments on Possible Dissemination Mechanisms	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							RECONSTITUTION INFLAMMATORY SYNDROME; HIV-POSITIVE PATIENT; MYCOBACTERIUM-ULCERANS; INFECTION; THERAPY; DISEASE; LEPROSY; BENIN; MODEL; CARE	Buruli ulcer (BU). a disease caused by Mycobacterium ulcerans. leads to the destruction of skin and sometimes bone. Here, we report a case of severe multifocal BU with osteomyelitis in a 6-year-old human immunodeficiency virus (HIV)-negative boy Such disseminated forms are poorly documented and generally occur in patients with HIV confection The advent of antibiotic treatment with streptomycin (S) and rifampin (R) raised hope that these multifocal BU cases could be reduced The present case raises two relevant points about multifocal BU the mechanism of dissemination that leads to the development of multiple foci and the difficulties of treatment of mull [focal forms of BU Biochemical (hypoproteinemia), hematological (anemia). clinical (traditional treatment), and genetic factors are discussed as possible risk factors for dissemination	[Sopoh, Ghislain Emmanuel] Ctr Depistage & Traitement Ulcere Buruli CDTUB Al, DNPS, Minist Hlth, Allada Atlantique, Benin; Univ Parakou, Fac Med, Parakou, Benin; PNT, LRM, Cotonou, Benin; PNLLUB, Cotonou, Benin; ITM, Immunol Unit, Antwerp, Belgium; ITM, Mycobacteriol Unit, Antwerp, Belgium	Sopoh, GE (reprint author), Ctr Depistage & Traitement Ulcere Buruli CDTUB Al, DNPS, Minist Hlth, Allada Atlantique, Benin.			SOPOH, Ghislain Emmanuel/0000-0003-1237-1047; Brun, luc Valere C./0000-0002-6024-3982	CDTUB Allada; European Union [INCO-CT-2005-051476]	We are grateful to the parents of the patient DR for giving their consent for publication of the history of their child, all of the staff of CDTUB Allada and partners who support the PNLLUB and the CDTUB Allada, in particular the Government of Benin, Burulico Project (European Union), project INCO-CT-2005-051476. Damien Action, Brussels, Belgium Directorate General for Development and Cooperation (DC DC), Brussels, Belgium. Raoul Follereau Foundation of Luxembourg. World Health Organization (WHO). Geneva. Switzerland We thank M T Silva and F Paasch for critical review of this manuscript	[Anonymous], 2008, Wkly Epidemiol Rec, V83, P145; Corti Marcelo, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P267, DOI 10.1590/S0036-46652007000400015; Debacker M, 2004, EMERG INFECT DIS, V10, P1391, DOI 10.3201/eid1008.030886; Eddyani M, 2009, J CLIN MICROBIOL, V47, P1700, DOI 10.1128/JCM.00197-09; Fock RA, 2008, J NUTR SCI VITAMINOL, V54, P371, DOI 10.3177/jnsv.54.371; Funada H, 1991, Kansenshogaku Zasshi, V65, P1297; Guarner J, 2003, EMERG INFECT DIS, V9, P651; Johnson RC, 2002, AIDS, V16, P1704, DOI 10.1097/00002030-200208160-00027; KESTENS L, 2009, CURR OPIN HIV AIDS, V3, P419; Kibadi K, 2008, Med Trop (Mars), V68, P137; Lagarrigue V, 2000, Med Trop (Mars), V60, P262; Lawn SD, 2007, BRIT MED J, V334, P217, DOI 10.1136/bmj.39107.480359.80; LIMBOS P, 1961, ANN SOC BELG MED TR, V2, P127; MAUVIEUX L, 2005, DCEM3 MODULE 17 MALA; Mulder AA, 2008, T ROY SOC TROP MED H, V102, P912, DOI 10.1016/j.trstmh.2008.05.026; O'Brien DP, 2009, MED J AUSTRALIA, V191, P564; Ouattara D, 2002, B SOC PATHOL EXOT, V95, P287; Portaels F., 2003, Bulletin des Seances, Academie Royale des Sciences d'Outre- Mer, V49, P161; PORTAELS F, 2008, B ALLF, V23, P48; PORTAELS F, 2001, MANUAL HLTH CARE PRO; Portaels F, 2009, CLIN DERMATOL, V27, P291, DOI 10.1016/j.clindermatol.2008.09.021; Pszolla N, 2003, CLIN INFECT DIS, V37, P78; Rodriguez L, 2005, CLIN DIAGN LAB IMMUN, V12, P502, DOI 10.1128/CDLI.12.4.502-507.2005; Schaible UE, 2007, PLOS MED, V4, P806, DOI 10.1371/journal.pmed.0040115; Schuette D, 2009, EXPERT OPIN BIOL TH, V9, P187, DOI [10.1517/14712590802631854 , 10.1517/14712590802631854]; Schutte D, 2007, PLOS NEGLECT TROP D, V1, DOI 10.1371/journal.pntd.0000002; Silva MT, 2009, LANCET INFECT DIS, V9, P699, DOI 10.1016/S1473-3099(09)70234-8; Singal A, 2006, LEPROSY REV, V77, P76; Skinsnes L K, 1976, Int J Lepr Other Mycobact Dis, V44, P346; Stienstra Y, 2006, GENES IMMUN, V7, P185, DOI 10.1038/sj.gene.6364281; Toll A, 2005, CLIN EXP DERMATOL, V30, P649, DOI 10.1111/j.1365-2230.2005.01892.x; Walsh DS, 2008, T ROY SOC TROP MED H, V102, P969, DOI 10.1016/j.trstmh.2008.06.006; Wang CT, 2000, J FORMOS MED ASSOC, V99, P710; *WHO, 2004, WHOCDSCPEGBUI10	34	13	13	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2010	83	2					307	313		10.4269/ajtmh.2010.09-0617				7	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	635YQ	WOS:000280694300017	20682873	Bronze, Green Published			2019-03-26	
J	Hasker, E; Lutumba, P; Mumba, D; Lejon, V; Buscher, P; Kande, V; Muyembe, JJ; Menten, J; Robays, J; Boelaert, M				Hasker, Epco; Lutumba, Pascal; Mumba, Dieudonne; Lejon, Veerle; Buscher, Phillipe; Kande, Victor; Muyembe, Jean Jacques; Menten, Joris; Robays, Jo; Boelaert, Marleen			Diagnostic Accuracy and Feasibility of Serological Tests on Filter Paper Samples for Outbreak Detection of T.b. gambiense Human African Trypanosomiasis	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							CATT/TRYPANOSOMA-BRUCEI-GAMBIENSE; SLEEPING-SICKNESS PATIENTS; SOUTHERN SUDAN; CEREBROSPINAL-FLUID; AGGLUTINATION-TEST; B.-GAMBIENSE; CONGO; CATT; SURVEILLANCE; ANTIBODIES	Control of human African trypanosomiasis (HAT) in the Democratic Republic of Congo is based on mass population screening by mobile teams, a costly and labor-intensive approach We hypothesized that blood samples collected on filter paper by village health workers and processed in a central laboratory might be a cost-effective alternative We estimated sensitivity and specificity of micro-card agglutination test for trypanosomasis (micro-CATT) and enzyme-linked immunosorbent assay (ELISA)/Tb gambiense on filter paper samples compared with parasitology-based case classification and used the results in a Monte Gallo simulation of a lot quality assurance sampling (LQAS) approach Micro-CATT and ELISA/Tb gambiense showed acceptable sensitivity (92 7% [95% Cl 87.4-98 0%] and 82 2% [95% CI 75.3-90.4%]) and very high specificity (99.4% [95% Cl 99 0-99 9%] and 99 8% [95% Cl 99.5-100%], respectively Conditional on high sample size per lot (>= 60%), both tests could reliably distinguish a 2% from a zero prevalence at village level Alternatively, these tests could be used to identify individual HAT suspects for subsequent confirmation.	[Hasker, Epco; Robays, Jo; Boelaert, Marleen] Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, B-2000 Antwerp, Belgium; [Lutumba, Pascal; Mumba, Dieudonne; Muyembe, Jean Jacques] Inst Natl Rech Biomed, Kinshasa, Zaire; [Kande, Victor] Programme Natl Lutte Trypanosomiase Humaine Afric, Kinshasa, Zaire; [Lejon, Veerle; Buscher, Phillipe] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Menten, Joris] Inst Trop Med, Clin Trial Unit, B-2000 Antwerp, Belgium	Hasker, E (reprint author), Inst Trop Med, Dept Publ Hlth, Epidemiol Unit, Natl Str 155, B-2000 Antwerp, Belgium.		Boelaert, Marleen/E-2698-2012; Buscher, Philippe/B-9956-2012	Boelaert, Marleen/0000-0001-8051-6776; Buscher, Philippe/0000-0002-1926-7472; Lejon, Veerle/0000-0002-6795-0962			BRUN R, 2009, LANCET, V375, P148, DOI DOI 10.1016/S0140-6736(09)60829-1; Buscher P, 1999, ACTA TROP, V73, P11, DOI 10.1016/S0001-706X(99)00009-1; Buscher P, 1995, 22 M INT SCI COUNC T, P46; Cattand P, 2001, TROP MED INT HEALTH, V6, P348, DOI 10.1046/j.1365-3156.2001.00669.x; Chappuis F, 2002, TROP MED INT HEALTH, V7, P942, DOI 10.1046/j.1365-3156.2002.00956.x; Elrayah I. E., 2007, Eastern Mediterranean Health Journal, V13, P1098; LANATA C F, 1991, World Health Statistics Quarterly, V44, P133; LANDIS JR, 1977, BIOMETRICS, V33, P174; Laveissiere C, 1998, B WORLD HEALTH ORGAN, V76, P559; Lejon V, 1998, ACTA TROP, V69, P151, DOI 10.1016/S0001-706X(97)00137-X; LUMSDEN WHR, 1979, T ROY SOC TROP MED H, V73, P312, DOI 10.1016/0035-9203(79)90092-0; Lutumba P, 2005, EMERG INFECT DIS, V11, P1382; Lutumba P, 2005, TROP MED INT HEALTH, V10, P347, DOI 10.1111/j.1365-3156.2005.01391.x; Lutumba P, 2007, EMERG INFECT DIS, V13, P248, DOI 10.3201/eid1302.060075; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; MIEZAN T, 1991, B WORLD HEALTH ORGAN, V69, P603; Moore A, 2001, TROP MED INT HEALTH, V6, P342, DOI 10.1046/j.1365-3156.2001.00714.x; Noireau F, 1991, Bull World Health Organ, V69, P603; Odiit M, 2004, ANN TROP MED PARASIT, V98, P339, DOI 10.1179/000349804225003389; Penchenier L, 2003, ACTA TROP, V85, P31, DOI 10.1016/S0001-706X(02)00232-2; Robays J, 2004, TROP MED INT HEALTH, V9, P542, DOI 10.1111/j.1365-3156.2004.01240.x; Tape TG, INTERPRETING DIAGNOS; Truc P, 2002, B WORLD HEALTH ORGAN, V80, P882; *UN INT CHILDR EM, 2010, INF COUNTR STAT; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; Woo P. T. K., 1970, Acta trop., V27, P384; World Health Organization, 1998, WHO TECH REP SER, P1; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	28	10	10	0	6	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637			AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2010	83	2					374	379		10.4269/ajtmh.2010.09-0735				6	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	635YQ	WOS:000280694300029	20682885	Bronze, Green Published			2019-03-26	
J	Praet, N; Rodriguez-Hidalgo, R; Speybroeck, N; Ahounou, S; Benitez-Ortiz, W; Berkvens, D; Van Hul, A; Barnonuevo-Samaniego, M; Saegerman, C; Dorny, P				Praet, Nicolas; Rodriguez-Hidalgo, Richar; Speybroeck, Niko; Ahounou, Serge; Benitez-Ortiz, Washington; Berkvens, Dirk; Van Hul, Anke; Barnonuevo-Samaniego, Margoth; Saegerman, Claude; Dorny, Pierre			Infection with versus Exposure to Taenia solium: What Do Serological Test Results Tell Us?	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							PORCINE CYSTICERCOSIS; NEUROCYSTICERCOSIS; SEROPREVALENCE; PREVALENCE; FRAMEWORK; ANTIGENS; TOOLS	Taenia solium cysticercosis is an endemic zoonosis in many developing countries Serological tests are the most appropriate diagnostic tools to understand the transmission dynamics of the parasite, but the performances of these methods in such a setting are not known A south Ecuadorian human population living in an endemic area was tested using three common serological tests Because none of them is a gold standard, a Bayesian Latent Class analysis was used to estimate the test characteristics Two definitions of a case were considered to differentiate between prevalence of current infection and prior exposure to the parasite. Differences between the performances of the same test in function of the definition of a case were observed This study shows that test results and prim information should be interpreted carefully in a Bayesian analysis framework. particularly when the latter is based on clinical studies	[Praet, Nicolas; Speybroeck, Niko; Ahounou, Serge; Berkvens, Dirk; Van Hul, Anke; Dorny, Pierre] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium; [Benitez-Ortiz, Washington; Barnonuevo-Samaniego, Margoth] Cent Univ Ecuador, Ctr Int Zoonosis, Quito, Ecuador; Catholic Univ Louvain, Inst Hlth & Soc, B-1200 Brussels, Belgium; [Berkvens, Dirk] Univ Ghent, Dept Anim Prod, Fac Biosci Engn, B-9000 Ghent, Belgium; [Saegerman, Claude] Univ Liege, Dept Infect & Parasit Dis, Res Unit Epidemiol & Risk Anal Appl Vet Sci, Fac Vet Med, Liege, Belgium; Cent Univ Ecuador, Fac Vet Med & Zootech, Quito, Ecuador	Praet, N (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.		Rodriguez-Hidalgo, Richar/P-8877-2015	Rodriguez-Hidalgo, Richar/0000-0002-9338-1062	Belgian Cooperation; Institute of Tropical Medicine in Antwerp, Belgium; Centro Internacional de Zoonosis in Quito, Ecuador	This work was supported by the Belgian Cooperation in the framework of the Institutional Collaboration between the Institute of Tropical Medicine in Antwerp, Belgium and the Centro Internacional de Zoonosis in Quito, Ecuador	Arruda GC, 2005, TROP MED INT HEALTH, V10, P1005, DOI 10.1111/j.1365-3156.2005.01480.x; Berkvens D, 2006, EPIDEMIOLOGY, V17, P145, DOI 10.1097/01.ede.0000198422.64801.8d; Bhattarai NR, 2009, TROP MED INT HEALTH, V14, P404, DOI 10.1111/j.1365-3156.2009.02242.x; Carpio A, 2002, LANCET INFECT DIS, V2, P751, DOI 10.1016/S1473-3099(02)00454-1; Dorny P, 2004, INT J PARASITOL, V34, P569, DOI 10.1016/j.ijpara.2003.11.014; Dorny P, 2003, ACTA TROP, V87, P79, DOI 10.1016/S0001-706X(03)00058-5; Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; Garcia HH, 2003, LANCET, V362, P547, DOI 10.1016/S0140-6736(03)14117-7; Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.1080/10618600.1996.10474713; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Praet N, 2010, INT J PARASITOL, V40, P85, DOI 10.1016/j.ijpara.2009.07.007; Rodriguez-Hidalgo R, 2006, MEM I OSWALDO CRUZ, V101, P779, DOI 10.1590/S0074-02762006000700012; TCHAMDJA E, 2007, THESIS I TROPICAL ME; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50	15	26	26	0	7	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	AUG	2010	83	2					413	415		10.4269/ajtmh.2010.10-0121				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	635YQ	WOS:000280694300035	20682891	Green Published, Bronze			2019-03-26	
J	Rai, B; Kaur, J; Catalina, M				Rai, Balwant; Kaur, Jasdeep; Catalina, Maria			Anti-oxidation actions of curcumin in two forms of bed rest: oxidative stress serum and salivary markers	ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE			English	Article						Curcumin; Serum; Saliva; Oxidative stress; Bed rest position; Space microgravity	VITAMIN-E; OXIDANTS; DAMAGE	Objective: To determine the preventive effects of curcumin on peroxidative damage under two bed rest conditions. Methods: 20 healthy male (10 with curcumin and 10 without curcumin) volunteers were selected. They were studied before, during, and just on bed rest conditions at -6 degrees head-down-tilt (HDT) bed rest and bed rest position (BD) for 10 days. We measured the salivary and serum oxidative markers such as Malonaldehyde, 8-hydroxydeoxyguanosine, vitamin C and E just before HDT & BD, during HOT & BD experiment, and in course time of recovery with curcumin and without curcumin groups. Results: The values of serum and salivary vitamin C & E showed statistically significant decrease in both bed rest conditions as compared to those of the conditions before and during the recovery stage. However, these levels were not significantly lowered in curcumin groups in contrast to the groups without curcumin (P>0.05). MDA and 8-OHdG, levels showed significant increase in simulating microgravity and zero gravity conditions as compared to those before and in the recovery stage. However, these levels were lower in curcumin groups in contrast to the groups without curcumin(P<0.05). Serum and salivary correlation analysis revealed a strong and highly significant correlation for MDA, vitamin C & E and 8 dihydro-2 deoxyguanosine (8-OHdG) in the conditions before, during and in the recovery periods in both bed rest conditions. Since saliva collection is easy and non-invasive, measurements of salivary marker levels may prove to be useful in the Space research. Conclusions: Curcumin prevents peroxidative damage in both bed rest conditions. Further study is required on antioxidation actions of curcumin in space microgravity conditions.	[Rai, Balwant] Catholic Univ Louvain, Sch Dent Oral Pathol & Maxillofacial Surg, Oral Imaging Ctr, B-3000 Louvain, Belgium; [Kaur, Jasdeep] Catholic Univ Louvain, Sch Dent Oral Pathol & Maxillofacial Surg, Forens Odontol Sect, B-3000 Louvain, Belgium; [Catalina, Maria] NASA, SSA NASA JPL Solar Syst Ambassador, Washington, DC USA	Rai, B (reprint author), Catholic Univ Louvain, Sch Dent, B-3000 Louvain, Belgium.	drbalwantraissct@rediffmail.com					Awad JA, 1996, GASTROENTEROL CLIN N, V25, P409, DOI 10.1016/S0889-8553(05)70255-7; Freed Lisa E, 2002, Adv Space Biol Med, V8, P177; Hollander J, 1998, FREE RADICAL BIO MED, V24, P385, DOI 10.1016/S0891-5849(97)00278-5; JANERO DR, 1991, J CELL PHYSIOL, V149, P347, DOI 10.1002/jcp.1041490302; Lee M.D, 1995, J GRAVIT PHYSL, V2, P68; Loft S, 1998, ACTA BIOCHIM POL, V45, P133; Markin A A, 1998, Aviakosm Ekolog Med, V32, P53; Markin A A, 1997, Aviakosm Ekolog Med, V31, P14; NIERENBERG DW, 1985, J CHROMATOGR, V345, P275, DOI 10.1016/0378-4347(85)80165-1; NOMURA J, 2000, J GRAVIT PHYSL, V7, P65; Rai B, 2006, WORLD J MED SCI, V1, P100; RAI B, 2007, J PAK DENT ASS, V16, P189; RAI B, 2006, J PAK DENT ASS, V15, P89; Rai B, 2007, REDOX REP, V12, P163, DOI 10.1179/135100007X200245; Sandur SK, 2007, FREE RADICAL BIO MED, V43, P568, DOI 10.1016/j.freeradbiomed.2007.05.009; SEN CK, 1995, J APPL PHYSIOL, V79, P675; Shahani K, 2010, CANCER RES, V70, P4443, DOI 10.1158/0008-5472.CAN-09-4362; Toyokuni S, 1997, LAB INVEST, V76, P365; Yang PC, 2003, INT J COMP INTEG M, V16, P455, DOI 10.1080/0951192031000080506	19	2	4	0	4	ASIAN PACIFIC J TROPICAL MED	HAIKOU	HAINAN MED UNIV, RM 318, ADMIN BLDG, XUEYUAN RD, HAIKOU, 571101, PEOPLES R CHINA	1995-7645			ASIAN PAC J TROP MED	Asian Pac. J. Trop. Med.	AUG	2010	3	8					651	654		10.1016/S1995-7645(10)60157-5				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	664WQ	WOS:000282994900014		Other Gold			2019-03-26	
J	Cavalli, A; Bamba, SI; Traore, MN; Boelaert, M; Coulibaly, Y; Polman, K; Pirard, M; Van Dormael, M				Cavalli, Anna; Bamba, Sory I.; Traore, Mamadou N.; Boelaert, Marleen; Coulibaly, Youssouf; Polman, Katja; Pirard, Marjan; Van Dormael, Monique			Interactions between Global Health Initiatives and Country Health Systems: The Case of a Neglected Tropical Diseases Control Program in Mali	PLOS NEGLECTED TROPICAL DISEASES			English	Article							QUALITATIVE RESEARCH; SERVICES	Background: Recently, a number of Global Health Initiatives (GHI) have been created to address single disease issues in low-income countries, such as poliomyelitis, trachoma, neonatal tetanus, etc.. Empirical evidence on the effects of such GHIs on local health systems remains scarce. This paper explores positive and negative effects of the Integrated Neglected Tropical Disease (NTD) Control Initiative, consisting in mass preventive chemotherapy for five targeted NTDs, on Mali's health system where it was first implemented in 2007. Methods and Findings: Campaign processes and interactions with the health system were assessed through participant observation in two rural districts (8 health centres each). Information was complemented by interviews with key informants, website search and literature review. Preliminary results were validated during feedback sessions with Malian authorities from national, regional and district levels. We present positive and negative effects of the NTD campaign on the health system using the WHO framework of analysis based on six interrelated elements: health service delivery, health workforce, health information system, drug procurement system, financing and governance. At point of delivery, campaign-related workload severely interfered with routine care delivery which was cut down or totally interrupted during the campaign, as nurses were absent from their health centre for campaign-related activities. Only 2 of the 16 health centres, characterized by a qualified, stable and motivated workforce, were able to keep routine services running and to use the campaign as an opportunity for quality improvement. Increased workload was compensated by allowances, which significantly improved staff income, but also contributed to divert attention away from core routine activities. While the campaign increased the availability of NTD drugs at country level, parallel systems for drug supply and evaluation requested extra efforts burdening local health systems. The campaign budget barely financed institutional strengthening. Finally, though the initiative rested at least partially on national structures, pressures to absorb donated drugs and reach short-term coverage results contributed to distract energies away from other priorities, including overall health systems strengthening. Conclusions: Our study indicates that positive synergies between disease specific interventions and nontargeted health services are more likely to occur in robust health services and systems. Disease-specific interventions implemented as parallel activities in fragile health services may further weaken their responsiveness to community needs, especially when several GHIs operate simultaneously. Health system strengthening will not result from the sum of selective global interventions but requires a comprehensive approach.	[Cavalli, Anna; Boelaert, Marleen; Pirard, Marjan; Van Dormael, Monique] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium; [Bamba, Sory I.; Traore, Mamadou N.; Coulibaly, Youssouf] Minist Sante, Direct Natl Sante, Bamako, Mali; [Polman, Katja] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium	Cavalli, A (reprint author), Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.	mvdormael@itg.be	Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776	Belgian Directorate-General for Development Cooperation (DGDC)	The study was funded by the Belgian Directorate-General for Development Cooperation (DGDC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Biesma RG, 2009, HEALTH POLICY PLANN, V24, P239, DOI 10.1093/heapol/czp025; Bill and Melinda Gates Foundation; McKinsey & Company, 2005, GLOB HLTH PARTN ASS; Brady MA, 2006, TRENDS PARASITOL, V22, P285, DOI 10.1016/j.pt.2006.05.007; Brugha R, 2001, BRIT MED J, V323, P152, DOI 10.1136/bmj.323.7305.152; Buse K, 2000, B WORLD HEALTH ORGAN, V78, P699; Coulibaly Y, 2008, TROP MED INT HEALTH, V13, P1430, DOI 10.1111/j.1365-3156.2008.02174.x; Fenwick A, 2006, SCIENCE, V313, P1077, DOI 10.1126/science.1127184; Hanefeld J, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-8; Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142; Hotez PJ, 2009, LANCET, V373, P1570, DOI 10.1016/S0140-6736(09)60233-6; Kuper A, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1035; Marchal B, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000059; Mills A, 2005, B WORLD HEALTH ORGAN, V83, P315; *MIN HLTH NAT HLTH, 2007, PLAN STRAT LUTT MAL; Mogedal S., 2000, DIS ERADICATION FRIE; Molyneux DH, 2005, PLOS MED, V2, P1064, DOI 10.1371/journal.pmed.0020336; Oliveira-Cruz V, 2003, J INT DEV, V15, P67, DOI DOI 10.1002/JID.966; Parker M, 2008, J BIOSOC SCI, V40, P161, DOI 10.1017/S0021932007002301; Patton M. Q, 2002, QUALITATIVE RES EVAL; Perez D, 2009, HEALTH POLICY PLANN, V24, P335, DOI 10.1093/heapol/czp028; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Reeves S, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1020; Samb B, 2009, LANCET, V373, P2137, DOI 10.1016/S0140-6736(09)60919-3; Schatzman L., 1973, FIELD RES STRATEGIES; Segall M, 2003, INT J HEALTH PLAN M, V18, pS5, DOI 10.1002/hpm.719; Shiffman J, 2006, HEALTH POLICY PLANN, V21, P411, DOI 10.1093/heapol/czl028; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; Unger JP, 2003, INT J HEALTH PLAN M, V18, pS27, DOI 10.1002/hpm.723; 2009, LANCET, V374, P10	29	39	39	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1935-2735			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	AUG	2010	4	8							e798	10.1371/journal.pntd.0000798				7	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	645HN	WOS:000281443200027	20808908	DOAJ Gold, Green Published			2019-03-26	
J	Guerra, CA; Howes, RE; Patil, AP; Gething, PW; Van Boeckel, TP; Temperley, WH; Kabaria, CW; Tatem, AJ; Manh, BH; Elyazar, IRF; Baird, JK; Snow, RW; Hay, SI				Guerra, Carlos A.; Howes, Rosalind E.; Patil, Anand P.; Gething, Peter W.; Van Boeckel, Thomas P.; Temperley, William H.; Kabaria, Caroline W.; Tatem, Andrew J.; Manh, Bui H.; Elyazar, Iqbal R. F.; Baird, J. Kevin; Snow, Robert W.; Hay, Simon I.			The International Limits and Population at Risk of Plasmodium vivax Transmission in 2009	PLOS NEGLECTED TROPICAL DISEASES			English	Article							DUFFY-BLOOD-GROUP; POLYMERASE-CHAIN-REACTION; ANOPHELES-GAMBIAE GILES; MALARIA SURVEILLANCE; UNITED-STATES; FALCIPARUM TRANSMISSION; DRY SEASON; INFECTION; RESISTANCE; ETHIOPIA	Background: A research priority for Plasmodium vivax malaria is to improve our understanding of the spatial distribution of risk and its relationship with the burden of P. vivax disease in human populations. The aim of the research outlined in this article is to provide a contemporary evidence-based map of the global spatial extent of P. vivax malaria, together with estimates of the human population at risk (PAR) of any level of transmission in 2009. Methodology: The most recent P. vivax case-reporting data that could be obtained for all malaria endemic countries were used to classify risk into three classes: malaria free, unstable (<0.1 case per 1,000 people per annum (p. a.)) and stable (>= 0.1 case per 1,000 p. a.) P. vivax malaria transmission. Risk areas were further constrained using temperature and aridity data based upon their relationship with parasite and vector bionomics. Medical intelligence was used to refine the spatial extent of risk in specific areas where transmission was reported to be absent (e. g., large urban areas and malaria-free islands). The PAR under each level of transmission was then derived by combining the categorical risk map with a high resolution population surface adjusted to 2009. The exclusion of large Duffy negative populations in Africa from the PAR totals was achieved using independent modelling of the gene frequency of this genetic trait. It was estimated that 2.85 billion people were exposed to some risk of P. vivax transmission in 2009, with 57.1% of them living in areas of unstable transmission. The vast majority (2.59 billion, 91.0%) were located in Central and South East (CSE) Asia, whilst the remainder were located in America (0.16 billion, 5.5%) and in the Africa+region (0.10 billion, 3.5%). Despite evidence of ubiquitous risk of P. vivax infection in Africa, the very high prevalence of Duffy negativity throughout Central and West Africa reduced the PAR estimates substantially. Conclusions: After more than a century of development and control, P. vivax remains more widely distributed than P. falciparum and is a potential cause of morbidity and mortality amongst the 2.85 billion people living at risk of infection, the majority of whom are in the tropical belt of CSE Asia. The probability of infection is reduced massively across Africa by the frequency of the Duffy negative trait, but transmission does occur on the continent and is a concern for Duffy positive locals and travellers. The final map provides the spatial limits on which the endemicity of P. vivax transmission can be mapped to support future cartographic-based burden estimations.	[Guerra, Carlos A.; Howes, Rosalind E.; Patil, Anand P.; Gething, Peter W.; Van Boeckel, Thomas P.; Temperley, William H.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England; [Van Boeckel, Thomas P.] Univ Libre Bruxelles, Brussels, Belgium; [Kabaria, Caroline W.; Snow, Robert W.] Univ Oxford, Wellcome Trust Collaborat Programme, KEMRI, Ctr Geog Med,Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya; [Tatem, Andrew J.] Univ Florida, Dept Geog, Gainesville, FL 32611 USA; [Tatem, Andrew J.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA; [Manh, Bui H.] Univ Oxford, Clin Res Unit, Natl Inst Infect & Trop Dis, Bach Mai Hosp, Hanoi, Vietnam; [Elyazar, Iqbal R. F.; Baird, J. Kevin] Eijkman Oxford Clin Res Unit, Jakarta, Indonesia; [Snow, Robert W.] Univ Oxford, Nuffield Dept Clin Med, CCVTM, Ctr Trop Med, Oxford, England	Guerra, CA (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, S Parks Rd, Oxford OX1 3PS, England.	carlos.guerraloaiza@zoo.ox.ac.uk; simon.hay@zoo.ox.ac.uk	Hay, Simon/F-8967-2015	Hay, Simon/0000-0002-0611-7272; Gething, Peter/0000-0001-6759-5449; Kabaria, Caroline/0000-0002-5641-5243; Snow, Robert/0000-0003-3725-6088	Wellcome Trust [079091, 085406, 079080, B9RJIXO]; Belgian Fond National pour la Recherche Scientifique; Fondation Wiener-Anspach; Bill and Melinda Gates Foundation [49446]; University of Oxford - Li Ka Shing Foundation; United States Navy; Oxford Tropical Network; South East Asia Infectious Disease Research Network; Wellcome Trust, United Kingdom	SIH is funded by a Senior Research Fellowship from the Wellcome Trust (#079091), which also supports CAG, PWG, and CWK. REH is funded by a Biomedical Resources Grant (#085406) from the Wellcome Trust to SIH. RWS is funded by a Wellcome Trust Principal Research Fellowship (#079080), which also supports APP and WHT. TPVB is funded by a grant from the Belgian Fond National pour la Recherche Scientifique and the Fondation Wiener-Anspach. AJT is supported by a grant from the Bill and Melinda Gates Foundation (#49446). BHM is funded by a grant from the University of Oxford - Li Ka Shing Foundation Global Health Programme. IRFE is funded by grants from the University of Oxford - Li Ka Shing Foundation Global Health Programme, the United States Navy, and the Oxford Tropical Network. JKB is funded by a grant from the Wellcome Trust (#B9RJIXO) and by the South East Asia Infectious Disease Research Network. This work forms part of the output of the Malaria Atlas Project (MAP, www.map.ox.ac.uk), principally funded by the Wellcome Trust, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2008, GLOB MAL ACT PLAN MA; Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003; Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011; Baird JK, 2009, CLIN MICROBIOL REV, V22, P508, DOI 10.1128/CMR.00008-09; Balk DL, 2006, ADV PARASIT, V62, P119, DOI 10.1016/S0065-308X(05)62004-0; Barcus MJ, 2007, AM J TROP MED HYG, V77, P984, DOI 10.4269/ajtmh.2007.77.984; Bicheron P., 2008, GLOBCOVER PRODUCTS D; Blossom DB, 2005, AM J TROP MED HYG, V73, P188, DOI 10.4269/ajtmh.2005.73.188; Bouma MJ, 1996, B WORLD HEALTH ORGAN, V74, P413; CAUSER LM, 2002, MMWR SURVEILL SUMM, V52, P9; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Cavasini CE, 2007, T ROY SOC TROP MED H, V101, P1042, DOI 10.1016/j.trstmh.2007.04.011; *CDCP, 2009, CDC HLTH INF INT TRA; COATNEY GR, 2003, PRIMATE MALARIAS; COLLINS WE, 1991, J AM MOSQUITO CONTR, V7, P569; Comellini L, 1998, ANN TROP PAEDIATR, V18, P41, DOI 10.1080/02724936.1998.11747924; Cortes H, 2003, TROP MED INT HEALTH, V8, P297, DOI 10.1046/j.1365-3156.2003.01029.x; Culleton R, 2009, J INFECT DIS, V200, P1465, DOI 10.1086/644510; CUTBUSH M, 1950, HEREDITY, V4, P383, DOI 10.1038/hdy.1950.31; Eliades M. James, 2005, Morbidity and Mortality Weekly Report, V54, P25; *EMRO, 2008, TECHN DISC MAL EL E; Erhabor O, 2006, Niger J Med, V15, P52; FAO, 2008, GLOB ADM UN LAYERS G; Feachem R, 2008, LANCET, V371, P1633, DOI [10.1016/S0140-6736(08)60424-9, 10.1016/S1473-3099(08)70045-8]; Filler Scott, 2003, MMWR Surveill Summ, V52, P1; Garnham PCC, 1988, MALARIA PRINCIPLES P, VI, P61; Gautret P, 2001, ACTA TROP, V78, P177, DOI 10.1016/S0001-706X(00)00181-9; Genton B, 2008, PLOS MED, V5, P881, DOI 10.1371/journal.pmed.0050127; Gething PW, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000724; Gray EM, 2005, AM J TROP MED HYG, V73, P553, DOI 10.4269/ajtmh.2005.73.553; Guerra CA, 2006, ADV PARASIT, V62, P157, DOI 10.1016/S0065-308X(05)62005-2; Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038; Guerra CA, 2006, TRENDS PARASITOL, V22, P353, DOI 10.1016/j.pt.2006.06.006; Hay SI, 2005, TROP MED INT HEALTH, V10, P1073, DOI 10.1111/j.1365-3156.2005.01487.x; Hay SI, 2005, NAT REV MICROBIOL, V3, P81, DOI 10.1038/nrmicro1069; HAY SI, 2010, PLOS MED IN PRESS; Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0; Hay SI, 2006, PLOS MED, V3, P2204, DOI 10.1371/journal.pmed.0030473; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000209; Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048; Hijmans RJ, 2005, INT J CLIMATOL, V25, P1965, DOI 10.1002/joc.1276; Himeidan Y. El-S., 2005, Eastern Mediterranean Health Journal, V11, P499; Holtz T H, 2001, MMWR CDC Surveill Summ, V50, P1; Illamperuma C, 2007, INFECTION, V35, P374, DOI 10.1007/s15010-007-6108-x; Kaneko A, 2000, LANCET, V356, P1560, DOI 10.1016/S0140-6736(00)03127-5; Kiszewski A, 2004, AM J TROP MED HYG, V70, P486, DOI 10.4269/ajtmh.2004.70.486; Kochar DK, 2009, AM J TROP MED HYG, V80, P194, DOI 10.4269/ajtmh.2009.80.194; Langhi DM, 2006, HEMATOLOGY, V11, P389, DOI 10.1080/10245330500469841; Lekweiry KM, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-92; Lindo JF, 2007, EMERG INFECT DIS, V13, P931, DOI 10.3201/eid1306.061227; Maitland K, 1997, PARASITOL TODAY, V13, P227, DOI 10.1016/S0169-4758(97)01061-2; Mali Sonja, 2008, Morbidity and Mortality Weekly Report, V57, P24; Mali Sonja, 2009, Morbidity and Mortality Weekly Report, V58, P1; Mangoni ED, 2003, AM J TROP MED HYG, V68, P159, DOI 10.4269/ajtmh.2003.68.159; MATHEWS HM, 1981, AM J TROP MED HYG, V30, P299, DOI 10.4269/ajtmh.1981.30.299; Mayxay M, 2004, TRENDS PARASITOL, V20, P233, DOI 10.1016/j.pt.2004.03.006; Menard D, 2010, P NATL ACAD SCI USA, V107, P5967, DOI 10.1073/pnas.0912496107; Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; *MIN SAUD CAB VERD, 2009, PLAN ESTR PREEL PAL; Mourant AE, 1976, DISTRIBUTION HUMAN B; Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X; Newman Robert D, 2002, MMWR Surveill Summ, V51, P15; Nikolaev B. P., 1935, INFLUENCE TEMPERATUR; OMER SM, 1968, NATURE, V217, P879, DOI 10.1038/217879b0; OMER SM, 1970, B WORLD HEALTH ORGAN, V42, P319; PAHO, 2006, REG STRAT PLAN MAL A; Pampana E., 1969, TXB MALARIA ERADICAT; Parakh A, 2009, ANN TROP PAEDIATR, V29, P253, DOI 10.1179/027249309X12547917868844; Peragallo MS, 1997, T ROY SOC TROP MED H, V91, P343, DOI 10.1016/S0035-9203(97)90101-2; Peruzzi Simona, 2007, Acta Biomed, V78, P170; POIRRIEZ J, 1991, ANN PARASIT HUM COMP, V66, P149, DOI 10.1051/parasite/1991664149; Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79; Rabarijaona LP, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-190; Rosenberg R, 2007, TRENDS PARASITOL, V23, P193, DOI 10.1016/j.pt.2007.02.009; Rubio JM, 1999, AM J TROP MED HYG, V60, P183, DOI 10.4269/ajtmh.1999.60.183; Ryan JR, 2006, AM J TROP MED HYG, V75, P575, DOI 10.4269/ajtmh.2006.75.575; Sattabongkot J, 2004, TRENDS PARASITOL, V20, P192, DOI 10.1016/j.pt.2004.02.001; Shah Snehal, 2004, Morbidity and Mortality Weekly Report, V53, P21; Shililu JI, 2004, J AM MOSQUITO CONTR, V20, P243; Sintasath DM, 2005, AM J TROP MED HYG, V72, P682, DOI 10.4269/ajtmh.2005.72.682; Skarbinski Jacek, 2006, Morbidity and Mortality Weekly Report, V55, P23; Snounou G, 1998, ACTA TROP, V70, P197, DOI 10.1016/S0001-706X(98)00021-7; Snow RW, 2008, PLOS MED, V5, P1068, DOI 10.1371/journal.pmed.0050142; SNOW RW, 2003, 11 NIH FOG INT CTR D; Taye A, 2006, ACTA TROP, V97, P50, DOI 10.1016/j.actatropica.2005.08.002; Tchen J, 2006, Med Trop (Mars), V66, P295; Teka H, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-220; Thwing Julie, 2007, Morbidity and Mortality Weekly Report, V56, P23; Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128; United Nations Population Division (UNPD), 2008, WORLD URB PROSP 2007; Wejda BUJ, 2002, J TRAVEL MED, V9, P277; WELCH SG, 1977, T ROY SOC TROP MED H, V71, P295, DOI 10.1016/0035-9203(77)90102-X; World Health Organization, 2010, INT TRAV HLTH SIT 1; Yekutiel P., 1980, ERADICATION INFECT D, P34; Zhang WY, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-206	96	281	287	4	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	AUG	2010	4	8							e774	10.1371/journal.pntd.0000774				11	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	645HN	WOS:000281443200006	20689816	DOAJ Gold, Green Published			2019-03-26	
J	Saad, AA; Ahmed, NG; Osman, OS; Al-Basheer, AA; Hamad, A; Deborggraeve, S; Buscher, P; Schoone, GJ; Schallig, HD; Laurent, T; Haleem, A; Osman, OF; Eltom, AM; Elbashir, MI; El-Safi, S				Saad, Alfarazdeg A.; Ahmed, Nuha G.; Osman, Osman S.; Al-Basheer, Ahmed Almustafa; Hamad, Awad; Deborggraeve, Stijn; Buescher, Philippe; Schoone, Gerard J.; Schallig, Henk D.; Laurent, Thierry; Haleem, Ahmed; Osman, Omran F.; Eltom, Ahmed Mohamedain; Elbashir, Mustafa I.; El-Safi, Sayda			Diagnostic Accuracy of the Leishmania OligoC-TesT and NASBA-Oligochromatography for Diagnosis of Leishmaniasis in Sudan	PLOS NEGLECTED TROPICAL DISEASES			English	Article							DIRECT AGGLUTINATION-TEST; HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; VISCERAL LEISHMANIASIS; KALA-AZAR; PCR	Background: The Leishmania OligoC-TesT and NASBA-Oligochromatography (OC) were recently developed for simplified and standardised molecular detection of Leishmania parasites in clinical specimens. We here present the phase II evaluation of both tests for diagnosis of visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and post kala-azar dermal leishmaniasis (PKDL) in Sudan. Methodology: The diagnostic accuracy of the tests was evaluated on 90 confirmed and 90 suspected VL cases, 7 confirmed and 8 suspected CL cases, 2 confirmed PKDL cases and 50 healthy endemic controls from Gedarif state and Khartoum state in Sudan. Principal Findings: The OligoC-TesT as well as the NASBA-OC showed a sensitivity of 96.8% (95% CI: 83.8%-99.4%) on lymph node aspirates and of 96.2% (95% CI: 89.4%-98.7%) on blood from the confirmed VL cases. The sensitivity on bone marrow was 96.9% (95% CI: 89.3%-99.1%) and 95.3% (95% CI: 87.1%-98.4%) for the OligoC-TesT and NASBA-OC, respectively. All confirmed CL and PKDL cases were positive with both tests. On the suspected VL cases, we observed a positive OligoC-TesT and NASBA-OC result in 37.1% (95% CI: 23.2%-53.7%) and 34.3% (95% CI: 20.8%-50.9%) on lymph, in 72.7% (95% CI: 55.8%-84.9%) and 63.6% (95% CI: 46.6%-77.8%) on bone marrow and in 76.9% (95% CI: 49.7%-91.8%) and 69.2% (95% CI: 42.4%-87.3%) on blood. Seven out of 8 CL suspected cases were positive with both tests. The specificity on the healthy endemic controls was 90% (95% CI: 78.6%-95.7%) for the OligoC-TesT and 100% (95% CI: 92.9%-100.0%) for the NASBA-OC test. Conclusions: Both tests showed high sensitivity on lymph, blood and tissue scrapings for diagnosis of VL, CL and PKDL in Sudan, but the specificity for clinical VL was significantly higher with NASBA-OC.	[Saad, Alfarazdeg A.; Ahmed, Nuha G.; Osman, Osman S.; Eltom, Ahmed Mohamedain; Elbashir, Mustafa I.] Univ Khartoum, Dept Biochem, Khartoum, Sudan; [Al-Basheer, Ahmed Almustafa; Hamad, Awad; El-Safi, Sayda] Univ Khartoum, Dept Microbiol & Parasitol, Khartoum, Sudan; [Deborggraeve, Stijn; Buescher, Philippe] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium; [Deborggraeve, Stijn] Katholieke Univ Leuven, Rega Inst, Leuven, Belgium; [Schoone, Gerard J.; Schallig, Henk D.] Koninklijk Inst Tropen KIT, Parasitol Unit, KIT Biomed Res, Amsterdam, Netherlands; [Laurent, Thierry] Coris BioConcept, Gembloux, Belgium; [Haleem, Ahmed] Univ Khartoum, Fac Lab Sci, Khartoum, Sudan; [Osman, Omran F.] Univ Khartoum, Fac Sci, Khartoum, Sudan	Saad, AA (reprint author), Univ Khartoum, Dept Biochem, Khartoum, Sudan.	sdeborggraeve@itg.be	Buscher, Philippe/B-9956-2012	Buscher, Philippe/0000-0002-1926-7472; Ahmed, Osman/0000-0002-2854-2552; Deborggraeve, Stijn/0000-0003-1501-5355	Commission of the European Community [015379]	This study received financial support from the Commission of the European Communities' Sixth Framework Programme, priority INCO-DEV, project TRYLEIDIAG, contract 015379. S. Deborggraeve is a postdoctoral fellow of the Research Foundation Flanders (FWO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhattarai NR, 2009, TROP MED INT HEALTH, V14, P404, DOI 10.1111/j.1365-3156.2009.02242.x; Boelaert M, 1999, AM J TROP MED HYG, V60, P129, DOI 10.4269/ajtmh.1999.60.129; BOOM R, 1990, J CLIN MICROBIOL, V28, P495; Chappuis F, 2005, J CLIN MICROBIOL, V43, P5973, DOI 10.1128/JCM.43.12.5973-5977.2005; CHAPPUIS F, 2007, NAT REV MICROBIOL, V5, pS7, DOI DOI 10.1038/NRMICRO1748; Deborggraeve S, 2008, TROP MED INT HEALTH, V13, P1378, DOI 10.1111/j.1365-3156.2008.02154.x; Deborggraeve S, 2008, J INFECT DIS, V198, P1565, DOI 10.1086/592509; GARITOUSSAINT M, 1994, T ROY SOC TROP MED H, V88, P301, DOI 10.1016/0035-9203(94)90088-4; HAILU A, 1990, T ROY SOC TROP MED H, V84, P673, DOI 10.1016/0035-9203(90)90141-Z; HARITH AE, 1988, J CLIN MICROBIOL, V26, P1321; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MUGASA CM, TROP MED IN IN PRESS; MUGASA CM, PARASIT VEC IN PRESS; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5; Ritmeijer K, 2006, AM J TROP MED HYG, V74, P76, DOI 10.4269/ajtmh.2006.74.76; Silva LD, 2006, AM J TROP MED HYG, V75, P739, DOI 10.4269/ajtmh.2006.75.739; ter Horst R, 2009, AM J TROP MED HYG, V80, P929, DOI 10.4269/ajtmh.2009.80.929; van der Meide WF, 2005, J CLIN MICROBIOL, V43, P5560, DOI 10.1128/JCM.43.11.5560-5566.2005; Veeken H, 2003, TROP MED INT HEALTH, V8, P164, DOI 10.1046/j.1365-3156.2003.00996.x; *WHO, 1996, WHOLEISH9640; Zijlstra EE, 2001, TROP MED INT HEALTH, V6, P108, DOI 10.1046/j.1365-3156.2001.00680.x; ZIJLSTRA EE, 2001, T R SOC TROP MED HYG, V95, P1	23	15	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1935-2727			PLOS NEGLECT TROP D	Plos Neglect. Trop. Dis.	AUG	2010	4	8							e776	10.1371/journal.pntd.0000776				5	Infectious Diseases; Parasitology; Tropical Medicine	Infectious Diseases; Parasitology; Tropical Medicine	645HN	WOS:000281443200008	20689822	DOAJ Gold, Green Published			2019-03-26	
J	Bekele, A; Baay, M; Mekonnen, Z; Suleman, S; Chatterjee, S				Bekele, A.; Baay, M.; Mekonnen, Z.; Suleman, S.; Chatterjee, S.			Human papillomavirus type distribution among women with cervical pathology - a study over 4 years at Jimma Hospital, southwest Ethiopia	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Article						Ethiopia; Jimma; HPV; human papillomavirus; cervical cancer; carcinoma	DEVELOPING-COUNTRIES; CANCER; PCR	Over the period 1998-2001 women attending Jimma hospital (southwest Ethiopia) with cervical dysplasia were screened for human papillomavirus (HPV), identifying a prevalence of 67.1% in this population. High-risk HPV types 16 (55.7%), 18 (8.2%), 56 (8.2%), 45 (4.1%), 39 (2.5%), 52 (1.6%), 31 (1.6%), 35 (1.6%), 58 (0.8%), 33 (0.8%), 59 (0.8%) caused severe pathology as single/multiple infection. Strategies need to be envisioned for vaccinating children, young women prior to first sexual contact and preventive screening of HPV high-risk types.	[Chatterjee, S.] Univ Antwerp, Fac Med, Pathol Lab, B-2020 Antwerp, Belgium; [Bekele, A.; Mekonnen, Z.] Jimma Univ, Dept Med Lab Sci & Pathol, Jimma, Ethiopia; [Baay, M.] Univ Antwerp, Fac Med, Lab Canc Res & Clin Oncol, B-2020 Antwerp, Belgium; [Suleman, S.] Jimma Univ, Sch Pharm, Jimma, Ethiopia	Chatterjee, S (reprint author), Univ Antwerp, Fac Med, Pathol Lab, B-2020 Antwerp, Belgium.	shyama.chatterjee@ua.ac.be			University of Antwerp and Jimma University, Ethiopia (VLIR-IUC)	The study was funded by a Flemish interuniversity cooperation between the University of Antwerp and Jimma University, Ethiopia (VLIR-IUC).	BASEMAN JG, 2005, J CLIN VIROL, V3251, P516; Cuzick J, 2008, VACCINE, V26, pK29, DOI 10.1016/j.vaccine.2008.06.019; *DEP EC SOC AFF, 2009, WORLD POP PROSP 2008; *DEP EC SOC AFF PO, 2008, WORLD FERT PATT 2007; Drain PK, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-172; Fanta BE, 2005, ETHIOPIAN MED J, V43, P151; FERLAY J, 2004, GLOBOCAN 2002 INCIDE; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Schiffman M, 2005, NEW ENGL J MED, V353, P2101, DOI 10.1056/NEJMp058171; Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527; Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866; *UN DEP EC SOC AFF, 2008, 2008 REP GLOB AIDS E; *UN DEP EC SOC AFF, 2007, WORLD CONTR US 2005; *WHO, 2003, WHS ETH; *WORLD BANK HNPSTA, 2007, HLTH NUTR POP HNP ST	20	10	10	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1360-2276	1365-3156		TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2010	15	8					890	893		10.1111/j.1365-3156.2010.02552.x				4	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	626BE	WOS:000279939900120	20545913	Bronze			2019-03-26	
J	De Brouwere, V; Richard, F; Witter, S				De Brouwere, Vincent; Richard, Fabienne; Witter, Sophie			Access to maternal and perinatal health services: lessons from successful and less successful examples of improving access to safe delivery and care of the newborn	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Editorial Material						perinatal mortality; maternal mortality; health system; developing countries	EXPERIENCE	The huge majority of the annual 6.3 million perinatal deaths and half a million maternal deaths take place in developing countries and are avoidable. However, most of the interventions aiming at reducing perinatal and maternal deaths need a health care system offering appropriate antenatal care and quality delivery care, including basic and comprehensive emergency obstetric care facilities. To promote the uptake of quality care, there are two possible approaches: influencing the demand and/or the supply of care. Five lessons emerged from experiences. First, it is difficult to obtain robust evidence of the effects of a particular intervention in a context, where they are always associated with other interventions. Second, the interventions tend to have relatively modest short-term impacts, when they address only part of the health system. Third, the long-term effects of an intervention on the whole health system are uncertain. Fourth, because newborn health is intimately linked with maternal health, it is of paramount importance to organise the continuum of care between mother and newborn. Finally, the transfer of experiences is delicate, and an intervention package that has proved to have a positive effect in one setting may have very different effects in other settings.	[De Brouwere, Vincent] Inst Rech Dev, Rabat, Morocco; [De Brouwere, Vincent] Inst Natl Adm Sanitaire, Rabat, Morocco; [Richard, Fabienne] Inst Trop Med, Qual & Human Resources Unit, B-2000 Antwerp, Belgium; [Witter, Sophie] Univ Aberdeen, Aberdeen AB9 1FX, Scotland	De Brouwere, V (reprint author), Inst Rech Dev, Rabat, Morocco.	vdbrouw@itg.be					Ansong-Tornui Janet, 2007, Ghana Med J, V41, P125; Bhutta ZA, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S7; Borghi J, 2006, LANCET, V368, P1457, DOI 10.1016/S0140-6736(06)69383-5; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Darmstadt GL, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S6; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Devadasan N, 2008, STUDIES HLTH SERVICE, V24, P257; Eldridge C, 2009, HEALTH POLICY PLANN, V24, P160, DOI 10.1093/heapol/czp002; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; Fauveau V, 2007, LANCET, V370, P1310, DOI 10.1016/S0140-6736(07)61571-2; FIGO Committee, 2009, INT J GYNECOL OBSTET, V104, P80; Graham W, 2008, TROP MED INT HEALTH, V13, P6, DOI 10.1111/j.1365-3156.2008.02082.x; Graham WJ, 2004, LANCET, V363, P23, DOI 10.1016/S0140-6736(03)15165-3; Gwatkin DR, 2000, B WORLD HEALTH ORGAN, V78, P3; Harvey SA, 2007, B WORLD HEALTH ORGAN, V85, P783, DOI 10.2471/BLT.06.038455; Haws RA, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S5; HILL K, 2007, LANCET, V370, P9595; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Hounton S, 2009, GLOBAL HEALTH ACTION, V2, DOI 10.3402/gha.v2i0.1947; HOUWELING TA, 2007, B WORLD HEALTH ORGAN, V85, P10; *I NAT STAT MIN SA, 2008, ENQ PREST SERV SOINS, P796; KAROLINSKI A, 2009, INT J GYNECOL OBSTET, V105, P2; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; KHALIL K, 2005, BIRTH-ISS PERINAT C, V32, P4; Kunst AE, 2001, STUDIES HLTH SERVICE, V17, P293; Lagarde M, 2007, JAMA-J AM MED ASSOC, V298, P16; MEESSEN B, 2006, TROP MED INT HEALTH, V11, P8; MEESSEN B, 2007, B WORLD HEALTH ORGAN, V85, P2; Menezes EV, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S4; Mfinanga Godfrey S, 2009, Health Res Policy Syst, V7, P6, DOI 10.1186/1478-4505-7-6; MORRIS SS, 2004, LANCET, V364, P9450; Ndiaye P, 2008, STUDIES HLTH SERVICE, V24, P117; ORACH CG, 2007, TROP MED INT HEALTH, V12, P3; ORACH CG, 2004, LANCET, V364, P9434; ORACH CG, 2006, HLTH POLICY PLAN, V21, P1; OUEDRAOGO C, 2008, STUDIES HLTH SERVICE, V24, P49; PENFOLD S, 2007, GHANA MED J, V41, P3; Pooley B, 2008, STUD HLTH SERV ORGAN, V24, P199; POR I, 2010, BMC PREGNANCY CHILDB, DOI DOI 10.1186/1471-2393-10-1; Renaudin P, 2007, INT J GYNECOL OBSTET, V99, P183, DOI 10.1016/j.ijgo.2007.07.006; RICHARD F, 2008, STUDIES HLTH SERVICE, V24, P11; RICHARD F, 2008, BRIT J OBSTET GYNAEC, V116, P38; RONSMANS C, 2006, LANCET, V368, P9546; RONSMANS C, 2006, LANCET, V368, P9542; RUSA L, 2009, PERFORMANCE INCENTIV, P190; RUSA L, 2009, TROP MED INT HEALTH, V15, P148; Skilled Care Initiative, 2005, SKILL CAR IN WHICH C; SOETERS R, 2006, B WORLD HEALTH ORGAN, V84, P11; SOUCAT A, 2008, SCALING PERFORMANCE; STANTON C, 2006, LANCET, V367, P9521; STANTON C, 2009, B WORLD HEALTH ORGAN, V87, P3; TURNER TJ, 2009, HLTH RES POLICY SYST, V7, P1; Van Damme W, 2008, STUDIES HSO P, V24, P225; Waiswa Peter, 2008, BMC Pregnancy Childbirth, V8, P21, DOI 10.1186/1471-2393-8-21; Wilkinson D, 2001, B WORLD HEALTH ORGAN, V79, P665; Witter S., 2008, STUDIES HLTH SERVICE, P167; Witter S, 2007, REPROD HEALTH MATTER, V15, P61, DOI 10.1016/S0968-8080(07)30325-X; World Health Organization, 2006, NEON PER MORT COUNTR; Yakoob MY, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S3; 1999, M BALT MAR MAY 10 12	60	31	31	1	9	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2010	15	8					901	909		10.1111/j.1365-3156.2010.02558.x				9	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	626BE	WOS:000279939900122	20545915	Bronze			2019-03-26	
J	Wouters, E; Vermeiren, P; Katabaro, M; Van Damme, W				Wouters, E.; Vermeiren, P.; Katabaro, M.; Van Damme, W.			Modelling social reality: limitations to measuring the impact of HIV/AIDS on rural households	TROPICAL MEDICINE & INTERNATIONAL HEALTH			English	Letter							AFRICA		[Wouters, E.] Univ Antwerp, Dept Sociol, B-2020 Antwerp, Belgium; [Wouters, E.] Univ Orange Free State, Ctr Hlth Syst Res & Dev, Bloemfontein, South Africa; [Katabaro, M.] Univ Pretoria, Dept Polit Sci, ZA-0002 Pretoria, South Africa; [Vermeiren, P.; Van Damme, W.] Inst Trop Med, Unit Hlth Policy & Financing, B-2000 Antwerp, Belgium	Wouters, E (reprint author), Univ Antwerp, Dept Sociol, B-2020 Antwerp, Belgium.	Edwin.Wouters@ua.ac.be	Van Damme, Wim/F-7404-2011; Wouters, Edwin/G-9073-2012	Wouters, Edwin/0000-0003-2268-3829			BACHMANNM, 2003, BMC PUBLIC HEALTH, V3, P14; Dixon S, 2002, BRIT MED J, V324, P232, DOI 10.1136/bmj.324.7331.232; Mahal A, 2008, AIDS, V22, pS95, DOI 10.1097/01.aids.0000327629.62350.59; Seeley J, 2010, TROP MED INT HEALTH, V15, P329, DOI 10.1111/j.1365-3156.2009.02458.x; Shiffman J, 2008, HEALTH POLICY PLANN, V23, P95, DOI 10.1093/heapol/czm045; WHO, 2008, WORLD MAL REP 2008; *WHO, 2008, GLOB TUB CONTR; Wouters E, 2009, AIDS CARE, V21, P1401, DOI 10.1080/09540120902884034	8	2	2	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1360-2276			TROP MED INT HEALTH	Trop. Med. Int. Health	AUG	2010	15	8					955	957		10.1111/j.1365-3156.2010.02569.x				3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	626BE	WOS:000279939900128	20545922	Bronze			2019-03-26	
